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Preface
Scope and Purpose of the HIV Molecular Immunology
Database
HIV Molecular Immunology is a companion volume to Human Retroviruses
and AIDS Genetic Sequence Compendium. This publication, the 2002 issue,
is the printed version of the Web-based HIV Immunology Database (http:
//hiv-web.lanl.gov/immunology). The web interface for this rela-
tional database has many search options, as well as interactive tools to help im-
munologists design reagents and interpret their results.
The data included in this database is extracted from the HIV immunology lit-
erature. HIV-specific B-cell and T-cell responses are summarized and annotated.
Immunological responses are divided into three sections, CTL, T helper, and
antibody. Within these sections, defined epitopes are organized by protein and
binding sites within each protein, moving from left to right through the coding
regions spanning the HIV genome. We include human responses to natural HIV
infections, as well as vaccine studies in a range of animal models and human
trials. Responses that are not specifically defined, such as responses to whole
proteins or monoclonal antibody responses to discontinuous epitopes, are sum-
marized at the end of each protein sub-section. Studies describing general HIV
responses to the virus, but not to any specific protein, are included at the end of
each section.
The annotation includes information such as cross-reactivity, escape muta-
tions, antibody sequence, TCR usage, functional domains that overlap with an
epitope, immune response associations with rates of progression and therapy,
and how specific epitopes were experimentally defined. Basic information such
as HLA specificities for T-cell epitopes, isotypes of monoclonal antibodies, and
epitope sequences are included whenever possible. All studies that we can find
that incorporate the use of a specific monoclonal antibody are included in the en-
try for that antibody. A single T cell epitope can have multiple entries, generally
one entry per study.
Finally, maps of all defined linear epitopes relative to the HXB2 reference
proteins are provided. Alignments of CTL, helper T-cell, and antibody epi-
topes are available through the search interface on our web site at http://
hiv-web.lanl.gov/immunology.
Only responses to HIV-1 and HIV-2 are included in the database. CTL re-
sponses to SIVs have been periodically summarized in our review section by Dr.
Dave Watkins and colleagues. (For their most recent review, please see: Where
Have All The Monkeys Gone?: Evaluating SIV-Specific CTL in the Post-Mamu-
A*01 Era David H. O’Connor, Todd M. Allen, and David I. Watkins, in the 2001
HIV Immunology compendium). Dr. Christian Brander and colleagues annually
provide a concise listing of optimal CTL epitopes. Additional reviews that our
editorial board deems of general interest to the HIV research immunology com-
munity are solicited each year. This year’s reviews are printed in the first section
of this database; reviews from previous years can be found at: http://www.
hiv.lanl.gov/content/hiv-db/REVIEWS/reviews.html.
Comments on the database or requests for the hard copy can be sent via email
to immuno@t10.lanl.gov.
Citing the Database
This publication may be cited as
HIV Molecular Immunology 2002. Bette T. M. Korber, Christian
Brander, Barton F. Haynes, Richard Koup, Carla Kuiken, John P.
Moore, Bruce D. Walker, and David I. Watkins, editors. Publisher:
Los Alamos National Laboratory, Theoretical Biology and Biophys-
ics, Los Alamos, New Mexico. LA-UR 03-5816.
About the Cover
The illustration used for the cover of this
year’s immunology compendium highlights
the location of the most variable amino acids
in gp41, and was extracted from the re-
view: Mutational Analyses and Natural Vari-
ability of the gp41 Ectodomain, by Rogier
W. Sanders, Bette Korber, Min Lu, Ben
Berkhout, and John P. Moore (this volume).
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Preface About the PDF
About the PDF
The complete HIV Molecular Immunology 2002 is available in Adobe Portable
Document Format (PDF) from our website, http://hiv-web.lanl.gov/
immunology. The PDF version is hypertext enabled and features ‘clickable’
table-of-contents, indexes, references and links to external web sites.
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Preface HIV/SIV Proteins
HIV/SIV Proteins
Name Size Function Localization
Gag MA p17 membrane anchoring; env interaction; nuclear transport of
viral core. (myristylated protein)
virion
CA p24 core capsid virion
NC p7 nucleocapsid, binds RNA virion
p6 binds Vpr virion
Protease (PR) p15 gag/pol cleavage and maturation virion
Reverse Transcriptase (RT) p66, p51 reverse transcription virion
RNase H (heterodimer) RNAse H activity virion
Integrase (IN) DNA provirus integration virion
Env gp120/gp41 external viral glycoproteins bind to CD4 and chemokine
co-receptors
plasma membrane, virion envelope
Tat p16/p14 viral transcriptional transactivator primarily in nucleolus/nucleus
Rev p19 RNA transport, stability and utilization factor (phosphoprotein) primarily in nuleolus/nucleus shuttling
between nucleolus and cytoplasm
Vif p23 viral infectivity factor, inhibits minus-strand viral DNA
hypermutation
cytoplasm (cytosol, membranes), virion
Vpr p10-15 promotes nuclear localization of preintegration complex,
inhibits cell division, arrests infected cells at G2/M
virion nucleus (nuclear membrane?)
Vpu p16 promotes extracellular release of viral particles; degrades CD4
in the ER; (phosphoprotein only in HIV-1 and SIVcpz)
integral membrane protein
Nef p27-p25 CD4 and class I downregulation (myristylated protein) plasma membrane, cytoplasm, (virion?)
Vpx p12-16 Vpr homolog present in HIV-2 and some SIVs absent in HIV-1 virion (nucleus?)
Tev p28 tripartite tat-env-rev protein (also named Tnv) primarily in nucleolus/nucleus
viii
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Abbreviations Preface
Abbreviations
Common abbreviations used in this database.
Abbrev. Meaning
Ab Antibody
ADCC Antibody-Dependent Cell-medicated Cytotoxicity
ADE Antibody-Dependent Enhancement
APC Antigen Presenting Cell
AZT Azidothymidine
CD4BS CD4 Binding Site
CD4i Antibody that has enhanced binding to gp120 in the
presence of SCD4 (CD4 induced)
CSF Cerebrospinal Fluid
CTL Cytotoxic T Lymphocyte
CTLp CTL precursor
DTT Dithiothrietol
EIA Enzyme Immuno Assay
ELISA Enzyme Linked ImmunoSorbent Assay
ER Endoplasmic reticulum
Fabs Fragment Antigen Binding-univalent antibody
fragment
FIV Feline Immunodeficiency Virus
gp Glycoprotein
HIV Human Immunodeficiency Virus
HLA Human Leukocyte Antigens
HLA-MHC Human Leukocyte Antigens-Major
Histocompatibility Complex
IFN Interferon
IL Interleukin
IN Integrase
Abbrev. Meaning
Ig Immunoglobulin
MAb Monoclonal Antibody
MHC Major Histocompatibility Complex
MRC Medical Research Council, UK
NAb Neutralizing Antibody
NIBSC National Institute for Biological Standards and
Control, UK
NIH National Institutes of Health
PBLs Peripheral Blood Lymphocyte
PBMC Peripheral Blood Mononuclear Cell
PR Protease
RAC Ricin A Chain
rec/r recombinant
RIP Recombinant Identification Program
RIPA Radio Immuno Precipitation assay
rsgp160 recombinant soluble gp160
RT Reverse Transcriptase
sCD4 soluble CD4
SDS Sodium Duodecyl Sulfate
SIV Simian Immunodeficiency Virus
Th T-helper cell
TNF Tumor Necrosis Factor
VLP Virus like particle, assembled from p55 gag
VV Vaccinia virus
WB Western Blot
ix
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Total Assessment of HIV-Specific CTL Responses: Epitope Clustering, Processing
Preferences, and the Impact of HIV Sequence Heterogeneity
Nicole Frahm1, Philip J.R. Goulder1,2, and Christian Brander1
1Partners AIDS Research Center, Massachusetts General Hospital, Boston, USA.
2The Peter Medawar Building for Pathogen Research, Oxford, UK.
The HIV Immunology database at the Los Alamos National Laboratory has
collected data on HIV-specific cellular immune responses for over 8 years now
and the list of targeted regions within the HIV protein sequences has been grow-
ing steadily. These compiled data and our own studies using comprehensive
sets of overlapping peptides indicate that almost all parts of the viral protein
sequence can be targeted by virus-specific T cells, especially CTL [Addo2003,
Frahm2003]. HIV is the pathogen that has been characterized most extensively
in terms of T-cell epitope distribution and the well-defined epitope landscape
of HIV has allowed for a number of studies beyond assessing CTL activity in
relation to HIV disease progression [Brander2002].
Targets of HIV-specific CTL
Whilst in the early years of HIV CTL epitope mapping, attention was focused on
structural proteins, more recent studies have included regulatory and accessory
proteins as well [Tomiyama1999a, Altfeld2001a, van Baalen1997, Addo2001,
Addo2002b]. High-throughput assays such as intracellular cytokine staining
(ICS), and the Elispot assay are now routinely used to assess genome wide
immune responses to HIV [Edwards2002, Frahm2003, Betts2001, Addo2003,
Novitsky2001, Novitsky2002]. This is especially true for the characterization
of CD8+ CTL responses, but newer data also include the identification of Th
cell activity. Studies from several labs, including ours, using overlapping pep-
tide sets spanning the entire HIV protein sequence have now shown that at
least 90% of these peptides can be targeted by HIV-specific CTL, indicating
In HIV Molecular Immunology 2002. Bette T. M. Korber, Christian Brander, Barton F. Haynes,
Richard Koup, Carla Kuiken, John P. Moore, Bruce D. Walker, and David I. Watkins, editors. Pub-
lisher: Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, New
Mexico. LA-UR 03-5816. pp. 3–21.
that all viral proteins undergo appropriate antigen processing in vivo and that
epitopes from all HIV proteins can be effectively presented to CD8 T cells
[Addo2003, Frahm2003]. However, there are specific patterns among these re-
sponses which will impact HIV vaccine design and which can potentially help
to address more fundamental aspects of antigen processing, antigen presentation
and T-cell repertoire development [Yusim2002].
Of special interest for these extended studies, but also for questions of CTL
escape and (sub-unit)-vaccine development, is the identification of optimally de-
fined CTL epitopes. Since 1995, largely through the voluntary contributions
of unpublished data from many laboratories, regularly updated lists of “opti-
mal CTL epitopes” have been made accessible through the Los Alamos National
Laboratory’s HIV database [Brander1995]. This year’s update again adds a num-
ber of new epitopes whilst some others were removed as they were erroneously
included before (mainly some HLA-A*0201 restricted epitopes from our own
lab which were based on epitope prediction only and which were not defined
with the same stringency as the other epitopes in this list). While the earliest
reports clearly focused on alleles common in individuals infected early in the US
epidemic, more attention is now given to individuals of non-Caucasian descent
[Frahm2003, Sabbaj2003]. In addition, epitopes from non-clade B infections are
increasingly identified [Novitsky2002, Novitsky2003, Bond2001, Fukada2002,
Lynch1998, Sriwanthana2001, Goulder2001]. The identification of these epi-
topes provides valuable information for vaccine development in non-Caucasians
and non-clade B infection.
In addition, these new epitopes, when characterized in full detail, can provide
important insights into HLA binding motifs for these less well characterized
alleles; again facilitating the design of a potential HIV vaccine. To support this
work, the HIV database offers additional tools such as
EPILIGN:
http:
//hiv-web.lanl.gov/content/hiv-db/EPILIGN/EPI.html,
PeptGen:
http://hiv-web.lanl.gov/content/hiv-db/PEPTGEN/
PeptGenSubmitForm.html
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MotifScan:
http://hiv-web.lanl.gov/content/hiv-db/MOTIFSCAN/
MotifScanner.html
as well as valuable links to other sites, including the
SYFPEITHI HLA binding motifs database:
http://www.syfpeithi.de/
and others:
http://hiv.basic.nwu.edu/HLA,
http://bimas.dcrt.nih.gov/cgi-bin/molbio/ken_parker_
comboform,
http://www.jenner.ac.uk/JenPep/
Clearly, these databases and prediction softwares can profit from each other and
facilitate the future identification of T-cell targets in HIV and other infections.
Immunodominant regions in HIV protein sequences
As mentioned above, the described optimal CTL epitopes are not evenly dis-
tributed over the entire viral genome. Rather, there are regions where many epi-
topes overlap. This phenomenon has been described as early as 1993 and various
explanations have been put forward [Goulder2000a, Buseyne1993]. Two factors
that seem to significantly contribute to this epitope clustering appear to be viral
sequence heterogeneity and processing preferences [Yusim2002].
Sequence heterogeneity affects all HIV proteins, albeit to variable degrees.
Relatively conserved regions in Gag and Nef have been identified as immun-
odominant regions in a study of more than 150 individuals of different ethnici-
ties [Frahm2003]. Independently of the HLA background, these clade B infected
individuals made strong responses to the peptides spanning these regions. When
comparing the sequence heterogeneity in published clade B sequences, these
data also show that peptides with low sequence entropy (more conserved) are
targeted more frequently than epitopes with higher entropy. It is likely that these
differences are due to the fact that the average phylogenetic distance of the test
reagent (consensus B sequence) to an individual‘s autologous viral sequence is
larger in higher variable regions than in more conserved ones and thus, responses
against the less conserved peptides are not detected due to differences between
test reagent and inoculum sequence [Yusim2002, Gaschen2002].
In addition to sequence incompatibility between test reagent and autologous
virus, certain regions of the HIV protein sequence may not be processed and
presented very effectively. Although 86% of our overlapping peptide sets used
in the study above were targeted by at least one individual in the cohort of 150
people, there are still some relatively conserved peptides that do not seem to in-
duce a detectable CTL response in natural HIV infection [Frahm2003]. These
peptides may lie within stretches of viral proteins that are relatively resistant to
proteasomal digestions or may lack adequate “Transporter associated with Anti-
gen Processing” (TAP) binding motifs [Brander2002, Yusim2002]. The HIV Im-
munology database provides valuable web links to software where sequences of
choice can be analyzed for proteasomal processing preferences (NetChop by C.
Kesmir et al., http://www.cbs.dtu.dk/services/NetChop/). Re-
cent work by Yusim et al., demonstrates the accuracy and predictive potential of
this algorithm and its usefulness in identifying CTL epitopes [Yusim2002].
Together, these studies indicate that CTL epitope clustering may reflect the
biased detection of these responses in rather conserved regions and that process-
ing preferences may play an important role in providing processed antigen. In
addition, sequence variability may not only affect CTL recognition but could
also have an effect on processing of viral proteins [Yellen-Shaw1997]. Although
we have been unable to show such an effect for the flanking regions of the im-
munodominant, HLA-A*0201 restricted CTL epitope SL9 (SLYNTVATL) in
HIV Gag p17, other studies outside the HIV field suggest that escape from
processing may be an effective means of immune evasion [Yellen-Shaw1997,
Kuckelkorn2002, Gileadi1999, Brander1999]. These studies also highlight the
importance of defining T-cell targets in maximal detail, so that prediction al-
gorithm such as NetChop and binding motif algorithms can be optimized by a
precisely characterized training set of defined epitopes. In addition, in order to
discriminate between processing escape and escape from T-cell receptor recog-
nition or HLA binding, the boundaries of targeted epitopes need to be optimally
determined. The present listing is designed to provide these data specifically
for HIV derived epitopes and we therefore still separate CTL epitopes in a list
of optimally and suboptimally defined epitopes. We hope that this discrimina-
tion continues to provide support for the HIV immunologists and laboratories
involved in antigen processing and presentation, who want to take advantage of
the exceptionally well defined epitope landscape of HIV.
As every year, we would like to express our gratitude to the large number
of researchers in the field who continuously contribute to this database. We
very much welcome any criticism, comments and additions to this list since we
are sure that some epitopes will unintentionally escape our attention, despite
close monitoring of the literature. Also, pertinent information, such as resources
for single HLA allele expressing cell lines, HLA subtype information and new
technologies for CTL epitope mapping could be listed or referenced in this list,
providing additional help to problems encountered by investigators.
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Table 1: Best Defined HIV CTL Epitopes
HLA Protein AA Sequence Reference
A*0101 (A1) gp160 787–795 RRGWEVLKY [Cao2002]
A*0201 (A2) 2 6 C [Falk1991, Barouch1995]
1◦ anchor L L
M V
2◦ anchor V
A*0201 (A2) p17 77–85 SLYNTVATL [Johnson1991, Parker1992, Parker1994]
A*0201 (A2) p1 1–10 FLGKIWPSYK [Yu2002b]
A*0201 (A2) RT 33–41 ALVEICTEM [Haas1998, Haas1999]
A*0201 (A2) RT 179–187 VIYQYMDDL [Harrer1996a]
A*0201 (A2) RT 309–317 ILKEPVHGV [Walker1989, Tsomides1991]
A*0201 (A2) Vpr 59–67 AIIRILQQL [Altfeld2001a, Altfeld2001b]
A*0201 (A2) gp160 311–320 RGPGRAFVTI [Alexander-Miller1996]
A*0201 (A2) gp160 813–822 SLLNATDIAV [Dupuis1995]
A*0201 (A2) Nef 136–145 PLTFGWCYKL [Haas1996, Maier1999]
A*0201 (A2) Nef 180–189 VLEWRFDSRL [Haas1996, Maier1999]
A*0202 (A2) 2 C [Barouch1995]
L L
V
A*0202 (A2) p17 77–85 SLYNTVATL [Goulder1999]
A*0205 (A2) p17 77–85 SLYNTVATL [Goulder1999]
A*0205 (A2) gp41 335–343 RIRQGLERA [Sabbaj2003]
A*0207 (A2) p24 164–172 YVDRFYKTL [Currier2002]
A*03 (A3) RT 73–82 KLVDFRELNK [Yu2002a]
A*03 (A3) RT 356–366 RMRGAHTNDVK [Yu2002a]
A*03 (A3) Integrase 179–188 AVFIHNFKRK [Yu2002a]
A*03 (A3) Vif 28–36 HMYISKKAK [Yu2002a]
A*03 (A3) Vif 158–168 KTKPPLPSVKK [Yu2002a]
A*03 (A3) Rev 57–66 ERILSTYLGR [Addo2002a, Yu2002a]
A*03 (A3) Nef 84–92 AVDLSHFLK [Yu2002a]
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Table 1 (cont.): Best Defined HIV CTL Epitopes
HLA Protein AA Sequence Reference
A*0301 (A3) 2 C [DiBrino1993, Rammensee1995]
L K
V Y
M F
A*0301 (A3) p17 18–26 KIRLRPGGK [Harrer1996b]
A*0301 (A3) p17 20–28 RLRPGGKKK [Goulder1997a, Culmann1999, Lewinsohn1999b,
Wilkes1999b]
A*0301 (A3) p17 20–29 RLRPGGKKKY [Goulder2000b]
A*0301 (A3) RT 33–43 ALVEICTEMEK [Haas1998, Haas1999]
A*0301 (A3) RT 93–101 GIPHPAGLK [Yu2002a]
A*0301 (A3) RT 158–166 AIFQSSMTK [Threlkeld1997]
A*0301 (A3) RT 269–277 QIYPGIKVR [Yu2002a]
A*0301 (A3) Vif 17–26 RIRTWKSLVK [Altfeld2001a, Yu2002a]
A*0301 (A3) gp160 37–46 TVYYGVPVWK [Johnson1994a]
A*0301 (A3) gp160 770–780 RLRDLLLIVTR [Takahashi1991]
A*0301 (A3) Nef 73–82 QVPLRPMTYK [Koenig1990, Culmann1991]
A*1101 (A11) 2 C [Zhang1993, Rammensee1995]
K
V
I
F
Y
A*1101 (A11) p17 84–92 TLYCVHQRI [Harrer1998]
A*1101 (A11) p24 217–227 ACQGVGGPGHK [Sipsas1997]
A*1101 (A11) RT 158–166 AIFQSSMTK [Johnson1994b, Zhang1993, Threlkeld1997]
A*1101 (A11) RT 341–350 IYQEPFKNLK [Culmann1999]
A*1101 (A11) RNase 80–88 QIIEQLIKK [Fukada1999]
A*1101 (A11) Integrase 179–188 AVFIHNFKRK [Fukada1999]
A*1101 (A11) gp160 199–207 SVITQACPK [Fukada1999]
A*1101 (A11) Nef 73–82 QVPLRPMTYK [Buseyne1999]
A*1101 (A11) Nef 75–82 PLRPMTYK [Culmann1991]
A*1101 (A11) Nef 84–92 AVDLSHFLK [Culmann1991]
A*23 (A23) gp41 74–82 RYLKDQQLL [Cao2003]
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Table 1 (cont.): Best Defined HIV CTL Epitopes
HLA Protein AA Sequence Reference
A*2402 (A24) 2 C [Maier1994]
Y I
L
F
A*2402 (A24) p17 28–36 KYKLKHIVW [Ikeda-Moore1998, Lewinsohn1999a]
A*2402 (A24) p24 162–172 RDYVDRFFKTL [Dorrell1999, Rowland-Jones1999]
A*2402 (A24) gp160 52–61 LFCASDAKAY [Lieberman1992, Shankar1996]
A*2402 (A24) gp160 585–593 RYLKDQQLL [Dai1992]
A*2402 (A24) Nef 134–141 RYPLTFGW [Goulder1997b, Ikeda-Moore1998]
A*2501 (A25) p24 13–23 QAISPRTLNAW [Kurane1999]
A*2501 (A25) p24 71–80 ETINEEAAEW [Klenerman1996, van Baalen1996]
A*2601 (A26) 12 6 C [Dumrese1998]
V Y
T F
I
L
F
D I
E L
V
A*2601 (A26) p24 35–43 EVIPMFSAL [Goulder1996a]
A*2601 (A26) Pol 604–612 ETKLGKAGY [Sabbaj2003]
A*2902 (A29) gp160 209–217 SFEPIPIHY [Altfeld2000a]
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Table 1 (cont.): Best Defined HIV CTL Epitopes
HLA Protein AA Sequence Reference
A*3002 (A30) 12 C [Rammensee1999]
Y Y
F
L
V
R
A*3002 (A30) p17 76–86 RSLYNTVATLY [Goulder2001]
A*3002 (A30) RT 173–181 KQNPDIVIY [Goulder2001]
A*3002 (A30) RT 263–271 KLNWASQIY [Goulder2001]
A*3002 (A30) RT 356–365 RMRGAHTNDV [Sabbaj2003]
A*3002 (A30) Integrase 219–227 KIQNFRVYY [Sabbaj2003, Addo2002c]
A*3002 (A30) gp160 704–712 IVNRNRQGY [Goulder2001]
A*3002 (A30) gp120 310–318 HIGPGRAFY [Sabbaj2003]
A*3002 (A30) gp41 283–291 KYCWNLLQY [Goulder2001]
A*3101 (A31) 2 C [Falk1994, Rammensee1999]
R
L
V
Y
F
A*3101 (A31) gp160 770–780 RLRDLLLIVTR [Safrit1994a, Safrit1994b]
A*3201 (A32) RT 392–401 PIQKETWETW [Harrer1996b]
A*3201 (A32) gp160 419–427 RIKQIINMW [Harrer1996b]
A*3303 (A33) gp41 187–196 VFAVLSIVNR [Hossain2001]
A*3303 (A33) gp41 320–327 EVAQRAYR [Hossain2001]
A*3303 (A33) Vpu 29–37 EYRKILRQR [Addo2002b]
A*3303 (A33) Nef 133–141 TRYPLTFGW [Cao2002]
A*6801 (A68) Tat 39–49 ITKGLGISYGR [Oxenius2002]
A*6802 (A68) Protease 3–11 ITLWQRPLV [Rowland-Jones1999]
A*6802 (A68) Protease 30–38 DTVLEEWNL [Rowland-Jones1999]
A*6802 (A68) gp160 777–785 IVTRIVELL [Wilkes1999a]
A*7401 (A19) Protease 3–11 ITLWQRPLV [Rowland-Jones1999]
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Table 1 (cont.): Best Defined HIV CTL Epitopes
HLA Protein AA Sequence Reference
B*07 (B7) p24 84–92 HPVHAGPIA [Yu2002a]
B*0702 (B7) 123 C [Englehard1993, Rammensee1999]
P L
A R
R K
B*0702 (B7) p24 16–24 SPRTLNAWV [Lewinsohn1999a]
B*0702 (B7) p24 48–56 TPQDLNTML [Wilson1999a, Wilkes1999c, Jin2000,
Wilson1997]
B*0702 (B7) p24 223–231 GPGHKARVL [Goulder1999]
B*0702 (B7) Vpr 34–42 FPRIWLHGL [Altfeld2001a]
B*0702 (B7) Vif 48–57 HPRVSSEVHI [Altfeld2001a]
B*0702 (B7) gp160 298–307 RPNNNTRKSI [Safrit1994b]
B*0702 (B7) gp160 843–851 IPRRIRQGL [Wilkes1999b]
B*0702 (B7) Nef 68–77 FPVTPQVPLR [Haas1996, Maier1999]
B*0702 (B7) Nef 68–76 FPVTPQVPL [Bauer1997, Frahm2002]
B*0702 (B7) Nef 71–79 TPQVPLRPM [Goulder1999]
B*0702 (B7) Nef 77–85 RPMTYKAAL [Bauer1997]
B*0702 (B7) Nef 106–115 RQDILDLWIY [Goulder1999]
B*0702 (B7) Nef 128–137 TPGPGVRYPL [Culmann-Penciolelli1994, Haas1996]
B*0801 (B8) 23 5 C [Hill1992, Sutton1993, DiBrino1994a]
K K L
R
PR
L
B*0801 (B8) p17 24–32 GGKKKYKLK [Rowland-Jones1993, Goulder1997d]
B*0801 (B8) p17 74–82 ELRSLYNTV [Goulder1997d]
B*0801 (B8) p24 128–135 EIYKRWII [Sutton1993, Goulder1997d]
B*0801 (B8) p24 197–205 DCKTILKAL [Sutton1993]
B*0801 (B8) RT 18–26 GPKVKQWPL [Walker1989, Sutton1993]
B*0801 (B8) gp160 2–10 RVKEKYQHL [Sipsas1997]
B*0801 (B8) gp160 586–593 YLKDQQLL [Johnson1992, Shankar1996]
B*0801 (B8) Nef 13–20 WPTVRERM [Goulder1997d]
B*0801 (B8) Nef 90–97 FLKEKGGL [Culmann-Penciolelli1994, Price1997]
B*14 (B14) p15 42–50 CRAPRKKGC [Yu2002b]
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Table 1 (cont.): Best Defined HIV CTL Epitopes
HLA Protein AA Sequence Reference
B*1402 (B14) 23 5 C [DiBrino1994b]
R R L
K H
L
Y
F
B*1402 (B14) p24 166–174 DRFYKTLRA [Harrer1996b]
B*1402 (B14) gp160 584–592 ERYLKDQQL [Johnson1992]
B*1501 (B62) 2 C
Q Y [Barber1997]
L F [Barber1997]
M [Barber1997]
B*1501 (B62) p24 137–145 GLNKIVRMY [Johnson1991, Goulder1999]
B*1501 (B62) RT 260–271 LVGKLNWASQIY [Johnson1999]
B*1501 (B62) RT 309–318 ILKEPVHGVY [Johnson1991, Johnson1999]
B*1501 (B62) Nef 19–27 RMRRAEPAA [Cao2002]
B*1501 (B62) Nef 117–127 TQGYFPDWQNY [Culmann1999]
B*1503 (B72) Integrase 263–271 RKAKIIRDY [Cao2003]
B*1503 (B72) Tat 38–47 FQTKGLGISY [Novitsky2001]
B*1503 (B72) Pol 651–660 VTDSQYALGI [Sabbaj2003]
B*1503 (B72) Nef 183–191 WRFDSRLAF [Cao2002]
B*1516 (B63) 2 9 [Barber1997, Seeger1998]
T Y
S I
V
F
B*1516 (B63) gp160 375–383 SFNCGGEFF [Wilson1997, Wilson1999a]
B*1801 (B18) p24 161–170 FRDYVDRFYK [Ogg1998]
B*1801 (B18) Vif 102–111 LADQLIHLHY [Altfeld2001a]
B*1801 (B18) Nef 135–143 YPLTFGWCY [Culmann1991, Culmann-Penciolelli1994]
B*2703 (B27) p24 131–140 RRWIQLGLQK [Rowland-Jones1998, Rowland-Jones1999]
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Table 1 (cont.): Best Defined HIV CTL Epitopes
HLA Protein AA Sequence Reference
B*2705 (B27) 12 C [Jardetzky1991, Rammensee1995]
R L
F
K K
R R
G I
A
B*2705 (B27) p17 19–27 IRLRPGGKK [McKinney1999, Lewinsohn1999a]
B*2705 (B27) p24 131–140 KRWIILGLNK [Nixon1988, Buseyne1993, Goulder1997c]
B*2705 (B27) gp160 786–795 GRRGWEALKY [Lieberman1992, Lieberman1999]
B*2705 (B27) Nef 105–114 RRQDILDLWI [Goulder1997a]
B*3501 (B35) 2 C [Hill1992, Rammensee1999]
P Y
A F
V M
S L
I
B*3501 (B35) p17 36–44 WASRELERF [Goulder1997b]
B*3501 (B35) p17 124–132 NSSKVSQNY [Rowland-Jones1995]
B*3501 (B35) p24 122–130 PPIPVGDIY [Rowland-Jones1995]
B*3501 (B35) p24 122–130 NPVPVGNIY [Rowland-Jones1995]
B*3501 (B35) RT 107–115 TVLDVGDAY [Wilkes1999b, Wilson1999b]
B*3501 (B35) RT 118–127 VPLDEDFRKY [Sipsas1997, Shiga1996]
B*3501 (B35) RT 175–183 NPDIVIYQY [Sipsas1997, Shiga1996]
B*3501 (B35) RT 175–183 HPDIVIYQY [Rowland-Jones1995]
B*3501 (B35) gp160 42–52 VPVWKEATTTL [Wilkes1999b]
B*3501 (B35) gp160 78–86 DPNPQEVVL [Shiga1996]
B*3501 (B35) gp160 606–614 TAVPWNASW [Johnson1994a]
B*3501 (B35) Nef 74–81 VPLRPMTY [Culmann1991, Culmann-Penciolelli1994]
B*3701 (B37) 2 C [Falk1993]
D F
E M
L
I
B*3701 (B37) Nef 120–128 YFPDWQNYT [Culmann1991, Culmann1999]
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Table 1 (cont.): Best Defined HIV CTL Epitopes
HLA Protein AA Sequence Reference
B*3801 (B38) gp160 104–112 MHEDIISLW [Cao2002]
B*3901 (B39) 2 C [Falk1995a]
R L
H
B*3901 (B39) p24 61–69 GHQAAMQML [Kurane1999]
B*4001 (B60) 2 C [Falk1995b]
E L
B*4001 (B60) p17 92–101 IEIKDTKEAL [Altfeld2000b]
B*4001 (B60) p24 44–52 SEGATPQDL [Altfeld2000b]
B*4001 (B60) p6 33–41 KELYPLTSL [Yu2002b]
B*4001 (B60) RT 202–210 IEELRQHLL [Altfeld2000b]
B*4001 (B60) gp160 805–814 QELKNSAVSL [Altfeld2000b]
B*4001 (B60) Nef 92–100 KEKGGLEGL [Altfeld2000b]
B*4002 (B61) p17 11–19 GELDRWEKI [Sabbaj2003]
B*4002 (B61) p24 70–78 KETINEEAA [Sabbaj2003]
B*4002 (B61) p24 78–86 AEWDRVHPV [Sabbaj2003]
B*4002 (B61) Nef 92–100 KEKGGLEGL [Sabbaj2003, Altfeld2000b]
B*4002 (B61) p15 64–71 TERQANFL [Sabbaj2003]
B*42 (B42) Integrase 260–268 VPRRKAKII [Kiepiela2002]
B*4201 (B42) p24 48–56 TPQDLNTML [Goulder2000a]
B*4201 (B42) RT 271–279 YPGIKVRQL [Wilkes1999b]
B*4201 (B42) Nef 128–137 TPGPGVRYPL [Goulder1999]
B*4402 (B44) 2 C [Rammensee1999]
E F
Y
B*4402 (B44) p24 162–172 RDYVDRFYKTL [Ogg1998]
B*4402 (B44) p24 174–184 AEQASQDVKNW [Lewinsohn1999a]
B*4402 (B44) gp160 31–40 AENLWVTVYY [Borrow1997]
B*4415 (B12) p24 28–36 EEKAFSPEV [Bird2002]
B*51 (B51) Vpr 29–37 EAVRHFPRI [Cao2003]
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Table 1 (cont.): Best Defined HIV CTL Epitopes
HLA Protein AA Sequence Reference
B*5101 (B51) 2 C [Falk1995a]
A F
P I
G
B*5101 (B51) RT 42–50 EKEGKISKI [Haas1998, Haas1999]
B*5101 (B51) RT 128–135 TAFTIPSI [Sipsas1997]
B*5101 (B51) gp160 416–424 LPCRIKQII [Tomiyama1999b]
B*5201 (B52) 2 C [Rammensee1999]
I
V
Q
B*5201 (B52) p24 143–150 RMYSPTSI [Wilkes1999b, Wilson1997]
B*53 (B53) Nef 135–143 YPLTFGWCF [Kiepiela2002]
B*5301 (B53) 2 C
P L [Hill1992]
B*5301 (B53) p24 48–56 TPYDINQML [Gotch1993]
B*5301 (B53) p24 176–184 QASQEVKNW [Buseyne1996, Buseyne1997, Buseyne1999]
B*5301 (B53) Tat 2–11 EPVDPRLEPW [Addo2001]
B*5301 (B53) Nef 135–143 YPLTFGWCY [Sabbaj2003]
B*5501 (B55) 2 C [Barber1995]
P
A
B*5501 (B55) gp160 42–51 VPVWKEATTT [Shankar1996, Lieberman1999]
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Table 1 (cont.): Best Defined HIV CTL Epitopes
HLA Protein AA Sequence Reference
B*5701 (B57) 12 C [Barber1997]
A F
T W
S
K Y
B*5701 (B57) p24 15–23 ISPRTLNAW [Johnson1991, Goulder1996b]
B*5701 (B57) p24 30–40 KAFSPEVIPMF [Goulder1996b]
B*5701 (B57) p24 108–118 TSTLQEQIGWF [Goulder1996b]
B*5701 (B57) p24 176–184 QASQEVKNW [Goulder1996b]
B*5701 (B57) RT 244–252 IVLPEKDSW [van der Burg1997, Hay1999]
B*5701 (B57) Integrase 173–181 KTAVQMAVF [Goulder1996b, Hay1999]
B*5701 (B57) Vpr 30–38 AVRHFPRIW [Altfeld2001a]
B*5701 (B57) Vif 31–39 ISKKAKGWF [Altfeld2001a]
B*5701 (B57) Rev 14–23 KAVRLIKFLY [Addo2001]
B*5701 (B57) Nef 116–125 HTQGYFPDWQ [Culmann1991]
B*5701 (B57) Nef 120–128 YFPDWQNYT [Culmann1991]
B57 (B57) Nef 116–124 HTQGYFPDW [Draenert2002]
B*5703 (B57) p24 30–37 KAFSPEVI [Goulder2000b]
B*5703 (B57) p24 30–40 KAFSPEVIPMF [Goulder2000b]
B*5801 (B58) 12 C [Barber1997, Falk1995b]
A F
T W
S
K
V
I
B*5801 (B58) p24 108–117 TSTVEEQQIW [Bertoletti1998]
B*5801 (B58) p24 108–117 TSTLQEQIGW [Goulder1996b]
B*5801 (B58) RT 375–383 IAMESIVIW [Kiepiela2002]
B*5801 (B58) Rev 14–23 KAVRLIKFLY [Addo2001]
B*81 (B81) Pol 715–723 LFLDGIDKA [Addo2002a]
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Table 1 (cont.): Best Defined HIV CTL Epitopes
HLA Protein AA Sequence Reference
B*8101 (B81) p24 48–56 TPQDLNTML [Goulder2000a]
B*8101 (B81) Vpr 34–42 FPRIWLHGL [Altfeld2001a]
Cw*0102 (Cw1) 23 C [Barber1997]
A L
L
P
Cw*0102 (Cw1) p24 36–43 VIPMFSAL [Goulder1997b]
Cw*0304 (Cw10) gp41 46–54 RAIEAQQHL [Currier2002, Trocha2002]
Cw*0401 (Cw4) 2 6 C [Falk1994]
Y L
P F
F M
V
I
L
Cw*0401 (Cw4) gp160 375–383 SFNCGGEFF [Wilson1997, Johnson1993]
Cw*0501 (Cw5) Rev 67–75 SAEPVPLQL [Addo2001]
Cw*07 (Cw7) Nef 105–115 KRQEILDLWVY [Kiepiela2002]
Cw*07 (Cw7) Nef 105–115 RRQDILDLWIY [Yu2002a]
Cw*0802 (Cw8) p24 48–56 TPQDLNTML [Goulder2000a]
Cw*0802 (Cw8) Nef 83–91 AAVDLSHFL [Cao2003]
Cw*12 (Cw12) Tat 30–37 CCFHCQVC [Cao2003, Nixon1999]
Cw*15 (Cw15) gp41 46–54 RAIEAQQHL [Trocha2002]
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The HIV-1 envelope glycoproteins mediate viral attachment and release of
the viral core in susceptible target cells. A single gp160 precursor protein is pro-
cessed intracellularly to yield the native form of the envelope complex, consist-
ing of three gp120 and three gp41 molecules associated through non-covalent in-
teractions. Upon receptor and co-receptor binding to the surface subunit gp120,
conformational changes within the envelope glycoprotein complex enable the
insertion of the hydrophobic fusion peptide of the transmembrane subunit gp41
into the target membrane. Subsequent rearrangements within gp41 allow fusion
of viral and cellular membranes. These late structural alterations are targeted by
the entry inhibitor T-20 (for reviews see 13, 20, 21, 24, 46, 75).
A considerable body of mutagenesis data on structure-function relationships
within the HIV-1 gp41 ectodomain (gp41e) has been published over the years.
The value of this data-set has been increased considerably by the determination
of the structure of the gp41e core, allowing some of the mutational effects to
be interpreted and at least partially understood (9, 12, 38, 41, 68, 71). The na-
tive, pre-fusion structure of gp41e in the trimeric gp120-gp41 complex on the
virion surface prior to receptor engagement is not known, however, and the var-
ious transitional structures of gp41 during the virus-cell fusion process are still
ill-defined. Consequently, the structural and functional consequences of many
amino acid substitutions in gp41e remain unclear.
In HIV Molecular Immunology 2002. Bette T. M. Korber, Christian Brander, Barton F. Haynes,
Richard Koup, Carla Kuiken, John P. Moore, Bruce D. Walker, and David I. Watkins, editors. Pub-
lisher: Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, New
Mexico. LA-UR 03-5816. pp. 23–44.
Here, we have summarized the results of published mutagenesis studies on
gp41e (see the accompanying table). The HXB2 reference strain has been used
as a basis for numbering individual amino acid residues (Figure 1). This informa-
tion should facilitate the research of those who study the HIV-1 envelope glyco-
proteins as fusogens or vaccine antigens. In general, we have tabulated only data
for single mutants, but several publications contain information on the effects of
multiple amino acid substitutions (25, 43, 44, 49, 56, 57, 62). The table does not
include information on every naturally occurring gp41e sequence variant, as the
variation is extensive. However, a summary of natural variability in clades B and
C is presented in Figure 2. Also, the last two columns in the table present the en-
tropy scores for gp41e positions that have a defined impact on Env function, for
both the B clade and the C clade. Not surprisingly, positions identified through
mutational analysis as those where substitutions can abrogate key functions, also
tend to be highly conserved among the natural variants. The clearest example is
provided by positions where substitutions essentially eliminate cell-cell fusion
(i.e., where fusion efficiencies in syncytium assays or reporter gene assays have
been reduced to less than 3% of the wild-type value). Sites at which substitutions
can abrogate cell-cell fusion tended to be more invariant among 123 B clade se-
quences (26/44, 59%), compared to those sites where amino acid changes did not
dramatically reduce fusion (11/39, 28%, Fisher’s exact test p= 0.004). Some un-
usual gp41e variants found in neutralization-resistant isolates are also included
in the table, as are variants that arise in response to selection pressure, both in
vitro and in vivo, from the entry inhibitor T-20, which targets gp41e.
The precision with which the available data could be analyzed was some-
times limited because different viral clones, isolates and assays were used to
obtain the experimental data. We have therefore chosen to summarize quantita-
tive parameters using the grading system –, +, ++ and +++, as indicated in the
footnotes. In some cases these grades had to be deduced from the primary re-
ports, so readers are encouraged to consult the original papers for quantitative
details; we regret any errors of interpretation we may have made during this es-
timation process. Not surprisingly, perhaps, different studies sometimes yielded
conflicting results. We have recorded the conflicting data sets but shall leave it
to the readers to judge which are the more plausible.
The natural variability of residues in clade B and C isolates was analyzed
and mapped on the structure of gp41 (see Figures 2 and 3). A focus of variable
residues in clade B sequences is located in the upper part of the C-terminal helix
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centered around the highly variable leucine-glutamate-glutamine (LEQ) triplet,
indicating that this region is under selective pressure. However, it is also possible
that certain changes in residues in this region have little impact on Env function,
particularly if there is some flexibility in Env structure(s) around this region. This
relatively variable region also contains four glycosylation sites, which could be
involved in immune evasion (30). Indeed, mutations that affect glycosylation
in this region can modulate neutralization sensitivity (65). Of note is that no
CTL or antibody epitopes have been mapped to this region despite the intense
positive selection. One interpretation of this observation is that the selection
pressure is exerted indirectly on distant antibody epitopes elsewhere in gp41e
or even in gp120 (32). Another is that some neutralizing antibodies remain as
yet undiscovered in this region of gp41e. In clade C viruses the variability is
somewhat shifted towards the 2F5 epitope, compared to clade B. Furthermore,
certain residues are significantly more variable in clade C viruses compared to
clade B, and vice versa, suggesting that subtly different selection pressures may
operate on viruses from the two clades.
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gp41 start, position 512 of HXB2 gp160
|
AVGIGALFL GFLGAAGSTM GAASMTLTVQ ARQLLSGIVQ 550
QQNNLLRAIE AQQHLLQLTV WGIKQLQARI LAVERYLKDQ QLLGIWGCSG 600
KLICTTAVPW NASWSNKSLE QIWNHTTWME WDREINNYTS LIHSLIEESQ 650
NQQEKNEQEL LELDKWASLW NWFNITNWLW YIKLFIMIVG GLVGLRIVFA 700
VLSIVNRVRQ GYSPLSFQTH LPTPRGPDRP EGIEEEGGER DRDRSIRLVN 750
GSLALIWDDL RSLCLFSYHR LRDLLLIVTR IVELLGRRGW EALKYWWNLL 800
QYWSQELKNS AVSLLNATAI AVAEGTDRVI EVVQGACRAI RHIPRRIRQG 850
LERILL 856
Figure 1: The HXB2 reference strain and the numbering of positions in the gp41
sequence. Only information on the ectodomain (residue 512–684) is incorpo-
rated in subsequent analyses.
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Figure 2: Variability of gp41e. The relative entropies of residues were mapped
onto a 2D representation of the HXB2 gp41e (adapted from 29, 61). The variabil-
ity of residues in clade B isolates (left panel) and clade C isolates (right panel) is
indicated according to their entropy values. The entropy is a simple measure of
variation in each position based on a sequence alignment (33). Not surprisingly,
entropy values for each amino acid were highly correlated with the ratio of the
nonsynonymous/synonymous substitution rates, a measure which is indicative
of selective pressure, calculated using PAML (76) (Spearman’s rank correlation
tests gave z = 7.3, p = 2× 10−13 for the B clade, and z = 7.5, p = 5× 10−14
for the C clade). We used the entropy scores as our measure of variability here
because they lent themselves to testing for differences in variability between the
B clade and C clade (33). The color coding for the sites is as follows: white,
invariant (entropy score of zero); light blue, very conserved (entropy score be-
low the median, corresponding to only one observed substitution); medium blue,
variable (entropy score above the median: 2 or more observed substitutions);
dark blue, highly variable (highest 10% of entropy scores: > 0.8 for clade B and
> 0.75 for clade C). Residues that are significantly more variable in clade B than
in clade C or vice versa (p value≤ 0.03 after a Bonferroni correction for multi-
ple tests, using a Monte Carlo scheme and randomizing the B and C clade data
10,000 times) are indicated by red circles. 123 clade B sequences and 48 clade C
sequences were used for the analyses. The four glycans and the major antibody
epitopes (non-neutralizing clusters I and II and the neutralizing 2F5/4E10/z13
cluster) are also indicated, as are regions labelled “indel” where insertions and
deletions are frequently observed in natural variants.
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Figure 3: The residues with the highest 10% of entropy scores in clade B are
indicated in red on the 3D structure model of Caffrey (pdb accession number
1IF3, (8)). These residues are only indicated in one monomer. The other two
monomers are shown in grey for orientation purposes.
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WT ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ + ++
A512 V16 NL4-3 Freed90 ++ ++ ++ ++ + 0.136 0
E NL4-3 Freed90 ++ ++ ++ ++ +
V513 E NL4-3 Freed90 ++ ++ ++ ++ – 0.326 0.44
A NL4-3 Buchschacher95 ++
G NL4-3 ++
R NL4-3 ++ ++ –
G514 V NL4-3 Delahunty96 ++ ++ ++ ++ 0.628 0.594
G516 V NL4-3 Delahunty96 +++ ++ ++ ++ 0.047 0.101
A517 17 HXB2 Kowalski91 ++ ++ ++ ++ ++ ++ 0.115 0
18 HXB2 Kowalski91 –
M518 V19 ELI1 Kozak97 +++ ++ 0.985 0.658
F519 L16 NL4-3 Freed90 ++ ++ ++ ++ + 0.19 0.473
V NL4-3 Delahunty96 +++ ++ ++ ++ ++
L520 R NL4-3 Freed90 ++ ++ ++ ++ – 0.13 0.101
G521 V NL4-3 Delahunty96 + ++ ++ ++ – – 0 0
F522 V NL4-3 Delahunty96 +++ ++ ++ + 0 0.302
G BH8 Pritsker99 ++ ++ +
G524 V NL4-3 Delahunty96 +++ ++ ++ ++ + + 0.083 0.101
A525 T20 LAI Bahbouhi01 ++ ++ ++ ++ 0.115 0.202
A526 E NL4-3 Freed90 ++ + + ++ – 0 0
G527 V NL4-3 Delahunty96 +++ ++ – – 0 0
S528 T HXB2 Cao93 + + – + – + 0 0
M530 S HXB2 Cao93 ++ – – + – – 0 0
G531 V NL4-3 Delahunty96 +++ ++ ++ ++ 0 0
L537 R NL4-3 Freed90 ++ + + ++ – 0 0
V539 E NL4-3 Freed90 ++ ++ ++ ++ + 0.083 0.334
Q540 L NL4-3 Freed90 ++ + + ++ – 0 0
R542 e in heptad-repeat G NL4-3 Freed90 ++ ++ ++ ++ + 0 0.101
Q543 f in heptad-repeat H PI Wei02, Kilby02 ++ 0.811 0.202
R ++
P543 L28 MN Park00 ++
L544 g in heptad-repeat S22 PI Fikkert02 ++ 0.094 0.234
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L545 a in heptad-repeat F21 JR-FL Sanders02 – + 0.047 0
N21 JR-FL ++ +
P21 JR-FL ++ +
G21 JR-FL ++ +
G547 c in heptad-repeat S22 NL4-3 Rimsky98 ++ 0 0.101
D22 NL4-3 ++
D22 PI Baldwin03 ++
V22 PI Poveda02 ++
D22 PI Wei02 ++
I548 d in heptad-repeat A HXB2 Cao93 ++ ++ + +++ ++ + ++ 0 0.101
T22 NL4-3 Rimsky98 ++
K22 PI Baldwin03 ++
V22 PI Wei02, Kilby02 ++
V21 JR-FL Sanders02 ++ +
L21 JR-FL ++ +
H21 JR-FL ++ +
N21 JR-FL ++ +
S21 JR-FL ++ +
G21 JR-FL ++ +
R21 JR-FL ++ +
V549 e in heptad-repeat M22 NL4-3 Rimsky98 ++ 0.047 0
M22 PI Wei02 ++
A22 PI ++
A22 PI Baldwin03 ++
W22 PI ++
G22 PI ++
A HXB2 Lu01 ++ ++ ++ ++ ++
Q551 g in heptad-repeat A HXB2 Lu01, Follis02 ++ ++ ++ ++ ++ ++ 0 0
Q552 a in heptad-repeat L HXB2 Cao93 ++ – – – 0 0
N554 c in heptad-repeat K22 PI Fikkert02 ++ 0.047 0
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L555 d in heptad-repeat G HXB2 Cao93 ++ – – – 0 0
A BH8 Poumbourios97 ++ – ++ – ++
V21 JR-FL Sanders02 –
W21 JR-FL –
Y21 JR-FL –
S21 JR-FL –
P21 JR-FL –
L556 e in heptad-repeat P HXB2 Chen94 ++ + – – 0.047 0
R HXB2 Weng98 – – –
E HXB2 – – –
A HXB2 + – –
D HXB2 Weng00 ++ ++ ++ –
G HXB2 ++ ++ ++ –
K HXB2 – –
N HXB2 ++ ++ ++ –
A HXB2 Lu01, Follis02 ++ + ++ – + ++
P21 JR-FL Sanders02 ++ +
R557 f in heptad-repeat P21 JR-FL Sanders02 ++ + 0.237 0.334
M PI Wei02 ++
A558 g in heptad-repeat R HXB2 Weng98 – – 0 0
E HXB2 + –
C HXB2 Weng00 ++ ++ ++ –
G HXB2 ++ ++ ++ –
T HXB2 ++ ++ ++ +
P21 JR-FL Sanders02 ++ +
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I559 a in heptad-repeat P HXB2 Chen93, Chen94 ++ ++ – – ++ – – ++ 0.047 0
A BH8 Poumbourios97 ++ – ++ – ++
V21 JR-FL Sanders02 + +
F21 JR-FL – +++
N21 JR-FL – +++
P21 JR-FL ++ ++ +++ –
G21 JR-FL + ++ +++ +
R21 JR-FL + +++
P LAI/
JR-FL
Sanders03b – –
G LAI/
JR-FL
– +
L LAI/
JR-FL
++ ++
E560 b in heptad-repeat P21 JR-FL Sanders02 +++ + 0.217 0
G19 ELI1 Kozak97 +
A561 c in heptad-repeat P21 JR-FL Sanders02 +++ + 0.094 0.101
S561 A28 MN Park00 ++
Q562 d in heptad-repeat L HXB2 Cao93 ++ + – – 0 0.101
A BH8 Poumbourios97 ++ ++ + ++ – ++
P21 JR-FL Sanders02 +++ +
Q563 e in heptad-repeat A HXB2 Weng00 ++ ++ ++ ++ 0.047 0
E HXB2 ++ ++ ++ –
M HXB2 ++ ++ ++ –
G HXB2 ++ ++ ++ ++
R HXB2 ++ ++ ++ +
A HXB2 Lu01, Follis02 ++ ++ ++ ++ ++ ++
P21 JR-FL Sanders02 +++ +
R564 f in heptad-repeat P21 JR-FL Sanders02 +++ + 0.047 0
H564 N28 MN Park00 ++
C26 HXB2 Rabenstein95 ++
L565 g in heptad-repeat P HXB2 Chen94 ++ ++ + ++ ++ – 0.402 0.584
A HXB2 Lu01, Follis02 ++ ++ ++ – – +
P21 JR-FL Sanders02 ++ +
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L566 a in heptad-repeat G HXB2 Cao93 ++ + + – – + 0.047 0
P HXB2 Chen93, Chen94 ++ ++ + + ++ – – ++
A BH8 Poumbourios97 ++ – ++ – ++
V23 BH8 Earl93 ++ ++ ++ ++
V21 JR-FL Sanders02 + ++ ++ ++
I21 JR-FL – +
N21 JR-FL + ++
T21 JR-FL + ++
P21 JR-FL + ++ +
K21 JR-FL – +
Q567 b in heptad-repeat R LAI Sanders03a ++ ++ 0.177 0
L568 c in heptad-repeat A HXB2 Cao93 ++ ++ + ++ ++ ++ – + 0 0
P HXB2 Chen94 ++ ++ + + ++ –
A HXB2 Ji00 +
T569 d in heptad-repeat A BH8 Poumbourios97 ++ – ++ – ++ 0 0.101
C HXB2 Farzan98 –
S21 JR-FL Sanders02 + +
P21 JR-FL + ++ ++ +
K21 JR-FL + ++
E21 JR-FL –
V570 e in heptad-repeat R HXB2 Weng98 ++ ++ ++ – ++ – 0 0
E35 HXB2 ++ ++ ++ ++
A HXB2 Weng00 ++ ++ ++ –
D HXB2 ++ ++ ++ –
E HXB2 ++ ++ ++ –
G HXB2 ++ ++ ++ –
I HXB2 ++ ++ ++ ++
A HXB2 Lu01, Follis02 ++ ++ ++ – – +
W571 f in heptad-repeat R HXB2 Cao93 ++ ++ + ++ ++ – – – 0 0
R HXB2 Ji00 ++
C26 HXB2 Rabenstein95 ++
G572 g in heptad-repeat G HXB2 Weng98 ++ – ++ – – – 0 0
A HXB2 Lu01 ++ ++ ++ – +++
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I573 a in heptad-repeat L HXB2 Dubay92 ++ ++ ++ ++ ++ ++ ++ 0.083 0
V HXB2 ++ ++ ++ ++ ++ ++ ++ ++
A HXB2 ++ ++ ++ + ++ + ++
G HXB2 ++ ++ ++ ++ – ++ – ++
E HXB2 ++ ++ ++ ++ – ++ – ++
D HXB2 ++ ++ ++ – ++ – ++
S HXB2 ++ ++ ++ – ++ – ++
P24 HXB2 Bernstein95 –
A24 HXB2 +
D24 HXB2 –
A25 HXB3 Shugars96 ++
S25 HXB3 –
P HXB2 Chen93, Chen94 ++ +++ + + ++ – – ++
P26 HXB2,
LAI
Wild94 ++ ++ + – –
A26 HXB2,
LAI
++ ++ ++ ++ + + –
S26 HXB2,
LAI
++ ++ ++ ++ – – –
P26 HXB2 Rabenstein95 –
D26 HXB2 –
S26 HXB2 –
S 168P Liu01 –
T 168P ++ ++ ++ ++ ++ ++ +
V LAI Sanders03a ++ ++
A BH8 Poumbourios97 ++ ++ ++ ++ – ++
V HXB2 Markosyan02 ++
A HXB2 +
S HXB2 +
P HXB2 –
L21 JR-FL Sanders02 ++ +
F21 JR-FL ++ +
Y21 JR-FL ++ +
Q21 JR-FL ++ +
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I573 N21 JR-FL ++ +
(cont) T21 JR-FL ++ +
P21 JR-FL ++ +
G21 JR-FL ++ +
K21 JR-FL ++ +
K574 b in heptad-repeat R BH8 McInerney98 ++ ++ ++ ++ ++ + 0 0
L576 d in heptad-repeat P HXB2 Chen94 ++ + + ++ – 0 0
A BH8 Poumbourios97 ++ – ++ – ++
C27 HXB2 Farzan98 ++ + – +++
V21 JR-FL Sanders02 – +
F21 JR-FL – +
Y21 JR-FL – +
Q21 JR-FL – +
N21 JR-FL – +
G21 JR-FL – +
K21 JR-FL – +
Q577 e in heptad-repeat R HXB2 Weng98 ++ ++ ++ ++ – 0.047 0.173
E HXB2 ++ ++ ++ + + +
A HXB2 Weng00 ++ ++ ++ +
D HXB2 ++ ++ ++ ++
E HXB2 ++ ++ ++ +
G HXB2 ++ ++ ++ ++
M HXB2 ++ ++ ++ +
C27 HXB2 Farzan98 ++ + – +++
A HXB2 Lu01 ++ ++ ++ ++ ++
A578 f in heptad-repeat G27 HXB2 Farzan98 ++ + – +++ 0.047 0.483
R579 g in heptad-repeat G HXB2 Weng00 ++ + ++ – 0 0.101
A HXB2 Lu01 ++ + ++ – ++
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I580 a in heptad-repeat P HXB2 Chen94 ++ ++ + – ++ – 0.432 0.173
A BH8 Poumbourios97 ++ ++ ++ ++ – ++
L21 JR-FL Sanders02 ++ +
H21 JR-FL ++ +
T21 JR-FL ++ +
P21 JR-FL ++ +
G21 JR-FL ++ +
L581 b in heptad-repeat Q28 MN Park00 ++ 0 0
A582 c in heptad-repeat T28 PI Reitz88 ++ 0.094 0.101
C26 HXB2 Rabenstein95 ++
V583 d in heptad-repeat A BH8 Poumbourios97 ++ + ++ ++ – ++ 0.244 0.503
C HXB2 Farzan98 –
L21 JR-FL Sanders02 ++ +
Q21 JR-FL ++ +
N21 JR-FL ++ +
S21 JR-FL ++ +
P21 JR-FL ++ +
R21 JR-FL ++ +
K21 JR-FL ++ +
E584 e in heptad-repeat A HXB2 Cao93 ++ – – + – – 0 0
Q BH8 Maerz01 ++ ++ ++ + +
D BH8 ++ ++ +
N BH8 ++ ++ –
Y586 f in heptad repeat R HXB2 Weng98 ++ + ++ + – 0 0.101
E HXB2 ++ + ++ + –
C29 HXB2 Farzan98 –
L587 a in heptad-repeat P HXB2 Chen93, Chen94 ++ ++ ++ – ++ – – ++ 0 0
A BH8 Poumbourios97 ++ ++ ++ ++ – ++
C29 HXB2 Farzan98 –
A21 JR-FL Sanders02 – +
P21 JR-FL – +
R21 JR-FL – +
D21 JR-FL – +
E21 JR-FL – +
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K588 R BH8 McInerney98 ++ ++ ++ ++ ++ ++ 1.112 0.775
D589 L HXB2 Cao93 ++ ++ +++ + ++ + – + 0 0.101
C30 JR-FL Binley00 ++
K BH8 Maerz01 ++ ++ ++ + –
Q591 A BH8 Maerz01 ++ ++ ++ ++ ++ 0.083 0.101
K BH8 ++ ++ ++
L LAI Sanders03c +
L592 V BH8 Maerz01 ++ ++ ++ 0 0.101
A BH8 ++ ++ ++
L593 V BH8 Maerz01 ++ ++ + – 0.143 0
A BH8 ++ ++ ++ – + –
Q LAI Sanders03c +/–
I595 F31 PI Moore93 ++ 0.162 0.555
W596 M HXB2 Cao93, Cao94 ++ ++ ++ + ++ – ++ ++ ++ 0 0
Y LAI,
NL4-3
Rovinski99 ++ ++
A LAI,
NL4-3
– +
C30 JR-FL Binley00 ++
F BH8 Maerz01 ++ ++ ++ + ++ ++
H BH8 ++ ++ +
L BH8 ++ ++ ++ + +
G597 P BH8 Maerz01 ++ ++ ++ – – 0 0
A BH8 ++ ++ ++ – –
S BH8 ++ ++ ++ – –
C598 S HXB2 Dedera92a ++ – – 0 0
S23 BH8 Earl93 ++ ++ ++ ++
G HXB2 Syu91 ++ – –
A LAI Van Anken03 –
G600 A LAI,
NL4-3
Rovinski99 ++ ++ 0 0.101
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K601 R BH8 McInerney98 ++ ++ ++ ++ ++ ++ 0.218 0
R LAI,
NL4-3
Rovinski99 ++ ++
E LAI,
NL4-3
++ ++
E BH8 Merat99 ++ + ++
E BH8 Maerz01 ++ ++ ++ + ++
H BH8 ++ ++ + ++
Q BH8 ++ ++ + ++
A BH8 ++ ++ ++
C604 S HXB2 Dedera92a ++ – – 0.047 0
S23 BH8 Earl93 ++ ++ ++ ++
G HXB2 Syu91 ++ – –
A LAI Van Anken03 –
T605 C30 JR-FL,
HXB2,
DH123,
89.6,
GUN1-
wt
Binley00 ++ ++ +++ ++ + 0.177 0.173
C LAI Sanders03c ++
Y LAI ++
V608 S HXB2 Cao93 – – – 0.094 0.101
C30 JR-FL Binley00 ++
P609 C30 JR-FL Binley00 ++ 0.047 0.101
W610 C30 JR-FL Binley00 ++ 0.047 0
F BH8 Maerz01 ++ ++ ++ – –
H BH8 ++ ++ ++ – –
N611 Glycosylation site Q HXB2 Dedera92b ++ ++ ++ + ++ ++ 0.141 0
H HXB2 Lee92 ++ ++ ++ +
S NL4-3 Dash94 ++ ++ ++ ++
Q SHIV-
KB9
Johnson01 ++ ++ ++
S613 Glycosylation site
N611
A HXB2 Lee92 ++ ++ + 0.94 0.274
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N616 Glycosylation site Q HXB2 Dedera92b + ++ 0.237 0
Q23 BH8 Earl93 ++ ++ ++ ++
H HXB2 Lee92 ++ ++ ++ ++
S NL4-3 Dash94 ++ ++ ++ ++
Q BH10 Perrin98 ++ ++ +
Q SHIV-
KB9
Johnson01 ++ ++ ++
K617 R BH8 McInerney98 ++ ++ ++ ++ ++ ++ 0.348 0.658
S618 Glycosylation site
N616
A HXB2 Lee92 ++ ++ – – 0.495 0.483
N624 d in heptad-repeat
Glycosylation site
(N625 in most
isolates)
H HXB2 Lee92 ++ ++ ++ + 1.153 1.305
Q BH10 Perrin98 ++ ++ ++
Q SHIV-
KB9
Johnson01 ++ ++ ++
N625 e in heptad-repeat
Glycosylation site
Q23 BH8 Earl93 ++ ++ ++ ++ 0.047 0.274
T626 f in heptad-repeat
Glycosylation site
N624
M HXB2 Cao93 ++ – – – – – – 0.244 0.444
M28 SHIV-
HXBc2P
Si01 ++
W628 a in heptad-repeat M HXB2 Cao93 – – – – 0 0
A HXB2 Weng00 ++ – ++ –
F HXB2 ++ – ++ –
A HXB2 Wang02 ++ – ++ – +
W631 d in heptad-repeat A HXB2 Wang02 ++ – ++ – – 0 0.101
D632 e in heptad-repeat N32 BH10 Perrin98 ++ ++ – 0.591 0.287
R633 f in heptad-repeat G PI Wei02 ++ 0.55 0.451
I635 a in heptad-repeat A HXB2 Wang02 ++ – ++ – + 0.047 0.173
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N637 c in heptad-repeat
Glycosylation site
K22 PI Baldwin03 ++ 0.141 0.101
Q HXB2 Dedera92b ++ ++
Q23 BH8 Earl93 ++ ++ ++ ++
H HXB2 Lee92 ++ ++ ++ –
S NL4-3 Dash94 ++ – – –
Q BH10 Perrin98 ++ ++ ++
Q SHIV-
KB9
Johnson01 ++ ++ ++
Y638 d in heptad-repeat A HXB2 Wang02 ++ ++ ++ ++ ++ 0.13 0
T639 e in heptad-repeat
Glycosylation site
N637
V HXB2 Lee92 ++ ++ + 0.083 0.202
A HXB2 Cao93 ++ – – – –
I642 a in heptad-repeat A HXB2 Wang02 ++ – ++ – ++ 0.094 0
A HXB2 Markosyan02 ++
S HXB2 ++
H643 b in heptad-repeat Y20 LAI Bahbouhi01 ++ ++ ++ ++ 0.115 0
Y LAI Sanders03a ++
L645 d in heptad-repeat A H64333 Wang02 ++ ++ ++ ++ ++ 0 0
E647 f in heptad-repeat L HXB2 Cao93 ++ +++ + ++ ++ 0.188 0.173
S649 a in heptad-repeat A HXB2 Wang02 ++ ++ ++ ++ ++ 0.401 0
Q652 d in heptad-repeat L HXB2 Cao93 ++ ++ + ++ ++ 0.047 0.101
L HXB2 Shu00 ++
A HXB2 Wang02 ++ ++ ++ ++ ++
K655 g in heptad-repeat R33 BH8 Poumbourios95 ++ ++ ++ ++ 0.213 1.093
N656 a in heptad-repeat L HXB2 Cao93 ++ ++ + ++ ++ ++ – + 0 0
L663 2F5 epitope F HXB2 Cao93 ++ +++ ++ ++ ++ 0.047 0.101
K665 2F5 epitope R33 BH8 Poumbourios95 ++ ++ ++ ++ 0.451 0.922
W666 2F5 epitope P HXB2 Cao93 ++ ++ ++ ++ ++ 0.047 0.101
A HXB2,
NL4-3
Salzwedel99 ++ ++ ++ ++
S668 2F5 epitope N28 HXB2 Back93 ++ 0.497 0.573
L669 P HXB2 Cao93 +++ ++ + +++ ++ ++ 0.047 0
W670 A HXB2,
NL4-3
Salzwedel99 ++ ++ ++ ++ 0.047 0
N671 4E10/z13 epitope P HXB2 Cao93 ++ ++ ++ ++ ++ 0.713 0.945
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W672 4E10/z13 epitope S HXB2 Cao93 ++ ++ ++ + +++ ++ ++ 0 0
S HXB2,
NL4-3
Salzwedel99 ++ ++ ++ ++
P HXB2,
NL4-3
++ ++ ++ ++ – +
F HXB2,
NL4-3
++ ++ ++ ++ + +
F673 4E10/z13 epitope P HXB2 Cao93 ++ ++ ++ + ++ ++ 0.94 0
S34 HXB2 Stern95 ++ ++
N674 4E10/z13 epitope H HXB2 Lee92 ++ ++ ++ ++ 1.038 1.375
S NL4-3 Dash94 ++ ++ ++ ++
D28 SHIV-
HXBc2P
Si01 ++
I675 4E10/z13 epitope S HXB2 Cao93 ++ ++ + ++ ++ 0 0
M28 HXB2 Back93 ++
N677 R HXB2 Cao93 ++ ++ + ++ ++ 1.237 0.769
W678 A HXB2 Cao93 ++ ++ + ++ ++ 0 0
A HXB2,
NL4-3
Salzwedel99 ++ ++ ++ ++
W680 A HXB2,
NL4-3
Salzwedel99 ++ ++ ++ ++ 0.047 0.101
Y681 P HXB2 Cao93 ++ ++ ++ ++ 0 0
K683 R BH8 McInerney98 ++ ++ ++ ++ ++ ++ 0.375 0.325
Table footnotes:
1 Residue numbering is based on HXB2 gp160, although the amino-acids studied may be different in the isolate used. The one-letter code for amino acids is used
2PI: primary isolate
3As assessed by western blot or immunoprecipitation. –, minimal or no expression; +, reduced expression; ++, expression similar to WT; +++, increased expression
4As assessed by surface biotinylation, iodination or FACS. When soluble gp140 constructs were used, the relative secretion levels (western blot or immunoprecipi-
tation) are given. –, minimal or no expression; +, reduced expression; ++, expression similar to WT; +++, increased expression
5As assessed by western blot or immunoprecipitation in combination with densitometric measurements. –, minimal or no processing; +, reduced processing; ++,
processing similar to WT; +++, increased processing
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6As assessed by western blot or immunoprecipitation in combination with densitometric measurements. –, minimal or no association; +, reduced association; ++,
association similar to WT; +++, increased association
7As assessed by immunoprecipitation with CD4-based reagents. ++, similar to WT; +++, increased CD4 binding
8As assessed by immunoprecipitation. –, no shedding; +, reduced shedding; ++, shedding similar to WT; +++, increased shedding. Note that CD4-induced shedding
and to a lesser extent gp120 association (i.e., the reverse of shedding), when measured in laboratory isolates, might be diminished in primary isolates that can retain
gp120 more efficiently.
9As assessed by syncytium formation or reporter gene assays. –, fusion lower than 3% of WT; +, fusion between 3 and 30% of WT; ++, fusion greater than 30% of
WT
10As assessed by western blot or immunoprecipitation. –, minimal or no incorporation; +, reduced incorporation; ++, incorporation similar to WT
11As assessed by various assays (replication complementation, use of reporter genes, p24 production). –, entry lower than 3% of WT; +, entry between 3 and 30%
of WT; ++, entry greater that 30% of WT
12–, no apparent replication; +, replication with a delay of more than 2 days compared to WT; ++ replication similar to WT
13As assessed by sucrose gradient fractionation, immunoprecipitation, velocity sedimentation or FPLC, unless indicated otherwise. –, oligomerization below 25%
of WT; +, oligomerization between 25% and 50% of WT; ++, oligomerization similar to WT. No distinction between dimerization, trimerization or tetramerization
is made.
14As assessed by Blue Native-PAGE. +, trimerization similar to WT SOS gp140 (occasional trimerization); ++, slightly more trimerization than in WT; +++,
significantly more trimerization than in WT.
15As analyzed using the N34(L6)C28 or N36(L6)C34 peptide model, unless indicated otherwise. –, melting temperature (Tm) below 40◦C; +, Tm between 40◦C and
60◦C; ++, Tm between 60◦C and 80◦C; +++, Tm over 80◦C
16Analyzed in a double mutant, A512V + F519L
17Four amino-acid insertion GIPA
18Six amino-acid insertion IHRWIA
19Involved in cell line adaptation
20Identified in an isolate which is resistant to the furin inhibitor (α1-PDX)
21Analyzed in soluble SOS gp140 constructs and so also contain the A501C and T605C substitutions
22Involved in T-20 resistance
23Analyzed in soluble gp140
24Analyzed in an N-peptide/Protein A fusion protein
25Analyzed in an N-peptide/maltose binding protein (MBP) fusion protein
26Thermal stability (74) or oligomerization (53) of N-peptides analyzed in the absence of C-peptides
27Analyzed in a triple mutant L576C + Q577C + A578G
28Involved in neutralization resistance
29Analyzed in a double mutant Y586C + L587C
30Analyzed in combination with gp120 cysteine substitutions in the context of soluble gp140
31Involved in resistance to soluble CD4
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32Generates a new glycosylation site
33Analyzed in a double mutant K655R + K665R
34Analyzed in a double mutant A582T + F673S
35Data on this mutant were corrected in reference 73
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Introduction
Computational methods used in vaccine design have been changing drastically
in recent years. In classical immunological research results could be recorded by
pen and pencil or in a spreadsheet, but new experimental high-throughput meth-
ods such as sequencing, DNA arrays, and proteomics have generated a wealth of
data that are not efficiently handled and mined by these approaches. This has fu-
eled the rapid growth of the field of Immunological Bioinformatics (or Immuno-
informatics) that addresses how to handle these large amounts of data in the field
of immunology and vaccine design. Many of the methods have been made avail-
able on the Internet and can be used by experimental researchers without expert
knowledge of bioinformatics. This review attempts to give an overview over the
methods currently available and to point out the strengths and weaknesses of the
different methods.
Immunological processes described by prediction servers
Only a small fraction of the possible peptides that can be generated from proteins
of pathogenic organisms actually generate an immune response. In order to be
presented to CD8+ T cells a precursor peptide must be generated by the protea-
some. This peptide may be trimmed at the N-terminal by other peptidases in the
cytosol (Levy et al., 2002). It must then bind to the transporter associated with
antigen processing (TAP) in order to be translocated to the endoplasmatic reticu-
lum (ER). Here it can be trimmed N-terminally by the aminopeptidase associated
In HIV Molecular Immunology 2002. Bette T. M. Korber, Christian Brander, Barton F. Haynes,
Richard Koup, Carla Kuiken, John P. Moore, Bruce D. Walker, and David I. Watkins, editors. Pub-
lisher: Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, New
Mexico. LA-UR 03-5816. pp. 45–51.
with antigen processing (ERAAP) while it binds to the major histocompatibility
complex class I (MHC I) molecule (Serwold, 2002). Hereafter it is transported
to the cell surface. Only half the peptides presented on the cell surface are im-
munogenic probably due to the limited size of the T cell receptor (TCR) reper-
toire. The most selective step is binding to the MHC I molecule, since only 1/200
binds with an affinity strong enough to generate an immune response (Yewdell,
1999). For comparison the selectivity of TAP binding is reported to be 1/7 (Uebel
et al., 1997). This all happens in competition with other peptides so in order for
a peptide to be immunogenic (immunodominant) it must go through the above
described process more efficiently than other peptides produced in a given cell
(Reviewed by Yewdell, 1999).
Whereas the MHC I molecule mainly samples peptides from the cytosol,
the MHC II molecule presents peptides from endocytosed proteins. Unfolded
polypeptides bind to MHC II in the endocytic organelles (Reviewed by Castllino,
1997). Both MHC I and MHC II are highly polymorphic, and the specificity of
the alleles are often very different. Different individuals will thus typically react
to a different set of peptides from a pathogen.
The specificity of some of the processes involved in antigen presentation
can be predicted from the amino acid sequence. This can for example be used
to select epitopes for use in a vaccine, and help to understand the role of the
immune system in infectious diseases, autoimmune diseases and cancers. Below
we describe a number of resources available on the web that can perform such
predictions.
Databases of MHC binding peptides
Several databases of MHC binding peptides now exist on the web (Table 1).
SYFPEITHI: The SYFPEITHI database contains information on peptide se-
quences, anchor positions, MHC specificity, source proteins, source organisms,
and publication references. The database comprise approximately 3500 peptide
sequences known to bind class I and class II MHC molecules and is based on
previous publications on T-cell epitopes and MHC ligands from many species
(Rammensee, 1999).
MHCPEP: The other major database of MHC binding peptides, MHCPEP,
(Brusic, 1997) comprises over 13,000 peptide sequences known to bind MHC
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molecules. Entries were compiled from published reports as well as from direct
submissions of experimental data. Each entry contains the peptide sequence,
its MHC specificity and, when available, experimental method, observed activ-
ity, binding affinity, source protein, anchor positions, and publication references.
Unfortunately the database has since June 1998 been static. The database can be
downloaded as an ASCII file.
JenPep: The JenPep database is a newer database that contains quantitative bind-
ing data of peptides to MHC and TAP, as well as T cell epitopes (Blythe, 2001).
The database contains more than 8000 entries .
FIMM: The database by Schoenbach &Brusic is a functional database of molec-
ular immunology. The database contains 571 antigens and 1591 peptides (Schon-
bach et al., 2002)
MHCBN: (Bhasin, 2002) is a database of MHC binding and non-binding pep-
tides containing 14,816 binders, 1,782 non-binders and 5,456 T-cell epitope en-
tries.
HLA Ligand/Motif database: This site’s database can be searched by defin-
ing allele and specificity, amino acid pattern, ligand/motif in sequence of amino
acids, author’s last name, or advanced search with more criteria.
HIV Molecular Immunology database: The HIVMolecular Immunology Data-
base is an annotated, searchable collection of HIV-1 cytotoxic and helper T-cell
epitopes and antibody binding sites. The goal of the database is to provide a
comprehensive listing of defined HIV epitopes (Korber et al., 2001).
EPIMHC: MHC ligand database that can be searched based on sequence, length,
class, species, and on whether a ligand is an epitope or not.
NIH will over the next five to seven years fund an “Immune Epitope Database
and Analysis Program”1 to design, develop, populate, and maintain a publicly
accessible, comprehensive Immune Epitope Database containing linear and con-
formational antibody epitopes and T cell epitopes. This database may eventually
incorporate most of the data from the above described databases.
Prediction of MHC binding
Several peptide-MHC binding prediction servers exist on the web (Table 2). As
indicated in the table some of the web based methods also allow prediction of
binding to Class II molecules. Most methods available on the web for predicting
1www.niaid.nih.gov/contract/archive/rfp0331.pdf
MHC-peptide binding are matrix methods. Parameters are often derived from
pool sequencing of ligands. Matrices or hidden Markov models may however
also be derived from a set of ligand sequences. In these methods the amino acid
on each position in the motif gives an independent contribution to the prediction
score. Neural networks are able to make more accurate predictions if correlations
between positions exist, and there are enough data to model them. This has the
potential advantage that it can take correlations between different positions in
the binding motif into account.
BIMAS: The BIMAS method was developed by Parker et al., (1994). The
method is based on coefficient tables deduced from the published literature. For
HLA-A2, peptide binding data were combined together to generate a table con-
taining 180 coefficients (20 amino acids x 9 positions), each of which repre-
sents the contribution of one particular amino acid residue at a specified position
within the peptide (Parker et al., 1994).
SYFPEITHI: The SYFPEITHI prediction is based on published motifs (pool
sequencing, natural ligands) and takes into consideration the amino acids in the
anchor and auxiliary anchor positions, as well as other frequent amino acids.
The score is calculated according to the following rules: The amino acids of a
certain peptide are given a specific value depending on whether they are anchor,
auxiliary anchor or preferred residue. Ideal anchors will be given 10 points,
unusual anchors 6–8 points, auxiliary anchors 4–6 and preferred residues 1–4
points. Amino acids that are regarded as having a negative effect on the binding
ability are given values between −1 and −3 (Rammensee, 1997; 1999). On the
SYFPEITHI web site predictions can be made for 5 different MHC II alleles in
addition to a number of Class I alleles.
PREDEPP: In this method the peptide structure in the MHC groove is used as
a template upon which peptide candidates are threaded, and their compatibility
to bind is evaluated by statistical pairwise potentials. This method has the ad-
vantage that it does not require experimental testing of peptide binding, and can
thus be used for alleles where only limited data are available (Schueler-Furman
et al., 2000).
Epipredict: Method using synthetic combinatorial peptide libraries to describe
peptide-HLA class II interaction in a quantitative way. The binding contribution
of every amino acid side chain in a class II-ligand is described by allele-specific
two-dimensional databases (Jung et al., 2001).
Predict: The Predict method use neural networks to predict Class I, II and TAP
binding (Yu et al., 2002).
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Propred: The Propred method (Singh, 2001) is based on the matrices published
by Sturniolo (1999), and is an implementation and extension of the TEPITOPE
program. (Hammer, 1995; Raddrizzani, 2000)). Besides differences that can
be attributed to round off errors we have in our tests not seen any differences
between the two implementations.
MHCPred: Prediction of binding to 11 different HLA class I alleles using a
three-dimensional quantitative structure-activity relationship method (Doytchi-
nova et al., 2002).
NetMHC: Prediction of HLA-A2 binding using neural networks. This method
predicts quantitatively the binding affinity, and is different from methods per-
forming classification only (binding versus non-binding according to a thresh-
old). The method has been trained using quantitative binding data generated
by the same assay (Buus et al., 2003), and some predicted binders have been
tested for their ability to induce a CTL response in mice and be recognized by
CD8+ T-cells from HLA-A2 HIV-1 positive patients (Corbet et al., 2003). Two
well-known prediction methods, TEPITOPE and EpiMatrix (Meister 1995; De
Groot, 1997) that are not available through the web are listed in Table 3. TEPI-
TOPE is popular since it allows prediction of peptides to many different Class II
molecules.
Prediction of proteasomal cleavage sites
The C terminal of MHC class I ligands must most likely be cleaved by the pro-
teasome. The proteasome usually generates precursors of MHC ligands with an
extension at the N-termini. These precursors can be trimmed at the N-terminal
in the ER. The existence of proteasome cleavage sites within epitopes need not
abrogate the immune response for such epitopes. They may, however, reduce
the availability, and thereby the immunogenecity of a given peptide (Yewdell,
1999). The proteasome thus plays an important role in selecting which peptides
are presented to CD8+ T cells. In vertebrates stimulation with IFN-γ leads to
the replacement of three subunits of the constitutive proteasome to form the so-
called immunoproteasome which has a different specificity (reviewed by Uebel,
1999). Different methods for predicting proteasomal cleavage sites exist on the
web (Table 4).
PAProC: Prediction Algorithm for Proteasomal Cleavages is a prediction tool
for cleavages by human and yeast proteasomes, based on experimental cleavage
data. (Kuttler, 2000; Nussbaum, 2001). An updated version of the PAProC
program based on in vitro immunoproteasome cleavage data (Toes, 2001) is also
in the making according to the PAProC homepage.
FRAGPREDICT comprises two different algorithms. One that aims at predict-
ing potential proteasomal cleavage, based on a statistical analysis of cleavage-
determining amino acid motifs present around the scissile bond (Holzhütter et
al., 1999, 2000). The second algorithm, which uses the results of the cleavage
site analysis as an input, provides predictions of major proteolytic fragments.
NetChop: (Kesmir, 2002) is a method based on neural networks that have been
trained on different data sets. C Kesmir suggests to use the C-term 2.0 network
which was trained on C-terminal cleavage sites of 1,110 publicly available MHC
class I ligands for predicting the boundaries of CTL. The specificity of this net-
work may resemble the specificity of the immunoproteasome.
Margalit’s group have also recently made their proteasomal cleavage site
propensities (Altuvia and Margalit, 2000) available on the net (bioinfo.md.
huji.ac.il/marg/cleavage/index.html).
Combined predictions
A number of sites providing combined predictions have been developed recently.
The MAPPP server (Table 2) allows the user to make an open reading frame
(ORF) search combined with MHC binding and proteasomal cleavage site pre-
dictions, and Raghava have a prediction server2 which implements matrices for
47 MHC Class-I alleles and proteasomal and immunoproteasomal models. The
NetMHC server allows combination of HLA-A2 and NetChop predictions.
MHC sequence databases
A number of databases containing sequences of proteins of immunological in-
terest exist on the web (Table 5).
HIG: The HLA Sequence Database currently contains 1,596 allele sequences.
To date (October 2002), some 263 HLA-A, 501 HLA-B, 125 HLA-C, 6 HLA-E,
1 HLA-F and 15 HLA-G class I alleles have been named. A total of 3 HLA-
DRA, 397 HLA-DRB, 22 HLA-DQA1, 53 HLA-DQB1, 20 HLA-DPA1, 100
HLA-DPB1, 4 HLA-DMA, 6 HLA-DMB, 8 HLA-DOA and 8 HLA-DOB class
II sequences have also been assigned. There are also 6 TAP1, 4 TAP2 and 54
2www.imtech.res.in/raghava/propred1/index.html
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MICA sequences. The HLA Sequence Database also contains the comprehen-
sive nomenclature for factors of the HLA system (listings for HLA class I and
class II allele names) which is very helpful since the HLA nomenclature is very
complicated and cumbersome.
IMGT: IMGT, the international ImMunoGeneTics project, is a collection of
databases specializing in Immunoglobulins, T cell receptors and the Major His-
tocompatibility Complex (MHC) of all vertebrate species. The IMGT project
was established in 1989 by the Université Montpellier II and the CNRS (Mont-
pellier, France) and works in close collaboration with the EBI.
ASHI: The American Society for Histocompatibility and Immunogenetics (ASHI)
hosts databases of gene and allele frequencies (www.ashi-hla.org/).
MHCDB: “Registered users only” database of MHC sequences. This is an
ACeDB-style database holding the Human Major Histocompatibility Database.
It is largely superseded by 6ace which is ACeDB-style database of human chro-
mosome 6 from the Sanger Centre.
Other sites
A number of other databases relevant to immunology and vaccine design are
listed in Table 6. Table 7 contains a compilation of lists of links. As stated in
Table 7 we will also make an HTML version of this article available on the net.
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Table 1: Databases of MHC binding peptides
Name Principal Investigator URL Description
SYFPEITHI Rammensee syfpeithi.bmi-heidelberg.com/scripts/MHCServer.dll/home.htm Database and prediction server for
peptides that bind MHC molecules.
MHCPEP Brusic, Harrison wehih.wehi.edu.au/mhcpep Database of MHC binding peptides
JenPep Flower www.jenner.ac.uk/JenPep Database of MHC and TAP binding
peptides
FIMM Schoenbach & Brusic sdmc.krdl.org.sg:8080/fimm Database of functional molecular
immunology/binding prediction
MHCBN Raghava www.imtech.res.in/raghava/mhcbn Tools for subunit vaccine design
HLA Ligand/Motif Database Hildebrand hlaligand.ouhsc.edu Ligand database/prediction
HIV Molecular Immunology Korber hiv-web.lanl.gov/content/immunology/ HIV CTL epitopes
EPIMHC Reinherz mif.dfci.harvard.edu/Tools/db_query_epimhc.html Peptides that bind to MHC
molecules
Table 2: HLA Peptide Binding Predictions
Name URL Description
BIMAS bimas.dcrt.nih.gov/molbio/hla_bind Prediction of MHC class I binding using matrices
SYFPEITHI syfpeithi.bmi-heidelberg.com/Scripts/MHCServer.dll/EpPredict.htm Prediction of Class I and II binding
PREDEPP bioinfo.md.huji.ac.il/marg/Teppred/mhc-bind MHC Class I epitope prediction
Epipredict www.epipredict.de/index.html Prediction of HLA class II restricted binding
Predict http://sdmc.krdl.org.sg:8080/predict-demo Prediction of Class I, II and TAP binding
Propred www.imtech.res.in/raghava/propred MHC class II prediction
MHCPred www.jenner.ac.uk/MHCPred HLA class I predictions
NetMHC www.cbs.dtu.dk/services/NetMHC Prediction of HLA-A2 binding using Neural
networks
MAPPP www.mpiib-berlin.mpg.de/MAPPP/expertquery.html Combined ORF, MHC binding and proteasomal
cleavage Registration needed for expert mode
Table 3: Non web MHC binding predictions
Name URL Description
TEPITOPE www.vaccinome.com PC Program for Class II predictions can be
downloaded
EpiMatrix epivax.com/epimatrix.html Commercial epitope prediction
50
DEC 2002
Web-based Tools for Vaccine Design Web-based Tools for Vaccine Design
R
eview
s
Table 4: Prediction of proteasomal cleavage sites
Name URL Description
Paproc paproc.de A matrix based method for prediction of
protasomal cleavage
FRAGPREDICT www.mpiib-berlin.mpg.de/MAPPP/cleavage.html Proteolytic fragment predicter
NetChop www.cbs.dtu.dk/services/NetChop A neural network based method for prediction of
proteasomal cleavage
Table 5: MHC sequence databases
Name URL Description
HIG www.anthonynolan.org.uk/HIG HLA sequence database
IMGT www.ebi.ac.uk/imgt Sequences of MHC, TCR and immunoglobulin
molecules
ASHI www.ashi-hla.org Sequences and Gene and Haplotype frequencies
MHCDB www.hgmp.mrc.ac.uk/Registered/Option/mhcdb.html Registered users only database of MHC
sequences
Table 6: Other sites
Name URL Description
HIV Molecular
Immunology database
hiv-web.lanl.gov/content/immunology HIV immunology
School of Crystallogra
phy, Birkbeck College,
University of London
www.cryst.bbk.ac.uk/pps97/assignments/projects/coadwell/MHCSTFU1.HTM Structure and Function of the Major
Histocompatibility Complex (MHC) Proteins
MHC-Peptide
Interaction Database
(MPID)
surya.bic.nus.edu.sg/mpid/ Structural information and characterization of
MHC peptide interaction
ELF hiv-web.lanl.gov/content/hiv-db/ALABAMA/epitope_analyzer.html Epitope Location Finder
ASHI www.ashi-hla.org The American Society for Histocompatibility and
Immunogenetics
Table 7: Links to lists of links
Name URL Description
Syfpeithi http://syfpeithi.bmi-heidelberg.com/Scripts/MHCServer.dll/Info.htm Rammensee’s links
FIMM http://sdmc.krdl.org.sg:8080/fimm Brusic’s links
CBS www.cbs.dtu.dk/courses/27485.imm/links.html Our links
HLA-RELATED LINKS home.att.net/ dorak/hla/linkhla.html Dorak’s links
This article www.cbs.dtu.dk/researchgroups/immunology/webreview.html The present article in HTML format
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II-A Summary
Part II includes tables, maps, and associated references of HIV-specific CTL
epitopes arranged sequentially according to the location of the proteins in the
HIV-1 genome. We attempted to make this section as comprehensive as possi-
ble, requiring that the epitope be contained within a defined region of a maxi-
mum of 30 amino acids, but not that the optimal boundaries be defined. Stud-
ies that were based on the analysis of whole proteins are described at the end
of each protein section. The same epitope can have multiple entries, and each
entry represents a single publication in this section of the database. For more
recent updates and useful searching capabilities, please see our web site: http:
//hiv-web.lanl.gov/immunology. For a concise listing of the best de-
fined CTL epitopes, see the summary by Christian Brander and Philip Goulder
on page 3 in Part I of this compendium. CTL protein reactions with no well-
defined epitopes are listed at the end of each protein section.
Recent studies utilize multiple functions attributed to T cells to define re-
sponses, and the simple distinctions of cytotoxic T-cell and helper T-cells have
become blurred as more is learned about the range of responses triggered in
CD4 and CD8 positive T-cells responding to antigenic stimulus. When adding
the most recent studies, we have tried to place T cell responses in a reasonable
manner into our traditional helper T cell and CTL sections, and to specify the
assay used to measure the response in each study.
II-A-1 CTL Epitope Tables
Each CTL reference has a six part basic entry:
HXB2 Location: The viral strain HXB2 (GenBank Accession Number K03455)
is used as a reference strain throughout this publication. The position of
the defined epitope location relative to the sequence of the HXB2 pro-
tein is indicated. The numbering in this table corresponds to the protein
maps. Because of HIV-1 variation the epitope may not actually be present
in HXB2, rather the position in HXB2 indicates the position aligned to the
epitope. HXB2 was selected as the reference strain because so many stud-
ies use HXB2, and because crystal structures for HXB2-related proteins
are often available. The precise positions of an epitope on the HXB2 refer-
ence strain can be readily obtained using the interactive position locator at
our web site: http://hiv-web.lanl.gov/content/hiv-db/
LOCATE_SEQ/locate.html.
Author Location: The amino acid positions of the epitope boundaries and the
reference sequence are listed as given in the primary publication. Fre-
quently, these positions as published are imprecise, and do not truly cor-
respond to the numbering of the sequence, but they provide a reasonable
guide to the peptide’s approximate location in the protein. Also, in many
cases the reference sequence identification was not provided, and in such
cases it is not possible to use these numbers to specify precise locations.
Epitope Sequence: The amino acid sequence of the epitope of interest as de-
fined in the reference, based on the reference strain used in the study defin-
ing the epitope. On occasions when only the position numbers and not the
actual peptide sequence was specified in the original publication, we tried
to fill in the peptide sequence based on the position numbers and refer-
ence strain. If the sequences were numbered inaccurately by the primary
authors, or if we made a mistake in this process, we may have misrepre-
sented the binding site’s amino acid sequence. Because of this uncertainty,
epitopes that were not explicitly written in the primary publication, that we
determined by looking up the reference strain and the numbered location,
are followed by a question mark in the table.
Immunogen: The original stimulus of the CTL response. Often this is an HIV-1
infection. If a vaccine was used as the original antigenic stimulation, not a
natural infection, this is noted on a separate line, and additional informa-
tion about the vaccine antigen is provided as available.
Species(HLA): The species responding and HLA or MHC specificity of the
epitope.
Reference: The primary reference (sometimes two or more directly related stud-
ies are included). Details for some of the earlier references are in Part V.
Following the entry for a given CTL epitope are brief comments explaining the
context in which the epitope was studied and what was learned about the epitope
in a given study.
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II-A-2 HIV Protein Epitope Maps
All HIV CTL epitopes mapped to within a region of 21 amino acids or less are
indicated on the HIV protein epitope maps. The location and HLA restriction
elements of CTL epitopes are indicated on protein sequences of HXB2. These
maps are meant to provide the relative location of defined epitopes on a given
protein, but the HXB2 sequence may not actually carry the epitope of interest, as
it may vary relative to the sequence for which the epitope was defined. Epitopes
with identical boundaries and HLA fields are included in the maps only once.
If one laboratory determines HLA presenting molecules at the serotype level
(example: A2) and another at the genotype level (example: A*0201) both will
be included in the map. MHC specificities are indicative of the host species;
when no MHC presenting molecule is defined, the host species is noted.
II-A-3 Alignments
To conserve space, no epitope alignments are provided in this book, but they can
be generated using the CTL epitope search tool at http://hiv-web.lanl.
gov/immunology. All epitopes are aligned to the HXB2 sequence, with the
sequence used to define the epitope indicated directly above it. Sequences are
sorted by their subtype and country of origin.
The master alignment files from which the epitope alignments were cre-
ated are available at our web site (http://hiv-web.lanl.gov/ALIGN_
CURRENT/ALIGN-INDEX.html). The alignments were modified in some
cases to optimize the alignment relative to the defined epitope and minimize in-
sertions and deletions; epitope alignments are generated by anchoring on the
C-terminal residue. A dash indicates identity to the consensus sequence, and a
period indicates an insertion made to maintain the alignment. Stop codons are
indicated with a $, and frameshifts by a #, or ambiguous codons (nucleotide
was r, y, or n) by an x; they are inserted to maintain the alignments. In con-
sensus sequences an upper case letter indicates the amino acid was present in
all sequences, a lower case letter indicates the amino acid was present in most
sequences in a given position, and a question mark indicates two or more amino
acids were represented with equal frequency.
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All HIV CTL epitopes arranged by protein position. The table entries are sorted in a nested way—first by protein, then by HXB2 start location and finally by HLA.
CTL reactions against proteins with undefined epitopes are listed at the end of the protein which stimulated the response.
II-B-1 p17 CTL Epitopes
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
p17 (11–19) GELDRWEKI HIV-1 infection human (B*4002) Sabbaj2002b
• Epitope name: Gag-GI9
• This study monitored epitope responses in HIV-1 infected minority women living in the United States
• 24 epitopes were described – 8 were novel, 8 used new restricting elements but were previously defined epitopes, and 8 were previously described
• Serial peptide truncations were used to define optimal epitopes for CTL cell lines isolated from 12 individuals, assayed by a Cr-release
• This epitope was newly defined in this study
• Patient 01RCH46 was Hispanic, on HAART, and had a viral load of 21000 and CD4 count of 623 – she also recognized KETINEEAA p24(70-78), HLA
B*4002, and TAFTIPSI, RT(128-135), HLA A*0217
• Among HIV+ individuals who carried HLA B40, 2/5 (40%) recognized this epitope
p17 (18–26) p17 (18–26 IIIB) KIRLRPGGK human (A*0301) Brander2001
• C. Brander notes that this is an A*0301 epitope
p17 (18–26) p17 (18–26 SF2) KIRLRPGGK HIV-1 infection human (A*0301) Altfeld2001a
• HIV+ individual AC-06 was tested for reactive overlapping peptides spanning all HIV-1 proteins in an ELISPOT and was found to react with 12 peptides
from 7 proteins, suggesting that the breadth of CTL responses are underestimated if accessory proteins are not included in the study
• The reactive peptide p17 gag WEKIRLRPGGKKKYK contained two A*0301-restricted epitopes, KIRLRPGGK and RLRPGGKKK A*0301
p17 (18–26) p17 (18–26 IIIB) KIRLRPGGK HIV-1 infection human (A3) Wilson1996
• Epitope defined in the context of the Pediatric AIDS Foundation ARIEL Project, a mother-infant HIV transmission study
• KIRLRPGGR and RIRLRPGGR, naturally occurring variants, were found in mother, and are escape mutants
p17 (18–26) p17 (18–26) KIRLRPGGK in vitro stimulation human (A3) Zarling1999
• This study compares the ability of macrophages and dendritic cells to stimulate primary responses in CD8+ lymphocytes isolated from HLA-appropriate
HIV-uninfected donors using peptide-pulsed APC – the dendritic cells performed better as APC for the stimulation of primary responses
• Strong CTL responses were elicited by the epitopes DRFYKTLRA and GEIYKRWII when presented by either immature or mature dendritic cells –
macrophages were not able to prime a CTL response against DRFYKTLRA
• A weak response to KLTPLCVSL was stimulated using macrophages as the APC
• No detectable response was observed for the following previously-defined HIV epitopes: KIRLRPGGK, ILKEPVHGV, IRLRPGGK, GPKVKQWPL
p17 (18–26) Gag (18–26) KIRLRPGGK HIV-1 infection human (A3) Brodie1999
• The ability of CTL effector cells was studied by expanding autologous HIV-1 Gag-specific CTL in vitro, and adoptive transfer
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HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
• The transferred CTLs migrated to the lymph nodes and transiently reduced circulating productively-infected CD4+ T cells, showing that CTL move to
appropriate target sites and mediate anti-viral effects
p17 (18–26) (18–26) KIRLRPGGK HIV-1 infection human (A3) Brodie2000
• Study tracks and quantifies in vivo migration of neo-marked CD8 HIV-specific CTL
• Adoptively transferred gene-marked HIV-specific CTL homed to specific lymph node sites, colocalizing within the parafollicular regions of the lymph node
adjacent to cells expressing HIV tat-fusion transcripts, indicative of viral replication
• The CTL clones expressed CCR5 and localized among HIV-1 infected cells expressing MIP-1alpha and MIP-1beta, CC-chemokines produced at sites of
viral replication, suggesting a possible homing mechanism
• This study provides a methodology for tracking and studying antigen specific CTL in vivo
p17 (18–26) p17 (18–26 IIIB) KIRLRPGGK HIV-1 infection SJL/J HLA transgenic
mice (A3)
Wilson1999a
• This study describes maternal CTL responses in the context of mother-to-infant transmission
• Detection of CTL escape mutants in the mother was associated with transmission, but the CTL-susceptible forms of the virus tended to be found in infected
infants
• KIRLRPGGR and RIRLRPGGR were escape mutants
• This epitope was recognized and many escape mutants were detected in an HLA A3 transmitting mother, and was recognized but invariant in an HLA A3
non-transmitting mother
p17 (18–26) p17 (18–26 IIIB) KIRLRPGGK HIV-1 infection human (A3) Goulder1997e, Goulder1997a
• Identical twin hemophiliac brothers were both infected with the same batch of factor VIII. One had a response to this epitope, the other did not.
[Goulder1997e] is a review of immune escape that summarizes this study.
p17 (18–26) p17 (subtype B) KIRLRPGGK HIV-1 exposed seronegative human (A3) Kaul2000
• 11/16 heavily HIV exposed but persistently seronegative sex-workers in Nairobi had HIV-specific CD8 gamma-IFN responses in the cervix – systemic
CD8+ T cell responses tended to be to the same epitopes but at generally lower levels than cervical CD8+ T cell responses
• Low risk individuals did not have such CD8+ cells
• CD8+ T cell epitopes: DTVLEDINL (3 individuals), SLYNVATL (4 individuals), LSPRTLNAW (3 individuals) and YPLTFGWCF (4 individuals) were
most commonly recognized by the HIV-resistant women
p17 (18–26) p17 (SF2) KIRLRPGGK HIV-1 infection human (A3) Goulder2000a
• WEKIRLRPGGKKKYKLK was the target of the dominant response in Caucasoids (38%) more frequently than non-Caucasoids (12%) – 7/10 that had a
dominant response to this epitope were A3, and 5/7 targeted RLRPGGKKK while 2/7 targeted KIRLRPGGK
• Three peptides GSEELRSLYNTVATL (p17 residues 71-85), SALSEGATPQDLNTMLNTVG (p24 41-60), and WEKIRLRPGGKKKYKLK(p17 16-30)
contained the dominant Gag-specific epitope in 31 out of 44 B-clade infected individuals from Boston who showed Gag-CTL responses
• Five peptides RLRPGGKKHYMIKHLVW (p17 20-36), ELRSLYNTVATLYCV (p17Gag 74-88), SALSEGATPQDLNTMLNTVG (p24 41-60),
FRDYVDRFFKTLRAEQA (p24 161-177), and SILDIKQGKEPFRDY (p24 149-164) contained dominant Gag-specific epitopes in 32 out of 37 C-clade
infected subjects from South Africa
p17 (18–26) p17 KIRLRPGGK HIV-1 infection human (A3) Seth2001
• CTL responses were studied by tetramer staining in 41 patients with combination therapy – activated CD8+ T-cells decline as the viral load drops in
response to therapy, but the overall level of antigen-specific cells capable of differentiating into effectors stays constant and new epitopes may be recognized
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p17 (18–26) p17 (18–26 SF2) KIRLRPGGK HIV-1 infection human (A3) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-A3+ individuals that had a CTL response to this epitope broken down by group: 3/7 group 1, 0/4 group 2, and 2/2 group 3
p17 (18–26) p17 (18–26) KIRLRPGGK HIV-1 infection, HIV-1 exposed
seronegative
human (A3) Kaul2001a
• KIRLRPGGK is cross-reactive for A, B, and D clades
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
p17 (18–26) p17 (JRCSF) KIRLRPGGK HIV-1 infection human (A3) Severino2000
• Primary HLA-A3+ CD4+ and HLA-mismatched lymphocytes from uninfected donors were infected with JRCSF after isolation then cocultured with the
A3-restricted CTL clone 11504/A7 specific for KIRLRPGGK, and viral inhibition was MHC-restricted
• Primary monocytes and monocyte-derived DC were generated from the same donors, replication of HIV-1 in these cell types was less efficient than in
lymphocytes and could also be inhibited by MHC-restricted CTL
• DC-lymphocyte cluster cultures allowed vigorous viral replication and MHC-restricted CTL viral inhibition was blunted or lost depending on the ratio of
DC to CD4+ lymphocyte in the culture
p17 (18–26) p17 (18–26) KIRLRPGGK HIV-1 infection human (A3) Day2001
• The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7 was
studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
• 2 to 17 epitopes were recognized in a given individual, A2-restricted CTL response tended to be narrow and never dominated the response, and 25/27
epitopes were targeted by at least one person
• All patients recognized at least 1 A3 epitope, up to 8 A3 epitopes, but none was clearly dominant
p17 (18–26) p17 KIRLRPGGK HIV-1 infection human (A3) Ostrowski2000
• The role of CD4+ T-cell help in expansion of virus-specific memory CTL was studied through co-culture ex vivo
• Optimal expansion of HIV-1-specific memory CTL depended on CD4+ T cell help in 9 of 10 patients – CD40 ligand trimer (CD40LT) could enhance CTL
in the absence of CD4+ T cell help to a variable degree in most of patients
• Those CTL that didn’t respond to CD40LT could expand with IL2 present, and IL15 produced by dendritic cells also contributes
• The T-helper epitope used for CD4+ T cell stimulation was the universal tetanus helper epitope TET830-843 (QYIKANSKFIGITE)
p17 (18–26) Gag (p17) (18–26) KIRLRPGGK HIV-1 infection human (A3) Yu2002a
• Epitope name: A3-KK9
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06 was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
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• 8/14 HLA-A3 positive individuals had detectable A3-restricted responses during acute infection. Only 5/15 of HLA-A3 epitopes tested were targeted
during acute infection. 7/8 individuals with acute responses had specific responses for this epitope.
• KIRLRPGGK and RLRPGGKKK were the most commonly recognized HLA-A3 epitopes during acute infection, after 1 year of treatment, and after STI.
RLRPGGKKK was immunodominant.
p17 (18–26) p17 (18–26) KIRLRPGGK HIV-1 infection human (A3, A3.1, B27) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
p17 (18–26) KIRLRPGGK HIV-1 infection human (B*0301) Wilson2000a
• Three individuals with highly focused HIV-specific CTL responses were studied during acute infection using tetramers – high frequencies of HIV-1-specific
CD8+ T cells were found prior to seroconversion, and there was a close temporal relationship between the number of circulating HIV-specific T cells and
viral load was also found
• All three patients were B*2705, with HLA alleles: A1, A30/31, B*2705, B35; A1, A*0301, B7, B2705; and A*0201, A*0301, B2705, B39
• ELISPOT was used to test a panel of CTL epitopes that had been defined earlier and were appropriate for the HLA haplotypes of the study subjects – 3/3
subjects showed a dominant response to the B*2705 epitope KRWIILGGLNK
• The subject with A*0201 had a moderatly strong response to SLYNTVATL
• Weak responses were observed to A*301-RLRPGGKKK, A*301-QVPLRPMTYK, and B7-TPGPGVRYPL in the subject who was HLA A1, A*0301, B7,
B*2705
• No acute response was detected to the following epitopes: A*201-ILKEPVHGV, A*301-KIRLRPGGK, A*301-AIFQSSMTK, A*301-TVYYGVPVWK,
B35-EPIVGAETF, B35-HPDIVIYQY, B35-PPIPVGEIY, B35-NSSKVSQNY, B35-VPLRPMTY, B35-DPNPQEVVL
p17 (18–27) p17 (18–27 LAI) KIRLRPGGKK human (B27) Brander1996b
• D. Lewinsohn, pers. comm.
p17 (18–27) p17 (18–27) KIRLRPGGKK HIV-1 infection human (B27) Birk1998b
• A study of p17 variation considering known p17 epitopes and individuals with known HLA types revealed that p17 evolution is influenced by immune
pressure from CTLs
p17 (18–31) p17 (18–31) KIRLRPGGKKKYKL HIV-1 infection human (A3) Birk1998b
• A study of p17 variation considering known p17 epitopes and individuals with known HLA types revealed that p17 evolution is influenced by immune
pressure from CTLs
p17 (18–31) p17 (18–31) KIRLRPGGKKKYKL HIV-1 infection human (B62) Lubaki1997
• Eighty two HIV-1-specific CTL clones from 5 long-term non-progressors were isolated and analyzed for breadth of CTL response
• A sustained Gag, Env and Nef response was observed, and clones were restricted by multiple HLA epitopes, indicating a polyclonal response
• A subject who was HLA-B62+ had CTL that recognized this peptide, and p24 LGLNKIVRMYS, and one additional unknown epitope
p17 (18–42) p17 (18–42 IIIB) KIRLRPGGKKKYKLKHIVW-
ASRELE
HIV-1 infection human (A3) Jassoy1992
• Epitope recognized by CTL clone derived from CSF
p17 (18–42) p17 (18–42 PV22) KIRLRPGGKKKYKLKHIVW-
ASRELE
HIV-1 infection human (A3) Jassoy1993
• HIV-1 specific CTLs release γ-IFN, and α- and β -TNF
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p17 (18–42) p17 (18–42 BH10) KIRLRPGGKKKYKLKHIVW-
ASRELE
HIV-1 infection human (Bw62) Johnson1991
• Gag CTL response was studied in three individuals
p17 (19–27) p17 (19–27 JRCSF) IRLRPGGKK HIV-1 infection scid-hu mouse (B*2705) Brander2001
• Noted by Brander to be B*2705 (Pers. Comm. D. Lewinsohn)
p17 (19–27) p17 (19–27 LAI) IRLRPGGKK human (B27) Brander1996b
p17 (19–27) p17 (19–27 JRCSF) IRLRPGGKK HIV-1 infection scid-hu mouse (B27) McKinney1999
• Epitope-specific CTL were infused in infected human PBL-SCID mice, and transient decreases in viral load were observed, however virus was not
eradicated and the HIV-specific CTL rapidly disappeared
• No escape mutants were observed
• Control CTL were long lived in both infected and uninfected mice, showing the rapid loss of CTL was due to target interaction
p17 (19–27) p17 (SF2) IRLRPGGKK HIV-1 infection human (B27) Goulder2000a
• WEKIRLRPGGKKKYKLK was the target of the dominant response in Caucasoids (38%) more frequently than non-Caucasoids (12%) – 2/3 individuals
that were B27+ had a dominant response to this epitope
• Three peptides GSEELRSLYNTVATL (p17 residues 71-85), SALSEGATPQDLNTMLNTVG (p24 41-60), and WEKIRLRPGGKKKYKLK(p17 16-30)
contained the dominant Gag-specific epitope in 31 out of 44 B-clade infected individuals from Boston who showed Gag-CTL responses
• Five peptides RLRPGGKKHYMIKHLVW (p17 20-36), ELRSLYNTVATLYCV (p17Gag 74-88), SALSEGATPQDLNTMLNTVG (p24 41-60),
FRDYVDRFFKTLRAEQA (p24 161-177), and SILDIKQGKEPFRDY (p24 149-164) contained dominant Gag-specific epitopes in 32 out of 37 C-clade
infected subjects from South Africa
p17 (19–27) p17 (19–27) IRLRPGGKK HIV-1 infection human (B27) Day2001
p17 (19–27) p17 (19–27) IRLRPGGKK HIV-1 infection human (B27) Goulder2001b
• Epitope name: IK9
• This B27 epitope is generally recognized only if there is escape in the B27 dominant epitope, p24 KRWIILGLNK
p17 (20–28) p17 (20–28) RLRPGGKKK HIV-1 infection human Betts2000
• Only 4/11 HLA-A2+ HIV+ individuals had CTL that reacted to SLYNTVATL, calling into question whether it is immunodominant
• 95 optimally-defined peptides from this database were used to screen for INFγ responses to other epitopes
• Three of the four individuals that responded to SLYNTVATL recognized HIV epitopes, and one individual who was A*0201, A31 and B51 and B58w4
recognized this epitope (previously described as HLA A3.1), as well as one other
p17 (20–28) p17 (20–28) RLRPGGKKK HIV-1 infection human (A*03) Goulder1997e, Goulder1997a
• Identical twin hemophiliac brothers were both infected with the same batch of factor VIII
• One had a response to gag A3 epitope RLRPGGKKK, the other non-responder carried the sequence RLRPGGKKC
• [Goulder1997a] is a review of immune escape that summarizes this study
p17 (20–28) p17 (20–28) RLRPGGKKK HIV-1 infection human (A*0301) Brander2001
• C. Brander notes that this is an A*0301
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p17 (20–28) p17 RLRPGGKKK HIV-1 infection human (A*0301) Wilson2000a
• Three individuals with highly focused HIV-specific CTL responses were studied during acute infection using tetramers – high frequencies of HIV-1-specific
CD8+ T cells were found prior to seroconversion, and there was a close temporal relationship between the number of circulating HIV-specific T cells and
viral load was also found
• All three patients were B*2705, with HLA alleles: A1, A30/31, B*2705, B35; A1, A*0301, B7, B2705; and A*0201, A*0301, B2705, B39
• ELISPOT was used to test a panel of CTL epitopes that had been defined earlier and were appropriate for the HLA haplotypes of the study subjects – 3/3
subjects showed a dominant response to the B*2705 epitope KRWIILGGLNK
• The subject with A*0201 had a moderatly strong response to SLYNTVATL
• Weak responses were observed to A*301-RLRPGGKKK, A*301-QVPLRPMTYK, and B7-TPGPGVRYPL in the subject who was HLA A1, A*0301, B7,
B*2705
• No acute response was detected to the following epitopes: A*201-ILKEPVHGV, A*301-KIRLRPGGK, A*301-AIFQSSMTK, A*301-TVYYGVPVWK,
B35-EPIVGAETF, B35-HPDIVIYQY, B35-PPIPVGEIY, B35-NSSKVSQNY, B35-VPLRPMTY, B35-DPNPQEVVL
p17 (20–28) p17 (20–28 SF2) RLRPGGKKK HIV-1 infection human (A*0301) Altfeld2001a
• HIV+ individual AC-06 was tested for reactive overlapping peptides spanning all HIV-1 proteins in an ELISPOT and was found to react with 12 peptides
from 7 proteins, suggesting that the breadth of CTL responses are underestimated if accessory proteins are not included in the study
• The reactive peptide p17 gag WEKIRLRPGGKKKYK contained two A*0301-restricted epitopes, KIRLRPGGK and RLRPGGKKK A*0301
p17 (20–28) Gag (p17) (20–28) RLRPGGKKK HIV-1 infection human (A*0301) Sabbaj2002a
• Epitope name: RK9
• IFNgamma T-cell responses in breast milk of 5 HIV-1 infected women from the US and 6 from Zambia were tested with using Elispot. 11/11 women
responded to Gag, 8/11 responded to Pol, 7/11 women to Nef, and 2/5 women to Env peptide pools. These responses were shown to be primarily due to
CD8+ T-cells in one woman, and another woman had cytolytic responses measured by Cr-release.
• Tetramer analysis of breast milk and peripheral blood samples of one volunteer showed responses to RLRPGGKKK in both compartments, 0.65% of
CD3+/CD8+ cells in breast milk, and 0.22% of CD3+/CD8+ cells in peripheral blood cells.
• The frequencies of responses in the two compartments differed, and 2/4 women that responded to epitopes in Nef 101-205 and Pol 601-710 showed
responses in breast milk but no detectable responses in peripheral blood cells.
p17 (20–28) RLRPGGKKK HIV-1 infection human (A03) Sabbaj2002b
• Epitope name: Gag-RK9
• Among HIV+ individuals who carried HLA A03, 7/20 (35%) recognized this epitope
p17 (20–28) p17 (20–28) RLRPGGKKK HIV-1 infection human (A3) Goulder2000c
• Two clonal CTL responses were generated in donor 021-BMC (HLA A3/3001, B42/-, Cw17/-) against different optimal versions of this epitope, one nine
amino acids long, one ten
• A previously described optimal A3 epitope overlapping this region, KIRLRPGGK, was not recognized by CTL from 021-BMC
p17 (20–28) p17 (20–28) RLRPGGKKK HIV-1 infection human (A3) Goulder1997f
• A control CTL line that reacts with this peptide was included in the study
p17 (20–28) p17 (20–28) RLRPGGKKK HIV-1 infection human (A3) Cao1997a
• The consensus peptide of A, B, and D clade viruses is RLRPGGKKK
• The consensus peptide of C clade viruses is RLRPGGKKH and is equally reactive
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p17 (20–28) p17 (SF2) RLRPGGKKK HIV-1 infection human (A3) Goulder2000a
• WEKIRLRPGGKKKYKLK was the target of the dominant response in Caucasoids (38%) more frequently than non-Caucasoids (12%) – 7/10 that had a
dominant response to this epitope were A3, and 5/7 targeted RLRPGGKKK while 2/7 targeted KIRLRPGGK
• Three peptides GSEELRSLYNTVATL (p17 residues 71-85), SALSEGATPQDLNTMLNTVG (p24 41-60), and WEKIRLRPGGKKKYKLK(p17 16-30)
contained the dominant Gag-specific epitope in 31 out of 44 B-clade infected individuals from Boston who showed Gag-CTL responses
• Five peptides RLRPGGKKHYMIKHLVW (p17 20-36), ELRSLYNTVATLYCV (p17Gag 74-88), SALSEGATPQDLNTMLNTVG (p24 41-60),
FRDYVDRFFKTLRAEQA (p24 161-177), and SILDIKQGKEPFRDY (p24 149-164) contained dominant Gag-specific epitopes in 32 out of 37 C-clade
infected subjects from South Africa
p17 (20–28) p17 (20–28 SF2) RLRPGGKKK HIV-1 infection human (A3) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-A3+ individuals that had a CTL response to this epitope broken down by group: 5/7 group 1, 2/4 group 2, and 2/2 group 3
p17 (20–28) p17 (20–28) RLRPGGKKK HIV-1 infection human (A3) Day2001
• The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7 was
studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
• 2 to 17 epitopes were recognized in a given individual, A2-restricted CTL response tended to be narrow and never dominated the response, and 25/27
epitopes were targeted by at least one person
• All patients recognized at least 1 A3 epitope, up to 8 A3 epitopes, but none was clearly dominant
p17 (20–28) p17 (20–28) RLRPGGKKK HIV-1 infection human (A3) Goulder2001b
• Epitope name: RK9
• Responses to this dominant A3-restricted Gag epitope are present during the time of decreasing viral load in acute infection
• Mutations in this epitope were observed in autologous clones of subjects who were A3-positive with a higher frequency than those who were A3-negative
(P = 0.0002)
• These mutations are being sexually transmitted in adult infections
p17 (20–28) Gag (p17) (20–28) RLRPGGKKK HIV-1 infection human (A3) Yu2002a
• Epitope name: A3-RK9
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06 was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
• 8/14 HLA-A3 positive individuals had detectable A3-restricted responses during acute infection. Only 5/15 of HLA-A3 epitopes tested were targeted
during acute infection. 7/8 individuals with acute responses had specific responses for this epitope.
• KIRLRPGGK and RLRPGGKKK were the most commonly recognized HLA-A3 epitopes during acute infection, after 1 year of treatment, and after STI.
RLRPGGKKK was immunodominant during acute infection and throughout the study period in the 5/6 individuals who targeted it.
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p17 (20–28) Gag (LAI) RLRPGGKKK HIV-1 infection human (A3) Lewinsohn2002
• CTL kill targets through releasing perforin, that forms pore in the plasma membrane, and granzymes, that induce apoptosis.
• Vpr is capable of arresting infected cells in the G2 phase, and it was hypothesized that Vpr may inhibit CTL-mediated apoptosis because it interacts with
the granzyme B molecular complex.
• Vpr expression in the target cell did not inhibit epitope specific lysis – neither perforin or granzyme mediated events were inhibited, as measured by a
Chromium release assay and a TUNEL assay.
• In contrast, deletion of Nef, which is thought to protect primary HIV infected cells by down-regulating cell-surface expression of MHC class I complexes,
increased the susceptibility of HIV-1 infected cells to CTL mediated killing 2-fold using the TUNEL assay
p17 (20–28) p17 RLRPGGKKK HIV-1 infection human (A3) Sabbaj2002a
• IFNgamma T-cell responses in breast milk of 5 HIV-1 infected women from the US and 6 from Zambia were tested with using Elispot. 11/11 women
responded to Gag, 8/11 responded to Pol, 7/11 women to Nef, and 2/5 women to Env peptide pools. These responses were shown to be primarily due to
CD8+ T-cells in one woman, and another woman had cytolytic responses measured by Cr-release.
• T-cells in breast milk from a volunteer who was HLA A3, A11, B35, B51 induced IFNgamma after stimulation with a peptide that carries known A3
epitope RLRPGGKKK.
• The frequencies of responses in the two compartments differed, and 2/4 women that responded to epitopes in Nef 101-205 and Pol 601-710 showed
responses in breast milk but no detectable responses in peripheral blood cells.
p17 (20–29) p17 (20–29 LAI) RLRPGGKKKY HIV-1 infection human (A*0301) Brander2001
• C. Brander notes this is an A*0301 epitope
p17 (20–29) p17 (20–29) RLRPGGKKKY HIV-1 infection human (A3) Goulder2000c
• Two clonal CTL responses were generated in donor 021-BMC (HLA A3/3001, B42/-, Cw17/-) against different optimal versions of this epitope, one nine
amino acids long, one ten
• A previously described optimal A3 epitope overlapping this region, KIRLRPGGK, was not recognized by CTL from 021-BMC
p17 (20–29) p17 (20–29) RLRPGGKKKY HIV-1 infection human (A3.1) Brander1995b
• Unpublished, C. Jassoy and Beatrice Culman, pers. comm.
p17 (20–29) p17 (20–29 LAI) RLRPGGKKKY HIV-1 infection human (A3.1) Wilkens1999
• Pers. comm., B. Wilkens and D. Ruhl
p17 (20–29) p17 (20–29) RLRPGGKKKY HIV-1 infection human (A30, A3.1) Betts2000
• Only 4/11 HLA-A2+ HIV+ individuals had CTL that reacted to SLYNTVATL, calling into question whether it is immunodominant
• 95 optimally-defined peptides from this database were used to screen for INFγ responses to other epitopes
• 1/11 of the A2+ individuals was A30, and one was A3, and both responded to RLRPGGKKKY
• The A2+ A3 individual also reacted with two other A3.1 epitopes
p17 (20–29) p17 (20–29 IIIB) RLRPGGKKKY HIV-1 infection human (B42) Wilson1996
• Epitope defined in the context of the Pediatric AIDS Foundation ARIEL Project, a mother-infant HIV transmission study
• RLRPGGKKRY, a naturally occurring variant, was found in non-transmitting mother and is recognized
• Binds HLA-A3 and Bw62 as well
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p17 (20–29) p17 (20–29) RLRPGGKKKY HIV-1 infection human (B42, Bw62) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
p17 (20–29) p17 (20–29) RLRPGGKKKY HIV-1 infection human (B62) Brodie2000
• Study tracks and quantifies in vivo migration of neo-marked CD8 HIV-specific CTL
• Adoptively transferred gene-marked HIV-specific CTL homed to specific lymph node sites, colocalizing within the parafollicular regions of the lymph node
adjacent to cells expressing HIV tat-fusion transcripts, indicative of viral replication
• The CTL clones expressed CCR5 and localized among HIV-1 infected cells expressing MIP-1alpha and MIP-1beta, CC-chemokines produced at sites of
viral replication, suggesting a possible homing mechanism
• This study provides a methodology for tracking and studying antigen specific CTL in vivo
p17 (20–29) p17 (20–29 LAI) RLRPGGKKKY human (Bw62) McMichael1994
• Review of HIV CTL epitopes
• Also P. Johnson, pers. comm.
p17 (20–30) p17 (SF2) RLRPGGKKKYK HIV-1 infection human Goulder2000a
• WEKIRLRPGGKKKYKLK was the target of the dominant response in Caucasoids (38%) more frequently than non-Caucasoids (12%) – the dominant
response in a Haitian immigrant living in Boston who was HLA A24/29 B7/B44 Cw6/7 was to this epitope, although the restricting element was not
determined
• Three peptides GSEELRSLYNTVATL (p17 residues 71-85), SALSEGATPQDLNTMLNTVG (p24 41-60), and WEKIRLRPGGKKKYKLK(p17 16-30)
contained the dominant Gag-specific epitope in 31 out of 44 B-clade infected individuals from Boston who showed Gag-CTL responses
• Five peptides RLRPGGKKHYMIKHLVW (p17 20-36), ELRSLYNTVATLYCV (p17Gag 74-88), SALSEGATPQDLNTMLNTVG (p24 41-60),
FRDYVDRFFKTLRAEQA (p24 161-177), and SILDIKQGKEPFRDY (p24 149-164) contained dominant Gag-specific epitopes in 32 out of 37 C-clade
infected subjects from South Africa
p17 (20–35) p17 (90–105 SF2) CLRPGGKKKYKLKHIV HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Twelve subjects had CTL that could recognize vaccinia-expressed LAI gag
• One of these 12 had CTL response to this peptide
• The responding subject was HLA A-2, A-24, B-13, B-35
p17 (21–35) Gag LRPGGKKKYKLKHIV HIV-1 infection human Weekes1999a
• Peptide 703.3: Memory CTL specific for HIV-1 may contribute to oligoclonal expansions within the CD57+ CD28- CD8+ CTLp populations
p17 (21–35) p17 (91–105 SF2) LRPGGKKKYKLKHIV HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Twelve subjects had CTL that could recognize vaccinia-expressed LAI gag
• One of these 12 had CTL response to this peptide
• The responding subject was HLA-A1, A2, B50, B57
p17 (21–35) Gag LRPGGKKKYKLKHIV HIV-1 infection human (A3) Weekes1999b
• Peptide 703.3: Almost all CD8+ T cells are CD28+ at birth, and the proportion of CD28-CD8+ cells increases with age – this study examines the
contribution of CD8+CD28- cells to CTL memory pools for CTL clones specific for two persistent human viruses, CMV and HIV – clones were found to
be similarly distributed in the CD28 depleted cell population
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• HIV CTL responses to 3 Env and 2 Gag peptides were studied
• The clonal composition of the TCR Vbeta responses was studied and was found to be highly focused, with one TCR beta-chain sequence tending to
dominate the peptide-specific response – clones to this epitope were Vbeta13.1 and Vbeta5.2
p17 (21–35) p17 (21–35) LRPGGKKKYKLKHIV human (B8) Nixon1991
• Two CTL epitopes defined (see also p24(191-205))
p17 (21–35) p17 (21–35) LRPGGKKKYKLKHIV HIV-1 infection human (not B8) vanBaalen1996
• Unknown HLA specificity, but not B8
p17 (21–40) p17 (21–40 subtype A) LRPGGKKKYRLKHLVWASRE HIV-1 infection human (Cw4) Dorrell1999
• CTL responses in three individuals with non-clade B infections were studied, 2 with subtype A infections, 1 with subtype C – their infections all originated
in East Africa
• This epitope was defined in an A subtype infection – the B clade variant (LRPGGKKKYKLKHIVWASRE) has two mutations relative to the A subtype
form, and the CTL from this patient were not A-B cross-reactive
p17 (22–31) Gag (22–31) RPGGKKRYKL HIV-1 infection human (B7) Jin2000b
• This B7 epitope is one of three subdominant CTL responses detected in a long-term non-progressor
• A dominant B7 epitope was defined using conventional methods, and three additional sub-dominant HLA B7 epitopes were defined by first using a
non-anchor based strategy, EpiMatrix, to identify 2078 possible epitopes in the autologous HIV-1, followed by B7 anchor residue prediction to narrow the
set to 55 peptides for experimental testing
p17 (24–31) p17 (24–31) GGKKKYKL human (B8) Goulder1997g
• The crystal structure of this peptide bound to HLA-B8 was used to predict new epitopes and the consequences of epitope variation
• The predictions were experimentally confirmed
• The anchors for HLA-B8 epitopes, as defined by peptide elution data, are P3 (K), P5 (K/R), and P8 (L)
• Structural data suggests that a positive charge at P5 is essential, but that the constraints on P3 may be less severe
• Small hydrophobic residues at P2 may be favorable for binding
• A spacious F-pocket favors mid-sized hydrophobic residues in the C-term anchor
p17 (24–31) p17 (24–31 SF2) GGKKKYKL HIV-1 infection human (B8) McAdam1998
• CTL from a patient infected with clade B virus did not recognize Ugandan variants of this epitope
p17 (24–31) p17 (24–31 LAI) GGKKKYKL HIV-1 infection human (B8) Reid1996
• The variants 7R: GGKKKYRL, 7Q: GGKKKYQL, 5R: GGKKRYKL, and 3R: GGRKKYKL, were studied
• Crystal structures were obtained to study these peptides in the context of HLA-B8, and CTL binding and activity were determined
• 3R has been detected in 3 patients, and it abolishes recognition causing extensive conformational changes upon binding including MHC main chain
movement
• 7Q and 7R alter the TCR exposed surface, and retain some recognition
• Reactivity of 5R depends on the T cell clone, this amino acid is embedded in the C pocket of B8 when the peptide is bound
• Optimal peptide is 8-mer, not 9-mer, and positions 3, 5, and 8 are the anchor residues
p17 (24–31) p17 (24–31 LAI) GGKKKYKL HIV-1 infection human (B8) Price1997
• A weak CTL response to the index peptide was observed in an HLA-B8+ infected individual
• Sequences from the earliest available time point showed that a variant at position 5, an anchor residue, GGKKQYKL, was present
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p17 (24–31) p17 (24–31 SF2) GGKKKYKL HIV-1 infection human (B8) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B8+ individuals that had a CTL response to this epitope broken down by group: 0/3 group 1, 1/3 group 2, and 2/2 group 3
p17 (24–31) p17 (24–31) GGKKKYRL HIV-1 infection, HIV-1 exposed
seronegative
human (B8) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
p17 (24–31) p17 (24–31) GGKKKYKL HIV-1 infection human (B8) Day2001
• B8-restricted CTL accounted for about 1/3 of the total CTL response in one individual
p17 (24–31) p17 GGKKKYKL HIV-1 infection human (B8) McMichael2002
• CTL response-eliciting vaccines are reviewed. The natural epitope interactions with the HLA class I presenting molecules and T-cell receptors are
described, using the structure of this epitope, taken from [Reid1996], as an example.
p17 (24–32) p17 (24–32 LAI) GGKKKYKLK HIV-1 infection human (B*0801) Brander2001
• C. Brander notes epitope to be presented by B*0801
p17 (24–32) p17 (24–32 LAI) GGKKKYKLK HIV-1 infection human (B8) Sutton1993
• Exploration of HLA-B8 binding motif through peptide elution
p17 (24–32) p17 (24–32 LAI) GGKKKYKLK HIV-1 infection human (B8) Rowland-Jones1993
• Study of an individual with partially defective antigen processing
p17 (24–32) p17 (24–32) GGKKKYKLK HIV-1 infection human (B8) Klenerman1994
• Naturally occurring variants GGKKKYQLK and GGKKRYRLK may act as antagonists
p17 (24–32) p17 (24–32) GGKKKYKLK HIV-1 infection human (B8) Klenerman1995
• Naturally occurring antagonist GGKKKYQLK found in viral PBMC DNA and RNA
p17 (24–32) p17 (24–32) GGKKKYKLK HIV-1 infection human (B8) Nowak1995
• Longitudinal study of CTL response and immune escape – the variant GGRKKYKLK binds to HLA-B8 but is not reactive
p17 (24–32) p17 (24–32) GGKKKYKLK HIV-1 infection human (B8) Dyer1999
• CTL specific responses were measured over a 1.3 to 1.5 year period in members of the Sydney Blood Bank Cohort (SBBC) who had been infected with a
natural attenuated strain of HIV-1 which was Nef-defective
• Some of these patients had prolonged high levels of CTL effector and memory cells despite low viral load
p17 (24–32) p17 GGKKKYKLK human (B8) Rowland-Jones1999
• CTL responses in seronegative highly HIV-exposed African female sex workers in Gambia and Nairobi were studied – these women had no delta 32
deletion in CCR5
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• In Gambia there is exposure to both HIV-1 and HIV-2, CTL responses to B35 epitopes in exposed, uninfected women are cross-reactive, and the B35 allele
seems to be protective
• HIV-2 sequence: GGKKKYKMK – no cross-reactivity [Phillips1991]
p17 (24–32) p17 (24–32) GGKKKKYKLK HIV-1 infection human (B8) Oxenius2000
• Epitope name: GGK
• Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific
CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load – three patients that had delayed initiation of
HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became
undetectable
• This epitope was recognized by 1/7 study subjects that were HLA-B8+
• Patient SC12(HLA A1, B8/39, Cw0701/0702, DR2/3, DR51/52, DQ2/6) had sustained therapy started during acute infection and maintained an
immunodominant response to FLKEKGGL throughout and minor responses to GEIYKRWII, DCKTILKAL, GGKKKYKLK – GEIYKRWII and
GGKKKYKLK responses were stimulated by a brief period off therapy
p17 (24–32) p17 GGKKKKYKKL HIV-1 infection human (B8) Seth2001
• CTL responses were studied by tetramer staining in 41 patients with combination therapy – activated CD8+ T-cells decline as the viral load drops in
response to therapy, but the overall level of antigen-specific cells capable of differentiating into effectors stays constant and new epitopes may be recognized
p17 (24–32) p17 GGKKKKYKLK HIV-1 infection human (B8) Oxenius2002b
• Epitope name: GGK
• Using previously defined epitopes [Oxenius2000, Oxenius2001a] in an IFNgamma Elispot assay, 13 chronically HIV-1 infected patients were studied over a
period including therapy with standard treatment interruptions (STI).
• STIs induced increased recognition of CTL epitopes, but there was no correlation between CTL responses with viral rebound rates, plateau viral loads, or
clearance rates.
p17 (24–35) p17 (25–35 SF2) GGKKKYKLKHIV HIV-1 infection human (B8) Goulder1997a, Phillips1991
• Longitudinal study of CTL escape mutants in people with the appropriate HLA types – little variation was observed in the immunodominant B27 epitope,
relative to B8 epitopes, which varied over time
• [Goulder1997a] is a review of immune escape that points out that there may be a protective effect associated with B27, and that HLA-B8 individuals tend to
progress more rapidly than HLA B27 patients
p17 (24–35) p17 (25–35) GGKKKYKLKHIV HIV-1 infection human (B8) Birk1998b
• A study of p17 variation considering known p17 epitopes and individuals with known HLA types revealed that p17 evolution is influenced by immune
pressure from CTLs
p17 (28–36) KYRLKHLVW HIV-1 infection human Kaul2001c
• This study examines CTL responses in HIV exposed, persistently seronegative individuals, HEPS, who eventually seroconverted – 11/114 HEPS Nairobi
sex workers eventually seroconverted, and for six of these HIV CTL reactive epitopes had been defined while seronegative
• The epidemiological factor associated with seroconversion was stopping sex work and HIV-specific CTL activity declines when HEPS sex workers stop
working for a period or retire
• This epitope was recognized in 1/22 HEPS sex worker controls (ML1573)
p17 (28–36) p17 (28–36 LAI) KYKLKHIVW human (A*2402) Brander2001
• Ikeda-Moore(1998) and D. Lewinsohn, pers. comm.
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• C. Brander notes that this is an A*2402 epitope
p17 (28–36) p17 (28–36 SF2) KYKLKHIVW HIV-1 infection human (A*2402) Ikeda-Moore1998
• Strong CTL activity to this peptide was detected in 2/3 HIV-infected individuals who were HLA A24+
• HLA A24 is very common in Japanese (70% carry it) and is common globally
• This epitope was detected by looking for peptides with appropriate A24 anchor residues (Y at position 2, carb-term ILF or W) – 16/17 such peptides bound
to A24 – KYKLKHIVW was found to be a naturally processed epitope that elicits a strong CTL response.
p17 (28–36) p17 (28–36 LAI) KYKLKHIVW human (A23) Goulder1999b
• P. Goulder, pers. comm.
p17 (28–36) p17 (28–36 LAI) KYKLKHIVW human (A24) Brander1996b
• D. Lewinsohn, pers. comm.
p17 (28–36) p17 (28–36 SF2) KYKLKHIVW HIV-1 infection human (A24) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-A24+ individuals that had a CTL response to this epitope broken down by group: 0/0 group 1, 2/3 group 2, and 0/0 group 3
p17 (28–36) p17 (28–36 93TH253
subtype CRF01)
KYKLKHIVW HIV-1 infection human (A24) Bond2001
• More than half of a cohort of HIV+ female sex workers (FSW) from Northern Thailand were HLA-A11 positive, and this study concentrated on A11
epitopes in this group, although E clade versions of previously defined B-clade A2 and A24 epitopes were also tested.
• The only HLA-A24 FSWs tested did not recognized the E clade version of this epitope KYKMKHLVW, which differs from the previously defined B clade
version by two amino acids, KYKLKHIVW
p17 (28–36) p17 (728–736 subtype
A)
KYRLKHLVW HIV-1 infection, HIV-1 exposed
seronegative
human (Cw4) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with
reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected
women
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure
• Among HLA-Cw4 women, 2/2 HEPS and 7/11 HIV-1 infected women recognized this epitope
• The dominant response to this HLA allele was to this epitope in both of the 2/2 HEPS cases and in 3 of the 7/11 HIV-1 infected women
p17 (28–36) p17 (28–36) KYRLKHLVW HIV-1 infection human (Cw4) Appay2000
• This epitope is newly defined in this study
• Combined tetramer and intracellular cytokine staining was used to study the function of circulating CD8+ T cells specific for HIV and CMV
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• HIV-specific CD8+ T cells expressed lower levels of perforin than CMV-specific CD8+ T cells from the same donor, and this was associated with persistent
CD27 expression on HIV-specific cells, suggesting impaired maturation
• In most donors, between 50% and 95% of the activated virus-specific CD8+ T cells produced IFN-γ and MIP-1β with a distinct subset that failed to
produce TNF-α
p17 (36–44) p17 (SF2) WASRELERF HIV-1 infection human Goulder2000a
• The dominant response in an African American who was HLA A3/33 B35/B53 Cw4/7 was to this epitope, although the restricting element was not
determined – this epitope fell outside the most recognized peptides in the study
• Three peptides GSEELRSLYNTVATL (p17 residues 71-85), SALSEGATPQDLNTMLNTVG (p24 41-60), and WEKIRLRPGGKKKYKLK(p17 16-30)
contained the dominant Gag-specific epitope in 31 out of 44 B-clade infected individuals from Boston who showed Gag-CTL responses
• Five peptides RLRPGGKKHYMIKHLVW (p17 20-36), ELRSLYNTVATLYCV (p17Gag 74-88), SALSEGATPQDLNTMLNTVG (p24 41-60),
FRDYVDRFFKTLRAEQA (p24 161-177), and SILDIKQGKEPFRDY (p24 149-164) contained dominant Gag-specific epitopes in 32 out of 37 C-clade
infected subjects from South Africa
p17 (36–44) p17 (35–43 LAI) WASRELERF HIV-1 infection human (B*3501) Goulder1997d
• Optimal epitope defined from within p17(30-44), LKHIVWASRELERFA
• Dominant CTL response in an HIV+ asymptomatic donor was to this epitope
• The Phe in the C-term anchor is distinct from the previously-defined Tyr for B*3501 C-term anchors
p17 (36–44) p17 (36–44 LAI) WASRELERF human (B*3501) Brander2001, Goulder1997b
• C. Brander notes this is a B*3501 epitope
p17 (36–44) p17 (36–44) WASRELERF HIV-1 infection human (B35) Birk1998b
• A study of p17 variation considering known p17 epitopes and individuals with known HLA types revealed that p17 evolution is influenced by immune
pressure from CTLs
p17 (36–44) p17 (36–44) WASRELERF HIV-1 infection human (B35) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
p17 (36–44) p17 (36–44 SF2) WASRELERF HIV-1 infection human (B35) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B35+ individuals that had a CTL response to this epitope broken down by group: 0/2 group 1, 0/2 group 2, and 1/1 group 3
p17 (36–44) WASRELERF HIV-1 infection human (B35) Sabbaj2002b
• Epitope name: Gag-WF9
• Among HIV+ individuals who carried HLA B35, 1/21 (5%) recognized this epitope
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p17 (69–93) p17 (69–93 BH10) QTGSEELRSLYNTVATLYC-
VHQRIE
HIV-1 infection human (A2) Johnson1991
• Gag CTL response studied in three individuals
p17 (71–79) p17 (71–79 LAI) GSEELRSLY human (A1) Brander1996b
• P. Goulder, pers. comm.
p17 (71–79) p17 (71–79) GSEELRSLY HIV-1 infection human (A1) Birk1998b
• A study of p17 variation considering known p17 epitopes and individuals with known HLA types revealed that p17 evolution is influenced by immune
pressure from CTLs
p17 (71–79) p17 (71–79 HXB2) GSEELRSLY HIV-1 infection human (A1) Oxenius2000
• Epitope name: GSE
• Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific
CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load – three patients that had delayed initiation of
HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became
undetectable
• This epitope was not recognized by the 6/8 study subjects that were HLA-A1
p17 (71–79) p17 (71–79) GSEELRSLY HIV-1 infection, HIV-1 exposed
seronegative
human (A1) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with
reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected
women
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure
• Among HLA-A1 women, 1/1 HEPS and 3/3 HIV-1 infected women recognized this epitope, and the response was the dominant HLA-A1 response in all
cases
p17 (71–79) p17 GSEELRSLY HIV-1 infection human (A1) Oxenius2002b
• Epitope name: GSE
• Using previously defined epitopes [Oxenius2000, Oxenius2001a] in an IFNgamma Elispot assay, 13 chronically HIV-1 infected patients were studied over a
period including therapy with standard treatment interruptions (STI).
• STIs induced increased recognition of CTL epitopes, but there was no correlation between CTL responses with viral rebound rates, plateau viral loads, or
clearance rates.
p17 (71–85) p17 (71–85 SF2) GSEELRSLYNTVATL HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Twelve subjects had CTL that could recognize vaccinia-expressed LAI gag
• One of these 12 had CTL response to this peptide
• The responding subject was HLA-A1, A11, B8, B27
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p17 (74–82) p17 ELRSLYNTV human (B*0801) Brander2001
• Noted by Brander to be a B*0801 epitope
p17 (74–82) p17 ELRSLYNTV human (B8) Goulder1997g
• Defined in a study of the B8 binding motif
p17 (74–82) p17 (74–82) ELRSLYNTV HIV-1 infection human (B8) Birk1998b
• A study of p17 variation considering known p17 epitopes and individuals with known HLA types revealed that p17 evolution is influenced by immune
pressure from CTLs
p17 (74–82) p17 (74–82) ELRSLYNTV HIV-1 infection human (B8) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
p17 (74–82) p17 (74–82) ELRSLYNTV HIV-1 infection human (B8) Day2001
• B8-restricted CTL accounted for about 1/3 of the total CTL response in one individual
p17 (76–86) p17 (74–86 LAI) RSLYNTVATLY human (A*3002) Brander2001
• C. Brander notes this is an A*3002 epitope
p17 (76–86) p17 (SF2) RSLYNTVATLY HIV-1 infection human (A*3002) Goulder2000a
• The CTL-dominant response was focused on this epitope in a single HIV+ individual from Boston – this epitope fell outside the most recognized peptides
in the study
• Three peptides GSEELRSLYNTVATL (p17 residues 71-85), SALSEGATPQDLNTMLNTVG (p24 41-60), and WEKIRLRPGGKKKYKLK(p17 16-30)
contained the dominant Gag-specific epitope in 31 out of 44 B-clade infected individuals from Boston who showed Gag-CTL responses
• Five peptides RLRPGGKKHYMIKHLVW (p17 20-36), ELRSLYNTVATLYCV (p17Gag 74-88), SALSEGATPQDLNTMLNTVG (p24 41-60),
FRDYVDRFFKTLRAEQA (p24 161-177), and SILDIKQGKEPFRDY (p24 149-164) contained dominant Gag-specific epitopes in 32 out of 37 C-clade
infected subjects from South Africa
p17 (76–86) Gag (96ZM651.8) RLSYNTVATLY human (A*3002) Novitsky2001
• This study is provides a survey of CTL responses and full length HIV-1 genome sequences from a C subtype infected Botswanan cohort
• Only 3 of 13 (23.1%) A*3002-positive subjects demonstrated moderate CTL responses to the peptide GTEELRSLYNTVATLYCVHE (residues 71 to 90),
which contains the previously described A*3002 epitope RLSYNTVATLY
p17 (76–86) p17 (76–86) RSLYNTVATLY HIV-1 infection human (A*3002) Goulder2001a
• Epitope name: RY11 (p17)
• HLA-A*3002 is very common in African populations, 50% of Zimbabweans express HLA-A30, 44% in African Zulu, so five new HIV epitopes were
characterized that are presented by this HLA molecule
• A rapid method was developed combining ELISPOT with intracellular IFN-γ staining of PBMCs to map optimal epitopes, then HLA presenting molecules
were defined – this method was completed within 48 to 72 hours of receipt of blood
• Two individuals were studied: Subject 199 (HLA A*0201/*3002 B*4402/51 Cw2/5), a Caucasian, and Subject 6007 (HLA A*3002/ B53/*5801 Cw4/7) an
African-Caribbean
• In both HLA-A*3002 individuals the response to RSLYNTVATLY was dominant
• Three quantitative assays, ELISPOT, precursor frequency and chromium release, confirmed a hierarchy of response: RY11 (p17) > KY9 (gp41) > KY9
(RT-53) > IY9 (gp41)
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• HLA-A*3001-positive targets do not present RSLYNTVATLY
p17 (76–86) RSLYNTVATLY HIV-1 infection human (A*3002) Sabbaj2002b
• Epitope name: Gag-RY11
• This study monitored epitope responses in HIV-1 infected minority women living in the United States
• 24 epitopes were described – 8 were novel, 8 used new restricting elements but were previously defined epitopes, and 8 were previously described
• Serial peptide truncations were used to define optimal epitopes for CTL cell lines isolated from 12 individuals, assayed by a Cr-release
• Subject 00RCH33 was on HAART had a viral load of 2900 and CD4 count of 727 and also recognized the epitopes YPLTFGWCY, Nef(135-143), HLA
B*5301; AETFYVDGA, RT(437-445), HLA B*4501; and HIGPGRAFY, gp160(310-318), HLA A*3002
• Among HIV+ individuals who carried HLA B30, 3/16 (19%) recognized this epitope
p17 (76–86) p17 (74–86 SF2) RSLYNTVATLY HIV-1 infection human (A30) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-A30+ individuals that had a CTL response to this epitope broken down by group: 0/1 group 1, 0/0 group 2, and 1/1 group 3
p17 (76–86) p17 RSLYNTVATLY HIV-1 infection human (A30) Altfeld2002
• Epitope name: A30-RY11(p17)
• Peripheral blood (PB) and lymph node (LN) CD8+ T-cell responses were compared in 15 asymptomatic HIV-1 infected patients using all known optimal
CTL epitopes (http://hiv-web.lanl.gov/content/hiv-db/REVIEWS/brander2001.html) for each person’s class I HLA alleles.
• 60 epitope responses were detected in both PB and LN samples of the 15 patients, and an additional 8 responses were detected only in LN. The total
magnitude of the response was similar in LN and PB, but the percentage of CD8+ T cells in the LN is lower so the number of HIV-specific cells per million
CD8+ T-cells is higher in the LN.
• 1 year post-HAART treatment in five patients studied, the magnitude of the CD8 T-cell response was decreased in both LN and PB, but more dramatically
in PB, and 13/25 epitope responses in the PB became undetectable, in contrast to 5/26 in the LN.
• Treatment interruption following HAART induced resulted in increased viremia accompanied by the restoration of the detection of 13 epitopes that had
become undetectable in the PB, and the addition of 9 novel epitope responses.
• Breakdowns of epitope responses were shown for 4 individuals. Patient D displayed the greatest response to B27-KK10 (p24), and also responded to
A30-RY11(p17), A32-PW10(RT), A30-KY11(RT), A32-RW10(gp120), and B18-YY9(Nef).
p17 (77–85) p17 SLYNTVATL HIV-1 infection human Sewell2000
• Review of the impact of CTL on viral immunity and escape that notes that SLYNTVATL-tetramer binding cells in individuals that react to this epitope
inversely correlate with plasma viral load
p17 (77–85) (SF2, HXBc2/Bal
chimeric)
SLYNTVATL HIV-1 infection Douek2002
• Epitope name: SL9
• Seven HIV-positive subjects tended to make their strongest CD8+ T-cell response against Gag; these responses had varying breadth and magnitude that
were unrelated to disease progression.
• Patient TX7 primarily recognized SL9 during a three year study period and used six T-cell clonotypes for this recognition.
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• SLYNTVATL was the only form of the epitope found initially, but three alternate forms eventually appeared: SLYNTVAVL, SLYNTIATL, and most
commonly SLYNTIAVL. These distinct forms bind A2, but have distinct abilities to stimulate different T-cell clonotypes.
• In subject TX7, the observed mutations of SL9 failed to escape overall CTL recognition, presumably because the six T-cell clonotypes allowed a more
flexible response.
• The BV17 T-cell clone recognized SL9 but not SLYNTIAVL, and BV17 became undetectable at week 20 when SLYNTIAVL predominated. Subsequently
BV17 became the second most common clone. Thus the relative frequency of of the T-cell clonotypes varied with respect to each other and to epitope
variation.
p17 (77–85) Gag p17 (77–85 LAI) SLYNTVATL HIV-1 infection human Luzuriaga2000
• Longitudinal study of 8 infants with prolonged viral suppression due to combination antiretroviral therapy showed no HIV-1 specific CTL responses in
peripheral blood cells. 6/8 were studied using a Chromium release assay and no response was detected using Gag expressed in vaccinia in the target cells.
Three HLA-A*0201 children were tested using SLYNTVATL or ILKEPVHGV HLA A*0201 tetramers and again no HIV-specific response was detected,
either using PBMC specimens, or PBMC which had been stimulated in vitro for a week.
• In contrast, one of the children with therapy suppressed HIV viral replication who was co-infected with HIV and EBV, while HIV-tetramer negative, had
EBV-tetramer staining cells at a frequency of 0.14% in the PBMC.
p17 (77–85) p17 (77–85) SLYNTVATL HIV-1 infection human (A*02) Huang2000
• The single cell ELISPOT assay was optimized and highly specific, and found to work well even after the primary cells had been frozen and thawed
• Increases in gamma IFN producing cells were observed in response to anti-retroviral therapy using single cell IFN-gamma-production ELISPOT
• 4/8 A*02 subjects had a positive response to this epitope indicating that it is a major epitope for CD8+ gamma IFN production
• In 3/3 HLA A*02, B*27 individuals, the dominant response in gag measured by both gamma IFN production and T cell lysis was a B27 epitope,
p24(263-272), not the A2 SLYNTVATL epitope
p17 (77–85) p17 (77–85) SLYNTVATL HIV-1 infection human (A*02) Rinaldo2000
• Epitope name: SL9
• Administration of triple-drug antiretroviral therapy (IDV, 3TC and ZDV) sometimes showed a transient increase and other times failed to increase CTL
responses in patients with advanced HIV disease, but there is a stable population of tetramer stained HIV-specific CD8+ CD45RO+ cells that can persist
after therapy and long periods of virus being below the level of detection
p17 (77–85) p17 SLYNTVATL HIV-1 infection human (A*02) Scott-Algara2001
• Epitope name: SL9
• This study examined with CTL response in HLA A*02+ children by tetramer staining for HLA-A2 immunodominant epitopes SLYNTVATL and
ILKEPVHGV
• 71% of the 28 HIV-1 infected HLA-A*02 positive children recognized both epitopes, with cells from 26 children stained positive by the gag tetramer
(SLYNTVATL) and 21 children by the pol tetramer (ILKEPVHGV)
• There were no differences observed in children that had therapy versus those that did not
• Tetramer-binding cells were memory activated CD28-, CD45RO+, CD45RA- HLADR+, CD69-, CD8+ T-cells
p17 (77–85) p17 (77–85 HXB2) SLYNTVATL HIV-1 infection human (A*0201) Brander1999
• Epitope name: SL9
• Multiple natural variations in the SL9 flanking regions of the immunodominant epitope SLYNTVATL were tested and found not to adversely affect CTL
recognition or prevent epitope processing, suggesting that viral escape from the HLA-A*0201-restricted CTL response against SLYNTVATL is probably
not linked to variations in the flanking regions of this epitope
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• The substitution Y79F was an escape mutation in that it interfered with CTL recognition by one CTL clone from an A*0201 infected individual, clone
13010.B17, but it was still recognized by another CTL clone, 115.D4
p17 (77–85) Gag SLYNTVATL HIV-1 infection human (A*0201) Tan1999
• Adoptive transfer of two autologous in vitro-expanded CTL clones against the A*0201 restricted epitopes SLYNTVATL and VIYQYMDDL were infused
into a patient – they were well tolerated, but the SLYNTVATL clone was shown by tetramer staining to be rapidly eliminated through apoptosis, and the
treatment had no impact upon viral load and CD4 and CD8 cell counts
p17 (77–85) p17 (77–85) SLYNTVATL HIV-1 infection human (A*0201) Betts2000
• Only 4/11 HLA-A2+ HIV+ individuals had CTL that reacted to SLYNTVATL, calling into question whether it is immunodominant
• 95 optimally-defined peptides from this database were used to screen for INFγ responses to other epitopes
• Individuals that did not respond to SLYNTVATL recognized other HIV epitopes, and 2/4 SLYNTVATL responders had stronger responses to epitopes
restricted by other class I alleles
• SLYNTVATL was the only response detected in a one individual that was HLA A*0201, B44, B70
p17 (77–85) p17 (77–85) SLYNTVATL HIV-1 infection human (A*0201) Ogg1999
• Epitope name: SL9
• CTL effector levels were measured after potent ARV therapy using HLA-tetramer complexes for the A*0201 epitopes SLYNTVATL and ILKEPVHGV in
seven patients, and the B*3501 epitope DPNPQEVVL in one additional patient
• Levels of CTL effectors typically decline for 5-7 days and then rebound, fluctuating during the first two weeks of therapy
• After the early fluctuation, there was a steady exponential decay with a median half-life of 45 days
p17 (77–85) p17 (77–85) SLYNTVATL HIV-1 infection human (A*0201) Altman1996
• Epitope name: SL9
• This paper introduces the tetramer methodology which permits quantification of specific CTL based on expression of specific TCRs – HLA-A2 tetramers
were prepared that can stain CTL lines specific for ILKEPVHGV and SLYNTVATL, and quantitate HIV-specific CD8+ cell lines in freshly isolated PBMCs
• Three patients only stained the Gag epitope SLYNTVATL, one patient had the highest frequency of tetramer staining to the Pol epitope (0.77%), less to the
Gag epitope (0.28%)
p17 (77–85) Gag SLYNTVATL HIV-1 infection human (A*0201) Gray1999
• Administration of highly active antiretroviral therapy (HAART) reduced CD8+ cell frequency, and the CD8+ cells detected by tetramer staining were likely
to be memory cells, indicating that persistently replicating viral populations are needed to maintain high frequencies of HIV-1 specific CTL
p17 (77–85) p17 (77–85 SF2) SLYNTVATL HIV-1 infection human (A*0201) McAdam1998
• Epitope name: SL9
• CTL from a patient infected with clade B virus did not recognize the clade A analog of this epitope
p17 (77–85) p17 (77–85) SLYNTVATL HIV-1 infection human (A*0201) Wilson1998a
• Epitope name: SL9
• HIV+ individuals were followed longitudinally using MHC tetramers in combination with 14 anti-BV chain MAbs, and clonal expansion of HIV-specific T
cells was followed in vivo
• Seven HIV+ people were studied, and all showed expansions of particular TCR BV clones, often several, relative to uninfected controls
• Three patients were followed in detail, TCR VB expansions persisted for 2 to 3 years, with occasional transient increases
• An A2-Gag specific line from one patient was found to be BV8, and at its highest level represented 17.5% of the patient’s CD8+ T cells
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p17 (77–85) p17 (77–85) SLYNTVATL HIV-1 infection human (A*0201) Ogg1998b
• Epitope name: SL9
• HLA-tetrameric complexes were used in a cross-sectional study of 14 untreated HLA A*0201 positive individuals, revealing an inverse relationship
between HIV Gag and Pol specific CTL effector cells (CTLe) and viral load
• Inclusion of both the p17 SLYNTVATL and RT ILKEPVHGV epitopes gives a good representation of HLA A*0201-restricted activity
• No correlation was observed between the CTLe and CD4 count or clearance rate of productively infected cells
p17 (77–85) p17 (77–85) SLYNTVATL in vitro stimulation human (A*0201) Walter1997
• Epitope name: SL9
• HLA-A2 heavy chain and β2-microglobulin expressed in E. coli were refolded in the presence of this peptide
• The HLA-A2-peptide complex elicited HLA-A2 peptide-specific CTL response in cells lacking HLA-A2
• Suggests that preformed HLA-peptide complexes could provide an alternate to intracellular processing for immunogens
p17 (77–85) p17 (77–85) SLYNTVATL HIV-1 infection human (A*0201) Lalvani1997
• Epitope name: SL9
• A peptide-based protocol was optimized for restimulation of CTLp using optimized peptide and IL-7 concentrations – importantly this protocol does not
stimulate a primary response, only secondary – peptide-specific CTLp counts could be obtained via staining with peptide-Class I tetramers
• This peptide was one of the test peptides for optimizing the protocol
p17 (77–85) p17 (76–84) SLYNTVATL in vitro stimulation human (A*0201) vanderBurg1996
• Epitope name: SL9
• Slow dissociation rate is associated with immunogenicity
• CTL generated by in vitro stimulation of PBMC derived from uninfected individual
p17 (77–85) p17 (77–85) SLYNTVATL HIV-1 infection human (A*0201) Goulder1997e, Goulder1997a
• Epitope name: SL9
• Identical twin hemophiliac brothers were both infected with the same batch of factor VIII
• One had a response to gag A2 epitope SLYNTVATL, the other to pol A2 epitope ILKEPVHGV
• Viral sequencing from the twin that had no response to SLYNTVATL indicated his virus had the substituted form SLHNAVAVL
• 71% of an additional set of 22 HIV-1 infected HLA-A*0201 positive donors preferentially responded to gag SLYNTVATL
• Those individuals with a pol ILKEPVHGV response tended to have mutations in or around SLYNTVATL
• An additional subject went from SLYNTVATL responder to non-responder coincident with a switch to the variant SLFNTVATL
• [Goulder1997a] is a review of immune escape that summarizes this study
p17 (77–85) Gag (77–85) SLYNTVATL HIV-1 infection human (A*0201) Gray1999
• Epitope name: SL9
• Peptide-tetramer complexes of A*0201 and SLYNTVATL or ILKEPVHGV were used to study individuals receiving HAART to determine the frequency of
Class I HLA-restricted anti-HIV CD8+ T cells
• 17/18 asymptomatic patients had a CTL response to one or both epitopes – 72% had a CTL response to SLYNTVATL
• After HAART, the majority of the epitope-specific CTL were apparently memory cells
p17 (77–85) p17 (77–85 subtype A) SLFNTVATL HIV-1 infection human (A*0201) Dorrell1999
• Epitope name: SL9
• CTL responses in three individuals with non-clade B infections were studied, 2 with subtype A infections, 1 with subtype C – their infections all originated
in East Africa
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• This epitope is most commonly SLYNTVATL in B subtype, and CTL from the C subtype infection did not recognize B clade gag or the 3Y form of the
epitope, but do recognize the predominant A and C clade form, SLFNTVATL
p17 (77–85) p17 (77–85) SLYNTVATL HIV-1 infection human (A*0201) Brander1998a
• Epitope name: SL9
• Of 17 infected HLA A*0201 subjects, 13 had CTL responses against the p17 SLYNTVATL epitope, six recognized ILKEPVHGV and five recognized
VIYQYMDDL, and there was no correlation between viral load and recognition of a specific epitope
• Only one subject had CTL against all three epitopes
• There was significant heterogeneity in the CTL response to this immunodominant epitope
• The overall variation in this epitope among the 17 who had a CTL response and 11 non-HLA A*0201 HIV-1+ individuals was similar, suggesting a lack of
immune pressure
• Subjects were part of the San Francisco City Clinic Cohort, the ARIEL project and from the Boston area
p17 (77–85) p17 (77–85 HXB2) SLYNTVATL HIV-1 infection human (A*0201) Hay1999b
• Epitope name: SL9
• CTL response to IPRRIRQGL was the immunodominant response in a rapid progressor – there was a subdominant response to SPAIFQSSM in Pol, and
interestingly, no response to commonly immunodominant HLA A*0201 epitope SLYNTVATL, although this individual was HLA A*0201
• The individual showed a strong initial CTL response at the time of the initial drop in viremia, but it was quickly lost, although memory cells persisted
• Despite the initial narrow response to two epitopes, no other CTL responses developed
• No HIV-specific lymphoproliferative responses were detected in this patient, and neutralizing antibody response was weak
• A variant of this epitope was observed in vivo (–F—-V-), but this mutation is recognized by SLYNTVATL-specific CTL, and in this case the patient’s cells
could present the peptide to SLYNTVATL-specific CTL
p17 (77–85) p17 (77–85) SLYNTVATL HIV-1 infection human (A*0201) Kalams1999b
• Two patients were followed before and after HAART – reduced plasma HIV-1 RNA levels resulted in a decline in HIV-specific in-vivo activated CTL such
that by day 260 CTL activities were undetectable
• ERYLKDQQL was the dominant response in one of the individuals, SLYNTVATL subdominant
• Sporadic breakthrough in viremia resulted in transient increases in CTLp
• Memory CTL frequency directed against Vac-Gag, Vac-RT, Vac-Env, and Vac-Nef initially increased with HAART and then decreased with the decline of
the viral load
p17 (77–85) Gag (77–85) SLYNTVATL HIV-1 infection human (A*0201) Spiegel2000
• High levels of CD8+ HIV-1 specific and cytomegalovirus specific CTL were detected by HLA-A*0201-peptide tetramers in 3 infected subjects with very
low CD4 counts, but CD8 T cell mediated effector activity was not seen
• Thus HIV-1 specific CD8+ cells may be present but may lack direct effector activity in late disease, suggesting that overcoming antigen unresponsiveness
may be a useful therapeutic strategy
p17 (77–85) Gag (77–85) SLYNTVATL HIV-1 infection human (A*0201) Larsson1999
• ELISPOT was used to assay the CD8 T cell response to the HIV-1 proteins Gag, Pol, Nef or Env expressed in vaccinia vectors in 19 HIV+ people
• The highest CTL frequency was directed at epitopes Pol
• In A*0201 individuals, higher numbers of spot-forming T cells were directed against HIV-1 proteins expressed in vaccinia than to peptides SLYNTVATL
and ILKEPVHGV presented by A2
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p17 (77–85) p17 (SF2) SLYNTVATL HIV-1 infection human (A*0201) Goulder2000a
• The CTL-dominant response was focused on this epitope in 11/25 HLA A2 (A*0201 or A*0202) HIV+ individuals from Boston and in 1/8 HLA A2 HIV+
individuals from Durban
• Three peptides GSEELRSLYNTVATL (p17 residues 71-85), SALSEGATPQDLNTMLNTVG (p24 41-60), and WEKIRLRPGGKKKYKLK(p17 16-30)
contained the dominant Gag-specific epitope in 31 out of 44 B-clade infected individuals from Boston who showed Gag-CTL responses
• Five peptides RLRPGGKKHYMIKHLVW (p17 20-36), ELRSLYNTVATLYCV (p17Gag 74-88), SALSEGATPQDLNTMLNTVG (p24 41-60),
FRDYVDRFFKTLRAEQA (p24 161-177), and SILDIKQGKEPFRDY (p24 149-164) contained dominant Gag-specific epitopes in 32 out of 37 C-clade
infected subjects from South Africa
p17 (77–85) p17 (77–85 LAI) SLYNTVATL human (A*0201) Brander2001
• C. Brander notes this is an A*0201 epitope
p17 (77–85) p17 (77–85 SF2) SLYNTVATL HIV-1 infection human (A*0201) Goulder2001a
• Epitope name: SL9
• This epitope is targeted by 75% of HLA-A*0201, HIV+ adults, and the magnitude of the response is inversely correlated with viral load
• CTL responses to SL9 and autologous SL9 variants were not detected in 11 HLA-A*0201 positive subjects during acute infection
• Longitudinal studies of two individuals (AC13 and PI004) showed that the initial control of viremia was independent of the SL9 CTL response
• Low Gag expression levels did not correlate with the delayed CTL response to this epitope
• Autologous SL9 variants SLYNTIAVL, SLYNTVAVL, SLFNTVATL, SLFNTVATL, and SLFNTVATL are each capable of inducing a range of CTL
responses, sometimes strong, sometimes diminished, and sometimes complete escape relative to the than the wild type variant SLYNTVATL in patients
with chronic HIV-1 infection – the ability to cross-react with a particular variant was patient dependent
p17 (77–85) p17 SLYNTVATL HIV-1 infection human (A*0201) Altfeld2001c
• Epitope name: p17 SL9
• HIV was scanned for all peptides which carried the A2-supermotif pattern conserved in more than 50% of B clade sequences – 233 peptides met this
criteria, and 30 of these bound to HLA-A*0201 – 20/30 bound to at least 3/5 of HLA-A2 supertype alleles tested
• Three additional previously described HLA-A2 epitopes were added to the set of 20, including p17 SL9, and 18/22 chronically infected HLA-A2
individuals had CTL that recognized at least one of the 23 peptides (median of 2 and maximum of 6), while 6/12 acute infected individuals recognized at
least 1 (median of 1 and maximum of 2)
• p17 SL9 was recognized in 12/22 patients with chronic HIV-1 infection
• Only 1/13 patients with acute HIV-1 infection recognized p17 SL9
p17 (77–85) Gag SLYNTVATL HIV-1 infection human (A*0201) Goepfert2000
• Epitope name: (SL9)
• This paper describes a comparison of results of different CTL assays, a SL9 tetramer assay and IFN-gamma ELISPOT, using 7 HIV-positive patients
• The IFN-gamma ELISPOT assay was compared using the single SL9, a pool of overlapping 20 mers, and recombinant vaccinia encoding Gag as antigen –
pooled peptides gave the highest number of spot forming cells, vaccinia gave high background
• A correlation with results of the tetramer assay was found only for ELISPOT using the Gag epitope as antigen, but the tetramer assay detected a 10-fold
higher number of cells than could produce IFN-gamma in the ELISPOT assay – the authors suggest not all tetramer-positive cells may produce
IFN-gamma, some may be undergoing apoptosis, some may be producing other cytokines
• The tetramer assay could detect a reaction to SLYNTVATL in most of the HLA-A*0201 chronically HIV-1 infected study subjects
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p17 (77–85) Gag (LAI) SLYNTVATL in vitro stimulation human (A*0201) Engelmayer2001
• Recombinant canarypox virus vector containing HIV-1 sequences, upon infection of mature dendritic cells, can trigger specific lysis through in vitro by
T-cells from HIV-1 infected individuals at levels comparable to the response seen to HIV carried in vaccinia vectors
• Recombinant canarypox virus vector containing HIV-1 sequences can also stimulate HIV-specific CD4+ helper T-cell responses
p17 (77–85) p17 (77–85 LAI) SLYNTVATL HIV-1 infection human (A*0201) Mollet2000
• Epitope name: G3
• A panel of 16 epitopes covering 15 class I alleles was tested in 14 HIV+ patients from an unselected Caucasian population treated with HAART, using
tetramer staining or CD8+ cell IFNgamma production to measure responses
• In general, during the first month of treatment viral load decreased and frequencies of HIV-specific CTL tripled and broadened – eight new HIV
specificities that were not previously detectable were newly detected, as were CMV specific CD8+ PBL – but with continued viral suppression,
HIV-specific responses diminished
• Viral rebounds gave different patterns of response: increases or decreases in pre-existing response, new specificities, or no change
p17 (77–85) Gag SLYNTVATL HIV-1 infection human (A*0201) Gea-Banacloche2000
• In a study including many long-term non-progressors, no correlation between plasma virus levels and number of HIV-specific CD8+ T-cells was found
• High frequencies of circulating CD8+ T-cells were HIV-1 specific, and the majority of these responses were to gag-pol gene products
• 4/21 subjects were HLA-(A*0201), and of these only 2 subjects (patient 3 and 19) tested positive to this epitope
p17 (77–85) p17 (77–85 SF2) SLYNTVATL HIV-1 infection human (A*0201) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• Tetramer staining with A2, beta2microglobulin, and either SLYNTVATL, KLVGKLNWA, or LTFGWCFKL revealed that tetramers detected more
HIV-specific sells in LTNP than in progressors, activated effector cells were the minority population, and ELISPOT correlated better with the effector cell
subpopulation than the total tetramer stained population
p17 (77–85) Gag (77–85) SLYNTVATL HIV-1 infection human (A*0201) Jin2000a
• The CTL effector levels (CTLe) were compared in long term non-progressors (LTNP) with low viral load and in patients whose virus was well-suppressed
by therapy, using a tetramer assay
• LTNPs have high memory CTLe numbers and low viral load, while HAART patients had low CTLe numbers and low viral load
p17 (77–85) p17 (77–85) SLYNTVATL HIV-1 infection human (A*0201) Appay2000
• Combined tetramer and intracellular cytokine staining was used to study the function of circulating CD8+ T cells specific for HIV and CMV
• HIV-specific CD8+ T cells expressed lower levels of perforin than CMV-specific CD8+ T cells from the same donor, and this was associated with persistent
CD27 expression on HIV-specific cells, suggesting impaired maturation
• In most donors, between 50% and 95% of the activated virus-specific CD8+ T cells produced IFN-γ and MIP-1β with a distinct subset that failed to
produce TNF-α
p17 (77–85) p17 (77–85) SLYNTVATL HIV-1 infection human (A*0201) Goulder2000b
• Tetramer assays were compared with three functional assays in 42 people with chronic HIV infection: ELISPOT, intracellular cytokine staining, and
precursor frequency (limiting dilution assay [LDA])
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• HIV-specific tetramer staining CTLs appeared to be active, and inert CTL were not found to play a significant role in chronic pediatric or adult HIV
infection
p17 (77–85) p17 SLYNTVATL HIV-1 infection human (A*0201) Ostrowski2000
• The role of CD4+ T-cell help in expansion of virus-specific memory CTL was studied through co-culture ex vivo
• Optimal expansion of HIV-1-specific memory CTL depended on CD4+ T cell help in 9 of 10 patients – CD40 ligand trimer (CD40LT) could enhance CTL
in the absence of CD4+ T cell help to a variable degree in most of patients
• Those CTL that didn’t respond to CD40LT could expand with IL2 present, and IL15 produced by dendritic cells also contributes
• The T-helper epitope used for CD4+ T cell stimulation was the universal tetanus helper epitope TET830-843 (QYIKANSKFIGITE)
p17 (77–85) SLYNTVATL Vaccine human (A*0201) Ferrari2001
Vaccine Vector/Type: canarypox prime with rgp120 boost, canarypox prime with rgp160 boost Strain: gp41 LAI, Gag LAI, gp120 MN, gp120 SF2 HIV
component: gp120, gp41, Gag, Pol and Nef epitope rich regions
• Two vaccinees with Gag responses were HLA-A*0201+, but neither made SLYNTVATL responses to the Gag vaccine, in contrast to its frequent
recognition in natural infections. No HLA-A*0201 responses were observed to an Env vaccine.
p17 (77–85) SLYNTVATL HIV-1 infection human (A*0201) Migueles2001
• CTL activity was monitored in 27 individuals, including 10 LTNP with an over-expression of HLA B*5701 – these individuals have viral loads below the
threshold of infection without therapy, and their immune response tends to be focused on peptides that contain B*5701 epitopes ISPRTLNAW,
KAFSPEVIPMF, TSTLQEQIGW, and QASQEVKNW.
• CTL responses are broader in B*5701+ individuals with progressive viremia than those that control viremia.
• The HLA-A*0201 SLYNTVATL epitope response was not as strong individuals that carried both A2 and B57.
p17 (77–85) Gag (77–85) SLYNTVATL HIV-1 infection human (A*0201) Sewell2002
• Epitope processing of three different HLA-A*0201 HIV epitopes was shown to use different pathways, which might influence patterns of
immunodominance. .174 cells were used that lack TAP1 and TAP2 genes, as well as the LMP2 and LMP7 genes that encode the beta-subunits of the
immunoproteasome. These genes could be added back through transfection to study processing.
• ILKEPVHGV was efficiently presented in TAP-1 and -2 transfected cells while VIYQYMDDL and SLYNTVATL were not. VIYQYMDDL was destroyed
by the MB1 subunit of the protease, and could be expressed in the presence of the proteasome inhibitor lactacystin, but SLYNTVATL expression was not
restored. SLYNTVATL expression was unaltered by lactacystin in a wild type cell line.
p17 (77–85) Gag (ADA) SLYNTVATL HIV-1 infected monocyte-derived murine (A*0201) Poluektova2002
• Epitope name: SL-9
• Nonobese diabetic NOD-C.B-17 SCID mice were reconstituted with HLA-A*0201 positive human PBL and injected with HIV-1 infected
monocyte-derived macrophages MDM in the basal ganglia to provide a mouse model of HIV-1 encephalitis.
• HLA-A*0201 CTL responses were detected by tetramer staining in the spleen in seven days, increased through day 14, and the numbers of productively
infected were reduced >85% in the second week.
p17 (77–85) p17 (77–85) SLYNTVATL computer prediction (A*0201) Schönbach2002
• Computational methods (artificial neural networks (ANN), hidden Markov models (HMM), binding matrices based on HLA association rates BIMAS)
were used to identify HLA-A*0201 and HLA-B*3501 HIV T-cell epitope candidates from 533 Gag, Env and Pol sequences of which 374 were derived
from HIV-1, 97 were derived from HIV-2 and 62 from SIV. Comparisons to known epitopes and between clades were made.
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• The SLYNTVATL epitope received focused discussion. SLYNTVATL, slFntvatl, slyntvaVl, and slyntIaVl are all recognized variants, ANN predicts all four
variants would be recognized, while BIMAS only predicts SLYNTVATL and slFntvatl would be recognized. However, [Sewell1997] suggested certain
substitutions may be antagonistic, including slFntvatl, and vaccines do not stimulate SLYNTVATL responses as well as natural infections. The authors note
these kinds of issues complicate the application of computational predictions of epitopes to vaccine design.
p17 (77–85) Gag (76–84) SLYNTVATL Vaccine murine (A*0201) Singh2002, Sykes1999
Vaccine Vector/Type: DNA HIV component: HIV-1 divided into a 32 plasmids in a ubiquitin expression library
• C3H (H-2k) transgenic mice carrying a fused HLA-A*0201 alpha1 and alpha2 and H-2Dk alpha3 hybrid class I molecule were immunized using an
epidermal gene gun with an ubiquitin expression library of 32 plasmids that spanned the HIV-1 genome. Ubiquitin targets the expressed HIV-1 peptides to
the proteasome.
• A single immunization with the UB-HIV-1 library vaccine induced potent, stable and multivalent CTL responses against all library members.
• Immunodominant epitopes SLYNTVATL (Gag), ILKEPVHGV(Pol), RIQRGPGRAFVTIGK(P18) and AFHHVAREK (Nef) elicited strong CD8+/IFN-
responses and stimulated CTL that were functional in a Cr-release assay and against wild type antigen.
• The presence of multiple plasmids HLA-A*0201-restricted CTL epitopes did not decrease CTL immunogenicity, and CTL responses to single peptide
immunizations were comparable to responses based on mixtures of either 16 or 32 peptides.
p17 (77–85) SLYNTVATL HIV-1 infection human (A*0201) Imami2002b
• 70 patients with chronic disease progression, 10 clinical non-progressors, and 3 immunologically discordant progressors (individuals who controlled
viremia but had progressive CD4+ T-cell decline) were analyzed for their T-helper cell responses to p24 and cytokine profile. Long term non-progressors
had much strong Th responses, particularly to p24 peptides, and they tended to be balanced between Th1, IL-2 producing and Th2, IL-4 producing
responses.
• One of the immunologically discordant progressors became symptomatic during the course of the study, and he had a rapid drop in proliferative response to
all antigens and also a shift from a Th1 to a Th2 response. To find out if the CD8 response also shifted in cytokine production, the CD8+ T-cell response to
SLYNTVATL in this patient was also tested. It to was found to shift, from IFNgamma to IL-4 producing in Elispot, and using a bioassay of indicator lines,
from IL-2 to IL-4 production.
p17 (77–85) p17 (77–85) SLYNTVATL human (A*0202) Brander2001
• C. Brander notes that this epitope can be presented by A*0201 and A*0202
p17 (77–85) p17 (SF2) SLYNTVATL HIV-1 infection human (A*0202) Goulder2000a
• The CTL-dominant response was focused on this epitope in 11/25 HLA A2 (A*0201 or A*0202) HIV+ individuals from Boston and in 1/8 HLA A2 HIV+
individuals from Durban
• Three peptides GSEELRSLYNTVATL (p17 residues 71-85), SALSEGATPQDLNTMLNTVG (p24 41-60), and WEKIRLRPGGKKKYKLK(p17 16-30)
contained the dominant Gag-specific epitope in 31 out of 44 B-clade infected individuals from Boston who showed Gag-CTL responses
• Five peptides RLRPGGKKHYMIKHLVW (p17 20-36), ELRSLYNTVATLYCV (p17Gag 74-88), SALSEGATPQDLNTMLNTVG (p24 41-60),
FRDYVDRFFKTLRAEQA (p24 161-177), and SILDIKQGKEPFRDY (p24 149-164) contained dominant Gag-specific epitopes in 32 out of 37 C-clade
infected subjects from South Africa
p17 (77–85) p17 (77–85 LAI) SLYNTVATL human (A*0205) Brander2001
• C. Brander notes that this epitope can be presented by A*0201 and A*0202
p17 (77–85) p17 (subtype A) SLYNTVATL HIV-1 exposed seronegative human (A*0214,
A*0201)
Kaul2000
• 11/16 heavily HIV exposed but persistently seronegative sex-workers in Nairobi had HIV-specific CD8 gamma-IFN responses in the cervix – systemic
CD8+ T cell responses tended to be to the same epitopes but at generally lower levels than cervical CD8+ T cell responses
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• Low risk individuals did not have such CD8+ cells
• CD8+ T cell epitopes: DTVLEDINL (3 individuals), SLYNVATL (4 individuals), LSPRTLNAW (3 individuals) and YPLTFGWCF (4 individuals) were
most commonly recognized by the HIV-resistant women
• The epitope variants SLYNTVATL and SLFNTVATL were both recognized
p17 (77–85) SLYNTVATL HIV-1 infection human (A02) Sabbaj2002b
• Epitope name: Gag-SL9
• Among HIV+ individuals who carried HLA A02, 17/30 (57%) recognized this epitope
p17 (77–85) Gag (77–85) SLYNTVATL Vaccine human (A2) Woodberry1999
Vaccine Vector/Type: vaccinia HIV component: polyepitope
• A polyepitope vaccine was generated in a vaccinia construct that contiguously encoded seven epitopes, all presented by HLA A-2
• HHD mice have a transgene of HLA A2 linked to the transmembrane and cytotoxic domains of H-2Dd – this transgene is the only MHC molecule
expressed in the mice
• CTL responses to Gag (77-85) SLYNTVATL, Pol (476-484) ILKEPVHGV, gp120 (120-128) KLTPLCVTL, and Nef (190-198) AFHHVAREL were
observed in HIV polytope HHD-vaccinated mice, and these responses were enhanced with vaccinia boost
• No CTL immune responses were generated against HLA A2-restricted HIV epitopes Nef 157-166 (PLTFGWCYKL), Pol 346-354 (VIYQYMDDL), and
Nef 180-189 (VLEWRFDSRL)
• Sixteen HLA A2+ patients were tested for their ability to make CTL responses by peptide restimulation in culture with the epitopes selected for inclusion in
the polytope – one individual recognized all seven of these epitopes; 7 patients had CTL cultures able to recognize at least one of the epitopes, and 6 of
those 7 recognized more than one epitope, but they were not able to test all peptides for all patients; many patients only had three peptides tested
• SLYNTVATL was recognized by 5/16 HLA-A2 patients
p17 (77–85) p17 (77–85) SLYNTVATL Vaccine human (A2) Carruth1999
Vaccine Vector/Type: canarypox Strain: MN, LAI HIV component: gp120, gp41, Gag, Protease
• The vaccine used was a live recombinant canarypox (CP) virus vaccine containing multiple HIV-1 genes (HIV-1 MN gp120, HIV-1 LAI gp41, HIV-1 LAI
Gag, HIV-1 LAI protease)
• CD4+ and CD8+ Gag and Env specific CTL responses were detected in only 1/5 vaccinated volunteers, and were not detectable 1 year after vaccination
• CTL responses to epitopes SLYNTVATL and TVYYGVPVWK from HIV+ control patients were used as positive controls
• The study explored why vaccinees were non-responsive – non-response was not due to inherent defects or differences in the ability of these individuals to
process and present antigen
• Lack of response to SLYNTVATL led the authors to speculate that the immunodominance of this epitope in natural infections may not be recapitulated by
vaccine antigen
p17 (77–85) p17 (77–85) SLYNTVATL HIV-1 infection human (A2) Birk1998b
• Epitope name: SL9
• A study of p17 variation considering known p17 epitopes and individuals with known HLA types revealed that p17 evolution is influenced by immune
pressure from CTLs
p17 (77–85) p17 (77–85) SLYNTVATL HIV-1 infection human (A2) Callan1998
• Epitope name: SL9
• Included as a negative control in a tetramer study of A2-EBV CTL response
p17 (77–85) p17 SLYNTVATL HIV-1 infection human (A2) Wagner1998a
• Epitope name: SL9
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• CTL specific for HIV epitopes were used to show that the mediators of both the cytolytic (granzyme A was used as the marker) and non-cytolytic (HIV-1
inhibitory chemokines MIP-1 α and RANTES were used as markers) anti-viral responses are localized within the CTL’s cytotoxic granules
p17 (77–85) p17 (77–85 HXB2) SLYNTVATL HIV-1 infection human (A2) Collins1998
• Epitope name: SL9
• Two CTL clones recognize this epitope, but not the NL4-3 form of the epitope SLYNTIAVL
• Nef down-regulates MHC class I molecules, which inhibits CTL killing, and this down-regulation can be partially compensated for by adding excess
soluble peptide
p17 (77–85) p17 (77–85) SLYNTVATL HIV-1 infection human (A2) Durali1998
• Epitope name: SL9
• Cross-clade CTL response was studied by determining the CTL activity in seven patients from Bangui, (6 A subtype, and 1 AG recombinant infections) and
one A subtype infection from a person living in France originally from Togo, to different antigens expressed in vaccinia
• Pol reactivity: 8/8 had CTL to A subtype, and 7/8 to B subtype, and HIV-2 Pol was not tested
• Gag reactivity: 7/8 reacted with A or B subtype gag, 3/8 with HIV-2 Gag
• Nef reactivity: 7/8 reacted with A subtype, and 5/8 with B subtype, none with HIV-2 Nef
• Env reactivity: 3/8 reacted with A subtype, 1/8 with B subtype, none with HIV-2 Env
• Patient B18 had the greatest breadth and diversity of response, and recognized Gag SLYNTVATL and Nef PLTFGWCFKL
p17 (77–85) p17 (77–85) SLYNTVATL HIV-1 infection human (A2) Kundu1998b
• Epitope name: SL9
• Allogeneic dendritic cells (DCs) were obtained from HLA-identical siblings, pulsed with rgp160 MN or A2-restricted HIV-1 epitope peptides, and infused
monthly into six HIV-infected patients
• 1/6 showed increased env-specific CTL and increased lymphoproliferative responses, 2/6 showed increase only in proliferative responses, and 3/6 showed
no change – pulsed DCs were well tolerated
• SLYNTVATL is a conserved HLA-A2 epitope included in this study – 3/6 patients had this sequence as their HIV direct sequence, one had the form
SLYNTVAVL and all four of these had a detectable CTL response – the other two had either the sequence SLFSAVAVL or SLFSAVAAL and no detectable
CTL response
p17 (77–85) p17 (77–85 IIIB) SLYNTVATL HIV-1 infection human (A2) Sipsas1997
• Epitope name: SL9
• HIV IIIB proteins were used to define the range of CTL epitopes recognized by 3 lab workers accidentally infected with HIV-1 IIIB
• SLYNTVAVL, a variant found in HIV-1 MANC, was also recognized
• SLFNTVAVL, a variant found in HIV-1 NY5CG, was also recognized
p17 (77–85) p17 SLYNTVATL HIV-1 infection human (A2) Rowland-Jones1998a
• Epitope name: SL9
• A CTL response was found in exposed but uninfected prostitutes from Nairobi using previously-defined B clade epitopes that tended to be conserved in A
and D clades – such cross-reactivity could protect against both A and D and confer protection in Nairobi where both subtypes are circulating
• The A subtype consensus is SLfNtvatL
• The D subtype consensus is SLyNTvATL
p17 (77–85) p17 SLYNTVATL HIV-1 infection human (A2) Sewell1997
• Epitope name: SL9
• Naturally occurring variants of this epitope escaped killing and acted as antagonists
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• The following variants were found in HIV-1 infected patients who mounted a strong response against this epitope: –F——, –F—-V-, –S——, -SF——,
–L——, —–I—, —–I-V-, –F–I—, –F–I-V-, –F-A—-
• All variants bound to A2 with at least half the affinity of SLYNTVATL except the triple mutant: –F–I-V-
• Antagonism could be observed at low concentrations, abrogating lysis at an antagonist:agonist ratio of 1:10 – the antagonism was observed in one
SLYNTVATL-specific CTL line but not another
p17 (77–85) p17 (77–85 HXB2) SLYNTVATL HIV-1 infection human (A2) Yang1997b
• Epitope name: SL9
• A chimeric universal T cell receptor was created by linking CD4 or an HIV-specific anti-gp41 Ig sequence to the signaling domain of the T cell receptor
chain ζ , and transduced into CD8+ cells
• The response using universal-receptor-bearing CD8+ cells to lyse infected cells in vitro was comparable to the natural occurring responses of CTL-clones
from HIV+ individuals in terms of kinetics and efficiency
• A CTL clone specific for this epitope was used for the comparison
p17 (77–85) p17 (77–85) SLYNTVATL in vitro stimulation human (A2) Stuhler1997
• Epitope name: SL9
• Keyhole limpit hemocyanin or tetanus toxoid Th epitope co-expression with peptide CTL epitopes on the same APC was required for induction of
peptide-specific CTL
p17 (77–85) p17 (77–85) SLYNTVATL HIV-1 infection human (A2) Yang1996
• Epitope name: SL9
• CD4+ cell lines acutely infected with HIV were studied to determine their susceptibility to lysis by CTL
• Clones specific for RT lysed HIV-1 infected cells at lower levels than Env or Gag specific clones
• The distinction was thought to be due to lower expression of RT relative to Env and Gag
• CTL can lyse infected cells early after infection, possibly prior to viral production
p17 (77–85) p17 (77–85) SLYNTVATL HIV-1 infection human (A2) Yang1997a
• Epitope name: SL9
• CTL inhibit HIV-1 replication at effector cell concentrations comparable to those found in vivo
• CTL produced HIV-1-suppressive soluble factors – MIP-1α , MIP-1β , RANTES, after antigen-specific activation
• CTL suppress HIV replication more efficiently in HLA-matched cells
p17 (77–85) p17 (77–85 LAI) SLYNTVATL HIV-1 infection human (A2) Parker1992, Parker1994
• Epitope name: SL9
• Examined in the context of motifs important for HLA-A2 binding
p17 (77–85) p17 (77–85 LAI) SLYNTVATL HIV-1 infection human (A2) McMichael1994
• Epitope name: SL9
• Review of HIV CTL epitopes
p17 (77–85) p17 (77–85) SLYNTVATL HIV-1 infection human (A2) Tsomides1994
• Epitope name: SL9
• CTL clones recognize naturally processed peptide
p17 (77–85) p17 (77–85) SLYNTVATL in vitro stimulation human (A2) Stuhler1997
• Epitope name: SL9
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• A three cell-type cluster consisting of APCs, Th, and CTLs is the minimal regulatory unit required for Th cell-dependent induction of CTLs
p17 (77–85) p17 (77–85) SLYNTVATL HIV-1 infection human (A2) Cao1997a
• Epitope name: SL9
• The consensus peptides of B and D clade viruses and some Cs have the sequence SLYNTVATL
• The consensus peptide of A, and some C strains have SLFNTVATL, a form that is cross-reactive
p17 (77–85) Gag (77–85) SLYNTVATL HIV-1 infection human (A2) Dyer1999
• Epitope name: SL9
• CTL specific responses were measured over a 1.3 to 1.5 year period in members of the Sydney Blood Bank Cohort (SBBC) who had been infected with a
natural attenuated strain of HIV-1 which was Nef-defective
• Some of these patients had prolonged high levels of CTL effector and memory cells despite low viral load
p17 (77–85) p17 (77–85) SLYNTVATL HIV-1 infection human (A2) Harrer1998
• Epitope name: SL9
• Two overlapping epitopes were recognized in a long-term survivor, restricted by two different HLA molecules, HLA-A11(TLYCVHQR) and -A2
(SLYNTVATL)
• Viral sequence substitutions were present in this individual which did not affect viral replication and did not alter CTL-recognition of the A2 epitope, but
reduced recognition of the A11 epitope, indicative of immune escape
p17 (77–85) p17 (77–85 SF2) SLYNTVATL HIV-1 infection human (A2) Altfeld2001a
• The relative contribution of CTL responses against HIV-1 Vpr, Vpu, and Vif were analyzed in multiple HIV-1-infected individuals
• Individuals with long-term nonprogressive and treated chronic HIV-1 infection targeted Vpr more frequently than individuals with treated acute infection
• Vpr is a frequent target of HIV-1 specific CD8+ T-cells – a response was detected in 45% of individuals tested and Vpr and p17 were the most preferentially
targeted proteins per unit length by CD8+ T-cells
• The A2 eptiopes Vpr AIIRLLQQL and p17 SLYNTVATL do not account for the dominance of Vpr and p17, the result holds even when HLA-A2+
individuals are excluded
p17 (77–85) p17 (BRU) SLYNTVATL in vitro stimulation human (A2) Buseyne2001
• Epitope name: SL9
• Exogenous presentation or cross-presentation of epitopes by antigen presenting cells (APC) without protein synthesis is an alternative pathway for CTL
epitope processing that may be important in the initial generation of viral specific CTL
• Dendritic cells treated with AZT to inhibit protein synthesis were able to elicit a strong specific CTL response in SLYNTVATL specific CTL line EM71-1
without protein synthesis, while macrophages demonstrated a decreased presentation efficiency
• Exogenous Gag epitope presentation was Env-dependent and required receptor-dependent fusion
p17 (77–85) p17 SLYNVATL HIV-1 infection human (A2) Kostense2001
• HLA tetramers to six epitopes were used to study HLA-A2, B8 and B57 CTL in 54 patients – HIV-specific tetramer positive cells were inversely correlated
with viral load in patients with high CD4, but in patients with CD4 T-cells below 400 high tetramer frequencies were found despite high viral load
• Most patients have high levels of HIV-specific T-cell expansions, but many of these cells aren’t functional
• In 15 of the patients, the proportion of IFN gamma producing tetramer cells correlated with AIDS-free survival
• In one patient with a SLYNVATL response, no SLYNVATL mutations were found among 21 clones despite high viral load (260,000 RNA copies/ml
serum), suggesting low in vivo efficacy of the SLYNVATL response
85
DEC 2002
C
TL
HIV CTL Epitope Tables p17 CTL Epitopes
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
p17 (77–85) p17 (77–85) SLYNTVATL HIV-1 infection human (A2) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
p17 (77–85) p17 SLYNVATL HIV-1 infection human (A2) Seth2001
• CTL responses were studied by tetramer staining in 41 patients with combination therapy – activated CD8+ T-cells decline as the viral load drops in
response to therapy, but the overall level of antigen-specific cells capable of differentiating into effectors stays constant and new epitopes may be recognized
• 6/10 A*0201+ individuals had HIV-specific tetramer staining cells, and 5 of these declined upon successful therapy
• 4/10 A*0201+ individuals with chronic HIV-1 infection recognized this epitope
• Prior to therapy, the mean percentage of CD8+ cells that recognized the immunodominant epitope SLYNVATL was six-fold greater than the percentage
recognizing the epitope ILKEPVHGV
p17 (77–85) p17 (77–85) SLYNTVATL HIV-1 infection human (A2) Islam2001
• Epitope name: SL9
• Transcript frequencies were followed for four CTL clones from patient 115, with a chronic and stable HIV-1 infection, were tracked in a longitudinal study
of samples collected 6-11 years post infection: clone M21 and E15 recognize ERYLKDQQL,and clone D87 recognizes variant ERYLQDQQL, and clone
p175b recognizes the A2 epitope SLYNTVATL
• This epitope sequence from clone p175b uses the Vbeta5, CDR3 (FDS), Jbeta2.7 TCR beta gene
• Responses were stable even through HAART with undetectable viral loads, but frequencies varied over time by 100-fold, ranging from 0.012% of the total
population for SLYNTVATL at its lowest point to 3.78% for M21, with the relative frequencies of clones shifting over time
p17 (77–85) p17 (77–85 SF2) SLYNTVATL HIV-1 infection human (A2) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-A2+ individuals that had a CTL response to this epitope broken down by group: 1/10 group 1, 2/6 group 2, and 2/4 group 3
p17 (77–85) p17 (77–85) SLFNTVATL HIV-1 infection, HIV-1 exposed
seronegative
human (A2) Kaul2001a
• Variants SL(F/Y)NTVATL are A/B clade specific
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with
reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected
women
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure
• Among HLA-A2 women, 1/10 HEPS and 22/26 HIV-1 infected women recognized this epitope, likelihood ratio 18.3, p value < 0.003, and
ILK(D/E)PVHGV tended to be more reactive in HEPS women, SL(F/Y)NTVATL in infected women
• The dominant response to this HLA allele was to this epitope in the 1/10 HEPS case and in 18 of the 22/26 HIV-1 infected women that responded
• Differences in epitope specificity were only seen for responses restricted by class I HLA alleles A2, A24, A*6802, B14, and B18, previously shown to be
associated with resistance to HIV-1 in this cohort
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• Subject ML 1250 had an A2 response to ILK(D/E)PVHGV prior to seroconversion, which switched to SL(F/Y)NTVATL post-seroconversion
• Subjects ML 1575 and ML 1592 had no response to SL(F/Y)NTVATL prior to seroconversion, but made responses post-seroconversion
• Subject ML 1760 had an A2 response to ILK(D/E)PVHGV prior to seroconversion, and gained responses to epitopes A2 SL(F/Y)NTVATL and B27
KRWII(L/M)GLNK post-seroconversion
p17 (77–85) p17 (77–85 93TH253
subtype CRF01)
SLYNTIATL HIV-1 infection human (A2) Sriwanthana2001
• Epitope name: G77-85
• This was a study of HIV-1 exposed persistently seronegative (HEPS) female sex workers in Chiang Mai, northern Thailand
• HLA-A11 is very common in this population, and was enriched among the HEPS sexworkers – weak CTL responses were detected in 4/7 HEPS women,
and CTL responses were found in 8/8 HIV+ controls, and 0/9 HIV- women that were not exposed
• This epitope was reactive in HIV+ control study subjects 125 and 144 who carried HLA-A2
p17 (77–85) p17 (77–85 93TH253
subtype CRF01)
SLYNTIATL HIV-1 infection human (A2) Bond2001
• More than half of a cohort of HIV+ female sex workers (FSW) from Northern Thailand were HLA-A11 positive, and this study concentrated on A11
epitopes in this group, although E clade versions of previously defined B-clade A2 and A24 epitopes were also tested.
• 2/4 tested FSWs recognized the E clade version of this epitope, SLYNTIATL, the B clade version is SLYNTVATL
• This epitope was only conserved in CRF01 and subtypes B and D, and exact matches were uncommon
p17 (77–85) p17 (77–85) SLYNTVATL HIV-1 infection human (A2) Day2001
• The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7 was
studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
• 2 to 17 epitopes were recognized in a given individual, A2-restricted CTL response tended to be narrow and never dominated the response, and 25/27
epitopes were targeted by at least one person
• SLYNTVATL was the dominant A2 epitope recognized in patients with chronic infection, except for Subject 11841 who recognized 5/8 epitopes
• Three subjects had an A2 response only to SLYNTVATL
• The two subjects with acute infection did not respond to SLYNTVATL
p17 (77–85) p17 (77–85) SLYNTVATL HIV-1 infection human (A2) Goulder2001c
• Epitope name: SL9
• Immune escape variants in this epitope where transmitted both horizontally and vertically in two families
• Eight transmitting mothers and 14 non-transmitters mothers were studied and variation within the SL9 epitope was associated carrying HLA-A2 (P=0.04),
but no link between variation from the SL9 consensus and vertical transmission was established
p17 (77–85) p17 (SF2) SLYNTVATL HIV-1 infection human (A2) Altfeld2000b
• This epitope was mapped by ELISPOT in a study identifying new HLA-B60 epitopes, and was one of the epitopes presented by another HLA molecule in
an HLA-B60 individual
• The response to the peptide was CD8 dependent, but the HLA presenting molecule and optimal epitope were not determined
p17 (77–85) p17 (77–85 LAI) SLYNTVATL HIV-1 infection human (A2) Kelleher2001a
• Ritonavir (RTV) inhibits chymotryptic activity in the 20S proteasome in vitro, as does Saquinavir (SQV) to a lesser extent; Indinavir (IDV) does not. Thus
there is concern protease inhibitors may adversely effect CTL epitope processing, but this paper indicates that processing is not inhibited at therapeutically
relevant concentrations of RTV when the proteasome is functioning in in an intracellular context.
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• RTV did not reduce antigen presentation and concentration of the two immunodominant Gag CTL epitopes (KRWIIMGLNK (B27) and SLYNTVATL
(A2)).
• RTV did not inhibit the processing and assembly of HLA-B35 or -A2, which are assembled with a rapid and moderate time course, respectively, or of
HLA-A3, -B27 and -B39.
p17 (77–85) p17 SLYNTVATL HIV-1 infection human (A2) Kaul2002
• Neisseria gonorrhea cervititis in 9 HIV+ Kenyan sex workers caused a functional deficiency in IFN-gamma production in HIV-1 epitope-specific CD8+
T-cells, detected by intracellular cytokine production and tetramer assays, while not affecting the total number of epitope-specific CTLs.
• Ghonorrhea caused the weaker HIV-1 specific CTL responses in 4 HIV-1 exposed persistently seronegative (HEPS) women to become undetectable by
Elispot and tetramer assays, and CMV-specific CTL in 2 HEPS subjects were shown to have impaired function with regard to IFN-gamma production.
p17 (77–85) Gag (p17) (77–85
NL43)
SLYNTVATL HIV-1 infection human (A2) Yang2002
• Nef down-modulates class I protein expression, and this study demonstrates directly that Nef-deleted HIV-1 NL-43 can be more effectively killed in vitro
than NL-43 with an intact Nef. The effect was shown to be specific for class I presentation of epitopes, and unlike Nef, deleting Vpr did not alter CTL
susceptibility of NL-43. The CTL clone 18030D23, specific for the class I A2 presented SLYNTVATL epitope, was one of four used in this study.
p17 (77–85) p17 (77–85 BRU) SLYNTVATL HIV-1 infection human (A2) Cohen2002
• The antigen presentation of two A2-restricted epitopes was compared, SLYNTVATL (p17) and ILKEPVHGV (RT). HIV-1 infected cells were more
sensitive to lysis by SLYNTVATL-specific CTL than by ILKEPVHGV-specific CTL, because of a higher density of SLYNTVATL-A2 resulting from
differences in processing.
• Incubation with a T1-cell proteolytic extract showed that by four hours, 25% of a p17 peptide had a C-term Leu-85 and were SLYNTVATL-precursors,
while ILKEPVHGV-precursors were far less frequent (6.8%) even with four times more proteolytic extract after 30 hours.
• p17 was preferentially cleaved between Leu85 and Tyr86, while appropriate Val484 and Tyr485 cleavage was minor for RT.
• In a competition experiment, RSLYNTVATL bound TAP 3.7-fold more efficiently than RT peptides.
• No difference in CTL avidity was detected in six patients with HLA-A2-restricted responses to these epitopes.
• No significant difference in HLA-A2 binding of to p17 or RT epitopes was observed.
p17 (77–85) p17 (77–85) SLYNTVATL Vaccine murine (A2) Kmieciak2001
Vaccine Strain: IIIB HIV component: Gag, Pol Adjuvant: IL-12 (IL-12p35 and IL-12p40)
• Transgenic mice expressing a HLA-A2/Kb chimeric protein were vaccinated with either a p17-p24-p51 fusion protein (vG/P-92) or the Gag-Pol precursor
protein (vVK1).
• Compared to vVK1, vG/P-92 induced a significant increase in Gag and Pol induced IFNgamma production and CTL responses, and to the epitopes
SLYNTVATL and ILKEPVHGV, as determined by Elispot and 51Cr-release assays.
p17 (77–85) Gag (77–85) SLYNTVATL HIV-1 infection human (A2) Appay2002
• Four HIV patients with prolonged clinically successful anti-viral therapy but with ongoing evidence of replication and Nef mRNA transcription, showed
specific T-cell responses by Elispot and Tetramer staining, maintained for 2-4 years after initiation of HAART.
• Nef epitope recognition was detected in all 4 subjects, gp120, Pol and Gag-specific in 1 or 2 subjects.
• The HIV-specific CD8+ T-cells had an intermediate maturation phenotype characterized by low levels of perforin and high levels of CD27 expression.
p17 (77–85) p17 SLYNTVATL HIV-1 exposed seronegative human (A2, A*0202) Rowland-Jones1998b
• Epitope name: SL9
• HIV-specific CTL were found in exposed seronegative prostitutes from Nairobi – these CTL may confer protection
• Seroprevalence in this cohort is 90-95% and their HIV-1 exposure is among the highest in the world
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• Most isolated HIV strains are clade A in Nairobi, although clades C and D are also found – B clade epitopes are often cross-reactive, however stronger
responses are frequently observed using A or D clade versions of epitopes
• This epitope is conserved among B and D clade viruses
• The Clade A version of the epitope, SLFNTVATL, was preferentially recognized by CTL
• This epitope was recognized by two different exposed seronegative prostitutes
p17 (77–85) p17 (77–85 LAI) SLYNTVATL Vaccine murine (A2.1) Peter2001
Vaccine Vector/Type: peptide Strain: LAI Adjuvant: P30, incomplete Freund’s adjuvant (IFA), Montanide (ISA 720), PLG-microparticle
• Epitope name: LR23
• The stability of peptide binding to HLA-A2.1 was determined for six HLA-A2.1 peptides included in this vaccine study – ILKEPVHGV (RT),
SLYNTVATL (p17), SLLNATDIAV (gp41) and LLWKGEGAV (RT) all bound with high affinity comparable to a influenza epitope reference
(GILGFVFTL), while RGPGRAFVTI and VIYQYMDDL bound with a lower affinity (relative binding activity = 0.01).
• The four high-affinity peptides formed stable complexes with half-lives ranging between 8 and 32 hours, while the low affinity peptides had half lives of
less than an hour.
• HLA-A2.1 transgenic mice were immunized with the six HIV-1 peptides and P30, as a universal T-helper epitope, with IFA or Montanide or microspheres
as adjuvants.
• All peptides except VIYQYMDDL induced a stong CTL response in Cr-release assays - stronger responses were observed when peptides were delivered
alone, indicating immunodominance when the combination was used.
p17 (77–85) p17 (77–85 LAI) SLYNTVATL Vaccine murine (A2.1) Peter2002
Vaccine Vector/Type: peptide Strain: LAI Adjuvant: P30, incomplete Freund’s adjuvant (IFA), IL-12
• Epitope name: LR23
• When HIV-1 peptides were used to vaccinate HLA-A2.1 transgenic A2-Kb mice, strong responses to five peptides were observed when the peptides were
given individually, but immunodominance limited the response to some of the peptides when they were given in combination [Peter2001]. IL-12 can
counteract immunodominance in BALB/c mice, so it was given with the multiple epitope vaccination, and was instead found to specifically eliminate the
HLA-A2.1-epitope CTL responses, but not Kb CTL responses. This was possibly a consequence of transient depletion of T-cells, B cells and macropahges
in the spleen.
p17 (77–85) p17 SLYNTVATL HIV-1 infection human (B*0201) Wilson2000a
• Three individuals with highly focused HIV-specific CTL responses were studied during acute infection using tetramers – high frequencies of HIV-1-specific
CD8+ T cells were found prior to seroconversion, and there was a close temporal relationship between the number of circulating HIV-specific T cells and
viral load was also found
• All three patients were B*2705, with HLA alleles: A1, A30/31, B*2705, B35; A1, A*0301, B7, B2705; and A*0201, A*0301, B2705, B39
• ELISPOT was used to test a panel of CTL epitopes that had been defined earlier and were appropriate for the HLA haplotypes of the study subjects – 3/3
subjects showed a dominant response to the B*2705 epitope KRWIILGGLNK
• The subject with A*0201 had a moderatly strong response to SLYNTVATL
• Weak responses were observed to A*301-RLRPGGKKK, A*301-QVPLRPMTYK, and B7-TPGPGVRYPL in the subject who was HLA A1, A*0301, B7,
B*2705
• No acute response was detected to the following epitopes: A*201-ILKEPVHGV, A*301-KIRLRPGGK, A*301-AIFQSSMTK, A*301-TVYYGVPVWK,
B35-EPIVGAETF, B35-HPDIVIYQY, B35-PPIPVGEIY, B35-NSSKVSQNY, B35-VPLRPMTY, B35-DPNPQEVVL
p17 (77–85) p17 (77–85) SLYNTVATL HIV-1 infection human (B62) Goulder1997a
• Epitope name: SL9
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• This paper is a review of CTL and immune evasion, but it presents a study of a shift from an HLA-A*0201 response to SLYNTVATL, to a B62 response to
GLNKIVRMY
• As long as a strong CTL response to SLYNTVATL was evident, the epitope variants SLFNTVATL or SLYNTIATL dominated the viral population –
eventually the CTL response to the index peptide became undetectable, the CTL response shifted to a focus on GLNKIVRMY, and the index peptide
SLYNTVATL once again established itself as the dominant form
p17 (77–85) Gag (77–85) SLYNTVATL human (HLA-A201) Sandberg2000
• This epitope served as a positive control in a study comparing peptide binding affinity to HLA-A201 to CTL responses upon vaccination with a nef DNA
vaccine
p17 (82–91) p17 (82–91 93TH253
subtype CRF01)
IATLWCVHQR HIV-1 infection, HIV-1 exposed
seronegative
human (A11) Sriwanthana2001
• Epitope name: G82-91
• This was a study of HIV-1 exposed persistently seronegative (HEPS) female sex workers in Chiang Mai, northern Thailand
• HLA-A11 is very common in this population, and was enriched among the HEPS sexworkers – weak CTL responses were detected in 4/7 HEPS women,
and CTL responses were found in 8/8 HIV+ controls, and 0/9 HIV- women that were not exposed
• This epitope was weakly reactive in the HEPS study subject 265 who was HLA A2/A11
• This epitope was strongly reactive in HIV+ study subject 053 who carried HLA-A11
p17 (82–91) p17 (82–91 93TH253
subtype CRF01)
IATLWCVHQR HIV-1 infection human (A11) Bond2001
• HLA-A11 CRF01 (called subtype E in Bond et al.) epitopes were identified that stimulated CTL from HIV+ female sex workers (FSW) from Northern
Thailand, of whom more than half were HLA-A11 positive
• 77 possible HLA-A11 epitopes were first defined using EpiMatrix, these were screened for binding to A11 finding and 26 bound, and 12 of these were
epitopes for CTL responses from 8 HLA-A11 positive FSWs, six were novel, six were previously identified
• This epitope was predicted by the EpiMatrix method to be likely to bind to A11, and it served as an epitope in the FSWs, it was one of the six A11 epitopes
that had been previously defined
• 3/8 tested FSWs recognized this epitope
• This epitope was not conserved in other subtypes, and exact matches were uncommon
p17 (84–91) Gag (83–90) TLYCVHQR HIV-1 infection human (A*1101) Fukada2002
• Counterparts for eight known clade B HLA A*1101 epitopes were generated for clade E (CRF01). Three epitopes, identical among clade A-E, were
cross-reactive and recognized by clade E infected individuals. The clade E and B analogs to three more HLA A*1101 epitopes was recognized in a clade
specific manner. Two other HLA A*1101 clade B defined epitopes were found not to have stimulated a response in clade E infected individuals.
• TLYCVHQR was found to elicit clade-specific responses in clade B (TLYCVHQR is most common, and is also common in clade A – the variant tlycvhqK
is common in clade B) and clade E (tlWcvhqr is most common). TLYCVHQR was not recognized by any CTL, tlycvhqK was recognized by CTL from 1/5
B clade infected Japanese subjects, and tlWcvhqr was not recognized by CTL from infected Thai subjects, so this seems to be a B clade exclusive epitope.
• The binding of the variant peptides to HLA A*1101 was comparable, but CTL that recognized tlycvhqK did not cross-recognize the other forms,
implicating TCR interaction differences.
p17 (84–91) p17 (83–91) TLYCVHQR HIV-1 infection human (A11) Harrer1998
• Two overlapping epitopes were recognized in a long-term survivor, restricted by two different HLA molecules, HLA-A11(TLYCVHQR) and -A2
(SLYNTVATL)
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• Viral sequence substitutions were present in this individual which did not affect viral replication and did not alter CTL-recognition of the A2 epitope, but
reduced recognition of the A11 epitope, indicative of immune escape
• A Q90E substitution resulted in a loss of the ability of the peptide to induce lysis, a R91K substitution was still reactive, and a R91Q substitution show a
reduced ability to stimulate lysis
p17 (84–92) p17 (84–92) TLYCVHQRI HIV-1 infection human (A*1101) Brander2001
• C. Brander notes that this is an A*1101 epitope
p17 (84–92) p17 (84–92) TLYCVHQRI HIV-1 infection human (A11) Brander1995b
• Epitope defined in the context of the Pediatric AIDS Foundation ARIEL Project, a mother-infant HIV transmission study
p17 (84–92) p17 (84–92) TLYCVHQRI HIV-1 infection human (A11) Birk1998b
• A study of p17 variation considering known p17 epitopes and individuals with known HLA types revealed that p17 evolution is influenced by immune
pressure from CTLs
p17 (84–92) p17 (84–92) TLYCVHQRI HIV-1 infection human (A11) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
p17 (84–92) p17 (84–92 SF2) TLYCVHQRI HIV-1 infection human (A11) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-A11+ individuals that had a CTL response to this epitope broken down by group: 0/3 group 1, 0/0 group 2, and 1/2 group 3
p17 (84–92) p17 (84–92) TLYCVHQRI HIV-1 infection, HIV-1 exposed
seronegative
human (A11) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
p17 (86–101) p17 (SF2) YCVHQRIEIKDTKEAL HIV-1 infection human Altfeld2000b
• This epitope was mapped by ELISPOT in a study identifying new HLA-B60 epitopes, and was one of the epitopes presented by another HLA molecule in
an HLA-B60 individual
• The response to the peptide was CD8 dependent, but the HLA presenting molecule and optimal epitope were not determined
p17 (86–101) p17 (SF2) YCVHQRIEIKDTKEAL HIV-1 infection human Altfeld2000b
• This epitope was mapped by ELISPOT in a study identifying new HLA-B60 epitopes, and was one of the epitopes presented by another HLA molecule in
an HLA-B60 individual
• The response to the peptide was CD8 dependent, but the HLA presenting molecule and optimal epitope were not determined
p17 (87–105) p17 (91–105 SF2) CRIDVKDTKEALEKIE HIV-1 infection human Lieberman1997b
• CTL expanded ex vivo were later infused into HIV-1 infected patients
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p17 (88–115) p17 (88–115 ARV) VHQRIEIKDTKEALDKIEE-
EQNKSKKKA
HIV-1 infection human (A2) Achour1990
• B cell epitope HGP-30 also serves as a CTL epitope
p17 (88–115) p17 (88–115 ARV) VHQRIEIKDTKEALDKIEE-
EQNKSKKKA
Vaccine murine BALB/c (H-2d) Hamajima1997
Vaccine Vector/Type: peptide HIV component: V3, HPG30, CD4BS Adjuvant: IL-12
• B cell epitope HGP-30 also serves as a CTL epitope
• Vaccine combined HGP-30, V3 loop peptide variants, and CD4 binding site peptide
• IL-12 expression plasmid included with the vaccination enhanced the CTL response
p17 (91–101) p17 (SF2) RIDVKDTKEAL HIV-1 infection human Goulder2000a
• The CTL-dominant response was focused on this epitope in an HIV+ Haitian living in Boston, who was A23/68 B45/72 Cw2/16 – this epitope fell outside
the most recognized peptides in the study
• Three peptides GSEELRSLYNTVATL (p17 residues 71-85), SALSEGATPQDLNTMLNTVG (p24 41-60), and WEKIRLRPGGKKKYKLK(p17 16-30)
contained the dominant Gag-specific epitope in 31 out of 44 B-clade infected individuals from Boston who showed Gag-CTL responses
• Five peptides RLRPGGKKHYMIKHLVW (p17 20-36), ELRSLYNTVATLYCV (p17Gag 74-88), SALSEGATPQDLNTMLNTVG (p24 41-60),
FRDYVDRFFKTLRAEQA (p24 161-177), and SILDIKQGKEPFRDY (p24 149-164) contained dominant Gag-specific epitopes in 32 out of 37 C-clade
infected subjects from South Africa
p17 (91–105) p17 (91–105 SF2) RIDVKDTKEALEKIE HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Twelve subjects had CTL that could recognize vaccinia-expressed LAI gag
• One of these 12 had CTL response to this peptide
• The responding subject was HLA-A3, A24, B8, B55
p17 (92–101) p17 (92–101) IEIKDTKEAL HIV-1 infection human (B*4001) Brander2001
• C. Brander notes this is a B*4001 epitope
p17 (92–101) p17 IEIKDTKEAL HIV-1 infection human (B60) Wagner1998a
• CTL specific for HIV epitopes were used to show that the mediators of both the cytolytic (granzyme A was used as the marker) and non-cytolytic (HIV-1
inhibitory chemokines MIP-1 α and RANTES were used as markers) anti-viral responses are localized within the CTL’s cytotoxic granules
p17 (92–101) p17 (92–101 SF2) IEIKDTKEAL HIV-1 infection human (B60) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B60+ individuals that had a CTL response to this epitope broken down by group: 0/2 group 1, 1/1 group 2, and 0/0 group 3
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p17 (92–101) Gag (92–101) IEIKDTKEAL HIV-1 infection human (B60) Yang2002
• Nef down-modulates class I protein expression, and this study demonstrates directly that Nef-deleted HIV-1 NL-43 can be more effectively killed in vitro
than NL-43 with an intact Nef. The effect was shown to be specific for class I presentation of epitopes, and unlike Nef, deleting Vpr did not alter CTL
susceptibility of NL43 infected cells. The CTL clone 161JD27, specific for the class I B60 presented epitope IEIKDTKEAL, was one of four used in this
study.
p17 (92–101) p17 (SF2) IEIKDTKEAL HIV-1 infection human (B60(B*4001) Altfeld2000b
• This epitope was mapped by ELISPOT in a study identifying new HLA-B60 epitopes
• B60 is present in 10-20% of the Caucasoid and very common in Asian populations
p17 (92–101) p17 (92–101) IEIKDTKEAL HIV-1 infection human (B60/B61) Day2001
• No immunodominant responses were detected to five B61-restricted epitopes tested
• All five B60-restricted epitopes were reactive in another subject, and the B60-restricted responses together contributed over one-third of the total CTL
response
p17 (93–101) p17 (SF2) DVKDTKEAL HIV-1 infection human Goulder2000a
• The CTL-dominant response was focused on this epitope in a HIV+ Caucasian from Boston, who was A1/*0201 B8/63 Cw7/- – this epitope fell outside the
most recognized peptides in the study
• Three peptides GSEELRSLYNTVATL (p17 residues 71-85), SALSEGATPQDLNTMLNTVG (p24 41-60), and WEKIRLRPGGKKKYKLK(p17 16-30)
contained the dominant Gag-specific epitope in 31 out of 44 B-clade infected individuals from Boston who showed Gag-CTL responses
• Five peptides RLRPGGKKHYMIKHLVW (p17 20-36), ELRSLYNTVATLYCV (p17Gag 74-88), SALSEGATPQDLNTMLNTVG (p24 41-60),
FRDYVDRFFKTLRAEQA (p24 161-177), and SILDIKQGKEPFRDY (p24 149-164) contained dominant Gag-specific epitopes in 32 out of 37 C-clade
infected subjects from South Africa
p17 (93–101) p17 (93–101) EIKDTKEAL Peptide-HLA interaction human (B8) DiBrino1994b
• Examined in the context of motifs important for HLA-B8 binding, predicted epitope based on Achour et al.
p17 (93–101) p17 (93–101) EIKDTKEAL HIV-1 infection human (B8) Birk1998b
• A study of p17 variation considering known p17 epitopes and individuals with known HLA types revealed that p17 evolution is influenced by immune
pressure from CTLs
p17 (93–101) p17 (93–101 LAI) EIKDTKEAL human (B8, B60) Brander1997
• Pers. Comm. from A. Trocha and S. Kalams to C. Brander and B. Walker
p17 (121–132) p17 (121–132 HXB2R) DTGHSNQVSQNY HIV-1 infection human (A33) Buseyne1993b
• Clustering of Gag p24 CTL epitopes recognized in 29 HIV-infected people
p17 (121–132) Gag (121–132 LAI) DTGHSNQVSQNY HIV-1 infection human (A33) Buseyne1993a
• Vertical transmission of HIV ranges from 13% to 39%
• Primary assays showed cytotoxic activity against at least one HIV protein was detected in 70% of infected children
• Epitopes recognized in five children were mapped using synthetic peptides and secondary cultures
• Patient EM17 (CDC P2A+C+D2) had a CTL response to two epitopes in Gag
p17 (124–132) p17 (124–132 LAI) NSSKVSQNY HIV-1 or HIV-2 infection human (B*3501) Brander2001
• Noted by Brander to be B*3501 epitope
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p17 (124–132) p17 NSSQVSQNY HIV-1 infection human (B*3501) Dorrell2001
• The crystal structure of this epitope bound to HLA-B*3501 shows that a serine can fit into the B pocket, which is shared between B35 and B53, with the
hydroxyl group of the P2 serine occupying a position almost identical to the P2 proline that was previously considered the anchor motif
• Novel B53 epitopes (DTINEEAAEW and QATQEVKNM) were defined in this study that showed that A and T can also serve as P2 anchor residues for the
B pocket of HLA-B35 and B53 – while S, T, and P could all fit into the B pocket and form a hydrogen bond, A would not form a bond, so the authors
propose compensatory interactions account for the high affinity of QATQEVKNM for B53
p17 (124–132) p17 (124–132 LAI) NSSKVSQNY HIV-1 infection human (B35) McMichael1994
• Review of HIV CTL epitopes
p17 (124–132) NSSKVSQNY HIV-1 infection human (B35) Wilson2000a
• Three individuals with highly focused HIV-specific CTL responses were studied during acute infection using tetramers – high frequencies of HIV-1-specific
CD8+ T cells were found prior to seroconversion, and there was a close temporal relationship between the number of circulating HIV-specific T cells and
viral load was also found
• All three patients were B*2705, with HLA alleles: A1, A30/31, B*2705, B35; A1, A*0301, B7, B2705; and A*0201, A*0301, B2705, B39
• ELISPOT was used to test a panel of CTL epitopes that had been defined earlier and were appropriate for the HLA haplotypes of the study subjects – 3/3
subjects showed a dominant response to the B*2705 epitope KRWIILGGLNK
• The subject with A*0201 had a moderatly strong response to SLYNTVATL
• Weak responses were observed to A*301-RLRPGGKKK, A*301-QVPLRPMTYK, and B7-TPGPGVRYPL in the subject who was HLA A1, A*0301, B7,
B*2705
• No acute response was detected to the following epitopes: A*201-ILKEPVHGV, A*301-KIRLRPGGK, A*301-AIFQSSMTK, A*301-TVYYGVPVWK,
B35-EPIVGAETF, B35-HPDIVIYQY, B35-PPIPVGEIY, B35-NSSKVSQNY, B35-VPLRPMTY, B35-DPNPQEVVL
p17 (124–132) p17 (124–132) NSSKVSQNY HIV-1 infection human (B35) Birk1998b
• A study of p17 variation considering known p17 epitopes and individuals with known HLA types revealed that p17 evolution is influenced by immune
pressure from CTLs
p17 (124–132) p17 (124–132 LAI) NSSKVSQNY HIV-1 or HIV-2 infection human (B35) Rowland-Jones1995b
• Established by titration
p17 (124–132) p17 (124–132 LAI) NSSKVSQNY in vitro stimulation human (B35) Lalvani1997
• A peptide-based protocol was optimized for restimulation of CTLp using optimized peptide and IL-7 concentrations – importantly this protocol does not
stimulate a primary response, only secondary – peptide-specific CTLp counts could be obtained via staining with peptide-Class I tetramers
• This peptide was one of the B35 presented test peptides used in control experiments showing that the assay gave no activity using lymphocytes from 21
healthy B35 seronegative donors
p17 (124–132) p17 NSSKVSQNY human (B35) Rowland-Jones1999
• CTL responses in seronegative highly HIV-exposed African female sex workers in Gambia and Nairobi were studied – these women had no delta 32
deletion in CCR5
• In Gambia there is exposure to both HIV-1 and HIV-2, CTL responses to B35 epitopes in exposed, uninfected women are cross-reactive
• HIV-2 version of this epitope is not conserved: PPSGKGGNY, but the CTLs are cross-reactive – this is one of five B35 CTL epitopes that are
cross-reactive, see also [Rowland-Jones1995b]
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p17 (124–132) p17 NSSKVSQNY HIV-1 infection human (B35) Seth2001
• CTL responses were studied by tetramer staining in 41 patients with combination therapy – activated CD8+ T-cells decline as the viral load drops in
response to therapy, but the overall level of antigen-specific cells capable of differentiating into effectors stays constant and new epitopes may be recognized
p17 (124–132) p17 (124–132 SF2) NSSKVSQNY HIV-1 infection human (B35) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B35+ individuals that had a CTL response to this epitope broken down by group: 0/2 group 1, 0/2 group 2, and 1/1 group 3
p17 (124–132) NSSKVSQNY HIV-1 infection human (B35) Sabbaj2002b
• Epitope name: Gag-NY9
• Among HIV+ individuals who carried HLA B35, 1/21 (5%) recognized this epitope
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p17-p24 (127–3) p17-p24 (127–135
subtype D)
QVSQNYPIV human (A*6802) Dong1998a
• Epitope starts in p17 and ends in p24
• Predicted on binding motif, no truncations analyzed
p17-p24 (131–6) p17-p24 (132–140 SF2) NYPIVQNL HIV-1 infection human (A*2402) Ikeda-Moore1997
• The epitope starts in p17 and ends in p24
• Defined using reverse immunogenetics – 59 HLA-A*2402 binding peptides were predicted by searching for A*2402 anchors in HIV proteins (Tyr at 2, and
Phe, Leu or Ile at the C term) – 53 of the 59 peptides bound A*2402
• This peptide induced CTL in 1/4 HIV-1+ people tested
• NYPIVQNL bound to A*2402 with medium strength, and the epitope can be processed in a vaccinia construct and presented – no CTL clone was obtained
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p24 (8–17) p24 (140–149) GQMVHQAISP HIV-1 infection human (B57) Betts2000
• Only 4/11 HLA-A2+ HIV+ individuals had CTL that reacted to SLYNTVATL, calling into question whether it is immunodominant
• 95 optimally-defined peptides from this database were used to screen for INFγ responses to other epitopes
• 1/11 of the A2+ individuals was HLA A*0201, A1, B57 and responded to four B57 epitopes and two others
p24 (8–20) p24 (140–152 IIIB) GQMVHQAISPRTL HIV-1 infection human (Cw3) Littaua1991
• Fine specificity of human Cw3 restricted Gag CTL epitope
p24 (8–27) p24 (140–159) GQMVHQAISPRTLNAWVKVV HIV-1 infection human (B14) Musey1997
• CTL specific for this epitope were found in the peripheral blood but not in the cervical mucosa of one donor
p24 (9–18) Gag (173–182) QMVHQAISPR HIV-1 infection human (A3 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind 3/5 HLA-A3 supertype alleles (A*0301, A*1101, A*3101, A*3301 and A*6801)
p24 (10–18) Gag (174–182) MVHQAISPR HIV-1 infection human (A3 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind 5/5 HLA-A3 supertype alleles (A*0301, A*1101, A*3101, A*3301 and A*6801)
p24 (11–24) p24 (SF2) VQHAISPRTLNAWV HIV-1 infection human Goulder2000a
• The CTL-dominant response was focused on this epitope in an HIV+ Haitian living in Boston, who was A34/68 B57/71 Cw3/7 – this epitope fell outside
the most recognized peptides in the study
• Three peptides GSEELRSLYNTVATL (p17 residues 71-85), SALSEGATPQDLNTMLNTVG (p24 41-60), and WEKIRLRPGGKKKYKLK(p17 16-30)
contained the dominant Gag-specific epitope in 31 out of 44 B-clade infected individuals from Boston who showed Gag-CTL responses
• Five peptides RLRPGGKKHYMIKHLVW (p17 20-36), ELRSLYNTVATLYCV (p17Gag 74-88), SALSEGATPQDLNTMLNTVG (p24 41-60),
FRDYVDRFFKTLRAEQA (p24 161-177), and SILDIKQGKEPFRDY (p24 149-164) contained dominant Gag-specific epitopes in 32 out of 37 C-clade
infected subjects from South Africa
p24 (11–32) p24 (143–164 BH10) VHQAISPRTLNAWVKVVEE-
KAF
HIV-1 infection human (Bw57) Johnson1991
• Gag CTL response studied in three individuals
p24 (12–20) Gag (146–154) HQAISPRTL HIV-1 infection chimpanzee (Patr-B*02) Balla-Jhagjhoorsingh1999b
• Certain HLA-alleles have been associated with long-term survival – among them are HLA-B*27 and HLA-B*57
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• Of more than 150 chimpanzees that have been reported to be infected with HIV-1, only one has developed AIDS
• CTL responses were studied in two HIV-1 infected chimpanzees that have strong CTL responses, and they were found to respond to highly conserved
epitopes that are recognized in humans in the context of HLA-B*27 and HLA-B*57
• The human HLA protein which presents this Patr-B*02 epitope is HLA-B*5701 but the amino acid sequences in the binding pockets of HLA-B*5701 and
Patr-B*02 are distinctive
p24 (13–20) p24 (145–152) QAISPRTL HIV-1 infection, HIV-1 exposed
seronegative
human (Cw3) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
p24 (13–23) p24 (145–155) QAISPRTLNAW HIV-1 infection human Betts2000
• Only 4/11 HLA-A2+ HIV+ individuals had CTL that reacted to SLYNTVATL, calling into question whether it is immunodominant
• 95 optimally-defined peptides from this database were used to screen for INFγ responses to other epitopes
• 1/11 of the A2+ individuals was HLA A*0201, A1, B57 and responded to QAISPRTLNAW noted previously to be A25
p24 (13–23) p24 (145–155 LAI) QAISPRTLNAW human (A*2501) Brander2001
• C. Brander notes that this is an A*2501 epitope
p24 (13–23) p24 (145–155 SF2) QAISPRTLNAV HIV-1 infection human (A25) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-A25+ individuals that had a CTL response to this epitope broken down by group: 0/0 group 1, 0/2 group 2, and 1/3 group 3
p24 (13–23) p24 (145–155 LAI) QAISPRTLNAW human (A5) Kurane1998
p24 (15–23) LSPRTLNAW HIV-1 infection, HIV-1 exposed
seronegative
human Kaul2001c
• This study examines CTL responses in HIV exposed, persistently seronegative individuals, HEPS, who eventually seroconverted – 11/114 HEPS Nairobi
sex workers eventually seroconverted, and for six of these HIV CTL reactive epitopes had been defined while seronegative
• The epidemiological factor associated with seroconversion was stopping sex work and HIV-specific CTL activity declines when HEPS sex workers stop
working for a period or retire
• ISPRTLNAW was consistently recognized by 1/22 HEPS sex worker controls (ML1250), and LSPRTLNAW was recognized by 2 additional HEPS sex
worker controls (ML1693 and ML1589)
p24 (15–23) p24 LSPRTLNAW HIV-1 infection human (B*57) Kaul2002
• Neisseria gonorrhea cervititis in 9 HIV+ Kenyan sex workers caused a functional deficiency in IFN-gamma production in HIV-1 epitope-specific CD8+
T-cells, detected by intracellular cytokine production and tetramer assays, while not affecting the total number of epitope-specific CTLs.
• Ghonorrhea caused the weaker HIV-1 specific CTL responses in 4 HIV-1 exposed persistently seronegative (HEPS) women to become undetectable by
Elispot and tetramer assays, and CMV-specific CTL in 2 HEPS subjects were shown to have impaired function with regard to IFN-gamma production.
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p24 (15–23) p24 (147–155 IIIB) ISPRTLNAW HIV-1 infection human (B*5701) Brander2001
• C. Brander notes this is a B*5701 epitope
p24 (15–23) ISPRTLNAW HIV-1 infection human (B*5701) Migueles2001
• HLA B*5701 was found in a very high frequency in HIV-1 infected non-progressors, 11/13 (85%) versus 19/200 (9.5%) of progressors. Non-progressors
tended to have an immune response that was highly focused on four p24 epitopes that were presented by B*5701, ISPRTLNAW, KAFSPEVIPMF,
TSTLQEQIGW, and QASQEVKNW.
p24 (15–23) ISPRTLNAW HIV-1 infection human (B*5701) Migueles2001
• CTL activity was monitored in 27 individuals, including 10 LTNP with an over-expression of HLA B*5701 – these individuals have viral loads below the
threshold of infection without therapy, and their immune response tends to be focused on peptides that contain B*5701 epitopes ISPRTLNAW,
KAFSPEVIPMF, TSTLQEQIGW, and QASQEVKNW.
• CTL responses are broader in B*5701+ individuals with progressive viremia than those that control viremia.
• The HLA-A*0201 SLYNTVATL epitope response was not as strong individuals that carried both A2, B57.
p24 (15–23) Gag (147–155 LAI) ISPRTLNAW HIV-1 infection human (B*5701
B*5801)
Klein1998
• B57 has been associated with long-term non-progression in the Amsterdam cohort
• The most pronounced CTL responses in HLA B*5701 LTS were to RT and Gag
p24 (15–23) p24 (147–155) ISPRTLNAW HIV-1 infection human (B57) Betts2000
• Only 4/11 HLA-A2+ HIV+ individuals had CTL that reacted to SLYNTVATL, calling into question whether it is immunodominant
• 95 optimally-defined peptides from this database were used to screen for INFγ responses to other epitopes
• 1/11 of the A2+ individuals was HLA A*0201, A1, B57 and responded to four B57 epitopes and two others, but not SLYNTVATL
p24 (15–23) Gag (SF2) ISPRTLNAW HIV-1 infection human (B57) Goulder2001a
• Epitope name: IW9
• This epitope elicited the second strongest CTL response in patient PI004 during acute infection, and maintained the response
• Three CTL responses, to epitopes TSTLQEQIGW, ISPRTLNAW, and KAFSPEVIPMF, were evident early after infection; CTL responses to SLYNTVATL,
QASQEVKNW, EIYKRWII, and FLKEKGGL were detectable at 5 months post-infection and beyond
p24 (15–23) p24 (147–155) ISPRTLNAW HIV-1 infection human (B57) Oxenius2000
• Epitope name: ISP
• Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific
CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load – three patients that had delayed initiation of
HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became
undetectable
• None of the 8 study subjects recognized this epitope but none were HLA B57+
p24 (15–23) p24 (15–23) ISPRTLNAW HIV-1 infection human (B57) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
p24 (15–23) p24 (147–155 SF2) ISPRTLNAW HIV-1 infection human (B57) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
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• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B57+ individuals that had a CTL response to this epitope broken down by group: 0/0 group 1, 0/0 group 2, and 2/2 group 3
p24 (15–23) ISPRTLNAW HIV-1 infection human (B57) Sabbaj2002b
• Epitope name: Gag-IW9
• Among HIV+ individuals who carried HLA B57, 2/5 (40%) recognized this epitope
• Among HIV+ individuals who carried HLA B58, 0/4 (0%) recognized this epitope
p24 (15–23) ISPRTLNAW HIV-1 infection human (B57) Oxenius2002b
• Epitope name: ISP
• Using previously defined epitopes [Oxenius2000, Oxenius2001a] in an IFNgamma Elispot assay, 13 chronically HIV-1 infected patients were studied over a
period including therapy with standard treatment interruptions (STI).
• STIs induced increased recognition of CTL epitopes, but there was no correlation between CTL responses with viral rebound rates, plateau viral loads, or
clearance rates.
p24 (15–23) p24 (147–155 IIIB) ISPRTLNAW HIV-1 infection human (B57, B*5801) Goulder1996b
• Five slow progressors made a response to this epitope, and in two it was the dominant response
• Peptide defined on the basis of B*5801 binding motif, yet not cross-restricted except at high concentrations
p24 (15–23) p24 (subtype A) LSPRTLNAW HIV-1 exposed seronegative human (B57, B58) Kaul2000
• 11/16 heavily HIV exposed but persistently seronegative sex-workers in Nairobi had HIV-specific CD8 gamma-IFN responses in the cervix – systemic
CD8+ T cell responses tended to be to the same epitopes but at generally lower levels than cervical CD8+ T cell responses
• Low risk individuals did not have such CD8+ cells
• CD8+ T cell epitopes: DTVLEDINL (3 individuals), SLYNVATL (4 individuals), LSPRTLNAW (3 individuals) and YPLTFGWCF (4 individuals) were
most commonly recognized by the HIV-resistant women
p24 (15–23) p24 (147–155) LSPRTLNAW HIV-1 infection, HIV-1 exposed
seronegative
human (B57, B58) Kaul2001a
• Variants (L/I)SPRTLNAW are specific for the A/B clades
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with
reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected
women
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure
• Among HLA-B57/B58 women, 4/6 HEPS and 14/17 HIV-1 infected women recognized this epitope
• The dominant response to this HLA allele was to this epitope in 2 of the 4/6 HEPS cases and in 7 of the 14/17 responsive HIV-1 infected women
p24 (16–24) p24 SPRTLNAWV HIV-1 infection chimpanzee Santra1999
• 3/4 animals displayed HIV-1 Gag-specific CTL activity
• Effector cells from two chimpanzees were able to recognize epitopes also recognized by human HIV-1 Gag-specific CTL (SPRTLNAWV, HLA-B7, and
DLNTMLNTV, HLA-B14)
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• No chimpanzee CTL were detected to the following human HIV-1 specific Gag epitopes, although they were embedded within 20mer peptides that
contained a reactive epitope: ISPRTLNAW, HLA-B57; KRWIILGLNK, HLA-B27; and DRFYKTLRA, HLA-B14
p24 (16–24) p24 (148–156) SPRTLNAWV human (B*0702) Brander2001
• C. Brander notes this is a B*0702 epitope
• Optimal peptide mapped by titration, Pers. Comm. from D. Lewinsohn to C. Brander and B. Walker
p24 (16–24) SPRTLNAWV HIV-1 infection human (B07) Sabbaj2002b
• Epitope name: Gag-SW9
• Among HIV+ individuals who carried HLA B07, 1/9 (11%) recognized this epitope
• Among HIV+ individuals who carried HLA B81, 1/6 (17%) recognized this epitope
p24 (16–24) p24 (148–156) SPRTLNAWV human (B7) Brander1997
• Optimal peptide mapped by titration, Pers. Comm. from D. Lewinsohn to C. Brander and B. Walker
p24 (16–24) p24 (148–156) SPRTLNAWV HIV-1 infection human (B7) Brodie2000
• Study tracks and quantifies in vivo migration of neo-marked CD8 HIV-specific CTL
• Adoptively transferred gene-marked HIV-specific CTL homed to specific lymph node sites, colocalizing within the parafollicular regions of the lymph node
adjacent to cells expressing HIV tat-fusion transcripts, indicative of viral replication
• The CTL clones expressed CCR5 and localized among HIV-1 infected cells expressing MIP-1alpha and MIP-1beta, CC-chemokines produced at sites of
viral replication, suggesting a possible homing mechanism
• This study provides a methodology for tracking and studying antigen specific CTL in vivo
p24 (16–24) p24 (148–156) SPRTLNAWV HIV-1 infection, HIV-1 exposed
seronegative
human (B7) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with
reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected
women
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure
• Subject ML 1203 started with CTL responses to A*6802 DTVLEDINL and to B7 FPVTPQVPLR prior to seroconversion, and upon seroconversion
acquired additional responses to A*6802 ETAYFILKL which became dominant, B7 TPGPGVIRYPL, B7 IPRRIRQGL, and B7 SPRTLNAWV
p24 (16–24) p24 (16–24) SPRTLNAWV HIV-1 infection human (B7) Day2001
• The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7 was
studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
• 2 to 17 epitopes were recognized in a given individual, A2-restricted CTL response tended to be narrow and never dominated the response, and 25/27
epitopes were targeted by at least one person
• Subjects with chronic HIV-1 infection recognized between 2-8 out of 11 B7-restricted epitopes
• An acute seroconvertor homozygous for the B7 allele recognized five B7-restricted epitopes
• The other acute seroconvertor failed to recognize any of the 11 B7-restricted epitopes tested
• The B7-restricted CTL response was highly variable and there was no clearly dominant epitope
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p24 (16–24) p24 (16–24) SPRTLNAWV HIV-1 infection human (B7) Yu2002a
• Epitope name: B7-SV9
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
• 1/11 HLA-B7 positive individuals had detectable B7-restricted responses to this epitope during acute infection – 10/15 of HLA-B7 epitopes tested were
targeted by at least one person during acute infection. 1/4 individuals had detectable responses to this epitope after STI.
p24 (16–24) p24 (subtype B) SPRTLNAWV HIV-1 exposed seronegative human (B7, B*8101) Kaul2000
• 11/16 heavily HIV exposed but persistently seronegative sex-workers in Nairobi had HIV-specific CD8 gamma-IFN responses in the cervix – systemic
CD8+ T cell responses tended to be to the same epitopes but at generally lower levels than cervical CD8+ T cell responses
• Low risk individuals did not have such CD8+ cells
• CD8+ T cell epitopes: DTVLEDINL (3 individuals), SLYNVATL (4 individuals), LSPRTLNAW (3 individuals) and YPLTFGWCF (4 individuals) were
most commonly recognized by the HIV-resistant women
p24 (16–24) Gag (subtype B) SPRTLNAWV HIV-1 exposed seronegative human (B7, B*8101) Rowland-Jones1998b
• HIV-specific CTL were found in exposed seronegative prostitutes from Nairobi – these CTL may confer protection
• Seroprevalence in this cohort is 90-95% and their HIV-1 exposure is among the highest in the world
• Most isolated HIV strains are clade A in Nairobi, although clades C and D are also found – B clade epitopes are often cross-reactive, however stronger
responses are frequently observed using A or D clade versions of epitopes
• This epitope is conserved among A, B, and D clade viruses
p24 (19–27) p24 (151–159) TLNAWVKVV HIV-1 infection human (A*02) Huang2000
• The single cell ELISPOT assay was optimized and highly specific, and found to work well even after the primary cells had been frozen and thawed
• Increases in gamma interferon producing cells were observed in response to anti-retroviral therapy using single cell IFN-gamma-production ELISPOT
• In 3/3 HLA-A*02, -B*27 subjects the immunodominant epitope was against HLA B*27 Gag p24 epitope KRWIILGL, not A2 Gag epitopes
p24 (19–27) p24 (151–159) TLNAWVKVV HIV-1 infection human (A*02) Rinaldo2000
• Administration of triple-drug antiretroviral therapy (IDV, 3TC and ZDV) sometimes showed a transient increase and other times failed to increase CTL
responses in patients with advanced HIV disease, but there is a stable population of tetramer stained HIV-specific CD8+ CD45RO+ cells that can persist
after therapy and long periods of virus being below the level of detection
p24 (19–27) p24 (151–159) TLNAWVKVV HIV-1 infection human (A2) Parker1992, Parker1994
• Study of sequence motifs preferred for peptide binding to class I HLA-A2
p24 (19–27) p24 (19–27) TLNAWVKVV HIV-1 infection human (A2) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
p24 (19–27) p24 (150–159) TLNAWVKVI HIV-1 infection, HIV-1 exposed
seronegative
human (A2) Kaul2001a
• Variants TLNAWVKV(I/V) are A/B clade specific
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• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
p24 (19–27) p24 (subtype B) TLNAWVKVV HIV-1 exposed seronegative human (A2, A*0202) Rowland-Jones1998b
• HIV-specific CTL were found in exposed seronegative prostitutes from Nairobi – these CTL may confer protection
• Seroprevalence in this cohort is 90-95% and their HIV-1 exposure is among the highest in the world
• Most isolated HIV strains are clade A in Nairobi, although clades C and D are also found – B clade epitopes are often cross-reactive, however stronger
responses are frequently observed using A or D clade versions of epitopes
• This epitope is conserved among A, B and D clade viruses
p24 (21–40) p24 (153–172 SF2) NAWVKVVEEKAFSPEVIPMF HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Twelve subjects had CTL that could recognize vaccinia-expressed LAI gag
• One of these 12 had CTL response to this peptide
• The responding subject was HLA-A2, -B21
p24 (21–40) p24 (153–172 SF2) NAWVKVVEEKAFSPEVIPMF Vaccine Rhesus macaque Wagner1998b
Vaccine Vector/Type: virus-like particle HIV component: gag, gp120, V3, CD4BS
• A VLP is a non-infectious virus-like particle self-assembled from HIV Pr55 gag – macaques were immunized with VLPs bound to either gp120 or
V3+CD4 linear domains Gag and Env specific CTL were stimulated in each case, and Ab response to gag and gp120 was elicited, but the gp120
neutralizing response occurred only with whole gp120, not V3+CD4 – despite the CTL and Ab response, immunized macaques were infected by
intervenous challenge with SHIV chimeric challenge stock [Wagner1998b]
• CTL specific for this epitope could be found both before and after SHIV challenge
p24 (21–40) Gag (153–172) NAWVKVVEEKAFSPEVIPMF HIV-1 infection human (B57) Brodie1999
• The ability of CTL effector cells was studied by expanding autologous HIV-1 Gag-specific CTL in vitro, and adoptively transferring them
• The transferred CTLs migrated to the lymph nodes and transiently reduced circulating productively infected CD4+ T cells, showing that CTL move to
appropriate target sites and mediate anti-viral effects
p24 (21–40) p24 (153–172) NAWVKVVEEKAFSPEVIPMF HIV-1 infection human (B57) Brodie2000
• Study tracks and quantifies in vivo migration of neo-marked CD8 HIV-specific CTL
• Adoptively transferred gene-marked HIV-specific CTL homed to specific lymph node sites, colocalizing within the parafollicular regions of the lymph node
adjacent to cells expressing HIV tat-fusion transcripts, indicative of viral replication
• The CTL clones expressed CCR5 and localized among HIV-1 infected cells expressing MIP-1alpha and MIP-1beta, CC-chemokines produced at sites of
viral replication, suggesting a possible homing mechanism
• This study provides a methodology for tracking and studying antigen specific CTL in vivo
p24 (21–42) p24 (153–174 BH10) NAWVKVVEEKAFSPEVIPM-
FSA
HIV-1 infection human (Bw57) Johnson1991
• Gag CTL response studied in three individuals
p24 (28–36) p24 EEKAFSPEV HIV-1 infection human (B*4415) Bird2002
• 5/233, (4 HIV-1 positive, 1 HEPS) (2.1%) Kenyan female sex workers carried the novel HLA allele B*4415.
• Residues forming the B pocket of HLA B*4415 were identical to HLA B*4001, B*4402 and B*4403. These alleles preferred E, an acidic residue, at the P2
position.
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• The amino acid residues forming the F pocket of allele B*4415 were not correlated with other known HLA molecules, but analogy suggests a binding
preference for small, neutral amino acids.
• Based on the binding motif x[DE]xxxxxx[VILA], 19 potential B*4415 epitopes were identified, and 1/19 was reactive in an Elispot, EEKAFSPEV.
p24 (28–47) p24 (160–179) EEKAFSPEVIPMFSALSEGA HIV-1 infection human (B27) Musey1997
• Cervical and peripheral blood derived CTL clones from an HIV-infected woman recognized this epitope
p24 (29–48) Gag (161–180 C
consensus)
EKAFSPEVPMFTALSEGAT HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
• This peptide was among the 28 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
p24 (30–37) p24 (162–170 LAI) KAFSPEVI HIV-1 infection human (B*5703) Brander2001
• C. Brander notes this is a B*5703 epitope
p24 (30–37) p24 (30–37) KAFSPEVI HIV-1 infection human (B57) Goulder2000c
• Two strong clonal CTL responses were generated in donor 026-BMC (HLA A3/-, B42/B57, Cw7/17) against different optimal versions of this epitope, one
8 amino acids long, one 11
• Improved stabilization of the B57-peptide complex was demonstrated by the 11 mer which fits the B57 binding motif, relative to the 8 mer, which does not
• B57 tolerates marked difference in optimal peptide length – and B57 is associated with non-progressive infection
p24 (30–37) KAFSPEVI HIV-1 infection human (B57) Sabbaj2002b
• Epitope name: Gag-KI8
• Among HIV+ individuals tested who carried HLA B57, 0/5 (0%) recognized this epitope.
p24 (30–40) p24 KAFSPEVIPMF HIV-1 infection, HIV-1 exposed
seronegative
human Kaul2001c
• This study examines CTL responses in HIV exposed, persistently seronegative individuals, HEPS, who eventually seroconverted – 11/114 HEPS Nairobi
sex workers eventually seroconverted, and for six of these HIV CTL reactive epitopes had been defined while seronegative
• The epidemiological factor associated with seroconversion was stopping sex work and HIV-specific CTL activity declines when HEPS sex workers stop
working for a period or retire
• This epitope was recognized by 1/22 HEPS sex worker controls, ML1250
p24 (30–40) p24 KAFSPEVIPMF HIV-1 infection human (B*57) Spiegel1999
• Study examines the effect of highly active antiretroviral therapy (HAART) on HIV-1 plasma viral load, CTLp and CTLe frequencies in 8 infected children
• CTLp (precursors) were measured by stimulating in culture and assaying using 51Cr release, against vaccina expressed IIIB Env, Gag, Pol, Nef, and CTLe
were measured by ELISPOT
• CTL against B*57-KAFSPEVIPMF was a de novo response observed in one of the children when viral load increased as a result of stopping therapy
• HIV-1 specific CTL responses initially increased in children with complete viral suppression, but then decreased, suggesting viral replication is needed to
maintain CTL responses
p24 (30–40) p24 (162–172 LAI) KAFSPEVIPMF HIV-1 infection human (B*5701) Goulder1996b
• This peptide was recognized by CTL from five slow progressors
• Peptide defined on the basis of B*5801 binding motif, yet not cross-restricted except at high concentrations
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• This epitope is highly conserved
p24 (30–40) p24 (162–172 LAI) KAFSPEVIPMF HIV-1 infection human (B*5701) Brander2001
• C. Brander notes this is a B*5701 epitope
p24 (30–40) KAFSPEVIPMF HIV-1 infection human (B*5701) Migueles2001
• HLA B*5701 was found in a very high frequency in HIV-1 infected non-progressors, 11/13 (85%) versus 19/200 (9.5%) of progressors. Non-progressors
tended to have an immune response that was highly focused on four p24 epitopes that were presented by B*5701, ISPRTLNAW, KAFSPEVIPMF,
TSTLQEQIGW, and QASQEVKNW.
• Attempts to make all for HLA B*5701-epitope tetramers were made, but only the HLA B*5701-KAFSPEVIPMF tetramer folded properly. The percentage
of CD8+ T cells staining with this HLA B*57 gag tetramer and the fraction of CD69+IFN-+ cells responding to autologous B cells pulsed with
KAFSPEVIPMF was highly correlated (r = 0.84; P = 0.005). The percent of CD8+ T cells that stain with the A*2 gag SLYNTVATL tetramer was low
(0-0.31%) in a A2+ B57+ LTNP, emphasizing the focus of the immune response on the B*5701 epitopes.
p24 (30–40) KAFSPEVIPMF HIV-1 infection human (B*5701) Migueles2001
• CTL activity was monitored in 27 individuals, including 10 LTNP with an over-expression of HLA B*5701 – these individuals have viral loads below the
threshold of infection without therapy, and their immune response tends to be focused on peptides that contain B*5701 epitopes ISPRTLNAW,
KAFSPEVIPMF, TSTLQEQIGW, and QASQEVKNW.
• CTL responses are broader in B*5701+ individuals with progressive viremia than those that control viremia.
• The HLA-A*0201 SLYNTVATL epitope response was not as strong in individuals that carried both A2 and B57.
p24 (30–40) p24 (30–40) KAFSPEVIPMF HIV-1 infection human (B*5701,
B*5703)
Gillespie2002
• Epitope name: KAFS
• CTL responses of eight HIV+ slow progressors from Nairobi Kenya or Oxford, UK who were B*5701 or B*5703 were studied, as B*57 is associated with
slow progression.
• This epitope is located between the structurally conserved alpha-helix 1 and alpha-helix 2 (H1-H2) region of the p24 capsid protein, and tends to elicit
strong reactions in B*57 individuals.
• Broad heterogeneous cross-clade reactivity to 6 clade variants of the KAFS peptide sequence were observed in one B*5701 and 5 B*5703 HLA-restricted
patients, measured by IFNγ productionElispot assays as well as tetramer binding. The clade variants were: KAFSPEVIPMF (clades A and B),
kGfNpevipmf (clades A/AC); kaLspevipmf (clade A); kafspevipVf (clade A); kafNpeIipmf (group O); kafspeIipmf (A/C); kafsQevipmf (A/C); and
kaLspevipmf KNFSPEVIPMF A/G). Not all variants were well recognized in all patients, for example kafsQevipmf was not able to induce IFN gamma
production in 3/6 tested, and had a diminished capacity to sensitize target cells for lysis.
p24 (30–40) p24 (162–172 LAI) KAFSPEVIPMF HIV-1 infection human (B*5703) Brander2001
• C. Brander notes this is a B*5703 epitope
p24 (30–40) KAFSPEVIPMF HIV-1 infection human (B*5703) Sabbaj2002b
• Epitope name: Gag-KF11
• This study monitored epitope responses in HIV-1 infected minority women living in the United States
• 24 epitopes were described – 8 were novel, 8 used new restricting elements but were previously defined epitopes, and 8 were previously described
• Serial peptide truncations were used to define optimal epitopes for CTL cell lines isolated from 12 individuals, assayed by a Cr-release
• Subject 00RCH59 was African American, on HAART, viral load 170, CD4 count 477
• Among HIV+ individuals who carried HLA-B57, 6/6 (100%) recognized this epitope
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p24 (30–40) p24 (30–40) KAFSPEVIPMF HIV-1 infection human (B57) Goulder2000c
• Two strong clonal CTL responses were generated in donor 026-BMC (HLA A3/-, B42/B57, Cw7/17) against different optimal versions of this epitope, one
8 amino acids long, one 11
• Improved stabilization of the B57-peptide complex was demonstrated by the 11mer which fits the B57 binding motif, relative to the 8 mer, which does not
• B57 tolerates marked difference in optimal peptide length – and B57 is associated with non-progressive infection
p24 (30–40) p24 (162–172) KAFSPEVIPMF HIV-1 infection human (B57) Betts2000
• Only 4/11 HLA-A2+ HIV+ individuals had CTL that reacted to SLYNTVATL, calling into question whether it is immunodominant
• 95 optimally-defined peptides from this database were used to screen for INFγ responses to other epitopes
• 1/11 of the A2+ individuals was HLA A*0201, A1, B57 and responded to four B57 epitopes and two others
p24 (30–40) p24 (SF2) KAFSPEVIPMF HIV-1 infection human (B57) Goulder2000a
• The CTL-dominant response was focused on this epitope in a HIV+ Caucasian living in Boston – this epitope is not among the most recognized peptides in
the study
• Three peptides GSEELRSLYNTVATL (p17 residues 71-85), SALSEGATPQDLNTMLNTVG (p24 41-60), and WEKIRLRPGGKKKYKLK(p17 16-30)
contained the dominant Gag-specific epitope in 31 out of 44 B-clade infected individuals from Boston who showed Gag-CTL responses
• Five peptides RLRPGGKKHYMIKHLVW (p17 20-36), ELRSLYNTVATLYCV (p17Gag 74-88), SALSEGATPQDLNTMLNTVG (p24 41-60),
FRDYVDRFFKTLRAEQA (p24 161-177), and SILDIKQGKEPFRDY (p24 149-164) contained dominant Gag-specific epitopes in 32 out of 37 C-clade
infected subjects from South Africa
p24 (30–40) Gag (SF2) KAFSPEVIPMF HIV-1 infection human (B57) Goulder2001a
• Epitope name: KF11
• Three CTL responses in patient PI004, to epitopes TSTLQEQIGW, ISPRTLNAW, and KAFSPEVIPMF, were evident early after infection; CTL responses
to SLYNTVATL, QASQEVKNW, EIYKRWII, and FLKEKGGL were detectable at 5 months post-infection and beyond
p24 (30–40) p24 (162–172) KAFSPEVIPMF HIV-1 infection human (B57) Oxenius2000
• Epitope name: KAF
• Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific
CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load – three patients that had delayed initiation of
HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became
undetectable
• None of the 8 study subjects recognized this epitope but none were HLA B57+
p24 (30–40) p24 KAFSPEVIPMF HIV-1 infection human (B57) Kostense2001
• HLA tetramers to six epitopes were used to study HLA-A2, B8 and B57 CTL in 54 patients – HIV-specific tetramer positive cells were inversely correlated
with viral load in patients with high CD4, but in patients with CD4 T-cells below 400 high tetramer frequencies were found despite high viral load
• Most patients have high levels of HIV-specific T-cell expansions, but many of these cells aren’t functional
• In 15 of the patients, the proportion of IFN gamma producing tetramer cells correlated with AIDS-free survival
p24 (30–40) p24 (162–172 SF2) KAFSPEVIPMF HIV-1 infection human (B57) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
106
DEC 2002
p24 CTL Epitopes HIV CTL Epitope Tables
C
TL
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B57+ individuals that had a CTL response to this epitope broken down by group: 0/0 group 1, 0/0 group 2, and 2/2 group 3
p24 (30–40) p24 (163–174) KAFSPEVIPMF HIV-1 infection human (B57) Appay2000
• Combined tetramer and intracellular cytokine staining was used to study the function of circulating CD8+ T cells specific for HIV and CMV
• HIV-specific CD8+ T cells expressed lower levels of perforin than CMV-specific CD8+ T cells from the same donor, and this was associated with persistent
CD27 expression on HIV-specific cells, suggesting impaired maturation
• In most donors, between 50% and 95% of the activated virus-specific CD8+ T cells produced IFN-γ and MIP-1β with a distinct subset that failed to
produce TNF-α
p24 (30–40) KAFSPEVIPMF HIV-1 infection human (B57) Sabbaj2002b
• Among HIV+ individuals who carried HLA B57, 1/5 (20%) recognized this epitope
p24 (30–40) p24 KAFSPEVIPMF HIV-1 infection human (B57) Oxenius2002b
• Epitope name: KAF
• Using previously defined epitopes [Oxenius2000, Oxenius2001a] in an IFNgamma Elispot assay, 13 chronically HIV-1 infected patients were studied over a
period including therapy with standard treatment interruptions (STI).
• STIs induced increased recognition of CTL epitopes, but there was no correlation between CTL responses with viral rebound rates, plateau viral loads, or
clearance rates.
p24 (30–40) p24 (153–164) KAFSPEVIPMF HIV-1 infection, HIV-1 exposed
seronegative
human (B57, B58) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with
reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected
women
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure
• Among HLA-B57/B58 women, 4/6 HEPS and 12/17 HIV-1 infected women recognized this epitope
• The dominant response to this HLA allele was to this epitope in 2 of the 4/6 HEPS cases and in 7 of the 12/17 HIV-1 infected women
p24 (30–40) p24 (30–40) KAFSPEVIPMF HIV-1 infection human (B57/B58) Kaul2002
• Neisseria gonorrhea cervititis in 9 HIV+ Kenyan sex workers caused a functional deficiency in IFN-gamma production in HIV-1 epitope-specific CD8+
T-cells, detected by intracellular cytokine production and tetramer assays, while not affecting the total number of epitope-specific CTLs.
• Ghonorrhea caused the weaker HIV-1 specific CTL responses in 4 HIV-1 exposed persistently seronegative (HEPS) women to become undetectable by
Elispot and tetramer assays, and CMV-specific CTL in 2 HEPS subjects were shown to have impaired function with regard to IFN-gamma production.
p24 (30–40) p24 (30–40) KAFSPEVIPMF HIV-1 infection human (B58) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
p24 (31–50) p24 (163–182) AFSPEVIPMFSALSEGATPQ HIV-1 infection human Lieberman1995
• HIV-specific CTL lines developed by ex vivo stimulation with peptide
p24 (31–50) p24 (163–182 SF2) AFSPEVIPMFSALSEGATPQ HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
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• Twelve subjects had CTL that could recognize vaccinia-expressed LAI gag
• One of these 12 had CTL response to this peptide
• The responding subject was HLA-A2, B21
p24 (31–50) p24 (163–182 SF2) AFSPEVIPMFSALSEGATPQ HIV-1 infection human Lieberman1997b
• CTL expanded ex vivo were later infused into HIV-1 infected patients
p24 (31–50) p24 (SF2) AFSPEVIPMFSALSEGATPQ HIV-1 infection human Altfeld2000b
• This epitope was mapped by ELISPOT in a study identifying new HLA-B60 epitopes, and was one of the epitopes presented by another HLA molecule in
an HLA-B60 individual
• The response to the peptide was CD4 dependent, but the HLA presenting molecule and optimal epitope were not determined
p24 (35–43) p24 (167–175 LAI) EVIPMFSAL human (A*2601) Goulder1996a
• Identified as optimal epitope within Gag sequence AFSPEVIPMFSALSEGATPQ
• Relatively conserved epitope within B clade and in other clades
• Suspected binding motif for HLA-A26 includes T or V anchor at position 2, negative charge at position 1
• C. Brander notes that this is an A*2601 epitope in the 1999 database
p24 (35–43) p24 (167–175 LAI) EVIPMFSAL human (A*2601) Brander2001
• C. Brander notes that this is an A*2601
p24 (35–43) p24 (167–175) EVIPMFSAL HIV-1 infection human (A26) Betts2000
• Only 4/11 HLA-A2+ HIV+ individuals had CTL that reacted to SLYNTVATL, calling into question whether it is immunodominant
• 95 optimally-defined peptides from this database were used to screen for INFγ responses to other epitopes
• 1/11 of the A2+ individuals that didn’t respond to SLYNTVATL reacted with seven other epitopes including this epitope
p24 (36–43) p24 (168–175 LAI) VIPMFSAL human (C*0102(Cw1)) Brander2001
• C. Brander notes this is a C*0102(Cw1) epitope
p24 (36–43) p24 (168–175 LAI) VIPMFSAL human (Cw*0102, Cw1) Goulder1997b
p24 (36–43) p24 (168–175) VIPMFSAL HIV-1 infection human (Cw01, 02) Betts2000
• Only 4/11 HLA-A2+ HIV+ individuals had CTL that reacted to SLYNTVATL, calling into question whether it is immunodominant
• 95 optimally-defined peptides from this database were used to screen for INFγ responses to other epitopes
• 1/11 of the A2+ individuals that didn’t respond to SLYNTVATL reacted with seven other epitopes including this epitope
p24 (37–52) Gag (169–184 LAI) IPMFSALSEGATPQDL HIV-1 infection human (B12) Buseyne1993a
• Vertical transmission of HIV ranges from 13% to 39%
• Primary assays showed cytotoxic activity against at least one HIV protein was detected in 70% of infected children
• Epitopes recognized in five children were mapped using synthetic
• Patient EM17 (CDC P2A+C+D2) had a CTL response to two epitopes in Gag
p24 (37–52) p24 (169–184 LAI) IPMFSALSEGATPQDL HIV-1 infection human (B12(44)) Buseyne1993b
• Clustering of Gag p24 CTL epitopes recognized in 29 HIV-infected people
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p24 (37–52) p24 (37–52) IPMFSALSEGATPDQL HIV-1 infection human (B44) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
p24 (39–58) Gag (171–190) MFTALSEGTPQDLNTMLNT HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
• This peptide was among the 8 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
p24 (41–60) p24 (173–192 SF2) SALSEGATPQDLNTMLNTVG HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Twelve subjects had CTL that could recognize vaccinia-expressed LAI gag
• Three of these 12 had CTL response to this peptide
• The responding subjects were HLA-A3, A32, B7, B14; and HLA-A2, A3, B14, B44
p24 (41–60) p24 (173–192 SF2) SALSEGATPQDLNTMLNTVG HIV-1 infection human Lieberman1997b
• CTL expanded ex vivo were later infused into HIV-1 infected patients
p24 (41–60) p24 (SF2) SALSEGATPQDLNTMLNTVG HIV-1 infection human Altfeld2000b
• This epitope was mapped by ELISPOT in a study identifying new HLA-B60 epitopes, and was one of the epitopes presented by another HLA molecule in
an HLA-B60 individual
• The response to the peptide was CD8 dependent, but the HLA presenting molecule and optimal epitope were not determined
p24 (41–60) p24 (179–188 subtype
A)
SALSEGATPQDLNMMLNIVG HIV-1 infection human (B*8101) Dorrell1999
• CTL responses in three individuals with non-clade B infections were studied, 2 with subtype A infections, 1 with subtype C – their infections all originated
in East Africa
• This CTL epitope is presented by B*8101 in one of the patients with an A subtype infection – B*8101 is a newly discovered HLA allele found in Africans,
and the epitope has yet to be mapped precisely
• This epitope is distinct in subtype A relative to subtypes B, C, and D which share the dominant sequence: SALSEGATPQDLNTMLNTVG
p24 (41–62) p24 (173–194 BH10) SALSEGATPQDLNTMLNTV-
GGH
HIV-1 infection human (B14) Johnson1991
• Gag CTL response studied in three individuals
p24 (43–52) p24 (subtype A) LSEGATPQDL HIV-1 infection human (B42, B44) Cao2000
• HIV-1 subtypes A and D dominate the Ugandan epidemic, and a vaccine trial using B clade antigen is underway – this study addresses relative levels of
cross-reactive CTL responses in Ugandans to A, D, and B clade recombinant vaccinia viruses expressing Gag, Env, Pol, RT or Nef from HIV-1 clades A, B,
and D
• Proteins corresponding to the subtype of the infecting strains tended to trigger higher levels of CTL response measured by percent specific lysis, but there
was extensive inter-subtype cross-reactivity with B clade proteins and the co-circulating subtype
• This optimal epitope sequence, recognized by CTL derived from a Ugandan with an A subtype infection (patient SP 511), is cross-reactive with subtypes A,
B and D peptides
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p24 (44–52) p24 (176–184) SEGATPQDL human (B*4001) Brander2001
• C. Brander notes this is a B*4001, B60 epitope (Pers. Comm. A. Trocha and S. Kalams)
p24 (44–52) p24 (SF2) SEGATPQDL HIV-1 infection human (B60(B*4001) Altfeld2000b
• This epitope was mapped by ELISPOT in a study identifying new HLA-B60 epitopes
• B60 is present in 10-20% of the Caucasoid and very common in Asian populations
p24 (44–52) p24 (44–52) SEGATPQDL HIV-1 infection human (B60/B61) Day2001
• No immunodominant responses were detected to five B61-restricted epitopes tested
• All five B60-restricted epitopes were reactive in another subject, the strongest CTL response directed against the B60-epitope p24 SEGATPQDL, and the
B60-restricted responses together contributed over one-third of the total CTL response
p24 (46–59) p24 (SF2) GATPQDLNTMLNTV HIV-1 infection human Goulder2000a
• The CTL-dominant response was focused on this epitope in a HIV+ African American living in Boston with HLA A*3002/68 B14/*5802 Cw6/8 – this
epitope fell within the most recognized peptides in the study
• Three peptides GSEELRSLYNTVATL (p17 residues 71-85), SALSEGATPQDLNTMLNTVG (p24 41-60), and WEKIRLRPGGKKKYKLK(p17 16-30)
contained the dominant Gag-specific epitope in 31 out of 44 B-clade infected individuals from Boston who showed Gag-CTL responses
• Five peptides RLRPGGKKHYMIKHLVW (p17 20-36), ELRSLYNTVATLYCV (p17Gag 74-88), SALSEGATPQDLNTMLNTVG (p24 41-60),
FRDYVDRFFKTLRAEQA (p24 161-177), and SILDIKQGKEPFRDY (p24 149-164) contained dominant Gag-specific epitopes in 32 out of 37 C-clade
infected subjects from South Africa
p24 (47–55) p24 (47–55) ATPQDLNTM HIV-1 infection human (B7) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
p24 (47–56) p24 (subtype A) ATPQDLNMML HIV-1 exposed seronegative human (B53) Kaul2000
• 11/16 heavily HIV exposed but persistently seronegative sex-workers in Nairobi had HIV-specific CD8 gamma-IFN responses in the cervix – systemic
CD8+ T cell responses tended to be to the same epitopes but at generally lower levels than cervical CD8+ T cell responses
• Low risk individuals did not have such CD8+ cells
• CD8+ T cell epitopes: DTVLEDINL (3 individuals), SLYNVATL (4 individuals), LSPRTLNAW (3 individuals) and YPLTFGWCF (4 individuals) were
most commonly recognized by the HIV-resistant women
p24 (47–58) p24 (181–192) CTPYDINQMLNC HIV-2 infection human (B58) Bertoletti1998a
• HIV-2 epitope defined from an infection in Gambia, Bertoletti, Pers. Comm.
p24 (48–56) Gag (96ZM651.8) TPQDLNTML human (A*4201,
B*8101)
Novitsky2001
• Epitope name: G180-TL9
• This study is provides a survey of CTL responses and full length HIV-1 genome sequences from a C subtype infected Botswanan cohort
• 19 of 46 (41.3%) had CTL responses to one or more peptides within the first immunodominant region of Gag (peptides TLNAWVKVIEEKAFSPEVIP,
EKAFSPEVIPMFTALSEGAT, and MFTALSEGATPQDLNTMLNT), with magnitudes of response with ELISPOT results median and range 495 (103 to
1,447) SFC/106 PBMC
• 7 of 11 HLA-A*4201+ subjects (64%) responded to peptide MFTALSEGATPQDLNTMLNT
• TPQDLNTML is a A*4201 epitope within TLNAWVKVIEEKAFSPEVIP
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p24 (48–56) p24 (180–188 IIIB) TPQDLNTML HIV-1 infection human (B*0702) Brander2001
• C. Brander notes this is a B*0702 epitope
p24 (48–56) p24 (179–187 LAI) TPQDLNTML human (B*4201) Brander2001
• C. Brander notes this is a B*4201 epitope
p24 (48–56) Gag (173–181 HIV-2) TPYDINQML HIV-2 infection human (B*5301) Brander2001
• C. Brander notes this is a B*5301 epitope
p24 (48–56) p24 (180–188 LAI) TPQDLNTML HIV-1 infection human (B*8101) Brander2001
• C. Brander notes this is a B*8101 epitope
p24 (48–56) TPQDLNTML HIV-1 infection human (B*8101,
B*5301, B07)
Sabbaj2002b
• Epitope name: Gag-TL9
• This study monitored epitope responses in HIV-1 infected minority women living in the United States
• 24 epitopes were described – 8 were novel, 8 used new restricting elements but were previously defined epitopes, and 8 were previously described
• Serial peptide truncations were used to define optimal epitopes for CTL cell lines isolated from 12 individuals, assayed by a Cr-release
• Subjects 00RCH86 and 03RCH59 both recognized this epitope, both restricted by HLA B*8101
• Subject 00RCH86 was African American, not on HAART, viral load 51000, CD4 count 520
• Subject 03RCH59 was African American, male, on HAART, viral load 22000, CD4 count 769
• Among HIV+ individuals who carried HLA B07, 2/9 (22%) recognized this epitope
• Among HIV+ individuals who carried HLA B*5301, 3/15 (20%) recognized this epitope
• Among HIV+ individuals who carried HLA B81, 4/6 (67%) recognized this epitope
p24 (48–56) p24 (C consensus) TPQDLNTML HIV-1 infection human (B42) Goulder2000a
• B42 and B81 are very similar, and both can present this epitope to B42-positive effector cells – this epitope is almost certainly optimal for B81 as well –
B42 and or B81 are expressed in 40-45% of Zulu and Xhosa infected individuals in South Africa, and in 14/18 B42 or B81+ individuals, the dominant gag
response was to TPQDLNTML
• Three peptides GSEELRSLYNTVATL (p17 residues 71-85), SALSEGATPQDLNTMLNTVG (p24 41-60), and WEKIRLRPGGKKKYKLK(p17 16-30)
contained the dominant Gag-specific epitope in 31 out of 44 B-clade infected individuals from Boston who showed Gag-CTL responses
• Five peptides RLRPGGKKHYMIKHLVW (p17 20-36), ELRSLYNTVATLYCV (p17Gag 74-88), SALSEGATPQDLNTMLNTVG (p24 41-60),
FRDYVDRFFKTLRAEQA (p24 161-177), and SILDIKQGKEPFRDY (p24 149-164) contained dominant Gag-specific epitopes in 32 out of 37 C-clade
infected subjects.
p24 (48–56) Gag TPQDLNTML HIV-1 infection human (B42) Goulder2000b
• Tetramer assays were compared with three functional assays in 42 people with chronic HIV infection: ELISPOT, intracellular cytokine staining, and
precursor frequency (limiting dilution assay [LDA])
• HIV-specific tetramer staining CTLs appeared to be active, and inert CTL were not found to play a significant role in chronic pediatric or adult HIV
infection
p24 (48–56) p24 TPQDLNQML human (B53) Rowland-Jones1999
• CTL responses in seronegative highly HIV-exposed African female sex workers in Gambia and Nairobi were studied – these women had no delta 32
deletion in CCR5
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• In Gambia there is exposure to both HIV-1 and HIV-2, CTL responses to B35 epitopes in exposed, uninfected women are cross-reactive, and the B35 allele
seems to be protective
• HIV-2 sequence: TPYDINQML, no cross-reactivity, [Gotch1993]
p24 (48–56) Gag (173–181 HIV-2) TPYDINQML HIV-2 infection human (B53) Gotch1993
p24 (48–56) Gag (180–188 subtype
A)
TPQDLNMML HIV-1 infection, in vitro
stimulation
human (B53) Dorrell2001
• In vitro restimulation of CTL specific for dominant epitopes from infected individuals is possible using recombinant modified vaccinia virus Ankara (MVA)
carrying A or D subtype HIV-1 Gag proteins
p24 (48–56) p24 (180–188 subtype A
consensus)
TPQDLNMML HIV-1 infection human (B53) Dorrell2001
• In clade A infected Gambians, three HLA-B53 epitopes were defined in Gag p24 using ELISPOT, tetramer, and cytotoxicity assays
• This optimal epitope was identified within the 20 mer reactive peptide that carried it by homology with a B53 epitope from HIV-2, a B subtype B7 peptide
that corresponds to it, as B53 is part of the B7 superfamily, and by the proline in the anchor at position 2
• TPQDLNMML was recognized in 6/7 HLA-B53 subjects and was immunodominant in most subjects
• TPQDLNMML was A subtype-specific with no cross-recognition of the subtype B, C, and D variant, TPQDLNTML, although the B/C/D variant bound
more efficiently to B53 – position 7 show great positional variation in crystal structures of two HLA-B53 complexes, suggesting variation here might
significantly alter the position of the peptide in the binding groove and thus affect TCR interactions
• Only one subject might have had a cross-reactive response with the HIV-2 and Mamu-A*01 variant CTPYDINQML, and this subject might have been dual
infected with HIV-2
p24 (48–56) p24 (180–188 IIIB) TPQDLNTML HIV-1 infection human (B7) Wilson1999a
• This study describes maternal CTL responses in the context of mother-to-infant transmission
• Detection of CTL escape mutants in the mother was associated with transmission, but the CTL-susceptible forms of the virus tended to be found in infected
infants
• No variants of this epitope were found in a non-transmitting mother that had a CTL response to this epitope
p24 (48–56) p24 (180–188) TPQDLNTML HIV-1 infection human (B7) Jin2000b
• This is the optimal epitope for the immunodominant response defined using a conventional approach in an HLA B7+ long-term non-progressor
• Three additional sub-dominant HLA B7 epitopes were defined using EpiMatrix, a non-anchor based strategy for defining potential epitopes, which
highlighted 2078 possible epitopes in the autologous HIV-1 derived from the study subject – this was followed by B7 anchor residue prediction which
narrowed the set to 55 peptides, three of which could serve as functional CTL epitopes
p24 (48–56) p24 (SF2) TPQDLNTML HIV-1 infection human (B7) Goulder2001a
• Epitope name: TL9
• Recognized by patient 9354 during chronic infection, used as a positive control in a study of the SLYNTVATL epitope
p24 (48–56) p24 (48–56) TPQDLNTML HIV-1 infection human (B7) Day2001
• The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7 was
studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
• 2 to 17 epitopes were recognized in a given individual, A2-restricted CTL response tended to be narrow and never dominated the response, and 25/27
epitopes were targeted by at least one person
• Subjects with chronic HIV-1 infection recognized between 2-8 out of 11 B7-restricted epitopes
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• An acute seroconvertor homozygous for the B7 allele recognized five B7-restricted epitopes
• The other acute seroconvertor failed to recognize any of the 11 B7-restricted epitopes tested
• The B7-restricted CTL response was highly variable and there was no clearly dominant epitope
p24 (48–56) p24 (48–56) TPQDLNTML HIV-1 infection human (B7) Yu2002a
• Epitope name: B7-TL9
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
• 1/11 HLA-B7 individuals had detectable B7-restricted responses to this epitope during acute infection – 10/15 of HLA-B7 epitopes tested were targeted by
at least one person during acute infection. 1/4 individuals had detectable responses to this epitope after STI.
p24 (48–56) p24 TPQDLNTML HIV-1 infection human (B7) Altfeld2002
• Epitope name: B7-TL9(p24)
• Peripheral blood (PB) and lymph node (LN) CD8+ T-cell responses were compared in 15 asymptomatic HIV-1 infected patients using all known optimal
CTL epitopes (http://hiv-web.lanl.gov/content/hiv-db/REVIEWS/brander2001.html) for each person’s class I HLA alleles.
• 60 epitope responses were detected in both PB and LN samples of the 15 patients, and an additional 8 responses were detected only in LN. The total
magnitude of the response was similar in LN and PB, but the percentage of CD8+ T cells in the LN is lower so the number of HIV-specific cells per million
CD8+ T-cells is higher in the LN.
• 1 year post-HAART treatment in five patients studied, the magnitude of the CD8 T-cell response was decreased in both LN and PB, but more dramatically
in PB, and 13/25 epitope responses in the PB became undetectable, in contrast to 5/26 in the LN.
• Treatment interruption following HAART induced resulted in increased viremia accompanied by the restoration of the detection of 13 epitopes that had
become undetectable in the PB, and the addition of 9 novel epitope responses.
• Breakdowns of epitope responses were shown for 4 individuals. Patient A displayed the greatest response to epitope B14-EL9(gp41), a strong response to
B7-TL9(p24), and responses to B7-TM9(Nef) and A32-PW10(RT).
p24 (48–56) p24 (180–188 LAI) TPQDLNTML HIV-1 infection human (C*0802(Cw8)) Brander2001
• C. Brander notes this is a C*0802(Cw8) epitope
p24 (48–57) Gag TPQDLNMMLN human (B7) De Groot2001
• The program Epimatrix was used in conjunction with the program Conservatrix to identify conservered regions of HIV that might serve as epitopes
• A subset of the potential epitopes was identified that could bind to the appropriate HLA-allele, and 15 predicted B7 superfamily (HLA B7, B8, and B58)
epitopes were identified that could stimulate IFNγ production in an ELISPOT assay
• TPQDLNMMLN was newly defined as an HLA-B7 epitope in this study, athough it was previously published as a B*8101 epitope
• TPQDLNMMLN was shown to stimulate an ELISPOT response, but could not be shown to bind to HLA-B7
• The variant TPQDLNTMLN was cross-reactive, had previously been identified as a HLA-B14 epitope, and could bind to HLA-B7
p24 (49–57) p24 (181–189 LAI) PQDLNTMLN HIV-1 infection human (B14, Cw8) Lubaki1997
• Eighty two HIV-1-specific CTL clones from 5 long-term non-progressors were isolated and analyzed for breadth of response
• A sustained Gag, Env and Nef response was observed, and clones were restricted by multiple HLA epitopes, indicating a polyclonal response
• Despite this being a well defined conserved epitope, none of the 11 gag-specific clones from a B-14 positive subject could recognize either it or p24
RAEQASQEV
• Christian Brander notes that B14 and Cw8 are in linkage disequilibrium, and that this epitope may be Cw8
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p24 (51–59) p24 DLNTMLNTV HIV-1 infection chimpanzee Santra1999
• 3/4 animals displayed HIV-1 Gag-specific CTL activity
• Effector cells from two chimpanzees were able to recognize two epitopes also recognized by human HIV-1 Gag-specific CTL (SPRTLNAWV, HLA-B7,
and DLNTMLNTV, HLA-B14)
• No chimpanzee CTL were detected to the following human HIV-1 specific Gag epitopes, although they were embedded within 20mer peptides that
contained a reactive epitope: ISPRTLNAW, HLA-B57; KRWIILGLNK, HLA-B27; and DRFYKTLRA, HLA-B14
p24 (51–59) p24 (subtype A) DLNMMLNIV HIV-1 exposed seronegative human (B14) Kaul2000
• 11/16 heavily HIV exposed but persistently seronegative sex-workers in Nairobi had HIV-specific CD8 gamma-IFN responses in the cervix – systemic
CD8+ T cell responses tended to be to the same epitopes but at generally lower levels than cervical CD8+ T cell responses
• Low risk individuals did not have such CD8+ cells
• CD8+ T cell epitopes: DTVLEDINL (3 individuals), SLYNVATL (4 individuals), LSPRTLNAW (3 individuals) and YPLTFGWCF (4 individuals) were
most commonly recognized by the HIV-resistant women
p24 (51–59) p24 DLNMMLNIV HIV-1 infection human (B14) Kaul2001c
• This study examines CTL responses in HIV exposed, persistently seronegative individuals, HEPS, who eventually seroconverted – 11/114 HEPS Nairobi
sex workers eventually seroconverted, and for six of these HIV CTL reactive epitopes had been defined while seronegative
• The epidemiological factor associated with seroconversion was stopping sex work and HIV-specific CTL activity declines when HEPS sex workers stop
working for a period or retire
• This epitope was recognized in 1/22 HEPS sex worker controls, ML1792
p24 (51–59) p24 (183–191 LAI) DLNTMLNTV HIV-1 infection human (B14) Mollet2000
• Epitope name: G5
• A panel of 16 epitopes covering 15 class I alleles was tested in 14 HIV+ patients from an unselected Caucasian population treated with HAART, using
CD8+ cell IFNgamma production to measure responses
• In general, during the first month of treatment viral load decreased and frequencies of HIV-specific CTL tripled and broadened – eight new HIV
specificities that were not previously detectable were newly detected, as were CMV specific CD8+ PBL – but with continued viral suppression,
HIV-specific responses diminished
• Viral rebounds gave different patterns of response: increases or decreases in pre-existing response, new specificities, or no change
p24 (51–59) p24 (183–191) DLNMMLNIV HIV-1 infection, HIV-1 exposed
seronegative
human (B14) Kaul2001a
• Variants DLNMMLNIV/DLNTMLNVV are specific for clades A/B
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with
reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected
women
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure
• Among HLA-B14 women, 4/4 HEPS and 3/7 HIV-1 infected women recognized this epitope, likelihood ratio 4.8, p value 0.1, and HEPS women tended to
respond to DLNMMLNIV/DLNTMLNVV, while infected women tended to respond to DRF(F/W)KTLRA
• The dominant response to this HLA allele was to this epitope for all 4/4 HEPS cases and in only one of the 3/7 HIV-1 infected women
• Differences in epitope specificity were only seen for responses restricted by class I HLA alleles A2, A24, A*6802, B14, and B18, previously shown to be
associated with resistance to HIV-1 in this cohort
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• Four epitopes were considered to be “resistant epitopes”, as they were preferentially reactive in HEPS women and so may confer resistance, and these were
found in three different proteins: A2 ILK(D/E)PVHGV in RT, A*6802 DTVLEDINL in Protease, B14 DLN(M/T)LN(I/V)V in p24 and B18
FRDYVDRF(Y/F)K also in p24
p24 (51–59) p24 DLNMMLNIV HIV-1 infection human (B14) Kaul2002
• Neisseria gonorrhea cervititis in 9 HIV+ Kenyan sex workers caused a functional deficiency in IFN-gamma production in HIV-1 epitope-specific CD8+
T-cells, detected by intracellular cytokine production and tetramer assays, while not affecting the total number of epitope-specific CTLs.
• Ghonorrhea caused the weaker HIV-1 specific CTL responses in 4 HIV-1 exposed persistently seronegative (HEPS) women to become undetectable by
Elispot and tetramer assays, and CMV-specific CTL in 2 HEPS subjects were shown to have impaired function with regard to IFN-gamma production.
p24 (51–59) p24 (183–191 LAI) DLNTMLNTV HIV-1 infection human (B14, Cw8) Johnson1992, Nixon1988
• Recent evidence indicates this is a Cw8 epitope; B14 and Cw8 are in linkage disequilibrium and the HLA presenting molecule is hard to distinguish (P.
Goulder, personal communication)
p24 (51–59) p24 DLNTMLNTV HIV-1 exposed seronegative human (B14, Cw8) Rowland-Jones1998a
• A CTL response was found in exposed but uninfected prostitutes from Nairobi using previously-defined B clade epitopes that tended to be conserved in A
and D clades – such cross-reactivity could protect against both A and D and confer protection in Nairobi where both subtypes are circulating
• The A subtype consensus is identical to the B clade epitope
• The D subtype consensus is dLNmMLNiV
• Recent evidence indicates this is a Cw8 epitope;B14 and Cw8 are in linkage disequilibrium and the HLA presenting molecule is hard to distinguish (P.
Goulder, personal communication)
p24 (51–59) p24 (183–191 LAI) DLNTMLNTV HIV-1 infection human (C*0802) Brander2001
• C. Brander notes this is a C*0802 epitope
p24 (51–59) p24 (183–191 LAI) DLNTMLNTV HIV-1 infection human (Cw8) McMichael1994
• Review of HIV CTL epitopes – defined by B14 motif found within a larger peptide
• Recent evidence indicates this is a Cw8 epitope;B14 and Cw8 are in linkage disequilibrium and the HLA presenting molecule is hard to distinguish (P.
Goulder, personal communication)
p24 (51–59) p24 (subtype B) DLNTMLNTV HIV-1 exposed seronegative human (Cw8, B*1402) Rowland-Jones1998b
• HIV-specific CTL were found in exposed seronegative prostitutes from Nairobi – these CTL may confer protection
• Seroprevalence in this cohort is 90-95% and their HIV-1 exposure is among the highest in the world
• Most isolated HIV strains are clade A in Nairobi, although clades C and D are also found – B clade epitopes are often cross-reactive, however stronger
responses are frequently observed using A or D clade versions of epitopes
• This epitope is conserved among B and D clade viruses
• The Clade A version of the epitope, DLNNMLNIV, was preferentially recognized by CTL
• Recent evidence indicates this is a Cw8 epitope;B14 and Cw8 are in linkage disequilibrium and the HLA presenting molecule is hard to distinguish (P.
Goulder, personal communication)
p24 (51–70) p24 (183–202 SF2) DLNTMLNTVGGHQAAMQMLK HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Twelve subjects had CTL that could recognize vaccinia-expressed LAI gag
• One of these 12 had CTL response to this peptide
• The responding subject was HLA-A26, A30, B38
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p24 (51–82) Gag (183–214 LAI) DLNTMLNTVGGHQAAMQML-
KETINEEAAEWDR
Vaccine human Gahery-Segard2000
Vaccine Vector/Type: lipopeptide HIV component: six peptides
• Anti-HIV lipopeptide vaccine consisting of six long amino acid peptides derived from Nef, Gag and Env HIV-1 proteins modified by a palmitoyl chain was
administered in a phase I trial
• A CD4+ T cell proliferative response to at least one of the six peptides was observed in 9/10 vaccinees – 2/10 reacted to this peptide
• 9/12 tested mounted a CTL response to at least one of the six peptides; each of the six peptides elicited a CTL response in at least one individual
• None of the 12 tested had an IgG response to this peptide
p24 (61–69) p24 (193–201 LAI) GHQAAMQML human (B*3901) Brander2001
• C. Brander notes this is a B*3901 epitope
p24 (61–69) p24 (193–201 LAI) GHQAAMQML human (B39) Kurane1998
• Optimal peptide defined by titration
p24 (61–71) p24 (193–203 BRU) GHQAAMQMLKE HIV-1 infection human (A2) Claverie1988
• One of 4 epitopes first predicted, then shown to stimulate HLA-A2 restricted CTL line
p24 (61–80) p24 (193–212 SF2) GHQAAMQMKETINEEAAEW HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Twelve subjects had CTL that could recognize vaccinia-expressed LAI gag
• One of these 12 had CTL response to this peptide
• The responding subject was HLA-A26, A30, B38
p24 (61–82) p24 (193–214 BH10) GHQAAMQMLKETINEEAAE-
WDR
HIV-1 infection human (Bw52) Johnson1991
• Gag CTL response studied in three individuals
p24 (62–70) p24 (194–202 LAI) HQAAMQMLK human (B52) Brander1996b
• P. Goulder, pers. comm.
p24 (65–73) Gag (199–207 HXB2) AMQMLKETI Vaccine murine (H-2d) Qiu1999
Vaccine Vector/Type: DNA Strain: HXB2 HIV component: gag
• Different expression vectors were tested to increase Gag expression in cell lines and create suitable vectors for DNA vaccines
• Stable Gag expression was achieved in murine p815 cells, using a Gag gene that had mutated silent base positions that disrupt inhibitory RNA sequences
which promote RNA degradation
• Silent mutations were more effective than introduction of the D retrovirus cis-acting posttranscriptional control element (CTE) for enhancing Gag
expression
• The gag vector with silent mutations given as a vaccine to BALB/c mice gave CTL responses in splenic mononuclear cells, using peptide pulsed cells as
targets
p24 (65–73) p24 (199–207 SF2) AMQMLKETI Vaccine murine (H-2d) Neidleman2000
Vaccine Vector/Type: protein, vaccinia Strain: SF2 HIV component: soluble Gag, or GagPol expressing vaccinia Adjuvant: heat-labile enterotoxin
(LT) from E. coli
• Epitope name: p7g
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• Intranasal immunization of CB6F1 (H2bxd) mice with soluble gag p55 with LT ADP-ribosyltransferase mutants (LTK63 and LTK73) from Escherichia coli
as adjuvants was tested
• Intranasal and intramucosal immunization of p55 gag protein with LTK63 or LTK72 adjuvant induced a CTL response comparable to intramuscular
immunization responses
• Oral co-administration of LTR72, with residual ADP-ribosyltransferase activity, induced systemic CTL responses, but LTK63 with no
ADP-ribosyltransferase activity did not
p24 (65–73) p24 (66–74) AMQMLKETI Vaccine murine (H-2d) Marsac2002
Vaccine Vector/Type: DNA HIV component: Gag Adjuvant: vesicular stomatitis virus glycoprotein (VSV-G)
• BALB/c mice were injected with plasmids expressing HIV-1 Gag with or without coinjection of a plasmid expressing vesicular stomatitis virus
glycoprotein (VSV-G). The combination encodes VSV-G pseudotyped Gag particles that can be taken up by cells for presentation in either the class I or
class II pathways, while exogenous Gag alone can only be taken into the class II pathway.
• Vaccination with DNA expressing VSV-G pseudotyped Gag particles rather than just Gag increase Gag-specific CTL responses generally as well as the
specific H-2d restricted anti-AMQMLKETI response.
p24 (65–73) Gag (p24) (199–207
SF2)
AMQMLKETI Vaccine murine (H-2kd) O’Hagan2002
Vaccine Vector/Type: recombinant protein Strain: SF2 HIV component: Gag p55 Adjuvant: CpG, MF59, DOTAP, DDA, PLG-microparticle, urea
• Epitope name: p7G
• Intramuscular or intraperitoneal immunization of BALB/c or CB6F1 mice with urea-solubilized, emulsified, or PLG-microparticle associated p55 Gag was
studied in conjunction with the adjuvant CpG. CpG did not enhance CTL immunity when combined with urea solubilized p55, but did when combined with
emulsions and PLG-microparticle antigen.
• CpG shifted the Ab response towards a IgG2a, and CpG was shown to upregulate CD86 on mouse bone-marrow derived dendritic cells.
p24 (65–73) p24 (199–207 SF2) AMQMLKETI Vaccine murine (H-2Kd) Doe1997
Vaccine Vector/Type: vaccinia HIV component: Gag, Pol
• Immunodominant murine CTL response to this peptide observed after immunization with vaccine VVgagpol
• Optimal peptide was defined
p24 (65–73) Gag (197–205) AMQMLKETI Vaccine murine (H-2Kd) Rayevskaya2001
Vaccine Vector/Type: Listeria monocytogenes HIV component: gag
• BALB/c mice were immunized with a highly attenuated recombinant Listeria monocytogenes, Lmdaldat, that can grow only when supplemented with
D-alanine, and that expresses HIV-1 HXB2 Gag
• Parenteral immunization provided protection against systemic and mucosal challenges with a recombinant vaccinia virus expressing HIV-1 gag, and a long
lasting memory CTL response against Gag in spleen, mesenteric lymph nodes, and Peyer’s patches directed against the gag protein
• Oral immunization gave protection only against mucosal virus challenge and was associated with a transient CTL response in the three lymphoid tissues
examined
• L. monocytogenes is a gram-positive bacteria that enters the macrophage on phagocytosis and lives in the cytoplasm – secreted L. monocytogenes antigens
are processed and presented by both class I and class II pathways
p24 (65–73) Gag (197–205 SF2) AMQMLKETI Vaccine murine (H-2Kd) Mata1998
Vaccine Vector/Type: Listeria monocytogenes Strain: HXB2 HIV component: Gag
• BALB/c mice were immunized with recombinant Listeria monocytogenes (Lm-Gag) expressing HIV-1 HXB2 Gag
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• L. monocytogenes is a gram-positive bacteria that enters the macrophage on phagocytosis and lives in the cytoplasm – secreted L. monocytogenes antigens
are processed and presented by both class I and class II pathways
• This is the immunodominant CTL epitope in Gag in BALB/c mice
• AMQMLKETI does not contain established Kd anchoring residue in position 2, tyrosine or phenylalanine, thus deviating from the typical Kd anchoring
motif – the lack of the aromatic anchor residue is compensated for by interaction of the glutamine at P3 with pocket D of Kd
p24 (65–73) Gag (HXB2) AMQMLKETI Vaccine murine (H-2Kd) Haglund2002a
Vaccine Vector/Type: vesicular stomatitis virus (VSV), vaccinia Strain: Env, IIIB; Gag HXB2 HIV component: Gag, Env
• BALB/c mice were vaccinated with rec vesicular stomatitis virus (rVSV) expressing either HIV-1 Gag, Env, or both, and compared to using rec Env and
Gag in vaccinia virus (rVVs). The primary response was determined by cell lysis, cytokine production and tetramer staining.
• Primary CTL responses to the immunodominant Gag (AMQMLKETI) epitope peaked in 7 days for GAG-rVSV, 3% of the cells were tetramer positive, and
this response was 8-fold higher than for Gag-rVV.
• Vaccinating with GagEnv-rVSV carrying both Gag and Env allowed recognition of both HIV-1 proteins, but at reduced levels compared to either
Gag-rVSV or Env-rVSV alone.
• Intranasal immunization with Env-rVSV yielded CTL responses that were strong but reduced compared to an intraperitoneal route.
p24 (65–73) Gag (HXB2) AMQMLKETI Vaccine murine (H-2Kd) Haglund2002b
Vaccine Vector/Type: vesicular stomatitis virus (VSV), vaccinia Strain: Env, IIIB; Gag HXB2 HIV component: Gag, Env
• BALB/c mice were vaccinated with rec vesicular stomatitis virus (rVSV) expressing either HIV-1 Gag or Env, or both, and retention of memory responses
and recall responses were studied by tetramer staining and IFN-gamma production.
• Seven months after vaccination with Env-rVSV, 6% of the CD8+ cells were tetramer positive for the immunodominant Env epitope; these cells had a
memory phenotype, CD44-Hi positive.
• Env in rec vaccinia virus (Env-rVV) elicited a strong recall response, with up to 45% to the CD8+ T-cell population tetramer positive and activated
(expressing CD62L-Lo), and capable of IFN-gamma production.
• A prime with Env-rVSV and heterologous boost of Env-rVV gave remarkably high levels of memory cells, with approximately 1/3 of the CD8+
splenocytes being Env specific memory cells 150 days after the boost.
• A Gag-rVSV or EnvGag-rVSV prime and with a heterologous Gag-rVV or EnvGag-rVV boost combination gave 40% tetramer positive CD8+ cells, but
the fraction of IFN-gamma producing cells was only about 25%. Still the heterologous vector prime-boost combination showed a profound benefit.
• A HIV-1 protein rVSV prime, rVV boost was a more potent combination than a vector reversal of a rVV prime and rVSV boost.
p24 (69–86) Gag (201–218 LAI) LKETINEEAAEWDRVPV HIV-1 infection human Buseyne1993a
• Vertical transmission of HIV ranges from 13% to 39%
• Primary assays showed cytotoxic activity against at least one HIV protein was detected in 70% of infected children
• Epitopes recognized in five children were mapped using synthetic peptides and secondary cultures
• Patient EM28 (CDC P2A) had a CTL response to four epitopes in Gag
p24 (70–78) KETINEEAA HIV-1 infection human (B*4002) Sabbaj2002b
• Epitope name: Gag-KA9
• This study monitored epitope responses in HIV-1 infected minority women living in the United States
• 24 epitopes were described – 8 were novel, 8 used new restricting elements but were previously defined epitopes, and 8 were previously described
• Serial peptide truncations were used to define optimal epitopes for CTL cell lines isolated from 12 individuals, assayed by a Cr-release
• This epitope was newly defined in this study
• Patient 01RCH46 was Hispanic, on HAART, and had a viral load of 21000 and CD4 count of 623 – she also recognized GELDRWEKI, p17(11-19), HLA
B*4002, and TAFTIPSI, RT(128-135), HLA A*0217
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• Among HIV+ individuals who carried HLA B40, 3/5 (60%) recognized this epitope
p24 (71–80) p24 (203–212) ETINEEAAEW HIV-1 infection human (A*2501) Klenerman1996
• The epitope was defined through direct stimulation of PBMC with 20-mer peptides
• It is in a conserved region, ETINEEAAEW is found in most B, D, and E subtype isolates
• DTINEEAAEW is found in A and some D subtype sequences
p24 (71–80) p24 (203–212) ETINEEAAEW HIV-1 infection human (A*2501) Brander2001
• C. Brander notes this is an A*2501 epitope
p24 (71–80) p24 (203–212) ETINEEAAEW HIV-1 infection human (A*2501) vanBaalen1996
• Conserved between B and D subtypes, variable in other clades; a consensus of clades A,C, F, G, and H and a peptide of HIV-2ROD over this region were
not recognized by CTL recognizing the index peptide
• C. Brander notes that this is an A*2501 epitope in the 1999 database
p24 (71–80) p24 ETINEEAAEW human (A25) Rowland-Jones1999
• CTL responses in seronegative highly HIV-exposed African female sex workers in Gambia and Nairobi were studied – these women had no delta 32
deletion in CCR5
• In Gambia there is exposure to both HIV-1 and HIV-2, CTL responses to B35 epitopes in exposed, uninfected women are cross-reactive, and the B35 allele
seems to be protective
• HIV-2 sequence: EIINEEAAEW, no cross-reactivity [vanBaalen1996]
p24 (71–80) p24 (203–212 SF2) ETINEEAAEW HIV-1 infection human (A25) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-A25+ individuals that had a CTL response to this epitope broken down by group: 0/0 group 1, 0/2 group 2, and 1/3 group 3
p24 (71–80) DTINEEAAEW HIV-1 infection human (B*5301) Sabbaj2002b
• Epitope name: Gag-DW10
• Among HIV+ individuals who carried HLA B*5301, 2/15 (13%) recognized this epitope
p24 (71–80) ETINEEAAEW HIV-1 infection human (B*5301) Sabbaj2002b
• Epitope name: Gag-EW10
• Among HIV+ individuals who carried HLA B*5301, 2/15 (13%) recognized this epitope
p24 (71–80) p24 (203–212) DTINEEAAEW HIV-1 infection, HIV-1 exposed
seronegative
human (B53) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with
reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected
women
119
DEC 2002
C
TL
HIV CTL Epitope Tables p24 CTL Epitopes
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure
• Among HLA-B53 women, 0/2 HEPS and 7/9 HIV-1 infected women recognized this epitope
• The dominant response to this HLA allele was to this epitope in 4 of the 7/9 responsive HIV-1 infected women
p24 (71–80) p24 (203–212 subtype A
consensus)
DTINEEAAEW HIV-1 infection human (B53) Dorrell2001
• In clade A infected Gambians, three HLA-B53 epitopes were defined in Gag p24 using ELISPOT, tetramer, and cytotoxicity assays
• Two of the new epitopes lacked the predicted by P2 anchors, DTINEEAAEW and QATQEVKNM, and bound to B53 with high affinity, thus extending the
anchor residue motif for B53 and the related B35
• Two overlapping 20 mer peptides carry this complete epitope, but only one stimulates recognition, which could be due to different peptide processing
• DTINEEAAEW was recognized in only 2/7 HLA-B53 subjects
• DTINEEAAEW was not A subtype specific and there was cross-recognition although diminished, of the subtype B, C, and D variant, ETINEEAAEW
• In one of the two subjects there was cross-recognition of the HIV-2 version of the epitope, EIINEEAADW
p24 (71–90) p24 (203–222 SF2) ETINEEAAEWDRVHPVVHA-
GP
HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Twelve subjects had CTL that could recognize vaccinia-expressed LAI gag
• One of these 12 had CTL response to this peptide
• The responding subject was HLA-A2, B21
p24 (78–86) AEWDRVHPV HIV-1 infection human (B*4002) Sabbaj2002b
• Epitope name: Gag-AV9
• This study monitored epitope responses in HIV-1 infected minority women living in the United States
• 24 epitopes were described – 8 were novel, 8 used new restricting elements but were previously defined epitopes, and 8 were previously described
• Serial peptide truncations were used to define optimal epitopes for CTL cell lines isolated from 12 individuals, assayed by a Cr-release
• This epitope was newly defined in this study
• Patient 01RCH59 was Hispanic, not on HAART, and had a viral load of 5100 and CD4 count of 349 – she also recognized TERQANFL, p2p7p1p6(64-71),
HLA-B*4002, and KEKGGLEGL, Nef(92-100), HLA-B*4002
• Among HIV+ individuals who carried HLA B40, 4/5 (80%) recognized this epitope
p24 (83–92) p24 (215–223 IIIB) VHPVHAGPIA HIV-1 infection human (B55) Sipsas1997
• HIV IIIB proteins were used to define the range of CTL epitopes recognized by 3 lab workers accidentally infected with HIV-1 IIIB
• LHPVHAGPVA, a variant found in HIV-1 PH136, was also recognized
• LHPVHAGPIA, a variant found in HIV-1 RF, was also recognized
• LHPVHAGPIT, a variant found in HIV-1 MN, was also recognized
• LHPAQAGPIA, a variant found in HIV-1 JH3, was recognized at high peptide concentrations
p24 (84–92) p24 (84–92) HPVHAGPIA HIV-1 infection human (B7) Yu2002a
• Epitope name: B7-HA9
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
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• 1/11 HLA-B7 individuals had detectable B7-restricted responses to this epitope during acute infection—10/15 of HLA-B7 epitopes tested were targeted by
at least one person during acute infection. 3/4 individuals had detectable responses to this epitope after STI.
p24 (87–101) Gag (219–233 LAI) HAGPIAPGQMREPRG HIV-1 infection human Buseyne1993a
• Vertical transmission of HIV ranges from 13% to 39%
• Primary assays showed cytotoxic activity against at least one HIV protein was detected in 70% of infected children
• Epitopes recognized in five children were mapped using synthetic peptides and secondary cultures
• Patient EM28 (CDC P2A) had a CTL response to four epitopes in Gag
p24 (87–101) p24 (219–233 BRU) HAGPIAPGQMREPRG HIV-1 infection human (A2) Claverie1988
• One of 4 epitopes predicted then shown to stimulate HLA-A2 restricted CTL line
p24 (91–110) p24 (223–242 SF2) IAPGQMREPRGSDIAGTTST HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Twelve subjects had CTL that could recognize vaccinia-expressed LAI gag
• One of these 12 had CTL response to this peptide
• The responding subject was HLA-A2, A24, B13, B35
p24 (101–120) p24 (233–252 SF2) GSDIAGTTSTLQEQIGWMTN HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Twelve subjects had CTL that could recognize vaccinia-expressed LAI gag
• One of these 12 had CTL response to this peptide
• The responding subject was HLA-A26, A30, B38
p24 (107–115) Gag (239–247 SF2) TTSTLQEQI Vaccine murine (H-2Kd) Mata1998
Vaccine Vector/Type: Listeria monocytogenes Strain: HXB2 HIV component: Gag
• BALB/c mice were immunized with recombinant Listeria monocytogenes (Lm-Gag) expressing HIV-1 HXB2 Gag
• L. monocytogenes is a gram-positive bacteria that enters the macrophage on phagocytosis and lives in the cytoplasm – secreted L. monocytogenes antigens
are processed and presented by both class I and class II pathways
p24 (108–117) TSTLQRQIGW HIV-1 infection human Kaul2001c
• This study examines CTL responses in HIV exposed, persistently seronegative individuals, HEPS, who eventually seroconverted – 11/114 HEPS Nairobi
sex workers eventually seroconverted, and for six of these HIV CTL reactive epitopes had been defined while seronegative
• The epidemiological factor associated with seroconversion was stopping sex work and HIV-specific CTL activity declines when HEPS sex workers stop
working for a period or retire
• This epitope was recognized in 1/22 HEPS sex worker controls (ML1250)
p24 (108–117) TSTLQEQIGW HIV-1 infection human (B*5701) Migueles2001
• HLA B*5701 was found in a very high frequency in HIV-1 infected non-progressors, 11/13 (85%) versus 19/200 (9.5%) of progressors. Non-progressors
tended to have an immune response that was highly focused on four p24 epitopes that were presented by B*5701, ISPRTLNAW, KAFSPEVIPMF,
TSTLQEQIGW, and QASQEVKNW.
p24 (108–117) TSTLQEQIGW HIV-1 infection human (B*5701) Migueles2001
• CTL activity was monitored in 27 individuals, including 10 LTNP with an over-expression of HLA B*5701 – these individuals have viral loads below the
threshold of infection without therapy, and their immune response tends to be focused on peptides that contain B*5701 epitopes ISPRTLNAW,
KAFSPEVIPMF, TSTLQEQIGW, and QASQEVKNW.
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• CTL responses are broader in B*5701+ individuals with progressive viremia than those that control viremia.
• The HLA-A*0201 SLYNTVATL epitope response was not as strong individuals that carried both A2, B57.
p24 (108–117) p24 (241–250 LAI) TSTVEEQQIW HIV-2 infection human (B*5801) Brander2001
• C. Brander notes this is a B*5801 epitope
p24 (108–117) p24 (240–249 LAI) TSTLQEQIGW HIV-1 infection human (B*5801) Brander2001
• C. Brander notes this is a B*5801 epitope
p24 (108–117) p24 (233–252) TSTLQEQIGW HIV-1 infection human (B57) Bernard1998
• This study focuses on six rare long-term survivor HIV-infected people who were infected for many years without exhibiting immune dysregulation – such
immunologically normal HIV-infected (INHI) cases occur at a frequency between 0.1 and 1% in the infected population
• No direct CTL were found in any of the six INHIs, but above background CTLp activity was founded in 3/6 INHIs
• Epitope sequences were deduced from larger reactive peptides based on HLA binding motifs – XSXXXXXXXW is a B57 binding motif, and CTL activity
against TSTLQEQIGW has been found in two other B57 long-term non-progressors
p24 (108–117) Gag (SF2) TSTLQEQIGW HIV-1 infection human (B57) Goulder2001a
• Epitope name: TW10
• Dominant epitope in acute infection in patient PI004, who did not receive any antiviral therapy
• 1-2 months post seroconversion, subject PI004 displayed a significant decrease in TW10 peptide recognition, followed by an increased CTL response
against epitope SL9, SLYNTVATL and other epitopes
• Three CTL responses, to epitopes TSTLQEQIGW, ISPRTLNAW, and KAFSPEVIPMF, were evident early after infection; CTL responses to SLYNTVATL,
QASQEVKNW, EIYKRWII, and FLKEKGGL were detectable at 5 months post-infection and beyond
p24 (108–117) p24 (108–117) TSTLQEQIGW HIV-1 infection human (B57) Oxenius2000
• Epitope name: TST
• Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific
CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load – three patients that had delayed initiation of
HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became
undetectable
• None of the 8 study subjects recognized this epitope but none were HLA B57+
p24 (108–117) p24 (108–117) TSTLQEQIGW HIV-1 infection human (B57) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
p24 (108–117) p24 TSTLQEQIGW HIV-1 infection human (B57) Kaul2002
• Neisseria gonorrhea cervititis in 9 HIV+ Kenyan sex workers caused a functional deficiency in IFN-gamma production in HIV-1 epitope-specific CD8+
T-cells, detected by intracellular cytokine production and tetramer assays, while not affecting the total number of epitope-specific CTLs.
• Ghonorrhea caused the weaker HIV-1 specific CTL responses in 4 HIV-1 exposed persistently seronegative (HEPS) women to become undetectable by
Elispot and tetramer assays, and CMV-specific CTL in 2 HEPS subjects were shown to have impaired function with regard to IFN-gamma production.
p24 (108–117) p24 TSTLQEQIGW HIV-1 infection human (B57) Oxenius2002b
• Epitope name: TST
• Using previously defined epitopes [Oxenius2000, Oxenius2001a] in an IFNgamma Elispot assay, 13 chronically HIV-1 infected patients were studied over a
period including therapy with standard treatment interruptions (STI).
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• STIs induced increased recognition of CTL epitopes, but there was no correlation between CTL responses with viral rebound rates, plateau viral loads, or
clearance rates.
p24 (108–117) p24 (235–243) TSTLQEQIGW HIV-1 infection, HIV-1 exposed
seronegative
human (B57, B58) Kaul2001a
• TSTLQEQIGW cross reacts with both for the A and B clades
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
p24 (108–117) p24 (241–250) TSTVEEQQIW HIV-2 infection human (B58) Bertoletti1998a
• HIV-2 epitope defined from an infection in Gambia, Bertoletti, Pers. Comm.
• All HIV-2 sequences from the database are TSTVEEQIQW in this region, not TSTVEEQQW as in the paper
p24 (108–117) p24 TSTLQEQIGW HIV-1 exposed seronegative human (B58) Rowland-Jones1999
• CTL responses in seronegative highly HIV-exposed African female sex workers in Gambia and Nairobi were studied – these women had no delta 32
deletion in CCR5
• In Gambia there is exposure to both HIV-1 and HIV-2, CTL responses to B35 epitopes in exposed, uninfected women are cross-reactive, and the B35 allele
seems to be protective
• HIV-2 sequence: TSTVEEQIQW, CTL are cross-reactive, [Bertoletti1998b]
p24 (108–117) p24 (240–249) TSTLQEQIGW HIV-2 infection human (B58) Bertoletti1998b
• CTL responses in HLA-B*5801 positive HIV-2 infected individuals have a dominant response to Gag and tolerate extensive substitution, thus
HLA-B*5801+ individuals may have an enhanced potential for cross-protection between HIV-1 and HIV-2
• This can be an immunodominant epitope in HLA-B57 and B*5801 infected individuals, and is associated with long-term non-progression [Goulder1996b]
• HIV-2 sequence: HIV-2 ROD has the epitope sequence TSTVEEQIQW, and the CTL from a person infected with HIV-2 was cross-reactive with HIV-1
epitopes
• The epitope is TSTLQEQIGW in HIV-1 B clade, and TSTVEEQIQW in HIV-2 ROD
• HLA B*5801 and B35 may preferentially select HIV-1 and HIV-2 cross-reactive epitopes
p24 (108–117) p24 (240–249 SF2) TSTLQEQIGW HIV-1 infection human (B58) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B58+ individuals that had a CTL response to this epitope broken down by group: 0/0 group 1, 1/1 group 2, and 0/0 group 3
p24 (108–117) p24 (108–117) TSTLQEQIGW HIV-1 infection human (B58) Goulder2001c
• Epitope name: TW10
• Responses to this dominant A3-restricted Gag epitope are present during the time of decreasing viral load in acute infection
• Mutations in this epitope were observed in autologous clones of subjects who were B58-positive with a higher frequency than those who were B58-negative
(P = 0.02)
• These mutations are being sexually transmitted in adult infections
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p24 (108–118) p24 (240–249 LAI) TSTLQEQIGWF HIV-1 infection human (B*57, B*5801) Goulder1996b
• Response to this epitope was found in 4 slow progressing HLA-B*57 individuals, in 2 it was dominant or very strong
• For one donor (from Zimbabwe) this was defined as the optimal peptide
• This epitope can be presented in the context of the closely related HLA molecules B*5801 and B*57
p24 (108–118) p24 (240–249 LAI) TSTLQEQIGWF HIV-1 infection human (B*5701) Brander2001
• C. Brander notes this is a B*5701 epitope
p24 (108–118) TSTLQEQIGWF HIV-1 infection human (B57) Sabbaj2002b
• Epitope name: Gag-TF11
• Among HIV+ individuals who carried HLA B57, 2/5 (40%) recognized this epitope
p24 (109–117) Gag (241–249 LAI) STLQEQIGW HIV-1 infection human (B*5701
B*5801)
Klein1998
• B57 has been associated with long-term non-progression in the Amsterdam cohort
• The most pronounced CTL responses in HLA B*5701 LTS were to RT and Gag
p24 (109–117) STLQEQIGW HIV-1 infection human (B57) Sabbaj2002b
• Epitope name: Gag-SW9
• Among HIV+ individuals who carried HLA B57, 1/5 (20%) recognized this epitope
• Among HIV+ individuals who carried HLA B58, 1/4 (25%) recognized this epitope
p24 (118–126) Gag (282–290) MTNNPPIPV HIV-1 infection human (A2 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind three of the five HLA-A2 supertypes alleles (A*0201, A*0202, A*0203, A*0206 and A*6802
p24 (121–135) p24 (253–267) NPPIPVGEIYKRWII HIV-1 infection human (B8) Gotch1990
• High frequency of memory and effector Gag-specific CTL
p24 (121–135) p24 (255–274 SF2) NPPIPVGEIYKRWII HIV-1 infection human (B8) Goulder1997a, Phillips1991
• Longitudinal study of CTL escape mutants in people with the appropriate HLA types – little variation was observed in the immunodominant B27 epitope,
relative to B8 epitopes, which varied over time
• [Goulder1997a] is a review of immune escape that points out that there may be a protective effect associated with B27, and that HLA-B8 individuals tend to
progress more rapidly than HLA B27 patients
p24 (121–135) p24 (121–135) NPPIPVGEIYKRWII HIV-1 infection human (B8) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
p24 (121–140) p24 (253–272) NPPIPVGEIYKRWIILGLNK HIV-1 infection human Lieberman1995
• HIV-specific CTL lines developed by ex vivo stimulation with peptide
124
DEC 2002
p24 CTL Epitopes HIV CTL Epitope Tables
C
TL
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
p24 (121–140) p24 (253–272 SF2) NPPIPVGEIYKRWIILGLNK HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Twelve subjects had CTL that could recognize vaccinia-expressed LAI gag
• Two of these 12 had CTL response to this peptide
• The responding subjects were HLA-A2, A3, B8, B62, and HLA-A1, B8, B18
p24 (121–140) p24 (253–272 SF2) NPPIPGEIKRWIILGNIK HIV-1 infection human Lieberman1997b
• CTL expanded ex vivo were later infused into HIV-1 infected patients
p24 (121–140) p24 (255–274 SF2) NPPIPVGEIYKRWIILGLNK HIV-1 infection human vanBaalen1993
• Gag CTL epitope precursor frequencies were estimated and peptide mapping was performed
p24 (121–142) p24 (253–274 BH10) NPPIPVGEIYKRWIILGLN-
KIV
HIV-1 infection human (B8) Johnson1991
• Gag CTL response studied in three individuals
p24 (121–152) Gag (183–214 LAI) NPPIPVGEIYKRWIILGLN-
KIVRMYSPTSILD
Vaccine human Gahery-Segard2000
Vaccine Vector/Type: lipopeptide HIV component: six peptides
• Anti-HIV lipopeptide vaccine consisting of six long amino acid peptides derived from Nef, Gag and Env HIV-1 proteins modified by a palmitoyl chain was
administered in a phase I trial
• A CD4+ T cell proliferative response to at least one of the six peptides was observed in 9/10 vaccinees – 9/10 reacted to this peptide
• 9/12 tested mounted a CTL response to at least one of the six peptides; each of the six peptides elicited a CTL response in at least one individual – this
peptide was particularly immunogenic, eliciting a CTL response in four vaccinees
• All of the 12 tested had an IgG response to this peptide
p24 (121–152) Gag NPPIPVGEIYKRWIILGLN-
KIVRMYSPTSILD
HIV-1 infection, Vaccine human (A*0201) Seth2000
Vaccine Vector/Type: lipopeptide HIV component: gag peptide
• Immunization of 2/4 HIV seropositive HLA selected individuals with a 32 amino acid Gag lipopeptide that contains CTL epitopes restricted by HLA A33,
B8, B27, B35, and Bw62 gave a transient increase in peptide-specific bulk CTL response, but they did not decrease plasma viral load.
• Placebo and HLA mis-matched controls showed no change in CTL
• The responders carried HLA Bw62 and B35 – the two HLA-matched that did not respond carried B35 and B8
p24 (122–130) p24 PPIPVGDIH HIV-1 infection human Kaul2001c
• This study examines CTL responses in HIV exposed, persistently seronegative individuals, HEPS, who eventually seroconverted – 11/114 HEPS Nairobi
sex workers eventually seroconverted, and for six of these HIV CTL reactive epitopes had been defined while seronegative
• The epidemiological factor associated with seroconversion was stopping sex work and HIV-specific CTL activity declines when HEPS sex workers stop
working for a period or retire
• This epitope was recognized in 1/22 HEPS sex worker controls, ML887
p24 (122–130) p24 (260–268 LAI) PPIPVGDIY HIV-1 or HIV-2 infection human (B*3501) Brander2001
• C. Brander notes this is a B*3501 epitope
p24 (122–130) p24 (245–253 HIV-2) NPVPVGNIY HIV-1 infection human (B*3501) Rowland-Jones1995b
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p24 (122–130) p24 (245–253 HIV-2) NPVPVGNIY HIV-1 infection human (B*3501) Brander2001
• C. Brander notes this is a B*3501 epitope
p24 (122–130) p24 (260–268 LAI) PPIPVGDIY HIV-1 or HIV-2 infection human (B35) Rowland-Jones1995b
• Defined as minimal peptide by titration curve, PPIPVGEIY and HIV-2 form NPVPVGNIY are also recognized
p24 (122–130) p24 (260–268 LAI) PPIPVGDIY in vitro stimulation human (B35) Lalvani1997
• A peptide-based protocol was optimized for restimulation of CTLp using optimized peptide and IL-7 concentrations – importantly this protocol does not
stimulate a primary response, only secondary – peptide-specific CTLp counts could be obtained via staining with peptide-Class I tetramers
• This peptide was one of the B35 presented test peptides used in control experiments showing that the assay gave no activity using lymphocytes from 21
healthy B35 seronegative donors
p24 (122–130) p24 (260–268 LAI) PPIPVGDIY HIV-1 infection human (B35) McMichael1994
• Review of HIV CTL epitopes
p24 (122–130) p24 (subtype B) PPIPVGEIY HIV-1 exposed seronegative human (B35) Rowland-Jones1998b
• HIV-specific CTL were found in exposed seronegative prostitutes from Nairobi – these CTL may confer protection
• Seroprevalence in this cohort is 90-95% and their HIV-1 exposure is among the highest in the world
• Most isolated HIV strains are clade A in Nairobi, although clades C and D are also found – B clade epitopes are often cross-reactive, however stronger
responses are frequently observed using A or D clade versions of epitopes
• This epitope is conserved among B and D clade viruses
• The Clade A version of the epitope, PPIPVGDIY, was preferentially recognized by CTL
p24 (122–130) PPIPVGEIY HIV-1 infection human (B35) Wilson2000a
• Three individuals with highly focused HIV-specific CTL responses were studied during acute infection using tetramers—high frequencies of HIV-1-specific
CD8+ T cells were found prior to seroconversion, and there was a close temporal relationship between the number of circulating HIV-specific T cells and
viral load
• All three patients were B*2705, with HLA alleles: A1, A30/31, B*2705, B35; A1, A*0301, B7, B2705; and A*0201, A*0301, B2705, B39
• ELISPOT was used to test a panel of CTL epitopes that had been defined earlier and were appropriate for the HLA haplotypes of the study subjects – 3/3
subjects showed a dominant response to the B*2705 epitope KRWIILGGLNK
• The subject with A*0201 had a moderatly strong response to SLYNTVATL
• Weak responses were observed to A*301-RLRPGGKKK, A*301-QVPLRPMTYK, and B7-TPGPGVRYPL in the subject who was HLA A1, A*0301, B7,
B*2705
• No acute response was detected to the following epitopes: A*201-ILKEPVHGV, A*301-KIRLRPGGK, A*301-AIFQSSMTK, A*301-TVYYGVPVWK,
B35-EPIVGAETF, B35-HPDIVIYQY, B35-PPIPVGEIY, B35-NSSKVSQNY, B35-VPLRPMTY, B35-DPNPQEVVL
p24 (122–130) p24 PPIPVGDIY human (B35) Rowland-Jones1999
• CTL responses in seronegative highly HIV-exposed African female sex workers in Gambia and Nairobi were studied – these women had no delta 32
deletion in CCR5
• In Gambia there is exposure to both HIV-1 and HIV-2, CTL responses to B35 epitopes in exposed, uninfected women are cross-reactive, and the B35 allele
seems to be protective
• HIV-2 version of this epitope is not conserved: NPVPVGNIY, but the CTLs are cross-reactive – one of five B35 CTL epitopes that are cross-reactive, see
also [Rowland-Jones1995b]
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p24 (122–130) p24 (260–268) PPIPVGDIY HIV-1 infection human (B35) Oxenius2000
• Epitope name: PPI
• Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific
CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load – three patients that had delayed initiation of
HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became
undetectable
• One of two HLA B35+ among the eight study subjects recognized this epitope
• Patient SC15 (HLA A1/68, B8/35, Bw4/6, Cw4/0704) was given acute and sustained therapy and recognized epitopes PPIPVGDIY and VPLRPMTY
during 331 days of HAART treatment
p24 (122–130) p24 (122–130) PPIPVGDIY HIV-1 infection human (B35) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
p24 (122–130) p24 (254–262 SF2) PPIPVGDIY HIV-1 infection human (B35) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B35+ individuals that had a CTL response to this epitope broken down by group: 0/2 group 1, 0/2 group 2, and 1/1 group 3
p24 (122–130) p24 (260–268) PPIPVGDIY HIV-1 infection, HIV-1 exposed
seronegative
human (B35) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with
reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected
women
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure
• Among HLA-B35 women, 1/3 HEPS and 3/4 HIV-1 infected women recognized this epitope
• The dominant response to this HLA allele was to this epitope in the 1/3 HEPS case and in the all 3/4 responsive HIV-1 infected women
• Subject ML 857 shifted from a A*6802 DTVLEDINL and B35 (H/N)PDIVIYQY response prior to seroconversion to a B35 PPIPVGDIY and B35
VPLRPMTY response post-seroconversion
p24 (122–130) PPIPVGDIY HIV-1 infection human (B35) Sabbaj2002b
• Epitope name: Gag-PY9
• Among HIV+ individuals who carried HLA B35, 2/21 (10%) recognized this epitope
• Among HIV+ individuals who carried HLA B*5301, 0/11 (0%) recognized this epitope
p24 (122–130) p24 PPIPVGEIY HIV-1 infection, Vaccine human (B35) Hanke2000, Wee2002
Vaccine Vector/Type: DNA prime with vaccinia MVA boost Strain: subtype A HIV component: p17, p24, polyepitope
127
DEC 2002
C
TL
HIV CTL Epitope Tables p24 CTL Epitopes
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
• The HIV-1 subtype A focused vaccine HIVA contains p24 and p17, in a reversed order relative to the Gag polyprotein to prevent myristylation of p17,
which could direct the protein to the cell membrane and inhibit efficient peptide processing and class I presentation, as well as a polyepitope string of
conserved, often immunodominant epitopes that were selected to have particularly good cross-reactive potential for the A-clade epidemic in Nairobi,
Kenya. A DNA and MVA prime-boost vaccination protocol using the HIVA antigen will be used in a phase III clinical trial in Kenya. This epitope is
included in the polyepitope string [Hanke2000].
• Multiple CD4+ or CD8+ T-cell vaccine-induced responses to peptide pools were detected using intracellular cytokine staining and IFNgamma Elispot
assays after vaccination of 5 macaques. The response to the Mamu A*01 SIV p27 epitope p11C (CTPYDINQM), included in the polyepitope region, was
not immunodominant in the Mamu A*01 vaccinated macaques, possibly because of processing limitations in context of the artificial polyepitope string
[Wee2002].
p24 (124–138) p24 (256–270 LAI) IPVGEIYKRWIILGL HIV-1 infection human (B8) Buseyne1993b
• Clustering of Gag p24 CTL epitopes recognized in 29 HIV-infected people
p24 (124–138) Gag (256–270 LAI) IPVEGEIYKRWIILGL HIV-1 infection human (B8) Buseyne1993a
• Vertical transmission of HIV ranges from 13% to 39%
• Primary assays showed cytotoxic activity against at least one HIV protein was detected in 70% of infected children
• Epitopes recognized in five children were mapped using synthetic peptides and secondary cultures
• Two children, EM16 (CDC P2A+D2) and EM18 (CDC P2A), had a CTL response to this epitope, and it was shown to be presented by B8 in EM18
p24 (127–135) p24 (259–267 SF2) GDIYKRWII HIV-1 infection human (B*0801) McAdam1998
• GDIYKRWII specific CTL clone also recognized GEIYKRWII
p24 (127–135) p24 (261–269) GEIYKRWII HIV-1 infection human (B8) Sutton1993
• Predicted epitope based on B8-binding motifs, from larger peptide NPPIPVGEIYKRWII
p24 (127–135) p24 (259–267) GEIYKRWII in vitro stimulation human (B8) Zarling1999
• This study compares the ability of macrophages and dendritic cells to stimulate primary responses in CD8+ lymphocytes isolated from HLA-appropriate
HIV-uninfected donors using peptide-pulsed APC – the dendritic cells performed better as APC for the stimulation of primary responses
• Strong CTL responses were elicited by the epitopes DRFYKTLRA and GEIYKRWII when presented by either immature or mature dendritic cells –
macrophages were not able to prime a CTL response against DRFYKTLRA
• A weak response to KLTPLCVSL was stimulated using macrophages as the APC
• No detectable response was observed for the following previously-defined HIV epitopes: KIRLRPGGK, ILKEPVHGV, IRLRPGGK, GPKVKQWPL
p24 (127–135) p24 (259–267 LAI) GEIYKRWII HIV-1 infection human (B8) Klenerman1994
• Naturally occurring variant GDIYKRWII may act as antagonist
p24 (127–135) p24 (259–267) GEIYKRWII HIV-1 infection human (B8) Betts2000
• Only 4/11 HLA-A2+ HIV+ individuals had CTL that reacted to SLYNTVATL, calling into question whether it is immunodominant
• 95 optimally-defined peptides from this database were used to screen for INFγ responses to other epitopes
• 1/11 of the HLA A2+ was HLA A*0201, A31, B8, B51 and responded to this epitope as well as seven others
p24 (127–135) p24 (259–267) GEIYKRWII HIV-1 infection human (B8) Nowak1995
• Longitudinal study of CTL response and study of immune escape – GDIYKRWII could also stimulate CTL, reactivity fluctuated
p24 (127–135) p24 (259–267) GEIYKRWII HIV-1 infection human (B8) McAdam1995
• Equivalent sequence GDIYKRWII also recognized by CTL from some donors
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p24 (127–135) p24 (259–267) GEIYKRWII HIV-1 infection human (B8) Oxenius2000
• Epitope name: GEI
• Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific
CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load – three patients that had delayed initiation of
HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became
undetectable
• Six of the 7/8 study subjects that were HLA B8 recognized this epitope
• Patient SC2 (HLA A1, B7/8, Cw0701/0702, DR4/53, DQ7) had CTL responsiveness against epitopes FLKEKGGL, GPKVKQWPL, and GEIYKRWII
peptides – FLKEKGGL tetramer staining steadily declined and at day 1340 the FLKEKGGL stained cells were no longer detected and the escape mutant
FLKENGGI was found in 8/10 clones
• Patient SC9 (HLA A1/2, B8/13, Cw0/0701, DR2/11, DQ6/7) had a CTL response against epitopes FLKEKGGL, ILKEPVHGV,
SQRRQDILDLWIYHTQGYFPDWQNY, and GEIYKRWII and all responses declined during therapy initiated at day 390 but were restored when therapy
become intermittent.
• Patient SC19(HLA A11/12, B8/44, Cw06/0701, DR3/7, DR52/53, DQ 2/8) had a CTL response to epitopes FLKEKGGL, GEIYKRWII,
ACQGVGGPGHK, AVDLSHFLK, and FNCGGEFFY that declined during therapy initiated at day 197
• Patient SC10(HLA A1/3, B8/35, DR1/8, DQ 4/5) had sustained therapy started during acute infection and maintained an immunodominant response to
FLKEKGGL and a response to GEIYKRWII through day 1088
• Patient SC12(HLA A1, B8/39, Cw0701/0702, DR2/3, DR51/52, DQ2/6) had sustained therapy started during acute infection and maintained an
immunodominant response to FLKEKGGL throughout and minor responses to GEIYKRWII, DCKTILKAL, GGKKKYKLK – GEIYKRWII and
GGKKKYKLK responses were stimulated by a brief period off therapy
• Patient SC11(HLA A1, B8, Cw0201, DR3/11, DR52, DQ2/7) started therapy early, remained on therapy for 40 days, then reinitiated HAART at day 640
had a CTL response to FLKEKGGL, GPKVKQWPL, and GEIYKRWII throughout and received a benefit from the early limited course therapy
p24 (127–135) p24 (259–267 SF2) GEIYKRWII HIV-1 infection human (B8) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B8+ individuals that had a CTL response to this epitope broken down by group: 2/3 group 1, 2/3 group 2, and 2/2 group 3
p24 (127–135) p24 GEIYKRWII HIV-1 infection human (B8) Oxenius2002b
• Epitope name: GEI
• Using previously defined epitopes [Oxenius2000, Oxenius2001a] in an IFNgamma Elispot assay, 13 chronically HIV-1 infected patients were studied over a
period including therapy with standard treatment interruptions (STI).
• STIs induced increased recognition of CTL epitopes, but there was no correlation between CTL responses with viral rebound rates, plateau viral loads, or
clearance rates.
p24 (127–135) p24 GEIYKRWII HIV-1 infection, Vaccine human (B8) Hanke2000, Wee2002
Vaccine Vector/Type: DNA prime with vaccinia MVA boost Strain: subtype A HIV component: p17, p24, polyepitope
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• The HIV-1 subtype A focused vaccine HIVA contains p24 and p17, in a reversed order relative to the Gag polyprotein to prevent myristylation of p17,
which could direct the protein to the cell membrane and inhibit efficient peptide processing and class I presentation, as well as a polyepitope string of
conserved, often immunodominant epitopes that were selected to have particularly good cross-reactive potential for the A-clade epidemic in Nairobi,
Kenya. A DNA and MVA prime-boost vaccination protocol using the HIVA antigen will be used in a phase III clinical trial in Kenya. This epitope is
included in the polyepitope string [Hanke2000].
• Multiple CD4+ or CD8+ T-cell vaccine-induced responses to peptide pools were detected using intracellular cytokine staining and IFNgamma Elispot
assays after vaccination of 5 macaques. The response to the Mamu A*01 SIV p27 epitope p11C (CTPYDINQM), included in the polyepitope region, was
not immunodominant in the Mamu A*01 vaccinated macaques, possibly because of processing limitations in context of the artificial polyepitope string
[Wee2002].
p24 (127–136) GEIYKRWIIL HIV-1 infection human (B*0801) Sabbaj2002b
• Epitope name: Gag-GL10
• This study monitored epitope responses in HIV-1 infected minority women living in the United States
• 24 epitopes were described – 8 were novel, 8 used new restricting elements but were previously defined epitopes, and 8 were previously described
• Serial peptide truncations were used to define optimal epitopes for CTL cell lines isolated from 12 individuals, assayed by a Cr-release
• Subject 00RCH87 was not on HAART, viral load 8300, CD4 count 313
• Among HIV+ individuals who carried HLA B08, 3/6 (50%) recognized this epitope
p24 (128–135) p24 (260–267 LAI) EIYKRWII human (B*0801) Brander2001
• C. Brander notes this is a B*0801 epitope
p24 (128–135) p24 (260–267 LAI) EIYKRWII human (B8) Goulder1997g
• Defined in a study of the B8 binding motif
p24 (128–135) p24 (SF2) EIYKRWII HIV-1 infection human (B8) Goulder2000a
• The CTL-dominant response was focused on this epitope in a HIV+ Caucasian living in Boston – this epitope did not fall within the three most recognized
peptides in the study
• Three peptides GSEELRSLYNTVATL (p17 residues 71-85), SALSEGATPQDLNTMLNTVG (p24 41-60), and WEKIRLRPGGKKKYKLK(p17 16-30)
contained the dominant Gag-specific epitope in 31 out of 44 B-clade infected individuals from Boston who showed Gag-CTL responses
• Five peptides RLRPGGKKHYMIKHLVW (p17 20-36), ELRSLYNTVATLYCV (p17Gag 74-88), SALSEGATPQDLNTMLNTVG (p24 41-60),
FRDYVDRFFKTLRAEQA (p24 161-177), and SILDIKQGKEPFRDY (p24 149-164) contained dominant Gag-specific epitopes in 32 out of 37 C-clade
infected subjects from South Africa
p24 (128–135) p24 (C consensus) DIYKRWII HIV-1 infection human (B8) Goulder2000a
• The CTL-dominant response was focused on this epitope in a HIV+ South African – this epitope did not fall within the five most recognized peptides in the
study
• Three peptides GSEELRSLYNTVATL (p17 residues 71-85), SALSEGATPQDLNTMLNTVG (p24 41-60), and WEKIRLRPGGKKKYKLK(p17 16-30)
contained the dominant Gag-specific epitope in 31 out of 44 B-clade infected individuals from Boston who showed Gag-CTL responses
• Five peptides RLRPGGKKHYMIKHLVW (p17 20-36), ELRSLYNTVATLYCV (p17Gag 74-88), SALSEGATPQDLNTMLNTVG (p24 41-60),
FRDYVDRFFKTLRAEQA (p24 161-177), and SILDIKQGKEPFRDY (p24 149-164) contained dominant Gag-specific epitopes in 32 out of 37 C-clade
infected subjects from South Africa
p24 (128–135) p24 (SF2) EIYKRWII HIV-1 infection human (B8) Goulder2001a
• Epitope name: EI8
• This peptide elicited a weak CTL response during acute HIV-1 infection in patient PI004
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• Three CTL responses to epitopes, TSTLQEQIGW, ISPRTLNAW, and KAFSPEVIPMF, were evident early after infection; CTL responses to SLYNTVATL,
QASQEVKNW, EIYKRWII, and FLKEKGGL were detectable at 5 months post-infection and beyond
p24 (128–135) p24 EIYKRWII HIV-1 infection human (B8) Kostense2001
• HLA tetramers to six epitopes were used to study HLA-A2, B8 and B57 CTL in 54 patients – HIV-specific tetramer positive cells were inversely correlated
with viral load in patients with high CD4, but in patients with CD4 T-cells below 400 high tetramer frequencies were found despite high viral load
• Most patients have high levels of HIV-specific T-cell expansions, but many of these cells aren’t functional
• In 15 of the patients, the proportion of IFN gamma producing tetramer cells correlated with AIDS-free survival
• 4/13 patients that reacted with EIYKRWII displayed epitope mutations in a minority of sequences, which did not correlate with disease progression or viral
load – these mutations were: Patient 156 (KIYKRWMI), Patient 36 (EIYKRRII), Patient 656 (KIYKRWII, EIYERWMI), and Patient 159 (EIYKRWVI).
• Stimulation with HLA-B8 p24 and Nef epitopes significantly increased Nef-specific T-cell numbers in 2 patients (748 and 1113)
• There were more functional IFN-gamma producing Nef-specific T-cells within the T-cell population than there were active p24 Gag-specific T-cells
p24 (128–135) p24 (259–267) DIYKRWII HIV-1 infection human (B8) Appay2000
• Combined tetramer and intracellular cytokine staining was used to study the function of circulating CD8+ T cells specific for HIV and CMV
• HIV-specific CD8+ T cells expressed lower levels of perforin than CMV-specific CD8+ T cells from the same donor, and this was associated with persistent
CD27 expression on HIV-specific cells, suggesting impaired maturation
• In most donors, between 50% and 95% of the activated virus-specific CD8+ T cells produced IFN-γ and MIP-1β with a distinct subset that failed to
produce TNF-α
p24 (128–135) p24 (128–135) EIYKRWII HIV-1 infection human (B8) Day2001
• B8-restricted CTL accounted for about 1/3 of the total CTL response in one individual
p24 (128–135) Gag EIYKRWII HIV-1 infection human (B8) Goulder2000b
• Tetramer assays were compared with three functional assays in 42 people with chronic HIV infection: ELISPOT, intracellular cytokine staining, and
precursor frequency (limiting dilution assay [LDA])
• HIV-specific tetramer staining CTLs appeared to be active, and inert CTL were not found to play a significant role in chronic pediatric or adult HIV
infection
p24 (128–135) p24 DIYKRWII HIV-1 infection human (B8) Appay2002
• Four HIV patients with prolonged clinically successful anti-viral therapy but with ongoing evidence of replication and Nef mRNA transcription, showed
specific T-cell responses by Elispot and Tetramer staining, maintained for 2-4 years after initiation of HAART.
• Nef epitope recognition was detected in all 4 subjects, gp120, Pol and Gag-specific in 1 or 2 subjects.
• The HIV-specific CD8+ T-cells had an intermediate maturation phenotype characterized by low levels of perforin and high levels of CD27 expression.
p24 (129–136) p24 (263–270 SF2) IYKRWIIL HIV-1 infection human (A*2402) Ikeda-Moore1997
• Defined using reverse immunogenetics – 59 HLA-A*2402 binding peptides were predicted by searching for A*2402 anchors in HIV proteins (Tyr at 2, and
Phe, Leu or Ile at the C term) – 53 of the 59 peptides bound A*2402
• This peptide induced CTL in 1/4 HIV-1+ people tested
• IYKRWIIL bound to A*2402 with medium strength, the epitope can be processed in a vaccinia construct and presented – two specific CTL clones were
obtained
p24 (129–138) p24 (263–272 SF2) IYKRWIILGL HIV-1 infection human (A*2402) Ikeda-Moore1997
• Defined using reverse immunogenetics – 59 HLA-A*2402 binding peptides were predicted by searching for A*2402 anchors in HIV proteins (Tyr at 2, and
Phe, Leu or Ile at the C term) – 53 of the 59 peptides bound A*2402
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• This peptide induced CTL in 1/4 HIV-1+ people tested
• IYKRWIILGL bound to A*2402 with medium strength, the epitope can be processed in a vaccinia construct and presented – two specific CTL clones were
obtained
p24 (129–138) p24 (263–272) IYKRWIILGL HIV-1 infection human (B27) Betts2000
• Only 4/11 HLA-A2+ HIV+ individuals had CTL that reacted to SLYNTVATL, calling into question whether it is immunodominant
• 95 optimally-defined peptides from this database were used to screen for INFγ responses to other epitopes
• 1/11 of the A2+ individuals was B27 and responded to IYKRWIILGL
p24 (130–148) p24 (265–280 BRU) YKRWIILGLNKIVRMYSPT HIV-1 infection human (B27) Dadaglio1991
• Used as a positive control for HLA specificity
p24 (131–139) Gag (265–273) KRWIILGLN HIV-1 infection chimpanzee (Patr-B*03) Balla-Jhagjhoorsingh1999b
• Certain HLA-alleles have been associated with long-term survival – among them are HLA-B*27 and HLA-B*57
• Of more than 150 chimpanzees that have been reported to be infected with HIV-1, only one has developed AIDS
• CTL responses were studied in two HIV-1 infected chimpanzees that have strong CTL responses, and they were found to respond to highly conserved
epitopes that are recognized in humans in the context of HLA-B*27 and HLA-B*57
• The human HLA protein which presents this Patr-B*03 epitope is HLA B*2705 but the amino acid sequences in the binding pockets of HLA-B*2705 and
Patr-B*03 are distinctive
p24 (131–140) Gag (263–272 LAI) KRWILLGLNK HIV-1 infection human Buseyne1993a
• Vertical transmission of HIV ranges from 13% to 39%
• Primary assays showed cytotoxic activity against at least one HIV protein was detected in 70% of infected children
• Epitopes recognized in five children were mapped using synthetic peptides and secondary cultures
• Patient EM28 (CDC P2A) had a CTL response to four epitopes in Gag
p24 (131–140) p24 (263–272) KRWIILLGLNK HIV-1 infection human (B*27) Huang2000
• The single cell ELISPOT assay was optimized and highly specific, and found to work well even after the primary cells had been frozen and thawed
• Increases in gamma interferon producing cells were observed in response to anti-retroviral therapy using single cell IFN-gamma-production ELISPOT
• In 3/3 HLA A*02, B*27 individuals, the dominant response in gag measured by both gamma IFN production and T cell lysis was to the B27 epitope,
KRWIILLGLNK, not the A2 SLYNTVATL epitope
p24 (131–140) p24 (263–272 SF2) KRWIILGLNK HIV-1 infection human (B*27) McAdam1998
• Epitope invariant across clades A, B, C, and D
p24 (131–140) p24 (260–269 HIV-2) RRWIQLGLQK human (B*2703) Brander2001
• C. Brander notes this is a B*2703 epitope
p24 (131–140) p24 KRWIILGGLNK HIV-1 infection human (B*2705) Wilson2000a
• Three individuals with highly focused HIV-specific CTL responses were studied during acute infection using tetramers – high frequencies of HIV-1-specific
CD8+ T cells were found prior to seroconversion, and there was a close temporal relationship between the number of circulating HIV-specific T cells and
viral load was also found
• All three patients were B*2705, with HLA alleles: A1, A30/31, B*2705, B35; A1, A*0301, B7, B2705; and A*0201, A*0301, B2705, B39
• Tetramers with peptide variants KRWIILGGLNK and KRWIIMGGLNK were used – CTL from most B27 donors recognize both variants, although one of
the three subjects recognized only KRWIILGGLNK
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• ELISPOT was used to test a panel of CTL epitopes that had been defined earlier and were appropriate for the HLA haplotypes of the study subjects – 3/3
subjects showed a dominant response to the B*2705 epitope KRWIILGGLNK
• The subject with A*0201 had a moderatly strong strong response to SLYNTVATL
• Weak responses were observed to A*301-RLRPGGKKK, A*301-QVPLRPMTYK, and B7-TPGPGVRYPL in the subject who was HLA A1, A*0301, B7,
B*2705
• No acute response was detected to the following epitopes: A*201-ILKEPVHGV, A*301-KIRLRPGGK, A*301-AIFQSSMTK, A*301-TVYYGVPVWK,
B35-EPIVGAETF, B35-HPDIVIYQY, B35-PPIPVGEIY, B35-NSSKVSQNY, B35-VPLRPMTY, B35-DPNPQEVVL
p24 (131–140) p24 (263–272 LAI) KRWIILGLNK HIV-1 infection human (B*2705) Brander2001
• C. Brander notes this is a B*2705 epitope
p24 (131–140) p24 (263–272) KRWIILGLNK HIV-1 infection human (B*2705) Kelleher2001b
• A mutation in 4/5 B*2705 patients had substitution to lysine (K) at HIV-1 gag residue 264 (R264K), in three the change occurred late in infection – in one
patient a substitution of glycine at HIV-1 gag residue 264 (R264G) was detected – these substitutions reduce binding to B27
• The R264K mutations were associated with a L268M mutation that may be compensatory, and R264G occurred in conjunction with E260D
• Positions 260, 264, and 268 all lie along one aspect of helix seven of the capsid protein, a region that is important for capsid self-association and assembly
• R264G and R264K escape mutation outgrowth occurred in conjunction with high viral loads
p24 (131–140) p24 (263–272) KRWIIMGLNK HIV-1 infection human (B*2705) Appay2000
• Combined tetramer and intracellular cytokine staining was used to study the function of circulating CD8+ T cells specific for HIV and CMV
• HIV-specific CD8+ T cells expressed lower levels of perforin than CMV-specific CD8+ T cells from the same donor, and this was associated with persistent
CD27 expression on HIV-specific cells, suggesting impaired maturation
• In most donors, between 50% and 95% of the activated virus-specific CD8+ T cells produced IFN-γ and MIP-1β with a distinct subset that failed to
produce TNF-α
p24 (131–140) p24 KRWIILLGLNK HIV-1 infection, Vaccine human (B*2705) Hanke2000, Wee2002
Vaccine Vector/Type: DNA prime with vaccinia MVA boost Strain: subtype A HIV component: p17, p24, polyepitope
• The HIV-1 subtype A focused vaccine HIVA contains p24 and p17, in a reversed order relative to the Gag polyprotein to prevent myristylation of p17,
which could direct the protein to the cell membrane and inhibit efficient peptide processing and class I presentation, as well as a polyepitope string of
conserved, often immunodominant epitopes that were selected to have particularly good cross-reactive potential for the A-clade epidemic in Nairobi,
Kenya. A DNA and MVA prime-boost vaccination protocol using the HIVA antigen will be used in a phase III clinical trial in Kenya. This epitope is
included in the polyepitope string [Hanke2000].
• Multiple CD4+ or CD8+ T-cell vaccine-induced responses to peptide pools were detected using intracellular cytokine staining and IFNgamma Elispot
assays after vaccination of 5 macaques. The response to the Mamu A*01 SIV p27 epitope p11C (CTPYDINQM), included in the polyepitope region, was
not immunodominant in the Mamu A*01 vaccinated macaques, possibly because of processing limitations in context of the artificial polyepitope string
[Wee2002].
p24 (131–140) p24 (263–272 LAI) KRWIILGLNK HIV-1 infection human (B*2705, B27) Goulder1997c, Goulder1997a
• HLA-B*2705 is associated with slow HIV disease progression
• 11/11 HLA-B*2705 donors make a response to this epitope, usually an immunodominant response
• This is a highly conserved epitope
• The HLA-B*2705 binding motif includes R at position 2, and L in the C-term position
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• [Goulder1997a] is a review on CTL immune escape that discusses this epitope in the context of the difficulty in detection of immune escape –
KRWIILGLNK and an R2K change, KKWIILGLNK, show little difference in titration curves, yet the K2 variants fail to bind to targets for more than 1
hour, while the R2 form can sensitize lysis by CTL for over 24 hours – minigene transfection experiments confirmed the importance of this for the CTL
response
p24 (131–140) p24 (260–269 HIV-2) RRWIQLGLQK human (B27) Brander1996b
• HIV-2, HLA-B*2703, S. Rowland-Jones, Pers. Comm.
p24 (131–140) p24 (263–272 LAI) KRWIILGLNK HIV-1 infection human (B27) Fan1997
• The capacity of dendritic cells to process and present antigen and stimulate anti-HIV-1 CTL memory responses was studied
p24 (131–140) Gag (263–272) KRWIILGLNK HIV-1 infection human (B27) Zheng1999
• Protein delivery (gp160 LAV, p66 LAV, and p24 NY5) to human dendritic cells (DC) with liposomes provides enhanced memory CTL response relative to
delivery of protein alone
• Chloroquine administration enhanced epitope presentation, and brefeldin A and peptide aldehyde inhibitors inhibited antigen presentation, suggesting
epitopes were processed by classical proteasome pathway
• The CTL response to p24 was measured in individuals with a response to B27-KRWIILGLNK
p24 (131–140) p24 (263–272 LAI) KRWIILGLNK HIV-1 infection human (B27) Wilson1998a
• HIV+ individuals were followed longitudinally using MHC tetramers in combination with 14 anti-BV chain MAbs, and clonal expansion of HIV-specific T
cells was followed in vivo
• Seven HIV+ people were studied, and all showed expansions of particular TCR BV clones, often several, relative to uninfected controls
• Three patients were followed in detail, TCR VB expansions persisted for 2 to 3 years, with occasional transient increases
p24 (131–140) p24 KRWIILGLNK HIV-1 infection human (B27) Rowland-Jones1997
• Described in this review as the first identified HIV CTL epitope
p24 (131–140) p24 (263–272 LAI) KRWIILGLNK HIV-1 infection human (B27) Buseyne1993b
• Clustering of Gag p24 CTL epitopes recognized in 29 HIV-infected people
p24 (131–140) p24 (263–272 LAI) KRWIILGLNK HIV-1 infection human (B27) McMichael1994
• Review of HIV CTL epitopes
p24 (131–140) p24 (263–272) KRWIIMGLNK HIV-1 infection human (B27) Klenerman1994
• Naturally occurring variant KRWIILGLNK may act as antagonist
p24 (131–140) p24 (263–272) KRWIIMGLNK HIV-1 infection human (B27) Klenerman1995
• Naturally occurring variant KRWIILGLNK may act as antagonist
p24 (131–140) p24 (265–274) KRWIILGLNK HIV-1 infection human (B27) Moss1995
• In one individual, TCR usage changed over time indicating that new populations of CTL can be recruited
• TCR usage showed a CTL clonal response to this epitope that persisted over 5 years
• CTL clones specific for HIV epitopes may represent between 0.2 and 1% of the total CD8+ population of T cells
p24 (131–140) p24 (265–276) KRWIILGLNK human (B27) Carreno1992
• Included in HLA-B27 binding peptide competition study
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p24 (131–140) p24 (265–274 SF2) KRWIILGLNK HIV-1 infection human (B27) Goulder1997a, Phillips1991
• Longitudinal study of CTL escape mutants – little variation was observed in the immunodominant B27 epitope, relative to B8 epitope
• [Goulder1997a] is a review of immune escape that points out that there may be a protective effect associated with B27, and that HLA-B8 individuals tend to
progress more rapidly than HLA B27 patients
p24 (131–140) p24 (263–272) KRWIILGLNK HIV-1 infection human (B27) Goulder1997a, Nietfeld1995
• Single point mutations were introduced and viral viability and CTL recognition tested – an Arg to Lys change at anchor position P2 abrogates binding to
B27, but doesn’t change viral viability in vitro
• [Goulder1997a] is a review of immune escape that summarizes this study
p24 (131–140) p24 (263–272) KRWIIMGNK HIV-1 infection human (B27) Nowak1995
• Longitudinal study of CTL response and immune escape – the form KRWIILGNK was also found, and both forms stimulate CTL
p24 (131–140) p24 (263–272) KRWIILGNK HIV-1 infection human (B27) Durali1998
• Cross-clade CTL response was studied by determining the CTL activity in seven patients from Bangui, (6 A subtype, and 1 AG recombinant infections) and
one A subtype infection from a person living in France originally from Togo, to different antigens expressed in vaccinia
• Pol reactivity: 8/8 had CTL to A subtype, and 7/8 to B subtype, and HIV-2 Pol was not tested
• Gag reactivity: 7/8 reacted with A or B subtype gag, 3/8 with HIV-2 Gag
• Nef reactivity: 7/8 reacted with A subtype, and 5/8 with B subtype, none with HIV-2 Nef
• Env reactivity: 3/8 reacted with A subtype, 1/8 with B subtype, none with HIV-2 Env
• One of the patients was shown to react to this epitope: KRWIILGNK
p24 (131–140) p24 (263–272) KRWIIMGLNK HIV-1 infection human (B27) Goulder1997f, Goulder1997a
• Six HLA-B27 donors studied make a strong response to this epitope
• In 4/6 cases, this was the immunodominant or only CTL response
• Two of the cases had an epitope switch to the form KKWIIMGLNK during a period of rapid decline to AIDS, following their asymptomatic period
• The arginine to lysine switch is in an anchor residue, and results in immune escape due to severely diminished binding to the B27 molecule
• [Goulder1997a] is a review of immune escape that summarizes this study in the context of CTL escape to fixation
p24 (131–140) p24 KRWIILGLNK human (B27) Rowland-Jones1999
• CTL responses in seronegative highly HIV-exposed African female sex workers in Gambia and Nairobi were studied – these women had no delta 32
deletion in CCR5
• In Gambia there is exposure to both HIV-1 and HIV-2, CTL responses to B35 epitopes in exposed, uninfected women are cross-reactive, and the B35 allele
seems to be protective
• HIV-2 sequence: RRWIQLGLQK – this epitope was not HIV-1 and HIV-2 cross-reactive
p24 (131–140) Gag (263–) KRWILGLNK computer prediction (B27) Schafer1998
• This study uses EpiMatrix for T cell epitope prediction to identify possible HLA-B27 and A-2 CTL epitopes in HIV
• Based on EpiMatrix predictions, 28 peptides were synthesized and tested using T2 binding assays for potential HLA A2 or B27 binding, and 12 of these
were shown to bind to the predicted HLA molecule
• Two of these 12 peptides had been previously identified as CTL epitopes: HLA-B27 KRWILGLNK and HLA-A2 ILKEPVHGV
• This peptide sequence is not conserved between clades, but is found in most B clade isolates
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p24 (131–140) p24 (263–282) KRWIILGLNK HIV-1 infection human (B27) Bernard1998
• This study focuses on six rare long-term survivor HIV-infected people who were infected for many years without exhibiting immune dysregulation – such
immunologically normal HIV-infected (INHI) cases occur at a frequency between 0.1 and 1% in the infected population
• No direct CTL were found in any of the six INHIs, but above background CTLp activity was founded in 3/6 INHIs
• Epitope sequences were deduced from larger reactive peptides based on HLA binding motifs – XRXXXXXXXK is a B*2705 binding motif
p24 (131–140) p24 (265–274 SF2) KRWIILGLNK HIV-1 infection human (B27) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B27+ individuals that had a CTL response to this epitope broken down by group: 0/0 group 1, 0/0 group 2, and 1/1 group 3
p24 (131–140) p24 (263–272) KRWIILGLNK HIV-1 infection, HIV-1 exposed
seronegative
human (B27) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with
reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected
women
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure
• Subject ML 1760 had an A2 response to ILK(D/E)PVHGV prior to seroconversion, and gained responses to epitopes A2 SL(F/Y)NTVATL and B27
KRWII(L/M)GLNK post-seroconversion
p24 (131–140) p24 (131–140) KRWIILGLNK HIV-1 infection human (B27) Day2001
p24 (131–140) p24 (260–299) RRWIQLGLQK HIV-1 infection human (B27) Day2001
p24 (131–140) p24 (131–140) KRWIILGLNK HIV-1 infection human (B27) Goulder2001b
• Epitope name: KK10
• 85% of B27+ adults have CTL that recognize this epitope, but only 2/6 children did
• Responses to this dominant B27-restricted Gag epitope are present during the time of decreasing viral load in acute infection
• Three children who shared B27 with their mothers did not respond to this epitope and inherited escape mutations from their mothers
• A transmitted R132T anchor residue mutation abrogated binding to B27
• In the three children infected with the non-binding KK10 variants, the dominant CTL specificity was still HLA-B27-restricted, but it was directed against
an epitope in p17, IRLRPGGKK, only rarely recognized in adults when KRWIILGLNK is the dominant response
• Mutations in this epitope were observed in autologous clones of subjects who were B27-positive with a higher frequency than those who were B27-negative
(P = 0.0005)
• These mutations are being sexually transmitted in adult infections
p24 (131–140) KRWIILGLNK HIV-1 infection human (B27) Sabbaj2002b
• Epitope name: Gag-KK10
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• Among HIV+ individuals who carried HLA B27, 2/3 (66%) recognized this epitope
p24 (131–140) p24 (263–272 LAI) KRWIIMGLNK HIV-1 infection human (B27) Kelleher2001a
• Ritonavir (RTV) inhibits chymotryptic activity in the 20S proteasome in vitro, as does Saquinavir (SQV) to a lesser extent; Indinavir (IDV) does not. Thus
there is concern protease inhibitors may adversely effect CTL epitope processing, but this paper indicates that processing is not inhibited at therapeutically
relevant concentrations of RTV when the proteasome is functioning in an intracellular context.
• RTV did not reduce antigen presentation and concentration of the two immunodominant Gag CTL epitopes (KRWIIMGLNK (B27) and SLYNTVATL
(A2)).
• RTV did not inhibit the processing and assembly of HLA-B35 or -A2, which are assembled with a rapid and moderate time course, respectively, or of
HLA-A3, -B27 and -B39.
p24 (131–140) p24 KRWIILGLNK HIV-1 infection human (B27) Altfeld2002
• Epitope name: B27-KK10(p24)
• Peripheral blood (PB) and lymph node (LN) CD8+ T-cell responses were compared in 15 asymptomatic HIV-1 infected patients using all known optimal
CTL epitopes (http://hiv-web.lanl.gov/content/hiv-db/REVIEWS/brander2001.html) for each person’s class I HLA alleles.
• 60 epitope responses were detected in both PB and LN samples of the 15 patients, and an additional 8 responses were detected only in LN. The total
magnitude of the response was similar in LN and PB, but the percentage of CD8+ T cells in the LN is lower so the number of HIV-specific cells per million
CD8+ T-cells is higher in the LN.
• 1 year post-HAART treatment in five patients studied, the magnitude of the CD8 T-cell response was decreased in both LN and PB, but more dramatically
in PB, and 13/25 epitope responses in the PB became undetectable, in contrast to 5/26 in the LN.
• Treatment interruption following HAART induced resulted in increased viremia accompanied by the restoration of the detection of 13 epitopes that had
become undetectable in the PB, and the addition of 9 novel epitope responses.
• Breakdowns of epitope responses were shown for 4 individuals. Patient C displayed the greatest response to B27-KK10(p24), and in decreasing order also
responded to A24-RW8(Nef), B7-IL9(gp41), A24-RL9(gp41), A24-YL8(gp41), and B7-TM9(Nef). Patient D also displayed the greatest response to
B27-KK10(p24), and also responded to A30-RY11(p17), A32-PW10(RT), A30-KY11(RT), A32-RW10(gp120), and B18-YY9(Nef).
p24 (131–140) Gag (263–272) KRWIILGLNK HIV-1 infection human (B27) Currier2002a
• Cross-reactive responses were found in PBMC isolated from individuals infected with either B or CRF01_AE clade viruses, as determined by Elispot
assays of target cells expressing recombinant vaccinia viruses expressing HIV-1 gag, env, nef and pol from many clades.
• Subject AIHP-6 (Thai, CDF01-AE infected) recognized this epitope. This subject showed cross-subtype CTL responses to gag constructs derived from
subtypes A, B, C, D, F, G, and H, and this epitope was perfectly preserved in all of these but subtype A which had the sequence KRWMILGLNK.
• This subject didn’t respond to a Gag CRF01 sequence which had a R->K mutation in position 2.
p24 (131–142) p24 (265–276) KRWIILGLNKIV Peptide-HLA interaction human (B27) Jardetzky1991
• Epitope examined in the context of peptide binding to HLA-B27
p24 (131–142) p24 (263–274 LAI) KRWIILGLNKIV HIV-1 infection human (B27) Fan1997
• The capacity of dendritic cells to process and present antigen and stimulate anti-HIV-1 CTL memory responses was studied
p24 (131–142) p24 (131–142) KRWIILGLNKIV HIV-1 infection human (B27) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
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p24 (131–145) p24 (SF2) KRWILGLNKIVRMY HIV-1 infection human Goulder2000a
• The CTL-dominant response was focused on this epitope in a HIV+ African American living in Boston with unknown HLA – this epitope did not fall
within the three most recognized peptides in the study
• Three peptides GSEELRSLYNTVATL (p17 residues 71-85), SALSEGATPQDLNTMLNTVG (p24 41-60), and WEKIRLRPGGKKKYKLK(p17 16-30)
contained the dominant Gag-specific epitope in 31 out of 44 B-clade infected individuals from Boston who showed Gag-CTL responses
• Five peptides RLRPGGKKHYMIKHLVW (p17 20-36), ELRSLYNTVATLYCV (p17Gag 74-88), SALSEGATPQDLNTMLNTVG (p24 41-60),
FRDYVDRFFKTLRAEQA (p24 161-177), and SILDIKQGKEPFRDY (p24 149-164) contained dominant Gag-specific epitopes in 32 out of 37 C-clade
infected subjects from South Africa
p24 (131–145) p24 (263–277 LAI) KRWIILGLNKIVMRY HIV-1 infection human (A33) Buseyne1993b
• Clustering of Gag p24 CTL epitopes recognized in 29 HIV-infected people
p24 (131–145) p24 (266–277) KRWIILGLNKIVRMY Vaccine human (B27) Nixon1988
Vaccine Vector/Type: vaccinia HIV component: Gag
• Gag CTL epitope mapped with rec gag-vaccinia and synthetic peptides
• This was the first HIV-1 epitope to be mapped
p24 (131–145) p24 (266–277 LAI) KRWIILGLNKIVMRY HIV-1 infection human (B27) Meyerhans1991
• Longitudinal study showing persistence of epitope despite CTL activity
p24 (131–145) p24 (265–279) KRWIILGLNKIVRMY HIV-1 infection human (B27) Nixon1990, Rowland-Jones1999
• HIV-1 and HIV-2 cross-reactive CTL clone, highly conserved epitope
• Reviewed in Rowland-Jones99, notes that it did not appear cross-reactive with HIV-2 in Rowland-Jones98, HIV-2 form: RRWIQLGLQK
p24 (131–146) p24 (265–279) KRWIILGLNKIVRMYC HIV-1 infection human (B27) Bouillot1989
• HLA-B27 restricted epitope also binds to HLA-A2 and HLA-B37 in solid phase assay
p24 (131–150) p24 (263–282 SF2) KRWIILGLNKIVRMYSPTSI HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Twelve subjects had CTL that could recognize vaccinia-expressed LAI gag
• One of these 12 A-2 had CTL response to this peptide
• The responding subject was HLA-A3, A32, B51, B62
p24 (131–150) p24 (265–284 SF2) KRWIILGLNKIVRMYSPTSI HIV-1 infection human (Bw62?) vanBaalen1993
• Gag CTL epitope precursor frequencies estimated
p24 (131–152) p24 (263–284 BH10) KRWIILGLNKIVRMYSPTS-
ILD
HIV-1 infection human (Bw62) Johnson1991
• Gag CTL response studied in three individuals
p24 (132–145) Gag KWILGLNKIVRMY HIV-1 infection human Weekes1999a
• Peptide 728: Memory CTL specific for HIV-1 may contribute to oligoclonal expansions within the CD57+ CD28- CD8+ CTLp populations
p24 (132–145) Gag KWILGLNKIVRMY HIV-1 infection human (B27) Weekes1999b
• Peptide 728: Almost all CD8+ T cells are CD28+ at birth, and the proportion of CD28-CD8+ cells increases with age – this study examines the contribution
of CD8+CD28- cells to CTL memory pools for CTL clones specific for two persistent human viruses, CMV and HIV – clones were found to be similarly
distributed the CD28 depleted cell population
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• HIV CTL responses to 3 Env and 2 Gag peptides were studied
• The clonal composition of the TCR Vbeta responses were studied and was found to be highly focused, with one TCR beta-chain sequence tending to
dominate the peptide-specific response – clones to this epitope were Vbeta22.1
p24 (134–143) p24 (subtype B) IILGLNKIVR HIV-1 exposed seronegative human (A33) Rowland-Jones1998b
• HIV-specific CTL were found in exposed seronegative prostitutes from Nairobi – these CTL may confer protection
• Seroprevalence in this cohort is 90-95% and their HIV-1 exposure is among the highest in the world
• Most isolated HIV strains are clade A in Nairobi, although clades C and D are also found – B clade epitopes are often cross-reactive, however stronger
responses are frequently observed using A or D clade versions of epitopes
• This epitope is conserved among A, B and D clade viruses
p24 (136–145) p24 (268–277 LAI) LGLNKIVRMY HIV-1 infection human (Bw62) McMichael1994
• Predicted from larger peptide
• Review of HIV CTL epitopes
• Also P. Johnson, Pers. Comm.
p24 (136–146) p24 (271–281) LGLNKIVRMYS HIV-1 infection human (B62) Lubaki1997
• Eighty two HIV-1-specific CTL clones from 5 long-term non-progressors were isolated and analyzed for breadth of response
• A sustained Gag, Env and Nef response was observed, and clones were restricted by multiple HLA epitopes, indicating a polyclonal response
• A subject who was B62+ had CTL that recognized this peptide, p17 KIRLRPGGKKKYKL, and one additional unknown epitope
• The two clones that recognized this epitope used two different Vβ genes, further demonstrating a polyclonal response
p24 (136–146) p24 (136–146) LGLNKIVRMYS HIV-1 infection human (B62) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
p24 (137–145) p24 (C consensus) GLNKIVRMY HIV-1 infection human Goulder2000a
• The CTL-dominant response was focused on this epitope in a HIV+ South African living in Durban, HLA A2/- B5802/62 Cw4/6 – this epitope did not fall
within the three most recognized peptides in the study
• Three peptides GSEELRSLYNTVATL (p17 residues 71-85), SALSEGATPQDLNTMLNTVG (p24 41-60), and WEKIRLRPGGKKKYKLK(p17 16-30)
contained the dominant Gag-specific epitope in 31 out of 44 B-clade infected individuals from Boston who showed Gag-CTL responses
• Five peptides RLRPGGKKHYMIKHLVW (p17 20-36), ELRSLYNTVATLYCV (p17Gag 74-88), SALSEGATPQDLNTMLNTVG (p24 41-60),
FRDYVDRFFKTLRAEQA (p24 161-177), and SILDIKQGKEPFRDY (p24 149-164) contained dominant Gag-specific epitopes in 32 out of 37 C-clade
infected subjects from South Africa
p24 (137–145) p24 (272–280 LAI) GLNKIVRMY HIV-1 infection human (B*1501) Brander2001
• C. Brander notes this is a B*1501 epitope
p24 (137–145) p24 (272–280 LAI) GLNKIVRMY HIV-1 infection human (B62) Goulder1997a
• This paper is a review of CTL and immune evasion, but it presents a study of a shift from an HLA-A*0201 response to SLYNTVATL, to a B62 response to
GLNKIVRMY
• As long as a strong CTL response to SLYNTVATL was evident, the epitope variants SLFNTVATL or SLYNTIATL dominated the viral population –
eventually the CTL response to the index peptide became undetectable, the CTL response shifted to a focus on GLNKIVRMY, and the index peptide
SLYNTVATL once again established itself as the dominant form
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p24 (137–145) p24 (SF2) GLNKIVRMY HIV-1 infection human (B62) Goulder2000a
• The CTL-dominant response was focused on this epitope in a HIV+ African American living in Boston – this epitope did not fall within the three most
recognized peptides in the study
• Three peptides GSEELRSLYNTVATL (p17 residues 71-85), SALSEGATPQDLNTMLNTVG (p24 41-60), and WEKIRLRPGGKKKYKLK(p17 16-30)
contained the dominant Gag-specific epitope in 31 out of 44 B-clade infected individuals from Boston who showed Gag-CTL responses
• Five peptides RLRPGGKKHYMIKHLVW (p17 20-36), ELRSLYNTVATLYCV (p17Gag 74-88), SALSEGATPQDLNTMLNTVG (p24 41-60),
FRDYVDRFFKTLRAEQA (p24 161-177), and SILDIKQGKEPFRDY (p24 149-164) contained dominant Gag-specific epitopes in 32 out of 37 C-clade
infected subjects from South Africa
p24 (137–145) p24 (267–277 SF2) GLNKIVRMY HIV-1 infection human (B62) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B62+ individuals that had a CTL response to this epitope broken down by group: 0/1 group 1, 0/1 group 2, and 1/1 group 3
p24 (137–145) p24 (137–145) GLNKIVRMY HIV-1 infection human (B62) Day2001
• No immunodominant responses were detected to four B62-restricted epitopes tested
p24 (143–150) p24 (273–283 IIIB) RMYSPTSI HIV-1 infection human (B*5201) Brander2001
• C. Brander notes this is a B*5201 epitope
p24 (143–150) p24 (273–283 IIIB) RMYSPTSI HIV-1 infection human (B52) Brander1999
• Epitope name: SL9
• Multiple natural variations in the SL9 flanking regions of the immunodominant epitope SLYNTVATL were tested and found not to adversely affect CTL
recognition or prevent epitope processing, suggesting that viral escape from the HLA-A*0201-restricted CTL response against SLYNTVATL is probably
not linked to variations in the flanking regions of this epitope
• The CTL response to RMYSPTSI was used as a control
p24 (143–150) p24 (273–283 IIIB) RMYSPTSI HIV-1 infection human (B52) Wilson1999a
• This study describes maternal CTL responses in the context of mother-to-infant transmission
• Detection of CTL escape mutants in the mother was associated with transmission, but the CTL-susceptible forms of the virus tended to be found in infected
infants
• No variants of this epitope were found in a non-transmitting mother that had a CTL response to this epitope
p24 (143–150) p24 (143–150) RMYSPTSI HIV-1 infection human (B52) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
p24 (151–170) p24 (283–302 SF2) LDIRQGPKEPFRDYVDRFYK HIV-1 infection human McAdam1998
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p24 (155–177) p24 (287–309) QGPKEPFRDYVDRFYKTLR-
AEQA
Vaccine murine Nakamura1997
Vaccine Vector/Type: peptide HIV component: p24
• Mice immunized with this synthetic peptide generated specific CTLs, a proliferative response, and antibodies
• The amino acids shown in the epitope field were based on the numbering provided by Nakamura et al., and may not be correct
• The CTL epitope was shown to be located in positions 291-300
p24 (157–178) p24 (290–309) PKEPFRDYVDRFYKTLRAE-
QAS
HIV-1 infection human (B14) Musey1997
• Cervical and peripheral blood derived CTL clones from an HIV-infected woman recognized this epitope
p24 (159–168) Gag (291–300) EPFRDYVDRF Vaccine murine (H-2d) Billaut-Mulot2001
Vaccine Vector/Type: DNA with DNA boost, DNA with recombinant protein boost Strain: LAI HIV component: Gag, Tat, Nef Adjuvant: IL18
• DNA vaccinated BALB/c mice primed and boosted with the multiepitopic vaccine with IL18 showed lymphoproliferative responses 7 weeks post
immunization
• Strong but non-lasting HIV-specific CTL responses were detected by a Cr-release assay and DNA prime/DNA boost was more effective than DNA prime
protein boost
• Immunization with either the multiepitopic DNA or with the mixed DNA vaccine induced HIV-1 specific Th1 cytokines (IL-2 and IFN-gamma)
• Co-administration of IL18 increased T-cell responses but decreased anti-HIV antibody levels
p24 (159–178) Gag (291–310) EPFRDYVDRFFKTLRAEQAT HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
• This peptide was among the 8 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
p24 (159–178) Gag (96ZM651.8) EPFRDYVDRFFKTLRAEQAT human (B*44031) Novitsky2001
• This study is provides a survey of CTL responses and full length HIV-1 genome sequences from a C subtype infected Botswanan cohort
• 16 of 46 (34.8%) had CTL responses to one or more peptides within the second immunodominant region region of Gag (peptides
SILDIKQGPKEPFRDYVDRF, EPFRDYVDRFFKTLRAEQAT, and FKTLRAEQATQEVKNWMTDT) with ELISPOT results median and range 500 (100
to 1,250) SFC/106 PBMC
• 3 of 6 (50%) carriers of HLA-B*44031 showed CTL responses to the peptide EPFRDYVDRFFKTLRAEQAT
p24 (161–170) FRDYVDRFFK HIV-1 infection human Kaul2001c
• This study examines CTL responses in HIV exposed, persistently seronegative individuals, HEPS, who eventually seroconverted – 11/114 HEPS Nairobi
sex workers eventually seroconverted, and for six of these HIV CTL reactive epitopes had been defined while seronegative
• The epidemiological factor associated with seroconversion was stopping sex work and HIV-specific CTL activity declines when HEPS sex workers stop
working for a period or retire
• This epitope was recognized in 1/22 HEPS sex worker controls, ML1732
p24 (161–170) p24 (subtype B, D) FRDYVDRFYK HIV-1 infection human (B*1801) Ogg1998a
• Noted in Brander 1999, this database, to be B*1801, FRDYVDRFY
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p24 (161–170) p24 (subtype B, D) FRDYVDRFYK HIV-1 infection human (B*1801) Brander2001
• C. Brander notes this is a B*1801 epitope
p24 (161–170) p24 (161–170) FRDYVDRFYK HIV-1 infection human (B18) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
p24 (161–170) p24 (293–302) FRDYVDRFYK HIV-1 infection, HIV-1 exposed
seronegative
human (B18) Kaul2001a
• Variants FRDYVDRF(Y/F)K are specific for the B,D/A,C clades
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with
reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected
women
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure
• Among HLA-B18 women, 3/4 HEPS and 1/9 HIV-1 infected women recognized this epitope, likelihood ratio 5.3, p value 0.04, and HEPS women tended to
respond to FRDYVDRFY/FK, while infected women tended to respond to YPLTFGWCY/F
• The dominant response to this HLA allele was to this epitope for all 3/4 HEPS cases and for the single HIV-1 infected women that responded to this epitope
• Four epitopes were considered to be “resistant epitopes”, as they were preferentially reactive in HEPS women and so may confer resistance, and these were
found in three different proteins: A2 ILK(D/E)PVHGV in RT, A*6802 DTVLEDINL in Protease, B14 DLNM/TLN(I/V)V in p24 and B18
FRDYVDRF(Y/F)K also in p24
• Differences in epitope specificity were only seen for responses restricted by class I HLA alleles A2, A24, A*6802, B14, and B18, previously shown to be
associated with resistance to HIV-1 in this cohort
p24 (161–170) p24 FRDYVDRFYK HIV-1 infection, Vaccine human, macaque (B18) Hanke2000, Wee2002
Vaccine Vector/Type: DNA prime with vaccinia MVA boost Strain: subtype A HIV component: p17, p24, polyepitope
• The HIV-1 subtype A focused vaccine HIVA contains p24 and p17, in a reversed order relative to the Gag polyprotein to prevent myristylation of p17,
which could direct the protein to the cell membrane and inhibit efficient peptide processing and class I presentation, as well as a polyepitope string of
conserved, often immunodominant epitopes that were selected to have particularly good cross-reactive potential for the A-clade epidemic in Nairobi,
Kenya. A DNA and MVA prime-boost vaccination protocol using the HIVA antigen will be used in a phase III clinical trial in Kenya. This epitope is
included in the polyepitope string [Hanke2000].
• Multiple CD4+ or CD8+ T-cell vaccine-induced responses to peptide pools were detected using intracellular cytokine staining and IFNgamma Elispot
assays after vaccination of 5 macaques. The response to the Mamu A*01 SIV p27 epitope p11C (CTPYDINQM), included in the polyepitope region, was
not immunodominant in the Mamu A*01 vaccinated macaques, possibly because of processing limitations in context of the artificial polyepitope string
[Wee2002].
p24 (161–180) p24 (293–312 SF2) FRDYVDRFYKTLRAEQASQD HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Twelve subjects had CTL that could recognize vaccinia-expressed LAI gag
• One of these 12 had CTL response to this peptide
• The responding subject was HLA-A2, A3, B8, B62
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p24 (161–180) p24 (293–312 SF2) FRDYVDRFYKTLRAEQASQD HIV-1 infection human Lieberman1997b
• CTL expanded ex vivo were later infused into HIV-1 infected patients
p24 (161–180) p24 (293–312 SF2) FRDYVDRFYKTLRAEQASQD HIV-1 infection human (B71) McAdam1998
p24 (162–172) p24 (296–306 subtype
A)
RDYVDRFFKTL HIV-1 infection human (A*2402) Dorrell1999
• CTL responses in three individuals with non-clade B infections were studied, 2 with subtype A infections, 1 with subtype C – their infections all originated
in East Africa
• This epitope is similar to the A24 DYVDRYFKT epitope found for B subtype, but CTL from this A subtype infection required the additional Arg – the B
clade sequence change from F to Y diminished CTL reactivity
• C. Brander notes that this is an A*2402 epitope in the 1999 database
p24 (162–172) p24 (296–306 subtype
A)
RDYVDRFFKTL HIV-1 infection human (A*2402) Brander2001
• C. Brander notes this is an A*2402 epitope
p24 (162–172) p24 (296–306) RDYVDRFFKTL HIV-1 infection, HIV-1 exposed
seronegative
human (A24) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with
reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected
women
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure
• Among HLA-A24 women, 0/4 HEPS and 6/10 HIV-1 infected women recognized this epitope, likelihood ratio 7.2, p value 0.03, and (R)YL(R/K)DQQLL
tended to be reactive in HEPS and infected women, RDYVDRFFKTL in infected women only
• The dominant response to this HLA allele was to this epitope in all of the 6/10 HIV-1 infected women
• Differences in epitope specificity were only seen for responses restricted by class I HLA alleles A2, A24, A*6802, B14, and B18, previously shown to be
associated with resistance to HIV-1 in this cohort
• Subject ML 1707 started with a CTL response to A*6802 DTVLEDINL prior to seroconversion, and switched to A*6802 ETAYFILKL and A24
RDYVDRFFKTL post-seroconversion
p24 (162–172) p24 (293–312 LAI) RDYVDRFYKTL HIV-1 infection human (B*4402) Brander2001
• C. Brander notes this is a B*4402 epitope
p24 (162–172) p24 (162–172) RDYVDRFYKTL HIV-1 infection human (B44) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
p24 (162–172) p24 (162–172) RDYVDRFYKTL HIV-1 infection human (B44) Day2001
p24 (162–172) p24 RDYVDRFYKTL HIV-1 infection, Vaccine human, macaque (B44) Hanke2000, Wee2002
Vaccine Vector/Type: DNA prime with vaccinia MVA boost Strain: subtype A HIV component: p17, p24, polyepitope
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• The HIV-1 subtype A focused vaccine HIVA contains p24 and p17, in a reversed order relative to the Gag polyprotein to prevent myristylation of p17,
which could direct the protein to the cell membrane and inhibit efficient peptide processing and class I presentation, as well as a polyepitope string of
conserved, often immunodominant epitopes that were selected to have particularly good cross-reactive potential for the A-clade epidemic in Nairobi,
Kenya. A DNA and MVA prime-boost vaccination protocol using the HIVA antigen will be used in a phase III clinical trial in Kenya. This epitope is
included in the polyepitope string [Hanke2000].
• Multiple CD4+ or CD8+ T-cell vaccine-induced responses to peptide pools were detected using intracellular cytokine staining and IFNgamma Elispot
assays after vaccination of 5 macaques. The response to the Mamu A*01 SIV p27 epitope p11C (CTPYDINQM), included in the polyepitope region, was
not immunodominant in the Mamu A*01 vaccinated macaques, possibly because of processing limitations in context of the artificial polyepitope string
[Wee2002].
p24 (162–172) p24 (293–312 LAI) RDYVDRFYKTL HIV-1 infection human (B44, A26 or
B70)
Ogg1998a
p24 (163–172) p24 (163–172) DYVDRFYKTL HIV-1 infection human (A24) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
p24 (164–172) Gag (296–304) YVDRFYKTL HIV-1 infection human (A*0207) Currier2002a
• Cross-reactive responses were found in PBMC isolated from individuals infected with either B or CRF01_AE clade viruses, as determined by Elispot
assays of target cells expressing recombinant vaccinia viruses expressing HIV-1 gag, env, nef and pol from many clades.
• The Thai subject VAIP-4 demonstrated broad CTL cross-reactivity towards gag constructs derived from subtypes A, B, C, D, F, G, H, and CRF-01_AE.
Sequence alignments of this epitope showed conservation for clades B and D, and Y->F substitutions at position 6 for subtypes A, C, CDR01-AE, F, G, and
H. YVDRFYKTL and the variant epitope YVDRFFKTL are recognized equally well.
p24 (164–172) p24 (298–306 subtype
A)
YVDRFFKTL HIV-1 infection human (A26 or B70) Dorrell1999
• CTL responses in three individuals with non-clade B infections were studied, 2 with subtype A infections, 1 with subtype C – their infections all originated
in East Africa
• This CTL epitope is conserved in A and C subtype, and B clade sequences tend to have a change from F to Y, YVDRFYKTL – both variants showed strong
CTL reactivity
• CTL reacted with targets presenting either in the context A26 or B70 – the epitope has the HLA-26 motif of Val at position 2 and Leu at the carboxy
terminus, and the B70 anchor residue motif is unknown
p24 (164–172) Gag (298–306 subtype
A)
YVDRFFKTL HIV-1 infection, in vitro
stimulation
human (A26 or B70) Dorrell2001
• In vitro restimulation of CTL specific for dominant epitopes from infected individuals is possible using recombinant modified vaccinia virus Ankara (MVA)
carrying A or D subtype HIV-1 Gag proteins
p24 (164–172) Gag (296–304
96ZM651.8)
YVDRFFKRL human (B*1510, B70) Novitsky2001
• This study provides a survey of CTL responses and full length HIV-1 genome sequences from a C subtype infected Botswanan cohort.
• 4 subjects who responsed to the CTL epitope YVDRFFKTL – all were HLA-B*1510 and also shared HLA-Cw03, suggesting linkage disequilibrium
• An HIV-1 B variant of the epitope YVDRFYKTL has been described, and was recognized byCTL from an HIV-1 subtype A-infected patient, and the HLA
restriction of the epitope was suggested to be A26 or B70 – HLA-B*1510 is equivalent to the serological specificity HLA B70
144
DEC 2002
p24 CTL Epitopes HIV CTL Epitope Tables
C
TL
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
p24 (164–172) p24 (164–172) YVDRFYKTL HIV-1 infection human (B70) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
p24 (166–174) p24 (298–306 LAI) DRFYKTLRA HIV-1 infection human (B*1402) Brander2001
• C. Brander notes this is a B*1402 epitope
p24 (166–174) p24 (298–306 IIIB) DRFYKTLRA HIV-1 infection human (B14) Wilson1996
• Epitope defined in the context of the Pediatric AIDS Foundation ARIEL Project, a mother-infant HIV transmission study
• DRFYKILRA, a naturally occurring variant, was found in mother, and is recognized although less reactive
• DQFYKTLRA, a naturally occurring variant, was found in infant and is not recognized
p24 (166–174) p24 (298–306 IIIB) DRFYKTLRA HIV-1 infection human (B14) Cao1997a
• The consensus peptide for clades B and D is DRFYKTLRA
• The consensus peptide for clades A and C is DRFFKTLRA and it is equally reactive
p24 (166–174) p24 (298–306 HXB2) DRFYKTLRA HIV-1 infection human (B14) Yang1997b
• A chimeric universal T cell receptor was created by linking CD4 or an HIV-specific anti-gp41 Ig sequence to the signaling domain of the T cell receptor
chain ζ , and transducing into CD8+ cells
• The response using universal-receptor-bearing CD8+ cells to lyse infected cells in vitro was comparable to the natural occurring responses of CTL-clones
from HIV+ individuals in terms of kinetics and efficiency
• A CTL clone specific for this epitope was used for the comparison
p24 (166–174) p24 DRFWKTLRA HIV-1 exposed seronegative human (B14) Rowland-Jones1998a
• A CTL response was found in exposed but uninfected prostitutes from Nairobi using previously-defined B clade epitopes that tended to be conserved in A
and D clades – such cross-reactivity could protect against both A and D and confer protection in Nairobi where both subtypes are circulating
• The D subtype consensus is identical to the B clade epitope
• The A subtype consensus is drFfKtLRA
p24 (166–174) p24 (298–306 LAI) DRFYKTLRA HIV-1 infection human (B14) Harrer1996b
p24 (166–174) p24 (298–306) DRFYKTLRA HIV-1 infection human (B14) Yang1996
• CD4+ cell lines acutely infected with HIV were studied to determine their susceptibility to lysis by CTL
• Clones specific for RT lysed HIV-1 infected cells at lower levels than Env or Gag specific clones
• The distinction was thought to be due to lower expression of RT relative to Env and Gag
• CTL can lyse infected cells early after infection, possibly prior to viral production
p24 (166–174) p24 (298–306) DRFYKTLRA HIV-1 infection human (B14) Yang1997a
• CTL inhibit HIV-1 replication at effector cell concentrations comparable to those found in vivo
• CTL produced HIV-1-suppressive soluble factors – MIP-1α , MIP-1β , RANTES, after antigen-specific activation
• CTL suppress HIV replication more efficiently in HLA-matched cells
p24 (166–174) p24 (298–306) DRFYKTLRA in vitro stimulation human (B14) Zarling1999
• This study compares the ability of macrophages and dendritic cells to stimulate primary responses in CD8+ lymphocytes isolated from HLA-appropriate
HIV-uninfected donors using peptide-pulsed APC – the dendritic cells performed better as APC for the stimulation of primary responses
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• Strong CTL responses were elicited by the epitopes DRFYKTLRA and GEIYKRWII when presented by either immature or mature dendritic cells –
macrophages were not able to prime a CTL response against DRFYKTLRA
• A weak response to KLTPLCVSL was stimulated using macrophages as the APC
• No detectable response was observed for the following previously-defined HIV epitopes: KIRLRPGGK, ILKEPVHGV, IRLRPGGK, GPKVKQWPL
p24 (166–174) p24 DRFYKLTRA human (B14) Rowland-Jones1999
• CTL responses in seronegative highly HIV-exposed African female sex workers in Gambia and Nairobi were studied – these women had no delta 32
deletion in CCR5
• In Gambia there is exposure to both HIV-1 and HIV-2, CTL responses to B35 epitopes in exposed, uninfected women are cross-reactive, and the B35 allele
seems to be protective
• HIV-2 sequence: DRFYKSLRA is cross-reactive, [Harrer1993]
p24 (166–174) p24 (298–306 IIIB) DRFYKTLRA HIV-1 infection human (B14) Wilson1999a
• This study describes maternal CTL responses in the context of mother-to-infant transmission
• Detection of CTL escape mutants in the mother was associated with transmission, but the CTL-susceptible forms of the virus tended to be found in infected
infants
• DRFYKILRA and DQFYKTLRA were escape mutants
p24 (166–174) p24 (SF2) DRFYKTLRA HIV-1 infection human (B14) Goulder2000a
• The CTL-dominant response was focused on this epitope in 2/5 HIV+ individuals who were HLA B14 living in Boston – this epitope did not fall within the
three most recognized peptides in the study
• Three peptides GSEELRSLYNTVATL (p17 residues 71-85), SALSEGATPQDLNTMLNTVG (p24 41-60), and WEKIRLRPGGKKKYKLK(p17 16-30)
contained the dominant Gag-specific epitope in 31 out of 44 B-clade infected individuals from Boston who showed Gag-CTL responses
• Five peptides RLRPGGKKHYMIKHLVW (p17 20-36), ELRSLYNTVATLYCV (p17Gag 74-88), SALSEGATPQDLNTMLNTVG (p24 41-60),
FRDYVDRFFKTLRAEQA (p24 161-177), and SILDIKQGKEPFRDY (p24 149-164) contained dominant Gag-specific epitopes in 32 out of 37 C-clade
infected subjects from South Africa
p24 (166–174) p24 (SF2) DRFYKTLRA HIV-1 infection human (B14) Goulder2001a
• Epitope name: DA9
• Data from patient AC13 suggest a role for this epitope in initial control of viremia in acute infection, as it is one of several subdominant CTL epitopes
recognized during the initial decline in viremia
• A CTL response to SL9, SLYNTVATL, was not evident until 18 months post-presentation
p24 (166–174) p24 (166–174) DRFYKTLRA HIV-1 infection human (B14) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
p24 (166–174) p24 (298–306 SF2) DRFYKTLRA HIV-1 infection human (B14) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
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• Number of HLA-B14+ individuals that had a CTL response to this epitope broken down by group: 3/3 group 1, 1/2 group 2, and 0/0 group 3
p24 (166–174) p24 (298–306) DRFFKTLRA HIV-1 infection, HIV-1 exposed
seronegative
human (B14) Kaul2001a
• Variants DRF(F/W)KTLRA are specific for clades A/B
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with
reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected
women
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure
• Among HLA-B14 women, 0/4 HEPS and 6/7 HIV-1 infected women recognized this epitope, likelihood ratio 14.4, p value 0.004 and HEPS women tended
to respond to DLNMMLNIV/DLNTMLNVV, while infected women tended to respond to DRF(F/W)KTLRA
• The dominant response to this HLA allele was to this epitope for all of the 6/7 HIV-1 infected women
• Differences in epitope specificity were only seen for responses restricted by class I HLA alleles A2, A24, A*6802, B14, and B18, previously shown to be
associated with resistance to HIV-1 in this cohort
p24 (166–174) p24 (SF2) DRFYKTLRA HIV-1 infection human (B14) Altfeld2000b
• This epitope was mapped by ELISPOT in a study identifying new HLA-B60 epitopes, and was one of the epitopes presented by another HLA molecule in
an HLA-B60 individual
p24 (166–174) p24 DRFYKTLRA HIV-1 infection human (B14) Cao2002
• AC13 is a B14 restricted CTL clone that recognizes DRFYKTLRA.
• CTL could be activated by a fusion protein of an HIV protein and anthrax lethal factor (LFn-HIV) that promotes antigen presenting cell uptake of
exogenous protein and allows processing through the MHC class I pathway. This strategy for CTL detection could allow antigen presentation without
generation of cells by the standard methods of using live viral vectors carrying a protein, or by loading the cells with peptides and by-passing processing.
p24 (166–174) p24 DRFWKTLRA HIV-1 infection human (B14) Kaul2002
• Neisseria gonorrhea cervititis in 9 HIV+ Kenyan sex workers caused a functional deficiency in IFN-gamma production in HIV-1 epitope-specific CD8+
T-cells, detected by intracellular cytokine production and tetramer assays, while not affecting the total number of epitope-specific CTLs.
• Ghonorrhea caused the weaker HIV-1 specific CTL responses in 4 HIV-1 exposed persistently seronegative (HEPS) women to become undetectable by
Elispot and tetramer assays, and CMV-specific CTL in 2 HEPS subjects were shown to have impaired function with regard to IFN-gamma production.
p24 (166–174) p24 DRFYKTLRA HIV-1 infection, Vaccine human (B14) Hanke2000, Wee2002
Vaccine Vector/Type: DNA prime with vaccinia MVA boost Strain: subtype A HIV component: p17, p24, polyepitope
• The HIV-1 subtype A focused vaccine HIVA contains p24 and p17, in a reversed order relative to the Gag polyprotein to prevent myristylation of p17,
which could direct the protein to the cell membrane and inhibit efficient peptide processing and class I presentation, as well as a polyepitope string of
conserved, often immunodominant epitopes that were selected to have particularly good cross-reactive potential for the A-clade epidemic in Nairobi,
Kenya. A DNA and MVA prime-boost vaccination protocol using the HIVA antigen will be used in a phase III clinical trial in Kenya. This epitope is
included in the polyepitope string [Hanke2000].
• Multiple CD4+ or CD8+ T-cell vaccine-induced responses to peptide pools were detected using intracellular cytokine staining and IFNgamma Elispot
assays after vaccination of 5 macaques. The response to the Mamu A*01 SIV p27 epitope p11C (CTPYDINQM), included in the polyepitope region, was
not immunodominant in the Mamu A*01 vaccinated macaques, possibly because of processing limitations in context of the artificial polyepitope string
[Wee2002].
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p24 (166–174) p24 (subtype B) DRFYKTLRA HIV-1 exposed seronegative human (B14, B*1402) Rowland-Jones1998b
• HIV-specific CTL were found in exposed seronegative prostitutes from Nairobi – these CTL may confer protection
• Seroprevalence in this cohort is 90-95% and their HIV-1 exposure is among the highest in the world
• Most isolated HIV strains are clade A in Nairobi, although clades C and D are also found – B clade epitopes are often cross-reactive, however stronger
responses are frequently observed using A or D clade versions of epitopes
• This epitope is conserved among B and D clade viruses
• The Clade A version of the epitope, DRFFKLTRA, was preferentially recognized by CTL
• This epitope was recognized by two different exposed and uninfected prostitutes
p24 (166–175) p24 (298–306 HX10) DRFYKTLRAE HIV-1 infection human (B14) Wagner1999
• The immunodominant CTL response in a long-term survivor was to this highly conserved and functionally relevant epitope
• By testing mutations in an HXB2 background, it was found that all mutations within the epitope that abrogated CTL recognition also abolished viral
infectivity
• The epitope in this study overlaps the major homology region for which highly conserved residues exist in all known lenti- and onco-viruses and yeast
transposons
• Patient was part of the study in [Harrer1996a]
p24 (169–188) Gag (301–320) FKTLRAEQATQDVKNWMTDT HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
• This peptide was among the 8 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
p24 (173–181) RAEQASQEV HIV-1 infection human Kaul2001c
• This study examines CTL responses in HIV exposed, persistently seronegative individuals, HEPS, who eventually seroconverted – 11/114 HEPS Nairobi
sex workers eventually seroconverted, and for six of these HIV CTL reactive epitopes had been defined while seronegative
• The epidemiological factor associated with seroconversion was stopping sex work and HIV-specific CTL activity declines when HEPS sex workers stop
working for a period or retire
• This epitope was 1/22 HEPS sex worker controls ML1792
p24 (173–181) p24 (305–313) RAEQASQEV HIV-1 infection human (Cw8) Johnson1991
• Originally reported as HLA-B14 restricted, but subsequently found not to be presented by cells transfected with B14
• Thought to be HLA-Cw8 restricted (C. Brander and B. Walker)
p24 (173–181) p24 RAEQASQEV HIV-1 exposed seronegative human (Cw8) Rowland-Jones1998a
• A CTL response was found in exposed but uninfected prostitutes from Nairobi using previously-defined B clade epitopes that tended to be conserved in A
and D clades – such cross-reactivity could protect against both A and D and confer protection in Nairobi where both subtypes are circulating
• The A subtype consensus is RAeQAtQEV
• The D subtype consensus is RAEQsQdV
• Thought to be HLA-Cw8 restricted, not B14 as originally reported (C. Brander, B. Walker, and S. Rowland-Jones, personal communication)
p24 (173–181) p24 (305–313) RAEQASQEV HIV-1 infection human (Cw8) Price1995
• Study of cytokines released by HIV-1 specific activated CTL
• Thought to be HLA-Cw8 restricted, not B14 as originally reported (C. Brander, B. Walker, and S. Rowland-Jones, personal communication)
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p24 (173–181) p24 (305–313) RAEQASQEV HIV-1 infection human (Cw8) Lubaki1997
• Eighty two HIV-1-specific CTL clones from 5 long-term non-progressors were isolated and analyzed for breadth of response
• A sustained Gag, Env and Nef response was observed, and clones were restricted by multiple HLA epitopes, indicating a polyclonal response
• Despite this being a well defined conserved epitope, and thought to be presented by B14, none of the 11 gag-specific clones from a B-14 positive subject
could recognize either it or p24 PQDLNTMLN
• Thought to be HLA-Cw8 restricted, not B14 as originally reported (C. Brander, B. Walker, and S. Rowland-Jones, personal communication)
p24 (173–181) p24 (305–313) RAEQASQEV HIV-1 infection, HIV-1 exposed
seronegative
human (Cw8) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
p24 (174–184) p24 (306–316 LAI) AEQASQDVKNW human (B*4402) Brander2001
• C. Brander notes this is a B*4402 epitope
p24 (174–184) p24 (306–316 LAI) AEQASQDVKNW human (B*4402, B44) Brander1997
• Pers. Comm. from D. Lewinsohn to C. Brander and B. Walker, C Brander et al., this database, 1999
p24 (174–184) Gag (306–316) AEQASQEVKNW HIV-1 infection human (B44) Brodie1999
• The ability of CTL effector cells was studied by expanding autologous HIV-1 Gag-specific CTL in vitro, and adoptively transferring them
• The transferred CTLs migrated to the lymph nodes and transiently reduced circulating productively infected CD4+ T cells, showing that CTL move to
appropriate target sites and mediate anti-viral effects
p24 (174–184) p24 (306–316) AEQASQEVKNW HIV-1 infection human (B44) Brodie2000
• Study tracks and quantifies in vivo migration of neo-marked CD8 HIV-specific CTL
• Adoptively transferred gene-marked HIV-specific CTL homed to specific lymph node sites, colocalizing within the parafollicular regions of the lymph node
adjacent to cells expressing HIV tat-fusion transcripts, indicative of viral replication
• The CTL clones expressed CCR5 and localized among HIV-1 infected cells expressing MIP-1alpha and MIP-1beta, CC-chemokines produced at sites of
viral replication, suggesting a possible homing mechanism
• This study provides a methodology for tracking and studying antigen specific CTL in vivo
p24 (174–184) p24 (306–316 LAI) AEQASQDVKNW HIV-1 infection human (B44) Mollet2000
• Epitope name: G3
• A panel of 16 epitopes covering 15 class I alleles was tested in 14 HIV+ patients from an unselected Caucasian population treated with HAART, using
CD8+ cell IFNgamma production to measure responses
• In general, during the first month of treatment viral load decreased and frequencies of HIV-specific CTL tripled and broadened – eight new HIV
specificities that were not previously detectable were newly detected, as were CMV specific CD8+ PBL – but with continued viral suppression,
HIV-specific responses diminished
• Viral rebounds gave different patterns of response: increases or decreases in pre-existing response, new specificities, or no change
p24 (174–184) p24 (174–184) AEQASQDVKNW HIV-1 infection human (B44) Day2001
• B44-restricted CTL response was strongest to this epitope in one individual
p24 (174–184) p24 AEQASQDVKNW HIV-1 infection human (B44) Altfeld2002
• Epitope name: B44-AW11(p24)
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• Peripheral blood (PB) and lymph node (LN) CD8+ T-cell responses were compared in 15 asymptomatic HIV-1 infected patients using all known optimal
CTL epitopes (http://hiv-web.lanl.gov/content/hiv-db/REVIEWS/brander2001.html) for each person’s class I HLA alleles.
• 60 epitope responses were detected in both PB and LN samples of the 15 patients, and an additional 8 responses were detected only in LN. The total
magnitude of the response was similar in LN and PB, but the percentage of CD8+ T cells in the LN is lower so the number of HIV-specific cells per million
CD8+ T-cells is higher in the LN.
• 1 year post-HAART treatment in five patients studied, the magnitude of the CD8 T-cell response was decreased in both LN and PB, but more dramatically
in PB, and 13/25 epitope responses in the PB became undetectable, in contrast to 5/26 in the LN.
• Treatment interruption following HAART induced resulted in increased viremia accompanied by the restoration of the detection of 13 epitopes that had
become undetectable in the PB, and the addition of 9 novel epitope responses.
• Breakdowns of epitope responses were shown for 4 individuals. Patient B displayed the greatest response to epitope B44-AW11(p24) and also responded to
A32-PW10(RT) in both PB and LN samples, while a third response against epitope A32-RW10(gp120) was only detected in the LN sample.
p24 (175–186) p24 (307–318) EQASQEVKNWMT HIV-1 infection human (B44) Quayle1998
• HIV is found in semen both as cell-associated and cell-free forms, and HIV-specific CTL could be found in the semen of 5/5 men with CD4 greater than
500 – 3 of the men were analyzed in detail and had broad CTL to gag, env and pol
• Two CTL lines from one donor recognized this epitope
• Isolation of CTLs specific to HIV in both male and female urinal tracts provide evidence that virus-specific lymphocytes come from the urogenital mucosa,
and the authors speculate that CTL in mucosal tissues may be correlated with lower viral load in semen and reduced transmission
p24 (176–184) p24 (308–316 LAI) QASQEVKNW HIV-1 infection human (B*5301) Brander2001
• C. Brander notes this is a B*5301 epitope
p24 (176–184) QASQEVKNW HIV-1 infection human (B*5301, B57) Sabbaj2002b
• Epitope name: Gag-QW9
• This study monitored epitope responses in HIV-1 infected minority women living in the United States
• 24 epitopes were described – 8 were novel, 8 used new restricting elements but were previously defined epitopes, and 8 were previously described
• Serial peptide truncations were used to define optimal epitopes for CTL cell lines isolated from 12 individuals, assayed by a Cr-release
• Subject 01RCH59 was Hispanic, was not on HAART, viral load 5100, CD4 count 349, and she also recognized PIQKETWETW, RT(392-401), A*3201
• Among HIV+ individuals who carried HLA B*5301, 11/15 (73%) recognized this epitope
• Among HIV+ individuals who carried HLA B57, 3/6 (60%) recognized this epitope
p24 (176–184) p24 (309–317 LAI) QASQEVKNW HIV-1 infection human (B*5701) Goulder1996b
• Recognition of this peptide by two long-term non-progressors
• Peptide defined on the basis of B*5801 binding motif, yet not cross-restricted except at high concentrations
• Described as B*5701 in C. Brander et al., this database, 1999
p24 (176–184) p24 (311–319 LAI) QASQEVKNW HIV-1 infection human (B*5701) Brander2001
• C. Brander notes this is a B*5701 epitope
p24 (176–184) QASQEVKNW HIV-1 infection human (B*5701) Migueles2001
• HLA B*5701 was found in a very high frequency in HIV-1 infected non-progressors, 11/13 (85%) versus 19/200 (9.5%) of progressors. Non-progressors
tended to have an immune response that was highly focused on four p24 epitopes that were presented by B*5701, ISPRTLNAW, KAFSPEVIPMF,
TSTLQEQIGW, and QASQEVKNW.
• Only QASQEVKNW was recognized in all of the LTNP’s tested.
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p24 (176–184) QASQEVKNW HIV-1 infection human (B*5701) Migueles2001
• CTL activity was monitored in 27 individuals, including 10 LTNP with an over-expression of HLA B*5701 – these individuals have viral loads below the
threshold of infection without therapy, and their CD8+ T-cell response tends to be focused on peptides that contain B*5701 epitopes ISPRTLNAW,
KAFSPEVIPMF, TSTLQEQIGW, or QASQEVKNW.
• CTL responses are broader in B*5701+ individuals with progressive viremia than those that control viremia.
• The HLA-A*0201 SLYNTVATL epitope response was not as strong individuals that carried both A2, B57.
p24 (176–184) p24 (308–316 LAI) QASQEVKNW HIV-1 infection human (B53) Buseyne1997
• Minimal sequence determined through epitope mapping
• This is a relatively conserved epitope
• HLA-Cw*0401 was defined as the restricting element, but cells that carry Cw*0401 varied in their ability to present this epitope – this could be the result of
diminished cell-surface expression of Cw*0401 in some cells
• The HLA presenting molecule for this epitope was originally described as Cw*0401, but subsequent experiments with an HLA B53+ C4- cell line and with
C1R cells transfected with HLA-B53 have shown that the HLA restricting element is HLA-B53 (Pers. Comm., Dr. Florence Buseyne, 2000)
p24 (176–184) (LAI) QASQEVKNW human (B53) Brander2001, Buseyne1999
p24 (176–184) p24 (NL43) QASQEVKNW in vitro stimulation human (B53) Buseyne2001
• Epitope name: QW9
• Exogenous presentation or cross-presentation of epitopes by antigen presenting cells (APC) without protein synthesis is an alternative pathway for CTL
epitope processing that may be important in the initial generation of viral specific CTL
• Dendritic cells treated with AZT to inhibit protein synthesis were able to elicit a strong specific CTL response in QASQEVKNW specific CTL clone 141
without protein synthesis, while macrophages demonstrated a decreased presentation efficiency
• Exogenous Gag epitope presentation was Env-dependent and required receptor-dependent fusion
p24 (176–184) p24 (308–316) QATQEVKNW HIV-1 infection, HIV-1 exposed
seronegative
human (B53) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with
reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected
women
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure
• Among HLA-B53 women, 1/2 HEPS and 7/9 HIV-1 infected women recognized this epitope
p24 (176–184) p24 (308–316 subtype A
consensus)
QATQEVKNM HIV-1 infection human (B53) Dorrell2001
• In clade A infected Gambians, three HLA-B53 epitopes were defined in Gag p24 using ELISPOT, tetramer, and cytotoxicity assays
• Two of the new epitopes lacked the predicted by P2 anchors, DTINEEAAEW and QATQEVKNM, and bound to B53 with high affinity, thus extending the
anchor residue motif for B53 and the related B35
• While S, T, and P could all fit into the HLA-B35 or HLA-B53 B pocket and form a hydrogen bond, A would not form a bond, so the authors propose
compensatory interactions account for the high affinity of QATQEVKNM for B53
• QATQEVKNM was recognized in 6/7 HLA-B53 subjects
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• Cross-recognition of QATQEVKNM was not studied here, but it was noted that both the A, QATQEVKNM, and B, QASQDVKNW, subtype version of
this epitope, are also presented by HLA-B57 and B58, common HLA alleles in Africans
p24 (176–184) Gag (SF2) QASQEVKNW HIV-1 infection human (B57) Goulder2001a
• Epitope name: QW9
• This peptide elicited a weak CTL response during acute infection of patient PI004
• Three CTL responses, to epitopes TSTLQEQIGW, ISPRTLNAW, and KAFSPEVIPMF, were evident early after infection; CTL responses to SLYNTVATL,
QASQEVKNW, EIYKRWII, and FLKEKGGL were detectable at 5 months post-infection and beyond
p24 (176–184) (LAI) QASQEVKNW human (Cw4) Brander2001, Buseyne1999
p24 (176–184) p24 (176–184) QASGEVKNW HIV-1 infection, HIV-1 exposed
seronegative
human (Cw4) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
p24 (176–185) p24 (311–319 SF2) QASKEVKNWV HIV-1 infection human (B57) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B57+ individuals that had a CTL response to this epitope broken down by group: 0/0 group 1, 0/0 group 2, and 1/2 group 3
p24 (177–185) p24 (177–185) ATQEVKNWM HIV-1 infection, HIV-1 exposed
seronegative
human (B53) Kaul2001a
• Variants A(T/S)QEVKNWM are specific for the A/B clades
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with
reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected
women
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure
• Among HLA-B53 women, 1/2 HEPS and 5/9 HIV-1 infected women recognized this epitope
• The dominant response to this HLA allele was to this epitope in the 1/2 HEPS case and in only one of the 5/9 HIV-1 infected women
p24 (180–189) p24 (313–322) EVKNWMTETL HIV-1 infection, HIV-1 exposed
seronegative
human (B53) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
p24 (181–190) p24 (313–322 LAI) VKNWMTETLL human (B8) Brander1996b
• P. Johnson, pers. comm.
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p24 (191–205) Gag (320–328 BH10,
LAI)
VQNANPDCKTILKAL HIV-1 infection human Maksiutov2002
• This study employs an antigenic similarity matrix to compare HIV-1 antigenic determinants with human proteins.
• This CTL epitope (the HIV-1 LAI fragment with high similarity to a human protein overlapping this epitope is TLLVQNANP) has similarity with growth
differentiation factor 11, fragment THLVQQANP.
p24 (191–205) p24 (191–205) VQNANPDCKTILKAL HIV-1 infection human (B51) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
p24 (191–205) p24 (323–337) VQNANPDCKTILKAL HIV-1 infection human (B8) Nixon1991
• Two CTL epitopes defined (see also p17(21-35))
p24 (191–205) p24 (325–339 SF2) VQNANPDCKTILKAL HIV-1 infection human (B8) Goulder1997a, Phillips1991
• Longitudinal study of CTL escape mutants in people with the appropriate HLA types – little variation was observed in the immunodominant B27 epitope,
relative to the B8 epitopes, which varied over time
• [Goulder1997a] is a review of immune escape that points out that there may be a protective effect associated with B27, and that HLA-B8 individuals tend to
progress more rapidly than HLA B27 patients
p24 (191–210) p24 (323–342 SF2) VQNANPDCKTILKALGPAAT HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Twelve subjects had CTL that could recognize vaccinia-expressed LAI gag
• Three of these 12 had CTL response to this peptide
• The responding subjects were HLA-A3, A24, B8, B55; HLA-A1, A11, B8, B27
p24 (191–210) p24 (323–342 SF2) VQNANPDCKTILKALGPAAT HIV-1 infection human Lieberman1997b
• CTL expanded ex vivo were later infused into HIV-1 infected patients
p24 (193–201) Gag (327–335 SF2) NANPDCKTI HIV-1 infection human (B*5101) Tomiyama1999
• HLA-B27, -B51, and -B57 are associated with slow progression to AIDS, while HLA-B35, -B8, -B24 are associated with a rapid progression to AIDS (Nat.
Med. 2:405, 1996;Lancet 22:1187, 1986;Hum Immunol 22:73, 1988;Hum Immunol 44:156, 1995)
• 15% of Japanese populations carry HLA-B51 while HLA-B27 and -B57 are detected in less than 0.3%
• Of the 172 HIV-1 peptides with HLA-B*5101 anchor residues, 33 bound to HLA-B*5101, seven of these peptides were reactive with CTL from 3 B*5101
positive individuals, and six were properly processed
• Four of the six epitopes were highly conserved among B subtype sequences, NANPDCKTI is conserved
p24 (193–201) p24 (325–333) NANPDCKTI? HIV-1 infection human (B51) Betts2000
• Only 4/11 HLA-A2+ HIV+ individuals had CTL that reacted to SLYNTVATL, calling into question whether it is immunodominant
• 95 optimally-defined peptides from this database were used to screen for INFγ responses to other epitopes
• 3/11 of the HLA A2+ individuals were HLA B51 and two of these responded to this epitope as well as to other epitopes
p24 (193–201) p24 (324–335 IIIB) NANPDCKTI HIV-1 infection human (B51) Wilson1999a
• This study describes maternal CTL responses in the context of mother-to-infant transmission
• Detection of CTL escape mutants in the mother was associated with transmission, but the CTL-susceptible forms of the virus tended to be found in infected
infants
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• No variants of this epitope were found in a non-transmitting mother that had a CTL response to this epitope
p24 (193–201) p24 (323–333) NANPDCKTI HIV-1 infection human (B51) Oxenius2000
• Epitope name: NAN
• Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific
CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load – three patients that had delayed initiation of
HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became
undetectable
• None of the 8 study subjects recognized this epitope but none were HLA B51+
p24 (193–201) p24 (191–205) NANPDCKTI HIV-1 infection human (B8) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
p24 (195–202) p24 (323–342) NPDCKTIL HIV-1 infection human (B35) Bernard1998
• This study focuses on six rare long-term survivor HIV-infected people who were infected for many years without exhibiting immune dysregulation – such
immunologically normal HIV-infected (INHI) cases occur at a frequency between 0.1 and 1% in the infected population
• No direct CTL were found in any of the six INHIs, but above background CTLp activity was founded in 3/6 INHIs
• Epitope sequences were deduced from larger reactive peptides based on HLA binding motifs – XPXXXXXL is a B35 binding motif
p24 (195–202) NPDCKTIL HIV-1 infection human (B35) Sabbaj2002b
• Epitope name: Gag-NL8
• Among HIV+ individuals who carried HLA B35, 3/17 (18%) recognized this epitope
p24 (197–205) p24 (329–337 LAI) DCKTILKAL human (B*0801) Brander2001
• C. Brander notes this is a B*0801 epitope
p24 (197–205) p24 (329–337 LAI) DCKTILKAL human (B8) Sutton1993
• Predicted epitope based on B8-binding motifs, from larger peptide VQNANPDCKTILKAL
p24 (197–205) p24 (329–337) DCKTILKAL HIV-1 infection human (B8) Nowak1995
• In a longitudinal study of CTL response and immune escape – the variant DCRTILKAL was also found, binds to B8, but is not recognized
p24 (197–205) p24 (329–337) DCKTILKAL human (B8) McAdam1995
• Defined as minimal epitope by titration and binding studies
p24 (197–205) p24 (197–205) DCKTILKAL human (B8) Goulder1997g
• Included in a study of the B8 binding motif
p24 (197–205) p24 (329–337) DCKTILKAL HIV-1 infection human (B8) Oxenius2000
• Epitope name: DCK
• Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific
CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load – three patients that had delayed initiation of
HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became
undetectable
• This epitope was recognized at a low level by only 1 of the 7/8 study subjects that were HLA B8
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• Patient SC12(HLA A1, B8/39, Cw0701/0702, DR2/3, DR51/52, DQ2/6) had sustained therapy started during acute infection and maintained an
immunodominant response to FLKEKGGL throughout and minor responses to GEIYKRWII, DCKTILKAL, GGKKKYKLK – GEIYKRWII and
GGKKKYKLK responses were stimulated by a brief period off therapy
p24 (197–205) p24 (197–205) DCKTILKAL HIV-1 infection human (B8) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
p24 (197–205) p24 (197–205) DCKTILKAL HIV-1 infection human (B8) Day2001
• B8-restricted CTL accounted for about 1/3 of the total CTL response in one individual
p24 (197–205) p24 DCKTILKAL HIV-1 infection human (B8) Oxenius2002b
• Epitope name: DCK
• Using previously defined epitopes [Oxenius2000, Oxenius2001a] in an IFNgamma Elispot assay, 13 chronically HIV-1 infected patients were studied over a
period including therapy with standard treatment interruptions (STI).
• STIs induced increased recognition of CTL epitopes, but there was no correlation between CTL responses with viral rebound rates, plateau viral loads, or
clearance rates.
p24 (199–218) Gag (331–350) KTILRALGPGATLEEMMTAC HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
• This peptide was among the 28 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
p24 (211–230) p24 (345–364 SF2) LEEMMTACQGVGGPGHKARV HIV-1 infection human vanBaalen1993
• Gag CTL epitope precursor frequencies estimated, peptide mapping
p24 (211–230) p24 (343–362 SF2) LEEMMTACQGVGGPGHKARV HIV-1 infection human (B7) McAdam1998
p24 (211–231) p24 (343–362 SF2) LEEMMTACQGVGGPGHKAR-
VL
HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Twelve subjects had CTL that could recognize vaccinia-expressed LAI gag
• One of these 12 had CTL response to this peptide
• The responding subject was HLA-A1, A2, B50, B57
p24 (217–227) p24 (349–359 IIIB) ACQGVGGPGHK HIV-1 infection human (A*1101) Brander2001
• C. Brander notes this is an A*1101 epitope
p24 (217–227) Gag (349–359) ACQGVGGPGHK HIV-1 infection human (A*1101) Fukada2002
• Counterparts for eight known clade B HLA A*1101 epitopes were generated for clade E (CRF01). Three epitopes, identical among clade A-E, were
cross-reactive and recognized by clade E infected individuals. The clade E and B analogs to three more HLA A*1101 epitopes was recognized in a clade
specific manner. Two other HLA A*1101 clade B defined epitopes were found not to have stimulated a response in clade E infected individuals.
• ACQGVGGPGHK was found to elicit clade-specific responses in clade B (ACQGVGGPGHK is most common in clades A and B) and clade E
(acqgvggpShk is most common and is also common in clades C and D). ACQGVGGPGHK was recognized by CTL from 4/5 B clade infected Japanese
subjects, and acqgvggpShk from 3/7 E clade infected Thai subjects.
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• The binding of the two variants to HLA A*1101 was almost identical, but bulk CTL generated from individuals did not cross-react with the cross-clade
peptides, indicating the lack of cross-reactivity was due to TCR specificity.
p24 (217–227) p24 (349–359 IIIB) ACQGVGGPGHK HIV-1 infection human (A11) Sipsas1997
• HIV IIIB proteins were used to define the range of CTL epitopes recognized by three lab workers accidentally infected with HIV-1 IIIB
• ACQGVGGPSHK, a variant found in HIV RF, was also recognized
p24 (217–227) p24 (SF2) ACQGVGGPGHK HIV-1 infection human (A11) Goulder2000a
• The CTL-dominant response was focused on this epitope in a HIV+ Caucasian living in Boston – this epitope did not fall within the three most recognized
peptides in the study
• Three peptides GSEELRSLYNTVATL (p17 residues 71-85), SALSEGATPQDLNTMLNTVG (p24 41-60), and WEKIRLRPGGKKKYKLK(p17 16-30)
contained the dominant Gag-specific epitope in 31 out of 44 B-clade infected individuals from Boston who showed Gag-CTL responses
• Five peptides RLRPGGKKHYMIKHLVW (p17 20-36), ELRSLYNTVATLYCV (p17Gag 74-88), SALSEGATPQDLNTMLNTVG (p24 41-60),
FRDYVDRFFKTLRAEQA (p24 161-177), and SILDIKQGKEPFRDY (p24 149-164) contained dominant Gag-specific epitopes in 32 out of 37 C-clade
infected subjects from South Africa
p24 (217–227) p24 (349–359) ACQGVGGPGHK HIV-1 infection human (A11) Oxenius2000
• Epitope name: ACQ
• Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific
CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load – three patients that had delayed initiation of
HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became
undetectable
• Both of the 2/8 HLA-A11 study subjects recognized this CTL epitope
• Patient SC19(HLA A11/12, B8/44, Cw06/0701, DR3/7, DR52/53, DQ 2/8) had a CTL response to epitopes FLKEKGGL, GEIYKRWII,
ACQGVGGPGHK, AVDLSHFLK, and FNCGGEFFY that declined during therapy initiated at day 197
• Patient SC18(HLA A2/11, B8/44, Cw06/0701, DR3/7, DR52/53, DQ2) recognizes the epitopes ACQGVGGPGHK, QVPLRPMTYK, AVDLSHFLK, and
one called QIY but not fully described – he had brief therapy upon seroconversion and has had low viral load during 600 days of follow up
p24 (217–227) p24 (216–226) ACQGVGGPGHK HIV-1 infection human (A11) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
p24 (217–227) p24 (349–359 SF2) ACQGVGGPGHK HIV-1 infection human (A11) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-A11+ individuals that had a CTL response to this epitope broken down by group: 0/3 group 1, 0/0 group 2, and 2/2 group 3
p24 (217–227) p24 ACQGVGGPGHK HIV-1 infection human (A11) Oxenius2002b
• Epitope name: ACQ
• Using previously defined epitopes [Oxenius2000, Oxenius2001a] in an IFNgamma Elispot assay, 13 chronically HIV-1 infected patients were studied over a
period including therapy with standard treatment interruptions (STI).
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• STIs induced increased recognition of CTL epitopes, but there was no correlation between CTL responses with viral rebound rates, plateau viral loads, or
clearance rates.
p24 (221–231) p24 (353–363 LAI) VGGPGHKARVL HIV-1 infection human (B7) Mollet2000
• Epitope name: G1
• A panel of 16 epitopes covering 15 class I alleles was tested in 14 HIV+ patients from an unselected Caucasian population treated with HAART, using
CD8+ cell IFNgamma production to measure responses
• In general, during the first month of treatment viral load decreased and frequencies of HIV-specific CTL tripled and broadened – eight new HIV
specificities that were not previously detectable were newly detected, as were CMV specific CD8+ PBL – but with continued viral suppression,
HIV-specific responses diminished
• Viral rebounds gave different patterns of response: increases or decreases in pre-existing response, new specificities, or no change
p24 (223–231) p24 (223–231 SF2) GPGHKARVL HIV-1 infection human (B*0702) Altfeld2001a
• Epitope name: GL9
• HIV+ individual AC-06 was tested for reactive overlapping peptides spanning all HIV-1 proteins in an ELISPOT and was found to react with 12 peptides
from 7 proteins, suggesting that the breadth of CTL responses are underestimated if accessory proteins are not included in the study
• The response to GPGHKARVL was dominant
p24 (223–231) p24 (355–363 LAI) GPGHKARVL HIV-1 infection human (B7) Goulder1997e, Goulder1997a
• Identical twin hemophiliac brothers were both infected with the same batch of factor VIII
• One had a strong response to this peptide, the other a weak response
• [Goulder1997a] is a review of immune escape that summarizes this study
p24 (223–231) p24 (SF2) GPSHKARVL HIV-1 infection human (B7) Goulder2000a
• The CTL-dominant response was focused on this epitope in a HIV+ Caucasian living in Boston – this epitope did not fall within the three most recognized
peptides in the study
• Three peptides GSEELRSLYNTVATL (p17 residues 71-85), SALSEGATPQDLNTMLNTVG (p24 41-60), and WEKIRLRPGGKKKYKLK(p17 16-30)
contained the dominant Gag-specific epitope in 31 out of 44 B-clade infected individuals from Boston who showed Gag-CTL responses
• Five peptides RLRPGGKKHYMIKHLVW (p17 20-36), ELRSLYNTVATLYCV (p17Gag 74-88), SALSEGATPQDLNTMLNTVG (p24 41-60),
FRDYVDRFFKTLRAEQA (p24 161-177), and SILDIKQGKEPFRDY (p24 149-164) contained dominant Gag-specific epitopes in 32 out of 37 C-clade
infected subjects from South Africa
p24 (223–231) p24 (SF2) GPSHKARVL HIV-1 infection human (B7) Goulder2000a
• The CTL-dominant response was focused on this epitope in a HIV+ Caucasian living in Boston – this epitope did not fall within the three most recognized
peptides in the study
• Three peptides GSEELRSLYNTVATL (p17 residues 71-85), SALSEGATPQDLNTMLNTVG (p24 41-60), and WEKIRLRPGGKKKYKLK(p17 16-30)
contained the dominant Gag-specific epitope in 31 out of 44 B-clade infected individuals from Boston who showed Gag-CTL responses
• Five peptides RLRPGGKKHYMIKHLVW (p17 20-36), ELRSLYNTVATLYCV (p17Gag 74-88), SALSEGATPQDLNTMLNTVG (p24 41-60),
FRDYVDRFFKTLRAEQA (p24 161-177), and SILDIKQGKEPFRDY (p24 149-164) contained dominant Gag-specific epitopes in 32 out of 37 C-clade
infected subjects from South Africa
p24 (223–231) (LAI) GPGHKARVL (B7) Brander2001, Goulder1999a
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p24 (223–231) p24 (223–231 SF2) GPGHKARVL HIV-1 infection human (B7) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B7+ individuals that had a CTL response to this epitope broken down by group: 1/4 group 1, 2/3 group 2, and 0/1 group 3
p24 (223–231) p24 (223–231) GPGHKARVL HIV-1 infection human (B7) Day2001
• The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7 was
studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
• 2 to 17 epitopes were recognized in a given individual, A2-restricted CTL response tended to be narrow and never dominated the response, and 25/27
epitopes were targeted by at least one person
• Subjects with chronic HIV-1 infection recognized between 2-8 out of 11 B7-restricted epitopes
• An acute seroconvertor homozygous for the B7 allele recognized five B7-restricted epitopes
• The other acute seroconvertor failed to recognize any of the 11 B7-restricted epitopes tested
• The B7-restricted CTL response was highly variable and there was no clearly dominant epitope
p24 (223–231) p24 (223–231) GPGHKARVL HIV-1 infection human (B7) Yu2002a
• Epitope name: B7-GL9
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
• Only two epitopes were detected during acute infection in patient AC-06, B7 restricted gp41 epitope IPRRIRQGL and Gag GPGHKARVL. GPGHKARVL
was the first targeted peptide, and remained immunodominant through the 34 month study period.
• 3/11 HLA-B7 individuals had detectable B7-restricted responses to this epitope during acute infection – 10/15 of HLA-B7 epitopes tested were targeted by
at least one person during acute infection. 1/4 individuals had detectable responses to this epitope after STI.
p24 p24 (C consensus) HIV-1 infection human Goulder2000a
• The CTL-dominant response was focused on this epitope in a HIV+ South African – this epitope did not fall within the five most recognized peptides in the
study
• Three peptides GSEELRSLYNTVATL (p17 residues 71-85), SALSEGATPQDLNTMLNTVG (p24 41-60), and WEKIRLRPGGKKKYKLK(p17 16-30)
contained the dominant Gag-specific epitope in 31 out of 44 B-clade infected individuals from Boston who showed Gag-CTL responses
• Five peptides RLRPGGKKHYMIKHLVW (p17 20-36), ELRSLYNTVATLYCV (p17Gag 74-88), SALSEGATPQDLNTMLNTVG (p24 41-60),
FRDYVDRFFKTLRAEQA (p24 161-177), and SILDIKQGKEPFRDY (p24 149-164) contained dominant Gag-specific epitopes in 32 out of 37 C-clade
infected subjects from South Africa
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p24-p2p7p1p6
(223–1)
Gag GPGHKARVLA human (B7) De Groot2001
• The program Epimatrix was used in conjunction with the program Conservatrix to identify conservered regions of HIV that might serve as epitopes
• A subset of the potential epitopes was identified that could bind to the appropriate HLA-allele, and 15 predicted B7 superfamily (HLA B7, B8, and B58)
epitopes were identified that could stimulate IFNγ production in an ELISPOT assay
• GPGHKARVLA was confirmed as an HLA-B7 epitope in this study, and had been previously published
p24-p2p7p1p6
(225–8)
Gag (357–372 LAI) GHKARVLAEATLSQVN HIV-1 infection human Buseyne1993a
• Vertical transmission of HIV ranges from 13% to 39%
• Primary assays showed cytotoxic activity against at least one HIV protein was detected in 70% of infected children
• Epitopes recognized in five children were mapped using synthetic peptides and secondary cultures
• Patient EM28 (CDC P2A) had a CTL response to four epitopes in Gag
p24-p2p7p1p6
(230–7)
Gag (386–) VLAEAMSQV HIV-1 infection human (A*0201) Altfeld2001c
• Epitope name: Gag-386
• HIV was scanned for all peptides which carried the A2-supermotif pattern conserved in more than 50% of B clade sequences – 233 peptides met this
criteria, and 30 of these bound to HLA-A*0201 – 20/30 bound to at least 3/5 of HLA-A2 supertype alleles tested
• Three additional previously described HLA-A2 epitopes were added to the set of 20, and 18/22 chronically infected HLA-A2 individuals had CTL that
recognized at least one of the 23 peptides (median of 2 and maximum of 6), while 6/12 acute infected individuals recognized at least 1 (median of 1 and
maximum of 2)
• VLAEAMSQV binds to all five HLA-A2 supertype alleles tested: A*0201, A*0202, A*0203, A*0206 and A*6802 (highest affinity)
• 4/22 individuals with chronic HIV-1 infection recognized this epitope, and it was immunodominant in 3/4 by ELISPOT
• 0/12 acutely infected individuals recognized this epitope
p24-p2p7p1p6
(230–7)
VLAEAMSQV HIV-1 infection human (A02) Sabbaj2002b
• Epitope name: Gag-VV9
• Among HIV+ individuals who carried HLA A02, 3/29 (10%) recognized this epitope
p24-p2p7p1p6
(230–7)
Gag (397–405) VLAEAMSQV HIV-1 infection human (A2 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind all five HLA-A2 supertypes alleles (A*0201, A*0202, A*0203, A*0206 and A*6802)
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p2p7p1p6 (5–13) Gag (SF2) SQVTNPANI Vaccine murine BALB/c
(H-2Db)
Paliard1998
Vaccine Strain: SF2 HIV component: Gag
• HIV-1(SF2)p55gag vaccination of H-2 mice activates a CTL response against this epitope
• CTL that recognized SQVTNPANI in the context of H-2Db cross-reacted with H-2 alloantigens H-2Ld and an unidentified self-peptide
• A postulate: heterozygosity at the MHC level could prevent the maturation of some T cell receptor combinations for foreign peptide and self-MHC
constructs because of thymic depletion and tolerance
p2p7p1p6 (18–37) Gag (96ZM651.8) SNFKGNKRMVKCFNCGKEGH human (A*02011) Novitsky2001
• This study is provides a survey of CTL responses and full length HIV-1 genome sequences from a C subtype infected Botswanan cohort
• 4 of 8 individuals (50%) who were positive for HLA-A*02011 responded to the peptide SNFKGNKRMVKCFNCGKEGH
p2p7p1p6 (42–50) p15 (42–50 SF2) CRAPRKKGC HIV-1 infection human (B14) Yu2002b
• 26/57 HIV-1 infected subjects displayed Gag p15-specific CD8+ T-cell IFNgamma responses were measured by Elispot and intracellular staining. The
immunodominant regions targeted by CD8+ T-cells were mapped to three functional domains: the zinc finger structures, the protease cleavage site p7/p1,
and to the Vpr binding site in p6.
• p15 contributed on average 17% of the total Gag response (rage 0-100%).
• 3 optimal CTL epitopes were mapped within p15: KELYPLTSL, CRAPRKKGC, and FLGKIWPSYK.
• 2/6 HLA-B14+ subjects recognized this epitope. The binding motif for B14 is C-term Cys, positions 2 and 5 Arg.
p2p7p1p6 (55–70) p15 (446–460 BRU) KEGHQMKDCTERQANF HIV-1 infection human (A2) Claverie1988
• One of 4 epitopes first predicted, then subsequently shown to stimulate an HLA-A2 restricted CTL line
p2p7p1p6 (64–71) TERQANFL HIV-1 infection human (B*4002) Sabbaj2002b
• Epitope name: Gag-TL8
• This study monitored epitope responses in HIV-1 infected minority women living in the United States
• 24 epitopes were described – 8 were novel, 8 used new restricting elements but were previously defined epitopes, and 8 were previously described
• Serial peptide truncations were used to define optimal epitopes for CTL cell lines isolated from 12 individuals, assayed by a Cr-release
• This epitope was newly defined in this study
• Patient 01RCH59 was Hispanic, not on HAART, and had a viral load of 5100 and CD4 count of 349 – she also recognized AEWDRVHPV, p24(78-86),
HLA-B*4002 and KEKGGLEGL, Nef(92-100), HLA-B*4002
• Among HIV+ individuals who carried HLA B40, 3/5 (60%) recognized this epitope
p2p7p1p6 (70–79) p15 (70–79 SF2) FLGKIWPSYK HIV-1 infection human (A*0201) Yu2002b
• 26/57 HIV-1 infected subjects displayed Gag p15-specific CD8+ T-cell IFNgamma responses were measured by Elispot and intracellular staining. The
immunodominant regions targeted by CD8+ T-cells were mapped to three functional domains: the zinc finger structures, the protease cleavage site p7/p1,
and to the Vpr binding site in p6.
• p15 contributed on average 17% of the total Gag response (rage 0-100%).
• 3 optimal CTL epitopes were mapped within p15: KELYPLTSL, CRAPRKKGC, and FLGKIWPSYK.
• FLGKIWPSYK was embedded in a peptide recognized by 14/57 (25%) of subjects.
• 13/24 (54%) of HLA-A*0201+ subjects recognized this peptide.
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p2p7p1p6 (83–97) Gag (453–462 BH10,
LAI)
GNFLQSRPEPTAPPF HIV-1 infection human Maksiutov2002
• This study employs an antigenic similarity matrix to compare HIV-1 antigenic determinants with human proteins.
• This CTL epitope (the HIV-1 LAI fragment with high similarity to a human protein overlapping this epitope is PEPTAPPFLQ) has similarity with the T-cell
surface glycoprotein CD5, fragment PEPTAPPRLQ.
p2p7p1p6 (83–97) p15 (418–433 BRU) GNFLQSRPEPTAPPF HIV-1 infection human (A2) Claverie1988
• One of 4 epitopes first predicted, then subsequently shown to stimulate an HLA-A2 restricted CTL line
p2p7p1p6 (118–126) p2p7p1p6 (118–126) KELYPLTSL human (B*4001(B60)) Brander2001
• C. Brander notes that this is a B*4001 epitope
p2p7p1p6 (118–126) p15 (118–126 SF2) KELYPLTSL HIV-1 infection human (B60, B*4001) Yu2002b
• Epitope name: p15-24
• 26/57 HIV-1 infected subjects displayed Gag p15-specific CD8+ T-cell IFNgamma responses were measured by Elispot and intracellular staining. The
immunodominant regions targeted by CD8+ T cells were mapped to three functional domains: the zinc finger structures, the protease cleavage site p7/p1,
and to the Vpr binding site in p6.
• p15 contributed on average 17% of the total Gag response (rage 0-100%).
• 3 optimal CTL epitopes were mapped within p15: KELYPLTSL, CRAPRKKGC, and FLGKIWPSYK.
• Four patients who were HLA-B60+ recognized KELYPLTSL.
• The binding motif for B60 is C-term Leu and 2nd position Glu.
• Four patients who did not carry HLA-B60 also recognized the 15 amino acid long peptide carrying KELYPLTSL, suggesting other epitopes in this
immediate region can be presented by other HLA class I molecules.
p2p7p1p6 (121–130) Gag (484–493) YPLTSLRSLF HIV-1 infection human (B7) Jin2000b
• This B7 epitope is one of three subdominant CTL responses detected in a long-term non-progressor
• A dominant B7 epitope was defined using conventional methods, and three additional sub-dominant HLA B7 epitopes were defined by first using a
non-anchor based strategy, EpiMatrix, to identify 2078 possible epitopes in the autologous HIV-1, followed by B7 anchor residue prediction to narrow the
set to 55 peptides for experimental testing
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Gag Gag (IIIB) Vaccine Rhesus macaque Paliard2000
Vaccine Vector/Type: virus-like particle HIV component: gag
• CTLs primed by HIV-1 p55 gag virus-like particle (VLP) vaccination recognized epitopes in four different 20 amino acid peptides p17/4, p17/8, p24/13 and
p14/9
• Cytotoxic T cell response lasted greater than 8.5 months
Gag Gag (IIIB) HIV-1 infection human Wasik2000
• HIV+ infants that progressed rapidly to AIDS had lower Th1 responses and decreased production of beta-chemokines and IL-2 relative to other HIV+
infants
• No HIV+ infants had no demonstrable CTL at birth, but Th1 responses accompanied by CTL responses developed in children with slowly progressive
disease, and not in rapid progressors
• CTLp frequencies were determined by limiting dilution using autologous B cells infected with vaccina/HIV constructs
Gag Gag (LAI) Vaccine human Salmon-Ceron1999
Vaccine Vector/Type: canarypox Strain: LAI, MN HIV component: gp41, Gag, Pro, V3
• The vaccine used was a rec canarypox with HIV-1 gp120 MN, tm/gag/protease LAI (vCP205), alone or with p24E-V3 MN synthetic peptide (CLTB-36))
• Twenty HIV negative subjects were vaccinated in phase I trial with combinations of vCP205 and CLTB-36
• Immunization with vCP205 induced HIV-1-specific ABs to gp120, V3, and p24 antigens, and CTL immune responses against vCP205 were detected after
the fourth immunization in 33% of the subjects against Env, Gag and Pol, but the CLTB-36 peptide did not produce AB or CTL immune responses against
p24 or gp160
Gag p24 Vaccine human Klein1997
Vaccine Vector/Type: virus-like particle HIV component: p24, p17
• Immunization of HIV+ people with an HIV-1 p17/p24 Ty virus-like particle (p24-VLP) resulted in a marginal, short-lived increased proliferative response
to p24 and p17 and a transient elevation in viral load
• Two of four subjects that received 500 or 1000 µg of p24-VLP had an increase in gag-specific CTL
Gag p24 (SF2) Vaccine murine, baboon O’Hagan2000
Vaccine Vector/Type: DNA Strain: SF2 HIV component: gp120, p24 Adjuvant: PLG-microparticle, MF59 adjuvant
• PLG (Polylactide co-glycolide polymer) microparticles administered in MF59 emulsion induced gp120 Ab responses and CTL immune responses against
p24 gag
Gag Gag HIV-1 infection human Lubaki1999
• Three strategies were used to analyze CTL activity: area under the net HIV-specific lysis curve (ACU), linear regression (LR) of net specific lysis, and the
standard method, lytic units (LU20)
• A correlation between low HIV plasma viral load and increased levels of HIV-specific Gag and Nef CTL activity was observed using ACU and LR, but not
LU20
Gag Gag HIV-1 infection human Kalams1999a
• The presence of HIV-1 p24-specific proliferative responses was positively correlated with Gag-specific memory CTL and negatively correlated with viral
load in untreated subjects
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• Gag proliferative responses were the most readily detected – Gag CTL responses were the only responses with a significant correlation with Gag stimulated
help, although there was a positive trend with Nef, Env and RT
Gag p55 (IIIB) HIV-1 infection human Greenough1999
• 7/128 HIV-1 infected hemophiliac were identified as long-term non-progressors (LTNPs) and were monitored for viral and host immune parameters over 15
years – LTNPs maintained a low viral load, high frequencies of CTL precursors directed against Gag antigen and low levels of HIV-specific effector CTL
activity – effector cell activity suggests low level ongoing viral replication
Gag Gag HIV-1 infection human Trickett1998
• Twelve HIV-1 infected patients were re-infused with their own lymphocytes, cryopreserved from an earlier time point in the infection
• Improvement in CD4+ and CD8+ T cells was seen in 7/12, and an increase in the CTL response to Gag was seen in one patient
Gag Gag (IIIB) HIV-1 infection human Betts1999
• This study demonstrated an inverse correlation between HIV Type I plasma viral load and CTL activity directed against HIV-1 Pol, and stronger combined
effects of Pol- and Env-specific CTL, in long-term survivors (LTS) of HIV-1 infection
Gag Gag (LAI) HIV-1 infection human Legrand1997
• Seventeen recently infected patients were tested for CTL response to HIV proteins Env, Gag, Pol, Rev, Nef, Vif and Tat
• An early response (within a month following PI) was noted in 87% of the subjects to Gag, 75% to Env, and 50% to Nef
• Early responses to Pol, Rev, Vif and Tat were rare
Gag Gag (IIIB) HIV-1 infection human Betts1997
• 6/8 individuals from Zambia infected with C clade virus had CTL that were able to make response to B clade HIV-1 IIIB vaccinia-expressed Gag, Pol and
Env proteins
• A vigorous cross-clade response was not limited to a particular protein, and the level of recognition of different proteins varied among the six patients
Gag Gag HIV-1 infection human De Maria1997
• CD3+ cells that also carry a natural killer cell receptor (NKR+) can exhibit down regulation of T cell function
• Anti-NKR IgM MAb masked this inhibitory function and increased HIV-1 specific CTL activity in phytohemagglutinin-activated PBMC cultured in the
presence of IL-2 from 3/5 patients, and in one other case anti-NKR MAb brought HIV-1 specific CTL activity to detectable levels
Gag Gag (LAI) Vaccine human Belshe1998
Vaccine Vector/Type: canarypox prime with rgp120 boost Strain: MN, LAI, SF2 HIV component: gp120, gp41, Gag, Protease
• The live canarypox vaccine ALVAC-HIV(vCP205) carrying MN gp120, LAI gp41, Gag and Protease, and boosted with SF-2 rpg120, was given to HIV-1
seronegative volunteers – HIV-specific Env or Gag CD8+ CTL were detected in 64% of the volunteers
Gag Gag (LAI) HIV-1 infection human Buseyne1998a
• This study showed a correlation between strong CTL memory and breadth of response in 7-12 month old infants, and remaining AIDS-free for the first year
of life, higher absolute CD4 and CD8 cells, and lower viral load
Gag Gag (LAI) HIV-1 infection human Buseyne1998b
• In infants with positive CTL responses, most responses showed cross-clade reactivity with somewhat diminished recognition of epitopes from different
subtypes
Gag Gag HIV-1 exposed seronegative human Goh1999
• 13/37 exposed uninfected individuals with repeated high-risk sexual exposure had HIV-1 specific CTL against Env, Gag, Pol, or a combination of proteins –
CTL activity was correlated with a CCR5 wildtype genotype
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• In this group, the highest CTLp frequencies were directed at Gag, but the most common response was to Env and four individuals had responses to multiple
HIV-1 proteins
Gag Gag (LAI) Vaccine human Evans1999
Vaccine Vector/Type: canarypox HIV component: gp120, gp41, Gag, Pro, Nef, RT
• A Canarypox vaccine expressing gp120, gp41, Gag, Protease, Nef and Pol CTL epitopes gave rise to CTL that could be detected in 61% of the volunteers –
responses to Gag, Env, Nef and Pol were detected 3-6 months after the last vaccination
Gag p17 HIV-1 infection human Kuiken1999
• A correlation between conserved regions of p17 or Nef and CTL epitope density was noted – the authors suggest that this may be due to a biological reason
such as epitope processing, or may possibly be an artifact of experimental strategy for epitope definition such that conserved epitopes would tend to be
identified because they would be more likely to be cross-reactive with the test reagents
• In contrast to p17 and Nef, p24 is a more conserved protein and known epitopes are evenly distributed across p24
Gag Gag (LAI) Vaccine Macaca nemestrina Kent1998
Vaccine Vector/Type: DNA prime with vaccinia boost Strain: LAI HIV component: Env, Gag
• Priming with an HIV-DNA vaccine and boosting with a vaccinia construct induced greater levels of HIV T cell immunity than either vaccine alone
• The proliferative response to Env and Gag after the DNA vaccination had a mean SI of 1.5-4, but after boosting with rHIV-fowlpox virus, there was a 6-17
fold increase in the mean SI for HIV Gag and Env. The T help response happened despite a fall in antibody titers, suggesting that the Th response was
primarily Th1, not Th2. The CTL response was also enhanced
Gag Gag/Pol (LAI, MN) Vaccine human Salmon-Ceron1999
Vaccine Vector/Type: canarypox Strain: MN, LAI HIV component: gp120, gp41, Gag, Protease
• A live attenuated canarypox vector expressing MN gp120 and LAI gp41/gag/protease could induce CTL and a lymphoproliferative response in healthy,
uninfected volunteers
Gag Gag/Pol (MN) Vaccine chimpanzee Kim1998
Vaccine Vector/Type: DNA HIV component: Env, Gag, Pol Adjuvant: CD86, CD80
• The study explores the use of co-stimulatory molecules co-expressed with an HIV-1 immunogen in a DNA vaccine to enhance the immune response –
co-expression of CD86, but not CD80, dramatically increased both HIV Env and Gag/Pol specific CTL and Th proliferative responses
Gag Gag (BRU) HIV-1 infection human Aladdin1999
• In vitro measurements of CTL-activity by Cr release assay in bulk culture showed no correlation between CTL-activity (gp120, Gag, Pol and Nef) and
disease progression as measured by viral load, CD4 and time to death
Gag Gag Vaccine Rhesus macaque Akahata2000
Vaccine Vector/Type: DNA Strain: ZF1 HIV component: complete genome
• Rhesus macaques were vaccinated by i.m. injection with naked plasmid DNA carrying an HIV-1 complete genome vaccine, strain ZF1, with a mutated zinc
finger in the nucleocapsid to prevent packaging
• Env and Gag specific CTL but no antibody responses were induced in 2/4 vaccinated monkeys (MM145 and MM153)
• 2/4 monkeys (MM146 and MM143) produced antibodies against p24 and/or gp160, but no CTL response was detected
• PBMC from all vaccinated monkeys produced IFN-gamma, in response to HIV-1 gp160, indicating a Th response – this response was 5 times higher in
MM145, the animal with the strongest CTL response
• 4 weeks post-challenge with SHIV NM-3rN plasma viral loads of both MM145 and MM153 (with a homologous Env) decreased to near or below the
detection limit
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• 6-8 weeks post-challenge with SHIV NM-3rN plasma viral loads of both MM146 and MM143 decreased near or below the detection limit
Gag Gag HIV-1 infection human Salerno-Goncalves2000
• A general test of CD8 anti-viral activity was developed based on proviral load of coculture of autologous CD8+ cells with CD4+ cells after homogeneous
superinfection with NSI virus
• Significantly decreased the CD4+ T-cell proviral loads were found in 12 HIV+ slow progressors relative to 10 rapid progressors
• Significant CD8+ mediated cytotoxicity directed against autologous cells infected with vaccinia carrying the HIV-1 gag gene was observed in slow
progressors in contrast to rapid progressors, but no correlation was found between plasma viral load in 22/22 asymptomatic HIV infected individuals
Gag Gag HIV-1 infection human Young2001
• Addition of recombinant rec human IL12 (rhIL12) to cultures increased HIV-specific lysis of HIV-Gag, Pol and gp120 vaccinia expressed antigens (11/15
tested increased lysis by > 5%) if the culture was derived from HIV+ individuals who had CD4 cells/ul > 500
• 2/10 individuals with <200 CD4 cells/ul, and 3/10 individuals with 200-500 CD4cells/ul, had an increase of >5% upon treatment of the culture with rhIL12,
so a few individuals in late stage disease had CD8 cells that maintained responsiveness to rhIL12
Gag p24 HIV-1 infection murine deQuiros2000
• CB-17 SCID-Hu mice engrafted with peripheral blood mononuclear cells of four long-term nonprogressors (viral load < 50 copies/ml) displayed resistance
to challenge with HIV-1 SF162, mediated by CD8+ T-cells and associated with proliferation in response to p24 – these patients did not have a higher level
of HIV-1 specific immunity in vitro, so the mechanism is unknown
Gag Gag (subtype A, B, D) HIV-1 infection human Cao2000
• HIV-1 subtypes A and D dominate the Ugandan epidemic, and a vaccine trial using B clade antigen is underway – this study addresses relative levels of
cross-reactive CTL responses in HIV infected Ugandans to A, D, and B clade recombinant vaccinia viruses expressing Gag, Env, RT or Nef from HIV-1
clades A, B, and D; =Proteins corresponding to the subtype of the infecting strains tended to trigger higher levels of CTL response measured by percent
specific lysis, but there was extensive inter-subtype cross-reactivity with B clade proteins and the co-circulating subtype
Gag Gag HIV-1 infection human White2001
• HIV-specific CTL activity was detected in the female reproductive tract of only 1/3 HIV-infected women who underwent a hysterectomy, although CTL
could be identified in the PBMC of all three women
Gag Gag (HXB2) HIV-1 infection human Chun2001
• Suppression of viral replication in the resting CD4+ T-cell reservoir by autologous CD8+ T-cells via CD4+/CD8+ cell contacts was observed in long-term
nonprogressors and patients undergoing antiretroviral treatment, but this activity appears to be independent of Gag-specific CTL activity
Gag Gag (IIIB) HIV-1 infection human Jin2000a
• The CTL precursor level (CTLp) was measured in long term non-progressors (LTNP) with low viral load using limiting dilution analysis and measuring
CTL against Env Gag and Pol expressed in vaccinia in autologous targets
• LTNPs have high memory CTL numbers and low viral load
Gag Gag HIV-1 exposed seronegative human Rowland-Jones2001
• This is a review that summarizes observations about HIV-specific CTL found in the HIV-1 exposed persistently seronegative (HEPS) population
• The CTL responses assayed by ELISPOT and by CTL precursor frequencies by limiting dilution analysis indicate that CTL in HEPS individuals tend to be
of a lower magnitude than in chronic HIV-1 infections – the responses in HEPS cases are below the level of detection by tetramer assays
• CD8+ CTL responses tend to be detectable in HEPS subjects only if they are recently exposed, and the response diminishes if exposure is reduced – it is not
clear if there is a stable memory population in HEPS cases
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• CD8+ CTL responses in the HEPS population are associated with HIV-1 specific CD4+ T cell responses, assayed by proliferation assays, IL-2 secretion,
and ELISPOT, and the authors consider the possibility that HIV-1-specific T-help responses improve the "quality" of the CD8+ response in HEPS
individuals relative to HIV-1 infected individuals, who tend to have a poor HIV-1-specific T-help response
• HIV-1 specific CD8+ CTL responses in HIV-1 infected individuals show reduced levels of perforin, and the T cells may not mature properly, and although
similar studies have not been conducted in HEPS individuals this is considered as a possible difference in the CTL immune response in HEPS and HIV-1
infected people
Gag Vaccine murine Nabel2002
Vaccine Vector/Type: DNA HIV component: Gag, Pol, Env, Gag-Pol fusion protein, Gag-Pol pseudoparticle
• Using DNA that had humanized codon usage, CTL responses to DNA vaccines containing either Gag, Pol, Gag-Pol fusion protein, or Gag-Pol
pseudoparticles suggested that the greatest breadth and most potent response was to the Gag-Pol fusion protein. The Gag-Pol fusion lacks the Gag
precursor protein required for viral assemble, so does not form releaseable particles; the author speculates that longer retention of the Gag-Pol protein with
in the cell may enhance antigen presentation.
Gag HIV-1 exposed seronegative human De Maria1994, Kuhn2002
• 6/24 HIV uninfected infants (ages 15-50 months) born to HIV+ mothers had HIV-1 specific CTL responses to vaccinia-expressed Nef, Gag/Pol, Env.
• Reviewed in [Kuhn2002].
Gag HIV-1 infection human Aldhous1994, Kuhn2002
• Six of nine HIV vertically infected infants had HIV-1 specific CTL responses to vaccinia expressed Tat (4/6), Pol (6/6), Env (1/6), or Gag (1/6), but not all
responses were detected at all time points.
• Two of eleven babies that were not infected though born to HIV+ mothers had detectable responses to Tat (1/2), Pol (2/2), Gag (1/2).
• Reviewed in [Kuhn2002].
Gag HIV-1 infection human Kuhn2002, Wasik1999
• In HIV-infected infants HIV-specific, CTL responses were not detectable in icord blood or in PBMC collected shortly after birth and were absent or
remained very low in 3 infants with a rapidly progressive disease. For those who progressed more slowly, the HIV-specific CTL activity varied.
• The two infants with high levels of Env peptide-stimulated IL-2 responses had the highest CTLp frequencies.
• Stronger responses were detected after initiation of the antiretroviral therapy.
• Two babies that were not infected though born to HIV+ mothers had detectable though low HIV-specific CTLp responses to Env (1/2), Pol (2/2), Gag (1/2)
cord blood and transiently in PBMC after birth.
• Reviewed in [Kuhn2002].
Gag HIV-1 infection human Kuhn2002, McFarland1994
• Only 9% of HIV+ infants had HIV-specific CTL against Env or Gag in unstimulated PBMC. After CD3 stimulation of PBMC, Gag and Env specific CTL
were found in PBMC from 91% and 78% of HIV-infected children, respectively, with high precursor frequencies.
• Reviewed in [Kuhn2002].
Gag HIV-1 infection human Yusim2002
• Epitopes that have been described in the literature and included in this database tend to cluster in conserved regions and be absent or rarely found highly
variable regions found in Nef, Env and p17.
• In the more conserved p24, and Pol proteins RT and Protease, epitopes are more evenly distributed. p17 is much more variable than p24.
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Gag p24 (HXB) HIV-1 infection human Lu2000a
• Bacillus anthrax lethal toxin (LFn)-HIV fusion proteins are candidate HIV vaccines that are safe in mice, and LFn-V3 region fusion proteins induce CD8 T
cells in BALBc mice. LFn causes exogenous protein to be taken up and processed in a class I pathway. Expressed proteins from Gag p24 and Nef
fragments cloned into the LFn expression plasmid stimulate gag-specific CD4 proliferation and CTL responses in HIV-infected donor PBMCs in vitro.
Gag (HXB2) HIV-1 infection human Edwards2002
• 96% (26/27) chronically infected HIV-1 infected patients elicited gamma-IFN CD8+ T-cell responses against Gag
• Nef and/or Pol CTL responses were detected in 86% of the subjects
• The magnitude and breadth of Gag and p24 T-cell responses correlated with absolute CD4 counts, and inversely correlated with viral load
• Pol and Int CTL responses correlated positively with absolute CD4+ T-cell count
• Nef and Env responses did not correlate with either CD4 counts or viral load
Gag HIV-1 infection human Larsson2002b
• Autologous mature dendritic cells with rec vaccinia expressing Gag, Pol, Nef and Env could amplify CD8+ T-cell Elispot responses 4-38 fold in five HIV+
patients on successful HAART treatment, relative to autologous monocytes. Some weak responses could only be detected using mature dendritic cells as
APCs, and this approach could be useful for detection of low frequency memory cells.
Gag (IIIB) HIV-1 infection human Trickett2002
• Conditions were optimized for ex-vivo expansion of CD8+ and CD4+ T-cells with the goal of functional T-cell production for autologous immunotherapy.
10,000-fold expansions were obtained in 14 days with optimized concentrations of IL-2, anti-CD3 and anti-CD28 coated microspheres, and decreasing
amounts of serum over the first 8 days.
Gag (IIIB) HIV-1 and HCV co-infection human Lauer2002
• HIV-1 and HCV immune responses were studied in 22 individuals who were co-infected with HIV-1 and hepatitis C virus (HCV). IFNgamma production
was measured in an Elispot assay of CD8+ T-cells using targets expressing either Gag, RT, Env and Nef in a vaccinia construct, or one of seven HCV
proteins.
• All 22 patients targeted at least one protein. 20/22 patients recognized RT, 17/22 patients recognized Gag, 13/22 subjects recognized Env and 11/22 patients
recognized Nef. Robust CTL activity was independent of disease progression or viral load.
• Despite high HCV viral loads, very few HCV CD8+ T-cell Elispot responses were detected. In a control HCV infected person who did not have HIV-1,
strong anti-HCV responses were mounted.
• HIV-specific CD4 proliferative responses were detected in 9/17 coinfected patients, but no HCV responses were detected.
Gag HIV-1 infection human Luzuriaga1995
• 2/3 infants infected in utero had detectable HIV-1 Gag and Env specific CTL responses, one by 4 months, one by 11 months of age. Levels of the responses
varied at different time point. Pol responses were not detected.
• 2/4 infants infected intrapartum had detectable responses, one note until 11 months, one not until 42 months.
• HIV-specific CTL were not detected in ten HIV- infants that were born to HIV+ mothers.
Gag Vaccine human Gupta2002
Vaccine Vector/Type: canarypox prime with rgp120 boost Strain: Gag, LAI; gp120, MN; and gp41, LAI HIV component: gag, env
• A safety and immunogeniticity study of a vaccine dosing schedule was studied in a trial conducted in high and low risk study subjects. There was a 76%
cumulative probability of detecting a Gag or Env CTL response by day 728.
Gag HIV-1 infection human Scott2001
• CTL responses before and after initiation of ART were studied in 13 HIV-1 vertically infected infants <6 months of age, and 4 that were >6 months of age.
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• Before ART 2/13 infants <6 months of age showed IFNgamma Elispot CD8+ T-cell responses, one to Nef and one to Env and Nef, and these responses
became undetectable after successful therapy– 3 infants were coinfected with CMV and all 3 had CMV-specific CD8+ T-cell responses.
• One older infant, at 23 months, had CTL responses against all for proteins tested, Gag, Pol, Nef and Env, and had the lowest plasma viremia of the study
group. 3/4 infants older than 6 months of age responded to either Nef or Pol.
• Administration of ART over 48 weeks broadened the HIV-1-specific CTL response in 2/4 of the older children that were incomplete responders.
Gag (IIIB, MN) HIV-1 infection human Larsson2002a
• Dendritic cells acquire and present HIV-1 antigens derived from dead, apoptotic cells or from non-infectious, fusion-competent HIV-1 virions, and these
DC cells could stimulate CD4+ and CD8+ T-cells resulting in IFNgamma production in an Elispot assay. Both HLA Class I and class II molecules were
used for presentation. This may be an important aspect of the initial immune response to HIV-1 infection of CD4+ cells in the mucosal subepithelia.
Gag (IIIB) HIV-1 infection human Ortiz2001
• Immune responses in eight chronically HIV-1 infected patients undergoing HAART therapy structured treatment interruptions (STI) were studied. STI
boosted HIV-1 specific CTL responses and elevated CTL responses were maintained up to 22 weeks after the last treatment interruption, but viral load
rebound to pretreatment levels and CD4 T-cell count decline was observed. CD8 responses in PBMC were measured by cytokine flow cytometry with
gp160, Gag p55, RT-Pol and Nef expressed in vaccinia.
Gag Gag HIV-1 infection human (A*0201 and
Cw*08)
Shacklett2000
• HIV-1 specific, MHC class I-restricted CTL killing was detected in duodenal and rectal gut associated lymphoid tissue (GALT) sites from three infected
individuals – the distribution of class I restricted CTL was different in the peripheral blood samples and GALT samples
Gag computer prediction (A*0201, B*3501) Schönbach2002
• Computational methods (artificial neural networks, hidden Markov models, binding matrices based on HLA association rates) were used to identify
HLA-A*0201 and HLA-B*3501 HIV T-cell epitope candidates from 533 Gag, Env and Pol sequences of which 374 were derived from HIV-1, 97 were
derived from HIV-2 and 62 from SIV. Comparisons to known epitopes and between clades were made.
Gag Gag HIV-1 infection human (B*35) Jin2002
• Patients with HLA-B*35 variants B*3502, B*3503, B*3504, and B*5301 tend to proceed to AIDS more quickly than those with B*3501.
• Of 32 patients with HLA-B*35 alleles CD8+ CTL responses were quantified using an intracellular cytokine staining assay – 75% had responses to Pol,
69% to Gag, 50% to Nef, and 41% to Env.
• The overall magnitude of CTL responses did not differ between those bearing B*3501 and the others. A higher percentage of Gag responses was observed
in those that had lower RNA levels that carried B*3501, and there was a negative association with viral load and CTL activity. The data is consistent with
higher levels of CTL responses contributing to protection in B*3501 individuals, but not in B*3502, B*3503, B*3504, and B*5301 individuals.
Gag Vaccine human (B60) Ferrari2001
Vaccine Vector/Type: canarypox prime with rgp120 boost, canarypox prime with rgp160 boost Strain: gp41 LAI, Gag LAI, gp120 MN, gp120 SF2 HIV
component: gp120, gp41, Gag, Pol and Nef epitope rich regions
• HLA-B60 responses dominated the responses against an Gag vaccine in an individual (022G0Z) who was HLA A1, A11, B8, B60. The strongest response
was against the MN peptide 107-136. Low level Gag responses were observed against B8 and A11 epitopes, no response was observed against A1 epitopes.
• Vaccinee 202T7 (HLA A2, B27, C25) made the strongest response to an epitope at positions 131-140 of Gag. The response was highly cross-reactive with
D clade Gag expressed from vaccinia, less so with C, and only minimally cross-reactive with A and CRF01.
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Gag p24 Vaccine murine (H-2b, H-2d ,
H-2k)
Iroegbu2000
Vaccine Vector/Type: DNA HIV component: p17/p24
• The p24 sequence is more conserved than is p17 within patient, and nonsynonymous substitutions are spread evenly throughout its coding regions, not
concentrated in CTL epitopes
• Minor changes in p24 did not alter the immunogenicity in H-2b,d, or k mice, while changes in p17 (92% similarity) did alter immunogenicity
Gag p24 Vaccine murine (H-2d) Qiu2000
Vaccine Vector/Type: DNA HIV component: gag
• Mice were injected with plasmid DNA at 0, 2 and 4 weeks and lymphocyte proliferation was measured after 6 weeks with recombinant p24 protein
• Secreted HIV-1 Gag expression vectors generated a stronger response than standard Gag or cytoplasmic Gag expression vectors
• IFN-gamma levels were increased compared to an undetectable IL-4 response
• CTL levels were also increased in secreted Gag expression vaccination studies
Gag Gag (SF2) Vaccine Rhesus macaque,
murine (H-2d)
zurMegede2000
Vaccine Vector/Type: vaccinia Strain: SF2 HIV component: Gag, Protease, codon-optimized
• Sequence-modified Rev-independent gag and gag-protease gene constructs lead to increased expression levels and elevated CTL and antibody
immunogenicity in BALB/c and CB6F1 mice
• A CTL response in mice could be detected after a single immunization with codon-optimized gag, using 2 ng of plasmid; wild type gag required 200 ng to
detect a response
• Recognition of 3 different Gag peptide pools was observed, indicating a polyclonal CTL response
• Significant gag-specific CTL responses were detected in 4/4 rhesus monkeys, in contrast to 1/4 using wildtype gag
Gag p24 Vaccine murine (H-2d) Halim2000
Vaccine Vector/Type: coxsackievirus HIV component: partial p24, polyepitope
• An avirulent recombinant coxsackievirus (CB4-P) construct was generated that can express p24 Gag sequences – CB4-P is attenuated even in
immunodeficient mice and T help responses can be elicited from peptides embedded in a surface loop of the VP1 capsid
• This paper describes the vaccine strategy and generation of constructs, and employs amino-terminal fusion of Gag sequences to the viral polyprotein with
subsequent cleavage to elicit CTL responses via MHC class I presentation in BALB/c mice
Gag Gag Vaccine murine (H-2d) Huang2001
Vaccine Vector/Type: DNA Strain: gag HxB2, pol NL43 HIV component: Gag, Pol
• Mice were immunized with four humanized DNA constructs: GagPol, that would form a pseudoparticle carrying Gag and Pol, Gag, Pol or a GagPol fusion
construct
• The GagPol pseudoparticle, Gag and GagPol fusion construct all elicited strong anti-Gag CTL, but only the GagPol fusion construct elicited strong anti-Pol
CTL
Gag Gag (HXB) Vaccine murine (H-2d , H-2b) Mata2001
Vaccine Vector/Type: Listeria monocytogenes Strain: HXB2 HIV component: Gag
• BALB/c and C57BL/6 mice were immunized with recombinant Listeria monocytogenes (Lm-Gag) expressing HIV-1 HXB2 Gag and mice were challenged
with vaccinia expressing Gag
• L. monocytogenes is a gram-positive bacteria that enters the macrophage on phocytosis and lives in the cytoplasm – secreted L. monocytogenes antigens
are processed and presented by both class I and class II pathways
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• CD4+ Th1 T-cells mediated the Gag specific immunological protection in mice immunized with Lm-Gag and challenged with vaccinia-Gag
• Gag-specific CTL may enhance viral clearance via IFN-gamma secretion, but are not essential for immunity;,
Gag Gag Vaccine murine (H-2d , H-2b) Mata2000
Vaccine Vector/Type: Listeria monocytogenes Strain: HXB2 HIV component: Gag
• BALB/c and C57BL/6 mice were immunized with recombinant Listeria monocytogenes (Lm-Gag) expressing HIV-1 HXB2 Gag and mice were challenged
with vaccinia expressing Gag
• L. monocytogenes is a gram-positive bacteria that enters the macrophage on phagocytosis and lives in the cytoplasm – secreted L. monocytogenes antigens
are processed and presented by both class I and class II pathways
• This article is a review of L. monocytogenes biology and its potential as a vaccine vector for HIV, comparing to other vector systems, and discussing CD4+
Th1 T-cells mediated Gag specific immunological protection in mice and the Gag CTL response
Gag Gag (SF2) Vaccine murine (H-2bxd) Otten2000
Vaccine Vector/Type: DNA, vaccinia Strain: SF2 HIV component: codon-optimized gag and pol
• CB6F1 were primed with gag DNA by im injection and challenged with vaccinia expressing Gag/Pol (rVVgag-pol)
• Gag-specific CTL responses were detected by IFNgamma secretion in the spleen, independent of the route (intraperitoneal, intranasal or intrarectal) of rVV
gag-pol challenge
• The gag DNA vaccine induced CTL responses in 4/4 monkeys 2 weeks post immunization, but antibody responses were detected in only 1/4 monkeys after
3 immunizations
• CTL cross-reactivity against Gag sequences 1-80, 254-323, and 421-496 was observed, suggesting multiple CTL epitope recognition
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Gag/Pol Gag/Pol (ARV-2 SF2) Vaccine Macaca nemestrina Kent2000
Vaccine Vector/Type: fowlpoxvirus Strain: ARV-2,SF2 HIV component: Gag, Pol Adjuvant: IFN-gamma
• Vaccination with FPV Gag/Pol-IFN-gamma increased HIV-1 specific CTL and T cell proliferative responses to Gag/Pol antigens, respectively, in infected
Macaca nemestrina
• HIV-1 viral loads remained low and unchanged following vaccinations
Gag/Pol RT Vaccine murine Kim1997d
Vaccine Vector/Type: DNA HIV component: Gag, Pol, Vif, Env Adjuvant: B7, IL-12
• A Gag/Pol or Env DNA vaccine, when delivered in conjunction with the plasmid encoding the co-stimulatory molecules CD86, gave a dramatic increase in
both the cytotoxic and proliferative responses in mice
• When CD86 was present, CTL response could be detected even without in vitro stimulation
Gag/Pol RT HIV-1 infection human Gamberg1999
• 13/13 subjects with advanced HIV infections showed CD8 T cell proliferation and differentiation of CTL in vitro, and six individuals showed HIV-specific
responses to Gag, Pol, Env or Nef antigens
• Data suggests that the functional and genetic integrity of the CD8 T cell repertoire (TCR V beta gene intrafamily genetic diversity) remains intact through
advanced HIV infection, although HIV-specific CTL activity decreases
Gag/Pol Vaccine murine Muthumani2002
Vaccine Vector/Type: adenovirus HIV component: Vpr, Nef, Gag/Pol
• Vpr can cause cells to go into G2 arrest, and it surpresses immune cell activation and inflammatory cytokine production, so co-immunization of BALB/c
mice with recombinant adenovirus expressing Vpr and HIV-1 antigens Nef or Gag/Pol was tested to see if Vpr reduced the immune response to the other
HIV antigens.
• Vpr compromised CD8+ T-cell lytic responses and T-helper proliferative responses in mice co-immunized with Vpr and Nef or Gag/Pol.
• In vitro, Vpr reduced T-cell cytokine production of IL-12 and TNFalpha, indicative of Vpr-mediated immune suppression.
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Protease (3–11) RT (71–79 subtype A,
B, D)
ITLWQRPLV human (A*6802) Brander2001
• C. Brander notes this is an A*6802 epitope
Protease (3–11) Pol ITLWQRPLV HIV-1 infection, Vaccine human (A*6802) Hanke2000, Wee2002
Vaccine Vector/Type: DNA prime with vaccinia MVA boost Strain: subtype A HIV component: p17, p24, polyepitope
• The HIV-1 subtype A focused vaccine HIVA contains p24 and p17, in a reversed order relative to the Gag polyprotein to prevent myristylation of p17,
which could direct the protein to the cell membrane and inhibit efficient peptide processing and class I presentation, as well as a polyepitope string of
conserved, often immunodominant epitopes that were selected to have particularly good cross-reactive potential for the A-clade epidemic in Nairobi,
Kenya. A DNA and MVA prime-boost vaccination protocol using the HIVA antigen will be used in a phase III clinical trial in Kenya. This epitope is
included in the polyepitope string [Hanke2000].
• Multiple CD4+ or CD8+ T-cell vaccine-induced responses to peptide pools were detected using intracellular cytokine staining and IFNgamma Elispot
assays after vaccination of 5 macaques. The response to the Mamu A*01 SIV p27 epitope p11C (CTPYDINQM), included in the polyepitope region, was
not immunodominant in the Mamu A*01 vaccinated macaques, possibly because of processing limitations in context of the artificial polyepitope string
[Wee2002].
Protease (3–11) Protease (71–79 LAI) ITLWQRPLV human (A*6802,
A*7401, A19)
Dong1998a
• Predicted on binding motif, no truncations analyzed
• Clade A/B/D consensus, S. Rowland-Jones, pers. comm.
Protease (3–11) RT (71–79 subtype A,
B, D)
ITLWQRPLV human (A*7401) Brander2001
• C. Brander notes this is an A*7401 epitope
Protease (3–11) Pol (59–65) ITLWQRPLV HIV-1 infection human (A28) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
Protease (3–11) RT (71–79 LAI) ITLWQRPLV HIV-1 infection human (A28supertype) Mollet2000
• Epitope name: P2
• A panel of 16 epitopes covering 15 class I alleles was tested in 14 HIV+ patients from an unselected Caucasian population treated with HAART, using
CD8+ cell IFNgamma production to measure responses
• In general, during the first month of treatment viral load decreased and frequencies of HIV-specific CTL tripled and broadened – eight new HIV
specificities that were not previously detectable were newly detected, as were CMV specific CD8+ PBL – but with continued viral suppression,
HIV-specific responses diminished
• Viral rebounds gave different patterns of response: increases or decreases in pre-existing response, new specificities, or no change
Protease (3–11) Pol ITLWQRPLV HIV-1 infection, HIV-1 exposed
seronegative
human (A74) Kaul2001a
• ITLWQRPLV cross-reacts with clades A, B and D
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• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
Protease (11–20) Pol (91–100) VTILIGGQLK HIV-1 infection human (A3 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind 3/5 HLA-A3 supertype alleles (A*0301, A*1101, A*3101, A*3301 and A*6801)
Protease (12–20) Pol (92–100) TIKIGGQLK HIV-1 infection human (A3 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind 3/5 HLA-A3 supertype alleles (A*0301, A*1101, A*3101, A*3301 and A*6801)
Protease (30–38) Pol (subtype B) DTVLEEMNL HIV-1 exposed seronegative human (A*6802) Rowland-Jones1998b
• HIV-specific CTL were found in exposed seronegative prostitutes from Nairobi – these CTL may confer protection
• Seroprevalence in this cohort is 90-95% and their HIV-1 exposure is among the highest in the world
• Most isolated HIV strains are clade A in Nairobi, although clades C and D are also found – B clade epitopes are often cross-reactive, however stronger
responses are frequently observed using A or D clade versions of epitopes
• This epitope is conserved among B and D clade viruses
• The Clade A version of the epitope: DTVLEDINL
• This epitope was recognized by two different exposed and uninfected prostitutes
• This epitope was identified by screening 49 HIV-1 peptides with the predicted A*6802 anchor residue motif x(VT)xxxxxx(VL)
Protease (30–38) Pol (subtype A) DTVLEDINL HIV-1 exposed seronegative human (A*6802) Kaul2000
• 11/16 heavily HIV exposed but persistently seronegative sex-workers in Nairobi had HIV-specific CD8 gamma-IFN responses in the cervix – systemic
CD8+ T cell responses tended to be to the same epitopes but at generally lower levels than cervical CD8+ T cell responses
• Low risk individuals did not have such CD8+ cells
• CD8+ T cell epitopes: DTVLEDINL (3 individuals), SLYNVATL (4 individuals), LSPRTLNAW (3 individuals) and YPLTFGWCF (4 individuals) were
most commonly recognized by the HIV-resistant women
Protease (30–38) RT (85–93 subtype D) DTVLEEWNL human (A*6802) Brander2001
• C. Brander notes this is an A*6802 epitope
Protease (30–38) Pol (subtype A) DTVLEDINL HIV-1 infection human (A*6802) Kaul2001c
• This study examines CTL responses in HIV exposed, persistently seronegative individuals, HEPS, who eventually seroconverted – 11/114 HEPS Nairobi
sex workers eventually seroconverted, and for six of these HIV CTL reactive epitopes had been defined while seronegative
• DTVLEDINL was recognized in 3 of the 6 women (ML857, ML1203, and ML1707), and the response was present in the last available sample prior to
seroconversion, 3-7 months
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• In each of the three women, 20/20 sequences of the infecting strain had no substitutions in this epitope, all were DTVLEDINL, so there was no evidence for
escape
• The epidemiological factor associated with seroconversion was stopping sex work and HIV-specific CTL activity declines when HEPS sex workers stop
working for a period or retire
• This epitope was recognized in 3/22 HEPS sex worker controls, ML851, ML1432, and ML1601
Protease (30–38) Pol (85–93) DTVLEDINL HIV-1 infection, HIV-1 exposed
seronegative
human (A*6802) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with
reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected
women
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure
• Among HLA-A*6802 women, 11/12 HEPS and 6/11 HIV-1 infected women recognized this epitope likelihood ratio 4.4, p value 0.08, and HEPS women
tended to respond to DTVLEDINL, infected women tended to ETAYFYILKL
• The dominant response to this HLA allele was to this epitope in 10 of the 11/12 HEPS cases, but in only 4 of the 6/11 HIV-1 infected women
• Differences in epitope specificity were only seen for responses restricted by class I HLA alleles A2, A24, A*6802, B14, and B18, previously shown to be
associated with resistance to HIV-1 in this cohort
• Four epitopes were considered to be “resistant epitopes”, as they were preferentially reactive in HEPS women and so may confer resistance, and these were
found in three different proteins: A2 ILK(D/E)PVHGV in RT, A*6802 DTVLEDINL in Protease, B14 DLN(M/T)LN(I/V)V in p24 and B18
FRDYVDRF(Y/F)K also in p24
• Subject ML 857 shifted from a A*6802 DTVLEDINL and B35 (H/N)PDIVIYQY response prior to seroconversion to a B35 PPIPVGDIY and B35
VPLRPMTY response post-seroconversion, and the loss of the pre-seroconversion response was not due to sequence variation within these epitopes
• Subject ML 1203 started with CTL responses to A*6802 DTVLEDINL and B7 FPVTPQVPLR prior to seroconversion, and upon seroconversion acquired
additional responses to A*6802 ETAYFILKL which became dominant, B7 TPGPGV/IRYPL, B7 IPRRIRQGL, and B7 SPRTLNAWV
• Subject ML 1707 started with a CTL response to A*6802 DTVLEDINL prior to seroconversion, and switched to A*6802 ETAYFILKL and A24
RDYVDRFFKTL post-seroconversion, and the loss of the pre-seroconversion response was not due to sequence variation within the epitope
• Subject ML 1830 made no detectable response prior to seroconversion, but responded to A*6802 DTVLEDINL and A*6802 ETAYFILKL
post-seroconversion
Protease (30–38) Pol DTVLEDINL HIV-1 infection human (A*6802) Kaul2002
• Neisseria gonorrhea cervititis in 9 HIV+ Kenyan sex workers caused a functional deficiency in IFN-gamma production in HIV-1 epitope-specific CD8+
T-cells, detected by intracellular cytokine production and tetramer assays, while not affecting the total number of epitope-specific CTLs.
• Ghonorrhea caused the weaker HIV-1 specific CTL responses in 4 HIV-1 exposed persistently seronegative (HEPS) women to become undetectable by
Elispot and tetramer assays, and CMV-specific CTL in 2 HEPS subjects were shown to have impaired function with regard to IFN-gamma production.
Protease (45–54) Pol (125–134) KMIGGIGGFI HIV-1 infection human (A2 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
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• This epitope can bind three of the five HLA-A2 supertypes alleles (A*0201, A*020 2, A*0203, A*0206 and A*6802)
Protease (75–84) Protease (75–84 MN) VLVGPTPVNI in vitro stimulation human (A*0201) Konya1997
• Peptide predicted to be reactive based on HLA-A*0201 binding motif
• Peptide could stimulate CTL in PBMC from 5/6 seronegative donors
• Peptide located in a highly conserved region of protease
• Both 9-mer and 10-mer could stimulate CTL: VLVGPTPVNI and LVGPTPVNI
• Binding affinity to A*0201 was measured,C_1/2maxµM = 6 for 10-mer, 3 for 9-mer
• MAL variant of Pr(75-84 MN), with substitutions V77, G78, and P79, gave reduced binding and CTL recognition
Protease (76–84) Pol (163–) LVGPTPVNI HIV-1 infection human (A*0201) Altfeld2001c
• Epitope name: Pol-163
• HIV was scanned for all peptides which carried the A2-supermotif pattern conserved in more than 50% of B clade sequences – 233 peptides met this
criteria, and 30 of these bound to HLA-A*0201 – 20/30 bound to at least 3/5 of HLA-A2 supertype alleles tested
• Three additional previously described HLA-A2 epitopes were added to the set of 20, and 18/22 chronically infected HLA-A2 individuals had CTL that
recognized at least one of the 23 peptides (median of 2 and maximum of 6), while 6/12 acute infected individuals recognized at least 1 (median of 1 and
maximum of 2)
• LVGPTPVNI binds to 4/5 HLA-A2 supertype alleles: A*0201, A*0202, A*0206 (highest affinity) and A*6802, but not A*0203
• 1/22 individuals with chronic HIV-1 infection recognized this epitope by ELISPOT
• 0/12 acutely infected individuals recognized this epitope
Protease (76–84) Pol (156–164) LVGPTPVNI HIV-1 infection human (A2 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind three of the five HLA-A2 supertypes alleles (A*0201, A*020 2, A*0203, A*0206 and A*6802)
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Protease-RT (95–5) Gag (175–184) CTLNFPISPI HIV-1 infection human (A2 supertype) Propato2001
• The epitope starts in Protease and ends in RT
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind all five HLA-A2 supertypes alleles (A*0201, A*0202, A*0203, A*0206 and A*6802)
Protease-RT (96–5) Pol (176–184) TLNFPISPI HIV-1 infection human (A2 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind three of the five HLA-A2 supertypes alleles (A*0201, A*020 2, A*0203, A*0206 and A*6802)
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RT (3–12) RT (LAI) SPIETVPVKL HIV-1 infection human (A2, B61) vanderBurg1997
• Recognized by CTL from a long-term survivor, EILKEPVGHGV was also recognized
• Highly conserved across clades
RT (3–12) Pol SPIETVPVKL human (B7) De Groot2001
• The program Epimatrix was used in conjunction with the program Conservatrix to identify conservered regions of HIV that might serve as epitopes
• A subset of the potential epitopes was identified that could bind to the appropriate HLA-allele, and 15 predicted B7 superfamily (HLA B7, B8, and B58)
epitopes could stimulate IFNγ production in an ELISPOT assay
• SPIETVPVKL was newly identified as HLA-B7 epitope in this study, it had been previously shown to be presented by HLA-A2 and B61
RT (5–29) RT (160–184 HXB2) IETVPVKLKPGMDGPKVKQ-
WPLTEE
HIV-1 infection human (B8) Walker1989
• One of five epitopes defined for RT-specific CTL clones in this study
RT (18–26) RT (185–193 LAI) GPKVKQWPL human (B*0801) Brander2001
• C. Brander notes this is a B*0801 epitope
RT (18–26) RT (18–26) GPKVKQWPL HIV-1 infection human (B8) Meier1995,
Menendez-Arias1998
• HIV proteins with mutations in this epitope allowed transactive inhibition of specific CTL-mediated lysis
• Article reviewed in [Menendez-Arias1998], with a discussion of antagonism
RT (18–26) RT (173–181) GPKVKQWPL human (B8) Goulder1997g,
Menendez-Arias1998
• Included in a study of the B8 binding motif
• Article reviewed in [Menendez-Arias1998], with a discussion of antagonism
RT (18–26) RT (185–193 LAI) GPKVKQWPL human (B8) Sutton1993
• Predicted epitope based on B8-binding motifs, from larger peptide IETVPVKLKPGMDGPKVKQWPLTEE
RT (18–26) RT (185–193 LAI) GPKVKQWPL HIV-1 infection human (B8) Klenerman1995,
Menendez-Arias1998
• Naturally occurring antagonist GPRVKQWPL found in viral PBMC DNA and RNA
• Article reviewed in [Menendez-Arias1998] with a discussion of antagonism
RT (18–26) RT (18–26) GPKVKQWPL in vitro stimulation human (B8) Zarling1999
• This study compares the ability of macrophages and dendritic cells to stimulate primary responses in CD8+ lymphocytes isolated from HLA-appropriate
HIV-uninfected donors using peptide-pulsed APC – the dendritic cells performed better as APC for the stimulation of primary responses
• Strong CTL responses were elicited by the epitopes DRFYKTLRA and GEIYKRWII when presented by either immature or mature dendritic cells –
macrophages were not able to prime a CTL response against DRFYKTLRA
• A weak response to KLTPLCVSL was stimulated using macrophages as the APC
• No detectable response was observed for the following previously-defined HIV epitopes: KIRLRPGGK, ILKEPVHGV, IRLRPGGK, GPKVKQWPL
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RT (18–26) RT (185–193) GPKVKQWPL HIV-1 infection human (B8) Oxenius2000
• Epitope name: GPK
• Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific
CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load – three patients that had delayed initiation of
HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became
undetectable
• Two of the 7/8 study subjects that were HLA B8+ recognized this epitope
• Patient SC2 (HLA A1, B7/8, Cw0701/0702, DR4/53, DQ7) had CTL responsiveness against epitopes FLKEKGGL, GPKVKQWPL, and GEIYKRWII
peptides – FLKEKGGL tetramer staining steadily declined and at day 1340 the FLKEKGGL stained cells were no longer detected and the escape mutant
FLKENGGI was found in 8/10 clones
• Patient SC11(HLA A1, B8, Cw0201, DR3/11, DR52, DQ2/7) started therapy early, remained on therapy for 40 days, then reinitiated HAART at day 640
had a CTL response to FLKEKGGL, GPKVKQWPL, and GEIYKRWII throughout and received a benefit from the early limited course therapy
RT (18–26) Pol GPKVKQWPL HIV-1 infection human (B8) Seth2001
• CTL responses were studied by tetramer staining in 41 patients with combination therapy – activated CD8+ T-cells decline as the viral load drops in
response to therapy, but the overall level of antigen-specific cells capable of differentiating into effectors stays constant and new epitopes may be recognized
RT (18–26) RT (185–193 SF2) GPKVKQWPL HIV-1 infection human (B8) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B8+ individuals that had a CTL response to this epitope broken down by group: 0/3 group 1, 0/3 group 2, and 2/2 group 3
RT (18–26) Pol (171–180) GPKVKQWPL HIV-1 infection, HIV-1 exposed
seronegative
human (B8) Kaul2001a
• GPKVKQWPL is cross-reactive for clades A, B, C, and D
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
RT (18–26) RT (18–26) GPKVKQWPL HIV-1 infection human (B8) Day2001
• B8-restricted CTL accounted for about 1/3 of the total CTL response in one individual
RT (18–26) RT GPKVKQWPL HIV-1 infection human (B8) Oxenius2002b
• Epitope name: GPK
• Using previously defined epitopes [Oxenius2000, Oxenius2001a] in an IFNgamma Elispot assay, 13 chronically HIV-1 infected patients were studied over a
period including therapy with standard treatment interruptions (STI).
• STIs induced increased recognition of CTL epitopes, but there was no correlation between CTL responses with viral rebound rates, plateau viral loads, or
clearance rates.
RT (18–27) Pol GPKVKQWPLT human (B7, B8) De Groot2001
• The program Epimatrix was used in conjunction with the program Conservatrix to identify conservered regions of HIV that might serve as epitopes
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• A subset of the potential epitopes was identified that could bind to the appropriate HLA-allele, and 15 predicted B7 superfamily (HLA B7, B8, and B58)
epitopes were identified that could stimulate IFNγ production in an ELISPOT assay
• GPKVKQWPLT was confirmed as a previously identified HLA-B8 epitope, and newly identified as an HLA-B7 epitope in this study
RT (33–41) RT (33–41 LAI) ALVEICTEM HIV-1 infection human (A*0201) Brander2001
• C. Brander notes this is an A*0201 epitope
RT (33–41) RT (33–41 LAI) ALVEICTEL HIV-1 infection human (A*0201) Samri2000
• This epitope contains the mutation M41L, a mutation induced by nucleosidee reverse transcriptase inhibitors
• Patient 201#5, (A*0201), was found by ELISPOT to recognize the mutated peptide after zidovudine treatment, but not the wild-type peptide – the mutation
M41L gave an increased A2 binding score (http://bimas.dcrt.nih.gov/molbio/hla_bind) compared to the wildtype RT sequence
• Three additional A*0201 individuals and one B27 individual did not respond to this epitope before or after treatment
• M41L occurred at anchor positions p2 and p9 in several computer predicted RT epitopes (33-41, 32-41, and 40-49)
(http//bimas.dcrt.nih.gov/molbio/hla_bind), and increased the predicted binding affinity for 6 HLA molecules (B2705, B5102, C3, A0201, B2705 and
B3901)
RT (33–41) RT (33–41) ALVEICTEM HIV-1 infection human (A2) Haas1998
• Of 98 patients in cross-sectional analysis, 78% had CTL against pol – RT was more immunogenic than Integrase and Protease (81%, 51%, and 24% of 37
patients, respectively)
• New clusters of epitopes were defined utilizing different HLA molecules
RT (33–41) RT (33–41) ALVEICTEM HIV-1 infection human (A2) Day2001
• The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7 was
studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
• 2 to 17 epitopes were recognized in a given individual, A2-restricted CTL response tended to be narrow and never dominated the response, and 25/27
epitopes were targeted by at least one person
• SLYNTVATL was the dominant A2 epitope recognized in patients with chronic infection, except for Subject 11841 who recognized 5/8 epitopes and who
had a dominant A-2 response to ALVEICTEM
RT (33–43) RT (33–43) ALVEICTEMEK HIV-1 infection human (A*0301) Haas1998
• Of 98 patients in cross-sectional analysis, 78% had CTL against pol – RT was more immunogenic than Integrase and Protease (81%, 51%, and 24% of 37
patients, respectively)
• New clusters of epitopes were defined utilizing different HLA molecules
• C. Brander notes that this is an A*0301 epitope in the 1999 database, G. Haas pers. comm.
RT (33–43) RT (33–43) ALVEICTEMEK HIV-1 infection human (A*0301) Brander2001
• C. Brander notes this is an A*0301 epitope
RT (33–43) RT (33–43) ALVEICTEMEK HIV-1 infection human (A3) Day2001
• The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7 was
studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
• 2 to 17 epitopes were recognized in a given individual, A2-restricted CTL response tended to be narrow and never dominated the response, and 25/27
epitopes were targeted by at least one person
• All patients recognized at least 1 A3 epitope, up to 8 A3 epitopes, but none was clearly dominant
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RT (38–52) RT (203–209) CTEMEKEGKISKIGP Vaccine murine (H-2d) Burnett2000
Vaccine Vector/Type: Salmonella HIV component: RT epitope
• A live attenuated bacterial vaccine, Salmonella SL3261-pHART, with an inserted HIV epitope in the Lpp-OmpA-HIV fusion protein, induced a specific
CTL response in BALB/c mice (<15% lysis assayed by Cr-release of target cells)
RT (38–52) RT (205–219 BRU) CTEMEKEGKISKIGP Vaccine murine (H2k) De Groot1991,
Menendez-Arias1998
Vaccine Vector/Type: recombinant protein Strain: BRU HIV component: RT
• Murine and human helper and CTL epitope.
• Epitope noted in a review by [Menendez-Arias1998] to be located in the "fingers" domain of RT and is a helper and CTL epitope.
RT (38–52) RT (205–219) CTEMEKEGKISKIGP HIV-1 infection human (broad) Hosmalin1990,
Menendez-Arias1998
• Murine and human helper and CTL epitope.
• Epitope noted in a review by [Menendez-Arias1998] to be located in the "fingers" domain of RT and is a helper and CTL epitope.
RT (39–47) RT (206–214) TEMEAEGKI in vitro stimulation C3H/HeJ mice Leggatt1997
• Ala-substituted nonamer-peptide used to test a non-radioactive assay for murine CTL recognition of peptide-MHC class I complexes
• The new assay is CTL adherence assay (CAA), and is based on the discovery that CTL develop adhesive properties upon TCR triggering
• Substitutions in TEMEAEGKI that reduce cytolytic activity were correctly detected by CAA
RT (39–47) RT TEMEKEGKI murine (H-2Kk) Leggatt1998
• Epitope variants were examined for CTL response in concert with H-2Kk MHC class I binding – all of the following combinations were observed: (i) two
single mutations which did not alone abrogated CTL activity did abrogate activity when combined, (ii) loss of recognition of a single substitution could be
restored by an additional substitution, and (iii) sometimes there was recognition of two single substitutions as well as the combination of those substitutions
• 2E and 9I are anchor residues for H-2Kk – if you have M in the third position, it enhances H-2Kk binding 10-fold, but polymorphism at this site is important
for the overall conformation of the peptide and can influence T cell recognition
RT (42–50) RT (42–50 LAI) EKEGKISKI HIV-1 infection human (B*5101) Brander2001
• C. Brander notes this is a B*5101 epitope
RT (42–50) RT (42–50 LAI) EKEGKISKI HIV-1 infection human (B51) Haas1998
• Of 98 patients in cross-sectional analysis, 78% had CTL against pol – RT was more immunogenic than Integrase and Protease (81%, 51%, and 24% of 37
patients, respectively)
• New clusters of epitopes were defined utilizing different HLA molecules
RT (57–65) Pol (236–244) NTPVFAIKK HIV-1 infection human (A3 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind 3/5 HLA-A3 supertype alleles (A*0301, A*1101, A*3101, A*3301 and A*6801)
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RT (73–82) RT (73–82 LAI) KLVDFRELNK HIV-1 infection human (A3) Samri2000
• This epitope contains the mutation L74V, a frequent mutation induced by nucleoside reverse transcriptase inhibitors
• The wild-type, but not the mutated peptide, was recognized before and after zidovudine treatment in A3-restricted patients 252#0 and 252#4
• Mutation L74V affects the p2 anchor position in RT epitopes and was predicted to reduce binding to A3 (http://bimas.dcrt.nih.gov/molbio/hla_bind)
RT (73–82) RT (228–237) KLVDFRELNK HIV-1 infection human (A3) Yu2002a
• Epitope name: A3-KK10
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
• 0/14 HLA-A3 positive individuals had detectable A3-restricted responses to this epitope during acute infection, but only 5/15 of HLA-A3 epitopes tested
were targeted during acute infection. 3/7 individuals began to have detectable responses to this epitope after STI.
RT (93–101) (LAI) GIPHPAGLK (A3) Altfeld2000a, Brander2001
RT (93–101) RT (248–257) GIPHPAGLK HIV-1 infection human (A3) Yu2002a
• Epitope name: A3-GK9
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
• 0/14 HLA-A3 positive individuals had detectable A3-restricted responses to this epitope during acute infection, but only 5/15 of HLA-A3 epitopes tested
were targeted during acute infection. 1/7 individuals began to have detectable responses to this epitope after STI.
RT (93–102) Pol (240–249 93TH253
subtype CRF01)
GIPHPAGLKK HIV-1 exposed seronegative human (A11) Sriwanthana2001
• Epitope name: P248-257
• This was a study of HIV-1 exposed persistently seronegative (HEPS) female sex workers in Chiang Mai, northern Thailand
• HLA-A11 is very common in this population, and was enriched among the HEPS sexworkers – weak CTL responses were detected in 4/7 HEPS women,
and CTL responses were found in 8/8 HIV+ controls, and 0/9 HIV- women that were not exposed
• This epitope was weakly reactive in the HEPS study subject 265 who was HLA A2/A11 and after a second stimulation in vitro gave a strong response in
HEPS study subject 128 who was HLA A11/A33
RT (93–102) Pol (240–249 93TH253
subtype CRF01)
GIPHPAGLKK HIV-1 infection human (A11) Bond2001
• HLA-A11 CRF01 (called subtype E in Bond et al.) epitopes were identified that stimulated CTL from HIV+ female sex workers (FSW) from Northern
Thailand, of whom more than half were HLA-A11 positive
• 77 possible HLA-A11 epitopes were first defined using EpiMatrix, these were screened for binding to A11 finding and 26 bound, and 12 of these were
epitopes for CTL responses from 8 HLA-A11 positive FSWs, six were novel, six were previously identified
• This is one of the new A11 epitopes identified through the streamlined EpiMatrix method, and 2/8 tested FSWs recognized it
• This epitope was highly conserved in other subtypes, and exact matches were common
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RT (98–113) Pol (254–264 BH10,
LAI)
AGLKKKKSVTVLDVGD HIV-1 infection human Maksiutov2002
• This study employs an antigenic similarity matrix to compare HIV-1 antigenic determinants with human proteins.
• This CTL epitope (the HIV-1 LAI fragment with high similarity to a human protein overlapping this epitope is GLKKKKSVTVL) has similarity with the
CD166 antigen (activated leukocyte-cell adhesion molecule), fragment GLKKRESLTLI.
RT (98–113) RT (252–266) AGLKKKKSVTVLDVGD HIV-1 infection human (Cw4) Bernard1998
• This study focuses on six rare long-term survivor HIV-infected people who were infected for many years without exhibiting immune dysregulation – such
immunologically normal HIV-infected (INHI) cases occur at a frequency between 0.1 and 1% in the infected population
• No direct CTL were found in any of the six INHIs, but above background CTLp activity was founded in 3/6 INHIs
RT (103–117) RT (257–251) KKSVTVLDVGDAYFS HIV-1 infection human (Cw4) Bernard1998
• This study focuses on six rare long-term survivor HIV-infected people who were infected for many years without exhibiting immune
• No direct CTL were found in any of the six INHIs, but above background CTLp activity was founded in 3/6 INHIs
RT (107–115) RT (262–270 IIIB) TVLDVGDAY (B*3501) Brander2001
• C. Brander notes this is a B*3501 epitope
RT (107–115) RT (262–270 IIIB) TVLDVGDAY HIV-1 infection human (B35) Menendez-Arias1998,
Wilson1996
• Epitope defined in the context of the Pediatric AIDS Foundation ARIEL Project, a mother-infant HIV transmission study
• TVLDMGDAC is a naturally occurring variant that is less reactive
• [Menendez-Arias1998], in a review, notes that this epitope includes a catalytic residue (Asp-110) in the active site of RT
RT (107–115) Pol (262–270 IIIB) TVLDVGDAY HIV-1 infection human (B35) Wilson1999a
• This study describes maternal CTL responses in the context of mother-to-infant transmission
• Detection of CTL escape mutants in the mother was associated with transmission, but the CTL-susceptible forms of the virus tended to be found in infected
infants
• An additional variant that gave a positive CTL response: TVLDMGDAC
RT (107–115) Pol (262–270) TVLDVGDAY HIV-1 infection human (B35) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
RT (107–115) RT (262–270 SF2) TVLDVGDAY HIV-1 infection human (B35) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B35+ individuals that had a CTL response to this epitope broken down by group: 1/2 group 1, 0/2 group 2, and 0/1 group 3
RT (107–115) TVLDVGDAY HIV-1 infection human (B35) Sabbaj2002b
• Epitope name: Pol-TY9
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• Among HIV+ individuals who carried HLA B35, 8/21 (38%) recognized this epitope
RT (107–115) Pol TVLDVGDAY HIV-1 infection human (B35) Sabbaj2002a
• IFNgamma T-cell responses in breast milk of 5 HIV-1 infected women from the US and 6 from Zambia were tested with using Elispot. 11/11 women
responded to Gag, 8/11 responded to Pol, 7/11 women to Nef, and 2/5 women to Env peptide pools. These responses were shown to be primarily due to
CD8+ T-cells in one woman, and another woman had cytolytic responses measured by Cr-release.
• T-cells in breast milk from a volunteer who was HLA A3, A11, B35, B51 induced IFNgamma after stimulation with either of two overlapping peptides that
carry known B35 epitope TVLDVGDAY.
• The frequencies of responses in the two compartments differed, and 2/4 women that responded to epitopes in Nef 101-205 and Pol 601-710 showed
responses in breast milk but no detectable responses in peripheral blood cells.
RT (108–118) RT (267–277) VLDVGDAYFSV in vitro stimulation human (A*0201) vanderBurg1996
• High dissociation rate, but immunogenic in primary CTL induction after repeated stimulations with peptide
• CTL generated by in vitro stimulation of PBMC derived from uninfected individual
RT (108–118) RT (267–277) VLDVGDAYFSV HIV-1 infection human (A2) Kundu1998b
• Allogeneic dendritic cells (DCs) were obtained from HLA-identical siblings, pulsed with rgp160 MN or A2-restricted HIV-1 epitope peptides, and infused
monthly into six HIV-infected patients
• 1/6 showed increased env-specific CTL and increased lymphoproliferative responses, 2/6 showed increase only in proliferative responses, and 3/6 showed
no change – pulsed DCs were well tolerated
• VLDVGDAYFSV is a conserved HLA-A2 epitope included in this study – 4/6 patients had this sequence as their HIV direct sequence, but only one of
these had a detectable CTL response – the other two had the sequences EEDVGDAYFSV and ELDVGDAYFSV and no detectable CTL response
RT (108–118) RT (267–277) VLDVGDAYFSV in vitro stimulation human (A2) vanderBurg1995
• Binds HLA-A*0201 – CTL generated by in vitro stimulation of PBMC from an HIV negative donor
• VLDVGDAYFSV is in a functional domain
RT (108–118) Pol (263–273) VLDVGDAYFSV HIV-1 infection human (A2, A*0201) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
RT (108–122) RT (257–251) VLDVGDAYFSVPLDE HIV-1 infection human (Cw4) Bernard1998
• This study focuses on six rare long-term survivor HIV-infected people who were infected for many years without exhibiting immune dysregulation – such
immunologically normal HIV-infected (INHI) cases occur at a frequency between 0.1 and 1% in the infected population
• No direct CTL were found in any of the six INHIs, but above background CTLp activity was founded in 3/6 INHIs
RT (113–120) Pol (268–275 SF2) DAYFSVPL HIV-1 infection human (B*5101, B24) Tomiyama1999
• HLA-B27, -B51, and -B57 are associated with slow progression to AIDS, while HLA -B35, -B8, -B24 are associated with a rapid progression to AIDS
(Nat. Med. 2:405, 1996;Lancet 22:1187, 1986;Hum Immunol 22:73, 1988;Hum Immunol 44:156, 1995)
• 15% of Japanese populations carry HLA-B51 while HLA-B27 and -B57 are detected in less than 0.3%
• Of the 172 HIV-1 peptides with HLA-B*5101 anchor residues, 33 bound to HLA-B*5101, seven of these peptides were reactive with CTL from 3 B*5101
positive individuals, and six were properly processed
• Four of the six epitopes were highly conserved among B subtype sequences, DAYFSVPL is conserved
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RT (116–135) Pol (271–290) FSVPLDEDFRKYTAFTIPSI HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
• This peptide was among the 28 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
RT (117–126) Pol (264–273 93TH253
subtype CRF01)
SVPLDESFRK HIV-1 exposed seronegative human (A11) Sriwanthana2001
• Epitope name: P272-281
• This was a study of HIV-1 exposed persistently seronegative (HEPS) female sex workers in Chiang Mai, northern Thailand
• HLA-A11 is very common in this population, and was enriched among the HEPS sexworkers – weak CTL responses were detected in 4/7 HEPS women,
and CTL responses were found in 8/8 HIV+ controls, and 0/9 HIV- women that were not exposed
• This epitope after a second stimulation in vitro gave a strong response in HEPS study subject 128 who was HLA A11/A33
RT (117–126) Pol (264–273 93TH253
subtype CRF01)
SVPLDESFRK HIV-1 infection human (A11) Bond2001
• HLA-A11 CRF01 (called subtype E in Bond et al.) epitopes were identified that stimulated CTL from HIV+ female sex workers (FSW) from Northern
Thailand, of whom more than half were HLA-A11 positive
• 77 possible HLA-A11 epitopes were first defined using EpiMatrix, these were screened for binding to A11 finding and 26 bound, and 12 of these were
epitopes for CTL responses from 8 HLA-A11 positive FSWs, six were novel, six were previously identified
• This is one of the new A11 epitopes identified through the streamlined EpiMatrix method, and 3/8 tested FSWs recognized it
• This epitope was only conserved in CRF01, and subtype A and B, and exact matches were uncommon
RT (118–127) RT (273–282 SF2) VPLDKDFRKY HIV-1 infection human (B*3501) Menendez-Arias1998,
Tomiyama1997
• A CTL clone responsive to this epitope was obtained
• 4/7 B35-positive individuals had a CTL response to this epitope
• A K to E substitution at position 5 abrogates specific lysis, and reduces binding to B*3501
• [Menendez-Arias1998], in a review, notes that a Glu to Lys (E to K) change abrogates CTL activity, but that both VPLDEDFRKY and VPLDKDFRKY can
serve as HLA-B35 epitopes, so the change must alter T cell receptor binding – residues in this epitope may be important for polymerase activity
RT (118–127) RT (273–282 IIIB) VPLDEDFRKY HIV-1 infection human (B*3501) Brander2001
• C. Brander notes this is a B*3501 epitope
RT (118–127) Pol (273–282) VPLDKDFRKY HIV-1 infection human (B*3501) Tomiyama2000a
• CD8+ T-cells that bound one of six HIV-specific B*3501-epitope tetramers did not express CD28 or CD45A
• A significant increase in CD28-CD45RA- cells and a decrease of CD28+CD45RA+ cells was observed in chronically HIV-1-infected individuals relative to
healthy individuals
• CD28-CD45RA- cells are likely to be effector cells and have high levels of perforin in their cytoplasm
• The mean percentage of total CD28- CD8+ cells in chronically infected HIV-1-infected patients was 76.6% in comparison to HIV-1-uninfected individuals
(40.6%)
RT (118–127) (SF2) VPLDEDFRKY HIV-1 infection human (B*3501) Tomiyama2000b
• Epitope name: HIV-B3501-SF2-4
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• B*3501 VPLDEDFRKY tetramer binding did not inhibit CTL activity of a clone that react with both HLA-B*3501 than HLA-B*5101 presentation of the
epitope IPLTEEAEL
RT (118–127) RT (273–282 IIIB) VPLDEDFRKY HIV-1 infection human (B*3501, B35) Shiga1996
• Binds HLA-B*3501
RT (118–127) (SF2) VPLDKDFRKY HIV-1 infection human (B35) Kawana1999
• HLA B35 is associated with rapid disease progression
• The sequences of 9 previously described HIV-1 B35 CTL epitopes were obtained in 10 HLA B35+ and 19 HLA B35- individuals
• 3/9 CTL epitopes had substitutions that were more common in B35+ individuals than in B35- individuals – only one of these reduced the binding of the
peptide to B35 and was shown to be an escape mutation
• —–E—- was found in 8/10 of the B35+ individuals, and three of the B35- individuals – the D –> E substituted peptide had similar binding affinity to B35
and was equally susceptible to a CTL clone
RT (118–127) RT (273–282 IIIB) VPLDEDFRKY HIV-1 infection human (B35) Sipsas1997
• HIV IIIB proteins were used to define the range of CTL epitopes recognized by three lab workers accidentally infected with HIV-1 IIIB
• VPLDKDFRKY, a variant found in HIV MN, was not recognized
• VPHDEDFRKY, a variant found in HIV YU2, was not recognized
• This epitope was type-specific and conserved in only one other B subtype sequence
RT (118–127) RT (273–282 SF2) VPLDEDFRKY HIV-1 infection human (B35) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B35+ individuals that had a CTL response to this epitope broken down by group: 1/2 group 1, 0/2 group 2, and 1/1 group 3
RT (118–127) VPLDEDFRKY HIV-1 infection human (B35) Sabbaj2002b
• Epitope name: Pol-VY10
• Among HIV+ individuals who carried HLA B35, 5/21 (24%) recognized this epitope
RT (126–135) RT (293–302 HXB) KYTAFTIPSI HIV-1 infection human (A2) Shankar1998
• A novel CTL clone was defined with a panel of recombinant vaccinia-RT-infected B-LCL target cells using PBMCs donated by a patient who was
HIV-seropositive for 6 years and had not received any antiretroviral therapy
• There is evidence that some CTL epitopes are poorly presented on the surface of infected cells, but this RT epitope was recognized as effectively on
HIV-infected cells as on peptide-pulsed targets
RT (127–135) Pol (316–) YTAFTIPSI HIV-1 infection human (A2) Altfeld2001c
• Epitope name: Pol-316
• HIV was scanned for all peptides which carried the A2-supermotif pattern conserved in more than 50% of B clade sequences – 233 peptides met this
criteria, and 30 of these bound to HLA-A*0201 – 20/30 bound to at least 3/5 of HLA-A2 supertype alleles tested
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• Three additional previously described HLA-A2 epitopes were added to the set of 20, and 18/22 chronically infected HLA-A2 individuals had CTL that
recognized at least one of the 23 peptides (median of 2 and maximum of 6), while 6/12 acute infected individuals recognized at least 1 (median of 1 and
maximum of 2)
• 2/22 individuals with chronic HIV-1 infection recognized this epitope in ELISPOT
• 0/12 acutely infected individuals recognized this epitope
• YTAFTIPSI binds to five HLA-A2 supertype alleles: A*0201, A*0202,A*0203, A*0206 and A*6802 (highest affinity)
RT (127–135) Pol (306–314) YTAFTIPSI HIV-1 infection human (A2 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind all five HLA-A2 supertypes alleles (A*0201, A*0202, A*0203, A*0206 and A*6802)
RT (128–135) TAFTIPSI HIV-1 infection human (A*0217,
B*5101)
Sabbaj2002b
• Epitope name: Pol-TI8
• This study monitored epitope responses in HIV-1 infected minority women living in the United States
• 24 epitopes were described – 8 were novel, 8 used new restricting elements but were previously defined epitopes, and 8 were previously described
• Serial peptide truncations were used to define optimal epitopes for CTL cell lines isolated from 12 individuals, assayed by a Cr-release
• Patient 01RCH46 was Hispanic, on HAART, and had a viral load of 21000 and CD4 count of 623 – she also recognized GELDRWEKI, p17(11-19), HLA
B*4002, and KETINEEAA p24(70-78), HLA B*4002
• Among HIV+ individuals who carried HLA A*02, 7/36 (19%) recognized this epitope, two of which also carried B*5101 which can also restrict this
epitope
RT (128–135) RT (295–302 IIIB) TAFTIPSI HIV-1 infection human (B*5101) Brander2001
• C. Brander notes this is a B*5101 epitope
RT (128–135) Pol (283–290 SF2) TAFTIPSI HIV-1 infection human (B*5101) Tomiyama1999
• HLA-B27, -B51, and -B57 are associated with slow progression to AIDS, while HLA-B35, -B8, -B24 are associated with a rapid progression to AIDS (Nat.
Med. 2:405, 1996;Lancet 22:1187, 1986;Hum Immunol 22:73, 1988;Hum Immunol 44:156, 1995)
• 15% of Japanese populations carry HLA-B51 while HLA-B27 and -B57 are detected in less than 0.3%
• Of the 172 HIV-1 peptides with HLA-B*5101 anchor residues, 33 bound to HLA-B*5101, seven of these peptides were reactive with CTL from 3 B*5101
positive individuals, and six were properly processed
• Four of the six epitopes were highly conserved among B subtype sequences, but TAFTIPSI is somewhat variable
RT (128–135) RT (295–302) TAFTIPSI HIV-1 infection human (B*5101) Samri2000
• Epitope name: P5
• The epitope TAFTIPSI was recognized by patient 246#1 in a study of the effects of therapy escape mutations on CTL recognition
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RT (128–135) RT (128–135 IIIB) TAFTIPSI HIV-1 infection human (B*5101) Moore2002b
• HIV polymorphisms in the RT protein were examined relation to HLA alleles found in a population of 473 participants in the Western Australian HIV
Cohort Study. 64 significant associations between polymorphisms at particular positions and HLA alleles were detected, for HLA-B7, -B12, -B35 and
-B15. Fifteen of these were in positions with known epitopes, 4 in anchor residues, 11 in other positions. Six additional polymorphic sites associated with
particular HLA molecules flanked known epitopes and may relate to processing.
• TAFTIPSI was one of two epitopes characterized in detail. C-terminal I135x substitutions were associated with people who carried HLA-B5 – 39/40 (98%)
of HLA-B*5101 individuals had substitutions in this position, while only 127/431 (29%) who did not have HLA-B*5101 did. The predominant substitution
was kytaftipsT, and this mutation is predicted to abrogate binding to HLA-B*5101.
RT (128–135) RT (295–302 IIIB) TAFTIPSI HIV-1 infection human (B51) Menendez-Arias1998,
Sipsas1997
• HIV IIIB proteins were used to define the range of CTL epitopes recognized by 3 lab workers accidentally infected with HIV-1 IIIB
• TAFTIPST, a variant found in HIV-1 CAM1, was also recognized but 100-fold more peptide was needed
• TAFTIPSV, a variant found in HIV-1 VE1RT, was also recognized, but 10-fold more peptide was needed
• TVFTIPSI, a variant found in HIV-1 MANC, was also recognized
• [Menendez-Arias1998], in a review, notes that this epitope includes a region near the active site of RT – the substitution of the position two conservative
change from A to V decreases CTL recognition
RT (128–135) RT (295–302) TAFTIPSI HIV-1 infection human (B51) Betts2000
• Only 4/11 HLA-A2+ HIV+ individuals had CTL that reacted to SLYNTVATL, calling into question whether it is immunodominant
• 95 optimally-defined peptides from this database were used to screen for INFγ responses to other epitopes
• Three of the four individuals that responded to SLYNTVATL recognized additional HIV epitopes, and all three were also HLA B51 and recognized this
epitope as well as other epitopes
RT (128–135) RT (295–302) TAFTIPSI HIV-1 infection human (B51) Oxenius2000
• Epitope name: TAF
• Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific
CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load – three patients that had delayed initiation of
HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became
undetectable
• None of the 8 study subjects recognized this epitope but none were HLA B51+
RT (128–135) RT (295–302 LAI) TAFTIPSI HIV-1 infection human (B51) Mollet2000
• Epitope name: P5
• A panel of 16 epitopes covering 15 class I alleles was tested in 14 HIV+ patients from an unselected Caucasian population treated with HAART, using
CD8+ cell IFNgamma production to measure responses
• In general, during the first month of treatment viral load decreased and frequencies of HIV-specific CTL tripled and broadened – eight new HIV
specificities that were not previously detectable were newly detected, as were CMV specific CD8+ PBL – but with continued viral suppression,
HIV-specific responses diminished
• Viral rebounds gave different patterns of response: increases or decreases in pre-existing response, new specificities, or no change
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RT (128–135) Pol TAFTIPSI HIV-1 infection human (B51) Sabbaj2002a
• IFNgamma T-cell responses in breast milk of 5 HIV-1 infected women from the US and 6 from Zambia were tested with using Elispot. 11/11 women
responded to Gag, 8/11 responded to Pol, 7/11 women to Nef, and 2/5 women to Env peptide pools. These responses were shown to be primarily due to
CD8+ T-cells in one woman, and another woman had cytolytic responses measured by Cr-release.
• T-cells in breast milk from a volunteer who was HLA A3, A11, B35, B51 induced IFNgamma after stimulation with either of two overlapping peptides that
carry known B51 epitope TAFTIPSI.
• The frequencies of responses in the two compartments differed, and 2/4 women that responded to epitopes in Nef 101-205 and Pol 601-710 showed
responses in breast milk but no detectable responses in peripheral blood cells.
RT (151–159) Pol (306–314 SF2) QGWKGSPAI HIV-1 infection human (B*5101) Tomiyama1999
• HLA-B27, -B51, and -B57 are associated with slow progression to AIDS
• 15% of Japanese populations carry HLA-B51 while HLA-B27 and -B57 are detected in less than 0.3%
• Of the 172 HIV-1 peptides with HLA-B*5101 anchor residues, 33 bound to HLA-B*5101, seven of these peptides were reactive with CTL from 3 B*5101
positive individuals, and six were properly processed
• Four of the six epitopes were highly conserved among B subtype sequences, QGWKGSPAI is conserved
RT (153–165) RT (308–320) WKGSPAIFQSSMT HIV-1 infection human (B7) Brander1995b
• Epitope defined in the context of the Pediatric AIDS Foundation ARIEL Project, a mother-infant HIV transmission study
RT (153–165) Pol (308–320) WKGPAIFQSSMT HIV-1 infection human (B7) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
RT (153–167) RT (SF2) WKGSPAIFQSSMTKI HIV-1 infection human Altfeld2001a
• HIV+ individual AC-06 was tested for reactive overlapping peptides spanning all HIV-1 proteins in an ELISPOT and was found to react with 12 peptides
from 7 proteins, suggesting that the breadth of CTL responses are underestimated if accessory proteins are not included in the study
• RT peptides SQIYPGIKVRQLCKL and WKGSPAIFQSSMTKI were recognized
RT (156–164) RT (311–319 SF2) SPAIFQSSM HIV-1 infection human (B*3501) Menendez-Arias1998,
Tomiyama1997
• A CTL clone responsive to this epitope was obtained
• Only 1/7 B35-positive individuals had a CTL response to this epitope
• [Menendez-Arias1998], in a review, notes that this epitope is near the active site of RT
RT (156–164) RT (311–319 SF2) SPAIFQSSM HIV-1 infection human (B35) Menendez-Arias1998,
Shiga1996
• Binds HLA-B*3501
• [Menendez-Arias1998], in a review, notes that this epitope includes catalytic residues in the active site of RT
RT (156–164) Pol (311–319) SPAIFQSSM HIV-1 infection human (B35) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
RT (156–164) Pol (156–164 HXB2) SPAIFQSSM HIV-1 infection human (B7) Hay1999b
• CTL response to IPRRIRQGL was the immunodominant response in a rapid progressor – there was a subdominant response to SPAIFQSSM in Pol, and
interestingly, no response to commonly immunodominant HLA A*0201 epitope SLYNTVATL, although this individual was HLA A*0201
188
DEC 2002
RT CTL Epitopes HIV CTL Epitope Tables
C
TL
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
• The individual showed a strong initial CTL response at the time of the initial drop in viremia, but it was quickly lost, although memory cells persisted
• Despite the initial narrow response to two epitopes, no other CTL responses developed
• No HIV-specific lymphoproliferative responses were detected in this patient, and neutralizing antibody response was weak
• Variants of this epitopes were observed in vivo (spaifqCsm, spSifqssm), but the binding motifs for B7 were preserved (P2, and C-term aromatic or
hydrophobic)
RT (156–164) Pol SPAIFQSSM HIV-1 infection human (B7) Islam2001
• Subject 053i was followed longitudinally from acute infection through death, and had rapid progression to AIDS
• This individual had a dominant response to IPRRIRQGL with strong in vivo activated responses and in vitro stimulated memory responses and a
subdominant response to SPAIFQSSM – during the course of disease progression (4 Years), the functional CTL responses were lost and no sequence
variation occurred with in both epitopes, but CTL clones specific for IPRRIRQGL persisted throughout
RT (156–164) RT (323–331 SF2) SPAIFQSSM HIV-1 infection human (B7) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B7+ individuals that had a CTL response to this epitope broken down by group: 0/4 group 1, 0/3 group 2, and 1/1 group 3
RT (156–164) RT (156–164) SPAIFQSSM HIV-1 infection human (B7) Yu2002a
• Epitope name: B7-SM9
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
• 1/11 HLA-B7 individuals had detectable B7-restricted responses to this epitope during acute infection – 10/15 of HLA-B7 epitopes tested were targeted by
at least one person during acute infection. 3/4 individuals had detectable responses to this epitope after STI.
RT (156–165) RT (311–319 LAI) SPAIFQSSMT HIV-1 infection human (B35) Samri2000
• Epitope name: P4
• This epitope contains the mutation P157S which can be induced by nucleosidee reverse transcriptase inhibitors
• It was recognized by patient 252#0 in a study of the effects of therapy escape mutations on CTL recognition
RT (156–165) RT (311–319 SF2) SPAIFQSSMT human (B7) Brander1997,
Menendez-Arias1998
• Pers. Comm. from C. Hey and D. Ruhl to C. Brander and B. Walker
• [Menendez-Arias1998], in a review, notes that this epitope includes catalytic residues in the active site of RT
RT (156–165) RT (311–319 SF2) SPAIFQSSMT HIV-1 infection human (B7) Mollet2000
• Epitope name: P4
• A panel of 16 epitopes covering 15 class I alleles was tested in 14 HIV+ patients from an unselected Caucasian population treated with HAART, using
CD8+ cell IFNgamma production to measure responses
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• In general, during the first month of treatment viral load decreased and frequencies of HIV-specific CTL tripled and broadened – eight new HIV
specificities that were not previously detectable were newly detected, as were CMV specific CD8+ PBL – but with continued viral suppression,
HIV-specific responses diminished
• Viral rebounds gave different patterns of response: increases or decreases in pre-existing response, new specificities, or no change
RT (156–165) Pol SPAIFQSSMT human (B7) De Groot2001
• The program Epimatrix was used in conjunction with the program Conservatrix to identify conservered regions of HIV that might serve as epitopes
• A subset of the potential epitopes was identified that could bind to the appropriate HLA-allele, and 15 predicted B7 superfamily (HLA B7, B8, and B58)
epitopes could stimulate IFNγ production in an ELISPOT assay
• SPAIFQSSMT was confirmed as a previously identified HLA-B7 epitope in this study
RT (156–165) RT (IIIB) SPAIFQSSMT HIV-1 infection human (B7) Moore2002b
• HIV polymorphisms in the RT protein were examined relation to HLA alleles found in a population of 473 participants in the Western Australian HIV
Cohort Study. 64 significant associations between polymorphisms at particular positions and HLA alleles were detected, for HLA-B7, -B12, -B35 and
-B15. Fifteen of these were in positions with known epitopes, 4 in anchor residues, 11 in other positions. Six additional polymorphic sites associated with
particular HLA molecules flanked known epitopes and may relate to processing.
• HLA-B7+ individuals with a S162x (18/33) substitution had higher viral loads than those that did not, suggesting escape was associated with diminished
immune control of viremia.
RT (158–166) RT (325–333 LAI) AIFQSSMTK HIV-1 infection human (A*0301) Brander2001
• C. Brander notes this is an A*0301 epitope
RT (158–166) Pol AIFQSSMTK HIV-1 infection, Vaccine human, macaque
(A*0301, A11, A33)
Hanke2000, Wee2002
Vaccine Vector/Type: DNA prime with vaccinia MVA boost Strain: subtype A HIV component: p17, p24, polyepitope
• The HIV-1 subtype A focused vaccine HIVA contains p24 and p17, in a reversed order relative to the Gag polyprotein to prevent myristylation of p17,
which could direct the protein to the cell membrane and inhibit efficient peptide processing and class I presentation, as well as a polyepitope string of
conserved, often immunodominant epitopes that were selected to have particularly good cross-reactive potential for the A-clade epidemic in Nairobi,
Kenya. A DNA and MVA prime-boost vaccination protocol using the HIVA antigen will be used in a phase III clinical trial in Kenya. This epitope is
included in the polyepitope string [Hanke2000].
• Multiple CD4+ or CD8+ T-cell vaccine-induced responses to peptide pools were detected using intracellular cytokine staining and IFNgamma Elispot
assays after vaccination of 5 macaques. The response to the Mamu A*01 SIV p27 epitope p11C (CTPYDINQM), included in the polyepitope region, was
not immunodominant in the Mamu A*01 vaccinated macaques, possibly because of processing limitations in context of the artificial polyepitope string
[Wee2002].
RT (158–166) RT (325–333 LAI) AIFQSSMTK HIV-1 infection human (A*1101) Brander2001
• C. Brander notes this is an A*1101 epitope
RT (158–166) Pol (313–321) AIFQSSMTK HIV-1 infection human (A*1101) Fukada2002
• Counterparts for eight known clade B HLA A*1101 epitopes were generated for clade E (CRF01). Three epitopes, identical among clade A-E, were
cross-reactive and recognized by clade E infected individuals. The clade E and B analogs to three more HLA A*1101 epitopes was recognized in a clade
specific manner. Two other HLA A*1101 clade B defined epitopes were found not to have stimulated a response in clade E infected individuals.
• AIFQSSMTK is commonly found in viruses representing subtypes A-E. It was strongly recognized by CTL from 2/5 B clade infected Japanese subjects,
and 5/6 E clade infected Thai subjects.
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RT (158–166) RT (325–333) AIFQSSMTK HIV-1 infection human (A*1101, A3,
A*0301, A*6801)
Menendez-Arias1998,
Threlkeld1997
• Study of the fine specificity of an A3-like super-type epitope (the A3 super-type includes A*0301, A*1101, A*3101, A*3301, and A*6801)
• A3 super-type is characterized by a hydrophobic or hydroxyl containing anchor residue at position 2, and a positive charge in the C-term position
• While most lines were specific, promiscuous cloned CTL lines were also derived from HIV+ donors that could recognize epitope presented by either A3 or
A11 or A*6801
• Alanine substitutions throughout the epitope and natural variants indicate that the same amino acid positions are critical for presentation by either MHC
molecule, A3 or A11
• AIFQSSMTK is presented by three members of the A3 superfamily: A*0301, A*1101, and A*6801, and the naturally occurring variants A1S and K9R are
recognized with similar efficiency to wild type epitope – AIFQRSMTR can also bind to two additional members of the A3 superfamily, A*3101 and
A*3301
RT (158–166) RT AIFQSSMTK HIV-1 infection human (A11) Wagner1998a
• CTL specific for HIV epitopes were used to show that the mediators of both the cytolytic (granzyme A was used as the marker) and non-cytolytic (HIV-1
inhibitory chemokines MIP-1 α and RANTES were used as markers) anti-viral responses are localized within the CTL’s cytotoxic granules
RT (158–166) RT (325–333 LAI) AIFQSSMTK Peptide-HLA interaction human (A11) Menendez-Arias1998,
Zhang1993
• Exploration of A11 binding motif, based on Nixon et al. 1991
RT (158–166) RT (325–333 LAI) AIFQSSMTK HIV-1 infection human (A11) McMichael1994
• Review of HIV CTL epitopes
RT (158–166) Pol (305–313 93TH253
subtype CRF01)
AIFQSSMTK HIV-1 infection, HIV-1 exposed
seronegative
human (A11) Sriwanthana2001
• Epitope name: P313-321
• This was a study of HIV-1 exposed persistently seronegative (HEPS) female sex workers in Chiang Mai, northern Thailand
• HLA-A11 is very common in this population, and was enriched among the HEPS sexworkers – weak CTL responses were detected in 4/7 HEPS women,
and CTL responses were found in 8/8 HIV+ controls, and 0/9 HIV- women that were not exposed
• This epitope was weakly reactive in the HEPS study subject 128 who was HLA A11/A33
• This epitope was strongly reactive in HIV+ study subjects 053 and 184 who carried HLA-A11
RT (158–166) Pol (305–313 93TH253
subtype CRF01)
AIFQSSMTK HIV-1 infection human (A11) Bond2001
• HLA-A11 CRF01 (called subtype E in Bond et al.) epitopes were identified that stimulated CTL from HIV+ female sex workers (FSW) from Northern
Thailand, of whom more than half were HLA-A11 positive
• 77 possible HLA-A11 epitopes were first defined using EpiMatrix, these were screened for binding to A11 finding and 26 bound, and 12 of these were
epitopes for CTL responses from 8 HLA-A11 positive FSWs, six were novel, six were previously identified
• This epitope was predicted by the EpiMatrix method to be likely to bind to A11, and it served as an epitope in the FSWs, it was one of the six A11 epitopes
that had been previously defined
• 6/8 tested FSWs recognized this epitope
• An HLA-A11 tetramer was made for this epitope, which was recognized by two subjects – and both subjects had expanded tetramer staining T-cell
populations after in vitro stimulation
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• This epitope was highly conserved in other subtypes, and exact matches were common
RT (158–166) RT (158–166 IIIB) AIFQSSMTK HIV-1 infection human (A11) Moore2002b
• HIV polymorphisms in the RT protein were examined relation to HLA alleles found in a population of 473 participants in the Western Australian HIV
Cohort Study. 64 significant associations between polymorphisms at particular positions and HLA alleles were detected, for HLA-B7, -B12, -B35 and
-B15. Fifteen of these were in positions with known epitopes, 4 in anchor residues, 11 in other positions. Six additional polymorphic sites associated with
particular HLA molecules flanked known epitopes and may relate to processing.
• HLA-A11+ individuals with a K166x (4/19) substitution had higher viral loads than those that did not, suggesting escape was associated with diminished
immune control of viremia.
RT (158–166) Pol SIFQSSMTK HIV-1 infection human (A11) Appay2002
• Four HIV patients with prolonged clinically successful anti-viral therapy but with ongoing evidence of replication and Nef mRNA transcription, showed
specific T-cell responses by Elispot and Tetramer staining, maintained for 2-4 years after initiation of HAART.
• Nef epitope recognition was detected in all 4 subjects, gp120, Pol and Gag-specific in 1 or 2 subjects.
• The HIV-specific CD8+ T-cells had an intermediate maturation phenotype characterized by low levels of perforin and high levels of CD27 expression.
RT (158–166) RT (325–333 IIIB) AIFQSSMTK HIV-1 infection human (A3) Wilson1996
• Epitope defined in the context of the Pediatric AIDS Foundation ARIEL Project, a mother-infant HIV transmission study
• AIFQSSMTR and AILQSSMTK, naturally occurring variants, were found in infant, and are recognized
• TISQSSMTK, a naturally occurring variant, was found in infant and is not recognized
RT (158–166) RT (325–333 LAI) AIFQSSMTK HIV-1 infection human (A3) Cao1997a
• The consensus peptide of B and D clade viruses is AIFQSSMTK
• The consensus peptide of a subset of As is AIFQASMTK and it is less able to stimulate the CTL clone
• The consensus peptide of a subset of As is SIFQSSMTK and is as reactive as the originally defined epitope
RT (158–166) Pol (325–333 IIIB) AIFQSSMTK HIV-1 infection human (A3) Wilson1999a
• This study describes maternal CTL responses in the context of mother-to-infant transmission
• Detection of CTL escape mutants in the mother was associated with transmission, but the CTL-susceptible forms of the virus tended to be found in infected
infants
• One variant found in an infant gave a positive CTL response: AIFQSSMTR
• AIFLSSMTK and TISQSSMTK were escape mutants
RT (158–166) RT (325–333 SF2) AIFQSSMTK HIV-1 infection human (A3) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-A3+ individuals that had a CTL response to this epitope broken down by group: 0/7 group 1, 0/4 group 2, and 1/2 group 3
RT (158–166) RT (158–166) AIFQSSMTK HIV-1 infection human (A3) Day2001
• The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7 was
studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
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• 2 to 17 epitopes were recognized in a given individual, A2-restricted CTL response tended to be narrow and never dominated the response, and 25/27
epitopes were targeted by at least one person
• All patients recognized at least 1 A3 epitope, up to 8 A3 epitopes, but none was clearly dominant
• In two of the subjects, AIFQSSMTK was the dominant epitope
RT (158–166) RT Pol (313–321) AIFQSSMTK HIV-1 infection human (A3) Yu2002a
• Epitope name: A3-ATK9
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
• 0/14 HLA-A3 positive individuals had detectable A3-restricted responses to this epitope during acute infection, but only 5/15 of HLA-A3 epitopes tested
were targeted during acute infection. 3/7 individuals began to have detectable responses to this epitope after STI.
RT (158–166) Pol (337–345) AIFQSSMTK HIV-1 infection human (A3 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind 3/5 HLA-A3 supertype alleles (A*0301, A*1101, A*3101, A*3301 and A*6801)
RT (158–166) Pol (313–321) AIFQSSMTK HIV-1 infection human (A3, A11) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
RT (158–166) Pol (325–333) AIFQSSMTK HIV-1 infection, HIV-1 exposed
seronegative
human (A3, A11, A33) Kaul2001a
• Variants (S/A)IFQSSMTK are specific for the A/B clades
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with
reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected
women
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure
• Among HLA-A3 women, 2/2 HEPS and 3/3 HIV-1 infected women recognized this epitope
• The dominant response to this HLA allele was to this epitope in one of the 2/2 HEPS cases and in one of the 3/3 HIV-1 infected women
RT (158–166) RT (325–333) AIFQSSMTK HIV-1 infection human (A3.1) Brander1995b
• Epitope defined in the context of the Pediatric AIDS Foundation ARIEL Project, a mother-infant HIV transmission study
RT (158–166) RT (325–333) AIFQSSMTK HIV-1 infection human (A3.1) Betts2000
• Only 4/11 HLA-A2+ HIV+ individuals had CTL that reacted to SLYNTVATL, calling into question whether it is immunodominant
• 95 optimally-defined peptides from this database were used to screen for INFγ responses to other epitopes
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• 1/11 of the A2+ individuals was HLA A3 and reacted with this epitope as well as two other A3.1 epitopes
RT (158–166) RT (325–333 LAI) AIFQSSMTK human (A33) Rowland-Jones1995a
• Defined as minimal peptide by titration curve, S. Rowland-Jones, Pers. Comm.
RT (158–166) AIFQSSMTK HIV-1 infection human (A33) Kaul2001c
• This study examines CTL responses in HIV exposed, persistently seronegative individuals, HEPS, who eventually seroconverted – 11/114 HEPS Nairobi
sex workers eventually seroconverted, and for six of these HIV CTL reactive epitopes had been defined while seronegative
• The epidemiological factor associated with seroconversion was stopping sex work and HIV-specific CTL activity declines when HEPS sex workers stop
working for a period or retire
• This epitope was recognized in 1/22 HEPS sex worker controls, ML1668
RT (158–166) RT (325–333 LAI) AIFQSSMTK HIV-1 infection human (A3supertype) Mollet2000
• Epitope name: P3
• A panel of 16 epitopes covering 15 class I alleles was tested in 14 HIV+ patients from an unselected Caucasian population treated with HAART, using
CD8+ cell IFNgamma production to measure responses
• In general, during the first month of treatment viral load decreased and frequencies of HIV-specific CTL tripled and broadened – eight new HIV
specificities that were not previously detectable were newly detected, as were CMV specific CD8+ PBL – but with continued viral suppression,
HIV-specific responses diminished
• Viral rebounds gave different patterns of response: increases or decreases in pre-existing response, new specificities, or no change
RT (158–166) AIFQSSMTK HIV-1 infection human (B*0301) Wilson2000a
• Three individuals with highly focused HIV-specific CTL responses were studied during acute infection using tetramers – high frequencies of HIV-1-specific
CD8+ T cells were found prior to seroconversion, and there was a close temporal relationship between the number of circulating HIV-specific T cells and
viral load was also found
• All three patients were B*2705, with HLA alleles: A1, A30/31, B*2705, B35; A1, A*0301, B7, B2705; and A*0201, A*0301, B2705, B39
• ELISPOT was used to test a panel of CTL epitopes that had been defined earlier and were appropriate for the HLA haplotypes of the study subjects – 3/3
subjects showed a dominant response to the B*2705 epitope KRWIILGGLNK
• The subject with A*0201 had a moderatly strong response to SLYNTVATL
• Weak responses were observed to A*301-RLRPGGKKK, A*301-QVPLRPMTYK, and B7-TPGPGVRYPL in the subject who was HLA A1, A*0301, B7,
B*2705
• No acute response was detected to the following epitopes: A*201-ILKEPVHGV, A*301-KIRLRPGGK, A*301-AIFQSSMTK, A*301-TVYYGVPVWK,
B35-EPIVGAETF, B35-HPDIVIYQY, B35-PPIPVGEIY, B35-NSSKVSQNY, B35-VPLRPMTY, B35-DPNPQEVVL
RT (158–182) RT (325–349 PV22) AIFQSSMTKILEPFRKQNP-
DIVIYQ
HIV-1 infection human (A11) Jassoy1993
• HIV-1 specific CTLs release γ-IFN, and α- and β -TNF
RT (158–182) RT (325–349) AIFQSSMTKILEPFRKQNP-
DIVIYQ
HIV-1 infection human (A11) Price1995
• Study of cytokines released by HIV-1 specific activated CTL
RT (164–172) Pol (343–351) MTKILEPFR HIV-1 infection human (A3 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
194
DEC 2002
RT CTL Epitopes HIV CTL Epitope Tables
C
TL
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind 4/5 HLA-A3 supertype alleles (A*0301, A*1101, A*3101, A*3301 and A*6801)
RT (173–181) RT (173–181 LAI) KQNPDIVIY human (A*3002) Brander2001, Goulder2001a
• C. Brander notes this is an A*3002 epitope
RT (173–181) RT KQNPDIVIY HIV-1 infection human (A*3002) Goulder2001a
• Epitope name: KY9 (RT-53)
• HLA-A*3002 is very common in African populations, 50% of Zimbabweans express HLA-A30, 44% in African Zulu, so five new HIV epitopes were
characterized that are presented by this HLA molecule
• A rapid method was developed combining ELISPOT with intracellular IFN-γ staining of PBMCs to map optimal epitopes, then HLA presenting molecules
were defined – this method was completed within 48 to 72 hours of receipt of blood
• Two individuals were studied: Subject 199 (HLA A*0201/*3002 B*4402/51 Cw2/5), a Caucasian, and Subject 6007 (HLA A*3002/ B53/*5801 Cw4/7) an
African-Caribbean
• In both HLA-A*3002 individuals the response to RSLYNTVATLY was dominant
• In subject 199 four additional A*3002 epitopes were identified
• Three quantitative assays, ELISPOT, precursor frequency and chromium release, confirmed a hierarchy of response: RY11 (p17) > KY9 (gp41) > KY9
(RT-53) > IY9 (gp41)
RT (175–183) RT (328–336 IIIB) NPDIVIYQY HIV-1 infection human (B*3501) Tomiyama1997
• A CTL clone responsive to this epitope was obtained
• 3/7 B35-positive individuals had a CTL response to this epitope
• D to E, or V to I, substitutions at positions 3 or 5, respectively, reduces CTL activity and binding to B*3501
RT (175–183) RT (328–336 IIIB) NPDIVIYQY HIV-1 infection human (B*3501) Brander2001
• C. Brander notes this is a B*3501 epitope
RT (175–183) RT (342–350 LAI) HPDIVIYQY HIV-1 infection human (B*3501) Brander2001
• C. Brander notes this is a B*3501 epitope
RT (175–183) Pol (330–338) NPDIVIYQY HIV-1 infection human (B*3501) Tomiyama2000a
• CD8+ T-cells that bound one of six HIV-specific B*3501-epitope tetramers did not express CD28 or CD45A
• A significant increase in CD28-CD45RA- cells and a decrease of CD28+CD45RA+ cells was observed in chronically HIV-1-infected individuals relative to
healthy individuals
• CD28-CD45RA- cells are likely to be effector cells and have high levels of perforin in their cytoplasm
• The mean percentage of total CD28- CD8+ cells in chronically infected HIV-1-infected patients was 76.6% in comparison to HIV-1-uninfected individuals
(40.6%)
RT (175–183) RT (175–183 IIIB) NPDIVIYQY HIV-1 infection human (B*3501) Moore2002b
• HIV polymorphisms in the RT protein were examined relation to HLA alleles found in a population of 473 participants in the Western Australian HIV
Cohort Study. 64 significant associations between polymorphisms at particular positions and HLA alleles were detected, for HLA-B7, -B12, -B35 and
-B15. Fifteen of these were in positions with known epitopes, 4 in anchor residues, 11 in other positions. Six additional polymorphic sites associated with
particular HLA molecules flanked known epitopes and may relate to processing.
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• NPDIVIYQY was one of two epitopes characterized in detail. D177x substitutions are know to specifically abrogate binding to HLA-B*3501, and not other
B*35 subtypes. D177x substitutions were associated with people who carried HLA-B*3501 and not other B*35 subtypes; considering high resolution
typing generally strengthened the B*35 associations.
RT (175–183) RT (342–350 LAI) HPDIVIYQY HIV-1 infection human (B35) McMichael1994
• Review of HIV CTL epitopes
RT (175–183) RT (329–337) HPDIVIYQY HIV-1 infection human (B35) Rowland-Jones1995b
• NPDIVIYQY preferred sequence for some CTL clones, HIV-2 NPDVILIQY is also recognized
RT (175–183) (SF2) NPDIVIYQY HIV-1 infection human (B35) Kawana1999
• HLA B35 is associated with rapid disease progression
• The sequences of 9 previously described HIV-1 B35 CTL epitopes were obtained in 10 HLA B35+ and 19 HLA B35- individuals
• 3/9 CTL epitopes had substitutions that were more common in B35+ individuals than in B35- individuals – only one of these reduced the binding of the
peptide to B35 and was shown to be an escape mutation
• npEiviyqy was found in 8/10 of the B35+ individuals, and two of the B35- individuals—the D–>E substituted peptide had reduced binding affinity to B35
and may be an escape mutant.
RT (175–183) RT (329–337) HPDIVIYQY in vitro stimulation human (B35) Lalvani1997
• A peptide-based protocol was optimized for restimulation of CTLp using optimized peptide and IL-7 concentrations – importantly this protocol does not
stimulate a primary response, only secondary – peptide-specific CTLp counts could be obtained via staining with peptide-Class I tetramers
• This peptide was one of the B35 presented test peptides used in control experiments showing that the assay gave no activity using lymphocytes from 21
healthy B35 seronegative donors
RT (175–183) RT (328–336 IIIB) NPDIVIYQY HIV-1 infection human (B35) Menendez-Arias1998,
Shiga1996
• Binds HLA-B*3501
• CTL activity to this epitope was originally detected in a long-term survivor, however it has since been found in normal progressors – it is cross-reactive with
HIV-2 (HPDILIYQY), but D3E and V5I substitutions reduce binding [Menendez-Arias1998]
RT (175–183) RT (328–336 IIIB) NPDIVIYQY HIV-1 infection human (B35) Menendez-Arias1998,
Sipsas1997
• HIV IIIB proteins were used to define the range of CTL epitopes recognized by 3 lab workers accidentally infected with HIV-1 IIIB
• NPDIIIYQY, a variant found in HIV-1 JRCSF, was also recognized
• NPEIVIYQY, was also recognized
• NPDLVIYQY, was also recognized
• [Menendez-Arias1998], in a review, notes that the YXDD motif, highly conserved among polymerases, overlaps this epitope – CTL activity to this epitope
was originally detected in a long-term survivor, however it has since been found in normal progressors – it is cross-reactive with HIV-2 (HPDILIYQY), but
D3E and V5I substitutions reduce binding
RT (175–183) RT NPDIVIYQY HIV-1 exposed seronegative human (B35) Menendez-Arias1998,
Rowland-Jones1998a
• A CTL response was found in exposed but uninfected prostitutes from Nairobi using previously-defined B clade epitopes that tended to be conserved in A
and D clades – such cross-reactivity could protect against both A and D and confer protection in Nairobi where both subtypes are circulating
• The A subtype consensus is HPDIVIYQY
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• The D subtype consensus is NPEIVIYQY
• [Menendez-Arias1998], in a review, notes that the YXDD motif, highly conserved among polymerases, overlaps this epitope – CTL activity to this epitope
was originally detected in a long-term survivor, however it has since been found in normal progressors – it is cross-reactive with HIV-2 (HPDILIYQY), but
D3E and V5I substitutions reduce binding
RT (175–183) Pol (subtype B) NPDIVIYQY HIV-1 exposed seronegative human (B35) Rowland-Jones1998b
• HIV-specific CTL were found in exposed seronegative prostitutes from Nairobi – these CTL may confer protection
• Seroprevalence in this cohort is 90-95% and their HIV-1 exposure is among the highest in the world
• Most isolated HIV strains are clade A in Nairobi, although clades C and D are also found – B clade epitopes are often cross-reactive, however stronger
responses are frequently observed using A or D clade versions of epitopes
• Clade A version of epitope HPDIVIYQY, Clade D NPEIVIYQY
RT (175–183) Pol HPDIVIYQY human (B35) Rowland-Jones1999
• CTL responses in seronegative highly HIV-exposed African female sex workers in Gambia and Nairobi were studied – these women had no delta 32
deletion in CCR5
• In Gambia there is exposure to both HIV-1 and HIV-2, CTL responses to B35 epitopes in exposed, uninfected women are cross-reactive, and the B35 allele
seems to be protective
• HIV-2 version of this epitope is not conserved: NPDVILIQY, but the CTLs are cross-reactive – one of five B35 CTL epitopes that are cross-reactive, see
also [Rowland-Jones1995b]
RT (175–183) HPDIVIYQY HIV-1 infection human (B35) Wilson2000a
• Three individuals with highly focused HIV-specific CTL responses were studied during acute infection using tetramers – high frequencies of HIV-1-specific
CD8+ T cells were found prior to seroconversion, and there was a close temporal relationship between the number of circulating HIV-specific T cells and
viral load was also found
• All three patients were B*2705, with HLA alleles: A1, A30/31, B*2705, B35; A1, A*0301, B7, B2705; and A*0201, A*0301, B2705, B39
• ELISPOT was used to test a panel of CTL epitopes that had been defined earlier and were appropriate for the HLA haplotypes of the study subjects – 3/3
subjects showed a dominant response to the B*2705 epitope KRWIILGGLNK
• The subject with A*0201 had a moderately strong response to SLYNTVATL
• Weak responses were observed to A*301-RLRPGGKKK, A*301-QVPLRPMTYK, and B7-TPGPGVRYPL in the subject who was HLA A1, A*0301, B7,
B*2705
• No acute response was detected to the following epitopes: A*201-ILKEPVHGV, A*301-KIRLRPGGK, A*301-AIFQSSMTK, A*301-TVYYGVPVWK,
B35-EPIVGAETF, B35-HPDIVIYQY, B35-PPIPVGEIY, B35-NSSKVSQNY, B35-VPLRPMTY, B35-DPNPQEVVL
RT (175–183) Pol (subtype A) HPDIVIYQY HIV-1 infection human (B35) Kaul2001c
• This study examines CTL responses in HIV exposed, persistently seronegative individuals, HEPS, who eventually seroconverted – 11/114 HEPS Nairobi
sex workers eventually seroconverted, and for six of these HIV CTL reactive epitopes had been defined while seronegative
• HPDIVIYQY or NPDIVIYQY was recognized in 1 of the 6 women (ML857), and the response was present in the last available sample prior to
seroconversion, 7 months
• 20/20 sequences of the infecting strain had three substitutions in this epitope, all 20 were NpQiIiyqy, and this form was not recognized by CTL from ML
857 – this was the only case in the study where a virus carrying an unrecognized form of the epitope broke through
• The epidemiological factor associated with seroconversion was stopping sex work and HIV-specific CTL activity declines when HEPS sex workers stop
working for a period or retire
• NPDIVIYQY was recognized by 1/22 HEPS control sex workers, ML887
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RT (175–183) RT (175–183 SF2) NPDIVIYQY HIV-1 infection human (B35) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B35+ individuals that had a CTL response to this epitope broken down by group: 1/2 group 1, 0/2 group 2, and 1/1 group 3
RT (175–183) Pol (342–350) HPDIVIYQY HIV-1 infection, HIV-1 exposed
seronegative
human (B35) Kaul2001a
• Variants (H/N)PDIVIYQY are specific for the A/B clades
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with
reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected
women
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure
• Among HLA-B35 women, 2/3 HEPS and 1/4 HIV-1 infected women recognized this epitope
• The dominant response to this HLA allele was to this epitope in only one of the 2/3 HEPS cases, and was not to this epitope in the one responsive HIV-1
infected women
• Subject ML 857 shifted from a A*6802 DTVLEDINL and B35 (H/N)PDIVIYQY response prior to seroconversion to a B35 PPIPVGDIY and B35
VPLRPMTY response post-seroconversion and the loss of the pre-seroconversion response was not due to sequence variation within these epitopes
RT (175–183) HPDIVIYQY HIV-1 infection human (B35) Sabbaj2002b
• Epitope name: Pol-HY9
• Among HIV+ individuals who carried HLA B35, 4/21 (19%) recognized this epitope
RT (175–183) Pol NPDIVIYQY HIV-1 infection human (B35) Sabbaj2002a
• IFNgamma T-cell responses in breast milk of 5 HIV-1 infected women from the US and 6 from Zambia were tested with using Elispot. 11/11 women
responded to Gag, 8/11 responded to Pol, 7/11 women to Nef, and 2/5 women to Env peptide pools. These responses were shown to be primarily due to
CD8+ T-cells in one woman, and another woman had cytolytic responses measured by Cr-release.
• T-cells in breast milk from a volunteer who was HLA A3, A11, B35, B51 induced IFNgamma after stimulation with a peptide that carries known B35
epitope NPDIVIYQY.
• The frequencies of responses in the two compartments differed, and 2/4 women that responded to epitopes in Nef 101-205 and Pol 601-710 showed
responses in breast milk but no detectable responses in peripheral blood cells.
RT (175–183) Pol HPDIVIYQY HIV-1 infection, Vaccine human, macaque (B35) Hanke2000, Wee2002
Vaccine Vector/Type: DNA prime with vaccinia MVA boost Strain: subtype A HIV component: p17, p24, polyepitope
• The HIV-1 subtype A focused vaccine HIVA contains p24 and p17, in a reversed order relative to the Gag polyprotein to prevent myristylation of p17,
which could direct the protein to the cell membrane and inhibit efficient peptide processing and class I presentation, as well as a polyepitope string of
conserved, often immunodominant epitopes that were selected to have particularly good cross-reactive potential for the A-clade epidemic in Nairobi,
Kenya. A DNA and MVA prime-boost vaccination protocol using the HIVA antigen will be used in a phase III clinical trial in Kenya. This epitope is
included in the polyepitope string [Hanke2000].
198
DEC 2002
RT CTL Epitopes HIV CTL Epitope Tables
C
TL
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
• Multiple CD4+ or CD8+ T-cell vaccine-induced responses to peptide pools were detected using intracellular cytokine staining and IFNgamma Elispot
assays after vaccination of 5 macaques. The response to the Mamu A*01 SIV p27 epitope p11C (CTPYDINQM), included in the polyepitope region, was
not immunodominant in the Mamu A*01 vaccinated macaques, possibly because of processing limitations in context of the artificial polyepitope string
[Wee2002].
RT (175–184) RT (175–184 LAI) NPDIVIYQYM HIV-1 infection human (B51) Samri2000
• This epitope contains the mutation M184V, a frequent mutation induced by nucleoside reverse transcriptase inhibitors
• Patient 246#1 (B51), was found by ELISPOT to recognize the wild type and the mutated peptide after zidovudine treatment
• The resistance mutation M184V gave an increased predicted binding score to B51 (http://bimas.dcrt.nih.gov/molbio/hla_bind) compared to the wildtype RT
sequence and also an increased ELISPOT reactivity
RT (175–199) RT (342–366 LAI) NPDIVIYQYMDDLYVGSDL-
EIGQHR
HIV-1 infection human (A11) Menendez-Arias1998,
Walker1989
• One of five epitopes defined for RT-specific CTL clones in this study
RT (179–187) RT VIYQYMDDL Vaccine human (A*0201) Hanke1998a, Hanke1998b
Vaccine Vector/Type: vaccinia HIV component: polyepitope
• This epitope was shown to be processed and presented to appropriate CTL clones upon infection of human target cells with vaccinia virus Ankara (VVA)
carrying 20 HIV-1 epitopes recognized by humans
RT (179–187) RT VIYQYMDDL HIV-1 infection human (A*0201) Tan1999
• Adoptive transfer of two autologous in vitro-expanded CTL clones against the A*0201 restricted epitopes SLYNTVATL and VIYQYMDDL were infused
into a patient – they were well tolerated, but the SLYNTVATL clone was shown by tetramer staining to be rapidly eliminated through apoptosis, and the
treatment had no impact upon viral load and CD4 and CD8 cell counts
• Tetramer staining failed for the VIYQYMDDL epitope as the tetramer was unstable
RT (179–187) Pol (346–354) VIYQYMDDL HIV-1 infection human (A*0201) Sewell1999
• Proteasome regulation influences epitope processing and could influence patterns of immunodominance
• The proteasome is inhibited by lactacystin treatment, and gamma IFN induces expression of proteasome subunits, LMP2 and LMP7, which combine with
the proteasome to create an immunoproteasome
• IFN-gamma induction of the immunoproteasome and lactacystin inhibition increases the presentation of the A*0201 VIYQYMDDL epitope, but decreases
the presentation of the A*0201 ILKEPVHGV epitope, which is immunodominant within pol proteins, showing the two epitopes are processed by different
pathways
• ILKEPVHGV seems to be processed by the classical proteasome pathway, while VIYQYMDDL appears to be destroyed by this pathway
• This epitope contains the catalytic site (YMDD) of RT, a conserved sequence in HIV-1 which restricts escape mutants
RT (179–187) RT (346–354 LAI) VIYQYMDDL HIV-1 infection human (A*0201) Harrer1996a,
Menendez-Arias1998
• The substitution VIYQYVDDL abrogates CTL response and confers drug resistance
• [Menendez-Arias1998], in a review, notes that this epitope includes catalytic residues (Asp-185 and Asp-186) in the active site of RT
RT (179–187) RT (346–354 LAI) VIYQYMDDL HIV-1 infection human (A*0201) Brander2001
• C. Brander notes this is an A*0201 epitope
199
DEC 2002
C
TL
HIV CTL Epitope Tables RT CTL Epitopes
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
RT (179–187) RT (346–354) VIYQYMDDL HIV-1 infection human (A*0201) Brander1998a,
Menendez-Arias1998
• Of 17 infected HLA A*0201 subjects, 13 had CTL responses against the p17 SLYNTVATL epitope, six recognized ILKEPVHGV and five recognized
VIYQYMDDL, and there was no correlation between viral load and recognition of a specific epitope or evidence of immune escape
• Only one subject had CTL against all three epitopes
• Subjects were part of the San Francisco City Clinic Cohort, the ARIEL project and from the Boston area
• In the review [Menendez-Arias1998] the authors note that substitution of three residues in this epitope can confer resistance to RT inhibitors (1, 3, and 6) –
substitutions V1E and M6V abolish CTL activity, and M6V confers resistance to 3TC – substitution Y3C reduces CTL activity and is associated with
resistance to non-nucleoside RT inhibitors
RT (179–187) RT VIYQYMDDL HIV-1 infection human (A*0201) Altfeld2001c
• Epitope name: RT VL9
• HIV was scanned for all peptides which carried the A2-supermotif pattern conserved in more than 50% of B clade sequences – 233 peptides met this
criteria, and 30 of these bound to HLA-A*0201 – 20/30 bound to at least 3/5 of HLA-A2 supertype alleles tested
• Three additional previously described HLA-A2 epitopes were added to the set of 20, including RT VL9, and 18/22 chronically infected HLA-A2
individuals had CTL that recognized at least one of the 23 peptides (median of 2 and maximum of 6), while 6/12 acute infected individuals recognized at
least 1 (median of 1 and maximum of 2)
• RT VL9 was not recognized by any of the 22 HLA-A2 patients with chronic HIV-1 infection or the 13 HLA-A2 patients with acute HIV-1 infection
included in this study
RT (179–187) RT (346–354) VIYQYMDDL HIV-1 infection human (A*0201) Dela Cruz2000
• Epitope name: VL9
• Integration of HIV RT CTL epitopes into the N-terminus of the HLA-A2 heavy chain, or tethering the epitopes to the target chain, resulted in
epitope-specific lysis by CD8+ CTL
• These antigens could also be used to stimulate primary responses in vitro
RT (179–187) Pol (346–354) VIYQYMDDL HIV-1 infection human (A*0201) Sewell2002
• Epitope processing of three different HLA-A*0201 HIV epitopes was shown to use different pathways, which might influence patterns of
immunodominance. .174 cells were used that lack TAP1 and TAP2 genes, as well as the LMP2 and LMP7 genes that encode the beta-subunits of the
immunoproteasome. These genes could be added back through transfection to study processing.
• ILKEPVHGV was efficiently presented in TAP-1 and -2 transfected cells while VIYQYMDDL and SLYNTVATL were not. VIYQYMDDL was destroyed
by the MB1 subunit of the protease, and could be expressed in the presence of the proteasome inhibitor lactacystin, but SLYNTVATL expression was not
restored. SLYNTVATL expression was unaltered by lactacystin in a wild type cell line.
RT (179–187) Pol VIYQYMDDL HIV-1 infection, Vaccine human, macaque
(A*0201)
Hanke2000, Wee2002
Vaccine Vector/Type: DNA prime with vaccinia MVA boost Strain: subtype A HIV component: p17, p24, polyepitope
• The HIV-1 subtype A focused vaccine HIVA contains p24 and p17, in a reversed order relative to the Gag polyprotein to prevent myristylation of p17,
which could direct the protein to the cell membrane and inhibit efficient peptide processing and class I presentation, as well as a polyepitope string of
conserved, often immunodominant epitopes that were selected to have particularly good cross-reactive potential for the A-clade epidemic in Nairobi,
Kenya. A DNA and MVA prime-boost vaccination protocol using the HIVA antigen will be used in a phase III clinical trial in Kenya. This epitope is
included in the polyepitope string [Hanke2000].
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• Multiple CD4+ or CD8+ T-cell vaccine-induced responses to peptide pools were detected using intracellular cytokine staining and IFNgamma Elispot
assays after vaccination of 5 macaques. The response to the Mamu A*01 SIV p27 epitope p11C (CTPYDINQM), included in the polyepitope region, was
not immunodominant in the Mamu A*01 vaccinated macaques, possibly because of processing limitations in context of the artificial polyepitope string
[Wee2002].
RT (179–187) RT VIYQYMMDL HIV-1 exposed seronegative human (A2) Rowland-Jones1998a
• A CTL response was found in exposed but uninfected prostitutes from Nairobi using previously-defined B clade epitopes that tended to be conserved in A
and D clades – such cross-reactivity could protect against both A and D and confer protection in Nairobi where both subtypes are circulating
• The A and D consensus sequences are both VIYQYMMDL
RT (179–187) Pol (346–354) VIYQYMDDL Vaccine human (A2) Woodberry1999
Vaccine Vector/Type: DNA prime with vaccinia boost HIV component: polyepitope
• A polyepitope vaccine was generated in a vaccinia construct that contiguously encoded seven epitopes, all presented by HLA A-2
• HHD mice have a transgene of HLA A2 linked to the transmembrane and cytotoxic domains of H-2Dd – this transgene is the only MHC molecule
expressed in the mice
• CTL responses to Gag (77-85) SLYNTVATL, Pol (476-484) ILKEPVHGV, gp120 (120-128) KLTPLCVTL, and Nef (190-198) AFHHVAREL were
observed in HIV polytope HHD-vaccinated mice, and these responses were enhanced with vaccinia boost
• No CTL immune responses were generated against HLA A2-restricted HIV epitopes Nef 157-166 (PLTFGWCYKL), Pol 346-354 (VIYQYMDDL), and
Nef 180-189 (VLEWRFDSRL)
• Sixteen HLA A2+ patients were tested for their ability to make CTL responses by peptide restimulation in culture with the epitopes selected for inclusion in
the polytope – one individual recognized all seven of these epitopes; 7 patients had CTL cultures able to recognize at least one of the epitopes, and 6 of
those 7 recognized more than one epitope, but they were not able to test all peptides for all patients; many patients only had three peptides tested
• VIYQYMDDL was recognized by 3 of the HLA-A2 patients
RT (179–187) RT (179–187) VIYQYMDDL HIV-1 infection human (A2) Schmitt2000
• The mutation M184V confers resistance to lamivudine, and is in the middle of the HLA-A2 epitope VIYQYMDDL
• 1/28 individuals tested produced HIV-1 RT-specific CTL that recognized the peptide representing the lamivudine escape mutants VIYQYVDDL and
VIYQYIDDL, but failed to recognize the wildtype epitope VIYQYMDDL
• This suggests immunotherapy stimulating anti-VIYQYVDDL responses maybe helpful for reducing lamivudine escape
RT (179–187) RT (179–187) VIYQYMDDL HIV-1 infection human (A2) Haas1998
• Of 98 patients in cross-sectional analysis, 78% had CTL against pol – RT was more immunogenic than Integrase and Protease (81%, 51%, and 24% of 37
patients, respectively)
RT (179–187) Pol (339–347 93TH253
subtype CRF01)
VIYQYMDDL HIV-1 infection human (A2) Sriwanthana2001
• Epitope name: P334-342
• This was a study of HIV-1 exposed persistently seronegative (HEPS) female sex workers in Chiang Mai, northern Thailand
• HLA-A11 is very common in this population, and was enriched among the HEPS sexworkers – weak CTL responses were detected in 4/7 HEPS women,
and CTL responses were found in 8/8 HIV+ controls, and 0/9 HIV- women that were not exposed
• This epitope was reactive in HIV+ control study subject 144 who carried HLA-A2
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RT (179–187) Pol (339–347 93TH253
subtype CRF01)
VIYQYMDDL HIV-1 infection human (A2) Bond2001
• More than half of a cohort of HIV+ female sex workers (FSW) from Northern Thailand were HLA-A11 positive, and this study concentrated on A11
epitopes in this group, although E clade versions of previously defined B-clade A2 and A24 epitopes were also tested.
• 2/4 tested FSWs recognized the E clade version of this epitope, which is identical to the previously defined B clade version VIYQYMDDL
• This epitope was conserved in many subtypes, and exact matches were very uncommon
RT (179–187) RT (179–187) VIYQYMDDL HIV-1 infection human (A2) Day2001
• The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7 was
studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
• 2 to 17 epitopes were recognized in a given individual, A2-restricted CTL response tended to be narrow and never dominated the response, and 25/27
epitopes were targeted by at least one person
RT (179–187) Pol (346–354 LAI) VIYQYMDDL HIV-1 infection human (A2) Kelleher2001a
• Ritonavir (RTV) inhibits chymotryptic activity in the 20S proteasome in vitro, as does Saquinavir (SQV) to a lesser extent; Indinavir (IDV) does not. Thus
there is concern protease inhibitors may adversely effect CTL epitope processing, but this paper indicates that processing is not inhibited at therapeutically
relevant concentrations of RTV when the proteasome is functioning in an intracellular context.
• RTV did not alter the presentation two RT A2 epitopes processed by distinct pathways: ILKEPVHGV, generated by the constitutive proteasome containing
the MB1 beta subunit, and VIYQYMDDL which is dependent on IFNgamma induction of LMP7 which replaces MB1 in the immunoproteasome, and is
destroyed by MB1 in the constitutive proteasome.
• RTV did not inhibit the processing and assembly of HLA-B35 or -A2, which are assembled with a rapid and moderate time course, respectively, or of
HLA-A3, -B27 and -B39.
RT (179–187) Pol (subtype B) VIYQYMMDL HIV-1 exposed seronegative human (A2, A*0202) Rowland-Jones1998b
• HIV-specific CTL were found in exposed seronegative prostitutes from Nairobi – these CTL may confer protection
• Seroprevalence in this cohort is 90-95% and their HIV-1 exposure is among the highest in the world
• Most isolated HIV strains are clade A in Nairobi, although clades C and D are also found – B clade epitopes are often cross-reactive, however stronger
responses are frequently observed using A or D clade versions of epitopes
• This epitope is conserved among A, B and D clade viruses
RT (179–187) RT (346–354 LAI) VIYQYMDDL Vaccine murine (A2.1) Peter2001
Vaccine Vector/Type: peptide Strain: LAI Adjuvant: P30, incomplete Freund’s adjuvant (IFA), Montanide (ISA 720), PLG-microparticle
• Epitope name: LR26
• The stability of peptide binding to HLA-A2.1 was determined for six HLA-A2.1 peptides included in this vaccine study – ILKEPVHGV (RT),
SLYNTVATL (p17), SLLNATDIAV (gp41) and LLWKGEGAV (RT) all bound with high affinity comparable to a influenza epitope reference
(GILGFVFTL), while RGPGRAFVTI and VIYQYMDDL bound with a lower affinity (relative binding activity = 0.01).
• The four high-affinity peptides formed stable complexes with half-lives ranging between 8 and 32 hours, while the low affinity peptides had half lives of
less than an hour.
• HLA-A2.1 transgenic mice were immunized with the six HIV-1 peptides and P30, as a universal T-helper epitope, with IFA or Montanide or microspheres
as adjuvants.
• All peptides except VIYQYMDDL induced a stong CTL response in Cr-release assays - stronger responses were observed when peptides were delivered
alone, indicating immunodominance when the combination was used.
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RT (179–187) RT (346–354 LAI) VIYQYMDDL Vaccine murine (A2.1) Peter2002
Vaccine Vector/Type: peptide Strain: LAI Adjuvant: P30, incomplete Freund’s adjuvant (IFA), IL-12
• Epitope name: LR26
• When HIV-1 peptides were used to vaccinate HLA-A2.1 transgenic A2-Kb mice, strong responses to five peptides were observed when the peptides were
given individually, but immunodominance limited the response to some of the peptides when they were given in combination [Peter2001]. IL-12 can
counteract immunodominance in BALB/c mice, so it was given with the multiple epitope vaccination, and was instead found to specifically eliminate the
HLA-A2.1-epitope CTL responses, but not Kb CTL responses. This was possibly a consequence of transient depletion of T-cells, B cells and macropahges
in the spleen.
RT (180–189) RT (LAI) IYQYMDDLYV HIV-1 infection human (A*0201) Menendez-Arias1998,
vanderBurg1997
• Recognized by CTL from a progressor, spans important RT functional domain
• A previous study determined that this was an epitope recognized by a long-term survivor
RT (181–189) RT (181–189 LAI) YQYMDDLYV HIV-1 infection human (A*0201) Samri2000
• This epitope contains the mutation M184V, a frequent mutation induced by nucleoside reverse transcriptase inhibitors
• High levels of recognition by ELISPOT were observed for zidovudine induced mutation YQYVDDLYV and for the wildtype peptide YQYMDDLYV in
patient 250#0 (HLA-A*0201), but neither were recognized by patient 201#5 (also HLA-A*0201)
• Both the wild-type and the mutated peptide were computer predicted to have a high binding affinity for A2 (http//bimas.dcrt.nih.gov/molbio/hla_bind)
RT (192–201) RT (192–201) DLEIGQHRTK HIV-1 infection human (A3) Haas1998
• Of 98 patients in cross-sectional analysis, 78% had CTL against pol – RT was more immunogenic than Integrase and Protease (81%, 51%, and 24% of 37
patients, respectively)
• New clusters of epitopes were defined utilizing different HLA molecules
RT (192–216) RT (359–383 HXB2) DLEIGQHRTKIEELRQHLL-
RWGLTT
HIV-1 infection human (Bw60) Menendez-Arias1998,
Walker1989
• One of five epitopes defined for RT-specific CTL clones in this study
RT (192–216) RT (191–215) DLEIGQHRTKIEELRQHLL-
RWGFTT
HIV-1 infection human (polyclonal) Haas1997, Menendez-Arias1998
• Polyclonal CTL recognition switched from RT 191-215 to RT 514-524 when AZT therapy selected for the resistance mutation, and presumably the escape
variant, RT T215Y
RT (198–212) RT (SF2) HRTKIEELRQHLLRW HIV-1 infection human Altfeld2000b
• This epitope was mapped by ELISPOT in a study identifying new HLA-B60 epitopes, and was one of the epitopes presented by another HLA molecule in
an HLA-B60 individual
• The response to the peptide was CD8 dependent, but the HLA presenting molecule and optimal epitope were not determined
RT (201–209) RT (201–209) KIEELRQHL HIV-1 infection human (A2) Haas1998
• Of 98 patients in cross-sectional analysis, 78% had CTL against pol – RT was more immunogenic than Integrase and Protease (81%, 51%, and 24% of 37
patients, respectively)
• New clusters of epitopes were defined utilizing different HLA molecules
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RT (201–210) Pol KIEELRQHLL human (B58) De Groot2001
• The program Epimatrix was used in conjunction with the program Conservatrix to identify conservered regions of HIV that might serve as epitopes
• A subset of the potential epitopes was identified that could bind to the appropriate HLA-allele, and 15 predicted B7 superfamily (HLA B7, B8, and B58)
epitopes could stimulate IFNγ production in an ELISPOT assay
• KIEELRQHLL was newly identified as a HLA-B58 epitope in this study, it had been previously shown to be presented by HLA-A2 and Bw60
• KIEELRQHLL did not bind detectably to B7
RT (202–210) RT (202–210 LAI) IEELRQHLL human (B*4001) Altfeld2000b, Brander2001
• C. Brander notes this is a B*4001 epitope
RT (202–210) RT (SF2) IEELRQHLL HIV-1 infection human (B60) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B60+ individuals that had a CTL response to this epitope broken down by group: 0/2 group 1, 1/1 group 2, and 0/0 group 3
RT (202–210) RT (SF2) IEELRQHLL HIV-1 infection human (B60(B*4001) Altfeld2000b
• This epitope was mapped by ELISPOT in a study identifying new HLA-B60 epitopes
• B60 is present in 10-20% of the Caucasoid and very common in Asian populations
RT (202–210) RT (202–210) IEELRQHLL HIV-1 infection human (B60/B61) Day2001
• No immunodominant responses were detected to five B61-restricted epitopes tested
• All five B60-restricted epitopes were reactive in another subject, and the B60-restricted responses together contributed over one-third of the total CTL
response
RT (203–212) RT (LAI) EELRQHLLRW HIV-1 infection human (B44) Menendez-Arias1998,
vanderBurg1997
• The only epitope recognized by CTL from a long-term survivor in two samples taken six years apart
• Recognized by CTL from a progressor, EILKEPVGHGV and TWETWWTEYW were also recognized
RT (209–220) RT (209–220) LLRWGLTTPDKK HIV-1 infection human (A2) Haas1998
• Of 98 patients in cross-sectional analysis, 78% had CTL against pol – RT was more immunogenic than Integrase and Protease (81%, 51%, and 24% of 37
patients, respectively)
• New clusters of epitopes were defined utilizing different HLA molecules
RT (243–252) RT (LAI) PIVLPEKDSW HIV-1 infection human (B*5701) Menendez-Arias1998,
vanderBurg1997
• Recognized by CTL from a progressor and a long-term survivor, KITTESIVIW was also recognized
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RT (243–252) RT (LAI) PIVLPEKDSW HIV-1 infection human (B*5701) Menendez-Arias1998,
vanderBurg1997
• Recognized by CTL from long-term survivor, whose CTL response persisted for more than 10 years – the substitution V3M reduced affinity but was well
recognized, on the other hand V3T and D8G did not reduce affinity, but abrogated CTL response
RT (243–252) RT (410–419) PIVLPEKDSW HIV-1 infection human (B57) Oxenius2000
• Epitope name: PIV
• Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific
CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load – three patients that had delayed initiation of
HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became
undetectable
• None of the 8 study subjects recognized this epitope but none were HLA B57+
RT (243–252) RT PIVLPEKDSW HIV-1 infection human (B57) Oxenius2002b
• Epitope name: PIV
• Using previously defined epitopes [Oxenius2000, Oxenius2001a] in an IFNgamma Elispot assay, 13 chronically HIV-1 infected patients were studied over a
period including therapy with standard treatment interruptions (STI).
• STIs induced increased recognition of CTL epitopes, but there was no correlation between CTL responses with viral rebound rates, plateau viral loads, or
clearance rates.
RT (244–252) RT (399–407) IVLPEKDSW human (B*5701) Brander2001
• Subtype of B57 not determined
• C. Brander notes this is a B*5701 epitope
RT (244–252) RT (244–252 LAI) IVLPEKDSW HIV-1 infection human (B*5701,
B*5801)
Klein1998
• This peptide was defined as the optimal epitope
• B57 has been associated with long-term non-progression in the Amsterdam cohort.
• The most pronounced CTL responses in HLA B*5701 LTS were to RT and Gag
• B57 restricted CTL responses are targeted at multiple proteins, but one LTS had a response that was dominated by reactivity to the epitope – two variants
were found in this LTS: ITLPEKESW, which bound to B*5701 with similar affinity as the index peptide but was an escape mutant that was not recognized
by CTL, and IMLPEKDSW, which bound to B*5701 with reduced affinity but could still be recognized
• In an additional HIV+ LTS, only the variant IELPEKDSW was found, and this epitope was recognized by CTL but had less affinity for B*5701 than the
index peptide
• This epitope was recognized in the context of both HLA-B*5701 and B*5801
RT (244–252) Pol (244–252) IVLPEKDSW HIV-1 infection human (B*5801) Appay2000
• Combined tetramer and intracellular cytokine staining was used to study the function of circulating CD8+ T cells specific for HIV and CMV
• HIV-specific CD8+ T cells expressed lower levels of perforin than CMV-specific CD8+ T cells from the same donor, and this was associated with persistent
CD27 expression on HIV-specific cells, suggesting impaired maturation
• In most donors, between 50% and 95% of the activated virus-specific CD8+ T cells produced IFN-γ and MIP-1β with a distinct subset that failed to
produce TNF-α
RT (244–252) RT (399–407) IVLPEKDSW human (B57) vanderBurg1997
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RT (244–252) RT (244–252) IVLPEKDSW HIV-1 infection human (B57) Guillon2002
• An early-expressed Nef protein was modified to contain Env and Pol epitopes to enable the study the effect of expression kinetics on CTL mediated
suppression of replication. The "EpiNef" construct was inserted into a recombinant vaccinia virus which was used to infect a target cell line; the target cells
were lysed by CTL clones specific for the Env and Pol epitopes indicating that they were properly processed.
RT (244–252) RT (244–252
ACH320.2A.2.1)
IVLPEKDSW HIV-1 infection (B57) vanBaalen2002
• Tat, Rev and Nef are the first HIV proteins expressed upon acute infection of T-cells (< 6 hours), and RT is not expressed until after 24 hours. The
B14-restricted Rev-SAEPVPLQL specific CD8 T-cell clone TCC108, and the B57-restricted RT-IVLPEKDSW specific CD8 T-cell clone TCL1C11 were
co-incubated with CD4+ cultures innoculated with HIV-1 at low MOI. Co-incubation with the Rev-specific CTL resulted in two logs less HIV-1 production
in ten days of culture. When the RT epitope was cloned into the Nef gene of the infecting strain, another early expressed protein, it proved as effective as
the Rev epitope at inhibiting viral production. A mathematical model of CTL-target interactions suggest early proteins are important for vaccine design.
RT (245–252) Pol IVPEKDSW HIV-1 infection human (B57) Kostense2001
• HLA tetramers to six epitopes were used to study HLA-A2, B8 and B57 CTL in 54 patients – HIV-specific tetramer positive cells were inversely correlated
with viral load in patients with high CD4, but in patients with CD4 T-cells below 400 high tetramer frequencies were found despite high viral load
• Most patients have high levels of HIV-specific T-cell expansions, but many of these cells aren’t functional
• In 15 of the patients, the proportion of IFN gamma producing tetramer cells correlated with AIDS-free survival
RT (259–267) Pol KLVGKLNWA HIV-1 infection human (A2 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind four of the five HLA-A2 supertypes alleles (A*0201, A*020 2, A*0203, A*0206 and A*6802)
• Tetramer staining with A2, beta2microglobulin, and either SLYNTVATL, KLVGKLNWA, or LTFGWCFKL revealed that tetramers detected more
HIV-specific sells in LTNP than in progressors, activated effector cells were the minority population, and ELISPOT correlated better with the effector cell
subpopulation than the total tetramer stained population
RT (260–271) RT (415–426 IIIB) LVGKLNWASQIY HIV-1 infection human (B*1501) Brander2001
• C. Brander notes this is a B*1501 epitope
RT (260–271) RT (260–271) LVGKLNWASQIY HIV-1 infection human (B62) Day2001
• No immunodominant responses were detected to four B62-restricted epitopes tested
RT (260–271) RT (415–426 IIIB) LVGKLNWASQIY HIV-1 infection human (Bw62) Brander1996b,
Menendez-Arias1998
• P. Johnson, Pers. Comm.
RT (263–271) RT (263–271 LAI) KLNWASQIY human (A*3002) Brander2001, Goulder2001a
• C. Brander notes this is an A*3002 epitope
RT (263–271) RT KLNWASQIY HIV-1 infection human (A*3002) Goulder2001a
• Epitope name: KY9 (RT-35)
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• HLA-A*3002 is very common in African populations, 50% of Zimbabweans express HLA-A30, 44% in African Zulu, so five new HIV epitopes were
characterized that are presented by this HLA molecule
• A rapid method was developed combining ELISPOT with intracellular IFN-γ staining of PBMCs to map optimal epitopes, then HLA presenting molecules
were defined – this method was completed within 48 to 72 hours of receipt of blood
• Two individuals were studied: Subject 199 (HLA A*0201/*3002 B*4402/51 Cw2/5), a Caucasian, and Subject 6007 (HLA A*3002/ B53/*5801 Cw4/7) an
African-Caribbean
• In both HLA-A*3002 individuals the response to RSLYNTVATLY was dominant
• In subject 199 four additional A*3002 epitopes were identified
• Three quantitative assays, ELISPOT, precursor frequency and chromium release, confirmed a hierarchy of response: RY11 (p17) > KY9 (gp41) > KY9
(RT-53) > IY9 (gp41)
RT (263–271) RT KLNWASQIY HIV-1 infection human (A30) Altfeld2002
• Epitope name: A30-KY11(RT)
• Peripheral blood (PB) and lymph node (LN) CD8+ T-cell responses were compared in 15 asymptomatic HIV-1 infected patients using all known optimal
CTL epitopes (http://hiv-web.lanl.gov/content/hiv-db/REVIEWS/brander2001.html) for each person’s class I HLA alleles.
• 60 epitope responses were detected in both PB and LN samples of the 15 patients, and an additional 8 responses were detected only in LN. The total
magnitude of the response was similar in LN and PB, but the percentage of CD8+ T cells in the LN is lower so the number of HIV-specific cells per million
CD8+ T-cells is higher in the LN.
• 1 year post-HAART treatment in five patients studied, the magnitude of the CD8 T-cell response was decreased in both LN and PB, but more dramatically
in PB, and 13/25 epitope responses in the PB became undetectable, in contrast to 5/26 in the LN.
• Treatment interruption following HAART resulted in increased viremia accompanied by the restoration of the detection of 13 epitopes that had become
undetectable in the PB, and the addition of 9 novel epitope responses.
• Breakdowns of epitope responses were shown for 4 individuals. Patient D displayed the greatest response to B27-KK10 (p24), and also responded to
A30-RY11(p17), A32-PW10(RT), A30-KY11(RT), A32-RW10(gp120), and B18-YY9(Nef).
RT (266–285) Pol (421–440) WASQIYPGIKVRQLCKLLRG HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
• This peptide was among the 28 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
RT (268–282) RT (SF2) SQIYPGIKVRQLCKL HIV-1 infection human Altfeld2001a
• HIV+ individual AC-06 was tested for reactive overlapping peptides spanning all HIV-1 proteins in an ELISPOT and was found to react with 12 peptides
from 7 proteins, suggesting that the breadth of CTL responses are underestimated if accessory proteins are not included in the study
• RT peptides SQIYPGIKVRQLCKL and WKGSPAIFQSSMTKI were recognized
RT (269–277) Pol (424–432) QIYAGIKVK HIV-1 infection human (A*1101) Fukada2002
• binding affinity, inter-clade comparisons
• Counterparts for eight known clade B HLA A*1101 epitopes were generated for clade E (CRF01). Three epitopes, identical among clade A-E, were
cross-reactive and recognized by clade E infected individuals. The clade E and B analogs to three more HLA A*1101 epitopes was recognized in a clade
specific manner. Two other HLA A*1101 clade B defined epitopes were found not to have stimulated a response in clade E infected individuals.
• QIYAGIKVK is commonly found in viruses representing subtypes A, B and E. It was strongly recognized by CTL from 1/5 B clade infected Japanese
subjects, and 5/7 E clade infected Thai subjects.
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• QIYAGIKVK had the highest A*1101 binding affinity, but qiyagikvR and qiyPgikvR (the most common C and D clade variant both bound to A*1101).
QIYAGIKVK and qiyagikvR were both cross-presented by a clone from a B clade infection, but qiyPgikvR was not.
RT (269–277) (LAI) QIYPGIKVR (A3) Altfeld2000a, Brander2001
RT (269–277) RT (269–277) QIYPGIKVR HIV-1 infection human (A3) Day2001
• The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7 was
studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
• 2 to 17 epitopes were recognized in a given individual, A2-restricted CTL response tended to be narrow and never dominated the response, and 25/27
epitopes were targeted by at least one person
• All patients recognized at least 1 A3 epitope, up to 8 A3 epitopes, but none was clearly dominant
RT (269–277) RT (424–432) QIYPGIKVR HIV-1 infection human (A3) Yu2002a
• Epitope name: A3-QR9
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
• 1/14 HLA-A3 positive individuals had detectable A3-restricted responses to this epitope during acute infection, but only 5/15 of HLA-A3 epitopes tested
were targeted during acute infection. 4/7 individuals began to have detectable responses to this epitope after STI.
RT (271–279) (LAI) YPGIKVRQL HIV-1 infection human (B*4201) Brander2001
• C. Brander notes this is a B*4201 epitope
RT (271–279) RT (438–446 IIIB) YPGIKVRQL HIV-1 infection human (B42) Menendez-Arias1998,
Wilson1996
• YAGIKVRQL and YPGIKVKQL are naturally occurring variants that are both reactive
• YHKIKVRQL is a naturally occurring variant that has not been tested
• Epitope defined in the context of the Pediatric AIDS Foundation ARIEL Project, a mother-infant HIV transmission study
RT (271–279) Pol (438–446 IIIB) YPGIKVRQL HIV-1 infection human (B42) Wilson1999a
• This study describes maternal CTL responses in the context of mother-to-infant transmission
• Detection of CTL escape mutants in the mother was associated with transmission, but the CTL-susceptible forms of the virus tended to be found in infected
infants
• An additional variant that gave a positive CTL response: YPGIKVKQL, YAGIKVRQL
• YHGIKVRQL was an escape mutant
RT (293–301) RT (448–456 SF2) IPLTEEAEL HIV-1 infection human (B*3501) Menendez-Arias1998,
Tomiyama1997
• A CTL clone responsive to this epitope was obtained
• Only 1/7 B35-positive individuals had a CTL response to this epitope
• An E to K substitution at position 5 abrogates specific lysis, but not binding to B*3501
• An I to V substitution at position 1, P to Q at position 2, and E to K at 5, abrogates specific lysis and binding to B*3501
• An I to V substitution at position 1 did not alter reactivity
• Reviewed in [Menendez-Arias1998], this epitope lies in the thumb region of RT
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RT (293–301) Pol (448–456 SF2-24) IPLTEEAEL HIV-1 infection human (B*3501 AND
B*5101)
Tomiyama2000b
• Epitope name: HIV-B35-SF2-24
• This epitope is naturally processed and presented by both HLA-B*3501 and HLA-B*5101 and is cross-recognized by a single CTL clone
• IPLTEEAEL binds approximately four times more tightly to HLA-B*3501 than HLA-B*5101.
RT (293–301) Pol (489–456) IPLTEEAEL HIV-1 infection human (B*3501,
B*5301, B*5101,
B*0702)
Ueno2002
• The IPLTEEAEL epitope was known to be presented by both HLA-B*3501 and -B*5101 to a dual specific CTL clone. A single TCR complex bearing
Valpha12.1 and Vbeta5.6 was shown recognize the epitope in either HLA-B*3501 and -B*5101. Furthermore, this TCR also recognized the peptide
presented by B*5301 and B*0702 in cytolytic CTL assays, demonstrating that this single TCR complex recognizes the same peptide presented by a range
of HLA class I molecules.
RT (293–301) (SF2) IPLTEEAEL HIV-1 infection human (B35) Kawana1999
• HLA B35 is associated with rapid disease progression
• The sequences of 9 previously described HIV-1 B35 CTL epitopes were obtained in 10 HLA B35+ and 19 HLA B35- individuals
• 3/9 CTL epitopes had substitutions that were more common in B35+ individuals than in B35- individuals but this was one of the six that had no B35
associated pattern of mutation
RT (293–301) RT (448–456 SF2) IPLTEEAEL HIV-1 infection human (B35, B51) Menendez-Arias1998,
Shiga1996
• Binds HLA-B*3501 and B*5101
• Reviewed in [Menendez-Arias1998], this epitope lies in the thumb region of RT
RT (293–301) Pol (447–455) IPLTEEAEL HIV-1 infection, HIV-1 exposed
seronegative
human (B51) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
RT (294–318) RT (461–485 HXB2) PLTEEAELELAENREILKE-
PVHGVY
HIV-1 infection human (A2) Menendez-Arias1998,
Walker1989
• One of five epitopes defined for RT-specific CTL clones in this study
RT (308–317) RT (LAI) EILKEPVGHV HIV-1 infection human (A*0201) Menendez-Arias1998,
vanderBurg1997
• Recognized by CTL from a long-term survivor, SPIETVPVKL was also recognized
• Recognized by CTL from a progressor, EELRQHLLRW and TWETWWTEYW were also recognized
RT (309–317) RT (476–484 LAI) ILKEPVHGV HIV-1 infection human Luzuriaga2000
• Longitudinal study of 8 infants with prolonged viral suppression due to combination antiretroviral therapy showed no HIV-1 specific CTL responses in
peripheral blood cells. 6/8 were studied using a Chromium release assay and no response was detected using Gag expressed in vaccinia in the target cells.
Three HLA-A*0201 children were tested using SLYNTVATL or ILKEPVHGV HLA A*0201 tetramers and again no HIV-specific response was detected,
either using PBMC specimens, or PBMC which had been stimulated in vitro for a week.
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• In contrast, one of the children with suppressed HIV viral replication who was co-infected with HIV and EBV, while HIV-tetramer negative, had
EBV-tetramer staining cells at a frequency of 0.14% in the PBMC.
RT (309–317) RT (476–484) ILKEPVHGV HIV-1 infection human (A*02) Huang2000
• The single cell ELISPOT assay was optimized and highly specific, and found to work well even after the primary cells had been frozen and thawed
• Increases in gamma interferon producing cells were observed in response to anti-retroviral therapy using single cell IFN-gamma-production ELISPOT
RT (309–317) RT (476–484) ILKEPVHGV HIV-1 infection human (A*02) Rinaldo2000
• Administration of triple-drug antiretroviral therapy (IDV, 3TC and ZDV) sometimes showed a transient increase and other times failed to increase CTL
responses in patients with advanced HIV disease, but there is a stable population of tetramer stained HIV-specific CD8+ CD45RO+ cells that persist after
therapy and long periods of virus being below the level of detection
RT (309–317) RT ILKEPVHGV HIV-1 infection human (A*02) Scott-Algara2001
• Epitope name: IV9
• This study examined with CTL response in HLA A*02+ children by tetramer staining for HLA-A2 immunodominant epitopes SLYNTVATL and
ILKEPVHGV
• 71% of the 28 HIV-1 infected HLA-A*02 positive children recognized both epitopes, with cells from 26 children stained positive by the gag tetramer
(SLYNTVATL) and 21 children by the pol tetramer (ILKEPVHGV)
• There were no differences observed in children that had therapy versus those that did not
• Tetramer-binding cells were memory activated CD28-, CD45RO+, CD45RA- HLADR+, CD69-, CD8+ T-cells
RT (309–317) ILKEPVHGV HIV-1 infection human (A*0201) Wilson2000a
• Three individuals with highly focused HIV-specific CTL responses were studied during acute infection using tetramers – high frequencies of HIV-1-specific
CD8+ T cells were found prior to seroconversion, and there was a close temporal relationship between the number of circulating HIV-specific T cells and
viral load was also found
• All three patients were B*2705, with HLA alleles: A1, A30/31, B*2705, B35; A1, A*0301, B7, B2705; and A*0201, A*0301, B2705, B39
• ELISPOT was used to test a panel of CTL epitopes that had been defined earlier and were appropriate for the HLA haplotypes of the study subjects – 3/3
subjects showed a dominant response to the B*2705 epitope KRWIILGGLNK
• The subject with A*0201 had a moderatly strong response to SLYNTVATL
• Weak responses were observed to A*301-RLRPGGKKK, A*301-QVPLRPMTYK, and B7-TPGPGVRYPL in the subject who was HLA A1, A*0301, B7,
B*2705
• No acute response was detected to the following epitopes: A*201-ILKEPVHGV, A*301-KIRLRPGGK, A*301-AIFQSSMTK, A*301-TVYYGVPVWK,
B35-EPIVGAETF, B35-HPDIVIYQY, B35-PPIPVGEIY, B35-NSSKVSQNY, B35-VPLRPMTY, B35-DPNPQEVVL
RT (309–317) Pol (476–484) ILKEPVHGV HIV-1 infection human (A*0201) Spiegel2000
• High levels of CD8+ HIV-1 specific and cytomegalovirus specific CTL were detected by HLA-A*0201-peptide tetramers in 3 infected subjects with very
low CD4 counts, but CD8 T cell mediated effector activity was not seen
• Thus HIV-1 specific CD8+ cells may be present but may lack direct effector activity in late disease, suggesting that overcoming antigen unresponsiveness
may be a useful therapeutic strategy
RT (309–317) Pol (476–484) ILKEPVHGV HIV-1 infection human (A*0201) Sewell1999
• Proteasome regulation influences epitope processing and could influence immunodominance
• The proteasome is inhibited by lactacystin treatment, and gamma IFN induces expression of proteasome subunits, LMP2 and LMP7, which combine with
the proteasome to create an immunoproteasome
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• IFN-gamma induction of the immunoproteasome and lactacystin inhibition increases the presentation of the A*0201 VIYQYMDDL epitope, but decreases
the presentation of the A*0201 ILKEPVHGV epitope, which is immunodominant within pol proteins, showing the two epitopes are processed by different
pathways
• ILKEPVHGV seems to be processed by the classical proteasome pathway, while VIYQYMDDL appears to be destroyed by this pathway
• This epitope contains the catalytic site (YMDD) of RT, a conserved sequence in HIV-1 which restricts escape mutants
RT (309–317) Pol (476–484) ILKEPVHGV HIV-1 infection human (A*0201) Loing2000
• The ILKEPVHGV was modified by the addition of an N-palmitoyl-lysine residue at the P0, P1 or P10 positions of the parent peptide to create a lipopeptide
for direct antigen delivery to the cytoplasm for processing
• The N-terminal modification increased the life span for functional CTL recognition up to 48 hours in comparison to the parent peptide
RT (309–317) Pol (510–518) ILKEPVHGV Vaccine human (A*0201) Larsson1999
Vaccine Vector/Type: vaccinia, canarypox HIV component: Gag, Pol, Nef, Env
• ELISPOT was used to assay the CD8 T cell response to the HIV-1 proteins Gag, Pol, Nef or Env expressed in vaccinia or canarypox vectors in 19 HIV+
people
• The highest CTL frequency was directed at epitopes in Pol
• In A*0201 individuals, higher numbers of spot-forming T cells were directed against HIV-1 proteins expressed in vaccinia than to peptides SLYNTVATL
and ILKEPVHGV presented by A2
RT (309–317) RT (476–484) ILKEPVHGV HIV-1 infection human (A*0201) Wilson1998a
• HIV+ individuals were followed longitudinally using MHC tetramers in combination with 14 anti-BV chain MAbs, and clonal expansion of HIV-specific T
cells was followed in vivo
• Seven HIV+ people were studied, and all showed expansions of particular TCR BV clones, often several, relative to uninfected controls
• Three patients were followed in detail, TCR VB expansions persisted for 2 to 3 years, with occasional transient increases
RT (309–317) RT (476–484) ILKEPVHGV HIV-1 infection human (A*0201) Betts2000
• Only 4/11 HLA-A2+ HIV+ individuals had CTL that reacted to SLYNTVATL, calling into question whether it is immunodominant
• 95 optimally-defined peptides from this database were used to screen for INFγ responses to other epitopes
• 2/11 of the A2+ individuals responded to ILKEPVHGV, and neither of these two responded to SLYNTVATL
RT (309–317) Pol ILKEPVHGV HIV-1 infection human (A*0201) Gray1999
• Administration of highly active antiretroviral therapy (HAART) reduced CD8+ cell frequency, and the CD8+ cells detected by tetramer staining were likely
to be memory cells, indicating that persistently replicating viral populations are needed to maintain high frequencies of HIV-1 specific CTL
RT (309–317) RT (476–484) ILKEPVHGV HIV-1 infection human (A*0201) Menendez-Arias1998,
Ogg1998b
• HLA-tetrameric complexes were used in a cross-sectional study of 14 untreated HLA A*0201 positive individuals, revealing an inverse relationship
between HIV Gag and Pol specific CTL effector cells (CTLe) and viral load
• Inclusion of both the p17 SLYNTVATL and RT ILKEPVHGV epitopes gives a good representation of HLA A*0201-restricted activity
• No correlation was observed between the CTLe and CD4 count or clearance rate of productively infected cells
RT (309–317) RT ILKEPVHGV Vaccine human (A*0201) Hanke1998a, Hanke1998b
Vaccine Vector/Type: vaccinia HIV component: polyepitope
• This epitope was shown to be processed and presented to appropriate CTL clones upon infection of human target cells with vaccinia virus Ankara (VVA)
carrying 20 HIV-1 epitopes recognized by humans
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RT (309–317) RT (476–484) ILKEPVHGV in vitro stimulation human (A*0201) Konya1997,
Menendez-Arias1998
• This epitope was included as a positive control
• Binding affinity to A*0201 was measured,C_1/2maxµM = 12
RT (309–317) RT (468–476) ILKEPVHGV in vitro stimulation human (A*0201) vanderBurg1996
• Immunogenic in humans, slow dissociation rate, and associated with immunogenicity in transgenic HLA-A*0201/Kb mice
• CTL generated by in vitro stimulation of PBMC derived from uninfected individual
RT (309–317) RT (468–476) ILKEPVHGV in vitro stimulation human (A*0201) vanderBurg1995
• Binds HLA-A*0201 – CTL generated by in vitro stimulation of PBMC from an HIV negative donor
RT (309–317) RT (476–484) ILKEPVHGV HIV-1 infection human (A*0201) Menendez-Arias1998,
Pogue1995
• Mutational study: position 1 I to Y increases complex stability with HLA-A*0201
RT (309–317) RT (476–484) ILKEPVHGV HIV-1 infection human (A*0201) Goulder1997e, Goulder1997a,
Menendez-Arias1998
• Identical twin hemophiliac brothers were both infected with the same batch of factor VIII
• One had a response to gag A2 epitope SLYNTVATL, the other to pol A2 epitope ILKEPVHGV
• Viral sequencing from the twin that had no response to SLYNTVATL indicated his virus had the substituted form SLHNAVAVL
• 71% of an additional set of 22 HIV-1 infected HLA-A*0201 positive donors preferentially responded to gag SLYNTVATL
• Those individuals with a pol ILKEPVHGV response tended to have mutations in or around SLYNTVATL
• [Goulder1997a] is a review of immune escape that summarizes this study
RT (309–317) RT (309–317) ILKEPVHGV HIV-1 infection human (A*0201) Altman1996
• This paper introduces the tetramer methodology which permits quantification of specific CTL based on expression of specific TCRs—HLA-A2 tetramers
were prepared that can stain CTL lines specific for ILKEPVHGV and SLYNTVATL, and can quantify HIV-specific CD8+ cell lines in freshly isolated
PBMCs.
• Three patients only stained the Gag epitope SLYNTVATL, one patient had the highest frequency of tetramer staining to the Pol epitope (0.77%), less to the
Gag epitope (0.28%)
• The A2-Pol CD8+ clones were CD45RO positive and HLA-DR and CD38 negative, suggesting a memory rather than effector phenotype
RT (309–317) RT (476–484) ILKEPVHGV in vitro stimulation human (A*0201) Menendez-Arias1998,
Walter1997
• HLA-A2 heavy chain and β2-microglobulin expressed in E. coli were refolded in the presence of this peptide
• The HLA-A2-peptide complex elicited HLA-A2 peptide-specific CTL response in cells lacking HLA-A2
• Suggests that preformed HLA-peptide complexes could provide an alternate to intracellular processing for immunogens
RT (309–317) RT (464–472) ILKEPVHGV HIV-1 infection human (A*0201) Gray1999
• Peptide-tetramer complexes of A*0201 and SLYNTVATL or ILKEPVHGV were used to study individuals receiving HAART to determine the frequency of
Class I HLA-restricted anti-HIV CD8+ T cells
• 17/18 asymptomatic patients had a CTL response to one or both epitopes – 72% had a CTL response to SLYNTVATL
• After HAART, the majority of the epitope-specific CTL were apparently memory cells
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RT (309–317) RT (476–484) ILKEPVHGV HIV-1 infection human (A*0201) Brander1998a, Brander2001
• Of 17 infected HLA A*0201 subjects, 13 had CTL responses against the p17 SLYNTVATL epitope, six recognized ILKEPVHGV and five recognized
VIYQYMDDL, and there was no correlation between viral load and recognition of a specific epitope or evidence of immune escape
• Only one subject had CTL against all three epitopes
• Subjects were part of the San Francisco City Clinic Cohort, the ARIEL project and from the Boston area
• C. Brander notes this is an A*0201 epitope
RT (309–317) Pol (476–484) ILKEPVHGV HIV-1 infection human (A*0201) Ogg1999
• CTL effector levels were measured after potent ARV therapy using HLA-tetramer complexes for the A*0201 epitopes SYLVTVATL and ILKEPVHGV in
seven patients, and the B*3501 epitope DPNPQEVVL in one additional patient
• Levels of CTL effectors typically decline for 5-7 days and then rebound, fluctuating during the first two weeks of therapy
• After the early fluctuation, there was a steady exponential decay with a median half-life of 45 days
RT (309–317) RT (476–484 LAI) ILKEPVHGV HIV-1 infection human (A*0201) Brander2001
• C. Brander notes this is a A*0201 epitope
RT (309–317) RT (476–484) ILKEPVHGV HIV-1 infection, in vitro
stimulation
human (A*0201) Dela Cruz2000
• Epitope name: IV9
• Integration of HIV RT CTL epitopes into the N-terminus of the HLA-A2 heavy chain, or tethering the epitopes to the target chain, resulted in
epitope-specific lysis by CD8+ CTL
• These antigens could also be used to stimulate primary responses in vitro
RT (309–317) RT (309–317) ILKEPVHGV HIV-1 infection human (A*0201) Samri2000
• Epitope name: P1
• The epitope was recognized by patient 250#0 but not in another A*0201+ patient, 201#5, in a study of the effects of therapy escape mutations on CTL
recognition
RT (309–317) Pol (LAI) ILKEPVHGV in vitro stimulation human (A*0201) Engelmayer2001
• Recombinant canarypox virus vector containing HIV-1 sequences, upon infection of mature dendritic cells, can trigger specific lysis through in vitro by
T-cells from HIV-1 infected individuals at levels comparable to the response seen to HIV carried in vaccinia vectors
• Recombinant canarypox virus vector containing HIV-1 sequences can also stimulate HIV-specific CD4+ helper T-cell responses
RT (309–317) Pol ILKEPVHGV HIV-1 infection human (A*0201) Gea-Banacloche2000
• In a study including many long-term non-progressors, no correlation between plasma virus levels and number of HIV-specific CD8+ T-cells was found
• High frequencies of circulating CD8+ T-cells were HIV-1 specific, and the majority of these responses were to gag-pol gene products
• 4/21 subjects were HLA-(A*0201), and of these only 2 subjects (patient 3 and 19) tested positive to this epitope
RT (309–317) Pol (476–484) ILKEPVHGV HIV-1 infection human (A*0201) Jin2000a
• The CTL effector levels (CTLe) were compared in long term non-progressors (LTNP) with low viral load and in patients whose virus was well-suppressed
by therapy, using a tetramer assay
• LTNPs have high memory CTLe numbers and low viral load, while HAART patients had low CTLe numbers and low viral load
RT (309–317) Pol (476–484) ILKEPVHGV HIV-1 infection human (A*0201) Appay2000
• Combined tetramer and intracellular cytokine staining was used to study the function of circulating CD8+ T cells specific for HIV and CMV
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• HIV-specific CD8+ T cells expressed lower levels of perforin than CMV-specific CD8+ T cells from the same donor, and this was associated with persistent
CD27 expression on HIV-specific cells, suggesting impaired maturation
• In most donors, between 50% and 95% of the activated virus-specific CD8+ T cells produced IFN-γ and MIP-1β with a distinct subset that failed to
produce TNF-α
RT (309–317) Pol ILKEPVHGV HIV-1 infection human (A*0201) Ostrowski2000
• The role of CD4+ T-cell help in expansion of virus-specific memory CTL was studied through co-culture ex vivo
• Optimal expansion of HIV-1-specific memory CTL depended on CD4+ T cell help in 9 of 10 patients – CD40 ligand trimer (CD40LT) could enhance CTL
in the absence of CD4+ T cell help to a variable degree in most of patients
• Those CTL that didn’t respond to CD40LT could expand with IL2 present, and IL15 produced by dendritic cells also contributes
• The T-helper epitope used for CD4+ T cell stimulation was the universal tetanus helper epitope TET830-843 (QYIKANSKFIGITE)
RT (309–317) RT (309–317) ILKEPVHGV Vaccine human, murine
(transgenic) (A*0201)
Guardiola2001
Vaccine Vector/Type: HIV-1 peptide in filamentous bacteriophage major coat protein HIV component: RT peptide
• Epitope name: RT2
• HLA-A2 transgenic mice were injected with bacteriophage antigens expressing a Th epitope and the HIV CTL epitope ILKEPVHGV, and epitope-specific
cytotoxic activity was induced.
RT (309–317) Pol (476–484) ILKEPVHGV HIV-1 infection human (A*0201) Sewell2002
• Epitope processing of three different HLA-A*0201 HIV epitopes was shown to use different pathways, which might influence patterns of
immunodominance. .174 cells were used that lack TAP1 and TAP2 genes, as well as the LMP2 and LMP7 genes that encode the beta-subunits of the
immunoproteasome. These genes could be added back through transfection to study processing.
• ILKEPVHGV was efficiently presented in TAP-1 and -2 transfected cells while VIYQYMDDL and SLYNTVATL were not. VIYQYMDDL was destroyed
by the MB1 subunit of the protease, and could be expressed in the presence of the proteasome inhibitor lactacystin, but SLYNTVATL expression was not
restored. SLYNTVATL expression was unaltered by lactacystin in a wild type cell line.
RT (309–317) Pol ILKEPVHGV HIV-1 infected monocyte-derived murine (A*0201) Poluektova2002
• Epitope name: IL-9
• Nonobese diabetic NOD-C.B-17 SCID mice were reconstituted with HLA-A*0201 positive human PBL and injected with HIV-1 infected
monocyte-derived macrophages MDM in the basal ganglia to provide a mouse model of HIV-1 encephalitis.
• HLA-A*0201 CTL responses were detected by tetramer staining in the spleen in seven days, increased through day 14, and the numbers of productively
infected were reduced >85% in the second week.
RT (309–317) RT (309–317) ILKEPVHGV Vaccine murine (transgenic)
(A*0201)
Boissonnas2002
Vaccine Vector/Type: peptide HIV component: RT Adjuvant: CFA
• Ten naturally occurring variants of the Nef epitope VLMWQFDSRL were tested for their affinity to HLA-A*0201 and for their ability to induce
gamma-IFN and cytotoxic functions through vaccination of HLA-A*0201 transgenic mice.
• ILKEPVHGV could induce HLA-A*0201 vaccine responses, and was a positive control.
RT (309–317) Pol (468–476) ILKEPVHGV Vaccine murine (A*0201) Singh2002, Sykes1999
Vaccine Vector/Type: DNA HIV component: HIV-1 divided into a 32 plasmids in a ubiquitin expression library
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• C3H (H-2k) transgenic mice carrying a fused HLA-A*0201 alpha1 and alpha2 and H-2Dk alpha3 hybrid class I molecule were immunized using an
epidermal gene gun with an ubiquitin expression library of 32 plasmids that spanned the HIV-1 genome. Ubiquitin targets the expressed HIV-1 peptides to
the proteasome.
• A single immunization with the UB-HIV-1 library vaccine induced potent, stable and multivalent CTL responses against all library members.
• Immunodominant epitopes SLYNTVATL (Gag), ILKEPVHGV(Pol), RIQRGPGRAFVTIGK(P18) and AFHHVAREK (Nef) elicited strong CD8+/IFN-
responses and stimulated CTL that were functional in a Cr-release assay and against wild type antigen.
• The presence of multiple plasmids HLA-A*0201-restricted CTL epitopes did not decrease CTL immunogenicity, and CTL responses to single peptide
immunizations were comparable to responses based on mixtures of either 16 or 32 peptides.
RT (309–317) Pol ILKEPVHGV HIV-1 infection, Vaccine human, macaque
(A*0201)
Hanke2000, Wee2002
Vaccine Vector/Type: DNA prime with vaccinia MVA boost Strain: subtype A HIV component: p17, p24, polyepitope
• The HIV-1 subtype A focused vaccine HIVA contains p24 and p17, in a reversed order relative to the Gag polyprotein to prevent myristylation of p17,
which could direct the protein to the cell membrane and inhibit efficient peptide processing and class I presentation, as well as a polyepitope string of
conserved, often immunodominant epitopes that were selected to have particularly good cross-reactive potential for the A-clade epidemic in Nairobi,
Kenya. A DNA and MVA prime-boost vaccination protocol using the HIVA antigen will be used in a phase III clinical trial in Kenya. This epitope is
included in the polyepitope string [Hanke2000].
• Multiple CD4+ or CD8+ T-cell vaccine-induced responses to peptide pools were detected using intracellular cytokine staining and IFNgamma Elispot
assays after vaccination of 5 macaques. The response to the Mamu A*01 SIV p27 epitope p11C (CTPYDINQM), included in the polyepitope region, was
not immunodominant in the Mamu A*01 vaccinated macaques, possibly because of processing limitations in context of the artificial polyepitope string
[Wee2002].
RT (309–317) RT (476–484 LAI) ILKEPVHGV HIV-1 infection human (A*0201,
A*0205)
Mollet2000
• Epitope name: P1
• A panel of 16 epitopes covering 15 class I alleles was tested in 14 HIV+ patients from an unselected Caucasian population treated with HAART, using
tetramer staining or CD8+ cell IFNgamma production to measure responses
• In general, during the first month of treatment viral load decreased and frequencies of HIV-specific CTL tripled and broadened – eight new HIV
specificities that were not previously detectable were newly detected, as were CMV specific CD8+ PBL – but with continued viral suppression,
HIV-specific responses diminished
• Viral rebounds gave different patterns of response: increases or decreases in pre-existing response, new specificities, or no change
RT (309–317) ILKEPVHGV HIV-1 infection human (A02) Sabbaj2002b
• Epitope name: Pol-IV9
• Among HIV+ individuals who carried HLA A02, 9/29 (31%) recognized this epitope
RT (309–317) Pol (476–484) ILKEPVHGV Vaccine human (A2) Woodberry1999
Vaccine Vector/Type: vaccinia HIV component: polyepitope
• A polyepitope vaccine was generated in a vaccinia construct that contiguously encoded seven epitopes, all presented by HLA A-2
• HHD mice have a transgene of HLA A2 linked to the transmembrane and cytotoxic domains of H-2Dd – this transgene is the only MHC molecule
expressed in the mice
• CTL responses to Gag (77-85) SLYNTVATL, Pol (476-484) ILKEPVHGV, gp120 (120-128) KLTPLCVTL, and Nef (190-198) AFHHVAREL were
observed in HIV polytope HHD-vaccinated mice, and these responses were enhanced with vaccinia boost
215
DEC 2002
C
TL
HIV CTL Epitope Tables RT CTL Epitopes
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
• No CTL immune responses were generated against HLA A2-restricted HIV epitopes Nef 157-166 (PLTFGWCYKL), Pol 346-354 (VIYQYMDDL), and
Nef 180-189 (VLEWRFDSRL)
• Sixteen HLA A2+ patients were tested for their ability to make CTL responses by peptide restimulation in culture with the epitopes selected for inclusion in
the polytope – one individual recognized all seven of these epitopes; 7 patients had CTL cultures able to recognize at least one of the epitopes, and 6 of
those 7 recognized more than one epitope, but they were not able to test all peptides for all patients; many patients only had three peptides tested
• ILKEPVHGV was recognized by 2 of the patients
RT (309–317) RT (476–484) ILKEPVHGV HIV-1 infection human (A2) Kolowos1999
• TCR usage in CTL specific for this epitope was examined in three patients and identical Vbeta6.1 and Valpha2.5 gene segments were used and two of the
patients had very similar complementarity-determining regions – clonal expansion of RT-HIV-specific CTL can contribute to the skewed TCR repertoire in
HIV-1 infected patients
• CTL clones from all three patients showed similar sensitivity to mutation in the epitope, ilkepvhEv was well recognized (the sequence from SF2),
ilkDpvhgv was not (the common A clade form)
RT (309–317) RT (476–484) ILKEPVHGV HIV-1 infection human (A2) Collins1998
• Nef down-regulates MHC class I molecules, which inhibits CTL killing of HIV-infected targets
• The anti-RT CTL clone killed Nef- cells less efficiently than anti-gag clones, correlated with the reduced expression of RT
RT (309–317) RT (476–484 LAI) ILKEPVHGV HIV-1 infection human (A2) Fan1997
• The capacity of dendritic cells to process and present antigen and stimulate anti-HIV-1 CTL memory responses was studied
RT (309–317) RT (464–472) ILKEPVHGV HIV-1 infection human (A2) Kundu1998b
• Allogeneic dendritic cells (DCs) were obtained from HLA-identical siblings, pulsed with rgp160 MN or A2-restricted HIV-1 epitope peptides, and infused
monthly into six HIV-infected patients
• 1/6 showed increased env-specific CTL and increased lymphoproliferative responses, 2/6 showed increase only in proliferative responses, and 3/6 showed
no change – pulsed DCs were well tolerated
• ILKEPVHGV is a conserved HLA-A2 epitope included in this study – 5/6 patients had this sequence as their HIV direct sequence, and these had a
detectable CTL response– one person carried the form ILREPVHGV and had no detectable CTL
RT (309–317) RT (476–484) ILKEPVHGV HIV-1 infection human (A2) Menendez-Arias1998,
Tsomides1994
• CTL clones recognize naturally processed peptide – peptide abundance corresponded to level of CTL killing
RT (309–317) RT (476–484) ILKEPVHGV HIV-1 exposed seronegative human (A2) Rowland-Jones1998a
• A CTL response was found in exposed but uninfected prostitutes from Nairobi using previously-defined B clade epitopes that tended to be conserved in A
and D clades – such cross-reactivity could protect against both A and D and confer protection in Nairobi where both subtypes are circulating
• The A subtype consensus is ILKDPVHGV
• The D subtype consensus is identical to the epitope ILKEPVHGV
RT (309–317) RT (476–484) ILKEPVHGV HIV-1 infection human (A2) Cao1997a, Menendez-Arias1998
• The consensus peptides of B and D clade viruses and some As have the sequence ILKEPVHGV
• The consensus peptide of a subset of A clade viruses, ILKDPVHGV, is not cross-reactive
RT (309–317) RT (476–484) ILKEPVHGV HIV-1 infection human (A2) Menendez-Arias1998, Yang1996
• CD4+ cell lines acutely infected with HIV were studied to determine their susceptibility to lysis by CTL
• Clones specific for RT lysed HIV-1 infected cells at lower levels than Env or Gag specific clones
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• The distinction was thought to be due to lower expression of RT relative to Env and Gag
• CTL can lyse infected cells early after infection, possibly prior to viral production
RT (309–317) RT (476–484) ILKEPVHGV HIV-1 infection human (A2) Yang1997a
• CTL inhibit HIV-1 replication at effector cell concentrations comparable to those found in vivo
• CTL produced HIV-1-suppressive soluble factors – MIP-1α , MIP-1β , RANTES, after antigen-specific activation
• CTL suppress HIV replication more efficiently in HLA-matched cells
RT (309–317) RT (309–317) ILKEPVHGV HIV-1 infection human (A2) Menendez-Arias1998, Moss1995
• Two clones were obtained with different TCR usage, V_β1 and V_β21
RT (309–317) RT (476–484) ILKEPVHGV HIV-1 infection human (A2) Menendez-Arias1998,
Musey1997
• Cervical CTL clones from an HIV-infected woman recognized this epitope
RT (309–317) RT (476–484 LAI) ILKEPVHGV HIV-1 infection human (A2) Menendez-Arias1998,
Tsomides1991
• Precise identification of the nonamer that binds to A2
RT (309–317) RT (476–484 LAI) ILKEPVHGV Peptide-HLA interaction human (A2) Connan1994,
Menendez-Arias1998
• Promotes assembly of HLA-A2 molecules in T2 cell lysates
RT (309–317) RT (510–518) ILKEPVHGV in vitro stimulation human (A2) Parker1992
• Studied in the context of HLA-A2 peptide binding
RT (309–317) Pol (476–484) ILKEPVHGV HIV-1 infection human (A2) Dyer1999
• CTL specific responses were measured over a 1.3 to 1.5 year period in members of the Sydney Blood Bank Cohort (SBBC) who had been infected with a
natural attenuated strain of HIV-1 which was Nef-defective
• Some of these patients had prolonged high levels of CTL effector and memory cells despite low viral load
RT (309–317) RT (476–484) ILKEPVHGV in vitro stimulation human (A2) Zarling1999
• This study compares the ability of macrophages and dendritic cells to stimulate primary responses in CD8+ lymphocytes isolated from HLA-appropriate
HIV-uninfected donors using peptide-pulsed APC – the dendritic cells performed better as APC for the stimulation of primary responses
• Strong CTL responses were elicited by the epitopes DRFYKTLRA and GEIYKRWII when presented by either immature or mature dendritic cells –
macrophages were not able to prime a CTL response against DRFYKTLRA
• A weak response to KLTPLCVSL was stimulated using macrophages as the APC
• No detectable response was observed for the following previously-defined HIV epitopes: KIRLRPGGK, ILKEPVHGV, IRLRPGGK, GPKVKQWPL
RT (309–317) RT (480–) ILKEPVHGV computer prediction (A2) Schafer1998
• This study uses EpiMatrix for T cell epitope prediction to identify possible HLA-B27 and A-2 CTL epitopes in HIV
• Based on EpiMatrix predictions, 28 peptides were synthesized and tested using T2 binding assays for potential HLA A2 or B27 binding, and 12 of these
were shown to bind to the predicted HLA molecule
• Two of these 12 peptides had been previously identified as CTL epitopes: HLA-B27 KRWILGLNK and HLA-A2 ILKEPVHGV
• This sequence is not conserved between clades, but is found only in a small number of B clade isolates
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RT (309–317) RT ILKEPVHGV HIV-1 infection human (A2) Altfeld2001c
• Epitope name: RT IV9
• HIV was scanned for all peptides which carried the A2-supermotif pattern conserved in more than 50% of B clade sequences – 233 peptides met this
criteria, and 30 of these bound to HLA-A*0201 – 20/30 bound to at least 3/5 of HLA-A2 supertype alleles tested
• Three additional previously described HLA-A2 epitopes were added to the set of 20, and 18/22 chronically infected HLA-A2 individuals had CTL that
recognized at least one of the 23 peptides (median of 2 and maximum of 6), while 6/12 acute infected individuals recognized at least 1 (median of 1 and
maximum of 2)
• This peptide binds to four HLA-A2 supertype alleles: A*0201, A*0202, A*0206 (highest affinity) and A*6802
• RT IV9 was recognized in 7/22 patients with chronic HIV-1 infection
• 1/13 patients with acute HIV-1 infection recognized RT IV9
RT (309–317) Pol (subtype A) ILKDPVHGV HIV-1 infection human (A2) Kaul2001c
• This study examines CTL responses in HIV exposed, persistently seronegative individuals, HEPS, who eventually seroconverted – 11/114 HEPS Nairobi
sex workers eventually seroconverted, and for six of these HIV CTL reactive epitopes had been defined while seronegative
• ILKDPVHGV or ILKEPVHGV was recognized in 1 of the 6 women (ML1760), and the response was present in the last available sample prior to
seroconversion, 12 months
• 20/20 sequences of the infecting strain had no substitutions in this epitope, all were ILKDPVHGV, so there was no evidence for escape
• The epidemiological factor associated with seroconversion was stopping sex work and HIV-specific CTL activity declines when HEPS sex workers stop
working for a period or retire
• This epitope was recognized by 4/22 HEPS control sex workers: ML887, ML1192, ML1250, and ML1749
RT (309–317) RT (476–484) ILKEPVHGV HIV-1 infection human (A2) Oxenius2000
• Epitope name: ILK
• Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific
CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load – three patients that had delayed initiation of
HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became
undetectable
• One of the 2/8 HLA-A2+ study subjects recognized this CTL epitope
• Patient SC9 (HLA A1/2, B8/13, Cw0/0701, DR2/11, DQ6/7) had a CTL response against epitopes FLKEKGGL, ILKEPVHGV,
SQRRQDILDLWIYHTQGYFPDWQNY, and GEIYKRWII peptides and all responses declined during therapy initiated at day 390 but were restored when
therapy become intermittent
RT (309–317) Pol ILKEPVHGV HIV-1 infection human (A2) Kostense2001
• HLA tetramers to six epitopes were used to study HLA-A2, B8 and B57 CTL in 54 patients – HIV-specific tetramer positive cells were inversely correlated
with viral load in patients with high CD4, but in patients with CD4 T-cells below 400 high tetramer frequencies were found despite high viral load
• Most patients have high levels of HIV-specific T-cell expansions, but many of these cells aren’t functional
• In 15 of the patients, the proportion of IFN gamma producing tetramer cells correlated with AIDS-free survival
RT (309–317) Pol ILKEPVHGV HIV-1 infection human (A2) Seth2001
• CTL responses were studied by tetramer staining in 41 patients with combination therapy – activated CD8+ T-cells decline as the viral load drops in
response to therapy, but the overall level of antigen-specific cells capable of differentiating into effectors stays constant and new epitopes may be recognized
• 6/10 A*0201+ individuals had HIV-specific tetramer staining cells, and 5 of these declined upon successful therapy
• 3/10 A*0201+ individuals with chronic HIV-1 infection recognized this epitope
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• Prior to therapy, the mean percentage of CD8+ cells that recognized the immunodominant epitope SLYNVATL was six-fold greater than the percentage
recognizing the epitope ILKEPVHGV
RT (309–317) RT (476–484 SF2) ILKEPVHGV HIV-1 infection human (A2) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-A2+ individuals that had a CTL response to this epitope broken down by group: 1/10 group 1, 0/6 group 2, and 3/4 group 3
RT (309–317) Pol (476–484) ILKDPVHGV HIV-1 infection, HIV-1 exposed
seronegative
human (A2) Kaul2001a
• Variants ILK(D/E)PVHGV are A/B clade specific
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with
reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected
women
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure
• Among HLA-A2 women, 7/10 HEPS and 14/26 HIV-1 infected women recognized this epitope, and ILK(D/E)PVHGV tended to be more reactive in HEPS
women, SL(F/Y)NTVATL in infected women
• The dominant response to this HLA allele was to this epitope in all 7/10 HEPS cases but in only 5 of the 14/26 HIV-1 infected women
• Four epitopes were considered to be “resistant epitopes”, as they were preferentially reactive in HEPS women and so may confer resistance, and these were
found in three different proteins: A2 ILK(D/E)PVHGV in RT, A*6802 DTVLEDINL in Protease, B14 DLN(M/T)LN(I/V)V in p24 and B18
FRDYVDRF(Y/F)K also in p24
• Differences in epitope specificity were only seen for responses restricted by class I HLA alleles A2, A24, A*6802, B14, and B18, previously shown to be
associated with resistance to HIV-1 in this cohort
• Subject ML 1250 had an A2 response to ILK(D/E)PVHGV prior to seroconversion, which switched to SL(F/Y)NTVATL post-seroconversion
• Subject ML 1760 had an A2 response to ILK(D/E)PVHGV prior to seroconversion, and gained responses to epitopes A2 SL(F/Y)NTVATL and B27
KRWII(L/M)GLNK post-seroconversion
RT (309–317) Pol (93TH253 subtype
CRF01)
ILRIPVHGV HIV-1 infection human (A2) Sriwanthana2001
• Epitope name: P464-472
• This was a study of HIV-1 exposed persistently seronegative (HEPS) female sex workers in Chiang Mai, northern Thailand
• HLA-A11 is very common in this population, and was enriched among the HEPS sexworkers – weak CTL responses were detected in 4/7 HEPS women,
and CTL responses were found in 8/8 HIV+ controls, and 0/9 HIV- women that were not exposed
• This epitope was reactive in HIV+ control study subject 144 who carried HLA-A2
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RT (309–317) Pol (93TH253 subtype
CRF01)
ILRIPVHGV HIV-1 infection human (A2) Bond2001
• More than half of a cohort of HIV+ female sex workers (FSW) from Northern Thailand were HLA-A11 positive, and this study concentrated on A11
epitopes in this group, although E clade versions of previously defined B-clade A2 and A24 epitopes were also tested.
• 1/4 tested FSWs recognized the E clade version of this epitope, which differs from the previously defined B clade version by two amino acids:
ILKEPVHGV
• This epitope was not conserved in many subtypes, and exact matches were very rare
RT (309–317) RT (309–317) ILKEPVHGV HIV-1 infection human (A2) Day2001
• The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7 was
studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
• 2 to 17 epitopes were recognized in a given individual, A2-restricted CTL response tended to be narrow and never dominated the response, and 25/27
epitopes were targeted by at least one person
RT (309–317) Pol (476–484 LAI) ILKEPVHGV HIV-1 infection human (A2) Kelleher2001a
• Ritonavir (RTV) inhibits chymotryptic activity in the 20S proteasome in vitro, as does Saquinavir (SQV) to a lesser extent; Indinavir (IDV) does not. Thus
there is concern protease inhibitors may adversely effect CTL epitope processing, but this paper indicates that processing is not inhibited at therapeutically
relevant concentrations of RTV when the proteasome is functioning in in an intracellular context.
• RTV did not alter the presentation two RT A2 epitopes processed by distinct pathways: ILKEPVHGV, generated by the constitutive proteasome containing
the MB1 beta subunit, and VIYQYMDDL which is dependent on IFNgamma induction of LMP7 which replaces MB1 in the immunoproteasome, and is
destroyed by MB1 in the constitutive proteasome.
• RTV did not inhibit the processing and assembly of HLA-B35 or -A2, which are assembled with a rapid and moderate time course, respectively, or of
HLA-A3, -B27 and -B39.
RT (309–317) Pol ILKDPVHGV HIV-1 infection human (A2) Kaul2002
• Neisseria gonorrhea cervititis in 9 HIV+ Kenyan sex workers caused a functional deficiency in IFN-gamma production in HIV-1 epitope-specific CD8+
T-cells, detected by intracellular cytokine production and tetramer assays, while not affecting the total number of epitope-specific CTLs.
• Ghonorrhea caused the weaker HIV-1 specific CTL responses in 4 HIV-1 exposed persistently seronegative (HEPS) women to become undetectable by
Elispot and tetramer assays, and CMV-specific CTL in 2 HEPS subjects were shown to have impaired function with regard to IFN-gamma production.
RT (309–317) RT (476–484 NL43) ILKEPVHGV HIV-1 infection human (A2) Yang2002
• Nef down-modulates class I protein expression, and this study demonstrates directly that Nef-deleted HIV-1 NL-43 can be more effectively killed in vitro
than NL-43 with an intact Nef. The effect was shown to be specific for class I presentation of epitopes, and unlike Nef, deleting Vpr did not alter CTL
susceptibility of NL-43 infected cells. The CTL clone 68A62, specific for the class I A2 presented ILKEPVHGV epitope, was one of four used in this study.
RT (309–317) RT (476–484 BRU) ILKEPVHGV HIV-1 infection human (A2) Cohen2002
• The antigen presentation of two A2-restricted epitopes was compared, SLYNTVATL (p17) and ILKEPVHGV (RT). HIV-1 infected cells were more
sensitive to lysis by SLYNTVATL-specific CTL than by ILKEPVHGV-specific CTL, because of a higher density of SLYNTVATL-A2 resulting from
differences in processing.
• Incubation with a T1-cell proteolytic extract showed that by four hours, 25% of a p17 peptide had a C-term Leu-85 and were SLYNTVATL-precursors,
while ILKEPVHGV-precursors were far less frequent (6.8%) even with four times more proteolytic extract after 30 hours.
• p17 was preferentially cleaved between Leu85 and Tyr86, while appropriate Val484 and Tyr485 cleavage was minor for RT.
• In a competition experiment, RSLYNTVATL bound TAP 3.7-fold more efficiently than RT peptides.
• No difference in CTL avidity was detected in six patients with HLA-A2-restricted responses to these epitopes.
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• No significant difference in HLA-A2 binding of to p17 or RT epitopes was observed.
RT (309–317) Pol (476–484) ILKEPVHGV Vaccine murine (A2) De Lucca2002
Vaccine Vector/Type: peptide Adjuvant: Freund’s adjuvant
• Epitope name: p9
• BALB/c mice immunized with the p9 peptide, ILKEPVHGV, elicited specific lymphocyte proliferation activity.
• Exposure of lymphocytes from HIV-negative, HLA-A2 positive people to p9-RNA stimulated lymphocyte proliferation activity to p9. Anti-p9 CTL activity
in human lymphocytes incubated with RNA extracted from lymphoid organs of p9-vaccinated mice could be more intensely stimulated.
• This murine RNA also mediated RNA-dependent protein kinase (PKR) and NFkappaB activation in the human lymphocytes, which may be driving the
enhanced CTL stimulation in the human cells.
RT (309–317) RT ILKEPVHGV HIV-1 infection human (A2) Oxenius2002b
• Epitope name: ILK
• Using previously defined epitopes [Oxenius2000, Oxenius2001a] in an IFNgamma Elispot assay, 13 chronically HIV-1 infected patients were studied over a
period including therapy with standard treatment interruptions (STI).
• STIs induced increased recognition of CTL epitopes, but there was no correlation between CTL responses with viral rebound rates, plateau viral loads, or
clearance rates.
RT (309–317) p51 (476–484) ILKEPVHGV Vaccine murine (A2) Kmieciak2001
Vaccine Strain: IIIB HIV component: Gag, Pol Adjuvant: IL-12 (IL-12p35 and IL-12p40)
• Transgenic mice expressing a HLA-A2/Kb chimeric protein were vaccinated with either a p17-p24-p51 fusion protein (vG/P-92) or the Gag-Pol precursor
protein (vVK1).
• Compared to vVK1, vG/P-92 induced a significant increase in Gag and Pol induced IFNgamma production and CTL responses, and to the epitopes
SLYNTVATL and ILKEPVHGV, as determined by Elispot and 51Cr-release assays.
RT (309–317) Pol (476–484) ILKEPVHGV HIV-1 infection human (A2 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind three of the five HLA-A2 supertypes alleles (A*0201, A*020 2, A*0203, A*0206 and A*6802)
RT (309–317) Pol (464–472) ILKEPVHGV HIV-1 infection human (A2, A*0201) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
RT (309–317) Pol (subtype B) ILKEPVHGV HIV-1 exposed seronegative human (A2, A*0202) Rowland-Jones1998b
• HIV-specific CTL were found in exposed seronegative prostitutes from Nairobi – these CTL may confer protection
• Seroprevalence in this cohort is 90-95% and their HIV-1 exposure is among the highest in the world
• Most isolated HIV strains are clade A in Nairobi, although clades C and D are also found – B clade epitopes are often cross-reactive, however stronger
responses are frequently observed using A or D clade versions of epitopes
• This epitope is conserved among B and D clade viruses
• Clade A version of the epitope, ILKDPVHGV, was preferentially recognized by CTL
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RT (309–317) RT (309–317) ILKEPVHGV Vaccine, in vitro stimulation human, murine (A2, A2
transgenic)
De Berardinis2000
Vaccine Vector/Type: HIV-1 peptide in filamentous bacteriophage major coat protein HIV component: RT peptides
• Epitope name: RT2
• Phage display of the CTL epitope, ILKEPVHGV coupled with T helper epitope KDSWTVNDIQKLVGK, elicited specific CTL responses in vitro in
PBMC from HIV negative individuals in and in vivo in immunization of HLA-A2 transgenic mice
• Bacteriophage presentation of peptides is generally used for stimulation of antibodies, and this novel discovery of CTL epitope processing and presentation
suggests new possibilities for these vectors
RT (309–317) Pol ILKEPVHGV Vaccine SJL/J HLA transgenic
mice (A2.1)
Ishioka1999
Vaccine Vector/Type: DNA HIV component: polyepitope
• A minigene vaccine construct encoding 6 HLA 2.1 and 3 HLA A11 restricted CTL epitopes, the universal Th cell epitope PADRE (pan-DR epitope) and an
ER translocating signal sequence was constructed
• The epitopes were chosen for dominant recognition by CTLs during HBV and HIV infections in humans
• HLA transgenic mice were used for quantitating in vivo immunogenicity of DNA vaccines encoding HLA-restricted CTL epitopes – strong responses were
observed to all nine epitopes, and CTL memory persisted up to four months after a single injection
RT (309–317) RT (476–484 LAI) ILKEPVHGV Vaccine murine (A2.1) Peter2001
Vaccine Vector/Type: peptide Strain: LAI Adjuvant: P30, incomplete Freund’s adjuvant (IFA), Montanide (ISA 720), PLG-microparticle
• Epitope name: LR22
• The stability of peptide binding to HLA-A2.1 was determined for six HLA-A2.1 peptides included in this vaccine study – ILKEPVHGV (RT),
SLYNTVATL (p17), SLLNATDIAV (gp41) and LLWKGEGAV (RT) all bound with high affinity comparable to a influenza epitope reference
(GILGFVFTL), while RGPGRAFVTI and VIYQYMDDL bound with a lower affinity (relative binding activity = 0.01).
• The four high-affinity peptides formed stable complexes with half-lives ranging between 8 and 32 hours, while the low affinity peptides had half lives of
less than an hour.
• HLA-A2.1 transgenic mice were immunized with the six HIV-1 peptides and P30, as a universal T-helper epitope, with IFA or Montanide or microspheres
as adjuvants.
• All peptides except VIYQYMDDL induced a stong CTL response in Cr-release assays - stronger responses were observed when peptides were delivered
alone, indicating immunodominance when the combination was used.
RT (309–317) RT (476–484 LAI) ILKEPVHGV Vaccine murine (A2.1) Peter2002
Vaccine Vector/Type: peptide Strain: LAI Adjuvant: P30, incomplete Freund’s adjuvant (IFA), IL-12
• Epitope name: LR22
• When HIV-1 peptides were used to vaccinate HLA-A2.1 transgenic A2-Kb mice, strong responses to five peptides were observed when the peptides were
given individually, but immunodominance limited the response to some of the peptides when they were given in combination [Peter2001]. IL-12 can
counteract immunodominance in BALB/c mice, so it was given with the multiple epitope vaccination, and was instead found to specifically eliminate the
HLA-A2.1-epitope CTL responses, but not Kb CTL responses. This was possibly a consequence of transient depletion of T-cells, B cells and macropahges
in the spleen.
RT (309–318) RT (476–485 LAI) ILKEPVHGVY HIV-1 infection human (B*1501) Brander2001
• C. Brander notes this is a B*1501 epitope
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RT (309–318) RT (309–318) IKLEPVHGVY HIV-1 infection human (B62) Day2001
• No immunodominant responses were detected to four B62-restricted epitopes tested
RT (309–318) RT (476–485 LAI) ILKEPVHGVY HIV-1 infection human (Bw62) McMichael1994,
Menendez-Arias1998
• Review of HIV CTL epitopes
RT (309–318) Pol ILKEPVHGVY HIV-1 infection, Vaccine human (Bw62) Hanke2000, Wee2002
Vaccine Vector/Type: DNA prime with vaccinia MVA boost Strain: subtype A HIV component: p17, p24, polyepitope
• The HIV-1 subtype A focused vaccine HIVA contains p24 and p17, in a reversed order relative to the Gag polyprotein to prevent myristylation of p17,
which could direct the protein to the cell membrane and inhibit efficient peptide processing and class I presentation, as well as a polyepitope string of
conserved, often immunodominant epitopes that were selected to have particularly good cross-reactive potential for the A-clade epidemic in Nairobi,
Kenya. A DNA and MVA prime-boost vaccination protocol using the HIVA antigen will be used in a phase III clinical trial in Kenya. This epitope is
included in the polyepitope string [Hanke2000].
• Multiple CD4+ or CD8+ T-cell vaccine-induced responses to peptide pools were detected using intracellular cytokine staining and IFNgamma Elispot
assays after vaccination of 5 macaques. The response to the Mamu A*01 SIV p27 epitope p11C (CTPYDINQM), included in the polyepitope region, was
not immunodominant in the Mamu A*01 vaccinated macaques, possibly because of processing limitations in context of the artificial polyepitope string
[Wee2002].
RT (328–352) RT (495–515 LAI) EIQKQGQGQWTYQIYQEPF-
KNLKTG
HIV-1 infection human (A11) Menendez-Arias1998,
Walker1989
• One of five epitopes defined for RT-specific CTL clones in this study
RT (340–350) RT (507–516) QIYQEPFKNLK HIV-1 infection human Menendez-Arias1998, Price1995
• Study of cytokines released by HIV-1 specific activated CTL
RT (340–350) Pol (487–497 93TH253
subtype CRF01)
QIYQEPFKNLK HIV-1 infection, HIV-1 exposed
seronegative
human (A11) Sriwanthana2001
• Epitope name: P495-505
• This was a study of HIV-1 exposed persistently seronegative (HEPS) female sex workers in Chiang Mai, northern Thailand
• HLA-A11 is very common in this population, and was enriched among the HEPS sexworkers – weak CTL responses were detected in 4/7 HEPS women,
and CTL responses were found in 8/8 HIV+ controls, and 0/9 HIV- women that were not exposed
• This epitope was weakly reactive in the HEPS study subject 128 who was HLA A11/A33
• This epitope was reactive in HIV+ study subjects 053 and 184 who carried HLA-A11
RT (340–350) Pol (487–497 93TH253
subtype CRF01)
QIYQEPFKNLK HIV-1 infection human (A11) Bond2001
• HLA-A11 CRF01 (called subtype E in Bond et al.) epitopes were identified that stimulated CTL from HIV+ female sex workers (FSW) from Northern
Thailand, of whom more than half were HLA-A11 positive
• 77 possible HLA-A11 epitopes were first defined using EpiMatrix, these were screened for binding to A11 finding and 26 bound, and 12 of these were
epitopes for CTL responses from 8 HLA-A11 positive FSWs, six were novel, six were previously identified
• This epitope was not predicted by the EpiMatrix method to be likely to bind to A11, though it served as an epitope in the FSWs, and it was one of the six
A11 epitopes that had been previously defined
• 5/8 tested FSWs recognized this epitope
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• This epitope was highly conserved in other subtypes, although exact matches were not very common
RT (340–352) RT (507–519 LAI) QIYQEPFKNLKTG HIV-1 infection human (A11) Johnson1994c,
Menendez-Arias1998
• This epitope was listed in a review
RT (340–352) Pol (495–507) QIYQEPFKNLKTG HIV-1 infection human (A11) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
RT (341–350) RT (508–516) IYQEPFKNLK HIV-1 infection human (A*1101) Culmann1998
• C. Brander notes that this is an A*1101 epitope in the 1999 database
RT (341–350) RT (508–517 LAI) IYQEPFKNLK HIV-1 infection human (A*1101) Brander2001
• C. Brander notes this is an A*1101 epitope
RT (341–350) RT (508–517 SF2) IYQEPFKNLK HIV-1 infection human (A11) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-A11+ individuals that had a CTL response to this epitope broken down by group: 0/3 group 1, 0/0 group 2, and 1/2 group 3
RT (341–350) Pol (508–516) IYQEPFKNLK HIV-1 infection, HIV-1 exposed
seronegative
human (A11) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
RT (356–365) RMRGAHTNDV HIV-1 infection human (A*3002) Sabbaj2002b
• Epitope name: Pol-RV10
• This study monitored epitope responses in HIV-1 infected minority women living in the United States
• 24 epitopes were described – 8 were novel, 8 used new restricting elements but were previously defined epitopes, and 8 were previously described
• Serial peptide truncations were used to define optimal epitopes for CTL cell lines isolated from 12 individuals, assayed by a Cr-release
• Subject 01RCH50 also recognized the epitope WRFDSRLAF, Nef(183-191), B*1503
• Among HIV+ individuals who carried HLA A30, 5/16 (31%) recognized this epitope
RT (356–366) RT (15–26) RMRGAHTNDVK HIV-1 infection human (A3) Yu2002a
• Epitope name: A3-RK11
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
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• 0/14 HLA-A3 positive individuals had detectable A3-restricted responses to this epitope during acute infection, but only 5/15 of HLA-A3 epitopes tested
were targeted during acute infection. 5/7 individuals began to have detectable responses to this epitope after STI.
RT (364–372) RT (518–526 U455) DVKQLTEVV human (A28, A*6802) Dong1998a,
Menendez-Arias1998
• Predicted on binding motif, no truncations analyzed
• Reacts with clade A consensus (U455), and with the peptide DVKQLAEAV, from the D clade
RT (364–372) RT (470–478 subtype A) DVKQLTEVV HIV-1 infection human (B70) Dorrell1999
• CTL responses in three individuals with non-clade B infections were studied, 2 with subtype A infections, 1 with subtype C – their infections all originated
in East Africa
• This CTL response was defined in a patient with an A subtype infection
• Bulk cultures from this patient gave a CTL response that could recognize the subtype D form of this epitope, with two substitutions (DVKQLAEAV),
though a CTL line from these cultures didn’t recognize the B clade variant (DVKQLTEAV)
RT (366–385) Pol (521–540) KQLTEAVOKIAMESIVIWGK HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
• This peptide was among the 28 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
RT (374–383) RT (LAI) KITTESIVIW HIV-1 infection human (B*5701) Menendez-Arias1998,
vanderBurg1997
• Patients studied were from the Amsterdam cohort
• CTL epitopes of 3 rapid progressors were compared to 4 long-term survivors (LTS); no differences could be found in the degree of conservation between
them
• Epitope recognized by LTS and by a progressor
RT (374–383) RT (LAI) KITTESIVIW HIV-1 infection human (B*5701) vanderBurg1997
• Recognized by CTL from a progressor and a long-term survivor, PIVLPEKDSW was also recognized
RT (375–383) RT (375–383 LAI) ITTESIVIW HIV-1 infection human (B*5701
B*5801)
Klein1998
• Another patient recognized the ten-mer version of this epitope, KITTESIVIW [vanderBurg1997]
• B57 has been associated with long-term non-progression in the Amsterdam cohort
• The most pronounced CTL responses in HLA B*5701 LTS were to RT and Gag
• The patient that recognized ITTESIVIW also recognized IVLPEKDSW
RT (375–383) RT (375–383 SF2) ITTESIVIW HIV-1 infection human (B57) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
225
DEC 2002
C
TL
HIV CTL Epitope Tables RT CTL Epitopes
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
• Number of HLA-B57+ individuals that had a CTL response to this epitope broken down by group: 0/0 group 1, 0/0 group 2, and 1/2 group 3
RT (392–401) RT (559–568 LAI) PIQKETWETW human (A*3201) Harrer1996b,
Menendez-Arias1998
• Reviewed in [Menendez-Arias1998], suggest the epitope is HLA B53/Cw2
• C. Brander notes that this is an A*3201 epitope in the 1999 database
RT (392–401) RT (559–568 LAI) PIQKETWETW human (A*3201) Brander2001
• C. Brander notes this is an A*3201 epitope
RT (392–401) PIQKETWETW HIV-1 infection human (A*3201) Sabbaj2002b
• Epitope name: Pol-PW10
• This study monitored epitope responses in HIV-1 infected minority women living in the United
• 24 epitopes were described – 8 were novel, 8 used new restricting elements but were previou
• Serial peptide truncations were used to define optimal epitopes for CTL cell lines isolated
• Subject 01RCH59 was Hispanic, was not on HAART, viral load 5100, CD4 count 349, and she also recognized QASQEVKNW, p24(176-184), B*5301
• Among HIV+ individuals who carried HLA A32, 1/2 (50%) recognized this epitope
RT (392–401) RT (559–568 SF2) PIQKETWETW HIV-1 infection human (A32) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-A32+ individuals that had a CTL response to this epitope broken down by group: 0/0 group 1, 1/1 group 2, and 0/0 group 3
RT (392–401) RT PIQKETWETW HIV-1 infection human (A32) Altfeld2002
• Epitope name: A32-PW10(RT)
• Peripheral blood (PB) and lymph node (LN) CD8+ T-cell responses were compared in 15 asymptomatic HIV-1 infected patients using all known optimal
CTL epitopes (http://hiv-web.lanl.gov/content/hiv-db/REVIEWS/brander2001.html) for each person’s class I HLA alleles.
• 60 epitope responses were detected in both PB and LN samples of the 15 patients, and an additional 8 responses were detected only in LN. The total
magnitude of the response was similar in LN and PB, but the percentage of CD8+ T cells in the LN is lower so the number of HIV-specific cells per million
CD8+ T-cells is higher in the LN.
• 1 year post-HAART treatment in five patients studied, the magnitude of the CD8 T-cell response was decreased in both LN and PB, but more dramatically
in PB, and 13/25 epitope responses in the PB became undetectable, in contrast to 5/26 in the LN.
• Treatment interruption following HAART induced resulted in increased viremia accompanied by the restoration of the detection of 13 epitopes that had
become undetectable in the PB, and the addition of 9 novel epitope responses.
• Breakdowns of epitope responses were shown for 4 individuals. Patient A displayed the greatest response to epitope B14-EL9(gp41), a strong response to
B7-TL9(p24), and responses to B7-TM9(Nef) and A32-PW10(RT). Patient B displayed the greatest response to epitope B44-AW11(p24) and also
responded to A32-PW10(RT) in both PB and LN samples, while a third response against epitope A32-RW10(gp120) was only detected in the LN sample.
Patient D displayed the greatest response to B27-KK10 (p24), and also responded to A30-RY11(p17), A32-PW10(RT), A30-KY11(RT),
A32-RW10(gp120), and B18-YY9(Nef).
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RT (397–406) RT (LAI) TWETWWTEYW HIV-1 infection human (B44) Menendez-Arias1998,
vanderBurg1997
• Recognized by CTL from two progressors, EILKEPVGHGV and EELRQHLLRW were also recognized by one, and RETKLGKAGY was also recognized
by the other
RT (416–424) Pol (563–571 93TH253
subtype CRF01)
FVNTPPLVK HIV-1 exposed seronegative human (A11) Sriwanthana2001
• Epitope name: P571-579
• This was a study of HIV-1 exposed persistently seronegative (HEPS) female sex workers in Chiang Mai, northern Thailand
• HLA-A11 is very common in this population, and was enriched among the HEPS sexworkers – weak CTL responses were detected in 4/7 HEPS women,
and CTL responses were found in 8/8 HIV+ controls, and 0/9 HIV- women that were not exposed
• This epitope was weakly reactive in the HEPS study subject 128 who was HLA A11/A33
RT (416–424) Pol (563–571 93TH253
subtype CRF01)
FVNTPPLVK HIV-1 infection human (A11) Bond2001
• HLA-A11 CRF01 (called subtype E in Bond et al.) epitopes were identified that stimulated CTL from HIV+ female sex workers (FSW) from Northern
Thailand, of whom more than half were HLA-A11 positive
• 77 possible HLA-A11 epitopes were first defined using EpiMatrix, these were screened for binding to A11 finding and 26 bound, and 12 of these were
epitopes for CTL responses from 8 HLA-A11 positive FSWs, six were novel, six were previously identified
• This is one of the new A11 epitopes identified through the streamlined EpiMatrix method, and 1/8 tested FSWs recognized it
• This epitope was conserved many subtypes (but not subtype H), but exact matches were not very common
RT (421–429) RT (421–429) PLVKLWYQL HIV-1 infection human (A2) Haas1998
• Of 98 patients in cross-sectional analysis, 78% had CTL against pol – RT was more immunogenic than Integrase and Protease (81%, 51%, and 24% of 37
patients, respectively)
• New clusters of epitopes were defined utilizing different HLA molecules
RT (432–440) RT (587–597 SF2) EPIVGAETF HIV-1 infection human (B*3501) Menendez-Arias1998,
Tomiyama1997
• A CTL clone responsive to this epitope was obtained
• 5/7 B35-positive individuals had a CTL response to this epitope
• An E to D substitution at position 1, and V to I at position 4, reduces activity but not binding to B*3501
• [Menendez-Arias1998] note in their review that this epitope is near the protease cleavage site and conservation of this region is important for proper viral
maturation
RT (432–440) Pol (587–595) EPIVGAETF HIV-1 infection human (B*3501) Tomiyama2000a
• CD8+ T-cells that bound one of six HIV-specific B*3501-epitope tetramers did not express CD28 or CD45A
• A significant increase in CD28-CD45RA- cells and a decrease of CD28+CD45RA+ cells was observed in chronically HIV-1-infected individuals relative to
healthy individuals
• CD28-CD45RA- cells are likely to be effector cells and have high levels of perforin in their cytoplasm
• The mean percentage of total CD28- CD8+ cells in chronically infected HIV-1-infected patients was 76.6% in comparison to HIV-1-uninfected individuals
(40.6%)
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RT (432–440) EPIVGAETF HIV-1 infection human (B35) Wilson2000a
• Three individuals with highly focused HIV-specific CTL responses were studied during acute infection using tetramers – high frequencies of HIV-1-specific
CD8+ T cells were found prior to seroconversion, and there was a close temporal relationship between the number of circulating HIV-specific T cells and
viral load was also found
• All three patients were B*2705, with HLA alleles: A1, A30/31, B*2705, B35; A1, A*0301, B7, B2705; and A*0201, A*0301, B2705, B39
• ELISPOT was used to test a panel of CTL epitopes that had been defined earlier and were appropriate for the HLA haplotypes of the study subjects – 3/3
subjects showed a dominant response to the B*2705 epitope KRWIILGGLNK
• The subject with A*0201 had a moderatly strong response to SLYNTVATL
• Weak responses were observed to A*301-RLRPGGKKK, A*301-QVPLRPMTYK, and B7-TPGPGVRYPL in the subject who was HLA A1, A*0301, B7,
B*2705
• No acute response was detected to the following epitopes: A*201-ILKEPVHGV, A*301-KIRLRPGGK, A*301-AIFQSSMTK, A*301-TVYYGVPVWK,
B35-EPIVGAETF, B35-HPDIVIYQY, B35-PPIPVGEIY, B35-NSSKVSQNY, B35-VPLRPMTY, B35-DPNPQEVVL
RT (432–440) Pol (587–595) EPIVGAETF HIV-1 infection human (B35) Dyer1999
• CTL specific responses were measured over a 1.3 to 1.5 year period in members of the Sydney Blood Bank Cohort (SBBC) who had been infected with a
natural attenuated strain of HIV-1 which was Nef-defective
• Some of these patients had prolonged high levels of CTL effector and memory cells despite low viral load
RT (432–440) RT (587–596 SF2) EPIVGAETF HIV-1 infection human (B35, B51) Shiga1996
• Binds HLA-B*3501, and is also presented by B51 – but CTL could not kill RT-vaccinia virus infected cells that expressed B51
RT (432–440) Pol (587–595) EPIVGAETF HIV-1 infection human (B35, B51) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
RT (432–441) Pol (587–596) EPIVGAETFY HIV-1 infection human (B*3501) Tomiyama2000a
• CD8+ T-cells that bound one of six HIV-specific B*3501-epitope tetramers did not express CD28 or CD45A
• A significant increase in CD28-CD45RA- cells and a decrease of CD28+CD45RA+ cells was observed in chronically HIV-1-infected individuals relative to
healthy individuals
• CD28-CD45RA- cells are likely to be effector cells and have high levels of perforin in their cytoplasm
• The mean percentage of total CD28- CD8+ cells in chronically infected HIV-1-infected patients was 76.6% in comparison to HIV-1-uninfected individuals
(40.6%)
RT (432–441) RT (587–597 SF2) EPIVGAETFY HIV-1 infection C3H/HeJ mice (B35) Menendez-Arias1998,
Shiga1996
• Binds HLA-B*3501, but not presented by B51, in contrast to the peptide EPIVGAETF
• [Menendez-Arias1998] note in their review that this epitope is located near the protease cleavage site and conservation of this region is important for viral
maturation
• This epitope spans the Pol p66 RT – p15 (RNAse) domain
RT (432–441) RT (587–597 SF2) EPIVGAETFY HIV-1 infection human (B35) Kawana1999
• HLA B35 is associated with rapid disease progression
• The sequences of 9 previously described HIV-1 B35 CTL epitopes were obtained in 10 HLA B35+ and 19 HLA B35- individuals
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• 3/9 CTL epitopes had substitutions that were more common in B35+ individuals than in B35- individuals, but this was one of the six that had no B35
associated pattern of mutation
RT (434–447) RT (LAI) IVGAETFYVDGAAS HIV-1 infection human (A*6802) Menendez-Arias1998,
vanderBurg1997
• Recognized by CTL from a long-term survivor that recognized a set of 5 overlapping peptides spanning IVGAETFYVDGAAS as well as PIVLPEKDSW
and KITTESIVIW
• A*6802 is a subset of HLA-A28
• This epitope spans the Pol p66 RT – p15 (RNAse) domain
RT (436–445) RT (591–600 IIIB) GAETFYVDGA HIV-1 infection human (B45) Menendez-Arias1998
• This epitope spans the Pol p66 RT – p15 (RNAse) domain
RT (436–445) Pol (591–600 IIIB) GVETFYVDGA HIV-1 infection human (B45) Wilson1999a
• This study describes maternal CTL responses in the context of mother-to-infant transmission
• Detection of CTL escape mutants in the mother was associated with transmission, but the CTL-susceptible forms of the virus tended to be found in infected
infants
• No variants of this epitope were found in a non-transmitting mother who had a CTL response to it
• This epitope spans the Pol p66 RT – p15 (RNAse) domain
RT (437–445) AETFYVDGA HIV-1 infection human (B*4501) Sabbaj2002b
• Epitope name: Pol-AA9
• This study monitored epitope responses in HIV-1 infected minority women living in the United States
• 24 epitopes were described – 8 were novel, 8 used new restricting elements but were previously defined epitopes, and 8 were previously described
• Serial peptide truncations were used to define optimal epitopes for CTL cell lines isolated from 12 individuals, assayed by a Cr-release
• Subject 00RCH33 was on HAART had a viral load of 2900 and CD4 count of 727 and also recognized the epitopes YPLTFGWCY, Nef(135-143), HLA
B*5301; RSLYNTVATLY, p17(76-86), HLA A*3002; and HIGPGRAFY, gp160(310-318), HLA A*3002
• Among HIV+ individuals who carried HLA B45, 3/9 (33%) recognized this epitope
RT (437–447) RT (592–602 LAI) AETFYVDGAAN human (A28) Brander1996b,
Menendez-Arias1998
• P. Johnson, pers. comm.
• This epitope spans the Pol p66 RT – p15 (RNAse) domain
RT (437–447) Pol (592–602) AETFYVDGAAN HIV-1 infection human (A28) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
RT (438–448) RT (593–603 IIIB) ETFYVDGAANR HIV-1 infection human (A26) Menendez-Arias1998
• This epitope spans the Pol p66 RT – p15 (RNAse) domain
RT (438–448) Pol (593–603 IIIB) ETFYVDGAANR HIV-1 infection human (A26) Wilson1999a
• This study describes maternal CTL responses in the context of mother-to-infant transmission
• Detection of CTL escape mutants in the mother was associated with transmission, but the CTL-susceptible forms of the virus tended to be found in infected
infants
• One other variant was found that gave a positive, though reduced, CTL response: ETYYVNGAANR
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• This epitope spans the Pol p66 RT – p15 (RNAse) domain
RT (448–457) RT RETKLGKAGY HIV-1 infection human (A29) vanderBurg1997
• Patients studied were from the Amsterdam cohort
• CTL epitopes of 3 rapid progressors were compared to 4 long-term survivors (LTS) and no differences could be found in the degree of conservation
between them
• Epitope recognized by a LTS
• This epitope occurs in the p15 (RNAse) domain of Pol p66 RT
RT (449–457) ETKLGKAGY HIV-1 infection human (A*2601) Sabbaj2002b
• Epitope name: Pol-EY9
• This study monitored epitope responses in HIV-1 infected minority women living in the United States
• 24 epitopes were described – 8 were novel, 8 used new restricting elements but were previously defined epitopes, and 8 were previously described
• Serial peptide truncations were used to define optimal epitopes for CTL cell lines isolated from 12 individuals, assayed by a Cr-release
• Subject 03RCH40 was African American, had a viral load of 2500, CD4 count of 372, was not on HAART, and also recognized the epitope DILDLWIY,
Nef(108-115), HLA Cw*0701
• Among HIV+ individuals who carried HLA A26, 2/8 (25%) recognized this epitope
RT (481–505) RT (648–672) AIYLALQDSGLEVNIVTDS-
QYALGI
HIV-1 infection human Menendez-Arias1998, Price1995
• Study of cytokines released by HIV-1 specific activated CTL
• This epitope occurs in the p15 (RNAse) domain of Pol p66 RT
RT (481–505) RT (648–672 PV22) AIYLALQDSGLEVNIVTDS-
QYALGI
HIV-1 infection human (B14) Kalams1994,
Menendez-Arias1998
• A CTL response used to study gene usage in HLA-B14 response
• This epitope occurs in the p15 (RNAse) domain of Pol p66 RT
RT (485–493) Pol (649–659 BH10,
LAI)
ALQDSGLEV HIV-1 infection human Maksiutov2002
• This study employs an antigenic similarity matrix to compare HIV-1 antigenic determinants with human proteins.
• This CTL epitope (the HIV-1 LAI fragment with high similarity to a human protein overlapping this epitope is IYLALQDSGLE) has similarity with the
epidermal growth factor receptor kinase substrate EPS8, fragment ISAAASDSGVE.
RT (485–493) RT (640–648 HXB2R) ALQDSGLEV Vaccine human (A2) Brander1995a
Vaccine Strain: HXB2 HIV component: RT
• Epitope studied in the context of inclusion in a synthetic vaccine
• This epitope occurs in the p15 (RNAse) domain of Pol p66 RT
RT (485–493) RT (640–648 HXB2R) ALQDSGLEV HIV-1 infection human (A2.1) Brander1995a, Brander1996a
• This epitope was recognized by PBMC from 3/14 HIV+ asymptomatic patients
• This epitope was used along with Env CTL epitope TLTSCNTSV and a tetanus toxin T helper epitope for a synthetic vaccine
• This vaccine failed to induce a CTL response, although a helper response was evident
• This epitope occurs in the p15 (RNAse) domain of Pol p66 RT
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RT (485–505) RT (648–672) ALQDSGLEVVTDSQYALGI HIV-1 infection human (B14) Brander1995b
• Unpublished, S. Kalams
• This epitope occurs in the p15 (RNAse) domain of Pol p66 RT
RT (496–505) VTDSQYALGI HIV-1 infection human (B*1503) Sabbaj2002b
• Epitope name: Pol-VI10
• This study monitored epitope responses in HIV-1 infected minority women living in the United States
• 24 epitopes were described – 8 were novel, 8 used new restricting elements but were previously defined epitopes, and 8 were previously described
• Serial peptide truncations were used to define optimal epitopes for CTL cell lines isolated from 12 individuals, assayed by a Cr-release
• Subject 01RCH51 was an African American on HAART, viral load 980, CD4 count 811
• Among HIV+ individuals who carried HLA B15, 1/17 (6%) recognized this epitope
RT (496–505) Pol (subtype B) VTDSQYALGI HIV-1 exposed seronegative human (B14, B*1402) Rowland-Jones1998b
• HIV-specific CTL were found in exposed seronegative prostitutes from Nairobi – these CTL may confer protection
• Seroprevalence in this cohort is 90-95% and their HIV-1 exposure is among the highest in the world
• Most isolated HIV strains are clade A in Nairobi, although clades C and D are also found – B clade epitopes are often cross-reactive, however stronger
responses are frequently observed using A or D clade versions of epitopes
• This epitope is conserved among A, B and D clade viruses
RT (496–505) RT (663–672 IIIB) VTDSQYALGI HIV-1 infection human (Cw8) Brander1996b
• Unpublished, P. Johnson
• Published in this database in 1995 as B14, but B14 transfected cells did not present the peptide and it is thought to be presented by the genetically linked
Cw8 molecule instead [Brander1996b]
• This epitope occurs in the p15 (RNAse) domain of Pol p66 RT
RT (496–505) RT VTDSQYALGI HIV-1 exposed seronegative human (Cw8) Rowland-Jones1998a
• A CTL response was found in exposed but uninfected prostitutes from Nairobi using previously-defined B clade epitopes that tended to be conserved in A
and D clades – such cross-reactivity could protect against both A and D and confer protection in Nairobi where both subtypes are circulating
• The A and D subtype consensus are identical to the B clade epitope
• Thought to be HLA-Cw8 restricted, not B14 as originally reported (C. Brander, B. Walker, and S. Rowland-Jones, personal communication)
• This epitope occurs in the p15 (RNAse) domain of Pol p66 RT
RT (509–518) Pol QPDKSESELV human (B7) De Groot2001
• The program Epimatrix was used in conjunction with the program Conservatrix to identify conservered regions of HIV that might serve as epitopes
• A subset of the potential epitopes was identified that could bind to the appropriate HLA-allele, and 15 predicted B7 superfamily (HLA B7, B8, and B58)
epitopes were identified that could stimulate IFNγ production in an ELISPOT assay
• QPDKSESELV was newly identified as an HLA-B7 epitope in this study
RT (516–525) RT (516–525) ELVNQIIEQL HIV-1 infection human (A2) Haas1998
• Of 98 patients in cross-sectional analysis, 78% had CTL against pol – RT was more immunogenic than Integrase and Protease (81%, 51%, and 24% of 37
patients, respectively)
• New clusters of epitopes were defined utilizing different HLA molecules
• This epitope occurs in the p15 (RNAse) domain of Pol p66 RT
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RT (520–528) Pol (520–528 LAI) QIIEQLIKK human (A*1101) Brander2001, Fukada1999
• C. Brander notes this is an A*1101 epitope
RT (520–528) Pol (675–683) QIIEQLIKK HIV-1 infection human (A*1101) Fukada2002
• Counterparts for eight known clade B HLA A*1101 epitopes were generated for clade E (CRF01). Three epitopes, identical among clade A-E, were
cross-reactive and recognized by clade E infected individuals. The clade E and B analogs to three more HLA A*1101 epitopes was recognized in a clade
specific manner. Two other HLA A*1101 clade B defined epitopes were found not to have stimulated a response in clade E infected individuals.
• QIIEQLIKK was found to elicit clade-specific responses in clade B (QIIEQLIKK is most common) and clade E (qiieElikk is most common). QIIEQLIKK
was strongly recognized by CTL from 1/5 B clade infected Japanese subjects, and qiieElikk from 3/7 E clade infected Thai subjects. The variant qiieKliEk,
common in the A subtype, was also recognized in 2/7 E clade infected Thai subjects.
• The binding of QIIEQLIKK, qiieElikk and qiieKliEk to HLA A*1101 was similar, but CTL clones from individuals did not cross-react with the cross-clade
peptides indicating that the substitutions inhibited TCR interaction.
RT (530–538) Pol (680–691 BH10,
LAI)
KVYLAWVPA HIV-1 infection human Maksiutov2002
• This study employs an antigenic similarity matrix to compare HIV-1 antigenic determinants with human proteins.
• This CTL epitope (the HIV-1 LAI fragment with high similarity to a human protein overlapping this epitope is IKKEKVYLAWV) has similarity with
B-cell growth factor precursor, fragment IKKERLWLGPV.
RT (530–538) KVYLAWVPA HIV-1 infection human (A*0301) Sabbaj2002b
• Epitope name: Pol-KA9
• This study monitored epitope responses in HIV-1 infected minority women living in the United States
• 24 epitopes were described – 8 were novel, 8 used new restricting elements but were previously defined epitopes, and 8 were previously described
• Serial peptide truncations were used to define optimal epitopes for CTL cell lines isolated from 12 individuals, assayed by a Cr-release
• This epitope was newly defined in this study
• Patient 04RCH86 was Hispanic, not on HAART, and had a viral load of 7600 and CD4 count of i774
• Among HIV+ individuals who carried HLA A*03, 2/21 (10%) recognized this epitope
RT (532–540) Pol (714–722) YLAWVPAHK HIV-1 infection human (A3 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind 5/5 HLA-A3 supertype alleles (A*0301, A*1101, A*3101, A*3301 and A*6801)
RT (532–540) RT (532–540) YLAWVPAHK HIV-1 infection human (B7) Haas1998
• Of 98 patients in cross-sectional analysis, 78% had CTL against pol – RT was more immunogenic than Integrase and Protease (81%, 51%, and 24% of 37
patients, respectively)
• New clusters of epitopes were defined utilizing different HLA molecules
• This epitope occurs in the p15 (RNAse) domain of Pol p66 RT
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Integrase (20–28) Pol (762–770) RAMASDFNL HIV-1 infection human (A2 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind three of the five HLA-A2 supertypes alleles (A*0201, A*020 2, A*0203, A*0206 and A*6802)
Integrase (22–31) Pol (764–773) MASDFNLPPV HIV-1 infection human (A2 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind all five HLA-A2 supertypes alleles (A*0201, A*0202, A*0203, A*0206 and A*6802)
Integrase (28–36) Pol (743–751 SF2) LPPVVAKEI HIV-1 infection human (B*5101) Tomiyama1999
• HLA-B27, -B51, and -B57 are associated with slow progression to AIDS, while HLA-B35, -B8, -B24 are associated with a rapid progression to AIDS (Nat.
Med. 2:405, 1996;Lancet 22:1187, 1986;Hum Immunol 22:73, 1988;Hum Immunol 44:156, 1995)
• 15% of Japanese populations carry HLA-B51 while HLA-B27 and -B57 are detected in less than 0.3%
• Of the 172 HIV-1 peptides with HLA-B*5101 anchor residues, 33 bound to HLA-B*5101, seven of these peptides were reactive with CTL from 3 B*5101
positive individuals, and six were properly processed
• Four of the six epitopes were highly conserved among B subtype sequences – LPPVVAKEI is highly conserved
Integrase (82–89) RT (797–804 SF2) GYIEAEVI HIV-1 infection human (A*2402) Ikeda-Moore1997
• Defined using reverse immunogenetics – 59 HLA-A*2402 binding peptides were predicted by searching for A*2402 anchors in HIV proteins (Tyr at 2, and
Phe, Leu or Ile at the C term) – 53 of the 59 peptides bound A*2402
• This peptide induced CTL in 1/4 HIV-1+ people tested
• GYIEAEVI bound to A*2402 weakly, the epitope can be processed in a vaccinia construct and presented – two specific CTL clones were obtained
Integrase (89–98) Pol (805–814 BH10,
LAI)
IPAETGQETA HIV-1 infection human Maksiutov2002
• This study employs an antigenic similarity matrix to compare HIV-1 antigenic determinants with human proteins.
• This CTL epitope (the HIV-1 LAI fragment with high similarity to a human protein overlapping this epitope is PAETGQETAY) has similarity with Integrin
beta-4 precursor (GP150)(CD104), fragment PAETNGEITAY.
Integrase (89–98) Pol IPAETGQETA human (B56) De Groot2001
• The program Epimatrix was used in conjunction with the program Conservatrix to identify conservered regions of HIV that might serve as epitopes
• A subset of the potential epitopes was identified that could bind to the appropriate HLA-allele, and 15 predicted B7 superfamily (HLA B7, B8, and B58)
epitopes could stimulate IFNγ production in an ELISPOT assay
• IPAETGQETA was newly identified as an HLA-B56 epitope in this study
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Integrase (96–104) Integrase (823–831) ETAYFILKL human (A*6802) Dong1998b
• Epitope found in clade A, B, and D – Pers. Comm. S. Rowland-Jones and T. Dong
Integrase (96–104) Pol (subtype A) ETAYFILKL HIV-1 exposed seronegative human (A*6802) Kaul2000
• 11/16 heavily HIV exposed but persistently seronegative sex-workers in Nairobi had HIV-specific CD8 gamma-IFN responses in the cervix – systemic
CD8+ T cell responses tended to be to the same epitopes but at generally lower levels than cervical CD8+ T cell responses
• Low risk individuals did not have such CD8+ cells
• CD8+ T cell epitopes: DTVLEDINL (3 individuals), SLYNVATL (4 individuals), LSPRTLNAW (3 individuals) and YPLTFGWCF (4 individuals) were
most commonly recognized by the HIV-resistant women
Integrase (96–104) Pol ETAYFILKL HIV-1 infection human (A*6802) Kaul2001c
• This study examines CTL responses in HIV exposed, persistently seronegative individuals, HEPS, who eventually seroconverted – 11/114 HEPS Nairobi
sex workers eventually seroconverted, and for six of these HIV CTL reactive epitopes had been defined while seronegative
• The epidemiological factor associated with seroconversion was stopping sex work and HIV-specific CTL activity declines when HEPS sex workers stop
working for a period or retire
• This epitope was recognized in 1/22 HEPS sex worker controls (ML1671)
Integrase (96–104) Pol (744–752) ETAYFYILKL HIV-1 infection, HIV-1 exposed
seronegative
human (A*6802) Kaul2001a
• ETAYFYILKL cross-reacts with clades A, B and D
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with
reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected
women
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure
• Among HLA-A*6802 women, 3/12 HEPS and 9/11 HIV-1 infected women recognized this epitope likelihood ratio 7.9, p value 0.01, and HEPS women
tended to respond to DTVLEDINL, while infected women to ETAYFYILKL
• The dominant response to this HLA allele was to this epitope in 2 of the 3/12 HEPS cases and in all 9/11 HIV-1 infected women that responded to the
epitope
• Differences in epitope specificity were only seen for responses restricted by class I HLA alleles A2, A24, A*6802, B14, and B18, previously shown to be
associated with resistance to HIV-1 in this cohort
• Subject ML 1203 started with CTL responses to A*6802 DTVLEDINL and to B7 FPVTPQVPLR prior to seroconversion, and upon seroconversion
acquired additional responses to A*6802 ETAYFILKL which became dominant, B7 TPGPG(V/I)RYPL, B7 IPRRIRQGL, and B7 SPRTLNAWV
• Subject ML 1707 started with a CTL response to A*6802 DTVLEDINL prior to seroconversion, and switched to A*6802 ETAYFILKL and A24
RDYVDRFFKTL post-seroconversion
• Subject ML 1830 made no detectable response prior to seroconversion, but responded to A*6802 DTVLEDINL and A*6802 ETAYFILKL
post-seroconversion
Integrase (96–104) Pol (744–752) ETAYFILKL HIV-1 infection human (A*6802) Appay2000
• This epitope is newly defined in this study
• Combined tetramer and intracellular cytokine staining was used to study the function of circulating CD8+ T cells specific for HIV and CMV
• HIV-specific CD8+ T cells expressed lower levels of perforin than CMV-specific CD8+ T cells from the same donor, and this was associated with persistent
CD27 expression on HIV-specific cells, suggesting impaired maturation
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• In most donors, between 50% and 95% of the activated virus-specific CD8+ T cells produced IFN-γ and MIP-1β with a distinct subset that failed to
produce TNF-α
Integrase (127–135) Pol (869–877) KAACWWAGI HIV-1 infection human (A2 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind three of the five HLA-A2 supertypes alleles (A*0201, A*0202, A*0203, A*0206 and A*6802)
Integrase (173–181) Pol (888–896) KTAVQMAVF human (B*5701) Brander2001
• C. Brander notes this is a B*5701 epitope
• Epitope is motif based, personal communication from C. Hay
• Subtype of B57 not determined
Integrase (173–181) Pol (888–896) KTAVQMAVF human (B57) Hay1999a
• Epitope is motif based, personal communication from C. Hay
Integrase (177–186) Pol (919–928) QMAVFIHNFK HIV-1 infection human (A3 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind 5/5 HLA-A3 supertype alleles (A*0301, A*1101, A*3101, A*3301 and A*6801)
Integrase (178–186) Pol (920–928) MAVFIHNFK HIV-1 infection human (A3 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind 3/5 HLA-A3 supertype alleles (A*0301, A*1101, A*3101, A*3301 and A*6801)
Integrase (179–187) Pol (921–929) AVFIHNFKR HIV-1 infection human (A3 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind 5/5 HLA-A3 supertype alleles (A*0301, A*1101, A*3101, A*3301 and A*6801)
Integrase (179–188) Integrase (179–188 LAI) AVFIHNFKRK human (A*1101) Brander2001, Fukada1999
• C. Brander notes this is an A*1101 epitope
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Integrase (179–188) Pol (894–903) AVFIHNFKRK HIV-1 infection human (A*1101) Fukada2002
• Counterparts for eight known clade B HLA A*1101 epitopes were generated for clade E (CRF01). Three epitopes, identical among clade A-E, were
cross-reactive and recognized by clade E infected individuals. The clade E and B analogs to three more HLA A*1101 epitopes was recognized in a clade
specific manner. Two other HLA A*1101 clade B defined epitopes were found not to have stimulated a response in clade E infected individuals.
• AVFIHNFKRK is commonly found in viruses representing subtypes A-E. It was strongly recognized by CTL from 4/7 E clade infected Thai subjects.
Integrase (179–188) Pol (894–903 93TH253
subtype CRF01)
AVFIHNFKRK HIV-1 exposed seronegative human (A11) Bond2001
• Epitope name: P894-903
• This was a study of HIV-1 exposed persistently seronegative (HEPS) female sex workers in Chiang Mai, northern Thailand
• HLA-A11 is very common in this population, and was enriched among the HEPS sexworkers – weak CTL responses were detected in 4/7 HEPS women,
and CTL responses were found in 8/8 HIV+ controls, and 0/9 HIV- women that were not exposed
• This epitope was weakly reactive in the HEPS study subjects 265 who was HLA A2/A11 and 128 who was HLA A11/A33, and had been predicted to be a
possible A11 epitope using Epimer in [Bond2001]
Integrase (179–188) Int (894–904) AVFIHNFKRK HIV-1 infection human (A3) Yu2002a
• Epitope name: A3-AK10
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
• 0/14 HLA-A3 positive individuals had detectable A3-restricted responses to this epitope during acute infection, but only 5/15 of HLA-A3 epitopes tested
were targeted during acute infection. 1/7 individuals began to have detectable responses to this epitope after STI.
Integrase (179–196) Pol (894–911) AVFIHNFKRKGGIGGYSA HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
• This peptide was among the 28 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
Integrase (210–227) Pol (925–942) TKELQKQIIKIQNFRVYY HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
• This peptide was among the 28 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
Integrase (219–227) KIQNFRVYY HIV-1 infection human (A*3002) Sabbaj2002b
• Epitope name: Pol-KY9
• This study monitored epitope responses in HIV-1 infected minority women living in the United States
• 24 epitopes were described – 8 were novel, 8 used new restricting elements but were previously defined epitopes, and 8 were previously described
• Serial peptide truncations were used to define optimal epitopes for CTL cell lines isolated from 12 individuals, assayed by a Cr-release
• Patient 00RCH28 was African American, not on HAART, had a viral load of 5900 and CD4 count of 889, and she also recognized RIRQGLERA,
gp160(846-854), A*0205
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• Among HIV+ individuals who carried HLA A30, 6/16 (38%) recognized this epitope
Integrase (219–228) Pol (919–928) KIQNFRVYYR HIV-1 infection human (A3 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind 5/5 HLA-A3 supertype alleles (A*0301, A*1101, A*3101, A*3301 and A*6801)
Integrase (241–249) Pol (576–584) LLWKGEGAV in vitro stimulation human (A*0201) vanderBurg1996
• Slow dissociation rate, associated with immunogenicity in transgenic HLA-A*0201/Kb mice
• CTL generated by in vitro stimulation of PBMC derived from uninfected individual
Integrase (241–249) Pol (956–964) LLWKGEGAV HIV-1 infection human (A2) Kundu1998b
• Allogeneic dendritic cells (DCs) were obtained from HLA-identical siblings, pulsed with rgp160 MN or A2-restricted HIV-1 epitope peptides, and infused
monthly into six HIV-infected patients
• 1/6 showed increased Env-specific CTL and increased lymphoproliferative responses, 2/6 showed increase only in proliferative responses, and 3/6 showed
no change – pulsed DCs were well tolerated
• LLWKGEGAV is a conserved HLA-A2 epitope included in this study – 6/6 patients had this sequence as their HIV direct sequence, but only four of these
had a detectable CTL response
Integrase (241–249) Pol (956–964 HXB2R) LLWKGEGAV Peptide-HLA interaction human (A2) Parker1992, Parker1994
• Studied in the context of HLA-A2 peptide binding
Integrase (241–249) Pol (956–964 HXB2R) LLWKGEGAV Peptide-HLA interaction human (A2) Brander1995a
• No CTL activity found in HIV-infected subjects, epitope studied in the context of inclusion in a synthetic vaccine
Integrase (241–249) Pol (956–964) LLWKGEGAW HIV-1 infection human (A2, A*0201) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
Integrase (241–249) RT (956–964 HXB2R) LLWKGEGAV Vaccine murine (A2.1) Peter2001
Vaccine Vector/Type: peptide Strain: LAI Adjuvant: P30, incomplete Freund’s adjuvant (IFA), Montanide (ISA 720), PLG-microparticle
• Epitope name: LR28
• The stability of peptide binding to HLA-A2.1 was determined for six HLA-A2.1 peptides included in this vaccine study – ILKEPVHGV (RT),
SLYNTVATL (p17), SLLNATDIAV (gp41) and LLWKGEGAV (RT) all bound with high affinity comparable to a influenza epitope reference
(GILGFVFTL), while RGPGRAFVTI and VIYQYMDDL bound with a lower affinity (relative binding activity = 0.01).
• The four high-affinity peptides formed stable complexes with half-lives ranging between 8 and 32 hours, while the low affinity peptides had half lives of
less than an hour.
• HLA-A2.1 transgenic mice were immunized with the six HIV-1 peptides and P30, as a universal T-helper epitope, with IFA or Montanide or microspheres
as adjuvants.
• All peptides except VIYQYMDDL induced a stong CTL response in Cr-release assays - stronger responses were observed when peptides were delivered
alone, indicating immunodominance when the combination was used.
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Integrase (241–249) RT (956–964 HXB2R) LLWKGEGAV Vaccine murine (A2.1) Peter2002
Vaccine Vector/Type: peptide Strain: LAI Adjuvant: P30, incomplete Freund’s adjuvant (IFA), IL-12
• Epitope name: LR28
• When HIV-1 peptides were used to vaccinate HLA-A2.1 transgenic A2-Kb mice, strong responses to five peptides were observed when the peptides were
given individually, but immunodominance limited the response to some of the peptides when they were given in combination [Peter2001]. IL-12 can
counteract immunodominance in BALB/c mice, so it was given with the multiple epitope vaccination, and was instead found to specifically eliminate the
HLA-A2.1-epitope CTL responses, but not Kb CTL responses. This was possibly a consequence of transient depletion of T-cells, B cells and macropahges
in the spleen.
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Pol RT (LAI) HIV-1 infection human Buseyne1998a
• This study showed a correlation between strong CTL memory and breadth of response in 7-12 month old infants, and remaining AIDS-free for the first year
of life, higher absolute CD4 and CD8 cells, and lower viral load
Pol p66 (LAV) HIV-1 infection human Zheng1999
• Protein delivery (gp160 LAV, p66 LAV, and p24 NY5) to human dendritic cells (DC) with liposomes provides enhanced memory CTL response relative to
delivery of protein alone
• Chloroquine administration enhanced epitope presentation, and brefeldin A and peptide aldehyde inhibitors inhibited antigen presentation, suggesting
epitopes were processed by classical proteasome pathway
Pol Pol (IIIB) HIV-1 infection human Wasik2000
• HIV+ infants that progressed rapidly to AIDS had lower Th1 responses and decreased production of beta-chemokines and IL-2 relative to other HIV+
infants
• No HIV+ infants had no demonstrable CTL at birth, but Th1 responses accompanied by CTL responses developed in children with slowly progressive
disease, and not in rapid progressors
• CTLp frequencies were determined by limiting dilution using autologous B cells infected with vaccina/HIV constructs
Pol Pol (LAI) Vaccine human Salmon-Ceron1999
Vaccine Vector/Type: canarypox Strain: LAI, MN HIV component: gp41, Gag, Pro, V3
• The vaccine used was a rec canarypox with HIV-1 gp120 MN, tm/gag/protease LAI (vCP205), alone or with p24E-V3 MN synthetic peptide (CLTB-36))
• Twenty HIV negative subjects were vaccinated in phase I trial with combinations of vCP205 and CLTB-36
• Immunization with vCP205 induced HIV-1-specific ABs to gp120, V3, and p24 antigens, and CTL immune responses against vCP205 were detected after
the fourth immunization in 33% of the subjects against Env, Gag and Pol, but the CLTB-36 peptide did not produce AB or CTL immune responses against
p24 or gp160
Pol Pol (172–219 subtype B) Vaccine human Gorse1999b
Vaccine Vector/Type: canarypox prime with rgp120 boost Strain: LAI and SF2 HIV component: Env, Gag, Pro, Nef, Pro
• The vaccine used was rec canarypox expressing HIV-1 env, gag, pol, nef and protease (vCP300) with or without administration of HIV-1 SF-2 rgp120
• In vitro inducible CTL activity against HIV-1 Env, Gag, Pol, and Nef antigens was observed in 79% (15 of 19) of vaccine recipients
• The combination of vCP300 and vP1291 together resulted in an overall increase in CTL induction and detection sensitivity
Pol Pol (IIIB) HIV-1 infection human Betts1999
• This study demonstrated an inverse correlation between HIV Type I plasma viral load and CTL activity directed against HIV-1 Pol, and stronger combined
effects of Pol- and Env-specific CTL, in long-term survivors (LTS) of HIV-1 infection
Pol Pol (BRU) HIV-1 infection human Aladdin1999
• In vitro measurements of CTL-activity by Cr release assay in bulk culture showed no correlation between CTL-activity (gp120, Gag, Pol and Nef) and
disease progression as measured by viral load, CD4 and time to death
Pol RT (LAI) HIV-1 infection human Buseyne1998b
• In infants with positive CTL responses, most responses showed cross-clade reactivity with somewhat diminished recognition of epitopes from different
subtypes
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Pol RT Vaccine murine Kim1997c
Vaccine Vector/Type: DNA HIV component: Gag, Pol, Vif, Env Adjuvant: B7, IL-12
• A gag/pol, vif or gp160 DNA vaccine, when delivered in conjunction with the plasmid encoding the co-stimulatory molecules B7 and IL-12, gave a
dramatic increase in both the cytotoxic and proliferative responses in mice
• When IL-12 was present, CTL response could be detected even without in vitro stimulation
Pol RT HIV-1 infection human Trickett1998
• Twelve HIV-1 infected patients were re-infused with their own lymphocytes, cryopreserved from an earlier time point in the infection
• Improvement in CD4+ and CD8+ T cells were seen in 7/12, and an increase in the CTL response to Pol was seen in one patient
Pol RT HIV-1 infection human Froebel1997
• Two HIV-1 infected children with contrasting disease courses were followed longitudinally – one died of AIDS, the other is a long-term non-progressor
• Reactivity against Gag, Pol, Env and Tat proteins was tested by PBMC bulk cultured cells reacting with protein expressed in vaccinia constructs in
autologous EBV transformed B cells
• The child who progressed consistently had CTL against Pol and Tat
• The long-term non-progressing child had no detectable CTL, but was heterozygous for a mutation in the CCR5 receptor and for HLA-B49, which has been
shown to be associated with slower progression
Pol Pol (IIIB) HIV-1 infection human Betts1997
• 6/8 individuals from Zambia infected with C clade virus had CTL that were able to make response to B clade HIV-1 IIIB vaccinia-expressed Gag, Pol and
Env proteins
• A vigorous cross-clade response was not limited to a particular protein, and the level of recognition of different proteins varied among the six patients
Pol RT HIV-1 infection human De Maria1997
• CD3+ cells that also carry a natural killer cell receptor (NKR+) can exhibit down regulation of T cell function
• Anti-NKR IgM MAb masked this inhibitory function and increased HIV-1 specific CTL activity in phytohemagglutinin-activated PBMC cultured in the
presence of IL-2 from 3/5 patients, and in one other case anti-NKR MAb brought HIV-1 specific CTL activity to detectable levels
Pol Pol (LAI, MN) HIV-1 exposed seronegative human Goh1999
• 13/37 exposed uninfected individuals with repeated high-risk sexual exposure had HIV-1 specific CTL against Env, Gag, Pol, or a combination of proteins –
CTL activity was correlated with a CCR5 wildtype genotype
• In this group, the highest CTLp frequencies were directed at Gag, but the most common response was to Env and four individuals had responses to multiple
HIV-1 proteins
Pol Pol (LAI) Vaccine human Evans1999
Vaccine Vector/Type: canarypox HIV component: gp120, gp41, Gag, Pro, Nef, RT
• A Canarypox vaccine expressing gp120, gp41, Gag, Protease, Nef and Pol CTL epitopes gave rise to CTL that could be detected in 61% of the volunteers –
responses to Gag, Env, Nef and Pol were detected 3-6 months after the last vaccination
Pol Gag/Pol (MN) Vaccine chimpanzee Kim1998
Vaccine Vector/Type: DNA HIV component: Env, Gag, Pol Adjuvant: CD86, CD80
• The study explores the use of co-stimulatory molecules co-expressed with an HIV-1 immunogen in a DNA vaccine to enhance the immune response –
co-expression of CD86, but not CD80, dramatically increased both HIV Env and Gag/Pol specific CTL and Th proliferative responses
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Pol Pol (IIIB) HIV-1 infection human Jin1998a
• CTL precursor frequencies were determined in HIV-1 infected pregnant women, and significantly higher CTLp frequencies to Pol and Nef were found in
non-transmitting mothers than in transmitting mothers;
Pol Pol HIV-1 infection human Young2001
• Addition of recombinant rec human IL12 (rhIL12) to cultures increased HIV-specific lysis of HIV-Gag, Pol and gp120 vaccinia expressed antigens (11/15
tested increased lysis by > 5%) if the culture was derived from HIV+ individuals who had CD4 cells/ul > 500
• 2/10 individuals with <200 CD4 cells/ul, and 3/10 individuals with 200-500 CD4cells/ul, had an increase of >5% upon treatment of the culture with rhIL12,
so a few individuals in late stage disease had CD8 cells that maintained responsiveness to rhIL12
Pol RT (subtype A, B, D) HIV-1 infection human Cao2000
• HIV-1 subtypes A and D dominate the Ugandan epidemic, and a vaccine trial using B clade antigen is underway – this study addresses relative levels of
cross-reactive CTL responses in HIV infected Ugandans to A, D, and B clade recombinant vaccinia viruses expressing Gag, Env, Pol, RT or Nef from
HIV-1 clades A, B, and D.
• Proteins corresponding to the subtype of the infecting strains tended to trigger higher levels of CTL response measured by percent specific lysis, but there
was extensive inter-subtype cross-reactivity with B clade proteins and the co-circulating subtype.
Pol Pol HIV-1 infection human White2001
• HIV-specific CTL activity was detected in the female reproductive tract of only 1/3 HIV-infected women who underwent a hysterectomy, although CTL
could be identified in the PBMC of all three women
Pol Pol (IIIB) HIV-1 infection human Jin2000a
• The CTL precursor level (CTLp) was measured in long term non-progressors (LTNP) with low viral load using limiting dilution analysis and measuring
CTL against Env Gag and Pol expressed in vaccinia in autologous targets
• LTNPs have high memory CTL numbers and low viral load
Pol Pol HIV-1 exposed seronegative human Rowland-Jones2001
• This is a review that summarizes observations about HIV-specific CTL found in the HIV-1 exposed persistently seronegative (HEPS) population
• The CTL responses assayed by ELISPOT and by CTL precursor frequencies by limiting dilution analysis indicate that CTL in HEPS individuals tend to be
of a lower magnitude than in chronic HIV-1 infections – the responses in HEPS cases are below the level of detection by tetramer assays
• CD8+ CTL responses tend to be detectable in HEPS subjects only if they are recently exposed, and the response diminishes if exposure is reduced – it is not
clear if there is a stable memory population in HEPS cases
• CD8+ CTL responses in the HEPS population are associated with HIV-1 specific CD4+ T cell responses, assayed by proliferation assays, IL-2 secretion,
and ELISPOT, and the authors consider the possibility that HIV-1-specific T-help responses improve the "quality" of the CD8+ response in HEPS
individuals relative to HIV-1 infected individuals, who tend to have a poor HIV-1-specific T-help response
• HIV-1 specific CD8+ CTL responses in HIV-1 infected individuals show reduced levels of perforin, and the T cells may not mature properly, and although
similar studies have not been conducted in HEPS individuals this is considered as a possible difference in the CTL immune response in HEPS and HIV-1
infected people
Pol HIV-1 exposed seronegative human De Maria1994, Kuhn2002
• 6/24 HIV uninfected infants (ages 15-50 months) born to HIV+ mothers had HIV-1 specific CTL responses to vaccinia-expressed Nef, Gag/Pol, Env.
• Reviewed in [Kuhn2002].
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Pol HIV-1 infection human Kuhn2002, Wasik1999
• In HIV-infected infants HIV-specific, CTL responses were not detectable in icord blood or in PBMC collected shortly after birth and were absent or
remained very low in 3 infants with a rapidly progressive disease. For those who progressed more slowly, the HIV-specific CTL activity varied.
• The two infants with high levels of Env peptide-stimulated IL-2 responses had the highest CTLp frequencies.
• Stronger responses were detected after initiation of the antiretroviral therapy.
• Two babies that were not infected though born to HIV+ mothers had detectable though low HIV-specific CTLp responses to Env (1/2), Pol (2/2), Gag (1/2)
cord blood and transiently in PBMC after birth.
• Reviewed in [Kuhn2002].
Pol HIV-1 infection human Aldhous1994, Kuhn2002
• Six of nine HIV vertically infected infants had HIV-1 specific CTL responses to vaccinia expressed Tat (4/6), Pol (6/6), Env (1/6), or Gag (1/6), but not all
responses were detected at all time points.
• Two of eleven babies that were not infected though born to HIV+ mothers had detectable responses Tat (1/2), Pol (2/2), Gag (1/2).
• Reviewed in [Kuhn2002].
Pol HIV-1 infection human Yusim2002
• Epitopes that have been described in the literature and included in this database tend to cluster in conserved regions and be absent or rarely found highly
variable regions found in Nef, Env and p17.
• In the more conserved p24, and Pol proteins RT and Protease, epitopes are more evenly distributed, however, epitopes were not found that span the
invariant, most highly conserved regions of RT and Protease. This might be due to the virus evolving conserved features that disallow the CTL responses in
these most conserved regions, as functional constraints for enzyme function would not tolerate change and normal capacity for immune escape by rapid
evolution is lost in these domains.
Pol HIV-1 infection human Loemba2002
• Therapeutic RT inhibitors were used to select in vitro for resistance mutations in subtype C viruses. Many of the resistance mutations were located within
analogs to CTL epitopes that had been defined for the B subtype,
Pol (IIIB) HIV-1 infection human Ortiz2002
• Subjects treated with HAART early in HIV-infection showed a correlation between the number of viremic episodes and the total as well as the Pol-specific
CD8 T-cell activity as measured by Elispot SFC per million PBMC summed across Pol, Env, Nef and Gag. The subjects treated early after infection had
higher levels of CD8+ T-cell activity (N = 31) than those treated later (N = 23), and a greater capacity to enhance CD8+ T-cell responses to viremic
episodes.
Pol (MN) HIV-1 infection human Edwards2002
• 96% (26/27) chronically infected HIV-1 infected patients elicited gamma-IFN CD8+ T-cell responses against Gag
• Nef and/or Pol CTL responses were detected in 86% of the subjects
• The magnitude and breadth of Gag and p24 T-cell responses correlated with absolute CD4 counts, and inversely correlated with viral load
• Pol and Int CTL responses correlated positively with absolute CD4+ T-cell count
• Nef and Env responses did not correlate with either CD4 counts or viral load
Pol HIV-1 infection human Larsson2002b
• Autologous mature dendritic cells with rec vaccinia expressing Gag, Pol, Nef and Env could amplify CD8+ T-cell Elispot responses 4-38 fold in five HIV+
patients on successful HAART treatment, relative to autologous monocytes. Some weak responses could only be detected using mature dendritic cells as
APCs, and this approach could be useful for detection of low frequency memory cells.
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Pol (IIIB) HIV-1 infection human Trickett2002
• Conditions were optimized for ex-vivo expansion of CD8+ and CD4+ T-cells with the goal of functional T-cell production for autologous immunotherapy.
10,000-fold expansions were obtained in 14 days with optimized concentrations of IL-2, anti-CD3 and anti-CD28 coated microspheres, and decreasing
amounts of serum over the first 8 days.
Pol (IIIB) HIV-1 and HCV co-infection human Lauer2002
• HIV-1 and HCV immune responses were studied in 22 individuals who were co-infected with HIV-1 and hepatitis C virus (HCV). IFNgamma production
was measured in an Elispot assay of CD8+ T-cells using targets expressing either Gag, RT, Env and Nef in a vaccinia construct, or one of seven HCV
proteins.
• All 22 patients targeted at least one protein. 20/22 patients recognized RT, 17/22 patients recognized Gag, 13/22 subjects recognized Env and 11/22 patients
recognized Nef. Robust CTL activity was independent of disease progression or viral load.
• Despite high HCV viral loads, very few HCV CD8+ T-cell Elispot responses were detected. In a control HCV infected person who did not have HIV-1,
strong anti-HCV responses were mounted.
• HIV-specific CD4 proliferative responses were detected in 9/17 coinfected patients, but no HCV responses were detected.
Pol HIV-1 infection human Scott2001
• CTL responses before and after initiation of ART were studied in 13 HIV-1 vertically infected infants <6 months of age, and 4 that were >6 months of age.
• Before ART 2/13 infants <6 months of age showed IFNgamma Elispot CD8+ T-cell responses, one to Nef and one to Env and Nef, and these responses
became undetectable after successful therapy– 3 infants were coinfected with CMV and all 3 had CMV-specific CD8+ T-cell responses.
• One older infant, at 23 months, had CTL responses against all for proteins tested, Gag, Pol, Nef and Env, and had the lowest plasma viremia of the study
group. 3/4 infants older than 6 months of age responded to either Nef or Pol.
• Administration of ART over 48 weeks broadened the HIV-1-specific CTL response in 2/4 of the older children that were incomplete responders.
Pol (IIIB, MN) HIV-1 infection human Larsson2002a
• Dendritic cells acquire and present HIV-1 antigens derived from dead, apoptotic cells or from non-infectious, fusion-competent HIV-1 virions, and these
DC cells could stimulate CD4+ and CD8+ T-cells resulting in IFNgamma production in an Elispot assay. Both HLA Class I and class II molecules were
used for presentation. This may be an important aspect of the initial immune response to HIV-1 infection of CD4+ cells in the mucosal subepithelia.
Pol (IIIB) HIV-1 infection human Ortiz2001
• Immune responses in eight chronically HIV-1 infected patients undergoing HAART therapy structured treatment interruptions (STI) were studied. STI
boosted HIV-1 specific CTL responses and elevated CTL responses were maintained up to 22 weeks after the last treatment interruption, but viral load
rebound to pretreatment levels and CD4 T-cell count decline was observed. CD8 responses in PBMC were measured by cytokine flow cytometry with
gp160, Gag p55, RT-Pol and Nef expressed in vaccinia.
Pol Pol HIV-1 infection human (A*0201 and
Cw*08)
Shacklett2000
• HIV-1 specific, MHC class I-restricted CTL killing was detected in duodenal and rectal gut associated lymphoid tissue (GALT) sites from three infected
individuals – the distribution of class I restricted CTL was different in the peripheral blood samples and GALT samples
Pol computer prediction (A*0201, B*3501) Schönbach2002
• Computational methods (artificial neural networks, hidden Markov models, binding matrices based on HLA association rates) were used to identify
HLA-A*0201 and HLA-B*3501 HIV T-cell epitope candidates from 533 Gag, Env and Pol sequences of which 374 were derived from HIV-1, 97 were
derived from HIV-2 and 62 from SIV. Comparisons to known epitopes and between clades were made.
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Pol RT (IIIB) HIV-1 infection human (A2) Moore2002b
• HIV polymorphisms in the RT protein were examined relation to HLA alleles found in a population of 473 participants in the Western Australian HIV
Cohort Study. 64 significant associations between polymorphisms at particular positions and HLA alleles were detected, for HLA-B7, -B12, -B35 and
-B15. Fifteen of these were in positions with known epitopes, 4 in anchor residues, 11 in other positions. Six additional polymorphic sites associated with
particular HLA molecules flanked known epitopes and may relate to processing.
• 25 negative associations were also found between polymorphism and HLA alleles. The authors propose this is due to escape mutations in epitopes
presented by common HLA types dominating in the population, and give examples of five amino acids which are in the consensus and tend to be stable in
those with the most common HLA allele, HLA-A2.
Pol Pol HIV-1 infection human (B*35) Jin2002
• Patients with HLA-B*35 variants B*3502, B*3503, B*3504, and B*5301 tend to proceed to AIDS more quickly than those with B*3501.
• Of 32 patients with HLA-B*35 alleles CD8+ CTL responses were quantified using an intracellular cytokine staining assay – 75% had responses to Pol,
69% to Gag, 50% to Nef, and 41% to Env.
• The overall magnitude of CTL responses did not differ between those bearing B*3501 and the others. A higher percentage of Gag responses was observed
in those that had lower RNA levels that carried B*3501, and there was a negative association with viral load and CTL activity. The data is consistent with
higher levels of CTL responses contributing to protection in B*3501 individuals, but not in B*3502, B*3503, B*3504, and B*5301 individuals.
Pol Pol Vaccine murine (H-2d) Huang2001
Vaccine Vector/Type: DNA Strain: gag HxB2, pol NL43 HIV component: Gag, Pol
• Mice were immunized with four humanized DNA constructs: GagPol, that would form a pseudoparticle carrying Gag and Pol, Gag, Pol or a GagPol fusion
construct
• The GagPol pseudoparticle, Gag and GagPol fusion construct all elicited strong anti-Gag CTL, but only the GagPol fusion construct elicited strong anti
-Pol CTL
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Vif (17–26) RIRTWKSLVK HIV-1 infection human Yusim2002
• Epitopes that have been described in the literature and included in this database tend to cluster in conserved regions and be absent or rarely found highly
variable regions found in Nef, Env and p17.
• While the uneven distribution of epitopes may be in part due to a limited cross-recognition of specific responses because of differences between peptides
used to probe the immune response and autologous strains, regions with a paucity of defined epitopes also had higher frequencies of amino acids that tend
to not be found in C-terminal positions of epitopes, and had lower cleavage prediction scores for epitope processing. This suggests that in the regions of the
virus where variation is best tolerated traces of immune escape have left an imprint on the viral population. Epitopes also were concentrated in alpha-helix
and turn regions in the proteins.
• In the more conserved p24, and Pol proteins RT and Protease, epitopes are more evenly distributed.
• What was learned from proteins where many epitopes have been defined (Gag, Pol, Env and Nef) was used to develop an algorithm to predict where
epitopes would be localized in Rev, Tat, Vif, and Vpr. Predictions were made blinded, and then compared to the first 15 epitopes defined in these proteins;
the epitopes were concentrated in the predicted regions.
Vif (17–26) Vif (17–26 SF2) RIRTWKSLVK HIV-1 infection human (A*0301) Altfeld2001a
• Epitope name: RK10
• CTL responses against HIV-1 Vpr, Vpu, and Vif were analyzed in multiple HIV-1-infected individuals
• 10/29 (35%) individuals tested responded to Vif
• This epitope was recognized by 3/15 individuals expressing A*0301 allele
• HIV+ individual AC-06 was tested for reactive overlapping peptides spanning all HIV-1 proteins in an ELISPOT and was found to react with 12 peptides
from 7 proteins, suggesting that the breadth of CTL responses are underestimated if accessory proteins are not included in the study
• Overlapping Vif peptides QVDRMRIRTWKSLVK and RIRTWKSLVKHHMYI both reacted with T-cells from AC-06 and contained epitope
RIRTWKSLVK
Vif (17–26) Vif (17–26) RIRTWKSLVK HIV-1 infection human (A*0301) Addo2002b
• CTL responses against regulatory and accessory proteins in 70 HIV-1 infected patients were studied using overlapping peptides and Elispot.
• 28% targeted one or more overlapping Tat peptides; 36%, Rev peptides; 33%, Vif peptides; 40%, Vpr peptides; and 2%, Vpu peptides.
• All known optimally defined epitopes were summarized for the five proteins.
Vif (17–26) RIRTWKSLVK HIV-1 infection human (A03) Sabbaj2002b
• Epitope name: Vif-RK10
• Among HIV+ individuals who carried HLA A03, 3/21 (14%) recognized this epitope
Vif (17–26) (LAI) RIRTWKSLVK (A3) Altfeld2000a, Brander2001
Vif (17–26) Vif (17–26) RIRTWKSLVK HIV-1 infection human (A3) Yu2002a
• Epitope name: A3-RK10
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
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• 0/14 HLA-A3 positive individuals had detectable A3-restricted responses to this epitope during acute infection, but only 5/15 of HLA-A3 epitopes tested
were targeted during acute infection. 1/7 individuals had detectable responses to this epitope after STI.
Vif (27–41) Vif HHMYISKKAKGWGWFYR HIV-1 infection human Addo2002b
• CTL responses against regulatory and accessory proteins in 70 HIV-1 infected patients were studied using overlapping peptides and Elispot – 33% (23/70)
targeted one or more Vif peptides, and this peptide was the most frequently recognized epitope in Vif (25%).
• The regulatory proteins Rev and Tat combined contributed to 3%, and the accessory proteins Vif, Vpr and Vpu to 7%, of the total magnitude of HIV-1
specific CTL responses in a subset of 22 HIV-1 infected individuals in whom all HIV-1 proteins were studied.
Vif (28–36) Vif (28–36) HMYISKKAK HIV-1 infection human (A*0301) Addo2002b
• CTL responses against regulatory and accessory proteins in 70 HIV-1 infected patients were studied using overlapping peptides and Elispot.
• 28% targeted one or more overlapping Tat peptides; 36%, Rev peptides; 33%, Vif peptides; 40%, Vpr peptides; and 2%, Vpu peptides.
• All known optimally defined epitopes were summarized for the five proteins.
Vif (28–36) Vif (28–36) HMYISKKAK HIV-1 infection human (A3) Yu2002a
• Epitope name: A3-HK9
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
• 0/14 HLA-A3 positive individuals had detectable A3-restricted responses to this epitope during acute infection, but only 5/15 of HLA-A3 epitopes tested
were targeted during acute infection. 2/7 individuals had detectable responses to this epitope after STI.
Vif (31–39) ISKKAKGWF HIV-1 infection human Yusim2002
• Epitopes that have been described in the literature and included in this database tend to cluster in conserved regions and be absent or rarely found highly
variable regions found in Nef, Env and p17.
• While the uneven distribution of epitopes may be in part due to a limited cross-recognition of specific responses because of differences between peptides
used to probe the immune response and autologous strains, regions with a paucity of defined epitopes also had higher frequencies of amino acids that tend
to not be found in C-terminal positions of epitopes, and had lower cleavage prediction scores for epitope processing. This suggests that in the regions of the
virus where variation is best tolerated traces of immune escape have left an imprint on the viral population. Epitopes also were concentrated in alpha-helix
and turn regions in the proteins.
• In the more conserved p24, and Pol proteins RT and Protease, epitopes are more evenly distributed.
• What was learned from proteins where many epitopes have been defined (Gag, Pol, Env and Nef) was used to develop an algorithm to predict where
epitopes would be localized in Rev, Tat, Vif, and Vpr. Predictions were made blinded, and then compared to the first 15 epitopes defined in these proteins;
the epitopes were concentrated in the predicted regions.
Vif (31–39) Vif (31–39 SF2) ISKKAKGWF HIV-1 infection human (B*5701) Altfeld2001a
• CTL responses against HIV-1 Vpr, Vpu, and Vif were analyzed in multiple HIV-1-infected individuals
• 10/29 (35%) individuals tested responded to Vif
• This epitope was recognized by 2/6 individuals expressing B*5701 allele
Vif (31–39) Vif (31–39) ISKKAKGWF HIV-1 infection human (B*5701) Addo2002b
• CTL responses against regulatory and accessory proteins in 70 HIV-1 infected patients were studied using overlapping peptides and Elispot.
• 28% targeted one or more overlapping Tat peptides; 36%, Rev peptides; 33%, Vif peptides; 40%, Vpr peptides; and 2%, Vpu peptides.
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• All known optimally defined epitopes were summarized for the five proteins.
Vif (48–57) HPRVSSEVHI HIV-1 infection human Yusim2002
• Epitopes that have been described in the literature and included in this database tend to cluster in conserved regions and be absent or rarely found highly
variable regions found in Nef, Env and p17.
• While the uneven distribution of epitopes may be in part due to a limited cross-recognition of specific responses because of differences between peptides
used to probe the immune response and autologous strains, regions with a paucity of defined epitopes also had higher frequencies of amino acids that tend
to not be found in C-terminal positions of epitopes, and had lower cleavage prediction scores for epitope processing. This suggests that in the regions of the
virus where variation is best tolerated traces of immune escape have left an imprint on the viral population. Epitopes also were concentrated in alpha-helix
and turn regions in the proteins.
• In the more conserved p24, and Pol proteins RT and Protease, epitopes are more evenly distributed.
• What was learned from proteins where many epitopes have been defined (Gag, Pol, Env and Nef) was used to develop an algorithm to predict where
epitopes would be localized in Rev, Tat, Vif, and Vpr. Predictions were made blinded, and then compared to the first 15 epitopes defined in these proteins;
the epitopes were concentrated in the predicted regions.
Vif (48–57) Vif (48–57 SF2) HPRVSSEVHI HIV-1 infection human (B*0702) Altfeld2001a
• Epitope name: HI10
• CTL responses against HIV-1 Vpr, Vpu, and Vif were analyzed in multiple HIV-1-infected individuals
• 10/29 (35%) individuals tested responded to Vif
• This epitope was recognized by 3/8 individuals expressing B*0702 allele
• HIV+ individual AC-06 was tested for reactive overlapping peptides spanning all HIV-1 proteins in an ELISPOT and was found to react with 12 peptides
from 7 proteins, suggesting that the breadth of CTL responses are underestimated if accessory proteins are not included in the study
• Overlapping Vif peptides HHYESTHPRVSSEVH and THPRVSSEVHIPLG both reacted with T-cells from AC-06 and contained epitope HPRVSSEVHI
Vif (48–57) Vif (48–57) HPRVSSVHI HIV-1 infection human (B*0702) Addo2002b
• CTL responses against regulatory and accessory proteins in 70 HIV-1 infected patients were studied using overlapping peptides and Elispot.
• 28% targeted one or more overlapping Tat peptides; 36%, Rev peptides; 33%, Vif peptides; 40%, Vpr peptides; and 2%, Vpu peptides.
• All known optimally defined epitopes were summarized for the five proteins.
Vif (48–57) Vif (48–57) HPRVSSEVHI HIV-1 infection human (B7) Yu2002a
• Epitope name: B7-HI10
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
• 0/11 HLA-B7 individuals had detectable B7-restricted responses to this epitope during acute infection – 10/15 of HLA-B7 epitopes tested were targeted by
at least one person during acute infection. 2/4 individuals had detectable responses to this epitope after STI.
Vif (61–80) Vif (61–80) EARLVIKTYWGLOTGERDWH HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
• This peptide was among the 28 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
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Vif (71–90) Vif (71–90) GLQTGERDWHLGHGVSIEWR HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
• This peptide was among the 28 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
Vif (102–111) LADQLIHLHY HIV-1 infection human Yusim2002
• Epitopes that have been described in the literature and included in this database tend to cluster in conserved regions and be absent or rarely found highly
variable regions found in Nef, Env and p17.
• While the uneven distribution of epitopes may be in part due to a limited cross-recognition of specific responses because of differences between peptides
used to probe the immune response and autologous strains, regions with a paucity of defined epitopes also had higher frequencies of amino acids that tend
to not be found in C-terminal positions of epitopes, and had lower cleavage prediction scores for epitope processing. This suggests that in the regions of the
virus where variation is best tolerated traces of immune escape have left an imprint on the viral population. Epitopes also were concentrated in alpha-helix
and turn regions in the proteins.
• In the more conserved p24, and Pol proteins RT and Protease, epitopes are more evenly distributed.
• What was learned from proteins where many epitopes have been defined (Gag, Pol, Env and Nef) was used to develop an algorithm to predict where
epitopes would be localized in Rev, Tat, Vif, and Vpr. Predictions were made blinded, and then compared to the first 15 epitopes defined in these proteins;
the epitopes were concentrated in the predicted regions.
Vif (102–111) Vif (102–111 SF2) LADQLIHLHY HIV-1 infection human (B*1801) Altfeld2001a
• CTL responses against HIV-1 Vpr, Vpu, and Vif were analyzed in multiple HIV-1-infected individuals
• 10/29 (35%) individuals tested responded to Vif
• This epitope was recognized by 2/5 individuals expressing B*1801 allele
Vif (102–111) Vif (102–111) LADQLIHLHY HIV-1 infection human (B*1801) Addo2002b
• CTL responses against regulatory and accessory proteins in 70 HIV-1 infected patients were studied using overlapping peptides and Elispot.
• 28% targeted one or more overlapping Tat peptides; 36%, Rev peptides; 33%, Vif peptides; 40%, Vpr peptides; and 2%, Vpu peptides.
• All known optimally defined epitopes were summarized for the five proteins.
Vif (158–168) Vif (158–168) KTKPPLPSVKK HIV-1 infection human (A*0301) Addo2002b
• CTL responses against regulatory and accessory proteins in 70 HIV-1 infected patients were studied using overlapping peptides and Elispot.
• 28% targeted one or more overlapping Tat peptides; 36%, Rev peptides; 33%, Vif peptides; 40%, Vpr peptides; and 2%, Vpu peptides.
• All known optimally defined epitopes were summarized for the five proteins.
Vif (158–168) Vif (158–168) KTKPPLPSVKK HIV-1 infection human (A3) Yu2002a
• Epitope name: A3-KK11
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
• 0/14 HLA-A3 positive individuals had detectable A3-restricted responses to this epitope during acute infection, but only 5/15 of HLA-A3 epitopes tested
were targeted during acute infection. 2/7 individuals had detectable responses to this epitope after STI.
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Vif (160–169) Vif KPPLPSVKKL human (B7) De Groot2001
• The program Epimatrix was used in conjunction with the program Conservatrix to identify conservered regions of HIV that might serve as epitopes
• A subset of the potential epitopes was identified that could bind to the appropriate HLA-allele, and 15 predicted B7 superfamily (HLA B7, B8, and B58)
epitopes could stimulate IFNγ production in an ELISPOT assay
• KPPLPSVKKL was newly identified as an HLA-B7 epitope in this study
Vif Vif Vaccine murine Kim1997c
Vaccine Vector/Type: DNA HIV component: Gag, Pol, Vif, Env Adjuvant: B7, IL-12
• A gag/pol, vif or env DNA vaccine, when delivered in conjunction with the plasmid encoding the co-stimulatory molecules B7 and IL-12, gave a dramatic
increase in both the cytotoxic and proliferative responses in mice
• When IL-12 was present, CTL response could be detected even without in vitro stimulation
Vif Vif Vaccine murine (H-2d) Ayyavoo2000
Vaccine Vector/Type: DNA HIV component: Vif, Vpu, Nef
• Splenocytes from BALB/c mice immunized with pVVN-P DNA were incubated with Vif, Vpu or Nef antigens for 3 days and assayed for IL-4 and
IFN-gamma levels
• Antigen stimulation increased IFN-gamma production in pVVN-P immunized mice, indicating a Th1 response
• IL-4 production was not significantly changed after antigen stimulation compared to control levels
• Cross-clade CTL activity was also observed: A, B clade, CRF01(AE) clade antigens could serve as targets for the B clade immunization-stimulated CTL –
an HIV-1 AC recombinant, however, did not stimulate a CTL response, but was expressed at lower levels on the target cell
Vif Vif Vaccine murine (H-2d) Ayyavoo2000
Vaccine Vector/Type: DNA HIV component: Vif, Vpu, Nef
• Splenocytes from BALB/c mice immunized with pVVN-P DNA were incubated with Vif, Vpu or Nef antigens for 3 days and assayed for IL-4 and
IFN-gamma levels
• Antigen stimulation increased IFN-gamma production in pVVN-P immunized mice, indicating a Th1 response
• IL-4 production was not significantly changed after antigen stimulation compared to control levels
• Cross-clade CTL activity was also observed: A, B clade, CRF01(AE) clade antigens could serve as targets for the B clade immunization-stimulated CTL –
an HIV-1 AC recombinant, however, did not stimulate a CTL response, but was expressed at lower levels on the target cell
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Vpr (12–20) REPHNEWTL HIV-1 infection human Yusim2002
• Epitopes that have been described in the literature and included in this database tend to cluster in conserved regions and be absent or rarely found highly
variable regions found in Nef, Env and p17.
• While the uneven distribution of epitopes may be in part due to a limited cross-recognition of specific responses because of differences between peptides
used to probe the immune response and autologous strains, regions with a paucity of defined epitopes also had higher frequencies of amino acids that tend
to not be found in C-terminal positions of epitopes, and had lower cleavage prediction scores for epitope processing. This suggests that in the regions of the
virus where variation is best tolerated traces of immune escape have left an imprint on the viral population. Epitopes also were concentrated in alpha-helix
and turn regions in the proteins.
• In the more conserved p24, and Pol proteins RT and Protease, epitopes are more evenly distributed.
• What was learned from proteins where many epitopes have been defined (Gag, Pol, Env and Nef) was used to develop an algorithm to predict where
epitopes would be localized in Rev, Tat, Vif, and Vpr. Predictions were made blinded, and then compared to the first 15 epitopes defined in these proteins;
the epitopes were concentrated in the predicted regions.
Vpr (12–20) Vpr (12–20 SF2) REPHNEWTL HIV-1 infection human (B*4002) Altfeld2001a
• CTL responses against HIV-1 Vpr, Vpu, and Vif were analyzed in multiple HIV-1-infected individuals
• Individuals with long-term nonprogressive and treated chronic HIV-1 infection targeted Vpr more frequently than individuals with treated acute infection
• Only one B*4002+ individual was tested, and had a CTL response against REPHNEWTL
• Vpr is a frequent target of HIV-1 specific CD8+ T-cells – a response was detected in 45% of individuals tested and Vpr and p17 were the most preferentially
targeted proteins per unit length by CD8+ T-cells
Vpr (12–20) Vpr (12–20) REPHNEWTL HIV-1 infection human (B*4002) Addo2002b
• CTL responses against regulatory and accessory proteins in 70 HIV-1 infected patients were studied using overlapping peptides and Elispot.
• 28% targeted one or more overlapping Tat peptides; 36%, Rev peptides; 33%, Vif peptides; 40%, Vpr peptides; and 2%, Vpu peptides.
• All known optimally defined epitopes were summarized for the five proteins.
Vpr (30–38) AVRHFRPIW HIV-1 infection human Yusim2002
• Epitopes that have been described in the literature and included in this database tend to cluster in conserved regions and be absent or rarely found highly
variable regions found in Nef, Env and p17.
• While the uneven distribution of epitopes may be in part due to a limited cross-recognition of specific responses because of differences between peptides
used to probe the immune response and autologous strains, regions with a paucity of defined epitopes also had higher frequencies of amino acids that tend
to not be found in C-terminal positions of epitopes, and had lower cleavage prediction scores for epitope processing. This suggests that in the regions of the
virus where variation is best tolerated traces of immune escape have left an imprint on the viral population. Epitopes also were concentrated in alpha-helix
and turn regions in the proteins.
• In the more conserved p24, and Pol proteins RT and Protease, epitopes are more evenly distributed.
• What was learned from proteins where many epitopes have been defined (Gag, Pol, Env and Nef) was used to develop an algorithm to predict where
epitopes would be localized in Rev, Tat, Vif, and Vpr. Predictions were made blinded, and then compared to the first 15 epitopes defined in these proteins;
the epitopes were concentrated in the predicted regions.
Vpr (30–38) Vpr (29–38 SF2) AVRHFPRIW HIV-1 infection human (B*5701) Altfeld2001a
• CTL responses against HIV-1 Vpr, Vpu, and Vif were analyzed in multiple HIV-1-infected individuals
• This epitope was recognized by 4/6 individuals expressing B*5701 allele
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• Individuals with long-term nonprogressive and treated chronic HIV-1 infection targeted Vpr more frequently than individuals with treated acute infection
• Vpr is a frequent target of HIV-1 specific CD8+ T-cells – a response was detected in 45% of individuals tested and Vpr and p17 were the most preferentially
targeted proteins per unit length by CD8+ T-cells
Vpr (30–38) Vpr (29–38) AVRHFPRIW HIV-1 infection human (B*5701) Addo2002b
• CTL responses against regulatory and accessory proteins in 70 HIV-1 infected patients were studied using overlapping peptides and Elispot.
• 28% targeted one or more overlapping Tat peptides; 36%, Rev peptides; 33%, Vif peptides; 40%, Vpr peptides; and 2%, Vpu peptides.
• All known optimally defined epitopes were summarized for the five proteins.
Vpr (30–38) AVRHFPRIW HIV-1 infection human (B57) Sabbaj2002b
• Epitope name: Vpr-AW9
• Among HIV+ individuals who carried HLA B57, 1/7 (14%) recognized this epitope
Vpr (31–50) Vpr (31–50) VRHFPRPWLHSLGQYIYETY HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
• This peptide was among the 8 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
Vpr (34–42) FPRIWLHGL HIV-1 infection human Yusim2002
• Epitopes that have been described in the literature and included in this database tend to cluster in conserved regions and be absent or rarely found highly
variable regions found in Nef, Env and p17.
• While the uneven distribution of epitopes may be in part due to a limited cross-recognition of specific responses because of differences between peptides
used to probe the immune response and autologous strains, regions with a paucity of defined epitopes also had higher frequencies of amino acids that tend
to not be found in C-terminal positions of epitopes, and had lower cleavage prediction scores for epitope processing. This suggests that in the regions of the
virus where variation is best tolerated traces of immune escape have left an imprint on the viral population. Epitopes also were concentrated in alpha-helix
and turn regions in the proteins.
• In the more conserved p24, and Pol proteins RT and Protease, epitopes are more evenly distributed.
• What was learned from proteins where many epitopes have been defined (Gag, Pol, Env and Nef) was used to develop an algorithm to predict where
epitopes would be localized in Rev, Tat, Vif, and Vpr. Predictions were made blinded, and then compared to the first 15 epitopes defined in these proteins;
the epitopes were concentrated in the predicted regions.
Vpr (34–42) Vpr (34–42 SF2) FPRIWLHGL HIV-1 infection human (B*0702) Altfeld2001a
• Epitope name: FL9
• CTL responses against HIV-1 Vpr, Vpu, and Vif were analyzed in multiple HIV-1-infected individuals
• This epitope was recognized by 2/2 individuals expressing B*8101 allele and 4/8 individuals expressing B*0702 allele
• Individuals with long-term nonprogressive and treated chronic HIV-1 infection targeted Vpr more frequently than individuals with treated acute infection
• Vpr is a frequent target of HIV-1 specific CD8+ T-cells – a response was detected in 45% of individuals tested and Vpr and p17 were the most preferentially
targeted proteins per unit length by CD8+ T-cells
• HIV+ individual AC-06 was tested for reactive overlapping peptides spanning all HIV-1 proteins in an ELISPOT and was found to react with 12 peptides
from 7 proteins, suggesting that the breadth of CTL responses are underestimated if accessory proteins are not included in the study
• FPRIWLHGL was the only epitope identified in Vpr for AC-06
Vpr (34–42) Vpr (34–42) FPRIWLHGL HIV-1 infection human (B*0702) Addo2002b
• CTL responses against regulatory and accessory proteins in 70 HIV-1 infected patients were studied using overlapping peptides and Elispot.
251
DEC 2002
C
TL
HIV CTL Epitope Tables Vpr CTL Epitopes
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
• 28% targeted one or more overlapping Tat peptides; 36%, Rev peptides; 33%, Vif peptides; 40%, Vpr peptides; and 2%, Vpu peptides.
• All known optimally defined epitopes were summarized for the five proteins.
Vpr (34–42) Vpr (34–42 SF2) FPRIWLHGL HIV-1 infection human (B*8101) Altfeld2001a
• Epitope name: FL9
• CTL responses against HIV-1 Vpr, Vpu, and Vif were analyzed in multiple HIV-1-infected individuals
• This epitope was recognized by 2/2 individuals expressing B*8101 allele and 4/8 individuals expressing B*0702 allele
• Individuals with long-term nonprogressive and treated chronic HIV-1 infection targeted Vpr more frequently than individuals with treated acute infection
• Vpr is a frequent target of HIV-1 specific CD8+ T-cells – a response was detected in 45% of individuals tested and Vpr and p17 were the most preferentially
targeted proteins per unit length by CD8+ T-cells
Vpr (34–42) Vpr (34–42) FPRIWLHGL HIV-1 infection human (B*8101) Addo2002b
• CTL responses against regulatory and accessory proteins in 70 HIV-1 infected patients were studied using overlapping peptides and Elispot.
• 28% targeted one or more overlapping Tat peptides; 36%, Rev peptides; 33%, Vif peptides; 40%, Vpr peptides; and 2%, Vpu peptides.
• All known optimally defined epitopes were summarized for the five proteins.
Vpr (34–42) Vpr (34–42) FPRIWLHGL HIV-1 infection human (B7) Yu2002a
• Epitope name: B7-FL9
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
• 1/11 HLA-B7 individuals had detectable B7-restricted responses to this epitope during acute infection – 10/15 of HLA-B7 epitopes tested were targeted by
at least one person during acute infection. 2/4 individuals had detectable responses to this epitope after STI.
Vpr (55–70) Vpr AGVEAIIRILQQLLFI HIV-1 infection human Addo2002b
• CTL responses against regulatory and accessory proteins in 70 HIV-1 infected patients were studied using overlapping peptides and Elispot – 40% (28/70)
targeted one or more Vpr peptides, and this peptide was the most frequently recognized epitope in Vpr (41%).
• The regulatory proteins Rev and Tat combined contributed to 3%, and the accessory proteins Vif, Vpr and Vpu to 7%, of the total magnitude of HIV-1
specific CTL responses in a subset of 22 HIV-1 infected individuals in whom all HIV-1 proteins were studied.
Vpr (59–67) AIIRILQQL HIV-1 infection human Yusim2002
• Epitopes that have been described in the literature and included in this database tend to cluster in conserved regions and be absent or rarely found highly
variable regions found in Nef, Env and p17.
• While the uneven distribution of epitopes may be in part due to a limited cross-recognition of specific responses because of differences between peptides
used to probe the immune response and autologous strains, regions with a paucity of defined epitopes also had higher frequencies of amino acids that tend
to not be found in C-terminal positions of epitopes, and had lower cleavage prediction scores for epitope processing. This suggests that in the regions of the
virus where variation is best tolerated traces of immune escape have left an imprint on the viral population. Epitopes also were concentrated in alpha-helix
and turn regions in the proteins.
• In the more conserved p24, and Pol proteins RT and Protease, epitopes are more evenly distributed.
• What was learned from proteins where many epitopes have been defined (Gag, Pol, Env and Nef) was used to develop an algorithm to predict where
epitopes would be localized in Rev, Tat, Vif, and Vpr. Predictions were made blinded, and then compared to the first 15 epitopes defined in these proteins;
the epitopes were concentrated in the predicted regions.
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Vpr (59–67) Vpr (58–66 LAI) AIIRILQQL human (A*0201) Altfeld2001c, Brander2001
• C. Brander notes this is an A*0201 epitope
Vpr (59–67) Vpr (58–66 SF2) AIIRILQQL HIV-1 infection human (A*0201) Altfeld2001a
• Epitope name: AL9
• CTL responses against HIV-1 Vpr, Vpu, and Vif were analyzed in multiple HIV-1-infected individuals
• This epitope was recognized by 8/24 individuals expressing A*0201 allele
• Epitope is located within a highly conserved alpha helix in Vpr
• Individuals with long-term nonprogressive and treated chronic HIV-1 infection targeted Vpr more frequently than individuals with treated acute infection
• Vpr is a frequent target of HIV-1 specific CD8+ T-cells – a response was detected in 45% of individuals tested and Vpr and p17 were the most preferentially
targeted proteins per unit length by CD8+ T-cells
• The A2 eptiopes Vpr AIIRLLQQL and p17 SLYNTVATL do not account for the dominance of Vpr and p17, the result holds even when HLA-A2+
individuals are excluded
Vpr (59–67) Vpr (59–) AIIRILQQL HIV-1 infection human (A*0201) Altfeld2001c
• Epitope name: Vpr-59
• HIV was scanned for all peptides which carried the A2-supermotif pattern conserved in more than 50% of B clade sequences – 233 peptides met this
criteria, and 30 of these bound to HLA-A*0201 – 20/30 bound to at least 3/5 of HLA-A2 supertype alleles tested
• Three additional previously described HLA-A2 epitopes were added to the set of 20, and 18/22 chronically infected HLA-A2 individuals had CTL that
recognized at least one of the 23 peptides (median of 2 and maximum of 6), while 6/12 acute infected individuals recognized at least 1 (median of 1 and
maximum of 2)
• AIIRILQQL binds to four HLA-A2 supertype alleles: A*0203, A*0201, A*0206 and A*6802 (highest affinity), but not A*0202
• 5/22 individuals with chronic HIV-1 infection recognized this epitope, but with low magnitude responses in ELISPOT
• 2/12 HLA-A2 patients with acute HIV-1 infection responded strongly to this peptide, but during chronic infection SL9 and Gag-386 tended to be
immunodominant while Vpr-59 was weak and sub-dominant
• One of the the acutely infected individuals, AC13, was HLA A*0201/68 B44/14 and also had a strong acute response to gp41 epitope SV10 SLLNATDIAV
• This peptide was shown to be properly processed and presented in TAP-competent B-cell lines in vitro
Vpr (59–67) Vpr (58–66) AIIRILQQL HIV-1 infection human (A*0201) Addo2002b
• CTL responses against regulatory and accessory proteins in 70 HIV-1 infected patients were studied using overlapping peptides and Elispot.
• 28% targeted one or more overlapping Tat peptides; 36%, Rev peptides; 33%, Vif peptides; 40%, Vpr peptides; and 2%, Vpu peptides.
• All known optimally defined epitopes were summarized for the five proteins.
Vpr (59–67) AIIRILQQL HIV-1 infection human (A02) Sabbaj2002b
• Epitope name: Vpr-AL9
• Among HIV+ individuals who carried HLA A02, 4/35 (11%) recognized this epitope
Vpr (59–67) Vpr (59–) AIIRILQQL HIV-1 infection human (A2) Goulder2001a
• Epitope name: AL9
• Data from patient AC13 suggest a role for this epitope in initial control of viremia in acute infection, as it is one of several subdominant CTL epitopes
recognized during the initial decline in viremia
• A CTL response to SL9, SLYNTVATL, was not evident until 18 months post-presentation
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Vpr (59–67) Vpr (59–67 SF2) AIIRILQQL HIV-1 infection human (A2) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-A2+ individuals that had a CTL response to this epitope broken down by group: 1/10 group 1, 0/6 group 2, and 0/4 group 3
Vpr (59–67) Vpr (59–67) AIIRILQQL HIV-1 infection human (A2 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind four of the five HLA-A2 supertypes alleles (A*0201, A*020 2, A*0203, A*0206 and A*6802)
Vpr (62–70) Vpr (62–) RILQQLLFI HIV-1 infection human (A*0201) Altfeld2001c
• Epitope name: Vpr-62
• HIV was scanned for all peptides which carried the A2-supermotif pattern conserved in more than 50% of B clade sequences – 233 peptides met this
criteria, and 30 of these bound to HLA-A*0201 – 20/30 bound to at least 3/5 of HLA-A2 supertype alleles tested
• Three additional previously described HLA-A2 epitopes were added to the set of 20, and 18/22 chronically infected HLA-A2 individuals had CTL that
recognized at least one of the 23 peptides (median of 2 and maximum of 6), while 6/12 acute infected individuals recognized at least 1 (median of 1 and
maximum of 2)
• This epitope binds to three HLA-A2 supertype alleles: A*0202, A*6802 (strongest affinity) and A*0203
• 3/22 chronically infected patients had a weak ELISPOT response to this epitope
• 0/12 HLA-A2 patients with acute HIV-1 infection responded to this peptide
Vpr (62–70) Vpr (62–70) RILQQLLFI HIV-1 infection human (A*0201) Addo2002b
• CTL responses against regulatory and accessory proteins in 70 HIV-1 infected patients were studied using overlapping peptides and Elispot.
• 28% targeted one or more overlapping Tat peptides; 36%, Rev peptides; 33%, Vif peptides; 40%, Vpr peptides; and 2%, Vpu peptides.
• All known optimally defined epitopes were summarized for the five proteins.
Vpr (62–70) Vpr (62–70) RILQQLLFI HIV-1 infection human (A2 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind three of the five HLA-A2 supertypes alleles (A*0201, A*0202, A*0203, A*0206 and A*6802
Vpr Vaccine murine Muthumani2002
Vaccine Vector/Type: adenovirus HIV component: Vpr, Nef, Gag/Pol
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• Vpr can cause cells to go into G2 arrest, and it surpresses immune cell activation and inflammatory cytokine production, so co-immunization of BALB/c
mice with recombinant adenovirus expressing Vpr and HIV-1 antigens Nef or Gag/Pol was tested to see if Vpr reduced the immune response to the other
HIV antigens.
• Vpr compromised CD8+ T-cell lytic responses and T-helper proliferative responses in mice co-immunized with Vpr and Nef or Gag/Pol.
• In vitro, Vpr reduced T-cell cytokine production of IL-12 and TNFalpha, indicative of Vpr-mediated immune suppression.
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Tat (2–11) WPVDPRLEPW HIV-1 infection human Yusim2002
• Epitopes that have been described in the literature and included in this database tend to cluster in conserved regions and be absent or rarely found highly
variable regions found in Nef, Env and p17.
• While the uneven distribution of epitopes may be in part due to a limited cross-recognition of specific responses because of differences between peptides
used to probe the immune response and autologous strains, regions with a paucity of defined epitopes also had higher frequencies of amino acids that tend
to not be found in C-terminal positions of epitopes, and had lower cleavage prediction scores for epitope processing. This suggests that in the regions of the
virus where variation is best tolerated traces of immune escape have left an imprint on the viral population. Epitopes also were concentrated in alpha-helix
and turn regions in the proteins.
• In the more conserved p24, and Pol proteins RT and Protease, epitopes are more evenly distributed.
• What was learned from proteins where many epitopes have been defined (Gag, Pol, Env and Nef) was used to develop an algorithm to predict where
epitopes would be localized in Rev, Tat, Vif, and Vpr. Predictions were made blinded, and then compared to the first 15 epitopes defined in these proteins;
the epitopes were concentrated in the predicted regions.
Tat (2–11) EPVDPRLEPW HIV-1 infection human (B*5301) Sabbaj2002b
• Epitope name: Tat-EW10
• Among HIV+ individuals who carried HLA B*5301, 3/15 (20%) recognized this epitope
Tat (2–11) (LAI) EPVDPRLEPW (B53) Addo2001, Brander2001
Tat (2–11) Tat (2–11 BRU) EPVDPRLEPW HIV-1 infection human (B53) Addo2001
• Epitope name: Tat 1
• Rev and Tat are expressed early in the virus life cycle and thus may be important targets for CTL against HIV early in infection and for vaccines – therefore
CTL responses against Tat and Rev were screened using overlapping peptides
• 11/57 (19.3%) HIV-1+ individuals recognized at least 1 Tat peptide, and 21/57 (37%) responded to at least 1 Rev peptide
• EPVDPRLEPW was recognized by four individuals, but only two were B53, thus this epitope can probably be presented by other HLA alleles
Tat (2–11) Tat (2–11) EPVDPRLEPW HIV-1 infection human (B53) Addo2002b
• CTL responses against regulatory and accessory proteins in 70 HIV-1 infected patients were studied using overlapping peptides and Elispot.
• 28% targeted one or more overlapping Tat peptides; 36%, Rev peptides; 33%, Vif peptides; 40%, Vpr peptides; and 2%, Vpu peptides.
• All known optimally defined epitopes were summarized for the five proteins.
Tat (16–30) Tat (16–30) SQPKTACNKCYCKRC HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
• This peptide was among the 28 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
Tat (17–26) QPKTACTTCY HIV-1 infection human Yusim2002
• Epitopes that have been described in the literature and included in this database tend to cluster in conserved regions and be absent or rarely found highly
variable regions found in Nef, Env and p17.
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• While the uneven distribution of epitopes may be in part due to a limited cross-recognition of specific responses because of differences between peptides
used to probe the immune response and autologous strains, regions with a paucity of defined epitopes also had higher frequencies of amino acids that tend
to not be found in C-terminal positions of epitopes, and had lower cleavage prediction scores for epitope processing. This suggests that in the regions of the
virus where variation is best tolerated traces of immune escape have left an imprint on the viral population. Epitopes also were concentrated in alpha-helix
and turn regions in the proteins.
• In the more conserved p24, and Pol proteins RT and Protease, epitopes are more evenly distributed.
• What was learned from proteins where many epitopes have been defined (Gag, Pol, Env and Nef) was used to develop an algorithm to predict where
epitopes would be localized in Rev, Tat, Vif, and Vpr. Predictions were made blinded, and then compared to the first 15 epitopes defined in these proteins;
the epitopes were concentrated in the predicted regions.
Tat (17–26) Tat (17–26) QPKTACTTCY HIV-1 infection human (B35) Addo2002b
• CTL responses against regulatory and accessory proteins in 70 HIV-1 infected patients were studied using overlapping peptides and Elispot.
• 28% targeted one or more overlapping Tat peptides; 36%, Rev peptides; 33%, Vif peptides; 40%, Vpr peptides; and 2%, Vpu peptides.
• All known optimally defined epitopes were summarized for the five proteins.
Tat (36–50) (subtype C) VCFQTKGLGISYGRK human Novitsky2001
• This study is provides a survey of CTL responses and full length HIV-1 genome sequences from a C subtype infected Botswanan cohort
• 17 of 46 patient reacted with Tat immunodominant peptide VCFQTKGLGISYGRK
• Most of the CTL responses occurred despite a mismatch between the autologous viral sequence and peptide – complete matches were seen only in 4 of 19
cases (21%) and the mismatched CTL tended not to respond to the autologous viral peptide indicative of immune escape
Tat (36–50) Tat (36–50) VCFQTKGLGISYGRK HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
• This peptide was among the 8 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
Tat (36–52) Tat VCFTTKALGISYGRKKR HIV-1 infection human Addo2002b
• CTL responses against regulatory and accessory proteins in 70 HIV-1 infected patients were studied using overlapping peptides and Elispot – 28% (19/70)
targeted one or more Tat peptides, and this peptide was the most frequently recognized epitope in Tat (27%).
• The regulatory proteins Rev and Tat combined contributed to 3%, and the accessory proteins Vif, Vpr and Vpu to 7%, of the total magnitude of HIV-1
specific CTL responses in a subset of 22 HIV-1 infected individuals in whom all HIV-1 proteins were studied.
Tat (38–47) (subtype C) FQTKGLGISY human (B*1503) Novitsky2001
• Epitope name: T38-FY10
• This study is provides a survey of CTL responses and full length HIV-1 genome sequences from a C subtype infected Botswanan cohort
• 17 of 46 patient reacted with Tat immunodominant peptide VCFQTKGLGISYGRK
• FQTKGLGISY was the optimal epitope in the peptide VCFQTKGLGISYGRK among B*1503+ individuals
Tat (39–49) Tat (38–48) ITKGLGISYGR HIV-1 infection human (A*6801) Oxenius2002a
• Epitope name: Tat-4.8
• This epitope and HLA-A*6801 presenting molecule were rapidly defined using a modified Elispot assay.
• The 11-mer is the optimal epitope but A*6801 epitopes tolerate length variation.
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Tat (39–49) Tat (38–48) ITKGLGISYGR HIV-1 infection human (A68) Addo2002b
• CTL responses against regulatory and accessory proteins in 70 HIV-1 infected patients were studied using overlapping peptides and Elispot.
• 28% targeted one or more overlapping Tat peptides; 36%, Rev peptides; 33%, Vif peptides; 40%, Vpr peptides; and 2%, Vpu peptides.
• All known optimally defined epitopes were summarized for the five proteins.
Tat (40–49) TKALGISYGR HIV-1 infection human Yusim2002
• Epitopes that have been described in the literature and included in this database tend to cluster in conserved regions and be absent or rarely found highly
variable regions found in Nef, Env and p17.
• While the uneven distribution of epitopes may be in part due to a limited cross-recognition of specific responses because of differences between peptides
used to probe the immune response and autologous strains, regions with a paucity of defined epitopes also had higher frequencies of amino acids that tend
to not be found in C-terminal positions of epitopes, and had lower cleavage prediction scores for epitope processing. This suggests that in the regions of the
virus where variation is best tolerated traces of immune escape have left an imprint on the viral population. Epitopes also were concentrated in alpha-helix
and turn regions in the proteins.
• In the more conserved p24, and Pol proteins RT and Protease, epitopes are more evenly distributed.
• What was learned from proteins where many epitopes have been defined (Gag, Pol, Env and Nef) was used to develop an algorithm to predict where
epitopes would be localized in Rev, Tat, Vif, and Vpr. Predictions were made blinded, and then compared to the first 15 epitopes defined in these proteins;
the epitopes were concentrated in the predicted regions.
Tat (49–57) Tat (49–57) RKKRRQRRR murine Kim1997a
• The Tat peptide RKKRRQRRR when conjugated to a protein can cause that protein to be taken up by APCs and presented to CTL
• The system was demonstrated by vaccinating mice with an OVA-Tat peptide conjugate and immunizing H-2 Kb mice
• The CTL response to the H-2 Kb specific OVA peptide SIINFEKL was stimulated
Tat (49–57) Tat (49–57) RKKRRQRRR Vaccine murine (H-2d) Billaut-Mulot2001
Vaccine Vector/Type: DNA with DNA boost, DNA with recombinant protein boost Strain: LAI HIV component: Gag, Tat, Nef Adjuvant: IL18
• DNA vaccinated BALB/c mice primed and boosted with the multiepitopic vaccine with IL18 showed lymphoproliferative responses 7 weeks post
immunization
• Strong but non-lasting HIV-specific CTL responses were detected by a Cr-release assay and DNA prime/DNA boost was more effective than DNA prime
protein boost
• Immunization with either the multiepitopic DNA or with the mixed DNA vaccine induced HIV-1 specific Th1 cytokines (IL-2 and IFN-gamma)
• Co-administration of IL18 increased T-cell responses but decreased anti-HIV antibody levels
Tat (83–92) Tat GPKESKKKVE human (B58) De Groot2001
• The program Epimatrix was used in conjunction with the program Conservatrix to identify conservered regions of HIV that might serve as epitopes
• A subset of the potential epitopes was identified that could bind to the appropriate HLA-allele, and 15 predicted B7 superfamily (HLA B7, B8, and B58)
epitopes could stimulate IFNγ production in an ELISPOT assay
• GPKESKKKVE was newly identified as an HLA-B58 epitope in this study
Tat Tat Vaccine human Calarota1999
Vaccine Vector/Type: DNA HIV component: Nef, Rev Tat
• 9/9 HIV-1+ subjects were given one of three DNA vaccinations for nef, rev or tat, and novel proliferative and CTL responses were generated
• The nef DNA immunization induced the highest and most consistent CTLp activity, IFN-gamma production, and IL-6 and IgG responses
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• Highly active antiretroviral treatment (HAART) did not induce new HIV-specific CTL responses but reduced viral load, while DNA vaccination induced
new immune responses but did not reduce viral load – thus this is a potentially complementary and promising combination
Tat Tat HIV-1 infection human Froebel1997
• Two HIV-1 infected children with contrasting disease courses were followed longitudinally – one died of AIDS, the other is a long-term non-progressor
• Reactivity against Gag, Pol, Env and Tat proteins was tested by PBMC bulk cultured cells reacting with protein expressed in vaccinia constructs in
autologous EBV transformed B cells
• The child who progressed consistently had CTL against Pol and Tat
• The long-term non-progressing child had no detectable CTL, but was heterozygous for a mutation in the CCR5 receptor and for HLA-B49, which has been
shown to be associated with slower progression
Tat Tat HIV-1 infection, Vaccine human Calarota2001
Vaccine Vector/Type: DNA HIV component: Nef, Rev, Tat Adjuvant: CpG motifs
• This review discusses the cellular immune response, and comments on the stimulatory role of CpG motifs and how HIV-1 DNA vaccines can boost the CTL
and Th proliferative responses in asymptomatic HIV+ individuals
Tat Tat Vaccine macaque Cafaro2001
Vaccine Vector/Type: DNA Strain: BH-10 HIV component: Tat Adjuvant: CpG, ISCOM
• Macaques (macaca fascicularis) were immunized with HIV-1 Tat on an adenovirus major late promotor in a plasmid with 23 CpG sequences, 12
unmethylated
• The vaccinated animals contained a primary infection challenge with SHIV89.6P, preventing CD4+ T-cell decline in the animals, suggesting Tat may be
useful at blocking viral replication at its early stage
Tat HIV-1 infection human Aldhous1994, Kuhn2002
• Six of nine HIV vertically infected infants had HIV-1 specific CTL responses to vaccinia expressed Tat (4/6), Pol (6/6), Env (1/6), or Gag (1/6), but not all
responses were detected at all time points.
• Two of eleven babies that were not infected though born to HIV+ mothers had detectable responses to Tat (1/2), Pol (2/2), Gag (1/2).
• Reviewed in [Kuhn2002].
Tat Tat HIV-1 infection, Vaccine human Gruters2002
• This paper is a review that makes a case for using Tat and Rev as part of a vaccine strategy.
• CTL against Tat and Rev were found preferentially in long term non-progressors.
• Tat/Rev vaccinations of macaques provided protection or reduction in viremia, with high levels of CTL providing protection from challenge, lower levels of
CTL having lower viremia, while Gag/Pol vaccinations with did not result in decreased viremia.
• Early expression of Tat/Rev may in part explain the enhanced benefit of a CTL response directed at these proteins, and CTL escape is more prominent in
these proteins.
Tat Tat Vaccine murine (H-2d) Xin2001
Vaccine Vector/Type: adeno-associated virus (AAV) HIV component: Env, Tat, Rev Adjuvant: IL2
• An AAV vector expressing HIV-1 env, tat, and rev genes (AAV-HIV vector) was used to vaccinate BALB/c mice
• A single injection stimulated and long lasting serum IgG, fecal IgA, and HIV-specific CTL
• Boosting enhanced the humoral response, and IL2 enhanced T-cell immunity.
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Rev (9–23) Rev (9–23 HXB2) DEELIRTVRLIKLLY HIV-1 infection human Blazevic1995
• Induces both Th and CTL activities, no HLA restriction analysis performed
Rev (11–23) Rev (14–23) KAVRRLIKFLY HIV-1 infection human (B*5701) Addo2002b
• CTL responses against regulatory and accessory proteins in 70 HIV-1 infected patients were studied using overlapping peptides and Elispot.
• 28% targeted one or more overlapping Tat peptides; 36%, Rev peptides; 33%, Vif peptides; 40%, Vpr peptides; and 2%, Vpu peptides.
• All known optimally defined epitopes were summarized for the five proteins.
Rev (11–23) Rev (14–23) KAVRRLIKFLY HIV-1 infection human (B*5801) Addo2002b
• CTL responses against regulatory and accessory proteins in 70 HIV-1 infected patients were studied using overlapping peptides and Elispot.
• 28% targeted one or more overlapping Tat peptides; 36%, Rev peptides; 33%, Vif peptides; 40%, Vpr peptides; and 2%, Vpu peptides.
• All known optimally defined epitopes were summarized for the five proteins.
Rev (12–31) Rev (11–30 SF2) LLKAVRLIKFLYQSNPPPNF HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Only one subject had CTL that could recognize vaccinia-expressed LAI Rev
• This subject had a CTL response to this peptide, and was HLA-A2, A24, B13, B35
Rev (14–23) KAVRLIKFLY HIV-1 infection human Yusim2002
• Epitopes that have been described in the literature and included in this database tend to cluster in conserved regions and be absent or rarely found highly
variable regions found in Nef, Env and p17.
• While the uneven distribution of epitopes may be in part due to a limited cross-recognition of specific responses because of differences between peptides
used to probe the immune response and autologous strains, regions with a paucity of defined epitopes also had higher frequencies of amino acids that tend
to not be found in C-terminal positions of epitopes, and had lower cleavage prediction scores for epitope processing. This suggests that in the regions of the
virus where variation is best tolerated traces of immune escape have left an imprint on the viral population. Epitopes also were concentrated in alpha-helix
and turn regions in the proteins.
• In the more conserved p24, and Pol proteins RT and Protease, epitopes are more evenly distributed.
• What was learned from proteins where many epitopes have been defined (Gag, Pol, Env and Nef) was used to develop an algorithm to predict where
epitopes would be localized in Rev, Tat, Vif, and Vpr. Predictions were made blinded, and then compared to the first 15 epitopes defined in these proteins;
the epitopes were concentrated in the predicted regions.
Rev (14–23) Rev (14–23 subtype B) KAVRLIKFLY human (B*5701) Addo2001, Brander2001
• C. Brander notes this is a B*5701 epitope
Rev (14–23) Rev (14–23 BRU) KAVRIKLFLY HIV-1 infection human (B*5701) Addo2001
• Rev and Tat are expressed early in the virus life cycle and thus may be important targets for CTL against HIV early in infection and for vaccines – therefore
CTL responses against Tat and Rev were screened using overlapping peptides
• 11/57 (19.3%) HIV-1+ individuals recognized at least 1 Tat peptide, and 21/57 (37%) responded to at least 1 Rev peptide
• This epitope was also recognized by another individual in whom it was restricted by HLA*B5801, an allele closely related to HLA*B5701, suggesting
cross-presentation by the two HLA alleles
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Rev (14–23) Rev (14–23 subtype B) KAVRLIKFLY human (B*5801) Addo2001, Brander2001
• C. Brander notes this is a B*5801 epitope
Rev (14–23) Rev (14–23 BRU) KAVRIKLFLY HIV-1 infection human (B*5801) Addo2001
• Rev and Tat are expressed early in the virus life cycle and thus may be important targets for CTL against HIV early in infection and for vaccines – therefore
CTL responses against Tat and Rev were screened using overlapping peptides
• 11/57 (19.3%) HIV-1+ individuals recognized at least 1 Tat peptide, and 21/57 (37%) responded to at least 1 Rev peptide
• This epitope was also recognized by another individual in whom it was restricted by HLA*B5701, an allele closely related to HLA*B5801, suggesting
cross-presentation by the two HLA alleles
Rev (25–39) Rev (25–39 HXB2) SNPPPNPEGTRQARR HIV-1 infection human Blazevic1995
• Induces both Th and CTL activities, no HLA restriction analysis performed
Rev (33–48) Rev (33–48 HXB2) GTRQARRNRRRRWRER HIV-1 infection human Blazevic1995
• Induces both Th and CTL activities, no HLA restriction analysis performed
Rev (41–56) Rev (41–56 HXB2) RRRRWRERQRQIHSIS HIV-1 infection human Blazevic1995
• Induces both Th and CTL activities
Rev (55–63) Rev (55–63 LAI) ISERILSTY HIV-1 infection human (A1) vanBaalen1997
• Predicted to be an HLA-A1 epitope based on anchor residues 2S and 9Y
• Both forms LSGWL(L or I)STY, with intact anchors, were found in an HLA-A1+ individual with Rev-responsive CTL
• An HLA-A1 individual who did not make a Rev response had lost the C-term anchor, ISGWILS(T or N)S
• 3/7 long-term non-progressors and 0/5 progressors were positive for HLA-B57 (associated with prolonged survival)
• CTLp frequencies to Rev and Tat were inversely correlated with rapid progression to AIDS, but not Gag, RT or Nef
Rev (55–63) Rev (55–63) ISERILSTY HIV-1 infection, HIV-1 exposed
seronegative
human (A1) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
Rev (57–66) ERILSTYLGR HIV-1 infection human Yusim2002
• Epitopes that have been described in the literature and included in this database tend to cluster in conserved regions and be absent or rarely found highly
variable regions found in Nef, Env and p17.
• While the uneven distribution of epitopes may be in part due to a limited cross-recognition of specific responses because of differences between peptides
used to probe the immune response and autologous strains, regions with a paucity of defined epitopes also had higher frequencies of amino acids that tend
to not be found in C-terminal positions of epitopes, and had lower cleavage prediction scores for epitope processing. This suggests that in the regions of the
virus where variation is best tolerated traces of immune escape have left an imprint on the viral population. Epitopes also were concentrated in alpha-helix
and turn regions in the proteins.
• In the more conserved p24, and Pol proteins RT and Protease, epitopes are more evenly distributed.
• What was learned from proteins where many epitopes have been defined (Gag, Pol, Env and Nef) was used to develop an algorithm to predict where
epitopes would be localized in Rev, Tat, Vif, and Vpr. Predictions were made blinded, and then compared to the first 15 epitopes defined in these proteins;
the epitopes were concentrated in the predicted regions.
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Rev (57–66) Rev (57–66) ERILSTYLGR HIV-1 infection human (A3) Yu2002a
• Epitope name: A3-ER10
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
• 0/14 HLA-A3 positive individuals had detectable A3-restricted responses to this epitope during acute infection, but only 5/15 of HLA-A3 epitopes tested
were targeted during acute infection. 1/7 individuals had detectable responses to this epitope after STI.
Rev (58–66) Rev (58–66) RILSTYLGR HIV-1 infection human (A*0301) Addo2002b
• CTL responses against regulatory and accessory proteins in 70 HIV-1 infected patients were studied using overlapping peptides and Elispot.
• 28% targeted one or more overlapping Tat peptides; 36%, Rev peptides; 33%, Vif peptides; 40%, Vpr peptides; and 2%, Vpu peptides.
• All known optimally defined epitopes were summarized for the five proteins.
Rev (66–81) Rev RSAEPVPLQLPPLERL HIV-1 infection human Addo2002b
• CTL responses against regulatory and accessory proteins in 70 HIV-1 infected patients were studied using overlapping peptides and Elispot – 36% (25/70)
targeted one or more Rev peptides, and this peptide was the most frequently recognized epitope in Rev (32%).
• The regulatory proteins Rev and Tat combined contributed to 3%, and the accessory proteins Vif, Vpr and Vpu to 7%, of the total magnitude of HIV-1
specific CTL responses in a subset of 22 HIV-1 infected individuals in whom all HIV-1 proteins were studied.
Rev (67–75) SAEPVPLQL HIV-1 infection human Yusim2002
• Epitopes that have been described in the literature and included in this database tend to cluster in conserved regions and be absent or rarely found highly
variable regions found in Nef, Env and p17.
• While the uneven distribution of epitopes may be in part due to a limited cross-recognition of specific responses because of differences between peptides
used to probe the immune response and autologous strains, regions with a paucity of defined epitopes also had higher frequencies of amino acids that tend
to not be found in C-terminal positions of epitopes, and had lower cleavage prediction scores for epitope processing. This suggests that in the regions of the
virus where variation is best tolerated traces of immune escape have left an imprint on the viral population. Epitopes also were concentrated in alpha-helix
and turn regions in the proteins.
• In the more conserved p24, and Pol proteins RT and Protease, epitopes are more evenly distributed.
• What was learned from proteins where many epitopes have been defined (Gag, Pol, Env and Nef) was used to develop an algorithm to predict where
epitopes would be localized in Rev, Tat, Vif, and Vpr. Predictions were made blinded, and then compared to the first 15 epitopes defined in these proteins;
the epitopes were concentrated in the predicted regions.
Rev (67–75) Rev (65–77 BH10, LAI) SAEPVPLQL HIV-1 infection human Maksiutov2002
• This study employs an antigenic similarity matrix to compare HIV-1 antigenic determinants with human proteins.
• This CTL epitope (the HIV-1 LAI fragment with high similarity to a human protein overlapping this epitope is GRSAEPVPLQLPP) has similarity with
transforming growth factor beta binding protein protein I, fragment ARSAEPEVATAPP.
• This CTL epitope (the HIV-1 LAI fragment with high similarity to a human protein overlapping this epitope is EPVPLQLPPL) also has similarity with the
epidermal growth factor receptor substrate 15, fragment EPVPMSLPPA.
Rev (67–75) (LAI) SAEPVPLQL (B14) Brander2001, vanBaalen2000
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Rev (67–75) Rev SAEPVPLQL HIV-1 infection human (B14) Schutten2001
• Molecularly cloned primary NSI macrophage tropic strain 2.1 and SI non-macrophage tropic strain 1.2 were isolated from study participant ACH320 and
use to infect irradiated XID mice that had been reconstituted with human PBMC from B14+ seronegative donors – results indicate CTL may favor selective
outgrowth of macrophage tropic strains
• The CTL clone TCC108 specific for SAEPVPLQL, previously described by van Baalen 1997, and van Baalen 1998, was stimulated in vitro and given to
the mice to apply specific CTL pressure
• The macrophage-tropic HIV-1 strain #2.1 escaped CTL pressure more efficiently (7/14 animals) than its non-macrophage-tropic counterpart #1.2(SI) – the
latter isolate was suppressed in 13/14 animals – macrophage may serve as a CTL sanctuary and reduced pressure on macrophage tropic HIV strains may
allow additional replication to assist with acquisition of escape
• Specific HIV-1 variants selectively induced by TCC108 were for strain 1.2: SEEPVPLQL, and for strain 2.1: SAEHVPLQL, SAESVPLQL, SVEPVPLQL,
SLEPVPLQL, SAEPVPFQL, and SAEPVPFQL
Rev (67–75) Rev (67–75) SAEPVPLQL HIV-1 infection human (B14) vanBaalen2002
• Tat, Rev and Nef are the first HIV proteins expressed upon acute infection of T-cells (< 6 hours), and RT is not expressed until after 24 hours. The
B14-restricted Rev-SAEPVPLQL specific CD8 T-cell clone TCC108, and the B57-restricted RT-IVLPEKDSW specific CD8 T-cell clone TCL1C11 were
co-incubated with CD4+ cultures innoculated with HIV-1 at low MOI. Co-incubation with the Rev-specific CTL resulted in two logs less HIV-1 production
in ten days of culture. When the RT epitope was cloned into the Nef gene of the infecting strain, another early expressed protein, it proved as effective as
the Rev epitope at inhibiting viral production. A mathematical model of CTL-target interactions suggest early proteins are important for vaccine design.
Rev (67–75) Rev (67–75) SAEPVPLQL HIV-1 infection human (B14) Addo2002b
• CTL responses against regulatory and accessory proteins in 70 HIV-1 infected patients were studied using overlapping peptides and Elispot.
• 28% targeted one or more overlapping Tat peptides; 36%, Rev peptides; 33%, Vif peptides; 40%, Vpr peptides; and 2%, Vpu peptides.
• All known optimally defined epitopes were summarized for the five proteins.
Rev (67–75) Rev (67–75 IIIB) SAEPVPLQL HIV-1 infection human (B14, Cw8) vanBaalen1998
• The Rev-specific CTL response studied here was from an individual infected with HIV-1 for more than 12 years without developing symptoms – Rev and
Tat are expressed early and CTL activity against these proteins has been correlated with long-term survival
• The CTL clone TCC108 specific for this epitope was studied in vitro
• CTLs added immediately after infection suppressed viral production, indicative of CTL interference with viral production prior to lysis – CTL-mediated
lysis occurred after the onset of progeny viral release, but prior to peak viral production
• Rapid selection of a E69K mutation, which abolished CTL, recognition was observed
• The epitope was originally listed as B14, but Cw8 and B14 are in linkage disequilibrium, and in this case were not distinguished (Pers. Comm., Christian
Brander, 1999)
Rev (67–75) (LAI) SAEPVPLQL human (Cw5) Addo2001, Brander2001
Rev (67–75) Rev (SF2) SAEPVPLQL HIV-1 infection human (Cw5) Goulder2001a
• Epitope name: SL9
• Data from patient AC13 suggest a role for this epitope in initial control of viremia in acute infection, as it is one of several subdominant CTL epitopes
recognized during the initial decline in viremia
• A CTL response to SL9, SLYNTVATL, was not evident until 18 months post-presentation
Rev (67–75) Rev (67–75 SF2) SAEPVPLQL HIV-1 infection human (Cw5) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
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• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-Cw5+ individuals that had a CTL response to this epitope broken down by group: 2/6 group 1, 0/1 group 2, and 0/2 group 3
Rev (67–75) Rev (67–75) SAEPVPLQL HIV-1 infection human (Cw5/Cw8) Addo2002b
• CTL responses against regulatory and accessory proteins in 70 HIV-1 infected patients were studied using overlapping peptides and Elispot.
• 28% targeted one or more overlapping Tat peptides; 36%, Rev peptides; 33%, Vif peptides; 40%, Vpr peptides; and 2%, Vpu peptides.
• All known optimally defined epitopes were summarized for the five proteins.
Rev (67–75) Rev (69–77 BRU) SAEPVPLQL HIV-1 infection human (Cw8) Addo2001
• Epitope name: Rev SL9
• Rev and Tat are expressed early in the virus life cycle and thus may be important targets for CTL against HIV early in infection and for vaccines – therefore
CTL responses against Tat and Rev were screened using overlapping peptides
• 11/57 (19.3%) HIV-1+ individuals recognized at least 1 Tat peptide, and 21/57 (37%) responded to at least 1 Rev peptide
• This epitope is the first HIV-specific CTL epitope resticted by HLA-Cw5
• This epitope was recognized by 2/5 individuals expressing HLA-Cw8 and by 5/11 individuals expressing Cw5 allele, which differs from Cw8 by 4 amino
acids, suggesting promiscuous presentation of the epitope between those HLA molecules
• Longitudinal data was available for 6 Rev-SL9 responders, who were treated during acute infection, and the response was stable 2 and 12 months after
initiaion of HAART, measurements by ELISPOT and flow-based intracellular cytokine staining (ICS) were concordant – in two subjects the response was
heightened by transient reexposure to antigen with treatment interruption at 12 to 14 months
Rev (75–83) LPPLERLTL HIV-1 infection human Yusim2002
• Epitopes that have been described in the literature and included in this database tend to cluster in conserved regions and be absent or rarely found highly
variable regions found in Nef, Env and p17.
• While the uneven distribution of epitopes may be in part due to a limited cross-recognition of specific responses because of differences between peptides
used to probe the immune response and autologous strains, regions with a paucity of defined epitopes also had higher frequencies of amino acids that tend
to not be found in C-terminal positions of epitopes, and had lower cleavage prediction scores for epitope processing. This suggests that in the regions of the
virus where variation is best tolerated traces of immune escape have left an imprint on the viral population. Epitopes also were concentrated in alpha-helix
and turn regions in the proteins.
• In the more conserved p24, and Pol proteins RT and Protease, epitopes are more evenly distributed.
• What was learned from proteins where many epitopes have been defined (Gag, Pol, Env and Nef) was used to develop an algorithm to predict where
epitopes would be localized in Rev, Tat, Vif, and Vpr. Predictions were made blinded, and then compared to the first 15 epitopes defined in these proteins;
the epitopes were concentrated in the predicted regions.
Rev Rev Vaccine human Calarota1999
Vaccine Vector/Type: DNA HIV component: Nef, Rev Tat
• 9/9 HIV-1+ subjects were given one of three DNA vaccinations for nef, rev or tat, and novel proliferative and CTL responses were generated
• The nef DNA immunization induced the highest and most consistent CTLp activity, IFN-gamma production, and IL-6 and IgG responses
• Highly active antiretroviral treatment (HAART) did not induce new HIV-specific CTL responses but reduced viral load, while DNA vaccination induced
new immune responses but did not reduce viral load – thus this is a potentially complementary and promising combination
264
DEC 2002
Rev CTL Epitopes HIV CTL Epitope Tables
C
TL
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
Rev (subtype C) human Novitsky2001
• This study is provides a survey of CTL responses and full length HIV-1 genome sequences from a C subtype infected Botswanan cohort
• Anti-Rev CTL responses were distributed throughout the protein and 27 of 47 subjects (57%) demonstrated HIV-1C Rev-specific ELISPOT CTL responses
of more than 100 SFC/106 PBMC
Rev Rev HIV-1 infection, Vaccine human Calarota2001
Vaccine Vector/Type: DNA HIV component: Nef, Rev, Tat Adjuvant: CpG motifs
• This review discusses the cellular immune response, and comments on the stimulatory role of CpG motifs and how HIV-1 DNA vaccines can boost the CTL
and Th proliferative responses in asympotomatic HIV+ individuals
Rev Rev HIV-1 infection, Vaccine human Gruters2002
• This paper is a review that makes a case for using Tat and Rev as part of a vaccine strategy.
• CTL against Tat and Rev were found preferentially in long term non-progressors.
• Tat/Rev vaccinations of macaques provided protection or reduction in viremia, with high levels of CTL providing protection from challenge, lower levels of
CTL having lower viremia, while Gag/Pol vaccinations with did not result in decreased viremia.
• Early expression of Tat/Rev may in part explain the enhanced benefit of a CTL response directed at these proteins, and CTL escape is more prominent in
these proteins.
Rev Rev Vaccine murine (H-2d) Ishii1997
Vaccine Vector/Type: DNA with CMV promotor with cationic liposome HIV component: gp160, Rev
• pCMV160/Rev is a DNA vaccine candidate carrying gp160 and Rev linked to a cytomegalovirus (CMV promotor)
• pCMV160/Rev given in conjunction with a cationic liposome gave enhanced DTH, Ab and CTL responses
Rev Rev Vaccine murine (H-2d) Ihata1999
Vaccine Vector/Type: DNA HIV component: rev Adjuvant: CD40
• pcRev DNA i.m. vaccination in BALB/c mice induced Th1, Th2 and IgG responses, and enhanced the CTL response to Rev, but did not induce mucosal IgA
Rev Rev Vaccine murine (H-2d) Xin2001
Vaccine Vector/Type: adeno-associated virus (AAV) HIV component: Env, Tat, Rev Adjuvant: IL2
• An AAV vector expressing HIV-1 env, tat, and rev genes (AAV-HIV vector) was used to vaccinate BALB/c mice
• A single injection stimulated and long lasting serum IgG, fecal IgA, and HIV-specific CTL
• Boosting enhanced the humoral response, and IL2 enhanced T-cell immunity
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Vpu (4–13) Vpu LVILAIVALV human (B7) De Groot2001
• The program Epimatrix was used in conjunction with the program Conservatrix to identify conservered regions of HIV that might serve as epitopes
• A subset of the potential epitopes was identified that could bind to the appropriate HLA-allele, and 15 predicted B7 superfamily (HLA B7, B8, and B58)
epitopes could stimulate IFNγ production in an ELISPOT assay
• LVILAIVALV was newly identified as an HLA-B7 epitope in this study using ELISPOT, but could not be shown to bind to B7
Vpu (25–40) Vpu IVFIEYRKLRQRKID HIV-1 infection human Addo2002b
• CTL responses against regulatory and accessory proteins in 70 HIV-1 infected patients were studied using overlapping peptides and Elispot – only 2%
(2/70) targeted one or more Vpu peptides, including this peptide.
• The regulatory proteins Rev and Tat combined contributed to 3%, and the accessory proteins Vif, Vpr and Vpu to 7%, of the total magnitude of HIV-1
specific CTL responses in a subset of 22 HIV-1 infected individuals in whom all HIV-1 proteins were studied.
Vpu (29–37) Vpu (29–37) EYRLKILRQR HIV-1 infection human (A*3303) Addo2002b
• CTL responses against regulatory and accessory proteins in 70 HIV-1 infected patients were studied using overlapping peptides and Elispot.
• 28% targeted one or more overlapping Tat peptides; 36%, Rev peptides; 33%, Vif peptides; 40%, Vpr peptides; and 2%, Vpu peptides.
• All known optimally defined epitopes were summarized for the five proteins.
Vpu (29–37) Vpu (29–37) EYRLKILRQR HIV-1 infection human (A*3303) Addo2002a
• Detection of HIV CTL epitopes is rare in Vpu, and this is the first optimally defined Vpu epitope.
• This CTL response was first detected in a long term non-progressor, and 3/6 HLA A*3303 positive individuals were found to have a CTL response to this
epitope.
• HLA A*3303 is common in West Africa and Asia.
Vpu Vpu Vaccine murine (H-2d) Ayyavoo2000
Vaccine Vector/Type: DNA HIV component: Vif, Vpu, Nef
• Splenocytes from BALB/c mice immunized with pVVN-P DNA were incubated with Vif, Vpu or Nef antigens for 3 days and assayed for IL-4 and
IFN-gamma levels
• Antigen stimulation increased IFN-gamma production in pVVN-P immunized mice, indicating a Th1 response
• IL-4 production was not significantly changed after antigen stimulation compared to control levels
• Cross-clade CTL activity was also observed: A, B clade, CRF01(AE) clade antigens could serve as targets for the B clade immunization-stimulated CTL –
an HIV-1 AC recombinant, however, did not stimulate a CTL response, but was expressed at lower levels on the target cell
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gp160 (2–10) gp160 (2–10 IIIB) RVKEKYQHL HIV-1 infection human (B*0801) Brander2001
• C. Brander notes this is a B*0801 epitope
gp160 (2–10) gp160 (2–10 IIIB) RVKEKYQHL HIV-1 infection human (B8) Sipsas1997
• HIV IIIB proteins were used to define the range of CTL epitopes recognized by 3 lab workers accidentally infected with HIV-1 IIIB
• Type-specific epitope, unique to the LAI and IIIB because of a deletion of three amino acids that are present in all other subtype B HIV-1s
• RVKGIRKNYQHL, a variant found in JRCSF, was not recognized
• This epitope is in the signal sequence of gp120
gp160 (2–10) gp120 (2–10) RVKEKYQHL HIV-1 infection human (B8) Day2001
• B8-restricted CTL accounted for about 1/3 of the total CTL response in one individual
gp160 (6–12) gp120 (6–15 CM243
subtype CRF01)
TQMNWPNLWK HIV-1 exposed seronegative human (A11) Sriwanthana2001
• Epitope name: E6-15
• This was a study of HIV-1 exposed persistently seronegative (HEPS) female sex workers in Chiang Mai, northern Thailand
• HLA-A11 is very common in this population, and was enriched among the HEPS sexworkers – weak CTL responses were detected in 4/7 HEPS women,
and CTL responses were found in 8/8 HIV+ controls, and 0/9 HIV- women that were not exposed
• This epitope after a second stimulation in vitro gave a weak response in HEPS study subject 186 who was HLA A2/A11
gp160 (6–12) gp120 (6–15 CM243
subtype CRF01)
TQMNWPNLWK HIV-1 infection human (A11) Bond2001
• HLA-A11 CRF01 (called subtype E in Bond et al.) epitopes were identified that stimulated CTL from HIV+ female sex workers (FSW) from Northern
Thailand, of whom more than half were HLA-A11 positive
• 77 possible HLA-A11 epitopes were first defined using EpiMatrix, these were screened for binding to A11 finding and 26 bound, and 12 of these were
epitopes for CTL responses from 8 HLA-A11 positive FSWs, six were novel, six were previously identified
• This is one of the new A11 epitopes identified through the streamlined EpiMatrix method, and 2/8 tested FSWs recognized it
• This epitope was not conserved in other subtypes, and exact matches were rare
gp160 (30–49) gp120 AAEQLWVTVYYGVPVWKEAT HIV-1 infection human (A11) Weekes1999b
• Peptide 7035.1: Almost all CD8+ T cells are CD28+ at birth, and the proportion of CD28-CD8+ cells increases with age – this study examines the
contribution of CD8+CD28- cells to CTL memory pools for CTL clones specific for two persistent human viruses, CMV and HIV – clones were found to
be similarly distributed in the CD28 depleted cell population
• HIV CTL responses to 3 Env and 2 Gag peptides were studied
• The clonal composition of the TCR Vbeta responses was studied and was found to be highly focused, with one TCR beta-chain sequence tending to
dominate the peptide-specific response – clones to this epitope were Vbeta6
gp160 (31–39) gp120 (30–38 SF2) AENLWVTVY HIV-1 infection human (B44) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
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• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B44+ individuals that had a CTL response to this epitope broken down by group: 1/8 group 1, 2/3 group 2, and 3/4 group 3
gp160 (31–39) gp120 (30–38) AENLWVTVY HIV-1 infection human (B44) Day2001
gp160 (31–39) gp120 AENLWVTVY HIV-1 infection human (B44) Cao2002
• AC2 is a B44 restricted CTL clone that recognizes AENLWVTVY.
• CTL could be activated by a fusion protein of an HIV protein and anthrax lethal factor (LFn-HIV) that promotes antigen presenting cell uptake of
exogenous protein and allows processing through the MHC class I pathway. This strategy for CTL detection could allow antigen presentation without
generation of cells by the standard methods of using live viral vectors carrying a protein, or by loading the cells with peptides and by-passing processing.
gp160 (31–40) gp160 (30–39 WEAU) AENLWVTVYY HIV-1 infection human (B*4402) Brander2001
• C. Brander notes this is a B*4402 epitope
gp160 (31–40) gp160 (30–39 WEAU) AENLWVTVYY HIV-1 infection human (B44) Borrow1997, Borrow1998,
Goulder1997a
• Two CTL lines from the patient WEAU were studied – one had an optimal peptide of (A)AENLWVTVYY, and the other (A)AENLWVTVY, and both
responded equally well with one or two N-term Alanines
• Rapidly post-infection, a strong immunodominant response was observed against this epitope
• The naturally occurring forms of the peptide found in WEAU were tested as targets for early WEAU CTLs – the form TENLWVTVY was as reactive as the
wild type AENLWVTVY – but the forms AKNLWVTVY, AGNLWVTVY, AANLWVTVY did not serve as targets
• The glutamic acid in the second position is a B44 anchor residue
• [Goulder1997a] and [Borrow1998] are reviews of immune escape that summarizes this study in the context of CTL escape to fixation
gp160 (31–55) gp120 (32–56 LAI) TEKLWVTVYYGVPVWKEAT-
TTLFCA
Vaccine human (B18) Johnson1994a
Vaccine Vector/Type: vaccinia HIV component: gp160
• HLA restricted CTL response to epitope in HIV-1 vaccinia-env vaccinees
gp160 (31–55) gp120 (32–56 LAI) TEKLWVTVYYGVPVWKEAT-
TTLFCA
Vaccine human (B18) Ferris1999, Hammond1995
Vaccine Vector/Type: vaccinia HIV component: gp160
• This peptide can be processed for HLA-B18 presentation by both TAP-1/2 independent and dependent pathways
gp160 (33–42) gp120 (32–41 LAI) KLWVTVYYGV Vaccine human (A2) Dupuis1995
Vaccine Vector/Type: recombinant protein Strain: MN HIV component: gp160
• CTL from HLA-A2 positive subject react with this peptide
gp160 (33–42) Env (32–41 subtype B) KLWVTVYYGV HIV-1 infection, Vaccine human (A2.1) Kundu1998a
Vaccine Vector/Type: recombinant protein Strain: MN HIV component: gp160
• Ten HIV-1+ HLA A2 asymptomatic individuals were given two courses of HIV-1 MN rgp160 vaccine over a 2 year period
• Two hundred and fifty three HIV-1 peptides of 9 or 10 aa possessing the HLA-A2.1 binding motif (Leu at position 2, Val at the C terminus) were identified
in gp160, of which 25 had a high or intermediate binding affinity
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• Eleven peptides were studied that had high HLA-A2 binding affinity – a CTL response was detected to 9/11 peptides in at least 1 individual
• CTL responses after reimmunization may include recall responses – only individuals with vaccine cross-reactive sequences prior to vaccination showed
detectable CTL responses
gp160 (34–55) gp120 (25–46 BRU) LWVTVYYGVPVWKEATTTL-
FCA
HIV-1 infection human (A2) Dadaglio1991
• Defined through peptide blocking of CTL activity, and Env deletions
gp160 (36–46) gp120 (36–46 CM243
subtype CRF01)
VTVYYGVPVWR HIV-1 exposed seronegative human (A11) Sriwanthana2001
• Epitope name: E36-4
• This was a study of HIV-1 exposed persistently seronegative (HEPS) female sex workers in Chiang Mai, northern Thailand
• HLA-A11 is very common in this population, and was enriched among the HEPS sexworkers – weak CTL responses were detected in 4/7 HEPS women,
and CTL responses were found in 8/8 HIV+ controls, and 0/9 HIV- women that were not exposed
• This epitope after a second stimulation in vitro gave a weak response in HEPS study subject 186 who was HLA A2/A11
gp160 (36–46) gp120 (36–46 CM243
subtype CRF01)
VTVYYGVPVWR HIV-1 infection human (A11) Bond2001
• HLA-A11 CRF01 (called subtype E in Bond et al.) epitopes were identified that stimulated CTL from HIV+ female sex workers (FSW) from Northern
Thailand, of whom more than half were HLA-A11 positive
• 77 possible HLA-A11 epitopes were first defined using EpiMatrix, these were screened for binding to A11 finding and 26 bound, and 12 of these were
epitopes for CTL responses from 8 HLA-A11 positive FSWs, six were novel, six were previously identified
• This epitope was not predicted by the EpiMatrix method to be likely to bind to A11, though it served as an epitope in the FSWs, and it was one of the six
A11 epitopes that had been previously defined
• 1/8 tested FSWs recognized this epitope
• This epitope was only conserved in CRF01 and subtypes B and C, and exact matches were uncommon
gp160 (36–46) gp120 VTVYYGVPVWK HIV-1 infection human (A11 and
A*6801)
Threlkeld1997
• Study of the fine specificity of an A3-like-HLA-super-type epitope (the A3-super-type includes A*0301, A*1101, A*3101, A*3301, and A*6801)
• The A3 super-type is characterized as a hydrophobic or hydroxyl containing anchor residue at position 2, and a positive charge in the C-term position
• While most lines were specific, a promiscuous cloned CTL line was derived from an HIV+ donor that could recognize this epitope presented by either A11
or A*6801
gp160 (37–46) gp120 (37–46 LAI) TVYYGVPVWK Vaccine human (A*0301) Johnson1994b
Vaccine Vector/Type: vaccinia HIV component: gp160
• Multiple CTL clones obtained from two vaccinees
• C. Brander notes that this is an A*0301 epitope in the 1999 database
gp160 (37–46) gp120 (37–46 LAI) TVYYGVPVWK Vaccine human (A*0301) Brander2001
Vaccine Vector/Type: vaccinia HIV component: gp160
• C. Brander notes this is an A*0301 epitope
gp160 (37–46) gp120 TVYYGVPVWK HIV-1 infection, Vaccine human (A*0301) Hanke2000, Wee2002
Vaccine Vector/Type: DNA prime with vaccinia MVA boost Strain: subtype A HIV component: p17, p24, polyepitope
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• The HIV-1 subtype A focused vaccine HIVA contains p24 and p17, in a reversed order relative to the Gag polyprotein to prevent myristylation of p17,
which could direct the protein to the cell membrane and inhibit efficient peptide processing and class I presentation, as well as a polyepitope string of
conserved, often immunodominant epitopes that were selected to have particularly good cross-reactive potential for the A-clade epidemic in Nairobi,
Kenya. A DNA and MVA prime-boost vaccination protocol using the HIVA antigen will be used in a phase III clinical trial in Kenya. This epitope is
included in the polyepitope string [Hanke2000].
• Multiple CD4+ or CD8+ T-cell vaccine-induced responses to peptide pools were detected using intracellular cytokine staining and IFNgamma Elispot
assays after vaccination of 5 macaques. The response to the Mamu A*01 SIV p27 epitope p11C (CTPYDINQM), included in the polyepitope region, was
not immunodominant in the Mamu A*01 vaccinated macaques, possibly because of processing limitations in context of the artificial polyepitope string
[Wee2002].
gp160 (37–46) TVYYGVPVWK HIV-1 infection human (A03) Sabbaj2002b
• Epitope name: Env-VK9
• Among HIV+ individuals who carried HLA A03, 0/20 (0%) recognized this epitope
gp160 (37–46) Env TVYYGVPVWK Vaccine SJL/J HLA transgenic
mice (A11)
Ishioka1999
Vaccine Vector/Type: DNA HIV component: polyepitope
• A minigene vaccine construct encoding 6 HLA 2.1 and 3 HLA A11 restricted CTL epitopes, the universal Th cell epitope PADRE (pan-DR epitope) and an
ER translocating signal sequence was constructed
• The epitopes were chosen for dominant recognition by CTLs during HBV and HIV infections in humans
• HLA transgenic mice were used for quantitating in vivo immunogenicity of DNA vaccines encoding HLA-restricted CTL epitopes.
gp160 (37–46) gp120 (37–46) TVYYGVPVWK Vaccine human (A3) Carruth1999
Vaccine Vector/Type: canarypox Strain: MN, LAI HIV component: gp120, gp41, Gag, Protease
• The vaccine used was a live recombinant canarypox (CP) virus vaccine containing multiple HIV-1 genes (HIV-1 MN gp120, HIV-1 LAI gp41, HIV-1 LAI
Gag, HIV-1 LAI protease)
• CD4+ and CD8+ Gag and Env specific CTL responses were detected in only 1/5 vaccinated volunteers, and were not detectable 1 year after vaccination
• CTL responses to epitopes SLYNTVATL and TVYYGVPVWK from HIV+ control patients were used as positive controls
• The study explored why vaccinees were non-responsive – non-response was not due to inherent defects or differences in the ability of these individuals to
process and present antigen
gp160 (37–46) gp120 (37–46 LAI) TVYYGVPVWK HIV-1 infection human (A3) Goulder1997e, Goulder1997a
• Identical twin hemophiliac brothers were both infected with the same batch of factor VIII
• One had a response to this epitope, the other did not
• [Goulder1997a] is a review of immune escape that summarizes this study
gp160 (37–46) gp120 (36–45) TVYYGVPVWK HIV-1 infection human (A3) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
gp160 (37–46) gp120 (37–46) TVYYGVPVWK HIV-1 infection human (A3) Day2001
• The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7 was
studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
• 2 to 17 epitopes were recognized in a given individual, A2-restricted CTL response tended to be narrow and never dominated the response, and 25/27
epitopes were targeted by at least one person
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• All patients recognized at least 1 A3 epitope, up to 8 A3 epitopes, but none was clearly dominant
gp160 (37–46) Env (49–58) TVYYGVPVWK HIV-1 infection human (A3 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind 3/5 HLA-A3 supertype alleles (A*0301, A*1101, A*3101, A*3301 and A*6801)
gp160 (37–46) gp120 (38–41 LAI) TVYYGVPVWK Vaccine human (A3.1) Johnson1994a
Vaccine Vector/Type: vaccinia HIV component: gp160
• Highly conserved epitope recognized by multiple CTL clones from vaccinee
gp160 (37–46) gp120 (37–46 LAI) TVYYGVPVWK Vaccine human (A3.1) Ferris1999, Hammond1995
Vaccine Vector/Type: vaccinia HIV component: gp160
• This peptide can be processed for HLA-A3.1 presentation by TAP-1/2 independent and dependent pathways
gp160 (37–46) gp120 (37–46 LAI) TVYYGVPVWK HIV-1 infection human (B*0301) Wilson2000a
• Three individuals with highly focused HIV-specific CTL responses were studied during acute infection using tetramers – high frequencies of HIV-1-specific
CD8+ T cells were found prior to seroconversion, and there was a close temporal relationship between the number of circulating HIV-specific T cells and
viral load was also found
• All three patients were B*2705, with HLA alleles: A1, A30/31, B*2705, B35; A1, A*0301, B7, B2705; and A*0201, A*0301, B2705, B39
• ELISPOT was used to test a panel of CTL epitopes that had been defined earlier and were appropriate for the HLA haplotypes of the study subjects – 3/3
subjects showed a dominant response to the B*2705 epitope KRWIILGGLNK
• The subject with A*0201 had a moderatly strong response to SLYNTVATL
• Weak responses were observed to A*301-RLRPGGKKK, A*301-QVPLRPMTYK, and B7-TPGPGVRYPL in the subject who was HLA A1, A*0301, B7,
B*2705
• No acute response was detected to the following epitopes: A*201-ILKEPVHGV, A*301-KIRLRPGGK, A*301-AIFQSSMTK, A*301-TVYYGVPVWK,
B35-EPIVGAETF, B35-HPDIVIYQY, B35-PPIPVGEIY, B35-NSSKVSQNY, B35-VPLRPMTY, B35-DPNPQEVVL
gp160 (38–48) gp120 (45–55) VYYGVPVWKEA HIV-1 infection human (Cw7) Nehete1998a
• Three long-term non-progressors and one asymptomatic HIV+ individual were studied and found to have HLA class I C-restricted CD8+ Env-specific
CTLs – Cw7 specific CTL were found against three peptides, including this one
• HLA-C antigens are expressed on lymphoid cells to a lesser extent than either HLA-A or -B
• HLA-C confers protection against lysis by natural killer cells and by non-MHC-restricted effector T cells and Cw7 directly governs this resistance to lysis –
the authors hypothesize that pathogens that inhibit antigen expression and class I expression may particularly down regulate Cw7, thus triggering non-MHC
restricted killing
gp160 (42–51) gp120 (42–51 PV22) VPVWKEATTT HIV-1 infection human (B*5501) Brander2001
• C. Brander notes this is a B*5501 epitope
gp160 (42–51) gp120 (42–51 PV22) VPVWKEATTT HIV-1 infection human (B55) Brander1995b
• P. Johnson, unpublished
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gp160 (42–51) gp120 (41–55) VPVWKEATTT HIV-1 infection human (B55) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
gp160 (42–52) Env (43–52 BH10, LAI) VPVWKEATTTL HIV-1 infection human Maksiutov2002
• This study employs an antigenic similarity matrix to compare HIV-1 antigenic determinants with human proteins.
• This CTL epitope (the HIV-1 LAI fragment with high similarity to a human protein overlapping this peptide is PVWKEATTTL) has similarity with the
platelet membrane glycoprotein IIIA precursor (GLIIIA) (integrin beta-3) (CD61): PLYKEATSTF.
gp160 (42–52) gp120 (42–52) VPVWKEATTTL HIV-1 infection human (B*3501) Brander2001
• C. Brander notes this is a B*3501 epitope
gp160 (42–52) gp120 (42–52 PV22) VPVWKEATTTL HIV-1 infection human (B35) Cao1997a
• VPVWKEATTTL is the consensus sequence for clades B and D
• VPVWKDAETTL is the consensus sequence for clade A and it is cross-reactive
• VPVWKEADTTL is the consensus sequence for clade C and it is cross-reactive
• VPVWKEADTTL is the consensus sequence for clade E and even with three substitutions still retains some cross-reactivity
gp160 (42–52) gp120 (41–51) VPVWKEATTTL HIV-1 infection human (B35) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
gp160 (42–61) gp120 (49–68) VPVWKEATTTLFCASDAKAY HIV-1 infection human Lieberman1995
• HIV-specific CTL lines developed by ex vivo stimulation with peptide
gp160 (42–61) gp120 (49–68 SF2) VPVWKEATTTLFCASDAKAY HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Eleven subjects had CTL that could recognize vaccinia-expressed LAI gp160
• Three of these 11 had CTL response to this peptide
• The responding subjects were HLA-A2, A3, B8, B62; HLA-A3, A24, B7, B38
gp160 (42–61) gp120 (49–68 SF2) VPVWKEATTTLFCASDAKAY HIV-1 infection human Lieberman1997b
• CTL expanded ex vivo were later infused into HIV-1 infected patients
gp160 (50–59) Env (62–71) TTLFCASDAK HIV-1 infection human (A3 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind 3/5 HLA-A3 supertype alleles (A*0301, A*1101, A*3101, A*3301 and A*6801)
gp160 (51–59) Env (63–71) TLFCASDAK HIV-1 infection human (A3 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
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• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind 3/5 HLA-A3 supertype alleles (A*0301, A*1101, A*3101, A*3301 and A*6801)
gp160 (52–61) gp120 (59–68 HXB2) LFCASDAKAY HIV-1 infection human (A*2402) Lieberman1992
• CTL epitope defined by T cell line and peptide mapping
• C. Brander notes that this is an A*2402 epitope in the 1999 database
gp160 (52–61) gp120 (53–62 LAI) LFCASDAKAY HIV-1 infection human (A*2402) Brander2001
• C. Brander notes this is an A*2402 epitope
gp160 (52–61) gp120 (53–62) LFCASDAKAY HIV-1 infection, HIV-1 exposed
seronegative
human (A24) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
gp160 (52–61) gp120 (53–62 LAI) LFCASCAKAY HIV-1 infection human (B38) Shankar1996
• Uncertain whether optimal, binds A24 as well
gp160 (52–71) gp120 (59–78) LFCASDAKAYDTEVHINVW-
AT
HIV-1 infection human Lieberman1995
• HIV-specific CTL lines developed by ex vivo stimulation with peptide
gp160 (52–71) gp120 (59–78 SF2) LFCASDAKAYDTEVHINVW-
AT
HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Eleven subjects had CTL that could recognize vaccinia-expressed LAI gp160
• One of these 11 had CTL response to this peptide
• The responding subject was HLA-A2 and B-21
gp160 (62–80) gp120 (69–88 SF2) DTEVHNVWATHACVPTDPN HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Eleven subjects had CTL that could recognize vaccinia-expressed LAI gp160
• One of these 11 had CTL response to this peptide
• The responding subject was HLA-A2 and B-21
gp160 (78–86) gp120 (77–85) DPNPQEVVL HIV-1 infection human (B*3501) Ogg1998b
• This epitope was included to illustrate the specificity of HIV-tetrameric staining, in a cross-sectional study correlating HLA A*0201 CTL effector cells and
low viral load
gp160 (78–86) gp120 (77–85 SF2) DPNPQEVVL HIV-1 infection human (B*3501) Brander2001
• C. Brander notes this is a B*3501 epitope
gp160 (78–86) gp120 (77–85 SF2) DPNPQEVVL HIV-1 infection human (B*3501) Tomiyama1997
• A CTL clone responsive to this epitope was obtained
• 2/7 B35-positive individuals have a CTL response to this epitope
• This epitope is highly variable
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• The substitutions: 1N, 3S and 7I, 7L and 9M, 8I, 8K all abrogate specific CTL lysis, while only 8K reduces binding to B*3501
• The substitution 8V to 8E does not reduce specific CTL activity
gp160 (78–86) Env (77–85) DPNPQEVVL HIV-1 infection human (B*3501) Ogg1999
• CTL effector levels were measured after potent ARV therapy using HLA-tetramer complexes for the A*0201 epitopes SYLVANTVATL and ILKEPVHGV
in seven patients, and the B*3501 epitope DPNPQEVVL in one additional patient
• Levels of CTL effectors typically decline for 5-7 days and then rebound, fluctuating during the first two weeks of therapy
• After the early fluctuation, there was a steady exponential decay with a median half-life of 45 days
gp160 (78–86) Env (77–85) DPNPQEVVL HIV-1 infection human (B35) Dyer1999
• CTL specific responses were measured over a 1.3 to 1.5 year period in members of the Sydney Blood Bank Cohort (SBBC) who had been infected with a
natural attenuated strain of HIV-1 which was Nef-defective
• Some of these patients had prolonged high levels of CTL effector and memory cells despite low viral load
gp160 (78–86) DPNPQEVVL HIV-1 infection human (B35) Wilson2000a
• Three individuals with highly focused HIV-specific CTL responses were studied during acute infection using tetramers – high frequencies of HIV-1-specific
CD8+ T cells were found prior to seroconversion, and there was a close temporal relationship between the number of circulating HIV-specific T cells and
viral load was also found
• All three patients were B*2705, with HLA alleles: A1, A30/31, B*2705, B35; A1, A*0301, B7, B2705; and A*0201, A*0301, B2705, B39
• ELISPOT was used to test a panel of CTL epitopes that had been defined earlier and were appropriate for the HLA haplotypes of the study subjects – 3/3
subjects showed a dominant response to the B*2705 epitope KRWIILGGLNK
• The subject with A*0201 had a moderatly strong response to SLYNTVATL
• Weak responses were observed to A*301-RLRPGGKKK, A*301-QVPLRPMTYK, and B7-TPGPGVRYPL in the subject who was HLA A1, A*0301, B7,
B*2705
• No acute response was detected to the following epitopes: A*201-ILKEPVHGV, A*301-KIRLRPGGK, A*301-AIFQSSMTK, A*301-TVYYGVPVWK,
B35-EPIVGAETF, B35-HPDIVIYQY, B35-PPIPVGEIY, B35-NSSKVSQNY, B35-VPLRPMTY, B35-DPNPQEVVL
gp160 (78–86) (SF2) DPNPQEVVL HIV-1 infection human (B35) Kawana1999
• HLA B35 is associated with rapid disease progression
• The sequences of 9 previously described HIV-1 B35 CTL epitopes were obtained in 10 HLA B35+ and 19 HLA B35- individuals
• 3/9 CTL epitopes had substitutions that were more common in B35+ individuals than in B35- individuals, but this was one of the six that had no B35
associated pattern of mutation
gp160 (78–86) gp120 (77–85 SF2) DPNPQEVVL HIV-1 infection human (B35) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B35+ individuals that had a CTL response to this epitope broken down by group: 1/2 group 1, 0/2 group 2, and 0/1 group 3
gp160 (78–86) DPNPQEVVL HIV-1 infection human (B35) Sabbaj2002b
• Epitope name: Env-DL9
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• Among HIV+ individuals who carried HLA B35, 3/20 (15%) recognized this epitope
gp160 (78–86) gp120 (77–85 SF2) DPNPQEVVL HIV-1 infection human (B35, B51) Shiga1996
• Binds HLA-B*3501 and B*5101 – binds and kills gp120-vaccinia virus infected cells carrying B35 or B51
gp160 (78–86) gp120 (77–85) DPNPQEVVL HIV-1 infection, HIV-1 exposed
seronegative
human (B51) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
gp160 (103–111) Env (102–110) QMHEDIISL HIV-1 infection human (A*0201) Kmieciak1998a
• CTL responses in six patients to four Env epitopes were studied: D2: LLNATAIAV, 5.3: RLRDLLLIV, D1: KLTPLCVTL, and 4.3: QMHEDIISL – all
have A2 anchor residues;
• The C terminal epitopes (D2 and 5.3) were highly variable and the variability was considered responsible for limited CTL response, while D1 and 4.3,
N-terminal epitopes, were much more conserved and gave evidence of high levels of CTL response in vitro;
• Peptides 4.3 and D1 bound HLA-A*0201 molecules with high affinity;
• Peptides 4.3 and D1 stimulated CTL with a relatively limited TCR Vbeta repertoire;
gp160 (104–119) gp120 (111–126 IIIB) MQEDIISLWDQSLKPC in vitro stimulation human Macatonia1991
• Primary CTL response with cells from non-infected donors stimulated by the peptide
gp160 (105–117) gp120 (MN) HEDIISLWDQSLK HIV-1 infection chimpanzee Lubeck1997
• No epitope-specific CTL were detected in chimpanzees immunized with adenovirus-HIV-1 MN gp160 recombinant despite a response to peptides P18 and
T1
• Helper and cytotoxic T cells have been found to be stimulated by this peptide (T2)
gp160 (105–117) gp120 (112–124 IIIB) HEDIISLWDQSLK HIV-1 exposed seronegative human Pinto1995
• CTL and T helper cell reactivity in healthcare workers exposed to HIV
gp160 (105–117) gp120 (112–124 IIIB) HEDIISLWDQSLK HIV-1 infection human (A2) Clerici1991a
• Helper and cytotoxic T cells can be stimulated by this peptide (T2)
gp160 (108–116) Env (107–115 subtype
B)
IISLWDQSL Vaccine human (A2.1) Kundu1998a
Vaccine Vector/Type: recombinant protein Strain: MN HIV component: gp160
• Ten HIV-1+ HLA A2 asymptomatic individuals were given two courses of HIV-1 MN rgp160 vaccine over a 2 year period
• Two hundred and fifty three HIV-1 peptides of 9 or 10 aa possessing the HLA-A2.1 binding motif (Leu at position 2, Val at the C terminus) were identified
in gp160, of which 25 had a high or intermediate binding affinity
• Eleven peptides were studied that had high HLA-A2 binding affinity – a CTL response was detected to 9/11 peptides in at least 1 individual
• CTL responses after reimmunization may include recall responses – only individuals with vaccine cross-reactive sequences prior to vaccination showed
detectable CTL responses
gp160 (109–117) Env (109–117 CM243
subtype CRF01)
ISLWDQSLK HIV-1 exposed seronegative human (A11) Bond2001
• Epitope name: E109-117
• This was a study of HIV-1 exposed persistently seronegative (HEPS) female sex workers in Chiang Mai, northern Thailand
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• HLA-A11 is very common in this population, and was enriched among the HEPS sexworkers – weak CTL responses were detected in 4/7 HEPS women,
and CTL responses were found in 8/8 HIV+ controls, and 0/9 HIV- women that were not exposed
• This epitope was weakly reactive in the HEPS study subject 265 who was HLA A2/A11, and had been predicted to be a possible A11 epitope using Epimer
in [Bond2001]
gp160 (112–130) gp120 (119–139 SF2) WDQSLKPCVKLTPLCVSLK HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Eleven subjects had CTL that could recognize vaccinia-expressed LAI gp160
• One of these 11 had CTL response to this peptide
• The responding subject was HLA-A2 and B-21
gp160 (117–126) Env (72–81) KPCVKLTPLC HIV-1 infection human (B7) Jin2000b
• This B7 epitope is one of three subdominant CTL responses detected in a long-term non-progressor
• A dominant B7 epitope was defined using conventional methods, and three additional sub-dominant HLA B7 epitopes were defined by first using a
non-anchor based strategy, EpiMatrix, to identify 2078 possible epitopes in the autologous HIV-1, followed by B7 anchor residue prediction to narrow the
set to 55 peptides for experimental testing
gp160 (121–129) Env (120–128) KLTPLCVTL HIV-1 infection human (A*0201) Kmieciak1998a
• CTL responses in six patients to four Env epitopes were studied: D2: LLNATAIAV, 5.3: RLRDLLLIV, D1: KLTPLCVTL, and 4.3: QMHEDIISL—all
have A2 anchor residues
• The C terminal epitopes (D2 and 5.3) were highly variable and the variability was considered responsible for limited CTL response, while D1 and 4.3,
N-terminal epitopes, were much more conserved and gave evidence of high levels of CTL response in vitro
• Peptides 4.3 and D1 bound HLA-A*0201 molecules with high affinity
• Peptides 4.3 and D1 stimulated CTL with a relatively limited TCR Vβ repertoire
• In a longitudinal study, the CTL response to the variable D2 epitope diminished over time, while the response to the conserved epitope D1 stayed higher
over time
gp160 (121–129) Env (134–) KLTPLCVTL HIV-1 infection human (A*0201) Altfeld2001c
• Epitope name: Env-134
• HIV was scanned for all peptides which carried the A2-supermotif pattern conserved in more than 50% of B clade sequences – 233 peptides met this
criteria, and 30 of these bound to HLA-A*0201 – 20/30 bound to at least 3/5 of HLA-A2 supertype alleles tested
• Three additional previously described HLA-A2 epitopes were added to the set of 20, and 18/22 chronically infected HLA-A2 individuals had CTL that
recognized at least one of the 23 peptides (median of 2 and maximum of 6), while 6/12 acute infected individuals recognized at least 1 (median of 1 and
maximum of 2)
• 2/22 individuals with chronic HIV-1 infection recognized this epitope in ELISPOT
• 0/12 acutely infected individuals recognized this epitope
• KLTPLCVTL binds to four HLA-A2 supertype alleles: A*0201, A*0202, A*0203 and A*6802 (highest affinity).
gp160 (121–129) gp120 (120–128 LAI) KLTPLCVTL Vaccine human (A2) Dupuis1995
Vaccine Vector/Type: recombinant protein Strain: MN HIV component: gp160
• CTL from HLA-A2 positive subject react with this peptide
gp160 (121–129) gp120 (120–128) KLTPLCVTL Vaccine human (A2) Woodberry1999
Vaccine Vector/Type: vaccinia HIV component: polyepitope
• A polyepitope vaccine was generated in a vaccinia construct that contiguously encoded seven epitopes, all presented by HLA A-2
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• HHD mice have a transgene of HLA A2 linked to the transmembrane and cytotoxic domains of H-2Dd – this transgene is the only MHC molecule
expressed in the mice
• CTL responses to Gag (77-85) SLYNTVATL, Pol (476-484) ILKEPVHGV, gp120 (120-128) KLTPLCVTL, and Nef (190-198) AFHHVAREL were
observed in HIV polytope HHD-vaccinated mice, and these responses were enhanced with vaccinia boost
• No CTL immune responses were generated against HLA A2-restricted HIV epitopes Nef 157-166 (PLTFGWCYKL), Pol 346-354 (VIYQYMDDL), and
Nef 180-189 (VLEWRFDSRL)
• Sixteen HLA A2+ patients were tested for their ability to make CTL responses by peptide restimulation in culture with the epitopes selected for inclusion in
the polytope – one individual recognized all seven of these epitopes; 7 patients had CTL cultures able to recognize at least one of the epitopes, and 6 of
those 7 recognized more than one epitope, but they were not able to test all peptides for all patients; many patients only had three peptides tested
• KLTPLCVTL was recognized by 3 of the patients
gp160 (121–129) gp120 (120–128) KLTPLCVTL HIV-1 infection human (A2) Kundu1998b
• Allogeneic dendritic cells (DCs) were obtained from HLA-identical siblings, pulsed with rgp160 MN or A2-restricted HIV-1 epitope peptides, and infused
monthly into six HIV-infected patients
• 1/6 showed increased env-specific CTL and increased lymphoproliferative responses, 2/6 showed increase only in proliferative responses, and 3/6 showed
no change – pulsed DCs were well tolerated
• KLTPLCVTL is a conserved HLA-A2 epitope included in this study – all six patients had this sequence as their HIV direct sequence, and a detectable CTL
response
• CTL demonstrated against peptide-coated target, epitope is naturally processed and enhancible with vaccine
gp160 (121–129) gp120 (120–128) KLTPLCVTL HIV-1 infection human (A2) Kmieciak1998b
• Increased CTL response to cells expressing a VV construct ∆v3 mutant compared with a full-length env gene product
gp160 (121–129) gp120 (121–129) KLTPLCVSL in vitro stimulation human (A2) Zarling1999
• This study compares the ability of macrophages and dendritic cells to stimulate primary responses in CD8+ lymphocytes isolated from HLA-appropriate
HIV-uninfected donors using peptide-pulsed APC – the dendritic cells performed better as APC for the stimulation of primary responses
• Strong CTL responses were elicited by the epitopes DRFYKTLRA and GEIYKRWII when presented by either immature or mature dendritic cells –
macrophages were not able to prime a CTL response against DRFYKTLRA
• A weak response to KLTPLCVSL was stimulated using macrophages as the APC
• No detectable response was observed for the following previously-defined HIV epitopes: KIRLRPGGK, ILKEPVHGV, IRLRPGGK, GPKVKQWPL
gp160 (121–129) gp120 (120–128) KTLPLCVTL HIV-1 infection human (A2) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
gp160 (121–129) gp120 (121–129 IIIB) KLTPLCVTL Vaccine murine (A2) Kiszka2002
Vaccine Vector/Type: DNA, DNA with recombinant protein boost Strain: IIIB HIV component: gp160, gp160deltaV3 Adjuvant: IL-12 (IL-12p35 and
IL-12p40)
• Epitope name: D1
• Transgenic mice expressing a HLA-A2/Kb chimeric protein were vaccinated with a full length gp160 or with gp160deltaV3, with the V3 loop deleted.
Mice given gp160deltaV3 had a broader immune response than those given gp160, with increased responses to conserved HLA-A2 epitopes in the C1
region of gp120, KLTPLCVTL, and the C-term region of gp41, SLLNATAIAV.
• Greater resistance was conferred by the gp160deltaV3 than the gp160 vaccine to a challenge of vaccinia expressing heterologous gp160 from primary
isolates (VI-06 and 89.6), and the resistance was conferred by CD8+ T-cells.
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gp160 (121–129) Env (134–142) KLTPLCVTL HIV-1 infection human (A2 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind four of the five HLA-A2 supertypes alleles (A*0201, A*020 2, A*0203, A*0206 and A*6802)
gp160 (121–129) Env KLTPLCVTL Vaccine SJL/J HLA transgenic
mice (A2.1)
Ishioka1999
Vaccine Vector/Type: DNA HIV component: polyepitope
• A minigene vaccine construct encoding 6 HLA 2.1 and 3 HLA A11 restricted CTL epitopes, the universal Th cell epitope PADRE (pan-DR epitope) and an
ER translocating signal sequence was constructed
• The epitopes were chosen for dominant recognition by CTLs during HBV and HIV infections in humans
• HLA transgenic mice were used for quantitating in vivo immunogenicity of DNA vaccines encoding HLA-restricted CTL epitopes – strong responses were
observed to all nine epitopes, and CTL memory persisted up to four months after a single injection
gp160 (121–129) Env (120–128 subtype
B)
KLTPLCVTL Vaccine human (A2.1) Kundu1998a
Vaccine Vector/Type: recombinant protein Strain: MN HIV component: gp160
• Ten HIV-1+ HLA A2 asymptomatic individuals were given two courses of HIV-1 MN rgp160 vaccine over a 2 year period
• Two hundred and fifty three HIV-1 peptides of 9 or 10 aa possessing the HLA-A2.1 binding motif (Leu at position 2, Val at the C terminus) were identified
in gp160, of which 25 had a high or intermediate binding affinity
• Eleven peptides were studied that had high HLA-A2 binding affinity – a CTL response was detected to 9/11 peptides in at least 1 individual
• CTL responses after reimmunization may include recall responses – only individuals with vaccine cross-reactive sequences prior to vaccination showed
detectable CTL responses
gp160 (156–165) Env (162–171 BH10,
LAI)
NCSFNISTSI HIV-1 infection human Maksiutov2002
• This study employs an antigenic similarity matrix to compare HIV-1 antigenic determinants with human proteins.
• This CTL epitope (the HIV-1 LAI fragment with high similarity to a human protein overlapping this epitope is STSIRGKVQK) has similarity with the
macrophage colony stimulating factor I receptor fragment SISIRLKVQK.
gp160 (156–165) gp120 (156–165) NCSFNISTSI HIV-1 infection human (Cw*08) Ferris1999
• Recognized by CTL clone LWF A5, isolated from a lab worker exposed to HIV-1 in 1985
• The processing of this epitope is TAP1/2-dependent, as are most Env epitopes, and it contains two N-linked glycosylation sites that are glycosylated in Env
• Only peptide that has been deglycosylated, a process that changes asparagine (N) to aspartic acid (D) was recognized: the aspartic acid at position 5 was
critical, position 1 could be either D or N
• This peptide also contains a Cys involved in a disulfide linkage but reducing conditions did not effect recognition by CTL clone LWF A5
• The HIV-1 Env epitopes are typically processed by a TAP1/2 dependent mechanism, which involves cotranslational translocation into the ER,
glycosylation, export back into the cytosol, and deglycosylation for processing, and retransport into the ER for the association with class I molecules
• The particular pathway of generating an epitope may have an impact on the presentation of that epitope, quantitatively as well as qualitatively
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gp160 (156–165) gp120 (156–165 IIIB) NCSFNISTSI HIV-1 infection human (Cw8) Sipsas1997
• HIV IIIB proteins were used to define the range of CTL epitopes recognized by 3 lab workers accidentally infected with HIV-1 IIIB
• NCSFNITTSI, a variant found in HIV-1 MN, was not recognized, thus this epitope was type-specific
• NCSFNISTSI contains two potential N-linked glycosylation sites and cysteine residue, possibly related to the requirement for a high sensitizing dose of
peptide for CTL activity
gp160 (188–207) gp120 (193–212 BRU) TTSYTLTSCNTSVITQACPK HIV-1 infection human (A2) Dadaglio1991
• Defined through blocking CTL activity, and Env deletions
gp160 (191–200) gp120 (194–202 CM243
subtype CRF01)
YRLINCNTSV HIV-1 infection human (A2) Sriwanthana2001
• Epitope name: E191-200
• This was a study of HIV-1 exposed persistently seronegative (HEPS) female sex workers in Chiang Mai, northern Thailand
• HLA-A11 is very common in this population, and was enriched among the HEPS sexworkers – weak CTL responses were detected in 4/7 HEPS women,
and CTL responses were found in 8/8 HIV+ controls, and 0/9 HIV- women that were not exposed
• This epitope was reactive in HIV+ control study subject 144 who carried HLA-A2
gp160 (191–200) gp120 (194–202 CM243
subtype CRF01)
YRLINCNTSV HIV-1 infection human (A2) Bond2001
• More than half of a cohort of HIV+ female sex workers (FSW) from Northern Thailand were HLA-A11 positive, and this study concentrated on A11
epitopes in this group, although E clade versions of previously defined B-clade A2 and A24 epitopes were also tested.
• 1/4 tested FSWs recognized the E clade version of this epitope, which differs from the previously defined B clade version by four amino acids,
KLTSCNTSV
• This epitope was somewhat conserved in 4/8 subtypes: CRF01 (E), B, C, and D
gp160 (192–200) gp120 (192–199) KLTSCNTSV HIV-1 infection human (A*02) Rinaldo2000
• Epitope name: SL9
• Administration of triple-drug antiretroviral therapy (IDV, 3TC and ZDV) sometimes showed a transient increase and other times failed to increase CTL
responses in patients with advanced HIV disease, but there is a stable population of tetramer stained HIV-specific CD8+ CD45RO+ cells that persist after
therapy and long periods of virus being below the level of detection
gp160 (192–200) gp120 (192–199
HXB2R)
KLTSCNTSV HIV-1 infection human (A2) Brander1995a
• Epitope predicted on HLA binding motif, and studied in the context of inclusion in a synthetic vaccine
gp160 (192–200) gp120 (192–199) KLTSCNTSV HIV-1 infection human (A2) Huang2000
• The single cell ELISPOT assay was optimized and highly specific, and found to work well even after the primary cells had been frozen and thawed
• Increases in gamma interferon producing cells were observed in response to anti-retroviral therapy using single cell IFN-gamma-production ELISPOT
gp160 (192–200) gp120 (197–205) TLTSCNTSV Peptide-HLA interaction human (A2) Garboczi1992
• Crystallization of HLA-A2 molecules complexed with antigenic peptides – refers to Dadaglio et al 1991
gp160 (192–200) gp120 (199–207) TLTSCNTSV HIV-1 infection human (A2.1) Brander1996a
• This epitope was recognized by PBMC from 6/14 HIV+ asymptomatic patients
• This epitope was used along with pol CTL epitope ALQDSGLEV and a tetanus toxin T helper epitope for a synthetic vaccine
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• This vaccine failed to induce a CTL response, although a helper response was evident
gp160 (192–211) gp120 (199–219 SF2) SLTSCNTSVITQACPKVSFE HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Eleven subjects had CTL that could recognize vaccinia-expressed LAI gp160
• One of these 11 had CTL response to this peptide
• The responding subject was HLA-A2, -B21
gp160 (199–207) Env (202–210) SVITQACPK HIV-1 infection human (A*1101) Fukada2002
• Counterparts for eight known clade B HLA A*1101 epitopes were generated for clade E (CRF01). Three epitopes, identical among clade A-E, were
cross-reactive and recognized by clade E infected individuals. The clade E and B analogs to three more HLA A*1101 epitopes was recognized in a clade
specific manner. Two other HLA A*1101 clade B defined epitopes were found not to have stimulated a response in clade E infected individuals.
• SVITQACPK was found to elicit clade-specific responses in clade B (SVITQACPK is most common, sAitqacpk is most common variant in clade A, C and
D) and clade E (saiKqacpk is most common). SVITQACPK was recognized by CTL from 3/5 B clade infected Japanese subjects, and aiKqacpk by CTL
from 0/7 E clade infected Thai subjects, so this seems to be a B clade exclusive epitope.
• The binding of the three variant peptides to HLA A*1101 was comparable, implicating TCR interaction differences.
gp160 (201–225) gp120 (201–225 LAI) ITQACPKVSFEPIPHYCAP-
AGFAI
Vaccine human (CD4+ CTL) Johnson1994b, Johnson1994a
Vaccine Vector/Type: vaccinia HIV component: gp160
• CD4+ CTL isolated from LAI IIIB gp160 vaccinees
gp160 (202–221) gp120 (209–228) TQACPKVSFEPIPIHYCAPA HIV-1 infection human Lieberman1995
• HIV-specific CTL lines developed by ex vivo stimulation with peptide
gp160 (202–221) gp120 TQACPKVSFEPIPIHYCAPA HIV-1 infection human Weekes1999b
• Peptide 740.18: Almost all CD8+ T cells are CD28+ at birth, and the proportion of CD28-CD8+ cells increases with age – this study examines the
contribution of CD8+CD28- cells to CTL memory pools for CTL clones specific for two persistent human viruses, CMV and HIV – clones were found to
be similarly distributed the CD28 depleted cell population
• HIV CTL responses to 3 Env and 2 Gag peptides were studied
• The clonal composition of the TCR Vbeta responses were studied and was found to be highly focused, with one TCR beta-chain sequence tending to
dominate the peptide-specific response – clones to this epitope were Vbeta13.1
gp160 (202–221) gp120 TQACPKVSFEPIPIHYCAPA HIV-1 infection human Weekes1999a
• Peptide 740.18: Memory CTL specific for HIV-1 may contribute to oligoclonal expansions within the CD57+ CD28- CD8+ CTLp populations
gp160 (202–221) gp120 (209–228 SF2) TQACPKVSFEPIPIHYCAPA HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Eleven subjects had CTL that could recognize vaccinia-expressed LAI gp160
• One of these 11 had CTL response to this peptide
gp160 (202–221) gp120 (209–228 SF2) TQACPKVSFEPIPIHYCAPA HIV-1 infection human Lieberman1997b
• CTL expanded ex vivo were later infused into HIV-1 infected patients
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gp160 (207–216) gp120 (subtype A) KMTFEPIPIH HIV-1 infection human (A29) Cao2000
• HIV-1 subtypes A and D dominate the Ugandan epidemic, and a vaccine trial using B clade antigen is underway – this study addresses relative levels of
cross-reactive CTL responses in Ugandans to A, D, and B clade recombinant vaccinia viruses expressing Gag, Env, Pol, RT or Nef from HIV-1 clades A, B,
and D
• Proteins corresponding to the subtype of the infecting strains tended to trigger higher levels of CTL response measured by percent specific lysis, but there
was extensive inter-subtype cross-reactivity with B clade proteins and the co-circulating subtype
• CTL derived from subtype A clade infection (patient SP 528), recognized the subtype A version of the peptide (KMSFEPIPIH), had a slightly reduced
specific lysis using the B clade version of the peptide (KVSFEPIPIH), and no lysis using the D clade version of the epitope (KVTFEPIPIH)
• Patient SP 528 is HLA A1, A29, B57, B81, Bw4, Bw6
gp160 (208–217) gp120 (subtype B) VSFEPIPIHY HIV-1 exposed seronegative human (A29) Kaul2000
• 11/16 heavily HIV exposed but persistently seronegative sex-workers in Nairobi had HIV-specific CD8 gamma-IFN responses in the cervix – systemic
CD8+ T cell responses tended to be to the same epitopes but at generally lower levels than cervical CD8+ T cell responses
• Low risk individuals did not have such CD8+ cells
• CD8+ T cell epitopes: DTVLEDINL (3 individuals), SLYNVATL (4 individuals), LSPRTLNAW (3 individuals) and YPLTFGWCF (4 individuals) were
most commonly recognized by the HIV-resistant women
gp160 (208–217) gp120 (263–272) VSFEPIPHY HIV-1 infection, HIV-1 exposed
seronegative
human (A29) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
gp160 (208–219) Env VSFEPIPPHYCA HIV-1 infection human (A2) Cao2002
• SP 511 is an A2 restricted CTL clone generated from a Ugandan subject that recognizes VSFEPIPPHYCA.
• CTL could be activated by a fusion protein of an HIV protein and anthrax lethal factor (LFn-HIV) that promotes antigen presenting cell uptake of
exogenous protein and allows processing through the MHC class I pathway. This strategy for CTL detection could allow antigen presentation without
generation of cells by the standard methods of using live viral vectors carrying a protein, or by loading the cells with peptides and by-passing processing.
gp160 (209–217) (LAI) SFEPIPIHY (A29) Altfeld2000a, Brander2001
gp160 (209–217) gp120 (213–221 SF2) SFEPIPIHY HIV-1 infection human (A29) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-A29+ individuals that had a CTL response to this epitope broken down by group: 1/3 group 1, 0/0 group 2, and 0/0 group 3
gp160 (212–231) gp120 PIPIHYCAPAGFAILKCNNK HIV-1 infection human Weekes1999a
• Peptide 740.19: Memory CTL specific for HIV-1 may contribute to oligoclonal expansions within the CD57+ CD28- CD8+ CTLp populations
gp160 (212–231) gp120 (219–238 HXB2) PIPIHYCAPAGFAILKCNNK HIV-1 infection human Lieberman1992
• CTL epitope defined by T cell line and peptide mapping
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gp160 (212–231) gp120 (219–238) PIPIHYCAPAGFAILKCNNK HIV-1 infection human Lieberman1995
• HIV-specific CTL lines developed by ex vivo stimulation with peptide
gp160 (212–231) gp120 PIPIHYCAPAGFAILKCNNK HIV-1 infection human (A2) Weekes1999b
• Peptide 740.19: Almost all CD8+ T cells are CD28+ at birth, and the proportion of CD28-CD8+ cells increases with age – this study examines the
contribution of CD8+CD28- cells to CTL memory pools for CTL clones specific for two persistent human viruses, CMV and HIV – clones were found to
be similarly distributed in the CD28 depleted cell population
• HIV CTL responses to 3 Env and 2 Gag peptides were studied
• The clonal composition of the TCR Vbeta responses was studied and was found to be highly focused, with one TCR beta-chain sequence tending to
dominate the peptide-specific response – clones to this epitope were Vbeta13.6
gp160 (212–231) gp120 PIPIHYCAPAGFAILKCNNK HIV-1 infection human (B57) Jin1998b
• Progressive HIV-1 infection and CD4 decline was associated decreased the IL-2-expandable HIV-1 CTL response in 10 asymptomatic HIV-infected
patients – this observation may be partially due to a reduction and impaired function of T helper cells, CTL exhaustion and APC dysfunction
• Continued presence of HIV-1 specific memory cells (CTLp) was observed in three patients, one to GIWGCSGKLICTTAV, one to ALIWEDLRSLCLFSY,
and one to PIPIHYCAPAGFAILKCNNK
gp160 (237–246) Env GPCKNVSTVQ human (B56) De Groot2001
• The program Epimatrix was used in conjunction with the program Conservatrix to identify conservered regions of HIV that might serve as epitopes
• A subset of the potential epitopes was identified that could bind to the appropriate HLA-allele, and 15 predicted B7 superfamily (HLA B7, B8, and B58)
epitopes were identified that could stimulate IFNγ production in an ELISPOT assay
• GPCKNVSTVQ was newly defined as an epitope in this study, was shown to stimulate an ELISPOT response, and to bind to HLA-B7
gp160 (239–247) gp120 (241–249 LAI) CTNVSTVQC HIV-1 infection human (Cw8) Sipsas1997
• HIV IIIB proteins were used to define the range of CTL epitopes recognized by 3 lab workers accidentally infected with HIV-1 IIIB
• CTNVSTVQC contains a potential N-linked glycosylation site and cysteine residues, possibly related to a requirement for a high sensitizing dose of peptide
for CTL activity
gp160 (242–261) gp120 (249–268) VSTVQCTHGIRPVVSTQLLL HIV-1 infection human Lieberman1995
• HIV-specific CTL lines developed by ex vivo stimulation with peptide
gp160 (242–261) gp120 (249–268 SF2) VSTVQCTHGIRPVVSTQLLL HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Eleven subjects had CTL that could recognize vaccinia-expressed LAI gp160
• One of these 11 had CTL response to this peptide
• The responding subject was HLA-2, -B21
gp160 (242–261) gp120 (249–268) VSTVQCTHGIRPVVSTQLLL HIV-1 infection human Lieberman1997b
• CTL expanded ex vivo were later infused into HIV-1 infected patients
gp160 (252–260) gp120 (255–263 SF2) RPIVSTQLL HIV-1 infection human (B*3501) Tomiyama1997
• A CTL clone responsive to this epitope was obtained
• Only 1/7 B35-positive individuals had a CTL response to this epitope
• An I to V substitution at position 3 reduces specific lysis, but not binding to B*3501
• A Q to H substitution at position 7 abrogates specific lysis, but not binding to B*3501
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gp160 (252–260) gp120 (255–263 SF2) RPIVSTQLL HIV-1 infection human (B35) Shiga1996
• Binds HLA-B*3501
gp160 (252–260) (SF2) RPIVSTQLL HIV-1 infection human (B35) Kawana1999
• HLA B35 is associated with rapid disease progression
• The sequences of 9 previously described HIV-1 B35 CTL epitopes were obtained in 10 HLA B35+ and 19 HLA B35- individuals
• 3/9 CTL epitopes had substitutions that were more common in B35+ individuals than in B35- individuals, but this was one of the six that had no B35
associated pattern of mutation
gp160 (252–261) Env RPVVSTQLLL human (B7) De Groot2001
• The program Epimatrix was used in conjunction with the program Conservatrix to identify conservered regions of HIV that might serve as epitopes
• A subset of the potential epitopes was identified that could bind to the appropriate HLA-allele, and 15 of the predicted B7 superfamily (HLA B7, B8, and
B58) epitopes were identified that could stimulate IFNγ production in an ELISPOT assay
• RPVVSTQLLL was one of the 15, and had been previously identified as an HLA-B7 epitope, and was confirmed in this study
gp160 (252–271) Env (256–268 BH10,
LAI)
RPVVSTQLLLNGSLAEEEVV HIV-1 infection human Maksiutov2002
• This study employs an antigenic similarity matrix to compare HIV-1 antigenic determinants with human proteins.
• This CTL epitope (the HIV-1 LAI fragment with high similarity to a human protein overlapping this epitope is STQLLLNGSLAEE) has similarity with the
lymphatic endothelium-specific hyaluronan receptor LYVE-1 fragment TTRLLVQGSLRAEE.
gp160 (252–271) gp120 (256–275 LAI) RPVVSTQLLLNGSLAEEEVV HIV-1 infection human (B7) Shankar1996
gp160 (291–307) Env (292–301 BH10,
LAI)
SVEINCTRPNNNTRKSI HIV-1 infection human Maksiutov2002
• This study employs an antigenic similarity matrix to compare HIV-1 antigenic determinants with human proteins.
• This CTL epitope (the HIV-1 LAI fragment with high similarity to a human protein overlapping this epitope is VEINCTRPNN) has similarity with the FasI
receptor precursor (Apptosis-mediating surface antigen fas) (APO-1 antigen) (CD95 antigen) fragment VEINCTRQN.
gp160 (291–307) gp120 (295–312 BRU) SVEINCTRPNNNTRKSI HIV-1 infection human (A2) Dadaglio1991
• Defined through blocking CTL activity, and Env deletions
gp160 (291–307) gp120 (291–307 IIIB) SVEINCTRPNNNTRKRI Vaccine murine (A2) Kiszka2002
Vaccine Vector/Type: DNA, DNA with recombinant protein boost Strain: IIIB HIV component: gp160 Adjuvant: IL-12 (IL-12p35 and IL-12p40)
• Transgenic mice expressing a HLA-A2/Kb chimeric protein were vaccinated with a full length gp160 or with gp160deltaV3, with the V3 loop deleted.
Mice given gp160deltaV3 had a broader immune response than those given gp160, with increased responses to conserved HLA-A2 epitopes in the C1
region of gp120, KLTPLCVTL, and the C-term region of gp41, SLLNATAIAV.
• Greater resistance was conferred by the gp160deltaV3 than the gp160 vaccine to a challenge of vaccinia expressing heterologous gp160 from primary
isolates (VI-06 and 89.6), and the resistance was conferred by CD8+ T-cells.
• The most intense CTL responses to the intact gp160 vaccine were directed at three V3 peptides.
gp160 (297–322) gp120 (297–322 IIIB) TRPNNNTRKRIRIQRGPGR-
AFVTIGK
Vaccine murine (H-2Dd) Chang1999
Vaccine Vector/Type: peptide Strain: IIIB HIV component: V3 Adjuvant: liposome
• Induction of peptide-specific CTLs in BALB/c mice was dependent on immunization with peptide encapsulated liposomes containing MPL as adjuvant
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• T26K (26mer) elicited a stronger AB and CTL response than R15K (a V3 15mer, RIQRGPGRAFVTIGK)
gp160 (297–330) Env (303–335 BX08) TRPNNNTRKSIHIGPGRAF-
YATGEIIGDIRQAH
Vaccine human Gahery-Segard2000
Vaccine Vector/Type: lipopeptide HIV component: six peptides
• Anti-HIV lipopeptide vaccine consisting of six long amino acid peptides derived from Nef, Gag and Env HIV-1 proteins modified by a palmitoyl chain was
administered in a phase I trial
• A CD4+ T cell proliferative response to at least one of the six peptides was observed in 9/10 vaccinees – 6/10 reacted to this peptide
• 9/12 tested mounted a CTL response to at least one of the six peptides; each of the six peptides elicited a CTL response in at least one individual – this
peptide was particularly immunogenic, eliciting a CTL response in five vaccinees
• None of the 12 tested had an IgG response to gp120 or gp160 and vaccinees could be differentiated from HIV-1 seropositive individuals with a commercial
HIV detection kit – no neutralizing antibodies were observed
gp160 (298–307) gp120 (298–307) RPNNNTRKSI HIV-1 infection human (B*07) Ferris1999, Hammond1995
• The processing of this epitope is TAP1/2-dependent, as are most Env epitopes, and it contains an N-linked glycosylation site that is glycosylated in Env
• Peptide that had been deglycosylated, a process that changes asparagine (N) to aspartic acid (D) (RPNDNTRKSI) was recognized a 100-fold more
efficiently than either glycosylated or non-glycosylated RPNNNTRKSI
• Position 5 is not involved with HLA B*07 binding, so is probably important for TCR recognition
• HIV-1 Env epitopes are typically processed by a TAP1/2 dependent mechanism, which involves cotranslational translocation into the ER, glycosylation,
export back into the cytosol, and deglycosylation for processing, and retransport into the ER for the association with class I molecules
• The particular pathway of generating an epitope may have an impact on the presentation of that epitope, quantitatively as well as qualitatively
gp160 (298–307) gp120 (302–312 HXB2) RPNNNTRKSI HIV-1 infection human (B*0702) Brander2001
• C. Brander notes this is a B*0702 epitope
gp160 (298–307) gp120 (302–312 HXB2) RPNNNTRKSI HIV-1 infection human (B7) Safrit1994b
• CTL from two acute seroconversion cases
gp160 (298–307) gp120 (302–312 HXB2) RPNNNTRKSI HIV-1 infection human (B7) Hammond1995
• Peptide processed by a TAP-1/2-dependent pathway only
• CTL from an acute seroconverter
gp160 (298–307) gp120 (302–312 HXB2) RPNNNTRKSI HIV-1 infection human (B7) Wolinsky1996
• Longitudinal study of epitope variation in vivo
gp160 (298–307) gp120 (302–311 subtype
B)
RPNNNTRKSI HIV-1 infection human (B7) Wilson1998b
• The extent of CTL interclade cross-reactivity from CTL isolated from individuals newly infected with B clade virus was studied, and extensive
cross-reactivity was observed
• Two HLA B7 individuals had CTL response to B_LAI, A_92UG037 and C_92BR025 gp160, but were B clade strain MN non-responders – the authors
note that the B7 epitope RPNNNTRKSI is immunodominant, conserved between the LAI and clade A and C strains, but is very divergent in MN
(RPNYNKRKRI), and that this epitope might be dominating the specificity of the response in the HLA B7 individuals
gp160 (298–307) gp120 (303–312 SF2) RPNNNTRKSI HIV-1 infection human (B7) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
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• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B7+ individuals that had a CTL response to this epitope broken down by group: 0/4 group 1, 1/3 group 2, and 1/1 group 3
gp160 (298–307) gp120 (298–307) RPNNNTRKSI HIV-1 infection human (B7) Day2001
• The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7 was
studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
• 2 to 17 epitopes were recognized in a given individual, A2-restricted CTL response tended to be narrow and never dominated the response, and 25/27
epitopes were targeted by at least one person
• Subjects with chronic HIV-1 infection recognized between 2-8 out of 11 B7-restricted epitopes
• An acute seroconvertor homozygous for the B7 allele recognized five B7-restricted epitopes
• The other acute seroconvertor failed to recognize any of the 11 B7-restricted epitopes tested
• The B7-restricted CTL response was highly variable and there was no clearly dominant epitope
gp160 (298–307) gp120 (298–307) RPNNNTRKSI HIV-1 infection human (B7) Yu2002a
• Epitope name: B7-RI10
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
• 4/11 HLA-B7 individuals had detectable B7-restricted responses to this epitope during acute infection – 10/15 of HLA-B7 epitopes tested were targeted by
at least one person during acute infection. 1/4 individuals had detectable responses to this epitope after STI.
gp160 (298–307) gp120 RPNNNTRKSI HIV-1 infection human (B7) Appay2002
• Four HIV patients with prolonged clinically successful anti-viral therapy but with ongoing evidence of replication and Nef mRNA transcription, showed
specific T-cell responses by Elispot and Tetramer staining, maintained for 2-4 years after initiation of HAART.
• Nef epitope recognition was detected in all 4 subjects, gp120, Pol and Gag-specific in 1 or 2 subjects.
• The HIV-specific CD8+ T-cells had an intermediate maturation phenotype characterized by low levels of perforin and high levels of CD27 expression.
gp160 (298–307) gp120 (303–312 IIIB) RPNNNTRKSI HIV-1 infection human (B7?) Wilson1996
• Epitope defined in the context of the Pediatric AIDS Foundation ARIEL Project, a mother-infant HIV transmission study
• RPNNNTRKDI and RPNNNTRKGI, naturally occurring variants, were found in non-transmitting mother – ability to recognize these variants has not yet
been determined
gp160 (299–319) Env (299–319) PNNNTRKSIRIGPGQTFYA HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
• This peptide was among the 28 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
gp160 (303–322) gp120 TRKSIHIGPGRAFYTTGE Vaccine murine BALB/c Luo1998
Vaccine Vector/Type: virus-like particle Strain: B subtype consensus HIV component: gag, V3
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• Intramuscular injection of chimeric gag-env virus-like particles (VLPs) containing V3 loop sequences into BALB/c mice induce V3 specific CTL –
TRKSIHIGPGRAFYTTGE is a B subtype consensus that stimulated a cross-reactive CTL response
gp160 (304–318) gp120 (304–318 IIIB) RKSIRIQRGPGRAFV Vaccine murine (H-2d) Kang1999
Vaccine Vector/Type: virus-like particle Strain: HIV-2 VLP, MN, IIIB, RF, SF2 HIV component: gag, V3
• Virus-like particles could be formed from HIV-2 gag after deleting 143 amino acids at the C-terminal end – a proline rich region in positions 373-377 was
critical to VLP formation
• CTL responses in BALB/c mice were induced by chimeric gag-V3 particles against the V3 region of HIV-1 clade B isolates IIIB (SIRIQRGRAFVTI), MN
(KRIHIGPGRAFYTTK), RF (SITKGPGRVIYATGQ), and SF2 (SIYIGPGRAFHTTGR)
• The vaccine induced CTL were cross-reactive with a broad spectrum of B clade isolates, with the exception of the RF V3 which did not induce CTL
gp160 (306–322) gp160 (LAI) SIRIQGPGRAFVTIGI Vaccine murine (H-2Dd) Deml1999
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160 Adjuvant: CpG oligodeoxynucleotide, alum
• Addition of CpG oligodeoxynucleotide to a gp160/alum vaccine given to BALB/c mice shifted the response to Th0/Th1 from Th2, but no still CTL
response to this immunodominant epitope was induced
gp160 (308–321) Env (IIIB) RIQRGPGRAFVTIG Vaccine murine (Dd) Ahlers2001
Vaccine Vector/Type: peptide Strain: IIIB HIV component: V3
• Epitope name: P18IIIB
• BALB/c and A.AL were immunized with an Env-peptide vaccine construct containing the CTL epitope P18IIIB and the T helper epitope T1,
KQIINMWQEVGKAMYA.
• Substitution of Glu (wt) to Ala in T1, kqiinmwqAvgkamya, caused increased affinity for MHC class II Ek, resulting in the upregulation of CD40L in the
responding Th cells, and shifting the response towards Th1. Increased Th responses stimulated DCs to produce higher levels of IL-12, and B7-1 and B7-2,
and enhanced CTL responses to P18.
• The modified epitope, T1A, elicited stronger protection against increasing doses of viral challenge with vaccinia expressing HIV-1 IIIB gp120 compared to
the wt epitope T1.
gp160 (308–322) gp160 (MN) RIHIGPGRAFYTTKN Vaccine human Pinto1999
Vaccine Vector/Type: peptide Strain: MN HIV component: V3 Adjuvant: Montanide ISA 51
• Peptide P18: Eight HIV+ individuals were vaccinated with peptides containing specific T helper, CTL and Ab epitopes in Montanide ISA 51 in a Phase I
trial
• Four displayed a 4-fold increase in PCLUS 3-18 MN-specific T helper responses
• One patient developed a new, sustained P18MN-peptide-specific CTL response – the patient’s HLA haplotype was A2,30; B53,7; Cw2,4, and anti-HLA A2
antibody did not inhibit the response, suggesting it was not A2
• Patients with low baseline Ab levels developed an increase of neutralizing Ab titers
• No significant change was observed in plasma HIV viral loads and CD4 cell counts
gp160 (308–322) gp120 (MN) RIHIGPGRAFYTTKN HIV-1 infection chimpanzee Lubeck1997
• Epitope-specific CTL detected in chimpanzees immunized with adenovirus-HIV-1 MN gp160 recombinant
• CTL response may account for protection against subsequent HIV-1 SF2 challenge in a chimpanzee lacking neutralizing antibodies
gp160 (308–322) gp120 (315–329 IIIB) RIQRGPGRAFVTIGK HIV-1 exposed seronegative human Pinto1995
• CTL and T helper cell reactivity in healthcare workers exposed to HIV
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gp160 (308–322) gp120 (313–327 MN) RIHIGPGRAFYTTKN HIV-1 exposed seronegative human Pinto1995
• CTL and T helper cell reactivity in healthcare workers exposed to HIV
gp160 (308–322) gp120 (110–122) RIQRGPGRAFVTIGK Vaccine murine Moore2002a
Vaccine Vector/Type: DNA Strain: IIIB Adjuvant: IL-2, IL-12, IL-15, GMCSF, FLt3 ligand (FL)
• Intramuscular immunization of BALB/c mice with DNA vaccines carrying either gp160 or Nef in the expression vector plasmid pNGVL gave different
responses – gp160 induced strong gp160-specific CTL and IFN-responses and low-titer humoral responses, and Nef generated humoral (IgG1, IgG2a)
responses and IFN-responses but little CTL activity.
• Co-injection of DNA plasmids encoding cytokines and/or hematopoietic growth factors, IL2, IL-12, IL-15, Flt3 ligand (FL), and GMCSF tended to give
responses that were enhanced quantitatively, but not altered qualitatively.
• Co-administration of GMCSF most strongly enhanced CTL and IFN-responses against pNGVL-gp160.
• Repeated immunization with pNGVL-Nef failed to induce CTL responses. Co-administration of IL-12 most strongly enhanced humoral and IFNgamma
responses.
• FL, which enhances innate immune responses, in combination with IL-2, IL-12 or IL-15 generated with most potent Nef responses.
gp160 (308–322) Env (315–329) RIQRGPGRAFVTIGK Vaccine murine (A*0201) Singh2002, Sykes1999
Vaccine Vector/Type: DNA HIV component: HIV-1 divided into a 32 plasmids in a ubiquitin expression library
• Epitope name: P18
• C3H (H-2k) transgenic mice carrying a fused HLA-A*0201 alpha1 and alpha2 and H-2Dk alpha3 hybrid class I molecule were immunized using an
epidermal gene gun with an ubiquitin expression library of 32 plasmids that spanned the HIV-1 genome. Ubiquitin targets the expressed HIV-1 peptides to
the proteasome.
• A single immunization with the UB-HIV-1 library vaccine induced potent, stable and multivalent CTL responses against all library members.
• Immunodominant epitopes SLYNTVATL (Gag), ILKEPVHGV(Pol), RIQRGPGRAFVTIGK(P18) and AFHHVAREK (Nef) elicited strong CD8+/IFN-
responses and stimulated CTL that were functional in a Cr-release assay and against wild type antigen.
• The presence of multiple plasmids HLA-A*0201-restricted CTL epitopes did not decrease CTL immunogenicity, and CTL responses to single peptide
immunizations were comparable to responses based on mixtures of either 16 or 32 peptides.
gp160 (308–322) gp120 (315–329 IIIB) RIQRGPGRAFVTIGK Vaccine human (A11) Achour1994
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: gp160
• One of 3 HLA type restrictions associated with this peptide
gp160 (308–322) gp120 (315–329 BRU) RIQRGPGRAFVTIGK HIV-1 infection human (A2) Dadaglio1991
• Defined through blocking CTL activity, and Env deletions
gp160 (308–322) gp120 (315–329 IIIB) RIQRGPGRAFVTIGK HIV-1 infection human (A2) Clerici1991a
• Helper and cytotoxic T cells can be stimulated by this peptide (P18)
gp160 (308–322) gp120 (308–322 IIIB) RIQRGPGRAFVTIGK Vaccine murine (A2) Kiszka2002
Vaccine Vector/Type: DNA, DNA with recombinant protein boost Strain: IIIB HIV component: gp160 Adjuvant: IL-12 (IL-12p35 and IL-12p40)
• Transgenic mice expressing a HLA-A2/Kb chimeric protein were vaccinated with a full length gp160 or with gp160deltaV3, with the V3 loop deleted.
Mice given gp160deltaV3 had a broader immune response than those given gp160, with increased responses to conserved HLA-A2 epitopes in the C1
region of gp120, KLTPLCVTL, and the C-term region of gp41, SLLNATAIAV.
• Greater resistance was conferred by the gp160deltaV3 than the gp160 vaccine to a challenge of vaccinia expressing heterologous gp160 from primary
isolates (VI-06 and 89.6), and the resistance was conferred by CD8+ T-cells.
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• The most intense CTL responses to the intact gp160 vaccine were directed at three V3 peptides.
gp160 (308–322) gp120 (315–329 IIIB) RIQRGPGRAFVTIGK Vaccine human (A2, A3) Achour1993
Vaccine Vector/Type: vaccinia HIV component: gp160
• Two of 3 HLA type restrictions associated with this peptide
gp160 (308–322) gp120 (315–329 IIIB) RIQRGPGRAFVTIGK Vaccine murine (Dd) Takahashi1989a
Vaccine Vector/Type: peptide Strain: IIIB HIV component: V3
• Positions R(8) and F(10) are important for MHC/peptide interaction.
gp160 (308–322) gp120 (315–329 IIIB) RIQRGPGRAFVTIGK Vaccine murine (Dd) Sastry1992
Vaccine Vector/Type: peptide Strain: IIIB HIV component: V3
• Free peptide injected into the footpad of a mouse could stimulate specific CTL
gp160 (308–322) gp120 (315–329 IIIB) RIQRGPGRAFVTIGK Vaccine murine (Dd) Ahlers1997b
Vaccine Vector/Type: peptide Strain: MN HIV component: V3
• PCLUS 3-18MN synthetic peptide vaccine construct contained T1 helper epitope covalently linked to truncated P18 CTL epitope
• A substitution in the T1 peptide stimulated an enhanced Th response and class II binding specificity, which in turn enhanced CTL induction by vaccine
• Construct PCLUS 3-18MN is currently in a phase I vaccine clinical trial
gp160 (308–322) gp120 (313–327 MN) RIHIGPGRAFYTTKN Vaccine murine (Dd) Takahashi1989b
Vaccine Vector/Type: vaccinia Strain: MN, IIIB HIV component: gp160
• Y(11 MN) exchange with V(11 IIIB) interchanges specificities
gp160 (308–322) gp120 (313–327 IIIB,
MN, RF)
SITKGPGRVIYATGQ Vaccine murine (Dd) Takahashi1992
Vaccine Vector/Type: vaccinia Strain: RF HIV component: gp160
• Comparison of MN, IIIB, and RF specificities, position 11 is critical
gp160 (308–322) gp160 (315–329 IIIB) RIQRGPGRAFVTIGK in vitro stimulation murine (Dd) Yokosuka2002
• Epitope name: P18
• The TCR repertoire and its specificity was studied through analyzing the spectrum of TCR-alpha and beta chains able to reconstitute a reaction to the H-2
Dd-restricted P18 peptide. The RT-1 TCR alpha chain was able to react with 1/3 of the tested TCR beta chains to create a specific response. Experiments in
transgenic mice also supported the observation that a single TCR alpha chain would confer the specificity of the response and could interact with a large
variety of TCR beta chains.
gp160 (308–322) gp120 (HXB2) RIQRGPGRAFVTIGK Vaccine murine (H-2d) Griffiths1993
Vaccine Vector/Type: recombinant protein HIV component: Gag, V3
• Gag-V3 fusion protein immunization elicited V3 CTL response in mice
gp160 (308–322) gp120 (HXB2) RIQRGPGRAFVTIGK Vaccine murine (H-2d) Deml1997
Vaccine Vector/Type: virus-like particle HIV component: Gag, Env
• Env bound to virus-like particles (VLPs) can elicit a CTL response that is dependent on the amount of Env presented on the VLP
gp160 (308–322) gp120 (313–327 MN) RIHIGPGRAFYTTKN Vaccine murine BALB/c (H-2d) Fomsgaard1998a
Vaccine Vector/Type: DNA Strain: MN HIV component: gp160, V3
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• Enhanced B and CTL responses to the V3 region occur following epidermal immunization by gene gun with a chimeric DNA vaccine of V3-hepatitis B
surface antigen relative to a gp160 plasmid vaccine
gp160 (308–322) gp120 (313–327 MN) RIHIGPGRAFYTTKN Vaccine murine BALB/c (H-2d) Ahlers1996, Ahlers1997a
Vaccine Vector/Type: peptide Strain: MN HIV component: V3 Adjuvant: GMCSF, IL-12
• Vaccine constructs containing helper, antibody and CTL peptide epitopes induce strong Th1, CTL and NAb responses against the autologous HIV-1 virus
• The peptide CTL response was as cross-reactive as one elicited by a vaccinia construct expressing rgp160 MN
• GM-CSF and IL-12 were the two cytokines most effective for inducing and boosting CTLs
gp160 (308–322) gp120 (315–329 IIIB) RIQRGPGRAFVTIGK Vaccine murine (H-2d) Layton1993
Vaccine Vector/Type: virus-like particle Strain: IIIB HIV component: V3, Gag
• V3-Ty-Virus-like particles can induce type-specific CTL in mice in the absence of adjuvant
gp160 (308–322) gp120 (IIIB) RIQRGPGRAFVTIGK Vaccine murine (H-2d) Barouch1998
Vaccine Vector/Type: DNA Strain: IIIB HIV component: gp120 Adjuvant: IL-2 or IL-2/Ig
• A discistronic IL-2 gp120 expression vector gave a weaker CTL response than gp120 alone in the expression vector, however co-administration of an
Il-2/IgG fusion protein enhanced the immune response and administration of a Il-2/IgG plasmid had a response that depended on the timing of
administration.
• This study showed that a response to an HIV-1 DNA vaccine could be either augmented or suppressed by plasmid Cytokine/Ig administration
gp160 (308–322) Env (308–322 IIIB) RIQRGPGRAFVTIGK Vaccine murine (H-2d) Uno-Furuta2001
Vaccine Vector/Type: peptide Strain: IIIB HIV component: V3 loop Adjuvant: in vivo electroporation, immunostimulatory sequence ISS, B7-1
• Epitope name: P18
• Peptide immunization usually doesn’t elicit a good CTL response because epitopes are not internalized and processed and presented, so vaccination with
electric pulsing was tried (i.m. injection followed by 8 electric pulses), to enhance peptide uptake through electroporation
• BALB/c immunized with HIV P18 or hepatitis C P17 peptides with an electric pulse elicited a CTL response, those that did not receive the pulse did not
• The CTL response was enhanced by addition of immunostimulatory sequences ISS in the plasmid pCMV-LacZ, that contains hexamers GACGTC,
AGCGCT, AACGCT, sequences common in prokaryotic genomes but rare in eukaryotic genomes that elicit Th1 cytokines and result in B cell and T-cell
proliferation
• The CTL response was also enhanced by addition of B7-1 cDNA – the B7 family of proteins transduce co-stimulatory signals through interaction with
CD28
gp160 (308–322) gp160 (MN) RIHIGPGRAFYTTKN Vaccine murine BALB/c and
C57/BL6 (H-2d , H-2b)
Fomsgaard1998b
Vaccine Vector/Type: DNA Strain: MN HIV component: gp160
• CTL responses to a primary gene gun vaccination were rapid and strong for several methods of vaccinations: i.m., bupivacaine pretreatment, cardiotoxin
pretreatment or gene gun – the CTL response was more rapid and consistent than the antibody response
gp160 (308–322) gp120 (315–329 IIIB) RIQRGPGRAFVTIGK Vaccine murine (H-2d,p,u,q) Shirai1992, Shirai1993
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: gp160
• In a murine system multiple class I molecules can present this peptide, called P18, to CTL, including H-2Dd , H-2Dp, H-2Dq, H-2Lq
• The MHC class I molecule Dd as well as H-2u,p,q, were found to present peptides P18 and HP53
• The V-β usage in T cells showing cross-reaction between these two peptides was conserved for H-2d,u,p, but not in H-2q
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gp160 (308–322) gp160 (IIIB) GIHIGPGRAFYAARK Vaccine murine (H-2Dd) Morris2000
Vaccine Vector/Type: recombinant protein, peptide Strain: IIIB HIV component: gp160 Adjuvant: mucosal adjuvant LT(R192G)
• LT(R192G) induces gp160-specific serum and mucosal IgG1 and IgG2a, systemic CTL activity and Th1 and Th2 cytokine responses upon internasal
immunization
gp160 (308–322) gp120 (315–329 IIIB) RIQRGPGRAFVTIGK Vaccine murine (H-2Dd) Porgador1997
Vaccine Vector/Type: peptide Strain: IIIB HIV component: V3 Adjuvant: cholera toxin adjuvant
• A intranasal peptide vaccine with cholera toxin as a mucosal adjuvant was given.
• IIIB peptide referred to as R15K
• Peptide-specific CTLs were induced after in vitro restimulation with peptide-pulsed targets
• R15K was superior at inducing CTL compared to the RGPGRAFVTI, in contrast to the findings of Nehete et al.
• Memory CTL responses were induced
gp160 (308–322) gp120 (315–329 IIIB) RIQRGPGRAFVTIGK Vaccine (H-2Dd) Chiba1999
Vaccine Vector/Type: vaccinia with H1 influenza HA gene cassette Strain: IIIB HIV component: P18
• Vaccine was capable of priming P18IIIB specific CTL in BALB/c mice, but could not induce a P18IIIB-specific antibody response
gp160 (308–322) gp120 (multiple) RIHIGPGRAFYTTKN Vaccine murine (H-2Dd) Casement1995
Vaccine Vector/Type: peptide Strain: MN, SC HIV component: V3
• V3 peptides from MN and SC induce murine CTL that are cross-reactive with diverse strains
gp160 (308–322) gp120 (313–327 MN) RIHIGPGRAFYTTKN Vaccine murine (H-2Dd) Newman1997
Vaccine Vector/Type: recombinant protein Strain: MN HIV component: gp120 Adjuvant: QS-21 adjuvant
• MN vaccine induced CTL reactive with MN, IIIB and RF vaccinia-expressed Env, but not this peptide
gp160 (308–322) gp120 (315–329 IIIB) RIQRGPGRAFVTIGK Vaccine murine (H-2Dd) Newman1997
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp120 Adjuvant: QS-21 adjuvant
• IIIB vaccine induced IIIB type-specific CTL to this peptide (P18), and an additional Env CTL response that was cross-reactive
gp160 (308–322) gp120 (315–329) RIQRGPGRAFVTIGK Vaccine murine (H-2Dd) Takahashi1988
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: gp160
• V3 loop CTL response in mice vaccinated with gp160
gp160 (308–322) gp120 (315–329) RIQRGPGRAFVTIGK Vaccine murine BALB/c
(H-2Dd)
Fukasawa1998
Vaccine Vector/Type: liposome Strain: IIIB HIV component: V3 Adjuvant: oligomannose
• The peptide RIQRGPGRAFVTIGK was incorporated into liposomes and given as a subcutaneous injection, which induces a MHC class I restricted CTL
response in mice
• Liposomes coated with oligomannose show no toxicity and can elicit a potent CTL response upon a single subcutaneous infection, while non-coated
liposomes do not, suggesting that oligomannose may be a good adjuvant for CTL responses
gp160 (308–322) RIQRGPGRAFVTIGK Vaccine murine (H-2Dd) Lu2000a
Vaccine Vector/Type: fusion protein with anthrax delivery domain HIV component: V3 Adjuvant: B. anthracia lethal toxin LF component
• Epitope name: P18
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• Bacillus anthrax lethal toxin (LFn)-HIV fusion proteins are candidate HIV vaccines that are safe in mice, and LFn-V3 region fusion proteins induce CD8 T
cells in BALBc mice. LFn causes exogenous protein to be taken up and processed in a class I pathway. Expressed proteins from Gag p24 and nef fragments
cloned into the LFn expression plasmid stimulate gag-specific CD4 proliferation and CTL responses in HIV-infected donor PBMCs in vitro.
gp160 (308–322) gp120 (V3) (MN) RIHIGPGRAFYTTKN Vaccine murine (H-2Dd) Staats2001
Vaccine Vector/Type: peptide Strain: IIIB HIV component: V3 Adjuvant: cholera toxin (CT), IL-1alpha, IL-12, IL-18, GM-CSF
• Cholera toxin (CT) is a potent adjuvant used in animal studies that is not safe in humans, so combinations of cytokins were used in nasal immunization of
BALB/c mice V3 peptides to attempt to replace CT as a potent adjuvant.
• Peptide vaccine induced CTL activity was significantly increased by IL-1alpha , IL-18, and GMCSF given alone as adjuvant, but CT gave more potent CTL
activity than any single cytokine.
• Combinations of cytokins could be more potent that CT as an adjuvant. The highest tetramer binding of H-2Dd peptide-specific PBMC after nasal
immunization was observed with IL-1alpha plus IL-18 as adjuvant.
• Nasal immunization with HIV peptide in the presence of IL-1alpha, IL-12 and GM- CSF induced IFN-gamma-secreting cells in the cervical lymph node,
the lung and the spleen, and was associated with upregulation of MHC class II and B7.1 on nonlymphocytes in NALT/nasal mucosal cells.
• Consistent results were obtained for the IIIB and the MN peptides.
gp160 (308–322) gp160 (315–329 MN) RIHIGPGRAFYTTKN in vitro stimulation murine (H-2Dd) Yokosuka2002
• Epitope name: P18
• The TCR repertoire and its specificity was studied through analyzing the spectrum of TCR-alpha and beta chains able to reconstitute a reaction to the H-2
Dd-restricted P18 peptide. The RT-1 TCR alpha chain was able to react with 1/3 of the tested TCR beta chains to create a specific response. Experiments in
transgenic mice also supported the observation that a single TCR alpha chain would confer the specificity of the response and could interact with a large
variety of TCR beta chains.
gp160 (308–322) gp120 (315–329 IIIB) RIQRGPGRAFVTIGK Vaccine murine (H-2Dd,p,q,
H-2u)
Shirai1996b
Vaccine Vector/Type: vaccinia HIV component: gp160
• Multiple murine MHC can cross-present this epitope (P18) and HP53, DRVIEVVQGAYRAIR, to specific CTL
gp160 (309–317) gp120 (310–318 SF2) IYIGPGRAF HIV-1 infection human (A*2402) Ikeda-Moore1997
• Defined using reverse immunogenetics – 59 HLA-A*2402 binding peptides were predicted by searching for A*2402 anchors in HIV proteins (Tyr at 2, and
Phe, Leu or Ile at the C term) – 53 of the 59 peptides bound A*2402
• This peptide induced CTL in 1/4 HIV-1+ people tested
• IYIGPGRAF bound to A*2402 strongly, the epitope can be processed in a vaccinia construct and presented – no specific CTL clones were obtained
gp160 (309–318) gp120 (314–323 CM243
subtype CRF01)
ITVGPGQVFY HIV-1 infection human (A11) Sriwanthana2001
• Epitope name: E309-318
• This was a study of HIV-1 exposed persistently seronegative (HEPS) female sex workers in Chiang Mai, northern Thailand
• HLA-A11 is very common in this population, and was enriched among the HEPS sexworkers – weak CTL responses were detected in 4/7 HEPS women,
and CTL responses were found in 8/8 HIV+ controls, and 0/9 HIV- women that were not exposed
• This epitope was strongly reactive in HIV+ control study subject 184 who carried HLA-A11
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gp160 (309–318) gp120 (314–323 CM243
subtype CRF01)
ITVGPGQVFY HIV-1 infection human (A11) Bond2001
• HLA-A11 CRF01 (called subtype E in Bond et al.) epitopes were identified that stimulated CTL from HIV+ female sex workers (FSW) from Northern
Thailand, of whom more than half were HLA-A11 positive
• 77 possible HLA-A11 epitopes were first defined using EpiMatrix, these were screened for binding to A11 finding and 26 bound, and 12 of these were
epitopes for CTL responses from 8 HLA-A11 positive FSWs, six were novel, six were previously identified
• This is one of the new A11 epitopes identified through the streamlined EpiMatrix method, and 2/8 tested FSWs recognized it
• This epitope was not conserved in other subtypes, and exact matches were rare
gp160 (310–318) HIGPGRAFY HIV-1 infection human (A*3002) Sabbaj2002b
• Epitope name: Env-HY9
• This study monitored epitope responses in HIV-1 infected minority women living in the United States
• 24 epitopes were described – 8 were novel, 8 used new restricting elements but were previously defined epitopes, and 8 were previously described
• Serial peptide truncations were used to define optimal epitopes for CTL cell lines isolated from 12 individuals, assayed by a Cr-release
• This epitope was newly defined in this study
• Subject 00RCH33 was on HAART had a viral load of 2900 and CD4 count of 727 and also recognized the epitopes YPLTFGWCY, Nef(135-143), HLA
B*5301; AETFYVDGA, RT(437-445), HLA B*4501; and RSLYNTVATLY, p17(76-86), HLA A*3002
• Among HIV+ individuals who carried HLA A30, 3/16 (19%) recognized this epitope
gp160 (310–318) HIGPGRAFY HIV-1 infection human (A02) Sabbaj2002b
• Epitope name: Env-HY9
• Among HIV+ individuals who carried HLA A02, 6/29 (21%) recognized this epitope
gp160 (310–323) gp120 (315–328 MN) HIGPGRAFYTTKNI Vaccine murine (H-2Dd) Arp1999
Vaccine Vector/Type: canarypox prime with pseudovirion boost Strain: MN, IIIB HIV component: gp120, Gag, Pro
• Epitope name: p97
• The vaccine vCP205, canarypox vector, MN gp120 + Gag/Pro IIIB, with a HIV-1 pseudovirion boost was given to mice;)
• HIV-1 pseudovirion boost enhanced the CTL to this epitope in immunized BALB/ c mice as measured by CTL lysis and IFN gamma production
gp160 (311–318) (MN) IGPGRAFY Vaccine murine (H-2Dd) Golding2002a
Vaccine Vector/Type: B. abortus-peptide conjugate Strain: MN HIV component: V3
• Intranasal immunization of B. abortus conjugated to V3 peptides induces mucosal IFN-gamma producing T-cell responses in BALB/c mice
gp160 (311–319) gp120 (311–320 IIIB) RGPGRAFVT Vaccine murine (A2) Kiszka2002
Vaccine Vector/Type: DNA, DNA with recombinant protein boost Strain: IIIB HIV component: gp160 Adjuvant: IL-12 (IL-12p35 and IL-12p40)
• Transgenic mice expressing a HLA-A2/Kb chimeric protein were vaccinated with a full length gp160 or with gp160deltaV3, with the V3 loop deleted.
Mice given gp160deltaV3 had a broader immune response than those given gp160, with increased responses to conserved HLA-A2 epitopes in the C1
region of gp120, KLTPLCVTL, and the C-term region of gp41, SLLNATAIAV.
• Greater resistance was conferred by the gp160deltaV3 than the gp160 vaccine to a challenge of vaccinia expressing heterologous gp160 from primary
isolates (VI-06 and 89.6), and the resistance was conferred by CD8+ T-cells.
• The most intense CTL responses to the intact gp160 vaccine were directed at three V3 peptides.
gp160 (311–319) gp120 (312–320 SF2) IGPGRAFHT Vaccine murine (Dd) Selby1997
Vaccine Vector/Type: DNA Strain: SF2 HIV component: gp120
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• Murine CTL response to peptide observed after immunization with DNA plasmid containing HIV-1 (SF2) gp120 gene regulated by bacteriophage T7
promoter
• CTL response required coadministration of rec vaccinia virus expressing T7 RNA polymerase or T7 RNA polymerase soluble protein
gp160 (311–319) gp120 (SF2) IGPGRAFHT Vaccine murine (H-2Dd) Barnett1997
Vaccine Vector/Type: DNA prime with rgp120 boost Strain: SF2 HIV component: gp120
• CTL were induced by vaccine, and restimulated in vitro with V3 peptide
• DNA vaccine with protein boost stimulated both CTL and antibodies
• Strains SF2 (IGPGRAFHT), US4 (IGPGRAFYA), and CM235 (IGPGQVFYR) were tested
gp160 (311–320) gp160 (318–327 IIIB) RGPGRAFVTI Vaccine Macaca fuscata Okuda1997
Vaccine Vector/Type: DNA prime with peptide boost Strain: IIIB HIV component: gp160, V3, CD4BS, HPG30
• Murine BALB/c (H-2d) and macaque both showed highest level of CTL vaccine response when a DNA vaccine was boosted with a peptide including four
peptide subtypes of the V3 region, HPG-30 and a fragment of the CD4 binding region
gp160 (311–320) gp120 (318–327) RGPGRAFVTI HIV-1 infection human Kmieciak1998b
• Increased CTL response to cells expressing a VV construct ∆V3 mutant compared with a full-length env gene product
• This epitope doesn’t have A2 anchors, but has features that confer promiscuous A2 binding, which may relate to the inhibitory effect seen in this paper
gp160 (311–320) Env (IIIB) RGPGRAFVTI Vaccine murine BALB/c Lu1999
Vaccine Vector/Type: DNA Strain: IIIB HIV component: gp160, rev Adjuvant: MIP-1alpha
• MIP-1alpha co-inoculation increased IgG1/IgG2a ratio T-helper type 1 response.
• A MIP-1 alpha expression plasmid increased the CTL response to this DNA vaccine, as well as the T help response, presumably by the MIP-1 alpha
interacting with T lymphocytes and macrophages
gp160 (311–320) RGPGRAFVTI Vaccine murine Barouch2002
Vaccine Vector/Type: DNA Strain: BH10 HIV component: gp120 Adjuvant: GMCSF (bicistronic)
• Epitope name: P18
• gp120 encoding DNA co-injected with a plasmid carrying GMCSF gave meager CD4+ T-cell responses in BALB/c mice relative to the enhanced response
to bicistronic gp120 and GMCSF cloned into the same vector and expressed from the same promoter.
• Both mono and bicistronic DNA vaccines induced similar CTL responses directed against the H-2Dd restricted P18 peptide RGPGRAFTVTI in murine
splenocytes despite the greatly enhanced proliferative responses.
gp160 (311–320) gp120 (313–322 BRU) RGPGRAFVTI Vaccine murine Arora2001
Vaccine Vector/Type: DNA Strain: BRU HIV component: gp160, tat, rev
• Epitope name: Pep 09
• Plasmid DNA encoding gp160, tat, rev was given i.m. to immunize BALB/c mice.
• Vaccine-induced CTL activity produced a low degree of cell lysis of V3-peptide pulsed target cells, using a B (RGPGRAFVTI) or C (RIGGPGQTFYATG)
clade V3 peptides. Th1 proliferative T-cell responses were observed, and weak Ab responses.
gp160 (311–320) gp160 (318–327 IIIB) RGPGRAFVTI in vitro stimulation human (A*0201) Alexander-Miller1996
• This eptiope stimulates a CTL line derived from an HIV negative donor.
• This immunogenic peptide does not have the known binding motif for A2.1
• The same optimal peptide for this human HLA-A2.1 epitope was observed for a murine H-2 Dd epitope
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gp160 (311–320) gp120 (311–320 IIIB) RGPGRAFVTI human (A*0201) Brander2001
• C. Brander notes this is an A*0201 epitope
gp160 (311–320) gp160 (318–327 IIIB) RGPGRAFVTI Vaccine human (A2) Achour1996
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: gp160
• Individual was immunized with rec vaccinia gp160 IIIB and boosted with purified gp160
• Lysis only occurs with IIIB P18 peptide pulsed onto autologous targets; MN, RF, SIMI P18 peptides fail to stimulate CTL
• Restimulating immune cells from gp160 IIIB vaccinees with MN, RF, or SIMI P18 did not enhance the MN, RF, or SIMI specific CTL response
gp160 (311–320) gp160 (318–327 SIMI) MGPKRAFYAT Vaccine human (A2) Achour1996
Vaccine Vector/Type: vaccinia prime with rgp160 boost Strain: SIMI HIV component: gp160
• Individual was immunized with rec vaccinia gp160 SIMI and boosted with purified recombinant gp160 SIMI
• P18 MN and RF peptides were able to stimulate the HIV-specific CTL that arose in response to the SIMI vaccination, thus the P18 MN peptide
(IGPGRAFYTT) and the P18 RF peptide (KGPGRVIYAT) could cross-react
• The P18 IIIB peptide does not cross-react (RGPGRAFVTI in the epitope region)
• gp160 SIMI primed immune cells could generate a significantly broader specificity when stimulated with P18 MN or P18RF peptides, but not P18 IIIB
gp160 (311–320) gp120 (311–320) RGPGRAFVTI HIV-1 infection human (A2) Day2001
• The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7 was
studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
• 2 to 17 epitopes were recognized in a given individual, A2-restricted CTL response tended to be narrow and never dominated the response, and 25/27
epitopes were targeted by at least one person
gp160 (311–320) gp160 (318–327 IIIB) RGPGRAFVTI Vaccine murine (A2.1) Peter2001
Vaccine Vector/Type: peptide Strain: LAI Adjuvant: P30, incomplete Freund’s adjuvant (IFA), Montanide (ISA 720), PLG-microsphere
• Epitope name: LR25
• The stability of peptide binding to HLA-A2.1 was determined for six HLA-A2.1 peptides included in this vaccine study – ILKEPVHGV (RT),
SLYNTVATL (p17), SLLNATDIAV (gp41) and LLWKGEGAV (RT) all bound with high affinity comparable to a influenza epitope reference
(GILGFVFTL), while RGPGRAFVTI and VIYQYMDDL bound with a lower affinity (relative binding activity = 0.01).
• The four high-affinity peptides formed stable complexes with half-lives ranging between 8 and 32 hours, while the low affinity peptides had half lives of
less than an hour.
• HLA-A2.1 transgenic mice were immunized with the six HIV-1 peptides and P30, as a universal T-helper epitope, with IFA or Montanide or microspheres
as adjuvants.
• All peptides except VIYQYMDDL induced a stong CTL response in Cr-release assays - stronger responses were observed when peptides were delivered
alone, indicating immunodominance when the combination was used.
gp160 (311–320) gp160 (318–327 IIIB) RGPGRAFVTI Vaccine murine (D) Nehete1995
Vaccine Vector/Type: peptide Strain: IIIB HIV component: V3
• RGPGRAFVTI was defined as the optimal peptide for vaccination, out of RIQRGPGRAFVTIGK
• This peptide, in a carrier-free form in Freund’s adjuvant, could stimulate Env specific CTL in BALB/c mice
gp160 (311–320) gp160 (318–327 IIIB) RGPGRAFVTI Vaccine murine (Dd) Takahashi1993
Vaccine Vector/Type: peptide Strain: IIIB HIV component: V3
• Successful priming with vaccination of peptide pulsed splenic dendritic cells
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gp160 (311–320) gp160 (318–327 IIIB) RGPGRAFVTI Vaccine murine (Dd) Takahashi1996
Vaccine Vector/Type: peptide Strain: IIIB HIV component: V3
• Exposure of CD8+ CTL to free peptide corresponding to the epitope results in strong inhibition of the CTL response to targets presensitized with the same
peptide
• The authors propose this is due to a “self-veto”, where the CTL is inactivated by a CD8+ cell carrying the appropriate peptide-MHC complex
gp160 (311–320) gp160 RGPGRAFVTI Vaccine murine (H-2d) Gherardi2000
Vaccine Vector/Type: DNA, vaccinia HIV component: env Adjuvant: IL-12
• Induction of HIV-1 specific CD8 gamma IFN secreting cells was enhanced when IL-12 and Env were given together in a prime, followed by a VV
expressing Env boost
• If IL-12 was also delivered as a boost from the viral vector, impairment of the IL-12 effects was noted, indicating that the vaccination schedule can be a
critical parameter for success with DNA and vaccinia vectors used in combination with immunomodulators
• The negative effect observed when IL-12 was delivered with the boost involved nitric oxide
gp160 (311–320) Env RGPGRAFVTI Vaccine murine (H-2d) Xin1999
Vaccine Vector/Type: DNA Strain: IIIB HIV component: gp160, rev Adjuvant: IL-15 and IL-2, IL-12
• A study of the DNA vaccine pCMV160IIIB/REV with IL-15 and IL-2 or IL-12 expression plasmids.
• Intranasal immunization of BALB/c mice with HIV DNA and IL-15 plasmid induced increased Th1 and CTL responses
• Co-administration of IL-15 with IL-12 or IL-2 plasmids did not alter the effect of IL-15
• Both the CTL (peptide pulsed targets) and DTH response (injection of peptide into footpad) to this peptide was monitored
• The Ab response to NNTRKSIRIQRGPGRAFVTIGKIGN was monitored, and IL-15 co-administration resulted in a decrease in the IgG1/IgG2a ratio
gp160 (311–320) Env RGPGRAFVTI Vaccine murine (H-2d) Villacres1999
Vaccine Vector/Type: vaccinia, Sindbis HIV component: V3
• HIV-1 epitope p18 was expressed in two different vaccine vectors and the CTL response was compared in BALB/c mice
• Class I tetramer staining showed that up to 13% of the CD8+ splenocytes were p18 specific in the acute response using vaccinia, only 4% using Sindbis
• vp18 had more gamma IFN secreting splenocytes and activated CD4+ and CD8+ T cells
• The overall decline in CD8+ T cells in the transition into memory was 2-3 fold for both vectors
• Sindbis virus recombinants induced protective memory cytotoxic T cells, although reduced quantitatively, without vaccinia associated inflamation and
replication
gp160 (311–320) Env (318–327) RGPGRAFVTI murine (H-2d) Lopez2000
• A series of protease and proteasome inhibitors was used to identify elements of the processing pathway of this epitope, called p18, both from within Env
and from within a chimeric hepatitis B protein which allows proper processing
• Lactacystin, a proteasome inhibitor, partially inhibits endogenous processing of p18 epitope suggesting both a proteasome pathway and an additional
pathway can be used
• Both TAP dependent and TAP-independent pathways can be used
• 1,10-phenanthrolin (metallopeptidases inhibitor) blocks epitope presentation demonstrating metalloproteinase processing in the Tap-dependent pathway
• The Tap-independent pathway does not involve processing by metalloproteinases
• This epitope is immunodominant in mice, and is presented by multiple human HLA alleles – it as been suggested that the high processing efficiency of this
epitope might result in poor presentation of co-expressed epitopes
gp160 (311–320) gp120 RGPGRAFVTI Vaccine murine (H-2d) Hanke1998a, Hanke1998b
Vaccine Vector/Type: vaccinia HIV component: polyepitope
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• This murine epitope was incorporated into a vaccine of CTL epitopes expressed together including 20 HIV epitopes recognized by humans from 12 HLA
types, one murine HIV epitope and three macaque HIV epitopes, delivered in a vaccinia virus Ankara (VVA) construct
• The murine vaccination was more effective at generating CTL when given i.v. rather than i.m.
gp160 (311–320) gp160 (318–327 IIIB) RGPGRAFVTI Vaccine murine BALB/c (H-2d) Hamajima1997
Vaccine Vector/Type: peptide HIV component: V3, HPG30, CD4BS Adjuvant: IL-12
• B cell epitope HGP-30 also serves as a CTL epitope
• Vaccine combined HGP-30, V3 loop peptide variants, and CD4 binding site peptide
• IL-12 expression plasmid included with the vaccination enhanced the CTL response
gp160 (311–320) gp160 (318–327 IIIB) RGPGRAFVTI Vaccine murine (H-2d) Arai2000
Vaccine Vector/Type: DNA Strain: IIIB HIV component: gp160 Adjuvant: 8 Br-cAMP/CMV promotor
• Low-dosage 8 Br-cAMP given in combination with a DNA vaccine to BALB/c mice increased IgG and sIgA levels, and enhanced Th1, Th2 and CTL
activity – the adjuvant activity may be mediated by activation of the CMV promotor in the DNA vaccine
gp160 (311–320) gp120 (318–327 IIIB) RGPGRAFVTI Vaccine murine (H-2d) Goletz1997
Vaccine Vector/Type: fusion protein with anthrax delivery domain HIV component: gp120
• Anthrax lethal toxin can deliver proteins to the cytosol of eukaryotic cells
• A fusion protein linking the delivery domain of the anthrax protein to gp120 achieved cellular uptake, and gp120 was processed allowing presentation of
this V3 epitope to CTL in vitro
gp160 (311–320) gp160 (318–327 IIIB) RGPGRAFVTI in vitro stimulation murine (H-2d) Takahashi2001
• Epitope name: I-10
• Pre-incubation of HIV-1 (IIIB) gp160 specific CTL with peptide without APCs reduced cytolytic activity 3.5 fold and induced peptide concentration
dependent IL-2 unresponsiveness that might be due to IL-2Rbeta down regulation
• An enhanced cytolytic activity was observed by addition of anti-IFN-gamma, TNF-alpha or MIP-1beta to I-10 suppressed CTLs
gp160 (311–320) gp160 (IIIB) RGPGRAFVTI Vaccine murine (H-2d) Shirai2001
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: gp160
• Helicobacter pylori induces Th1 responses early, but predominantly Th2 responses later in infection (at 6 weeks) – differentiation of HIV-1 gp160 CD4+
help and CD8+ CTL effector cells in response to HIV gp160-vaccinia vaccination is impaired in BALB/c mice infected with H. pylori
gp160 (311–320) gp120 (318–327 IIIB) RGPGRAFVTI Vaccine murine (H-2d,p,u) Shirai1997
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: gp160
• Three class I MHC, H-2d,p,u, that differ in sequence and serology, cross-present this peptide to T cells of each of the other haplotypes
• The amino acids R, F, and I are each critical for strong CTL activity with all three MHC molecules
gp160 (311–320) gp160 RGPGRAFVTI Vaccine murine (H-2d17) Hanke1998a
Vaccine Vector/Type: vaccinia HIV component: polyepitope
• MVA is an attenuated vaccinia that can not replicate in mammalian cells – strings of CTL epitopes were delivered and expressed in a MVA DNA vector
• γ IFN and CTL activity were induced after a single vaccination
• An MVA boost enhanced the response
gp160 (311–320) Env (89.6) IGPGRARYAR Vaccine murine BALB/c (H-2D) Belyakov1998b
Vaccine Vector/Type: vaccinia Strain: 89.6 HIV component: gp160
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• Recombinant modified vaccinia virus Ankara (MVA), an attenuated vaccina which has lost the ability to replicate in mammalian cells, was used as the live
vector for this vaccine study
• A single intrarectal mucosal immunization resulted in long lasting mucosal CTL responses and production of proinflammatory cytokines in mucosal sites,
indicating that MVA was as effective in inducing mucosal CTL as replicating recombinant vaccinia
gp160 (311–320) Env (IIIB) IGPGRARYAR Vaccine murine BALB/c (H-2D) Belyakov1998a
Vaccine Vector/Type: peptide Strain: IIIB HIV component: V3
• HIV protection and mucosal CTL response was studied – an HIV peptide immunogen could protect against gp160 expressing vaccinia in a murine
intrarectal challenge system in which neutralizing Abs did not play a role, demonstrating mucosal CTL at the site of exposure can be protective
gp160 (311–320) gp120 (MN) IGPGRAFYTT Vaccine murine (H-2Dd) Lapham1996
Vaccine Vector/Type: B. abortus-peptide conjugate
• B. abortus-peptide conjugate induced a virus-specific CTL response in CD4+ lymphocyte depleted mice
gp160 (311–320) gp160 (IIIB) RGPGRAFVTI Vaccine murine (H-2Dd) Bruce1999
Vaccine Vector/Type: non-replicating adenovirus Strain: IIIB HIV component: Env, Rev
• A good HIV-1 Env immune response using non-replicating adenovirus vectors in BALB/c mice is dependent upon the presence of the stimulatory tat/rev
5’splice-donor site sequence and the presence of Rev
• Administration of monocistronic RAd501 expressing env and RAd46 expressing rev resulted in a positive CTL response, but required two immunizations
for a CTL response comparable to that induced by the bicistronic virus RAd142
• Administration of RAd501 alone gave a low CTL response, but no humoral response, suggesting a lower level of antigen may be required to stimulate CTL
gp160 (311–320) gp120 (MN) IGPGRAFYTT Vaccine murine (H-2Dd) Lapham1996
Vaccine Vector/Type: B. abortus-peptide conjugate
• B. abortus-peptide conjugate induced a virus-specific CTL response in CD4+ lymphocyte depleted mice
gp160 (311–320) gp160 (318–327 IIIB) RGPGRAFVTI Peptide-HLA interaction murine (H-2Dd) Takeshita1995
• XGPXRXXXXI are critical for binding, consistent with H-2Dd motif XGPX(RKH)XXX(X)(LIF)
gp160 (311–320) Env RGPGRAFTVTI Vaccine murine (H-2Dd) Hanke1999a, Hanke1999b
Vaccine Vector/Type: DNA HIV component: V3
• Vaccinated mice elicited a CTL response to a gene gun-delivered multiepitope vaccine to two epitopes studied that are known to elicit CTL in mice:
SYIPSAEKI from Plasmodium berghei and RGPGRAFTVTI from HIV-1 Env
• Different vaccination protocols were tested and it was found that a gene gun mediated delivery followed by an MVA boost was as good as i. m.
immunization followed by a MVA boost – this is advantageous as gene gun delivery requires far less DNA than i.m. DNA priming
• CTL activity was high (60% - 70% specific lysis at effector target) when vaccinated with a single gene gun immunization and an MVA boost, and improved
with two gene gun vaccinations
gp160 (311–320) Env (IIIB) RGPGRAFVTI in vitro stimulation murine (H-2Dd) Nakagawa2000
• Epitope name: I-10
• The CTL line LINE-IIIB was generated by repetitive restimulation of BALB/c spleen cells with vSC-25, IIIB gp160-expressing vaccinia
• RGPGRAFVTI represents the active minimal epitope within the previously described immunodominant epitope P18IIIB (RIQRGPGRAFVTIGK,
gp160(308-322)
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• External processing of P18IIIB results in the removal of the 2 C-terminal residues (GK) of I-10 by ACE (angiotensin-1-converting-enzyme) in sera to
produce I-10, and this processing is essential for target cell presentation of RIQRGPGRAFVTIGK
gp160 (311–320) Env (IIIB) RGPGRAFVTI Vaccine murine (H-2Dd) Haglund2002a
Vaccine Vector/Type: vesicular stomatitis virus (VSV), vaccinia Strain: Env, IIIB; Gag HXB2 HIV component: Gag, Env
• Epitope name: p18-I10
• BALB/c mice were vaccinated with rec vesicular stomatitis virus (rVSV) expressing either HIV-1 Gag, Env, or both, and compared to using rec Env and
Gag in vaccinia virus (rVVs). The primary response was determined by cell lysis, cytokine production and tetramer staining.
• Primary CTL responses to the immunodominant Env (RGPGRAFVTI) epitope peaked 5-7 days after intraperitoneal vaccination with Env-rVSV, 40% of
the CD8+ cells were tetramer positive, and this response was 6-fold higher than the response to Env-rVV.
• Vaccinating with GagEnv-rVSV carrying both Gag and Env allowed recognition of both HIV-1 proteins, but at reduced levels compared to either
Gag-rVSV or Env-rVSV alone.
• Intranasal immunization with Env-rVSV yielded CTL responses that were strong but reduced compared to an intraperitoneal route.
gp160 (311–320) Env (IIIB) RGPGRAFVTI Vaccine murine (H-2Dd) Haglund2002b
Vaccine Vector/Type: vesicular stomatitis virus (VSV), vaccinia Strain: Env, IIIB; Gag, HXB2 HIV component: Gag, Env
• Epitope name: p18-I10
• BALB/c mice were vaccinated with rec vesicular stomatitis virus (rVSV) expressing either HIV-1 Gag or Env, or both, and retention of memory responses
and recall responses were studied by tetramer staining and IFN-gamma production.
• Seven months after vaccination with Env-rVSV, 6% of the CD8+ cells were tetramer positive for the immunodominant Env epitope; these cells had a
memory phenotype, CD44-Hi positive.
• Env in rec vaccinia virus (Env-rVV) elicited a strong recall response, with up to 45% to the CD8+ T-cell population tetramer positive and activated
(expressing CD62L-Lo), and capable of IFN-gamma production.
• A prime with Env-rVSV and heterologous boost of Env-rVV gave remarkably high levels of memory cells, with approximately 1/3 of the CD8+
splenocytes being Env specific memory cells 150 days after the boost.
• A Gag-rVSV or EnvGag-rVSV prime and with a heterologous Gag-rVV or EnvGag-rVV boost combination gave 40% tetramer positive CD8+ cells, but
the fraction of IFN-gamma producing cells was only about 25%. Still the heterologous vector prime-boost combination showed a profound benefit.
• A HIV-1 protein rVSV prime, rVV boost was a more potent combination than a vector reversal of a rVV prime and rVSV boost.
gp160 (311–320) gp120 (V3) (IIIB) RGPGRAFVTI Vaccine murine (H-2Dd) Staats2001
Vaccine Vector/Type: peptide Strain: IIIB HIV component: V3 Adjuvant: cholera toxin (CT), IL-1alpha, IL-12, IL-18, GM-CSF
• Cholera toxin (CT) is a potent adjuvant used in animal studies that is not safe in humans, so combinations of cytokins were used in nasal immunization of
BALB/c mice V3 peptides to attempt to replace CT as a potent adjuvant.
• Peptide vaccine induced CTL activity was significantly increased by IL-1alpha , IL-18, and GMCSF given alone as adjuvant, but CT gave more potent CTL
activity than any single cytokine.
• Combinations of cytokins could be more potent that CT as an adjuvant. The highest tetramer binding of H-2Dd peptide-specific PBMC after nasal
immunization was observed with IL-1alpha plus IL-18 as adjuvant.
• Nasal immunization with HIV peptide in the presence of IL-1alpha, IL-12 and GM- CSF induced IFN-gamma-secreting cells in the cervical lymph node,
the lung and the spleen, and was associated with upregulation of MHC class II and B7.1 on nonlymphocytes in NALT/nasal mucosal cells.
• Consistent results were obtained for the IIIB and the MN peptides.
gp160 (311–320) gp160 (318–327 IIIB) RGPGRAFVTI Vaccine murine (H-2Dd) Wierzbicki2002
Vaccine Vector/Type: DNA prime with vaccinia boost Strain: IIIB HIV component: gp160 Adjuvant: PLG-microparticle, liposome, beta-glucan
lentinan, IL-2/Ig
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• BALB/c mice were give an oral immunization with (PLG)-encapsulated plasmid DNA expressing gp160 and a boost of rec gp160 vaccinia vectors (rVV)
with addition of murine IL-2/Ig plasmid or lentinan-associated liposomes. Lentinan increased CTL activity as measured by Cr-release assays against the
immunodominant epitope RGPGRAFVTI, but didn’t alter Ab responses. IL-2/Ig increased both type I and II activities, and increased Env specific CTL and
Abs. Administration of liposomes and PLG microparticles with adjuvants facilitated gastrointestinal uptake.
gp160 (311–320) gp120 (LAI) RGPGRAFVTI Vaccine murine (H-2Dd) Horner2001
Vaccine Vector/Type: protein Strain: LAI HIV component: gp120 and Pr55gag Adjuvant: immunostimulatory sequence (ISS), CpG
• Epitope name: P18
• Immunostimulatory sequences (ISS), also known as CpG motifs, stimulate innate immunity and enhance vaccine-specific immune responses.
• Intranasal immunization (i.n.) of BALB/c mice was more effective than intradermal (i.d.), and immunization with a gp120-ISS conjugate was more potent
than immunizing with gp120 and separate ISS molecule – increased IgG1, IgG2a, IFN-gamma, MIP1-alpha and MIP1-beta production was observed, and
only i.n. immunization gave IgA responses.
• The highest mucosal CTL activity in both the Lamina Propria and the Peyer’s Patch was observed following intranasal delivery with the gp120/ISS
conjugate.
• Cytokine, chemokine and CTL responses following gp120/ISS conjugate vaccination were CD4+ T-cell independent; gp120 specific antibodies were
dependent on helper T cells.
gp160 (311–320) gp160 (V3) (IIIB) RGPGRAFVTI Vaccine murine (H-2Dd) Takahashi2002
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: gp160
• Epitope name: I10
• During acute infection, high doses of virus result in "clonal exhaustion", a depletion of antigen specific T-cells.
• Recently stimulated CTL from BALB/c mice vaccinated with gp160-vaccinia showed a dose- and time-dependent induction of apoptosis when stimulated
with antigenic peptide or H-2Dd/peptide tetramers.
• Restimulated CTL showed an upregulation of CD3-chain phosphorylation in comparison to cells stimulated with target cells, indicative of TCR-mediated
apoptosis. Furthermore, apoptosis was inhibited by cyclosporin A and U0126, a mitogen activated kinase inhibitor specific for the ERK1/ERK2 MAPK
kinase pathway, and a caspase 3 inhibitor.
gp160 (311–320) gp160 (V3) (MN) IGPGRAFYAT Vaccine murine (H-2Dd) Takahashi2002
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: gp160
• Epitope name: MNT10
• During acute infection, high doses of virus result in "clonal exhaustion", a depletion of antigen specific T-cells.
• Recently stimulated CTL from BALB/c mice vaccinated with gp160-vaccinia showed a dose- and time-dependent induction of apoptosis when stimulated
with antigenic peptide or H-2Dd/peptide tetramers.
• Restimulated CTL showed an upregulation of CD3-chain phosphorylation in comparison to cells stimulated with target cells, indicative of TCR-mediated
apoptosis. Furthermore, apoptosis was inhibited by cyclosporin A and U0126, a mitogen activated kinase inhibitor specific for the ERK1/ERK2 MAPK
kinase pathway, and a caspase 3 inhibitor.
gp160 (311–320) gp160 (318–327 IIIB) RGPGRAFVTI Vaccine murine (Ld) Tobery1997
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: env, nef
• An HIV-1 Env vaccine was targeted for rapid cytoplasmic degradation
• The rapidly degraded form rapidly stimulated CTL to this peptide, faster than the normal vaccinia-env
• The rapidly degraded form also stimulated greater specific CTL lysis and higher CTLp frequencies than normal Env
• Similar results were obtained for a Nef protein designed for rapid degradation
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gp160 (312–320) gp120 (V3 loop) (IIIB) GPGRAFVTI Vaccine murine (H-2d) Vázquez Blomquist2002
Vaccine Vector/Type: fowlpoxvirus Strain: LR150, IIIB, JY1, RF, MN, BRVA HIV component: concatonated 15 mer sections of six V3 loops
• BALB/c mice were vaccinated with a polyepitope V3 vaccine in a fowlpoxvirus carrying concatonated 15 mer sections of the V3 loops of HIV-1 isolates
LR150, JY1, RF , MN, BRVA and IIIB with 5-aa linkers between, fused to the N-term of p64K protein from Neisseria meningitidis.
• Intraperitoneal immunization elicited the strongest V3-specific IFN-gamma response in splenocytes, compared to intravenous and subcutaneous
immunization. Intraperitoneal immunization conferred protection in a recombinant vaccinia virus challenge model.
• The immunodominant response was directed against the IIIB peptide (the IIIB immunizing peptide was SIRIQRGPGRAFVTI, the peptide used to probe
the response by Elispot was GPGRAFVTI).
• Low CTL responses were also detected to the LR150 (SRGIRIGPGRAILAT) and RF (RKRITMGPGRVYYTT) peptides, no responses were detected to the
JY1 (RQSTPIGLGQALYTT), BRVA (RKSITKGPGRVIYAT), or MN (RKRIHIGPGRAFYTT) peptides.
gp160 (314–322) gp120 (314–322) GRAFVTIGK Peptide-HLA interaction human (B27) Jardetzky1991
• Study of peptide binding to HLA-B27
gp160 (337–361) gp120 (337–368 LAI) KWNNTLKQIDSKLREQFGN-
NKTIIF
Vaccine human (CD4+ CTL) Johnson1994a
Vaccine Vector/Type: vaccinia HIV component: gp160
• CD4+ CTL clones were obtained from an HIV-1 vaccinia-env vaccinee
gp160 (339–354) gp120 (339–361 LAI) NNTLKQIDSKLREQFG Vaccine human (CD4+ CTL) Johnson1994b
Vaccine Vector/Type: vaccinia HIV component: gp160
• CD4+ CTL isolated from LAI IIIB gp160 vaccinees
gp160 (340–348) gp120 (346–354 CM243
subtype CRF01)
RVLKQVTEK HIV-1 infection human (A11) Sriwanthana2001
• Epitope name: E340-348
• This was a study of HIV-1 exposed persistently seronegative (HEPS) female sex workers in Chiang Mai, northern Thailand
• HLA-A11 is very common in this population, and was enriched among the HEPS sexworkers – weak CTL responses were detected in 4/7 HEPS women,
and CTL responses were found in 8/8 HIV+ controls, and 0/9 HIV- women that were not exposed
• This epitope was weakly reactive in HIV+ control study subject 053 who carried HLA-A11
gp160 (340–348) gp120 (346–354 CM243
subtype CRF01)
RVLKQVTEK HIV-1 infection human (A11) Bond2001
• HLA-A11 CRF01 (called subtype E in Bond et al.) epitopes were identified that stimulated CTL from HIV+ female sex workers (FSW) from Northern
Thailand, of whom more than half were HLA-A11 positive
• 77 possible HLA-A11 epitopes were first defined using EpiMatrix, these were screened for binding to A11 finding and 26 bound, and 12 of these were
epitopes for CTL responses from 8 HLA-A11 positive FSWs, six were novel, six were previously identified
• This is one of the new A11 epitopes identified through the streamlined EpiMatrix method, and 2/8 tested FSWs recognized it
• This epitope was not conserved in other subtypes, and exact matches were rare
gp160 (340–349) gp120 (W6.ID) NTLKQIVIKL Vaccine chimpanzee (Patr-B*14) Balla-Jhagjhoorsingh1999a
Vaccine Vector/Type: recombinant protein Strain: W6.ID HIV component: gp120
• An HIV-1 rgp120 vaccine induced strong humoral and cellular immune response in sibling chimpanzees, but only one of the two made a detectable CTL
response to this Patr-B*14 restricted immunodominant epitope
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gp160 (369–375) gp120 (374–380 BRU) PEIVTHS HIV-1 infection human (A2) Dadaglio1991
• Defined through blocking CTL activity, and Env deletions
gp160 (375–383) gp120 (379–387 LAI) SFNCGGEFF HIV-1 infection human (B*1516) Brander2001
• C. Brander notes this is a B*1516 epitope
gp160 (375–383) gp120 (375–383 IIIB) SFTCGGEFF HIV-1 infection human (B15) Wilson1999a
• This study describes maternal CTL responses in the context of mother-to-infant transmission
• Detection of CTL escape mutants in the mother was associated with transmission, but the CTL-susceptible forms of the virus tended to be found in infected
infants
• An additional variant that gave a positive, though reduced, CTL response: SSTCGGEFF and SFTCGGGFF
• SFTCGGGVF was an escape mutant
gp160 (375–383) gp120 (375–383 SF2) SFNCGGEFF HIV-1 infection human (B15) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B15+ individuals that had a CTL response to this epitope broken down by group: 0/0 group 1, 1/1 group 2, and 0/1 group 3
gp160 (375–383) gp120 (375–383 IIIB) SFNCGGEFF HIV-1 infection human (B63, B15) Wilson1997a
• This is the optimal peptide for two CTL clones that recognize this epitope in the context of two different HLA molecules, Cw4 and B15
• Predominant form in proviral DNA of the individual with B15 restricted CTL was SFTCGGEFF and this was recognized
• Recognition of a minor autologous variant (SFNCRGEFF) from the B15 donor was greatly reduced
gp160 (375–383) gp120 (376–383 PV22) SFNCGGEFF HIV-1 infection human (C*0401) Brander2001
• C. Brander notes this is a C*0401 epitope
gp160 (375–383) gp120 SFNCGGEFF HIV-1 infection human (Cw*0401,
Cw*0407)
Bird2002
• 4/123 (2 HIV-1 positive, 2 HEPS) Kenyan female sex workers carried the novel allele HLA Cw*0407.
• HLA Cw*0407 did not differ from Cw*0401 in the region associated with the binding pocket, and Cw*0407 was shown to cross-present a previously
defined Cw*0401 epitope, SFNCGGEFF (gp120).
gp160 (375–383) gp120 (376–383 PV22) SFNCGGEFF HIV-1 infection human (Cw4) Johnson1993
• Conserved epitope
gp160 (375–383) gp120 (376–383 PV22) SFNCGGEFF HIV-1 infection human (Cw4) Wolinsky1996
• Longitudinal study of epitope variation in vivo
gp160 (375–383) gp120 (376–383) SFNCGGEFF HIV-1 infection, HIV-1 exposed
seronegative
human (Cw4) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
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• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with
reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected
women
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure
• Among HLA-Cw4 women, 1/2 HEPS and 10/11 HIV-1 infected women recognized this epitope
• The dominant response to this HLA allele was to this epitope in 6 of the 10/11 responsive HIV-1 infected women, and not in the HEPS case
gp160 (376–383) gp120 FNCGGEFF human (Cw4) Rowland-Jones1999
• CTL responses in seronegative highly HIV-exposed African female sex workers in Gambia and Nairobi were studied – these women had no delta 32
deletion in CCR5
• In Gambia there is exposure to both HIV-1 and HIV-2, CTL responses to B35 epitopes in exposed, uninfected women are cross-reactive,
• HIV-2 sequence: TNCRGEFL – no cross-reactivity [Johnson1993]
gp160 (376–384) gp120 (376–384 IIIB) FNCGGEFFY HIV-1 infection human (A29) Wilson1997a
• This is the optimal peptide for two CTL clones derived from two different donors
• FNCRGEFFY and FNCRGGFFY are major and minor autologous variants in one of the donors, and showed reduced or no stimulatory activity for CTL
from the host
• The IIIB form and the form FNCAGEFFY were present in the other donor, and the CTL line had reduced activity with the FNCAGEFFY form relative to
the index peptide
gp160 (376–384) gp120 (376–384 IIIB) PNCGGEFFY HIV-1 infection human (A29) Wilson1999a
• This study describes maternal CTL responses in the context of mother-to-infant transmission
• Detection of CTL escape mutants in the mother was associated with transmission, but the CTL-susceptible forms of the virus tended to be found in infected
infants
• PNCRGEFFY was an escape variant
gp160 (376–384) gp120 (376–384 LAI) FNCGGEFFY HIV-1 infection human (A29) Mollet2000
• Epitope name: E2
• A panel of 16 epitopes covering 15 class I alleles was tested in 14 HIV+ patients from an unselected Caucasian population treated with HAART, using
CD8+ cell IFNgamma production to measure responses
• In general, during the first month of treatment viral load decreased and frequencies of HIV-specific CTL tripled and broadened – eight new HIV
specificities that were not previously detectable were newly detected, as were CMV specific CD8+ PBL – but with continued viral suppression,
HIV-specific responses diminished
• Viral rebounds gave different patterns of response: increases or decreases in pre-existing response, new specificities, or no change
gp160 (376–384) gp120 (376–384) FNCGGEFFY HIV-1 infection human (B8) Oxenius2000
• Epitope name: FNC
• Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific
CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load – three patients that had delayed initiation of
HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became
undetectable
• One of the 7/8 study subjects that were HLA B8 recognized this CTL epitope
• Patient SC19(HLA A11/12, B8/44, Cw06/0701, DR3/7, DR52/53, DQ 2/8) had a CTL response to epitopes FLKEKGGL, GEIYKRWII,
ACQGVGGPGHK, AVDLSHFLK, and FNCGGEFFY that declined during therapy initiated at day 197
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gp160 (376–384) gp160 FNCGGEFFY HIV-1 infection human (B8) Oxenius2002b
• Epitope name: FNC
• Using previously defined epitopes [Oxenius2000, Oxenius2001a] in an IFNgamma Elispot assay, 13 chronically HIV-1 infected patients were studied over a
period including therapy with standard treatment interruptions (STI).
• STIs induced increased recognition of CTL epitopes, but there was no correlation between CTL responses with viral rebound rates, plateau viral loads, or
clearance rates.
gp160 (376–387) gp120 (381–392 BRU) KNCGGEFFYCNS HIV-1 infection human (A2) Dadaglio1991
• Defined through blocking CTL activity, and Env deletions
gp160 (377–387) gp120 (377–387) NSGGEFFYSNS human (A2) Hickling1990
• Peptides recognized by class I restricted CTL can bind to class II
gp160 (383–391) gp120 (385–393) FYCNTTQLF HIV-1 infection human (A*2402) Ikeda-Moore1997
• Defined using reverse immunogenetics – 59 HLA-A*2402 binding peptides were predicted by searching for A*2402 anchors in HIV proteins (Tyr at 2, and
Phe, Leu or Ile at the C term) – 53 of the 59 peptides bound A*2402
• This peptide induced CTL in 1/4 HIV-1+ people tested
• FYCNTTQLF bound to A*2402 strongly, the epitope can be processed in a vaccinia construct and presented – two specific CTL clones were obtained
gp160 (410–429) gp120 (410–429 PV22) GSDTITLPCRIKQFINMWQE in vitro stimulation human (CD4+DRA) Bouhdoud2000
• CTL were studied through PBMC stimulation in vitro by gp120 pulsed autologous monocytes.
• Human CD4+ CTL clone (Een217) is an MHC class II HLA-DRA restricted CTL clone that can lyse antigen presenting HLA-DRA-transfected murine L
cells – natural variants of the epitope resulted in an anergic response
• Low concentrations of the HXB2-derived variant (GSDTITLPCRIKQIINMWQK) induced T cell anergy – higher concentrations could induce proliferation
and cytotoxic activity
• CDC42 (TGDIITLPCRIKQII-NRWQV), Eli (TNTNITLQCRIKQIIKMVAG) and Z3 (CTGNITLPCRIKQIIMNWQE) variants did not induce
proliferation, cytotoxic or anergic responses
gp160 (416–424) Env (413–421 SF2) LPCRIKQII HIV-1 infection human (B*5101) Tomiyama1999
• HLA-B27, -B51, and -B57 are associated with slow progression to AIDS, while HLA-B35, -B8, -B24 are associated with a rapid progression to AIDS (Nat.
Med. 2:405, 1996;Lancet 22:1187, 1986;Hum Immunol 22:73, 1988;Hum Immunol 44:156, 1995)
• 15% of Japanese populations carry HLA-B51 while HLA-B27 and -B57 are detected in less than 0.3%
• Of the 172 HIV-1 peptides with HLA-B*5101 anchor residues, 33 bound to HLA-B*5101, seven of these peptides were reactive with CTL from 3 B*5101
positive individuals, and six were properly processed
• Four of the six epitopes were highly conserved among B subtype sequences, LPCRIKQII is not conserved
gp160 (416–424) gp160 (416–424 LAI) LPCRIKQII human (B*5101) Brander2001
• C. Brander notes this is a B*5101 epitope
gp160 (416–424) gp120 (378–385) LPCRIKQII HIV-1 infection, HIV-1 exposed
seronegative
human (B51) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
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gp160 (416–429) gp120 (410–429
H3DCG)
LPCRIKQFINMWQE HIV-1 infection human (DR4 CD4+) Siliciano1988
• CD4+ CTL restricted by class II HLA-DR4, targets primed by CD4 mediated uptake of gp120
gp160 (416–435) gp120 (421–440 LAI) LPCRIKQFINMWQEVGKAMY HIV-1 infection human (A2) Dadaglio1991
• Defined through blocking CTL activity, and Env deletions
gp160 (419–427) gp120 (424–432 HXB2) RIKQIINMW human (A*3201) Harrer1996b
• C. Brander notes that this is an A*3201 epitope in the 1999 database
gp160 (419–427) gp120 (419–427 HXB2) RIKQIINMW human (A*3201) Brander2001
• C. Brander notes this is an A*3201 epitope
gp160 (419–427) gp120 (419–427) RIKQIINMW? HIV-1 infection human (A29, A32) Betts2000
• Only 4/11 HLA-A2+ HIV+ individuals had CTL that reacted to SLYNTVATL, calling into question whether it is immunodominant
• 95 optimally-defined peptides from this database were used to screen for INFγ responses to other epitopes
• 1/11 of the A2+ individuals was A29 and responded to RIKQIINMW, and another responder was A32 and these are thought to be presenting molecules
• The sequence is unclear – Betts calls both peptide 30 and peptide 32 gp120 419–427 and the peptide sequences are not provided
gp160 (419–427) gp120 (424–432 LAI) RIKQFINMW HIV-1 infection human (A32) Ray1998
• Autologous virus was used to detect CTL in two individuals, and in both cases strain-specific autologous CTL were found
• The autologous epitope sequence was RIKQIINMW, MN and RF were KIKQFINMW and RIKQFVNMW respectively, and all were reactive with CTL
clones
gp160 (419–427) gp120 (420–428) RIKQIINMW HIV-1 infection human (A32) Ferris1999
• This epitope is processed by a TAP1/2 dependent mechanism
gp160 (419–427) gp120 RIKQIINMW HIV-1 infection human (A32) Altfeld2002
• Epitope name: A32-RW10(gp120)
• Peripheral blood (PB) and lymph node (LN) CD8+ T-cell responses were compared in 15 asymptomatic HIV-1 infected patients using all known optimal
CTL epitopes (http://hiv-web.lanl.gov/content/hiv-db/REVIEWS/brander2001.html) for each person’s class I HLA alleles.
• 60 epitope responses were detected in both PB and LN samples of the 15 patients, and an additional 8 responses were detected only in LN. The total
magnitude of the response was similar in LN and PB, but the percentage of CD8+ T cells in the LN is lower so the number of HIV-specific cells per million
CD8+ T-cells is higher in the LN.
• 1 year post-HAART treatment in five patients studied, the magnitude of the CD8 T-cell response was decreased in both LN and PB, but more dramatically
in PB, and 13/25 epitope responses in the PB became undetectable, in contrast to 5/26 in the LN.
• Treatment interruption following HAART induced resulted in increased viremia accompanied by the restoration of the detection of 13 epitopes that had
become undetectable in the PB, and the addition of 9 novel epitope responses.
• Breakdowns of epitope responses were shown for 4 individuals. Patient B displayed the greatest response to epitope B44-AW11(p24) and also responded to
A32-PW10(RT) in both PB and LN samples, while a third response against epitope A32-RW10(gp120) was only detected in the LN sample. Patient D
displayed the greatest response to B27-KK10 (p24), and also responded to A30-RY11(p17), A32-PW10(RT), A30-KY11(RT), A32-RW10(gp120), and
B18-YY9(Nef).
gp160 (421–435) gp120 (421–440 LAI) KQFINMWQEVGKAMY HIV-1 infection human (A2) Dadaglio1991
• Defined through blocking CTL activity, and Env deletions
304
DEC 2002
gp160 CTL Epitopes HIV CTL Epitope Tables
C
TL
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
gp160 (421–436) gp120 (428–443 IIIB) KQIINMWQEVGKAMYA HIV-1 exposed seronegative human Pinto1995
• CTL and T helper cell reactivity in healthcare workers exposed to HIV
gp160 (421–436) gp120 (MN) KQIINMWQEVGKAMYA HIV-1 infection chimpanzee Lubeck1997
• Epitope-specific CTL detected in chimpanzees immunized with adenovirus-HIV-1 MN gp160 recombinant
• CTL response may account for protection against subsequent HIV-1 SF2 challenge in a chimpanzee lacking neutralizing antibodies
• Helper and cytotoxic T cells can be stimulated by this peptide (T1)
gp160 (421–436) gp120 (428–443 IIIB) KQIINMWQEVGKAMYA HIV-1 infection human (A2) Clerici1991a
• Helper and cytotoxic T cells can be stimulated by this peptide (T1)
gp160 (421–436) gp120 (428–443 IIIB) KQIINMWQEVGKAMYA HIV-1 infection human (A2) Cease1987
• Helper and cytotoxic T cells can be stimulated by this peptide (T1)
gp160 (421–436) gp120 (428–443 IIIB) KQIINMWQEVGKAMYA Vaccine murine (H-2a,b, f ) Shirai1992
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: gp160
• In a murine system multiple class I molecules can present to CTL
gp160 (432–451) gp120 (439–458 IIIB) KAMYAPPISGQIRCSSNITG Vaccine Rhesus macaque Wagner1998b
Vaccine Vector/Type: virus-like particle HIV component: gag, gp120, V3, CD4BS
• A VLP is a non-infectious virus-like particle self-assembled from HIV Pr55 gag – macaques were immunized with VLPs bound to either gp120 or
V3+CD4 linear domains Gag and Env specific CTL were stimulated in each case, and Ab response to gag and gp120 was elicited, but the gp120
neutralizing response occurred only with whole gp120, not V3+CD4 – despite the CTL and Ab response, immunized macaques were infected by
intervenous challenge with SHIV chimeric challenge stock
• CTL specific for this epitope could be found both before and after SHIV challenge
gp160 (434–443) gp120 (431–440) MYAPPIGGQI Vaccine murine (H-2Kd) Duarte1996
Vaccine Vector/Type: peptide
• Tolerization of CTL response with continued administration of soluble peptide
gp160 (435–443) Env (89.6) YAPPISGQI Vaccine Rhesus macaque Barouch2000, Shen2000
Vaccine Vector/Type: DNA Strain: 89.6 HIV component: SIVmac239 Gag and HIV-1 89.6P Env Adjuvant: IL2/Ig
• Epitope name: p41A
• Monkeys that received the DNA vaccines augmented with IL-2/Ig were infected when challenged with pathogenic SHIV-89.6P, but had potent CTL
responses, stable CD4+ T-cell counts, preserved virus-specific CD4+ T-cell responses, low to undetectable viral loads, and no evidence of disease or
mortality by day 140 after challenge – monkeys that got a sham vaccine had high viral load, progressed to disease, and were half were dead by day 140
• IL2/Ig consisting of interleukin-2 (IL-2) for immune stimulation, and the Fc portion of immunoglobulin G (IgG) for stability, was delivered either as protein
or as DNA – both enhance the CTL response to vaccination, DNA IL2/Ig giving the most intense response
• Responses to a dominant Mamu A*01 gag epitope SIV Gag p11C (CTPYDINQM) and a subdominant epitope HIV-1 Env p41A (YAPPISGQI) were
tracked and had good durability prior to challenge, and the higher the prechallenge peak p11C CTL response, the lower the post-challenge viral load
• No NAb responses were detected in the vaccinated monkeys prior to challenge, and comparable peak NAb titers developed in vaccinated monkeys and
control monkeys with preserved CD4+ T-cells
• Shen et al. 2000 is an accompanying commentary
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gp160 (435–443) Env (89.6) YAPPISGQI Vaccine Rhesus macaque Barouch2001b
Vaccine Vector/Type: vaccinia Strain: 89.6 HIV component: SIVmac239 Gag/Pol and HIV-1 89.6P Env Adjuvant: IL2/Ig
• Epitope name: p41A
• Four monkeys were vaccinated with a modified vaccinia Ankara (MVA) vaccine that elicited strong CTL to the immunodominant SIV gag eptiope in 4/4
animals, and 1/4 made a response to the HIV Env epitope YAPPISGQI, as determined by tetramer staining and chromium release assays
• The animals were infected when challenged with pathogenic SHIV-89.6P, but had potent CTL responses, secondary NAb responses upon challenge, partial
preservation of CD4+ T-cell counts, lower viral loads, and no evidence of disease or mortality by day 168 after challenge – monkeys that got a sham
vaccine had high viral load, progressed to disease, and 2/4 were dead by day 168
gp160 (435–443) YAPPISGQI SHIV infection Rhesus macaque (Mamu
A*01)
Egan1999
• SHIV-infected rhesus macaques have high frequencies of response to the SIVmac epitope gag p11C,C-M (CTPYDINQM) but only a fraction of A*01
monkeys tested have responses to SIVmac pol epitope STPPLVRLV and HIV-1 env epitope YAPPISGQI
gp160 (435–443) gp41 (89.6) YAPPISGQI SHIV infection, Vaccine Rhesus macaque (Mamu
A*01)
Barouch2001a
Vaccine Vector/Type: vaccinia MVA, DNA Strain: 89.6, HXBc2 HIV component: SIV Gag and HIV-1 Env Adjuvant: IL2/Ig
• Epitope name: p41A
• Mamu-A*01+ rhesus monkeys infected with SHIV-89.6 and SHIV-HXBc2 make immunodominant responses to SIV Gag p11C epitope (CTPYDINQM)
and a subdominant response to HIV-1 Env p41A epitope (YAPPISGQI)
• The binding affinities are the same for the two Mamu A*01 epitopes, so that is not what dictates the dominance.
• Monkeys vaccinated with MVA vectors carrying SIV gag/pol and HIV-1 env showed the same p11C epitope dominance and p41A epitope subdominance,
but co-dominance was observed and the response to p41A increased when DNA vaccination was done using the SIV and HIV genes under CMV promotor
control with IL2-IG adjuvant
gp160 (444–453) Env RCSSNITGLL human (B56) De Groot2001
• The program Epimatrix was used in conjunction with the program Conservatrix to identify conservered regions of HIV that might serve as epitopes
• A subset of the potential epitopes was identified that could bind to the appropriate HLA-allele, and 15 of the predicted B7 superfamily (HLA B7, B8, and
B58) epitopes were identified that could stimulate IFNγ production in an ELISPOT assay
• RCSSNITGLL was newly defined as an epitope in this study, and was shown to stimulate an ELISPOT response, despite not detectably binding to HLA-B7
gp160 (489–508) Env (496–506 BH10,
LAI)
VKIEPLGVAPTKAKRRVVQR HIV-1 infection human Maksiutov2002
• This study employs an antigenic similarity matrix to compare HIV-1 antigenic determinants with human proteins.
• This CTL epitope (the HIV-1 LAI fragment with high similarity to a human protein overlapping this epitope is VAPTKAKRRVV) has similarity with the
mast/stem cell growth factor receptor precursor fragment VVPTKADKRRSV.
gp160 (489–508) Env (497–512 BH10,
LAI)
VKIEPLGVAPTKAKRRVVQR HIV-1 infection human Maksiutov2002
• This study employs an antigenic similarity matrix to compare HIV-1 antigenic determinants with human proteins.
• This CTL epitope (the HIV-1 LAI fragment with high similarity to a human protein overlapping this epitope is APTKAKRRVVQREKRA) has similarity
with the human interferon-related IFRD2 (PC4-B) protein fragment ARTKARSRVRDKRA.
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gp160 (489–508) gp120 (494–513 BRU) VKIEPLGVAPTKAKRRVVQR HIV-1 infection human (A2) Dadaglio1991
• Defined through blocking CTL activity, and Env deletions
gp160 (519–543) gp41 (519–543) FLGFLGAAGSTMGAASLTL-
TVQARC
HIV-1 infection human (Cw7) Nehete1998a
• Three long-term non-progressors and one asymptomatic HIV+ individual were studied and found to have HLA class I C-restricted CD8+ Env-specific
CTLs – Cw7 specific CTL were found against three peptides, including this one
• HLA-C antigens are expressed on lymphoid cells to a lesser extent, 10% of either HLA-A or HLA-B
• HLA-C confers protection against lysis by natural killer cells and by non-MHC-restricted effector T cells and Cw7 directly governs this resistance to lysis –
the authors hypothesize that pathogens that inhibit antigen expression and class I expression may particularly down regulate Cw7, thus triggering non-MHC
restricted killing
gp160 (552–571) Env (552–571) QSNLLRAIEAQQHMLQLTVW HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
• This peptide was among the 28 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
gp160 (557–565) gp41 (557–565 IIIB) RAIEAQQHL HIV-1 infection human Wilson1996
• Epitope defined in the context of the Pediatric AIDS Foundation ARIEL Project, a mother-infant HIV transmission study
• RAIDAQQHL and RVIEAQQHL, naturally occurring variants, were found in mother and are recognized
gp160 (557–565) gp41 (557–565) RAIEAQQHL HIV-1 infection human Betts2000
• Only 4/11 HLA-A2+ HIV+ individuals had CTL that reacted to SLYNTVATL, calling into question whether it is immunodominant
• 95 optimally-defined peptides from this database were used to screen for INFγ responses to other epitopes
• 1/11 of the A2+ individuals was HLA A*0201, A32, B60, B78, and responded to RAIEAQQHL, previously noted to be B51
gp160 (557–565) gp41 (557–565 IIIB) RAIEAQQHL HIV-1 infection human Wilson1999a
• This study describes maternal CTL responses in the context of mother-to-infant transmission
• Detection of CTL escape mutants in the mother was associated with transmission, but the CTL-susceptible forms of the virus tended to be found in infected
infants
• This epitope was invariant in both the mother and her infant
gp160 (557–565) Env (555–567 BH10,
LAI)
RAIEAQQHL HIV-1 infection human Maksiutov2002
• This study employs an antigenic similarity matrix to compare HIV-1 antigenic determinants with human proteins.
• This CTL epitope (the HIV-1 LAI fragment with high similarity to a human protein overlapping this epitope is LLRAIEAQQHLL) has similarity with
human MHC class II regulatory factor RFX1 fragment LLRLMEDQQHMA.
gp160 (557–565) gp41 (557–565 IIIB) RAIEAQQHL HIV-1 infection human (B*5101) Brander2001
• C. Brander notes this is a B*5101 epitope
gp160 (557–565) gp41 (557–665) RAIEAQQWQ HIV-1 infection human (B*5101) Samri2000
• Epitope name: E3
• The epitope was recognized by patient 246#1 in a study of the effects of therapy escape mutations on CTL recognition
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gp160 (557–565) gp41 (557–565 IIIB) RAIEAQQHL HIV-1 infection human (B51) Sipsas1997
• HIV IIIB proteins were used to define the range of CTL epitopes recognized by 3 lab workers accidentally infected with HIV-1 IIIB
• KAIEAQQHL, a variant found in HIV-1 NY5CG, was also recognized
• RAIEAQQHM, a variant found in HIV-1 JRCSF, was also recognized
• RAIDAQQHL, a variant found in HIV-1 ETR, was also recognized
• RAIKAQQHL, a variant found in HIV-1 CDC42, was also recognized
gp160 (557–565) gp41 (557–565) RAIEAQQHL HIV-1 infection human (B51) Ferris1999
• This epitope can be processed by a TAP1/2 dependent mechanism
gp160 (557–565) gp41 (557–565) RAIEAQQWQ HIV-1 infection human (B51) Oxenius2000
• Epitope name: RAI
• Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific
CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load – three patients that had delayed initiation of
HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became
undetectable
• None of the 8 study subjects recognized this epitope but none were HLA B51+
gp160 (557–565) gp41 (47–55) RAIEAQQHL HIV-1 infection human (B51) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
gp160 (557–565) gp41 (557–565 LAI) RAIEAQQHL HIV-1 infection human (B51) Mollet2000
• Epitope name: E3
• A panel of 16 epitopes covering 15 class I alleles was tested in 14 HIV+ patients from an unselected Caucasian population treated with HAART, using
CD8+ cell IFNgamma production to measure responses
• In general, during the first month of treatment viral load decreased and frequencies of HIV-specific CTL tripled and broadened – eight new HIV
specificities that were not previously detectable were newly detected, as were CMV specific CD8+ PBL – but with continued viral suppression,
HIV-specific responses diminished
• Viral rebounds gave different patterns of response: increases or decreases in pre-existing response, new specificities, or no change
gp160 (557–565) Env (gp160) (557–565) RAIEAQQHL HIV-1 infection human (Cw*0304) Currier2002a
• Cross-reactive responses were found in PBMC isolated from individuals infected with either B or CRF01_AE clade viruses, as determined by Elispot
assays of target cells expressing recombinant vaccinia viruses expressing HIV-1 gag, env, nef and pol from many clades.
• CTL from subject US101, infected with a clade B virus, displayed broad cross-reactivity to HIV-1 clade A, B, C, D, CRF01_AE, F G, recognized this
epitope. Clade B and C had a L->M change in the C-term position that was tolerated. The H clade Env was not cross-reactive, and had the sequence
RAIAARQHM.
gp160 (565–573) Env (731–739) LLQLTVWGI HIV-1 infection human (A2 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
308
DEC 2002
gp160 CTL Epitopes HIV CTL Epitope Tables
C
TL
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
• This epitope can bind four of the five HLA-A2 supertypes alleles (A*0201, A*020 2, A*0203, A*0206 and A*6802)
gp160 (570–589) gp41 (571–590 LAI) VWGIKQLQARILAVERYLKD Vaccine human (CD4+
CTL(DR-1))
Kent1997a
Vaccine Vector/Type: vaccinia prime with rgp160 boost Strain: LAI HIV component: gp160
• VWGIKQLQARILAVERYLKD, present in HIV-1 LAI, was the immunizing strain
• VWGIKQLQARVLAVERYLKD, present in HIV-1 MN, was also recognized
• VWGIKQPQARVLAVERYLRD was the form carried by the autologous strain that infected the vaccinee
• Lysis of the target cells by CD4+ CTL was inhibited with the addition of the peptide representing the autologous strain
• The infecting virus epitope also antagonized the proliferative functions of the CD4+ CTL clone
• The behavior of the autologous strain presents a possible mechanism for vaccine failure since the infecting virus not only escapes CTL activity, but inhibits
the ability of CTL to recognize other variants
gp160 (572–590) gp41 (572–590 BRU) GIKQLQARILAVERYLKDQ Vaccine human (DPw4.2) Hammond1991
Vaccine Vector/Type: recombinant protein Strain: BRU HIV component: gp160
• CD4+ CTL
gp160 (575–599) gp41 (575–599 IIIB) QLQARILAVERYLKDQQLL-
GIWGCS
HIV-1 infection human (B14) Jassoy1992
• Epitope recognized by CTL clone derived from CSF
gp160 (583–592) gp41 (583–592 PV22) VERYLKDQQL HIV-1 infection human (B14) Jassoy1993
• HIV-1 specific CTLs release γ-IFN, and α- and β -TNF
gp160 (584–592) gp41 (584–592) ERYLKDQQL HIV-1 infection human Price1995
• Study of cytokines released by HIV-1 specific activated CTL
gp160 (584–592) gp41 (584–592) ERYLKDQQL HIV-1 infection human Borrow1994
• Three out of five patients with HIV-1 symptomatic infection controlled their viral infection well and mounted an early, strong HIV-1 specific MHC
restricted CTL response
• One of the three, study subject BORI, specifically recognized this peptide
gp160 (584–592) gp41 (584–592 HXB2) ERYLKDQQL HIV-1 infection human (A32, B14) Mollet2000
• Epitope name: E4
• A panel of 16 epitopes covering 15 class I alleles was tested in 14 HIV+ patients from an unselected Caucasian population treated with HAART, using
CD8+ cell IFNgamma production to measure responses
• In general, during the first month of treatment viral load decreased and frequencies of HIV-specific CTL tripled and broadened – eight new HIV
specificities that were not previously detectable were newly detected, as were CMV specific CD8+ PBL – but with continued viral suppression,
HIV-specific responses diminished
• Viral rebounds gave different patterns of response: increases or decreases in pre-existing response, new specificities, or no change
gp160 (584–592) gp41 ERYLRDQQL HIV-1 infection human (B*14) Kaul2002
• Neisseria gonorrhea cervititis in 9 HIV+ Kenyan sex workers caused a functional deficiency in IFN-gamma production in HIV-1 epitope-specific CD8+
T-cells, detected by intracellular cytokine production and tetramer assays, while not affecting the total number of epitope-specific CTLs.
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• Ghonorrhea caused the weaker HIV-1 specific CTL responses in 4 HIV-1 exposed persistently seronegative (HEPS) women to become undetectable by
Elispot and tetramer assays, and CMV-specific CTL in 2 HEPS subjects were shown to have impaired function with regard to IFN-gamma production.
gp160 (584–592) gp41 (584–592 PV22) ERYLKDQQL HIV-1 infection human (B*1402) Brander2001
• C. Brander notes this is a B*1402 epitope
gp160 (584–592) gp41 ERYLKDQQL HIV-1 infection human (B14) Wagner1998a
• CTL specific for HIV epitopes were used to show that the mediators of both the cytolytic (granzyme A was used as the marker) and non-cytolytic (HIV-1
inhibitory chemokines MIP-1 α and RANTES were used as markers) anti-viral responses are localized within the CTL’s cytotoxic granules
gp160 (584–592) gp41 (584–592) ERYLKDQQL HIV-1 infection human (B14) Kalams1999b
• Two patients were followed before and after HAART – reduced plasma HIV-1 RNA levels resulted in a decline in HIV in vivo activated specific CTL such
that by day 260 CTL activities were undetectable
• ERYLKDQQL was the dominant response in one of the individuals, SLYNTVATL subdominant
• Sporadic breakthrough in viremia resulted in increases in CTLp
• Peptide-tetramer staining demonstrated that declining levels of in vivo-activated CTL were associated with a decrease in expression of CD38
• Memory CTL frequency directed against Vac-Gag, Vac-RT, Vac-Env, and Vac-Nef initially increased with HAART and then decreased with the decline of
the viral load
gp160 (584–592) gp41 (591–599 SF2) ERYLKDQQL HIV-1 infection human (B14) Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Eleven subjects had CTL that could recognize vaccinia-expressed LAI gp160
• One of these 11 had CTL response to this peptide
• The responding subject was HLA-A3, -A32, -B7, -B14
gp160 (584–592) gp41 (591–599 SF2) ERYLKDQQL HIV-1 infection human (B14) Cao1997a
• The consensus sequence for clades B, C, and D is ERYLKDQQL
• The consensus sequence for clade A is ERYLRDQQL and it is equally reactive
• The consensus sequence for clade E is ERYLKDQKF and it is not reactive
gp160 (584–592) gp41 ERYLKDQQL HIV-1 exposed seronegative human (B14) Rowland-Jones1998a
• A CTL response was found in exposed but uninfected prostitutes from Nairobi using previously-defined B clade epitopes that tended to be conserved in A
and D clades – such cross-reactivity could protect against both A and D and confer protection in Nairobi where both subtypes are circulating
• The A and D subtype consensus are identical to the B clade epitope, ERyLkDQQL
gp160 (584–592) gp41 (584–592) ERYLKDQQL HIV-1 infection human (B14) Sipsas1997
• HIV IIIB proteins were used to define the range of CTL epitopes recognized by 3 lab workers accidentally infected with HIV-1 IIIB
gp160 (584–592) gp41 (584–592) ERYLKDQQL HIV-1 infection human (B14) Yang1996
• CD4+ cell lines acutely infected with HIV were studied to determine their susceptibility to lysis by CTL
• Clones specific for RT lysed HIV-1 infected cells at lower levels than Env or Gag specific clones
• The distinction was thought to be due to lower expression of RT relative to Env and Gag
• CTL can lyse infected cells early after infection, possibly prior to viral production
gp160 (584–592) gp41 (584–592) ERYLKDQQL HIV-1 infection human (B14) Yang1997a
• CTL inhibit HIV-1 replication at effector cell concentrations comparable to those found in vivo
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• CTL produced HIV-1-suppressive soluble factors – MIP-1α , MIP-1β , RANTES, after antigen-specific activation
• CTL suppress HIV replication more efficiently in HLA-matched cells
gp160 (584–592) gp41 (584–592 PV22) ERYLKDQQL HIV-1 infection human (B14) Johnson1992
• Two overlapping CTL epitopes were mapped with different HLA restriction (also see YLKDQQLL HLA-B8)
gp160 (584–592) gp41 (584–592 PV22) ERYLKDQQL HIV-1 infection human (B14) Jassoy1993
• HIV-1 specific CTLs release γ-IFN, and α- and β -TNF
gp160 (584–592) gp41 (584–592 HXB2) ERYLKDQQL HIV-1 infection human (B14) Kalams1994, Kalams1996
• Longitudinal study of T cell receptor usage in a single individual
• Persistence of oligoclonal response to this epitope for over 5 years
gp160 (584–592) gp41 (584–592) ERYLKDQQL Peptide-HLA interaction human (B14) DiBrino1994a
• Epitope studied in the context of HLA-B14 binding
gp160 (584–592) gp41 (584–592) ERYLKDQQL HIV-1 infection human (B14) Hammond1995
• This peptide can be processed for HLA-B14 presentation in a TAP-1/2 independent pathway
gp160 (584–592) gp41 (584–592) ERYLKDQQL HIV-1 infection human (B14) Kalams1996
• CTL response to this epitope was studied in 5 HLA-B14 positive persons
• CTL responses were detected in all five, and CTL clones were isolated from 4/5
• A diverse repertoire of TCRs recognized this epitope, with similar fine specificities
• 3/5 subjects showed no variation in viral sequence, 2/5 had a dominant variant that resulted in poor recognition, ERYLQDQQL
• A minor CTL response specific for the ERYLQDQQL could be detected by two individuals, but the major CTL response was to the ERYLKDQQL form
even when it was the minority form
• Some single amino acid substitutions were well tolerated by most of the CTL clones tested, but others, particularly in the center three amino acid positions,
abrogated peptide stimulatory activity
gp160 (584–592) gp120 (584–592) ERYLKDQQL HIV-1 infection human (B14) Ferris1999, Hammond1995
• This epitope is processed by both TAP1/2 dependent and independent mechanisms
gp160 (584–592) gp41 ERYLKDQQL human (B14) Rowland-Jones1999
• CTL responses in seronegative highly HIV-exposed African female sex workers in Gambia and Nairobi were studied – these women had no delta 32
deletion in CCR5
• In Gambia there is exposure to both HIV-1 and HIV-2, CTL responses to B35 epitopes in exposed, uninfected women are cross-reactive, and the B35 allele
seems to be protective
• HIV-2 sequence: EKYLQDQAR – no cross-reactivity [Johnson1992]
gp160 (584–592) gp41 (SF2) ERYLKDQQL HIV-1 infection human (B14) Goulder2001a
• Epitope name: EL9
• Data from patient AC13 suggest a role for this epitope in initial control of viremia in acute infection, as it is one of several subdominant CTL epitopes
recognized during the initial decline in viremia
• A CTL response to SL9, SLYNTVATL, was not evident until 18 months post-presentation
• Recognized by two A*0201-positive chronically infected subjects
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gp160 (584–592) gp41 (584–592) ERYLKDQQL HIV-1 infection human (B14) Islam2001
• Epitope name: 588K
• Transcript frequencies of four CTL clones from patient 115, with a chronic and stable HIV-1 infection, were tracked in a longitudinal study of samples
collected 6-11 years post infection: clone M21 and E15 recognize ERYLKDQQL,and clone D87 recognizes variant ERYLQDQQL, and clone p175b
recognizes the A2 epitope SLYNTVATL
• CTL clone M21 uses the Vbeta 4, CDR3 VKDGA, Jbeta 1.2 TCR beta gene, and clone E15 uses the Vbeta 4, CDR3 VEDWGGAS Jbeta 2.1 TCR beta
gene, and D87 uses Vbeta8, ALNRVD, Jbeta2.1
• Responses were stable even through HAART with undetectable viral loads but frequencies varied over time by 100-fold, ranging from 0.012% of the total
population for SLYNTVATL at its lowest point to 3.78% for M21, with the relative frequencies of clones shifting over time
gp160 (584–592) gp41 (589–597 SF2) ERYLKDQQL HIV-1 infection human (B14) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B14+ individuals that had a CTL response to this epitope broken down by group: 3/3 group 1, 1/2 group 2, and 0/0 group 3
gp160 (584–592) gp41 (589–597) ERYLRDQQL HIV-1 infection, HIV-1 exposed
seronegative
human (B14) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
gp160 (584–592) gp41 (JRCSF) ERYLKDQQL HIV-1 infection human (B14) Severino2000
• Primary HLA-B14+ CD4+ CD3+ and HLA-mismatched lymphocytes from uninfected donors were infected with JRCSF after isolation then cocultured
with the B14-restricted CTL clone 15160/D75 specific for ERYLKDQQL, and viral inhibition was MHC-restricted
• Primary monocytes and monocyte-derived DC were generated from the same donors, replication of HIV-1 in these cell types was less efficient than in
lymphocytes and could also be inhibited by MHC-restricted CTL
• DC-lymphocyte cluster cultures allowed vigorous viral replication and MHC-restricted CTL viral inhibition was blunted or lost depending on the ratio of
DC to CD4+ lymphocyte in the culture
gp160 (584–592) gp41 (SF2) ERYLKQQL HIV-1 infection human (B14) Altfeld2000b
• This epitope was mapped by ELISPOT in a study identifying new HLA-B60 epitopes, and was one of the epitopes presented by another HLA molecule in
an HLA-B60 individual
gp160 (584–592) Env (589–597) ERYLKDQQL HIV-1 infection human (B14) Guillon2002
• An early-expressed Nef protein was modified to contain Env and Pol epitopes to enable the study the effect of expression kinetics on CTL mediated
suppression of replication. The "EpiNef" construct was inserted into a recombinant vaccinia virus which was used to infect a target cell line; the target cells
were lysed by CTL clones specific for the Env and Pol epitopes indicating that they were properly processed.
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gp160 (584–592) gp41 (584–592) ERYLKDQQL HIV-1 infection human (B14) Yang2002
• Nef down-modulates class I protein expression, and this study demonstrates directly that Nef-deleted HIV-1 NL-43 can be more effectively killed in vitro
than NL-43 with an intact Nef. The effect was shown to be specific for class I presentation of epitopes, and unlike Nef, deleting Vpr did not alter CTL
susceptibility of NL43 infected cells. The CTL clone 15160D75, specific for the class I B14 presented epitope ERYLKDQQL, was one of four used in this
study.
gp160 (584–592) gp41 ERYLKDQQL HIV-1 infection human (B14) Altfeld2002
• Epitope name: B14-EL9(gp41)
• Peripheral blood (PB) and lymph node (LN) CD8+ T-cell responses were compared in 15 asymptomatic HIV-1 infected patients using all known optimal
CTL epitopes (http://hiv-web.lanl.gov/content/hiv-db/REVIEWS/brander2001.html) for each person’s class I HLA alleles.
• 60 epitope responses were detected in both PB and LN samples of the 15 patients, and an additional 8 responses were detected only in LN. The total
magnitude of the response was similar in LN and PB, but the percentage of CD8+ T cells in the LN is lower so the number of HIV-specific cells per million
CD8+ T-cells is higher in the LN.
• 1 year post-HAART treatment in five patients studied, the magnitude of the CD8 T-cell response was decreased in both LN and PB, but more dramatically
in PB, and 13/25 epitope responses in the PB became undetectable, in contrast to 5/26 in the LN.
• Treatment interruption following HAART resulted in increased viremia accompanied by the restoration of the detection of 13 epitopes that had become
undetectable in the PB, and the addition of 9 novel epitope responses.
• Breakdowns of epitope responses were shown for 4 individuals. Patient A displayed the greatest response to epitope B14-EL9(gp41), a strong response to
B7-TL9(p24), and responses to B7-TM9(Nef) and A32-PW10(RT).
gp160 (584–592) gp41 ERYLKDQQL HIV-1 infection, Vaccine human (B14) Hanke2000, Wee2002
Vaccine Vector/Type: DNA prime with vaccinia MVA boost Strain: subtype A HIV component: p17, p24, polyepitope
• The HIV-1 subtype A focused vaccine HIVA contains p24 and p17, in a reversed order relative to the Gag polyprotein to prevent myristylation of p17,
which could direct the protein to the cell membrane and inhibit efficient peptide processing and class I presentation, as well as a polyepitope string of
conserved, often immunodominant epitopes that were selected to have particularly good cross-reactive potential for the A-clade epidemic in Nairobi,
Kenya. A DNA and MVA prime-boost vaccination protocol using the HIVA antigen will be used in a phase III clinical trial in Kenya. This epitope is
included in the polyepitope string [Hanke2000].
• Multiple CD4+ or CD8+ T-cell vaccine-induced responses to peptide pools were detected using intracellular cytokine staining and IFNgamma Elispot
assays after vaccination of 5 macaques. The response to the Mamu A*01 SIV p27 epitope p11C (CTPYDINQM), included in the polyepitope region, was
not immunodominant in the Mamu A*01 vaccinated macaques, possibly because of processing limitations in context of the artificial polyepitope string
[Wee2002].
gp160 (584–592) gp41 (subtype B) ERYLKDQQL HIV-1 exposed seronegative human (B14, B*1402) Rowland-Jones1998b
• HIV-specific CTL were found in exposed seronegative prostitutes from Nairobi – these CTL may confer protection
• Seroprevalence in this cohort is 90-95% and their HIV-1 exposure is among the highest in the world
• Most isolated HIV strains are clade A in Nairobi, although clades C and D are also found – B clade epitopes are often cross-reactive, however stronger
responses are frequently observed using A or D clade versions of epitopes
• This epitope is conserved among B and D clade viruses
• The Clade A version of the epitope is ERYLRDQQL
gp160 (585–592) gp41 (584–591 SF2) RYLRDQQL HIV-1 infection human (A*2402) Ikeda-Moore1997
• Defined using reverse immunogenetics – 59 HLA-A*2402 binding peptides were predicted by searching for A*2402 anchors in HIV proteins (Tyr at 2, and
Phe, Leu or Ile at the C term) – 53 of the 59 peptides bound A*2402
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• This peptide induced CTL in 2/4 HIV-1+ people tested
• RYLRDQQL bound to A*2402 weakly, the epitope can be processed in a vaccinia construct and presented – two specific CTL clones were obtained
gp160 (585–592) gp41 (590–597 LAI) RYLKDQQL HIV-1 infection human (B27) Shankar1996
gp160 (585–593) gp41 (584–591 SF2) RYLRDQQLL HIV-1 infection human (A*2402) Ikeda-Moore1997
• Defined using reverse immunogenetics – 59 HLA-A*2402 binding peptides were predicted by searching for A*2402 anchors in HIV proteins (Tyr at 2, and
Phe, Leu or Ile at the C term) – 53 of the 59 peptides bound A*2402
• This peptide induced CTL in 4/4 HIV-1+ people tested
• RYLRDQQLL bound to A*2402 strongly, the epitope can be processed in a vaccinia construct and presented – two specific CTL clones were obtained
gp160 (585–593) gp41 (591–598 LAI) RYLKDQQLL human (A*2402) Brander2001
• C. Brander notes this is an A*2402 epitope
gp160 (585–593) gp41 RYLKDQQLL HIV-1 infection human (A24) Altfeld2002
• Epitope name: A24-RL9(gp41)
• Peripheral blood (PB) and lymph node (LN) CD8+ T-cell responses were compared in 15 asymptomatic HIV-1 infected patients using all known optimal
CTL epitopes (http://hiv-web.lanl.gov/content/hiv-db/REVIEWS/brander2001.html) for each person’s class I HLA alleles.
• 60 epitope responses were detected in both PB and LN samples of the 15 patients, and an additional 8 responses were detected only in LN. The total
magnitude of the response was similar in LN and PB, but the percentage of CD8+ T cells in the LN is lower so the number of HIV-specific cells per million
CD8+ T-cells is higher in the LN.
• 1 year post-HAART treatment in five patients studied, the magnitude of the CD8 T-cell response was decreased in both LN and PB, but more dramatically
in PB, and 13/25 epitope responses in the PB became undetectable, in contrast to 5/26 in the LN.
• Treatment interruption following HAART induced resulted in increased viremia accompanied by the restoration of the detection of 13 epitopes that had
become undetectable in the PB, and the addition of 9 novel epitope responses.
• Breakdowns of epitope responses were shown for 4 individuals. Patient C displayed the greatest response to B27-KK10(p24), and in decreasing order also
responded to A24-RW8(Nef), B7-IL9(gp41), A24-RL9(gp41), A24-YL8(gp41), and B7-TM9(Nef).
gp160 (585–595) gp41 (584–591 SF2) RYLRDQQLLGI HIV-1 infection human (A*2402) Ikeda-Moore1997
• Defined using reverse immunogenetics – 59 HLA-A*2402 binding peptides were predicted by searching for A*2402 anchors in HIV proteins (Tyr at 2, and
Phe, Leu or Ile at the C term) – 53 of the 59 peptides bound A*2402
• This peptide induced CTL in 4/4 HIV-1+ people tested
• RYLRDQQLLGI bound to A*2402 with medium strength, the epitope can be processed in a vaccinia construct and presented – two specific CTL clones
were obtained
gp160 (585–595) Env (584–594) RYLRDQQLLGI Vaccine human (A*2402) Kawana-Tachikawa2002
Vaccine Vector/Type: Sendai virus vector system (SeV) HIV component: class I/peptide complexes
• Epitope name: Env584-11
• A Sendai virus vector system (SeV) was developd that expressed HLA-A*2402-restricted class I/peptide complexes; this system could be used to detect
responses and has the potential to elicit immune responses.
• MHC class I/peptide tetramers could be made using this system that bound to epitope-specific CTLs in PBMCs.
• Cells transfection with SeV modified to express A*2402-HIV epitope complexes induced CTL mediated specific cell lysis.
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gp160 (586–593) gp160 YLRDQQLL HIV-1 infection human Kaul2001c
• This study examines CTL responses in HIV exposed, persistently seronegative individuals, HEPS, who eventually seroconverted – 11/114 HEPS Nairobi
sex workers eventually seroconverted, and for six of these HIV CTL reactive epitopes had been defined while seronegative
• The epidemiological factor associated with seroconversion was stopping sex work and HIV-specific CTL activity declines when HEPS sex workers stop
working for a period or retire
• This epitope was recognized in 1/22 HEPS sex worker controls, ML887
gp160 (586–593) gp41 (584–591 NL43) YLKDQQLL HIV-1 infection human (A*2402) Dai1992
• The lysine (K) is critical for eliciting a HLA-A24 CTL response
• C. Brander notes that this is an A*2402 epitope in the 1999 database, and suggested that the epitope is RYLKQQLL
gp160 (586–593) gp41 (591–598) YLRDQQLL HIV-1 infection, HIV-1 exposed
seronegative
human (A24) Kaul2001a
• Variants (R)YL(R/K)DQQLL are specific for the A/B clade
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with
reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected
women
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure
• Among HLA-A24 women, 3/4 HEPS and 10/10 HIV-1 infected women recognized this epitope, and (R)YL(R/K)DQQLL tended to be reactive in HEPS
and infected women, RDYVDRFFKTL in infected women only
• The dominant response to this HLA allele was to this epitope in all 3/4 HEPS cases but in only 4 of the 10/10 HIV-1 infected women
• Differences in epitope specificity were only seen for responses restricted by class I HLA alleles A2, A24, A*6802, B14, and B18, previously shown to be
associated with resistance to HIV-1 in this cohort
gp160 (586–593) gp41 (580–587 CM243
subtype CRF01)
YLKDQQLL HIV-1 infection human (A24) Bond2001
• More than half of a cohort of HIV+ female sex workers (FSW) from Northern Thailand were HLA-A11 positive, and this study concentrated on A11
epitopes in this group, although E clade versions of previously defined B-clade A2 and A24 epitopes were also tested.
• The only HLA-A24 FSW tested did not recognized the E clade version of this epitope RYLKDQKLL, which differs from the previously defined B clade
version by one amino acid, YLKDQQLL, with an additional amino acid added on
gp160 (586–593) gp41 (subtype A) YLKDQQLL HIV-1 infection, Vaccine human, macaque (A24,
B8)
Hanke2000, Wee2002
Vaccine Vector/Type: DNA prime with vaccinia MVA boost Strain: subtype A HIV component: p17, p24, polyepitope
• The HIV-1 subtype A focused vaccine HIVA contains p24 and p17, in a reversed order relative to the Gag polyprotein to prevent myristylation of p17,
which could direct the protein to the cell membrane and inhibit efficient peptide processing and class I presentation, as well as a polyepitope string of
conserved, often immunodominant epitopes that were selected to have particularly good cross-reactive potential for the A-clade epidemic in Nairobi,
Kenya. A DNA and MVA prime-boost vaccination protocol using the HIVA antigen will be used in a phase III clinical trial in Kenya. This epitope is
included in the polyepitope string [Hanke2000].
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• Multiple CD4+ or CD8+ T-cell vaccine-induced responses to peptide pools were detected using intracellular cytokine staining and IFNgamma Elispot
assays after vaccination of 5 macaques. The response to the Mamu A*01 SIV p27 epitope p11C (CTPYDINQM), included in the polyepitope region, was
not immunodominant in the Mamu A*01 vaccinated macaques, possibly because of processing limitations in context of the artificial polyepitope string
[Wee2002].
gp160 (586–593) gp41 (586–593 LAI) YLKDQQLL HIV-1 infection human (A24, B8) Mollet2000
• Epitope name: E1
• A panel of 16 epitopes covering 15 class I alleles was tested in 14 HIV+ patients from an unselected Caucasian population treated with HAART, using
CD8+ cell IFNgamma production to measure responses
• In general, during the first month of treatment viral load decreased and frequencies of HIV-specific CTL tripled and broadened – eight new HIV
specificities that were not previously detectable were newly detected, as were CMV specific CD8+ PBL – but with continued viral suppression,
HIV-specific responses diminished
• Viral rebounds gave different patterns of response: increases or decreases in pre-existing response, new specificities, or no change
gp160 (586–593) gp41 (586–593) YLKDQQLL HIV-1 infection human (B*0801) Brander2001
• C. Brander notes this is a B*0801 epitope
gp160 (586–593) gp41 (586–593) YLKDQQLL HIV-1 infection human (B8) Johnson1992
• Two overlapping CTL epitopes were mapped with different HLA restriction (also see ERYLKDQQL HLA-B14)
gp160 (586–593) gp41 (586–593) YLKDQQLL Peptide-HLA interaction human (B8) Sutton1993
• Predicted epitope based on B8-binding motifs, from larger peptide QLQARILAVERYLKDQQLLGIWGCS
gp160 (586–593) gp41 (76–83) YLKDQQLL human (B8) Goulder1997g
• Included in a study of the B8 binding motif
gp160 (586–593) gp41 YLKDQQLL human (B8) Rowland-Jones1999
• CTL responses in seronegative highly HIV-exposed African female sex workers in Gambia and Nairobi were studied – these women had no delta 32
deletion in CCR5
• In Gambia there is exposure to both HIV-1 and HIV-2, CTL responses to B35 epitopes in exposed, uninfected women are cross-reactive
• HIV-2 sequence: YLQDQARL – no cross-reactivity [Johnson1992]
gp160 (586–593) gp41 (586–593) YLKDQQLL HIV-1 infection, HIV-1 exposed
seronegative
human (B8) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
gp160 (586–593) gp41 (586–593) YLKDQQLL HIV-1 infection human (B8) Day2001
• B8-restricted CTL accounted for about 1/3 of the total CTL response in one individual
gp160 (586–598) gp41 (586–598) YLRDQQLLGIWGC HIV-1 infection human (Cw7) Nehete1998a
• Three long-term non-progressors and one asymptomatic HIV+ individual were studied and found to have HLA class I C-restricted CD8+ Env-specific
CTLs – Cw7 specific CTL were found against three peptides, including this one
• HLA-C antigens are expressed on lymphoid cells to a lesser extent, 10% of either HLA-A or HLA-B
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• HLA-C confers protection against lysis by natural killer cells and by non-MHC-restricted effector T cells and Cw7 directly governs this resistance to lysis –
the authors hypothesize that pathogens that inhibit antigen expression and class I expression may particularly down regulate Cw7, thus triggering non-MHC
restricted killing
gp160 (594–608) gp41 GIWGCSGKLICTTAV HIV-1 infection human (B57) Jin1998b
• Progressive HIV-1 infection and CD4 decline was associated decreased the IL-2-expandable HIV-1 CTL response in 10 asymptomatic HIV-infected
patients – this observation may be partially due to a reduction and impaired function of T helper cells, CTL exhaustion and APC dysfunction
• Continued presence of HIV-1 specific memory cells (CTLp) was observed in three patients, one to GIWGCSGKLICTTAV, one to ALIWEDLRSLCLFSY,
and one to PIPIHYCAPAGFAILKCNNK
gp160 (606–614) gp41 (605–615 LAI) TAVPWNASW Vaccine human (B*3501) Brander2001
Vaccine Vector/Type: vaccinia HIV component: gp160
• C. Brander notes this is a B*3501 epitope
gp160 (606–614) gp41 (606–614 HXB2) TAVPWNASW HIV-1 infection human (B*3501) Ferris1996
• Natural form of this peptide is not glycosylated, suggesting initial Class I processing may occur in the cytosol
gp160 (606–614) gp41 (605–615 LAI) TAVPWNASW Vaccine human (B35) Johnson1994b
Vaccine Vector/Type: vaccinia HIV component: gp160
• Epitope for vaccine induced CD8+ clone
gp160 (606–614) gp41 (606–614 LAI) TAVPWNASW Vaccine human (B35) Johnson1994a
Vaccine Vector/Type: vaccinia HIV component: gp160
• HLA restricted CTL response to epitope in HIV-1 vaccinia-env vaccinees
gp160 (606–614) gp41 (606–614 LAI) TAVPWNASW Vaccine human (B35) Hammond1995
Vaccine Vector/Type: vaccinia HIV component: gp160
• Peptide only processed by a TAP-1/2-dependent pathway
gp160 (606–614) gp41 (606–614) TAVPWNASW HIV-1 infection human (B35) Ferris1999
• This epitope is processed by a TAP1/2 dependent mechanism
gp160 (606–614) gp41 (subtype B) TAVPWNASW HIV-1 exposed seronegative human (B35) Rowland-Jones1998b
• HIV-specific CTL were found in exposed seronegative prostitutes from Nairobi – these CTL may confer protection
• Seroprevalence in this cohort is 90-95% and their HIV-1 exposure is among the highest in the world
• Most isolated HIV strains are clade A in Nairobi, although clades C and D are also found – B clade epitopes are often cross-reactive, however stronger
responses are frequently observed using A or D clade versions of epitopes
• This epitope is conserved among A, B and D clade viruses
gp160 (606–614) gp41 (606–614) TAVPWNASW HIV-1 infection, HIV-1 exposed
seronegative
human (B35) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
gp160 (634–648) gp41 (641–655 SF2) EIDNYTNTIYTLLEE HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Eleven subjects had CTL that could recognize vaccinia-expressed LAI gp160
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• One of these 11 had CTL response to this peptide
• The responding subject was HLA-A1, A2, B51, and B57
gp160 (678–686) Env (679–687 subtype
B)
WLWYIKIFI Vaccine human (A2.1) Kundu1998a
Vaccine Vector/Type: recombinant protein Strain: MN HIV component: gp160
• Ten HIV-1+ HLA A2 asymptomatic individuals were given two courses of HIV-1 MN rgp160 vaccine over a 2 year period
• Two hundred and fifty three HIV-1 peptides of 9 or 10 aa possessing the HLA-A2.1 binding motif (Leu at position 2, Val at the C terminus) were identified
in gp160, of which 25 had a high or intermediate binding affinity
• Eleven peptides were studied that had high HLA-A2 binding affinity – a CTL response was detected to 9/11 peptides in at least 1 individual
• CTL responses after reimmunization may include recall responses – only individuals with vaccine cross-reactive sequences prior to vaccination showed
detectable CTL responses
gp160 (680–688) gp41 (679–687 SF2) WYIKIFIMI HIV-1 infection human (A*2402) Ikeda-Moore1997
• Defined using reverse immunogenetics – 59 HLA-A*2402 binding peptides were predicted by searching for A*2402 anchors in HIV proteins (Tyr at 2, and
Phe, Leu or Ile at the C term) – 53 of the 59 peptides bound A*2402
• This peptide induced CTL in 1/4 HIV-1+ people tested
• WYIKIFIFMI bound to A*2402 strongly, the epitope can be processed in a vaccinia construct and presented – two specific CTL clones were obtained
gp160 (685–693) Env (686–694 subtype
B)
FIMIVGGLV Vaccine human (A2.1) Kundu1998a
Vaccine Vector/Type: recombinant protein Strain: MN HIV component: gp160
• Ten HIV-1+ HLA A2 asymptomatic individuals were given two courses of HIV-1 MN rgp160 vaccine over a 2 year period
• Two hundred and fifty three HIV-1 peptides of 9 or 10 aa possessing the HLA-A2.1 binding motif (Leu at position 2, Val at the C terminus) were identified
in gp160, of which 25 had a high or intermediate binding affinity
• Eleven peptides were studied that had high HLA-A2 binding affinity – a CTL response was detected to 9/11 peptides in at least 1 individual
• CTL responses after reimmunization may include recall responses – only individuals with vaccine cross-reactive sequences prior to vaccination showed
detectable CTL responses
• ALTERNATIVE EPITOPE: IMIVGGLVGL – no CTL response was shown to the peptides FIMIVGGLV or IMIVGGLVGL
gp160 (698–707) Env (696–706) VFAVLSIVNR HIV-1 infection human (A*3303) Hossain2001, Takiguchi2000
• HLA-A33 a very common allele in Asian, with HLA-A*3303 the most common among the Japanese. New A*3303 epitopes were defined to better
characterize the immune response in this population.
• The anchor motif for HLA*3303 (A, I, L, V, F, Y in position 2 (F and Y bind most strongly), and R (K is also tolerated) in the C-terminal position) was
used to define 82 potentially reactive peptides in Env; 37/82 peptides bound to A*3303; 3/37 peptides could induce peptide-specific CTL in bulk PBMC
cultures from 1/3 HLA A*3303 positive individuals tested.
• CTL clones were isolated that killed target cells in a concentration dependent manner after pulsing with the VFAVLSIVNR peptide, that could also kill cells
transfected with env expressed from a vaccinia vector. Bulk cultures were tested from six additional people, and only 1/6 reacted with this peptide, but the
peptide is in a highly variable region.
gp160 (700–708) Env (695–705 BH10,
LAI)
AVLSVVNRV HIV-1 infection human Maksiutov2002
• This study employs an antigenic similarity matrix to compare HIV-1 antigenic determinants with human proteins.
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• This CTL epitope (the HIV-1 LAI fragment with high similarity to a human protein overlapping this epitope is LRIVFAVLSVV) has similarity with the
human chemokine-factor 3 fragment LRLVFALVTAV .
gp160 (700–708) gp41 (705–714) AVLSVVNRV HIV-1 infection human (A2) Ferris1999
• This epitope is processed by a TAP1/2 dependent mechanism
gp160 (701–720) gp41 (701–720 BH10) VLSIVNRVRQGYSPLSFQTH HIV-1 infection human (A32) Safrit1994a
• Recognized by CTL derived from acute seroconverter
gp160 (702–721) Env (702–721) LSIVNRVRQGYSPLSFQTLT HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
• This peptide was among the 28 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
gp160 (704–712) gp160 (704–712 LAI) IVNRNRQGY human (A*3002) Brander2001, Goulder2001a
• C. Brander notes this is an A*3002 epitope
gp160 (704–712) gp41 IVNRVRQGY HIV-1 infection human (A*3002) Goulder2001a
• Epitope name: IY9 (gp41)
• HLA-A*3002 is very common in African populations, 50% of Zimbabweans express HLA-A30, 44% in African Zulu, so five new HIV epitopes were
characterized that are presented by this HLA molecule
• A rapid method was developed combining ELISPOT with intracellular IFN-γ staining of PBMCs to map optimal epitopes, then HLA presenting molecules
were defined – this method was completed within 48 to 72 hours of receipt of blood
• Two individuals were studied: Subject 199 (HLA A*0201/*3002 B*4402/51 Cw2/5), a Caucasian, and Subject 6007 (HLA A*3002/ B53/*5801 Cw4/7) an
African-Caribbean
• In both HLA-A*3002 individuals the response to RSLYNTVATLY was dominant
• In subject 199 four additional A*3002 epitopes were identified
• Three quantitative assays, ELISPOT, precursor frequency and chromium release, confirmed a hierarchy of response: RY11 (p17) > KY9 (gp41) > KY9
(RT-53) > IY9 (gp41)
gp160 (742–761) Env (742–761) RDRSIRLVSGFLALAWDDLR HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
• This peptide was among the 28 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
gp160 (747–755) gp41 (747–755) RLVNGSLAL HIV-1 infection human (A2) Parker1992
• Studied in the context of HLA-A2 peptide binding
gp160 (747–755) gp41 (741–749 CM243
subtype CRF01)
RLVSGFLAL HIV-1 infection human (A2) Sriwanthana2001
• Epitope name: E747-755
• This was a study of HIV-1 exposed persistently seronegative (HEPS) female sex workers in Chiang Mai, northern Thailand
• HLA-A11 is very common in this population, and was enriched among the HEPS sexworkers – weak CTL responses were detected in 4/7 HEPS women,
and CTL responses were found in 8/8 HIV+ controls, and 0/9 HIV- women that were not exposed
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• This epitope was reactive in HIV+ control study subject 144 who carried HLA-A2
gp160 (747–755) gp41 (741–749 CM243
subtype CRF01)
RLVSGFLAL HIV-1 infection human (A2) Bond2001
• More than half of a cohort of HIV+ female sex workers (FSW) from Northern Thailand were HLA-A11 positive, and this study concentrated on A11
epitopes in this group, although E clade versions of previously defined B-clade A2 and A24 epitopes were also tested.
• 2/4 tested FSWs recognized the E clade version of this epitope, which differs from the previously defined B clade version by two amino acids,
RLVNGSLAL
• This epitope was somewhat conserved 4/8 subtypes: CRF01 (E), B, C, and G
gp160 (754–768) gp41 ALIWEDLRSLCLFSY HIV-1 infection human (B55) Jin1998b
• Progressive HIV-1 infection and CD4 decline was associated decreased the IL-2-expandable HIV-1 CTL response in 10 asymptomatic HIV-infected
patients – this observation may be partially due to a reduction and impaired function of T helper cells, CTL exhaustion and APC dysfunction
• Continued presence of HIV-1 specific memory cells (CTLp) was observed in three patients, one to GIWGCSGKLICTTAV, one to ALIWEDLRSLCLFSY,
and one to PIPIHYCAPAGFAILKCNNK
gp160 (767–775) gp41 (766–774 SF2) SYRRLRDLL HIV-1 infection human (A*2402) Ikeda-Moore1997
• Defined using reverse immunogenetics – 59 HLA-A*2402 binding peptides were predicted by searching for A*2402 anchors in HIV proteins (Tyr at 2, and
Phe, Leu or Ile at the C term) – 53 of the 59 peptides bound A*2402
• This peptide induced CTL in 1/4 HIV-1+ people tested
• SYRRLRDLL bound to A*2402 moderately, the epitope can be processed in a vaccinia construct and presented – two specific CTL clones were obtained
gp160 (767–780) gp41 (606–614 LAI) SYHRLRDLLLIVTR HIV-1 infection human (A31) Hammond1995
• Peptide only processed by a TAP-1/2-dependent pathway
• CTL from an acute seroconverter
gp160 (769–777) gp41 (769–777 BH10) HRLRDLLLI HIV-1 infection human Safrit1994a
• Recognized by CTL derived from acute seroconverter
gp160 (770–778) Env (679–777) RLRDLLLIV HIV-1 infection human (A*0201) Kmieciak1998a
• CTL responses in six patients to four Env epitopes were studied: D2: LLNATAIAV, 5.3: RLRDLLLIV, D1: KLTPLCVTL, and 4.3: QMHEDIISL – all
have A2 anchor residues
• The C terminal epitopes (D2 and 5.3) were highly variable and the variability was considered responsible for limited CTL response, while D1 and 4.3,
N-terminal epitopes, were much more conserved and gave evidence of high levels of CTL response in vitro
• Peptides 5.3 and D2 bound to HLA A*0201 with low affinity.
gp160 (770–780) gp41 (775–785) RLRDLLLIVTR HIV-1 infection human Betts2000
• Only 4/11 HLA-A2+ HIV+ individuals had CTL that reacted to SLYNTVATL, calling into question whether it is immunodominant
• 95 optimally-defined peptides from this database were used to screen for INFγ responses to other epitopes
• 1/11 of the HLA A2+ was HLA A*0201, A31, B8, B51 and responded to this epitope that has been previously noted to be HLA A3.1, as well as seven
others
gp160 (770–780) gp41 (768–778 NL43) RLRDLLLIVTR HIV-1 infection human (A*0301) Takahashi1991
• CD8+ T cell clone
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gp160 (770–780) gp41 (775–785 LAI) RLRDLLLIVTR HIV-1 infection human (A*0301) Brander2001
• C. Brander notes this is an A*0301 epitope
gp160 (770–780) gp41 (770–780 BH10) RLRDLLLIVTR HIV-1 infection human (A*3101) Safrit1994a, Safrit1994b
• Recognized by CTL derived from acute seroconverter
• C. Brander notes that this is an A*3101 epitope in the 1999 database
gp160 (770–780) gp160 (770–780 LAI) RLRDLLLIVTR human (A*3101) Brander2001
• C. Brander notes this is an A*3002 epitope
gp160 (770–780) gp41 (768–778 NL43) RLRDLLLIVTR HIV-1 infection human (A3) Cao1997a
• The consensus peptide of clade B is RLRDLLLIVTR
• The consensus peptide of clades A, C and E is RLRDFILIVTR and it is less reactive
• The consensus peptide of clade D is SLRDLLLIVTR and it is less reactive
gp160 (770–780) gp41 (775–785) RLRDLLLIVTR HIV-1 infection, HIV-1 exposed
seronegative
human (A3) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
gp160 (770–780) gp41 (770–780) RLRDLLLIVTR HIV-1 infection human (A3) Day2001
• The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7 was
studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
• 2 to 17 epitopes were recognized in a given individual, A2-restricted CTL response tended to be narrow and never dominated the response, and 25/27
epitopes were targeted by at least one person
• All patients recognized at least 1 A3 epitope, up to 8 A3 epitopes, but none was clearly dominant
gp160 (770–780) Nef (73–82) RLRDLLLIVTR HIV-1 infection human (A3) Day2001
• The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7 was
studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
• 2 to 17 epitopes were recognized in a given individual, A2-restricted CTL response tended to be narrow and never dominated the response, and 25/27
epitopes were targeted by at least one person
• All patients recognized at least 1 A3 epitope, up to 8 A3 epitopes, but none was clearly dominant
• In two of the subjects, RLRDLLLIVTR was the dominant epitope
gp160 (770–780) gp41 (769–780) RLRDLLLIVTR HIV-1 infection human (A3) Yu2002a
• Epitope name: A3-RR11
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
• 0/14 HLA-A3 positive individuals had detectable A3-restricted responses to this epitope during acute infection, but only 5/15 of HLA-A3 epitopes tested
were targeted during acute infection. 1/7 individuals began to have detectable responses to this epitope after STI.
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gp160 (770–780) gp41 (770–780) RLRDLLLIVTR HIV-1 infection human (A31) Ferris1999, Hammond1995
• This epitope is processed by a TAP1/2 dependent mechanism
gp160 (777–785) gp41 (782–790 LAI) IVTRIVELL human (A*6802) Brander2001
• C. Brander notes this is an A*6802 epitope
gp160 (781–802) gp120 (788–809) IVELLGRRGWEALKYWWNL-
LQY
HIV-1 infection human Lieberman1995
• HIV-specific CTL lines developed by ex vivo stimulation with peptide
gp160 (781–802) gp41 (788–809 HXB2) IVELLGRRGWEALKYWWNL-
LQY
HIV-1 infection human (B27) Lieberman1992
• CTL epitope defined by T cell line and peptide mapping
gp160 (786–794) gp41 (791–799 LAI) GRRGWEALK HIV-1 infection human (B27) McMichael1994
• Review of HIV CTL epitopes
• Also: J. Liebermann 1992 and pers. comm. J. Liebermann
gp160 (786–795) gp41 (791–800 LAI) GRRGWEALKY HIV-1 infection human (B*2705) Brander2001
• C. Brander notes this is a B*2705 epitope
gp160 (786–795) gp41 (791–800 LAI) GRRGWEALKY HIV-1 infection human (B27) Lieberman1998
• Optimal peptide mapped by titration J. Lieberman, Pers. Comm.
gp160 (786–795) gp41 (786–795) GRRGWEALKY HIV-1 infection human (B27) Day2001
gp160 (794–802) gp160 (794–802 LAI) KYCWNLLQY human (A*3002) Brander2001, Goulder2001a
• C. Brander notes this is an A*3002 epitope
gp160 (794–802) gp41 KYCWNLLQY HIV-1 infection human (A*3002) Goulder2001a
• Epitope name: KY9 (gp41)
• HLA-A*3002 is very common in African populations, 50% of Zimbabweans express HLA-A30, 44% in African Zulu, so five new HIV epitopes were
characterized that are presented by this HLA molecule
• A rapid method was developed combining ELISPOT with intracellular IFN-γ staining of PBMCs to map optimal epitopes, then HLA presenting molecules
were defined – this method was completed within 48 to 72 hours of receipt of blood
• Two individuals were studied: Subject 199 (HLA A*0201/*3002 B*4402/51 Cw2/5), a Caucasian, and Subject 6007 (HLA A*3002/ B53/*5801 Cw4/7) an
African-Caribbean
• In both HLA-A*3002 individuals the response to RSLYNTVATLY was dominant
• In subject 199 four additional A*3002 epitopes were identified
• Three quantitative assays, ELISPOT, precursor frequency and chromium release, confirmed a hierarchy of response: RY11 (p17) > KY9 (gp41) > KY9
(RT-53) > IY9 (gp41)
gp160 (794–814) gp41 (SF2) KYCWNLLQYWSQELKNSAV-
SL
HIV-1 infection human Altfeld2000b
• This epitope was mapped by ELISPOT in a study identifying new HLA-B60 epitopes, and was one of the epitopes presented by another HLA molecule in
an HLA-B60 individual
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• The response to the peptide was CD8 dependent, but the HLA presenting molecule and optimal epitope were not determined
gp160 (795–816) gp41 (802–823 HXB2) YWWNLLQYWSQELKNSAVN-
LLN
HIV-1 infection human Lieberman1992
• CTL epitope defined by T cell line and peptide mapping
gp160 (799–807) Env (800–808 subtype
B)
LLQYWSQEL Vaccine human (A2.1) Kundu1998a
Vaccine Vector/Type: recombinant protein Strain: MN HIV component: gp160
• Ten HIV-1+ HLA A2 asymptomatic individuals were given two courses of HIV-1 MN rgp160 vaccine over a 2 year period
• Two hundred and fifty three HIV-1 peptides of 9 or 10 aa possessing the HLA-A2.1 binding motif (Leu at position 2, Val at the C terminus) were identified
in gp160, of which 25 had a high or intermediate binding affinity
• Eleven peptides were studied that had high HLA-A2 binding affinity – a CTL response was detected to 9/11 peptides in at least 1 individual
• CTL responses after reimmunization may include recall responses – only individuals with vaccine cross-reactive sequences prior to vaccination showed
detectable CTL responses
gp160 (805–814) Env (799–813 BH10,
LAI)
QELKNSAVSL HIV-1 infection human Maksiutov2002
• This study employs an antigenic similarity matrix to compare HIV-1 antigenic determinants with human proteins.
• This CTL epitope (the HIV-1 LAI fragment with high similarity to a human protein overlapping this epitope is LLQYWSQELKNSAVS) has similarity with
the complement component C6 fragment LTQFSSEELKNSGLT.
• This CTL epitope (the HIV-1 LAI fragment with high similarity to a human protein overlapping this epitope is NSAVSLLNATAIAVA) also has similarity
with the human INT-2 proto-oncogene protein precursor (fibroblast growth factor-3) fragment NSAYSILEITAVEVG.
gp160 (805–814) gp41 (810–819 LAI) QELKNSAVSL human (B*4001) Brander2001
• C. Brander notes this is a B*4001,B60 epitope
gp160 (805–814) gp41 (SF2) QELKNSAVSL HIV-1 infection human (B60(B*4001)) Altfeld2000b
• This epitope was mapped by ELISPOT in a study identifying new HLA-B60 epitopes
• B60 is present in 10-20% of the Caucasoid and very common in Asian populations
gp160 (805–814) gp41 (805–814) QELKNSAVSL HIV-1 infection human (B60/B61) Day2001
• No immunodominant responses were detected to five B61-restricted epitopes tested
• All five B60-restricted epitopes were reactive in another subject, and the B60-restricted responses together contributed over one-third of the total CTL
response
gp160 (813–822) gp41 (814–823 LAI) SLLNATDIAV Vaccine human (A*0201) Dupuis1995
Vaccine Vector/Type: recombinant protein Strain: MN HIV component: gp160
• Of two CTL clones, one reacted only with 815-823, the other with 814-823 and 815-823
• Noted to be A*0201 in Brander et al., 1999 database
gp160 (813–822) gp41 (818–827 LAI) SLLNATDIAV Vaccine human (A*0201) Brander2001
Vaccine Vector/Type: recombinant protein Strain: MN HIV component: gp160
• C. Brander notes this is an A*0201 epitope
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gp160 (813–822) gp41 (814–823) SLLNATDIAV HIV-1 infection human (A2) Kundu1998b
• Allogeneic dendritic cells (DCs) were obtained from HLA-identical siblings, pulsed with rgp160 MN or A2-restricted HIV-1 epitope peptides, and infused
monthly into six HIV-infected patients
• 1/6 showed increased env-specific CTL and increased lymphoproliferative responses, 2/6 showed increase only in proliferative responses, and 3/6 showed
no change – pulsed DCs were well tolerated
• SLLNATDIAV is a conserved HLA-A2 epitope included in this study – 4/6 patients had this sequence as their HIV direct sequence, and 3 of these had a
detectable CTL response – the other two had either the sequence SLFNAIDIAV or SLLNTTDIVV and no detectable CTL response
• CTL demonstrated against peptide-coated target, epitope is naturally processed and enhancible with vaccine
gp160 (813–822) gp41 (818–827) SLLNATDIAV HIV-1 infection human (A2) Betts2000
• Only 4/11 HLA-A2+ HIV+ individuals had CTL that reacted to SLYNTVATL, calling into question whether it is immunodominant
• 95 optimally-defined peptides from this database were used to screen for INFγ responses to other epitopes
• 1/11 of the A2+ individuals that didn’t respond to SLYNTVATL reacted with seven other epitopes, including this epitope
gp160 (813–822) gp41 (SF2) SLLNATAIAV HIV-1 infection human (A2) Goulder2001a
• Epitope name: SV10
• Dominant CTL epitope in acute infection of patient AC13– response to this epitope corresponded to reduction of initial viremia
• Several other subdominant CTL epitopes were identified in the acute phase, but a response to SL9, SLYNTVATL, was not evident until 18 months
post-presentation
gp160 (813–822) gp41 (77–85 SF2) SLLNATDIAV HIV-1 infection human (A2) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-A2+ individuals that had a CTL response to this epitope broken down by group: 1/10 group 1, 2/6 group 2, and 1/4 group 3
gp160 (813–822) gp41 (814–823 CM243
subtype CRF01)
SLLNATAIAV HIV-1 infection human (A2) Sriwanthana2001
• Epitope name: E813-82
• This was a study of HIV-1 exposed persistently seronegative (HEPS) female sex workers in Chiang Mai, northern Thailand
• HLA-A11 is very common in this population, and was enriched among the HEPS sexworkers – weak CTL responses were detected in 4/7 HEPS women,
and CTL responses were found in 8/8 HIV+ controls, and 0/9 HIV- women that were not exposed
• This epitope was reactive in HIV+ control study subjects 125 and 144 who carried HLA-A2
gp160 (813–822) gp41 (814–823 CM243
subtype CRF01)
SLLNATAIAV HIV-1 infection human (A2) Bond2001
• More than half of a cohort of HIV+ female sex workers (FSW) from Northern Thailand were HLA-A11 positive, and this study concentrated on A11
epitopes in this group, although E clade versions of previously defined B-clade A2 and A24 epitopes were also tested.
• 1/4 tested FSWs recognized the E clade version of this epitope, which differs from the previously defined B clade version by one amino acid, SLLNATDIAV
• This epitope was somewhat conserved 4/8 subtypes: CRF01 (E), B, D, and F
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gp160 (813–822) gp41 (813–822) SLLNATDIAV HIV-1 infection human (A2) Day2001
• The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7 was
studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
• 2 to 17 epitopes were recognized in a given individual, A2-restricted CTL response tended to be narrow and never dominated the response, and 25/27
epitopes were targeted by at least one person
gp160 (813–822) gp41 (813–822 IIIB) SLLNATAIAV Vaccine murine (A2) Kiszka2002
Vaccine Vector/Type: DNA, DNA with recombinant protein boost Strain: IIIB HIV component: gp160, gp160deltaV3 Adjuvant: IL-12 (IL-12p35 and
IL-12p40)
• Epitope name: D2
• Transgenic mice expressing a HLA-A2/Kb chimeric protein were vaccinated with a full length gp160 or with gp160deltaV3, with the V3 loop deleted.
Mice given gp160deltaV3 had a broader immune response than those given gp160, with increased responses to conserved HLA-A2 epitopes in the C1
region of gp120, KLTPLCVTL, and the C-term region of gp41, SLLNATAIAV.
• Greater resistance was conferred by the gp160deltaV3 than the gp160 vaccine to a challenge of vaccinia expressing heterologous gp160 from primary
isolates (VI-06 and 89.6), and the resistance was conferred by CD8+ T-cells.
gp160 (813–822) Env (814–823 subtype
B)
SLLNATDIAV Vaccine human (A2.1) Kundu1998a
Vaccine Vector/Type: recombinant protein Strain: MN HIV component: gp160
• Ten HIV-1+ HLA A2 asymptomatic individuals were given two courses of HIV-1 MN rgp160 vaccine over a 2 year period
• Two hundred and fifty three HIV-1 peptides of 9 or 10 aa possessing the HLA-A2.1 binding motif (Leu at position 2, Val at the C terminus) were identified
in gp160, of which 25 had a high or intermediate binding affinity
• Eleven peptides were studied that had high HLA-A2 binding affinity – a CTL response was detected to 9/11 peptides in at least 1 individual
• CTL responses after reimmunization may include recall responses – only individuals with vaccine cross-reactive sequences prior to vaccination showed
detectable CTL responses
• CTL to overlapping peptides in this region gave a positive response in the greatest number of patients
• ALTERNATIVE EPITOPES: LLNATDIAV and LLNATDIAVA – CTL were induced by vaccine in those that had the sequence SLLNATAIAVA in their
own infection, but not in those with: NLLNTIAIAVA or NLFNTTAIAVA or SLLNATAITVA
gp160 (813–822) gp41 (814–823 LAI) SLLNATDIAV Vaccine murine (A2.1) Peter2001
Vaccine Vector/Type: peptide Strain: LAI Adjuvant: P30, incomplete Freund’s adjuvant (IFA), Montanide (ISA 720), PLG-microparticle
• Epitope name: LR27
• The stability of peptide binding to HLA-A2.1 was determined for six HLA-A2.1 peptides included in this vaccine study – ILKEPVHGV (RT),
SLYNTVATL (p17), SLLNATDIAV (gp41) and LLWKGEGAV (RT) all bound with high affinity comparable to a influenza epitope reference
(GILGFVFTL), while RGPGRAFVTI and VIYQYMDDL bound with a lower affinity (relative binding activity = 0.01).
• The four high-affinity peptides formed stable complexes with half-lives ranging between 8 and 32 hours, while the low affinity peptides had half lives of
less than an hour.
• HLA-A2.1 transgenic mice were immunized with the six HIV-1 peptides and P30, as a universal T-helper epitope, with IFA or Montanide or microspheres
as adjuvants.
• All peptides except VIYQYMDDL induced a stong CTL response in Cr-release assays - stronger responses were observed when peptides were delivered
alone, indicating immunodominance when the combination was used.
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gp160 (813–822) gp41 (814–823 LAI) SLLNATDIAV Vaccine murine (A2.1) Peter2002
Vaccine Vector/Type: peptide Strain: LAI Adjuvant: P30, incomplete Freund’s adjuvant (IFA), IL-12
• Epitope name: LR27
• When HIV-1 peptides were used to vaccinate HLA-A2.1 transgenic A2-Kb mice, strong responses to five peptides were observed when the peptides were
given individually, but immunodominance limited the response to some of the peptides when they were given in combination [Peter2001]. IL-12 can
counteract immunodominance in BALB/c mice, so it was given with the multiple epitope vaccination, and was instead found to specifically eliminate the
HLA-A2.1-epitope CTL responses, but not Kb CTL responses. This was possibly a consequence of transient depletion of T-cells, B cells and macropahges
in the spleen.
gp160 (813–822) gp41 SLLNATDIAV HIV-1 infection human (A68) Altfeld2001c
• Epitope name: gp41 SV10
• HIV was scanned for all peptides which carried the A2-supermotif pattern conserved in more than 50% of B clade sequences – 233 peptides met this
criteria, and 30 of these bound to HLA-A*0201 – 20/30 bound to at least 3/5 of HLA-A2 supertype alleles tested
• Three additional previously described HLA-A2 epitopes were added to the set of 20, and 18/22 chronically infected HLA-A2 individuals had CTL that
recognized at least one of the 23 peptides (median of 2 and maximum of 6), while 6/12 acute infected individuals recognized at least 1 (median of 1 and
maximum of 2)
• This epitope binds to three HLA-A2 supertype alleles: A*6802 (highest affinity), A*0202 and A*0203 (but not A*0201 and not A*0206)
• This epitope did not elicit an ELISPOT response in 22 chronic HIV HLA-A2 infections, but elicited a strong response in 1/12 acute HLA-A2 infections –
this individual, AC13, was HLA A*0201/68 B44/14 and also had a strong response to HLA-A2 vpr epitope AIIRILQQL
gp160 (814–822) Env (815–823) LLNATAIAV HIV-1 infection human (A*0201) Kmieciak1998a
• CTL responses in six patients to four Env epitopes were studied: D2: LLNATAIAV, 5.3: RLRDLLLIV, D1: KLTPLCVTL, and 4.3: QMHEDIISL—all
have A2 anchor residues.
• The C terminal epitopes (D2 and 5.3) were highly variable and the variability was considered responsible for limited CTL response, while D1 and 4.3,
N-terminal epitopes, were much more conserved and gave evidence of high levels of CTL response in vitro.
• Peptides 5.3 and D2 bound to HLA A*0201 with low affinity and were variable, particularly D2.
• Substitutions in peptide D2: llnTIaiav did not abrogate the response, but diminished it.
• In a longitudinal study, the CTL response to the variable D2 epitope diminished over time, while the response to the conserved epitope D1 stayed higher.
gp160 (814–822) gp41 (815–823 LAI) LLNATDIAV Vaccine human (A2) Dupuis1995
Vaccine Vector/Type: recombinant protein Strain: MN HIV component: gp160
• Of two CTL clones, one reacted only with 815-823, the other with 814-823 and 815-823
gp160 (814–822) Env (815–823) LLNATAIAV HIV-1 infection human (A2) Kmieciak1998b
• Increased CTL response to cells expressing a VV construct ∆V3 mutant compared with a full-length env gene product
gp160 (822–832) gp41 (SF2) VAEGTDRVIEI HIV-1 infection human Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
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• Number of individuals that had a CTL response to this epitope (HLA presenting molecule uncertain) broken down by group: 0 group 1, 1 group 2, and 0
group 3
gp160 (827–841) gp41 (834–848 IIIB) DRVIEVVQGAYRAIR HIV-1 exposed seronegative human Pinto1995
• CTL and T helper cell reactivity in healthcare workers exposed to HIV
gp160 (827–841) gp41 (834–848 IIIB) DRVIEVVQGAYRAIR HIV-1 infection human (A2) Clerici1991a
• Helper and cytotoxic T cells can be stimulated by this peptide (Th4)
gp160 (827–841) gp41 (834–848 IIIB) DRVIEVVQGAYRAIR Vaccine murine (H-2d,p,u,q) Shirai1992
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: gp160
• In a murine system multiple class I molecules can present to CTL
gp160 (827–841) gp41 (834–848 IIIB) DRVIEVVQGAYRAIR Vaccine murine (H-2d,p,u,q) Shirai1996b
Vaccine Vector/Type: vaccinia HIV component: gp160
• Multiple murine MHC can cross-present this epitope (HP53), and P18 RIQRGPGRAFVTIGK, to specific CTL
gp160 (828–836) gp41 (829–837 LAI) RVIEVLQRA Vaccine human (A2) Dupuis1995
Vaccine Vector/Type: recombinant protein Strain: MN HIV component: gp160
• CTL from HLA-A2 positive subject react with this peptide
gp160 (828–836) gp41 (829–837 CM243
subtype CRF01)
KVIEVAQGA HIV-1 infection human (A2) Bond2001
• More than half of a cohort of HIV+ female sex workers (FSW) from Northern Thailand were HLA-A11 positive, and this study concentrated on A11
epitopes in this group, although E clade versions of previously defined B-clade A2 and A24 epitopes were also tested.
• 1/4 tested FSWs recognized the E clade version of this epitope, which differs from the previously defined B clade version by three amino acids, RvievLqRa
• This epitope was only conserved in CRF01 (subtype E), and identities were rare
gp160 (828–836) Env (829–837 subtype
B)
RVIEVLQRA Vaccine human (A2.1) Kundu1998a
Vaccine Vector/Type: recombinant protein Strain: MN HIV component: gp160
• Ten HIV-1+ HLA A2 asymptomatic individuals were given two courses of HIV-1 MN rgp160 vaccine over a 2 year period
• Two hundred and fifty three HIV-1 peptides of 9 or 10 aa possessing the HLA-A2.1 binding motif (Leu at position 2, Val at the C terminus) were identified
in gp160, of which 25 had a high or intermediate binding affinity
• Eleven peptides were studied that had high HLA-A2 binding affinity – a CTL response was detected to 9/11 peptides in at least 1 individual
• CTL responses after reimmunization may include recall responses – individuals with vaccine cross-reactive sequences prior to vaccination showed
detectable CTL responses
gp160 (830–854) gp41 (831–853) IEVVQGAYRAIIRHIPRRI-
RQGLERI
HIV-1 infection human Price1995
• Study of cytokines released by HIV-1 specific activated CTL
gp160 (831–838) Env (830–837) EVAQRAYR HIV-1 infection human (A*3303) Hossain2001, Takiguchi2000
• HLA-A33 a very common allele in Asia, with HLA-A*3303 the most common among the Japanese. New A*3303 epitopes were defined to better
characterize the immune response in this population.
327
DEC 2002
C
TL
HIV CTL Epitope Tables gp160 CTL Epitopes
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
• The anchor motif for HLA*3303 (A, I, L, V, F, Y in position 2 (F and Y bind most strongly), and R (K is also tolerated) in the C-terminal position) was
used to define 82 potentially reactive peptides in Env; 37/82 peptides bound to A*3303; 3/37 peptides could induce peptide-specific CTL in bulk PBMC
cultures from 1/3 HLA A*3303 positive individuals tested.
• 2/3 peptides that reacted with the bulk culture, EVAQRAYR and VIEVAQRAYR, were overlapping, with one encompassing the other, but EVAQRAYR was
shown to be the one that was reactive with a CTL clone.
• CTL clones were isolated that killed target cells in a concentration dependent manner after pulsing with the EVAQRAYR peptide, that could also kill cells
transfected with env expressed from a vaccinia vector. Bulk cultures were tested from six additional people, and only 2/6 reacted with this peptide, but the
peptide is in a highly variable region.
gp160 (835–843) Env (834–842 SF2) RAYRAILHI HIV-1 infection human (B*5101) Tomiyama1999
• HLA-B27, -B51, and -B57 are associated with slow progression to AIDS, while HLA-B35, -B8, -B24 are associated with a rapid progression to AIDS (Nat.
Med. 2:405, 1996;Lancet 22:1187, 1986;Hum Immunol 22:73, 1988;Hum Immunol 44:156, 1995)
• 15% of Japanese populations carry HLA-B51 while HLA-B27 and -B57 are detected in less than 0.3%
• Of the 172 HIV-1 peptides with HLA-B*5101 anchor residues, 33 bound to HLA-B*5101, seven of these peptides were reactive with CTL from 3 B*5101
positive individuals, and six were properly processed
• This peptide could stimulate CTL from one person, however this CTL clone did not recognize B*5101 positive target cells infected with HIV-1
recombinant vaccinia expressing Env, so it was not confirmed that this peptide was a properly processed epitope
gp160 (837–856) gp120 (844–863) YRAIRHIPRRIRQGLERILL HIV-1 infection human Lieberman1995
• HIV-specific CTL lines developed by ex vivo stimulation with peptide
gp160 (837–856) gp120 (844–863 SF2) YRAIRHIPRRIRQGLERILL HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Eleven subjects had CTL that could recognize vaccinia-expressed LAI gp160
• One of these 11 had CTL response to this peptide
• The responding subject was HLA-A2, A26, B7, and B38
gp160 (837–856) gp120 (844–863 LAI) YRAIRHIPRRIRQGLERILL HIV-1 infection human (B35) Shankar1996
gp160 (837–856) gp41 (844–863 HXB2) YRAIRHIPRRIRQGLERILL HIV-1 infection human (B8) Lieberman1992
• CTL epitope defined by T cell line and peptide mapping
gp160 (842–856) gp41 (SF2) HIPRRIRQGLERALL HIV-1 infection human Altfeld2001a
• HIV+ individual AC-06 was tested for reactive overlapping peptides spanning all HIV-1 proteins in an ELISPOT and was found to react with 12 peptides
from 7 proteins, suggesting that the breadth of CTL responses are underestimated if accessory proteins are not included in the study
• The only Env peptide recognized was gp41 HIPRRIRQGLERALL
gp160 (843–851) gp41 (848–856 LAI) IPRRIRQGL human (B*0702) Brander2001
• C. Brander notes this is a B*0702 epitope
gp160 (843–851) gp41 (848–856 LAI) IPRRIRQGL human (B7) Brander1995b
• Epitope defined in the context of the Pediatric AIDS Foundation ARIEL Project, a mother-infant HIV transmission study
gp160 (843–851) IPRRIRQGL HIV-1 infection human (B7) Soudeyns1999
• Following primary infection, progressive diversification and accumulation of mutations of HIV-env nucleotide sequences was observed, focused in V2 in
one individual and in V8 in another
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• The patient with the V2 diversification showed only transient CTL against Env and Nef
• The patient with the V8 diversification had an immunodominant CTL response to V8 epitope IPRRIRQGL, and multiple escape variants emerged within a
year: ipTrirqgl and ipTrirqgF, which abrogated the CT response in vitro, and also iprrLqgl and iprrirqDl which gave diminished responses.
gp160 (843–851) gp41 (848–856 LAI) IPRRIRQGL HIV-1 infection human (B7) Cao1997a
• The consensus peptide of clades A, B, D, and F is IPRRIRQGL
• The consensus peptide of clade C is iprrirqgF, and it is equally reactive.
gp160 (843–851) gp41 (848–856 subtype
B)
IPRRIRQGL HIV-1 infection human (B7) Wilson1998b
• The extent of CTL interclade cross-reactivity from CTL isolated from individuals newly infected with B clade virus was studied, and extensive
cross-reactivity was observed
• Two HLA B7 individuals had CTL response to B_LAI, A_92UG037 and C_92BR025 gp160, but were B clade strain MN non-responders – the authors
note that the B7 epitope IPRRIRQGL is conserved between the LAI and clade A and C strains, but that MN has a non-conservative Arg to Thr substitution
at position three that may be contributing to the specificity of the response in the HLA B7 individuals
gp160 (843–851) gp41 (843–851 HXB2) IPRRIRQGL HIV-1 infection human (B7) Hay1999b
• CTL response to IPRRIRQGL was the immunodominant response in a rapid progressor – there was a subdominant response to SPAIFQSSM in Pol, and
interestingly, no response to commonly immunodominant HLA A*0201 epitope SLYNTVATL, although this individual was HLA A*0201
• The individual showed a strong initial CTL response at the time of the initial drop in viremia, but it was quickly lost, although memory cells persisted
• Despite the initial narrow response to two epitopes, no other CTL responses developed
• No HIV-specific lymphoproliferative responses were detected in this patient, and neutralizing antibody response was weak
• Variants were observed in vivo, the most common form of the viral epitope at presentation at 3 months was the only form that did not elicit a CTL response:
iprrTrqgl; the other forms detected were iprrirqgF, iprriLqgF, VprrirqgF and they could elicit a CTL response although the response to iprriLqgF was
reduced
• A second rapid progressor had a detectable CTL response exclusively to this epitope
gp160 (843–851) gp41 (subtype A) IPRRIRQGF HIV-1 infection human (B7) Cao2000
• HIV-1 subtypes A and D dominate the Ugandan epidemic, and a vaccine trial using B clade antigen is underway – this study addresses relative levels of
cross-reactive CTL responses in Ugandans to A, D, and B clade recombinant vaccinia viruses expressing Gag, Env, Pol, RT or Nef from HIV-1 clades A, B,
and D
• Proteins corresponding to the subtype of the infecting strains tended to trigger higher levels of CTL response measured by percent specific lysis, but there
was extensive inter-subtype cross-reactivity with B clade proteins and the co-circulating subtype
• This optimal epitope sequence, recognized by CTL derived from a Ugandan with an A subtype infection, is cross-reactive with subtypes A and B, but not in
subtype D
gp160 (843–851) gp41 IPRRIRQGL HIV-1 infection human (B7) Islam2001
• Subject 053i was followed longitudinally from acute infection through death, and had rapid progression to AIDS
• This individual had a dominant response to IPRRIRQGL with strong in vivo activated responses and in vitro stimulated memory responses and a
subdominant response to SPAIFQSSM – during the course of disease progression (4 Years), the functional CTL responses were lost and no sequence
variation occurred with in both epitopes
• At 3 months post-presentation, seven IPRRIRQGL CTL clones were obtained, five used the T-cell receptor Vbeta 6S1 and Jbeta 2.7 and had the CDR3
WAASS, two used Vbeta16S1, ERSPPGD, Jbeta 2.7 and one CTL clone isolated at 39 months was Vbeta 14S1, CR3 PTAAG, and Jbeta 2.1 – all of these
clones persisted over the course of the infection, even to time of death, despite the loss of CTL functional responses over time
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gp160 (843–851) gp41 (843–851 SF2) IPRRIRQGL HIV-1 infection human (B7) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B7+ individuals that had a CTL response to this epitope broken down by group: 2/4 group 1, 1/3 group 2, and 1/1 group 3
gp160 (843–851) gp41 (848–856) IPRRIRQGL HIV-1 infection, HIV-1 exposed
seronegative
human (B7) Kaul2001a
• IPRRIRQGL cross-reacts with clades A, B and D
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with
reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected
women
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure
• Among HLA-B7 women, 2/5 HEPS and 5/6 HIV-1 infected women recognized this epitope
• The dominant response to this HLA allele was to this epitope in 2 of the 5/6 HIV-1 infected women that responded to the epitope, but in neither of the 2/5
HEPS cases
• Subject ML 1203 started with CTL responses to A*6802 DTVLEDINL and to B7 FPVTPQVPLR prior to seroconversion, and upon seroconversion
acquired additional responses to A*6802 ETAYFILKL which became dominant, B7 TPGPGV/IRYPL, B7 IPRRIRQGL, and B7 SPRTLNAWV
gp160 (843–851) gp41 (843–851) IPRRIRQGL HIV-1 infection human (B7) Day2001
• The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7 was
studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
• 2 to 17 epitopes were recognized in a given individual, A2-restricted CTL response tended to be narrow and never dominated the response, and 25/27
epitopes were targeted by at least one person
• Subjects with chronic HIV-1 infection recognized between 2-8 out of 11 B7-restricted epitopes
• An acute seroconvertor homozygous for the B7 allele recognized five B7-restricted epitopes
• The other acute seroconvertor failed to recognize any of the 11 B7-restricted epitopes tested
• The B7-restricted CTL response was highly variable and there was no clearly dominant epitope
gp160 (843–851) gp41 (SF2) IPRRIRQGL HIV-1 infection human (B7) Altfeld2000b
• This epitope was mapped by ELISPOT in a study identifying new HLA-B60 epitopes, and was one of the epitopes presented by another HLA molecule in
an HLA-B60 individual
gp160 (843–851) gp41 (842–852) IPRRIRQGL HIV-1 infection human (B7) Yu2002a
• Epitope name: B7-IL9
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
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• Only two epitopes were detected during acute infection in patient AC-06, B7 restricted gp41 epitope IPRRIRQGL and Gag GPGHKARVL. GPGHKARVL
was the first targeted peptide, and remained immunodominant through the 34 month study period.
• 6/11 HLA-B7 individuals had detectable B7-restricted responses to this epitope during acute infection – 10/15 of HLA-B7 epitopes tested were targeted by
at least one person during acute infection. 2/4 individuals had detectable responses to this epitope after STI.
gp160 (843–851) gp41 IPRRIRQGL HIV-1 infection human (B7) Altfeld2002
• Epitope name: B7-IL9(gp41)
• Peripheral blood (PB) and lymph node (LN) CD8+ T-cell responses were compared in 15 asymptomatic HIV-1 infected patients using all known optimal
CTL epitopes (http://hiv-web.lanl.gov/content/hiv-db/REVIEWS/brander2001.html) for each person’s class I HLA alleles.
• 60 epitope responses were detected in both PB and LN samples of the 15 patients, and an additional 8 responses were detected only in LN. The total
magnitude of the response was similar in LN and PB, but the percentage of CD8+ T cells in the LN is lower so the number of HIV-specific cells per million
CD8+ T-cells is higher in the LN.
• 1 year post-HAART treatment in five patients studied, the magnitude of the CD8 T-cell response was decreased in both LN and PB, but more dramatically
in PB, and 13/25 epitope responses in the PB became undetectable, in contrast to 5/26 in the LN.
• Treatment interruption following HAART induced resulted in increased viremia accompanied by the restoration of the detection of 13 epitopes that had
become undetectable in the PB, and the addition of 9 novel epitope responses.
• Breakdowns of epitope responses were shown for 4 individuals. Patient C displayed the greatest response to B27-KK10(p24), and in decreasing order also
responded to A24-RW8(Nef), B7-IL9(gp41), A24-RL9(gp41), A24-YL8(gp41), and B7-TM9(Nef).
gp160 (845–856) gp41 (852–863 HXB2) RRIRQGLERILL HIV-1 infection human (A30, B8) Lieberman1992
• CTL epitope defined by T cell line and peptide mapping
gp160 (845–856) gp41 (852–863 LAI) RRIRQGLERILL HIV-1 infection human (B7) Shankar1996
gp160 (846–854) RIRQGLERA HIV-1 infection human (A*0205) Sabbaj2002b
• Epitope name: Env-RA9
• This study monitored epitope responses in HIV-1 infected minority women living in the United States
• 24 epitopes were described – 8 were novel, 8 used new restricting elements but were previously defined epitopes, and 8 were previously described
• Serial peptide truncations were used to define optimal epitopes for CTL cell lines isolated from 12 individuals, assayed by a Cr-release
• This epitope was newly defined in this study
• Patient 00RCH28 was African American, not on HAART, had a viral load of 5900 and CD4 count of 889, and she also recognized IN(219-227),
KIQNFRVYY, A*3002
• Among HIV+ individuals who carried HLA A02, 6/21 (29%) recognized this epitope
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Env gp160 (LAI, MN) Vaccine human Belshe1998
Vaccine Vector/Type: canarypox prime with rgp120 boost Strain: MN, LAI, SF2 HIV component: gp120, gp41, Gag, Protease
• The live canarypox vaccine ALVAC-HIV(vCP205) carrying MN gp120, LAI gp41, Gag and Protease, and boosted with SF-2 rpg120, was given to HIV-1
seronegative volunteers – HIV-specific Env or Gag CD8+ CTL were detected in 64% of the volunteers
Env gp160 (LAV) HIV-1 infection human Zheng1999
• Protein delivery (gp160 LAV, p66 LAV, and p24 NY5) to human dendritic cells (DC) with liposomes provides enhanced memory CTL response relative to
delivery of protein alone
• Chloroquine administration enhanced epitope presentation, and brefeldin A and peptide aldehyde inhibitors inhibited antigen presentation, suggesting
epitopes were processed by classical proteasome pathway
Env Env (IIIB) HIV-1 infection human Wasik2000
• HIV+ infants that progressed rapidly to AIDS had lower Th1 responses and decreased production of IL-2, as well as beta-chemokines, relative to other
HIV+ infants
• No HIV+ infants had no demonstrable CTL at birth, but Th1 responses accompanied by CTL responses developed in children with slowly progressive
disease, and not in rapid progressors
• CTLp frequencies were determined by limiting dilution using autologous B cells infected with vaccina/HIV constructs
Env gp120 HIV-1 infection human Soudeyns2000
• Analysis of T cell receptor beta chain variable region repertoire indicates that antiretroviral therapy (ART) and highly active antiretroviral therapy
(HAART) decrease global CD8 T cell oligoclonality during primary HIV infection
• A sharp decline in HIV-1 gp120-specific CTL clones was observed in HAART-treated subjects
Env Env (LAI, MN) Vaccine human Salmon-Ceron1999
Vaccine Vector/Type: canarypox Strain: LAI, MN HIV component: gp41, Gag, Pro, V3
• The vaccine used was a rec canarypox with HIV-1 gp120 MN, tm/gag/protease LAI (vCP205), alone or with p24E-V3 MN synthetic peptide (CLTB-36))
• Twenty HIV negative subjects were vaccinated in phase I trial with combinations of vCP205 and CLTB-36
• Immunization with vCP205 induced HIV-1-specific ABs to gp120, V3, and p24 antigens, and CTL immune responses against vCP205 were detected after
the fourth immunization in 33% of the subjects against Env, Gag and Pol, but the CLTB-36 peptide did not produce AB or CTL immune responses against
p24 or gp160
Env Env HIV-1 infection human Gamberg1999
• 13/13 subjects with advanced HIV infections showed CD8 T cell proliferation and differentiation of CTL in vitro, and six individuals showed HIV-specific
responses to Gag, Pol, Env or Nef antigens
• Data suggests that the functional and genetic integrity of the CD8 T cell repertoire (TCR betaV gene intrafamily genetic diversity) remains intact through
advanced HIV infection, although HIV-specific CTL activity decreases
Env Env (LAI, MN) Vaccine human Gorse1999b
Vaccine Vector/Type: canarypox prime with rgp120 boost Strain: LAI and SF2 HIV component: Env, Gag, Pro, Nef, Pro
• The vaccine used was rec canarypox expressing HIV-1 env, gag, pol, nef and protease (vCP300) with or without administration of HIV-1 SF-2 rgp120
• In vitro inducible CTL activity against HIV-1 Env, Gag, Pol, and Nef antigens was observed in 79% (15 of 19) of vaccine recipients
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• The combination of vCP300 and vP1291 together resulted in an overall increase in CTL induction and detection sensitivity
Env Env (LAI) HIV-1 infection human Buseyne1998b
• In infants with positive CTL responses, most responses showed cross-clade reactivity with somewhat diminished recognition of epitopes from different
subtypes
Env gp120 (IIIB) Vaccine Rhesus macaque Shiver1997
Vaccine Vector/Type: DNA Strain: IIIB HIV component: gp120, gp160
• DNA vaccinations of Rhesus monkeys with a gp120 or gp160 DNA vaccine elicited a strong CD8 cytotoxic T cell response
Env gp160 HIV-1 infection Macaca nemestrina Kent1997b
• Macaques can be infected with HIV, and clear the infection within 6 months, so it is of interest to examine their initial immune response
• A strong CTL response against env, pol and gag antigens can be detected
• The CTL response peaked by 4 weeks and declined dramatically by 8 weeks
• The response in the lymph nodes and peripheral blood was comparable
Env gp160 Vaccine murine Kim1997c
Vaccine Vector/Type: DNA HIV component: Gag, Pol, Vif, Env Adjuvant: B7, IL-12
• A gag/pol, vif or env DNA vaccine, when delivered in conjunction with the plasmid encoding the co-stimulatory molecules B7 and IL-12, gave a dramatic
increase in both the cytotoxic and proliferative responses in mice
• When IL-12 was present, CTL response could be detected even without in vitro stimulation
Env gp160 Vaccine murine Kim1997d
Vaccine Vector/Type: DNA HIV component: Gag, Pol, Vif, Env Adjuvant: B7, IL-12
• A gag/pol or env DNA vaccine, when delivered in conjunction with the plasmid encoding the co-stimulatory molecules CD86, gave a dramatic increase in
both the cytotoxic and proliferative responses in mice
• When CD86 was present, CTL response could be detected even without in vitro stimulation
Env gp120 (HXBc2) Vaccine Rhesus macaque Letvin1997
Vaccine Vector/Type: DNA prime with rgp160 boost Strain: HXBc2 HIV component: gp160
• Vaccination of Macaques mulatta (Rhesus monkeys) with an HXBc2 env DNA prime and a protein boost elicited a T cell proliferative response, a CTL
response, and type-specific neutralizing antibodies
• Vaccinated animals challenged with SHIV-HXB2 were protected from infection
Env gp120 (MN) Vaccine human MacGregor1998
Vaccine Vector/Type: DNA Strain: MN HIV component: Env, Rev
• An HIV DNA env and rev vaccine given to 15 asymptomatic HIV+ individuals at three different dosages, 30, 100 or 300 ug, was safe
• The CTL response to gp120 was enhanced in 0/4 patients in the 30 µg group, 2/3 patients in the 100 µg group, and 0/3 in the 300 µg group – but the
non-responding patients in the 300 µg group had a strong CTL response prior to vaccination, and the CTL results are inconclusive
Env gp120 (IIIB) HIV-1 infection human Trickett1998
• Twelve HIV-1 infected patients were re-infused with their own lymphocytes, cryopreserved from an earlier time point in the infection
• Improvement in CD4+ and CD8+ T cells was seen in 7/12, and an increase in the CTL response to Env was seen in one patient
Env gp120 (LAI) HIV-1 infection human Legrand1997
• Seventeen recently infected patients were tested for CTL response to HIV proteins Env, Gag, Pol, Rev, Nef, Vif and Tat
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• An early response (within a month following PI) was noted in 87% of the subjects to Gag, 75% to Env, and 50% to Nef
• Early responses to Pol, Rev, Vif and Tat were rare
Env gp120 (LAI) Vaccine human Corey1998
Vaccine Vector/Type: vaccinia prime with rgp120 boost Strain: LAI, SF2, MN HIV component: gp160
• Vaccinia-naive subjects were vaccinated with vaccinia-gp160 LAI and boosted with gp120 SF2, LAI, MN, or 160 MN
• 26/51 had an anti-Env CTL response, and those that were boosted with gp120 tended to produce Abs that neutralized autologous laboratory strains with
some cross-reactivity
Env Env (IIIB) HIV-1 infection human Betts1997
• 6/8 individuals from Zambia infected with C clade virus had CTL that were able to make response to B clade HIV-1 IIIB vaccinia-expressed Gag, Pol and
Env proteins
• A vigorous cross-clade response was not limited to a particular protein, and the level of recognition of different proteins varied among the six patients
Env Env HIV-1 infection human De Maria1997
• CD3+ cells that also carry a natural killer cell receptor (NKR+) can exhibit down regulation of T cell function
• Anti-NKR IgM MAb masked this inhibitory function and increased HIV-1 specific CTL activity in phytohemagglutinin-activated PBMC cultured in the
presence of IL-2 from 3/5 patients, and in one other case anti-NKR MAb brought HIV-1 specific CTL activity to detectable levels
Env Env (IIIB) HIV-1 infection human Betts1999
• This study demonstrated an inverse correlation between HIV Type I plasma viral load and CTL activity directed against HIV-1 Pol, and stronger combined
effects of Pol- and Env-specific CTL, in long-term survivors (LTS) of HIV-1 infection
Env Env (LAI) HIV-1 infection human Buseyne1998a
• This study showed a correlation between strong CTL memory and breadth of response in 7-12 month old infants, and remaining AIDS-free for the first year
of life, higher absolute CD4 and CD8 cells, and lower viral load
Env Env HIV-1 exposed seronegative human Goh1999
• 13/37 exposed uninfected individuals with repeated high-risk sexual exposure had HIV-1 specific CTL against Env, Gag, Pol, or a combination of proteins –
CTL activity was correlated with a CCR5 wildtype genotype
• In this group, the highest CTLp frequencies were directed at Gag, but the most common response was to Env and four individuals had responses to multiple
HIV-1 proteins
Env Env (LAI, MN) Vaccine human Evans1999
Vaccine Vector/Type: canarypox HIV component: gp120, gp41, Gag, Pro, Nef, RT
• A Canarypox vaccine expressing gp120, gp41, Gag, Protease, Nef and Pol CTL epitopes gave rise to CTL that could be detected in 61% of the volunteers –
responses to Gag, Env, Nef and Pol were detected 3-6 months after the last vaccination
Env Env (LAI) Vaccine Macaca nemestrina Kent1998
Vaccine Vector/Type: DNA prime with vaccinia boost Strain: LAI HIV component: Env, Gag
• Priming with an HIV-DNA vaccine and boosting with a vaccinia construct induced greater levels of HIV T cell immunity than either vaccine alone
• The proliferative response to Env and Gag after the DNA vaccination had a mean SI of 1.5-4, but after boosting with rHIV-fowlpox virus, there was a 6-17
fold increase in the mean SI for HIV Gag and Env. The T help response happened despite a fall in antibody titers, suggesting that the Th response was
primarily Th1, not Th2. The CTL response was also enhanced
334
DEC 2002
Env CTL Epitopes HIV CTL Epitope Tables
C
TL
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
Env Env (LAI, MN) Vaccine human Salmon-Ceron1999
Vaccine Vector/Type: canarypox Strain: MN, LAI HIV component: gp120, gp41, Gag, Protease
• A live attenuated canarypox vector expressing MN gp120 and LAI gp41/gag/protease could induce CTL and a lymphoproliferative response in healthy,
uninfected volunteers
Env Env (MN) Vaccine chimpanzee Kim1998
Vaccine Vector/Type: DNA HIV component: Env, Gag, Pol Adjuvant: CD86, CD80
• The study explores the use of co-stimulatory molecules co-expressed with an HIV-1 immunogen in a DNA vaccine to enhance the immune response –
co-expression of CD86, but not CD80, dramatically increased both HIV Env and Gag/Pol specific CTL and Th proliferative responses
Env gp120 (IIIB) Vaccine Rhesus macaque Notka1999
Vaccine Vector/Type: Semliki-Forest Virus with virus-like particle boost Strain: IIIB HIV component: gag, gp120
• Immunization of SIV Pr56Gag-derived VLPs with HIV-1 gp120 anchored on their surface induced Abs, CTL and Th responses to HIV gp120; priming with
the HIV antigens in Semliki-Forest Viruses enhanced the immunological outcome
• Immunized monkeys challenged with SHIV showed a more rapid reduction of plasma viremia
Env Env HIV-1 exposed seronegative human Akridge1999
• This study suggests that HIV-1-resistance in exposed and uninfected individuals is not only associated with the 32-bp deletion in the HIV-1 co-receptor
CCR5, but can be related to HIV-1 specific CTL immunity
Env gp120 (BRU) HIV-1 infection human Aladdin1999
• In vitro measurements of CTL-activity by Cr release assay in bulk culture showed no correlation between CTL-activity (gp120, Gag, Pol and Nef) and
disease progression as measured by viral load, CD4 and time to death
Env gp120 HIV-1 infection human Aladdin2000
• The administration of IL-2 caused an initial enhancement of CD4 cell counts that was accompanied by a decrease in CTL activity – IL-2 therapy did not
reduce initial HIV viral load and viral replication was ultimately enhanced
Env Env HIV-1 infection human Jin1998a
• CTL precursor frequencies were determined in HIV-1 infected pregnant women, and higher CTLp frequencies to Pol and SF2 Nef, but not IIIB Nef, were
found in non-transmitting mothers than in transmitting mothers – Nef CTL responses have been found in uninfected infants born to HIV+ women
(Lazuriaga95);
• Very different CTLp frequencies were observed in env depending on whether IIIB, MN, RF, BK, or SF2 was used as antigen – no association between env
specific CTL and transmission was observed
Env Env Vaccine Zavala2001
Vaccine Vector/Type: vaccinia HIV component: Env
• This paper is a review of vaccinia in the context of vaccines strategies that use different vectors to prime and boost, and emphasizes a unique capacity of
vaccinia to very efficiently boost memory T-cell responses
• HIV is discussed in the context of Gonazalo et al. 1999, where a V3 CTL epitope expressed in reFlu was boosted most effectively by vaccinia expressing
the full Env
Env Env Vaccine Rhesus macaque Akahata2000
Vaccine Vector/Type: DNA Strain: ZF1 HIV component: complete genome
• Rhesus macaques were vaccinated by i.m. injection with naked plasmid DNA carrying an HIV-1 complete genome vaccine, strain ZF1, with a mutated zinc
finger in the nucleocapsid to prevent packaging
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• Env and Gag specific CTL but no antibody responses were induced in 2/4 vaccinated monkeys (MM145 and MM153)
• 2/4 monkeys (MM146 and MM143) produced antibodies against p24 and/or gp160, but no CTL response was detected
• PBMC from all vaccinated monkeys produced IFN-gamma, in response to HIV-1 gp160, indicating a Th response – this response was 5 times higher in
MM145, the animal with the strongest CTL response
• 4 weeks post-challenge with SHIV NM-3rN plasma viral loads of both MM145 and MM153 (with a homologous Env) decreased to near or below the
detection limit
• 6-8 weeks post-challenge with SHIV NM-3rN plasma viral loads of both MM146 and MM143 decreased near or below the detection limit
Env gp120 HIV-1 infection human Young2001
• Addition of recombinant rec human IL12 (rhIL12) to cultures increased HIV-specific lysis of HIV-Gag, Pol and gp120 vaccinia expressed antigens (11/15
tested increased lysis by > 5%) if the culture was derived from HIV+ individuals who had CD4 cells/ul > 500
• 2/10 individuals with <200 CD4 cells/ul, and 3/10 individuals with 200-500 CD4cells/ul, had an increase of >5% upon treatment of the culture with rhIL12,
so a few individuals in late stage disease had CD8 cells that maintained responsiveness to rhIL12
Env Env (subtype A, B, D) HIV-1 infection human Cao2000
• HIV-1 subtypes A and D dominate the Ugandan epidemic, and a vaccine trial using B clade antigen is underway – this study addresses relative levels of
cross-reactive CTL responses in HIV infected Ugandans to A, D, and B clade recombinant vaccinia viruses expressing Gag, Env, Pol, RT or Nef from
HIV-1 clades A, B, and D
• Proteins corresponding to the subtype of the infecting strains tended to trigger higher levels of CTL response measured by percent specific lysis, but there
was extensive inter-subtype cross-reactivity with B clade proteins and the co-circulating subtype
Env Env Vaccine human AVEG022PT2001
Vaccine Vector/Type: canarypox, recombinant protein Strain: MN (gp120), LAI (gp120, protease and gag), and SF2 gp120 HIV component: Env, Gag,
Protease Adjuvant: MF-59 adjuvant
• 26/42 subjects who received CP vac-env-pro vaccine had a CTL response measured by Cr-release, while only 3/17 who were vaccinated with rec gp120 had
a CTL response
• A combination of a CP vac-env-pro vaccine with rec gp120 gave CD8+ T-cells in 62% of subjects, and NAbs in 91% of subjects
Env Env HIV-1 infection human White2001
• HIV-specific CTL activity was detected in the female reproductive tract of only 1/3 HIV-infected women who underwent a hysterectomy, although CTL
could be identified in the PBMC of all three women
Env Env (IIIB) HIV-1 infection human Jin2000a
• The CTL precursor level (CTLp) was measured in long term non-progressors (LTNP) with low viral load using limiting dilution analysis and measuring
CTL against Env Gag and Pol expressed in vaccinia in autologous targets
• LTNPs have high memory CTL numbers and low viral load
Env Env (IIIB) HIV-1 infection human Jin2000a
• The CTL effector levels (CTLe) were compared in long term non-progressors (LTNP) with low viral load and in patients whose virus was well-suppressed
by therapy, using a tetramer assay
• LTNPs have high memory CTLe numbers and low viral load, while HAART patients had low CTLe numbers and low viral load
Env Env HIV-1 exposed seronegative human Rowland-Jones2001
• This is a review that summarizes observations about HIV-specific CTL found in the HIV-1 exposed persistently seronegative (HEPS) population
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• The CTL responses assayed by ELISPOT and by CTL precursor frequencies by limiting dilution analysis indicate that CTL in HEPS individuals tend to be
of a lower magnitude than in chronic HIV-1 infections – the responses in HEPS cases are below the level of detection by tetramer assays
• CD8+ CTL responses tend to be detectable in HEPS subjects only if they are recently exposed, and the response diminishes if exposure is reduced – it is not
clear if there is a stable memory population in HEPS cases
• CD8+ CTL responses in the HEPS population are associated with HIV-1 specific CD4+ T cell responses, assayed by proliferation assays, IL-2 secretion,
and ELISPOT, and the authors consider the possibility that HIV-1-specific T-help responses improve the "quality" of the CD8+ response in HEPS
individuals relative to HIV-1 infected individuals, who tend to have a poor HIV-1-specific T-help response
• HIV-1 specific CD8+ CTL responses in HIV-1 infected individuals show reduced levels of perforin, and the T cells may not mature properly, and although
similar studies have not been conducted in HEPS individuals this is considered as a possible difference in the CTL immune response in HEPS and HIV-1
infected people
Env Vaccine murine Nabel2002
Vaccine Vector/Type: DNA HIV component: Gag, Pol, Env
• Env DNA constructs were designed that were codon optimized for human genes, express Env in the absence of the regulatory protein Rev, both increasing
Env expression levels, deletions in the cleavage site and in the fusion domain. These constructs increased Ab responses to Env, while not diminishing CTL
responses, when injected into mice.
• Removing N-linked glycosylation sites did not alter the humoral or cellular immune responses to this HIV protein, as has been seen in analogous SIV
experiments.
Env HIV-1 exposed seronegative human De Maria1994, Kuhn2002
• 6/24 HIV uninfected infants (ages 15-50 months) born to HIV+ mothers had HIV-1 specific CTL responses to vaccinia-expressed Nef, Gag/Pol, Env.
• Reviewed in [Kuhn2002].
Env HIV-1 infection human Kuhn2002, Wasik1999
• In HIV-infected infants HIV-specific, CTL responses were not detectable in cord blood or in PBMC collected shortly after birth and were absent or
remained very low in 3 infants with a rapidly progressive disease. For those who progressed more slowly, the HIV-specific CTL activity varied.
• The two infants with high levels of Env peptide-stimulated IL-2 responses had the highest CTLp frequencies.
• Stronger responses were detected after initiation of the antiretroviral therapy.
• Two babies that were not infected though born to HIV+ mothers had detectable though low HIV-specific CTLp responses to Env (1/2), Pol (2/2), Gag (1/2)
cord blood and transiently in PBMC after birth.
• Reviewed in [Kuhn2002].
Env HIV-1 infection human Aldhous1994, Kuhn2002
• Six of nine HIV vertically infected infants had HIV-1 specific CTL responses to vaccinia expressed Tat (4/6), Pol (6/6), Env (1/6), or Gag (1/6), but not all
responses were detected at all time points.
• Two of eleven babies that were not infected though born to HIV+ mothers had detectable responses Tat (1/2), Pol (2/2), Gag (1/2).
• Reviewed in [Kuhn2002].
Env HIV-1 infection human Kuhn2002, McFarland1994
• Only 9% of HIV+ infants had HIV-specific CTL against Env or Gag in unstimulated PBMC. After CD3 stimulation of PBMC, Gag and Env specific CTL
were found in PBMC from 91% and 78% of HIV-infected children, respectively, with high precursor frequencies.
• 2/9 babies that were not infected though born to HIV+ mothers had detectable responses to Env.
• Reviewed in [Kuhn2002].
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Env HIV-1 infection human Yusim2002
• Epitopes that have been described in the literature and included in this database tend to cluster in conserved regions and be absent or rarely found highly
variable regions found in Nef, Env and p17.
• While the uneven distribution of epitopes may be in part due to a limited cross-recognition of specific responses because of differences between peptides
used to probe the immune response and autologous strains, regions with a paucity of defined epitopes also had higher frequencies of amino acids that tend
to not be found in C-terminal positions of epitopes, and had lower cleavage prediction scores for epitope processing. This suggests that in the regions of the
virus where variation is best tolerated traces of immune escape have left an imprint on the viral population. Epitopes also were concentrated in alpha-helix
and turn regions in the proteins.
• In the more conserved p24, and Pol proteins RT and Protease, epitopes are more evenly distributed.
Env HIV-1 infection human Trabattoni2002
• CD8+ T-cells that were stimulated by HIV-1 Env expressing targets from 25 HIV+ patients receiving ART and 17 ART-naive patients were compared. CTL
from the individuals receiving ART showed increased TNFalpha production and a reduction of perforin and granzyme expressing CTL, suggesting a
functional defect in ART-treated individuals, and a potential benefit of immunomodulants during therapy.
Env (HXB2) HIV-1 infection human Edwards2002
• 96% (26/27) chronically infected HIV-1 infected patients elicited gamma-IFN CD8+ T-cell responses against Gag
• Nef and/or Pol CTL responses were detected in 86% of the subjects
• The magnitude and breadth of Gag and p24 T-cell responses correlated with absolute CD4 counts, and inversely correlated with viral load
• Pol and Int CTL responses correlated positively with absolute CD4+ T-cell count
• Nef and Env responses did not correlate with either CD4 counts or viral load
Env Env Vaccine murine Ishii2001
Vaccine Vector/Type: DNA Strain: IIIB HIV component: gp160, Rev Adjuvant: cationic liposome, IL2, GMCSF
• Vaccination route of HIV-1 DNA immunization with gp160 and Rev genes was compared including intranasal (i.n.), intramuscular (i.m.), and topical
application of DNA directly on the skin after elimination of keratinocyte layers using a strong adhesive. Topical exposure resulted in high level CTL
responses, IFN-gamma and IL-4 production, and delayed type hypersensitivity (DTH). Topical application favored Th2 responses.
• DNA delivered topically with adjuvant-like cationic liposomes gave a stronger response than DNA alone, and co-administration of the DNA vaccine with
IL-12 and GM-CSF expression vectors enhanced cytotoxic activity and DTH.
Env HIV-1 infection human Larsson2002b
• Autologous mature dendritic cells with rec vaccinia expressing Gag, Pol, Nef and Env could amplify CD8+ T-cell Elispot responses 4-38 fold in five HIV+
patients on successful HAART treatment, relative to autologous monocytes. Some weak responses could only be detected using mature dendritic cells as
APCs, and this approach could be useful for detection of low frequency memory cells.
Env (IIIB) HIV-1 infection human Trickett2002
• Conditions were optimized for ex-vivo expansion of CD8+ and CD4+ T-cells with the goal of functional T-cell production for autologous immunotherapy.
10,000-fold expansions were obtained in 14 days with optimized concentrations of IL-2, anti-CD3 and anti-CD28 coated microspheres, and decreasing
amounts of serum over the first 8 days.
Env (IIIB) HIV-1 and HCV co-infection human Lauer2002
• HIV-1 and HCV immune responses were studied in 22 individuals who were co-infected with HIV-1 and hepatitis C virus (HCV). IFNgamma production
was measured in an Elispot assay of CD8+ T-cells using targets expressing either Gag, RT, Env and Nef in a vaccinia construct, or one of seven HCV
proteins.
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• All 22 patients targeted at least one protein. 20/22 patients recognized RT, 17/22 patients recognized Gag, 13/22 subjects recognized Env and 11/22 patients
recognized Nef. Robust CTL activity was independent of disease progression or viral load.
• Despite high HCV viral loads, very few HCV CD8+ T-cell Elispot responses were detected. In a control HCV infected person who did not have HIV-1,
strong anti-HCV responses were mounted.
• HIV-specific CD4 proliferative responses were detected in 9/17 coinfected patients, but no HCV responses were detected.
Env HIV-1 infection human Luzuriaga1995
• 2/3 infants infected in utero had detectable HIV-1 Gag and Env specific CTL responses, one by 4 months, one by 11 months of age. Levels of the responses
varied at different time point. Pol responses were not detected.
• 2/4 infants infected intrapartum had detectable responses, one note until 11 months, one not until 42 months.
• HIV-specific CTL were not detected in ten HIV- infants that were born to HIV+ mothers.
Env Vaccine human Gupta2002
Vaccine Vector/Type: canarypox prime with rgp120 boost HIV component: gag, env Adjuvant: Gag, LAI; gp120, MN; and gp41, LAI
• A safety and immunogeniticity study of a vaccine dosing schedule was studied in a trial conducted in high and low risk study subjects. There was a 76%
cumulative probability of detecting a Gag or Env CTL response by day 728.
Env HIV-1 infection human Scott2001
• CTL responses before and after initiation of ART were studied in 13 HIV-1 vertically infected infants <6 months of age, and 4 that were >6 months of age.
• Before ART 2/13 infants <6 months of age showed IFNgamma Elispot CD8+ T-cell responses, one to Nef and one to Env and Nef, and these responses
became undetectable after successful therapy– 3 infants were coinfected with CMV and all 3 had CMV-specific CD8+ T-cell responses.
• One older infant, at 23 months, had CTL responses against all for proteins tested, Gag, Pol, Nef and Env, and had the lowest plasma viremia of the study
group. 3/4 infants older than 6 months of age responded to either Nef or Pol.
• Administration of ART over 48 weeks broadened the HIV-1-specific CTL response in 2/4 of the older children that were incomplete responders.
Env (IIIB) HIV-1 infection human Ortiz2001
• Immune responses in eight chronically HIV-1 infected patients undergoing HAART therapy structured treatment interruptions (STI) were studied. STI
boosted HIV-1 specific CTL responses and elevated CTL responses were maintained up to 22 weeks after the last treatment interruption, but viral load
rebound to pretreatment levels and CD4 T-cell count decline was observed. CD8 responses in PBMC were measured by cytokine flow cytometry with
gp160, Gag p55, RT-Pol and Nef expressed in vaccinia.
• One of seven subjects with a detectable NAb response had an augmented neutralization titer in response to STI.
Env (SF2) HIV-1 infection human Tomiyama2002
• Nef down-regulates class I molecules, and the killing activity of HLA B*3501, A*2402, B*5101 and B*3303-restricted HIV-1-epitope specific CTL clones
was inhibited by an HIV-1 strain carrying Nef, relative to a Nef-deleted virus; while Nef-induced HLA class I down-regulation inhibited lysis, it did not
abolish cytokine production by HIV-1-specific CD8+ T-cells.
Env computer prediction (A*0201, B*3501) Schönbach2002
• Computational methods (artificial neural networks, hidden Markov models, binding matrices based on HLA association rates) were used to identify
HLA-A*0201 and HLA-B*3501 HIV T-cell epitope candidates from 533 Gag, Env and Pol sequences of which 374 were derived from HIV-1, 97 were
derived from HIV-2 and 62 from SIV. Comparisons to known epitopes and between clades were made.
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Env Vaccine human (A1, A2, A24,
B62, A25, A26, A30,
A31, B8, B17, B39,
B51, B57, B60, B62,
B70)
Ferrari2001
Vaccine Vector/Type: canarypox prime with rgp120 boost, canarypox prime with rgp160 boost Strain: gp41 LAI, Gag LAI, gp120 MN, gp120 SF2 HIV
component: gp120, gp41, Gag, Pol and Nef epitope rich regions
• HLA-B62 responses dominated the responses against an Env vaccine in an individual (022JAV) who was HLA A2, A26, B35, B62. The strongest response
was against the MN peptide 381-400; a response diminished by half was observed against vaccinia expressed clade A and clade C relative to clade B.
• Class I presentation of Env CTL responses in vaccinee 022A12K: A25 > B39, A1 and B8 were undetectable.
• Class I presentation of Env CTL responses in vaccinee 022A12N: B57 » A2 > A26 and B60.
• Class I presentation of Env CTL responses in vaccinee 034GP3: A31 > A24 > B62 > B51.
• Class I presentation of Env CTL responses in vaccinee 0348PP: B17 > B70, A1 and A30 were undetectable.
Env gp120 (303–327) HIV-1 infection human (A2, A3, A11,
B27)
Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
• For this cluster of epitopes spanning the tip of the V3 loop, they suggest including a sequence from each clade
Env Vaccine human (A2, B8) Ferrari2001
Vaccine Vector/Type: canarypox prime with rgp120 boost, canarypox prime with rgp160 boost Strain: gp41 LAI, Gag LAI, gp120 MN, gp120 SF2 HIV
component: gp120, gp41, Gag, Pol and Nef epitope rich regions
• No HLA-A*0201 or B8 responses were made against the Env vaccine in individuals carrying these alleles, despite these being common presenting
molecules for CTL responses to natural infections.
Env Env HIV-1 infection human (B*35) Jin2002
• Patients with HLA-B*35 variants B*3502, B*3503, B*3504, and B*5301 tend to proceed to AIDS more quickly than those with B*3501.
• Of 32 patients with HLA-B*35 alleles CD8+ CTL responses were quantified using an intracellular cytokine staining assay – 75% had responses to Pol,
69% to Gag, 50% to Nef, and 41% to Env.
• The overall magnitude of CTL responses did not differ between those bearing B*3501 and the others. A higher percentage of Gag responses was observed
in those that had lower RNA levels that carried B*3501, and there was a negative association with viral load and CTL activity. The data is consistent with
higher levels of CTL responses contributing to protection in B*3501 individuals, but not in B*3502, B*3503, B*3504, and B*5301 individuals.
Env gp41 (842–850 IIIB,
BH8)
HIV-1 infection human (B7) Pantaleo1997, Soudeyns1997
• Clonotype-specific PCR and analysis of in vivo HIV-specific CTL showed that in early infection HIV-specific CTL clones preferentially accumulate in
blood rather than lymph nodes and that they accumulate prior to down-regulation of virus
Env gp160 (MN) Vaccine murine (H-2d) Vinner1999
Vaccine Vector/Type: DNA Strain: MN HIV component: gp160, gp120, codon-optimized
• Mammalian codon optimization renders gp160 expression Rev independent, increases gp160 expression levels, and DNA vaccination of BALB/c mice
yields a higher antibody response with an earlier onset than wild type
• Secreted gp120 gave higher antibody titers than membrane bound gp160
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• In contrast to antibodies, synthetic codon-optimized DNA did not alter the CTL response, wild type genes generated equally strong CTL responses
Env (IIIB) Vaccine murine (H-2d) Kato2000
Vaccine Vector/Type: peptide HIV component: V3 Adjuvant: Cholera Toxin adjuvant, IL-4, GMCSF
• A multicomponent peptide vaccine VC1 with cholera toxin adjuvant was given to mice.
• Immunization of BALB/c mice with VC1 and CT induced a strong CTL response which was enhanced by IL-12 expressing plasmids
• Immunization with VC1 and CT resulted in HIV-1 specific IgA antibody responses, which were increased by the combination of IL-4 or GM-CSF
expressing plasmids
Env gp160 (IIIB) Vaccine murine (H-2d) Kaneko2000
Vaccine Vector/Type: DNA Strain: IIIB HIV component: gp160 Adjuvant: PLG-microparticle
• A PLG-microparticle encapsulated DNA encoding gp160 was given to mice.
• Oral DNA vaccination of BALB/c mice induced mucosal and systemic gp160 glycoprotein-specific cellular and humoral immune responses, and mice
vaccinated orally had higher resistance to HIV-env expressing vaccinia intrarectal challenge than mice vaccinated i.m.
Env Env Vaccine murine (H-2d) Ishii1997
Vaccine Vector/Type: DNA with CMV promotor with cationic liposome HIV component: gp160, Rev
• pCMV160/Rev is a DNA vaccine candidate carrying gp160 and Rev linked to a cytomegalovirus (CMV promotor)
Env Env Vaccine murine (H-2d) Xin2001
Vaccine Vector/Type: adeno-associated virus (AAV) HIV component: Env, Tat, Rev Adjuvant: IL2
• An AAV vector expressing HIV-1 env, tat, and rev genes (AAV-HIV vector) was used to vaccinate BALB/c mice
• A single injection stimulated and long lasting serum IgG, fecal IgA, and HIV-specific CTL
• Boosting enhanced the humoral response, and IL2 enhanced T-cell immunity
Env Env Vaccine murine (H-2d) Gonzalo1999
Vaccine Vector/Type: influenza, vaccinia Strain: IIIB HIV component: V3, Env
• The use of two different live vectors for priming and boosting has a synergistic effect on the immune response against HIV-1 – a 5-6 fold enhanced CTL
response in Balb/c mice occurred when they were immunized with rec influenza virus (Flu-Env) expressing the V3 loop epitope from HIV-1 strain IIIB, and
boosted with a vaccinia virus recombinant (VV-Env) expressing the complete HIV-1-IIIB env protein, comared to either immunogen alone
Env Env (subtype B) Vaccine murine (H-2d) McGettigan2001
Vaccine Vector/Type: rabies virus Strain: NL4-3, 89.6 HIV component: gp160
• BALB/c were immunized with a replication competent recombinant rabies virus (RV) vaccine expressing HIV-1 gp160
• A single vaccination induced induced strong and long-lasting (4.5 months) gp160-specific CTL cytotoxic responses
• Although the greatest specific lysis was achieved when the vaccine strain was also used as the in vitro the target strain to assess the response, there was
extensive CTL cross-reactivity against other B clade HIV-1 envelope proteins, implying CTL recognition of multiple epitopes within the HIV-1 envelope
protein
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Env Env (SIV) SIV infection Rhesus macaque
(Mamu-A*11, -B*03,
-B*04, and -B*17)
Dzuris2000
• Cell binding assays for Mamu molecules were employed to describe the peptide binding motifs for Mamu-A*11, -B*03, -B*03, -B*04, and -B*17 CTL
epitopes – a similarity for Mamu-A*11 and -B*03 and human HLA-B*44 and -B*27, respectively, was observed – all epitopes studied were SIV epitopes,
so not specifically listed here
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Nef (1–16) Nef (1–16) MGGKWSKSSIVGWPAV HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
• This peptide was among the 28 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
Nef (13–20) Nef (13–20 LAI) WPTVRERM HIV-1 infection human (B*0801) Brander2001, Goulder1997g
• C. Brander notes this is a B*0801 epitope
Nef (13–20) Nef (HXB2) WPTVRERM HIV-1 infection (B*0801) Peng2001
• Deletion of the 19 N-terminal amino acids from Nef including the myristolation signal eliminates Nef-induced down-regulation of MHC class I and CD4
molecules. Such a construct has the potential to serve as a more potent immunogen. The known T-cell epitopes that that would be disputed by this deletion
are minimal, including the HLA-B8 CTL epitope WPTVRERM.
Nef (13–20) Nef (13–20 LAI) WPTVRERM HIV-1 infection human (B8) Goulder1997g
• Unusual epitope for HLA-B8, but compatible with crystal structure predictions
Nef (13–20) Nef (13–20) WPTVRERM HIV-1 infection human (B8) Betts2000
• Only 4/11 HLA-A2+ HIV+ individuals had CTL that reacted to SLYNTVATL, calling into question whether it is immunodominant
• 95 optimally-defined peptides from this database were used to screen for INFγ responses to other epitopes
• 1/11 of the HLA A2+ was HLA A*0201, A31, B8, B51 and responded to this epitope as well as seven others
Nef (13–20) Nef (13–20 SF2) WPTVRERM HIV-1 infection human (B8) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B8+ individuals that had a CTL response to this epitope broken down by group: 1/3 group 1, 0/3 group 2, and 1/2 group 3
Nef (13–20) Nef (13–20) WPTVRERM HIV-1 infection human (B8) Day2001
• B8-restricted CTL accounted for about 1/3 of the total CTL response in one individual
Nef (42–50) Nef (44–52 HXB3) ALTSSNTAA Vaccine murine (HLA-A201
transgenic)
Sandberg2000
Vaccine Vector/Type: DNA, peptide Strain: HXB3 HIV component: Nef Adjuvant: Freund’s adjuvant
• Ten Nef 9-mer peptides were predicted to have a strong binding affinity with HLA-A*0201 – of these, four did bind strongly by a T2 class I stabilization
assay, several others bound weakly
• A CTL immune response to only 3/10 peptides was detected by a 51Cr-release assay after immunization of HLA-A201 transgenic mice with either nef
DNA under the control of a CMV promotor, coated on gold particles delivered to abdominal skin by gene gun
• ALTSSNTAA was also tested by subcutaneous injection of Nef peptides in Freund’s adjuvant
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• ALTSSNTAA bound weakly to HLA-A2, but it had the strongest CTL response among the three elicited by the DNA vaccine and a strong response to the
peptide vaccination
Nef (48–56) Nef (58–66 JRFL) TAATNADCA Vaccine murine (H-2b) Liang2002
Vaccine Vector/Type: DNA Strain: JRFL
• BALB/c, C3H/HeN and C57BL/6 mice were given intramuscular immunization with Nef DNA constructs – C57BL/6 responded to this epitope.
• The Nef mutant that lacked the myristylation site (G–>A) at position 2, and the dileucine motif (L –> A at positions 174 and 175) was impaired in terms of
its ability to elicit induction of Nef-specific CD4+ and CD8+ T-cell responses. The myristylation site is critical for Nef membrane localization and function,
and the di-leucine motif for the down-regulation of surface CD4 molecules, and the mutation of these regions could yield a safer vaccine.
• N-terminal addition of human tissue plasminogen activator (TPA) to Nef, enhanced CD8+ T-cell responses and could compensate for the G2A, L174A,
L175A mutations – this enhanced immunogenicity correlated with enhanced levels of protein expression in transfected cells.
Nef (62–81) Nef (61–80) EEEEVGFPVTPQVPLRPMTY HIV-1 infection human Lieberman1995
• HIV-specific CTL lines developed by ex vivo stimulation with peptide
Nef (62–81) Nef (61–80 SF2) EEEEVGFPVTPQVPLRPMTY HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Twelve subjects had CTL that could recognize vaccinia-expressed LAI Nef
• Two of these 12 had CTL response to this peptide
• The responding subjects were HLA-A11, A24, B8, B35, and HLA not determined
Nef (62–81) Nef (61–80 SF2) EEEEVGFVTPQVPLRPMTY HIV-1 infection human Lieberman1997b
• CTL expanded ex vivo were later infused into HIV-1 infected patients
Nef (62–81) Nef (SF2) EEEEVGFPVTPQVPLRPMTY HIV-1 infection human Altfeld2001a
• HIV+ individual AC-06 was tested for reactive overlapping peptides spanning all HIV-1 proteins in an ELISPOT and was found to react with 12 peptides
from 7 proteins, suggesting that the breadth of CTL responses are underestimated if accessory proteins are not included in the study
• Nef peptides PQVPLRRMTYKAAVDLSHFL, KAAVDLSHFLKEKGGLEGLI and EEEEVGFPVTPQVPLRPMTY were recognized and the first two
share KAAVDLSHFL (a Cw8 epitope), the first and last share PQVPLRPMTY
Nef (66–80) Nef (66–80 BRU) VGFPVTPQVPLRMT HIV-1 infection human (A1, B8) Hadida1992
• HIV-1 specific CTLs detected in lymphoid organs of HIV-1 infected patients
Nef (66–80) Nef (64–78) VGFPVTPQVPLRMT HIV-1 infection human (A1, B8) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
Nef (66–97) Nef (66–97 LAI) VGFPVTPQVPLRPMTYKAA-
VDLSHFLKEKGGL
Vaccine human Gahery-Segard2000
Vaccine Vector/Type: lipopeptide HIV component: six peptides
• Anti-HIV lipopeptide vaccine consisting of six long amino acid peptides derived from Nef, Gag and Env HIV-1 proteins modified by a palmitoyl chain was
administered in a phase I trial
• A CD4+ T cell proliferative response to at least one of the six peptides was observed in 9/10 vaccinees – 5/10 reacted to this Nef peptide
• 9/12 tested mounted a CTL response to at least one of the six peptides; each of the six peptides elicited a CTL response in at least one individual
• 5/12 tested had an IgG response to this peptide
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Nef (67–81) Nef (67–81) GFPVRPQVPLRPMTY HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
• This peptide was among the 28 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
Nef (68–76) Nef (72–80 SF2) FPVRPQVPL HIV-1 infection human (B*3501) Tomiyama1997
• A CTL clone responsive to this epitope was obtained
• 3/7 B35-positive individuals had a CTL response to this epitope
• An R to T substitution at position 4 abrogates specific lysis, but not binding to B*3501
Nef (68–76) Nef (72–80) FPVRPQVPL HIV-1 infection human (B*3501) Tomiyama2000a
• CD8+ T-cells that bound one of six HIV-specific B*3501-epitope tetramers did not express CD28 or CD45A
• A significant increase in CD28-CD45RA- cells and a decrease of CD28+CD45RA+ cells was observed in chronically HIV-1-infected individuals relative to
healthy individuals
• CD28-CD45RA- cells are likely to be effector cells and have high levels of perforin in their cytoplasm
• The mean percentage of total CD28- CD8+ cells in chronically infected HIV-1-infected patients was 76.6% in comparison to HIV-1-uninfected individuals
(40.6%)
Nef (68–76) Nef (72–80 SF2) FPVRPQVPL HIV-1 infection human (B35) Shiga1996
• Binds HLA-B*3501
Nef (68–76) (SF2) FPVRPQVPL HIV-1 infection human (B35) Kawana1999
• HLA B35 is associated with rapid disease progression
• The sequences of 9 previously described HIV-1 B35 CTL epitopes were obtained in 10 HLA B35+ and 19 HLA B35- individuals
• 3/9 CTL epitopes had substitutions that were more common in B35+ individuals than in B35- individuals, but this was one of the six that had no B35
associated pattern of mutation
Nef (68–76) Nef (66–74) FPVRPQVPL HIV-1 infection human (B35) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
Nef (68–76) Nef (68–76 BRU) FPVTPQVPL HIV-1 infection human (B35) Choppin2001
• Seventy-three 8-11 mer peptides were generated based on putative anchor motifs in the Nef BRU sequence for HLA A2, A3, A24, B7, B8, and B35; these
73 peptides had 81 motifs. 54% bound to the predicted HLA molecule, particularly A2, B7/35, and B8. The strength of HLA-peptide binding was not
directly related to the number of individuals that recognized a protein.
• 20s proteasome cleavage of the Nef protein positions 66-100 showed a large fraction of peptides were cleaved ending at: 87L, 83A, 81Y, 71P, 68F and 67G.
The frequency of recognition may be in part dictated by the cleavage step in processing.
• FPVTPQVPL was recognized in 1/13 (8%) of individuals with HLA B7, and 1/12 (8%) of individuals with HLA B35. It was a high affinity HLA binder.
Nef (68–76) Nef (68–76) FPVTPQVPL in vitro stimulation human (B7) Wilson1999b
• Dendritic cells are the most potent for priming T cell responses – DCs can stimulate autologous CTL responses from T cells cultured from HIV negative
donors
• Th1-biasing cytokines IL-12 or IFN alpha enhance CTL responses in vitro whether the epitope is delivered by pulsing from peptide, or expressed from
within
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• B7 and A2 Nef epitopes were studied – FPVTPQVPL has a high affinity for B7
Nef (68–76) Nef (68–76) FPVTPQVPL HIV-1 infection human (B7) Day2001
• The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7 was
studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
• 2 to 17 epitopes were recognized in a given individual, A2-restricted CTL response tended to be narrow and never dominated the response, and 25/27
epitopes were targeted by at least one person
• Subjects with chronic HIV-1 infection recognized between 2-8 out of 11 B7-restricted epitopes
• An acute seroconvertor homozygous for the B7 allele recognized five B7-restricted epitopes
• The other acute seroconvertor failed to recognize any of the 11 B7-restricted epitopes tested
• The B7-restricted CTL response was highly variable and there was no clearly dominant epitope
Nef (68–76) Nef (68–76 BRU) FPVTPQVPL HIV-1 infection human (B7) Choppin2001
• Seventy-three 8-11 mer peptides were generated based on putative anchor motifs in the Nef BRU sequence for HLA A2, A3, A24, B7, B8, and B35; these
73 peptides had 81 motifs. 54% bound to the predicted HLA molecule, particularly A2, B7/35, and B8. The strength of HLA-peptide binding was not
directly related to the number of individuals that recognized a protein.
• 20s proteasome cleavage of the Nef protein positions 66-100 showed a large fraction of peptides were cleaved ending at: 87L, 83A, 81Y, 71P, 68F and 67G.
The frequency of recognition may be in part dictated by the cleavage step in processing.
• FPVTPQVPL was recognized in 1/13 (8%) of individuals with HLA B7, and 1/12 of individuals with HLA B35. It was a high affinity HLA binder.
Nef (68–76) Nef (68–76) FPVTPQVPL HIV-1 infection human (B7) Yu2002a
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
• 0/11 HLA-B7 individuals had detectable B7-restricted responses to this epitope during acute infection – 10/15 of HLA-B7 epitopes tested were targeted by
at least one person during acute infection. Also, none of 4 individuals had detectable responses to this epitope after STI.
Nef (68–77) Nef (68–77 LAI) FPVTPQVPLR HIV-1 infection human (B*0702) Brander2001
• C. Brander notes this is a B*0702 epitope
Nef (68–77) Nef (68–77 LAI) FPVTPQVPLR HIV-1 infection human (B7) Haas1996
• There was a high degree of variation in three CTL epitopes in Nef in four slow and non-progressors, and variant specific CTLs arose over time to eliminate
variants, indicating immune selection
Nef (68–77) Nef (subtype B) FPVTPQVPLR HIV-1 infection human (B7) Kaul2001c
• This study examines CTL responses in HIV exposed, persistently seronegative individuals, HEPS, who eventually seroconverted – 11/114 HEPS Nairobi
sex workers eventually seroconverted, and for six of these HIV CTL reactive epitopes had been defined while seronegative
• FPVTPQVPLR was recognized in 1 of the 6 women (ML1203), and the response was present in the last available sample prior to seroconversion, 7 months
• 20/20 sequences of the infecting strain had no substitutions in this epitope, all were FPVTPQVPLR, so there was no evidence for escape
• The epidemiological factor associated with seroconversion was stopping sex work and HIV-specific CTL activity declines when HEPS sex workers stop
working for a period or retire
• This epitope was recognized in 1/22 HEPS sex worker controls, ML851
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Nef (68–77) Nef (66–75) FPVRPQVPLR HIV-1 infection human (B7) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
Nef (68–77) Nef (68–77 SF2) FPVTPQVPLR HIV-1 infection human (B7) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B7+ individuals that had a CTL response to this epitope broken down by group: 0/4 group 1, 0/3 group 2, and 1/1 group 3
Nef (68–77) Nef (68–77) FPVTPQVPLR HIV-1 infection, HIV-1 exposed
seronegative
human (B7) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with
reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected
women
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure
• Subject ML 1203 started with CTL responses to A*6802 DTVLEDINL and to B7 FPVTPQVPLR prior to seroconversion, and upon seroconversion
acquired additional responses to A*6802 ETAYFILKL which became dominant, B7 TPGPG(V/I)RYPL, B7 IPRRIRQGL, and B7 SPRTLNAWV
Nef (68–77) Nef (68–77) FPVTPQVPLR HIV-1 infection human (B7) Day2001
• The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7 was
studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
• 2 to 17 epitopes were recognized in a given individual, A2-restricted CTL response tended to be narrow and never dominated the response, and 25/27
epitopes were targeted by at least one person
• Subjects with chronic HIV-1 infection recognized between 2-8 out of 11 B7-restricted epitopes
• An acute seroconvertor homozygous for the B7 allele recognized five B7-restricted epitopes
• The other acute seroconvertor failed to recognize any of the 11 B7-restricted epitopes tested
• The B7-restricted CTL response was highly variable and there was no clearly dominant epitope
Nef (68–77) Nef (68–76) FPVTPQVPLR HIV-1 infection human (B7) Yu2002a
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
• 0/11 HLA-B7 individuals had detectable B7-restricted responses to this epitope during acute infection – 10/15 of HLA-B7 epitopes tested were targeted by
at least one person during acute infection. Also, none of 4 individuals had detectable responses to this epitope after STI.
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Nef (68–81) Nef (82–95 HXB2) FPVTPQVPLRMTY HIV-1 infection human Guimaráes2002
• Nef sequences were obtained from Brazilians to study epitope diversity in this geographic region—the HXB2 sequence is FPVTPQVPLRMTY, but
fpvRpqvplrmty was observed in most Brazilian sequences regardless of the subtype (A, C, D and F).
Nef (68–84) Nef FPVRPQVPLRPMTYKGA human Jubier-Maurin1999
• 41 new HIV-1 strains describing envelope subtypes of HIV-1 A-H were genetically characterized in the nef region – 34 subtypes were classified in the same
subtype in nef and env and 7 of the 41 strains were recombinants
• This region was defined as a CTL epitope region that is conserved among HIV-1 M group subtypes
Nef (71–79) Nef (71–79 LAI) TPQVPLRPM HIV-1 infection human (B*0702) Brander2001
• C. Brander notes this is a B*0702 epitope
Nef (71–79) Nef (71–79 BRU) TPQVPLRPM HIV-1 infection human (B35) Choppin2001
• Seventy-three 8-11 mer peptides were generated based on putative anchor motifs in the Nef BRU sequence for HLA A2, A3, A24, B7, B8, and B35; these
73 peptides had 81 motifs. 54% bound to the predicted HLA molecule, particularly A2, B7/35, and B8. The strength of HLA-peptide binding was not
directly related to the number of individuals that recognized a protein.
• 20s proteasome cleavage of the Nef protein positions 66-100 showed a large fraction of peptides were cleaved ending at: 87L, 83A, 81Y, 71P, 68F and 67G.
The frequency of recognition may be in part dictated by the cleavage step in processing.
• TPQVPLRPM was recognized in 1/10 (10%) of individuals with HLA B7, and 1/10 (10%) of individuals with HLA B35. It was a moderate affinity HLA
binder.
Nef (71–79) Nef (71–79 SF2) TPQVPLRPM HIV-1 infection human (B7) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B7+ individuals that had a CTL response to this epitope broken down by group: 0/4 group 1, 0/3 group 2, and 1/1 group 3
Nef (71–79) Nef (71–79) TPQVPLRPM HIV-1 infection human (B7) Day2001
• The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7 was
studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
• 2 to 17 epitopes were recognized in a given individual, A2-restricted CTL response tended to be narrow and never dominated the response, and 25/27
epitopes were targeted by at least one person
• Subjects with chronic HIV-1 infection recognized between 2-8 out of 11 B7-restricted epitopes
• An acute seroconvertor homozygous for the B7 allele recognized five B7-restricted epitopes
• The other acute seroconvertor failed to recognize any of the 11 B7-restricted epitopes tested
• The B7-restricted CTL response was highly variable and there was no clearly dominant epitope
Nef (71–79) Nef (71–79 BRU) TPQVPLRPM HIV-1 infection human (B7) Choppin2001
• Seventy-three 8-11 mer peptides were generated based on putative anchor motifs in the Nef BRU sequence for HLA A2, A3, A24, B7, B8, and B35; these
73 peptides had 81 motifs. 54% bound to the predicted HLA molecule, particularly A2, B7/35, and B8. The strength of HLA-peptide binding was not
directly related to the number of individuals that recognized a protein.
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• 20s proteasome cleavage of the Nef protein positions 66-100 showed a large fraction of peptides were cleaved ending at: 87L, 83A, 81Y, 71P, 68F and 67G.
The frequency of recognition may be in part dictated by the cleavage step in processing.
• TPQVPLRPM was recognized in 1/10 (10%) of individuals with HLA B7, and 1/10 (10%) individuals with HLA B35. It was a moderate affinity HLA
binder.
Nef (71–79) Nef (71–79) TPQVPLRPM HIV-1 infection human (B7) Yu2002a
• Epitope name: B7-TM9
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
• 0/11 HLA-B7 individuals had detectable B7-restricted responses to this epitope during acute infection – 10/15 of HLA-B7 epitopes tested were targeted by
at least one person during acute infection. 2/4 individuals had detectable responses to this epitope after STI.
Nef (71–79) Nef TPQVPLRPM HIV-1 infection human (B7) Altfeld2002
• Epitope name: B7-TM9(Nef)
• Peripheral blood (PB) and lymph node (LN) CD8+ T-cell responses were compared in 15 asymptomatic HIV-1 infected patients using all known optimal
CTL epitopes (http://hiv-web.lanl.gov/content/hiv-db/REVIEWS/brander2001.html) for each person’s class I HLA alleles.
• 60 epitope responses were detected in both PB and LN samples of the 15 patients, and an additional 8 responses were detected only in LN. The total
magnitude of the response was similar in LN and PB, but the percentage of CD8+ T cells in the LN is lower so the number of HIV-specific cells per million
CD8+ T-cells is higher in the LN.
• 1 year post-HAART treatment in five patients studied, the magnitude of the CD8 T-cell response was decreased in both LN and PB, but more dramatically
in PB, and 13/25 epitope responses in the PB became undetectable, in contrast to 5/26 in the LN.
• Treatment interruption following HAART induced resulted in increased viremia accompanied by the restoration of the detection of 13 epitopes that had
become undetectable in the PB, and the addition of 9 novel epitope responses.
• Breakdowns of epitope responses were shown for 4 individuals. Patient A displayed the greatest response to epitope B14-EL9(gp41), a strong response to
B7-TL9(p24), and responses to B7-TM9(Nef) and A32-PW10(RT). Patient C displayed the greatest response to B27-KK10(p24), and in decreasing order
also responded to A24-RW8(Nef), B7-IL9(gp41), A24-RL9(gp41), A24-YL8(gp41), and B7-TM9(Nef).
Nef (71–81) Nef (75–85 SF2) RPQVPLRPMTY HIV-1 infection human (B*3501) Tomiyama1997
• A CTL clone responsive to this epitope was obtained
• 4/7 B35-positive individuals had a strong CTL response to this epitope
• An R to T substitution at position 1 abrogates specific lysis, but not binding to B*3501
• An R to H substitution at position 7 did not alter reactivity
Nef (71–81) Nef (75–85) RPQVPLRPMTY HIV-1 infection human (B*3501) Tomiyama2000a
• CD8+ T-cells that bound one of six HIV-specific B*3501-epitope tetramers did not express CD28 or CD45A
• A significant increase in CD28-CD45RA- cells and a decrease of CD28+CD45RA+ cells was observed in chronically HIV-1-infected individuals relative to
healthy individuals
• CD28-CD45RA- cells are likely to be effector cells and have high levels of perforin in their cytoplasm
• The mean percentage of total CD28- CD8+ cells in chronically infected HIV-1-infected patients was 76.6% in comparison to HIV-1-uninfected individuals
(40.6%)
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Nef (71–81) Nef (75–85 SF2) RPQVPLRPMTY HIV-1 infection human (B35) Shiga1996
• Binds HLA-B*3501
Nef (71–81) (SF2) RPQVPLRPMTY HIV-1 infection human (B35) Kawana1999
• HLA B35 is associated with rapid disease progression
• The sequences of 9 previously described HIV-1 B35 CTL epitopes were obtained in 10 HLA B35+ and 19 HLA B35- individuals
• 3/9 CTL epitopes had substitutions that were more common in B35+ individuals than in B35- individuals – only one of these reduced the binding of the
peptide to B35 and was shown to be an escape mutation
• rpqvplrpmtF was found in 9/10 of the B35+ individuals, none of the B35- individuals—the Y–>F substituted peptide had a similar binding affinity with B35
and was recognized by a CTL clone equally with wildtype.
Nef (71–81) Nef (69–79) RPQVPLRPMTY HIV-1 infection human (B35) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
Nef (71–81) Nef (71–81 BRU) TPQVPLRPMTY HIV-1 infection human (B35) Choppin2001
• Seventy-three 8-11 mer peptides were generated based on putative anchor motifs in the Nef BRU sequence for HLA A2, A3, A24, B7, B8, and B35; these
73 peptides had 81 motifs. 54% bound to the predicted HLA molecule, particularly A2, B7/35, and B8. The strength of HLA-peptide binding was not
directly related to the number of individuals that recognized a protein.
• 20s proteasome cleavage of the Nef protein positions 66-100 showed a large fraction of peptides were cleaved ending at: 87L, 83A, 81Y, 71P, 68F and 67G.
The frequency of recognition may be in part dictated by the cleavage step in processing.
• TPQVPLRPMTY was recognized in 9/12 (75%) of individuals with HLA B7, and 5/10 (50%) of individuals with HLA B35. It was a moderate affinity
HLA binder, and the C-term Y readily cleaved in vitro.
Nef (71–81) Nef RPQVPLRPMTY HIV-1 infection, Vaccine human, macaque (B51) Hanke2000, Wee2002
Vaccine Vector/Type: DNA prime with vaccinia MVA boost Strain: subtype A HIV component: p17, p24, polyepitope
• The HIV-1 subtype A focused vaccine HIVA contains p24 and p17, in a reversed order relative to the Gag polyprotein to prevent myristylation of p17,
which could direct the protein to the cell membrane and inhibit efficient peptide processing and class I presentation, as well as a polyepitope string of
conserved, often immunodominant epitopes that were selected to have particularly good cross-reactive potential for the A-clade epidemic in Nairobi,
Kenya. A DNA and MVA prime-boost vaccination protocol using the HIVA antigen will be used in a phase III clinical trial in Kenya. This epitope is
included in the polyepitope string [Hanke2000].
• Multiple CD4+ or CD8+ T-cell vaccine-induced responses to peptide pools were detected using intracellular cytokine staining and IFNgamma Elispot
assays after vaccination of 5 macaques. The response to the Mamu A*01 SIV p27 epitope p11C (CTPYDINQM), included in the polyepitope region, was
not immunodominant in the Mamu A*01 vaccinated macaques, possibly because of processing limitations in context of the artificial polyepitope string
[Wee2002].
Nef (71–81) Nef (71–81 BRU) TPQVPLRPMTY HIV-1 infection human (B7) Choppin2001
• Seventy-three 8-11 mer peptides were generated based on putative anchor motifs in the Nef BRU sequence for HLA A2, A3, A24, B7, B8, and B35; these
73 peptides had 81 motifs. 54% bound to the predicted HLA molecule, particularly A2, B7/35, and B8. The strength of HLA-peptide binding was not
directly related to the number of individuals that recognized a protein.
• 20s proteasome cleavage of the Nef protein positions 66-100 showed a large fraction of peptides were cleaved ending at: 87L, 83A, 81Y, 71P, 68F and 67G.
The frequency of recognition may be in part dictated by the cleavage step in processing.
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• TPQVPLRPMTY was recognized in 9/12 (75%) of individuals with HLA B7, and 5/10 (50%) of individuals with HLA B35. It was a moderate affinity
HLA binder, and the C-term Y readily cleaved in vitro.
Nef (72–86) Nef (72–86) PQVPLRPMTYKGAFD HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
• This peptide was among the 28 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
Nef (72–91) Nef (71–90 SF2) PQVPLRMTYKAAVDLSHFL HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Eleven subjects had CTL that could recognize vaccinia-expressed LAI Nef
• Three of these 11 had CTL response to this peptide
• The responding subjects were HLA-A3, A32, B51, B62; HLA-A11, A24, B8, B53
Nef (72–91) Nef (71–90 SF2) PQVPLRPMTYKAAVDLSHFL HIV-1 infection human Lieberman1997b
• CTL expanded ex vivo were later infused into HIV-1 infected patients
Nef (72–91) Nef (SF2) PQVPLRRMTYKAAVDLSHFL HIV-1 infection human Altfeld2001a
• HIV+ individual AC-06 was tested for reactive overlapping peptides spanning all HIV-1 proteins in an ELISPOT and was found to react with 12 peptides
from 7 proteins, suggesting that the breadth of CTL responses are underestimated if accessory proteins are not included in the study
• Nef peptides PQVPLRRMTYKAAVDLSHFL, KAAVDLSHFLKEKGGLEGLI and EEEEVGFPVTPQVPLRPMTY were recognized and the first two
share KAAVDLSHFL (a Cw8 epitope), the first and last share PQVPLRPMTY
Nef (73–82) Nef (73–82) QVPLRPMTYK HIV-1 infection human Garcia1997
• The anti-Nef CTL line P1 specific for this epitope is able to kill target cells via two mechanisms
• First: Ca2+-dependent, perforin-dependent Nef-specific lysis
• Second: Ca2+-independent, CD95-dependent apoptosis that could also kill non-specific targets
• Findings indicate that the two mechanisms are not mutually exclusive in human CTL, as they are in mice
• CTL mediated CD95-dependent apoptosis may play a role in pathogenesis
Nef (73–82) Nef (73–82 NL43) QVPLRPMTYK HIV-1 infection human (A*0301) Koenig1990
• 81 Tyr is critical for binding to A3.1
• C. Brander notes that this is an A*0301 epitope in the 1999 database
Nef (73–82) Nef (73–82 LAI) QVPLRPMTYK human (A*0301) Brander2001
• C. Brander notes this is an A*0301 epitope
Nef (73–82) Nef QVPLRPMTYK HIV-1 infection, Vaccine human, macaque
(A*0301, A11)
Hanke2000, Wee2002
Vaccine Vector/Type: DNA prime with vaccinia MVA boost Strain: subtype A HIV component: p17, p24, polyepitope
• The HIV-1 subtype A focused vaccine HIVA contains p24 and p17, in a reversed order relative to the Gag polyprotein to prevent myristylation of p17,
which could direct the protein to the cell membrane and inhibit efficient peptide processing and class I presentation, as well as a polyepitope string of
conserved, often immunodominant epitopes that were selected to have particularly good cross-reactive potential for the A-clade epidemic in Nairobi,
Kenya. A DNA and MVA prime-boost vaccination protocol using the HIVA antigen will be used in a phase III clinical trial in Kenya. This epitope is
included in the polyepitope string [Hanke2000].
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• Multiple CD4+ or CD8+ T-cell vaccine-induced responses to peptide pools were detected using intracellular cytokine staining and IFNgamma Elispot
assays after vaccination of 5 macaques. The response to the Mamu A*01 SIV p27 epitope p11C (CTPYDINQM), included in the polyepitope region, was
not immunodominant in the Mamu A*01 vaccinated macaques, possibly because of processing limitations in context of the artificial polyepitope string
[Wee2002].
Nef (73–82) QVPLRPMTYK HIV-1 infection human (A03) Sabbaj2002b
• Epitope name: Nef-QK10
• Among HIV+ individuals who carried HLA A03, 9/20 (45%) recognized this epitope
Nef (73–82) Nef (73–82) QVPLRPMTYK HIV-1 infection human (A11) Le Borgne2000
• Soluble factors in supernatant from both an HIV-specific cloned CTL line and an EBV (Epstein-Barr-virus) CTL line inhibit viral replication, but do not
block viral entry in CD4+ T lymphocytes, by a noncytotoxic mechanism
Nef (73–82) Nef (73–82 LAI) QVPLRPMTYK HIV-1 infection human (A11) Robertson1993
• Development of a retroviral vector (pNeoNef) to generate autologous CTL targets
• [Hunziker1998] suggests that HLA-A2 does not in fact present this epitope
• The initial assignment of HLA-A2 presentation for this epitope was based on a serological HLA typing. Subsequently, the authors revisited the issue with
genetic HLA typing and found that HLA-A11 was the correct presenting molecule (Dr. Florence Buseyne, Pers. Comm., 2000)
Nef (73–82) Nef (73–82 LAI) QVPLRPMTYK HIV-1 infection human (A11) Couillin1994, Goulder1997a
• Mutational variation in HIV epitopes in individuals with appropriate HLA types can result in evasion of CTL response
• [Goulder1997a] is a review of immune escape that summarizes this study
Nef (73–82) Nef (73–82 LAI) QVPLRPMTYK HIV-1 infection human (A11) Couillin1995
• Mutations found in this epitope in HLA-A11 positive and negative donors were characterized
Nef (73–82) (LAI) QVPLRPMTYK (A11) Brander2001, Buseyne1999
Nef (73–82) Nef (73–82) QVPLRPMTYK HIV-1 infection human (A11) Oxenius2000
• Epitope name: QVP
• Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific
CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load – three patients that had delayed initiation of
HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became
undetectable
• One of the 2/8 HLA-A11 study subjects recognized this CTL epitope
• Patient SC18(HLA A2/11, B8/44, Cw06/0701, DR3/7, DR52/53, DQ2) recognizes the epitopes ACQGVGGPGHK, QVPLRPMTYK, AVDLSHFLK, and
one called QIY but not fully described – he had brief therapy upon seroconversion and has had low viral load during 600 days of follow up
Nef (73–82) Nef (73–82) QVPLRPMTYK HIV-1 infection, HIV-1 exposed
seronegative
human (A11) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
Nef (73–82) Nef (73–82) QVPLRPMTYK HIV-1 infection human (A11) Appay2000
• Combined tetramer and intracellular cytokine staining was used to study the function of circulating CD8+ T cells specific for HIV and CMV
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• HIV-specific CD8+ T cells expressed lower levels of perforin than CMV-specific CD8+ T cells from the same donor, and this was associated with persistent
CD27 expression on HIV-specific cells, suggesting impaired maturation
• In most donors, between 50% and 95% of the activated virus-specific CD8+ T cells produced IFN-γ and MIP-1β with a distinct subset that failed to
produce TNF-α
Nef (73–82) Nef (71–80 93TH253
subtype CRF01)
QVPLRPMTYK HIV-1 infection, HIV-1 exposed
seronegative
human (A11) Sriwanthana2001
• Epitope name: N73-82
• This was a study of HIV-1 exposed persistently seronegative (HEPS) female sex workers in Chiang Mai, northern Thailand
• HLA-A11 is very common in this population, and was enriched among the HEPS sexworkers – weak CTL responses were detected in 4/7 HEPS women,
and CTL responses were found in 8/8 HIV+ controls, and 0/9 HIV- women that were not exposed
• This epitope was weakly reactive in HEPS study subjects 265 who was HLA A2/A11 and 128 who was HLA A11/A33, and after a second in vitro
stimulation, in study subject 256 who was HLA A11/33, making it the most reactive epitope tested in HLA-A11 HEPS women, with 3/4 responding
• This epitope was strongly reactive in HIV+ study subject 053 who carried HLA-A11
Nef (73–82) Nef (71–80 93TH253
subtype CRF01)
QVPLRPMTYK HIV-1 infection human (A11) Bond2001
• HLA-A11 CRF01 (called subtype E in Bond et al.) epitopes were identified that stimulated CTL from HIV+ female sex workers (FSW) from Northern
Thailand, of whom more than half were HLA-A11 positive
• 77 possible HLA-A11 epitopes were first defined using EpiMatrix, these were screened for binding to A11 finding and 26 bound, and 12 of these were
epitopes for CTL responses from 8 HLA-A11 positive FSWs, six were novel, six were previously identified
• This epitope was predicted by the EpiMatrix method to be likely to bind to A11, and it served as an epitope in the FSWs, it was one of the six A11 epitopes
that had been previously defined
• 4/8 tested FSWs recognized this epitope
• An HLA-A11 tetramer was made for this epitope, which was recognized by two subjects – only one subject had an expanded tetramer staining T-cell
population after in vitro stimulation
• This epitope was highly conserved in other subtypes, and exact matches were common
Nef (73–82) Nef QVPLRPMTYK HIV-1 infection human (A11) Oxenius2002b
• Epitope name: QVP
• Using previously defined epitopes [Oxenius2000, Oxenius2001a] in an IFNgamma Elispot assay, 13 chronically HIV-1 infected patients were studied over a
period including therapy with standard treatment interruptions (STI).
• STIs induced increased recognition of CTL epitopes, but there was no correlation between CTL responses with viral rebound rates, plateau viral loads, or
clearance rates.
Nef (73–82) Nef QVPLRPMTYK HIV-1 infection human (A11) Appay2002
• Four HIV patients with prolonged clinically successful anti-viral therapy but with ongoing evidence of replication and Nef mRNA transcription, showed
specific T-cell responses by Elispot and Tetramer staining, maintained for 2-4 years after initiation of HAART.
• Nef epitope recognition was detected in all 4 subjects, gp120, Pol and Gag-specific in 1 or 2 subjects – two patients recognized this epitope, one using
HLA-A3, one using HLA-A11
• The HIV-specific CD8+ T-cells had an intermediate maturation phenotype characterized by low levels of perforin and high levels of CD27 expression.
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Nef (73–82) Nef (73–81) QVPLRPMTYK HIV-1 infection human (A2, A3, A11,
B35)
Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
Nef (73–82) Nef (73–82 LAI) QVPLRPMTYK HIV-1 infection human (A3) Chassin1999
• Mutations in Nef that flank this epitope, Thr71Lys and Ala83Gly, may account for an observed loss of CTL reactivity, with escape due to the introduction
of proteasome processing defects
Nef (73–82) Nef (73–82) QVPLRPMTYK HIV-1 infection human (A3) Durali1998
• Cross-clade CTL response was studied by determining the CTL activity in seven patients from Bangui, (6 A subtype, and 1 AG recombinant infections) and
one A subtype infection from a person living in France originally from Togo, to different antigens expressed in vaccinia
• Pol reactivity: 8/8 had CTL to A subtype, and 7/8 to B subtype, and HIV-2 Pol was not tested
• Gag reactivity: 7/8 reacted with A or B subtype gag, 3/8 with HIV-2 Gag
• Nef reactivity: 7/8 reacted with A subtype, and 5/8 with B subtype, none with HIV-2 Nef
• Env reactivity: 3/8 reacted with A subtype, 1/8 with B subtype, none with HIV-2 Env
• One of the patients was shown to react to this epitope: QVPLRPMTYK
Nef (73–82) Nef (73–82 LAI) QVPLRPMTYK HIV-1 infection human (A3) Goulder1997e, Goulder1997a
• Identical twin hemophiliac brothers were both infected with the same batch of factor VIII
• Both had a response to this epitope
• [Goulder1997a] is a review of immune escape that summarizes this study
Nef (73–82) Nef (73–82) QVPLRPMTYK HIV-1 infection human (A3) Lubaki1997
• Eighty two HIV-1-specific CTL clones from 5 long-term non-progressors were isolated and analyzed for breadth of response
• A sustained Gag, Env and Nef response was observed, and clones were restricted by multiple HLA epitopes, indicating a polyclonal response
• An A3+ subject had a strong response to this epitope, with 10/11 CTL clones being specific for this epitope, isolated at two time points, 1 year apart
Nef (73–82) Nef (73–82) QVPLRPMTYK HIV-1 infection human (A3) Samri2000
• Epitope name: N1
• The epitope was recognized by patients 252#0 and 252#4 in a study of the effects of therapy escape mutations on CTL recognition
Nef (73–82) Nef (73–82 SF2) QVPLRRMTYK HIV-1 infection human (A3) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-A3+ individuals that had a CTL response to this epitope broken down by group: 3/7 group 1, 1/4 group 2, and 1/2 group 3
Nef (73–82) Nef (SF2) QVPLRPMTYK HIV-1 infection human (A3) Altfeld2000b
• This epitope was mapped by ELISPOT in a study identifying new HLA-B60 epitopes, and was one of the epitopes presented by another HLA molecule in
an HLA-B60 individual
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Nef (73–82) Nef (73–82) QVPLRPMTYK HIV-1 infection human (A3) Yu2002a
• Epitope name: A3-QK10
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
• 3/14 HLA-A3 positive individuals had detectable A3-restricted responses to this epitope during acute infection, but only 5/15 of HLA-A3 epitopes tested
were targeted during acute infection. 5/7 individuals had detectable responses to this epitope after STI.
Nef (73–82) Nef QVPLRPMTYK HIV-1 infection human (A3) Appay2002
• Four HIV patients with prolonged clinically successful anti-viral therapy but with ongoing evidence of replication and Nef mRNA transcription, showed
specific T-cell responses by Elispot and Tetramer staining, maintained for 2-4 years after initiation of HAART.
• Nef epitope recognition was detected in all 4 subjects, gp120, Pol and Gag-specific in 1 or 2 subjects – two patients recognized this epitope, one using
HLA-A3, one using HLA-A11.
• The HIV-specific CD8+ T-cells had an intermediate maturation phenotype characterized by low levels of perforin and high levels of CD27 expression.
Nef (73–82) Nef (73–82 LAI) QVPLRPMTYK HIV-1 infection human (A3 supertype) Mollet2000
• Epitope name: N1
• A panel of 16 epitopes covering 15 class I alleles was tested in 14 HIV+ patients from an unselected Caucasian population treated with HAART, using
CD8+ cell IFNgamma production to measure responses
• In general, during the first month of treatment viral load decreased and frequencies of HIV-specific CTL tripled and broadened – eight new HIV
specificities that were not previously detectable were newly detected, as were CMV specific CD8+ PBL – but with continued viral suppression,
HIV-specific responses diminished
• Viral rebounds gave different patterns of response: increases or decreases in pre-existing response, new specificities, or no change
Nef (73–82) Nef (94–103) QVPLRPMTYK HIV-1 infection human (A3 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind 3/5 HLA-A3 supertype alleles (A*0301, A*1101, A*3101, A*3301 and A*6801)
Nef (73–82) Nef (73–82 BRU) QVPLRPMTYK HIV-1 infection human (A3, A11, B35) Culmann1991
• Nef CTL clones from HIV+ donors
Nef (73–82) Nef (73–82 LAI) QVPLRPMTYK HIV-1 infection human (A3.1) Koenig1995
• Alanine substitutions L76A, R77A, M79A, T80A significantly decreased immunogenicity of peptide
• Nef CTL clones (4N225) were infused into an HIV-1 infected volunteer to evaluate effects of infusion on viral load/patient health
• Infusion led to outburst of escape variants which resulted in higher viral load/accelerated disease progression
Nef (73–82) Nef (73–82) QVPLRPMTYK HIV-1 infection human (A3.1) Betts2000
• Only 4/11 HLA-A2+ HIV+ individuals had CTL that reacted to SLYNTVATL, calling into question whether it is immunodominant
• 95 optimally-defined peptides from this database were used to screen for INFγ responses to other epitopes
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• 1/11 of the A2+ individuals was A3, and responded to QVPLRPMTYK as well as two other A3.1 epitopes
Nef (73–82) Nef (73–82) QVPLRPMTYK HIV-1 infection human (B*0301) Wilson2000a
• Three individuals with highly focused HIV-specific CTL responses were studied during acute infection using tetramers – high frequencies of HIV-1-specific
CD8+ T cells were found prior to seroconversion, and there was a close temporal relationship between the number of circulating HIV-specific T cells and
viral load was also found
• All three patients were B*2705, with HLA alleles: A1, A30/31, B*2705, B35; A1, A*0301, B7, B2705; and A*0201, A*0301, B2705, B39
• ELISPOT was used to test a panel of CTL epitopes that had been defined earlier and were appropriate for the HLA haplotypes of the study subjects – 3/3
subjects showed a dominant response to the B*2705 epitope KRWIILGGLNK
• The subject with A*0201 had a moderatly strong response to SLYNTVATL
• Weak responses were observed to A*301-RLRPGGKKK, A*301-QVPLRPMTYK, and B7-TPGPGVRYPL in the subject who was HLA A1, A*0301, B7,
B*2705
• No acute response was detected to the following epitopes: A*201-ILKEPVHGV, A*301-KIRLRPGGK, A*301-AIFQSSMTK, A*301-TVYYGVPVWK,
B35-EPIVGAETF, B35-HPDIVIYQY, B35-PPIPVGEIY, B35-NSSKVSQNY, B35-VPLRPMTY, B35-DPNPQEVVL
Nef (73–82) Nef (73–82 LAI) QVPLRPMTYK human (B27) Culmann1998
• Optimal epitope mapped by peptide titration
Nef (73–82) Nef (73–82 LAI) SVPLRPMTYK HIV-1 infection human (B35 or C4) Buseyne1993a
• Vertical transmission of HIV ranges from 13% to 39%
• Primary assays showed cytotoxic activity against at least one HIV protein was detected in 70% of infected children
• Epitopes recognized in five children were mapped using synthetic peptides and secondary cultures
• Patient EM13, who had a CTL response to three epitopes in Nef, was infected via blood transfusion after birth and went from CDC stage P2A to P2E
during the study
Nef (73–83) Nef (73–82 BRU) QVPLRPMTYKA HIV-1 infection human (A3) Choppin2001
• Seventy-three 8-11 mer peptides were generated based on putative anchor motifs in the Nef BRU sequence for HLA A2, A3, A24, B7, B8, and B35; these
73 peptides had 81 motifs. 54% bound to the predicted HLA molecule, particularly A2, B7/35, and B8. The strength of HLA-peptide binding was not
directly related to the number of individuals that recognized a protein.
• 20s proteasome cleavage of the Nef protein positions 66-100 showed a large fraction of peptides were cleaved ending at: 87L, 83A, 81Y, 71P, 68F and 67G.
The frequency of recognition may be in part dictated by the cleavage step in processing.
• QVPLRPMTYKA was recognized in 9/15 (60%) of individuals with HLA A3. It was a high affinity HLA-A3 binder.
Nef (74–81) Nef (74–82) VPLRPMTY human (A3) Carreno1992
• Included in HLA-A3 binding peptide competition study
Nef (74–81) Nef (73–82 LAI) VPLRPMTY HIV-1 or HIV-2 infection human (B*3501) Brander2001
• C. Brander notes this is a B*3501 epitope
Nef (74–81) Nef (75–82) VPLRPMTY Peptide-HLA interaction human (B*3501) Smith1996
• Crystal structure of VPLRPMTY-class I B allele HLA-B*3501 complex
Nef (74–81) Nef VPLRPMTY HIV-1 infection human (B*3501) Ostrowski2000
• The role of CD4+ T-cell help in expansion of virus-specific memory CTL was studied through co-culture ex vivo
• Optimal expansion of HIV-1-specific memory CTL depended on CD4+ T cell help in 9 of 10 patients – CD40 ligand trimer (CD40LT) could enhance CTL
in the absence of CD4+ T cell help to a variable degree in most of patients
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• Those CTL that didn’t respond to CD40LT could expand with IL2 present, and IL15 produced by dendritic cells also contributes
• The T-helper epitope used for CD4+ T cell stimulation was the universal tetanus helper epitope TET830-843 (QYIKANSKFIGITE)
Nef (74–81) Nef (subtype B) VPLRPMTY HIV-1 exposed seronegative human (B35) Kaul2000
• 11/16 heavily HIV exposed but persistently seronegative sex-workers in Nairobi had HIV-specific CD8 gamma-IFN responses in the cervix – systemic
CD8+ T cell responses tended to be to the same epitopes but at generally lower levels than cervical CD8+ T cell responses
• Low risk individuals did not have such CD8+ cells
• CD8+ T cell epitopes: DTVLEDINL (3 individuals), SLYNVATL (4 individuals), LSPRTLNAW (3 individuals) and YPLTFGWCF (4 individuals) were
most commonly recognized by the HIV-resistant women
Nef (74–81) Nef VPLRPMTY HIV-1 infection human (B35) Wilson2000a
• Three individuals with highly focused HIV-specific CTL responses were studied during acute infection using tetramers – high frequencies of HIV-1-specific
CD8+ T cells were found prior to seroconversion, and there was a close temporal relationship between the number of circulating HIV-specific T cells and
viral load was also found
• All three patients were B*2705, with HLA alleles: A1, A30/31, B*2705, B35; A1, A*0301, B7, B2705; and A*0201, A*0301, B2705, B39
• ELISPOT was used to test a panel of CTL epitopes that had been defined earlier and were appropriate for the HLA haplotypes of the study subjects – 3/3
subjects showed a dominant response to the B*2705 epitope KRWIILGGLNK
• The subject with A*0201 had a moderatly strong response to SLYNTVATL
• Weak responses were observed to A*301-RLRPGGKKK, A*301-QVPLRPMTYK, and B7-TPGPGVRYPL in the subject who was HLA A1, A*0301, B7,
B*2705
• No acute response was detected to the following epitopes: A*201-ILKEPVHGV, A*301-KIRLRPGGK, A*301-AIFQSSMTK, A*301-TVYYGVPVWK,
B35-EPIVGAETF, B35-HPDIVIYQY, B35-PPIPVGEIY, B35-NSSKVSQNY, B35-VPLRPMTY, B35-DPNPQEVVL
Nef (74–81) Nef (73–82 LAI) VPLRPMTY HIV-1 or HIV-2 infection human (B35) Culmann1991, McMichael1994
• Review of HIV CTL epitopes – defined by B35 motif found within a larger peptide
Nef (74–81) Nef (73–82 LAI) VPLRPMTY HIV-1 or HIV-2 infection human (B35) Rowland-Jones1995b
• VPLRPMTY also recognized by CTL from HIV-2 seropositives; epitope is conserved
Nef (74–81) Nef VPLRPMTY HIV-1 exposed seronegative human (B35) Rowland-Jones1998a
• A CTL response was found in exposed but uninfected prostitutes from Nairobi using previously-defined B clade epitopes that tended to be conserved in A
and D clades – such cross-reactivity could protect against both A and D and confer protection in Nairobi where both subtypes are circulating
• The A and D subtype consensus are identical to the B clade epitope
Nef (74–81) Nef (75–82) VPLRPMTY in vitro stimulation human (B35) Lalvani1997
• A peptide-based protocol was optimized for restimulation of CTLp using optimized peptide and IL-7 concentrations – importantly this protocol does not
stimulate a primary response, only secondary – peptide-specific CTLp counts could be obtained via staining with peptide-Class I tetramers
• This peptide was one of the B35 presented test peptides used in control experiments showing that the assay gave no activity using lymphocytes from 21
healthy B35 seronegative donors
Nef (74–81) Nef (subtype B) VPLRPMTY HIV-1 exposed seronegative human (B35) Rowland-Jones1998b
• HIV-specific CTL were found in exposed seronegative prostitutes from Nairobi – these CTL may confer protection
• Seroprevalence in this cohort is 90-95% and their HIV-1 exposure is among the highest in the world
• Most isolated HIV strains are clade A in Nairobi, although clades C and D are also found – B clade epitopes are often cross-reactive, however stronger
responses are frequently observed using A or D clade versions of epitopes
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• This epitope is conserved among A, B, and D clade viruses
Nef (74–81) Nef VPLRPMTY human (B35) Rowland-Jones1999
• CTL responses in seronegative highly HIV-exposed African female sex workers in Gambia and Nairobi were studied – these women had no delta 32
deletion in CCR5
• In Gambia there is exposure to both HIV-1 and HIV-2, CTL responses to B35 epitopes in exposed, uninfected women are cross-reactive,
• HIV-2 version of this epitope is conserved: VPLRPMTY, and CTLs are cross-reactive – one of five B35 CTL epitopes that are cross-reactive, see also
[Rowland-Jones1995b]
Nef (74–81) Nef (74–81) VPLRPMTY HIV-1 infection human (B35) Oxenius2000
• Epitope name: VPL
• Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific
CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load – three patients that had delayed initiation of
HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became
undetectable
• One of two HLA B35+ among the eight study subjects recognized this epitope
• Patient SC15 (HLA A1/68, B8/35, Bw4/6, Cw4/0704) was given acute and sustained therapy and recognized epitopes PPIPVGDIY and VPLRPMTY
during 331 days of HAART treatment
Nef (74–81) Nef (75–82) VPLRPMTY HIV-1 infection, HIV-1 exposed
seronegative
human (B35) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with
reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected
women
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure
• Subject ML 857 shifted from a A*6802 DTVLEDINL and B35 (H/N)PDIVIYQY response prior to seroconversion to a B35 PPIPVGDIY and B35
VPLRPMTY response post-seroconversion
Nef (74–81) VPLRPMTY HIV-1 infection human (B35) Sabbaj2002b
• Epitope name: Nef-VY8
• Among HIV+ individuals who carried HLA B35, 12/22 (55%) recognized this epitope
• Among HIV+ individuals who carried HLA B*5301, 0/11 (0%) recognized this epitope
Nef (74–81) Nef (74–81 BRU) VPLRPMTY HIV-1 infection human (B35) Choppin2001
• Seventy-three 8-11 mer peptides were generated based on putative anchor motifs in the Nef BRU sequence for HLA A2, A3, A24, B7, B8, and B35; these
73 peptides had 81 motifs. 54% bound to the predicted HLA molecule, particularly A2, B7/35, and B8. The strength of HLA-peptide binding was not
directly related to the number of individuals that recognized a protein.
• 20s proteasome cleavage of the Nef protein positions 66-100 showed a large fraction of peptides were cleaved ending at: 87L, 83A, 81Y, 71P, 68F and 67G.
The frequency of recognition may be in part dictated by the cleavage step in processing.
• VPLRPMTY was recognized in 5/16 (31%) of individuals with HLA B35, and it was a moderate affinity HLA binder. Cleavage at the C-term Y was
frequent in vitro.
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Nef (74–81) VPLRPMTY HIV-1 infection, Vaccine human, macaque (B35) Hanke2000, Wee2002
Vaccine Vector/Type: DNA prime with vaccinia MVA boost Strain: subtype A HIV component: p17, p24, polyepitope
• The HIV-1 subtype A focused vaccine HIVA contains p24 and p17, in a reversed order relative to the Gag polyprotein to prevent myristylation of p17,
which could direct the protein to the cell membrane and inhibit efficient peptide processing and class I presentation, as well as a polyepitope string of
conserved, often immunodominant epitopes that were selected to have particularly good cross-reactive potential for the A-clade epidemic in Nairobi,
Kenya. A DNA and MVA prime-boost vaccination protocol using the HIVA antigen will be used in a phase III clinical trial in Kenya. This epitope is
included in the polyepitope string [Hanke2000].
• Multiple CD4+ or CD8+ T-cell vaccine-induced responses to peptide pools were detected using intracellular cytokine staining and IFNgamma Elispot
assays after vaccination of 5 macaques. The response to the Mamu A*01 SIV p27 epitope p11C (CTPYDINQM), included in the polyepitope region, was
not immunodominant in the Mamu A*01 vaccinated macaques, possibly because of processing limitations in context of the artificial polyepitope string
[Wee2002].
Nef (74–82) Nef (73–82) VPLRPMTYK Peptide-HLA interaction human (A11) Zhang1993
• Exploration of A11 binding motif
Nef (75–82) Nef (75–82 LAI) PLRPMTYK HIV-1 infection human (A*1101) McMichael1994
• Review of HIV CTL epitopes
• C. Brander notes that this is an A*1101 epitope in the 1999 database
Nef (75–82) Nef (75–82 LAI) PLRPMTYK HIV-1 infection human (A*1101) Brander2001
• C. Brander notes this is an A*1101 epitope
Nef (77–85) Nef (77–85 LAI) RPMTYKAAL HIV-1 infection human (B*0702) Bauer1997
• Structural constraints on the Nef protein may prevent escape
• Noted in Brander 1999, this database, to be B*0702
Nef (77–85) Nef (77–85 LAI) RPMTYKAAL HIV-1 infection human (B*0702) Brander2001
• C. Brander notes this is a B*0702 epitope
Nef (77–85) Nef (75–83 IIIB) RPMTYKAAL HIV-1 infection human (B7) Oxenius2001b
• Study of tetramer staining of B7 around RPMTYKAAL gave quantitative results that were very different than functional measurements based on an
ELISPOT assay
• Autologous clones were checked and 39/40 clones from two time points had the variant sequence RPMTYKGAL – tetramers based on RPMTYKGAL
gave a more intense and uniform staining and bound with higher affinity to the RPMTYKGAL Vbeta14 TCR
Nef (77–85) Nef (77–85 SF2) RPMTYKAAL HIV-1 infection human (B7) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B7+ individuals that had a CTL response to this epitope broken down by group: 1/4 group 1, 0/3 group 2, and 1/1 group 3
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Nef (77–85) Nef (77–85) RPMTYKAAL HIV-1 infection human (B7) Day2001
• The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7 was
studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
• 2 to 17 epitopes were recognized in a given individual, A2-restricted CTL response tended to be narrow and never dominated the response, and 25/27
epitopes were targeted by at least one person
• Subjects with chronic HIV-1 infection recognized between 2-8 out of 11 B7-restricted epitopes
• An acute seroconvertor homozygous for the B7 allele recognized five B7-restricted epitopes
• The other acute seroconvertor failed to recognize any of the 11 B7-restricted epitopes tested
• The B7-restricted CTL response was highly variable and there was no clearly dominant epitope
Nef (77–85) Nef (77–85) RPMTYKAAV HIV-1 infection human (B7) Day2001
• The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7 was
studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
• 2 to 17 epitopes were recognized in a given individual, A2-restricted CTL response tended to be narrow and never dominated the response, and 25/27
epitopes were targeted by at least one person
• Subjects with chronic HIV-1 infection recognized between 2-8 out of 11 B7-restricted epitopes
• An acute seroconvertor homozygous for the B7 allele recognized five B7-restricted epitopes
• The other acute seroconvertor failed to recognize any of the 11 B7-restricted epitopes tested
• The B7-restricted CTL response was highly variable and there was no clearly dominant epitope
Nef (77–85) Nef (77–85 BRU) RPMTYKAAV HIV-1 infection human (B7) Choppin2001
• Seventy-three 8-11 mer peptides were generated based on putative anchor motifs in the Nef BRU sequence for HLA A2, A3, A24, B7, B8, and B35; these
73 peptides had 81 motifs. 54% bound to the predicted HLA molecule, particularly A2, B7/35, and B8. The strength of HLA-peptide binding was not
directly related to the number of individuals that recognized a protein.
• 20s proteasome cleavage of the Nef protein positions 66-100 showed a large fraction of peptides were cleaved ending at: 87L, 83A, 81Y, 71P, 68F and 67G.
The frequency of recognition may be in part dictated by the cleavage step in processing.
• RPMTYKAAV was recognized in 7/10 (70%) of individuals with HLA B7, and 0/3 (0%) of individuals with HLA B35. It was a moderate affinity HLA
binder.
Nef (77–85) Nef (77–85) RPMTYKAAL HIV-1 infection human (B7) Yu2002a
• Epitope name: B7-RL9
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
• 3/11 HLA-B7 individuals had detectable B7-restricted responses to this epitope during acute infection – 10/15 of HLA-B7 epitopes tested were targeted by
at least one person during acute infection. 2/4 individuals had detectable responses to this epitope after STI.
Nef (77–85) Nef (77–85) RPMTYKAAV HIV-1 infection human (B7) Yu2002a
• Epitope name: B7-RV9
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
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• 2/11 HLA-B7 individuals had detectable B7-restricted responses to this epitope during acute infection – 10/15 of HLA-B7 epitopes tested were targeted by
at least one person during acute infection. 3/4 individuals had detectable responses to this epitope after STI.
Nef (77–91) Nef (77–91) RPMTYKGAFDLSFFL HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
• This peptide was among the 28 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
Nef (79–87) Nef (81–89 HXB3) MTYKAALDL Vaccine murine (HLA-A201
transgenic)
Sandberg2000
Vaccine Vector/Type: DNA, peptide Strain: HXB3 HIV component: Nef Adjuvant: Freund’s adjuvant
• Ten Nef 9-mer peptides were predicted to have a strong binding affinity with HLA-A*0201 – of these, four did bind strongly by a T2 class I stabilization
assay, several others bound weakly
• A CTL immune response to only 3/10 peptides was detected by a 51Cr-release assay after immunization of HLA-A201 transgenic mice with either nef
DNA under the control of a CMV promotor coated on, gold particles delivered to abdominal skin by gene gun
• MTYKAALDL bound weakly to HLA-A2, but the DNA nef vaccine elicited a good CTL response
Nef (82–91) Nef (82–91 LAI) KAAVDLSHFL HIV-1 infection human (C*0802) Nixon1999
• A patient who made a mono-specific CTL response to this Nef specific epitope was given effective anti-retroviral therapy within 90 days of infection,
reducing the antigenic stimulous
• Within 7 days of therapy, his CTLp frequency dropped from 60 to 4 per million PBMC, as his viremia dropped
• The patient went from having an activated effector population (detected by CTLp and clone specific RNA) to a non-activated quiescent population (detected
by the CTL-clone specific DNA)
Nef (82–91) Nef (82–91 LAI) KAAVDLSHFL HIV-1 infection human (C*0802(Cw8)) Brander2001
• C. Brander notes this is a C*0802(Cw8) epitope
Nef (82–91) Nef (82–91 SF2) KAAVDLSHFL HIV-1 infection human (Cw8) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-Cw8+ individuals that had a CTL response to this epitope broken down by group: 1/3 group 1, 0/0 group 2, and 0/1 group 3
Nef (82–91) Nef (SF2) KAAVDLSHFL HIV-1 infection human (Cw8) Altfeld2000b
• This epitope was mapped by ELISPOT in a study identifying new HLA-B60 epitopes, and was one of the epitopes presented by another HLA molecule in
an HLA-B60 individual
Nef (82–96) Nef (82–96) KGAFDLSFFLKEKGG HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
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• This peptide was among the 8 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
Nef (82–101) Nef (81–100 SF2) KAAVDLSHFLKEKGGLEGLI HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Eleven subjects had CTL that could recognize vaccinia-expressed LAI Nef
• Three of these 11 had CTL response to this peptide
• The responding subjects were HLA-A1, A2, B8, B14; HLA-A11, A24, B8, B53
Nef (82–101) Nef (SF2) KAAVDLSHFLKEKGGLEGLI HIV-1 infection human Altfeld2001a
• HIV+ individual AC-06 was tested for reactive overlapping peptides spanning all HIV-1 proteins in an ELISPOT and was found to react with 12 peptides
from 7 proteins, suggesting that the breadth of CTL responses are underestimated if accessory proteins are not included in the study
• Nef peptides PQVPLRRMTYKAAVDLSHFL, KAAVDLSHFLKEKGGLEGLI and EEEEVGFPVTPQVPLRPMTY were recognized and the first two
share KAAVDLSHFL (a Cw8 epitope), the first and last share PQVPLRPMTY
Nef (83–91) Nef (83–91 BRU) AAVDLSHFL HIV-1 infection human (A2) Choppin2001
• Seventy-three 8-11 mer peptides were generated based on putative anchor motifs in the Nef BRU sequence for HLA A2, A3, A24, B7, B8, and B35; these
73 peptides had 81 motifs. 54% bound to the predicted HLA molecule, particularly A2, B7/35, and B8. The strength of HLA-peptide binding was not
directly related to the number of individuals that recognized a protein.
• 20s proteasome cleavage of the Nef protein positions 66-100 showed a large fraction of peptides were cleaved ending at: 87L, 83A, 81Y, 71P, 68F and 67G.
The frequency of recognition may be in part dictated by the cleavage step in processing.
• AAVDLSHFL was recognized in 3/18 (17%) of individuals with HLA A2. It was a low affinity HLA binder.
Nef (83–91) Nef (85–93 HXB3) AALDLSHFL Vaccine murine (HLA-A201
transgenic)
Sandberg2000
Vaccine Vector/Type: DNA, peptide Strain: HXB3 HIV component: Nef Adjuvant: Freund’s adjuvant
• Ten Nef 9-mer peptides were predicted to have strong binding affinity for HLA-A*0201 – of these, four did bind strongly by a T2 class I stabilization assay,
several others bound weakly
• A CTL immune response to only 3/10 peptides was detected by a 51Cr-release assay after immunization of HLA-A201 transgenic mice with nef DNA
under the control of a CMV promotor, coated on gold particles delivered to abdominal skin by gene gun
• AALDLSHFL was predicted to have a strong binding capacity for HLA-A2, and did, but it was the only one of the peptides recognized that was a strong
binder, the other two recognized peptides were weak binders
• AALDLSHFL was also tested by subcutaneous injection of Nef peptides in Freund’s adjuvant and gave a strong response to the peptide
Nef (83–92) Nef (81–90 93TH253
subtype CRF01)
GAFDLSFFLK HIV-1 infection human (A11) Sriwanthana2001
• Epitope name: N83-92
• This was a study of HIV-1 exposed persistently seronegative (HEPS) female sex workers in Chiang Mai, northern Thailand
• HLA-A11 is very common in this population, and was enriched among the HEPS sexworkers – weak CTL responses were detected in 4/7 HEPS women,
and CTL responses were found in 8/8 HIV+ controls, and 0/9 HIV- women that were not exposed
• This epitope was strongly reactive in HIV+ study subjects 053 and 184 who carried HLA-A11.
Nef (83–92) Nef (81–90 93TH253
subtype CRF01)
GAFDLSFFLK HIV-1 infection human (A11) Bond2001
• HLA-A11 CRF01 (called subtype E in Bond et al.) epitopes were identified that stimulated CTL from HIV+ female sex workers (FSW) from Northern
Thailand, of whom more than half were HLA-A11 positive
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• 77 possible HLA-A11 epitopes were first defined using EpiMatrix, these were screened for binding to A11 finding and 26 bound, and 12 of these were
epitopes for CTL responses from 8 HLA-A11 positive FSWs, six were novel, six were previously identified
• This epitope was predicted by the EpiMatrix method to be likely to bind to A11, and it served as an epitope in the FSWs, it was one of the six A11 epitopes
that had been previously defined
• 4/8 tested FSWs recognized this epitope
• This epitope was only conserved in CRF01 and subtype C, and exact matches were uncommon
Nef (83–94) Nef (83–94 BRU) AAVDLSHFLKEK HIV-1 infection human (A11) Culmann1991
• Epitope defined by boundaries of overlapping peptides that stimulate Nef CTL clones
Nef (84–91) Nef (84–91 LAI) AVDLSHFL HIV-1 infection human (Bw62) Culmann-Penciolelli1994
Nef (84–91) Nef (84–91) AVDLSHFL HIV-1 infection human (Bw62) Betts2000
• Only 4/11 HLA-A2+ HIV+ individuals had CTL that reacted to SLYNTVATL, calling into question whether it is immunodominant
• 95 optimally-defined peptides from this database were used to screen for INFγ responses to other epitopes
• 1/11 of the A2+ individuals that didn’t respond to SLYNTVATL reacted with seven other epitopes including this epitope
Nef (84–92) Nef (84–92 LAI) AVDLSHFLK HIV-1 infection human (A*1101) Brander2001
• C. Brander notes this is an A*1101 epitope
Nef (84–92) 84 (92–) AVDLSHFLK HIV-1 infection human (A*1101) Fukada2002
• Counterparts for eight known clade B HLA A*1101 epitopes were generated for clade E (CRF01). Three epitopes, identical among clade A-E, were
cross-reactive and recognized by clade E infected individuals. The clade E and B analogs to three more HLA A*1101 epitopes was recognized in a clade
specific manner. Two other HLA A*1101 clade B defined epitopes were found not to have stimulated a response in clade E infected individuals.
• AVDLSHFLK was found to elicit clade-specific responses in clade B (AVDLSHFLK is most common, aLdlshflk is a common variant also found in clade
A) and clade E (aFdlsFflk is most common and is also common in clade C). AVDLSHFLK was strongly recognized by CTL from 2/5 B clade infected
Japanese subjects, as was aLdlshflk, and aFdlsFflk by CTL from 5/7 E clade infected Thai subjects.
• The binding of aFdlsFflk to HLA A*1101 was 10-50 times lower than the other variants, and bulk CTL generated from individuals did not cross-react with
the cross-clade peptides.
Nef (84–92) Nef (84–92 LAI) AVDLSHFLK HIV-1 infection human (A11) McMichael1994
• Review of HIV CTL epitopes
• C. Brander notes that this is an A*1101 epitope in the 1999 database
Nef (84–92) Nef (84–92) AVDLSHFLK HIV-1 infection human (A11) Betts2000
• Only 4/11 HLA-A2+ HIV+ individuals had CTL that reacted to SLYNTVATL, calling into question whether it is immunodominant
• 95 optimally-defined peptides from this database were used to screen for INFγ responses to other epitopes
• 1/11 of the A2+ individuals that didn’t respond to SLYNTVATL reacted with seven other epitopes including this epitope
Nef (84–92) Nef (84–92 LAI) AVDLSHFLK HIV-1 infection human (A11) Couillin1994, Goulder1997a
• Mutational variation in HIV epitopes in individuals with appropriate HLA types can result in evasion of CTL response
• [Goulder1997a] is a review of immune escape that summarizes this study
Nef (84–92) Nef (84–92 LAI) AVDLSHFLK HIV-1 infection human (A11) Couillin1995
• Mutations found in this epitope in HLA-A11 positive and negative donors were characterized
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Nef (84–92) Nef (84–92) AVDLSHFLK HIV-1 infection human (A11) Oxenius2000
• Epitope name: AVD
• Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific
CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load – three patients that had delayed initiation of
HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became
undetectable
• Both of the 2/8 HLA-A11 study subjects recognized this CTL epitope
• Patient SC19(HLA A11/12, B8/44, Cw06/0701, DR3/7, DR52/53, DQ 2/8) had a CTL response to epitopes FLKEKGGL, GEIYKRWII,
ACQGVGGPGHK, AVDLSHFLK, and FNCGGEFFY that declined during therapy initiated at day 197
• Patient SC18(HLA A2/11, B8/44, Cw06/0701, DR3/7, DR52/53, DQ2) recognizes the epitopes ACQGVGGPGHK, QVPLRPMTYK, AVDLSHFLK, and
one called QIY but not fully described – he had brief therapy upon seroconversion and has had low viral load during 600 days of follow up
Nef (84–92) Nef (82–90) AVDLSHFLK HIV-1 infection human (A11) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
Nef (84–92) Nef (84–92 SF2) AVDLSHFLK HIV-1 infection human (A11) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-A11+ individuals that had a CTL response to this epitope broken down by group: 0/3 group 1, 0/0 group 2, and 2/2 group 3
Nef (84–92) Nef (84–92) AVDLSHFLK HIV-1 infection, HIV-1 exposed
seronegative
human (A11) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
Nef (84–92) Nef AVDLSHFLK HIV-1 infection human (A11) Oxenius2002b
• Epitope name: AVD
• Using previously defined epitopes [Oxenius2000, Oxenius2001a] in an IFNgamma Elispot assay, 13 chronically HIV-1 infected patients were studied over a
period including therapy with standard treatment interruptions (STI).
• STIs induced increased recognition of CTL epitopes, but there was no correlation between CTL responses with viral rebound rates, plateau viral loads, or
clearance rates.
Nef (84–92) Nef AVDLSHFLK HIV-1 infection, Vaccine human, macaque (A11) Hanke2000, Wee2002
Vaccine Vector/Type: DNA prime with vaccinia MVA boost Strain: subtype A HIV component: p17, p24, polyepitope
• The HIV-1 subtype A focused vaccine HIVA contains p24 and p17, in a reversed order relative to the Gag polyprotein to prevent myristylation of p17,
which could direct the protein to the cell membrane and inhibit efficient peptide processing and class I presentation, as well as a polyepitope string of
conserved, often immunodominant epitopes that were selected to have particularly good cross-reactive potential for the A-clade epidemic in Nairobi,
Kenya. A DNA and MVA prime-boost vaccination protocol using the HIVA antigen will be used in a phase III clinical trial in Kenya. This epitope is
included in the polyepitope string [Hanke2000].
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• Multiple CD4+ or CD8+ T-cell vaccine-induced responses to peptide pools were detected using intracellular cytokine staining and IFNgamma Elispot
assays after vaccination of 5 macaques. The response to the Mamu A*01 SIV p27 epitope p11C (CTPYDINQM), included in the polyepitope region, was
not immunodominant in the Mamu A*01 vaccinated macaques, possibly because of processing limitations in context of the artificial polyepitope string
[Wee2002].
Nef (84–92) Nef (84–92 BRU) AVDLSHFLK HIV-1 infection human (A3) Choppin2001
• Seventy-three 8-11 mer peptides were generated based on putative anchor motifs in the Nef BRU sequence for HLA A2, A3, A24, B7, B8, and B35; these
73 peptides had 81 motifs. 54% bound to the predicted HLA molecule, particularly A2, B7/35, and B8. The strength of HLA-peptide binding was not
directly related to the number of individuals that recognized a protein.
• 20s proteasome cleavage of the Nef protein positions 66-100 showed a large fraction of peptides were cleaved ending at: 87L, 83A, 81Y, 71P, 68F and 67G.
The frequency of recognition may be in part dictated by the cleavage step in processing.
• AVDLSHFLK was recognized in 4/12 (33%) of individuals with HLA A3. It was a high affinity HLA-A3 binder.
Nef (84–92) Nef (84–94) AVDLSHFLK HIV-1 infection human (A3) Yu2002a
• Epitope name: A3-ALK9
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
• 0/14 HLA-A3 positive individuals had detectable A3-restricted responses to this epitope during acute infection, but only 5/15 of HLA-A3 epitopes tested
were targeted during acute infection. 1/7 individuals began to have detectable responses to this epitope after STI.
Nef (86–94) Nef DLSHFLKEK HIV-1 infection, Vaccine human, macaque
(A*0301)
Hanke2000, Wee2002
Vaccine Vector/Type: DNA prime with vaccinia MVA boost Strain: subtype A HIV component: p17, p24, polyepitope
• The HIV-1 subtype A focused vaccine HIVA contains p24 and p17, in a reversed order relative to the Gag polyprotein to prevent myristylation of p17,
which could direct the protein to the cell membrane and inhibit efficient peptide processing and class I presentation, as well as a polyepitope string of
conserved, often immunodominant epitopes that were selected to have particularly good cross-reactive potential for the A-clade epidemic in Nairobi,
Kenya. A DNA and MVA prime-boost vaccination protocol using the HIVA antigen will be used in a phase III clinical trial in Kenya. This epitope is
included in the polyepitope string [Hanke2000].
• Multiple CD4+ or CD8+ T-cell vaccine-induced responses to peptide pools were detected using intracellular cytokine staining and IFNgamma Elispot
assays after vaccination of 5 macaques. The response to the Mamu A*01 SIV p27 epitope p11C (CTPYDINQM), included in the polyepitope region, was
not immunodominant in the Mamu A*01 vaccinated macaques, possibly because of processing limitations in context of the artificial polyepitope string
[Wee2002].
Nef (86–94) Nef (86–94) DLSHFLKEK HIV-1 infection, HIV-1 exposed
seronegative
human (A3) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
Nef (86–94) Nef (84–92 LAI) DLSHFLKEK HIV-1 infection human (A3.1) McMichael1994
• Review of HIV CTL epitopes
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Nef (86–100) Nef (86–100 LAI) DLSHFLKEKGGLEGL HIV-1 infection human (A2) Robertson1993
• Development of a retroviral vector (pNeoNef) to generate autologous targets
Nef (86–100) Nef (86–100 LAI) DLSHFLKEKGGLEGL HIV-1 infection human (B35) Buseyne1993b
Nef (86–100) Nef (86–100 LAI) DLSHFLKEKGGLEGL HIV-1 infection human (B35 or C4) Buseyne1993a
• Vertical transmission of HIV ranges from 13% to 39%
• Primary assays showed cytotoxic activity against at least one HIV protein was detected in 70% of infected children
• Epitopes recognized in five children were mapped using synthetic peptides and secondary cultures
• Patient EM13, who had a CTL response to three epitopes in Nef, was infected via blood transfusion after birth and went from CDC stage P2A to P2E
during the study
Nef (87–102) Nef FSHFLKEKGGLEGLIY human Jubier-Maurin1999
• 41 new HIV-1 strains describing envelope subtypes of HIV-1 A-H were genetically characterized in the nef region – 34 subtypes were classified in the same
subtype in nef and env and 7 of the 41 strains were recombinants
• This region was defined as a CTL epitope region that is conserved among HIV-1 M group subtypes
Nef (88–100) Nef (103–116) SHFLKEKGGLEGL HIV-1 infection human Guimaráes2002
• Nef sequences were obtained from Brazilians to study epitope diversity in this geographic region—most B subtype sequences are SHFLKEKGGLEGL, but
sFflkekgglegl is found in most subtype C samples.
Nef (90–97) Nef (89–97) FLKEKGGL HIV-1 infection human Betts2000
• Only 4/11 HLA-A2+ HIV+ individuals had CTL that reacted to SLYNTVATL, calling into question whether it is immunodominant
• 95 optimally-defined peptides from this database were used to screen for INFγ responses to other epitopes
• 1/11 of the A2+ individuals that responded to SLYNTVATL reacted with seven other epitopes including this epitope previously described as presented by
B8
Nef (90–97) Nef FLKEKGGL HIV-1 infection human (A3) Ostrowski2000
• The role of CD4+ T-cell help in expansion of virus-specific memory CTL was studied through co-culture ex vivo
• Optimal expansion of HIV-1-specific memory CTL depended on CD4+ T cell help in 9 of 10 patients – CD40 ligand trimer (CD40LT) could enhance CTL
in the absence of CD4+ T cell help to a variable degree in most of patients
• Those CTL that didn’t respond to CD40LT could expand with IL2 present, and IL15 produced by dendritic cells also contributes
• The T-helper epitope used for CD4+ T cell stimulation was the universal tetanus helper epitope TET830-843 (QYIKANSKFIGITE)
Nef (90–97) FLKEKGGL HIV-1 infection human (B*08) Sabbaj2002b
• Epitope name: Nef-FL8
• Among HIV+ individuals who carried HLA B*08, 1/3 (33%) recognized this epitope.
Nef (90–97) Nef (89–97 LAI) FLKEKGGL HIV-1 infection human (B*0801) Brander2001
• C. Brander notes this is a B*0801 epitope
Nef (90–97) Nef (89–97 LAI) FLKEKGGL HIV-1 infection human (B8) Price1997
• CTL escape variants appeared over time in HLA-B8 HIV-1+ individual, providing evidence of immune escape
• Most variants appear at position 5, an anchor residue
• FLKE(E,N or Q)GGL showed reduced binding efficiency and recognition
• Double mutants (FIKENGGL, FLEENGGL, and FLKGNGGL) completely escaped recognition
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• [Goulder1997a] is a review of immune escape that summarizes this study in the context of CTL escape to fixation
Nef (90–97) Nef (90–97 IIIB) FLKEKGGL HIV-1 infection human (B8) Spiegel1999
• Study examines the effect of highly active antiretroviral therapy (HAART) on HIV-1 plasma viral load, CTLp and CTLe frequencies in 8 infected children
• CTLp (precursors) were measured by stimulating in culture and assaying using 51Cr release, against vaccina expressed IIIB Env, Gag, Pol, Nef
• B7-FLKEKGGL tetramer complex was used for one of the children that was HLA-B7, and this infant showed a vigorous response (> 4% of CD8+ T cells)
at 9 months of age
• HIV-1 specific CTL responses initially increased in children with complete viral suppression, but then decreased, suggesting viral replication is needed to
maintain CTL responses
Nef (90–97) Nef FLKEKGGL Vaccine human (B8) Hanke1998a, Hanke1998b
Vaccine Vector/Type: vaccinia HIV component: polyepitope
• This epitope was shown to be processed and presented to appropriate CTL clones upon infection of human target cells with vaccinia virus Ankara (VVA)
carrying 20 HIV-1 epitopes recognized by humans
Nef (90–97) Nef (88–95) FLKEKGGL HIV-1 infection human (B8) Goulder1997g
• Natural variants for this epitope have been observed in several donors
• Substitutions Q5, N5, E5 that alter anchor position 5 are not well recognized
• Substitution I2 binds well to B8 and is recognized
Nef (90–97) Nef (90–97) FLKEKGGL HIV-1 infection human (B8) Dyer1999
• CTL specific responses were measured over a 1.3 to 1.5 year period in members of the Sydney Blood Bank Cohort (SBBC) who had been infected with a
natural attenuated strain of HIV-1 which was Nef-defective
• Some of these patients had prolonged high levels of CTL effector and memory cells despite low viral load
Nef (90–97) Nef (SF2) FLKEKGGL HIV-1 infection human (B8) Goulder2001a
• Epitope name: FL8
• This peptide elicited a weak CTL response during acute HIV-1 infection in patient PI004
• Three CTL responses, to epitopes TSTLQEQIGW, ISPRTLNAW, and KAFSPEVIPMF, were evident early after infection; CTL responses to SLYNTVATL,
QASQEVKNW, EIYKRWII, and FLKEKGGL were detectable at 5 months post-infection and beyond
• FL8 was recognized in an additional patient, AC29, in chronic infection
Nef (90–97) Nef (92–99) FLKEKGGL HIV-1 infection human (B8) Oxenius2001a
• Epitope name: FLK
• Characterization of specific CTL phenotype patterns in response to variation of the virus load in response to antiviral therapy in 3 patients with chronic
HIV-1 infection
• CTL activation in response to increasing viral load sequential, and co-segregated with apoptosis only during later stages of the response, suggesting
antigen-specific cell-death is restricted to distinct CTL sub-populations
Nef (90–97) Nef (92–99) FLKEKGGL HIV-1 infection human (B8) Oxenius2000
• Epitope name: FLK
• Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific
CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load – three patients that had delayed initiation of
HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became
undetectable
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• Six of the 7/8 study subjects that were HLA B8 recognized this early dominant CTL epitope
• Patient SC2 (HLA A1, B7/8, Cw0701/0702, DR4/53, DQ7) had CTL responsiveness against epitopes FLKEKGGL, GPKVKQWPL, and GEIYKRWII
peptides – FLKEKGGL tetramer staining steadily declined and at day 1340 the FLKEKGGL stained cells were no longer detected and the escape mutant
FLKENGGI was found in 8/10 clones
• Patient SC9 (HLA A1/2, B8/13, Cw0/0701, DR2/11, DQ6/7) had a CTL response against epitopes FLKEKGGL, ILKEPVHGV,
SQRRQDILDLWIYHTQGYFPDWQNY, and GEIYKRWII peptides and all responses declined during therapy initiated at day 390 but were restored when
therapy become intermittent
• Patient SC19(HLA A11/12, B8/44, Cw06/0701, DR3/7, DR52/53, DQ 2/8) had a CTL response to epitopes FLKEKGGL, GEIYKRWII,
ACQGVGGPGHK, AVDLSHFLK, and FNCGGEFFY that declined during therapy initiated at day 197
• Patient SC10(HLA A1/3, B8/35, DR1/8, DQ 4/5) had sustained therapy started during acute infection and maintained an immunodominant response to
FLKEKGGL and a response to GEIYKRWII through day 1088
• Patient SC12(HLA A1, B8/39, Cw0701/0702, DR2/3, DR51/52, DQ2/6) had sustained therapy started during acute infection and maintained an
immunodominant response to FLKEKGGL throughout and minor responses to GEIYKRWII, DCKTILKAL, GGKKKYKLK – GEIYKRWII and
GGKKKYKLK responses were stimulated by a brief period off therapy
• Patient SC11(HLA A1, B8, Cw0201, DR3/11, DR52, DQ2/7) started therapy early, remained on therapy for 40 days, then reinitiated HAART at day 640
had a CTL response to FLKEKGGL, GPKVKQWPL, and GEIYKRWII throughout and received a benefit from the early limited course therapy
Nef (90–97) Nef FLKEKGGL HIV-1 infection human (B8) Kostense2001
• HLA tetramers to six epitopes were used to study HLA-A2, B8 and B57 CTL in 54 patients – HIV-specific tetramer positive cells were inversely correlated
with viral load in patients with high CD4, but in patients with CD4 T-cells below 400 high tetramer frequencies were found despite high viral load
• Most patients have high levels of HIV-specific T-cell expansions, but many of these cells aren’t functional
• In 15 of the patients, the proportion of IFN gamma producing tetramer cells correlated with AIDS-free survival
• Stimulation with HLA-B8 p24 and Nef epitopes significantly increased Nef-specific T-cell numbers in 2 patients (748 and 1113)
• There were more functional IFN-gamma producing Nef-specific T-cells within the T-cell population than there were active p24 Gag-specific T-cells
• No correlation between elevated numbers of Nef-specific CTL cells and plasma viral load was observed
Nef (90–97) Nef (88–95) FLKEKGGL HIV-1 infection human (B8) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
Nef (90–97) Nef (88–95 SF2) FLKEKGGL HIV-1 infection human (B8) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B8+ individuals that had a CTL response to this epitope broken down by group: 3/3 group 1, 1/3 group 2, and 1/2 group 3
Nef (90–97) Nef (89–97) FLKEKGGL HIV-1 infection human (B8) Appay2000
• Combined tetramer and intracellular cytokine staining was used to study the function of circulating CD8+ T cells specific for HIV and CMV
• HIV-specific CD8+ T cells expressed lower levels of perforin than CMV-specific CD8+ T cells from the same donor, and this was associated with persistent
CD27 expression on HIV-specific cells, suggesting impaired maturation
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• In most donors, between 50% and 95% of the activated virus-specific CD8+ T cells produced IFN-γ and MIP-1β with a distinct subset that failed to
produce TNF-α
Nef (90–97) Nef (90–97) FLKEKGGL HIV-1 infection human (B8) Day2001
• B8-restricted CTL accounted for about 1/3 of the total CTL response in one individual
• The response to FLKEKGGL was the second highest response in magnitude compared to all the HLA class I A- and B-restricted epitopes tested in this
individual
Nef (90–97) Nef FLKEKGGL HIV-1 infection human (B8) Goulder2000b
• Tetramer assays were compared with three functional assays in 42 people with chronic HIV infection: ELISPOT, intracellular cytokine staining, and
precursor frequency (limiting dilution assay [LDA])
• HIV-specific tetramer staining CTLs appeared to be active, and inert CTL were not found to play a significant role in chronic pediatric or adult HIV
infection
Nef (90–97) Nef (90–97 BRU) FLKEKGGL HIV-1 infection human (B8) Choppin2001
• Seventy-three 8-11 mer peptides were generated based on putative anchor motifs in the Nef BRU sequence for HLA A2, A3, A24, B7, B8, and B35; these
73 peptides had 81 motifs. 54% bound to the predicted HLA molecule, particularly A2, B7/35, and B8. The strength of HLA-peptide binding was not
directly related to the number of individuals that recognized a protein.
• 20s proteasome cleavage of the Nef protein positions 66-100 showed a large fraction of peptides were cleaved ending at: 87L, 83A, 81Y, 71P, 68F and 67G.
The frequency of recognition may be in part dictated by the cleavage step in processing.
• FLKEKGGL was recognized in 12/14 (86%) of individuals with HLA B8, and it was a high affinity HLA binder.
Nef (90–97) Nef FLKEKGGL HIV-1 infection human (B8) Oxenius2002b
• Epitope name: FLK
• Using previously defined epitopes [Oxenius2000, Oxenius2001a] in an IFNgamma Elispot assay, 13 chronically HIV-1 infected patients were studied over a
period including therapy with standard treatment interruptions (STI).
• STIs induced increased recognition of CTL epitopes, but there was no correlation between CTL responses with viral rebound rates, plateau viral loads, or
clearance rates.
Nef (90–97) Nef FLKEKGGL HIV-1 infection human (B8) Appay2002
• Four HIV patients with prolonged clinically successful anti-viral therapy but with ongoing evidence of replication and Nef mRNA transcription, showed
specific T-cell responses by Elispot and Tetramer staining, maintained for 2-4 years after initiation of HAART.
• Nef epitope recognition was detected in all 4 subjects, gp120, Pol and Gag-specific in 1 or 2 subjects – two patients recognized FLKEKGGL.
• The HIV-specific CD8+ T-cells had an intermediate maturation phenotype characterized by low levels of perforin and high levels of CD27 expression.
Nef (90–97) Nef FLKEKGGL HIV-1 infection human (B8) Appay2002
• Four HIV patients with prolonged clinically successful anti-viral therapy but with ongoing evidence of replication and Nef mRNA transcription, showed
specific T-cell responses by Elispot and Tetramer staining, maintained for 2-4 years after initiation of HAART.
• Nef epitope recognition was detected in all 4 subjects, gp120, Pol and Gag-specific in 1 or 2 subjects – two patients recognized FLKEKGGL.
• The HIV-specific CD8+ T-cells had an intermediate maturation phenotype characterized by low levels of perforin and high levels of CD27 expression.
Nef (90–97) Nef FLKEKGGL HIV-1 infection, Vaccine human, macaque (B8) Hanke2000, Wee2002
Vaccine Vector/Type: DNA prime with vaccinia MVA boost Strain: subtype A HIV component: p17, p24, polyepitope
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• The HIV-1 subtype A focused vaccine HIVA contains p24 and p17, in a reversed order relative to the Gag polyprotein to prevent myristylation of p17,
which could direct the protein to the cell membrane and inhibit efficient peptide processing and class I presentation, as well as a polyepitope string of
conserved, often immunodominant epitopes that were selected to have particularly good cross-reactive potential for the A-clade epidemic in Nairobi,
Kenya. A DNA and MVA prime-boost vaccination protocol using the HIVA antigen will be used in a phase III clinical trial in Kenya. This epitope is
included in the polyepitope string [Hanke2000].
• Multiple CD4+ or CD8+ T-cell vaccine-induced responses to peptide pools were detected using intracellular cytokine staining and IFNgamma Elispot
assays after vaccination of 5 macaques. The response to the Mamu A*01 SIV p27 epitope p11C (CTPYDINQM), included in the polyepitope region, was
not immunodominant in the Mamu A*01 vaccinated macaques, possibly because of processing limitations in context of the artificial polyepitope string
[Wee2002].
Nef (90–100) Nef (90–100 BRU) FLKEKGGLEGL HIV-1 infection human (A2) Choppin2001
• Seventy-three 8-11 mer peptides were generated based on putative anchor motifs in the Nef BRU sequence for HLA A2, A3, A24, B7, B8, and B35; these
73 peptides had 81 motifs. 54% bound to the predicted HLA molecule, particularly A2, B7/35, and B8. The strength of HLA-peptide binding was not
directly related to the number of individuals that recognized a protein.
• 20s proteasome cleavage of the Nef protein positions 66-100 showed a large fraction of peptides were cleaved ending at: 87L, 83A, 81Y, 71P, 68F and 67G.
The frequency of recognition may be in part dictated by the cleavage step in processing.
• FLKEKGGLEGL was recognized in 8/12 (67%) of individuals with HLA A2. It was a low affinity HLA A2 binder.
Nef (92–100) (LAI) KEKGGLEGL human (B*4001) Brander2001
• C. Brander notes this is a B*4001,B60 epitope
Nef (92–100) KEKGGLEGL HIV-1 infection human (B*4002) Sabbaj2002b
• Epitope name: Nef-KL9
• This study monitored epitope responses in HIV-1 infected minority women living in the United States
• 24 epitopes were described – 8 were novel, 8 used new restricting elements but were previously defined epitopes, and 8 were previously described
• Serial peptide truncations were used to define optimal epitopes for CTL cell lines isolated from 12 individuals, assayed by a Cr-release
• Patient 01RCH59 was Hispanic, not on HAART, and had a viral load of 5100 and CD4 count of 349 – she also recognized TERQANFL, p2p7p1p6(64-70),
HLA-B*4002 and AEWDRVHPV, p24(78-86), HLA-B*4002
• Among HIV+ individuals who carried HLA B40, 3/5 (60%) recognized this epitope
Nef (92–100) Nef (90–98 SF2) KEKGGLEGL HIV-1 infection human (B60) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B60+ individuals that had a CTL response to this epitope broken down by group: 2/2 group 1, 1/1 group 2, and 0/0 group 3
Nef (92–100) Nef KEKGGLEGL HIV-1 infection human (B60) Cao2002
• KM is a B60 restricted CTL clone that recognizes KEKGGLEGL.
• CTL could be activated by a fusion protein of an HIV protein and anthrax lethal factor (LFn-HIV) that promotes antigen presenting cell uptake of
exogenous protein and allows processing through the MHC class I pathway. This strategy for CTL detection could allow antigen presentation without
generation of cells by the standard methods of using live viral vectors carrying a protein, or by loading the cells with peptides and by-passing processing.
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Nef (92–100) Nef (SF2) KEKGGLEGL HIV-1 infection human (B60(B*4001) Altfeld2000b
• This epitope was the dominant B60 (encoded by B*4001) response in 6/8 HLA-B60 individuals, and recognized in all eight
• This epitope was also recognized two expressing HLA-B61 individuals (B61 is usually encoded by B*4002, but this study did not distinguish between
B*4002, B*4003, B*4004, B*4006, and B*4008)
• ELISPOT was a rapid an effective method that was used to define five novel B60 epitopes
• HLA-B60 is present in 10-20% of the Caucasoid population and B60/B61 are very common in Asian populations
Nef (92–100) Nef (92–100) KEKGGLEGL HIV-1 infection human (B60/B61) Day2001
• No immunodominant responses were detected to five B61-restricted epitopes tested
• All five B60-restricted epitopes were reactive in another subject, and the B60-restricted responses together contributed over one-third of the total CTL
response
Nef (92–112) Nef (SF2) KEKGGLEGLIHSQRRQDIL-
DL
HIV-1 infection human Altfeld2000b
• This epitope was mapped by ELISPOT in a study identifying new HLA-B60 epitopes, and was one of the epitopes presented by another HLA molecule in
an HLA-B60 individual
• The response to the peptide was CD8 dependent, but the HLA presenting molecule and optimal epitope were not determined
Nef (92–112) Nef (SF2) KEKGGLEGLIHSQRRQDIL-
DL
HIV-1 infection human Altfeld2000b
• This epitope was mapped by ELISPOT in a study identifying new HLA-B60 epitopes, and was one of the epitopes presented by another HLA molecule in
an HLA-B60 individual
• The response to the peptide was CD8 dependent, but the HLA presenting molecule and optimal epitope were not determined
Nef (93–106) Nef (93–106 BRU) EKGGLEGLIHSQRR HIV-1 infection human (A1, B8) Hadida1992
• HIV-1 specific CTLs detected in lymphoid organs of HIV-1 infected patients
Nef (97–111) Nef (97–111) LEGLIYSKKRQEILD HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
• This peptide was among the 28 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
Nef (102–115) Nef (102–115 LAI) HSQRRQDILDLWIY HIV-1 infection human (B7) Goulder1997e, Goulder1997a
• Identical twin hemophiliac brothers were both infected with the same batch of factor VIII
• One had a strong response to this peptide, the other did not
• [Goulder1997a] is a review of immune escape that summarizes this study
Nef (102–121) Nef (101–120 SF2) HSQRRQDILDLQIYHTQGYF HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Eleven subjects had CTL that could recognize vaccinia-expressed LAI Nef
• Two of these 11 had CTL response to this peptide
• The responding subjects were HLA-A2, A3, B8, B62 and HLA-A2, B21
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Nef (103–127) Nef (103–127 PV22) SQRRQDILDLWIYHTQGYF-
PDWQNY
HIV-1 infection human (B13) Jassoy1993
• HIV-1 specific CTLs release γ-IFN, and α- and β -TNF
Nef (103–127) Nef (103–127) SQRRQDILDLWIYHTQGYF-
PDWQNY
HIV-1 infection human (B13) Oxenius2000
• Epitope name: SQR
• Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific
CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load – three patients that had delayed initiation of
HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became
undetectable
• The only study subject out of eight that was HLA B13+ recognized this epitope
• Patient SC9 (HLA A1/2, B8/13, Cw0/0701, DR2/11, DQ6/7) had a CTL response against epitopes FLKEKGGL, ILKEPVHGV,
SQRRQDILDLWIYHTQGYFPDWQNY, and GEIYKRWII peptides and all responses declined during therapy initiated at day 390 but were restored when
therapy become intermittent
Nef (105–114) Nef (105–114 LAI) RRQDILDLWI HIV-1 infection human (B*2705) Goulder1997c
• Defined as optimal epitope from within reactive peptide HSQRRQDILDLWIYHTQGYF [Nef(102-121 LAI)]
• HLA-B*2705 is associated with slow HIV disease progression
• The HLA-B*2705 binding motif includes R at position 2, and L in the C-term position
Nef (105–114) Nef (105–114 LAI) RRQDILDLWI HIV-1 infection human (B*2705) Brander2001
• C. Brander notes this is a B*2705 epitope
Nef (105–114) Nef (105–114 SF2) RRQDILDLWI HIV-1 infection human (B27) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B27+ individuals that had a CTL response to this epitope broken down by group: 0/0 group 1, 0/0 group 2, and 1/1 group 3
Nef (105–114) Nef (105–114) RRQDILDLWI HIV-1 infection human (B27) Day2001
• B27-restricted CTL response was strongest to this epitope in one individual
Nef (105–114) RRQDILDLWI HIV-1 infection human (B27) Sabbaj2002b
• Epitope name: Nef-RI10
• Among HIV+ individuals who carried HLA B27, 1/2 (50%) recognized this epitope
Nef (105–115) Nef (105–115) RRQDILDLWIY HIV-1 infection human (Cw7) Yu2002a
• Epitope name: Cw7-RY11
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• AC-06 was homozygous at all three class I alleles (A3, B7, Cw7), and was treated during acute infection and had supervised treatment interruptions (STI).
He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15 restricted by HLA-A3,
11 by HLA-B7, and 1 response to RRQDILDLWIY restricted by HLA-Cw7.
Nef (106–115) (LAI) RQDILDLWIY (B7) Brander2001, Goulder1999a
Nef (108–115) DILDLWIY HIV-1 infection human (Cw*0701) Sabbaj2002b
• Epitope name: Nef-DY8
• This study monitored epitope responses in HIV-1 infected minority women living in the United States
• 24 epitopes were described – 8 were novel, 8 used new restricting elements but were previously defined epitopes, and 8 were previously described
• Serial peptide truncations were used to define optimal epitopes for CTL cell lines isolated from 12 individuals, assayed by a Cr-release
• Subject 03RCH40 was African American, had a viral load of 2500, CD4 count of 372, was not on HAART, and also recognized the epitope ETKLGKAGY,
RT(449-457), A*2601
• Among HIV+ individuals who carried HLA Cw07, 2/18 (11%) recognized this epitope
Nef (112–126) Nef (112–126) LWVYHTQGYFPDWQN HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
• This peptide was among the 28 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
Nef (112–133) Nef (111–132) LWIYHTQGYFPDWQNYTPG-
PGV
HIV-1 infection human Lieberman1995
• HIV-specific CTL lines developed by ex vivo stimulation with peptide
Nef (112–133) Nef (111–132 SF2) LWIYHTQGYFPDWQNYTPG-
PGV
HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Eleven subjects had CTL that could recognize vaccinia-expressed LAI Nef
• Four of these 11 had CTL response to this peptide
• The responding subjects were HLA-A2, B21; HLA-A1, A3, B7, B15; HLA-A2, A26, B7, B38
Nef (112–133) Nef (111–132 SF2) LWIYHTQGYFPDWQNYTPG-
PGV
HIV-1 infection human Lieberman1997b
• CTL expanded ex vivo were later infused into HIV-1 infected patients
Nef (113–125) Nef (113–125 BRU) WIYHTQGYFPDWQ HIV-1 infection human (B17) Culmann1989
• Nef CTL clones from HIV+ donors
Nef (113–127) Nef (128–142) WIYHTQGYFDPWQNY HIV-1 infection human Guimaráes2002
• Nef sequences were obtained from Brazilians to study epitope diversity in this geographic region – WIYHTQGYFDPWQNY displayed an (H) to (N)
substitution in Brazilian Nef-gene subtype C samples, and this substitution is often found in other subtypes tested.
Nef (113–128) Nef (113–128 BRU) WIYHTQGYFPDWQNYT HIV-1 infection human (A1) Hadida1992
• HIV-1 specific CTLs detected in lymphoid organs of HIV-1 infected patients
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Nef (113–128) Nef (113–128 LAI) WIYHTQGYFPDWQNYT HIV-1 infection human (A1) Mollet2000
• Epitope name: N2
• A panel of 16 epitopes covering 15 class I alleles was tested in 14 HIV+ patients from an unselected Caucasian population treated with HAART, using
CD8+ cell IFNgamma production to measure responses
• In general, during the first month of treatment viral load decreased and frequencies of HIV-specific CTL tripled and broadened – eight new HIV
specificities that were not previously detectable were newly detected, as were CMV specific CD8+ PBL – but with continued viral suppression,
HIV-specific responses diminished
• Viral rebounds gave different patterns of response: increases or decreases in pre-existing response, new specificities, or no change
Nef (114–127) Nef VYHTQGYFPDWQNY HIV-1 infection human Jubier-Maurin1999
Nef (115–125) Nef (115–125 BRU) YHTQGYFPDWQ HIV-1 infection human (B17) Culmann1991
• Nef CTL clones from HIV+ donors
Nef (116–125) Nef (116–125 BRU) HTQGYFPDWQ HIV-1 infection human (B*5701) Brander2001
• C. Brander notes this is a B*5701 epitope
• Subtype of B57 not determined
Nef (116–125) Nef (116–125) HTQGYFPDWQ HIV-1 infection human (B57) Betts2000
• Only 4/11 HLA-A2+ HIV+ individuals had CTL that reacted to SLYNTVATL, calling into question whether it is immunodominant
• 95 optimally-defined peptides from this database were used to screen for INFγ responses to other epitopes
• One of the A2+ individuals was HLA A*0201, A1, B57 and responded to four B57 epitopes and two others
Nef (116–125) Nef (116–125 BRU) HTQGYFPDWQ HIV-1 infection human (B57) Culmann1991
• Nef CTL clones from HIV+ donors, optimal peptide mapped
Nef (116–125) Nef (116–125) HTQGYFPDWQ HIV-1 infection human (B57) Oxenius2000
• Epitope name: HTQ
• Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific
CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load – three patients that had delayed initiation of
HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became
undetectable
• None of the 8 study subjects recognized this epitope but none were HLA B57+
Nef (116–125) HTQGYFPDWQ HIV-1 infection human (B57) Sabbaj2002b
• Epitope name: Nef-HQ10
• Among HIV+ individuals who carried HLA B57, 0/5 (0%) recognized this epitope
Nef (117–127) Nef (117–127) TQGYFPDWQNY HIV-1 infection human Betts2000
• Only 4/11 HLA-A2+ HIV+ individuals had CTL that reacted to SLYNTVATL, calling into question whether it is immunodominant
• 95 optimally-defined peptides from this database were used to screen for INFγ responses to other epitopes
• 1/11 of the A2+ individuals was HLA A*0205/A*0208, A30, B27, B44 but responded to HLA Bw62 epitope TQGYFPDWQNY, and one of the other
individuals that was A2+, but otherwise of unknown HLA type, reacted with seven epitopes including this one
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Nef (117–127) Nef (117–127 LAI) TQGYFPDWQNY HIV-1 infection human (B*1501) Brander2001
• C. Brander notes this is a B*1501 epitope
Nef (117–127) Nef (117–127) TQGYFPDWQNY HIV-1 infection human (B62) Day2001
• No immunodominant responses were detected to four B62-restricted epitopes tested
Nef (117–127) Nef (117–127 LAI) TQGYFPDWQNY HIV-1 infection human (Bw62) Culmann1998
• Optimal peptide defined by titration
Nef (117–128) Nef (117–128 BRU) TQGYFPDWQNYT HIV-1 infection human (B17, B37) Culmann1991
• Nef CTL clones from HIV+ donors
Nef (117–147) Nef (117–147 LAI) TQGYFPDWQNYTPGPGVRY-
PLTFGWCYKLVP
Vaccine human Gahery-Segard2000
Vaccine Vector/Type: lipopeptide HIV component: six peptides
• Anti-HIV lipopeptide vaccine consisting of six long amino acid peptides derived from Nef, Gag and Env HIV-1 proteins modified by a palmitoyl chain was
administered in a phase I trial
• A CD4+ T cell proliferative response to at least one of the six peptides was observed in 9/10 vaccinees – 1/10 reacted to this Nef peptide
• 9/12 tested mounted a CTL response to at least one of the six peptides; each of the six peptides elicited a CTL response in at least one individual
• 10/12 tested had an IgG response to this peptide
Nef (118–127) Nef (118–127 LAI) QGYFPDWQNY human (Bw62) McMichael1994
• Review of HIV CTL epitopes
Nef (120–128) Nef (120–128) YFPDWQNYT HIV-1 infection human Betts2000
• Only 4/11 HLA-A2+ HIV+ individuals had CTL that reacted to SLYNTVATL, calling into question whether it is immunodominant
• 95 optimally-defined peptides from this database were used to screen for INFγ responses to other epitopes
• 1/11 of the A2+ individuals was HLA A*0205/A*0208, A30, B27, B44 but responded to HLA B37 epitope IYKRWIILGL, and one of the other individuals
that was A2+, but otherwise of unknown HLA type, reacted with seven epitopes including this one
Nef (120–128) Nef (118–126 SF2) YFPDWQNYT HIV-1 infection human (A1) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-A1+ individuals that had a CTL response to this epitope broken down by group: 0/3 group 1, 0/2 group 2, and 1/2 group 3
Nef (120–128) Nef (120–128 LAI) YFPDWQNYT HIV-1 infection human (B*3701) Brander2001
• C. Brander notes this is a B*3701 and B*5701 epitope
Nef (120–128) Nef (120–128 LAI) YFPDWQNYT HIV-1 infection human (B*5701) Brander2001
• C. Brander notes this is a B*5701 epitope
• Subtype of B57 not determined
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Nef (120–128) Nef (120–128 IIIB) FFPDWKNYT HIV-1 infection human (B15) Wilson1999a
• This study describes maternal CTL responses in the context of mother-to-infant transmission
• Detection of CTL escape mutants in the mother was associated with transmission, but the CTL-susceptible forms of the virus tended to be found in infected
infants
• LFPDWKNYT is an escape mutant
Nef (120–128) Nef (120–128 LAI) YFPDWQNYT HIV-1 infection human (B37, B57) Culmann1998
• Nef CTL clones from HIV+ donors – optimum peptide mapped by titration
Nef (120–128) YFPDWQNYT HIV-1 infection human (B57) Sabbaj2002b
• Epitope name: Nef-YT9
• Among HIV+ individuals who carried HLA B57, 1/5 (20%) recognized this epitope
Nef (120–144) Nef (120–144 SF2) YFPDWQNYTPGPGIRYPLT-
FGWCYK
HIV-1 infection human (A24) Jassoy1992
• Epitope recognized by CTL clone derived from CSF
Nef (122–136) Nef (122–136) PDWQNYTPGPGVRYP HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
• This peptide was among the 8 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
Nef (122–141) Nef (121–140 SF2) PDWQNYTPGPGVRYPLTFGW HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Eleven subjects had CTL that could recognize vaccinia-expressed LAI Nef
• Three of these 11 had CTL response to this peptide
• The responding subjects were HLA-A2, B21; HLA-A3, A24, B7, B38
Nef (123–137) Nef (123–137 IIIB) QWQNYTPGPGVRYPL HIV-1 infection human Wilson1996
• Epitope defined in the context of the Pediatric AIDS Foundation ARIEL Project, a mother-infant HIV transmission study
• FFPDYTPGPGTRFPL and FFPDYKPGPGTRFPL, naturally occurring variants, were found in mother and are not recognized
• LFPDYKPGPGTRFPL and FFPDYKPGPGTRFPL, naturally occurring variants, were found in infant and are not recognized
Nef (126–135) Nef (126–135 BRU) NYTPGPGVRY HIV-1 infection human (A24) Choppin2001
• Seventy-three 8-11 mer peptides were generated based on putative anchor motifs in the Nef BRU sequence for HLA A2, A3, A24, B7, B8, and B35; these
73 peptides had 81 motifs. 54% bound to the predicted HLA molecule, particularly A2, B7/35, and B8. The strength of HLA-peptide binding was not
directly related to the number of individuals that recognized a protein.
• 20s proteasome cleavage of the Nef protein positions 66-100 showed a large fraction of peptides were cleaved ending at: 87L, 83A, 81Y, 71P, 68F and 67G.
The frequency of recognition may be in part dictated by the cleavage step in processing.
• NYTPGPGVRY was recognized in 3/10 (30%) of individuals with HLA A24. It was a moderate affinity HLA-A24 binder.
Nef (126–138) Nef (126–138 BRU) NYTPGPGVRYPLT HIV-1 infection human (B7) Culmann1991
• Nef CTL clones from HIV+ donors
376
DEC 2002
Nef CTL Epitopes HIV CTL Epitope Tables
C
TL
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
Nef (127–141) Nef (127–141) YTPGPGVRYPLTFGW HIV-1 infection human Novitsky2002
• HLA, viral sequence, and Elispot data was obtained from 105 HIV-1 positive Botswanans; Elispot data was obtained from between 55 and 64 subjects for
each HIV protein.
• Nef and p24 had the highest percentage of reactive peptides, and p24 had the highest magnitude of HIV-1 responses.
• This peptide was among the 8 most reactive C clade peptides from among over 350 tested spanning all HIV proteins.
Nef (128–135) Nef (128–135 LAI) TPGPGVRY in vitro stimulation human (B*0702) Lucchiari-Hartz2000
• Five naturally processed MHC class I ligands were identified in Nef in the conserved immunogenic region Nef between 123-152
• All five could be transported by TAP, and 4/5 had N-termini that were major cleavage points for the proteasome, only one had extended precursor fragments
• Both TPGPGVRYPL and TPGPGVRY are naturally processed ligands that can be eluted from HLA-B7 molecules, both are recognized by the same CTL,
and both peptides seem to be the direct product of a proteasomal digest
• The peptide TPGPGVRY is present in a high copy number, TPGPGVRYPL at a more moderate level, possibly due to a major cleavage site between the Y
and P
Nef (128–136) TPGPGVRYP HIV-1 infection human (B07) Sabbaj2002b
• Epitope name: Nef-TP9
• Among HIV+ individuals who carried HLA B07, 4/9 (44%) recognized this epitope
Nef (128–137) Nef TPGPGIRYPL HIV-1 infection human Kaul2001c
• This study examines CTL responses in HIV exposed, persistently seronegative individuals, HEPS, who eventually seroconverted – 11/114 HEPS Nairobi
sex workers eventually seroconverted, and for six of these HIV CTL reactive epitopes had been defined while seronegative
• The epidemiological factor associated with seroconversion was stopping sex work and HIV-specific CTL activity declines when HEPS sex workers stop
working for a period or retire
• This epitope was recognized by 1/22 HEPS control sex workers, ML851
Nef (128–137) Nef (128–137 LAI) TPGPGVRYPL HIV-1 infection human (B*0702) Brander2001
• C. Brander notes this is a B*0702 epitope
Nef (128–137) Nef (128–137 LAI) TPGPGVRYPL in vitro stimulation human (B*0702) Lucchiari-Hartz2000
• Five naturally processed MHC class I ligands were identified in Nef in the conserved immunogenic region Nef between 123-152
• All five could be transported by TAP, and 4/5 had N-termini that were major cleavage points for the proteasome, only one had extended precursor fragments
• Both TPGPGVRYPL and TPGPGVRY are naturally processed ligands that can be eluted from HLA-B7 molecules, both are recognized by the same CTL,
and both peptides seem to be the direct product of a proteasomal digest
• The peptide TPGPGVRY is present in a high copy number, TPGPGVRYPL at a more moderate level, possibly due to a major cleavage site between the Y
and P
Nef (128–137) Nef (128–137 LAI) TPGPGVRYPL human (B*4201) Brander2001
• C. Brander notes this is a B*4201 epitope
Nef (128–137) Nef (128–137 BRU) TPGPGVRYPL HIV-1 infection human (B35) Choppin2001
• Seventy-three 8-11 mer peptides were generated based on putative anchor motifs in the Nef BRU sequence for HLA A2, A3, A24, B7, B8, and B35; these
73 peptides had 81 motifs. 54% bound to the predicted HLA molecule, particularly A2, B7/35, and B8. The strength of HLA-peptide binding was not
directly related to the number of individuals that recognized a protein.
• 20s proteasome cleavage of the Nef protein positions 66-100 showed a large fraction of peptides were cleaved ending at: 87L, 83A, 81Y, 71P, 68F and 67G.
The frequency of recognition may be in part dictated by the cleavage step in processing.
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• TPGPGVRYPL was recognized in 8/16 (50%) of individuals with HLA B7, and 1/9 (11%) of individuals with HLA B35. It was a high affinity HLA binder.
Nef (128–137) TPGPGVRYPL HIV-1 infection human (B7) Wilson2000a
• Three individuals with highly focused HIV-specific CTL responses were studied during acute infection using tetramers – high frequencies of HIV-1-specific
CD8+ T cells were found prior to seroconversion, and there was a close temporal relationship between the number of circulating HIV-specific T cells and
viral load was also found
• All three patients were B*2705, with HLA alleles: A1, A30/31, B*2705, B35; A1, A*0301, B7, B*2705; and A*0201, A*0301, B*2705, B39
• ELISPOT was used to test a panel of CTL epitopes that had been defined earlier and were appropriate for the HLA haplotypes of the study subjects – 3/3
subjects showed a dominant response to the B*2705 epitope KRWIILGGLNK
• The subject with A*0201 had a moderatly strong response to SLYNTVATL
• Weak responses were observed to A*301-RLRPGGKKK, A*301-QVPLRPMTYK, and B7-TPGPGVRYPL in the subject who was HLA A1, A*0301, B7,
B*2705
• No acute response was detected to the following epitopes: A*201-ILKEPVHGV, A*301-KIRLRPGGK, A*301-AIFQSSMTK, A*301-TVYYGVPVWK,
B35-EPIVGAETF, B35-HPDIVIYQY, B35-PPIPVGEIY, B35-NSSKVSQNY, B35-VPLRPMTY, B35-DPNPQEVVL
Nef (128–137) Nef (128–137 LAI) TPGPGVRYPL HIV-1 infection human (B7) Haas1996, Haas1997
• There was a high degree of variation in three CTL epitopes in Nef in four slow and non-progressors, and variant specific CTLs arose over time to eliminate
variants, indicating immune selection
• The epitope position was taken from [Haas1997]
Nef (128–137) Nef TPGPGVRYPL HIV-1 exposed seronegative human (B7) Rowland-Jones1998a
• A CTL response was found in exposed but uninfected prostitutes from Nairobi using previously-defined B clade epitopes that tended to be conserved in A
and D clades – such cross-reactivity could protect against both A and D and confer protection in Nairobi where both subtypes are circulating
• The D subtype consensus is identical to the B clade epitope
• The A subtype consensus is TPGPGIRYPL
Nef (128–137) Nef (subtype B) TPGPGVRYPL HIV-1 exposed seronegative human (B7) Rowland-Jones1998b
• HIV-specific CTL were found in exposed seronegative prostitutes from Nairobi – these CTL may confer protection
• Seroprevalence in this cohort is 90-95% and their HIV-1 exposure is among the highest in the world
• Most isolated HIV strains are clade A in Nairobi, although clades C and D are also found – B clade epitopes are often cross-reactive, however stronger
responses are frequently observed using A or D clade versions of epitopes
• This epitope is conserved among B and D clade viruses
• The Clade A version of the epitope: TPGPGIRYPL
Nef (128–137) Nef (128–137) TPGPGVRYPL in vitro stimulation human (B7) Wilson1999b
• Dendritic cells are the most potent for priming T cell responses – DCs can stimulate autologous CTL responses from T cells cultured from HIV negative
donors
• Th1-biasing cytokines IL-12 or IFN alpha enhance CTL responses in vitro whether the epitope is delivered by pulsing from peptide, or expressed from
within
• CTL from a B7 donor displayed no reactivity to this epitope, although it had been immunodominant in another study [Haas1996]
Nef (128–137) Nef (128–137 SF2) TPGPGVRYPL HIV-1 infection human (B7) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
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• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B7+ individuals that had a CTL response to this epitope broken down by group: 0/4 group 1, 0/3 group 2, and 1/1 group 3
Nef (128–137) Nef (128–137) TPGPGVRYPL HIV-1 infection, HIV-1 exposed
seronegative
human (B7) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with
reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected
women
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure
• Among HLA-B7 women, 4/5 HEPS and 5/6 HIV-1 infected women recognized this epitope
• The dominant response to this HLA allele was to this epitope in 3 of the 4/5 HEPS cases and in 2 of the 5/6 HIV-1 infected women
• Subject ML 1203 started with CTL responses to A*6802 DTVLEDINL and to B7 FPVTPQVPLR prior to seroconversion, and upon seroconversion
acquired additional responses to A*6802 ETAYFILKL which became dominant, B7 TPGPG(V/I)RYPL, B7 IPRRIRQGL, and B7 SPRTLNAWV
Nef (128–137) Nef (128–137) TPGPGVRYPL HIV-1 infection human (B7) Appay2000
• Combined tetramer and intracellular cytokine staining was used to study the function of circulating CD8+ T cells specific for HIV and CMV
• HIV-specific CD8+ T cells expressed lower levels of perforin than CMV-specific CD8+ T cells from the same donor, and this was associated with persistent
CD27 expression on HIV-specific cells, suggesting impaired maturation
• In most donors, between 50% and 95% of the activated virus-specific CD8+ T cells produced IFN-γ and MIP-1β with a distinct subset that failed to
produce TNF-α
Nef (128–137) Nef (128–137) TPGPGVRYPL HIV-1 infection human (B7) Day2001
• The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7 was
studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
• 2 to 17 epitopes were recognized in a given individual, A2-restricted CTL response tended to be narrow and never dominated the response, and 25/27
epitopes were targeted by at least one person
• Subjects with chronic HIV-1 infection recognized between 2-8 out of 11 B7-restricted epitopes
• An acute seroconvertor homozygous for the B7 allele recognized five B7-restricted epitopes
• The other acute seroconvertor failed to recognize any of the 11 B7-restricted epitopes tested
• The B7-restricted CTL response was highly variable and there was no clearly dominant epitope
Nef (128–137) Nef (128–137 BRU) TPGPGVRYPL HIV-1 infection human (B7) Choppin2001
• Seventy-three 8-11 mer peptides were generated based on putative anchor motifs in the Nef BRU sequence for HLA A2, A3, A24, B7, B8, and B35; these
73 peptides had 81 motifs. 54% bound to the predicted HLA molecule, particularly A2, B7/35, and B8. The strength of HLA-peptide binding was not
directly related to the number of individuals that recognized a protein.
• 20s proteasome cleavage of the Nef protein positions 66-100 showed a large fraction of peptides were cleaved ending at: 87L, 83A, 81Y, 71P, 68F and 67G.
The frequency of recognition may be in part dictated by the cleavage step in processing.
• TPGPGVRYPL was recognized in 8/16 (50%) of individuals with HLA B7, and 1/9 (11%) of individuals with HLA B35. It was a high affinity HLA binder.
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Nef (128–137) Nef TPGPGVRYPL HIV-1 infection human (B7) Yu2002a
• Epitope name: B7-TL10
• CTL responses in 18 acutely HIV-infected HLA-A3 (n=7) or -B7 (n=4) or both -A3 and B7 (n=7) positive individuals were studied.
• One individual, AC-06, was homozygous at all three class I alleles (A3, B7, Cw7), was treated during acute infection and had supervised treatment
interruptions (STI). He had only two detectable CTL responses during acute infection, but after STI this broadened to 27 distinct epitopes including 15
restricted by HLA-A3, 11 by HLA-B7, and 1 by HLA-Cw7.
• 0/11 HLA-B7 individuals had detectable B7-restricted responses to this epitope during acute infection – 10/15 of HLA-B7 epitopes tested were targeted by
at least one person during acute infection. 2/4 individuals had detectable responses to this epitope after STI.
Nef (128–137) Nef TPGPGVRYPL HIV-1 infection human (B7) Appay2002
• Four HIV patients with prolonged clinically successful anti-viral therapy but with ongoing evidence of replication and Nef mRNA transcription, showed
specific T-cell responses by Elispot and Tetramer staining, maintained for 2-4 years after initiation of HAART.
• Nef epitope recognition was detected in all 4 subjects, gp120, Pol and Gag-specific in 1 or 2 subjects.
• The HIV-specific CD8+ T-cells had an intermediate maturation phenotype characterized by low levels of perforin and high levels of CD27 expression.
Nef (128–137) Nef TPGPGVRYPL HIV-1 infection, Vaccine human, macaque (B7) Hanke2000, Wee2002
Vaccine Vector/Type: DNA prime with vaccinia MVA boost Strain: subtype A HIV component: p17, p24, polyepitope
• The HIV-1 subtype A focused vaccine HIVA contains p24 and p17, in a reversed order relative to the Gag polyprotein to prevent myristylation of p17,
which could direct the protein to the cell membrane and inhibit efficient peptide processing and class I presentation, as well as a polyepitope string of
conserved, often immunodominant epitopes that were selected to have particularly good cross-reactive potential for the A-clade epidemic in Nairobi,
Kenya. A DNA and MVA prime-boost vaccination protocol using the HIVA antigen will be used in a phase III clinical trial in Kenya. This epitope is
included in the polyepitope string [Hanke2000].
• Multiple CD4+ or CD8+ T-cell vaccine-induced responses to peptide pools were detected using intracellular cytokine staining and IFNgamma Elispot
assays after vaccination of 5 macaques. The response to the Mamu A*01 SIV p27 epitope p11C (CTPYDINQM), included in the polyepitope region, was
not immunodominant in the Mamu A*01 vaccinated macaques, possibly because of processing limitations in context of the artificial polyepitope string
[Wee2002].
Nef (128–137) Nef (subtype B) TPGPGVRYPL HIV-1 exposed seronegative human (B7(*8101)) Rowland-Jones1998b
• HIV-specific CTL were found in exposed seronegative prostitutes from Nairobi – these CTL may confer protection
• Seroprevalence in this cohort is 90-95% and their HIV-1 exposure is among the highest in the world
• Most isolated HIV strains are clade A in Nairobi, although clades C and D are also found – B clade epitopes are often cross-reactive, however stronger
responses are frequently observed using A or D clade versions of epitopes
• Clade A version of the epitope: TPGPGIRYPL, clade D version: TPGPGIRYPL
Nef (128–137) Nef (128–137 subtype
B)
TPGPGVRYPL HIV-1 exposed seronegative human (B7, B*8101) Kaul2000
• 11/16 heavily HIV exposed but persistently seronegative sex-workers in Nairobi had HIV-specific CD8 gamma-IFN responses in the cervix – systemic
CD8+ T cell responses tended to be to the same epitopes but at generally lower levels than cervical CD8+ T cell responses
• Low risk individuals did not have such CD8+ cells
• CD8+ T cell epitopes: DTVLEDINL (3 individuals), SLYNVATL (4 individuals), LSPRTLNAW (3 individuals) and YPLTFGWCF (4 individuals) were
most commonly recognized by the HIV-resistant women
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Nef (130–139) Nef (130–139 BRU) GPGVRYPLTF HIV-1 infection human (B35) Choppin2001
• Seventy-three 8-11 mer peptides were generated based on putative anchor motifs in the Nef BRU sequence for HLA A2, A3, A24, B7, B8, and B35; these
73 peptides had 81 motifs. 54% bound to the predicted HLA molecule, particularly A2, B7/35, and B8. The strength of HLA-peptide binding was not
directly related to the number of individuals that recognized a protein.
• 20s proteasome cleavage of the Nef protein positions 66-100 showed a large fraction of peptides were cleaved ending at: 87L, 83A, 81Y, 71P, 68F and 67G.
The frequency of recognition may be in part dictated by the cleavage step in processing.
• GPGVRYPLTF was recognized in 0/10 (0%) of individuals with HLA B7, and 1/11 (9%) of individuals with HLA B35, although it was a high affinity HLA
binder.
Nef (130–143) Nef (130–143 LAI) GPGVRYPLTFGWCY HIV-1 infection human (B*57) Goulder1996b
• CTL response to this epitope observed in 4 long-term survivors
• Peptide defined on the basis of B*5801 binding motif, yet not cross-restricted except at high concentrations
Nef (130–143) Nef (121–141) GPGVRYPLTFGWCY HIV-1 infection human (B57) Ferrari2000
• One of the 51 HIV-1 epitopes selected by Ferrari et al. as good candidate CTL epitopes for vaccines by virtue of being conserved and presented by common
HLA alleles
Nef (132–144) Nef GIRYPLTFGWCFK human Jubier-Maurin1999
• 41 new HIV-1 strains describing envelope subtypes of HIV-1 A-H were genetically characterized in the nef region – 34 subtypes were classified in the same
subtype in nef and env and 7 of the 41 strains were recombinants
• This region was defined as a CTL epitope region that is conserved among HIV-1 M group subtypes
Nef (132–147) Nef (132–147 BRU) GVRYPLTFGWCYKLVP HIV-1 infection human (A1, B8) Hadida1992
• HIV-1 specific CTLs detected in lymphoid organs
Nef (132–147) Nef (132–147 BRU) GVRYPLTFGWCYKLVP HIV-1 infection human (B18) Culmann1991
• Nef CTL clones from HIV+ donors
Nef (132–147) Nef (132–147) GVRYPLTFGWCYKLVP Vaccine murine (H-2d) Billaut-Mulot2001
Vaccine Vector/Type: DNA with DNA boost, DNA with recombinant protein boost Strain: LAI HIV component: Gag, Tat, Nef Adjuvant: IL18
• DNA vaccinated BALB/c mice primed and boosted with the multiepitopic vaccine with IL18 showed lymphoproliferative responses 7 weeks post
immunization
• Strong but non-lasting HIV-specific CTL responses were detected by a Cr-release assay and DNA prime/DNA boost was more effective than DNA prime
protein boost
• Immunization with either the multiepitopic DNA or with the mixed DNA vaccine induced HIV-1 specific Th1 cytokines (IL-2 and IFN-gamma)
• Co-administration of IL18 increased T-cell responses but decreased anti-HIV antibody levels
Nef (133–148) Nef (133–148 LAI) VRYPLTFGWCYKLVPV human (B57) Brander1996b
• P. Goulder, pers. comm.
Nef (134–141) Nef (138–147 LAI) RYPLTFGW HIV-1 infection human (A*2402) Brander2001
• C. Brander notes this is an A*2402 epitope
Nef (134–141) Nef (138–147 SF2) RYPLTFGW HIV-1 infection human (A24) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
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• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-A24+ individuals that had a CTL response to this epitope broken down by group: 0/0 group 1, 2/3 group 2, and 0/0 group 3
Nef (134–141) Nef RYPLTFGW HIV-1 infection human (A24) Altfeld2002
• Epitope name: A24-RW8(Nef)
• Peripheral blood (PB) and lymph node (LN) CD8+ T-cell responses were compared in 15 asymptomatic HIV-1 infected patients using all known optimal
CTL epitopes (http://hiv-web.lanl.gov/content/hiv-db/REVIEWS/brander2001.html) for each person’s class I HLA alleles.
• 60 epitope responses were detected in both PB and LN samples of the 15 patients, and an additional 8 responses were detected only in LN. The total
magnitude of the response was similar in LN and PB, but the percentage of CD8+ T cells in the LN is lower so the number of HIV-specific cells per million
CD8+ T-cells is higher in the LN.
• 1 year post-HAART treatment in five patients studied, the magnitude of the CD8 T-cell response was decreased in both LN and PB, but more dramatically
in PB, and 13/25 epitope responses in the PB became undetectable, in contrast to 5/26 in the LN.
• Treatment interruption following HAART induced resulted in increased viremia accompanied by the restoration of the detection of 13 epitopes that had
become undetectable in the PB, and the addition of 9 novel epitope responses.
• Breakdowns of epitope responses were shown for 4 individuals. Patient C displayed the greatest response to B27-KK10(p24), and in decreasing order also
responded to A24-RW8(Nef), B7-IL9(gp41), A24-RL9(gp41), A24-YL8(gp41), and B7-TM9(Nef).
Nef (134–141) Nef (134–141 LAI) RYPLTFGW human (B27) Culmann1998
• Optimal peptide defined by titration
Nef (134–143) Nef (138–147 SF2) RYPLTFGWCF HIV-1 infection human (A*2402) Ikeda-Moore1997
• Defined using reverse immunogenetics – 59 HLA-A*2402 binding peptides were predicted by searching for A*2402 anchors in HIV proteins (Tyr at 2, and
Phe, Leu or Ile at the C term) – 53 of the 59 peptides bound A*2402
• This peptide induced CTL in 3/4 HIV-1+ people tested
• RYPLTFGWCF bound to A*2402 strongly, the epitope can be processed in a vaccinia construct and presented – two specific CTL clones were obtained
Nef (134–143) Nef (138–147) RYPLTFGWCF Vaccine human (A*2402) Kawana-Tachikawa2002
Vaccine Vector/Type: Sendai virus vector system (SeV) HIV component: class I/peptide complexes
• Epitope name: Nef138-10
• A Sendai virus vector system (SeV) was developed that expressed HLA-A*2402-restricted class I/peptide complexes; this system could be used to detect
responses and has the potential to elicit immune responses.
• MHC class I/peptide tetramers could be made using this system that bound to epitope-specific CTLs in PBMCs.
• Cells transfection with SeV modified to express A*2402-HIV epitope complexes induced CTL mediated specific cell lysis.
Nef (134–143) Nef (134–143 BRU) RYPLTFGWCY HIV-1 infection human (A24) Choppin2001
• Seventy-three 8-11 mer peptides were generated based on putative anchor motifs in the Nef BRU sequence for HLA A2, A3, A24, B7, B8, and B35; these
73 peptides had 81 motifs. 54% bound to the predicted HLA molecule, particularly A2, B7/35, and B8. The strength of HLA-peptide binding was not
directly related to the number of individuals that recognized a protein.
• 20s proteasome cleavage of the Nef protein positions 66-100 showed a large fraction of peptides were cleaved ending at: 87L, 83A, 81Y, 71P, 68F and 67G.
The frequency of recognition may be in part dictated by the cleavage step in processing.
• RYPLTFGWCY was recognized in 5/12 (42%) of individuals with HLA A24. It was a moderate affinity HLA-A24 binder.
382
DEC 2002
Nef CTL Epitopes HIV CTL Epitope Tables
C
TL
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
Nef (134–144) Nef (134–144 LAI) RYPLTFGWCYK HIV-1 infection human (B18) Couillin1994, Goulder1997a
• Mutational variation in HIV epitopes in individuals with appropriate HLA types can result in evasion of CTL response
• [Goulder1997a] is a review of immune escape that summarizes this study
Nef (134–144) Nef (134–144) RYPLTFGWCYK HIV-1 infection human (B18) Oxenius2000
• Epitope name: RYP
• Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific
CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load – three patients that had delayed initiation of
HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became
undetectable
• None of the 8 study subjects recognized this epitope but none were HLA B18+
Nef (135–143) Nef (135–143 LAI) YPLTFGWCY in vitro stimulation human (B*0702) Lucchiari-Hartz2000
• Five naturally processed MHC class I ligands were identified in Nef in the conserved immunogenic region Nef between 123-152
• All five could be transported by TAP, and 4/5 had N-termini that were major cleavage points for the proteasome, only one had extended precursor fragments
• YPLTFGWCY is the naturally processed ligand for B7, and this epitope is the only one of the five that may require trimming at the N-termini
• YPLTFGWCY is present in low copy number in the cell, possibly due to a predominant proteasomal cleavage site between Y and P
Nef (135–143) Nef (135–143 LAI) YPLTFGWCY HIV-1 exposed seronegative human (B*1801) Brander2001
• C. Brander notes this is a B*1801 epitope
Nef (135–143) YPLTFGWCY HIV-1 infection human (B*5301, B35) Sabbaj2002b
• Epitope name: Nef-YY9
• This study monitored epitope responses in HIV-1 infected minority women living in the United States
• 24 epitopes were described – 8 were novel, 8 used new restricting elements but were previously defined epitopes, and 8 were previously described
• Serial peptide truncations were used to define optimal epitopes for CTL cell lines isolated from 12 individuals, assayed by a Cr-release
• Subject 00RCH33 was on HAART had a viral load of 2900 and CD4 count of 727 and also recognized the epitopes HIGPGRAFY, gp160(310-318), HLA
A*3002; AETFYVDGA, RT(437-445), HLA B*4501; and RSLYNTVATLY, p17(76-86), HLA A*3002
• Among HIV+ individuals who carried HLA B53, 8/15 (53%) recognized this epitope – one subject also carried B7, previously shown to restrict this epitope
• Among HIV+ individuals who carried HLA B35, 13/19 (68%) recognized this epitope
Nef (135–143) Nef (subtype D) YPLTFGWCF HIV-1 exposed seronegative human (B18) Kaul2000
• 11/16 heavily HIV exposed but persistently seronegative sex-workers in Nairobi had HIV-specific CD8 gamma-IFN responses in the cervix – systemic
CD8+ T cell responses tended to be to the same epitopes but at generally lower levels than cervical CD8+ T cell responses
• Low risk individuals did not have such CD8+ cells
• CD8+ T cell epitopes: DTVLEDINL (3 individuals), SLYNVATL (4 individuals), LSPRTLNAW (3 individuals) and YPLTFGWCF (4 individuals) were
most commonly recognized by the HIV-resistant women
Nef (135–143) Nef (135–143 LAI) YPLTFGWCY HIV-1 exposed seronegative human (B18) Culmann1991,
Culmann-Penciolelli1994
• Nef CTL clones from HIV+ donors
Nef (135–143) Nef (135–143 SF2) YPLTFGWCY HIV-1 infection human (B18) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
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• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B18+ individuals that had a CTL response to this epitope broken down by group: 0/3 group 1, 1/2 group 2, and 0/0 group 3
Nef (135–143) Nef YPLTFGWCF HIV-1 infection human (B18) Kaul2002
• Neisseria gonorrhea cervititis in 9 HIV+ Kenyan sex workers caused a functional deficiency in IFN-gamma production in HIV-1 epitope-specific CD8+
T-cells, detected by intracellular cytokine production and tetramer assays, while not affecting the total number of epitope-specific CTLs.
• Ghonorrhea caused the weaker HIV-1 specific CTL responses in 4 HIV-1 exposed persistently seronegative (HEPS) women to become undetectable by
Elispot and tetramer assays, and CMV-specific CTL in 2 HEPS subjects were shown to have impaired function with regard to IFN-gamma production.
Nef (135–143) Nef YPLTFGWCY HIV-1 infection human (B18) Altfeld2002
• Epitope name: B18-YY9(Nef)
• Peripheral blood (PB) and lymph node (LN) CD8+ T-cell responses were compared in 15 asymptomatic HIV-1 infected patients using all known optimal
CTL epitopes (http://hiv-web.lanl.gov/content/hiv-db/REVIEWS/brander2001.html) for each person’s class I HLA alleles.
• 60 epitope responses were detected in both PB and LN samples of the 15 patients, and an additional 8 responses were detected only in LN. The total
magnitude of the response was similar in LN and PB, but the percentage of CD8+ T cells in the LN is lower so the number of HIV-specific cells per million
CD8+ T-cells is higher in the LN.
• 1 year post-HAART treatment in five patients studied, the magnitude of the CD8 T-cell response was decreased in both LN and PB, but more dramatically
in PB, and 13/25 epitope responses in the PB became undetectable, in contrast to 5/26 in the LN.
• Treatment interruption following HAART induced resulted in increased viremia accompanied by the restoration of the detection of 13 epitopes that had
become undetectable in the PB, and the addition of 9 novel epitope responses.
• Breakdowns of epitope responses were shown for 4 individuals. Patient D displayed the greatest response to B27-KK10 (p24), and also responded to
A30-RY11(p17), A32-PW10(RT), A30-KY11(RT), A32-RW10(gp120), and B18-YY9(Nef).
Nef (135–143) Nef (135–143) YPLTFGWCY HIV-1 infection, HIV-1 exposed
seronegative
human (B18, B49) Kaul2001a
• Variants YPLTFGWC(Y/F) are specific for the B/D clades
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with
reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected
women
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure
• Among HLA-B18 women, 1/4 HEPS and 8/9 HIV-1 infected women recognized this epitope, likelihood ratio 5.3, p value 0.04, and HEPS women tended to
respond to FRDYVDRF(Y/F)K, while infected women tended to respond to YPLTFGWC(Y/F)
• The dominant response to this HLA allele was to this epitope for the one reactive HEPS case and in all 8/9 HIV-1 infected women
• Differences in epitope specificity were only seen for responses restricted by class I HLA alleles A2, A24, A*6802, B14, and B18, previously shown to be
associated with resistance to HIV-1 in this cohort
Nef (135–143) Nef (139–147 SF2) YPLTFGWCF HIV-1 infection human (B35) Shiga1996
• Binds HLA-B*3501
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Nef (135–143) Nef (135–143 BRU) YPLTFGWCY HIV-1 infection human (B35) Choppin2001
• Seventy-three 8-11 mer peptides were generated based on putative anchor motifs in the Nef BRU sequence for HLA A2, A3, A24, B7, B8, and B35; these
73 peptides had 81 motifs. 54% bound to the predicted HLA molecule, particularly A2, B7/35, and B8. The strength of HLA-peptide binding was not
directly related to the number of individuals that recognized a protein.
• 20s proteasome cleavage of the Nef protein positions 66-100 showed a large fraction of peptides were cleaved ending at: 87L, 83A, 81Y, 71P, 68F and 67G.
The frequency of recognition may be in part dictated by the cleavage step in processing.
• YPLTFGWCY was recognized in 2/13 (15%) of individuals with HLA B7, and 11/14 (79%) of individuals with HLA B35, and it was a moderate affinity
HLA binder.
Nef (135–143) Nef YPLTFGWCY HIV-1 infection human (B35) Sabbaj2002a
• IFNgamma T-cell responses in breast milk of 5 HIV-1 infected women from the US and 6 from Zambia were tested with using Elispot. 11/11 women
responded to Gag, 8/11 responded to Pol, 7/11 women to Nef, and 2/5 women to Env peptide pools. These responses were shown to be primarily due to
CD8+ T-cells in one woman, and another woman had cytolytic responses measured by Cr-release.
• T-cells in breast milk from a volunteer who was HLA A3, A11, B35, B51 induced IFNgamma after stimulation with a peptide that carries known B35
epitope YPLTFGWCY.
• The frequencies of responses in the two compartments differed, and 2/4 women that responded to epitopes in Nef 101-205 and Pol 601-710 showed
responses in breast milk but no detectable responses in peripheral blood cells.
Nef (135–143) Nef YPLTFGWCY HIV-1 exposed seronegative human (B49) Rowland-Jones1998a
• A CTL response was found in exposed but uninfected prostitutes from Nairobi using previously-defined B clade epitopes that tended to be conserved in A
and D clades – such cross-reactivity could protect against both A and D and confer protection in Nairobi where both subtypes are circulating
• The A subtype consensus is identical to the B clade epitope
• The D subtype consensus is ypltfgwcF.
Nef (135–143) Nef (subtype B) YLPTFGWCY HIV-1 exposed seronegative human (B49) Rowland-Jones1998b
• HIV-specific CTL were found in exposed seronegative prostitutes from Nairobi – these CTL may confer protection
• Seroprevalence in this cohort is 90-95% and their HIV-1 exposure is among the highest in the world
• Most isolated HIV strains are clade A in Nairobi, although clades C and D are also found – B clade epitopes are often cross-reactive, however stronger
responses are frequently observed using A or D clade versions of epitopes
• This epitope is conserved among A and B clade viruses
• The Clade D version of the epitope, YPLTFGWCF, was preferentially recognized by CTL
Nef (135–143) YPLTFGWCY HIV-1 infection human (B49) Kaul2001c
• This study examines CTL responses in HIV exposed, persistently seronegative individuals, HEPS, who eventually seroconverted – 11/114 HEPS Nairobi
sex workers eventually seroconverted, and for six of these HIV CTL reactive epitopes had been defined while seronegative
• The epidemiological factor associated with seroconversion was stopping sex work and HIV-specific CTL activity declines when HEPS sex workers stop
working for a period or retire
• This epitope, YPLTFGWC(Y/F), was recognized in 1/22 HEPS sex worker controls (ML1668)
Nef (135–143) Nef (135–143 BRU) YPLTFGWCY HIV-1 infection human (B7) Choppin2001
• Seventy-three 8-11 mer peptides were generated based on putative anchor motifs in the Nef BRU sequence for HLA A2, A3, A24, B7, B8, and B35; these
73 peptides had 81 motifs. 54% bound to the predicted HLA molecule, particularly A2, B7/35, and B8. The strength of HLA-peptide binding was not
directly related to the number of individuals that recognized a protein.
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• 20s proteasome cleavage of the Nef protein positions 66-100 showed a large fraction of peptides were cleaved ending at: 87L, 83A, 81Y, 71P, 68F and 67G.
The frequency of recognition may be in part dictated by the cleavage step in processing.
• YPLTFGWCY was recognized in 2/13 (15%) of individuals with HLA B7, and 11/14 (79%) of individuals with HLA B35, and it was a moderate affinity
HLA binder.
Nef (136–144) Nef (136–144 BRU) PLTFGWCYK HIV-1 infection human (A3) Choppin2001
• Seventy-three 8-11 mer peptides were generated based on putative anchor motifs in the Nef BRU sequence for HLA A2, A3, A24, B7, B8, and B35; these
73 peptides had 81 motifs. 54% bound to the predicted HLA molecule, particularly A2, B7/35, and B8. The strength of HLA-peptide binding was not
directly related to the number of individuals that recognized a protein.
• 20s proteasome cleavage of the Nef protein positions 66-100 showed a large fraction of peptides were cleaved ending at: 87L, 83A, 81Y, 71P, 68F and 67G.
The frequency of recognition may be in part dictated by the cleavage step in processing.
• PLTFGWCYK was recognized in 3/12 (25%) of individuals with HLA A3. It was a low affinity HLA-A3 binder.
Nef (136–145) Nef (136–145) PLTFGWCYKL in vitro stimulation human (A*0201) Wilson1999b
• Dendritic cells are the most potent for priming T cell responses – DCs can stimulate autologous CTL responses from T cells cultured from HIV negative
donors
• Th1-biasing cytokines IL-12 or IFN alpha enhance CTL responses in vitro whether the epitope is delivered by pulsing from peptide, or expressed from
within
• B7 and A2 Nef epitopes were studied and the relative binding affinity of A2 epitopes for A2 was: PLTFGWCYKL greater than VLEWRFDSRL which was
much greater than AFHHVAREL
• Noted in Brander et al., 1999 this database, to be A*0201
Nef (136–145) Nef (136–145 LAI) PLTFGWCYKL human (A*0201) Brander2001
• C. Brander notes this is an A*0201 epitope
Nef (136–145) Nef (136–145 LAI) PLTFGWCYKL in vitro stimulation human (A*0201) Lucchiari-Hartz2000
• Five naturally processed MHC class I ligands were identified in Nef in the conserved immunogenic region Nef between 123-152
• All five could be transported by TAP, and 4/5 had N-termini that were major cleavage points for the proteasome, only one had extended precursor fragments
• The CTL that recognized PLTFGWCYKL also recognized PLTFGWCYKLV, and both forms of the epitope are naturally processed and both seem to be the
direct product of a proteasomal digest, although in low copy number
Nef (136–145) PLTFGWCYKL HIV-1 infection human (A02) Sabbaj2002b
• Epitope name: Nef-PL10
• Among HIV+ individuals who carried HLA A02, 3/29 (10%) recognized this epitope
Nef (136–145) Nef (136–145) PLTFGWCFKL HIV-1 infection human (A2) Durali1998
• Cross-clade CTL response was studied by determining the CTL activity in seven patients from Bangui, (6 A subtype, and 1 AG recombinant infections) and
one A subtype infection from a person living in France originally from Togo, to different antigens expressed in vaccinia
• Pol reactivity: 8/8 had CTL to A subtype, and 7/8 to B subtype, and HIV-2 Pol was not tested
• Gag reactivity: 7/8 reacted with A or B subtype gag, 3/8 with HIV-2 Gag
• Nef reactivity: 7/8 reacted with A subtype, and 5/8 with B subtype, none with HIV-2 Nef
• Env reactivity: 3/8 reacted with A subtype, 1/8 with B subtype, none with HIV-2 Env
• Patient B18 had the greatest breadth and diversity of response, and recognized Gag SLYNTVATL and Nef PLTFGWCFKL
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Nef (136–145) Nef (157–166) PLTFGWCFKL Vaccine human (A2) Woodberry1999
Vaccine Vector/Type: DNA prime with vaccinia boost HIV component: polyepitope
• A polyepitope vaccine was generated in a vaccinia construct that contiguously encoded seven epitopes, all presented by HLA A-2
• HHD mice have a transgene of HLA A2 linked to the transmembrane and cytotoxic domains of H-2Dd – this transgene is the only MHC molecule
expressed in the mice
• CTL responses to Gag (77-85) SLYNTVATL, Pol (476-484) ILKEPVHGV, gp120 (120-128) KLTPLCVTL, and Nef (190-198) AFHHVAREL were
observed in HIV polytope HHD-vaccinated mice, and these responses were enhanced with vaccinia boost
• No CTL immune responses were generated against HLA A2-restricted HIV epitopes Nef 157-166 (PLTFGWCYKL), Pol 346-354 (VIYQYMDDL), and
Nef 180-189 (VLEWRFDSRL)
• Sixteen HLA A2+ patients were tested for their ability to make CTL responses by peptide restimulation in culture with the epitopes selected for inclusion in
the polytope – one individual recognized all seven of these epitopes; 7 patients had CTL cultures able to recognize at least one of the epitopes, and 6 of
those 7 recognized more than one epitope, but they were not able to test all peptides for all patients; many patients only had three peptides tested
• PLTFGWCFKL was recognized by 1 of the HLA-A2 patients
Nef (136–145) Nef (135–144 93TH253
subtype CRF01)
PLTFGWCYKL HIV-1 infection human (A2) Bond2001
• More than half of a cohort of HIV+ female sex workers (FSW) from Northern Thailand were HLA-A11 positive, and this study concentrated on A11
epitopes in this group, although E clade versions of previously defined B-clade A2 and A24 epitopes were also tested.
• 0/4 tested FSWs recognized the E clade version of this epitope PLCFGWCFKL, which differs from the previously defined B clade version by two amino
acids, PLTFGWCYKL
• This epitope was only conserved in CRF01 (subtype E) and subtype B
Nef (136–145) Nef (136–145) PLTFGWCYKL HIV-1 infection human (A2) Day2001
• The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7 was
studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
• 2 to 17 epitopes were recognized in a given individual, A2-restricted CTL response tended to be narrow and never dominated the response, and 25/27
epitopes were targeted by at least one person
Nef (136–145) Nef (136–145 BRU) PLTFGWCYKL HIV-1 infection human (A2) Choppin2001
• Seventy-three 8-11 mer peptides were generated based on putative anchor motifs in the Nef BRU sequence for HLA A2, A3, A24, B7, B8, and B35; these
73 peptides had 81 motifs. 54% bound to the predicted HLA molecule, particularly A2, B7/35, and B8. The strength of HLA-peptide binding was not
directly related to the number of individuals that recognized a protein.
• 20s proteasome cleavage of the Nef protein positions 66-100 showed a large fraction of peptides were cleaved ending at: 87L, 83A, 81Y, 71P, 68F and 67G.
The frequency of recognition may be in part dictated by the cleavage step in processing.
• PLTFGWCYKL was recognized in 9/28 (32%) of individuals with HLA A2. It was a low affinity HLA-A2 binder.
Nef (136–146) Nef (136–146 LAI) PLTFGWCYKLV in vitro stimulation human (A*0201) Lucchiari-Hartz2000
• Five naturally processed MHC class I ligands were identified in Nef in the conserved immunogenic region Nef between 123-152
• All five could be transported by TAP, and 4/5 had N-termini that were major cleavage points for the proteasome, only one had extended precursor fragments
• The CTL that recognized PLTFGWCYKL also recognized PLTFGWCYKLV, and both forms of the epitope are naturally processed and both seem to be the
direct product of a proteasomal digest, although in low copy number
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Nef (137–145) Nef (158–166) LTFGWCFKL HIV-1 infection human (A2 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind all five HLA-A2 supertypes alleles (A*0201, A*0202, A*0203, A*0206 and A*6802)
Nef (137–145) Nef (139–147 HXB3) LTFGWCFKL Vaccine murine (HLA-A201
transgenic)
Sandberg2000
Vaccine Vector/Type: DNA, peptide Strain: HXB3 HIV component: Nef Adjuvant: Freund’s adjuvant
• Ten Nef 9-mer peptides were predicted to have a strong binding affinity with HLA-A*0201 – of these, four did bind strongly by a T2 class I stabilization
assay, several others bound weakly
• A CTL immune response to only 3/10 peptides was detected by a 51Cr-release assay after immunization of HLA-A201 transgenic mice with either nef
DNA under the control of a CMV promotor, coated on gold particles delivered to abdominal skin by gene gun – LTFGWCFKL did not elicit a CTL response
• LTFGWCFKL was also tested by subcutaneous injection of Nef peptides in Freund’s adjuvant, because it bound strongly to HLA-A*0201, and the peptide
vaccination did elicit a response
• The lack of response to the nef DNA vaccine and the response to the peptide suggests LTFGWCFKL may not be processed
Nef (137–146) Nef (221A) LTFGWCFKLV HIV-1 infection human (A2) Altfeld2001c
• Epitope name: Nef-221a
• HIV was scanned for all peptides which carried the A2-supermotif pattern conserved in more than 50% of B clade sequences – 233 peptides met this
criteria, and 30 of these bound to HLA-A*0201 – 20/30 bound to at least 3/5 of HLA-A2 supertype alleles tested
• Three additional previously described HLA-A2 epitopes were added to the set of 20, and 18/22 chronically infected HLA-A2 individuals had CTL that
recognized at least one of the 23 peptides (median of 2 and maximum of 6), while 6/12 acute infected individuals recognized at least 1 (median of 1 and
maximum of 2)
• 1/22 individuals with chronic HIV-1 infection recognized this epitope in ELISPOT
• 2/12 acutely infected individuals recognized this epitope
• LTFGWCFKLV binds to five HLA-A2 supertype alleles:A*0203, A*0201 (highest affinity), A*0206, A*6802 and A*0202
Nef (137–146) Nef (158–167) LTFGWCFKLV HIV-1 infection human (A2 supertype) Propato2001
• Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16
for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes
• Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs
• A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was
observed, which may contribute to the inability of LTNPs to clear virus
• This epitope can bind all five HLA-A2 supertypes alleles (A*0201, A*0202, A*0203, A*0206 and A*6802)
• Tetramer staining with A2, beta2microglobulin, and either SLYNTVATL, KLVGKLNWA, or LTFGWCFKL revealed that tetramers detected more
HIV-specific sells in LTNP than in progressors, activated effector cells were the minority population, and ELISPOT correlated better with the effector cell
subpopulation than the total tetramer stained population
Nef (162–181) Nef (161–180) TSLLHPVSLHGMDDPEREVL HIV-1 infection human Lieberman1995
• HIV-specific CTL lines developed by ex vivo stimulation with peptide
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Nef (162–181) Nef (161–180 SF2) TSLLHPVSLHGMDDPEREVL HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Eleven subjects had CTL that could recognize vaccinia-expressed LAI Nef
• One of these 11 had CTL response to this peptide
Nef (162–181) Nef (101–120 SF2) TSLLHPVSLHGMDDPEREVL HIV-1 infection human Lieberman1997b
• CTL expanded ex vivo were later infused into HIV-1 infected patients
Nef (162–181) Nef (161–180 SF2) TSLLHPVSLHGMDDPEREVL HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Eleven subjects had CTL that could recognize vaccinia-expressed LAI Nef
• One of these 11 had CTL response to this peptide
Nef (166–177) Nef (160–179 SF2) HPVSLHGMDDPE HIV-1 infection human (B35) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-B35+ individuals that had a CTL response to this epitope broken down by group: 1/2 group 1, 0/2 group 2, and 0/1 group 3
Nef (172–191) Nef (171–190 SF2) GMDDPEREVLEWRFDSRLAF HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Eleven subjects had CTL that could recognize vaccinia-expressed LAI Nef
• One of these 11 had CTL response to this peptide
• The responding subject was HLA-A2, B21
Nef (175–184) Nef (175–184) DPEKEVLQWK HIV-1 infection human (B7) Jin2000b
• This a B7 epitope, a subdominant CTL response, was defined by an un-conventional approach used to predict epitopes in an HLA B7+ long-term
non-progressor
• Three additional sub-dominant HLA B7 epitopes were defined using EpiMatrix, a non-anchor based strategy for defining potential epitopes, which
highlighted 2078 possible epitopes in the autologous HIV-1 derived from the study subject, followed by B7 anchor residue prediction which narrowed the
set to 55 peptides, three of which could serve as functional CTL epitopes
Nef (180–189) Nef (180–189 LAI) VLEWRFDSRL HIV-1 infection human (A*0201) Haas1996, Haas1997
• There was a high degree of variation in three CTL epitopes in Nef in four slow and non-progressors, and variant specific CTLs arose over time to eliminate
variants, indicating immune selection
• Noted in Brander et al., 1999 this database, to be A*0201
Nef (180–189) Nef (180–189 LAI) VLEWRFDSRL human (A*0201) Brander2001
• C. Brander notes this is an A*0201 epitope
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Nef (180–189) Nef (180–189 LAI) VLMWQFDSRL Vaccine murine (transgenic)
(A*0201)
Boissonnas2002
Vaccine Vector/Type: peptide Strain: Natural variants HIV component: Nef Adjuvant: CFA
• Ten naturally occurring variants of this epitope were tested for their affinity to HLA-A*0201 and for their ability to induce gamma-IFN and cytotoxic
functions through vaccination of HLA-A*0201 transgenic mice.
• Only two variants could induce vaccine responses: VLMWQFDSRL, a high affinity binder, and VLQWRFDSRL a medium affinity binder to A*0201.
• In vivo priming with Nef peptide VLMWQFDSRL induced cross-reactive CTL to 6/7 peptides tested (AlmwKfdsKl, vlmwKfdsrl, vlmwKfdsKl,
vlQwRfdsKl, vlVwrfdTrl, and vlAwKLdsrl but not the LAI peptide vlEwrfdsrl)
• In vivo priming with Nef peptide VLQWRFDTRL induced cross-reactive CTL to 3/6 variant Nef peptides (vlMwQfdsrl, vlqwrfdSrl and vlEwrfdsrl).
Nef (180–189) Nef (190–198) VLEWRFDSRL Vaccine murine (A*0201) Singh2002, Sykes1999
Vaccine Vector/Type: DNA HIV component: HIV-1 divided into a 32 plasmids in a ubiquitin expression library
• C3H (H-2k) transgenic mice carrying a fused HLA-A*0201 alpha1 and alpha2 and H-2Dk alpha3 hybrid class I molecule were immunized using an
epidermal gene gun with an ubiquitin expression library of 32 plasmids that spanned the HIV-1 genome. Ubiquitin targets the expressed HIV-1 peptides to
the proteasome.
• A single immunization with the UB-HIV-1 library vaccine induced potent, stable and multivalent CTL responses against all library members.
• Immunodominant epitopes SLYNTVATL (Gag), ILKEPVHGV(Pol), RIQRGPGRAFVTIGK(P18) and AFHHVAREK (Nef) elicited strong CD8+/IFN-
responses and stimulated CTL that were functional in a Cr-release assay and against wild type antigen.
• The presence of multiple plasmids HLA-A*0201-restricted CTL epitopes did not decrease CTL immunogenicity, and CTL responses to single peptide
immunizations were comparable to responses based on mixtures of either 16 or 32 peptides.
Nef (180–189) Nef (180–189) VLEWRFDSRL in vitro stimulation human (A2) Wilson1999b
• Dendritic cells are the most potent for priming T cell responses – DCs can stimulate autologous CTL responses from T cells cultured from HIV negative
donors
• Th1-biasing cytokines IL-12 or IFN alpha enhance CTL responses in vitro whether the epitope is delivered by pulsing from peptide, or expressed from
within
• B7 and A2 Nef epitopes were studied and the relative binding affinity of A2 epitopes for A2 was: PLTFGWCYKL greater than VLEWRFDSRL which was
much greater than AFHHVAREL
Nef (180–189) Nef (180–189) VLEWRFDSRL Vaccine human (A2) Woodberry1999
Vaccine Vector/Type: DNA prime with vaccinia boost HIV component: polyepitope
• A polyepitope vaccine was generated in a vaccinia construct that contiguously encoded seven epitopes, all presented by HLA A-2
• HHD mice have a transgene of HLA A2 linked to the transmembrane and cytotoxic domains of H-2Dd – this transgene is the only MHC molecule
expressed in the mice
• CTL responses to Gag (77-85) SLYNTVATL, Pol (476-484) ILKEPVHGV, gp120 (120-128) KLTPLCVTL, and Nef (190-198) AFHHVAREL were
observed in HIV polytope HHD-vaccinated mice, and these responses were enhanced with vaccinia boost
• No CTL immune responses were generated against HLA A2-restricted HIV epitopes Nef 157-166 (PLTFGWCYKL), Pol 346-354 (VIYQYMDDL), and
Nef 180-189 (VLEWRFDSRL)
• Sixteen HLA A2+ patients were tested for their ability to make CTL responses by peptide restimulation in culture with the epitopes selected for inclusion in
the polytope – one individual recognized all seven of these epitopes; 7 patients had CTL cultures able to recognize at least one of the epitopes, and 6 of
those 7 recognized more than one epitope, but they were not able to test all peptides for all patients; many patients only had three peptides tested
• VLEWRFDSRL was recognized by 2 of the HLA-A2 patients
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Nef (180–189) Nef (180–189 LAI) VLEWRFDSRL HIV-1 infection human (A2) Mollet2000
• Epitope name: N3
• A panel of 16 epitopes covering 15 class I alleles was tested in 14 HIV+ patients from an unselected Caucasian population treated with HAART, using
CD8+ cell IFNgamma production to measure responses
• In general, during the first month of treatment viral load decreased and frequencies of HIV-specific CTL tripled and broadened – eight new HIV
specificities that were not previously detectable were newly detected, as were CMV specific CD8+ PBL – but with continued viral suppression,
HIV-specific responses diminished
• Viral rebounds gave different patterns of response: increases or decreases in pre-existing response, new specificities, or no change
Nef (180–189) Nef (179–188 93TH253
subtype CRF01)
VLEWRFDSRL HIV-1 infection human (A2) Bond2001
• More than half of a cohort of HIV+ female sex workers (FSW) from Northern Thailand were HLA-A11 positive, and this study concentrated on A11
epitopes in this group, although E clade versions of previously defined B-clade A2 and A24 epitopes were also tested.
• 0/4 tested FSWs recognized the E clade version of this epitope VLIWKFDSAL, which differs from the previously defined B clade version by three amino
acids, VLEWRFDSRL
Nef (180–189) Nef (180–189) VLEWRFDSRL HIV-1 infection human (A2) Day2001
• The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7 was
studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
• 2 to 17 epitopes were recognized in a given individual, A2-restricted CTL response tended to be narrow and never dominated the response, and 25/27
epitopes were targeted by at least one person
Nef (182–198) Nef (182–198 BRU) EWRFDSRLAFHHVAREL HIV-1 infection human (A1, B8) Hadida1992
• HIV-1 specific CTLs detected in lymphoid organs of HIV-1 infected patients
Nef (182–198) Nef (182–198 LAI) EWRFDSRLAFHHVAREL HIV-1 infection human (A2, A25(10)) Hadida1995
• The C-terminal region of Nef (182-205) contains multiple CTL epitopes with 5 distinct HLA restrictions
Nef (182–198) Nef (182–198 BRU) EWRFDSRLAFHHVAREL HIV-1 infection human (A25) Cheynier1992
• CTL isolated in children born to HIV-1 positive mothers
Nef (182–198) Nef (182–198 LAI) EWRFDSRLAFHHVAREL HIV-1 infection human (B35) Hadida1995
• The C-terminal region of Nef (182-205) contains multiple CTL epitopes with 5 distinct HLA restrictions
Nef (182–198) Nef (182–198 LAI) EWRFDSRLAFHHVAREL Vaccine murine (H-2d) VanderRyst1998
Vaccine Vector/Type: Mengo virus, vaccinia Strain: LAI HIV component: Nef
• Macaca mulatta did not have a detectable response to Rec Mengo virus-HIV-1 Nef 65-206 vaccine
• BALB/c mice had a weak response to this epitope in the Mengo virus construct – in contrast, HIV-1 Nef induces a strong CTL response in mice when
presented in a vaccinia background
Nef (182–201) Nef (191–205 SF2) EWRFDSRLAFHHVARELHPE HIV-1 infection human Lieberman1997a
• Of 25 patients, most had CTL specific for more than 1 HIV-1 protein
• Eleven subjects had CTL that could recognize vaccinia-expressed LAI Nef
• One of these 11 had CTL response to this peptide
• The responding subject was HLA-A2, B21
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Nef (182–205) Nef (182–205 LAI) EWRFDSRLAFHHVARELHP-
EYFKN
Vaccine human Gahery-Segard2000
Vaccine Vector/Type: lipopeptide HIV component: six peptides
• Anti-HIV lipopeptide vaccine consisting of six long amino acid peptides derived from Nef, Gag and Env HIV-1 proteins modified by a palmitoyl chain was
administered in a phase I trial
• A CD4+ T cell proliferative response to at least one of the six peptides was observed in 9/10 vaccinees – 4/10 reacted to this Nef peptide
• 9/12 tested mounted a CTL response to at least one of the six peptides; each of the six peptides elicited a CTL response in at least one individual
• None of the 12 tested had an IgG response to this peptide
Nef (183–191) WRFDSRLAF HIV-1 infection human (B*1503) Sabbaj2002b
• Epitope name: Nef-WF9
• This study monitored epitope responses in HIV-1 infected minority women living in the United States
• 24 epitopes were described – 8 were novel, 8 used new restricting elements but were previously defined epitopes, and 8 were previously described
• Serial peptide truncations were used to define optimal epitopes for CTL cell lines isolated from 12 individuals, assayed by a Cr-release
• This epitope was newly defined in this study
• Subject 01RCH50 also recognized the epitope RMRGAHTNDV, RT(356-365), A*3002 – she was African American, was on HAART, had a viral load of
960 and CD4 count of 728
• Among HIV+ individuals who carried HLA B15, 3/17 (18%) recognized this epitope
Nef (186–193) Nef (186–193 LAI) DSRLAFHH HIV-1 infection human (B35) Hadida1995
• The C-terminal region of Nef (182-205) contains multiple CTL epitopes with 5 distinct HLA restrictions
Nef (186–194) Nef (186–194) DSRLAFHHM HIV-1 infection, HIV-1 exposed
seronegative
human (A24) Kaul2001a
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
Nef (186–194) Nef (186–194 BRU) DSRLAFHHV human (B51) Connan1994
• Resulted in the assembly of HLA-B51
Nef (188–196) Nef (188–196 LAI) RLAFHHVAR HIV-1 infection human (B52) Hadida1995
• The C-terminal region of Nef (182-205) contains multiple CTL epitopes with 5 distinct HLA restrictions
Nef (188–201) Nef (188–201 LAI) RLAFHHVARELHPE HIV-1 infection human (B35 or C4) Buseyne1993a
• Vertical transmission of HIV ranges from 13% to 39%
• Primary assays showed cytotoxic activity against at least one HIV protein was detected in 70% of infected children
• Epitopes recognized in five children were mapped using synthetic peptides and secondary cultures
• Patient EM13, who had a CTL response to three epitopes in Nef, was infected via blood transfusion after birth and went from CDC stage P2A to P2E
during the study
Nef (190–198) ALKHRAYEL HIV-1 infection human Kaul2001c
• This study examines CTL responses in HIV exposed, persistently seronegative individuals, HEPS, who eventually seroconverted – 11/114 HEPS Nairobi
sex workers eventually seroconverted, and for six of these HIV CTL reactive epitopes had been defined while seronegative
• The epidemiological factor associated with seroconversion was stopping sex work and HIV-specific CTL activity declines when HEPS sex workers stop
working for a period or retire
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• This epitope was in 1/22 HEPS controls, ML1749
Nef (190–198) Nef AFHHVAREL HIV-1 infection human (A*0201) Altfeld2001c
• Epitope name: Nef AL9
• HIV was scanned for all peptides which carried the A2-supermotif pattern conserved in more than 50% of B clade sequences – 233 peptides met this
criteria, and 30 of these bound to HLA-A*0201 – 20/30 bound to at least 3/5 of HLA-A2 supertype alleles tested
• Three additional previously described HLA-A2 epitopes were added to the set of 20, including Nef AL9, and 18/22 chronically infected HLA-A2
individuals had CTL that recognized at least one of the 23 peptides (median of 2 and maximum of 6), while 6/12 acute infected individuals recognized at
least 1 (median of 1 and maximum of 2)
• RT VL9 was not recognized by any of the 22 HLA-A2 patients with chronic HIV-1 infection or the 13 HLA-A2 patients with acute HIV-1 infection
included in this study
Nef (190–198) Nef ALKHRAYEL HIV-1 infection, Vaccine human, macaque
(A*0201)
Hanke2000, Wee2002
Vaccine Vector/Type: DNA prime with vaccinia MVA boost Strain: subtype A HIV component: p17, p24, polyepitope
• The HIV-1 subtype A focused vaccine HIVA contains p24 and p17, in a reversed order relative to the Gag polyprotein to prevent myristylation of p17,
which could direct the protein to the cell membrane and inhibit efficient peptide processing and class I presentation, as well as a polyepitope string of
conserved, often immunodominant epitopes that were selected to have particularly good cross-reactive potential for the A-clade epidemic in Nairobi,
Kenya. A DNA and MVA prime-boost vaccination protocol using the HIVA antigen will be used in a phase III clinical trial in Kenya. This epitope is
included in the polyepitope string [Hanke2000].
• Multiple CD4+ or CD8+ T-cell vaccine-induced responses to peptide pools were detected using intracellular cytokine staining and IFNgamma Elispot
assays after vaccination of 5 macaques. The response to the Mamu A*01 SIV p27 epitope p11C (CTPYDINQM), included in the polyepitope region, was
not immunodominant in the Mamu A*01 vaccinated macaques, possibly because of processing limitations in context of the artificial polyepitope string
[Wee2002].
Nef (190–198) Nef (190–198 LAI) AFHHVAREL HIV-1 exposed seronegative human (A2) Rowland-Jones1998a
• CTL recognition reported in the context of HLA-B52 and A2.1, A2.2 and A2.4
• A CTL response was found in exposed but uninfected prostitutes from Nairobi using previously-defined B clade epitopes that tended to be conserved in A
and D clades – such cross-reactivity could protect against both A and D and confer protection in Nairobi where both subtypes are circulating
• The A subtype consensus is ALKHRAYEL
• The D subtype consensus is AfEHKAREm
• [Hunziker1998] suggests that HLA-A2 does not in fact present this epitope, and notes that it does not promote A2 assembly [Connan1994] – also see
[Brander1998b]
• [Hunziker1998] maintains that HLA-A2 does not present this epitope contrary to an earlier report [Hadida1995], (also see [Brander1998a])—despite the
position of Hunziker et al., Rowland-Jones and colleagues are confident that this epitope in its A clade form is presented by HLA-A*0201 and A*0202, and
it is one of the most common responses seen in both seropositive and exposed-uninfected donors from Nairobi (Rupert Kaul, Pers. Comm.)
Nef (190–198) Nef (190–198) AFHHVAREL in vitro stimulation human (A2) Wilson1999b
• Dendritic cells are the most potent for priming T cell responses – DCs can stimulate autologous CTL responses from T cells cultured from HIV negative
donors
• Th1-biasing cytokines IL-12 or IFN alpha enhance CTL responses in vitro whether the epitope is delivered by pulsing from peptide, or expressed from
within
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• B7 and A2 Nef epitopes were studied and the relative binding affinity of A2 epitopes for A2 was: PLTFGWCYKL greater than VLEWRFDSRL which was
much greater than AFHHVAREL
Nef (190–198) Nef (190–198) AFHHVAREL Vaccine human (A2) Woodberry1999
Vaccine Vector/Type: vaccinia HIV component: polyepitope
• A polyepitope vaccine was generated in a vaccinia construct that contiguously encoded seven epitopes, all presented by HLA A-2
• HHD mice have a transgene of HLA A2 linked to the transmembrane and cytotoxic domains of H-2Dd – this transgene is the only MHC molecule
expressed in the mice
• CTL responses to Gag (77-85) SLYNTVATL, Pol (476-484) ILKEPVHGV, gp120 (120-128) KLTPLCVTL, and Nef (190-198) AFHHVAREL were
observed in HIV polytope HHD-vaccinated mice, and these responses were enhanced with vaccinia boost
• No CTL immune responses were generated against HLA A2-restricted HIV epitopes Nef 157-166 (PLTFGWCYKL), Pol 346-354 (VIYQYMDDL), and
Nef 180-189 (VLEWRFDSRL)
• Sixteen HLA A2+ patients were tested for their ability to make CTL responses by peptide restimulation in culture with the epitopes selected for inclusion in
the polytope – one individual recognized all seven of these epitopes; 7 patients had CTL cultures able to recognize at least one of the epitopes, and 6 of
those 7 recognized more than one epitope, but they were not able to test all peptides for all patients; many patients only had three peptides tested
• AFHHVAREL was recognized by 2 of the patients
Nef (190–198) Nef (190–198 SF2) AFHHVAREL HIV-1 infection human (A2) Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Previously described and newly defined optimal epitopes were tested for CTL response
• Number of HLA-A2+ individuals that had a CTL response to this epitope broken down by group: 0/10 group 1, 1/6 group 2, and 0/4 group 3
Nef (190–198) Nef (190–198) ALKHRAYEL HIV-1 infection, HIV-1 exposed
seronegative
human (A2) Kaul2001a
• Variants ALKHRAYEL and AFHHVAREL are A/B clade specific
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87
HIV-1-infected female Nairobi sex workers
Nef (190–198) Nef (subtype B) AFHHVAREL HIV-1 exposed seronegative human (A2, A*0202,
A*0201)
Rowland-Jones1998b
• HIV-specific CTL were found in exposed seronegative prostitutes from Nairobi – these CTL may confer protection
• Seroprevalence in this cohort is 90-95% and their HIV-1 exposure is among the highest in the world
• Most isolated HIV strains are clade A in Nairobi, although clades C and D are also found – B clade epitopes are often cross-reactive, however stronger
responses are frequently observed using A or D clade versions of epitopes
• Clade A version of the epitope: ALKHRAYEL, Clade D epitope: AFEHKAREM
• This epitope was recognized by two different exposed and uninfected prostitutes
Nef (190–198) Nef (190–198 LAI) AFHHVAREK HIV-1 infection human (A3) Hadida1995
• Naturally occurring L to K anchor substitution abrogates A2 binding, but permits HLA-A3 binding
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Nef (192–206) Nef (192–206 BRU) HHVARELHPEYFKNC HIV-1 infection human (A1) Hadida1992
• HIV-1 specific CTLs detected in lymphoid organs of HIV-1 infected patients
Nef Nef (IIIB) HIV-1 infection human Wasik2000
• HIV+ infants that progressed rapidly to AIDS had lower Th1 responses and decreased production of beta-chemokines and IL-2 relative to other HIV+
infants
• No HIV+ infants had no demonstrable CTL at birth, but Th1 responses accompanied by CTL responses developed in children with slowly progressive
disease, and not in rapid progressors
• CTLp frequencies were determined by limiting dilution using autologous B cells infected with vaccina/HIV constructs
Nef Nef HIV-1 infection human De Maria1997
• CD3+ cells that also carry a natural killer cell receptor (NKR+) can exhibit down regulation of T cell function
• Anti-NKR IgM MAb masked this inhibitory function and increased HIV-1 specific CTL activity in phytohemagglutinin-activated PBMC cultured in the
presence of IL-2 from 3/5 patients, and in one other case anti-NKR MAb brought HIV-1 specific CTL activity to detectable levels
Nef Nef HIV-1 infection human Lubaki1999
• Three strategies were used to analyze CTL activity: area under the net HIV-specific lysis curve (ACU), linear regression (LR) of net specific lysis, and the
standard method, lytic units (LU20)
• A correlation between low HIV plasma viral load and increased levels of HIV-specific Gag and Nef CTL activity was observed using ACU and LR, but not
LU20
Nef Nef (LAI) Vaccine human Gorse1999b
Vaccine Vector/Type: canarypox prime with rgp120 boost Strain: LAI and SF2 HIV component: Env, Gag, Pro, Nef, Pro
• The vaccine used was rec canarypox expressing HIV-1 env, gag, pol, nef and protease (vCP300) with or without administration of HIV-1 SF-2 rgp120
• In vitro inducible CTL activity against HIV-1 Env, Gag, Pol, and Nef antigens was observed in 79% (15 of 19) of vaccine recipients
• The combination of vCP300 and vP1291 together resulted in an overall increase in CTL induction and detection sensitivity
Nef Nef HIV-1 infection human Gamberg1999
• 13/13 subjects with advanced HIV infections showed CD8 T cell proliferation and differentiation of CTL in vitro, and six individuals showed HIV-specific
responses to Gag, Pol, Env or Nef antigens
• Data suggests that the functional and genetic integrity of the CD8 T cell repertoire (TCR betaV gene intrafamily genetic diversity) remains intact through
advanced HIV infection, although HIV-specific CTL activity decreases
Nef Nef Vaccine human Calarota1999
Vaccine Vector/Type: DNA HIV component: Nef, Rev Tat
• 9/9 HIV-1+ subjects were given one of three DNA vaccinations for nef, rev or tat, and novel proliferative and CTL responses were generated
• The nef DNA immunization induced the highest and most consistent CTLp activity, IFN-gamma production, and IL-6 and IgG responses
• Highly active antiretroviral treatment (HAART) did not induce new HIV-specific CTL responses but reduced viral load, while DNA vaccination induced
new immune responses but did not reduce viral load – thus this is a potentially complementary and promising combination
Nef Nef (LAI) HIV-1 infection human Buseyne1998a
• This study showed a correlation between strong CTL memory and breadth of response in 7-12 month old infants, and remaining AIDS-free for the first year
of life, higher absolute CD4 and CD8 cells, and lower viral load
395
DEC 2002
C
TL
HIV CTL Epitope Tables Nef CTL Epitopes
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
Nef Nef (LAI) HIV-1 infection human Buseyne1998b
• In infants with positive CTL responses, most responses showed cross-clade reactivity with somewhat diminished recognition of epitopes from different
subtypes
Nef Nef (LAI) Vaccine human Evans1999
Vaccine Vector/Type: canarypox HIV component: gp120, gp41, Gag, Pro, Nef, RT
• A Canarypox vaccine expressing gp120, gp41, Gag, Protease, Nef and Pol CTL epitopes gave rise to CTL that could be detected in 61% of the volunteers –
responses to Gag, Env, Nef and Pol were detected 3-6 months after the last vaccination
Nef Nef HIV-1 infection human daSilva1998
• CTL dense regions of Nef tend to lie in conserved domains with low non-synonymous substitution per site – authors consider that this may be due to a host
adaptation to infection that focuses the CTL response to be directed against conserved functional domains [daSilva1998]
Nef Nef (LAI) HIV-1 infection human Legrand1997
• Seventeen recently infected patients were tested for CTL response to HIV proteins Env, Gag, Pol, Rev, Nef, Vif and Tat
• An early response (within a month following PI) was noted in 87% of the subjects to Gag, 75% to Env, and 50% to Nef
• Early responses to Pol, Rev, Vif and Tat were rare
Nef Nef (LAI) HIV-1 infection human Zerhouni1997
• CTL responses to Env, Gag, Nef and RT were tested at various phases of disease progression – 10 asymptomatic patients generally had CTL responses to
all proteins, 10 ARC patients responded well to all proteins except Nef, and AIDS patients had few responses to any proteins
Nef Nef HIV-1 infection Kuiken1999
• A correlation between conserved regions of Nef and CTL epitope density was also noted in [Kuiken1999]. The authors suggest that this may be due to
biological reasons such as the one described above [daSilva1998], or due to epitope processing, or may possibly be an artifact of experimental strategy for
epitope definition such that conserved epitopes would tend to be identified because they would be more likely to be cross-reactive with the test reagents
• Both p17 and Nef show a correlation between epitope density and conserved regions in the protein – in contrast, p24 is a more conserved protein and
known epitopes are evenly distributed across p24
Nef Nef (BRU) HIV-1 infection human Aladdin1999
• In vitro measurements of CTL-activity by Cr release assay in bulk culture showed no correlation between CTL-activity (gp120, Gag, Pol and Nef) and
disease progression as measured by viral load, CD4 and time to death
Nef Nef (SF2) HIV-1 infection human Jin1998a
• CTL precursor frequencies were determined in HIV-1 infected pregnant women, and higher CTLp frequencies to Pol and SF2 Nef, but not IIIB Nef, were
found in non-transmitting mothers than in transmitting mothers – Nef CTL responses have been found in uninfected infants born to HIV+ women
(Lazuriaga95);
Nef (subtype C) human Novitsky2001
• This study is provides a survey of CTL responses and full length HIV-1 genome sequences from a C subtype infected Botswanan cohort
• 37 of 45 subjects (82%) demonstrated Nef specific ELISPOT CTL responses of more than 100 SFC/106 PBMC
• Two Nef-immunodominant regions were identified, one spanned amino acid positions 67 to 96 using HXB2 numbering system while the second
corresponded to amino acid positions 122 to 141
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• While there was some subtype B and C cross-reactivity, there was greater breadth and intensity of response if the CTL from HIV-1-infected individuals was
probed with ELISPOT using peptides derived from the same subtype (a median of three Nef epitopes recognized within subtype C compared with one Nef
epitope recognized from subtype B peptides, and ELISPOT results with a median of 763 SFC/106 PBMC among responses to HIV-1 C, versus a median of
318 SFC/106 PBMC among responses to HIV-1 B
Nef Nef (subtype A, B, D) HIV-1 infection human Cao2000
• HIV-1 subtypes A and D dominate the Ugandan epidemic, and a vaccine trial using B clade antigen is underway – this study addresses relative levels of
cross-reactive CTL responses in HIV infected Ugandans to A, D, and B clade recombinant vaccinia viruses expressing Gag, Env, Pol, RT or Nef from
HIV-1 clades A, B, and D
• Proteins corresponding to the subtype of the infecting strains tended to trigger higher levels of CTL response measured by percent specific lysis, but there
was extensive inter-subtype cross-reactivity with B clade proteins and the co-circulating subtype
Nef Nef HIV-1 infection, Vaccine human Calarota2001
Vaccine Vector/Type: DNA HIV component: Nef, Rev, Tat Adjuvant: CpG motifs
• This review discusses the cellular immune response, and comments on the stimulatory role of CpG motifs and how HIV-1 DNA vaccines can boost the CTL
and Th proliferative responses in asympotomatic HIV+ individuals
Nef HIV-1 exposed seronegative human De Maria1994, Kuhn2002
• 6/24 HIV uninfected infants (ages 15-50 months) born to HIV+ mothers had HIV-1 specific CTL responses to vaccinia-expressed Nef, Gag/Pol, Env.
• Reviewed in [Kuhn2002].
Nef HIV-1 infection human Yusim2002
• Epitopes that have been described in the literature and included in this database tend to cluster in conserved regions and be absent or rarely found highly
variable regions found in Nef, Env and p17.
• While the uneven distribution of epitopes may be in part due to a limited cross-recognition of specific responses because of differences between peptides
used to probe the immune response and autologous strains, regions with a paucity of defined epitopes also had higher frequencies of amino acids that tend
to not be found in C-terminal positions of epitopes, and had lower cleavage prediction scores for epitope processing. This suggests that in the regions of the
virus where variation is best tolerated traces of immune escape have left an imprint on the viral population. Epitopes also were concentrated in alpha-helix
and turn regions in the proteins.
• In the more conserved p24, and Pol proteins RT and Protease, epitopes are more evenly distributed.
Nef Nef (HXB) HIV-1 infection human Lu2000a
• Bacillus anthrax lethal toxin (LFn)-HIV fusion proteins are candidate HIV vaccines that are safe in mice, and LFn-V3 region fusion proteins induce CD8 T
cells in BALBc mice. LFn causes exogenous protein to be taken up and processed in a class I pathway. Expressed proteins from Gag p24 and nef fragments
cloned into the LFn expression plasmid stimulate gag-specific CD4 proliferation and CTL responses in HIV-infected donor PBMCs in vitro.
Nef (BRU) HIV-1 infection human Edwards2002
• 96% (26/27) chronically infected HIV-1 infected patients elicited gamma-IFN CD8+ T-cell responses against Gag
• Nef and/or Pol CTL responses were detected in 86% of the subjects
• The magnitude and breadth of Gag and p24 T-cell responses correlated with absolute CD4 counts, and inversely correlated with viral load
• Pol and Int CTL responses correlated positively with absolute CD4+ T-cell count
• Nef and Env responses did not correlate with either CD4 counts or viral load
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Nef HIV-1 infection human Larsson2002b
• Autologous mature dendritic cells with rec vaccinia expressing Gag, Pol, Nef and Env could amplify CD8+ T-cell Elispot responses 4-38 fold in five HIV+
patients on successful HAART treatment, relative to autologous monocytes. Some weak responses could only be detected using mature dendritic cells as
APCs, and this approach could be useful for detection of low frequency memory cells.
Nef (SF2) HIV-1 and HCV co-infection human Lauer2002
• HIV-1 and HCV immune responses were studied in 22 individuals who were co-infected with HIV-1 and hepatitis C virus (HCV). IFNgamma production
was measured in an Elispot assay of CD8+ T-cells using targets expressing either Gag, RT, Env and Nef in a vaccinia construct, or one of seven HCV
proteins.
• All 22 patients targeted at least one protein. 20/22 patients recognized RT, 17/22 patients recognized Gag, 13/22 subjects recognized Env and 11/22 patients
recognized Nef. Robust CTL activity was independent of disease progression or viral load.
• Despite high HCV viral loads, very few HCV CD8+ T-cell Elispot responses were detected. In a control HCV infected person who did not have HIV-1,
strong anti-HCV responses were mounted.
• HIV-specific CD4 proliferative responses were detected in 9/17 coinfected patients, but no HCV responses were detected.
Nef HIV-1 infection human Scott2001
• CTL responses before and after initiation of ART were studied in 13 HIV-1 vertically infected infants <6 months of age, and 4 that were >6 months of age.
• Before ART 2/13 infants <6 months of age showed IFNgamma Elispot CD8+ T-cell responses, one to Nef and one to Env and Nef, and these responses
became undetectable after successful therapy– 3 infants were coinfected with CMV and all 3 had CMV-specific CD8+ T-cell responses.
• One older infant, at 23 months, had CTL responses against all for proteins tested, Gag, Pol, Nef and Env, and had the lowest plasma viremia of the study
group. 3/4 infants older than 6 months of age responded to either Nef or Pol.
• Administration of ART over 48 weeks broadened the HIV-1-specific CTL response in 2/4 of the older children that were incomplete responders.
Nef (IIIB) HIV-1 infection human Ortiz2001
• Immune responses in eight chronically HIV-1 infected patients undergoing HAART therapy structured treatment interruptions (STI) were studied. STI
boosted HIV-1 specific CTL responses and elevated CTL responses were maintained up to 22 weeks after the last treatment interruption, but viral load
rebound to pretreatment levels and CD4 T-cell count decline was observed. CD8 responses in PBMC were measured by cytokine flow cytometry with
gp160, Gag p55, RT-Pol and Nef expressed in vaccinia.
Nef Vaccine murine Muthumani2002
Vaccine Vector/Type: adenovirus HIV component: Vpr, Nef, Gag/Pol
• Vpr can cause cells to go into G2 arrest, and it surpresses immune cell activation and inflammatory cytokine production, so co-immunization of BALB/c
mice with recombinant adenovirus expressing Vpr and HIV-1 antigens Nef or Gag/Pol was tested to see if Vpr reduced the immune response to the other
HIV antigens.
• Vpr compromised CD8+ T-cell lytic responses and T-helper proliferative responses in mice co-immunized with Vpr and Nef or Gag/Pol.
• In vitro, Vpr reduced T-cell cytokine production of IL-12 and TNFalpha, indicative of Vpr-mediated immune suppression.
Nef Nef HIV-1 infection human (A*0201 and
Cw*08)
Shacklett2000
• HIV-1 specific, MHC class I-restricted CTL killing was detected in duodenal and rectal gut associated lymphoid tissue (GALT) sites from three infected
individuals – the distribution of class I restricted CTL was different in the peripheral blood samples and GALT samples
Nef Nef HIV-1 infection human (B*35) Jin2002
• Patients with HLA-B*35 variants B*3502, B*3503, B*3504, and B*5301 tend to proceed to AIDS more quickly than those with B*3501.
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• Of 32 patients with HLA-B*35 alleles CD8+ CTL responses were quantified using an intracellular cytokine staining assay – 75% had responses to Pol,
69% to Gag, 50% to Nef, and 41% to Env.
• The overall magnitude of CTL responses did not differ between those bearing B*3501 and the others. A higher percentage of Gag responses was observed
in those that had lower RNA levels that carried B*3501, and there was a negative association with viral load and CTL activity. The data is consistent with
higher levels of CTL responses contributing to protection in B*3501 individuals, but not in B*3502, B*3503, B*3504, and B*5301 individuals.
Nef Nef (BRU) Vaccine murine (H-2Dd) Collings1999
Vaccine Vector/Type: DNA Strain: BRU HIV component: nef
• A comparison of DNA vaccination with HIV-1 Nef expression vectors pBN-CMV-NEF and pBN-RSV-NEF (self-replicating), pCGE2-NEF
(non-replicating).
• CTL immune responses were detected using all three expression vectors, while a humoral immune response to Nef was only observed in the self-replicating
expression vectors; possibly antibody responses require higher levels of protein expression
Nef Nef (SIV) SIV infection Rhesus macaque
(Mamu-A*11, -B*03,
-B*04, and -B*17)
Dzuris2000
• Cell binding assays for Mamu molecules were employed to describe the peptide binding motifs for Mamu-A*11, -B*03, -B*03, -B*04, and -B*17 CTL
epitopes – a similarity for Mamu-A*11 and -B*03 and human HLA-B*44 and -B*27, respectively, was observed – all epitopes studied were SIV epitopes,
so not specifically listed here
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HIV-1 HIV-1 infection human Schito2001
• Longitudinal analysis (72 weeks) of 15 patients with acute or recent HIV-1 infection implies that HAART treatment alone can not completely conserve
CD8+ cell homeostasis and preserve the original T-cell receptor repertoire
HIV-1 HIV-1 infection human Mackewicz2000
• Non-cytotoxic anti-HIV responses of CD8+ T cells cultured with CD4 infected HIV cells are mediated be blocking expression of viral RNA, and do not
influence viral replication steps through integration of provirus
HIV-1 Vaccine Altes2002
• This study employs a mathematical model to study the consequences of increasing the T-helper response through a vaccine, which would have
counter-balancing effects in a new infection: a more intense response provides more help but also more target cells. The model indicates that if the infecting
virus had a low replication rate, then CTLp and CD4 helper cells could control an infection. Only a vaccine that could increase CTL responsiveness could
reduce viral set point with observed replication rates.
• A CD4+ T-cell response without maintained CTL response was deleterious in this model.
HIV-1 HIV-1 infection human Currier2002b
• Elispot standardization was sought using a reference peptide pool of 23, 8-11 mer epitopes from Influenza, cytomegalovirus (CMV), and Epstein Bar Virus
(EBV) presented by 11 common HLA class I molecules.
• 15/17 (88%) HIV- and 14/20 (70%) HIV+ individuals reacted with this test set and in vitro simulation of the PBMC from these individuals were capable of
killing cells expressing the target antigen.
HIV-1 HIV-1 infection human, macaque Wodarz2002
• Mathematical modeling is used to support the idea that T-helper cell dysfunction results in a compromised ability to maintain an anti-HIV CTL memory
response. Models suggest strategies to restore CTL memory through therapy and improve long-term immunological control of the virus.
HIV-1 HIV-1 infection, Vaccine human Zinkernagel2002
• HIV immunity and vaccine strategies are compared with to other pathogens. We do not have a successful vaccine agains TB leprosy, HIV, HCV and most
parasites, and the author suggests this is associated with the need for a strong T-cell response to these diseases. Vaccine strategies that achieve a
physiological low does infection that is well controlled but persists may be required to alter the immunopathological consequences of infection with HIV.
HIV-1 Vaccine human Gaschen2002
• The concept of using an artificial consensus sequence for vaccine design is discussed, comparing the concepts of a model ancestor sequence or a consensus
sequence, with illustrations of the potential advantages of the strategy based on C-clade comparisons.
• See also a comment [Nickle2003], and reply [Gao2003]
HIV-1 HIV-1 infection human, macaque Johnson2002
• Reviews evidence for CTL escape in HIV epitopes in natural human infections, and in SIV infections of macaque where viral clones with a known time of
infection and multiple animals with the same HLA molecules can be tracked.
• Vigorous CTL responses are made despite class I down-regulation by the Nef protein, but it may delay cytolysis of infected cells. Too great a loss of MHC
proteins may enhance NK cell killing so the fitness advantage of this function of Nef may be in balance.
HIV-1 HIV-1 infection, Vaccine human Newman2002
Vaccine HIV component: polyepitope
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• This extensive review covers many aspects of T-cell immunity and natural HIV infections, and considers how this knowledge might be applied to a
polyepitope vaccine approach. Strategies concerning ways to avoid the creation of junctional epitopes and use of linkers to enhance processing of such
constructs are discussed.
• The C-terminal flanking residue (C1) was found to be associated with immunodominance of epitopes, such that R or K (positive charge) > N or Q (amide) >
C, G, A, T, S (small) > F, W, Y (aromatic) > I, L, M, V (aliphatic) > D (negative). As this position is outside and proximal to the epitope, processing and
cleavage is the likely reason for this observation.
• Changing the C1 residue from F to K for an HLA-A2 presented epitope from HBV resulted in a change from the epitope being non-immunogenic to
strongly immunogenic.
HIV-1 HIV-1 infection, Vaccine human Johnston2001
• Reviews the current state of HIV vaccine approaches, and discusses the role of CTL induced immunity in protection or partial protection in animal studies,
likening it to the CTL found in HEPS studies.
HIV-1 HIV-1 infection human Klenerman2002
• The importance of breadth, or spread, of CTL responses is discussed, as narrowly focused responses can be more readily escaped.
• Some HLA types and specific epitope recognition may be associated with a better disease outcome. Reasons for this are considered, including NK cell
activity, epitope affinity, epitope conservation, and class I specific induction of more effective T-cell receptors.
HIV-1 HIV-1 infection human Kuhn2002
• Intrauterine exposure of infants to HIV from their mothers results in HIV-1 specific T-helper cell proliferative responses in 1/3 of exposed uninfected
babies, and HIV-1 specific CTL in some. Such responses are evident, but it is unknown whether they are associated with lack of infection, but there is some
evidence that HIV-1 T-cell responses may reduce transmission in breastfeeding mothers. Summary tables are provided of CD4 and CD8 responses detected
in earlier studies.
HIV-1 HIV-1 infection human Kuhn2002, Levy1998
• A non-HLA-specific, non-chemokine-mediated CD8+ T-cell non-cytotoxic anti-HIV response, measured by suppression of acute viral infection of CD4
cells, was detectable in approximately 16/31 (52%) of uninfected children born of infected mothers, was more commonly detected in those <1 year old, and
could reflect a protective response.
• Reviewed in [Kuhn2002].
HIV-1 Vaccine human Altes2001
• Mathematical modeling suggests if the effector CTL vaccine response exceeds the level of response seen in chronic infection, that a memory CTL
population is established that can respond very quickly to protect from infection.
HIV-1 Vaccine human Copeland2002
• This review summarizes cytokines and chemokines produced by CD8+ T-cells that can interfere with HIV’s infection and replication.
HIV-1 Vaccine Edgeworth2002
• This review summarizes HIV vaccine strategies, adjuvants, current clinical trials and animal models.
HIV-1 Vaccine Graham2002
• This review summarizes HIV vaccine approaches and clinical trials.
HIV-1 Env (HXB2) Vaccine murine, guinea pig Chakrabarti2002
Vaccine Vector/Type: DNA Strain: HXB2 HIV component: gp140deltaCFI, gp160 deletions
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• Intramuscular injection of plasmid DNA was used to vaccinate BALB/c or Huntley guinea pigs with a series of codon-optimized modified HIV-1 HXB2
envelopes – modifications included elimination of glycosylation sites, deletions, and exchange of the V3 loop to change from a X4 or R5 phenotype.
• The mutant envelope gp140deltaCFI gave the most promising result, enhancing antibody responses while retaining the ability to stimulate a strong CTL
response.
• gp140deltaCFI has deletions in the cleavage site, fusogenic domain and spacing of the heptad repeats, and was designed to mimic a fusion intermediate.
HIV-1 Env (gp160) (384–467) Vaccine rabbit, macaque Michel1993
Vaccine Vector/Type: hepatitis B surface antigen lipoprotein particles HsBAg Strain: LAI HIV component: V3
• Immunization with recombinant HIV1 V3/HBsAg hybrid particles into rabbits or macaques elicited and maintained for several months anti-V3 or HIV-1
Env proliferative, CTL and Ab responses.
HIV-1 Gag (HXB2) HIV-1 infection human Garba2002
• CD8+ Tcells from 25% of HIV positive individuals produce TGF-beta1 in response to stimulation with HIV proteins, and this can significantly reduce
CD8+ T-cell IFN-gamma induction to HIV and vaccinia proteins.
• Different peptides can preferentially induce TGF-beta1 or IFN-gamma from CD8+ T-clymphocytes from the same individual, and TGF-beta1
non-specifically suppresses HIV-specific immune responses.
HIV-1 Pol (HXB2) HIV-1 infection human Garba2002
• CD8+ Tcells from 25% of HIV positive individuals produce TGF-beta1 in response to stimulation with HIV proteins, and this can significantly reduce
CD8+ T-cell IFN-gamma induction to HIV and vaccinia proteins.
• Different peptides can preferentially induce TGF-beta1 or IFN-gamma from CD8+ T-clymphocytes from the same individual, and TGF-beta1
non-specifically suppresses HIV-specific immune responses.
HIV-1 Env (MN) HIV-1 infection human Garba2002
• CD8+ Tcells from 25% of HIV positive individuals produce TGF-beta1 in response to stimulation with HIV proteins, and this can significantly reduce
CD8+ T-cell IFN-gamma induction to HIV and vaccinia proteins.
• Different peptides can preferentially induce TGF-beta1 or IFN-gamma from CD8+ T-clymphocytes from the same individual, and TGF-beta1
non-specifically suppresses HIV-specific immune responses.
HIV-1 Vaccine human (A11) Ariyoshi2002
• This review summarizes issues discussed at a meeting held to discuss options for determining CTL responses to vaccines. Problems are noted: cost for any
assay are prohibitive for a Phase III study, Elispot shows interlaboratory variation but could be extended to many samples. HLA-A11 is very common in
Thailand – over 30% carry the HLA-A11 allele. Predominant strains may be evolving to evade recognition of A11 restricted epitopes. Few full length
CRF01 sequences are available. Epitopes may differ in vaccinees and infected individuals.
HIV-1 Vaccine human (B27, B8) McMichael2002
• CTL response-eliciting vaccines are reviewed. The natural epitope interactions with the HLA class I presenting molecules and T-cell receptors are
described, and the impact of breadth of CTL responses and diversity considered in a vaccine context.
• Interesting specific examples are given concerning anchor chain residues. For B27, the B pocket fits Arg (R) but not Lys (K), so even this conservative
change is not tolerated. In B8 either R or K can fit in the B pocket, but the substitution will cause conformational shifts in other parts of the epitope.
HIV-1 gp120 (V3) and p24
(IIIB, MN, BH10)
Vaccine murine (H-2d) Buonaguro2002
Vaccine Vector/Type: virus-like particle Strain: gp120 A clade UG5.94UG018, and B clade IIIB HIV component: gp120 and Pr55gag
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• BALB/c mice were given intraperitoneal immunization with virus-like particle (VLPs) expressing recombinant subtype A gp120 and Pr55gag in the
absence of adjuvants.
• High dose-independent humoral responses against both gp120 and p24 peptides were detected. Antibodies able to elicit 50% neutralization against A clade
IIIB and the autologous clade a virus were obtained.
• Recombinant rgp120 (clade B, MN) induced T-cell proliferative responses in vitro from vaccinated animals.
• CTL activity was observed against splenocytes expressing Env (clade A) and Gag (clade B, BH10) from a vaccinia construct.
HIV-1 Vaccine murine (MHC H2d) Lieberman2002
Vaccine Vector/Type: Listeria monocytogenes HIV component: Gag
• Attenuated Listeria monocytogenes vectors elicit strong persistent CTL responses in vaccinations of BALB/c mice and can protect mice from a
vaccinia-gag challenge.
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LDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKT
160 170 180 190 200
B*5301
B*5301, B57
B*5701
B53
B57
Cw4
B57
ILKALGPAATLEEMMTACQGVGGPGHKARVL
210 220 230
human A*1101
B51 A11
B8 B7
human B*0702
B*5101 human
B51 B7
B8 human
B35 B7
B*0801 B7
B8
human
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II-C-3 p2p7p1p6 CTL Epitope Map
AEAMSQVTNSATIMMQRGNFRNQRKIVKCFNCGKEGHTARNCRAPRKKGC
10 20 30 40 50
H-2Db B14
A*02011
WKCGKEGHQMKDCTERQANFLGKIWPSYKGRPGNFLQSRPEPTAPPEESF
60 70 80 90 100
A2 human
B*4002 A2
A*0201
RSGVETTTPPQKQEPIDKELYPLTSLRSLFGNDPSSQ
110 120 130
B*4001(B60)
B60, B*4001
B7
II-C-4 Protease CTL Epitope Map
PQVTLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMSLPGRWKPKMIGGI
10 20 30 40 50
A*6802 A*6802
A*6802,A*7401,A19 A2 supertype
A*7401
A28
A28supertype
A74
A3 supertype
A3 supertype
GGFIKVRQYDQILIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF
60 70 80 90
A2 supertype A*0201
A*0201
A2 supertype
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II-C-5 RT CTL Epitope Map
PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKI
10 20 30 40 50
A2, B61 A*0201
B7 A2
B*0801 H-2d
B8 H2k
B7,B8 broad
A*0301
A3
C3H/HeJ mice
H-2Kk
B*5101
B51
GPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGL
60 70 80 90 100
H-2d A3 A3
H2k A3
broad A11
A3 supertype human
Cw4
KKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLP
110 120 130 140 150
A3 B*5101, B24
A3 human
A11 A11
human A2
Cw4 A2
Cw4 A2 supertype
B*3501 A*0217, B*5101
B35 B*5101
A*0201 B51
A2
A2, A*0201
Cw4
B*3501
B*3501,B35
B35
QGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRT
160 170 180 190 200
B*5101 A*3002 A3
B7 B*3501 human
human A*0201
B*3501 B35
B35 B35
B7 B51
B35 A*0201
B7 A2
A*0301 A2, A*0202
A*0301, A11, A33 A2.1
A*1101 A*0201
A*1101, A3, A*0301, A*6801 A*0201
A11
A3
A3 supertype
A3, A11
A3,A11,A33
A3.1
A33
A3supertype
B*0301
A3 supertype
KIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKD
210 220 230 240 250
A3 B*5701
human B57
A2 B*5701
B58 B*5701, B*5801
B*4001 B*5801
B60 B57
B60(B*4001 B57
B60/B61 B57
B44
A2
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SWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTEEAE
260 270 280 290 300
B*5701 A*3002 B*3501
B57 A30 B*3501 AND B*5101
B*5701 human
B*5701, B*5801 human B*3501, B*5301, B*5101, B*0702
B*5801 A*1101 B35
B57 A3 B35, B51
B57 A3 B51
B57 B*4201
A2 supertype
B*1501
B62
Bw62
B42
LELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLK
310 320 330 340 350
B*3501 human
B*3501 AND B*5101 A11
B*3501, B*5301, B*5101, B*0702 A11
B35 A*1101
B35, B51 A11
B51
A*0201
human
A*02
A*0201
A*0201
A*0201
A*0201
A*0201
A*0201,A*0205
A02
A2
A2
A2
A2 supertype
A2, A*0201
A2, A*0202
A2, A2 transgenic
A2.1
A2.1
B*1501
B62
Bw62
TGKYARMRGAHTNDVKQLTEAVQKITTESIVIWGKTPKFKLPIQKETWET
360 370 380 390 400
A11 A28, A*6802 A*3201
A*3002 B*5701 A32
A3 B*5701 B*5801 B44
B70
human
B57
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WWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRET
410 420 430 440 450
A*3201 A11 A*6802
A32 A2 A26
B44 B*3501 A*2601
B35
B35, B51
B*3501
B35
B35
B45
B*4501
A28
A29
KLGKAGYVTNRGRQKVVTLTDTTNQKTELQAIYLALQDSGLEVNIVTDSQ
460 470 480 490 500
A29 human
A*2601 A2
A2.1
B14
B*1503
B14, B*1402
Cw8
YALGIIQAQPDQSESELVNQIIEQLIKKEKVYLAWVPAHKGIGGNEQVDK
510 520 530 540 550
B14 A2
B*1503 A*1101
B14, B*1402 human
Cw8 A*0301
B7 A3 supertype
B7
LVSAGIRKVL
560
II-C-6 Integrase CTL Epitope Map
FLDGIDKAQDEHEKYHSNWRAMASDFNLPPVVAKEIVASCDKCQLKGEAM
10 20 30 40 50
A2 supertype
A2 supertype
B*5101
HGQVDCSPGIWQLDCTHLEGKVILVAVHVASGYIEAEVIPAETGQETAYF
60 70 80 90 100
A*2402
human
B56
A*6802
LLKLAGRWPVKTIHTDNGSNFTGATVRAACWWAGIKQEFGIPYNPQSQGV
110 120 130 140 150
A*6802 A2 supertype
VESMNKELKKIIGQVRDQAEHLKTAVQMAVFIHNFKRKGGIGGYSAGERI
160 170 180 190 200
B*5701
B57
A3 supertype
A3 supertype
A3 supertype
A*1101
A11
A3
human
VDIIATDIQTKELQKQITKIQNFRVYYRDSRNPLWKGPAKLLWKGEGAVV
210 220 230 240 250
human A*0201
A*3002 A2
A3 supertype A2, A*0201
A2.1
IQDNSDIKVVPRRKAKIIRDYGKQMAGDDCVASRQDED
260 270 280
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II-C-7 Rev CTL Epitope Map
MAGRSGDSDEELIRTVRLIKLLYQSNPPPNPEGTRQARRNRRRRWRERQR
10 20 30 40 50
human human
B*5701 human
B*5801
human
human
B*5701
B*5801
human
QIHSISERILGTYLGRSAEPVPLQLPPLERLTLDCNEDCGTSGTQGVGSP
60 70 80 90 100
human human
A1 human
human
A3
A*0301
human
B14
B14
B14, Cw8
Cw5
Cw5/Cw8
Cw8
QILVESPTVLESGTKE
110
II-C-8 Tat CTL Epitope Map
MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKALGISYGRK
10 20 30 40 50
human human
B*5301 human
B53 B*1503
B53 A*6801
human A68
human human
B35 murine
H-2d
KRRQRRRAHQNSQTHQASLSKQPTSQPRGDPTGPKEXKKKVERETETDPF
60 70 80 90 100
human B58
murine
H-2d
D
101
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II-C-9 Vif CTL Epitope Map
MENRWQVMIVWQVDRMRIRTWKSLVKHHMYVSGKARGWFYRHHYESPHPR
10 20 30 40 50
human human
A*0301 B*0702
A03 B7
A3
A3
human
A*0301
A3
human
B*5701
ISSEVHIPLGDARLVITTYWGLHTGERDWHLGQGVSIEWRKKRYSTQVDP
60 70 80 90 100
human human
B*0702
B7
human
ELADQLIHLYYFDCFSDSAIRKALLGHIVSPRCEYQAGHNKVGSLQYLAL
110 120 130 140 150
human
B*1801
AALITPKKIKPPLPSVTKLTEDRWNKPQKTKGHRGSHTMNGH
160 170 180 190
A*0301
A3
B7
II-C-10 Vpr CTL Epitope Map
MEQAPEDQGPQREPHNEWTLELLEELKNEAVRHFPRIWLHGLGQHIYETY
10 20 30 40 50
human human
B*4002 B*5701
B57
human
human
B*0702
B*8101
B7
GDTWAGVEAIIRILQQLLFIHFRIGCRHSRIGVTRQRRARNGASRS
60 70 80 90
human
human
A*0201
A02
A2
A2 supertype
A*0201
A2 supertype
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II-C-11 Vpu CTL Epitope Map
TQPIPIVAIVALVVAIIIAIVVWSIVIIEYRKILRQRKIDRLIDRLIERA
10 20 30 40 50
B7 human
A*3303
EDSGNESEGEISALVEMGVEMGHHAPWDVDDL
60 70 80
II-C-12 gp160 CTL Epitope Map
MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWKEATT
10 20 30 40 50
B*0801 A11
B8 B44 A3 supertype
A11 B*4402
B44
A2
A2.1
A11
A11 and A*6801
A*0301
A03
A11
A3
A3 supertype
A3.1
B*0301
Cw7
B*5501
B55
human
B*3501
B35
human
TLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVVLVNVTENFNMWKNDM
60 70 80 90 100
B*5501 human
B55 B*3501
human B35
B*3501 B35, B51
B35 B51
human
A3 supertype
A3 supertype
A*2402
A24
B38
human
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VEQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTNTNSSSGRMIME
110 120 130 140 150
A*0201 A*0201
human
human
chimpanzee
A2
A2.1
A11
human
B7
A2
A2
A2 supertype
A2.1
A2.1
KGEIKNCSFNISTSIRGKVQKEYAFFYKLDIIPIDNDTTSYKLTSCNTSV
160 170 180 190 200
human A2
Cw*08 A2
Cw8 A*02
A2
A2.1
human
A*1101
ITQACPKVSFEPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHG
210 220 230 240 250
A2 B56
human Cw8
A*1101 human
human
A29
A29
A2
A29
A29
human
A2
B57
IRPVVSTQLLLNGSLAEEEVVIRSVNFTDNAKTIIVQLNTSVEINCTRPN
260 270 280 290 300
human human
B*3501 A2
B35 A2
B7 B*07
human B*0702
B7 B7
B7?
human
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NNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKLR
310 320 330 340 350
human CD4+ CTL
A2 A11
A2 Patr-B*14
B*07
B*0702
B7
B7?
human
murine BALB/c
H-2d
H-2Dd
Dd
human
murine
chimpanzee
A*0201
A11
A2
A2
A2, A3
Dd
Dd
H-2d
H-2d
H-2d, H-2b
H-2d,p,u,q
H-2Dd
H-2Dd
H-2Dd
H-2Dd,p,q, H-2u
A*2402
A11
NNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKLR
310 320 330 340 350
A*3002
A02
H-2Dd
H-2Dd
A2
Dd
H-2Dd
human
murine
murine BALB/c
Macaca fuscata
A*0201
A2
A2.1
D
Dd
H-2d
H-2d
H-2d,p,u
H-2d17
H-2D
H-2Dd
Ld
H-2d
B27
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EQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNSTW
360 370 380 390 400
CD4+ CTL A2
B*1516
B15
B63,B15
C*0401
Cw*0401, Cw*0407
Cw4
Cw4
A29
B8
A2
A2
A*2402
STEGSNNTEGSDTITLPCRIKQIINMWQKVGKAMYAPPISGQIRCSSNIT
410 420 430 440 450
CD4+DRA B56
B*5101 H-2Kd
B51 Rhesus macaque
DR4 CD4+
A2
A*3201
A29,A32
A32
A2
human
chimpanzee
A2
H-2a,b,f
Rhesus macaque
Mamu A*01
GLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTK
460 470 480 490 500
Rhesus macaque human
B56 A2
AKRRVVQREKRAVGIGALFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQ
510 520 530 540 550
human
A2
QQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSG
560 570 580 590 600
human B14
human human
B*5101 A32, B14
B51 B*14
Cw*0304 B*1402
A2 supertype B14
CD4+ CTL(DR-1)
DPw4.2
B14, B*1402
A*2402
B27
A*2402
A24
A*2402
human
A*2402
A24
A24, B8
A24,B8
B*0801
B8
Cw7
B57
KLICTTAVPWNASWSNKSLEQIWNHTTWMEWDREINNYTSLIHSLIEESQ
610 620 630 640 650
B57 human
B*3501
B35
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NQQEKNEQELLELDKWASLWNWFNITNWLWYIKLFIMIVGGLVGLRIVFA
660 670 680 690 700
A2.1 A*3303
A*2402 human
A2.1
A2
VLSIVNRVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDRDRSIRLVN
710 720 730 740 750
A*3303 human
human A2
A2
A32
human
A*3002
GSLALIWDDLRSLCLFSYHRLRDLLLIVTRIVELLGRRGWEALKYWWNLL
760 770 780 790 800
human A*0201 A*3002
A2 A*2402 B27
B55 A*6802 human
A31 A2.1
human B*2705
human
A*0301
A*3101
A3
A31
B27
QYWSQELKNSAVSLLNATAIAVAEGTDRVIEVVQGACRAIRHIPRRIRQG
810 820 830 840 850
A*3002 A*0201 A*3303
human human
A2.1 human human
human A2
B*4001 H-2d,p,u,q
B60(B*4001) A2 A30, B8
B60/B61 A2.1 B7
A2 B*5101
A2 human
A2.1 B35
A2.1 B8
A68 B*0702
A*0201 B7
A2 A*0205
LERILL
856
human
B35
B8
human
B*0702
B7
A30, B8
B7
A*0205
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II-C-13 Nef CTL Epitope Map
MGGKWSKSSVIGWPTVRERMRRAEPAADRVGAASRDLEKHGAITSSNTAA
10 20 30 40 50
human HLA-A201 transgenic
B*0801 H-2b
B*0801
B8
TNAACAWLEAQEEEEVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLEGL
60 70 80 90 100
H-2b A1, B8 human
human A3
human B*08
B*3501 A*0301
B35 A3
B7 A3.1
B*0702 A2
B7 B35
human B*0801
human A1, B8
B*0702 human
B35 B8
B7 B8
B*3501 A2
B35 B*4001
B51 B*4002
B7 B60
human human
human
human B60(B*4001
A*0301 B60/B61
A*0301, A11 human
A03
A11
A11
A2, A3, A11, B35
A3
A3 supertype
A3, A11, B35
A3.1
B*0301
B27
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TNAACAWLEAQEEEEVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLEGL
60 70 80 90 100
B35 or C4
A3
A3
B*3501
B35
B35
A11
A*1101
B*0702
B7
human
HLA-A201 transgenic
C*0802
C*0802(Cw8)
Cw8
human
human
A2
HLA-A201 transgenic
A11
A11
Bw62
A*1101
A11
A11
A3
B35 or C4
human
IHSQRRQDILDLWIYHTQGYFPDXQNYTPGPGVRYPLTFGWCYKLVPVEP
110 120 130 140 150
human human B*0702
human B17 A*2402
human human
A1, B8 B17 A24
human human A2 supertype
B7 A24
human B35
B*2705 human
B27 B7
Cw7 human
B7 B*0702
Cw*0701 B07
human A3
A1 HLA-A201 transgenic
human A*0201
B*5701 B27
B57 A*2402
human A02
B*1501 A2
B62 A*0201
Bw62 A2
B17, B37 A2 supertype
Bw62
A1
B*3701
B*5701
B15
B37,B57
B57
human
human
B*0702
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IHSQRRQDILDLWIYHTQGYFPDXQNYTPGPGVRYPLTFGWCYKLVPVEP
110 120 130 140 150
B*4201
B35
B7
B7
B7(*8101)
B7,B*8101
B*57
B57
human
A1, B8
B18
H-2d
B57
A24
B18
B*1801
B*5301, B35
B18
B18,B49
B35
B49
B7
DKIEEANKGENTSLLHPVSLHGMDDPEREVLEWRFDSRLAFHHVARELHP
160 170 180 190 200
human human
B35 B35
human
B7
A*0201
A*0201
A*0201
A2
A1, B8
A2, A25(10)
A25
B35
H-2d
human
B*1503
A24
B51
B52
B35 or C4
A*0201
A*0201
A2
A2,  A*0202, A*0201
A3
A1
EYFKNC
206
human
B35 or C4
A1
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Part III
HIV Helper T-Cell Epitopes
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III-A Summary
Part III includes tables and maps of HIV-specific helper T-cell (Th) epitopes
arranged sequentially according to the location of the proteins in the HIV-1
genome. This section parallels the organization of the CTL section. We at-
tempted to make this section as comprehensive as possible, requiring that the
epitope be contained within a region of 30 amino acids maximum, but not that
the precise boundaries be defined. The HLA specificity is usually not determined
for Th epitopes. For more recent updates, epitope sequence alignments, and use-
ful searching capabilities, please see our web site: http://hiv-web.lanl.
gov/immunology. The same epitope can have multiple entries, as each en-
try represents a single publication. Helper T-cell responses to proteins with no
defined epitope are described at the end of each protein section.
Recent studies utilize multiple functions attributed to T cells to define re-
sponses, and the simple distinctions of cytotoxic T-cell and helper T-cells have
become blurred as more is learned about the range of responses triggered in
CD4 and CD8 positive T-cells responding to antigenic stimulus. When adding
the most recent studies to the database, we have tried to place T cell responses in
a reasonable manner into our traditional helper T cell and CTL sections, and to
specify the assay used to measure the response in each study.
III-A-1 Tables
Each Th epitope has a six-part basic entry:
HXB2 Location: The viral strain HXB2 (GenBank Accession Number K03455)
is used as a reference strain throughout this publication. The position of
the defined epitope location relative to the sequence of the HXB2 pro-
tein is indicated. The numbering in this table corresponds to the protein
maps. Because of HIV-1 variation the epitope may not actually be present
in HXB2, rather the position in HXB2 indicates the position aligned to the
epitope. HXB2 was selected as the reference strain because so many stud-
ies use HXB2, and because crystal structures for HXB2-related proteins
are often available. The precise positions of an epitope on the HXB2 refer-
ence strain can be readily obtained using the interactive position locator at
our web site: http://hiv-web.lanl.gov/content/hiv-db/
LOCATE_SEQ/locate.html.
Author Location: The amino acid positions of the epitope boundaries and the
reference sequence are listed as given in the primary publication. Fre-
quently, these positions as published are imprecise, and do not truly cor-
respond to the numbering of the sequence, but they provide a reasonable
guide to the peptide’s approximate location in the protein. Also, in many
cases the reference sequence identification was not provided, and in such
cases it is not possible to use these numbers to specify precise locations.
Epitope Sequence: The amino acid sequence of the epitope of interest as de-
fined in the reference, based on the reference strain used in the study defin-
ing the epitope. On occasions when only the position numbers and not the
actual peptide sequence was specified in the original publication, we tried
to fill in the peptide sequence based on the position numbers and refer-
ence strain. If the sequences were numbered inaccurately by the primary
authors, or if we made a mistake in this process, we may have misrepre-
sented the binding site’s amino acid sequence. Because of this uncertainty,
epitopes that were not explicitly written in the primary publication, that we
determined by looking up the reference strain and the numbered location,
are followed by a question mark in the table.
Immunogen: The antigenic stimulus of the Th response to the defined epitope.
Often this is an HIV-1 infection. If a vaccine was used as the original
antigenic stimulation, not a natural infection, this is noted on a separate
line, and additional information about the vaccine antigen is provided as
available.
Species(HLA): The species responding and HLA specificity of the epitope,
when known.
Reference: The primary reference (sometimes two or more directly related stud-
ies are included). Details for some of the earlier references are in Part V.
Following the entry for a given Th epitope are brief comments explaining the
context in which the epitope was studied and what was learned about the epitope
in a given study.
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Summary HIV Protein Epitope Maps
III-A-2 HIV Protein Epitope Maps
All HIV Th epitopes mapped to within a region of 21 amino acids or less are
indicated on the HIV protein epitope maps. The location and HLA restriction
elements of Th epitopes are indicated on protein sequences of HXB2. These
maps are meant to provide the relative location of defined epitopes on a given
protein, but the HXB2 sequence may not actually carry the epitope of interest, as
it may vary relative to the sequence for which the epitope was defined. Epitopes
with identical boundaries and HLA fields are included in the maps only once.
If one laboratory determines HLA presenting molecules at the serotype level
(example: A2) and another at the genotype level (example: A*0201) both will
be included in the map. MHC specificities are indicative of the host species;
when no MHC presenting molecule is defined, the host species is noted.
III-A-3 Alignments
To conserve space, no epitope alignments are provided in this book, but they
can be generated using the T helper epitope search tool at http://hiv-web.
lanl.gov/immunology. All epitopes are aligned to the HXB2 sequence,
with the sequence used to define the epitope indicated directly above it. Se-
quences are sorted by their subtype and country of origin.
The master alignment files from which the epitope alignments were cre-
ated are available at our web site (http://hiv-web.lanl.gov/ALIGN_
CURRENT/ALIGN-INDEX.html). The alignments were modified in some
cases to optimize the alignment relative to the defined epitope and minimize in-
sertions and deletions; epitope alignments are generated by anchoring on the
C-terminal residue. A dash indicates identity to the consensus sequence, and a
period indicates an insertion made to maintain the alignment. Stop codons are
indicated with a $, and frameshifts by a #, or ambiguous codons (nucleotide
was r, y, or n) by an x; they are inserted to maintain the alignments. In con-
sensus sequences an upper case letter indicates the amino acid was present in
all sequences, a lower case letter indicates the amino acid was present in most
sequences in a given position, and a question mark indicates two or more amino
acids were represented with equal frequency.
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III-B HIV Helper T-Cell Epitope Tables
All HIV Helper T-Cell epitopes arranged by protein position. The table entries are sorted in a nested way—first by protein, then by HXB2 start location within the
protein and finally by HLA presenting molecule. Epitopes for which the HXB2 location is unknown appear at the end of the listing of the protein in which they are
located.
III-B-1 p17 Helper T-Cell Epitopes
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
p17 (18–42) p17 (18–42 PV22) KIRLRPGGKKKYKLKHIVW-
ASRELE
HIV-1 infection human (DRB1*13) Lotti2002
• 10/49 chronically HIV-1 infected patients had low p55-Gag-specific CD4+ T cell responses prior to therapy, and these responses remained unchanged 3 and
6 months after initiation of HAART. There was no difference in level of response in those with or without a detectable p55 response.
• For one individual, patient F45 CDC stage A2, CD4+ p55 responding clones were generated. Her response was consistently strong and heterogeneous in
terms of HLA restriction and Vbeta usage, and some clones had a Th1 cytokine secretion profile (high IFNgamma production) while some had a Th2
profile (high IL-4 and IL-5 production). 5/10 CD4+ clones could also induce cytotoxicity.
• 4/10 clones from patient F45 had their epitopes mapped using overlapping peptides. Clone 6 recognized this peptide sequence restricted by DRB1*13. This
clone had a high SI (27.1 to p55, 90.6 to peptide) secreted IFNgamma, indicative of a Th1 response, as well as TNFalpha. Clone 6 was highly cytotoxic,
through a perforin-mediated pathway.
p17 (21–35) p17 (21–35 SF2) LRPGGKKKYKLKHIV HIV-1 infection human (DR13.02) Harcourt1998
• 43 asymptomatic HIV+ individuals were screened for proliferative responses to HIV – 12 showed a response, and dominant epitopes were mapped for two
individuals, one in p24 and one in p17
• Patient 024’s naturally occurring variant LRPGGKKKYQLKHIV also elicited a strong proliferative response.
• Naturally occurring variants of this epitope were found within the individual who made this response – several did not stimulate the CD4+ T-cell line that
recognized the index peptide, suggestive of immune escape
p17 (22–29) p17 (22–29 LAI) RPGGKKKY? HIV-1 infection human Schrier1989
• Stimulates T-cell proliferation in HIV-infected donors.
• Schrier lists this peptide as p24(22-29), but it appears to be in p17.
p17 (33–47) p17 (33–47 IIIB, B10) HIVWASRELERFAVN? HIV-1 infection human Wahren1989b, Wahren1989a
• Peptides were identified that commonly evoke T-cell responses – 57% of 90 HIV+ people had a T-cell response to this peptide
p17 (35–59) p17 (35–49 PV22) VWASRELERFAVNPGLLET-
SEGCRQ
HIV-1 infection human (DRB1*13) Lotti2002
• 10/49 chronically HIV-1 infected patients had low p55-Gag-specific CD4+ T cell responses prior to therapy, and these responses remained unchanged 3 and
6 months after initiation of HAART. There was no difference in level of response in those with or without a detectable p55 response.
• For one individual, patient F45 CDC stage A2, CD4+ p55 responding clones were generated. Her response was consistently strong and heterogeneous in
terms of HLA restriction and Vbeta usage, and some clones had a Th1 cytokine secretion profile (high IFNgamma production) while some had a Th2
profile (high IL-4 and IL-5 production). 5/10 CD4+ clones could also induce cytotoxicity.
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• 4/10 clones from patient F45 had their epitopes mapped using overlapping peptides. Clone 25 recognized this peptide sequence restricted by DRB1*13
using TCR Vbeta 5.1. This clone had a SI of 4.9 to p55, 13.7 to peptide, secreted low levels of IFNgamma, indicative of a Th1 response. Clone 25 had
cytotoxic activity, mediated through both a perforin and a Fas-based pathway.
p17 (93–107) p17 (93–107 IIIB, B10) EIKDTKEALDKIEEE HIV-1 infection human Wahren1989b, Wahren1989a
• 12 gag and 18 env peptides were identified that could commonly evoke T-cell responses.
p17 (118–132) p17 (118–132 IIIB, B10) AAADTGHSSQVSQNY HIV-1 infection human Wahren1989b, Wahren1989a
• 12 gag and 18 env peptides were identified that could commonly evoke T-cell responses.
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p24 (1–11) p24 (1–11 SF2) PIVQNLQGQMV HIV-1 infection human (DR1) Harcourt1998
• 43 asymptomatic HIV+ individuals were screened for proliferative responses to HIV – 12 showed a response, and dominant epitopes were mapped for two
individuals, one in p24 and one in p17
• Out of five truncated versions of peptide PIVQNLQGQMVHQAISPRTL, only p24(1-11) elicited a proliferative response
• Nine naturally occurring variants of this epitope were found within the individual who made this response – all bound to HLA-DR1, but three did not
stimulate the CD4+ T-cell line that recognized the index peptide, suggestive of immune escape
p24 (1–15) p24 (133–147 IIIB, B10) PIVQNIQGQMVHQAI HIV-1 infection human Wahren1989b, Wahren1989a
• Peptides were identified that commonly evoke T-cell responses – 62% of 90 HIV+ people had a T-cell response to this peptide
p24 (1–22) p24 (133–154 SF2) PIVQNIQGQMVHQAISPRT-
LNA
HIV-1 infection human Rosenberg1997
• While anti-HIV CD4 Th responses are characteristically undetectable in chronic infections, strong p24-specific proliferative responses were inversely
correlated with low viral load in 10 chronically infected people
• The dominant proliferative response in one of two long term survivors was to this peptide
p24 (7–21) Gag (171–185) QGQMVHQAISPRTLN HIV-1 infection human (DR supermotif) Wilson2001
• Epitope name: Gag 171
• Eleven peptides were identified that had the HLA-DR supermotif, all were found to bind to MHC class II DR molecules and all elicited proliferative
responses from multiple HIV-infected donors
• This epitope binds to nine HLA-DR alleles: DRB1*0101, DRB1*1501, DRB1*0401, DRBI*0405, DRB1*1302, DRB1*0701, DRB1*0901, DRB5*0101
and DRB4*0101 with an IC50 threshold below 1,000 nM
• This epitope sequence is conserved in 52% of clade B isolates
• 7/22 HIV infected individuals responded to this epitope (13/22 responded to some of the DR supermotif epitopes, the 9 non-responder peptides tended to
also not have recall responses to rec HIV-1 whole proteins)
p24 (7–21) Gag (171–185) QGQMVHQAISPRTLN Vaccine murine (I-Ab and
HLA-DR)
Livingston2002
Vaccine Vector/Type: DNA with CMV promotor, peptide HIV component: polyepitope Adjuvant: CFA
• Epitope name: Gag 171
• Four Th HIV epitopes presented by HLA-DR molecules were identified that also could be presented my murine class II molecule I-Ab, enabling testing of
vaccine strategies of in H-2b mice.
• Responses to pooled peptides, polyepitope peptides in a linear construct or in a branched MAP construct, and a DNA polyepitope construct with a CMV
promotor were compared. A linear arrangement in polyepitope construct created a junctional epitope that could be disrupted with the addition of GPGPG
spacers. The linear polyepitope construct with the GPGPG spacer worked well in terms of eliciting responses to all four peptides, using either DNA or
protein for the vaccination.
p24 (11–26) p24 (143–157) VHQAISPRTLNAWVKC in vitro stimulation human Bedford1997
• Epitope elicits a primary proliferative response in PBMC from uninfected donors
• Matches 3/3 anchor residues for HLA DR: VHQAISPRT
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p24 (11–30) Gag (143–152 SF2) VHQAISPRTLNAWVKVVEEK Vaccine murine (H-2d , H-2b) Mata1999
Vaccine Vector/Type: Listeria moncytogenes Strain: SF2 HIV component: p24
• Listeria moncytogenes is an intracellular bacterium that lives in the cytoplasm and generates a cell-mediated immune response
• Listeria moncytogenes vaccine expressing HIV-1 p24 protein (Lm-Gag) was used to stimulate gag specific CD4+ T cell proliferative responses in
BALB/c(H-2d) and C57BL/6(H-2b) mice
• Two of three reactive p24 peptides (out of 22 overlapping peptides that span p24) were recognized by both murine strains – this epitope is immunodominant
in C57BL/6 mice and also can stimulate a BALB/c response
• The proliferative response is due to CD4+, IFN-gamma producing cells, a Th1 response
p24 (11–30) p24 (143–162 HXB2) VHQAISPRTLNAWVKVVEEK Vaccine murine (H-2d , H-2b) Mata1999
Vaccine Vector/Type: Listeria monocytogenes Strain: HXB2 HIV component: Gag
• BALB/c and C57BL/6 mice were immunized with rec Listeria monocytogenes (Lm-Gag) expressing HIV-1 HXB2 Gag
• L. monocytogenes is a gram-positive bacteria that enters the macrophage on phagocytosis and lives in the cytoplasm – secreted L. monocytogenes antigens
are processed and presented by both class I and class II pathways
• The class II T helper response was probed using 20 mer peptides that overlapped by 10, and the peptides VHQAISPRTLNAWVKVVEEK and
FRDYVDRFYKTLRAEQASQD were recognized in H-2b and H-2d mice
p24 (21–36) p24 (153–167) NAWVKVVEEKAFSPEC in vitro stimulation human Bedford1997
• Epitope elicits a primary proliferative response in PBMC from uninfected donors
p24 (31–46) p24 (163–177) AFSPEVIPMFSALSEC in vitro stimulation human (A*0201) Bedford1997
• E elicits a primary proliferative response in PBMC from uninfected donors
• Peptide contains a CTL epitope identified in HIV-positive patients
• Peptide binds to HLA A*0201 and causes regulation of class I expression on T2 cells
• Matches 3/3 anchor residues for HLA DR: VIPMFSALS
p24 (31–52) p24 (163–184 SF2) AFSPEVIPMFSALSEGATP-
QDL
HIV-1 infection human Rosenberg1997
• Low viral load correlated with strong HIV-1-specific proliferative response
• A proliferative response to this epitope was detected in two long term survivors
p24 (41–56) p24 (173–187) SALSEGATPQDLNTMC in vitro stimulation human Bedford1997
• Epitope elicits a primary proliferative response in PBMC from uninfected donors
p24 (48–62) p24 (180–194) TPQDLNTMLNTVGGH HIV-1 infection human Adams1997
• One of four immunogenic Gag peptides used in study of proliferative response to p24
• Homology to an SIV epitope recognized by macaque T-cells
• T-cells from 8 of 19 HIV+ individuals responded to this epitope
• Improved assay system (increase in culture time to 8 days and addition of IL-2 to cultures) gave increased detection of proliferative response
p24 (51–66) p24 (183–197) DLNTMLNTYGGHQAAC in vitro stimulation human Bedford1997
• Epitope elicits a primary proliferative response in PBMC from uninfected donors
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p24 (51–82) Gag (183–214 LAI) DLNTMLNTVGGHQAAMQML-
KETINEEAAEWDR
Vaccine human Gahery-Segard2000
Vaccine Vector/Type: lipopeptide
• Anti-HIV lipopeptide vaccine consisting of six long peptides derived from Nef, Gag and Env HIV-1 proteins modified by a palmitoyl chain was
administered in a phase I trial
• A CD4+ T cell proliferative response to at least one of the six peptides was observed in 9/10 vaccinees – 2/10 reacted to this peptide
• 9/12 tested mounted a CTL responses to at least one of the six peptides, each of the six peptides elicited a CTL response in at least one individual
• None of the 12 tested had an IgG response to this peptide
p24 (69–88) Gag (p24) (201–220
IIIB)
LKETINEEAAEWDRVHPVHA in vitro stimulation human (DR) Venturini2002
• Epitope name: P21
• PBMC from a seronegative donor, the healthy brother of a pair of monozygotic twins discordant for HIV-1 infection, were used to generate HIV-1
Gag-specific CD4+ T-cell clones by in vitro immunization with HIV-1 overlapping 20mer peptides spanning p55. Six clones were generated by limiting
dilution. All reacted with p24 except one which recognized a p24 peptide and a p6 peptide. All CD4+ T cell clones were HLA clas II DR restricted.
• Clone 85 recognized this peptide using TCR Vbeta 8 and 18; the two TCR receptors indicates this limiting dilution represents a mixed population. This
clone was only activated by peptide, not by processed protein from vaccinia virus Gag-infected B-LCL.
p24 (71–86) p24 (203–217) ETINEEAAEWDRVHPC in vitro stimulation human Bedford1997
• Epitope elicits a primary proliferative response in PBMC from uninfected donors
p24 (73–97) p24 (205–229 PV22) INEEAAEWDRVHPVHAGPI-
APGQMR
HIV-1 infection human (DRB1*03) Lotti2002
• 10/49 chronically HIV-1 infected patients had low p55-Gag-specific CD4+ T cell responses prior to therapy, and these responses remained unchanged 3 and
6 months after initiation of HAART. There was no difference in level of response in those with or without a detectable p55 response.
• For one individual, patient F45 CDC stage A2, CD4+ p55 responding clones were generated. Her response was consistently strong and heterogeneous in
terms of HLA restriction and Vbeta usage, and some clones had a Th1 cytokine secretion profile (high IFNgamma production) while some had a Th2
profile (high IL-4 and IL-5 production). 5/10 CD4+ clones could also induce cytotoxicity.
• 4/10 clones from patient F45 had their epitopes mapped using overlapping peptides. Clone 12 recognized this peptide sequence restricted by DRB1*03
using TCR Vbeta 22. This clone had a SI of 12.4 to p55, 49.6 to peptide, secreted low levels of IFNgamma, indicative of a Th1 response. Clone 12 had
cytotoxic activity, mediated through both a perforin and a Fas-based pathway.
p24 (76–85) p24 (208–217) EAAEWDRVHP HIV-1 infection human Adams1997
• One of four immunogenic Gag peptides used in study of the proliferative response to p24
• T-cells from 11 of 24 HIV+ individuals responded to this epitope
• Improved assay system (increase in culture time to 8 days and addition of IL-2 to cultures) gave increased detection of proliferative response
p24 (76–90) p24 (208–222 IIIB, B10) EAAEWDRVHPVHAGP HIV-1 infection human Wahren1989b, Wahren1989a
• 12 gag and 18 env peptides were identified that could commonly evoke T-cell responses.
p24 (81–95) p24 (215–229 SF2) DRVHPVHAGPIAPGQ Vaccine macaque Mills1990
Vaccine Vector/Type: virus-like particle Strain: SF2 HIV component: p24
• Responses to 3 T-cell and multiple linear B-cell epitopes were found in vaccinated macaques
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p24 (81–102) p24 (213–234 SF2) DRVHPVHAGPIAPGQMREP-
RGS
HIV-1 infection human Rosenberg1997
• While anti-HIV CD4 Th responses are characteristically undetectable in chronic infections, strong p24-specific proliferative responses were inversely
correlated with low viral load in 10 chronically infected people
• The dominant proliferative response in one of two long term survivors was to this peptide
p24 (86–94) p24 (NY5) VHAGPIAPG HIV-1 infection human (DQ7) Norris2001
• Gag-specific CD4+ helper T-cell clones were derived from one long-term non-progressor (LTNP) (CTS-01), and three individuals given therapy during
acute infection, two before (AC-01 and AC-36) and one after (AC-25) STI. Gag peptide recognition induced proliferation, IFNgamma production and
perforin-mediated cytotoxicity in all CD4+ T-cell clones isolated.
• 3/23 p24-derived peptides tested induced proliferative p24-specific T-helper cell responses in the LTNP CDT-01. The immunodominant response was to the
peptide DRVHPVHAGPIAPGQMREPRGS (81-102), and 9/10 CD4+ T-cell clones reacted with it. One was characterized in detail and used a Bbeta4 TCR.
• The minimum peptide recognized by the clones from CDT-01 was VHAGPIAPG and it was restricted by HLA-DQ7.
p24 (87–101) p24 (219–233 BRU) HAGPIAPGQMREPRG in vitro stimulation murine (H-2b) Vaslin1994
• Peptide G2: could prime for in vitro immunoproliferative responses and for subsequent IgG responses
p24 (96–103) p24 (228–235 LAI) MREPRGSD HIV-1 infection human Schrier1989
• Stimulates T-cell proliferation in HIV-infected donors
p24 (96–110) p24 (228–242 IIIB, B10) MREPRGSKIAGTTST HIV-1 infection human Wahren1989b, Wahren1989a
• 12 gag and 18 env peptides were identified that could commonly evoke T-cell responses.
p24 (99–118) Gag (p24) (231–250
IIIB)
PRGSDIAGTTSTLQEQIGWM in vitro stimulation human (DR4) Venturini2002
• Epitope name: P24
• PBMC from a seronegative donor, the healthy brother of a pair of monozygotic twins discordant for HIV-1 infection, were used to generate HIV-1
Gag-specific CD4+ T-cell clones by in vitro immunization with HIV-1 overlapping 20mer peptides spanning p55. Six clones were generated by limiting
dilution. All reacted with p24 except one which recognized a p24 peptide and a p6 peptide. All CD4+ T cell clones were HLA clas II DR restricted.
• Clone 6 recognized three peptides including this one with a Th1 response using TCR Vbeta 6 (6s5A1N1). Sequencing TCR Vbeta regions of colonies from
clone 6 suggested this was a clonal population. Assays using different peptide concentrations suggest that this peptide does not carry the main epitope of
this clone.
p24 (101–115) p24 (235–249 SF2) GSDIAGTTSTLQEQI Vaccine macaque Mills1990
Vaccine Vector/Type: virus-like particle Strain: SF2 HIV component: p24
• Responses to 3 T-cell and multiple linear B-cell epitopes were found in vaccinated macaques – epitope response defined by T-cell clone
p24 (101–116) p24 GSDIAGTTSTLQEQIC in vitro stimulation human Bedford1997
• Epitope elicits a primary proliferative response in PBMC from uninfected donors
p24 (109–128) Gag (p24) (241–260
IIIB)
STLQEQIGWMTNNPPIPVGE in vitro stimulation human Venturini2002
• Epitope name: P25
• PBMC from a seronegative donor, the healthy brother of a pair of monozygotic twins discordant for HIV-1 infection, were used to generate HIV-1
Gag-specific CD4+ T-cell clones by in vitro immunization with HIV-1 overlapping 20mer peptides spanning p55. Six clones were generated by limiting
dilution. All reacted with p24 except one which recognized a p24 peptide and a p6 peptide. All CD4+ T cell clones were HLA clas II DR restricted.
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• Clone 50 recognized this peptide with a Th0 response (Th0 means that cytokines characteristic of both Th1 and Th2 responses were stimulated), using TCR
Vbeta 17, and was a homogeneous T-cell population. This clone was only activated by peptide, not by processed protein from vaccinia virus Gag-infected
B-LCL.
p24 (111–132) p24 (243–264 SF2) LQEQIGWMTNNPPIPVGEI-
YKR
HIV-1 infection human Rosenberg1997
• Low viral load correlated with strong HIV-1-specific proliferative response
• A proliferative response to this epitope was detected in two long term survivors
p24 (119–133) p24 (251–265) TNNPPIPBGEIYKRW HIV-1 infection human (DRB1*1301) Blankson2001b, Malhotra2001
• The DRB1*13-DQB1*06 haplotype is associated with maintained viral suppression after HAART – 7/7 early-treated DRB1*13-DQB1*06 positive people,
but only 3/14 (21%) of those who did not have DRB1*13-DQB1*06, maintained viral suppression for 18 months
• PBMC from individuals with the haplotype DRB1*13-DQB1*06 displayed increased IFNγ secretion and stronger proliferative responses against p24 80
weeks post treatment
• DRB1*13-DQB1*06 was also found to be enriched among long-term non-progressors (LTNPs) (it was in 9/18 versus, versus 21% of the general
population)
• This epitope was mapped with truncated peptides using the Elispot assay
• Two distinct DRB1*13 epitopes were defined in the peptide region spanning 251 to 270, and this 20-mer bound with very high affinity to DRB1*1302 –
DRB1*1301 and DRB1*1302 would be expected to have very similar binding properties
p24 (121–136) p24 (253–267) NPPIPVGEIYKRWIIC in vitro stimulation human Bedford1997
• Epitope elicits a primary proliferative response in PBMC from uninfected donors
p24 (121–140) Gag (253–272 SF2) NPPIPVGEIYKRWILGLNK Vaccine murine (H-2d) Mata1999
Vaccine Vector/Type: Listeria moncytogenes Strain: SF2 HIV component: p24
• Listeria moncytogenes is an intracellular bacterium that lives in the cytoplasm and generates a cell-mediated immune response
• Listeria moncytogenes vaccine expressing HIV-1 p24 protein (Lm-Gag) was used to stimulate gag specific CD4+ T cell proliferative responses in
BALB/c(H-2d) and C57BL/6(H-2b) mice
• Two of three reactive p24 peptides (out of 22 overlapping peptides that span p24) were recognized by both murine strains – this epitope is immunodominant
in BALB/c mice and did not stimulate a C57BL/6 response
• The proliferative response is due to CD4+, IFN-gamma producing cells, a Th1 response
p24 (121–140) p24 (253–272 HXB2) NPPIPVGEIYKRWIILGLNK Vaccine murine (H-2d) Mata1999
Vaccine Vector/Type: Listeria monocytogenes Strain: HXB2 HIV component: Gag
• BALB/c and C57BL/6 mice were immunized with rec Listeria monocytogenes (Lm-Gag) expressing HIV-1 HXB2 Gag
• L. monocytogenes is a gram-positive bacteria that enters the macrophage on phagocytosis and lives in the cytoplasm – secreted L. monocytogenes antigens
are processed and presented by both class I and class II pathways
• The class II T helper response was probed using 20 mer peptides that overlapped by 10, and the peptide MPPIPVGEIYKRWIILGLNK gave the
immunodominant response for the H-2d haplotype, but was not recognized in H-2b mice
p24 (121–152) Gag (183–214 LAI) NPPIPVGEIYKRWIILGLN-
KIVRMYSPTSILD
Vaccine human Gahery-Segard2000
Vaccine Vector/Type: lipopeptide
• Anti-HIV lipopeptide vaccine consisting of six long peptides derived from Nef, Gag and Env HIV-1 proteins modified by a palmitoyl chain was
administered in a phase I trial
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• A CD4+ T cell proliferative response to at least one of the six peptides was observed in 9/10 vaccinees – 9/10 reacted to this peptide
• 9/12 tested mounted a CTL responses to at least one of the six peptides, each of the six peptides elicited a CTL response in at least one individual – this
peptide was particularly immunogenic, eliciting a CTL response in four vaccinees
• All of the 12 tested had an IgG response to this peptide
p24 (127–141) Gag (294–308) GEIYKRWIILGLNKI HIV-1 infection human (DR supermotif) Wilson2001
• Epitope name: Gag 294
• Eleven peptides were identified that had the HLA-DR supermotif, all were found to bind to MHC class II DR molecules and all elicted proliferative
responses from multiple HIV-infected donors
• This epitope binds ten HLA-DR alleles: DRB1*0101, DRB1*1501, DRB1*0405, DRB1*1101, DRB1*1302, DRB1*0701, DRB1*0802, DRB1*0901,
DRB5*0101 and DRB4*0101 with an IC50 threshold below 1,000 nM
• This epitope sequence is conserved in 95% of clade B isolates
• 6/22 HIV infected individuals responded to this epitope (13/22 responded to some of the DR supermotif epitopes, the 9 non-responder peptides tended to
also not have recall responses to rec HIV-1 whole proteins)
p24 (128–137) p24 (260–269) EIYKRWIILG HIV-1 infection human (DRB1*1301,
DRB1*1302)
Blankson2001b, Malhotra2001
• The DRB1*13-DQB1*06 haplotype is associated with maintained viral suppression after HAART – 7/7 early-treated DRB1*13-DQB1*06 positive people,
but only 3/14 (21%) of those who did not have DRB1*13-DQB1*06, maintained viral suppression for 18 months
• PBMC from individuals with the haplotype DRB1*13-DQB1*06 displayed increased IFNγ secretion and stronger proliferative responses against p24 80
weeks post treatment
• DRB1*13-DQB1*06 was also found to be enriched among long-term non-progressors (it was in 9/18 versus, versus 21% of the general population)
• The truncated peptide that gave the optimal proliferative response for a Th1 phenotype clone was this nine-mer
• This region, shared by 2 overlapping peptides, was the reactive region for clones from two DRB1*13 patients, one carried DRB1*1301 and one
DRB1*1302
• Two distinct epitopes were defined in the peptide region spanning 251 to 270, and this 20-mer bound with very high affinity to DRB1*1302 – DRB1*1301
and DRB1*1302 would be expected to have very similar binding properties
p24 (129–148) Gag (p24) (261–280
IIIB)
IYKRWIILGLNKIVRMYSPT in vitro stimulation human Venturini2002
• Epitope name: P27
• PBMC from a seronegative donor, the healthy brother of a pair of monozygotic twins discordant for HIV-1 infection, were used to generate HIV-1
Gag-specific CD4+ T-cell clones by in vitro immunization with HIV-1 overlapping 20mer peptides spanning p55. Six clones were generated by limiting
dilution. All reacted with p24 except one which recognized a p24 peptide and a p6 peptide. All CD4+ T cell clones were HLA clas II DR restricted.
• Clone 74 recognized two peptides including this one with a Th1 response using TCR Vbeta 13 (13s1); it required 200 ng/ml (100 nM) and 1 µg/ml (0.5
µM) for stimulation by peptides 480-500 and 261-280, respectively. Sequencing TCR Vbeta regions of colonies from clone 74 suggested this was a clonal
population.
p24 (131–145) p24 (265–279 SF2) KRWIILGLNKIVRMY Vaccine macaque Mills1990
Vaccine Vector/Type: virus-like particle Strain: SF2 HIV component: p24
• Responses to 3 T-cell and multiple linear B-cell epitopes were found in vaccinated macaques – epitope response defined by T-cell clone
p24 (131–145) Gag (298–312) KRWIILGLNKIVRMY HIV-1 infection human (DR supermotif) Wilson2001
• Epitope name: Gag 298
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• Eleven peptides were identified that had the HLA-DR supermotif, all were found to bind to MHC class II DR molecules and all elicited proliferative
responses from multiple HIV-infected donors
• This epitope binds thirteen HLA-DR alleles: DRB4*0101, DRB5*0101, DRB1*0901, DRB1*0802, DRB1*0701, DRB1*1302, DRB1*1201, DRB1*1101,
DRB1*0405, DRB1*0401, DRB*0301, DRB1*1501 and DRB1*0101, with an IC50 threshold below 1,000 nM
• This epitope sequence is conserved in 94% of clade B isolate
• 8/22 HIV infected individuals responded to this epitope (13/22 responded to some of the DR supermotif epitopes, the 9 non-responder peptides tended to
also not have recall responses to rec HIV-1 whole proteins)
p24 (131–152) p24 (263–284 SF2) KRWIILGLNKIVRMYSPTS-
ILD
HIV-1 infection human Rosenberg1997
• Low viral load correlated with strong HIV-1-specific proliferative response
• A proliferative response to this epitope was detected in two long term survivors
p24 (135–154) p24 (267–286) ILGLNKIVRMYSPTSILDIR HIV-1 infection human Adams1997
• One of four immunogenic Gag peptides used in study of the proliferative response to p24
• 8 of 24 HIV+ individuals responded to this epitope
• Improved assay system (increase in culture time to 8 days and addition of IL-2 to cultures) gave increased detection of proliferative response
p24 (139–157) Gag (p24) (271–290
IIIB)
NKIVRMYSPTSILDIRQGP in vitro stimulation human (DR4) Venturini2002
• Epitope name: P28
• PBMC from a seronegative donor, the healthy brother of a pair of monozygotic twins discordant for HIV-1 infection, were used to generate HIV-1
Gag-specific CD4+ T-cell clones by in vitro immunization with HIV-1 overlapping 20mer peptides spanning p55. Six clones were generated by limiting
dilution. All reacted with p24 except one which recognized a p24 peptide and a p6 peptide. All CD4+ T cell clones were HLA clas II DR restricted.
• Clone 6 recognized three peptides including this one with a Th1 response using TCR Vbeta 6 (6s5A1N1). Sequencing TCR Vbeta regions of colonies from
clone 6 suggested this was a clonal population. Assays using different peptide concentrations suggest that this peptide, 271-290, contains the main epitope
of this clone. Upon activation, clone 6 was observed to induce a cytopathic effect in the adherent layer of fibroblasts expressing HLA DR4W14 and -W15.
Clone 6 was activated in response to vaccinia virus Gag-infected B-LCL, so could recognize naturally processed epitopes.
• Clone 37 recognized this peptide sequence with a Th2 response using TCR Vbeta 3, and was a homogeneous T-cell population. This clone was only
activated by peptide, not by processed protein from vaccinia virus Gag-infected B-LCL.
• Clone 97 recognized this peptide sequence with a using TCR Vbeta 9 and 14; the two TCR receptors used indicates this limiting dilution represents a mixed
population. This clone was only activated by peptide, not by processed protein from vaccinia virus Gag-infected B-LCL.
p24 (141–156) p24 (273–287) IVRMYSPTSILDIRQC in vitro stimulation human Bedford1997
• Epitope elicits a primary proliferative response in PBMC from uninfected donors
• Matches 3/3 anchor residues for HLA DR: IVRMYSPTS
p24 (146–160) p24 (278–292 IIIB, B10) SPTSILDIRQGPKEP HIV-1 infection human Wahren1989b, Wahren1989a
• 12 gag and 18 env peptides were identified that could commonly evoke T-cell responses.
p24 (149–168) Gag (p24) (281–300
IIIB)
SILDIRQGPKEPFRDYVDRF in vitro stimulation human (DR4) Venturini2002
• Epitope name: P29
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• PBMC from a seronegative donor, the healthy brother of a pair of monozygotic twins discordant for HIV-1 infection, were used to generate HIV-1
Gag-specific CD4+ T-cell clones by in vitro immunization with HIV-1 overlapping 20mer peptides spanning p55. Six clones were generated by limiting
dilution. All reacted with p24 except one which recognized a p24 peptide and a p6 peptide. All CD4+ T cell clones were HLA clas II DR restricted.
• Clone 6 recognized three peptides including this one with a Th1 response using TCR Vbeta 6 (6s5A1N1). Sequencing TCR Vbeta regions of colonies from
clone 6 suggested this was a clonal population. Assays using different peptide concentrations suggest that this peptide does not carry the main epitope of
this clone.
p24 (150–169) p24 (282–301) ILDIRQGPKEPFRDYVDRFY HIV-1 infection human Schrier1989
• Stimulates T-cell proliferation in HIV-infected donors
p24 (151–166) p24 (283–297) LDIRQGPKEPFRDYVC in vitro stimulation human Bedford1997
• Epitope elicits a primary proliferative response in PBMC from uninfected donors
p24 (155–177) p24 (287–309) QGPKEPFRDYVDRFYKTLR-
AEQA
Vaccine murine Nakamura1997
Vaccine Vector/Type: peptide
• Mice immunized with this peptide generated proliferative responses, CTLs and antibodies
• This immunogenic domain is from a highly conserved region of p24
p24 (156–170) p24 (288–302 IIIB, B10) GPKEPFRDYVDRFYK HIV-1 infection human Wahren1989b, Wahren1989a
• 12 gag and 18 env peptides were identified that could commonly evoke T-cell responses.
p24 (156–174) p24 (287–306) QPKEPFRDYVDRFYKTLRA HIV-1 infection human Adams1997
• One of four immunogenic Gag peptides used in study of the proliferative response to p24
• T-cells from 5 of 21 HIV+ individuals responded to this epitope
• Improved assay system (increase in culture time to 8 days and addition of IL-2 to cultures) gave increased detection of proliferative response
p24 (161–180) Gag (293–312 SF2) FRDYVDRFYKTLRAEQASQD Vaccine murine (H-2d , H-2b) Mata1999
Vaccine Vector/Type: Listeria moncytogenes Strain: SF2 HIV component: p24
• Listeria moncytogenes is an intracellular bacterium that lives in the cytoplasm and generates a cell-mediated immune response
• Listeria moncytogenes vaccine expressing HIV-1 p24 protein (Lm-Gag) was used to stimulate gag specific CD4+ T cell proliferative responses in
BALB/c(H-2d) and C57BL/6(H-2b) mice
• Two of three reactive p24 peptides (out of 22 overlapping peptides that span p24) were recognized by both murine strains – this peptide stimulated a
response in both BALB/c and C57BL/6 mice
• The proliferative response is due to CD4+, IFN-gamma producing cells, a Th1 response
p24 (161–180) p24 (293–312 HXB2) FRDYVDRFYKTLRAEQASQD Vaccine murine (H-2d , H-2b) Mata1999
Vaccine Vector/Type: Listeria monocytogenes Strain: HXB2 HIV component: Gag
• BALB/c and C57BL/6 mice were immunized with rec Listeria monocytogenes (Lm-Gag) expressing HIV-1 HXB2 Gag
• L. monocytogenes is a gram-positive bacteria that enters the macrophage on phagocytosis and lives in the cytoplasm – secreted L. monocytogenes antigens
are processed and presented by both class I and class II pathways
• The class II T helper response was probed using 20 mer peptides that overlapped by 10, and the peptides VHQAISPRTLNAWVKVVEEK and
FRDYVDRFYKTLRAEQASQD were recognized in H-2b and H-2d mice
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p24 (163–177) p24 (295–309) DYVDRFYKTLRAEQA HIV-1 infection human (DRB1*1302) Blankson2001b, Malhotra2001
• The DRB1*13-DQB1*06 haplotype is associated with maintained viral suppression after HAART – 7/7 early-treated DRB1*13-DQB1*06 positive people,
but only 3/14 (21%) of those who did not have DRB1*13-DQB1*06, maintained viral suppression for 18 months
• PBMC from individuals with the haplotype DRB1*13-DQB1*06 displayed increased IFNγ secretion and stronger proliferative responses against p24 80
weeks post treatment
• DRB1*13-DQB1*06 was also found to be enriched among long-term non-progressors (it was in 9/18 versus, versus 21% of the general population)
• This epitope was mapped with truncated peptides using the Elispot assay, and is highly conserved
p24 (175–199) p17 (307–331 PV22) EQASQEVKNWMTETLLVQN-
ANPDCK
HIV-1 infection human (DRB1*03) Lotti2002
• 10/49 chronically HIV-1 infected patients had low p55-Gag-specific CD4+ T cell responses prior to therapy, and these responses remained unchanged 3 and
6 months after initiation of HAART. There was no difference in level of response in those with or without a detectable p55 response.
• For one individual, patient F45 CDC stage A2, CD4+ p55 responding clones were generated. Her response was consistently strong and heterogeneous in
terms of HLA restriction and Vbeta usage, and some clones had a Th1 cytokine secretion profile (high IFNgamma production) while some had a Th2
profile (high IL-4 and IL-5 production). 5/10 CD4+ clones could also induce cytotoxicity.
• 4/10 clones from patient F45 had their epitopes mapped using overlapping peptides. Clone 26 recognized this peptide sequence restricted by DRB1*03.
This clone had a SI of 4.1to p55, 5.3 to peptide, secreted high levels of IFNgamma, indicative of a Th1 response, but also IL-4 and IL-5. Clone 26 had no
cytotoxic activity.
p24 (181–196) p24 (313–327) VKNWMTETLLVQNANC in vitro stimulation human Bedford1997
• Epitope elicits a primary proliferative response in PBMC from uninfected donors
• Matches 3/3 anchor residues for HLA DR: VKNWMTETL
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p2p7p1p6 (30–44) p15 (393–407 IIIB, B10) FNCGKEGHTARNCRA HIV-1 infection human Wahren1989b, Wahren1989a
• 12 gag and 18 env peptides were identified that could commonly evoke T-cell responses.
p2p7p1p6 (55–69) p15 (418–432 IIIB, B10) KEGHQMKDCTERQAN HIV-1 infection human Wahren1989b, Wahren1989a
• 12 gag and 18 env peptides were identified that could commonly evoke T-cell responses.
p2p7p1p6 (60–74) p15 (423–437 IIIB, B10) MKDCTERQANFLGKI HIV-1 infection human Wahren1989b, Wahren1989a
• 12 gag and 18 env peptides were identified that could commonly evoke T-cell responses.
p2p7p1p6 (76–83) p24 (439–446 LAI) PSYKGRPG HIV-1 infection human Schrier1989
• Stimulates T-cell proliferation in HIV-infected donors
• Schrier lists this peptide as p24(439-446), but because of the numbering used for Gag epitopes, we placed it in p2p7p1p6
p2p7p1p6 (83–97) p15 (446–460 BRU) GNFLQSRPEPTAPPA in vitro stimulation murine (H-2b) Vaslin1994
• Peptide G4: could prime for in vitro immunoproliferative responses and for subsequent IgG responses
p2p7p1p6 (98–112) p15 (473–487 IIIB, B10) ESFRSGVETTTPPQK HIV-1 infection human Wahren1989b, Wahren1989a
• Peptides were identified that commonly evoke T-cell responses – 50% of 90 HIV+ people had a T-cell response to this peptide
p2p7p1p6 (103–110) p24 (466–473 LAI) REETTTPS HIV-1 infection human Schrier1989
• Stimulates T-cell proliferation in HIV-infected donors
• Schrier lists this peptide as p24(466-473), but it is in p2p7p1p6.
p2p7p1p6 (117–137) Gag (p6) (480–500 IIIB) DKELYPLTSLRSLFGNDPS-
SQ
in vitro stimulation human Venturini2002
• PBMC from a seronegative donor, the healthy brother of a pair of monozygotic twins discordant for HIV-1 infection, were used to generate HIV-1
Gag-specific CD4+ T-cell clones by in vitro immunization with HIV-1 overlapping 20mer peptides spanning p55. Six clones were generated by limiting
dilution. All reacted with p24 except one which recognized a p24 peptide and a p6 peptide. All CD4+ T cell clones were HLA class II DR restricted.
• Clone 74 recognized two peptides, including this one, with a Th1 response using TCR Vβ 13 (13s1); it required 200 ng/ml (100 nM) and 1 µg/ml (0.5 µM)
for stimulation by peptides 480-500 and 261-280, respectively. Sequencing TCR Vbeta regions of colonies from clone 74 suggested this was a clonal
population. Clone 74 was activated in response to vaccinia virus Gag-infected B-LCL, so could recognize naturally processed epitopes.
440
DEC 2002
Gag Helper T-Cell Epitopes HIV Helper T-Cell Epitope Tables
T-H
elper
III-B-4 Gag Helper T-Cell Epitopes
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
Gag p24 HIV-1 infection, Vaccine human Kelleher1998b
Vaccine Vector/Type: virus-like particle HIV component: p24, p17
• Immunization of HIV+ people with a p24-VLP virus-like particle did not significantly impact CD4+ lymphocyte count, viral load, or p24 antibody titre
• Immunization with p24-VLP showed a modest, short-lived increased proliferative response to p24
Gag p24 HIV-1 infection, Vaccine human Maino2000
Vaccine Vector/Type: protein, gp120 depleted virus HZ321 (REMUNE(TM)) Strain: Z321 HIV component: p24, gp120 depleted virus
• 18 HIV-1-seropositive patients with a low frequency or no detectable CD4+ T cell response to HIV-1 antigen received an HIV-1 immunogen consisting of
10 units of native p24 and 100 ug of HZ321, a gp120 depleted antigen
• Using flow-cytometric methods, HIV-1 specific CD4+ T cells were shown to increase in response to immunization – in many patients significant
enhancement was observed after a single immunization
• The frequency of CD4+ T cells expressing cytokines in response to antigen by FACS was correlated with a lymphoproliferation assay
Gag p24 HIV-1 infection human Ruiz2000
• Structured treatment interruption in chronically infected patients allowed recovery of p24 Th proliferative responses after HAART therapy discontinuation
in 2/12 patients
• The Th response to p24 was identified during peak viremia in one patient, while in the second it was noted when viremia was controlled after restarting
antiviral therapy
Gag p24 HIV-1 infection human Lori1999
• Ten patients with acute, pre-seroconversion HIV-1 infections were treated with didanosine, indinavir and hydroxyurea – this treatment is associated with
normalization of immune parameters
• A vigorous HIV-specific Th response (stimulation index greater than 8) was observed in 7/8 patients treated before complete WB seroconversion, but in
only 1/5 controls treated after seroconversion
• Vigorous Th responses were detected as early as 34 days after treatment begin
• Patients treated prior to seroconversion had no loss of naive CD4 T lymphocytes, recovery of up to 35% of the naive CD8 cells in several weeks, and a
reduced latent viral reservoir
Gag p24 HIV-1 infection human Haslett2000
• 11/22 adult patients on HAART showed strong CD4+ T-cell IFN-gamma producing Th1 responses to HIV p24
• The magnitude of the Th1 response correlated with previous interruptions in HAART, suggesting the interruptions primed or boosted the response
• In contrast, the magnitude of the CD8+ CTL response did not correlate with interruptions in therapy, although a greater breadth in response was associated
with interruptions in HAART
Gag p24 HIV-1 infection, Vaccine human Klein1997
Vaccine Vector/Type: virus-like particle HIV component: p24, p17
• Immunization of HIV+ people with a HIV-1 p17/p24 Ty virus-like particle (p24-VLP) resulted in a marginal, short-lived increased proliferative response to
p24 and p17 and a transient elevation in viral load
• Two of four subjects that received 500 or 1000 ug of p24-VLP had an increase in gag-specific CTL
Gag p24 Vaccine human Moss1998
Vaccine Vector/Type: gp120 depleted virus HZ321 (REMUNE(TM)) Strain: Z321 HIV component: gp120 depleted virus
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• Immunization with gp120 depleted HZ321 virus (REMUNETM) triggered an increase in lymphocyte proliferative response to native p24, a clade B virus
and clade E viral antigens – Z321 is clade A in env and clade G in gag. [Moss1998]
Gag p24 HIV-1 infection human Rosenberg1999
• This paper reviews the role of T-cells in viral control and HIV disease outcome
• Strong anti-p24 lymphoproliferative responses were found in seven persons who were treated with potent anti-viral therapy during acute HIV-1 infection
syndrome
• This suggests that Th cells are part of the normal response to HIV-1 infection, but their numbers are rapidly diminished by either being infected during the
peak viremia or by activation-induced cell death – if peak viremia can be controlled, a robust anti-p24 Th response can be maintained
Gag p24 HIV-1 infection human Rosenberg1998
• Strong Th responses have been found in rare individuals who effectively maintain low viral loads
• If aggressive anti-retroviral therapy is given prior to sero-conversion, strong helper responses can be maintained.
Gag p17 Vaccine murine Birk1998a
Vaccine Vector/Type: recombinant protein HIV component: p17
• Different p17 genes derived from the same quasispecies and expressed and purified in E. coli primed different Th 1 and Th 2 subsets in mice, depending on
their H-2 type.
Gag Gag HIV-1 infection human Schiller2000
• Study of parameters that might influence the performance or reproducibility of clinical Th proliferative assays
• HIV-1 replication in vitro is unlikely to influence the assay
• Gag proteins including p17 and possibly p7 as well as p24 perform better than p24 alone
• Frozen samples can be used in T-proliferative assays, but with lower radiolabled thymidine incorporation
Gag Gag HIV-1 infection human Pitcher1999
• In contrast to earlier studies suggesting that HIV-1 specific Th responses were eliminated in the early stages of infection in most HIV+ individuals, this
paper shows using flow cytometric detection of antigen-induced cytokines that Th-1 CD4+ memory gag-specific Th cells are detectable in most HIV+
subjects
• Effective anti-viral therapy reduces the frequency of these cells, presumably due to reduced antigenic stimulus
Gag Gag HIV-1 infection human Plana1998
• Patients from later stages of infection given HAART do not show restoration of HIV-1 specific Th proliferative responses
Gag Gag HIV-1 infection human Kelleher1998a
• Env and gag Th epitopes were pooled and used to test Th proliferative responses after IL2 therapy – while IL2 therapy causes an increase in CD4+
lymphocyte count, it does not increase HIV-1 specific proliferative responses
Gag Gag (LAI) Vaccine Macaca nemestrina Kent1998
Vaccine Vector/Type: DNA prime with vaccinia boost Strain: LAI HIV component: ENV, GAG
• Priming with an HIV-DNA vaccine and boosting with a vaccinia construct induced greater levels of HIV T-cell immunity than either vaccine alone
• The proliferative response to Env and Gag after the DNA vaccination had a mean SI of 1.5-4, but after boosting with rHIV-fowlpox virus, there was a 6-17
fold increase in the mean SI for HIV Gag and Env – The Th response happened despite a fall in Ab titers, suggesting that the Th response was primarily
Th1, not Th2. The CTL response was also enhanced
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Gag Vaccine Rhesus macaque Heeney1999
Vaccine Vector/Type: DNA, protein, virus-like particle, ISCOM
• Ten different vaccine strategies were evaluated for their ability to protect from infection in a rhesus macaque model using a non-pathogenic SHIV challenge
• Protection correlated with the magnitude of NAb responses, beta-chemokines, and a balanced Th response
• DNA, protein+adjuvant, VLP and ISCOM vaccines were tested
• HIV-1/ISCOMS gave the highest NAb titers, Th1 and Th2 responses, was the only vaccine formulation tested with a detectable CTL response, and gave
enhanced beta-chemokine production
Gag Gag/Pol (MN) Vaccine chimpanzee Kim1998
Vaccine Vector/Type: DNA Strain: MN HIV component: GAG, POL, ENV Adjuvant: CD80 and CD86 expression vectors
• Co-stimulatory molecules co-expressed with an HIV-1 immunogen in a DNA vaccine used to enhance the immune response – co-expression of CD86, but
not CD80, dramatically increased both HIV Env and Gag/Pol specific CTL and Th proliferative responses
Gag Gag/Pol (LAI, MN) Vaccine human Salmon-Ceron1999
Vaccine Vector/Type: canarypox Strain: MN, LAI HIV component: gp120, gp41, Gag, Protease
• A live attenuated canarypox vector expressing MN gp120 and LAI gp41/gag/protease could induce CTL and a lymphoproliferative response in healthy
uninfected volunteers
Gag p55 (IIIB) HIV-1 infection human Zhang2001b
• T-helper cell proliferative responses to HIV p24, p55 and gp120 were tested in 27 patients with HIV infection – vigorous responses directed at Gag were
detected in ten patients, but an Env specific response was detected in only one patient
• Untreated patients showed a negative correlation between plasma viral load and HIV p24-specific T-cell responses, and the responses could be detected
after extended HAART therapy with viremia below the detection limit
Gag p24 HIV-1 infection human Carcelain2001
• Repeated structured HAART therapy interruptions (STI) in 3 chronically HIV infected patients induced rapid but transient (< 3 weeks) HIV-1 specific
CD4+ Th1 responses concurrently with viral rebound, as measured by proliferation assays and by IFNγ production by CD8-depleted PBMC
• Kinetics suggest that viral replication leads to rapid destruction of the HIV-specific Th1 cell response
• HIV-specific CD8+ T-cell responses were delayed relative to the Th1 responses and were not sustained
Gag Gag HIV-1 infection human Blankson2001a
• 5/10 chronically HIV infected patients with low CD4+ counts who received HAART therapy and experienced immune reconstitution displayed p24, p17
and p66 T-helper CD4 proliferative responses, in contrast to 0/8 chronically HIV infected patients with high CD4+ counts at the initiation of antiretroviral
treatment
• This surprising result could be due to the low CD4 nadir patients being more likely to have thymic regeneration or a peripheral expansion of T cells
Gag p24 HIV-1 infection human Angel2001
• Prolonged viral suppression resulting from potent anti-retroviral therapy allowed a T helper response to Gag p24 and PHA to develop in many HIV+
patients
• At baseline, 2/41 (4.9%) subjects had a proliferative response to Gag p24, and 7/41 (17.1%) had a response to PHA, but by week 72 of therapy, 53% had a
detectable response to p24 and 94% to PHA
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Gag p24 HIV-1 infection human Blazevic2000
• Prolonged viral suppression resulting from potent anti-retroviral therapy did not allow an HIV T helper response to p24 or gp160, but Th proliferative
responses to influenza, alloantigen, and PHA did develop in many HIV+ patients, and asymptomatic patients had stronger and more frequent Th response
recovery than AIDS patients
Gag Gag (SF2) HIV-1 infection human Altfeld2001b
• Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in
individuals treated during chronic infection
• The breadth and specificity of the CTL response was determined using Elispot by studying 19 individuals with pre-seroconversion therapy (Group 1), 11
individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection
(Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef
• Individuals who were given HAART during acute or early in infection had significantly stronger proliferative responses than individuals who were
chronically infected
Gag p24 HIV-1 infection human Oxenius2000
• Patients who started therapy at acute HIV infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV-specific
CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load – three patients that had delayed initiation of
HAART had no HIV-specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became
undetectable
• In 3/4 responders tested p24 gave the strongest T helper response
Gag p24 Vaccine rat Moss2001
Vaccine Vector/Type: gp120 depleted whole killed virus Strain: HZ321 (subtype A env, subtype G gag) HIV component: whole virus Adjuvant: CpG,
Freund’s adjuvant
• Lewis rats simultaneously immunized with HIV-1 antigen and with immunostimulatory sequences CpG had increased Th proliferative responses, but when
CpG was given as a prime prior to the injection of HIV-1 antigen it was not as effective
Gag p24 Vaccine rat Moss2000
Vaccine Vector/Type: gp120 depleted whole killed virus Strain: HZ321 (subtype A env, subtype G gag) HIV component: whole virus Adjuvant: CpG,
Freund’s adjuvant
• Lewis rats co-immunized with HIV-1 antigen in Freund’s and with immunostimulatory sequences CpG stimulated increased IFNγ expressing CD4+ and
CD8+ T cells and anti-p24 antibodies relative to antigen in Freund’s without CpG
Gag p24 HIV-1 infection human Kalams1999a
• The strength of p24 specific Gag proliferative responses (SIs) were inversely correlated with viral load in 21 ARV naive patients. The responses were Th1,
IFNγ producing. Proliferative responses against gp160 were rarely observed (only 4 cases).
• Gag specific CTL levels were correlated with Gag proliferative responses but were not correlated with viral load. 8 subjects lacked p24 specific Gag
proliferative responses, and 4/8 had no CTLp to any HIV-1 antigen tested.
Gag p24 HIV-1 infection human Kalams1998
• This paper reviews the role of specific T cell help in many viral infections, and covers the interplay between Th, CTL and survival, and discusses briefly
advantages of HAART during acute HIV infection to prevent the early decimation of the Th response in HIV infections.
Gag p24 HIV-1 infection human Wilson2000b
• Dysfunction of HIV-1 specific proliferative responses, but not responses to other antigens, is evident in HIV-1 progressive disease.
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• Vigorous HIV-1 specific responses to p24, Nef and gp120 with SI between 8-99 were seen in 6/7 long term non-progressors (LTNP), the seventh had a
borderline responses. IL-2 production was seen in all cases, and IL-4 production was also evident many responses.
• None of the progressors (0/5) had HIV-1 specific proliferative responses, or IL-2 or IL-4 induction.
• Non-HIV antigens (cytomegalovirus, PPD, Staphylococcus enterotoxin B, tetanus toxoid) gave similar responses in HIV-1+ LTNP, progressors, and HIV-1
controls.
Gag p24 HIV-1 infection human Alatrakchi2002
• LTNP co-infected with HCV and HIV showed higher frequencies of Th1 response to both HIV-1 p24 and HCV antigens.
• HIV-1 CD4 Th1 responses in untreated LTNP were inversely correlated with viral load.
Gag p24 HIV-1 infection human Lange2002
• Cross-sectional study compares CD4 T-cell count and age matched untreated HIV-1+ patients (N = 14) with patients undergoing HAART therapy (N = 14).
• The fractions of naive and memory T-cells were comparable for both groups, as were proliferative responses to non-HIV antigens. Lymphocyte
proliferation responses to HIV-1 p24 were of greater magnitude in the group treated with HAART (5/10 had SI >10, versus 1/12 in the untreated group),
suggesting that ongoing viral replication impairs the anti-Gag response, and the response can be improved and restored through HAART.
• DTH responses to recall antigens were tested, and responses to C. albicans and Trichophyton were comparable in both treated and untreated patients,
although patients on therapy had higher responses to mumps.
Gag p24 HIV-1 infection human Fidler2002
• 37/45 patients with primary HIV infection underwent a short course of antiretroviral therapy (SCART). 29/37 patients received triple ART therapy and
eight patients received four ART drugs. Initiation of SCART was effective in controlling HIV replication by ten weeks in all patients and preserving CD4+
T cell responses for up to 64 weeks after therapy.
• No induction of drug escape mutations was observed, although two individuals had escape mutations in their infecting virus at baseline.
• 34 UK infected patients were clade B infected. 11/45 subjects had non-UK acquired HIV infection, 2 were clade A, 1 was A/E, 1 was C, 1 was "untypable",
the rest were B.
• Recombinant HIV-1 derived gp120, p24, p66 and overlapping peptide pools spanning Tat and Nef were employed to measure CD4 T-cell frequencies in
ELISPOT assays. The strongest preservation of T helper responses 12 weeks off SCART was seen for p24-specific CD4+ T-cell responses.
• 6/8 of the untreated individuals were tested for CD4+ T-cell responses. 1 had no detectable response. 1 had detectable responses to all HIV-1 proteins tested
at baseline, but this narrowed to p24 and gp120, then became undetectable by 52 weeks. 3 had detectable and persistent responses, but only to p24.
• Post-therapy, the average spot forming cells for all proteins tested in 17/37 with 24 weeks of follow up had not declined, although the plasma viral RNA
was increasing. SFU using p24 were measurable following SCART and preserved at levels comparable to baseline.
Gag Vaccine human Klein1997, Lindenburg2002
Vaccine Vector/Type: virus-like particle Strain: IIIB HIV component: p17, p24 Adjuvant: aluminum hydroxide
• HIV-1 p17/p24:Ty virus-like particles therapeutic vaccination of 56 HIV-1 infected patients had no effect on disease progression, AIDS and CD4+ T-cell
decline in a longitudinal study, despite some evidence suggesting it can enhance Th anti-Gag proliferative responses in HIV+ individuals [Klein1997]
Gag p24 (NY5) HIV-1 infection human Norris2001
• Gag-specific CD4+ helper T-cell clones were derived from one long-term non-progressor (LTNP) (CTS-01), and three individuals given therapy during
acute infection, two before (AC-01 and AC-36) and one after (AC-25) STI.
• The immunodominant response in LTNP CTS-01 was to peptide 9, and 9/10 clones derived from this patient reacted with it. Three, two, and one clones
were obtained from the three patients given therapy. These six clones all reacted with different p24 peptides, and all had peptide induced proliferative
responses, IFNgamma production, and cytotoxic responses. The implications of cytoxic responses in CD4+ T-helper cells are discussed.
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Gag p24 HIV-1 infection human Palmer2002
• CD4+ T cell proliferative responses from 33 HIV-1 infected patients with HAART suppression were compared to 19 patients with active viral replication
(HAART failures and HAART naive). Patients with HAART suppression showed stronger p24- and p66-specific proliferative responses compared to
patient groups with active HIV-1 replication, suggesting active viral replication in vivo specifically reduces proliferation responses.
• No differences in the frequency of HIV-specific CD4+ T-cells that were positive for cytokine secretion in a flow cytometry assay were found in the HAART
suppressed group versus the group with active viral replication.
Gag p24 (SF2) HIV-1 infection human Imami2002b
• 70 patients with chronic disease progression, 10 clinical non-progressors, and 3 immunologically discordant progressors (individuals who controlled
viremia but had progressive CD4+ T-cell decline) were analyzed for their T-helper cell responses to p24 and cytokine profile.
• SF2 p24 20mer peptides overlapping by 10 were used to assess the response in the different groups. At least 1/10 and up to 7/10 nonprogressors had a
proliferative response with every one of the 22 p24 overlapping peptides. All peptides produced an IL-2 (Th1) response in at least one of the 10
nonprogressors. IL-4 (Th2) responses were strong, but somewhat less comprehensive as 6/22 peptides elicited no IL-4 production, and fewer IL-4 responses
were see per peptide. In contrast, only 1/10 progressors had a clear proliferative and IL-2 response to 2/22 peptides, and neither one made an IL-4 response.
• The results taken together suggest that a balanced Th1/Th2 response to HIV is important for viral control in long-term non-progression.
• One immunologically discordant progressor became symptomatic while on the study. He showed a rapid decline in proliferative activity at that point, and a
shift from a Th1 to a Th2 IL-4 producing response.
Gag (BRU) Vaccine murine Haas1991
Vaccine Vector/Type: inactivated virus Strain: BRU HIV component: whole virus Adjuvant: Complete Freund’s adjuvant (CFA)
• Of 5 mouse inbred lines tested: DBA/2 (H-2d, Ad, Ed), B10.A(4R) (H-2h4, Ak) and B10.A(5R) (H-2i5) showed particularly good CD4+ T cell
proliferative responses to HIV proteins (gp160, gp120, p17, p24, Nef and RT), after vaccination with inactivated virus.
• B10.BR (H-2k, Ak, Ek) and C57BL/6 (H-2b and Ab) had weaker responses.
Gag p24 (IIIB) in vitro stimulation human (A*0201) Engelmayer2001
• Recombinant canarypox virus vector containing HIV-1 sequences, upon infection of mature dendritic cells, can trigger specific lysis in vitro by T-cells from
HIV-1 infected individuals at levels comparable to the response seen to HIV carried in vaccinia vectors
• Recombinant canarypox virus vector containing HIV-1 sequences can also stimulate HIV-specific IFNγ CD4+ helper T cell responses to Gag from bulk or
purified CD4+ T cells
Gag p55 HIV-1 infection human (DRB1*13,
DRB1*03)
Lotti2002
• 10/49 chronically HIV-1 infected patients had low p55-Gag-specific CD4+ T cell responses prior to therapy, and these responses remained unchanged 3 and
6 months after initiation of HAART. There was no difference in level of response in those with or without a detectable p55 response.
• For one individual, patient F45 CDC stage A2, CD4+ p55 responding clones were generated. Her response was consistently strong and heterogeneous in
terms of HLA restriction and Vbeta usage. Two clones were DRB1*13 restricted and used TCR Vbeta 17+19 or 5.1. Three clones were DRB1*03
restricted and used TCR Vbeta 22. Some clones had a Th1 cytokine secretion profile (high IFNgamma production) while some had a Th2 profile (high IL-4
and IL-5 production).
Gag p24 Vaccine murine (H-2d) Qiu2000
Vaccine Vector/Type: DNA HIV component: GAG
• Mice were injected with plasmid DNA at 0, 2 and 4 weeks and lymphocyte proliferation was measured after 6 weeks with recombinant p24 protein
• Secreted HIV-1 Gag expression vectors generated a stronger response than standard Gag or cytoplasmic Gag expression vectors
• IFN-gamma levels were increased compared to an undetectable IL-4 response
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• CTL levels were also increased in secreted Gag expression vaccination studies
Gag Gag Vaccine murine (H-2d) Billaut-Mulot2001
Vaccine Vector/Type: DNA with DNA boost, DNA with recombinant protein boost Strain: LAI HIV component: Gag, Tat, Nef Adjuvant: IL18
• DNA vaccinated BALB/c mice primed and boosted with a multiepitopic vaccine with IL18 showed lymphoproliferative responses 7 weeks post
immunization
• Strong but non-lasting HIV-specific CTL responses were detected by a Cr-release assay and DNA prime + DNA boost was more effective than DNA prime
+ protein boost
• Immunization with either the multiepitopic DNA or with the mixed DNA vaccine resulted in Th1 cytokines production (IL-2 and IFNγ) in spleen cell
cultures stimulated by Tat and Gag, while Th2 cytokines IL-4 and IL-10 production was not detectable
• Co-administration of IL18 increased T-cell responses but decreased anti-HIV antibody levels
Gag p24 Vaccine murine (H-2d) Halim2000
Vaccine Vector/Type: coxsackievirus HIV component: partial p24, polyepitope
• An avirulent rec coxsackievirus (CB4-P) construct was generated that can express p24 Gag sequences – CB4-P is attenuated even in immunodeficient mice
and T help responses can be elicited from peptides embedded in a surface loop of the VP1 capsid
• This paper describes the vaccine strategy and generation of constructs, and employs amino-terminal fusion of Gag sequences to the viral polyprotein with
subsequent cleavage to elicit CTL responses via MHC class I presentation in BALB/c mice
Gag gp120 (V3) and p24
(IIIB, MN, BH10)
Vaccine murine (H-2d) Buonaguro2002
Vaccine Vector/Type: virus-like particle Strain: gp120 A clade UG5.94UG018, HIV-1 IIIB HIV component: gp120 and Pr55gag
• BALB/c mice were given intraperitoneal immunization in the absence of adjuvants with virus-like particles (VLPs) expressing recombinant subtype A
gp120 and Pr55gag
• High dose-independent humoral responses were elicited against both gp120 and p24 peptides, and CTL responses were observed against target cells
carrying vaccinia expressed gp120 and Gag.
Gag Gag (HXB2) Vaccine murine (H-2d , H-2b) Mata2001
Vaccine Vector/Type: Listeria monocytogenes Strain: HXB2 HIV component: Gag
• BALB/c and C57BL/6 mice were immunized with rec Listeria monocytogenes (Lm-Gag) expressing HIV-1 HXB2 Gag and mice were challenged with
vaccinia expressing Gag
• L. monocytogenes is a gram-positive bacteria that enters the macrophage on phagocytosis and lives in the cytoplasm – secreted L. monocytogenes antigens
are processed and presented by both class I and class II pathways
• CD4+ Th1 T-cells mediated the Gag specific immunological protection in mice immunized with Lm-Gag and challenged with vaccinia-Gag
• Gag-specific CTL may enhance viral clearance via IFNγ secretion, but are not essential for immunity
Gag Gag Vaccine murine (H-2d , H-2b) Mata2000
Vaccine Vector/Type: Listeria monocytogenes HIV component: Gag
• BALB/c and C57BL/6 mice were immunized with rec Listeria monocytogenes (Lm-Gag) expressing HIV-1 HXB2 Gag and mice were challenged with
vaccinia expressing Gag
• L. monocytogenes is a gram-positive bacteria that enters the macrophage on phagocytosis and lives in the cytoplasm – secreted L. monocytogenes antigens
are processed and presented by both class I and class II pathways
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• This article is a review of L. monocytogenes biology and its potential as a vaccine vector for HIV, comparing to other vector systems, and discussing CD4+
Th1 T-cells mediated Gag specific immunological protection in mice and the Gag CTL response
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RT (36–52) RT (36–52 BRU) EICTEMEKEGKISKIGP HIV-1 infection human De Groot1991
• 9 out of 17 humans can make strong IL2 responses to this epitope
RT (38–52) RT (38–52 BRU) CTEMEKEGKISKIGP Vaccine murine (H-2k) De Groot1991
Vaccine Vector/Type: recombinant protein Strain: BRU HIV component: RT
• T-cells from RT immunized mice have enhanced proliferative response with peptide
RT (39–53) RT (194–208) TEMEKEGKISKIGPE in vitro stimulation human Manca1995a
• Protein priming induced T-cells that recognize peptide, 4 clones from a single donor recognized this peptide
RT (48–62) RT (48–62 BRU) SKIGPENPYNTPVFA Vaccine murine (H-2k) De Groot1991
Vaccine Vector/Type: recombinant protein Strain: BRU HIV component: RT
• T-cells from RT immunized mice have enhanced proliferative response with peptide
RT (62–77) RT (62–77 BRU) AIKKKDSTKWRKLVDF Vaccine murine (H-2k) De Groot1991
Vaccine Vector/Type: recombinant protein Strain: BRU HIV component: RT
• T-cells from RT immunized mice have enhanced proliferative response with peptide
RT (88–102) RT (88–102 BRU) WEVQLGIPHPAGLKK Vaccine murine (H-2t4) De Groot1991
Vaccine Vector/Type: recombinant protein Strain: BRU HIV component: RT
• T-cells from RT immunized mice have enhanced proliferative response with peptide
RT (124–138) Pol (303–317) FRKYTAFTIPSINNE HIV-1 infection human (DR supermotif) Wilson2001
• Epitope name: Pol 303
• Eleven peptides were identified that had the HLA-DR supermotif, all were found to bind to MHC class II DR molecules and all elicited proliferative
responses from multiple HIV-infected donors
• This epitope binds seven HLA-DR alleles: DRB1*0901, DRB1*0802, DRB1*0701, DRB1*0405, DRB1*0401, DRB1*1501 and DRB1*0101, with an
IC50 threshold below 1,000 nM
• This epitope sequence is conserved in 68% of clade B isolates
• 8/22 HIV infected individuals responded to this epitope (13/22 responded to some of the DR supermotif epitopes, the 9 non-responder peptides tended to
also not have recall responses to rec HIV-1 whole proteins)
RT (124–138) Pol (303–317) FRKYTAFTIPSINNE Vaccine murine (I-Ab and
HLA-DR)
Livingston2002
Vaccine Vector/Type: DNA with CMV promotor, peptide HIV component: polyepitope Adjuvant: CFA
• Epitope name: Pol 303
• Four Th HIV epitopes presented by HLA-DR molecules were identified that also could be presented my murine class II molecule I-Ab, enabling testing of
vaccine strategies of in H-2b mice.
• Responses to pooled peptides, polyepitope peptides in a linear construct or in a branched MAP construct, and a DNA polyepitope construct with a CMV
promotor were compared. A linear arrangement in polyepitope construct created a junctional epitope that could be disrupted with the addition of GPGPG
spacers. The linear polyepitope construct with the GPGPG spacer worked well in terms of eliciting responses to all four peptides, using either DNA or
protein for the vaccination.
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RT (133–147) RT (133–147 BRU) PSINNETPGIRYQYN Vaccine murine (H-2k,i5) De Groot1991
Vaccine Vector/Type: recombinant protein Strain: BRU HIV component: RT
• T-cells from RT immunized mice have enhanced proliferative response with peptide
RT (144–158) RT (144–158 BRU) YQYNVLPQGWKGSPA Vaccine murine (H-2t4) De Groot1991
Vaccine Vector/Type: recombinant protein Strain: BRU HIV component: RT
• T-cells from RT immunized mice have enhanced proliferative response with peptide
RT (156–170) Pol (335–349) SPAIFQSSMTKILEP HIV-1 infection human (DR supermotif) Wilson2001
• Epitope name: Pol 596
• Eleven peptides were identified that had the HLA-DR supermotif, all were found to bind to MHC class II DR molecules and all elicited proliferative
responses from multiple HIV-infected donors
• This epitope binds nine HLA-DR alleles: DRB1*0101, DRB1*1501, DRB1*0405, DRB1*1101, DRB1*1302, DRB1*0701, DRB1*0901, DRB5*0101
and DRB3*0101, with an IC50 threshold below 1,000 nM
• This epitope sequence is conserved in 79% of clade B isolates
• 7/22 HIV infected individuals responded to this epitope (13/22 responded to some of the DR supermotif epitopes, the 9 non-responder peptides tended to
also not have recall responses to rec HIV-1 whole proteins)
RT (156–170) Pol (335–449) SPAIFQSSMTKILEP Vaccine murine (I-Ab and
HLA-DR)
Livingston2002
Vaccine Vector/Type: DNA with CMV promotor, peptide HIV component: polyepitope Adjuvant: CFA
• Epitope name: Pol 335
• Four Th HIV epitopes presented by HLA-DR molecules were identified that also could be presented my murine class II molecule I-Ab, enabling testing of
vaccine strategies of in H-2b mice.
• Responses to pooled peptides, polyepitope peptides in a linear construct or in a branched MAP construct, and a DNA polyepitope construct with a CMV
promotor were compared. A linear arrangement in polyepitope construct created a junctional epitope that could be disrupted with the addition of GPGPG
spacers. The linear polyepitope construct with the GPGPG spacer worked well in terms of eliciting responses to all four peptides, using either DNA or
protein for the vaccination.
RT (171–190) RT (171–190 HXB2) FRKQNPDIVIYQYMDDLYVG HIV-1 infection human (DR1, 2 or 3, 4
and 7)
vanderBurg1999
• T-cells specific for this epitope from the three donors were stimulated when presented with target cells pulsed with whole RT, indicating that the peptide is
naturally processed for multiple HLA-DR molecules
• Epitope binds to HLA-DR1, -DR2, -DR3, -DR4, and DR7, and can elicit Th1 cells that recognize peptide, protein, and HIV pulsed stimulator cells in the
context of DR1, 2 or 3, 4 and 7 – these HLA types cover more than half of the general population
RT (171–190) RT (171–190 HXB2) FRKQNPDIVIYQYMDDLYVG HIV-1 infection, in vitro
stimulation
human (DR1, DR2,
DR3, DR4, DR7)
vanderBurg1999
• The goal of this study was to identify Th epitopes that could be cross-presented by multiple class II HLA molecules. 5 RT peptides were identified that
could bind to more than one HLA class II protein, and but only 2/5 could stimulate strong proliferation responses in PBMC derived from multiple healthy
donors.
• This highly conserved epitope binds with high affinity to HLA-DR1, -DR2, -DR3, -DR4, and -DR7 but not HLA-DR5, and stimulated proliferation in 3/3
PBMC individuals with the appropriate HLA alleles.
• This epitope was able to be naturally processed in protein pulsed stimulator cells, and responding clones had a Th1 cytokine profile.
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• This epitope is highly conserved and spans the highly conserved YMDD motif, and showing only minor variability in clades A, B, and D.
RT (195–209) RT (IIIB) IGQHRTKIEELRQHL in vitro stimulation human Manca1995b
• Protein priming induced T-cells that recognize peptide
RT (196–215) RT (351–370) GQHRTKIEELRQHLLRWGLT in vitro stimulation human Manca1995a
• Protein priming induced T-cells that recognize peptide, 4 clones from a single donor recognized this peptide
RT (249–263) RT (IIIB) KDSWTWNDIQKLVGK in vitro stimulation human Manca1995b
• Peptide stimulation of PBMC from non-infected individuals in vitro
• Peptide priming did not induce T-cells that recognize whole protein
RT (249–263) RT (248–262) KDSWTVNDIQKLVGK in vitro stimulation human De Berardinis1999
• PBMC from donors GD (HLA DR 11; DRB52) and LD (HLA DR 11, 13; DRB52) recognized this epitope (pep23)
• A subset of T-cell lines generated from these donors were capable of recognizing pep23 expressed on the surface of filamentous phage fd, fused to the
major coat protein gVIIIp
• This peptide was selected to study phage presentation of peptide sequences because it was known to serve as a T-cell helper determinant which could
induce proliferation from a naive repertoire [Manca1995a]
RT (249–263) RT (249–263) KDSWTVNDIQKLVGK Vaccine, in vitro stimulation human (DR5) De Berardinis2000
Vaccine Vector/Type: HIV-1 peptide in filamentous bacteriophage major coat protein HIV component: RT peptides
• Epitope name: RT2
• Phage display of the CTL epitope, ILKEPVHGV coupled with T helper epitope KDSWTVNDIQKLVGK, elicited specific CTL responses in PBMC from
HIV negative individuals and in vivo in immunization of HLA-A2 transgenic mice
• Bacteriophage presentation of peptides is generally used for stimulation of antibodies, and this novel discovery of CTL epitope processing and presentation
suggests new possibilities for these vectors
• HIV-1 peptides were displayed in filamentous bacteriophage fd virion major coat protein pVIII
RT (249–263) RT (248–262 HXB2) KDSSTVNDIQKLVGK in vitro stimulation human (DRS) Fenoglio1999
• RT pep23 epitope exhibited antagonistic activity against proliferation of gp120-specific T-cells when flanked by unrelated amino acid sequence
• The glutathione S-transferase (GST)-peptide system can be used to display peptides; antigenicity was maintained when this peptide was expressed at the
C-term end, but antagonism resulted when this peptide was expressed at the N-term end
RT (251–261) RT (250–260) SSTVNDIQKLV in vitro stimulation human (DR5(11.01)) Manca1996
• This peptide was the minimal stimulatory sequence
• One Th line was stimulated by p66, one by a Glutathione-S-transferase (GST)-peptide fusion protein
• Constructs linking GST to the KDSSTVNDIQKLVGK peptide at the N-term end of GST stimulated Th cells, but not constructs linking at the C-term end
• The C and N termini of GST are not intrinsically permissive or non-permissive, presentation is epitope specific (see FAILKCNNK for contrast)
RT (258–272) RT (IIIB) QKLWGKLNWASQIYP in vitro stimulation human Manca1995b
• Peptide stimulation of PBMC from non-infected individuals in vitro
• Peptide priming did not induce T-cells that recognize whole protein
RT (271–290) RT (271–290 HXB2) YPGIKVRQLCKLLRGTKALT HIV-1 infection human vanderBurg1999
• Epitope can bind to at least 5 different HLA-DR molecules, and peptide on target cells can elicit Th responses from PBMC cultures from healthy donors,
however it does not seem to be processed properly from whole RT or virus
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RT (271–290) RT (271–290 HXB2) YPGIKVRQLCKLLRGTKALT HIV-1 infection, in vitro
stimulation
human (DR1, DR2,
DR3, DR5, DR7)
vanderBurg1999
• The goal of this study was to identify Th epitopes that could be cross-presented by multiple class II HLA molecules. 5 RT peptides were identified that
could bind to more than one HLA class II protein, but only 2/5 could stimulate strong proliferation responses in PBMC derived from multiple healthy
donors.
• This epitope binds with high affinity to HLA-DR1, -DR2, -DR3, -DR5, and -DR7 but not HLA-DR4, and stimulated proliferation in 3/4 individuals with
the appropriate HLA alleles.
• This epitope was not able to be naturally processed in protein-pulsed stimulator cells.
RT (276–290) RT (IIIB) WRQLCKLLRGTKALT in vitro stimulation human Manca1995b
• Protein priming induced T-cells that recognize peptide
RT (285–299) RT (IIIB) GTKALTEVIPLTEEA in vitro stimulation human Manca1995b
• Protein priming induced T-cells that recognize peptide
RT (294–308) RT (IIIB) PLTEEAELELAENRE in vitro stimulation human Manca1995b
• Protein priming induced T-cells that recognize peptide
RT (303–317) RT (IIIB) LAENREILKEPVHGV in vitro stimulation human Manca1995b
• Protein priming induced T-cells that recognize peptide
RT (384–398) RT (IIIB) GKTPKFKLPIQKETW in vitro stimulation human Manca1995b
• Protein priming induced T-cells that recognize peptide
RT (414–428) Pol (596–610) WEFVNTPPLVKLWYQ HIV-1 infection human (DR supermotif) Wilson2001
• Epitope name: Pol 596
• Eleven peptides were identified that had the HLA-DR supermotif, all were found to bind to MHC class II DR molecules and all elicited proliferative
responses from multiple HIV-infected donors
• This epitope binds eleven HLA-DR alleles: DRB1*0101, DRB1*1501, DRB1*0401, DRB1*0405, DRB1*1101, DRB1*1302, DRB1*0701, DRB1*0802,
DRB1*0901, DRB5*0101 and DRB4*0101, with an IC50 threshold below 1,000 nM
• This epitope sequence is conserved in 84% of clade B isolates
• 6/22 HIV infected individuals responded to this epitope (13/22 responded to some of the DR supermotif epitopes, the 9 non-responder peptides tended to
also not have recall responses to rec HIV-1 whole proteins)
RT (429–443) RT (IIIB) LEKEPIVGAETFYVD in vitro stimulation human Manca1995b
• Protein priming induced T-cells that recognize peptide
RT (432–450) RT (431–450 HXB2) EPIVGAETFYVDGAANRET HIV-1 infection, in vitro
stimulation
human (DR1, DR2,
DR3, DR4)
vanderBurg1999
• The goal of this study was to identify Th epitopes that could be cross-presented by multiple class II HLA molecules. 5 RT peptides were identified that
could bind to more than one HLA class II protein, and but only 2/5 could stimulate strong proliferation responses in PBMC derived from multiple healthy
donors.
• This epitope binds with high affinity to HLA-DR1, -DR2, -DR3, and -DR4, but stimulated a strong proliferation response in only 1/4 individuals tested so
was not considered broadly cross-presented.
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RT (526–540) RT (526–540 BRU) IKKEKVYLAWVPAHK Vaccine murine (Ad or Dd) Haas1991
Vaccine Vector/Type: peptide, inactivated virus, recombinant protein Strain: BRU HIV component: whole virus, RT Adjuvant: CFA
• Epitope name: W9
• Of 5 mouse inbred lines tested: DBA/2 (H-2d, Ad, Ed), B10.A(4R) (H-2h4, Ak) and B10.A(5R) (H-2i5) showed particularly good CD4+ T cell
proliferative responses to HIV proteins (gp160, gp120, p17, p24, Nef and RT), after vaccination with inactivated virus.
• B10.BR (H-2k, Ak, Ek) and C57BL/6 (H-2b and Ab) had weaker responses.
• The peptide KEKVYLAWVPAHKG was one of two RT peptides with Th cells recognition.
RT (528–541) RT (528–543 BRU) KEKVYLAWVPAHKG Vaccine murine (Ad and Dd) Haas1991
Vaccine Vector/Type: peptide, inactivated virus, recombinant protein Strain: BRU HIV component: whole virus, RT Adjuvant: CFA
• Epitope name: A3
• Of 5 mouse inbred lines tested: DBA/2 (H-2d, Ad, Ed), B10.A(4R) (H-2h4, Ak) and B10.A(5R) (H-2i5) showed particularly good CD4+ T cell
proliferative responses to HIV proteins (gp160, gp120, p17, p24, Nef and RT), after vaccination with inactivated virus.
• B10.BR (H-2k, Ak, Ek) and C57BL/6 (H-2b and Ab) had weaker responses.
• The peptide KEKVYLAWVPAHKG was one of two RT peptides with Th cells recognition. It could by itself prime different strains of mice for RT-specific
Th responses, and the C-term half of the peptide is highly conserved in HIV-1, HIV-2 and SIV strains.
RT (528–543) RT (528–543 BRU) KEKVYLAWVPAHKGIG Vaccine murine (H-2 f ,k,d) Haas1991
Vaccine Vector/Type: peptide Strain: BRU
• T-cells from peptide-primed mice could be restimulated by native RT
RT (529–543) Pol (711–725) EKVYLAWVPAHKGIG HIV-1 infection human (DR supermotif) Wilson2001
• Epitope name: Pol 711
• Eleven peptides were identified that had the HLA-DR supermotif, all were found to bind to MHC class II DR molecules and all elicited proliferative
responses from multiple HIV-infected donors
• This epitope binds ten HLA-DR alleles: DRB1*0101, DRB1*1501, DRB1*0401, DRB1*0405, DRB1*1101, DRB1*0701, DRB1*0802, DRB1*0901,
DRB5*0101 and DRB4*0101, with an IC50 threshold below 1,000 nM
• This epitope sequence is conserved in 94% of clade B isolates
• 6/22 HIV infected individuals responded to this epitope (13/22 responded to some of the DR supermotif epitopes, the 9 non-responder peptides tended to
also not have recall responses to rec HIV-1 whole proteins)
RT (529–543) Pol (711–725) EKVYLAWVPAHKGIG Vaccine murine (I-Ab and
HLA-DR)
Livingston2002
Vaccine Vector/Type: DNA with CMV promotor, peptide HIV component: polyepitope Adjuvant: CFA
• Epitope name: Pol 711
• Four Th HIV epitopes presented by HLA-DR molecules were identified that also could be presented my murine class II molecule I-Ab, enabling testing of
vaccine strategies of in H-2b mice.
• Responses to pooled peptides, polyepitope peptides in a linear construct or in a branched MAP construct, and a DNA polyepitope construct with a CMV
promotor were compared. A linear arrangement in polyepitope construct created a junctional epitope that could be disrupted with the addition of GPGPG
spacers. The linear polyepitope construct with the GPGPG spacer worked well in terms of eliciting responses to all four peptides, using either DNA or
protein for the vaccination.
• Although responses to this peptide indicated it was immunodominant, responses to all four peptides were made upon vaccination with linear constructs
when GPGPG spacers were used.
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RT (530–544) Pol (712–726) KVYLAWVPAHKGIGG HIV-1 infection human (DR supermotif) Wilson2001
• Epitope name: Pol 712
• Eleven peptides were identified that had the HLA-DR supermotif, all were found to bind to MHC class II DR molecules and all elicited proliferative
responses from multiple HIV-infected donors
• This epitope binds ten HLA-DR alleles: DRB1*0101, DRB1*1501, DRB1*0401, DRB1*0405, DRB1*1101, DRB1*0701, DRB1*0802, DRB1*0901,
DRB5*0101 and DRB4*0101, with an IC50 threshold below 1,000 nM
• This epitope sequence is conserved in 89% of clade B isolates
• 6/22 HIV infected individuals responded to this epitope (13/22 responded to some of the DR supermotif epitopes, the 9 non-responder peptides tended to
also not have recall responses to rec HIV-1 whole proteins)
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RT-Integrase (553–3) RT (720–730 LAI) SAGIRKVLFLD HIV-1 infection human Schrier1989
• Stimulates T-cell proliferation in HIV-infected donors
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Integrase (16–30) Pol (758–772) HSNWRAMASDFNLPP HIV-1 infection human (DR supermotif) Wilson2001
• Epitope name: Pol 758
• Eleven peptides were identified that had the HLA-DR supermotif, all were found to bind to MHC class II DR molecules and all elicited proliferative
responses from multiple HIV-infected donors
• This epitope binds eight HLA-DR alleles: DRB4*0101, DRB5*0101, DRB1*0901, DRB1*0701, DRB1*1101, DRB1*0405, DRB1*0401 and
DRB1*0101, with an IC50 threshold below 1,000 nM
• This epitope sequence is conserved in 68% of clade B isolates
• 8/22 HIV infected individuals responded to this epitope (13/22 responded to some of the DR supermotif epitopes, the 9 non-responder peptides tended to
also not have recall responses to rec HIV-1 whole proteins)
Integrase (172–186) RT (899–913 LAI) LKTAVQMAVFIHNFK HIV-1 infection human Schrier1989
• Stimulates T-cell proliferation in HIV-infected donors
Integrase (173–187) Pol (915–929) KTAVQMAVFFIHNFKR HIV-1 infection human (DR supermotif) Wilson2001
• Epitope name: Pol 915
• Eleven peptides were identified that had the HLA-DR supermotif, all were found to bind to MHC class II DR molecules and all elicited proliferative
responses from multiple HIV-infected donors
• This epitope binds seven HLA-DR alleles: DRB5*0101, DRB1*1302, DRB1*1101, DRB1*0405, DRB1*0401, DRB1*1501 and DRB1*0101, with an
IC50 threshold below 1,000 nM
• This epitope sequence is conserved in 94% of clade B isolates
• 6/22 HIV infected individuals responded to this epitope (13/22 responded to some of the DR supermotif epitopes, the 9 non-responder peptides tended to
also not have recall responses to rec HIV-1 whole proteins)
Integrase (196–210) RT (923–937 LAI) AGERIVDIIATDIQT HIV-1 infection human Schrier1989
• Stimulates T-cell proliferation in HIV-infected donors
Integrase (214–228) Pol (956–970) QKQITKIQNFRVYYR HIV-1 infection human (DR supermotif) Wilson2001
• Epitope name: Pol 956
• Eleven peptides were identified that had the HLA-DR supermotif, all were found to bind to MHC class II DR molecules and all elicited proliferative
responses from multiple HIV-infected donors
• This epitope binds twelve HLA-DR alleles: DRB4*0101, DRB5*0101, DRB1*0901, DRB1*0802, DRB1*0701, DRB1*1302, DRB1*1201, DRB1*1101,
DRB1*0405, DRB1*0401, DRB1*1501 and DRB1*0101, with an IC50 threshold below 1,000 nM
• This epitope sequence is conserved in 95% of clade B isolates
• 8/22 HIV infected individuals responded to this epitope (13/22 responded to some of the DR supermotif epitopes, the 9 non-responder peptides tended to
also not have recall responses to rec HIV-1 whole proteins)
Integrase (215–227) RT (942–954 LAI) KQITKIQNFRVYY HIV-1 infection human Schrier1989
• Stimulates T-cell proliferation in HIV-infected donors
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Pol Gag/Pol Vaccine murine Kim1997b
Vaccine Vector/Type: DNA HIV component: GAG, POL, VIF Adjuvant: B7 and IL-12 expression vector
• A gag/pol DNA vaccine delivered in conjunction with the plasmid encoding the co-stimulatory molecules B7 and IL-12 gives a dramatic increase in both
the cytotoxic and proliferative responses in mice
Pol Gag/Pol Vaccine murine Kim1997d
Vaccine Vector/Type: DNA HIV component: gp160, GAG, POL Adjuvant: CD86 expression vectors
• A gag/pol DNA vaccine delivered in conjunction with the plasmid encoding the co-stimulatory molecule CD86 gives an increase in proliferative responses
to Pr55 in mice
Pol Gag/Pol (MN) Vaccine chimpanzee Kim1998
Vaccine Vector/Type: DNA Strain: MN HIV component: GAG, POL, ENV Adjuvant: CD80 and CD86 expression vectors
• Co-stimulatory molecules co-expressed with an HIV-1 immunogen in a DNA vaccine used to enhance the immune response – co-expression of CD86, but
not CD80, dramatically increased both HIV Env and Gag/Pol specific CTL and Th proliferative responses
Pol Pol HIV-1 infection human Blankson2001a
• 5/10 chronically HIV infected patients with low CD4+ counts who received HAART therapy and experienced immune reconstitution displayed p24, p17
and p66 T-helper CD4 proliferative responses, in contrast to 0/8 chronically HIV infected patients with high CD4+ counts at the initiation of antiretroviral
treatment
• This surprising result could be due to the low CD4 nadir patients being more likely to have thymic regeneration or a peripheral expansion of T cells
Pol p66 HIV-1 infection human Oxenius2000
• Patients who started therapy at acute HIV infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific
CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load – three patients that had delayed initiation of
HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became
undetectable
Pol p66 HIV-1 infection human Palmer2002
• CD4+ T cell proliferative responses from 33 HIV-1 infected patients with HAART suppression were compared to 19 patients with active viral replication
(HAART failures and HAART naive). Patients with HAART suppression showed stronger p24- and p66-specific proliferative responses compared to
patient groups with active HIV-1 replication, suggesting active viral replication in vivo specifically reduces proliferation responses.
• No differences in the frequency of HIV-specific CD4+ T-cells that were positive for cytokine secretion in a flow cytometry assay were found in the HAART
suppressed group versus the group with active viral replication.
Pol (BRU) Vaccine murine Haas1991
Vaccine Vector/Type: inactivated virus Strain: BRU HIV component: whole virus, RT Adjuvant: Freund’s adjuvant (CFA)
• Of 5 mouse inbred lines tested DBA/2 (H-2d, Ad, Ed), B10.A(4R) (H-2h4, Ak) and B10.A(5R) (H-2i5) showed particularly good CD4+ T cell proliferative
responses to HIV proteins (gp160, gp120, p17, p24, Nef and RT), after vaccination with inactivated virus.
• B10.BR (H-2k, Ak, Ek) and C57BL/6 (H-2b and Ab) had weaker responses.
Pol RT (248–256 HXB2) in vitro stimulation human (DR5) Manca1995b
• CD4+ T-cell lines from uninfected individuals by stimulation with p66-pulsed APC
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• TcR Vβ Dβ Jβ sequences were obtained from p66-specific T-cell clones
• There were multiple responses to peptides throughout p66, but because of uncertain locations, they have not been mapped
• Response to peptide 248-256 was associated with DR5
Pol RT Vaccine murine (H-2d) Kim2000
Vaccine Vector/Type: DNA HIV component: GAG, POL, ENV Adjuvant: IL-2, IL-4 and IFNγ expression vectors
• Co-stimulatory molecules co-expressed with an HIV-1 immunogen in a DNA vaccine used to enhance the immune response – co-expression of Th1
cytokine IFN-gamma drove Th1 immune responses and enhanced CTL responses
Pol RT Vaccine murine (H-2d) Burnett2000
Vaccine Vector/Type: Salmonella HIV component: RT epitope
• A live attenuated bacterial vaccine, Salmonella SL3261-pHART, with an inserted HIV RT gene in the Lpp-OmpA-HIV fusion protein, induced a
lymphoproliferative Th response in BALB/c mice
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Vif (65–76) Vif (65–80) VITTYWGLHTGE HIV-1 infection human Ranki1997
• T-cell response to this epitope persisted after seroreversion
Vif (81–96) Vif (81–96) LGQGVSIEWRKQRYST HIV-1 infection human Ranki1997
• T-cell response to this epitope persisted after seroreversion
Vif Vif Vaccine murine (H-2d) Ayyavoo2000
Vaccine Vector/Type: DNA HIV component: Vif, Vpu, Nef
• Splenocytes from BALB/c mice immunized with pVVN-P DNA were incubated with Vif, Vpu or Nef antigens for 3 days and assayed for IL-4 and
IFN-gamma levels
• Antigen stimulation increased IFN-gamma production in pVVN-P immunized mice, indicating a Th1 response
• IL-4 production was not significantly changed after antigen stimulation compared to control levels
• Cross-clade CTL activity was also observed: A, B clade, CRF01(AE) clade antigens could serve as targets for the B clade immunization stimulated CTL –
an HIV-1 AC recombinant, however, did not stimulate a CTL response, but was expressed at lower levels on the target cell
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HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
Vpr (66–80) Vpr (66–80 IIIB) QLLFIHFRIGCRHSR HIV-1 infection human Sarobe1994
• This peptide was found to stimulate proliferative responses in 37.5% of HIV-1 positive individuals
Vpr (66–80) Vpr (66–80 IIIB) QLLFIHFRIGCRHSR Vaccine murine (H-2d) Sarobe1994
Vaccine Vector/Type: peptide
• Included as a Th stimulatory component of peptide vaccines that also incorporated B-cell epitopes
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Tat (1–20) Tat (1–20 LAI) MEPVDPRLEPWKHPGSQPKT Vaccine murine (H-2d) Hinkula1997
Vaccine Vector/Type: DNA Strain: LAI HIV component: NEF, TAT, REV
• Stronger, broader responses were observed in animals vaccinated with DNA epidermally rather than with intramuscular protein
• Some proliferative response to vaccination was observed to peptides throughout Nef and Tat, less for Rev
Tat (16–35) Tat (16–35 LAI) SQPKTACTTCYCKKCCFHCQ Vaccine murine (H-2d) Hinkula1997
Vaccine Vector/Type: DNA Strain: LAI HIV component: NEF, TAT, REV
• Stronger, broader responses were observed in animals vaccinated with DNA epidermally rather than with intramuscular protein
• Some proliferative response to vaccination was observed to peptides throughout Nef and Tat, less for Rev
Tat (17–32) Tat (17–32) QPKTACTNCYCKRCCF HIV-1 infection human Ranki1997
• T-cell response to this epitope persisted after seroreversion
Tat (17–32) Tat (17–32 HXB2) QPKTACTNCYCKKCCF HIV-1 infection human (DR5? plus
others)
Blazevic1993
• Epitope name: D26
• 9/14 (64%) of HIV-1 positive patients had proliferative T-cell responses associated with IL-2 production against at least one Tat-derived synthetic peptides
of twelve overlapping 15-16 mer peptides spanning Tat. T cell proliferation was associated with IL-2 production.
• 3/12 peptides were recognized.
• This immunodominant, highly conserved and most frequently recognized peptide was recognized by 57% of the HIV-1 infected patients. A beta-sheet
secondary structure was predicted at aa residues 21-28, but no amphipathic helix structure, suggested to be most favorable for T-cell epitopes, was indicated.
• This peptide contained epitopes restricted by several HLA DR alleles, although the frequency of DR5 was enriched (3/6) among the patients that
recognized the peptide.
Tat (31–50) Tat (31–50 LAI) CFHCQVCFTTKALGISYGRK Vaccine murine (H-2d) Hinkula1997
Vaccine Vector/Type: DNA Strain: LAI HIV component: NEF, TAT, REV
• Stronger, broader responses were observed in animals vaccinated with DNA epidermally rather than with intramuscular protein
• Some proliferative response to vaccination was observed to peptides throughout Nef and Tat, less for Rev
Tat (33–48) Tat (33–48) HCQVCFMTKGLGISYG HIV-1 infection human Ranki1997
• T-cell response to this epitope persisted after seroreversion
Tat (33–48) Tat (33–48 HXB2) HCQVCFITKALGISYG HIV-1 infection human (DR5? plus
others)
Blazevic1993
• Epitope name: D28
• 9/14 (64%) of HIV-1 positive patients had proliferative T-cell responses associated with IL-2 production against at least one Tat-derived synthetic peptides
of twelve overlapping 15-16 mer peptides spanning Tat. T cell proliferation was associated with IL-2 production.
• 3/12 peptides were recognized.
• 4/14 HIV+ people recognized this peptide.
• An alpha-helix structure was predicted at residues 39-44, but charge patterns did not indicate it was an amphipathic helix, suggested to be most favorable
for T-cell epitopes.
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• This peptide contained epitopes restricted by several HLA DR alleles, although the frequency of DR5 was enriched (2/4) among the patients that
recognized the peptide.
Tat (46–65) Tat (46–65 LAI) SYGRKKRRQRRRPPQGSQTH Vaccine murine (H-2d) Hinkula1997
Vaccine Vector/Type: DNA Strain: LAI HIV component: NEF, TAT, REV
• Stronger, broader responses were observed in animals vaccinated with DNA epidermally rather than with intramuscular protein
• Some proliferative response to vaccination was observed to peptides throughout Nef and Tat, less for Rev
Tat (61–80) Tat (61–80 LAI) GSQTHQVSLSKQPTSQPRGD Vaccine murine (H-2d) Hinkula1997
Vaccine Vector/Type: DNA Strain: LAI HIV component: NEF, TAT, REV
• Stronger, broader responses were observed in animals vaccinated with DNA epidermally; rather than with intramuscular protein
• Some proliferative response to vaccination was observed to peptides throughout Nef and Tat, less for Rev
Tat (65–80) Tat (65–80 HXB2) HQASLSKQPTSQPRGD HIV-1 infection human (DR2? plus
others)
Blazevic1993
• Epitope name: D32
• 9/14 (64%) of HIV-1 positive patients had proliferative T-cell responses associated with IL-2 production against at least one Tat-derived synthetic peptides
of twelve overlapping 15-16 mer peptides spanning Tat. T cell proliferation was associated with IL-2 production.
• 3/12 Tat peptides were recognized.
• 3/14 HIV+ people recognized this peptide.
• An alpha-helix structure was predicted at residues 65-72, but charge patterns did not indicate it was an amphipathic helix, suggested to be most favorable
for T-cell epitopes..
• This peptide contained epitopes restricted by several HLA DR alleles, although the frequency of DR2 was enriched (2/3) among the patients that
recognized the peptide.
Tat (67–86) Tat (67–86 LAI) VSLSKQPTSQPRGDPTGPKE Vaccine murine (H-2d) Hinkula1997
Vaccine Vector/Type: DNA Strain: LAI HIV component: NEF, TAT, REV
• Stronger, broader responses were observed in animals vaccinated with DNA epidermally rather than with intramuscular protein
• Some proliferative response to vaccination was observed to peptides throughout Nef and Tat, less for Rev
Tat Tat Vaccine human Calarota1999
Vaccine Vector/Type: DNA HIV component: NEF, REV, TAT
• 9/9 HIV-1+ subjects were given one of three DNA vaccinations for nef, rev or tat, and novel proliferative and CTL responses were generated
• The nef DNA immunization induced the highest and most consistent CTLp activity, IFN-gamma production, and IL-6 and IgG responses
• Highly active antiretroviral treatment (HAART) did not induce new HIV-specific CTL responses but reduced viral load, while DNA vaccination induced
new immune responses but did not reduce viral load – thus this is a potentially complementary and promising combination
Tat Tat HIV-1 infection, Vaccine human Calarota2001
Vaccine Vector/Type: DNA HIV component: Nef, Rev, Tat Adjuvant: CpG motifs
• This review discusses the cellular immune response, and comments on CpG induction of Th1 cytokines and enhanced immune responses, and HIV-1 DNA
vaccine boosting of CTL and Th proliferative responses in asymptomatic HIV+ individuals
Tat Tat in vitro stimulation human Corinti2002
• In vitro delivery of recombinant Tat protein conjugated to red blood cells (RBCs) via avidin-biotin bridges (RBC-Tat) to human dendritic cells was
compared to dendritic cells pulsed with rec Tat.
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• Dendritic cells pulsed with RBC-Tat elicited specific and significantly stronger CD4+ and CD8+ T-cell responses and required 1250-fold less antigen than
DCs stimulated with soluble Tat.
• Dendritic cells which were maturated in the presence of IFNgamma induced elevated IL-12 and TNF-alpha secretion. IFNgamma upregulated IP-10 and
down regulated TARC, chemokines which attract Th1 and Th2 cells, respectively.
Tat Tat (IIIB, BH10) in vitro stimulation human Fanales-Belasio2002
• Biologically active HIV-1 Tat is readily taken up by monocyte-derived dendritic cells (MDDC) (and activated endothelial cells), but not other APCs. Tat
must be in a native, non-oxidized conformation for efficient uptake. Tat upregulates MHC molecules, IL-12, TNFα , RANTES and MIP-1-α and MIP-1-β
production which drives Th1 immune responses and enhances antigen presentation.
• Native Tat enhanced the antigen presentation of MDDC and boosted proliferative recall and allogeneic antigen responses, and the authors propose it could
be used as an adjuvant to drive the immune response as well as an antigen.
Tat Tat Vaccine murine (H-2d) Billaut-Mulot2001
Vaccine Vector/Type: DNA with DNA boost, DNA with recombinant protein boost Strain: LAI HIV component: Gag, Tat, Nef Adjuvant: IL18
• DNA vaccinated BALB/c mice primed and boosted with a multiepitopic vaccine with IL18 gave lymphoproliferative responses 7 weeks post immunization
• Strong but non-lasting HIV-specific CTL responses were detected by a Cr-release assay and DNA prime + DNA boost was more effective than DNA prime
+ protein boost
• Immunization with either the multiepitopic DNA or with the mixed DNA vaccine resulted in Th1 cytokines production (IL-2 and IFNγ) in spleen cell
cultures stimulated by Tat and Gag, while Th2 cytokines IL-4 and IL-10 production was not detectable
• Co-administration of IL18 increased T-cell responses but decreased anti-HIV antibody levels
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Rev (9–23) Rev (9–23 HXB2) DEELIRTVRLIKLLY HIV-1 infection human Blazevic1995
• One of four peptides that stimulates in PBLs from HIV-1+ donors both CD4+ Th cell proliferation and CTL to autologous targets incubated with peptide
were stimulated
Rev (16–35) Rev (16–35 LAI) VRLIKFLYQSNPPPNPEGTR Vaccine murine (H-2d) Hinkula1997
Vaccine Vector/Type: DNA Strain: LAI HIV component: NEF, TAT, REV
• Stronger, broader responses were observed in animals vaccinated with DNA epidermally rather than with intramuscular protein
• Some proliferative response to vaccination was observed to peptides throughout Nef and Tat, less for Rev
Rev (25–39) Rev (25–39 HXB2) SNPPPNPEGTRQARR HIV-1 infection human Blazevic1995
• One of four peptides that stimulates in PBLs from HIV-1+ donors both CD4+ Th cell proliferation and CTL to autologous targets incubated with peptide
were stimulated
Rev (31–50) Rev (31–50 LAI) PEGTRQARRNRRRRWRERQR Vaccine murine (H-2d) Hinkula1997
Vaccine Vector/Type: DNA Strain: LAI HIV component: NEF, TAT, REV
• Stronger, broader responses were observed in animals vaccinated with DNA epidermally rather than with intramuscular protein
• Some proliferative response to vaccination was observed to peptides throughout Nef and Tat, less for Rev
Rev (33–48) Rev (33–48 HXB2) GTRQARRNRRRRWRER HIV-1 infection human Blazevic1995
• One of four peptides that stimulates in PBLs from HIV-1+ donors both CD4+ Th cell proliferation and CTL to autologous targets incubated with peptide
were stimulated
Rev (41–56) Rev (41–56 HXB2) RRRRWRERQRQIHSIS HIV-1 infection human Blazevic1995
• One of four peptides that stimulates in PBLs from HIV-1+ donors both CD4+ Th cell proliferation and CTL to autologous targets incubated with peptide
were stimulated
Rev (76–95) Rev (76–95 LAI) PPLERLTLDCNEDCGTSGTQ Vaccine murine (H-2b) Hinkula1997
Vaccine Vector/Type: DNA Strain: LAI HIV component: NEF, TAT, REV
• Stronger, broader responses were observed in animals vaccinated with DNA epidermally rather than with intramuscular protein
• Some proliferative response to vaccination was observed to peptides throughout Nef and Tat, less for Rev
Rev (96–116) Rev (96–116 LAI) GVGSPQILVESPTVLESGT-
KE
Vaccine murine (H-2d) Hinkula1997
Vaccine Vector/Type: DNA Strain: LAI HIV component: NEF, TAT, REV
• Stronger, broader responses were observed in animals vaccinated with DNA epidermally rather than with intramuscular protein
• Some proliferative response to vaccination was observed to peptides throughout Nef and Tat, less for Rev
Rev Rev Vaccine murine Chan1998
Vaccine Vector/Type: DNA HIV component: REV
• Rev M10 is a construct that was introduced into mice through a genetic vaccination
• Rev was used to test for down-regulation of HIV-1 in infected cells as a method for gene therapy – in the course of this study, Rev-specific IL-2 producing
Th cells developed in the mice
464
DEC 2002
Rev Helper T-Cell Epitopes HIV Helper T-Cell Epitope Tables
T-H
elper
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
Rev Rev Vaccine human Calarota1999
Vaccine Vector/Type: DNA HIV component: Nef, Rev Tat
• 9/9 HIV-1+ subjects were given one of three DNA vaccinations for nef, rev or tat, and novel proliferative and CTL responses were generated
• The nef DNA immunization induced the highest and most consistent CTLp activity, IFN-gamma production, and IL-6 and IgG responses
• Highly active antiretroviral treatment (HAART) did not induce new HIV-specific CTL responses but reduced viral load, while DNA vaccination induced
new immune responses but did not reduce viral load – thus this is a potentially complementary and promising combination
Rev Rev HIV-1 infection, Vaccine human Calarota2001
Vaccine Vector/Type: DNA HIV component: Nef, Rev, Tat Adjuvant: CpG motifs
• This review discusses the cellular immune response, and comments on CpG induction of Th1 cytokines and enhanced immune responses, and HIV-1 DNA
vaccine boosting of CTL and Th proliferative responses in asymptomatic HIV+ individuals
Rev Rev Vaccine human MacGregor2002
Vaccine Vector/Type: DNA with CMV promotor Strain: MN HIV component: Env, Rev Adjuvant: bupivacaine
• A phase I clinical trial of a HIV-1 Env and Rev DNA vaccine with a CMV promoter was conducted and Th proliferative, CTL and Elispot responses
monitored. The construct was modified for safety and included no LTRs or packaging signals. The vaccine strategy was safe, and elicited strong CD4-T cell
responses, but not CD8 T-cell responses. Rev elicited strong Th responses, and is a early produced protein so may confer advantages.
• With a 300 ug dose, 4/6 individuals had a lymphocyte proliferation (LP) responses to gp120, 3/6 to Rev.
• With a 1000 ug dose, 4/6 individuals had a LP and 2/6 had IFNgamma Elispot responses to gp160; 3/6 had LP, and 4/6 had IFNgamma Elispot responses to
Rev.
• No responses to three specific CTL epitopes were observed by Elispot in individuals with appropriate HLA. Some cytoxic activity against whole protein
was observed that was CD4+ T-cell mediated.
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HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
Vpu (19–34) Vpu (19–34) AIVVWSIVLIEYRKIL HIV-1 infection human Ranki1997
• T-cell response to this epitope persisted after seroreversion
Vpu Vpu Vaccine murine (H-2d) Ayyavoo2000
Vaccine Vector/Type: DNA HIV component: Vif, Vpu, Nef
• Splenocytes from BALB/c mice immunized with pVVN-P DNA were incubated with Vif, Vpu or Nef antigens for 3 days and assayed for IL-4 and
IFN-gamma levels
• Antigen stimulation increased IFN-gamma production in pVVN-P immunized mice, indicating a Th1 response
• IL-4 production was not significantly changed after antigen stimulation compared to control levels
• Cross-clade CTL activity was also observed: A, B clade, CRF01(AE) clade antigens could serve as targets for the B clade immunization stimulated CTL –
an HIV-1 AC recombinant, however, did not stimulate a CTL response, but was expressed at lower levels on the target cell
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HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
gp160 (30–51) gp120 (30–51 IIIB) ATEKLWVTVYYGVPVWKEA-
TTT?
HIV-1 infection human Geretti1994
• Epitope name: A1
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 2/15 responders recognized this peptide, mean SI = 4.6.
gp160 (32–44) gp120 (39–51) EQLWVTVYYGVPV Vaccine murine (H-2bxk) Sastry1991
Vaccine Vector/Type: peptide
• Peptides induced T-cell proliferative response to immunizing peptide and to gp160
gp160 (38–48) Env (45–55) VYYGVPVWKEA Vaccine Rhesus macaque Nehete1993
Vaccine Vector/Type: peptide
• Synthetic peptide derived from conserved region of the HIV-1 envelope that stimulates a proliferative response in mice
• Proliferative response to this peptide was observed in 3/3 immunized rhesus monkeys
gp160 (38–48) Env (45–55) VYYGVPVWKEA HIV-1 infection human, chimpanzee Nehete1998b
• Seven out of nine HIV-infected chimpanzees and eight out of seventeen HIV-positive humans exhibited positive proliferative responses to this conserved
peptide (peptide 104) – no HIV negative individuals showed a response
• This peptide, along with 4 other peptides from conserved regions of envelope, can induce proliferative responses to HIV and may be useful for vaccines
• Peptide 104 elicited proliferative responses in inbred mouse strains and outbred rhesus monkeys in previous study by same group
gp160 (38–48) gp120 (45–55) VYYGVPVWKEA Vaccine murine (H-2bxk,sxd) Sastry1991
Vaccine Vector/Type: peptide
• Peptides induced T-cell proliferative response to immunizing peptide and to gp160
gp160 (41–54) Env (48–60) GVPVWKEATTLFC Vaccine Rhesus macaque Nehete1993
Vaccine Vector/Type: peptide
• Synthetic peptide derived from conserved region of the HIV-1 envelope that stimulates a proliferative response in mice
• Despite the proliferative response to this peptide in mice, no response was observed in 3 rhesus monkeys
gp160 (41–54) gp120 (48–61) GVPVWKEATTLFC Vaccine murine (H-2sxd) Sastry1991
Vaccine Vector/Type: peptide
• Peptides induced T-cell proliferative response to immunizing peptide and to gp160
gp160 (41–60) gp120 (40–59 89.6) GVPVWREATTTLFCASDAKA Vaccine murine Dai2001
Vaccine Vector/Type: recombinant protein Strain: 89.6 HIV component: gp120 Adjuvant: R192G mutant heat-labile toxin from enterotoxigenic E.
coli (mLT)
• Epitope name: Peptide 2
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• Helper T-cell proliferative responses to gp120 vaccines in 2 mouse strains, CBA/J and BALB/c, were mapped using 47 overlapping peptides that span
gp120. Promiscuously immunodominant peptides were identified in both mice strains that were located in the outer domain of gp120 and were associated
with regions of local structural disorder in proximal N-terminal segments, suggesting 3-D protein structure influences Th antigen processing and the
frequency of immunogenic sequences.
• This peptide was highly reactive in 10/10 BALB/c mice tested, but only in 5/10 CBA/J mice.
gp160 (41–60) gp120 (40–59 89.6) GVPVWREATTTLFCASDAKA Vaccine murine (H-2d) Dai2001
Vaccine Vector/Type: recombinant protein Strain: 89.6 HIV component: gp120 Adjuvant: mutant R192G heat-labile toxin from E. coli as adjuvant
• Promiscuous immunodominant epitopes in gp120 were mapped by overlapping peptides in CBA/J H-2k and BALB/c H-2d mice, and all were found to be
in the outer domain, proximal to regions of structural disorder indicated by the crystal structure or by sequence divergence.
• This peptide was recognized by 10/10 BALB/c with an average SI of 6.4, the strongest reaction among BALB/c mice, but not by CBA/J mice, but
recognized well not by CBA/J mice, so is considered to be uniquely immunodominant for H-2d
• Uniquely immunodominant sequences tended to be in the inner domain of the protein
gp160 (42–61) gp120 (42–61 IIIB) VPVWKEATTTLFCASDAKA-
Y?
HIV-1 infection human Geretti1994
• Epitope name: A2
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 2/15 responders recognized this peptide, mean SI = 6.6.
gp160 (52–71) gp120 (52–71 IIIB) LFCASDAKAYDTEVHNVWA-
T?
HIV-1 infection human Geretti1994
• Epitope name: A3
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 3/15 responders recognized this peptide, mean SI = 4.3.
gp160 (61–80) gp120 (60–79 89.6) YDTEVHNVWATHACVPTDPN Vaccine murine Dai2001
Vaccine Vector/Type: recombinant protein Strain: 89.6 HIV component: gp120 Adjuvant: R192G mutant heat-labile toxin from enterotoxigenic E.
coli (mLT)
• Epitope name: Peptide 4
• Helper T-cell proliferative responses to gp120 vaccines in 2 mouse strains, CBA/J and BALB/c, were mapped using 47 overlapping peptides that span
gp120. Promiscuously immunodominant peptides were identified in both mice strains that were located in the outer domain of gp120 and were associated
with regions of local structural disorder in proximal N-terminal segments, suggesting 3-D protein structure influences Th antigen processing and the
frequency of immunogenic sequences.
• This peptide was highly reactive in 4/10 BALB/c mice tested, but only in 1/10 CBA/J mice.
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gp160 (62–80) gp120 (62–80 IIIB) DTEVHNVWATHACVPTDPN? HIV-1 infection human Geretti1994
• Epitope name: A4
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 1/15 responders recognized this peptide, SI = 3.5.
gp160 (65–75) gp120 (72–82) AHKVWATHACV Vaccine murine (H-2bxk,sxd) Sastry1991
Vaccine Vector/Type: peptide
• Peptides induced T-cell proliferative response to immunizing peptide and to gp160
gp160 (74–85) gp120 (74–85 LAI) CVPTDPNPQEVV HIV-1 infection human Schrier1989
• Stimulates T-cell proliferation in HIV-infected donors
gp160 (74–85) gp120 (81–92) CVPTNPVPQEVV Vaccine murine (H-2bxk,sxd) Sastry1991
Vaccine Vector/Type: peptide
• Peptides induced T-cell proliferative response to immunizing peptide and to gp160
gp160 (80–99) gp120 (51–70 HXB2) NPQEVVLVNTENFNMWKND in vitro stimulation human Li Pira1998
• Clonal heterogeneity was broad for a recall response to tetanus toxoid or PPD, but oligoclonal to primary HIV antigens, dominated in this case by TCR Vβ
13 usage
• Donor of PBMC that recognized this epitope had HLA-DR alleles 2 and 7
gp160 (81–100) gp120 (80–99 89.6) PQEVVLGNVTENFNMWKNNM Vaccine murine Dai2001
Vaccine Vector/Type: recombinant protein Strain: 89.6 HIV component: gp120 Adjuvant: R192G mutant heat-labile toxin from enterotoxigenic E.
coli (mLT)
• Epitope name: Peptide 6
• Helper T-cell proliferative responses to gp120 vaccines in 2 mouse strains, CBA/J and BALB/c, were mapped using 47 overlapping peptides that span
gp120. Promiscuously immunodominant peptides were identified in both mice strains that were located in the outer domain of gp120 and were associated
with regions of local structural disorder in proximal N-terminal segments, suggesting 3-D protein structure influences Th antigen processing and the
frequency of immunogenic sequences.
• This peptide was not reactive in any BALB/c mice tested (0/10), but was highly reactive in all (10/10) CBA/J mice.
gp160 (81–100) gp120 (80–99 89.6) PQEVVLGNVTENFNMWKNNM Vaccine murine (H-2k) Dai2001
Vaccine Vector/Type: recombinant protein Strain: 89.6 HIV component: gp120 Adjuvant: mutant R192G heat-labile toxin from E. coli as adjuvant
• Promiscuous immunodominant epitopes in gp120 were mapped by overlapping peptides in CBA/J H-2k and BALB/c H-2d mice, and all were found to be
in the outer domain, proximal to regions of structural disorder indicated by the crystal structure or by sequence divergence.
• This peptide was recognized by 10/10 CBA/J with an average SI of 8.2, and not by BALB/c mice, so is considered to be uniquely immunodominant for H-2k
• Uniquely immunodominant sequences tended to be in the inner domain of the protein
gp160 (81–101) gp120 (81–101 IIIB) PQEVVLVNVTENFNMWKND-
MV?
HIV-1 infection human Geretti1994
• Epitope name: B1
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• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 2/15 responders recognized this peptide, mean SI = 5.1.
gp160 (92–101) gp120 (90–100 W6.ID) YFNMWKNNMV Vaccine human Jones1999
Vaccine Vector/Type: recombinant protein Strain: W61D HIV component: gp120 Adjuvant: QS21/MPL adjuvant
• An HIV seronegative volunteer was vaccinated with rgp120 and a QS21/MPL adjuvant and HIV-1 specific T-cell lines were isolated
• One T-cell clone reacts with two overlapping peptides, and the region of overlap is: YFNMWKNNMV
• The first 20-mer peptide that this clone reacts with is PQEVVLGNVTEYFNMWKNNMV, and the IIIB version of this peptide does not induce proliferation
in the T-cell line that responds to the W61D version: IIIB: pqevvlVnvteNfDmwknDmv.
gp160 (92–111) gp120 (92–111 W6.ID) YFNMWKNNMVDQMHEDIISL Vaccine human Jones1999
Vaccine Vector/Type: recombinant protein Strain: W61D HIV component: gp120 Adjuvant: QS21/MPL adjuvant
• An HIV seronegative volunteer was vaccinated with rgp120 and a QS21/MPL adjuvant and HIV-1 specific T-cell lines were isolated
• The IIIB version of this peptide does not induce proliferation in the T-cell line that responds to the W61D version of the peptide NfDmwknDmvEqmhediisl.
• Six T-cell lines react with this peptide, but some of these can also be stimulated by other gp120 peptides located in different regions of gp120
gp160 (101–126) gp120 (101–126) VEQMHEDIISLWDQSLKPC-
VKLTPLC
Vaccine murine (H-2k) Sjolander1996
Vaccine Vector/Type: recombinant protein HIV component: gp160
• Study showing that T-cell determinants from glycoproteins can be dependent on the glycosylation of the protein
gp160 (102–114) gp120 (109–121) EQMHEDIISLWDQ Vaccine murine (H-2bxk) Sastry1991
Vaccine Vector/Type: peptide
• Peptides induced T-cell proliferative response to immunizing peptide and to gp160
gp160 (102–116) gp160 (109–123 IIIB) EQMHEDIISLWDQSL Vaccine murine (H-2d , H-2b) Berzofsky1991b,
Berzofsky1991a
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160 Adjuvant: Freund’s adjuvant
• B10.D2 (H-2Ad , Ed) and B10.A(R5) (H-2Ab, Eb) mice immunized with rec gp160 showed a proliferative response to EQMHEDIISLWDQSL
• EQMHEDIISLWDQSLKPCVK encompasses several murine Th epitopes including HEDIISLWDQSLK and is referred to as a "multideterminant region"
or cluster peptide
gp160 (102–116) gp120 (109–123 IIIB) EQMHEDIISLWDQSL Vaccine murine (H-2d,i5) Hale1989
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160
• Six multideterminant helper T-cell regions are recognized by mice of three or four MHC types
gp160 (102–121) gp120 (102–121 IIIB) EQMHEDIISLWDQSLKPCV-
K?
HIV-1 infection human Geretti1994
• Epitope name: B3
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
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• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 1/15 responders recognized this peptide, SI = 5.9.
gp160 (102–121) gp160 (109–128 IIIB) EQMHEDIISLWDQSLKPCVK HIV-1 infection, Vaccine human, murine (H-2k,
H-2s)
Berzofsky1991b,
Berzofsky1991a
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160 Adjuvant: Freund’s adjuvant
• EQMHEDIISLWDQSLKPCVK encompasses several murine Th epitopes and is referred to as a "multideterminant region" or cluster peptide
• Six multideterminant region cluster peptides were evaluated Th responses in different MHC/HLA backgrounds after vaccination of mice with gp160, or in
infected people
• This cluster peptide elicited proliferative responses in cells from vaccinated B10.BR mice (H-2Ak, Ek) and B10.S(9R) mice (H-2As, Es), while shorter
peptides from within this region stimulated H-2k, H-2d and H-2b responses, but not H-2s
• IL-2 production was observed in response to this peptide in 64% (23/36) of asymptomatic HIV-infected individuals
gp160 (105–117) gp120 (112–124 IIIB) HEDIISLWDQSLK HIV-1 infection human Clerici1997
• Epitope name: T2
• Used in a study of pentoxifylline’s influence on HIV specific T-cells
gp160 (105–117) gp120 (112–124 BH10) HEDIISLWDQSLK Vaccine human Berzofsky1988
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: gp160
• Epitope name: T2
• Proliferative response to T1 and T2 peptides in 14 immunized, uninfected humans
gp160 (105–117) gp120 (112–124 IIIB) HEDIISLWDQSLK HIV-1 infection human Clerici1989
• Epitope name: T2
• IL-2 production detection of Th lymphocytes from asymptomatic HIV-positive individuals
gp160 (105–117) gp120 (112–124 IIIB) HEDIISLWDQSLK HIV-1 infection human Clerici1991a
• Epitope name: T2
• Peptides stimulate Th cell function and CTL activity in similar patient populations
gp160 (105–117) gp120 (112–124) HEDIISLWDQSLK Vaccine human Clerici1991b
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160
• Epitope name: T2
• Immunizing uninfected individuals with rgp160 results in stronger Th response than does natural infection
gp160 (105–117) gp120 (112–124 IIIB) HEDIISLWDQSLK human Clerici1992
• Epitope name: T2
• Cell-mediated immune response to HIV-1 peptides in HIV-1 exposed seronegative men
gp160 (105–117) gp120 (112–124 IIIB) HEDIISLWDQSLK Vaccine Rhesus macaque Hosmalin1991
Vaccine Vector/Type: peptide prime with protein boost Strain: IIIB HIV component: gp160
• Epitope name: T2
• Peptide priming to induce T-cell help enhances antibody response to gp160 immunization
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gp160 (105–117) gp120 (112–124 IIIB) HEDIISLWDQSLK human Pinto1995
• Epitope name: T2
• CTL activity analyzed in parallel with Th reactivity in exposed but uninfected health care workers
gp160 (105–117) gp120 (112–124 IIIB) HEDIISLWDQSLK HIV-1 infection human Kaul1999
• Epitope name: T2
• Kenyan sex workers that remained seronegative were found to frequently have HIV-env peptide specific Th responses detected by an IL-2 assay (11/20
cases) and mucosal genital tract anti-HIV IgA (16/21 cases)
• Helper epitopes used in this study were noted to be previously described [Clerici1989], and were not explicitly described in [Kaul1999]
gp160 (105–117) gp120 HEDIISLWDQSLK HIV-1 infection, HIV-1 exposed
seronegative
human Kuhn2001
• Epitope name: T2
• In a S. African perinatal transmission study, 33% (33/86) of cord blood samples from infants with seropositive mothers produced T-helper responses
(measured by a bioassay measuring IL2 production in a murine cell line and confirmed with a proliferation assay) against a peptide cocktail containing Th
epitopes P18 MN, P18 IIIB, T1, T2, and TH4
• The mothers were predominantly infected with subtype C, but the T help response was detectable in a number of cord blood samples despite using peptides
based on B subtype reagents.
• 3/33 infants with cord blood T help responses to Env were infected in utero, 2/33 were lost to follow up, and 28/33 were not infected. 6/53 of the infants
with cord blood that was unresponsive to Env peptide stimulation were infected before delivery, and 8/47 contracted HIV intrapartum or via breast-feeding.
• Measurable HIV specific T help responses elicited in the immunologically immature newborn, possibly in response to in utero exposure, are associated
with a protective natural immunity that helps block mother-infant transmission of HIV-1.
gp160 (105–117) gp120 (112–124 IIIB) HEDIISLWDQSLK Vaccine murine (H-2k) Hale1989
Vaccine Strain: IIIB HIV component: gp160
• Epitope name: T2
• Six multideterminant helper T-cell regions are recognized by mice of three or four MHC types
gp160 (105–117) gp160 (112–124 IIIB) HEDIISLWDQSLK Vaccine murine (H-2k) Berzofsky1991b,
Berzofsky1991a
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160 Adjuvant: Freund’s adjuvant
• B10.BR (H-2Ak, Ek) mice immunized with rec gp160 showed a strong proliferative response to three overlapping peptides, QMHEDIISLWDQSL,
HEDIISLWDQSLK, and DIISLWDQSLKPCVK, and HEDIISLWDQSLK is common to between them
• EQMHEDIISLWDQSLKPCVK encompasses several murine Th epitopes including HEDIISLWDQSLK and is referred to as a "multideterminant region"
or cluster peptide
gp160 (105–117) gp120 (112–124 BH10) HEDIISLWDQSLK computer prediction murine (H-2k,s) Cease1987
• Epitope name: T2
• 1 of 2 functional epitopes identified using an amphipathic helix epitope prediction algorithm
gp160 (105–123) gp120 (112–130 IIIB) HEDIISLWDQSLKPCVKLT human Furci1997
• 9/11 exposed-uninfected individuals in this study had a proliferative response to a C5 peptide, but none reacted with this previously defined epitope
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gp160 (108–119) gp120 (108–119 LAI) IISLWDQSLKPC HIV-1 infection human Schrier1989
• Stimulates T-cell proliferation in HIV-infected donors
gp160 (110–125) gp120 (110–125) SLWDQSLKPCVKLTPL HIV-1 infection human Caruso1997
• As HIV-1-infected individuals progress to disease, T-cells show reduced ability to proliferate in response to HIV antigen, but retain the ability to express the
activation antigens CD25 and CD71
• The ability to express activation markers in response to HIV is retained, but the response to tetanus toxoid recall antigen is lost
• This study investigated CD25 and CD71 expression in PBMC from patients at various stages of progression, measuring the response to in vitro stimulation
by peptide cocktail containing four antigenic Env peptides, or p17 and p24
gp160 (111–123) gp120 (118–130) LWDQSLKPCVKLT Vaccine Rhesus macaque Nehete1993
Vaccine Vector/Type: peptide
• Synthetic peptide derived from conserved region of the HIV-1 envelope that stimulates a proliferative response in mice
• Proliferative response to this peptide was observed in 3/3 immunized rhesus monkeys
gp160 (112–130) gp120 (112–130 IIIB) WDQSLKPCVKLTPLCVSLK? HIV-1 infection human Geretti1994
• Epitope name: B4
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 3/15 responders recognized this peptide, average SI = 4.4.
gp160 (112–141) gp120 (112–141 NL43) WDQSLKPCVKLTPLCVSLK-
CTDLGNATNTN
Vaccine human Sitz1999
Vaccine Vector/Type: recombinant protein Strain: NL43 HIV component: gp120, gp160
• There was a great breadth of proliferative response to env peptides in 19 HIV-1 infected rgp160 and 17 HIV-1 infected rgp120 vaccine recipients
• Over 35% of vaccinees had a stimulation index of greater than 5 to this peptide
gp160 (115–126) gp120 (115–126 LAI) SLKPCVKLTPLC HIV-1 infection human Schrier1989
• Stimulates T-cell proliferation in HIV-infected donors
gp160 (115–129) gp120 (115–129 LAI) SLKPCVKLTPLCVSL Peptide-HLA interaction human (HLA-DR) Gaudebout1997
• Peptide bound to both HLA-DR*1101 and HLA-DR*0401 with high affinity
• Because of the distinctive binding pockets of HLA-DR*1101 and HLA-DR*0401, peptides that bound both were considered candidates for promiscuous
HLA-DR binding
gp160 (121–140) gp120 (120–139 89.6) KLTPLCVTLNCTNLNITKNT Vaccine murine Dai2001
Vaccine Vector/Type: recombinant protein Strain: 89.6 HIV component: gp120 Adjuvant: R192G mutant heat-labile toxin from enterotoxigenic E.
coli (mLT)
• Epitope name: Peptide 10
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• Helper T-cell proliferative responses to gp120 vaccines in 2 mouse strains, CBA/J and BALB/c, were mapped using 47 overlapping peptides that span
gp120. Promiscuously immunodominant peptides were identified in both mice strains that were located in the outer domain of gp120 and were associated
with regions of local structural disorder in proximal N-terminal segments, suggesting 3-D protein structure influences Th antigen processing and the
frequency of immunogenic sequences.
• This peptide was highly reactive in 5/10 BALB/c mice tested, but not in and (0/10) CBA/J mice.
gp160 (121–141) gp120 (131–151 IIIB) KLTPLCVSLKCTDLKNDTN-
TN?
HIV-1 infection human Geretti1994
• Epitope name: C1
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 3/15 responders recognized this peptide, average SI = 3.9.
gp160 (122–141) gp120 (121–140 MN) LTPLCVTLNCTDLRNTTNTN Vaccine guinea pig Chattergoon2002
Vaccine Vector/Type: protein, DNA Strain: MN HIV component: gp120 Adjuvant: complete Freund’s adjuvant (CFA)
• Epitope name: 1931
• Hartley guinea pigs were intradermally injected with either recombinant protein or plasmid expressed gp120 and monitored for delayed type hypersensivity
(DTH) responses after vaccination, which are related to Th1 T-cell responses. CFA did not augment responses in animals vaccinated with plasmid.
• A total of 7 gp120 peptides elicited a delayed type hypersensivity (DTH) response after vaccination, out of a set of 60 overlapping peptides that spanned
gp120. The vaccine delivery system, DNA versus rec protein, resulted in the recognition of distinct peptides.
• 3/5 animals vaccinated with rec gp120 responded by DTH to this peptide, while 0/6 vaccinated with plasmid gp120 DNA responded.
gp160 (122–141) gp120 (122–141 IIIB) LTPLCVSLKCTDLKNDTNT-
N?
HIV-1 infection human Geretti1994
• Epitope name: B5
•
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• 1/15 responders recognized this peptide, SI = 3.1.
gp160 (136–155) gp120 (141–160 MN) NSTAWNNSNSEGTIKGGEMK Vaccine guinea pig Chattergoon2002
Vaccine Vector/Type: protein, DNA Strain: MN HIV component: gp120 Adjuvant: complete Freund’s adjuvant (CFA)
• Epitope name: 1932
• Hartley guinea pigs were intradermally injected with either recombinant protein or plasmid expressed gp120 and monitored for delayed type hypersensivity
(DTH) responses after vaccination, which are related to Th1 T-cell responses. CFA did not augment responses in animals vaccinated with plasmid.
• A total of 7 gp120 peptides elicited a delayed type hypersensivity (DTH) response after vaccination, out of a set of 60 overlapping peptides that spanned
gp120. The vaccine delivery system, DNA versus rec protein, resulted in the recognition of distinct peptides.
• 4/5 animals vaccinated with rec gp120 responded by DTH to this peptide, as did 2/6 vaccinated with plasmid gp120 DNA.
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gp160 (138–159) gp120 (141–160 W6.ID) TTSNGWTGEIRKGEIKNCSF Vaccine human Jones1999
Vaccine Vector/Type: recombinant protein Strain: W61D HIV component: gp120 Adjuvant: QS21/MPL adjuvant
• An HIV seronegative volunteer was vaccinated with rgp120 and a QS21/MPL adjuvant and HIV-1 specific T-cell lines were isolated
• The IIIB version of this peptide does not induce proliferation in the T-cell line that responds to the W61D version of the peptide: IIIB:
ttsnSSGRMIMEgeikncsf.
gp160 (142–161) gp120 (142–161 IIIB) SSSGRMIMEKGEIKNCSFN-
I?
HIV-1 infection human Geretti1994
• Epitope name: C2
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• Five peptides were recognized most frequently: C2 (aa 142-161), C3 (aa 152-171), C5 (aa 172-191), E5 (aa 272-291) and G4 (aa 380-393). The first three
were in or near V2, the other two were proximal to the V3 and V4 loops.
• 4/15 responders recognized this immunodominant peptide, average SI = 4.3.
gp160 (147–168) gp120 (152–173 NL43) MMMEKGEIKNCSFNISTSI-
RGK
Vaccine human Sitz1999
Vaccine Vector/Type: recombinant protein Strain: NL43 HIV component: gp120, gp160
• There was a great breadth of proliferative response to env peptides in 19 HIV-1 infected rgp160 and 17 HIV-1 infected rgp120 vaccine recipients
• Over 50% of vaccinees had a stimulation index of greater than 5 to this peptide
gp160 (152–171) gp120 (152–171 IIIB) GEIKNCSFNISTSIRGKVQ-
K?
HIV-1 infection human Geretti1994
• Epitope name: C3
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• Five peptides were recognized most frequently: C2 (aa 142-161), C3 (aa 152-171), C5 (aa 172-191), E5 (aa 272-291) and G4 (aa 380-393). The first three
were in or near V2, the other two were proximal to the V3 and V4 loops.
• 4/15 responders recognized this immunodominant peptide, average SI = 4.4.
gp160 (155–169) Env (UG92005) KNCSFNITTELIDKK Vaccine murine (H-2 IAb) Surman2001
Vaccine Vector/Type: DNA, vaccinia, recombinant protein Strain: 1007 (clade B), UG92005 (clade D) HIV component: gp140 Adjuvant: Freund’s
adjuvant
• This epitope is located in the V2 region of UG92005 (UG, clade D) and the hybridoma that recognized it used Vβ5
• C57BL/6 mice were immunized with a prime-boost strategy involving three HIV-1 Env antigens: Mice were primed with DNA given i.m., 3-4 weeks later
boosted with VV, and 3-4 weeks later boosted again with purified protein in Freund’s adjuvant
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• The vaccinia construct is a pSC11-based VV vector with the first 38 amino acids contributed by BH10 and the rest of gp120 and gp41 by the vaccine strain,
the DNA construct is in the pJW4303 vector with a CMV promotor, and the purified protein is expressed from the pJW4303 vector transfected into
CHO-K1 cells
• Ten days after the final boost, hybridomas were made and tested for IL-2 production using either B6 spleen cells or H-2 IAb transfected L cells as targets
and Vβ usage was determined
• Mice were immunized with an Env from either one of two clades: HIV-1 1007, a clade B strain isolated from an individual from Memphis Tennesee, and
HIV-1 92UG005, a clade D vaccine isolated from Uganda in 1992 through the WHO
• 80 unique clonotypes were characterized from six mice
• H-2 IAb restricted T-helper epitopes were concentrated in 5 distinct regions within the Env sequence (2 clonotype responses in V2, 26 in C2, 22 in V3, 23
in V4C4, and 7 in gp41).
• Epitope hotspots tended to be proximal to heavily glycosylated regions of the Env sequence, in exposed, non-helical strands of the protein. The
non-uniform localization may be influenced by differential antigen processing and the glycosylation site proximity may allow binding to lectins and
promote trafficking through processing pathways.
gp160 (155–169) gp120 (160–174 LAI) KNCSFNISTSIRGKV human (HLA-DR) Gaudebout1997
• Peptide binds to both HLA-DR*1101 and HLA-DR*0401 with high affinity
• Because of the distinctive binding pockets of HLA-DR*1101 and HLA-DR*0401, peptides that bound both were considered candidates for promiscuous
HLA-DR binding
gp160 (159–178) gp120 (160–179 89.6) FYITTSIRNKVKKEYALFNR Vaccine murine Dai2001
Vaccine Vector/Type: recombinant protein Strain: 89.6 HIV component: gp120 Adjuvant: R192G mutant heat-labile toxin from enterotoxigenic E.
coli (mLT)
• Epitope name: Peptide 14
• Helper T-cell proliferative responses to gp120 vaccines in 2 mouse strains, CBA/J and BALB/c, were mapped using 47 overlapping peptides that span
gp120. Promiscuously immunodominant peptides were identified in both mice strains that were located in the outer domain of gp120 and were associated
with regions of local structural disorder in proximal N-terminal segments, suggesting 3-D protein structure influences Th antigen processing and the
frequency of immunogenic sequences.
• This peptide was highly reactive in 6/10 BALB/c mice tested, and in 4/10 CBA/J mice.
gp160 (162–181) gp120 (162–181 IIIB) STSIRGKVQKEYAFFYKLDI Vaccine Rhesus macaque Lekutis1997b
Vaccine Vector/Type: DNA Strain: IIIB HIV component: ENV
• HIV-1 env DNA vaccine induced Th cell response to this epitope in a rhesus monkeys
gp160 (162–182) gp120 (162–182 IIIB) STSIRGKVQKEYAFFYKLD-
II?
HIV-1 infection human Geretti1994
• Epitope name: C4
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 1/15 responders recognized this peptide, SI = 3.3.
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gp160 (169–189) gp120 (141–160 W6.ID) VQKEYALFYNLDVVPIDDD-
NA
Vaccine human Jones1999
Vaccine Vector/Type: recombinant protein Strain: W61D HIV component: gp120 Adjuvant: QS21/MPL adjuvant
• An HIV seronegative volunteer was vaccinated with rgp120 and a QS21/MPL adjuvant and HIV-1 specific T-cell lines were isolated
• The IIIB version of this peptide does not induce proliferation in the T-cell line that responds to the W61D version of the peptide ——F–K–II—N-TT
vqkeyaFfyKldIIpidNdTT.
• Two T-cell lines react specifically with this peptide
gp160 (172–191) gp120 (172–191 IIIB) EYAFFYKLDIIPIDNDTTSY Vaccine Rhesus macaque Lekutis1997b
Vaccine Vector/Type: DNA Strain: IIIB HIV component: ENV
• HIV-1 env DNA vaccine induced Th cell response to this epitope in a rhesus monkey
gp160 (172–191) gp120 (172–191 IIIB) EYAFFYKLDIIPIDNDTTS-
Y?
HIV-1 infection human Geretti1994
• Epitope name: C5
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• Five peptides were recognized most frequently: C2 (aa 142-161), C3 (aa 152-171), C5 (aa 172-191), E5 (aa 272-291) and G4 (aa 380-393). The first three
were in or near V2, the other two were proximal to the V3 and V4 loops.
• 4/15 responders recognized this immunodominant peptide, average SI = 7.4.
gp160 (175–189) Env (UG92005) LFYKLDVVQIDNSTN Vaccine murine (H-2 IAb) Surman2001
Vaccine Vector/Type: DNA, vaccinia, recombinant protein Strain: 1007 (clade B), UG92005 (clade D) HIV component: gp140 Adjuvant: Freund’s
adjuvant
• This epitope is located in the V2 region of UG92005 (UG, clade D) and the Vβ usage of the TCR was not determined
• C57BL/6 mice were immunized with a prime-boost strategy involving three HIV-1 Env antigens: Mice were primed with DNA given i.m., 3-4 weeks later
boosted with VV, and 3-4 weeks later boosted again with purified protein in Freund’s adjuvant
• The vaccinia construct is a pSC11-based VV vector with the first 38 amino acids contributed by BH10 and the rest of gp120 and gp41 by the vaccine strain,
the DNA construct is in the pJW4303 vector with a CMV promotor, and the purified protein is expressed from the pJW4303 vector transfected into
CHO-K1 cells
• Ten days after the final boost, hybridomas were made and tested for IL-2 production using either B6 spleen cells or H-2 IAb transfected L cells as targets
and Vβ usage was determined
• Mice were immunized with an Env from either one of two clades: HIV-1 1007, a clade B strain isolated from an individual from Memphis Tennesee, and
HIV-1 92UG005, a clade D vaccine isolated from Uganda in 1992 through the WHO
• 80 unique clonotypes were characterized from six mice
• H-2 IAb restricted T-helper epitopes were concentrated in 5 distinct regions within the Env sequence (2 clonotype responses in V2, 26 in C2, 22 in V3, 23
in V4C4, and 7 in gp41).
477
DEC 2002
T-
H
el
pe
r
HIV Helper T-Cell Epitope Tables gp160 Helper T-Cell Epitopes
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
• Epitope hotspots tended to be proximal to heavily glycosylated regions of the Env sequence, in exposed, non-helical strands of the protein. The
non-uniform localization may be influenced by differential antigen processing and the glycosylation site proximity may allow binding to lectins and
promote trafficking through processing pathways.
gp160 (186–215) gp120 (191–220 NL43) NDTTSYTLTSCNTSVITQA-
CPKVSFEPIPI
Vaccine human Sitz1999
Vaccine Vector/Type: recombinant protein Strain: NL43 HIV component: gp120, gp160
• There was a great breadth of proliferative response to env peptides in 19 HIV-1 infected rgp160 and 17 HIV-1 infected rgp120 vaccine recipients
• Over 30% of vaccinees had a stimulation index of greater than 5 to this peptide
gp160 (188–207) gp120 (89.6) NTKYRLISCNTSVITQACPK Vaccine murine Dai2001
Vaccine Vector/Type: recombinant protein Strain: 89.6 HIV component: gp120 Adjuvant: R192G mutant heat-labile toxin from enterotoxigenic E.
coli (mLT)
• Epitope name: Peptide 17
• Helper T-cell proliferative responses to gp120 vaccines in 2 mouse strains, CBA/J and BALB/c, were mapped using 47 overlapping peptides that span
gp120. Promiscuously immunodominant peptides were identified in both mice strains that were located in the outer domain of gp120 and were associated
with regions of local structural disorder in proximal N-terminal segments, suggesting 3-D protein structure influences Th antigen processing and the
frequency of immunogenic sequences.
• This peptide was reactive in only 1/10 BALB/c mice tested, but was one of the most reactive in CBA/J mice, reacting with 9/10 mice.
gp160 (188–207) gp120 (190–209 89.6) NTKYRLISCNTSVITQACPK Vaccine murine (H-2k) Dai2001
Vaccine Vector/Type: recombinant protein Strain: 89.6 HIV component: gp120 Adjuvant: mutant R192G heat-labile toxin from E. coli as adjuvant
• Promiscuous immunodominant epitopes in gp120 were mapped by overlapping peptides in CBA/J H-2k and BALB/c H-2d mice, and all were found to be
in the outer domain, proximal to regions of structural disorder indicated by the crystal structure or by sequence divergence.
• This peptide was recognized by 9/10 CBA/J with an average SI of 9.8, one of the two immunodominant peptides in CBA/J mice, and not by BALB/c mice,
so is considered to be uniquely immunodominant for H-2k
• Uniquely immunodominant sequences tended to be in the inner domain of the protein
gp160 (192–211) gp120 (192–211 IIIB) KLTSCNTSVITQACPKVSF-
E?
HIV-1 infection human Geretti1994
• Epitope name: D2
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 1/15 responders recognized this peptide, SI = 3.6.
gp160 (193–218) gp120 (193–218) LTSCNSVITQACPKVSFEP-
IPIHYC
Vaccine murine (H-2d,b) Sjolander1996
Vaccine Vector/Type: recombinant protein HIV component: gp160
• Study showing that T-cell determinants from glycoproteins can be dependent on the glycosylation of the protein
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gp160 (198–212) Env (1007) TSVITQACPKVSFEP Vaccine murine (H-2 IAb) Surman2001
Vaccine Vector/Type: DNA, vaccinia, recombinant protein Strain: 1007 (clade B), UG92005 (clade D) HIV component: gp140 Adjuvant: Freund’s
adjuvant
• This epitope is located in the C2 region of 1007 (US, clade B) and the Vβ usage of the TCRs for two clonotypes was Vβ3 and Vβ8.1-2
• C57BL/6 mice were immunized with a prime-boost strategy involving three HIV-1 Env antigens: Mice were primed with DNA given i.m., 3-4 weeks later
boosted with VV, and 3-4 weeks later boosted again with purified protein in Freund’s adjuvant
• The vaccinia construct is a pSC11-based VV vector with the first 38 amino acids contributed by BH10 and the rest of gp120 and gp41 by the vaccine strain,
the DNA construct is in the pJW4303 vector with a CMV promotor, and the purified protein is expressed from the pJW4303 vector transfected into
CHO-K1 cells
• Ten days after the final boost, hybridomas were made and tested for IL-2 production using either B6 spleen cells or H-2 IAb transfected L cells as targets
and Vβ usage was determined
• Mice were immunized with an Env from either one of two clades: HIV-1 1007, a clade B strain isolated from an individual from Memphis Tennesee, and
HIV-1 92UG005, a clade D vaccine isolated from Uganda in 1992 through the WHO
• 80 unique clonotypes were characterized from six mice
• H-2 IAb restricted T-helper epitopes were concentrated in 5 distinct regions within the Env sequence (2 clonotype responses in V2, 26 in C2, 22 in V3, 23
in V4C4, and 7 in gp41).
• Epitope hotspots tended to be proximal to heavily glycosylated regions of the Env sequence, in exposed, non-helical strands of the protein. The
non-uniform localization may be influenced by differential antigen processing and the glycosylation site proximity may allow binding to lectins and
promote trafficking through processing pathways.
gp160 (198–215) Env (1007) TSVITQACPKVSFEPIPI Vaccine murine (H-2 IAb) Surman2001
Vaccine Vector/Type: DNA, vaccinia, recombinant protein Strain: 1007 (clade B), UG92005 (clade D) HIV component: gp140 Adjuvant: Freund’s
adjuvant
• This epitope is located in the C2 region of 1007 (US, clade B) and the Vβ usage of the TCR was Vβ6
• C57BL/6 mice were immunized with a prime-boost strategy involving three HIV-1 Env antigens: Mice were primed with DNA given i.m., 3-4 weeks later
boosted with VV, and 3-4 weeks later boosted again with purified protein in Freund’s adjuvant
• The vaccinia construct is a pSC11-based VV vector with the first 38 amino acids contributed by BH10 and the rest of gp120 and gp41 by the vaccine strain,
the DNA construct is in the pJW4303 vector with a CMV promotor, and the purified protein is expressed from the pJW4303 vector transfected into
CHO-K1 cells
• Ten days after the final boost, hybridomas were made and tested for IL-2 production using either B6 spleen cells or H-2 IAb transfected L cells as targets
and Vβ usage was determined
• Mice were immunized with an Env from either one of two clades: HIV-1 1007, a clade B strain isolated from an individual from Memphis Tennesee, and
HIV-1 92UG005, a clade D vaccine isolated from Uganda in 1992 through the WHO
• 80 unique clonotypes were characterized from six mice
• H-2 IAb restricted T-helper epitopes were concentrated in 5 distinct regions within the Env sequence (2 clonotype responses in V2, 26 in C2, 22 in V3, 23
in V4C4, and 7 in gp41).
• Epitope hotspots tended to be proximal to heavily glycosylated regions of the Env sequence, in exposed, non-helical strands of the protein. The
non-uniform localization may be influenced by differential antigen processing and the glycosylation site proximity may allow binding to lectins and
promote trafficking through processing pathways.
gp160 (199–211) Env (204–216) SVITQACSKVSFE Vaccine Rhesus macaque Nehete1993
Vaccine Vector/Type: peptide
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• Synthetic peptide derived from conserved region of the HIV-1 envelope that stimulates a proliferative response in mice
• A weak or transient proliferative response to this peptide was observed in 3/3 immunized rhesus monkeys
gp160 (199–211) Env (204–216) SVITQACSKVSFE HIV-1 infection human, chimpanzee Nehete1998b
• HIV-infected chimpanzees and HIV-positive patients show positive proliferative responses to multiple peptides from five conserved regions of the HIV-1
Env
gp160 (199–211) gp120 (204–216) SVITQACSKVSFE Vaccine murine (H-2bxk,sxd) Sastry1991
Vaccine Vector/Type: peptide
• Peptides induced T-cell proliferative response in mice representing four haplotypes
gp160 (200–214) gp120 (205–219 LAI) VITQACPKVSFEPIP Peptide-HLA interaction human (HLA-DR) Gaudebout1997
• Peptide binds to both HLA-DR*1101 and HLA-DR*0401 with high affinity
• Because of the distinctive binding pockets of HLA-DR*1101 and HLA-DR*0401, peptides that bound both were considered candidates for promiscuous
HLA-DR binding
gp160 (201–212) Env (1007) ITQACPKVSFEP Vaccine murine (H-2 IAb) Surman2001
Vaccine Vector/Type: DNA, vaccinia, recombinant protein Strain: 1007 (clade B), UG92005 (clade D) HIV component: gp140 Adjuvant: Freund’s
adjuvant
• This epitope is located in the C2 region of 1007 (US, clade B) and the Vβ usage of the TCR was Vβ3
• The epitope described here is the region of overlap of two 15 mers that were both able to stimulate IL-2 production from the hybridoma
(TSVITQACPKVSFEP and ITQACPKVSFEPIPI)
• C57BL/6 mice were immunized with a prime-boost strategy involving three HIV-1 Env antigens: Mice were primed with DNA given i.m., 3-4 weeks later
boosted with VV, and 3-4 weeks later boosted again with purified protein in Freund’s adjuvant
• The vaccinia construct is a pSC11-based VV vector with the first 38 amino acids contributed by BH10 and the rest of gp120 and gp41 by the vaccine strain,
the DNA construct is in the pJW4303 vector with a CMV promotor, and the purified protein is expressed from the pJW4303 vector transfected into
CHO-K1 cells
• Ten days after the final boost, hybridomas were made and tested for IL-2 production using either B6 spleen cells or H-2 IAb transfected L cells as targets
and Vβ usage was determined
• Mice were immunized with an Env from either one of two clades: HIV-1 1007, a clade B strain isolated from an individual from Memphis Tennesee, and
HIV-1 92UG005, a clade D vaccine isolated from Uganda in 1992 through the WHO
• 80 unique clonotypes were characterized from six mice
• H-2 IAb restricted T-helper epitopes were concentrated in 5 distinct regions within the Env sequence (2 clonotype responses in V2, 26 in C2, 22 in V3, 23
in V4C4, and 7 in gp41).
• Epitope hotspots tended to be proximal to heavily glycosylated regions of the Env sequence, in exposed, non-helical strands of the protein. The
non-uniform localization may be influenced by differential antigen processing and the glycosylation site proximity may allow binding to lectins and
promote trafficking through processing pathways.
gp160 (206–220) Env (1007) PKVSFEPIPIHYCAP Vaccine murine (H-2 IAb) Surman2001
Vaccine Vector/Type: DNA, vaccinia, recombinant protein Strain: 1007 (clade B), UG92005 (clade D) HIV component: gp140 Adjuvant: Freund’s
adjuvant
• This epitope is located in the C2 region of 1007 (US, clade B) and 12 hybridomas recognized the peptide with Vβ usage of Vβ4,6,7,8.1-2,8.3,11,12 and
others not determined
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• C57BL/6 mice were immunized with a prime-boost strategy involving three HIV-1 Env antigens: Mice were primed with DNA given i.m., 3-4 weeks later
boosted with VV, and 3-4 weeks later boosted again with purified protein in Freund’s adjuvant
• The vaccinia construct is a pSC11-based VV vector with the first 38 amino acids contributed by BH10 and the rest of gp120 and gp41 by the vaccine strain,
the DNA construct is in the pJW4303 vector with a CMV promotor, and the purified protein is expressed from the pJW4303 vector transfected into
CHO-K1 cells
• Ten days after the final boost, hybridomas were made and tested for IL-2 production using either B6 spleen cells or H-2 IAb transfected L cells as targets
and Vβ usage was determined
• Mice were immunized with an Env from either one of two clades: HIV-1 1007, a clade B strain isolated from an individual from Memphis Tennesee, and
HIV-1 92UG005, a clade D vaccine isolated from Uganda in 1992 through the WHO
• 80 unique clonotypes were characterized from six mice
• H-2 IAb restricted T-helper epitopes were concentrated in 5 distinct regions within the Env sequence (2 clonotype responses in V2, 26 in C2, 22 in V3, 23
in V4C4, and 7 in gp41).
• Epitope hotspots tended to be proximal to heavily glycosylated regions of the Env sequence, in exposed, non-helical strands of the protein. The
non-uniform localization may be influenced by differential antigen processing and the glycosylation site proximity may allow binding to lectins and
promote trafficking through processing pathways.
gp160 (206–225) gp120 (211–230 MN) PKISFEPIPIHYCAPAGFAI Vaccine guinea pig Chattergoon2002
Vaccine Vector/Type: protein, DNA Strain: MN HIV component: gp120 Adjuvant: complete Freund’s adjuvant (CFA)
• Epitope name: 1957
• Hartley guinea pigs were intradermally injected with either recombinant protein or plasmid expressed gp120 and monitored for delayed type hypersensivity
(DTH) responses after vaccination, which are related to Th1 T-cell responses. CFA did not augment responses in animals vaccinated with plasmid.
• A total of 7 gp120 peptides elicited a delayed type hypersensivity (DTH) response after vaccination, out of a set of 60 overlapping peptides that spanned
gp120. The vaccine delivery system, DNA versus rec protein, resulted in the recognition of distinct peptides.
• 5/5 animals vaccinated with rec gp120 responded by DTH to this peptide, as did 2/6 vaccinated with plasmid gp120 DNA.
gp160 (206–230) gp120 (206–230) PKVSFEPIPIHYCAPAGFA-
ILKCNN
Vaccine murine (H-2d,b) Sjolander1996
Vaccine Vector/Type: recombinant protein HIV component: gp160
• Study showing that T-cell determinants from glycoproteins can be dependent on the glycosylation of the protein
gp160 (208–218) Env (UG92005) ITFEPIPIHYC Vaccine murine (H-2 IAb) Surman2001
Vaccine Vector/Type: DNA, vaccinia, recombinant protein Strain: 1007 (clade B), UG92005 (clade D) HIV component: gp140 Adjuvant: Freund’s
adjuvant
• This epitope is located in the C2 region of UG92005 (UG, clade D) and its was recognized by two hybridomas with Vβ usage Vβ12 and not determined
• The epitope described here is the region of overlap of two 15 mers that were both able to stimulate IL-2 production from the hybridoma
(PKITFEPIPIHYCAP and ITFEPIPIHYCAPAG)
• C57BL/6 mice were immunized with a prime-boost strategy involving three HIV-1 Env antigens: Mice were primed with DNA given i.m., 3-4 weeks later
boosted with VV, and 3-4 weeks later boosted again with purified protein in Freund’s adjuvant
• The vaccinia construct is a pSC11-based VV vector with the first 38 amino acids contributed by BH10 and the rest of gp120 and gp41 by the vaccine strain,
the DNA construct is in the pJW4303 vector with a CMV promotor, and the purified protein is expressed from the pJW4303 vector transfected into
CHO-K1 cells
• Ten days after the final boost, hybridomas were made and tested for IL-2 production using either B6 spleen cells or H-2 IAb transfected L cells as targets
and Vβ usage was determined
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• Mice were immunized with an Env from either one of two clades: HIV-1 1007, a clade B strain isolated from an individual from Memphis Tennesee, and
HIV-1 92UG005, a clade D vaccine isolated from Uganda in 1992 through the WHO
• 80 unique clonotypes were characterized from six mice
• H-2 IAb restricted T-helper epitopes were concentrated in 5 distinct regions within the Env sequence (2 clonotype responses in V2, 26 in C2, 22 in V3, 23
in V4C4, and 7 in gp41).
• Epitope hotspots tended to be proximal to heavily glycosylated regions of the Env sequence, in exposed, non-helical strands of the protein. The
non-uniform localization may be influenced by differential antigen processing and the glycosylation site proximity may allow binding to lectins and
promote trafficking through processing pathways.
gp160 (208–222) Env (UG92005) ITFEPIPIHYCAPAG Vaccine murine (H-2 IAb) Surman2001
Vaccine Vector/Type: DNA, vaccinia, recombinant protein Strain: 1007 (clade B), UG92005 (clade D) HIV component: gp140 Adjuvant: Freund’s
adjuvant
• This epitope is located in the C2 region of UG92005 (UG, clade D) and it was recognized by five hybridomas with Vβ usage Vβ5, 8.2, 12 and not
determined
• C57BL/6 mice were immunized with a prime-boost strategy involving three HIV-1 Env antigens: Mice were primed with DNA given i.m., 3-4 weeks later
boosted with VV, and 3-4 weeks later boosted again with purified protein in Freund’s adjuvant
• The vaccinia construct is a pSC11-based VV vector with the first 38 amino acids contributed by BH10 and the rest of gp120 and gp41 by the vaccine strain,
the DNA construct is in the pJW4303 vector with a CMV promotor, and the purified protein is expressed from the pJW4303 vector transfected into
CHO-K1 cells
• Ten days after the final boost, hybridomas were made and tested for IL-2 production using either B6 spleen cells or H-2 IAb transfected L cells as targets
and Vβ usage was determined
• Mice were immunized with an Env from either one of two clades: HIV-1 1007, a clade B strain isolated from an individual from Memphis Tennesee, and
HIV-1 92UG005, a clade D vaccine isolated from Uganda in 1992 through the WHO
• 80 unique clonotypes were characterized from six mice
• H-2 IAb restricted T-helper epitopes were concentrated in 5 distinct regions within the Env sequence (2 clonotype responses in V2, 26 in C2, 22 in V3, 23
in V4C4, and 7 in gp41).
• Epitope hotspots tended to be proximal to heavily glycosylated regions of the Env sequence, in exposed, non-helical strands of the protein. The
non-uniform localization may be influenced by differential antigen processing and the glycosylation site proximity may allow binding to lectins and
promote trafficking through processing pathways.
gp160 (208–227) gp120 (210–229 89.6) VSFQPIPIHYCVPAGFAMLK Vaccine murine Dai2001
Vaccine Vector/Type: recombinant protein Strain: 89.6 HIV component: gp120 Adjuvant: R192G mutant heat-labile toxin from enterotoxigenic E.
coli (mLT)
• Epitope name: Peptide 19
• Helper T-cell proliferative responses to gp120 vaccines in 2 mouse strains, CBA/J and BALB/c, were mapped using 47 overlapping peptides that span
gp120. Promiscuously immunodominant peptides were identified in both mice strains that were located in the outer domain of gp120 and were associated
with regions of local structural disorder in proximal N-terminal segments, suggesting 3-D protein structure influences Th antigen processing and the
frequency of immunogenic sequences.
• This peptide was reactive in 6/10 BALB/c mice tested, and in 6/10 CBA/J mice.
gp160 (210–223) gp120 (215–228) FEPIPIHYCAFPGF Vaccine murine (H-2bxk) Sastry1991
Vaccine Vector/Type: peptide
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• Peptides induced T-cell proliferative response to immunizing peptide and to gp160
gp160 (212–231) gp120 (221–240 W6.ID) PIPIHYCAPAGFAILKCNNK Vaccine human Jones1999
Vaccine Vector/Type: recombinant protein Strain: W61D HIV component: gp120 Adjuvant: QS21/MPL adjuvant
• An HIV seronegative volunteer was vaccinated with rgp120 and a QS21/MPL adjuvant and HIV-1 specific T-cell lines were isolated
• Two T-cell lines react specifically with this peptide
gp160 (212–231) gp120 (212–231 IIIB) PIPIHYCAPAGFAILKCNN-
K?
HIV-1 infection human Geretti1994
• Epitope name: D4
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 3/15 responders recognized this peptide, average SI = 4.2.
gp160 (214–220) Env (1007) PIHYCAP Vaccine murine (H-2 IAb) Surman2001
Vaccine Vector/Type: DNA, vaccinia, recombinant protein Strain: 1007 (clade B), UG92005 (clade D) HIV component: gp140 Adjuvant: Freund’s
adjuvant
• This epitope is located in the C2 region of 1007 (US, clade B) and the Vβ usage of the TCR was not determined
• The epitope described here is the region of overlap of two 15 mers that were both able to stimulate IL-2 production from the hybridoma
(PKVSFEPIPIHYCAP and PIHYCAPAGFAILKC)
• C57BL/6 mice were immunized with a prime-boost strategy involving three HIV-1 Env antigens: Mice were primed with DNA given i.m., 3-4 weeks later
boosted with VV, and 3-4 weeks later boosted again with purified protein in Freund’s adjuvant
• The vaccinia construct is a pSC11-based VV vector with the first 38 amino acids contributed by BH10 and the rest of gp120 and gp41 by the vaccine strain,
the DNA construct is in the pJW4303 vector with a CMV promotor, and the purified protein is expressed from the pJW4303 vector transfected into
CHO-K1 cells
• Ten days after the final boost, hybridomas were made and tested for IL-2 production using either B6 spleen cells or H-2 IAb transfected L cells as targets
and Vβ usage was determined
• Mice were immunized with an Env from either one of two clades: HIV-1 1007, a clade B strain isolated from an individual from Memphis Tennesee, and
HIV-1 92UG005, a clade D vaccine isolated from Uganda in 1992 through the WHO
• 80 unique clonotypes were characterized from six mice
• H-2 IAb restricted T-helper epitopes were concentrated in 5 distinct regions within the Env sequence (2 clonotype responses in V2, 26 in C2, 22 in V3, 23
in V4C4, and 7 in gp41).
• Epitope hotspots tended to be proximal to heavily glycosylated regions of the Env sequence, in exposed, non-helical strands of the protein. The
non-uniform localization may be influenced by differential antigen processing and the glycosylation site proximity may allow binding to lectins and
promote trafficking through processing pathways.
gp160 (215–225) Env (1007) IHYCAPAGFAI Vaccine murine (H-2 IAb) Surman2001
Vaccine Vector/Type: DNA, vaccinia, recombinant protein Strain: 1007 (clade B), UG92005 (clade D) HIV component: gp140 Adjuvant: Freund’s
adjuvant
• This epitope is located in the C2 region of 1007 (US, clade B) and the Vβ usage of the TCR was not determined
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• The epitope described here is the region of overlap of two 15 mers that were both able to stimulate IL-2 production from the hybridoma
(EPIPIHYCAPAGFAI and IHYCAPAGFAILKCN)
• C57BL/6 mice were immunized with a prime-boost strategy involving three HIV-1 Env antigens: Mice were primed with DNA given i.m., 3-4 weeks later
boosted with VV, and 3-4 weeks later boosted again with purified protein in Freund’s adjuvant
• The vaccinia construct is a pSC11-based VV vector with the first 38 amino acids contributed by BH10 and the rest of gp120 and gp41 by the vaccine strain,
the DNA construct is in the pJW4303 vector with a CMV promotor, and the purified protein is expressed from the pJW4303 vector transfected into
CHO-K1 cells
• Ten days after the final boost, hybridomas were made and tested for IL-2 production using either B6 spleen cells or H-2 IAb transfected L cells as targets
and Vβ usage was determined
• Mice were immunized with an Env from either one of two clades: HIV-1 1007, a clade B strain isolated from an individual from Memphis Tennesee, and
HIV-1 92UG005, a clade D vaccine isolated from Uganda in 1992 through the WHO
• 80 unique clonotypes were characterized from six mice
• H-2 IAb restricted T-helper epitopes were concentrated in 5 distinct regions within the Env sequence (2 clonotype responses in V2, 26 in C2, 22 in V3, 23
in V4C4, and 7 in gp41).
• Epitope hotspots tended to be proximal to heavily glycosylated regions of the Env sequence, in exposed, non-helical strands of the protein. The
non-uniform localization may be influenced by differential antigen processing and the glycosylation site proximity may allow binding to lectins and
promote trafficking through processing pathways.
gp160 (216–225) Env (UG92005) HYCAPAGFAI Vaccine murine (H-2 IAb) Surman2001
Vaccine Vector/Type: DNA, vaccinia, recombinant protein Strain: 1007 (clade B), UG92005 (clade D) HIV component: gp140 Adjuvant: Freund’s
adjuvant
• This epitope is located in the C2 region of UG92005 (UG, clade D) and Vβ usage of its TCR was not determined
• The epitope described here is the region of overlap of two 15 mers that were both able to stimulate IL-2 production from the hybridoma
(EPIPIHYCAPAGFAI and HYCAPAGFAILKCND)
• C57BL/6 mice were immunized with a prime-boost strategy involving three HIV-1 Env antigens: Mice were primed with DNA given i.m., 3-4 weeks later
boosted with VV, and 3-4 weeks later boosted again with purified protein in Freund’s adjuvant
• The vaccinia construct is a pSC11-based VV vector with the first 38 amino acids contributed by BH10 and the rest of gp120 and gp41 by the vaccine strain,
the DNA construct is in the pJW4303 vector with a CMV promotor, and the purified protein is expressed from the pJW4303 vector transfected into
CHO-K1 cells
• Ten days after the final boost, hybridomas were made and tested for IL-2 production using either B6 spleen cells or H-2 IAb transfected L cells as targets
and Vβ usage was determined
• Mice were immunized with an Env from either one of two clades: HIV-1 1007, a clade B strain isolated from an individual from Memphis Tennesee, and
HIV-1 92UG005, a clade D vaccine isolated from Uganda in 1992 through the WHO
• 80 unique clonotypes were characterized from six mice
• H-2 IAb restricted T-helper epitopes were concentrated in 5 distinct regions within the Env sequence (2 clonotype responses in V2, 26 in C2, 22 in V3, 23
in V4C4, and 7 in gp41).
• Epitope hotspots tended to be proximal to heavily glycosylated regions of the Env sequence, in exposed, non-helical strands of the protein. The
non-uniform localization may be influenced by differential antigen processing and the glycosylation site proximity may allow binding to lectins and
promote trafficking through processing pathways.
gp160 (220–234) gp120 (225–240 SF2) PAGFAILKCNNKTFN in vitro stimulation Manca1993
• T-cell line derived from unprimed, uninfected individual
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• Responds to APC pulsed with either synthetic peptide or gp120
• Human MAbs 448-D and 450-D enhance APC gp120 uptake and presentation
gp160 (220–234) gp120 (IIIB) PAGFAILKCNNKTFN Vaccine human Pozzi1994
Vaccine Vector/Type: Streptococcus gordonii HIV component: gp120
• Epitope name: pep24
• This previously described immunodominant Th cell epitope was fused to the streptococcal surface protein M6 (emm-6.1), for expression on the surface of
the bacterium Streptococcus gordonii.
• Recombinant bacteria showed efficient MHC class II mediated presentation of gp120 to T-cells by stimulation of a proliferative response in a human T cell
clone specific for pep24.
gp160 (220–235) gp120 (IIIB) PAGFAILKCNNKTFNY in vitro stimulation human (DR2) Manca1995b
• Peptide stimulation of PBMC from non-infected individuals in vitro
• Peptide priming does not always induce T-cells that recognize whole protein
• gp120 priming induced T-cells that recognize this peptide
gp160 (220–235) gp120 (220–235 HXB2) PAGFAILKCNNKTFNY in vitro stimulation human (DR2) Guzman1998
• Listeria monocytogenes, an intracellular pathogen which is ingested by macrophages and can escape from the phagosome to replicate in the cytoplasm, was
used successfully as carrier to deliver this gp120 epitope to CD4+ T-cells
gp160 (220–235) gp120 (191–205 HXB2) PAGFAILKCNNKTFNY in vitro stimulation human (DR2) Fenoglio1999
• gp120 pep24 epitope exhibited antagonistic activity against proliferation of gp120-specific T-cells when flanked by unrelated amino acid sequence
• The glutathione S-transferase (GST)-peptide system can be used to display peptides; antigenicity was maintained when this peptide was expressed at the
C-term end, but antagonism resulted when this peptide was expressed at the N-term end
gp160 (222–241) gp120 (222–241 IIIB) GFAILKCNNKTFNGTGPCT-
N?
HIV-1 infection human Geretti1994
• Epitope name: D5
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 2/15 responders recognized this peptide, average SI = 4.8.
gp160 (223–231) gp120 (238–246 HXB2) FAILKCNNK in vitro stimulation human Li Pira1998
• Clonal heterogeneity was broad for a recall response to tetanus toxoid or PPD, but oligoclonal to primary HIV antigens, dominated in this case by TCR Vβ
22 usage
• Donor of PBMC that recognized this epitope had HLA-DR alleles 2 and 6
• The only (detected) immunogenic variant of this epitope was derived from strain NOF (YAILKCNNK)
gp160 (223–231) gp120 (194–202 HXB2) FAILKCNNK in vitro stimulation human (DR2, 6) Manca1996
• Epitope was the minimal stimulatory sequence defined for two Th lines stimulated in vitro
• One Th line was stimulated by gp120, one by a Glutathione-S-transferase (GST)-peptide fusion
• Alanine substitutions at position 914, 196, and 202 abrogated activity for the GST-peptide stimulated line, but not for a gp120 stimulated line
485
DEC 2002
T-
H
el
pe
r
HIV Helper T-Cell Epitope Tables gp160 Helper T-Cell Epitopes
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
• Constructs combining GST and the PAGFAILKCNNKTFNY gp120 peptide at the C-term end of GST stimulated Th cells but not at the N-term end
gp160 (223–231) gp120 (194–202 HXB2) FAILKCNNK in vitro stimulation human (DR2, 6) Manca1996
• Epitope was the minimal stimulatory sequence defined for two Th lines stimulated in vitro
• One Th line was stimulated by p66, one by a Glutathione-S-transferase (GST)-peptide fusion protein
• Alanine substitutions at position 914, 196, and 202 abrogated activity for the GST-peptide stimulated line, but not for a gp120 stimulated line
• Constructs linking GST to the PAGFAILKCNNKTFNY gp120 peptide at the C-term end of GST stimulated Th cells, constructs linking at the N-term end
did not
• The C and N termini of GST are not intrinsically permissive or non-permissive, presentation is epitope specific (see SSTVNDIQKLV for contrast)
gp160 (223–231) gp120 (237–245 SF2,
HXB2)
FAILKCNNK murine BALB/c (H-2d) Fenoglio2000
• This peptide is an immunodominant Th epitope in BALB/c mice
• Substitutions in positions 237, 241, 243, 244 with Ala all cause reduced recognition
• Most natural analogs they tested did not cross-react, including peptides based on clade A, B, C, D, E and O sequences
• Position 237 and 244 when substituted with Ala cause an antagonistic response and the natural analogues of this epitope to loose antigenicity
• Some of the naturally occurring variants also cause an antagonistic response
gp160 (230–245) gp120 (IIIB) NKTFNGKGPCTNVSTY in vitro stimulation human Manca1995b
• Peptide stimulation of PBMC from non-infected individuals in vitro
• Peptide priming does not always induce T-cells that recognize whole protein
gp160 (232–251) gp120 (232–251 IIIB) TFNGTGPCTNVSTVQCTHG-
I?
HIV-1 infection human Geretti1994
• Epitope name: E1
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 3/15 responders recognized this peptide, average SI = 3.9.
gp160 (235–247) gp120 (240–252) GTGPCTNVSTVQC Vaccine Rhesus macaque Nehete1993
Vaccine Vector/Type: peptide
• Synthetic peptide derived from conserved region of the HIV-1 envelope that stimulates a proliferative response in mice
• Proliferative response to this peptide was observed in 1/3 immunized rhesus monkeys, with a weak transient response in the other two
gp160 (238–257) gp120 (240–249 89.6) PCTNVSTVQCTHGIRPVVST Vaccine murine Dai2001
Vaccine Vector/Type: recombinant protein Strain: 89.6 HIV component: gp120 Adjuvant: R192G mutant heat-labile toxin from enterotoxigenic E.
coli (mLT)
• Epitope name: Peptide 22
• Helper T-cell proliferative responses to gp120 vaccines in 2 mouse strains, CBA/J and BALB/c, were mapped using 47 overlapping peptides that span
gp120. Promiscuously immunodominant peptides were identified in both mice strains that were located in the outer domain of gp120 and were associated
with regions of local structural disorder in proximal N-terminal segments, suggesting 3-D protein structure influences Th antigen processing and the
frequency of immunogenic sequences.
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• This peptide was highly reactive in 6/10 BALB/c mice tested, but not in any (0/10) CBA/J mice.
gp160 (240–255) gp120 (IIIB) TNVSTVQCTHGRPIY in vitro stimulation human Manca1995b
• Peptide stimulation of PBMC from non-infected individuals in vitro
gp160 (242–261) gp120 (242–261 IIIB) VSTVQCTHGIRPVVSTQLL-
L?
HIV-1 infection human Geretti1994
• Epitope name: E2
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 1/15 responders recognized this peptide, SI = 3.4.
gp160 (242–261) gp120 (242–261 IIIB) VSTVQCTHGIRPVVSTQLLL SHIV infection Rhesus macaque
(DRB1*0406)
Lekutis1997a
• A novel C2 region Th epitope was described in SHIV-89.6 infected Macaca mulatta
gp160 (250–265) gp120 (IIIB) GIRPIVSTQLLLNGSC in vitro stimulation human Manca1995b
• Peptide stimulation of PBMC from non-infected individuals in vitro
• Peptide priming does not always induce T-cells that recognize whole protein
gp160 (252–271) gp120 (252–271 IIIB) RPVVSTQLLLNGSLAEEEV-
V?
HIV-1 infection human Geretti1994
• Epitope name: E3
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 1/15 responders recognized this peptide, average SI = 7.4.
gp160 (262–281) gp120 (262–281 IIIB) NGSLAEEEVVIRSVNFTDN-
A?
HIV-1 infection human Geretti1994
• Epitope name: E4
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 2/15 responders recognized this peptide, average SI = 3.1.
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gp160 (264–287) gp120 (269–292 NL43) SLAEEEVVIRSANFTDNAK-
TIIVQ
Vaccine human Sitz1999
Vaccine Vector/Type: recombinant protein Strain: NL43 HIV component: gp120, gp160
• There was a great breadth of proliferative response to env peptides in 19 HIV-1 infected rgp160 and 17 HIV-1 infected rgp120 vaccine recipients
• 50% of vaccinees had a stimulation index of greater than 5 to this peptide
gp160 (269–283) gp120 (269–283 IIIB,
B10)
EVVIRSANFTDNAKT HIV-1 infection human Wahren1989b, Wahren1989a
• 12 gag and 18 env peptides were identified that could commonly evoke T-cell responses.
gp160 (270–285) gp120 (IIIB) VVIRSDNFTNNAKTIC in vitro stimulation human Manca1995b
• Peptide stimulation of PBMC from non-infected individuals in vitro
• Peptide priming does not always induce T-cells that recognize whole protein
gp160 (272–291) gp120 (272–291 IIIB) IRSVNFTDNAKTIIVQLNT-
S?
HIV-1 infection human Geretti1994
• Epitope name: E5
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• Five peptides were recognized most frequently: C2 (aa 142-161), C3 (aa 152-171), C5 (aa 172-191), E5 (aa 272-291) and G4 (aa 380-393). The first three
were in or near V2, the other two were proximal to the V3 and V4 loops.
• 4/15 responders recognized this immunodominant peptide, average SI = 5.0.
gp160 (274–288) gp120 (274–288 IIIB,
B10)
SANFTDNAKTIIVQL HIV-1 infection human Wahren1989b, Wahren1989a
• 12 gag and 18 env peptides were identified that could commonly evoke T-cell responses.
gp160 (280–296) gp120 (IIIB) NAKTIIVQLNESVAIC in vitro stimulation human Manca1995b
• Peptide stimulation of PBMC from non-infected individuals in vitro
• Peptide priming does not always induce T-cells that recognize whole protein
gp160 (288–307) gp120 (290–309 89.6) LNESVVINCTRPNNNTRRRL Vaccine murine Dai2001
Vaccine Vector/Type: recombinant protein Strain: 89.6 HIV component: gp120 Adjuvant: R192G mutant heat-labile toxin from enterotoxigenic E.
coli (mLT)
• Epitope name: Peptide 27
• Helper T-cell proliferative responses to gp120 vaccines in 2 mouse strains, CBA/J and BALB/c, were mapped using 47 overlapping peptides that span
gp120. Promiscuously immunodominant peptides were identified in both mice strains that were located in the outer domain of gp120 and were associated
with regions of local structural disorder in proximal N-terminal segments, suggesting 3-D protein structure influences Th antigen processing and the
frequency of immunogenic sequences.
• This peptide was reactive in only 1/10 BALB/c mice tested, but reacted in 8/10 CBA/J mice.
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gp160 (289–297) gp120 (292–300 SF2) NESVAINCT Vaccine human Botarelli1991
Vaccine Vector/Type: recombinant protein Strain: SF2 HIV component: gp120
• A non-glycosylated form of SF2 gp120, env 2-3, was used as an immunogen – 20% of T-cell clones do not recognize the glycosylated form
gp160 (290–306) gp120 (296–312 LAI) SVVEINCTRPNNNTRKS HIV-1 infection human Schrier1989
• Stimulates T-cell proliferation in HIV-infected donors
gp160 (292–310) gp120 (292–310 IIIB) VEINCTRPNNNTRKRIRIQ? HIV-1 infection human Geretti1994
• Epitope name: F1
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• Only 1/15 responders recognized this peptide, but it had the highest SI in the study of 9.9.
gp160 (296–307) gp120 (301–324 RF) CTRPNNNTRKSI HIV-1 infection deLorimier1994
• Proton NMR spectroscopy was employed to analyze the solution conformation of a hybrid peptide, T1-SP10RF, in order to better understand the
immunogenicity of its’ T helper (KQIINMWQEVGKAMYA, CTRPNNNTRKSI), CTL (SITKGPGRVIYATG) and B-cell epitopes
(RKSITKGPGRVIYATG).
• This epitope embedded in the T1-SP10RF peptide does not form a helical amphipathic conformation. It lacks random-coil conformations, and this may
make a peptide less susceptible to complete proteolytic degredation and be favored within epitopes.
gp160 (296–314) gp120 (303–321 IIIB) CTRPNNNTRKSIRIQRGPG-
(Y)
Vaccine goat Palker1989
Vaccine Vector/Type: peptide Strain: IIIB
• Goats were immunized with peptides containing V3 type-specific neutralizing determinants coupled to T1
gp160 (297–321) gp120 (302–324 MN) TRPNYNKRKRIHIGPGRAF-
YTTK
Vaccine murine BALB/c (H-2d) Oscherwitz1999b
Vaccine Vector/Type: peptide Strain: MN HIV component: V3
• Epitope presented as a tandem repeat (eight copies) elicits stronger B-cell and T-cell responses than the epitope presented as a single copy
• This study indicates that the increased response was not due to neodeterminants created at the junction of the peptides, but rather due to an epitope density
effect, increased immunogenicity through a high ratio of epitope to protein
gp160 (297–330) Env (303–335 BX08) TRPNNNTRKSIHIGPGRAF-
YATGEIIGDIRQAH
Vaccine human Gahery-Segard2000
Vaccine Vector/Type: lipopeptide
• Anti-HIV lipopeptide vaccine consisting of six long peptides derived from Nef, Gag and Env HIV-1 proteins modified by a palmitoyl chain was
administered in a phase I trial
• A CD4+ T cell proliferative response to at least one of the six peptides was observed in 9/10 vaccinees – 6/10 reacted to this peptide
• 9/12 tested mounted a CTL responses to at least one of the six peptides, each of the six peptides elicited a CTL response in at least one individual – this
peptide was particularly immunogenic, eliciting a CTL response in five vaccinees
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• None of the 12 tested had an IgG response to gp120 or gp160 and vaccinees could be differentiated from HIV-1 seropositive individuals with a commercial
HIV detection kit – no neutralizing antibodies were observed
gp160 (298–307) Env (UG92005) RPYNNTRKGI Vaccine murine (H-2 IAb) Surman2001
Vaccine Vector/Type: DNA, vaccinia, recombinant protein Strain: 1007 (clade B), UG92005 (clade D) HIV component: gp140 Adjuvant: Freund’s
adjuvant
• This epitope is located in the V3 region of UG92005 (UG, clade D) and was recognized by a hybridoma with Vβ usage not determined
• The epitope described here is the region of overlap of two 15 mers that were both able to stimulate IL-2 production from the hybridoma
(TINCTRPYNNTRKGI and RPYNNTRKGIHIGPG)
• C57BL/6 mice were immunized with a prime-boost strategy involving three HIV-1 Env antigens: Mice were primed with DNA given i.m., 3-4 weeks later
boosted with VV, and 3-4 weeks later boosted again with purified protein in Freund’s adjuvant
• The vaccinia construct is a pSC11-based VV vector with the first 38 amino acids contributed by BH10 and the rest of gp120 and gp41 by the vaccine strain,
the DNA construct is in the pJW4303 vector with a CMV promotor, and the purified protein is expressed from the pJW4303 vector transfected into
CHO-K1 cells
• Ten days after the final boost, hybridomas were made and tested for IL-2 production using either B6 spleen cells or H-2 IAb transfected L cells as targets
and Vβ usage was determined
• Mice were immunized with an Env from either one of two clades: HIV-1 1007, a clade B strain isolated from an individual from Memphis Tennesee, and
HIV-1 92UG005, a clade D vaccine isolated from Uganda in 1992 through the WHO
• 80 unique clonotypes were characterized from six mice
• H-2 IAb restricted T-helper epitopes were concentrated in 5 distinct regions within the Env sequence (2 clonotype responses in V2, 26 in C2, 22 in V3, 23
in V4C4, and 7 in gp41).
• Epitope hotspots tended to be proximal to heavily glycosylated regions of the Env sequence, in exposed, non-helical strands of the protein. The
non-uniform localization may be influenced by differential antigen processing and the glycosylation site proximity may allow binding to lectins and
promote trafficking through processing pathways.
gp160 (298–319) gp120 (300–319 89.6) RPNNNTRRRLSIGPGRAFYA Vaccine murine Dai2001
Vaccine Vector/Type: recombinant protein Strain: 89.6 HIV component: gp120 Adjuvant: R192G mutant heat-labile toxin from enterotoxigenic E.
coli (mLT)
• Epitope name: Peptide 28
• Helper T-cell proliferative responses to gp120 vaccines in 2 mouse strains, CBA/J and BALB/c, were mapped using 47 overlapping peptides that span
gp120. Promiscuously immunodominant peptides were identified in both mice strains that were located in the outer domain of gp120 and were associated
with regions of local structural disorder in proximal N-terminal segments, suggesting 3-D protein structure influences Th antigen processing and the
frequency of immunogenic sequences.
• This peptide was reactive in 7/10 BALB/c mice tested, and in 5/10 CBA/J mice.
gp160 (301–325) gp120 (IIIB) NNTRKSIRIQRGPGRAFVT-
IGKIGN
Vaccine murine Sasaki1998
Vaccine Vector/Type: DNA Strain: IIIB HIV component: ENV, REV Adjuvant: QS-21 adjuvant
• The env response is what is being sought, but co-expression of rev is required
• Intramuscular versus nasal vaccination with DNA vaccine with a QS-21 adjuvant was studied
• QS-21 enhanced the IgG2a response mediated via Th1 cytokines IFNγ and IL-2 and delayed type hypersensitivity (DTH) in response to the V3 peptide was
measured by a foot pad swelling test [Sasaki1998]
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gp160 (302–315) gp120 (307–322 IIIB) NTRKSIRIQRGPGR Vaccine murine Goodman-Snitkoff1990
Vaccine Vector/Type: peptide Strain: IIIB HIV component: V3
• Identification of putative Th epitopes that can stimulate an antibody response in peptide-immunized mice
gp160 (302–321) gp120 (302–321 IIIB) NTRKRIRIQRGPGRAFVTI-
G?
HIV-1 infection human Geretti1994
• Epitope name: F2
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 1/15 responders recognized this peptide, SI = 5.6.
gp160 (302–327) gp120 (307–332 MN) NKRKRIHIGPGRAFYTTKN-
IIGTIR
Vaccine murine Anderson2001
Vaccine Vector/Type: peptide Strain: MN HIV component: V3 Adjuvant: Montainde ISA-51
• Hypervariable epitope constructs (HECs) are degenerative peptide cocktails that are made in a single peptide synthesis reaction. Vaccination with a V3
degenerative peptide cocktail containing 64 distinct peptides, NTRK-[SR]-I-[HR]-IGPG-[RQ]-AFY-[AT]-TG-[DE]-IG-[DN]-IRQ, elicited broader and
more durable Th responses than the MN V3 peptide alone in BALB/c mice immunized and boosted with V3 peptides, although the MN peptide elicited a
transient MN-specific V3 response.
gp160 (305–321) gp120 (312–329) (CG)KSIRIQRGPGRAFVT-
IG
HIV-1 infection human Adams1997
• Used as positive control in study examining T-cell response to four p24 Gag peptides
gp160 (308–319) gp120 (subtype C) (CKR)KIHIGPGQAFYT HIV-1 infection murine (H-2b,d,k,s) Ahluwalia1997
• A V3 loop peptide modified to resemble an Indian form (GPGQ) was incorporated into ISCOMS (immune stimulating complexes) or liposomes, and used
to immunize mice – the IgG2a/IgG2b Ab response was enhanced by the presentation in the ISCOM suggestive of a Th1 response
gp160 (308–321) gp120 (MN) RIHIGPGRAFYTTK Vaccine murine (H-2d) Klinman1995
Vaccine Vector/Type: peptide Strain: MN HIV component: V3
• Epitope name: SP10
• Hybrid T1-V3 peptide activates IL-4 and IL-6 in a dose dependent manner
• 10-mer from V3 contributes to this response
gp160 (308–322) gp120 (308–322 IIIB) RIHIGPGRAFYTTKN human Furci1997
• 9/11 exposed-uninfected individuals in this study had a proliferative response to a C5 peptide, but only 1/11 exposed-uninfected individuals recognized this
peptide
• 1/18 unexposed-uninfected controls could recognize this peptide
• Erroneously documented as IIIB sequence - most likely MN peptide
gp160 (308–322) gp120 (315–329 IIIB) RIQRGPGRAFVTIGK Vaccine Rhesus macaque Nehete1993
Vaccine Vector/Type: peptide
• Epitope name: P18
491
DEC 2002
T-
H
el
pe
r
HIV Helper T-Cell Epitope Tables gp160 Helper T-Cell Epitopes
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
• Synthetic peptide derived from conserved region of the HIV-1 envelope that stimulates a proliferative response in mice
• Despite the proliferative response to this peptide in mice and humans, no response was observed in 3 rhesus monkeys
gp160 (308–322) gp120 (315–329 IIIB) RIQRGPGRAFVTIGK HIV-1 infection human Wasik1997
• Epitope name: P18
• The breadth and intensity of the CTL response and the type of Th response was studied in seven rapidly progressing HIV-1+ infants
• IL-2 and γ IFN production from Th1 cells correlated with the CTLp frequency against HIV-1 Gag, Env, Nef and Pol
• IL-4 production from Th2 cells was inversely correlated with the CTLp frequency
• The HIV-1+ children with strong CTL responses had levels of anti-CD3 MAb induction of Th1 cells comparable to uninfected children
• The children that did not mount a good CTL response had dramatically decreased numbers of Th1 relative to Th2 cells
gp160 (308–322) gp120 (315–329 IIIB) RIQRGPGRAFVTIGK HIV-1 infection human Wasik2000
• Epitope name: P18
• Th responses measured by IL-2 responses to P18 and T1 in HIV-1 infected infants were undetectable at less than 1 month of age, and remained low in
children with AIDS symptoms, but increased with age in children with slowly progressive disease
• The kinetics and intensity of the CTL activity during the first year of life was related to the child’s ability to make Th1 responses
gp160 (308–322) gp120 (315–329 IIIB) RIQRGPGRAFVTIGK human Pinto1995
• Epitope name: P18
• CTL activity analyzed in parallel with Th reactivity in exposed but uninfected health care workers
gp160 (308–322) gp120 (315–329 MN) RIHIGPGRAFYTTKN human Pinto1995
• Epitope name: P18
• CTL activity analyzed in parallel with Th reactivity in exposed but uninfected health care workers
gp160 (308–322) gp120 (315–329 IIIB) RIQRGPGRAFVTIGK HIV-1 infection human Clerici1989
• Epitope name: P18
• IL-2 production detection of Th lymphocytes from asymptomatic HIV-positive individuals
gp160 (308–322) gp120 (315–329 IIIB) RIQRGPGRAFVTIGK HIV-1 infection human Clerici1991a
• Epitope name: P18
• Peptides stimulate Th cell function and CTL activity in similar patient populations
gp160 (308–322) gp120 (315–329 IIIB) RIQRGPGRAFVTIGK Vaccine human Clerici1991b
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160
• Epitope name: P18
• Immunizing uninfected individuals with rgp160 results in stronger Th response than does natural infection
gp160 (308–322) gp120 (315–329 IIIB) RIQRGPGRAFVTIGK human Clerici1992
• Epitope name: P18
• Cell-mediated immune response to HIV-1 peptides in HIV-1 exposed seronegative men
gp160 (308–322) gp120 (315–329 IIIB) RIQRGPGRAFVTIGK HIV-1 infection human Clerici1997
• Epitope name: P18
• used in a study of the influence of pentoxifylline on HIV specific T-cells
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gp160 (308–322) gp120 (MN) RIHIGPGRAFYTTKN human Clerici1992
• Epitope P18 MN: Cell-mediated immune response to HIV-1 peptides in HIV-1 exposed seronegative men
gp160 (308–322) gp160 (315–329 IIIB) RIQRGPGRAFVTIGK HIV-1 infection, HIV-1 exposed
seronegative
human Wasik1999
• Epitope name: P18
• IL-2 responses associated with beta-chemokine expression were detectable at birth in the majority of uninfected infants born to HIV+ mothers, declining by
age 6 months
• In both uninfected and infected infants of HIV-positive mothers, responses to the T1 peptide (KQIINMWQEVGKAMYA) were more frequent than
responses to P18
• T1 is a highly conserved epitope, whereas P18 has a higher mutation rate due to its location in the immunodominant V3 loop region
gp160 (308–322) gp120 (315–329 IIIB) RIQRGPGRAFVTIGK HIV-1 infection human Kaul1999
• Epitope name: P18
• Kenyan sex workers that remained seronegative were found to frequently have HIV-env peptide specific Th responses detected by an IL-2 assay (11/20
cases) and mucosal genital tract anti-HIV IgA (16/21 cases)
• Helper epitopes used in this study were noted to be previously described [Clerici1989], and were not explicitly described in [Kaul1999]
gp160 (308–322) gp120 (315–329 IIIB) RIQRGPGRAFVTIGK HIV-1 infection, HIV-1 exposed
seronegative
human Kuhn2001
• Epitope name: P18
• In a S. African perinatal transmission study, 33% (33/86) of cord blood samples from infants with seropositive mothers produced T-helper responses
(measured by a bioassay measuring IL2 production in a murine cell line and confirmed with a proliferation assay) against a peptide cocktail containing Th
epitopes P18 MN, P18 IIIB, T1, T2, and TH4
• The mothers were predominantly infected with subtype C, but the T help response was detectable in a number of cord blood samples despite using peptides
based on B subtype reagents.
• 3/33 infants with cord blood T help responses to Env were infected in utero, 2/33 were lost to follow up, and 28/33 were not infected. 6/53 of the infants
with cord blood that was unresponsive to Env peptide stimulation were infected before delivery, and 8/47 contracted HIV intrapartum or via breast-feeding.
• Measurable HIV specific T help responses elicited in the immunologically immature newborn, possibly in response to in utero exposure, are associated
with a protective natural immunity that helps block mother-infant transmission of HIV-1.
gp160 (308–322) gp120 (315–329 MN) RIHIGPGRAFYTTKN HIV-1 infection, HIV-1 exposed
seronegative
human Kuhn2001
• Epitope name: P18
• In a S. African perinatal transmission study, 33% (33/86) of cord blood samples from infants with seropositive mothers produced T-helper responses
(measured by a bioassay measuring IL2 production in a murine cell line and confirmed with a proliferation assay) against a peptide cocktail containing Th
epitopes P18 MN, P18 IIIB, T1, T2, and TH4
• The mothers were predominantly infected with subtype C, but the T help response was detectable in a number of cord blood samples despite using peptides
based on B subtype reagents.
• 3/33 infants with cord blood T help responses to Env were infected in utero, 2/33 were lost to follow up, and 28/33 were not infected. 6/53 of the infants
with cord blood that was unresponsive to Env peptide stimulation were infected before delivery, and 8/47 contracted HIV intrapartum or via breast-feeding.
• Measurable HIV specific T help responses elicited in the immunologically immature newborn, possibly in response to in utero exposure, are associated
with a protective natural immunity that helps block mother-infant transmission of HIV-1.
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gp160 (308–322) gp120 (315–329 IIIB) RIQRGPGRAFVTIGK HIV-1 infection human (DR) Baier1995
• Epitope name: P18
• Linked HIV-1 T1 and P18 peptides to anti-HLA-DR and IgD Fab fragments to enhance uptake by antigen presenting cells thus increase immunogenicity
gp160 (308–322) gp120 (315–329 IIIB) RIQRGPGRAFVTIGK Vaccine murine (H-2 Ad) Takahashi1990
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: gp160
• Epitope name: P18
• Induces both class II restricted CD4+ Th cells, and class I restricted CD8+ CTL
gp160 (308–322) gp120 (315–329 IIIB) RIQRGPGRAFVTIGK Peptide-HLA interaction murine (H-2 I-Ad) Takeshita1995
• Epitope name: P18
• Binds Class II H-2 I-Ad requiring riqrgPgRaFvti, and Class I H-2 Dd , requiring iGPgRaFvtI
gp160 (308–322) Env (IIIB) RIQRGPRAFVTIGK Vaccine murine (H-2d) Lu1999
Vaccine Vector/Type: DNA with CMV promotor Strain: IIIB HIV component: gp160, REV Adjuvant: MIP-1 alpha expression vector
• Epitope name: P18
• MIP-1a expression plasmid co-inoculated with a DNA vaccine consisting of HIV-1 pCMV160IIIB and pcREV enhanced the HIV-specific T-cell immune
response as measured by a CTL test against using V3 peptide pulsed targets, and a DTH test to V3 peptide.
• The IgG1/IgG2a response was lowered with co-inoculation of MIP-1 alpha, suggesting it preferentially elicits a Th1 response
gp160 (308–327) gp120 (306–325 MN) RIHIGPGRAFYTTKNIIGIT HIV-1 infection human (DRB1*0101) Hayball1997
• Tandem repeated presentation of epitope enhances binding to class II molecule and therefore induction of T-cell proliferation
• Tandem peptides are thought to enhance proliferation through improved recruiting of CD4 to the activation complex, which can counter-balance gp120’s
sequestering of CD4 and consequential inhibition of a proliferative response
gp160 (309–323) gp120 (309–323 IIIB,
B10)
EQRGPGRAFVTIGKI HIV-1 infection human Wahren1989b, Wahren1989a
• 12 gag and 18 env peptides were identified that could commonly evoke T-cell responses.
gp160 (309–325) gp120 (314–330) IQRGPGRAFVTIGKIGN HIV-1 infection human Caruso1997
• As HIV-1-infected individuals progress to disease, T-cells show reduced ability to proliferate in response to HIV antigen, but retain the ability to express the
activation antigens CD25 and CD71
• The ability to express activation markers in response to HIV is retained, but the response to tetanus toxoid recall antigen is lost
• This study investigated CD25 and CD71 expression in PBMC from patients at various stages of progression, measuring the response to in vitro stimulation
by peptide cocktail containing four antigenic Env peptides, or p17 and p24
gp160 (310–328) gp120 (310–329 89.6) SIGPGRAFYARRNIIGDIRQ Vaccine murine Dai2001
Vaccine Vector/Type: recombinant protein Strain: 89.6 HIV component: gp120 Adjuvant: R192G mutant heat-labile toxin from enterotoxigenic E.
coli (mLT)
• Epitope name: Peptide 29
• Helper T-cell proliferative responses to gp120 vaccines in 2 mouse strains, CBA/J and BALB/c, were mapped using 47 overlapping peptides that span
gp120. Promiscuously immunodominant peptides were identified in both mice strains that were located in the outer domain of gp120 and were associated
with regions of local structural disorder in proximal N-terminal segments, suggesting 3-D protein structure influences Th antigen processing and the
frequency of immunogenic sequences.
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• This peptide was reactive in 2/10 BALB/c mice tested, and in 8/10 CBA/J mice.
gp160 (311–319) RGPGRAFVT Vaccine murine Barouch2002
Vaccine Vector/Type: DNA Strain: BH10 HIV component: gp120 Adjuvant: GMCSF (bicistronic)
• gp120 encoding DNA co-injected with a plasmid carrying GMCSF gave meager CD4+ T-cell responses in BALB/c mice relative to bicistronic gp120 and
GMCSF cloned into the same vector and expressed from the same promoter.
• The bicistronic gp120/GM-CSF vaccine induced an approximately 10-fold increase of CD4+ T cell proliferative responses to gp120, as well as a significant
increase in IL-2, IL-4, IL-10, IFN-gamma and GM-CSF production, compared to immunization with the monocistronic pVIJ-gp120 with GMCSF. The
enhanced proliferative responses were substantiated by CD4+ T-cell Elispot.
• Both mono and bicistronic DNA vaccines induced similar CTL responses directed against the H-2Dd restricted P18 peptide RGPRAFTVTI in murine
splenocytes despite the enhanced proliferative responses.
gp160 (311–320) gp120 (IIIB) RGPGPAFVTI Vaccine murine (H-2d) Xin1998
Vaccine Vector/Type: DNA with CMV promotor Strain: IIIB HIV component: gp160, REV Adjuvant: IL-2 expression vector
• Intranasal immunization with IL-2 expression plasmid in addition to DNA vaccine amplifies cellular response to antigen, probably via activation of Th type
1 (Th1) cells
gp160 (311–320) gp120 (IIIB) RGPGPAFVTI Vaccine murine (H-2d) Xin1999
Vaccine Vector/Type: DNA with CMV promotor Strain: IIIB HIV component: gp160, REV Adjuvant: IL-15 expression vector
• Intranasal immunization with IL-15 expression plasmid in addition to DNA vaccine increases DTH response and CTL activity to the antigen, and decreases
the serum IgG1 to IgG2a ratio, enhancing Th type 1 (Th1) cell-mediated immunity
• Expression of IL-2 or IL-15 can enhance Th1 response to the vaccine, but they to do not appear to elicit a synergistic response
gp160 (311–320) gp120 (IIIB) RGPGPAFVTI Vaccine murine (H-2d) Ihata1999
Vaccine Vector/Type: DNA with CMV promotor Strain: IIIB HIV component: gp160, REV Adjuvant: CD40L expression vector
• CD40L expression increases DTH, and Th1-dependent responses based on enhanced IgG2a titers, with no lowering of IgG1 titers
• Elispot assay indicated co-injection with hCD40L resulted in greater numbers of IFN-gamma producing Th1cells, as well as increased IL-4 producing Th2
cells
• Results suggest hCD40L enhance both Th1 and Th2 cells, and such a pattern of induction is unique among adjuvants, as most adjuvants increase either Th1
or Th2
gp160 (311–322) Env (IIIB) RGPGRAFVTIGK Vaccine murine (H-2d) Kusakabe2000
Vaccine Vector/Type: DNA with CMV promotor Strain: IIIB HIV component: gp160, REV Adjuvant: pGM-CSF expression vector
• The timing of delivery of the pGM-CSF expression plasmid for intramuscular DNA pCMV160IIIB/REV vaccination impacts the Th response, maximizing
Th2 responses when administered 3 days prior to the DNA vaccine, and Th1 responses when administered 3 days after the DNA vaccine
gp160 (314–328) gp120 (314–328 IIIB,
B10)
GRAFVTIGKIGNMRQ HIV-1 infection human Wahren1989b, Wahren1989a
• 12 gag and 18 env peptides were identified that could commonly evoke T-cell responses.
gp160 (314–341) gp120 (319–346 NL43) GRAFVTIGKIGNMRQAHCN-
ISRAKWNAT
Vaccine human Sitz1999
Vaccine Vector/Type: recombinant protein Strain: NL43 HIV component: gp120, gp160
• There was a great breadth of proliferative response to env peptides in 19 HIV-1 infected rgp160 and 17 HIV-1 infected rgp120 vaccine recipients
• More than 25% of vaccinees had a stimulation index of greater than 5 to this peptide
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gp160 (315–328) Env (UG92005) RAYYTTNIVGNIRQ Vaccine murine (H-2 IAb) Surman2001
Vaccine Vector/Type: DNA, vaccinia, recombinant protein Strain: 1007 (clade B), UG92005 (clade D) HIV component: gp140 Adjuvant: Freund’s
adjuvant
• This epitope is located in the V3 region of UG92005 (UG, clade D) and was recognized by two hybridomas with Vβ usage not determined, but one used
Vα 8
• C57BL/6 mice were immunized with a prime-boost strategy involving three HIV-1 Env antigens: Mice were primed with DNA given i.m., 3-4 weeks later
boosted with VV, and 3-4 weeks later boosted again with purified protein in Freund’s adjuvant
• The vaccinia construct is a pSC11-based VV vector with the first 38 amino acids contributed by BH10 and the rest of gp120 and gp41 by the vaccine strain,
the DNA construct is in the pJW4303 vector with a CMV promotor, and the purified protein is expressed from the pJW4303 vector transfected into
CHO-K1 cells
• Ten days after the final boost, hybridomas were made and tested for IL-2 production using either B6 spleen cells or H-2 IAb transfected L cells as targets
and Vβ usage was determined
• Mice were immunized with an Env from either one of two clades: HIV-1 1007, a clade B strain isolated from an individual from Memphis Tennesee, and
HIV-1 92UG005, a clade D vaccine isolated from Uganda in 1992 through the WHO
• 80 unique clonotypes were characterized from six mice
• H-2 IAb restricted T-helper epitopes were concentrated in 5 distinct regions within the Env sequence (2 clonotype responses in V2, 26 in C2, 22 in V3, 23
in V4C4, and 7 in gp41).
• Epitope hotspots tended to be proximal to heavily glycosylated regions of the Env sequence, in exposed, non-helical strands of the protein. The
non-uniform localization may be influenced by differential antigen processing and the glycosylation site proximity may allow binding to lectins and
promote trafficking through processing pathways.
gp160 (317–331) gp160 (324–338 IIIB) FVTIGKIGNMRQAHC Vaccine murine (H-2k, H-2d) Berzofsky1991b,
Berzofsky1991a
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160 Adjuvant: Freund’s adjuvant
• B10.BR (H-2Ak, Ek) and B10.D2 (H-2Ad , Ed) mice immunized with rec gp160 showed a proliferative response to this peptide
• FVTIGKIGNMRQAHCNISRAKWNNTLKQIDSKL encompasses several murine Th epitopes including FVTIGKIGNMRQAHC and is referred to as a
"multideterminant region" or cluster peptide
gp160 (317–331) gp120 (324–338 IIIB) FVTIGKIGNMRQAHC Vaccine murine (H-2k,d) Hale1989
Vaccine Strain: IIIB HIV component: gp160
• Six multideterminant helper T-cell regions are recognized by mice of three or four MHC types
gp160 (317–336) gp120 (321–340 MN) YTTKNIIGTIRQAHCNSRA Vaccine guinea pig Chattergoon2002
Vaccine Vector/Type: protein, DNA Strain: MN HIV component: gp120 Adjuvant: complete Freund’s adjuvant (CFA)
• Epitope name: 1987
• Hartley guinea pigs were intradermally injected with either recombinant protein or plasmid expressed gp120 and monitored for delayed type hypersensivity
(DTH) responses after vaccination, which are related to Th1 T-cell responses. CFA did not augment responses in animals vaccinated with plasmid.
• A total of 7 gp120 peptides elicited a delayed type hypersensivity (DTH) response after vaccination, out of a set of 60 overlapping peptides that spanned
gp120. The vaccine delivery system, DNA versus rec protein, resulted in the recognition of distinct peptides.
• 4/5 animals vaccinated with rec gp120 responded by DTH to this peptide, as did 4/6 vaccinated with plasmid gp120 DNA.
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gp160 (317–349) gp160 (324–356 IIIB) FVTIGKIGNMRQAHCNISR-
AKWNNTLKQIDSKL
HIV-1 infection, Vaccine human, murine (H-2k,
H-2d)
Berzofsky1991b,
Berzofsky1991a
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160 Adjuvant: Freund’s adjuvant
• FVTIGKIGNMRQAHCNISRAKWNNTLKQIDSKL encompasses several murine Th epitopes and is referred to as a "multideterminant region" or cluster
peptide
• Six multideterminant region cluster peptides were evaluated Th responses in different MHC/HLA backgrounds after vaccination of mice with gp160, or in
infected people
• This cluster peptide elicited proliferative responses in cells from B10.BR mice (H-2Ak, Ek) and B10.D2 mice (H-2Ad , Ed), but shorter peptides from within
this region stimulated H-2k, H-2d , H-2b and H-2s responses
• IL-2 production in response to this peptide was observed in 58% (21/36) of asymptomatic HIV-infected individuals
gp160 (319–338) gp120 (320–339 89.6) RRNIIGDIRQAHCNISRAKW Vaccine murine Dai2001
Vaccine Vector/Type: recombinant protein Strain: 89.6 HIV component: gp120 Adjuvant: R192G mutant heat-labile toxin from enterotoxigenic E.
coli (mLT)
• Epitope name: Peptide 30
• Helper T-cell proliferative responses to gp120 vaccines in 2 mouse strains, CBA/J and BALB/c, were mapped using 47 overlapping peptides that span
gp120. Promiscuously immunodominant peptides were identified in both mice strains that were located in the outer domain of gp120 and were associated
with regions of local structural disorder in proximal N-terminal segments, suggesting 3-D protein structure influences Th antigen processing and the
frequency of immunogenic sequences.
• This peptide was highly reactive in 7/10 BALB/c mice tested, and in 7/10 CBA/J mice and was consider one of the 3 immunodominant peptides identified
that were shared in both mouse strains: RRNIIGDIRQAHCNISRAKW, NNTLQQIVIKLREKFRNKTI, GTNGTEGNDIITLQCRIKQI.
gp160 (319–338) gp120 (320–339 89.6) RRNIIGDIRQAHCNISRAKW Vaccine murine (H-2k, H-2d) Dai2001
Vaccine Vector/Type: recombinant protein Strain: 89.6 HIV component: gp120 Adjuvant: mutant R192G heat-labile toxin from E. coli as adjuvant
• Promiscuous immunodominant epitopes in gp120 were mapped by overlapping peptides in CBA/J H-2k and BALB/c H-2d mice, and all were found to be
in the outer domain, proximal to regions of structural disorder indicated by the crystal structure or by sequence divergence.
• This peptide was recognized by 7/10 CBA/J and 7/10 BALB/c mice with SI > 4, averaging 6.3 and 4.8, and is considered to be promiscuously
immunodominant
• Uniquely immunodominant sequences tended to be in the inner domain of the protein
gp160 (321–336) gp120 (IIIB) RIIGDIRKAHCNISRY in vitro stimulation human Manca1995b
• Peptide stimulation of PBMC from non-infected individuals in vitro
• Peptide priming does not always induce T-cells that recognize whole protein
gp160 (322–336) Env (1007) IIGDIRQAHCNISRE Vaccine murine (H-2 IAb) Surman2001
Vaccine Vector/Type: DNA, vaccinia, recombinant protein Strain: 1007 (clade B), UG92005 (clade D) HIV component: gp140 Adjuvant: Freund’s
adjuvant
• This epitope is located in the V3 region of 1007 (US, clade B) and was recognized by three hybridomas with Vβ usage Vβ 6 and not determined
• C57BL/6 mice were immunized with a prime-boost strategy involving three HIV-1 Env antigens: Mice were primed with DNA given i.m., 3-4 weeks later
boosted with VV, and 3-4 weeks later boosted again with purified protein in Freund’s adjuvant
• The vaccinia construct is a pSC11-based VV vector with the first 38 amino acids contributed by BH10 and the rest of gp120 and gp41 by the vaccine strain,
the DNA construct is in the pJW4303 vector with a CMV promotor, and the purified protein is expressed from the pJW4303 vector transfected into
CHO-K1 cells
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• Ten days after the final boost, hybridomas were made and tested for IL-2 production using either B6 spleen cells or H-2 IAb transfected L cells as targets
and Vβ usage was determined
• Mice were immunized with an Env from either one of two clades: HIV-1 1007, a clade B strain isolated from an individual from Memphis Tennesee, and
HIV-1 92UG005, a clade D vaccine isolated from Uganda in 1992 through the WHO
• 80 unique clonotypes were characterized from six mice
• H-2 IAb restricted T-helper epitopes were concentrated in 5 distinct regions within the Env sequence (2 clonotype responses in V2, 26 in C2, 22 in V3, 23
in V4C4, and 7 in gp41).
• Epitope hotspots tended to be proximal to heavily glycosylated regions of the Env sequence, in exposed, non-helical strands of the protein. The
non-uniform localization may be influenced by differential antigen processing and the glycosylation site proximity may allow binding to lectins and
promote trafficking through processing pathways.
gp160 (322–336) Env (UG92005) IVGNIRQAHCNVSKA Vaccine murine (H-2 IAb) Surman2001
Vaccine Vector/Type: DNA, vaccinia, recombinant protein Strain: 1007 (clade B), UG92005 (clade D) HIV component: gp140 Adjuvant: Freund’s
adjuvant
• This epitope is located in the V3 region of UG92005 (UG, clade D) and was recognized by three hybridomas with Vβ usage Vβ 6, 8.1, and not determined
• C57BL/6 mice were immunized with a prime-boost strategy involving three HIV-1 Env antigens: Mice were primed with DNA given i.m., 3-4 weeks later
boosted with VV, and 3-4 weeks later boosted again with purified protein in Freund’s adjuvant
• The vaccinia construct is a pSC11-based VV vector with the first 38 amino acids contributed by BH10 and the rest of gp120 and gp41 by the vaccine strain,
the DNA construct is in the pJW4303 vector with a CMV promotor, and the purified protein is expressed from the pJW4303 vector transfected into
CHO-K1 cells
• Ten days after the final boost, hybridomas were made and tested for IL-2 production using either B6 spleen cells or H-2 IAb transfected L cells as targets
and Vβ usage was determined
• Mice were immunized with an Env from either one of two clades: HIV-1 1007, a clade B strain isolated from an individual from Memphis Tennesee, and
HIV-1 92UG005, a clade D vaccine isolated from Uganda in 1992 through the WHO
• 80 unique clonotypes were characterized from six mice
• H-2 IAb restricted T-helper epitopes were concentrated in 5 distinct regions within the Env sequence (2 clonotype responses in V2, 26 in C2, 22 in V3, 23
in V4C4, and 7 in gp41).
• Epitope hotspots tended to be proximal to heavily glycosylated regions of the Env sequence, in exposed, non-helical strands of the protein. The
non-uniform localization may be influenced by differential antigen processing and the glycosylation site proximity may allow binding to lectins and
promote trafficking through processing pathways.
gp160 (322–336) Env (UG92005) IVGNIRQAHCNVSKA Vaccine murine (H-2 IAb) Surman2001
Vaccine Vector/Type: DNA, vaccinia, recombinant protein Strain: 1007 (clade B), UG92005 (clade D) HIV component: gp140 Adjuvant: Freund’s
adjuvant
• This epitope is located in the V3 region of UG92005 (UG, clade D) and was recognized by three hybridomas with Vβ usage Vβ 6, 8.1, and not determined
• C57BL/6 mice were immunized with a prime-boost strategy involving three HIV-1 Env antigens: Mice were primed with DNA given i.m., 3-4 weeks later
boosted with VV, and 3-4 weeks later boosted again with purified protein in Freund’s adjuvant
• The vaccinia construct is a pSC11-based VV vector with the first 38 amino acids contributed by BH10 and the rest of gp120 and gp41 by the vaccine strain,
the DNA construct is in the pJW4303 vector with a CMV promotor, and the purified protein is expressed from the pJW4303 vector transfected into
CHO-K1 cells
• Ten days after the final boost, hybridomas were made and tested for IL-2 production using either B6 spleen cells or H-2 IAb transfected L cells as targets
and Vβ usage was determined
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• Mice were immunized with an Env from either one of two clades: HIV-1 1007, a clade B strain isolated from an individual from Memphis Tennesee, and
HIV-1 92UG005, a clade D vaccine isolated from Uganda in 1992 through the WHO
• 80 unique clonotypes were characterized from six mice
• H-2 IAb restricted T-helper epitopes were concentrated in 5 distinct regions within the Env sequence (2 clonotype responses in V2, 26 in C2, 22 in V3, 23
in V4C4, and 7 in gp41).
• Epitope hotspots tended to be proximal to heavily glycosylated regions of the Env sequence, in exposed, non-helical strands of the protein. The
non-uniform localization may be influenced by differential antigen processing and the glycosylation site proximity may allow binding to lectins and
promote trafficking through processing pathways.
gp160 (322–341) gp120 (322–341 IIIB) KIGNMRQAHCNISRAKWNN-
T?
HIV-1 infection human Geretti1994
• Epitope name: F4
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 1/15 responders recognized this peptide, SI = 7.6.
gp160 (324–336) Env (UG92005) GNIRQAHCNVSKA Vaccine murine (H-2 IAb) Surman2001
Vaccine Vector/Type: DNA, vaccinia, recombinant protein Strain: 1007 (clade B), UG92005 (clade D) HIV component: gp140 Adjuvant: Freund’s
adjuvant
• This epitope is located in the V3 region of UG92005 (UG, clade D) and was recognized by two hybridoma with Vβ usage Vβ8.2 and not determined
• The epitope described here is the region of overlap of two 15 mers that were both able to stimulate IL-2 production from the hybridoma
(IVGNIRQAHCNVSKA and GNIRQAHCNVSKAKW)
• C57BL/6 mice were immunized with a prime-boost strategy involving three HIV-1 Env antigens: Mice were primed with DNA given i.m., 3-4 weeks later
boosted with VV, and 3-4 weeks later boosted again with purified protein in Freund’s adjuvant
• The vaccinia construct is a pSC11-based VV vector with the first 38 amino acids contributed by BH10 and the rest of gp120 and gp41 by the vaccine strain,
the DNA construct is in the pJW4303 vector with a CMV promotor, and the purified protein is expressed from the pJW4303 vector transfected into
CHO-K1 cells
• Ten days after the final boost, hybridomas were made and tested for IL-2 production using either B6 spleen cells or H-2 IAb transfected L cells as targets
and Vβ usage was determined
• Mice were immunized with an Env from either one of two clades: HIV-1 1007, a clade B strain isolated from an individual from Memphis Tennesee, and
HIV-1 92UG005, a clade D vaccine isolated from Uganda in 1992 through the WHO
• 80 unique clonotypes were characterized from six mice
• H-2 IAb restricted T-helper epitopes were concentrated in 5 distinct regions within the Env sequence (2 clonotype responses in V2, 26 in C2, 22 in V3, 23
in V4C4, and 7 in gp41).
• Epitope hotspots tended to be proximal to heavily glycosylated regions of the Env sequence, in exposed, non-helical strands of the protein. The
non-uniform localization may be influenced by differential antigen processing and the glycosylation site proximity may allow binding to lectins and
promote trafficking through processing pathways.
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gp160 (324–338) Env (UG92005) GNIRQAHCNVSKAKW Vaccine murine (H-2 IAb) Surman2001
Vaccine Vector/Type: DNA, vaccinia, recombinant protein Strain: 1007 (clade B), UG92005 (clade D) HIV component: gp140 Adjuvant: Freund’s
adjuvant
• This epitope is located in the V3 region of UG92005 (UG, clade D) and was recognized by eleven hybridomas with Vβ usage Vβ5, 7, 8.1, 8.2, 11 and not
determined – a Vβ 8.1’s and Vβ 8.2 also were shown to use Vα 8, and one of the ND used Vα 2
• C57BL/6 mice were immunized with a prime-boost strategy involving three HIV-1 Env antigens: Mice were primed with DNA given i.m., 3-4 weeks later
boosted with VV, and 3-4 weeks later boosted again with purified protein in Freund’s adjuvant
• The vaccinia construct is a pSC11-based VV vector with the first 38 amino acids contributed by BH10 and the rest of gp120 and gp41 by the vaccine strain,
the DNA construct is in the pJW4303 vector with a CMV promotor, and the purified protein is expressed from the pJW4303 vector transfected into
CHO-K1 cells
• Ten days after the final boost, hybridomas were made and tested for IL-2 production using either B6 spleen cells or H-2 IAb transfected L cells as targets
and Vβ usage was determined
• Mice were immunized with an Env from either one of two clades: HIV-1 1007, a clade B strain isolated from an individual from Memphis Tennesee, and
HIV-1 92UG005, a clade D vaccine isolated from Uganda in 1992 through the WHO
• 80 unique clonotypes were characterized from six mice
• H-2 IAb restricted T-helper epitopes were concentrated in 5 distinct regions within the Env sequence (2 clonotype responses in V2, 26 in C2, 22 in V3, 23
in V4C4, and 7 in gp41).
• Epitope hotspots tended to be proximal to heavily glycosylated regions of the Env sequence, in exposed, non-helical strands of the protein. The
non-uniform localization may be influenced by differential antigen processing and the glycosylation site proximity may allow binding to lectins and
promote trafficking through processing pathways.
gp160 (327–341) gp120 (327–341 HXB2) RQAHCNISRAKWNNT Vaccine murine (I-Ad) Warren1992
Vaccine Vector/Type: recombinant protein Strain: HXB2 HIV component: gp120
• Minimum epitope and MHC restriction determined for CTL clone that recognizes the N-terminal flank of the V3 loop
gp160 (327–346) gp120 (331–350 MN) RQAHCNISRAKWNDILRQIV Vaccine guinea pig Chattergoon2002
Vaccine Vector/Type: protein, DNA Strain: MN HIV component: gp120 Adjuvant: complete Freund’s adjuvant (CFA)
• Epitope name: 1988
• Hartley guinea pigs were intradermally injected with either recombinant protein or plasmid expressed gp120 and monitored for delayed type hypersensivity
(DTH) responses after vaccination, which are related to Th1 T-cell responses. CFA did not augment responses in animals vaccinated with plasmid.
• A total of 7 gp120 peptides elicited a delayed type hypersensivity (DTH) response after vaccination, out of a set of 60 overlapping peptides that spanned
gp120. The vaccine delivery system, DNA versus rec protein, resulted in the recognition of distinct peptides.
• 4/5 animals vaccinated with rec gp120 responded by DTH to this peptide, and 2/6 responded that were vaccinated with plasmid gp120 DNA.
gp160 (330–350) gp120 (330–349 IIIB) HCNISRAKWNNTLKQIASK-
LR?
HIV-1 infection human Geretti1994
• Epitope name: F5
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
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• 3/15 responders recognized this peptide, average SI = 5.5.
gp160 (331–345) gp120 (IIIB) CNISRAQWNNTLEQI in vitro stimulation human Manca1995b
• Peptide stimulation of PBMC from non-infected individuals in vitro
• Peptide priming does not always induce T-cells that recognize whole protein
gp160 (332–354) gp120 (337–359 NL43) NISRAKWNATLKQIASKLR-
EQFG
Vaccine human Sitz1999
Vaccine Vector/Type: recombinant protein Strain: NL43 HIV component: gp120, gp160
• There was a great breadth of proliferative response to env peptides in 19 HIV-1 infected rgp160 and 17 HIV-1 infected rgp120 vaccine recipients
• More than 30% of vaccinees had a stimulation index of greater than 5 to this peptide
gp160 (335–349) gp160 (342–356 IIIB) RAKWNNTLKQIDSKL Vaccine murine (H-2k, H-2b,
H-2s)
Berzofsky1991b,
Berzofsky1991a
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160 Adjuvant: Freund’s adjuvant
• B10.BR (H-2Ak, Ek), B10.A(5R) (H-2Ab, Eb) and B10.S(9R) (H-2As, Es) mice immunized with rec gp160 showed a proliferative response to this peptide
• FVTIGKIGNMRQAHCNISRAKWNNTLKQIDSKL encompasses several murine Th epitopes including RAKWNNTLKQIDSKL and is referred to as a
"multideterminant region" or cluster peptide
gp160 (335–349) gp120 (342–356 IIIB) RAKWNNTLKQICSKL Vaccine murine (H-2k,t4,i5) Hale1989
Vaccine Strain: IIIB HIV component: gp160
• Six multideterminant helper T-cell regions are recognized by mice of three or four MHC types
gp160 (337–356) gp120 (341–360 MN) KWNDTLRQIVSKLKEQFKNK Vaccine guinea pig Chattergoon2002
Vaccine Vector/Type: protein, DNA Strain: MN HIV component: gp120 Adjuvant: complete Freund’s adjuvant (CFA)
• Epitope name: 1989
• Hartley guinea pig were intradermally injected with either recombinant protein or plasmid expressed gp120 and monitored for delayed type hypersensivity
(DTH) responses after vaccination, which are related to Th1 T-cell responses. CFA did not augment responses in animals vaccinated with plasmid.
• A total of 7 gp120 peptides elicited a delayed type hypersensivity (DTH) response after vaccination, out of a set of 60 overlapping peptides that spanned
gp120. The vaccine delivery system, DNA versus rec protein, resulted in the recognition of distinct peptides.
• 3/5 animals vaccinated with rec gp120 responded by DTH to this peptide, and 2/6 responded that were vaccinated with plasmid gp120 DNA.
gp160 (339–359) gp120 (340–359 89.6) NNTLQQIVIKLREKFRNKTI Vaccine murine Dai2001
Vaccine Vector/Type: recombinant protein Strain: 89.6 HIV component: gp120 Adjuvant: R192G mutant heat-labile toxin from enterotoxigenic E.
coli (mLT)
• Epitope name: Peptide 32
• Helper T-cell proliferative responses to gp120 vaccines in 2 mouse strains, CBA/J and BALB/c, were mapped using 47 overlapping peptides that span
gp120. Promiscuously immunodominant peptides were identified in both mice strains that were located in the outer domain of gp120 and were associated
with regions of local structural disorder in proximal N-terminal segments, suggesting 3-D protein structure influences Th antigen processing and the
frequency of immunogenic sequences.
• This peptide was reactive in 6/10 BALB/c mice tested, and in 4/10 CBA/J mice and was consider one of the 3 immunodominant peptides identified that
were shared in both mouse strains: RRNIIGDIRQAHCNISRAKW, NNTLQQIVIKLREKFRNKTI, GTNGTEGNDIITLQCRIKQI.
gp160 (339–359) gp120 (340–359 89.6) NNTLQQIVIKLREKFRNKTI Vaccine murine (H-2k, H-2d) Dai2001
Vaccine Vector/Type: recombinant protein Strain: 89.6 HIV component: gp120 Adjuvant: mutant R192G heat-labile toxin from E. coli as adjuvant
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• Promiscuous immunodominant epitopes in gp120 were mapped by overlapping peptides in CBA/J H-2k and BALB/c H-2d mice, and all were found to be
in the outer domain, proximal to regions of structural disorder indicated by the crystal structure or by sequence divergence.
• This peptide was recognized by 4/10 CBA/J and 6/10 BALB/c mice with SI > 4, averaging 4.9 and 5.5 and is considered to be promiscuously
immunodominant
• Uniquely immunodominant sequences tended to be in the inner domain of the protein
gp160 (341–356) gp120 (IIIB) TLEQIVKKLREQFGNC in vitro stimulation human Manca1995b
• Peptide stimulation of PBMC from non-infected individuals in vitro
• Peptide priming does not always induce T-cells that recognize whole protein
gp160 (342–361) gp120 (342–361 IIIB) LKQIASKLREQFGNNKTII-
F?
HIV-1 infection human Geretti1994
• Epitope name: G1
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 2/15 responders recognized this peptide, average SI = 6.0.
gp160 (344–357) gp120 (346–359) QIVKKLREQFGNNK HIV-1 infection human Krowka1990
• Conjugation of HIV peptides to liposomes and rIL-2 stimulation may enhance cell-mediated responses
gp160 (349–368) gp120 (350–369 89.6) LREKFRNKTIAFNQSSGGD Vaccine murine Dai2001
Vaccine Vector/Type: recombinant protein Strain: 89.6 HIV component: gp120 Adjuvant: R192G mutant heat-labile toxin from enterotoxigenic E.
coli (mLT)
• Epitope name: Peptide 33
• Helper T-cell proliferative responses to gp120 vaccines in 2 mouse strains, CBA/J and BALB/c, were mapped using 47 overlapping peptides that span
gp120. Promiscuously immunodominant peptides were identified in both mice strains that were located in the outer domain of gp120 and were associated
with regions of local structural disorder in proximal N-terminal segments, suggesting 3-D protein structure influences Th antigen processing and the
frequency of immunogenic sequences.
• This peptide was reactive in 3/10 BALB/c mice tested, and in 5/10 CBA/J mice.
gp160 (350–370) gp120 (350–370 IIIB) REQFGNNKTIIFKQSSGGD-
PE?
HIV-1 infection human Geretti1994
• Epitope name: G2
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 1/15 responders recognized this peptide, average SI = 3.2.
gp160 (353–360) gp120 (355–362 IIIB) FGNNKTII SHIV infection Rhesus macaque Lekutis1997a
• C3 region minimal epitope determined through fine epitope mapping
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• Cell line was lost prior to confirmation of MHC requirements
gp160 (363–372) gp120 (368–377 LAI) QSSGGDPEIV HIV-1 infection human Schrier1989
• Stimulates T-cell proliferation in HIV-infected donors
gp160 (364–378) gp120 (364–378 IIIB,
B10)
SSGGKPEIVTHSFNC HIV-1 infection human Wahren1989b, Wahren1989a
• 12 gag and 18 env peptides were identified that could commonly evoke T-cell responses.
gp160 (369–383) gp120 (369–383 IIIB,
B10)
PEIVTHSFNCGGEFF HIV-1 infection human Wahren1989b, Wahren1989a
• 12 gag and 18 env peptides were identified that could commonly evoke T-cell responses.
gp160 (380–393) gp120 (380–393 IIIB) GEFFYCNSTQLFNS? HIV-1 infection human Geretti1994
• Epitope name: G4
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• Five peptides were recognized most frequently: C2 (aa 142-161), C3 (aa 152-171), C5 (aa 172-191), E5 (aa 272-291) and G4 (aa 380-393). The first three
were in or near V2, the other two were proximal to the V3 and V4 loops.
• 4/15 responders recognized this immunodominant peptide, average SI = 4.4.
gp160 (381–395) gp120 (IIIB) EFFYCNTTQLFNNTW in vitro stimulation human Manca1995b
• Peptide stimulation of PBMC from non-infected individuals in vitro
• Peptide priming does not always induce T-cells that recognize whole protein
gp160 (392–411) gp120 (392–411 IIIB) NSTWFNSTWSTEGSNNTEG-
S?
HIV-1 infection human Geretti1994
• Epitope name: G5
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 1/15 responders recognized this peptide, SI = 9.3.
gp160 (394–408) gp120 (394–408 IIIB,
B10)
TWFNSTWSTKGSNNT HIV-1 infection human Wahren1989b, Wahren1989a
• 12 gag and 18 env peptides were identified that could commonly evoke T-cell responses.
gp160 (396–411) gp120 (IIIB) FNNTWRLNHTEGTKGC in vitro stimulation human Manca1995b
• Peptide stimulation of PBMC from non-infected individuals in vitro
• Peptide priming does not always induce T-cells that recognize whole protein
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gp160 (399–413) gp120 (399–413 IIIB,
B10)
TWSTKGSNNTEGSDT HIV-1 infection human Wahren1989b, Wahren1989a
• 12 gag and 18 env peptides were identified that could commonly evoke T-cell responses.
gp160 (404–423) gp120 (400–419 89.6) GTNGTEGNDIITLQCRIKQI Vaccine murine Dai2001
Vaccine Vector/Type: recombinant protein Strain: 89.6 HIV component: gp120 Adjuvant: R192G mutant heat-labile toxin from enterotoxigenic E.
coli (mLT)
• Epitope name: Peptide 38
• Helper T-cell proliferative responses to gp120 vaccines in 2 mouse strains, CBA/J and BALB/c, were mapped using 47 overlapping peptides that span
gp120. Promiscuously immunodominant peptides were identified in both mice strains that were located in the outer domain of gp120 and were associated
with regions of local structural disorder in proximal N-terminal segments, suggesting 3-D protein structure influences Th antigen processing and the
frequency of immunogenic sequences.
• This peptide was reactive in 8/10 BALB/c mice tested, and in 6/10 CBA/J mice, and was consider one of the 3 immunodominant peptides identified that
were shared in both mouse strains: RRNIIGDIRQAHCNISRAKW, NNTLQQIVIKLREKFRNKTI, GTNGTEGNDIITLQCRIKQI.
gp160 (404–423) gp120 (400–419 89.6) GTNGTEGNDIITLQCRIKQI Vaccine murine (H-2k, H-2d) Dai2001
Vaccine Vector/Type: recombinant protein Strain: 89.6 HIV component: gp120 Adjuvant: mutant R192G heat-labile toxin from E. coli as adjuvant
• Promiscuous immunodominant epitopes in gp120 were mapped by overlapping peptides in CBA/J H-2k and BALB/c H-2d mice, and all were found to be
in the outer domain, proximal to regions of structural disorder indicated by the crystal structure or by sequence divergence.
• This peptide was recognized by 4/10 CBA/J and 6/10 BALB/c mice with SI > 4, averaging 4.9 and 5.5 and is considered to be promiscuously
immunodominant
• Uniquely immunodominant sequences tended to be in the inner domain of the protein
gp160 (405–420) Env (1007) SNNTVGNPIILPCRI Vaccine murine (H-2 IAb) Surman2001
Vaccine Vector/Type: DNA, vaccinia, recombinant protein Strain: 1007 (clade B), UG92005 (clade D) HIV component: gp140 Adjuvant: Freund’s
adjuvant
• This epitope is located in the V4C4 region of 1007 (US, clade B) and was recognized by 13 hybridomas with Vβ usage Vβ 4, 7, 8.1, 8.2, 10, 12 and not
determined – one of the Vβ 8.2 was shown to utilize Vα 2
• C57BL/6 mice were immunized with a prime-boost strategy involving three HIV-1 Env antigens: Mice were primed with DNA given i.m., 3-4 weeks later
boosted with VV, and 3-4 weeks later boosted again with purified protein in Freund’s adjuvant
• The vaccinia construct is a pSC11-based VV vector with the first 38 amino acids contributed by BH10 and the rest of gp120 and gp41 by the vaccine strain,
the DNA construct is in the pJW4303 vector with a CMV promotor, and the purified protein is expressed from the pJW4303 vector transfected into
CHO-K1 cells
• Ten days after the final boost, hybridomas were made and tested for IL-2 production using either B6 spleen cells or H-2 IAb transfected L cells as targets
and Vβ usage was determined
• Mice were immunized with an Env from either one of two clades: HIV-1 1007, a clade B strain isolated from an individual from Memphis Tennesee, and
HIV-1 92UG005, a clade D vaccine isolated from Uganda in 1992 through the WHO
• 80 unique clonotypes were characterized from six mice
• H-2 IAb restricted T-helper epitopes were concentrated in 5 distinct regions within the Env sequence (2 clonotype responses in V2, 26 in C2, 22 in V3, 23
in V4C4, and 7 in gp41).
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• Epitope hotspots tended to be proximal to heavily glycosylated regions of the Env sequence, in exposed, non-helical strands of the protein. The
non-uniform localization may be influenced by differential antigen processing and the glycosylation site proximity may allow binding to lectins and
promote trafficking through processing pathways.
gp160 (410–429) gp120 (410–429 PV22) GSDTITLPCRIKQFINMWQE HIV-1 infection human (DR4) Callahan1990
• Synthetic peptides representing natural variants were used to test for recognition in the context DR4
gp160 (410–429) gp120 (410–429 PV22) GSDTITLPCRIKQFINMWQE HIV-1 infection human (DR4(Dw10)) Polydefkis1990
• Human CD4+ T-cell clones lyse recombinant vaccinia virus-infected cells that synthesize envelope gp160
gp160 (412–431) gp120 (412–431 IIIB) DTITLPCRIKQIINMWQKV-
G?
HIV-1 infection human Geretti1994
• Epitope name: H2
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 1/15 responders recognized this peptide, SI = 5.7.
gp160 (416–431) gp120 (IIIB) LPCRIKQIINMWQEVY in vitro stimulation human Manca1995b
• Peptide stimulation of PBMC from non-infected individuals in vitro
• Peptide priming does not always induce T-cells that recognize whole protein
gp160 (418–436) Env (417–435) CRIKQIINMWQGVGKAMYA HIV-1 infection human, chimpanzee Nehete1998b
• HIV-infected chimpanzees and HIV-positive patients show positive proliferative responses to multiple peptides from five conserved regions of the HIV-1
Env
gp160 (421–436) gp120 (426–441 IIIB) KQFINMWQEWGKAMYA human Furci1997
• Epitope T1 variant: 9/11 exposed-uninfected individuals in this study had a proliferative response to a C5 peptide, but none reacted with this previously
defined epitope
• IIIB position 435 listed as W in this epitope as opposed to V in the sequence.
gp160 (421–436) gp120 (428–433 IIIB) KQIINMWQEVGKAMYA HIV-1 infection human Wasik2000
• Epitope name: T1
• Th responses measured by IL-2 responses to P18 and T1 in HIV-1 infected infants were undetectable at less than 1 month of age, and remained low in
children with AIDS symptoms, but increased with age in children with slowly progressive disease
• The kinetics and intensity of the CTL activity during the first year of life was related to the child’s ability to make Th1 responses
gp160 (421–436) gp120 (428–433 IIIB) KQIINMWQEVGKAMYA HIV-1 infection human Wasik1997
• Epitope name: T1
• The breadth and intensity of the CTL response and the type of Th response was studied in seven rapidly progressing HIV-1+ infants
• IL-2 and γ IFN production from Th1 cells correlated with the CTLp frequency against HIV-1 Gag, Env, Nef and Pol
• IL-4 production from Th2 cells was inversely correlated with the CTLp frequency
• The HIV-1+ children with strong CTL responses had levels of anti-CD3 MAb induction of Th1 cells comparable to those of uninfected children
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gp160 (421–436) gp120 (428–443 IIIB) KQIINMWQEVGKAMYA Vaccine human Berzofsky1988
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: gp160
• Epitope name: T1
• Proliferative response to T1 and T2 peptides in 14 immunized, uninfected humans
gp160 (421–436) gp120 (428–443 IIIB) KQIINMWQEVGKAMYA Vaccine goat Palker1989
Vaccine Vector/Type: peptide Strain: IIIB
• Epitope name: T1
• Goats immunized with peptides containing V3 type-specific neutralizing determinants coupled to T1
gp160 (421–436) gp120 (428–443 IIIB) KQIINMWQEVGKAMYA HIV-1 infection human Clerici1989
• Epitope name: T1
• IL-2 production detection of Th lymphocytes from asymptomatic HIV-positive individuals
gp160 (421–436) gp120 (428–443 IIIB) KQIINMWQEVGKAMYA HIV-1 infection human Clerici1991a
• Epitope name: T1
• Peptides stimulate Th cell function and CTL activity in similar patient populations
gp160 (421–436) gp120 (428–443 IIIB) KQIINMWQEVGKAMYA Vaccine human Clerici1991b
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160
• Epitope name: T1
• Immunizing uninfected individuals with rgp160 results in stronger Th response than does natural infection
gp160 (421–436) gp120 (428–443 IIIB) KQIINMWQEVGKAMYA human Clerici1992
• Epitope name: T1
• Cell-mediated immune response to HIV-1 peptides in HIV-1 exposed seronegative men
gp160 (421–436) gp120 (428–443 IIIB) KQIINMWQEVGKAMYA Vaccine murine diMarzo Veronese1994
Vaccine Vector/Type: bacteriophage coat protein Strain: MN HIV component: V3
• Epitope T1 was engineered into a filamentous bacteriophage coat protein, and the Th epitope stimulated Ab production to the V3 loop
gp160 (421–436) gp120 (428–443 IIIB) KQIINMWQEVGKAMYA Vaccine chimpanzee Haynes1993
Vaccine Vector/Type: peptide Strain: IIIB
• Epitope name: T1
• Hybrid T1-V3 peptide immunogenicity reduced when the fusogenic domain of gp41 was added
gp160 (421–436) gp120 (428–443 IIIB) KQIINMWQEVGKAMYA HIV-1 infection human Clerici1997
• Epitope name: T1
• Used in a study of the influence of pentoxifylline on HIV specific T-cells
gp160 (421–436) gp120 (428–443 IIIB) KQIINMWQEVGKAMYA human Pinto1995
• Epitope name: T1
• CTL activity analyzed in parallel with Th reactivity in exposed but uninfected health care workers
gp160 (421–436) gp160 (428–433 IIIB) KQIINMWQEVGKAMYA HIV-1 infection, HIV-1 exposed
seronegative
human Wasik1999
• Epitope name: T1
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• IL-2 responses associated with beta-chemokine expression were detectable at birth in the majority of uninfected infants born to HIV+ mothers, declining by
age 6 months
• T1 peptide: In both uninfected and infected infants of HIV-positive mothers, responses to the T1 peptide were more frequent than responses to P18
(RIQRGPGRAFVTIGK)
• T1 is a highly conserved epitope, whereas P18 has a higher mutation rate due to its location in the immunodominant V3 loop region
gp160 (421–436) gp120 (428–443 IIIB) KQIINMWQEVGKAMYA HIV-1 infection human Kaul1999
• Epitope name: T1
• Kenyan sex workers that remained seronegative were found to frequently have HIV-env peptide specific Th responses detected by an IL-2 assay (11/20
cases) and mucosal genital tract anti-HIV IgA (16/21 cases)
• Helper epitopes used in this study were noted to be previously described [Clerici1989], and were not explicitly described in [Kaul1999]
gp160 (421–436) gp120 (MN) KQIINMWQEVGKAMYA HIV-1 infection, Vaccine human Bartlett1998
Vaccine Vector/Type: peptide Strain: MN HIV component: polyepitope
• Epitope name: T1
• C4-V3 PV (polyvalent HIV envelope synthetic peptide immunogen) consisted of T1 helper epitope presented in tandem with a V3 loop CTL epitope from
one of four different North American strains
• This was a pilot phase I study involving vaccination of ten HIV-infected subjects who were HLA-B7-positive
• Enhanced lymphoproliferative response to peptide was observed in 5/8 vaccinees – increase in neutralizing antibody responses in 4/8 vacinees
gp160 (421–436) gp120 KQIINMWQEVGKAMYA HIV-1 infection, HIV-1 exposed
seronegative
human Kuhn2001
• Epitope name: T1
• In a S. African perinatal transmission study, 33% (33/86) of cord blood samples from infants with seropositive mothers produced T-helper responses
(measured by a bioassay measuring IL2 production in a murine cell line and confirmed with a proliferation assay) against a peptide cocktail containing Th
epitopes P18 MN, P18 IIIB, T1, T2, and TH4
• The mothers were predominantly infected with subtype C, but the T help response was detectable in a number of cord blood samples despite using peptides
based on B subtype reagents.
• 3/33 infants with cord blood T help responses to Env were infected in utero, 2/33 were lost to follow up, and 28/33 were not infected. 6/53 of the infants
with cord blood that was unresponsive to Env peptide stimulation were infected before delivery, and 8/47 contracted HIV intrapartum or via breast-feeding.
• Measurable HIV specific T help responses elicited in the immunologically immature newborn, possibly in response to in utero exposure, are associated
with a protective natural immunity that helps block mother-infant transmission of HIV-1.
gp160 (421–436) gp120 (428–443 RF) KQIINMWQEVGKAMYA HIV-1 infection deLorimier1994
• Epitope name: T1
• Proton NMR spectroscopy was employed to analyze the solution conformation of a hybrid peptide, T1-SP10RF, in order to better understand the
immunogenicity of its’ T helper (KQIINMWQEVGKAMYA, CTRPNNNTRKSI), CTL (SITKGPGRVIYATG) and B-cell epitopes
(RKSITKGPGRVIYATG).
• As a free peptide, the T1 segment, a T-helper epitope is in an extended conformation with nascent helical conformation. It may form a beta strand in native
gp120, and a nonnative conformation may account for the inability of free T1 peptide to elicit antibody responses, in contrast to the T1 segment in native
gp120. It lacks random-coil conformations, and it is suggested that this may make the peptide less susceptible to complete proteolytic degredation, and be
favored within epitopes.
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gp160 (421–436) gp120 (428–443 IIIB) KQIINMWQEVGKAMYA HIV-1 infection human (DR) Baier1995
• Epitope name: T1
• Linked HIV-1 T1 and P18 peptides to anti-HLA-DR and anti-IgD Fab fragments to enhance uptake by antigen presenting cells and thus increase
immunogenicity
gp160 (421–436) Env (421–436 IIIB) KQIINMWQEVGKAMYA Vaccine murine (Ek) Ahlers2001
Vaccine Vector/Type: peptide Strain: modified IIIB HIV component: Env
• Epitope name: T1
• BALB/c and A.AL were immunized with an Env-peptide vaccine construct containing the CTL epitope P18IIIB and a T helper epitope.
• Substitution of Glu (wt) to Ala, kqiinmwqAvgkamya, caused increased affinity for MHC class II Ek. This resulted in the upregulation of CD40L in the
responding Th cells, and shifted the response towards Th1. Increased Th responses stimulated DCs to produce higher levels of IL-12, and B7-1 and B7-2,
thus enhance CTL responses.
• The modified epitope, T1A, elicited stronger protection against increasing doses of viral challenge with vaccinia expressing HIV-1 IIIB gp120 compared to
the wildtype epitope T1.
gp160 (421–436) gp120 (428–443 IIIB) KQIINMWQEVGKAMYA Vaccine murine (H-2EαEβ k) Boehncke1993
Vaccine Vector/Type: peptide Strain: IIIB
• Epitope name: T1
• C3H H2k mice were used for immunization in the study because H-2k mice are particularly good T1 responders – T1 can be presented by EαEβ k but not
EαEβ b – the nature of the T1 class II molecular interaction was thoroughly explored
• Alanine substitutions across peptide did not negatively affect MHC binding or effective presentation of epitope, except at three critical residues (432N,
435Q, 439K), however substitutions with larger side chains often diminished activity – only a few amino acids were found to be critical for class II
interaction and for maintaining T-cell receptor specificity
• A gain in potency was observed when 436E was replaced with A, suggesting that substitutions in positions that interfere with binding might allow the
design of a more potent vaccine
gp160 (421–436) gp120 (428–443 IIIB) KQIINMWQEVGKAMYA Vaccine murine (H-2d) Klinman1995
Vaccine Vector/Type: peptide Strain: IIIB
• Epitope name: T1
• Hybrid T1-V3 peptide activates IL-4 and IL-6 in a dose dependent manner
gp160 (421–436) gp160 (428–443 IIIB) KQIINMWQEVGKAMYA Vaccine murine (H-2k, H-2s,
H-2d)
Berzofsky1991b,
Berzofsky1991a
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160 Adjuvant: Freund’s adjuvant
• B10.BR (H-2Ak, Ek), B10.D2 (H-2Ad , Ed) and B10.S(9R) (H-2As, Es) mice immunized with rec gp160 showed a proliferative response to this peptide
• KQIINMWQEVGKAMYAPPISGQIR encompasses several murine Th epitopes including KQIINMWQEVGKAMYA and is referred to as a
"multideterminant region" or cluster peptide
gp160 (421–436) gp120 (428–443 IIIB,
B10)
KQIINMWQEVGKAMYA computer prediction murine (H-2k,d,s) Cease1987
• Epitope name: T1
• 1 of 2 functional epitopes identified using an amphipathic helix epitope prediction algorithm
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gp160 (421–436) gp120 (428–443 IIIB) KQIINMWQEVGKAMYA Vaccine murine (H-2k,d,t4) Hale1989
Vaccine Strain: IIIB HIV component: gp160
• Epitope name: T1
• Six multideterminant helper T-cell regions are recognized by mice of three or four MHC types
gp160 (421–436) gp120 (428–443 IIIB) KQIINMWQEVGKAMYA Vaccine murine (H-2k) Ahlers1997b
Vaccine Vector/Type: peptide Strain: IIIB HIV component: polyepitope
• Epitope name: T1
• first identified Th epitope in HIV
• Alanine at position 436 (instead of E in wild-type) enhances MHC binding and antigenicity of peptide by several orders of magnitude
• Vaccines with a CTL epitope linked to a more potent helper epitope yielded greatly enhanced CTL response relative to the wildtype helper epitope
• T1 peptide linked to CTL epitopes in four vaccine constructs used to immunize mice: KQIINMWQEVGKAMYAPPISGQIRRIQRGPGRAFVTIGK,
KQIINMWQEVGKAMYAPPISGQIRRIQRGPGRAFVTI, KQIINMWQAVGKAMYAPPISGQIRRIQRGPGRAFVTIGK,
KQIINMWQAVGKAMYAPPISGQIRRIQRGPGRAFVTI
gp160 (421–444) gp160 (428–451 IIIB) KQIINMWQEVGKAMYAPPI-
SGQIR
HIV-1 infection, Vaccine human, murine (H-2k,
H-2b, H-2s, H-2d)
Berzofsky1991b,
Berzofsky1991a
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160 Adjuvant: Freund’s adjuvant
• KQIINMWQEVGKAMYAPPISGQIR encompasses several murine Th epitopes and is referred to as a "multideterminant region" or cluster peptide
• Six multideterminant region cluster peptides were evaluated Th responses in different MHC/HLA backgrounds after vaccination of mice with gp160, or in
infected people
• This cluster peptide elicited proliferative responses in cells from all H-2 haplotypes tested: B10.BR mice (H-2Ak, Ek), B10.D2 mice (H-2Ad , Ed),
B10.A(5R) mice (H-2Ab, Eb), and B10.S(9R) mice (H-2As, Es)
• IL-2 production in response to this peptide was observed in 73% (8/11) of asymptomatic HIV-infected individuals
gp160 (421–444) gp120 (428–451 IIIB) KQIIMNWQEVGKAMYAPPI-
SGQIR
Vaccine murine (H2d) Shirai1996a
Vaccine Vector/Type: peptide Strain: IIIB
• Epitope name: T1
• Linked to a CTL epitope from hepatitis C virus, induced CD4+ helper cells producing IL-2
gp160 (423–440) gp120 (428–445) FINMWQEVGKAMYAPPIS HIV-1 infection human Caruso1997
• As HIV-1-infected individuals progress to disease, T-cells show reduced ability to proliferate in response to HIV antigen, but retain the ability to express the
activation antigens CD25 and CD71
• The ability to express activation markers in response to HIV is retained, but the response to tetanus toxoid recall antigen is lost
• This study investigated CD25 and CD71 expression in PBMC from patients at various stages of progression, measuring the response to in vitro stimulation
by peptide cocktail containing four antigenic Env peptides, or p17 and p24
gp160 (424–438) gp120 (424–438 IIIB,
B10)
INMWQEVGKAMYAPP HIV-1 infection human Wahren1989b, Wahren1989a
• 12 gag and 18 env peptides were identified that could commonly evoke T-cell responses.
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gp160 (425–439) gp160 (432–446 IIIB) NMWQEVGKAMYAPPI Vaccine murine (H-2s) Berzofsky1991b,
Berzofsky1991a
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160 Adjuvant: Freund’s adjuvant
• B10.S(9R) (H-2As, Es) mice immunized with rec gp160 showed a proliferative response to this peptide
• KQIINMWQEVGKAMYAPPISGQIR encompasses several murine Th epitopes including NMWQEVGKAMYAPPI and is referred to as a
"multideterminant region" or cluster peptide
gp160 (425–439) gp120 (432–446 IIIB) NMWQEVGKAMYAPPI Vaccine murine (H-2t4) Hale1989
Vaccine Strain: IIIB HIV component: gp160
• Six multideterminant helper T-cell regions are recognized by mice of three or four MHC types
gp160 (426–441) gp120 (IIIB) MWQEVGKAMYAPPIGC in vitro stimulation human Manca1995b
• Peptide stimulation of PBMC from non-infected individuals in vitro
• Peptide priming does not always induce T-cells that recognize whole protein
gp160 (430–444) gp160 (437–451 IIIB) VGKAMYAPPISGQIR Vaccine murine (H-2k, H-2b,
H-2s, H-2d)
Berzofsky1991b,
Berzofsky1991a
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160 Adjuvant: Freund’s adjuvant
• This peptide elicited proliferative responses in cells from all H-2 haplotypes tested: B10.BR mice (H-2Ak, Ek), B10.D2 mice (H-2Ad , Ed), B10.A(5R) mice
(H-2Ab, Eb), and B10.S(9R) mice (H-2As, Es)
• KQIINMWQEVGKAMYAPPISGQIR encompasses several murine Th epitopes including VGKAMYAPPISGQIR and is referred to as a "multideterminant
region" or cluster peptide
gp160 (430–444) gp120 (437–451 IIIB) VGKAMYAPPISGQIR Vaccine murine (H-2k,d,i5,t4) Hale1989
Vaccine Strain: IIIB HIV component: gp160
• Six multideterminant helper T-cell regions are recognized by mice of three or four MHC types
gp160 (430–453) gp120 (430–453) VGKAMYAPPISGQIRCSSN-
ITGLL
Vaccine murine (H-2b) Sjolander1996
Vaccine Vector/Type: recombinant protein HIV component: gp160
• Study demonstrates that T-cell determinants from glycoproteins can depend on the glycosylation of the protein
• Peptide stimulation of an in vitro proliferative response required in vivo priming with glycosylated protein
• Local glycosylation sites thought not to be part of the epitope, but may be important for epitope processing
gp160 (432–451) gp120 (432–451 IIIB) KAMYAPPISGQIRCSSNIT-
G?
HIV-1 infection human Geretti1994
• Epitope name: H4
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 1/15 responders recognized this peptide, SI = 6.3.
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gp160 (433–447) Env (UG92005) AMYAPPIAGLIQCSS Vaccine murine (H-2 IAb) Surman2001
Vaccine Vector/Type: DNA, vaccinia, recombinant protein Strain: 1007 (clade B), UG92005 (clade D) HIV component: gp140 Adjuvant: Freund’s
adjuvant
• This epitope is located in the C4 region of UG92005 (UG, clade D) and was recognized by ten hybridomas with Vβ usage Vβ 6, 8.1, 8.2, 13, 14 and not
determined – among the ND Vβ set, three Vαs were identified, Vα 2, 8, and 11
• C57BL/6 mice were immunized with a prime-boost strategy involving three HIV-1 Env antigens: Mice were primed with DNA given i.m., 3-4 weeks later
boosted with VV, and 3-4 weeks later boosted again with purified protein in Freund’s adjuvant
• The vaccinia construct is a pSC11-based VV vector with the first 38 amino acids contributed by BH10 and the rest of gp120 and gp41 by the vaccine strain,
the DNA construct is in the pJW4303 vector with a CMV promotor, and the purified protein is expressed from the pJW4303 vector transfected into
CHO-K1 cells
• Ten days after the final boost, hybridomas were made and tested for IL-2 production using either B6 spleen cells or H-2 IAb transfected L cells as targets
and Vβ usage was determined
• Mice were immunized with an Env from either one of two clades: HIV-1 1007, a clade B strain isolated from an individual from Memphis Tennesee, and
HIV-1 92UG005, a clade D vaccine isolated from Uganda in 1992 through the WHO
• 80 unique clonotypes were characterized from six mice
• H-2 IAb restricted T-helper epitopes were concentrated in 5 distinct regions within the Env sequence (2 clonotype responses in V2, 26 in C2, 22 in V3, 23
in V4C4, and 7 in gp41).
• Epitope hotspots tended to be proximal to heavily glycosylated regions of the Env sequence, in exposed, non-helical strands of the protein. The
non-uniform localization may be influenced by differential antigen processing and the glycosylation site proximity may allow binding to lectins and
promote trafficking through processing pathways.
gp160 (436–451) gp120 (IIIB) APPIGGQISCSSNITY in vitro stimulation human Manca1995b
• Peptide stimulation of PBMC from non-infected individuals in vitro
• Peptide priming does not always induce T-cells that recognize whole protein
gp160 (438–460) gp120 (443–465 NL43) PISGQIRCSSNITGLLLTR-
DGGN
Vaccine human Sitz1999
Vaccine Vector/Type: recombinant protein Strain: NL43 HIV component: gp120, gp160
• There was a great breadth of proliferative response to env peptides in 19 HIV-1 infected rgp160 and 17 HIV-1 infected rgp120 vaccine recipients
• Close to 40% of vaccinees had a stimulation index of greater than 5 to this peptide
gp160 (439–448) gp120 (151–160 W6.ID) IGGQIRCSSN Vaccine human Jones1999
Vaccine Vector/Type: recombinant protein Strain: W61D HIV component: gp120 Adjuvant: QS21/MPL adjuvant
• HIV-1 specific T-cell lines isolated from an HIV seronegative volunteer vaccinated with rgp120 and a QS21/MPL adjuvant
• One T-cell line responds to two overlapping peptides, and the region of overlap is IGGQIRCSSN
• The IIIB version of the first reactive peptide, EVGKAMYAPPIGGQIRCSSN, has a single substitution and induces proliferation as well as the original
W61D peptide: evgkamyappiSgqircssn.
gp160 (446–461) gp120 (IIIB) SSNITGLLLTRDGGTC in vitro stimulation human Manca1995b
• Peptide stimulation of PBMC from non-infected individuals in vitro
• Peptide priming does not always induce T-cells that recognize whole protein
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gp160 (452–471) gp120 (452–471 IIIB) LLLTRDGGNSNNESEIFRP-
G?
HIV-1 infection human Geretti1994
• Epitope name: I1
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 2/15 responders recognized this peptide, average SI = 3.5.
gp160 (456–470) gp120 (IIIB) RDGGTNVTNDTEVFRC in vitro stimulation human Manca1995b
• Peptide stimulation of PBMC from non-infected individuals in vitro
• Peptide priming does not always induce T-cells that recognize whole protein
gp160 (459–473) gp120 (459–473 IIIB,
B10)
GNSNNESEIFRPGGG HIV-1 infection human Wahren1989b, Wahren1989a
• 12 gag and 18 env peptides were identified that could commonly evoke T-cell responses.
gp160 (468–483) gp120 (466–481) FRPGGGDMRDNWRSEL HIV-1 infection human Krowka1990
• Conjugation of HIV peptides to liposomes and rIL-2 stimulation may enhance cell-mediated responses
gp160 (472–491) gp120 (472–491 IIIB) GGDMRDNWRSELYKYKVVK-
I?
HIV-1 infection human Geretti1994
• Epitope name: I3
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 2/15 responders recognized this peptide, average SI = 7.2.
gp160 (474–488) gp120 (474–488 IIIB,
B10)
DMRDNWRSELYKYKV HIV-1 infection human Wahren1989b, Wahren1989a
• 12 gag and 18 env peptides were identified that could commonly evoke T-cell responses.
gp160 (476–490) gp160 (483–497 IIIB) RDNWRSELYKYKVVK Vaccine murine (H-2k, H-2s) Berzofsky1991b,
Berzofsky1991a
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160 Adjuvant: Freund’s adjuvant
• This peptide elicited proliferative responses in B10.BR mice (H-2Ak and B10.S(9R) mice (H-2As, Es)
• RDNWRSELYKYKVVKIEPLGVAPT encompasses several murine Th epitopes including RDNWRSELYKYKVVK and is referred to as a
"multideterminant region" or cluster peptide
gp160 (476–490) gp120 (483–497 IIIB) RDNWRSELYKYKVVK Vaccine murine (H-2d,t4) Hale1989
Vaccine Strain: IIIB HIV component: gp160
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• Six multideterminant helper T-cell regions are recognized by mice of three or four MHC types
gp160 (476–499) gp160 (483–506 IIIB) RDNWRSELYKYKVVKIEPL-
GVAPT
HIV-1 infection, Vaccine human, murine (H-2k,
H-2b, H-2s, H-2d)
Berzofsky1991b,
Berzofsky1991a
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160 Adjuvant: Freund’s adjuvant
• RDNWRSELYKYKVVKIEPLGVAPT encompasses several murine Th epitopes and is referred to as a "multideterminant region" or cluster peptide
• Six multideterminant region cluster peptides were evaluated Th responses in different MHC/HLA backgrounds after vaccination of mice with gp160, or in
infected people
• This cluster peptide elicited proliferative responses in cells from all H-2 haplotypes tested: B10.BR mice (H-2Ak, Ek), B10.D2 mice (H-2Ad , Ed),
B10.A(5R) mice (H-2Ab, Eb), and B10.S(9R) mice (H-2As, Es)
• IL-2 production in response to this peptide was observed in 52% (14/27) of asymptomatic HIV-infected individuals
gp160 (479–498) gp120 (481–500 MN) WRSELYKYKVVTIEPLGVAP Vaccine guinea pig Chattergoon2002
Vaccine Vector/Type: protein, DNA Strain: MN HIV component: gp120 Adjuvant: complete Freund’s adjuvant (CFA)
• Epitope name: 2013
• Hartley guinea pigs were intradermally injected with either recombinant protein or plasmid expressed gp120 and monitored for delayed type hypersensivity
(DTH) responses after vaccination, which are related to Th1 T-cell responses. CFA did not augment responses in animals vaccinated with plasmid.
• A total of 7 gp120 peptides elicited a delayed type hypersensivity (DTH) response after vaccination, out of a set of 60 overlapping peptides that spanned
gp120. The vaccine delivery system, DNA versus rec protein, resulted in the recognition of distinct peptides.
• 0/5 animals vaccinated with rec gp120 responded by DTH to this peptide, while 6/6 vaccinated with plasmid gp120 DNA responded.
gp160 (482–501) gp120 (482–501 IIIB) ELYKYKVVKIEPLGVAPTKA Vaccine Rhesus macaque Lekutis1997b
Vaccine Vector/Type: DNA Strain: IIIB HIV component: ENV
• HIV-1 env DNA vaccine induced Th cell response to this epitope in a rhesus monkey
• Epitope was recognized by both monkeys used in this study
gp160 (482–501) gp120 (482–501 IIIB) ELYKYKVVKIEPLGVAPTK-
A?
HIV-1 infection human Geretti1994
• Epitope name: I4
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 3/15 responders recognized this peptide, average SI = 6.0.
gp160 (483–502) gp120 (480–499 89.6) LYKYKVVRIEPIGVAPTRAK Vaccine murine Dai2001
Vaccine Vector/Type: recombinant protein Strain: 89.6 HIV component: gp120 Adjuvant: R192G mutant heat-labile toxin from enterotoxigenic E.
coli (mLT)
• Epitope name: Peptide 46
• Helper T-cell proliferative responses to gp120 vaccines in 2 mouse strains, CBA/J and BALB/c, were mapped using 47 overlapping peptides that span
gp120. Promiscuously immunodominant peptides were identified in both mice strains that were located in the outer domain of gp120 and were associated
with regions of local structural disorder in proximal N-terminal segments, suggesting 3-D protein structure influences Th antigen processing and the
frequency of immunogenic sequences.
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• This peptide was reactive in 7/10 BALB/c mice tested, and in only 1/10 CBA/J mice.
gp160 (484–496) gp120 (484–496 HXB2) YKYKVVKIEPLGV Vaccine Rhesus macaque
(DR*W201)
Lekutis1998
Vaccine Vector/Type: DNA Strain: HXB2 HIV component: ENV
• Variants of this epitope with substitutions at position 490(K) retained ability to bind to MHC class II, but failed to induce proliferation/cytokine secretion in
HIV-1 env-specific CD4+ Th cells
• The modified peptide antagonized the wildtype peptide-induced proliferative response
gp160 (484–498) gp120 (484–498 IIIB,
B10)
YKYKVVKIEPLGVAP HIV-1 infection human Wahren1989b, Wahren1989a
• 12 gag and 18 env peptides were identified that could commonly evoke T-cell responses.
gp160 (484–499) gp120 (492–506 IIIB) CKYKVVKIEPLGVAPT Vaccine murine (H-2d,k,t4,i5) Hale1989
Vaccine Strain: IIIB HIV component: gp160
• Six multideterminant helper T-cell regions are recognized by mice of three or four MHC types
gp160 (485–499) gp160 (492–506 IIIB) KYKVVKIEPLGVAPT Vaccine murine (H-2k, H-2b,
H-2s, H-2d)
Berzofsky1991b,
Berzofsky1991a
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160 Adjuvant: Freund’s adjuvant
• This peptide elicited proliferative responses in cells from all H-2 haplotypes tested: B10.BR mice (H-2Ak, Ek), B10.D2 mice (H-2Ad , Ed), B10.A(5R) mice
(H-2Ab, Eb), and B10.S(9R) mice (H-2As, Es)
• RDNWRSELYKYKVVKIEPLGVAPT encompasses several murine Th epitopes including KYKVVKIEPLGVAPT and is referred to as a
"multideterminant region" or cluster peptide
gp160 (485–500) gp120 (IIIB) KYKVIKIEPLGIAPTC in vitro stimulation human Manca1995b
• Peptide stimulation of PBMC from non-infected individuals in vitro
• Peptide priming does not always induce T-cells that recognize whole protein
gp160 (486–494) gp120 (486–494 IIIB) YKVVKIEPL SHIV infection Rhesus macaque
(DRB*W201)
Lekutis1997a
• C5 region minimal epitope determined through fine epitope mapping
gp160 (487–512) gp120 (494–518 IIIB) KVVKIEPLGVAPTKAKRRV-
VQREKRC
Vaccine murine Goodman-Snitkoff1990
Vaccine Vector/Type: peptide Strain: IIIB
• Identification of putative Th epitopes that stimulate an antibody response in peptide immunized mice
gp160 (492–512) gp120 (492–512 IIIB) EPLGVAPTKAKRRVVQREK-
RA?
HIV-1 infection human Geretti1994
• Epitope name: I5
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
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• 1/15 responders recognized this peptide, SI = 4.9.
gp160 (493–511) gp120 (490–508 89.6) PIGVAPTRAKRRTVQREKR Vaccine murine Dai2001
Vaccine Vector/Type: recombinant protein Strain: 89.6 HIV component: gp120 Adjuvant: R192G mutant heat-labile toxin from enterotoxigenic E.
coli (mLT)
• Epitope name: Peptide 47
• Helper T-cell proliferative responses to gp120 vaccines in 2 mouse strains, CBA/J and BALB/c, were mapped using 47 overlapping peptides that span
gp120. Promiscuously immunodominant peptides were identified in both mice strains that were located in the outer domain of gp120 and were associated
with regions of local structural disorder in proximal N-terminal segments, suggesting 3-D protein structure influences Th antigen processing and the
frequency of immunogenic sequences.
• This peptide was reactive in only 2/10 BALB/c mice tested, and in 8/10 CBA/J mice.
gp160 (499–511) gp120 (IIIB) TKAKRRVVEREKR in vitro stimulation human (DR) Wilson1997b
• Thought to be a mimic of a HLA class II DR β chain variable region
• Response to this epitope may cause a breakdown of self-tolerance
• Presentation of epitope induced autoreactive T-cell lines in PBMC from uninfected donors
• Suppression of proliferation to soluble antigens by the CD8+ fraction of TKAKRRVVEREKR stimulated T-cells was observed
gp160 (519–543) Env (519–543) FLGFLGAAGSTMGAASLTL-
TVQARC
Vaccine Rhesus macaque Nehete1993
Vaccine Vector/Type: peptide
• Synthetic peptide derived from conserved region of the HIV-1 envelope that stimulates a proliferative response in mice, and in rhesus monkeys
• Proliferative response to this peptide was observed in 3/3 immunized rhesus monkeys
gp160 (519–543) Env (519–543) FLGFLGAAGSTMGAASLTL-
TVQARQ
HIV-1 infection human, chimpanzee Nehete1998b
• HIV-infected chimpanzees and HIV-positive patients show positive proliferative responses to multiple peptides from five conserved regions of the HIV-1
Env
gp160 (519–543) gp41 (519–543) FLGFLGAAGSTMGAASLTL-
TVQARC
Vaccine murine (H-2bxk,sxd) Sastry1991
Vaccine Vector/Type: peptide
• Peptides induced T-cell proliferative response to immunizing peptide and to gp160
gp160 (547–561) gp41 (547–561 IIIB,
B10)
GIVQQQNNLLRAIEA HIV-1 infection human Wahren1989b, Wahren1989a
• 12 gag and 18 env peptides were identified that could commonly evoke T-cell responses.
gp160 (562–576) gp41 (562–576 IIIB,
B10)
QQHLLQLTVWGIKQL HIV-1 infection human Wahren1989b, Wahren1989a
• 12 gag and 18 env peptides were identified that could commonly evoke T-cell responses.
gp160 (572–591) gp41 (572–591) GIKQLQARILAVERYLKDQQ Vaccine murine (H-2d,b) Brown1995
Vaccine Vector/Type: peptide
• This peptide was a good immunogen in BALB/c and CBA mice, producing a strong proliferative response
• At least one of the four residues GIKQ enhances stimulation, and in CBA mice these residues influence the ability to prime T-cells in vivo
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• QLQARILAVERY stimulated the greatest in vitro T-cell response
• VERYLKDQQ was the minimal reactive sequence recognized by a T-cell line
gp160 (576–591) gp41 (576–591) LQARILAVERYLKDQQ Vaccine murine (H-2d,b) Brown1995
Vaccine Vector/Type: peptide
• This peptide was a poor immunogen in BALB/c and CBA mice used in this experiment, producing a weak proliferative response
gp160 (578–608) gp41 (585–615 IIIB) ARILAVERYLKDQQLLGIW-
GCSGKLICTTAV
Vaccine murine Goodman-Snitkoff1990
Vaccine Vector/Type: peptide
• Identification of putative Th epitopes that can stimulate an antibody response in peptide immunized mice
gp160 (579–601) gp41 (579–601) RILAVERYLKDQQLLGGIW-
GCSGK
Vaccine murine (H-2d,b) Brown1995
Vaccine Vector/Type: peptide
• This peptide was a good immunogen in BALB/c and CBA
• This peptide produced a strong Th response in both mice strains which was more responsive towards GIKQLQARILAVERYLKDQQ and
LQARILAVERYLKDQQ than to immunizing peptide
gp160 (579–604) gp41 (584–609 LAI) RILAVERYLKDQQLLGIWG-
CSGKLIC
HIV-1 infection human Schrier1989
• Stimulates T-cell proliferation in HIV-infected donors
gp160 (586–597) Env (586–598) YLRDQQLLGIWG HIV-1 infection human, chimpanzee Nehete1998b
• HIV-infected chimpanzees and HIV-positive patients show positive proliferative responses to multiple peptides from five conserved regions of the HIV-1
Env
gp160 (586–598) Env (586–598) YLRDQQLLGIWGC Vaccine murine, Rhesus macaque Nehete1993
Vaccine Vector/Type: peptide
• Synthetic peptide derived from conserved region of the HIV-1 envelope that stimulates a proliferative response in mice
• Proliferative response to this peptide was observed in 1/3 immunized rhesus monkeys, with a weak transient response in the other two
gp160 (593–604) gp41 (593–604 IIIB) LGIWGCSGKLIC HIV-1 infection human Bell1992
• Elicits T-cell proliferation and B cell responses, but only during the asymptomatic phase of HIV infection
gp160 (593–604) gp41 (598–609 LAV-1) LGLWGCSGKLIC Vaccine murine (H2d) Schrier1988
• Murine T-dependent B-cell response – 7/29 had a proliferative response to this peptide
gp160 (594–603) gp41 (594–603 IIIB) GIWGCSGKLI HIV-1 infection human Kelleher1998b
• Epitope documented as a “previously described’ epitope [Bell1992], but in Bell et al. it was described as gp41(594-603 IIIB), LGIWGCSGKLIC.
• Immunization with a p24-VLP virus-like particle did not significantly impact CD4+ lymphocyte count, viral load, or p24 antibody titre
• Immunization with p24-VLP did not increase the proliferative response to this gp41 epitope, however, there was a modest, short-lived increased
proliferative response to p24
gp160 (594–604) gp41 (consensus) GIWGCSGKLIC HIV-1 infection human Mutch1994
• Core region of peptides that can stimulate proliferative responses from seronegative and seropositive people
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gp160 (598–609) gp41 (603–614 LAI) CSGKLICTTAVP HIV-1 infection human Schrier1989
• Stimulates T-cell proliferation in HIV-infected donors
gp160 (604–615) gp41 (609–620 LAI) CTTAVPWNASWS HIV-1 infection human Schrier1989
• Stimulates T-cell proliferation in HIV-infected donors
gp160 (606–620) gp41 (UG92005) TNVPWNASWSNKSLE Vaccine murine (H-2 IAb) Surman2001
Vaccine Vector/Type: DNA, vaccinia, recombinant protein Strain: 1007 (clade B), UG92005 (clade D) HIV component: gp140 Adjuvant: Freund’s
adjuvant
• This gp140 epitope of UG92005 (UG, clade D) was recognized by five hybridomas with Vβ usage Vβ 8.1, 14 and not determined – one of the Vβ 8.1 was
shown to utilize Vα 8
• C57BL/6 mice were immunized with a prime-boost strategy involving three HIV-1 Env antigens: Mice were primed with DNA given i.m., 3-4 weeks later
boosted with VV, and 3-4 weeks later boosted again with purified protein in Freund’s adjuvant
• The vaccinia construct is a pSC11-based VV vector with the first 38 amino acids contributed by BH10 and the rest of gp120 and gp41 by the vaccine strain,
the DNA construct is in the pJW4303 vector with a CMV promotor, and the purified protein is expressed from the pJW4303 vector transfected into
CHO-K1 cells
• Ten days after the final boost, hybridomas were made and tested for IL-2 production using either B6 spleen cells or H-2 IAb transfected L cells as targets
and Vβ usage was determined
• Mice were immunized with an Env from either one of two clades: HIV-1 1007, a clade B strain isolated from an individual from Memphis Tennesee, and
HIV-1 92UG005, a clade D vaccine isolated from Uganda in 1992 through the WHO
• 80 unique clonotypes were characterized from six mice
• H-2 IAb restricted T-helper epitopes were concentrated in 5 distinct regions within the Env sequence (2 clonotype responses in V2, 26 in C2, 22 in V3, 23
in V4C4, and 7 in gp41).
• Epitope hotspots tended to be proximal to heavily glycosylated regions of the Env sequence, in exposed, non-helical strands of the protein. The
non-uniform localization may be influenced by differential antigen processing and the glycosylation site proximity may allow binding to lectins and
promote trafficking through processing pathways.
gp160 (609–616) gp41 (consensus) PWNASWSN HIV-1 infection human Mutch1994
• Core region of peptides that can stimulate proliferative responses from seronegative and seropositive people
gp160 (611–620) gp41 (1007, UG92005) NASWSNKSLE Vaccine murine (H-2 IAb) Surman2001
Vaccine Vector/Type: DNA, vaccinia, recombinant protein Strain: 1007 (clade B), UG92005 (clade D) HIV component: gp140 Adjuvant: Freund’s
adjuvant
• This gp41 epitope is conserved in 1007 (US, clade B) and UG92005 (UG, clade D) and was recognized by two hybridomas from two different mice that
were vaccinated with different clades – the Vβ usage was Vβ 4 and 14
• The epitope described here is the region of overlap of two 15 mers that were both able to stimulate IL-2 production from the hybridoma
(T[TN]VPWNASWSNKSLE and NASWSNKSLEQIWNN) – the only difference between 1007 and UG92005 for these two proteins is that 1007 has a T
and UG92005 has an N in the second position of the first peptide
• C57BL/6 mice were immunized with a prime-boost strategy involving three HIV-1 Env antigens: Mice were primed with DNA given i.m., 3-4 weeks later
boosted with VV, and 3-4 weeks later boosted again with purified protein in Freund’s adjuvant
• The vaccinia construct is a pSC11-based VV vector with the first 38 amino acids contributed by BH10 and the rest of gp120 and gp41 by the vaccine strain,
the DNA construct is in the pJW4303 vector with a CMV promotor, and the purified protein is expressed from the pJW4303 vector transfected into
CHO-K1 cells
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• Ten days after the final boost, hybridomas were made and tested for IL-2 production using either B6 spleen cells or H-2 IAb transfected L cells as targets
and Vβ usage was determined
• Mice were immunized with an Env from either one of two clades: HIV-1 1007, a clade B strain isolated from an individual from Memphis Tennesee, and
HIV-1 92UG005, a clade D vaccine isolated from Uganda in 1992 through the WHO
• 80 unique clonotypes were characterized from six mice
• H-2 IAb restricted T-helper epitopes were concentrated in 5 distinct regions within the Env sequence (2 clonotype responses in V2, 26 in C2, 22 in V3, 23
in V4C4, and 7 in gp41).
• Epitope hotspots tended to be proximal to heavily glycosylated regions of the Env sequence, in exposed, non-helical strands of the protein. The
non-uniform localization may be influenced by differential antigen processing and the glycosylation site proximity may allow binding to lectins and
promote trafficking through processing pathways.
gp160 (614–629) gp41 (IIIB) WSNKSLEDIWDNMTWC in vitro stimulation human Manca1995b
• Peptide stimulation of PBMC from non-infected individuals in vitro
• Peptide priming does not always induce T-cells that recognize whole protein
gp160 (634–649) gp41 (IIIB) EIDNYTNTIYTLLEEC in vitro stimulation human Manca1995b
• Peptide stimulation of PBMC from non-infected individuals in vitro
• Peptide priming does not always induce T-cells that recognize whole protein
gp160 (647–661) gp41 (647–661 IIIB,
B10)
EESQNQQEKNEQELL HIV-1 infection human Wahren1989b, Wahren1989a
• 12 gag and 18 env peptides were identified that could commonly evoke T-cell responses.
gp160 (650–662) gp41 (655–667 LAI) QNQQEKNEQELLE HIV-1 infection human Schrier1989
• Stimulates T-cell proliferation in HIV-infected donors
gp160 (667–681) gp41 (667–681 IIIB,
B10)
ASLWNWFNITNWLWY HIV-1 infection human Wahren1989b, Wahren1989a
• 12 gag and 18 env peptides were identified that could commonly evoke T-cell responses.
gp160 (682–696) gp41 (682–696 IIIB,
B10)
IKLFIMIVGGLVGLR HIV-1 infection human Wahren1989b, Wahren1989a
• 12 gag and 18 env peptides were identified that could commonly evoke T-cell responses.
gp160 (724–745) gp41 (731–752) PRGPDRPEGIEEEGGERDR-
DRS
Vaccine murine (H-2k) McInerney1999
Vaccine Vector/Type: peptide in cowpea mosaic virus (CPMV) HIV component: gp41 Adjuvant: adjuvant Quil A
• A gp41 peptide was expressed in a cowpea mosaic virus (CPMV) and mice were vaccinated with a purified chimeric particle – out of five adjuvants tested,
only Quil A could stimulate anti-gp41 antibodies and an in vitro proliferative response
• The antibodies were predominantly IgG2a, suggesting a Th1 response
gp160 (732–744) gp41 (737–749 LAI) GIEEEGGERDRDR HIV-1 infection human Schrier1989
• Stimulates T-cell proliferation in HIV-infected donors
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gp160 (780–794) gp160 (787–801 IIIB) RIVELLGRRGWEALK Vaccine murine (H-2k, H-2d ,
H-2s)
Berzofsky1991b,
Berzofsky1991a
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160 Adjuvant: Freund’s adjuvant
• This peptide elicited proliferative responses in cells from B10.BR mice (H-2Ak, Ek), B10.D2 mice (H-2Ad , Ed), and B10.S(9R) mice (H-2As, Es)
• RIVELLGRRGWEALKYWWNLLQYWSQELKNSAVS encompasses several murine Th epitopes including RIVELLGRRGWEALK and is referred to as
a "multideterminant region" or cluster peptide, but the longer peptide only stimulates cells from H-2k mice
gp160 (780–794) gp41 (787–801 IIIB) RIVELLGRRGWEALK Vaccine murine (H-2d,k,t4) Hale1989
Vaccine Strain: IIIB HIV component: gp160
• Six multideterminant helper T-cell regions are recognized by mice of three or four MHC types
gp160 (780–813) gp160 (787–820 IIIB) RIVELLGRRGWEALKYWWN-
LLQYWSQELKNSAVS
HIV-1 infection, Vaccine murine (H-2k) Berzofsky1991b,
Berzofsky1991a
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160 Adjuvant: Freund’s adjuvant
• RIVELLGRRGWEALKYWWNLLQYWSQELKNSAVS encompasses several murine Th epitopes and is referred to as a "multideterminant region" or
cluster peptide
• Six multideterminant region cluster peptides were evaluated Th responses in different MHC/HLA backgrounds after vaccination of mice with gp160, or in
infected people
• This cluster peptide elicited proliferative responses in cells from only B10.BR mice (H-2Ak, Ek), and not from B10.D2 mice (H-2Ad , Ed), B10.A(5R) mice
(H-2Ab, Eb), or B10.S(9R) mice (H-2As, Es)
• IL-2 production in response to this peptide was observed in 59% (17/29) of asymptomatic HIV-infected individuals
gp160 (794–808) gp160 (801–815 IIIB) KYWWNLLQYWSQELK Vaccine murine (H-2k, H-2d ,
H-2s)
Berzofsky1991b,
Berzofsky1991a
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160 Adjuvant: Freund’s adjuvant
• This peptide elicited proliferative responses in cells from B10.BR mice (H-2Ak, Ek), B10.D2 mice (H-2Ad , Ed), and B10.S(9R) mice (H-2As, Es)
• RIVELLGRRGWEALKYWWNLLQYWSQELKNSAVS encompasses several murine Th epitopes including KYWWNLLQYWSQELK and is referred to
as a "multideterminant region" or cluster peptide, but the longer peptide only stimulates cells from H-2k mice
gp160 (794–808) gp41 (801–815 IIIB) KYWWNLLQYWSQELK Vaccine murine (H-2k) Hale1989
Vaccine Strain: IIIB HIV component: gp160
• Six multideterminant helper T-cell regions are recognized by mice of three or four MHC types
gp160 (799–813) gp160 (806–820 IIIB) LLQYWSQELKNSAVS Vaccine murine (H-2k, H-2d ,
H-2s)
Berzofsky1991b,
Berzofsky1991a
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160 Adjuvant: Freund’s adjuvant
• This peptide elicited proliferative responses in cells from B10.BR mice (H-2Ak, Ek), B10.D2 mice (H-2Ad , Ed), and B10.S(9R) mice (H-2As, Es)
• RIVELLGRRGWEALKYWWNLLQYWSQELKNSAVS encompasses several murine Th epitopes including LLQYWSQELKNSAVS and is referred to as
a "multideterminant region" or cluster peptide, but the longer peptide only stimulates cells from H-2k mice
gp160 (799–813) gp41 (806–820 IIIB) LLQYWSQELKNSAVS Vaccine murine (H-2k,d,t4) Hale1989
Vaccine Strain: IIIB HIV component: gp160
• Six multideterminant helper T-cell regions are recognized by mice of three or four MHC types
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gp160 (799–813) gp41 (806–820 IIIB) LLQYWSQELKNSAVS Vaccine murine (H-2k,d,t4) Hale1989
Vaccine Strain: IIIB HIV component: gp160
• Six multideterminant helper T-cell regions are recognized by mice of three or four MHC types
gp160 (814–829) gp41 (IIIB) WLNATAIAVTEGTDRC in vitro stimulation human Manca1995b
• Peptide stimulation of PBMC from non-infected individuals in vitro
• Peptide priming does not always induce T-cells that recognize whole protein
gp160 (821–835) gp160 (828–842 IIIB) AVAEGTDRVIEVVQG Vaccine murine (H-2k, H-2b,
H-2s)
Berzofsky1991b,
Berzofsky1991a
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160 Adjuvant: Freund’s adjuvant
• This peptide elicited proliferative responses in cells from B10.BR mice (H-2Ak, Ek), B10.A(5R) mice (H-2Ab, Eb), and B10.S(9R) mice (H-2As, Es)
• AVAEGTDRVIEVVQGAYRAIRHIPRRIRQGLER encompasses several murine Th epitopes including AVAEGTDRVIEVVQG and is referred to as a
"multideterminant region" or cluster peptide
gp160 (821–835) gp41 (828–842 IIIB) AVAEGTDRVIEVVQG Vaccine murine (H-2k) Hale1989
Vaccine Strain: IIIB HIV component: gp160
• Six multideterminant helper T-cell regions are recognized by mice of three or four MHC types
gp160 (821–838) gp41 (827–843) YVAEGTDRVIEVVQGACR HIV-1 infection human Caruso1997
• As HIV-1-infected individuals progress to disease, T-cells show reduced ability to proliferate in response to HIV antigen, but retain the ability to express the
activation antigens CD25 and CD71
• The ability to express activation markers in response to HIV is retained, but the response to tetanus toxoid recall antigen is lost
• This study investigated CD25 and CD71 expression in PBMC from patients at various stages of progression, measuring the response to in vitro stimulation
by peptide cocktail containing four antigenic Env peptides, or p17 and p24
gp160 (821–853) gp160 (828–860 IIIB) AVAEGTDRVIEVVQGAYRA-
IRHIPRRIRQGLER
HIV-1 infection, Vaccine human, murine (H-2k,
H-2b, H-2s, H-2d)
Berzofsky1991b,
Berzofsky1991a
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160 Adjuvant: Freund’s adjuvant
• AVAEGTDRVIEVVQGAYRAIRHIPRRIRQGLER encompasses several murine Th epitopes and is referred to as a "multideterminant region" or cluster
peptide
• Six multideterminant region cluster peptides were evaluated for Th responses in different MHC/HLA backgrounds after vaccination of mice with gp160, or
in infected people
• This cluster peptide elicited proliferative responses in cells from all four MHC types tested: B10.BR mice (H-2Ak, Ek), B10.D2 mice (H-2Ad , Ed),
B10.A(5R) mice (H-2Ab, Eb), and B10.S(9R) mice (H-2As, Es)
• IL-2 production in response to this peptide was observed in only 8% (1/12) of asymptomatic HIV-infected individuals
gp160 (827–835) gp41 (834–842 IIIB) DRVIEVVQG Vaccine murine (H-2k) Hale1989
Vaccine Strain: IIIB HIV component: gp160
• Suggested H-2k epitope based on region of overlap
gp160 (827–841) gp41 (834–848 IIIB) DRVIEVVQGAYRAIR Vaccine Rhesus macaque Hosmalin1991
Vaccine Vector/Type: peptide prime with protein boost Strain: IIIB HIV component: gp160
• Epitope name: TH4
• Peptide priming to induce T-cell help enhances antibody response to gp160 immunization
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• Called Th4.1 and TH4
gp160 (827–841) gp41 (834–848 IIIB) DRVIEVVQGAYRAIR HIV-1 infection human Clerici1997
• Epitope name: TH4
• used in a study of the influence of pentoxifylline on HIV specific T-cells
gp160 (827–841) gp41 (834–848 IIIB) DRVIEVVQGAYRAIR human Pinto1995
• Epitope name: TH4
• CTL activity analyzed in parallel with Th reactivity in exposed but uninfected health care workers
• Called Th4.1 and TH4
gp160 (827–841) gp41 (834–848 IIIB) DRVIEVVQGAYRAIR HIV-1 infection human Clerici1991a
• Epitope name: TH4
• Peptides stimulate Th cell function and CTL activity in similar patient populations
• Called Th4.1 and TH4
gp160 (827–841) gp41 (834–848 IIIB) DRVIEVVQGAYRAIR Vaccine human Clerici1991b
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160
• Epitope name: TH4
• Immunizing uninfected individuals with rgp160 results in stronger Th response than does natural infection
• Called Th4.1 and TH4
gp160 (827–841) gp41 (834–848 IIIB) DRVIEVVQGAYRAIR human Clerici1992
• Epitope name: TH4
• Cell-mediated immune response to HIV-1 peptides in HIV-1 exposed seronegative men
• Called Th4.1 and TH4
gp160 (827–841) gp41 (834–848 IIIB) DRVIEVVQGAYRAIR HIV-1 infection human Clerici1989
• Epitope name: TH4
• IL-2 production detection of Th lymphocytes from asymptomatic HIV-positive individuals
• Called Th4.1 and TH4
gp160 (827–841) gp41 (834–848 IIIB) DRVIEVVQGAYRAIR HIV-1 infection human Kaul1999
• Epitope name: TH4
• Kenyan sex workers that remained seronegative were found to frequently have HIV-env peptide specific Th responses detected by an IL-2 assay (11/20
cases) and mucosal genital tract anti-HIV IgA (16/21 cases)
• Helper epitopes used in this study were noted to be previously described [Clerici1989], and were not explicitly described in [Kaul1999]
gp160 (827–841) gp41 DRVIEVVQGAYRAIR HIV-1 infection, HIV-1 exposed
seronegative
human Kuhn2001
• Epitope name: TH4, Th4.1
• In a S. African perinatal transmission study, 33% (33/86) of cord blood samples from infants with seropositive mothers produced T-helper responses
(measured by a bioassay measuring IL2 production in a murine cell line and confirmed with a proliferation assay) against a peptide cocktail containing Th
epitopes P18 MN, P18 IIIB, T1, T2, and TH4
• The mothers were predominantly infected with subtype C, but the T help response was detectable in a number of cord blood samples despite using peptides
based on B subtype reagents.
521
DEC 2002
T-
H
el
pe
r
HIV Helper T-Cell Epitope Tables gp160 Helper T-Cell Epitopes
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
• 3/33 infants with cord blood T help responses to Env were infected in utero, 2/33 were lost to follow up, and 28/33 were not infected. 6/53 of the infants
with cord blood that was unresponsive to Env peptide stimulation were infected before delivery, and 8/47 contracted HIV intrapartum or via breast-feeding.
• Measurable HIV specific T help responses elicited in the immunologically immature newborn, possibly in response to in utero exposure, are associated
with a protective natural immunity that helps block mother-infant transmission of HIV-1.
gp160 (827–841) gp160 (834–848 IIIB) DRVIEVVQGAYRAIR Vaccine murine (H-2k, H-2b) Berzofsky1991b,
Berzofsky1991a
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160 Adjuvant: Freund’s adjuvant
• This peptide elicited proliferative responses in cells from B10.BR mice (H-2Ak, Ek) and B10.A(5R) mice (H-2Ab, Eb)
gp160 (827–841) gp41 (834–848 IIIB) DRVIEVVQGAYRAIR Vaccine murine (H-2k,i5) Hale1989
Vaccine Strain: IIIB HIV component: gp160
• Epitope name: TH4
• Six multideterminant helper T-cell regions are recognized by mice of three or four MHC types
• Called Th4.1 and TH4
gp160 (829–843) gp160 (836–850 IIIB) VIEVVQGAYRAIRHI Vaccine murine (H-2k, H-2b) Berzofsky1991b,
Berzofsky1991a
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160 Adjuvant: Freund’s adjuvant
• This peptide elicited proliferative responses in cells from B10.BR mice (H-2Ak, Ek) and B10.A(5R) mice (H-2Ab, Eb)
gp160 (834–841) gp41 (841–848 IIIB) QGAYRAIR Vaccine murine (H-2i5) Hale1989
Vaccine Strain: IIIB HIV component: gp160
• Suggested H-2k epitope based on region of overlap
gp160 (834–848) gp160 (841–855 IIIB) QGAYRAIRHIPRRIR Vaccine murine (H-2k, H-2b,
H-2d , H-2s)
Berzofsky1991b,
Berzofsky1991a
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160 Adjuvant: Freund’s adjuvant
• This peptide elicited proliferative responses in cells from B10.BR mice (H-2Ak, Ek), B10.A(5R) mice (H-2Ab, Eb), B10.D2(H-2Ad , Ed), and B10.S(9R)
mice (H-2As, Es)
gp160 (834–848) gp41 (841–855 IIIB) QGAYRAIRHIPRRIR Vaccine murine (H-2d,t4,i5) Hale1989
Vaccine Strain: IIIB HIV component: gp160
• Six multideterminant helper T-cell regions are recognized by mice of three or four MHC types
gp160 (839–848) gp41 (846–855 IIIB) AIRHIPRRIR Vaccine murine (H-2d,t4) Hale1989
Vaccine Strain: IIIB HIV component: gp160
• Suggested H-2d,t4 epitope based on region of overlap
gp160 (839–853) gp160 (828–842 IIIB) AIRHIPRRIRQGLER Vaccine human, murine (H-2k,
H-2b, H-2s)
Berzofsky1991b,
Berzofsky1991a
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160 Adjuvant: Freund’s adjuvant
• This peptide elicited proliferative responses in cells from B10.BR mice (H-2Ak, Ek), B10.A(5R) mice (H-2Ab, Eb), and B10.S(9R) mice (H-2As, Es)
gp160 (839–853) gp41 (846–860 IIIB) AIRHIPRRIRQGLER Vaccine murine (H-2d,t4) Hale1989
Vaccine Strain: IIIB HIV component: gp160
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• Six multideterminant helper T-cell regions are recognized by mice of three or four MHC types
gp160 (842–856) gp41 (842–856 IIIB,
B10)
HIPRRIRQGLERILL HIV-1 infection human Wahren1989b, Wahren1989a
• 12 gag and 18 env peptides were identified that could commonly evoke T-cell responses.
gp160 gp120 (IIIB) HIV-1 infection human Geretti1994
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 4/15 responders recognized this peptide, average SI = 4.4.
gp160 gp120 (IIIB) HIV-1 infection human Geretti1994
• Th proliferative responses were studied in 36 asymptomatic HIV-1+ patients. PBMC from 15/36 patients responded to stimulation with gp120 synthetic
overlapping peptide pools. 10 of the responding patients recognized three or more peptide pools.
• After 12 months, most responses were lost or diminished, and specific responses fluctuated. 4/10 of the responders at baseline had new responses at 12
months, as did 5/15 non-responders.
• IL-2 production was a more sensitive and well-preserved measure of Th function than proliferation.
• 4/15 responders recognized this peptide, average SI = 4.4.
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Env gp120 (IIIB) Vaccine murine Shiver1997
Vaccine Vector/Type: DNA Strain: IIIB HIV component: gp120, gp160
• DNA vaccinations of BALBc mice with a gp120 or gp160 DNA vaccine elicited a strong T-cell proliferative response with Th1-like secretion of γ
interferon and IL-2, with little or no IL-4, as well as antigen specific gp120 Abs
• An intramuscular route of inoculation gave a stronger proliferative response than intradermal
• A proliferative response could be detected in all lymph tissues tested: spleen, PBMC, and mesenteric, iliac, and inguinal lymph nodes
Env gp120 Vaccine murine Kim1997d
Vaccine Vector/Type: DNA HIV component: gp160, GAG, POL Adjuvant: CD86 expression vector
• A gp160 DNA vaccine, when delivered in conjunction with the plasmid encoding the co-stimulatory molecule CD86, gives an increase in the proliferative
responses to gp120 in mice
Env gp120 human De Berardinis1997
• Sequences flanking helper T-cell immunogenic domains can be important for immunogenicity
Env gp120 HIV-1 infection human Rosenberg1997
• A strong proliferative response to p24 and gp160 was found in a healthy long term survivor
Env gp120 HIV-1 infection Macaca nemestrina Kent1997b
• Macaca nemestrina can be infected with HIV, and clear the infection within 6 months, so it is of interest to examine their initial immune response
• A strong proliferative response against gp160 with IL-4 production, indicating a Th2 response, was found with 4 weeks of infection
• The gp160 proliferative response by 8 weeks produces both IL-4 and γ interferon, indicating both Th1 and Th2 responses
Env gp120 (HXBc2) Vaccine Rhesus macaque Letvin1997
Vaccine Vector/Type: DNA prime with rgp160 boost Strain: HXBc2 HIV component: gp160
• Vaccination of Macaca mulatta (rhesus monkeys) with a HXBc2 env DNA prime and a protein boost elicited a T-cell proliferative response, a CTL
response, and type-specific neutralizing antibodies
• Vaccinated animals challenged with SHIV-HXB2 were protected from infection
Env gp120 (MN) HIV-1 infection, Vaccine human MacGregor1998
Vaccine Vector/Type: DNA Strain: MN HIV component: ENV, REV
• An HIV DNA env and rev vaccine given to 15 asymptomatic HIV+ individuals at three different dosages, 30, 100 or 300 µg, was safe
• All three groups showed an increased proliferative response after vaccination
Env Env human Mazzoli1997
• Study of HIV-specific immunity in seronegative partners of HIV-positive individuals – Env peptides could stimulate IL-2 production in 9/16 HIV-exposed
seronegative individuals, and only 1/50 low-risk controls
• Exposed-uninfected produced more IL-2 and less IL-10 then HIV-infected individuals
• 8/9 of those whose PBMC produce IL-2 in response to Env peptides had concomitantly detected urinary or vaginal tract anti-HIV IgA
Env Env HIV-1 infection human Plana1998
• Patients from later stages of infection given HAART do not show restoration of HIV-1 specific Th proliferative responses
524
DEC 2002
Env Helper T-Cell Epitopes HIV Helper T-Cell Epitope Tables
T-H
elper
HXB2 Location Author’s Location Sequence Immunogen Species (HLA) References
Env Env HIV-1 infection human Kelleher1998a
• Env and gag Th epitopes were pooled and used to test Th proliferative responses after IL2 therapy – while IL2 therapy causes an increase in CD4+
lymphocyte count, it does not increase HIV-1 specific proliferative responses
Env gp160 HIV-1 infection, Vaccine human Ratto-Kim1999
Vaccine Vector/Type: recombinant protein HIV component: gp160
• Vaccinations with rgp160 did not enhance Th immunoproliferative responses in individuals who were immunized every 2 months for 5 years starting early
in infection
Env gp160 HIV-1 infection, Vaccine human Leandersson2000
Vaccine Vector/Type: recombinant protein HIV component: gp160
• 27 HIV subtype B, 4 subtype C, 2 D and one of each subtype E, F, G infected individuals were either given rgp160 B clade immunizations or placebo. All
rgp160 immunized individuals showed increased proliferation responses to the B clade immunizing antigen rgp160.
• gp120 was prepared from A, B, C, D, and E subtype virions and used as antigenic stimulus – 7 of 10 tested individuals responded to native gp120 from at
least one additional subtype in addition to B subtype, while a placebo recipient did not respond to any gp120
• This study shows that cross-subtype HIV-specific T-cell proliferative responses can be stimulated in patients already infected with another HIV-1 subtype –
all immunized subjects could respond to the subtype B immunogen, but many developed responses to at least one more subtype
Env gp160 (MN) Vaccine human Gorse1999a
Vaccine Vector/Type: gp160 prime with gp120 boost Strain: MN HIV component: gp160, gp120
• Helper T-cell memory responses were induced by MN rgp160 as measured by proliferation and Th1 and Th2 cytokine release – this response could be
boosted by MN rgp120
Env gp120 Vaccine Rhesus macaque Heeney1998b
Vaccine Vector/Type: ISCOM or fowlpoxvirus Strain: SF2 HIV component: gp120
• Vaccinated monkeys with the highest level of Th1 and Th2 responses and the highest levels of NAbs were protected against a SHIV SF13 challenge – the
ISCOM strategy gave more potent anti -gp120 responses than the Fowl pox strategy
• When animals were challenged 4 months after boost, those that maintained high levels of HIV-1 specific IFN-gamma responses, indicative of a Th 1
response, were still protected
Env (IIIB) HIV-1 infection, Vaccine human Boyer1999
Vaccine Vector/Type: DNA Strain: IIIB HIV component: ENV, REV
• A DNA vaccine containing env and rev was tested for safety and immune response in 15 HIV+ asymptomatic individuals
• Enhanced proliferative activity and higher levels of MIP-1 alpha were detected in multiple study subjects
Env Env Vaccine murine BALB/c Rodríguez1999
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: gp160 Adjuvant: GM-CSF-ENV chimera
• A chimeric GM-CSF-env antigen expressed in a vaccinia vector elicits a higher HIV-specific env cellular immune response than when native env is used
Env Env (LAI) Vaccine Macaca nemestrina Kent1998
Vaccine Vector/Type: DNA prime with vaccinia boost Strain: LAI HIV component: ENV, GAG
• Priming with an HIV-DNA vaccine and boosting with a vaccinia construct induced greater levels of HIV T-cell immunity than either vaccine alone
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• The proliferative response to Env and Gag after the DNA vaccination had a mean SI of 1.5-4, but after boosting with rHIV-fowlpox virus, there was a 6-17
fold increase in the mean SI for HIV Gag and Env. The T help response happened despite a fall in antibody titers, suggesting that the Th response was
primarily Th1, not Th2. The CTL response was also enhanced
Env gp120 Vaccine Rhesus macaque Heeney1999
Vaccine Vector/Type: DNA, protein, virus-like particle, ISCOM
• Ten different vaccine strategies were evaluated for their ability to protect from infection in a rhesus macaque model using a non-pathogenic SHIV
challenge. Protection correlated with the magnitude of NAb responses, beta-chemokines, and a balanced Th response. DNA, protein+adjuvant, VLP and
ISCOM vaccines were tested.
• HIV-1/ISCOMS gave the highest NAb titers, Th1 and Th2 responses, was the only vaccine formulation tested with a detectable CTL response, and gave
enhanced beta-chemokine production.
Env gp160 (MN) HIV-1 infection, Vaccine human Kundu1998a
Vaccine Vector/Type: protein Strain: MN HIV component: gp160
• This study followed 10 HLA-A2 asymptomatic HIV+ individuals as they received MN gp160 vaccinations over a two year period.
• There was an increased lymphoproliferative response but this did not impact viral load or CTL response.
Env gp120 (SF2) Vaccine Rhesus macaque Verschoor1999
Vaccine Vector/Type: DNA, recombinant protein, ISCOM Strain: SF2 HIV component: gp120 Adjuvant: Adjuvant MF59
• 16 rhesus Macaques were vaccinated with either an epidermal SF2 gp120 DNA vaccine, rgp120 with a MF59 adjuvant, or rgp120 incorporated into
ISCOMs
• DNA vaccination elicited a weak Th type 1 response and low antibody response, rgp120/MF59 triggered a strong antibody response, and rgp120/ISCOM
induced both kinds of Th cells, and a strong humoral response.
• Animals were challenged with SF13 SHIV. Early induction of Th type 1 and type 2 responses with the rgp120/ISCOM vaccine provided the most effective
immunity, protecting from infection
Env Env (MN) Vaccine murine Kim1998
Vaccine Vector/Type: DNA Strain: MN HIV component: GAG, POL, ENV Adjuvant: CD80 and CD86 expression vectors
• Co-stimulatory molecules co-expressed with an HIV-1 immunogen in a DNA vaccine used to enhance the immune response – co-expression of CD86, but
not CD80, dramatically increased both HIV Env and Gag/Pol specific CTL and Th proliferative responses
Env Env (LAI, MN) Vaccine human Salmon-Ceron1999
Vaccine Vector/Type: canarypox Strain: MN, LAI HIV component: gp120, gp41, Gag, Protease
• A live attenuated canarypox vector expressing MN gp120 and LAI gp41/gag/protease could induce CTL and a lymphoproliferative response in healthy
uninfected volunteers
Env Env Vaccine Rhesus macaque Akahata2000
Vaccine Vector/Type: DNA Strain: ZF1 HIV component: complete genome
• Rhesus macaques were vaccinated by i.m. injection with naked plasmid DNA carrying an HIV-1 complete genome vaccine, strain ZF1, with a mutated zinc
finger in the nucleocapsid to prevent packaging
• Env and Gag specific CTL but no antibody responses were induced in 2/4 vaccinated monkeys (MM145 and MM153)
• 2/4 monkeys (MM146 and MM143) produced antibodies against p24 and/or gp160, but no CTL response was detected
• PBMC from all vaccinated monkeys produced IFNγ , in response to HIV-1 gp160, indicating a Th response – this response was 5 times higher in MM145,
the animal with the strongest CTL response
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• 4 weeks post-challenge with SHIV NM-3rN plasma viral loads of both MM145 and MM153 (with a homologous Env) decreased to near or below the
detection limit
• 6-8 weeks post-challenge with SHIV NM-3rN plasma viral loads of both MM146 and MM143 decreased near or below the detection limit
Env gp120 (W6.ID) HIV-1 infection human Zhang2001b
• T-helper cell proliferative responses to HIV p24, p55 and gp120 were tested in 27 patients with HIV infection – vigorous responses directed at Gag were
detected in ten patients, but an Env specific response was detected in only one patient
Env gp160 HIV-1 infection human Blazevic2000
• Prolonged viral suppression resulting from potent anti-retroviral therapy did not allow an HIV T helper response to p24 or gp160, but Th proliferative
responses to influenza, alloantigen, and PHA did develop in many HIV+ patients, and asymptomatic patients had stronger and more frequent Th response
recovery than AIDS patients
Env gp120 HIV-1 infection human Oxenius2000
• Patients who started therapy at acute HIV infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific
CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load – three patients that had delayed initiation of
HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became
undetectable
Env gp120 Vaccine human Sabbaj2000
Vaccine Vector/Type: canarypox prime with rgp120 boost HIV component: gp120
• Proliferative responses in PBMC of uninfected individuals that were vaccinated with canarypox vector expressing HIV-1 antigens (ALVAC-HIV) and
boosted with a recombinant gp120 subunit vaccine gave a Th1 and Th2 proliferative response upon stimulation with HIV-1 Env
• All vaccinees produced IFNγ and IL10, most also produced IL-2, IL-6, IL-4 and IL-5
Env gp120 HIV-1 infection, Vaccine human Hladik2001
Vaccine Vector/Type: recombinant protein Strain: MN HIV component: gp120 Adjuvant: no adjuvant
• 16/29 HIV-1 infected and 24/30 vaccinated individuals had DTH reactions within 48 hours after an intradermal rec gp120 injection. Of nine DTH positive
individuals, none had detectable proliferative responses. Thus skin testing may be a sensitive way to identify people with Th recall responses to vaccines, or
in the absence of lymphoproliferaion.
• No 48 hour DTH responses were detected among uninfected volunteers, although 10/35 (40%) of the high risk and 11/32 (34%) of the low risk individuals
developed an induration resembling DTH after 7-12 days, that may be indicative of primary induction of HIV-1 specific Th1-immunity.
Env gp120 HIV-1 infection human Wilson2000b
• Dysfunction of HIV-1 specific proliferative responses, but not responses to other antigens, is evident in HIV-1 progressive disease.
• Vigorous HIV-1 specific responses to p24, Nef and gp120 with SI between 8-99 were seen in 6/7 long term non-progressors (LTNP), the seventh had a
borderline responses. IL-2 production was seen in all cases, and IL-4 production was also evident many responses.
• None of the progressors (0/5) had HIV-1 specific proliferative responses, or IL-2 or IL-4 induction.
• Non-HIV antigens (cytomegalovirus, PPD, Staphylococcus enterotoxin B, tetanus toxoid) gave similar responses in HIV-1+ LTNP, progressors, and HIV-1
controls.
Env gp160 HIV-1 infection human Kalams1999a
• The strength of p24 specific Gag proliferative responses (SIs) were inversely correlated with viral load in 21 ARV naive patients. The responses were Th1,
IFNgamma producing.
• Proliferative responses against gp160 were rarely observed (only 4 cases).
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Env Env Vaccine human MacGregor2002
Vaccine Vector/Type: DNA with CMV promotor Strain: MN HIV component: Env, Rev Adjuvant: bupivacaine
• A phase I clinical trial of a HIV-1 Env and Rev DNA vaccine with a CMV promoter was conducted and Th proliferative, CTL and Elispot responses
monitored. The construct was modified for safety and included no LTRs or packaging signals. The vaccine strategy was safe, and elicited strong CD4-T cell
responses, but not CD8 T-cell responses. Rev elicited strong Th responses, and is a early produced protein so may confer advantages.
• With a 300 ug dose, 4/6 individuals had a lymphocyte proliferation (LP) responses to gp120, 3/6 to Rev.
• With a 1000 ug dose, 4/6 individuals had a LP and 2/6 had IFNgamma Elispot responses to gp160; 3/6 had LP, and 4/6 had IFNgamma Elispot responses to
Rev.
• No responses to three specific CTL epitopes were observed by Elispot in individuals with appropriate HLA. Some cytoxic activity against whole protein
was observed that was CD4+ T-cell mediated.
Env HIV-1 infection human Clerici2002b
• Specific immunity was compared in a two-year study of chronically HIV-1 infected i) HAART-naive patients who were not progressing and had strong
immune responses, ii) newly treated patients followed for 24 months after initiation of HAART, iii) and long-term HAART patients who had been on
HAART at least 12 months prior to the study.
• HAART naïve patients had strongest proliferative responses at time zero, but long-term HAART patients the most significant increase in specific responses
over the two year study period against HIV-1 gp160, influenza, and Candida. Similarly, IL-2 and IFNγ production in responses to gp160 was highest in the
naïve group at time zero, but increased the most in the long-term HAART treated patients.
• Short-term HAART patients showed a significant improvement in their CD4+ T cell count and a reduction of plasma viremia, and had augmented IL-7
production, which was slightly reduced in long-term HAART patients.
Env gp160 HIV-1 infection human Palmer2002
• CD4+ T cell proliferative responses from 33 HIV-1 infected patients with HAART suppression were compared to 19 patients with active viral replication
(HAART failures and HAART naive). Patients with HAART suppression showed stronger p24- and p66-specific proliferative responses compared to
patient groups with active HIV-1 replication, suggesting active viral replication in vivo specifically reduces proliferation responses.
• gp160 proliferation responses were apparent in 7/32 donors tested, but weaker overall, with a median value for the suppressed group not above that found
for HIV seronegative controls.
• No differences in the frequency of HIV-specific CD4+ T-cells that were positive for cytokine secretion in a flow cytometry assay were found in the HAART
suppressed group versus the group with active viral replication.
Env gp120 (SF2) HIV-1 infection human Imami2002b
• 70 patients with chronic disease progression, 10 clinical non-progressors, and 3 immunologically discordant progressors (individuals who controlled
viremia but had progressive CD4+ T-cell decline) were analyzed for their T-helper cell responses to p24 and cytokine profile.
• In a comparison of responses to HIV-1 proteins based on 10 non-progressors, 3 immunologically discordant, and 70 progressors, SIs were always much
higher for non-progressors and immunologically discordant than progressors. Among the non-progressors, the responses to different antigens were greater
using p24 peptides than native p24. Native p24, Nef, gp120 proteins, and Remune (gp120 depleted HIV-1, p24 is subtype G), had roughly comparable
distributions of SI values from the non-progressors, Nef and gp120 responses were somewhat diminished in immunologically discordant patients.
Env (BRU) Vaccine murine Haas1991
Vaccine Vector/Type: inactivated virus Strain: BRU HIV component: whole virus Adjuvant: Complete Freund’s adjuvant (CFA)
• Of 5 mouse inbred lines tested: DBA/2 (H-2d, Ad, Ed), B10.A(4R) (H-2h4, Ak) and B10.A(5R) (H-2i5) showed particularly good CD4+ T cell
proliferative responses to HIV proteins (gp160, gp120, p17, p24, Nef and RT), after vaccination with inactivated virus.
• B10.BR (H-2k, Ak, Ek) and C57BL/6 (H-2b and Ab) had weaker responses.
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Env gp120 Vaccine murine (H-2d) Kim2000
Vaccine Vector/Type: DNA HIV component: GAG, POL, ENV Adjuvant: IL-2, IL-4 and IFNγ expression vectors
• Co-stimulatory molecules co-expressed with an HIV-1 immunogen in a DNA vaccine used to enhance the immune response – co-expression of Th1
cytokine IFN-gamma drove Th1 immune responses and enhanced CTL responses
Env gp120 (IIIB) Vaccine murine (H-2d) Shirai2001
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: gp160
• Helicobacter pylori induces Th1 responses early, but predominantly Th2 responses later in infection (at 6 weeks) – differentiation of HIV-1 gp160 CD4+
help and CD8+ CTL effector cells in response to HIV gp160-vaccinia vaccination is impaired in BALB/c mice infected with H. pylori
Env gp120 (V3) and p24
(IIIB, MN, BH10)
Vaccine murine (H-2d) Buonaguro2002
Vaccine Vector/Type: virus-like particle Strain: gp120 A clade UG5.94UG018, HIV-1 IIIB HIV component: gp120 and Pr55gag
• BALB/c mice were given intraperitoneal immunization in the absence of adjuvants with virus-like particles (VLPs) expressing recombinant subtype A
gp120 and Pr55gag
• High dose-independent humoral responses were elicited against both gp120 and p24 peptides, and CTL responses were observed against target cells
carrying vaccinia expressed gp120 and Gag.
• Recombinant rgp120 (clade B, MN) induced T cell proliferative responses in vitro from vaccinated animals.
Env gp160 (IIIB) Vaccine murine (H2d) Morris2000
Vaccine Vector/Type: peptide, recombinant protein Strain: IIIB HIV component: gp160, V3 Adjuvant: Adjuvant LT(R192G)
• Mice were intranasally immunized with 20 ug of HIV-gp160 and 5 ug of peptide E7 (RIHIGPGRAFYAARK) with the adjuvant LT(R192G), a heat-labile
enterotoxin produced by E. coli
• Adjuvant LT(R192G) was required for stimulation of antigen-specific IgG1, IgG2 antibodies, and Th1 and Th2 cytokines responses to gp160, and
peptide-specific CTL responses
• Increased IFN-gamma, IL-10 and IL-6 cytokine production specific to gp160 was measured with co-immunization of gp160 with LT(R192G)
Env gp160 (IIIB) Vaccine murine (H2d) Arai2000
Vaccine Vector/Type: DNA with CMV promotor Strain: IIIB HIV component: gp160, REV Adjuvant: Br-cAMP
• The CMV promotor responds to the intracellular level of cAMP, and 8 Br-cAMP can increase transgene expression so it was co-administered with a
CMV-based DNA vaccine both intranasally and intramuscularly
• 8 Br-cAMP increased serum IgG responses, HIV-specific CTL, DTH and Th1 responses, and IgA in the intranasal vaccination
• A CAT assay study showed adjuvant effect was due to CMV promotor activation
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Nef (1–20) Nef (1–20 LAI) MGGKWSKSSVVGWPTVRERM Vaccine murine (H-2d) Hinkula1997
Vaccine Vector/Type: DNA Strain: LAI HIV component: NEF, TAT, REV
• Stronger, broader responses were observed in animals vaccinated with DNA epidermally rather than with intramuscular protein
• Proliferative response to vaccination was observed to peptides throughout Nef and Tat, less for Rev
Nef (1–20) Nef (1–20 HXB2) MGGKWSKSSVIGWPTVRERM HIV-1 infection (H-2d) Peng2001
• Deletion of the 19 N-terminal amino acids from Nef including the myristolation signal eliminates Nef-induced down-regulation of MHC class I and CD4
molecules. Such a construct has the potential to serve as a more potent immunogen. The known T-cell epitopes that that would be disputed by this deletion
are minimal, a murine H-2d Th epitope in the peptide MGGKWSKSSVIGWPTVRERM, and a HLA-B8 CTL epitope, WPTVRERM.
Nef (16–35) Nef (16–35 LAI) VRERMRRAEPAADGVGAASR Vaccine murine (H-2d) Hinkula1997
Vaccine Vector/Type: DNA Strain: LAI HIV component: NEF, TAT, REV
• Stronger, broader responses were observed in animals vaccinated with DNA epidermally rather than with intramuscular protein
• Some proliferative response to vaccination was observed to peptides throughout Nef and Tat, less for Rev
Nef (31–50) Nef (31–50 LAI) GAASRDLEKHGAITSSNTAA Vaccine murine (H-2d) Hinkula1997
Vaccine Vector/Type: DNA Strain: LAI HIV component: NEF, TAT, REV
• Stronger, broader responses were observed in animals vaccinated with DNA epidermally rather than with intramuscular protein
• Some proliferative response to vaccination was observed to peptides throughout Nef and Tat, less for Rev
Nef (45–69) Nef (45–69 BRU) SSNTAATNAACAWLEAQEE-
EEVGFP
Vaccine chimpanzee, rat Estaquier1992
Vaccine Vector/Type: peptide prime with protein boost Strain: BRU HIV component: Nef
• Antigenic domain: ATNAACAWL, priming with peptide enhanced subsequent Ab response to Nef protein immunization
Nef (45–69) Nef (45–69) SSNTAATNAACAWLEAQEE-
EEVGFP
Vaccine rat Rouaix1994
Vaccine Vector/Type: peptide Adjuvant: no adjuvant, aluminum hydroxide
• Covalently linking the potent Th epitope Nef 45-69, which can induce Th proliferative responses at low doses with no adjuvant in Lou/M rats, to a weaker
epitope from Schistosoma mansoni allows the induction of detectable Th responses to the Schistosoma epitope.
Nef (46–65) Nef (46–65 LAI) SNTAATNAACAWLEAQEEEE Vaccine murine (H-2d) Hinkula1997
Vaccine Vector/Type: DNA Strain: LAI HIV component: NEF, TAT, REV
• Stronger, broader responses were observed in animals vaccinated with DNA epidermally rather than with intramuscular protein
• Some proliferative response to vaccination was observed to peptides throughout Nef and Tat, less for Rev
Nef (56–68) Nef (56–68 HXB2) AWLEAQEEEEVGF Vaccine murine (DQ2, DQ3,
DQ5, DQ6, DQ7, DQ8,)
Pancré2002
Vaccine Vector/Type: peptide HIV component: Nef Adjuvant: CFA
• This highly conserved Nef epitope has promiscuous HLA-DQ class II binding potential. It has a can bind to 6 different HLA-DQ alleles, but did not bind to
any HLA-DR alleles tested. It bound to DQ2 and DQ8 with particularly high affinity, and with DQ7 with low affinity.
• DQ transgenic mice (in particular DQ8) mounted strong cellular and humoral responses after immunization with this peptide.
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• Ex vivo stimulation of CD4+ T-cells from 14 healthy donors (with diverse HLAs) with this peptide presented on autologous DCs resulted in Th1-associated
cytokine production. IFNgamma production was stimulated in 7/14 cases, both IFNgamma and IL-2 in 6/14, and just IL-2 in 1/14. No IL-4 or IL-5
production was observed.
• Peptide-specific CD4+ T-cell clones with different HLA presenting molecules demonstrated a preference for TCR Vbeta6.1.
Nef (61–80) Nef (61–80 LAI) QEEEEVGFPVTPQVPLRPMT Vaccine murine (H-2b) Hinkula1997
Vaccine Vector/Type: DNA Strain: LAI HIV component: NEF, TAT, REV
• Stronger, broader responses were observed in animals vaccinated with DNA epidermally rather than with intramuscular protein
• Some proliferative response to vaccination was observed to peptides throughout Nef and Tat, less for Rev
Nef (66–97) Nef (66–97 LAI) VGFPVTPQVPLRPMTYKAA-
VDLSHFLKEKGGL
Vaccine human Gahery-Segard2000
Vaccine Vector/Type: lipopeptide
• Anti-HIV lipopeptide vaccine consisting of six long peptides derived from Nef, Gag and Env HIV-1 proteins modified by a palmitoyl chain was
administered in a phase I trial
• A CD4+ T cell proliferative response to at least one of the six peptides was observed in 9/10 vaccinees – 5/10 reacted to this Nef peptide
• 9/12 tested mounted a CTL responses to at least one of the six peptides, each of the six peptides elicited a CTL response in at least one individual
• 5/12 tested had an IgG response to this peptide
Nef (76–95) Nef (76–95 LAI) LRPMTYKAAVDLSHFLKEKG Vaccine murine (H-2b) Hinkula1997
Vaccine Vector/Type: DNA Strain: LAI HIV component: NEF, TAT, REV
• Stronger, broader responses were observed in animals vaccinated with DNA epidermally rather than with intramuscular protein
• Some proliferative response to vaccination was observed to peptides throughout Nef and Tat, less for Rev
Nef (91–110) Nef (91–110 LAI) LKEKGGLEGLIHSQRRQDIL Vaccine murine (H-2b) Hinkula1997
Vaccine Vector/Type: DNA Strain: LAI HIV component: NEF, TAT, REV
• Stronger, broader responses were observed in animals vaccinated with DNA epidermally rather than with intramuscular protein
• Some proliferative response to vaccination was observed to peptides throughout Nef and Tat, less for Rev
Nef (98–112) Nef (98–112 BRU) EGLIHSQRRQDILDL Vaccine chimpanzee Estaquier1992
Vaccine Vector/Type: peptide prime with protein boost Strain: BRU HIV component: Nef
• Peptide alone could stimulate monkey T-cells in the absence of carrier protein – required carrier protein in rat
Nef (104–123) Nef (106–125 HXB3) QRRQDILDLWIYHTQGYFP-
D?
Vaccine murine (H-2b) Sandberg2000
Vaccine Vector/Type: DNA Strain: HXB3 HIV component: Nef
• A strong T helper proliferative response against a rec Nef protein was observed 2 weeks after immunization of HLA-A201 transgenic mice in a C57Bl/6
background – the response was weak by 4 weeks post immunization
• Mice were immunized with nef DNA under the control of a CMV promotor, coated on gold particles delivered to abdominal skin by a gene gun
• Primary responses were directed at peptides 106-125, 166-185, and 181-205, indicating a response to multiple epitopes
Nef (106–125) Nef (106–125 LAI) RQDILDLWIYHTQGYFPDWQ Vaccine murine (H-2b) Hinkula1997
Vaccine Vector/Type: DNA Strain: LAI HIV component: NEF, TAT, REV
• Stronger, broader responses were observed in animals vaccinated with DNA epidermally rather than with intramuscular protein
• Some proliferative response to vaccination was observed to peptides throughout Nef and Tat, less for Rev
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Nef (117–147) Nef (117–147 LAI) TQGYFPDWQNYTPGPGVRY-
PLTFGWCYKLVP
Vaccine human Gahery-Segard2000
Vaccine Vector/Type: lipopeptide
• Anti-HIV lipopeptide vaccine consisting of six long peptides derived from Nef, Gag and Env HIV-1 proteins modified by a palmitoyl chain was
administered in a phase I trial
• A CD4+ T cell proliferative response to at least one of the six peptides was observed in 9/10 vaccinees – 1/10 reacted to this Nef peptide
• 9/12 tested mounted a CTL responses to at least one of the six peptides, each of the six peptides elicited a CTL response in at least one individual
• 10/12 tested had an IgG response to this peptide
Nef (121–140) Nef (121–140 LAI) FPDWQNYTPGPGVRYPLTFG Vaccine murine (H-2b) Hinkula1997
Vaccine Vector/Type: DNA Strain: LAI HIV component: NEF, TAT, REV
• Stronger, broader responses were observed in animals vaccinated with DNA epidermally rather than with intramuscular protein
• Some proliferative response to vaccination was observed to peptides throughout Nef and Tat, less for Rev
Nef (136–155) Nef (136–155 LAI) PLTFGWCYKLVPVEPDKVEE Vaccine murine (H-2d) Hinkula1997
Vaccine Vector/Type: DNA Strain: LAI HIV component: NEF, TAT, REV
• Stronger, broader responses were observed in animals vaccinated with DNA epidermally rather than with intramuscular protein
• Some proliferative response to vaccination was observed to peptides throughout Nef and Tat, less for Rev
Nef (151–170) Nef (151–170 LAI) DKVEEANKGENTSLLHPVSL Vaccine murine (H-2d) Hinkula1997
Vaccine Vector/Type: DNA Strain: LAI HIV component: NEF, TAT, REV
• Stronger, broader responses were observed in animals vaccinated with DNA epidermally rather than with intramuscular protein
• Some proliferative response to vaccination was observed to peptides throughout Nef and Tat, less for Rev
Nef (164–183) Nef (166–185 HXB3) LLHPVSLHGMDDPEREVLE-
W?
Vaccine murine (H-2b) Sandberg2000
Vaccine Vector/Type: DNA Strain: HXB3 HIV component: Nef
• A strong T helper proliferative response against a rec Nef protein was observed 2 weeks after immunization of HLA-A201 transgenic mice in a C57Bl/6
background – the response was weak by 4 weeks post immunization
• Mice were immunized with nef DNA under the control of a CMV promotor, coated on gold particles delivered to abdominal skin by a gene gun
• Primary responses were directed at peptides 106-125, 166-185, and 181-205, indicating a response to multiple epitopes
Nef (166–185) Nef (166–185 LAI) HPVSLHGMDDPEREVLEWRF Vaccine murine (H-2b,d) Hinkula1997
Vaccine Vector/Type: DNA Strain: LAI HIV component: NEF, TAT, REV
• Stronger, broader responses were observed in animals vaccinated with DNA epidermally rather than with intramuscular protein
• Some proliferative response to vaccination was observed to peptides throughout Nef and Tat, less for Rev
Nef (179–198) Nef (181–205 HXB3) EVLEWRFDSRLAFHHVARE-
L?
Vaccine murine (H-2b) Sandberg2000
Vaccine Vector/Type: DNA Strain: HXB3 HIV component: Nef
• A strong T helper proliferative response against a rec Nef protein was observed 2 weeks after immunization of HLA-A201 transgenic mice in a C57Bl/6
background – the response was weak by 4 weeks post immunization
• Mice were immunized with nef DNA under the control of a CMV promotor, coated on gold particles delivered to abdominal skin by a gene gun
• Primary responses were directed at peptides 106-125, 166-185, and 181-205, indicating a response to multiple epitopes
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Nef (181–205) Nef (181–205 LAI) LEWRFDSRLAFHHVARELH-
PEYFKN
Vaccine murine (H-2d) Hinkula1997
Vaccine Vector/Type: DNA Strain: LAI HIV component: NEF, TAT, REV
• Stronger, broader responses were observed in animals vaccinated with DNA epidermally rather than with intramuscular protein
• Some proliferative response to vaccination was observed to peptides throughout Nef and Tat, less for Rev
Nef (182–205) Nef (182–205 LAI) EWRFDSRLAFHHVARELHP-
EYFKN
Vaccine human Gahery-Segard2000
Vaccine Vector/Type: lipopeptide
• Anti-HIV lipopeptide vaccine consisting of six long peptides derived from Nef, Gag and Env HIV-1 proteins modified by a palmitoyl chain was
administered in a phase I trial
• A CD4+ T cell proliferative response to at least one of the six peptides was observed in 9/10 vaccinees – 4/10 reacted to this Nef peptide
• 9/12 tested mounted a CTL responses to at least one of the six peptides, each of the six peptides elicited a CTL response in at least one individual
• None of the 12 tested had an IgG response to this peptide
Nef (185–200) Nef (183–198) FDSRLAFHHVARELHP HIV-1 infection human Ranki1997
• T-cell response to this epitope persisted after seroreversion
Nef (186–206) Nef(p27) (185–205
BRU)
DSRLAFHHVARELHPEYFK-
NC
Vaccine chimpanzee Bahraoui1990
Vaccine Vector/Type: recombinant protein Strain: BRU HIV component: gp160, p25, Nef, p17 and p24 Gag Adjuvant: muramyl-dipeptide base
adjuvant (Syntex)
• Epitope name: PF63
• Six chimpanzees were immunized with rec vaccinia viruses (VV) expressing HIV-1 gp160, Gag, and Nef.
• 2/6 chimpanzees showed persistent T-helper proliferative responses against a putative immunodominant epitope located at the C-term end of Nef.
Nef Nef (LAI) HIV-1 infection human daSilva1998
• This study compares the level of variation in Nef CTL epitopes to helper and MAb epitopes from the same region
• CTL epitopes tend to be more conserved than either helper or MAb epitopes and there are stronger functional constraints in the regions where CTL epitopes
cluster.
Nef Nef Vaccine human Calarota1999
Vaccine Vector/Type: DNA HIV component: Nef, Rev Tat
• 9/9 HIV-1+ subjects were given one of three DNA vaccinations for nef, rev or tat, and novel proliferative and CTL responses were generated
• The nef DNA immunization induced the highest and most consistent CTLp activity, IFN-gamma production, and IL-6 and IgG responses
• Highly active antiretroviral treatment (HAART) did not induce new HIV-specific CTL responses but reduced viral load, while DNA vaccination induced
new immune responses but did not reduce viral load – thus this is a potentially complementary and promising combination
Nef Nef HIV-1 infection, Vaccine human Calarota2001
Vaccine Vector/Type: DNA HIV component: Nef, Rev, Tat Adjuvant: CpG motifs
• This review discusses the cellular immune response, and comments on CpG induction of Th1 cytokines and enhanced immune responses, and HIV-1 DNA
vaccine boosting of CTL and Th proliferative responses in asymptomatic HIV+ individuals
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Nef Nef HIV-1 infection human Oxenius2000
• Patients who started therapy at acute HIV infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific
CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load – three patients that had delayed initiation of
HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became
undetectable
Nef Nef HIV-1 infection human Wilson2000b
• Dysfunction of HIV-1 specific proliferative responses, but not responses to other antigens, is evident in HIV-1 progressive disease.
• Vigorous HIV-1 specific responses to p24, Nef and gp120 with SI between 8-99 were seen in 6/7 long term non-progressors (LTNP), the seventh had a
borderline responses. IL-2 production was seen in all cases, and IL-4 production was also evident many responses.
• None of the progressors (0/5) had HIV-1 specific proliferative responses, or IL-2 or IL-4 induction.
• Non-HIV antigens (cytomegalovirus, PPD, Staphylococcus enterotoxin B, tetanus toxoid) gave similar responses in HIV-1+ LTNP, progressors, and HIV-1
controls.
Nef Nef (BRU) Vaccine murine Moureau2002
Vaccine Vector/Type: recombinant protein Strain: BRU HIV component: Nef Adjuvant: poly(DL-lactide-co-glycolide) (PLG), Freund’s adjuvant
• BALB/c mice were immunized with Nef alone, Nef with Freund’s adjuvant, or Nef encapsulated in poly(DL-lactide-co-glycolide) PLG microparticles.
• High Ab titers (predominantly IgG1) against Nef were retained for seven months in the mice infected with Nef-PLG, 3-fold higher than Nef in Freund’s,
5-fold higher than Nef alone.
• CD4+ T-cell lymphoproliferative were observed, and cytokine profiles indicated this was primarily a Th2 response.
Nef Nef (SF2) HIV-1 infection human Imami2002b
• 70 patients with chronic disease progression, 10 clinical non-progressors, and 3 immunologically discordant progressors (individuals who controlled
viremia but had progressive CD4+ T-cell decline) were analyzed for their T-helper cell responses to p24 and cytokine profile.
• In a comparison of responses to HIV-1 proteins based on 10 non-progressors, 3 immunologically discordant, and 70 progressors, SIs were always much
higher for non-progressors and immunologically discordant than progressors. Among the non-progressors, the responses to different antigens were greater
using p24 peptides than native p24. Native p24, Nef, gp120 proteins, and Remune (gp120 depleted HIV-1, p24 is subtype G), had roughly comparable
distributions of SI values from the non-progressors, Nef and gp120 responses were somewhat diminished in immunologically discordant patients.
Nef (BRU) Vaccine murine Haas1991
Vaccine Vector/Type: inactivated virus Strain: BRU HIV component: whole virus, RT Adjuvant: Complete Freund’s adjuvant (CFA)
• Of 5 mouse inbred lines tested: DBA/2 (H-2d, Ad, Ed), B10.A(4R) (H-2h4, Ak) and B10.A(5R) (H-2i5) showed particularly good CD4+ T cell
proliferative responses to HIV proteins (gp160, gp120, p17, p24, Nef and RT), after vaccination with inactivated virus.
• B10.BR (H-2k, Ak, Ek) and C57BL/6 (H-2b and Ab) had weaker responses.
Nef Nef Vaccine murine (H-2d) Ayyavoo2000
Vaccine Vector/Type: DNA HIV component: Vif, Vpu, Nef
• Splenocytes from BALB/c mice immunized with pVVN-P DNA were incubated with Vif, Vpu or Nef antigens for 3 days and assayed for IL-4 and
IFN-gamma levels
• Antigen stimulation increased IFN-gamma production in pVVN-P immunized mice, indicating a Th1 response
• IL-4 production was not significantly changed after antigen stimulation compared to control levels
• Cross-clade CTL activity was also observed: A, B clade, CRF01(AE) clade antigens could serve as targets for the B clade immunization stimulated CTL –
an HIV-1 AC recombinant, however, did not stimulate a CTL response, but was expressed at lower levels on the target cell
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HIV-1 HIV-1 infection human Kuhn2002
• Intrauterine exposure of infants to HIV from their mothers results in HIV-1 specific T-helper cell proliferative responses in 1/3 of exposed uninfected babies,
and HIV-1 specific CTL in some. It is unknown whether these responses are associated with lack of infection, but there is some evidence that HIV-1 T-cell
responses may reduce transmission in breastfeeding mothers. Summary tables are provided of CD4 and CD8 T-cell responses detected in earlier studies.
HIV-1 HIV-1 infection, Vaccine human Kahn2000
Vaccine Vector/Type: gp120 depleted virus HZ321 (REMUNE(TM)) Strain: Z321 HIV component: gp120-depleted HIV-1 antigen Adjuvant:
Incomplete Freund adjuvant (IFA)
• No benefit was observed in terms of progression free survival for HIV-1 patients on ART given vaccinations with HIV-1 antigen (N=1,262) versus those
vaccinated with placebo (N=1,265). There was no statistically different outcome in HIV RNA, CD4 percentage, or body weight. HIV-1 ART patients that
were vaccinated did have higher absolute CD4 counts.
HIV-1 HIV-1 infection, Vaccine human Moss1999
Vaccine Vector/Type: gp120 depleted virus HZ321 (REMUNE(TM)) Strain: Z321 HIV component: gp120-depleted HIV-1 antigen Adjuvant:
Incomplete Freund adjuvant (IFA)
• 15 HIV-1+ patients on ARV given vaccinations with HIV-1 antigen versus vaccinated with placebo. Lymphocyte proliferation of CD4+, CD8+ memory
cells and NK cells to p24 and Remune HIV-1 antigen increased in HAART treated patients after vaccination.
HIV-1 HIV-1 infection, Vaccine human Moss1997
Vaccine Vector/Type: gp120 depleted virus HZ321 (REMUNE(TM)) Strain: Z321 HIV component: gp120-depleted HIV-1 antigen Adjuvant:
Incomplete Freund adjuvant (IFA)
• HIV-1 specific stimulation of T-cell proliferation, and beta-chemokines (RANTES) and Th1-type cytokine (IFNgamma) production are found after
immunization of HIV-1+ individuals with HIV-1 immunogen.
HIV-1 HIV-1 infection, Vaccine human Levine1996
Vaccine Vector/Type: gp120 depleted virus HZ321 (REMUNE(TM)) Strain: Z321 HIV component: gp120-depleted HIV-1 antigen Adjuvant:
Incomplete Freund adjuvant (IFA)
• Long-term follow up of HIV-1+ individuals given HIV-1 immunogen, suggesting those patients who became HIV-DTH-responsive in response to the HIV-1
immunogen had a better clinical outcome. Of twelve who developed DTH-responsiveness, one got an opportunistic infection and died, and one developed
KS. Of the 13 patients who remained HIV-DTH-nonresponsive, 9 (69%) progressed to AIDS and 7 of these had died.
HIV-1 Vaccine human Turner1994
Vaccine Vector/Type: HIV-1 immunogen Adjuvant: Incomplete Freund adjuvant (IFA)
• A dose response study of HIV immunogen in IFA was conducted. Doses of 50, 100, 200, or 400 micrograms (total protein) were tested by DTH skin testing
to the inactivated HIV-1 antigen. The HIV-1 immunogen was well tolerated, and the minimum dose required to induce HIV-1 DTH was 100 micrograms.
HIV-1 HIV-1 infection human, macaque Wodarz2002
• Mathematical modeling is used to support the idea that T-helper cell dysfunction results in a compromised ability to maintain an anti-HIV CTL memory
response. Models suggest strategies to restore CTL memory through therapy and improve long-term immunological control of the virus.
HIV-1 HIV-1 infection, Vaccine human Imami2002a
Vaccine Vector/Type: gp120 depleted virus HZ321 (REMUNE(TM)), recombinant protein, virus-like particle, canarypox, adenovirus, DNA Adjuvant:
CpG, IL-2, GMCSF, IL-7, IL-12, Growth Hormone, Thymosin alpha-1.
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• This review addresses the use of immunotherapy and therapeutic immunization to help chronically infected patients maintain a strong anti-HIV-1 T-cell
response. The loss of anti HIV-1 proliferative responses early after infection is reviewed, as are therapeutic vaccinations, with or without HAART, and
strategies for immunomodulation that can be given with or without vaccination.
HIV-1 HIV-1 infection human Heeney2002
• Review of the importance of balanced Th1 and Th2 HIV-specific CD4 T-cell responses in control of infection and for vaccination strategies.
HIV-1 HIV-1 infection Bernaschi2002
• A cellular automata model was used to model the dynamics of HIV-1 infection and progression to disease. The model suggests the long aymptomatic
period is due to immune escape mutants with lower viral fitness, and with AIDS resulting from a drastic reduction of the T-helper cell reservoire.
HIV-1 Vaccine Altes2002
• This study employs a mathematical model to study the consequences of increasing the T-helper response through a vaccine, which would have
counter-balancing effects in a new infection: a more intense response provides more help but also more target cells. The model indicates that if the infecting
virus had a low replication rate, then CTLp and CD4 helper cells could control an infection. Only a vaccine that could increase CTL responsiveness could
reduce viral set point with observed replication rates.
• A CD4+ T-cell response without maintained CTL response was deleterious in this model.
HIV-1 HIV-1 infection Bajaria2002
• This paper presents a dynamical model of HIV infection and progression that includes CD4 T-cell naive and memory populations distributed between the
peripheral blood and the lymph nodes, as well as the effects of HAART. Increasing viral replication and infectivity and decreasing T-cell immunity had
impact on the rate of disease progression in this model.
HIV-1 (HZ321) Vaccine murine Ayash-Rashkovsky2002
Vaccine Vector/Type: gp120 depleted virus HZ321 (REMUNE(TM)) Strain: HZ321 Adjuvant: CpG, incomplete Freund’s adjuvant (IFA)
• Parasitic helminthic infections in humans, common in parts of Africa and Asia, can shift immune responses to Th2 responses. To model this, BALB/c mice
were infected with the parasite Schistosoma mansoni, and the infected mice showed a dominant Th2 immune response. Vaccination with gp120-depleted
HIV-1 viral particles and incomplete Freund’s adjuvant induced Th2 responses in these mice, but this could be shifted towards a Th1 profile when CpG
oligodeoxynucleotide was added to the vaccine as an immunostimulatory agent.
HIV-1 HIV-1 except gp120 HIV-1 infection human Ghanekar2001
• 12 long term non-progressors (>10 years) went on HAART, while 14 elected not to go on HAART. After a year on HAART, higher frequencies and
absolute numbers of HIV-specific memory CD4+ T-cells were observed in untreated patients than patients receiving HAART therapy, tested by stimulation
an proliferation responses to HIV Remune antigen (gp120 depleted vaccine).
• These results indicate a control of viral replication in therapy-naive patients may be mediated by their ability to respond to recall viral antigen, and that the
diminished response in treated patients may contribute to viral rebound.
HIV-1 HIV-1 infection human Pido-Lopez2002
• The thymic output in HAART-treated HIV-1 infected patients with progressive disease was studied. One patient also receiving steroid treatment therapy had
a weak response in a sjTREC assay indicating a dysfunctional thymus, while four patients not on steroids had clear positive sjTREC readings after HAART.
Stimulation of PBMC with multiple recall antigens including gp120, p24 and Nef and mitogens, and revealed that in the patient treated with steroids there
was and induction of a Th2 type response indicated by increased levels of IL-4 secretion in response to antigen.
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Linear helper T cell epitopes less than twenty-two amino acids long are
shown.
III-C-1 p17 T-Helper Epitope Map
MGARASVLSGGELDRWEKIRLRPGGKKKYKLKHIVWASRELERFAVNPGL
10 20 30 40 50
DR13.02
human
human
LETSEGCRQILGQLQPSLQTGSEELRSLYNTVATLYCVHQRIEIKDTKEA
60 70 80 90 100
human
LDKIEEEQNKSKKKAQQAAADTGHSNQVSQNY
110 120 130
human human
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III-C-2 p24 T-Helper Epitope Map
PIVQNIQGQMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQ
10 20 30 40 50
DR1 human human
human A*0201
DR supermotif human
I-Ab and HLA-DR
human
H-2d, H-2b
DLNTMLNTVGGHQAAMQMLKETINEEAAEWDRVHPVHAGPIAPGQMREPR
60 70 80 90 100
human DR DR4
human human human
human human human
human
macaque
DQ7
H-2b
GSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSI
110 120 130 140 150
H-2b DRB1*1301 human
human human DR4
human H-2d human
DR4 DR supermotif
macaque DRB1*1301, DRB1*1302
human human
human DR4
macaque
DR supermotif
human
human
LDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKT
160 170 180 190 200
human DRB1*1302
DR4 human
human
human
DR4
human
human
human
human
H-2d, H-2b
ILKALGPAATLEEMMTACQGVGGPGHKARVL
210 220 230
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III-C-3 p2p7p1p6 T-Helper Epitope Map
AEAMSQVTNSATIMMQRGNFRNQRKIVKCFNCGKEGHTARNCRAPRKKGC
10 20 30 40 50
human
WKCGKEGHQMKDCTERQANFLGKIWPSYKGRPGNFLQSRPEPTAPPEESF
60 70 80 90 100
human H-2b
human human
human
RSGVETTTPPQKQEPIDKELYPLTSLRSLFGNDPSSQ
110 120 130
human
human
human
III-C-4 Protease T-Helper Epitope Map
PQVTLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMSLPGRWKPKMIGGI
10 20 30 40 50
GGFIKVRQYDQILIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF
60 70 80 90
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III-C-5 RT T-Helper Epitope Map
PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKI
10 20 30 40 50
human
H-2k
human
H-2k
GPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGL
60 70 80 90 100
human H-2k H-2t4
H-2k
human
H-2k
KKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLP
110 120 130 140 150
H-2t4 DR supermotif
I-Ab and HLA-DR
H-2k,i5
H-2t4
QGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRT
160 170 180 190 200
H-2t4 DR1, 2 or 3, 4 and 7
DR supermotif human
I-Ab and HLA-DR human
DR1, DR2, DR3, DR4, DR7
KIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKD
210 220 230 240 250
human human
human DR5
DRS
SWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTEEAE
260 270 280 290 300
human human
DR5 human
DRS human
DR5(11.01) human
human
DR1, DR2, DR3, DR5, DR7
LELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLK
310 320 330 340 350
human
human
TGKYARMRGAHTNDVKQLTEAVQKITTESIVIWGKTPKFKLPIQKETWET
360 370 380 390 400
human
WWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRET
410 420 430 440 450
DR supermotif
human
DR1, DR2, DR3, DR4
KLGKAGYVTNRGRQKVVTLTDTTNQKTELQAIYLALQDSGLEVNIVTDSQ
460 470 480 490 500
YALGIIQAQPDQSESELVNQIIEQLIKKEKVYLAWVPAHKGIGGNEQVDK
510 520 530 540 550
Ad or Dd
Ad and Dd
H-2f,k,d
DR supermotif
I-Ab and HLA-DR
DR supermotif
LVSAGIRKVL
560
540
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III-C-6 Integrase T-Helper Epitope Map
FLDGIDKAQDEHEKYHSNWRAMASDFNLPPVVAKEIVASCDKCQLKGEAM
10 20 30 40 50
DR supermotif
HGQVDCSPGIWQLDCTHLEGKVILVAVHVASGYIEAEVIPAETGQETAYF
60 70 80 90 100
LLKLAGRWPVKTIHTDNGSNFTGATVRAACWWAGIKQEFGIPYNPQSQGV
110 120 130 140 150
VESMNKELKKIIGQVRDQAEHLKTAVQMAVFIHNFKRKGGIGGYSAGERI
160 170 180 190 200
human human
DR supermotif
VDIIATDIQTKELQKQITKIQNFRVYYRDSRNPLWKGPAKLLWKGEGAVV
210 220 230 240 250
human
DR supermotif
human
IQDNSDIKVVPRRKAKIIRDYGKQMAGDDCVASRQDED
260 270 280
III-C-7 Rev T-Helper Epitope Map
MAGRSGDSDEELIRTVRLIKLLYQSNPPPNPEGTRQARRNRRRRWRERQR
10 20 30 40 50
human human
H-2d
human
H-2d
human
QIHSISERILGTYLGRSAEPVPLQLPPLERLTLDCNEDCGTSGTQGVGSP
60 70 80 90 100
human H-2b
H-2d
QILVESPTVLESGTKE
110
H-2d
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III-C-8 Tat T-Helper Epitope Map
MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKALGISYGRK
10 20 30 40 50
H-2d H-2d
H-2d H-2d
human
DR5? plus others
human
DR5? plus others
KRRQRRRAHQNSQTHQASLSKQPTSQPRGDPTGPKEXKKKVERETETDPF
60 70 80 90 100
H-2d
H-2d
DR2? plus others
H-2d
D
101
III-C-9 Vif T-Helper Epitope Map
MENRWQVMIVWQVDRMRIRTWKSLVKHHMYVSGKARGWFYRHHYESPHPR
10 20 30 40 50
ISSEVHIPLGDARLVITTYWGLHTGERDWHLGQGVSIEWRKKRYSTQVDP
60 70 80 90 100
human
human
ELADQLIHLYYFDCFSDSAIRKALLGHIVSPRCEYQAGHNKVGSLQYLAL
110 120 130 140 150
AALITPKKIKPPLPSVTKLTEDRWNKPQKTKGHRGSHTMNGH
160 170 180 190
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III-C-10 Vpr T-Helper Epitope Map
MEQAPEDQGPQREPHNEWTLELLEELKNEAVRHFPRIWLHGLGQHIYETY
10 20 30 40 50
GDTWAGVEAIIRILQQLLFIHFRIGCRHSRIGVTRQRRARNGASRS
60 70 80 90
human
H-2d
III-C-11 Vpu T-Helper Epitope Map
TQPIPIVAIVALVVAIIIAIVVWSIVIIEYRKILRQRKIDRLIDRLIERA
10 20 30 40 50
human
EDSGNESEGEISALVEMGVEMGHHAPWDVDDL
60 70 80
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III-C-12 gp160 T-Helper Epitope Map
MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWKEATT
10 20 30 40 50
H-2bxk
Rhesus macaque
human, chimpanzee
H-2bxk,sxd
Rhesus macaque
H-2sxd
murine
H-2d
human
TLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVVLVNVTENFNMWKNDM
60 70 80 90 100
Rhesus macaque H-2bxk,sxd human
H-2sxd human
murine H-2bxk,sxd
H-2d human
human murine
human H-2k
murine human
human
human
VEQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTNTNSSSGRMIME
110 120 130 140 150
human human guinea pig
human Rhesus macaque human
human murine
H-2bxk
H-2d, H-2b
H-2d,i5
human
H-2k, H-2s
human
Rhesus macaque
H-2k
H-2k,s
human
human
human
human
HLA-DR
human
human
guinea pig
KGEIKNCSFNISTSIRGKVQKEYAFFYKLDIIPIDNDTTSYKLTSCNTSV
160 170 180 190 200
guinea pig human H-2 IAb
human human HLA-DR
human murine
H-2 IAb H-2k
HLA-DR human
murine H-2 IAb
Rhesus macaque Rhesus macaque
human human, chimpanzee
Rhesus macaque
H-2 IAb H-2bxk,sxd
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ITQACPKVSFEPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHG
210 220 230 240 250
murine H-2 IAb Rhesus macaque
H-2k unknown human
human human
H-2 IAb human
H-2 IAb human
Rhesus macaque DR2
human, chimpanzee human human
H-2bxk,sxd DR2,6 human
HLA-DR H-2d DRB1*0406
H-2 IAb human
H-2 IAb murine
guinea pig
H-2 IAb
H-2 IAb
murine
H-2bxk
human
H-2 IAb
H-2 IAb
IRPVVSTQLLLNGSLAEEEVVIRSVNFTDNAKTIIVQLNTSVEINCTRPN
260 270 280 290 300
human human human
murine human human
human human unknown
human human
DRB1*0406 human H-2 IAb
human human
human murine
human
goat
NNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKLR
310 320 330 340 350
murine H-2k, H-2d human
human H-2 IAb guinea pig
human murine murine
unknown H-2k,d human
goat H-2 IAb human
H-2 IAb guinea pig
murine H-2 IAb
human human
human human
H-2b,d,k,s H-2k, H-2b, H-2s
H-2d H-2k,t4,i5
human murine
Rhesus macaque H-2k, H-2d
DR human
H-2 Ad
H-2 I-Ad
H-2d
DRB1*0101
human
human
murine
murine
H-2d
H-2d
human
H-2k, H-2d
human
H-2 IAb
human
I-Ad
guinea pig
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EQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNSTW
360 370 380 390 400
guinea pig human human
murine human
H-2k, H-2d human
human human
human human
human human
murine
human
Rhesus macaque
human
human
STEGSNNTEGSDTITLPCRIKQIINMWQKVGKAMYAPPISGQIRCSSNIT
410 420 430 440 450
human unknown human
human human, chimpanzee
human goat
human human
murine human
H-2k, H-2d H-2 IAb
H-2 IAb H-2k, H-2b, H-2s, H-2d
DR4 human
DR4(Dw10)
human
human
human
murine
chimpanzee
DR
Ek
H-2$E\alpha E\beta ^k$
H-2d
H-2k, H-2s, H-2d
H-2k,d,s
H-2k,d,t4
H-2k
human
H-2s
H-2t4
human
H-2k,d,i5,t4
human
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GLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTK
460 470 480 490 500
human human human
human human
human human DR
human human
human guinea pig
human Rhesus macaque
H-2k, H-2s
H-2d,t4
murine
DR*W201
human
H-2d,k,t4,i5
H-2k, H-2b, H-2s, H-2d
human
DRB*W201
murine
AKRRVVQREKRAVGIGALFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQ
510 520 530 540 550
human human
Rhesus macaque
murine
human
murine
DR
QQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSG
560 570 580 590 600
human H-2d,b
human human, chimpanzee
H-2d,b
murine, Rhesus macaque
human
H2d
human
human
human
KLICTTAVPWNASWSNKSLEQIWNHTTWMEWDREINNYTSLIHSLIEESQ
610 620 630 640 650
human human human
H2d human
human human
human
human
human
H-2 IAb
human
H-2 IAb
NQQEKNEQELLELDKWASLWNWFNITNWLWYIKLFIMIVGGLVGLRIVFA
660 670 680 690 700
human human
human
human
VLSIVNRVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDRDRSIRLVN
710 720 730 740 750
human
GSLALIWDDLRSLCLFSYHRLRDLLLIVTRIVELLGRRGWEALKYWWNLL
760 770 780 790 800
H-2k, H-2d, H-2s
H-2d,k,t4
H-2k, H-2d, H-2s
H-2k
H-2k, H-2d, H-2s
H-2k,d,t4
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QYWSQELKNSAVSLLNATAIAVAEGTDRVIEVVQGACRAIRHIPRRIRQG
810 820 830 840 850
H-2k, H-2d, H-2s H-2k, H-2b, H-2s
H-2k H-2k
H-2k, H-2d, H-2s H-2k
H-2k,d,t4 human
human H-2d,t4
human
Rhesus macaque
H-2k, H-2b
H-2k,i5
H-2k, H-2b
H-2i5
H-2k, H-2b, H-2d, H-2s
H-2d,t4,i5
H-2k, H-2b, H-2s
H-2d,t4
human
LERILL
856
H-2k, H-2b, H-2s
H-2d,t4
human
III-C-13 Nef T-Helper Epitope Map
MGGKWSKSSVIGWPTVRERMRRAEPAADRVGAASRDLEKHGAITSSNTAA
10 20 30 40 50
H-2d H-2d
H-2d H-2d
H-2d
TNAACAWLEAQEEEEVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLEGL
60 70 80 90 100
H-2d H-2b
DQ2, DQ3, DQ5, DQ6, DQ7, DQ8, H-2b
H-2b chimpanzee
IHSQRRQDILDLWIYHTQGYFPDXQNYTPGPGVRYPLTFGWCYKLVPVEP
110 120 130 140 150
H-2b H-2b
chimpanzee H-2d
H-2b
H-2b
DKIEEANKGENTSLLHPVSLHGMDDPEREVLEWRFDSRLAFHHVARELHP
160 170 180 190 200
H-2d H-2b
H-2d H-2b
H-2b,d
human
chimpanzee
EYFKNC
206
chimpanzee
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IV-A Summary
Part IV section summarizes HIV-specific antibodies (Abs) arranged sequen-
tially according to the location of their binding domain, organized by protein.
We attempted to make this section as comprehensive as possible. For the mono-
clonal (MAbs) capable of binding to linear peptides, we require that the binding
site be contained within a region of 30 or so amino acids to define the epitope,
but not that the precise boundaries be defined. MAbs that do not bind to defined
linear peptides are grouped by category at the end of each protein. Antibody
categories, for example CD4 binding site (CD4BS) antibodies, are also noted in
the index at the beginning of this section. Studies of polyclonal Ab responses are
also included. Responses that are just characterized by binding to a protein, with
no known specific binding site, are listed at the end of each protein. For more
recent updates, epitope sequence alignments, and search capabilities, please see
our web site: http://hiv-web.lanl.gov/immunology.
IV-A-1 Indices
Three indices are provided. The first provides a concise list of anti-HIV-1 MAbs
by cross-competition category, with both discontinuous epitopes (for example,
CD4BS) and some well known linear epitopes (for example, cluster I) summa-
rized. The second lists the MAb’s IDs in alphabetical order so one can find their
location in the table. The third is a listing by order of appearance in the tables.
IV-A-2 Tables
Each MAb has an ten-part basic entry:
Number: Order of appearance in this table.
MAb ID: The name of the monoclonal antibody with synonyms in parentheses.
MAbs often have several names. For example, punctuation can be lost and
names are often shortened (M-70 in one paper can be M70 in another).
Polyclonal responses are listed as “polyclonal” in this field.
HXB2 Location: Position of the Ab binding site relative to the viral strain HXB2
(GenBank Accession Number K03455), which is used as a reference strain
throughout this publication. The numbering in this table corresponds to
the protein maps. Because of HIV-1 variation the epitope may not actu-
ally be present in HXB2, rather the position in HXB2 indicates the po-
sition aligned to the epitope. HXB2 was selected as the reference strain
because so many studies use HXB2, and because crystal structures for
HXB2-related proteins are often available. The precise positions of an
epitope on the HXB2 reference strain can be readily obtained using the
interactive position locator at our web site: http://hiv-web.lanl.
gov/content/hiv-db/LOCATE_SEQ/locate.html.
Author Location: The amino acid positions of the epitope boundaries and the
reference sequence used to define the epitope are listed as given in the
primary publication. Frequently, these positions as published are impre-
cise, and do not truly correspond to the numbering of the sequence, but
they provide a reasonable guide to the peptide’s approximate location in
the protein. Also, in many cases, position numbers were provided but the
reference sequence identification was not. Because of HIV-1’s variabil-
ity, position numbers require a reference strain to be meaningful. Binding
sites that cannot be defined through peptide binding or interference stud-
ies are labeled as discontinuous. The approximate location on the protein,
sequence number, and reference sequence are listed.
Sequence: The amino acid sequence of the binding region of interest, based
on the reference strain used in the study defining the binding site. On
occasions when only the position numbers and not the actual peptide se-
quence was specified in the original publication, we tried to fill in the
peptide sequence based on the position numbers and reference strain. If
the sequences were numbered inaccurately by the primary authors, or if
we made a mistake in this process, we may have misrepresented the bind-
ing site’s amino acid sequence. Because of this uncertainty, epitopes that
were not explicitly written in the primary publication, that we determined
by looking up the reference strain and the numbered location, are followed
by a question mark in the table.
Neutralizing: L: neutralizes lab strains. P: neutralizes at least some primary
isolates. no: does not neutralize. No information in this field means that
neutralization was either not discussed or unresolved in the primary pub-
lications referring to the MAb.
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Immunogen: The antigenic stimulus of the original B cell response. Often this
is an HIV-1 infection. If a vaccine was used as the original antigenic stim-
ulation, not a natural infection, this is noted on a separate line, and addi-
tional information about the vaccine antigen is provided as available.
Species(Isotype): The host that the antibody was generated in, and the isotype
of the antibody.
References: All publications that we could find that refer to the use of a specific
monoclonal antibody. First is a list of all references. Additional details for
some of older references can be found in Part V, although we have tried to
keep the entries self-contained since 1997. The "donor" field is meant to
serve as a potential guide to a source of information about an antibody or
how to obtain it, as well as to provide credit.
Notes: Describe the context of each study, and what was learned about the anti-
body in the study.
IV-A-3 HIV Protein Binding Site Maps
The names of MAbs and the location of well characterized linear binding sites
of 21 amino acids or less are indicated relative to the protein sequences of the
HXB2 clone. This map is meant to provide the relative location of epitopes
on a given protein, but the HXB2 sequence may not actually bind to the MAb of
interest, as it may vary relative to the sequence for which the epitope was defined.
Above each linear binding site, the MAb name is given followed by the species
in parentheses. Human is represented by ‘h’, non-human primate by ‘p’, mouse
by ‘m’, and others by ‘o’. More precise species designations for any given MAb
can be found using the web search interface or in the tables in this section.
IV-A-4 Alignments
To conserve space, no epitope alignments are provided in this book, but they
can be generated using the MAb search tool at http://hiv-web.lanl.
gov/immunology. All epitopes are aligned to the HXB2 sequence, with the
sequence used to define the epitope indicated directly above it. Sequences are
sorted by their subtype and country of origin.
The master alignment files from which the epitope alignments were cre-
ated are available at our web site (http://hiv-web.lanl.gov/ALIGN_
CURRENT/ALIGN-INDEX.html). The alignments were modified in some
cases to optimize the alignment relative to the defined epitope and minimize in-
sertions and deletions; epitope alignments are generated by anchoring on the
C-terminal residue. A dash indicates identity to the consensus sequence, and a
period indicates an insertion made to maintain the alignment. Stop codons are
indicated with a $, and frameshifts by a #, or ambiguous codons (nucleotide
was r, y, or n) by an x; they are inserted to maintain the alignments. In con-
sensus sequences an upper case letter indicates the amino acid was present in
all sequences, a lower case letter indicates the amino acid was present in most
sequences in a given position, and a question mark indicates two or more amino
acids were represented with equal frequency.
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IV-B Cross Reference Listing of MAbs
IV-B-1 MAbs by binding type
Cross reference by protein and binding type of MAb names and their order of appearance in the tables.
Binding type MAb ID (No.)
p17
C-term sc-FV p17 (33)
p24
C-term 13B5 (115)
Protease
N-term 1696 (170)
flap region F11.2.32 (172)
RT
palm domain 6B9 (193)
thumb domain 5F (194), 5G (195), 7C4 (196)
Integrase
Integrase DNA binding
domain
5D9 (213), 2-19 (216), 8-22 (217), 4-20 (218), 6-19 (219)
Integrase catalytic core 7-16 (210), 4F6 (211)
N-term 1C4 (197), 2C11 (198), 2E3 (199), 3E11 (200), 3F9 (201), 5F8 (202), 6G5 (203), 7B6 (204), 7C6 (205), 6C5 (206), 4D6 (209)
Pol
C-term 33 (244)
Vif
C-term TG001 (246)
Tat
C-term 1D2F11 (252), 2D9E7 (253), 4B4C4 (254), 5G7D8 (255), NT2/4D5.24 (256), 2D9D5 (258)
N-term NT3/2D1.1 (249), 1D9D5 (251)
Env (gp160)
C-domain polyclonal (601), 5B2 (669), 9G11 (670), TH-Ab1 (671), polyclonal (672), polyclonal (673), polyclonal (674), polyclonal
(675)
C-term 105-306 (574), 750-D (576), 722-D (580), polyclonal (581), 1131-A (582), 858-D (583), 989-D (584), Z13 (677), 1575 (698),
polyclonal (702), polyclonal (703), 1577 (705), polyclonal (706), 101-342 (853), 101-451 (854), 120-1 (855)
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Binding type MAb ID (No.)
C1 M85 (271), 7E2/4 (272), 4D4#85 (273), M92 (274), M86 (275), polyclonal (276), 133/237 (277), 133/290 (278), 133/11
(279), D/3G5 (280), D/6A11 (281), D/5E12 (282), L5.1 (283), 4A7C6 (284), 1D10 (285), B242 (286), 133/192 (287),
489.1(961) (288), 5B3 (289), B10 (290), B2 (291), C6 (292), MF49.1 (293), T1.1 (294), T7.1 (295), T9 (296), GV4D3 (297),
B27 (298), B9 (299), B35 (300), D/4B5 (301), D/5A11 (302), D/6B2 (303), B18 (304), B20 (305), MF39.1 (306), 187.2.1
(307), 37.1.1(ARP 327) (308), 6D8 (309), M96 (310), MF119.1 (311), MF4.1 (312), MF53.1 (313), MF58.1 (314), MF77.1
(315), T2.1 (316), 11/65 (317), W1 (318), T11 (319), GV1A8 (320), 11 (321), 12G10 (322), 135/9 (323), 7C10 (324), C4
(325), MF46.1 (326), 212A (856), 522-149 (857), L19 (858), M90 (859), MAG 104 (860), MAG 45 (861), MAG 95 (862),
MAG 97 (863), T9 (864), p7 (865)
C1-C2 L100 (866)
C1-C4 2/11c (867), A32 (868)
C1-C5 C11 (869), L81 (870)
C2 1006-30-D (367), 847-D (368), 213.1 (372), B12 (373), B13 (374), C13 (375), M89 (376), B21 (377), B23 (378), B24 (379),
B25 (380), B3 (381), B26 (382), B29 (383), B36 (384), 110.E (385), 110.C (386)
C3 2H1B (340), 110.D (522), B32 (523), 2F19C (871), B2C (872), polyclonal (873)
C3, C4 ICR38.1a (533)
C4 5C2E5 (528), G3-211 (529), G3-537 (530), G3-299 (534), G3-42 (535), G3-508 (536), G3-519 (537), G3-536 (538),
ICR38.8f (539), MO86/C3 (540), 13H8 (541), G45-60 (542), polyclonal (543), 1662 (544), 1663 (545), 1664 (546), 1697
(547), 1794 (548), 1804 (549), 1807 (550), 1808 (551), 1024 (874)
C5 9201 (556), 1C1 (557), 3F5 (558), 5F4/1 (559), 660-178 (560), 9301 (561), B221 (562), H11 (564), W2 (565), M38 (566),
1331A (569), 110.1 (570), 42F (571), 43F (572), RV110026 (573), GV1G2 (575), 450-D (577), 670-D (578), 23A (875),
D7324 (876)
CD4BS polyclonal (531), 1795 (532), 10/46c (877), 1027-30-D (878), 1125H (879), 120-1B1 (880), 1202-D (881), 1331E (882), 1570
(883), 1595 (884), 1599 (885), 15e (886), 205-43-1 (887), 205-46-9 (888), 21h (889), 28A11/B1 (890), 2G6 (891), 35F3/E2
(892), 38G3/A9 (893), 428 (894), 448-D (895), 44D2/D5 (896), 48-16 (897), 50-61A (898), 5145A (899), 558-D (900),
559/64-D (901), 55D5/F9 (902), 588-D (903), 654-D (904), 67G6/C4 (905), 729-D (906), 830D (907), 9CL (908), BM12
(909), D20 (910), D21 (911), D24 (912), D25 (913), D28 (914), D35 (915), D39 (916), D42 (917), D52 (918), D53 (919), D60
(920), DA48 (921), DO8i (922), F105 (923), F91 (924), GP13 (925), GP44 (926), GP68 (927), HF1.7 (928), HT5 (929), HT6
(930), HT7 (931), ICR 39.13g (932), ICR 39.3b (933), IgG1b12 (934), IgGCD4 (935), L28 (936), L33 (937), L41 (938), L42
(939), L52 (940), L72 (941), M12 (942), M13 (943), M6 (944), MAG 116 (945), MAG 12B (946), MAG 29B (947), MAG 3B
(948), MAG 55 (949), MAG 72 (950), MAG 86 (951), MAG 96 (952), MTW61D (953), S1-1 (954), T13 (955), T49 (956),
T56 (957), TH9 (958), anti-CD4BS summary (959), b11 (960), b13 (961), b14 (962), b3 (963), b6 (964), polyclonal (965)
CD4BS, C-term, N-term D33 (966)
CD4BS, CD4i, V3, V2 (967)
CD4i 17b (968), 21c (969), 23e (970), 48d (971), 49e (972), X5 (973)
Env oligomer T22 (974)
HIV-2 V3 anti-HIV-2 polyclonal (516)
Leucine zipper motif (593), (594)
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Binding type MAb ID (No.)
N-HR, C-HR, and six-helix
bundle
polyclonal (975)
N-term polyclonal (602), 2A2 (976), AC4 (977), AD3 (978), AD3 (979), ID6 (980), ID6 (981)
V1 35D10/D2 (330), 40H2/C7 (331), 43A3/E4 (332), 43C7/B9 (333), 45D1/B7 (334), 46E3/E6 (335), 58E1/B3 (336), 64B9/A6
(337), 69D2/A1 (338), 82D3/C3 (339)
V1, V2, V3, V4, V5 polyclonal (552)
V1-V2 11/68b (982), 62c (983), CRA-6 (984), L15 (985), T52 (986), T54 (987)
V1-V2 and V3-V5 polyclonal (988)
V2 6D5 (327), B33 (328), 697-D (341), 11/4c (348), 8.22.2 (349), 12b (350), G3-136 (351), G3-4 (352), 1088 (989), 110-B (990),
1357 (991), 1361 (992), 1393A (993), 66a (994), 66c (995), 684-238 (996), 830A (997), CRA-3 (998), CRA-4 (999), L17
(1000), SC258 (1001)
V2-CD4BS L25 (1002), L39 (1003), L40 (1004), L78 (1005)
V3 IIIB-V3-26 (387), IIIB-V3-21 (388), polyclonal (389), polyclonal (390), MO97/V3 (391), polyclonal (392), 55/1l (393), 8/38c
(394), 8/64b (395), polyclonal (396), polyclonal (397), polyclonal (398), polyclonal (399), 9284 (400), polyclonal (401),
polyclonal (402), polyclonal (403), polyclonal (404), MAG 109 (405), MAG 49 (406), MAG 53 (407), MAG 56 (408), 1324-E
(409), polyclonal (410), MO99/V3 (411), C311E (412), 924 (414), polyclonal (415), polyclonal (416), 10F10 (417), 2C4
(418), 412-D (419), polyclonal (420), CGP 47 439 (421), polyclonal (422), 178.1 (423), 257-D (424), 311-11-D (425),
41148D (426), 391/95-D (427), Aw (428), Bw (429), DO142-10 (430), Dv (431), Fv (432), Gv (433), Hv (434), polyclonal
(435), 50.1 (436), polyclonal (437), BAT123 (438), 838-D (439), 1006-15D (440), 782-D (441), 908-D (442), 1027-15D
(443), F19.26-4 (444), F19.48-3 (445), F19.57-11 (446), M77 (447), SP.BAL114 (448), SP.SF2:104 (449), polyclonal (450),
19b (451), 4G10 (452), 5F7 (453), G3-523 (454), MN215 (455), Nea 9301 (456), 4117C (457), 419-D (458), 453-D (459),
504-D (460), 83.1 (461), 5023B (462), F58/D1 (463), P1/D12 (464), P4/D10 (465), IIIB-13 V3 (466), IIIB-34 V3 (467),
A47/B1 (468), D59/A2 (469), G44/H7 (470), M096/V3 (471), µ5.5 (472), loop 2 (473), 268-D (474), 386-D (475), 5042A
(476), 5042B (477), 418-D (478), 5021 (479), 5025B (480), 5042 (481), 110.3 (482), 110.4 (483), 110.5 (484), 58.2 (485),
537-D (487), 5020 (488), RC25 (489), 5023A (490), 110.6 (491), polyclonal (492), 10/36e (493), 10/54 (494), 11/85b (495),
polyclonal (496), 0.5β (497), Cβ1, 0.5β (498), NM-01 (499), 1026 (500), 1034 (501), 59.1 (502), polyclonal (503), 10E3
(504), polyclonal (505), N11-20 (506), 5025A (507), N70-1.9b (508), 902 (509), 694/98-D (510), 9205 (514), 110.I (515),
IIIB-V3-01 (517), 447-52D (681), (1006), 110.J (1007), 1334-D (1008), 2182 (1009), 2191 (1010), 2219 (1011), 2412 (1012),
2442 (1013), 2456 (1014), 39F (1015), 55/68b (1016), 5G11 (1017), 6.1 (1018), 6.7 (1019), 8.27.3 (1020), 8E11/A8 (1021),
9305 (1022), AG1121 (1023), D47 (1024), F5.5 (1025), G3-1472 (1026), K24 (1027), TH1 (1028), anti-gp120/V3 (1029),
polyclonal (1030), polyclonal (1031), polyclonal (1032), polyclonal (1033), polyclonal (1034), polyclonal (1035), polyclonal
(1036)
V3 discontinuous 11/75a/21/41 (1037), 41.1 (1038), 55/45a/1l (1039)
V3 mimotope 1108 (1040)
V3, V4 polyclonal (1041)
V3-C4 MO101/V3,C4 (511), polyclonal (1042)
V3-C5 MO101/V3,C4 (512), MO101/V3,C4 (513)
V3-CD4BS D27 (1043), D56 (1044)
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Binding type MAb ID (No.)
V4 D/6D1 (518), 4D7/4 (519), 36.1(ARP 329) (520), C12 (521), polyclonal (524), B15 (525), B34 (526)
V5 polyclonal (553)
V5-C5 CRA1(ARP 323) (554), M91 (555), 8C6/1 (563)
adjacent to cluster II 2F5 (667)
alpha-helical C-HR, hairpin
intermediate
98-6 (663)
carbohydrates at glycosylation
residues in C2, C3, C4, and
V4
2G12 (1045)
cluster I 50-69 (605), 246-D (623), 181-D (625), 240-D (627), F240 (628), D49 (629), D61 (630), T32 (631), T34 (632), 1367 (1046)
cluster II D50 (660), 167-7 (664), ND-15G1 (665), 126-6 (1047), 1342 (1048), 1379 (1049), Fab D11 (1050), Fab D5 (1051), Fab G1
(1052), Fab M10 (1053), Fab M12 (1054), Fab M15 (1055), Fab S10 (1056), Fab S6 (1057), Fab S8 (1058), Fab S9 (1059),
Fab T3 (1060), Md-1 (1061)
cluster II, six-helix bundle 167-D (666), 1281 (1062)
cluster III Fab A9 (1063), Fab G15 (1064), Fab G5 (1065), Fab L1 (1066), Fab L11 (1067), Fab L2 (1068)
cytoplasmic domain Chessie 8 (1069)
gp120-CD4 complex 8F101 (1070), 8F102 (1071), CG-10 (1072), CG-25 (1073), CG-4 (1074), CG-76 (1075), CG-9 (1076)
immunodominant region 3D6 (658), 105-518 (1077)
p24+gp41 31A1 (1078), 39A64 (1079), 39B86 (1080), 9303 (1081)
six helix bundle NC-1 (1082)
Nef
C-term AE6 (1116), AG11 (1117), EH1 (1118), AE6 (1123)
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IV-B-2 Alphabetical listing of MAbs
Cross reference of MAb
names and their order of ap-
pearance in the tables. Al-
phanumeric sorting is sym-
bols, digits, uppercase letters
and lowercase letters.
MAb ID No.
593
594
708
709
710
711
712
967
1006
α(566-586) 589
µ5.5 472
0.5β 497
1-B-7 68
1-E-4 57
1-E-9 58
1.152 B3 178
1.153 G10 186
1.158 E2 179
1.160 B3 190
1.17.3 89
1.2 250
10-E-7 59
10-G-9 60
10.1 261
10/36e 493
10/46c 877
10/54 494
10/76b 344
1006-15D 440
1006-30-D 367
101-342 853
101-451 854
102-135 713
1024 874
1025 714
1026 500
1027-15D 443
1027-30-D 878
1034 501
105-134 715
105-306 574
105-518 1077
105-732 657
106/01 116
108/03 110
1088 989
10E3 504
10E7 171
10E9 716
10F10 417
11 321
11-C-5 61
11/41e 345
11/4b 346
11/4c 348
11/65 317
11/68b 982
11/75a/21/41 1037
11/85b 495
110-B 990
110.1 363
110.1 570
110.3 482
110.4 483
110.5 484
110.6 491
110.C 386
110.D 522
110.E 385
110.I 515
110.J 1007
110/015 111
1108 1040
1109/01 49
111/052 46
111/073 55
111/182 36
112/021 37
112/047 38
1125H 879
113/038 56
113/072 74
1131-A 582
115.8 633
11C10B10 105
11D11F2 106
11H9 24
12 224
12-B-4 102
120-1 855
120-16 662
120-1B1 880
1202-D 881
126-50 717
126-6 1047
1281 1062
12G-A8g2 19
12G-D7h11 20
12G-H1c7 21
12G10 322
12H-D3b3 18
12H2 718
12I-D12g2 22
12b 350
13 225
13-102-100 76
13.10 719
13/035 1086
13/042 1085
13/058 1096
1324-E 409
133/11 279
133/192 287
133/237 277
133/290 278
1331A 569
1331E 882
1334-D 1008
1342 1048
135/9 323
1357 991
1361 992
1367 1046
1379 1049
1393A 993
13B5 115
13E1 173
13H8 541
14 226
14D4E11 50
15-21 31
1570 883
1575 698
1576 685
1577 705
1578 686
1579 687
1583 688
1595 884
1599 885
15F8C7 45
15e 886
16 227
16/4/2 134
1662 544
1663 545
1664 546
167-7 664
167-D 666
1696 170
1697 547
17 208
178.1 423
1794 548
1795 532
17b 968
1804 549
1807 550
1808 551
181-D 625
183-H12-5C 135
187.2.1 307
1899 689
19 215
1907 690
1908 691
1909 692
19b 451
1A1 585
1A7 90
1B1 720
1B2C12 86
1B8.env 647
1C1 557
1C12B1 228
1C4 197
1D10 285
1D2F11 252
1D4A3 188
1D9 27
1D9D5 251
1E8 177
1F11 595
1F6 91
1F7 721
1G10 267
1G5C8 51
1G7 268
1H5 596
2-19 216
2-E-4 62
2-H-4 63
2.2B 722
2/11c 867
205-43-1 887
205-46-9 888
21 229
212A 856
557
DEC 2002
B
C
el
l
Cross Reference Listing of MAbs Alphabetical listing of MAbs
213.1 372
2182 1009
2191 1010
21c 969
21h 889
2219 1011
23A 875
23A5G4 92
23A5G5 93
23e 970
240-D 627
241-D 136
2412 1012
2442 1013
2456 1014
246-D 623
24G3 586
25.3 75
25/03 1089
257-D 424
25C2 587
26/028 1097
26/76 1090
268-D 474
28A11/B1 890
2A2 976
2A2/26 604
2A3 1109
2A6 137
2C11 198
2C4 418
2D9D5 258
2D9E7 253
2E3 199
2E3 1098
2E4 1110
2F11 622
2F19C 871
2F2 1106
2F5 667
2G12 1045
2G2 270
2G6 891
2H12 1111
2H1B 340
3-B-7 69
3-H-7 25
30:3E5 83
30D 723
31-11 32
31/03 1101
311-11-D 425
31710B 724
31A1 1078
31D6 180
31G8 181
32 230
32/1.24.89 11
32/5.8.42 3
32/5.8.42 4
322-151 359
32:32K 112
32E7 182
33 244
33D5 183
35 231
35D10/D2 330
35F3/E2 892
36.1(ARP 329) 520
37.1.1(ARP 327) 308
38/12b 356
38/60b 357
386-D 475
38:9.6K 80
38B5/C9 725
38G3/A9 893
391/95-D 427
39A64 1079
39B86 1080
39F 1015
39H10/A11 726
3A2 1112
3A6 35
3B10 12
3D10G6 94
3D12 232
3D12 1092
3D3 43
3D3.B8 360
3D5 727
3D6 658
3D9 597
3E11 13
3E11 200
3E6 1108
3F10 233
3F2 1091
3F5 558
3F9 201
3G12 1095
3G4 266
3H6 262
3H6 728
4 234
4 650
4-20 218
406/01 78
40D3/C11 729
40H2/C7 331
41-1 608
41-1 693
41-2 694
41-3 695
41-6 651
41-7 652
41.1 1038
41.4 609
41148D 426
4117C 457
412-D 419
418-D 478
419-D 458
41S-2 680
428 894
42F 571
43A3/E4 332
43C7/B9 333
43F 572
447-52D 681
448-D 895
44D2/D5 896
450-D 577
453-D 459
45D1/B7 334
46E3/E6 335
47-2 52
48-16 897
489.1(961) 288
48d 971
493-156 362
49B11/A1 730
49e 972
4A7C6 284
4B3 598
4B4C4 254
4C11.D8 361
4C9 28
4D4 599
4D4#85 273
4D6 209
4D7/4 519
4E10 676
4F6 211
4G10 452
4G2 600
4G9 259
4H2B1 29
4H4 1083
5-21-3 661
50-61A 898
50-69 605
50.1 436
5020 488
5021 479
5023A 490
5023B 462
5025A 507
5025B 480
504-D 460
5042 481
5042A 476
5042B 477
5145A 899
522-149 857
52G5/B9 731
537-D 487
55/1l 393
55/45a/1l 1039
55/68b 1016
558-D 900
559/64-D 901
55D5/F9 902
55E4/H1 732
56C4/C8 733
57B6/F1 734
57H5/D7 735
58.2 485
588-D 903
58E1/B3 336
59.1 502
5B2 184
5B2 669
5B3 289
5C2E5 528
5D9 213
5E2.A3k 138
5F 194
5F3 588
5F4/1 559
5F7 453
5F8 202
5G 195
5G11 1017
5G7D8 255
6-19 219
6-D-12 70
6-E-7 71
6.1 1018
6.1 1119
6.7 1019
60b 354
62c 983
63G4/E2 736
64B9/A6 337
654-D 904
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65B12/C5 737
660-178 560
66a 994
66c 995
670-D 578
67G6/C4 905
68.1 653
68.11 654
684-238 996
694/98-D 510
697-D 341
69D2/A1 338
6B9 193
6B9 235
6C4/S 342
6C5 206
6D5 327
6D8 309
6E10 738
6G5 203
7-1054 739
7-16 210
71-31 139
714/01 53
722-D 580
729-D 906
74 355
75 655
750-D 576
782-D 441
7B2 740
7B6 204
7C10 324
7C3 220
7C4 196
7C4 236
7C6 205
7E2/4 272
7F11 221
7F11 527
8-22 217
8-6 214
8-D-2 64
8-D-5 72
8-G-9 65
8-H-7 66
8.22.2 349
8.27.3 1020
8/38c 394
8/64b 395
82D3/C3 339
83.1 461
830A 997
830D 907
838-D 439
847-D 368
858-D 583
85G11/D8 741
86 616
87E4/A8 742
88-158/02 699
88-158/022 700
88-158/079 701
8B11 174
8C10 175
8C6/1 563
8E11/A8 1021
8E5 222
8E7 263
8F101 1070
8F102 1071
8G4 207
8G5 176
8H10 14
9-11 606
902 509
907 413
908-D 442
91-5 48
91-6 140
9201 556
9205 514
924 414
9284 400
9301 561
9303 1081
9305 1022
97B1/E8 743
98-4.3 141
98-4.9 142
98-43 607
98-6 663
989-D 584
9A4C4 104
9CL 908
9G11 670
9G2 264
9G5 30
9G5A 624
A32 868
A47/B1 468
A9 744
AC2 143
AC4 977
AD2 126
AD3 978
AD3 979
AE6 1116
AE6 1123
AG11 1117
AG1121 1023
AM5C6 1087
AM5C6 1088
Ab2 260
Ab3 269
Ab4 265
Aw 428
B10 290
B12 373
B13 374
B15 525
B18 304
B2 291
B20 305
B21 377
B221 562
B23 378
B24 379
B242 286
B25 380
B26 382
B27 298
B29 383
B2C 872
B3 381
B30 678
B31 683
B32 523
B33 328
B33 684
B34 526
B35 300
B36 384
B4 745
B4f8 16
B5 746
B6 747
B8 704
B9 299
BAT085 353
BAT123 438
BAT267 748
BAT401 749
BAT509 750
BC1071 144
BE10 145
BE3 108
BM12 909
Bw 429
Cβ1, 0.5β 498
C108G 343
C11 869
C12 521
C13 375
C2003 192
C31 751
C311E 412
C4 325
C5122 103
C5123 67
C5126 26
C5200 113
C6 292
C8 682
CA5 127
CB-13/5 41
CD-4/1 44
CD12B4 107
CD9 146
CG-10 1072
CG-25 1073
CG-4 1074
CG-76 1075
CG-9 1076
CGP 47 439 421
CH9B2 147
CRA-3 998
CRA-4 999
CRA-6 984
CRA1(ARP 323) 554
Chessie 8 1069
Chim 1 567
D/3G5 280
D/4B5 301
D/5A11 302
D/5E12 282
D/6A11 281
D/6B2 303
D/6D1 518
D1 752
D12 753
D16 754
D20 910
D21 911
D24 912
D25 913
D27 1043
D28 914
D33 966
D35 915
D39 916
D4 755
D42 917
D43 756
D47 1024
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D49 629
D50 660
D52 918
D53 919
D56 1044
D59/A2 469
D60 920
D61 630
D7324 876
DA48 921
DF3 128
DG8 123
DO142-10 430
DO8i 922
DZ 707
Dv 431
E7 1115
E9 1107
EB1A9 81
EB5 124
EC3 129
EC6 121
ED6 696
ED8 148
EF7 84
EH1 1118
EH12E1 149
F1 1105
F105 923
F11.2.32 172
F14.11 1100
F172-D8 659
F19.26-4 444
F19.48-3 445
F19.57-11 446
F223 757
F240 628
F285 758
F5-2 40
F5-4 96
F5.5 1025
F58/D1 463
F7 759
F91 924
FC12 130
FF1 73
FH2 114
Fab A1 610
Fab A12 760
Fab A2 761
Fab A4 611
Fab A9 1063
Fab D11 1050
Fab D5 1051
Fab G1 1052
Fab G15 1064
Fab G5 1065
Fab L1 1066
Fab L11 1067
Fab L2 1068
Fab L9 762
Fab M10 1053
Fab M12 1054
Fab M12B 612
Fab M15 1055
Fab M26B 613
Fab M8B 614
Fab S10 1056
Fab S6 1057
Fab S8 1058
Fab S9 1059
Fab T2 615
Fab T3 1060
Fv 432
G11G1 150
G11H3 151
G12 763
G2 764
G3-136 351
G3-1472 1026
G3-211 529
G3-299 534
G3-4 352
G3-42 535
G3-508 536
G3-519 537
G3-523 454
G3-536 538
G3-537 530
G44/H7 470
G45-60 542
GE4 131
GP13 925
GP44 926
GP68 927
GV1A8 320
GV1G2 575
GV4D3 297
GV4H3 364
Gv 433
H11 564
H2 765
H8 766
HBW4 767
HF1.7 928
HH3 125
HIVIG 768
HT5 929
HT6 930
HT7 931
Hv 434
HyHIV-1 5
HyHIV-15 34
HyHIV-19 152
HyHIV-2 6
HyHIV-21 15
HyHIV-22 17
HyHIV-3 7
HyHIV-4 8
HyHIV-5 9
HyHIV-6 10
ICR 39.13g 932
ICR 39.3b 933
ICR38.1a 533
ICR38.8f 539
ID6 980
ID6 981
ID8F6 39
IE8G2 153
IIIB-13 V3 466
IIIB-34 V3 467
IIIB-V3-01 517
IIIB-V3-21 388
IIIB-V3-26 387
IVI-4G6 769
IgG1b12 934
IgGCD4 935
J1 365
J3 366
J4 247
JB7 132
JF11 133
K14 770
K24 1027
L-anti-Tat 257
L100 866
L14 109
L14.17 1
L15 985
L17 1000
L19 858
L25 1002
L28 936
L33 937
L39 1003
L40 1004
L41 938
L42 939
L5.1 283
L52 940
L72 941
L78 1005
L81 870
LA9 (121-134) 697
LH-104-A 88
LH-104-B 117
LH-104-C 101
LH-104-E 85
LH-104-G 119
LH-104-I 118
LH-104-K 87
M-1 634
M-11 635
M-13 636
M-2 637
M-22 638
M-24 639
M-25 640
M-28 641
M-29 642
M-36 643
M-4 644
M-6 645
M096/V3 471
M12 122
M12 942
M13 943
M25 771
M38 566
M6 944
M77 447
M85 271
M86 275
M89 376
M90 859
M91 555
M92 274
M96 310
MAG 104 860
MAG 109 405
MAG 116 945
MAG 12B 946
MAG 29B 947
MAG 3B 948
MAG 45 861
MAG 49 406
MAG 53 407
MAG 55 949
MAG 56 408
MAG 6B 772
MAG 72 950
MAG 86 951
MAG 95 862
MAG 96 952
MAG 97 863
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MAb 35 223
MF119.1 311
MF169.1 369
MF170.1 370
MF39.1 306
MF4.1 312
MF46.1 326
MF49.1 293
MF53.1 313
MF58.1 314
MF77.1 315
MF87.1 371
MN215 455
MO101/V3,C4 511
MO101/V3,C4 512
MO101/V3,C4 513
MO28 773
MO30 774
MO43 775
MO86/C3 540
MO9.42.2 97
MO9.50.2 98
MO97/V3 391
MO99/V3 411
MTW61D 953
Md-1 1061
N11-20 506
N2-4 776
N70-1.9b 508
N70-2.3a 777
NC-1 1082
ND-15G1 665
NF1A1 1113
NF2B2 1120
NF3A3 1121
NF8B4 1122
NM-01 499
NT2/4D5.24 256
NT3/2D1.1 249
Nea 9301 456
P1/D12 464
P4/D10 465
P43110 778
P5-3 779
PC5009 590
RC25 489
RL4.72.1 77
RSD-33 347
RT-4 237
RT6H 189
RT7O 238
RT7U 239
RTMAb8 187
RV110026 573
S1-1 954
SC258 1001
SP.BAL114 448
SP.SF2:104 449
T1.1 294
T11 319
T13 955
T15G1 780
T2.1 316
T20 781
T22 974
T27 782
T3 783
T30 784
T32 631
T34 632
T4 785
T49 956
T52 986
T54 987
T56 957
T7.1 295
T9 296
T9 864
TG001 246
TG002 245
TH-Ab1 671
TH1 1028
TH9 958
V10 99
V10-9 618
V107 100
V7-8 154
W1 318
W2 565
X5 973
Z13 677
anti-CD4BS summary 959
anti-HIV-1 RT 240
anti-HIV-2 polyclonal 516
anti-K159 212
anti-gp120/V3 1029
anti-p24 155
b11 960
b13 961
b14 962
b3 963
b6 964
clone 3 649
human sera 156
i5B11 120
loop 2 473
multiple Fabs 786
multiple MAbs 787
multiple MAbs 788
multiple MAbs 789
p7 865
polyclonal 2
polyclonal 23
polyclonal 42
polyclonal 47
polyclonal 54
polyclonal 79
polyclonal 82
polyclonal 95
polyclonal 157
polyclonal 158
polyclonal 159
polyclonal 160
polyclonal 161
polyclonal 162
polyclonal 163
polyclonal 164
polyclonal 165
polyclonal 166
polyclonal 167
polyclonal 168
polyclonal 185
polyclonal 191
polyclonal 241
polyclonal 242
polyclonal 243
polyclonal 248
polyclonal 276
polyclonal 329
polyclonal 358
polyclonal 389
polyclonal 390
polyclonal 392
polyclonal 396
polyclonal 397
polyclonal 398
polyclonal 399
polyclonal 401
polyclonal 402
polyclonal 403
polyclonal 404
polyclonal 410
polyclonal 415
polyclonal 416
polyclonal 420
polyclonal 422
polyclonal 435
polyclonal 437
polyclonal 450
polyclonal 486
polyclonal 492
polyclonal 496
polyclonal 503
polyclonal 505
polyclonal 524
polyclonal 531
polyclonal 543
polyclonal 552
polyclonal 553
polyclonal 568
polyclonal 579
polyclonal 581
polyclonal 592
polyclonal 601
polyclonal 602
polyclonal 603
polyclonal 617
polyclonal 619
polyclonal 620
polyclonal 621
polyclonal 626
polyclonal 648
polyclonal 656
polyclonal 668
polyclonal 672
polyclonal 673
polyclonal 674
polyclonal 675
polyclonal 679
polyclonal 702
polyclonal 703
polyclonal 706
polyclonal 790
polyclonal 791
polyclonal 792
polyclonal 793
polyclonal 794
polyclonal 795
polyclonal 796
polyclonal 797
polyclonal 798
polyclonal 799
polyclonal 800
polyclonal 801
polyclonal 802
polyclonal 803
polyclonal 804
polyclonal 805
polyclonal 806
polyclonal 807
polyclonal 808
polyclonal 809
polyclonal 810
polyclonal 811
polyclonal 812
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polyclonal 813
polyclonal 814
polyclonal 815
polyclonal 816
polyclonal 817
polyclonal 818
polyclonal 819
polyclonal 820
polyclonal 821
polyclonal 822
polyclonal 823
polyclonal 824
polyclonal 825
polyclonal 826
polyclonal 827
polyclonal 828
polyclonal 829
polyclonal 830
polyclonal 831
polyclonal 832
polyclonal 833
polyclonal 834
polyclonal 835
polyclonal 836
polyclonal 837
polyclonal 838
polyclonal 839
polyclonal 840
polyclonal 841
polyclonal 842
polyclonal 843
polyclonal 844
polyclonal 845
polyclonal 846
polyclonal 847
polyclonal 848
polyclonal 849
polyclonal 850
polyclonal 851
polyclonal 852
polyclonal 873
polyclonal 965
polyclonal 975
polyclonal 988
polyclonal 1030
polyclonal 1031
polyclonal 1032
polyclonal 1033
polyclonal 1034
polyclonal 1035
polyclonal 1036
polyclonal 1041
polyclonal 1042
polyclonal 1084
polyclonal 1093
polyclonal 1094
polyclonal 1099
polyclonal 1102
polyclonal 1103
polyclonal 1104
polyclonal 1114
polyclonal 1124
polyclonal 1125
polyclonal 1126
polyclonal 1127
polyclonal 1128
polyclonal 1129
polyclonal 1130
polyclonal 1131
polyclonal α577-596 591
polyclonal α598-609 646
polyclonal HIVIG 169
sc-FV p17 33
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IV-B-3 MAbs by order of appearance in tables
No. MAb ID
p17
1 L14.17
2 polyclonal
3 32/5.8.42
4 32/5.8.42
5 HyHIV-1
6 HyHIV-2
7 HyHIV-3
8 HyHIV-4
9 HyHIV-5
10 HyHIV-6
11 32/1.24.89
12 3B10
13 3E11
14 8H10
15 HyHIV-21
16 B4f8
17 HyHIV-22
18 12H-D3b3
19 12G-A8g2
20 12G-D7h11
21 12G-H1c7
22 12I-D12g2
23 polyclonal
24 11H9
25 3-H-7
26 C5126
27 1D9
28 4C9
29 4H2B1
30 9G5
31 15-21
32 31-11
33 sc-FV p17
34 HyHIV-15
p24
35 3A6
36 111/182
37 112/021
38 112/047
39 ID8F6
40 F5-2
41 CB-13/5
42 polyclonal
43 3D3
44 CD-4/1
45 15F8C7
46 111/052
47 polyclonal
48 91-5
49 1109/01
50 14D4E11
51 1G5C8
52 47-2
53 714/01
54 polyclonal
55 111/073
56 113/038
57 1-E-4
58 1-E-9
59 10-E-7
60 10-G-9
61 11-C-5
62 2-E-4
63 2-H-4
64 8-D-2
65 8-G-9
66 8-H-7
67 C5123
68 1-B-7
69 3-B-7
70 6-D-12
71 6-E-7
72 8-D-5
73 FF1
74 113/072
75 25.3
76 13-102-100
77 RL4.72.1
78 406/01
79 polyclonal
80 38:9.6K
81 EB1A9
82 polyclonal
83 30:3E5
84 EF7
85 LH-104-E
86 1B2C12
87 LH-104-K
88 LH-104-A
89 1.17.3
90 1A7
91 1F6
92 23A5G4
93 23A5G5
94 3D10G6
95 polyclonal
96 F5-4
97 MO9.42.2
98 MO9.50.2
99 V10
100 V107
101 LH-104-C
102 12-B-4
103 C5122
104 9A4C4
105 11C10B10
106 11D11F2
107 CD12B4
108 BE3
109 L14
110 108/03
111 110/015
112 32:32K
113 C5200
114 FH2
115 13B5
116 106/01
117 LH-104-B
118 LH-104-I
p24-p2p7p1p6
119 LH-104-G
p2p7p1p6
120 i5B11
121 EC6
122 M12
123 DG8
124 EB5
125 HH3
126 AD2
127 CA5
128 DF3
129 EC3
130 FC12
131 GE4
132 JB7
133 JF11
Gag
134 16/4/2
135 183-H12-5C
136 241-D
137 2A6
138 5E2.A3k
139 71-31
140 91-6
141 98-4.3
142 98-4.9
143 AC2
144 BC1071
145 BE10
146 CD9
147 CH9B2
148 ED8
149 EH12E1
150 G11G1
151 G11H3
152 HyHIV-19
153 IE8G2
154 V7-8
155 anti-p24
156 human sera
157 polyclonal
158 polyclonal
159 polyclonal
160 polyclonal
161 polyclonal
162 polyclonal
163 polyclonal
164 polyclonal
165 polyclonal
166 polyclonal
167 polyclonal
168 polyclonal
169 polyclonal HIVIG
Protease
170 1696
171 10E7
172 F11.2.32
173 13E1
174 8B11
175 8C10
176 8G5
RT
177 1E8
178 1.152 B3
179 1.158 E2
180 31D6
181 31G8
182 32E7
183 33D5
184 5B2
185 polyclonal
186 1.153 G10
187 RTMAb8
188 1D4A3
189 RT6H
190 1.160 B3
191 polyclonal
192 C2003
193 6B9
194 5F
195 5G
196 7C4
Integrase
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197 1C4
198 2C11
199 2E3
200 3E11
201 3F9
202 5F8
203 6G5
204 7B6
205 7C6
206 6C5
207 8G4
208 17
209 4D6
210 7-16
211 4F6
212 anti-K159
213 5D9
214 8-6
215 19
216 2-19
217 8-22
218 4-20
219 6-19
220 7C3
221 7F11
222 8E5
223 MAb 35
Pol
224 12
225 13
226 14
227 16
228 1C12B1
229 21
230 32
231 35
232 3D12
233 3F10
234 4
235 6B9
236 7C4
237 RT-4
238 RT7O
239 RT7U
240 anti-HIV-1 RT
241 polyclonal
242 polyclonal
243 polyclonal
244 33
Vif
245 TG002
246 TG001
247 J4
248 polyclonal
Tat
249 NT3/2D1.1
250 1.2
251 1D9D5
252 1D2F11
253 2D9E7
254 4B4C4
255 5G7D8
256 NT2/4D5.24
257 L-anti-Tat
258 2D9D5
Rev
259 4G9
260 Ab2
261 10.1
262 3H6
263 8E7
264 9G2
265 Ab4
266 3G4
267 1G10
268 1G7
269 Ab3
270 2G2
gp160
271 M85
272 7E2/4
273 4D4#85
274 M92
275 M86
276 polyclonal
277 133/237
278 133/290
279 133/11
280 D/3G5
281 D/6A11
282 D/5E12
283 L5.1
284 4A7C6
285 1D10
286 B242
287 133/192
288 489.1(961)
289 5B3
290 B10
291 B2
292 C6
293 MF49.1
294 T1.1
295 T7.1
296 T9
297 GV4D3
298 B27
299 B9
300 B35
301 D/4B5
302 D/5A11
303 D/6B2
304 B18
305 B20
306 MF39.1
307 187.2.1
308 37.1.1(ARP 327)
309 6D8
310 M96
311 MF119.1
312 MF4.1
313 MF53.1
314 MF58.1
315 MF77.1
316 T2.1
317 11/65
318 W1
319 T11
320 GV1A8
321 11
322 12G10
323 135/9
324 7C10
325 C4
326 MF46.1
327 6D5
328 B33
329 polyclonal
330 35D10/D2
331 40H2/C7
332 43A3/E4
333 43C7/B9
334 45D1/B7
335 46E3/E6
336 58E1/B3
337 64B9/A6
338 69D2/A1
339 82D3/C3
340 2H1B
341 697-D
342 6C4/S
343 C108G
344 10/76b
345 11/41e
346 11/4b
347 RSD-33
348 11/4c
349 8.22.2
350 12b
351 G3-136
352 G3-4
353 BAT085
354 60b
355 74
356 38/12b
357 38/60b
358 polyclonal
359 322-151
360 3D3.B8
361 4C11.D8
362 493-156
363 110.1
364 GV4H3
365 J1
366 J3
367 1006-30-D
368 847-D
369 MF169.1
370 MF170.1
371 MF87.1
372 213.1
373 B12
374 B13
375 C13
376 M89
377 B21
378 B23
379 B24
380 B25
381 B3
382 B26
383 B29
384 B36
385 110.E
386 110.C
387 IIIB-V3-26
388 IIIB-V3-21
389 polyclonal
390 polyclonal
391 MO97/V3
392 polyclonal
393 55/1l
394 8/38c
395 8/64b
396 polyclonal
397 polyclonal
398 polyclonal
399 polyclonal
400 9284
401 polyclonal
402 polyclonal
403 polyclonal
404 polyclonal
405 MAG 109
406 MAG 49
564
DEC 2002
MAbs by order of appearance in tables Cross Reference Listing of MAbs
B
C
ell
407 MAG 53
408 MAG 56
409 1324-E
410 polyclonal
411 MO99/V3
412 C311E
413 907
414 924
415 polyclonal
416 polyclonal
417 10F10
418 2C4
419 412-D
420 polyclonal
421 CGP 47 439
422 polyclonal
423 178.1
424 257-D
425 311-11-D
426 41148D
427 391/95-D
428 Aw
429 Bw
430 DO142-10
431 Dv
432 Fv
433 Gv
434 Hv
435 polyclonal
436 50.1
437 polyclonal
438 BAT123
439 838-D
440 1006-15D
441 782-D
442 908-D
443 1027-15D
444 F19.26-4
445 F19.48-3
446 F19.57-11
447 M77
448 SP.BAL114
449 SP.SF2:104
450 polyclonal
451 19b
452 4G10
453 5F7
454 G3-523
455 MN215
456 Nea 9301
457 4117C
458 419-D
459 453-D
460 504-D
461 83.1
462 5023B
463 F58/D1
464 P1/D12
465 P4/D10
466 IIIB-13 V3
467 IIIB-34 V3
468 A47/B1
469 D59/A2
470 G44/H7
471 M096/V3
472 µ5.5
473 loop 2
474 268-D
475 386-D
476 5042A
477 5042B
478 418-D
479 5021
480 5025B
481 5042
482 110.3
483 110.4
484 110.5
485 58.2
486 polyclonal
487 537-D
488 5020
489 RC25
490 5023A
491 110.6
492 polyclonal
493 10/36e
494 10/54
495 11/85b
496 polyclonal
497 0.5β
498 Cβ1, 0.5β
499 NM-01
500 1026
501 1034
502 59.1
503 polyclonal
504 10E3
505 polyclonal
506 N11-20
507 5025A
508 N70-1.9b
509 902
510 694/98-D
511 MO101/V3,C4
512 MO101/V3,C4
513 MO101/V3,C4
514 9205
515 110.I
516 anti-HIV-2 polyclonal
517 IIIB-V3-01
518 D/6D1
519 4D7/4
520 36.1(ARP 329)
521 C12
522 110.D
523 B32
524 polyclonal
525 B15
526 B34
527 7F11
528 5C2E5
529 G3-211
530 G3-537
531 polyclonal
532 1795
533 ICR38.1a
534 G3-299
535 G3-42
536 G3-508
537 G3-519
538 G3-536
539 ICR38.8f
540 MO86/C3
541 13H8
542 G45-60
543 polyclonal
544 1662
545 1663
546 1664
547 1697
548 1794
549 1804
550 1807
551 1808
552 polyclonal
553 polyclonal
554 CRA1(ARP 323)
555 M91
556 9201
557 1C1
558 3F5
559 5F4/1
560 660-178
561 9301
562 B221
563 8C6/1
564 H11
565 W2
566 M38
567 Chim 1
568 polyclonal
569 1331A
570 110.1
571 42F
572 43F
573 RV110026
574 105-306
575 GV1G2
576 750-D
577 450-D
578 670-D
579 polyclonal
580 722-D
581 polyclonal
582 1131-A
583 858-D
584 989-D
585 1A1
586 24G3
587 25C2
588 5F3
589 α(566-586)
590 PC5009
591 polyclonal α577-596
592 polyclonal
593
594
595 1F11
596 1H5
597 3D9
598 4B3
599 4D4
600 4G2
601 polyclonal
602 polyclonal
603 polyclonal
604 2A2/26
605 50-69
606 9-11
607 98-43
608 41-1
609 41.4
610 Fab A1
611 Fab A4
612 Fab M12B
613 Fab M26B
614 Fab M8B
615 Fab T2
616 86
617 polyclonal
618 V10-9
619 polyclonal
620 polyclonal
621 polyclonal
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622 2F11
623 246-D
624 9G5A
625 181-D
626 polyclonal
627 240-D
628 F240
629 D49
630 D61
631 T32
632 T34
633 115.8
634 M-1
635 M-11
636 M-13
637 M-2
638 M-22
639 M-24
640 M-25
641 M-28
642 M-29
643 M-36
644 M-4
645 M-6
646 polyclonal α598-609
647 1B8.env
648 polyclonal
649 clone 3
650 4
651 41-6
652 41-7
653 68.1
654 68.11
655 75
656 polyclonal
657 105-732
658 3D6
659 F172-D8
660 D50
661 5-21-3
662 120-16
663 98-6
664 167-7
665 ND-15G1
666 167-D
667 2F5
668 polyclonal
669 5B2
670 9G11
671 TH-Ab1
672 polyclonal
673 polyclonal
674 polyclonal
675 polyclonal
676 4E10
677 Z13
678 B30
679 polyclonal
680 41S-2
681 447-52D
682 C8
683 B31
684 B33
685 1576
686 1578
687 1579
688 1583
689 1899
690 1907
691 1908
692 1909
693 41-1
694 41-2
695 41-3
696 ED6
697 LA9 (121-134)
698 1575
699 88-158/02
700 88-158/022
701 88-158/079
702 polyclonal
703 polyclonal
704 B8
705 1577
706 polyclonal
707 DZ
Env
708
709
710
711
712
713 102-135
714 1025
715 105-134
716 10E9
717 126-50
718 12H2
719 13.10
720 1B1
721 1F7
722 2.2B
723 30D
724 31710B
725 38B5/C9
726 39H10/A11
727 3D5
728 3H6
729 40D3/C11
730 49B11/A1
731 52G5/B9
732 55E4/H1
733 56C4/C8
734 57B6/F1
735 57H5/D7
736 63G4/E2
737 65B12/C5
738 6E10
739 7-1054
740 7B2
741 85G11/D8
742 87E4/A8
743 97B1/E8
744 A9
745 B4
746 B5
747 B6
748 BAT267
749 BAT401
750 BAT509
751 C31
752 D1
753 D12
754 D16
755 D4
756 D43
757 F223
758 F285
759 F7
760 Fab A12
761 Fab A2
762 Fab L9
763 G12
764 G2
765 H2
766 H8
767 HBW4
768 HIVIG
769 IVI-4G6
770 K14
771 M25
772 MAG 6B
773 MO28
774 MO30
775 MO43
776 N2-4
777 N70-2.3a
778 P43110
779 P5-3
780 T15G1
781 T20
782 T27
783 T3
784 T30
785 T4
786 multiple Fabs
787 multiple MAbs
788 multiple MAbs
789 multiple MAbs
790 polyclonal
791 polyclonal
792 polyclonal
793 polyclonal
794 polyclonal
795 polyclonal
796 polyclonal
797 polyclonal
798 polyclonal
799 polyclonal
800 polyclonal
801 polyclonal
802 polyclonal
803 polyclonal
804 polyclonal
805 polyclonal
806 polyclonal
807 polyclonal
808 polyclonal
809 polyclonal
810 polyclonal
811 polyclonal
812 polyclonal
813 polyclonal
814 polyclonal
815 polyclonal
816 polyclonal
817 polyclonal
818 polyclonal
819 polyclonal
820 polyclonal
821 polyclonal
822 polyclonal
823 polyclonal
824 polyclonal
825 polyclonal
826 polyclonal
827 polyclonal
828 polyclonal
829 polyclonal
830 polyclonal
831 polyclonal
832 polyclonal
833 polyclonal
834 polyclonal
835 polyclonal
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836 polyclonal
837 polyclonal
838 polyclonal
839 polyclonal
840 polyclonal
841 polyclonal
842 polyclonal
843 polyclonal
844 polyclonal
845 polyclonal
846 polyclonal
847 polyclonal
848 polyclonal
849 polyclonal
850 polyclonal
851 polyclonal
852 polyclonal
853 101-342
854 101-451
855 120-1
856 212A
857 522-149
858 L19
859 M90
860 MAG 104
861 MAG 45
862 MAG 95
863 MAG 97
864 T9
865 p7
866 L100
867 2/11c
868 A32
869 C11
870 L81
871 2F19C
872 B2C
873 polyclonal
874 1024
875 23A
876 D7324
877 10/46c
878 1027-30-D
879 1125H
880 120-1B1
881 1202-D
882 1331E
883 1570
884 1595
885 1599
886 15e
887 205-43-1
888 205-46-9
889 21h
890 28A11/B1
891 2G6
892 35F3/E2
893 38G3/A9
894 428
895 448-D
896 44D2/D5
897 48-16
898 50-61A
899 5145A
900 558-D
901 559/64-D
902 55D5/F9
903 588-D
904 654-D
905 67G6/C4
906 729-D
907 830D
908 9CL
909 BM12
910 D20
911 D21
912 D24
913 D25
914 D28
915 D35
916 D39
917 D42
918 D52
919 D53
920 D60
921 DA48
922 DO8i
923 F105
924 F91
925 GP13
926 GP44
927 GP68
928 HF1.7
929 HT5
930 HT6
931 HT7
932 ICR 39.13g
933 ICR 39.3b
934 IgG1b12
935 IgGCD4
936 L28
937 L33
938 L41
939 L42
940 L52
941 L72
942 M12
943 M13
944 M6
945 MAG 116
946 MAG 12B
947 MAG 29B
948 MAG 3B
949 MAG 55
950 MAG 72
951 MAG 86
952 MAG 96
953 MTW61D
954 S1-1
955 T13
956 T49
957 T56
958 TH9
959 anti-CD4BS summary
960 b11
961 b13
962 b14
963 b3
964 b6
965 polyclonal
966 D33
967
968 17b
969 21c
970 23e
971 48d
972 49e
973 X5
974 T22
975 polyclonal
976 2A2
977 AC4
978 AD3
979 AD3
980 ID6
981 ID6
982 11/68b
983 62c
984 CRA-6
985 L15
986 T52
987 T54
988 polyclonal
989 1088
990 110-B
991 1357
992 1361
993 1393A
994 66a
995 66c
996 684-238
997 830A
998 CRA-3
999 CRA-4
1000 L17
1001 SC258
1002 L25
1003 L39
1004 L40
1005 L78
1006
1007 110.J
1008 1334-D
1009 2182
1010 2191
1011 2219
1012 2412
1013 2442
1014 2456
1015 39F
1016 55/68b
1017 5G11
1018 6.1
1019 6.7
1020 8.27.3
1021 8E11/A8
1022 9305
1023 AG1121
1024 D47
1025 F5.5
1026 G3-1472
1027 K24
1028 TH1
1029 anti-gp120/V3
1030 polyclonal
1031 polyclonal
1032 polyclonal
1033 polyclonal
1034 polyclonal
1035 polyclonal
1036 polyclonal
1037 11/75a/21/41
1038 41.1
1039 55/45a/1l
1040 1108
1041 polyclonal
1042 polyclonal
1043 D27
1044 D56
1045 2G12
1046 1367
1047 126-6
1048 1342
1049 1379
1050 Fab D11
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1051 Fab D5
1052 Fab G1
1053 Fab M10
1054 Fab M12
1055 Fab M15
1056 Fab S10
1057 Fab S6
1058 Fab S8
1059 Fab S9
1060 Fab T3
1061 Md-1
1062 1281
1063 Fab A9
1064 Fab G15
1065 Fab G5
1066 Fab L1
1067 Fab L11
1068 Fab L2
1069 Chessie 8
1070 8F101
1071 8F102
1072 CG-10
1073 CG-25
1074 CG-4
1075 CG-76
1076 CG-9
1077 105-518
1078 31A1
1079 39A64
1080 39B86
1081 9303
1082 NC-1
Nef
1083 4H4
1084 polyclonal
1085 13/042
1086 13/035
1087 AM5C6
1088 AM5C6
1089 25/03
1090 26/76
1091 3F2
1092 3D12
1093 polyclonal
1094 polyclonal
1095 3G12
1096 13/058
1097 26/028
1098 2E3
1099 polyclonal
1100 F14.11
1101 31/03
1102 polyclonal
1103 polyclonal
1104 polyclonal
1105 F1
1106 2F2
1107 E9
1108 3E6
1109 2A3
1110 2E4
1111 2H12
1112 3A2
1113 NF1A1
1114 polyclonal
1115 E7
1116 AE6
1117 AG11
1118 EH1
1119 6.1
1120 NF2B2
1121 NF3A3
1122 NF8B4
1123 AE6
HIV-1
1124 polyclonal
1125 polyclonal
1126 polyclonal
1127 polyclonal
1128 polyclonal
1129 polyclonal
1130 polyclonal
1131 polyclonal
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IV-C HIV Antibodies Tables
All HIV MAbs and polyclonal Abs that bind to linear epitopes 30 amino acids or less in length arranged by protein position. The table entries are sorted in a nested
way—first by protein, then by HXB2 start location, then by antibody type and finally by antibody name. Abs that bind to conformational epitopes or with unknown
epitopes are listed at the end of each protein section.
IV-C-1 p17 Antibodies
No. MAb ID HXB2 Location Author’s Location Sequence Neutralizing Immunogen Species(Isotype)
1 L14.17 p17 (11–25) p17 (11–25 BRU) GELDRWEKIRLRPGG no Vaccine murine (IgG)
Vaccine Vector/Type: viral lysate Strain: BRU HIV component: virus
References Tatsumi1990, Robert-Hebmann1992b, Robert-Hebmann1992a
2 polyclonal p17 (11–25) p17 (11–25 LAI) GELDRWEKIRLRPGG N Vaccine mouse
Vaccine Vector/Type: recombinant protein, virus-like particle Strain: LAI HIV component: p24, p17, p55 Adjuvant: Freund’s adjuvant
References Truong1997
• An ELISA assay was used to study a panel of Gag peptides – mature p24 CA epitopes mapped to residues 176-192, 201-218, 233-253, 285-304, and were
recognized by antibodies elicited by rp24CA – one p17MA epitope, residues 11-25, and one p24CA epitope, residues 176-192, were recognized by
antibodies raised against anti-p55 virus-like particles, suggesting a differentantigenic properties for p24CA and p17MA antibodies depending on whether
they are produced against the mature soluble protein or the immature assembled form of the gag proteins [Truong1997]
3 32/5.8.42 p17 (12–19 +
100–105)
p17 (12–19 IIIB) ELDRWEKI+ALDKIE no Vaccine murine (IgG)
Vaccine Vector/Type: viral lysate
References Papsidero1989
• 32/5.8.42: Binds to two discontinuous regions, positions 12-19 and 100-105, peptides ELDRWEKI and ALDKIE – inhibited infectivity of cell free virus
[Papsidero1989]
4 32/5.8.42 p17 (12–19 +
100–105)
p17 (IIIB) ELDRWEKI+ALDKIE no Vaccine murine (IgG)
Vaccine Vector/Type: viral lysate HIV component: virus
References Papsidero1989
• 32/5.8.42: Inhibited infectivity of cell free virus – bound to two peptides, ELDRWEKI and ALDKIE, at positions 12-19 + 100-105 [Papsidero1989]
5 HyHIV-1 p17 (12–29) p17 (12–29 JMH1) ELDKWEKIRLRPGGKTLY no Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: p17
References Liu1995, Ota1998b
• HyHIV-1: This paper compares the results of affinity constant (Ka) measurements of anti-p17 MAbs using double Ab methods versus the faster,
isotope-free BIAcore system, and results were found to be similar for HyHIV-(1-6) – six MAbs all bind to the first alpha helix of p17, a functional domain
for both membrane binding and nuclear localization [Ota1998b]
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6 HyHIV-2 p17 (12–29) p17 (12–29 JMH1) ELDKWEKIRLRPGGKTLY no Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: p17
References Liu1995, Ota1998b
• HyHIV-2: This paper compares the results of affinity constant (Ka) measurements of anti-p17 MAbs using double Ab methods versus the faster,
isotope-free BIAcore system, and results were found to be similar for HyHIV-(1-6) – six MAbs all bind to the first alpha helix of p17, a functional domain
for both membrane binding and nuclear localization [Ota1998b]
7 HyHIV-3 p17 (12–29) p17 (12–29 JMH1) ELDKWEKIRLRPGGKTLY no Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: p17
References Liu1995, Ota1998b
• HyHIV-3: This paper compares the results of affinity constant (Ka) measurements of anti-p17 MAbs using double Ab methods versus the faster,
isotope-free BIAcore system, and results were found to be similar for HyHIV-(1-6) – six MAbs all bind to the first alpha helix of p17, a functional domain
for both membrane binding and nuclear localization [Ota1998b]
8 HyHIV-4 p17 (12–29) p17 (12–29 JMH1) ELDKWEKIRLRPGGKTLY? no Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: p17
References Liu1995, Ota1998a, Ota1998b
• HyHIV-4: epitope uncertain, based on the best estimate from JMH1 sequence– Ka is 1.8 x 107 M-1 for rec p17 – stains the surface of infected cells
indicating the antigen is exposed at the cell surface [Ota1998a]
• HyHIV-4: This paper compares the results of affinity constant (Ka) measurements of anti-p17 MAbs using double Ab methods versus the faster,
isotope-free BIAcore system, and results were found to be similar for HyHIV-(1-6) – six MAbs all bind to the first alpha helix of p17, a functional domain
for both membrane binding and nuclear localization [Ota1998b]
9 HyHIV-5 p17 (12–29) p17 (12–29 JMH1) ELDKWEKIRLRPGGKTLY no Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: p17
References Liu1995, Ota1998b
• HyHIV-5: This paper compares the results of affinity constant (Ka) measurements of anti-p17 MAbs using double Ab methods versus the faster,
isotope-free BIAcore system, and results were found to be similar for HyHIV-(1-6) – six MAbs all bind to the first alpha helix of p17, a functional domain
for both membrane binding and nuclear localization [Ota1998b]
10 HyHIV-6 p17 (12–29) p17 (12–29 JMH1) ELDKWEKIRLRPGGKTLY no Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: p17
References Liu1995, Ota1998b
• HyHIV-6: This paper compares the results of affinity constant (Ka) measurements of anti-p17 MAbs using double Ab methods versus the faster,
isotope-free BIAcore system, and results were found to be similar for HyHIV-(1-6) – six MAbs all bind to the first alpha helix of p17, a functional domain
for both membrane binding and nuclear localization [Ota1998b]
11 32/1.24.89 p17 (17–22) p17 (17–22 IIIB) EKIRLR L Vaccine murine (IgG)
Vaccine Vector/Type: viral lysate
References Papsidero1989
• 32/1.24.89: Inhibited infectivity of cell free virus [Papsidero1989]
12 3B10 p17 (19–38) p17 (19–38 SIVmac) IRLPGGKKKYMLKHVVWAA no Vaccine murine (IgG1)
Vaccine Vector/Type: inactivated virus Strain: AGM TYO-7 HIV component: virus
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References Otteken1992
• 3B10: Recognized an epitope present on HIV-2/SIVmac (MAC251/32H) , SIVagm, HIV-1, and SIVmnd, demonstrating that the matrix protein of all nine
HIV and SIV isolates tested in this study expresses at least one conserved immunogenic epitope recognized serologically [Otteken1992]
13 3E11 p17 (19–38) p17 (19–38 SIVmac) IRLPGGKKKYMLKHVVWAA no Vaccine murine (IgG1)
Vaccine Vector/Type: inactivated virus Strain: AGM TYO-7 HIV component: virus
References Otteken1992, Nilsen1996
• 3E11: There is another MAb with this ID that recognizes integrase [Nilsen1996]
• 3E11: Recognized an epitope present on HIV-2/SIVmac (MAC251/32H), SIVagm, HIV-1, and SIVmnd, demonstrating that the matrix protein of all nine
HIV and SIV isolates tested in this study expresses at least one highly conserved immunogenic epitope [Otteken1992]
14 8H10 p17 (30–52) p17 (30–52 JMH1) KLKHIVWASRELERFAVNPGLLE Vaccine murine (IgM)
Vaccine Vector/Type: peptide Strain: JMH-1 HIV component: p17 Adjuvant: BSA
References Ota1999a, Ota1999b
• 8H10: The p17 MAb also can bind to the V3 loop [Ota1999a]
• 8H10: Inhibits viral replication of the HIV-1 infected MT-4 cells by decreasing p17 DNA levels in the infected cells, and the effect of growing the 8H10
hybridoma in co-culture with HIV-1 infected MT-4 cells was studied [Ota1999b]
15 HyHIV-21 p17 (30–52) p17 (30–52 JMH1) KLKHIIWASRELERFAVNPGLLE no Vaccine murine (IgG2a)
Vaccine Vector/Type: recombinant protein HIV component: p17
References Liu1995, Ota1998a
• HyHIV-21: epitope uncertain, based on the best estimate from JMH1 sequence – Ka is 3.6 x 106 M-1 for rec p17 – stains the surface of infected cells
indicating the antigen is exposed at the cell surface –inhibited growth of HIV-1 JMH1 in MT-4 cells when added 24 hours after the initial culture [Ota1998a]
16 B4f8 p17 (51–65) p17 (51–65) LETSEGCRQILGQLQ no Vaccine rat (IgG2a)
Vaccine Vector/Type: infected-cell lysate Strain: IIIB HIV component: virus
References Shang1991
• -B4f8: Did not bind live infected cells, only cells that had been made permeable with acetone [Shang1991]
17 HyHIV-22 p17 (52–83) p17 (53–87 JMH1) ETSEGCRQILGQRQPSLQTGSEELR-
SLYNTIH
no Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: p17
References Liu1995, Ota1998a
• HyHIV-22: epitope uncertain, based on the best estimate from JMH1 sequence – stains the surface of infected cells indicating the antigen is exposed at the
cell surface – Ka is 2.3 x 105 M-1 for rec p17 [Ota1998a]
18 12H-D3b3 p17 (62–78) p17 (62–78) GQLQPSLQTGSEELRSL no Vaccine rat (IgG2a)
Vaccine Vector/Type: infected-cell lysate Strain: IIIB HIV component: virus
References Shang1991
• 12H-D3b3: Did not bind live infected cells, only cells that had been made permeable with acetone [Shang1991]
19 12G-A8g2 p17 (86–115) p17 (86–115) YCVHQRIEIKDTKEALDKIEEEQNK-
SKKKA
no Vaccine rat (IgG2a)
Vaccine Vector/Type: infected-cell lysate Strain: IIIB HIV component: virus
References Shang1991, Maksiutov2002
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• 12G-A8g2: Bound to 30-mer, but not to internal peptides – did not bind live infected cells – antigenic domain known as HPG30 [Shang1991]
• 12G-A8g2: This epitope is similar to a fragment of the human protein CD40 ligand TNF-related activation protein(T-cell antigen GP39) (CD154),
LDKIEDERN, as well as to a fragment of Lens-epithelium-derived growth factor, DIITEEDKSKKKGQ [Maksiutov2002].
20 12G-D7h11 p17 (86–115) p17 (86–115) YCVHQRIEIKDTKEALDKIEEEQNK-
SKKKA
no Vaccine rat (IgG2a)
Vaccine Vector/Type: infected-cell lysate Strain: IIIB HIV component: virus
References Shang1991, Maksiutov2002
• 12G-D7h11: Bound to 30-mer, but not to internal peptides – did not bind live infected cells – antigenic domain known as HPG30 [Shang1991]
• 12G-D7h11: This epitope is similar to a fragment of the human protein CD40 ligand TNF-related activation protein (T-cell antigen GP39) (CD154),
LDKIEDERN, as well as to a fragment of Lens-epithelium-derived growth factor, DIITEEDKSKKKGQ [Maksiutov2002].
21 12G-H1c7 p17 (86–115) p17 (86–115) YCVHQRIEIKDTKEALDKIEEEQNK-
SKKKA
no Vaccine rat (IgG)
Vaccine Vector/Type: infected-cell lysate Strain: IIIB HIV component: virus
References Shang1991, Maksiutov2002
• 12G-H1c7: Bound to 30-mer, but not to internal peptides – did not bind live infected cells – antigenic domain known as HPG30 [Shang1991]
• 12G-H1c7: This epitope is similar to a fragment of the human protein CD40 ligand TNF-related activation protein (T-cell antigen GP39) (CD154),
LDKIEDERN, as well as to a fragment of Lens-epithelium-derived growth factor, DIITEEDKSKKKGQ [Maksiutov2002].
22 12I-D12g2 p17 (86–115) p17 (86–115) YCVHQRIEIKDTKEALDKIEEEQNK-
SKKKA
no Vaccine rat (IgG2a)
Vaccine Vector/Type: infected-cell lysate Strain: IIIB HIV component: virus
References Shang1991, Maksiutov2002
• 12I-D12g2: Bound to 30-mer, but not to internal peptides – did not bind live infected cells – antigenic domain known as HPG30 [Shang1991]
• 12I-D12g2: This epitope is similar to a fragment of the human protein CD40 ligand TNF-related activation protein (T-cell antigen GP39) (CD154),
LDKIEDERN, as well as to a fragment of Lens-epithelium-derived growth factor, DIITEEDKSKKKGQ [Maksiutov2002].
23 polyclonal p17 (86–115) p17 (86–115) YSVHQRIDVKDTKEALEKIEEEQNK-
SKKKA
L Vaccine murine (IgA)
Vaccine Vector/Type: peptide HIV component: p17 Adjuvant: cholera toxin adjuvant
References Bukawa1995
• Polyclonal secretory IgA antibody raised by oral mucosal immunization is able to neutralize IIIB, SF2, and MN – HIV-1 neutralization may be due to the
V3, CD4 or HPG30 component of the multicomponent peptide immunogen [Bukawa1995]
24 11H9 p17 (101–115) p17 (101–115 SF2) LEKIEEEQNKSKKKA? Vaccine murine (IgG1)
Vaccine Vector/Type: inactivated virus Strain: CBL-1 HIV component: virus
Donor R. B. Ferns and R. S. Tedder
References Ferns1987, Ferns1989, Maksiutov2002
• 11H9: Reactive against p18 and p55 [Ferns1987]
• 11H9: This epitope is similar to a fragment of Lens-epithelium-derived growth factor, DIITEEDKSKKKGQ [Maksiutov2002]
• 11H9: UK Medical Research Council AIDS reagent: ARP344
25 3-H-7 (3H7) p17 (113–122) p17 (113–122 BH10) KKAQQAAADT L Vaccine murine (IgG)
Vaccine Strain: IIIB
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References Niedrig1989, Robert-Hebmann1992b, Robert-Hebmann1992a, Levin1997
• 3-H-7: No cross-reactivity with HIV-2 ROD or SIV MAC by immunoblot [Niedrig1989]
• 3-H-7: Called 3H7 – using a bicistronic vector, an intracellular Fab intrabody, 3H7, can inhibit HIV-1 infection when expressed in the cytoplasm of dividing
CD4+ T cells – HXBIIIB and SI primary isolate virions from 3H7 expressing cells were far less infectious – 3H7 intrabody acts both at the stage of nuclear
import and virus particle assembly [Levin1997]
26 C5126 p17 (113–122) p17 (113–122 HXB2) KKAQQAAADT no Vaccine murine (IgG1κ)
Vaccine Vector/Type: viral lysate HIV component: virus
References Hinkula1990
• C5126: Defined epitope by peptide blocking of binding to native protein – WB reactive with p53 and p17 [Hinkula1990]
27 1D9 p17 (119–132) p17 (121–134 SF2) AAGTGNSSQVSQNY Vaccine murine (IgG2a)
Vaccine Vector/Type: inactivated virus Strain: CBL-1 HIV component: virus
Donor R. B. Ferns and R. S. Tedder
References Ferns1987, Ferns1989
• 1D9: Reactive against p18, but not p55 [Ferns1987]
• 1D9: UK Medical Research Council AIDS reagent: ARP316
28 4C9 p17 (119–132) p18 (121–134 SF2) AAGTGNSSQVSQNY Vaccine murine (IgG2a)
Vaccine Vector/Type: inactivated virus Strain: CBL-1 HIV component: virus
Donor R. B. Ferns and R. S. Tedder
References Ferns1987, Ferns1989
• 4C9: Reactive against p18, but not p55 [Ferns1987]
• 4C9: UK Medical Research Council AIDS reagent: ARP342
29 4H2B1 p17 (119–132) p17 (121–134 SF2) AAGTGNSSQVSQNY murine (IgG1)
Donor R. B. Ferns and R. S. Tedder
References Ferns1987, Ferns1989
• 4H2B1: Reactive against p18 and p55 of multiple isolates [Ferns1987]
• 4H2B1: UK Medical Research Council AIDS reagent: ARP315
30 9G5 p17 (119–132) p17 (121–134 SF2) AAGTGNSSQVSQNY Vaccine murine (IgM)
Vaccine Vector/Type: inactivated virus Strain: CBL-1 HIV component: virus
Donor R. B. Ferns and R. S. Tedder
References Ferns1987, Ferns1989
• 9G5: Reactive against p18, but not p55 [Ferns1987]
• 9G5: UK Medical Research Council AIDS reagent: ARP343
31 15-21 p17 (121–132) p17 (121–132 BRU) DTGHSSQVSQNY no Vaccine murine (IgG)
Vaccine Strain: BRU
References Robert-Hebmann1992b, Robert-Hebmann1992a
32 31-11 p17 (121–132) p17 (121–132 BRU) DTGHSSQVSQNY no Vaccine murine (IgG)
Vaccine Strain: BRU
References Robert-Hebmann1992b, Robert-Hebmann1992a
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33 sc-FV p17 p17 (121–132) p17 (121–132 BRU) DTGHSSQVSQNY L Vaccine murine (IgG1κ)
Vaccine Strain: BRU
Ab type C-term Donor Paul Zhou, NIH, Bethesda, MD, USA
References Robert-Hebmann1992a, Tewari1998
• A single chain Ab (sc-FV) was made from an anti-p17 MAb, and intracellular binding of sc-FV resulted in inhibition of viral replication that was more
pronounced when the sc-FV was expressed in the cytoplasm instead of the nucleus [Tewari1998]
34 HyHIV-15 p17 (122–115) p17 (87–115 JMH1) SVHQRIDVKDTKEALEKIEEEQNKS-
KKKA?
L Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: p17
References Liu1995, Ota1998a
• HyHIV-15: epitope uncertain, based on the best estimate from JMH1 sequence – Ka is 1.4 x 107 M-1 for rec p17 – stains the surface of infected cells
indicating the antigen is exposed at the cell surface – inhibited growth of HIV-1 JMH1 in MT-4 cells when added 24 hours after the initial culture [Ota1998a]
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35 3A6 p24 (1–17) p24 (122–149 BH10) TGHSSQVSQNYPIVQNIQGQMVHQA-
ISP
no HIV-1 infection human (IgG1κ)
References Buchacher1992, Buchacher1994
• 3A6: The reactive peptide spans the p17/p24 border of gag [Buchacher1994]
• 3A6: Human MAbs against HIV generated by electrofusion of PBL from HIV-1 positive volunteers with CB-F7 cells [Buchacher1994]
36 111/182 p24 (1–20) p24 (134–153 IIIB) PIVQNIQGQMVHQAISPRTL no Vaccine murine (IgG1)
Vaccine Vector/Type: beta-galactosidase fusion protein Strain: IIIB HIV component: p24
References Niedrig1991
• 111/182: Test specific evidence of cross-reactivity between HIV-1, HIV-2 and SIV MAC [Niedrig1991]
37 112/021 p24 (1–20) p24 (134–153 IIIB) PIVQNIQGQMVHQAISPRTL no Vaccine murine (IgG1)
Vaccine Vector/Type: beta-galactosidase fusion protein Strain: IIIB HIV component: p24
References Niedrig1991
• 112/021: Test specific evidence of cross-reactivity between HIV-1, HIV-2 and SIV MAC [Niedrig1991]
38 112/047 p24 (1–20) p24 (134–153 IIIB) PIVQNIQGQMVHQAISPRTL no Vaccine murine (IgG1)
Vaccine Vector/Type: beta-galactosidase fusion protein Strain: IIIB HIV component: p24
References Niedrig1991
• 112/047: Test specific evidence of cross-reactivity between HIV-1, HIV-2 and SIV MAC [Niedrig1991]
39 ID8F6 p24 (11–25) p24 (143–157 BRU) VHQAISPRTLNAWVK no Vaccine murine (IgG1)
Vaccine Vector/Type: inactivated virus Strain: CBL-1 HIV component: virus
Donor R. B. Ferns and R. S. Tedder
References Ferns1987, Ferns1989
• ID8F6: Reacted with both p55 and p24 – showed less than 75% homologous inhibition [Ferns1987]
• ID8F6: UK Medical Research Council AIDS reagent: ARP348
40 F5-2 p24 (14–23) p24 (14–23 HXB2) AISPRTLNAW no murine
References Kusk1988, Kusk1992
• F5-2: In HIV-1+ individuals, antibody to AISPRTLNAW is associated with CD4 T-cell decline [Kusk1988, Kusk1992]
41 CB-13/5
(CB-mab-
p24/13-15)
p24 (21–25) p24 (152–156) NAWVK no murine (IgG1κ)
References Grunow1990, Franke1992, Kuttner1992, Glaser1996
• CB-13/5: It is not clear whether the MAbs CD-13/5 and CB-mab-p24/13-15 are the same, but from the shared references in the primary articles they seem
to be (database note)
• CB-13/5: Called CB-mab-p24/13-15 – the VDJ H and VJ L regions of CB-mab-p24/13-15 were sequenced [Kuttner1992]
• CB-13/5: Inhibits spread of HIV-1 in cell cultures [Franke1992]
• CB-13/5: Epitope described as VHQAISPRTLNAWVK – binding not affected by bound MAb CB-4/1 [Glaser1996]
42 polyclonal p24 (44–60) p24 (176–192 LAI) SEGATPQDLNTMLNTVG no Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein, virus-like particle Strain: LAI HIV component: p24, p17, p55 Adjuvant: Freund’s adjuvant
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References Truong1997
• An ELISA assay was used to study a panel of Gag peptides – mature p24 CA epitopes mapped to residues 176-192, 201-218, 233-253, 285-304, and were
recognized by antibodies elicited by rp24CA – one p17MA epitope, residues 11-25, and one p24CA epitope, residues 176-192, were recognized by
antibodies raised against anti-p55 virus-like particles, suggesting a different antigenic properties for p24CA and p17MA antibodies depending on whether
they are produced against the mature soluble protein or the immature assembled form of the gag proteins [Truong1997]
43 3D3 p24 (45–50) p24 (177–182 LAI) EGATPQ Vaccine murine (IgG2b)
Vaccine Vector/Type: inactivated virus Strain: CBL-1 HIV component: virus
Donor R. B. Ferns and R. S. Tedder
References Ferns1987, Ferns1989
• 3D3: Most broadly reactive of all the antibodies in this study[Ferns1987]
• 3D3: UK Medical Research Council AIDS reagent: ARP314
44 CD-4/1
(CB-4/1/1/F6)
p24 (46–56) p24 (182–197) GATPQDLNTML no Vaccine murine (IgG2aκ)
Vaccine Vector/Type: beta-galactosidase fusion protein HIV component: p24
References Grunow1990, Franke1992, Hohne1993, Glaser1996, Ehrhard1996
• CD-4/1: Inhibits spread of HIV-1 in cell cultures [Franke1992]
• CD-4/1: Affinity of CB-4/1 to native p24 is lower than to peptide or denatured p24 – proposed that the peptide binds in a loop conformation [Hohne1993]
• CD-4/1: Unusual p24-MAb binding kinetics, with biphasic association – probably due to conformational changes in p24, not to p24 dimerization
[Glaser1996]
• CD-4/1: Modification of p24 lysine residues by maleic anhydrid increased the affinity of CD-4/1, presumably due to conformational changes exposing a
cryptic epitope [Ehrhard1996]
45 15F8C7 p24 (47–56) p24 (183–197) ATPQDLNTML no Vaccine murine (IgG1)
Vaccine Vector/Type: purified HIV-1
References Janvier1990, Janvier1992
• 15F8C7: Mapped to aa209-217 through Pepscan method – cross-reacts with HIV-2 [Janvier1990] – maps to aa203-217 through EIA pentadecapeptide
[Janvier1992]
46 111/052 p24 (51–60) p24 (183–192 IIIB) DLNTMLNTVG no Vaccine murine (IgG1)
Vaccine Vector/Type: beta-galactosidase fusion protein Strain: IIIB HIV component: p24
References Niedrig1991
• 111/052: Weak cross-reaction with HIV-2 on WB, otherwise not cross-reactive with HIV-2 or SIV MAC [Niedrig1991]
47 polyclonal p24 (51–82) Gag (183–214 LAI) DLNTMLNTVGGHQAAMQMLKETINE-
EAAEWDR
no Vaccine human (IgG)
Vaccine Vector/Type: lipopeptide Strain: LAI HIV component: p24 Adjuvant: QS21
References Pialoux2001
• 28 subjects were vaccinated with six HIV-1 peptides that were selected to be particularly rich in CTL epitopes, presented in lipopeptides with or without
adjuvant QS21 – HIV-specific Ab responses were detected in 25/28 (89%), proliferative in 19/28 (79%), and CTL in 13/24 (54%) of testable volunteers –
only 4/28 had Ab responses to peptide G1, 4/28 had proliferative responses, and no patient had a CTL response [Pialoux2001]
48 91-5 p24 (64–75) p24 (196–207) AAMQMLKETINE no HIV-1 infection human (IgG1λ )
References Gorny1989, Tyler1990, Robinson1990b, Gorny1998
• 91-5: Synthesized by immortalization of peripheral blood cells with Epstein-Barr virus [Gorny1989]
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• 91-5: Did not enhance HIV-1 IIIB infection [Robinson1990b]
• 91-5: NIH AIDS Research and Reference Reagent Program: 1238
49 1109/01 p24 (69–86) p24 (201–218 BRU) LKETINEEAAEWDRVHPV no Vaccine murine (IgG)
Vaccine Strain: IIIB HIV component: virus
References Robert-Hebmann1992b, Robert-Hebmann1992a
50 14D4E11 p24 (69–86) p24 (201–218 BRU) LKETINEEAAEWDRVHPV no Vaccine murine (IgG1)
Vaccine Vector/Type: purified HIV-1
References Janvier1990, Robert-Hebmann1992b, Robert-Hebmann1992a
• 14D4E11: Mapped to aa209-217 through Pepscan method (original paper, AAEWDRVHP) – cross-reacts with HIV-2 [Janvier1990] and to aa203-217
through EIA pentadecapeptide [Janvier1992]
51 1G5C8 p24 (69–86) p24 (201–218 BRU) LKETINEEAAEWDRVHPV no Vaccine murine (IgG2b)
Vaccine Vector/Type: protein HIV component: p24
References Janvier1990, Robert-Hebmann1992b, Robert-Hebmann1992a
• 1G5C8: Mapped to aa209-217 through Pepscan method (original paper, AAEWDRVHP) [Janvier1990] and to aa203-217 through EIA pentadecapeptide
[Janvier1992]
52 47-2 p24 (69–86) p24 (201–218 BRU) LKETINEEAAEWDRVHPV no Vaccine murine (IgG)
Vaccine Strain: BRU
References Robert-Hebmann1992b, Robert-Hebmann1992a
53 714/01 p24 (69–86) p24 (201–218 BRU) LKETINEEAAEWDRVHPV no Vaccine murine (IgG)
Vaccine Strain: IIIB HIV component: virus
References Robert-Hebmann1992b, Robert-Hebmann1992a
54 polyclonal p24 (69–86) p24 (201–218 LAI) LKETINEEAAEWDRVHPV no Vaccine murine
Vaccine Vector/Type: recombinant protein, virus-like particle Strain: LAI HIV component: p24, p17, p55 Adjuvant: Freund’s adjuvant
References Truong1997
• An ELISA assay was used to study a panel of Gag peptides – mature p24 CA epitopes mapped to residues 176-192, 201-218, 233-253, 285-304, and were
recognized by antibodies elicited by rp24CA – one p17MA epitope, residues 11-25, and one p24CA epitope, residues 176-192, were recognized by
antibodies raised against anti-p55 virus-like particles, suggesting a different antigenic properties for p24CA and p17MA antibodies depending on whether
they are produced against the mature soluble protein or the immature assembled form of the gag proteins [Truong1997]
55 111/073 p24 (71–81) p24 (203–213 IIIB) ETINEEAAEWD no Vaccine murine (IgG1)
Vaccine Vector/Type: beta-galactosidase fusion protein Strain: IIIB HIV component: p24
References Niedrig1991
• 111/073: cross-reactive between HIV-1, HIV-2 and SIV MAC by multiple assays [Niedrig1991]
56 113/038 p24 (71–81) p24 (203–213 IIIB) ETINEEAAEWD no Vaccine murine (IgG1)
Vaccine Vector/Type: beta-galactosidase fusion protein Strain: IIIB HIV component: p24
References Niedrig1991
• 113/038: cross-reactive between HIV-1, HIV-2 and SIV MAC by multiple assays [Niedrig1991]
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57 1-E-4 p24 (71–85) p24 (203–217) ETINEEAAEWDRVHP no Vaccine murine (IgG)
Vaccine Strain: IIIB HIV component: virus
References Niedrig1989
• 1-E-4: One of nine MAbs that bind to this peptide [Niedrig1989]
58 1-E-9 p24 (71–85) p24 (203–217) ETINEEAAEWDRVHP no Vaccine murine (IgG)
Vaccine Strain: IIIB HIV component: virus
References Niedrig1989
• 1-E-9: One of nine MAbs that bind to this peptide [Niedrig1989]
59 10-E-7 p24 (71–85) p24 (203–217) ETINEEAAEWDRVHP no Vaccine murine (IgG1)
Vaccine Strain: IIIB HIV component: virus
References Niedrig1988, Niedrig1989
• 10-E-7: Cross reactive between HIV-1, HIV-2 and SIV [Niedrig1988]
• 10-E-7: One of nine MAbs that bind to this peptide – cross-reactive with HIV-2 ROD and SIV MAC [Niedrig1989]
60 10-G-9 p24 (71–85) p24 (203–217) ETINEEAAEWDRVHP no Vaccine murine (IgG1)
Vaccine Strain: IIIB HIV component: virus
References Niedrig1988, Niedrig1989
• 10-G-9: HIV-1 specific [Niedrig1988]
• 10-G-9: One of nine MAbs that bind to this peptide [Niedrig1989]
61 11-C-5 p24 (71–85) p24 (203–217) ETINEEAAEWDRVHP no Vaccine murine (IgG1)
Vaccine Strain: IIIB HIV component: virus
References Niedrig1988, Niedrig1989
• 11-C-5: HIV-1 specific [Niedrig1988]
• 11-C-5: One of nine MAbs that bind to this peptide [Niedrig1989]
62 2-E-4 p24 (71–85) p24 (203–217) ETINEEAAEWDRVHP no Vaccine murine (IgG2a)
Vaccine Strain: IIIB HIV component: virus
References Niedrig1988, Niedrig1989
• 2-E-4: Cross reactive between HIV-1, HIV-2 and SIV by ELISA, HIV-1 and HIV-2 by WB [Niedrig1988]
• 2-E-4: One of nine MAbs that bind to this peptide – cross-reactive with HIV-2 ROD [Niedrig1989]
63 2-H-4 p24 (71–85) p24 (203–217) ETINEEAAEWDRVHP no Vaccine murine (IgG1)
Vaccine Strain: IIIB HIV component: virus
References Niedrig1988, Niedrig1989
• 2-H-4: Cross reactive between HIV-1, HIV-2 and SIV by ELISA, HIV-1 and HIV-2 by WB [Niedrig1988]
• 2-H-4: One of nine MAbs that bind to this peptide – cross-reactive with HIV-2 ROD [Niedrig1989]
64 8-D-2 p24 (71–85) p24 (203–217) ETINEEAAEWDRVHP no Vaccine murine (IgG2a)
Vaccine Strain: IIIB HIV component: virus
References Niedrig1989, Robert-Hebmann1992b, Robert-Hebmann1992a
• 8-D-2: HIV-1 specific [Niedrig1988]
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• 8-D-2: One of nine MAbs that bind to this peptide [Niedrig1989]
65 8-G-9 p24 (71–85) p24 (203–217) ETINEEAAEWDRVHP no Vaccine murine (IgG)
Vaccine Strain: IIIB HIV component: virus
References Niedrig1989
• 8-G-9: One of nine MAbs that bind to this peptide [Niedrig1989]
66 8-H-7 p24 (71–85) p24 (203–217) ETINEEAAEWDRVHP no Vaccine murine (IgG3)
Vaccine Strain: IIIB HIV component: virus
References Niedrig1988, Niedrig1989, Robert-Hebmann1992b, Robert-Hebmann1992a
• 8-H-7: One of nine MAbs that bind to this peptide [Niedrig1989]
67 C5123 p24 (71–85) p24 (203–217 HXB2) ETINEEAAEWDRVHP no Vaccine murine (IgG1κ)
Vaccine Vector/Type: viral lysate HIV component: virus
References Hinkula1990
• C5123: Epitope defined by peptide blocking of binding to native protein – WB reactive with p53 and p24 [Hinkula1990]
68 1-B-7 p24 (76–85) p24 (208–217 BH10) EAAEWDRVHP no Vaccine murine (IgG1)
Vaccine Strain: IIIB
References Niedrig1988, Niedrig1989
• 1-B-7: Reacts with two overlapping peptides, region of overlap is given – reacted with HIV-2 and SIV MAC [Niedrig1989]
69 3-B-7 p24 (76–85) p24 (208–217 BH10) EAAEWDRVHP no Vaccine murine (IgG1)
Vaccine Strain: IIIB
References Niedrig1988, Niedrig1989
• 3-B-7: Reacts with two overlapping peptides, region of overlap is given – reacted with HIV-2 [Niedrig1989]
70 6-D-12 p24 (76–85) p24 (208–217 BH10) EAAEWDRVHP no Vaccine murine (IgG1)
Vaccine Strain: IIIB
References Niedrig1988, Niedrig1989
• 6-D-12: Reacts with two overlapping peptides, region of overlap is given – reacted with HIV-2 [Niedrig1989]
71 6-E-7 p24 (76–85) p24 (208–217 BH10) EAAEWDRVHP no Vaccine murine (IgG1)
Vaccine Strain: IIIB
References Niedrig1988, Niedrig1989
• 6-E-7: Reacts with two overlapping peptides, region of overlap is given – reacted with HIV-2 and SIV MAC [Niedrig1989]
72 8-D-5 p24 (76–85) p24 (208–217 BH10) EAAEWDRVHP no Vaccine murine (IgG)
Vaccine Strain: IIIB
References Niedrig1988, Niedrig1989
• 8-D-5: Reacts with two overlapping peptides, region of overlap is given – bound only HIV-1 [Niedrig1989]
73 FF1 p24 (76–90) p24 (208–222 HXB2) EAAEWDRVHPVHAGP no Vaccine murine (IgG1κ)
Vaccine Vector/Type: inactivated virus
References Hinkula1990
• FF1: Epitope defined by peptide blocking of binding to native protein – WB reactive with p53 and p24 [Hinkula1990]
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74 113/072 p24 (81–90) p24 (213–222 IIIB) DRVHPVHAGP no Vaccine murine (IgG1)
Vaccine Vector/Type: beta-galactosidase fusion protein Strain: IIIB HIV component: p24
References Niedrig1991
• 113/072: Weak cross-reaction with HIV-2 on WB, otherwise not cross-reactive with HIV-2 or SIV MAC [Niedrig1991]
75 25.3 p24 (82–102) p24 (82–102) RVHPVHAGPIAPGQMREPRGS no murine (IgG1κ)
ReferencesMomany1996
• 25.3: Crystal structure of the CA protein bound to Fab 25.3 was solved – monomers form 7 alpha-helices arranged in a coiled-coil – Fab binds to a long
antigenic peptide that separates the longest helices, with a salt bridge at CA 82 R, and interactions as far away as positions 100 and 102 [Momany1996]
76 13-102-100 p24 (84–94) p24 (102–112 IIIB) HPVHAGPIAPG murine (IgG)
Donor Advanced Technologies, Inc., Columbia, MD
References Parker1996, Qian1998
• 13-102-100: Binding site (HPVHAGPIAPG) defined by epitope footprinting – first binding p24 to MAb, then allowing proteolytic cleavage to take place to
cleave unprotected residues, then performing mass spectrometry to identify protected residues of epitope [Parker1996]
• 13-102-100: Affinity capillary electrophoresis was used to fine map this epitope, and the optimal peptide was defined as VHAGPIAPGIAP – this method
uses migration time shifts to probe relative affinities of Abs – the antibody binds to the cyclophilin A binding domain [Qian1998]
77 RL4.72.1 p24 (87–101) p24 (219–233 BRU) HAGPIAPGQMREPRG no Vaccine murine (IgG)
Vaccine Vector/Type: inactivated virus Strain: clade D strain NDK HIV component: virus
References Tatsumi1990, Robert-Hebmann1992b, Robert-Hebmann1992a
• RL4.72.1: Immunized with inactivated HIV NDK, D clade, reacts with B clade peptide [Robert-Hebmann1992a]
78 406/01 p24 (101–121) p24 (233–253 BRU) GSDIAGTTSTLQEQIGWMTNN no Vaccine murine (IgG)
Vaccine Strain: IIIB
References Robert-Hebmann1992b, Robert-Hebmann1992a
79 polyclonal p24 (101–121) p24 (233–253 LAI) GSDIAGTTSTLQEQIGWMTNL no Vaccine murine
Vaccine Vector/Type: recombinant protein, virus-like particle Strain: LAI HIV component: p24, p17, p55 Adjuvant: Freund’s adjuvant
References Truong1997
• An ELISA assay was used to study a panel of Gag peptides – mature p24 CA epitopes mapped to residues 176-192, 201-218, 233-253, 285-304, and were
recognized by antibodies elicited by rp24CA – one p17MA epitope, residues 11-25, and one p24CA epitope, residues 176-192, were recognized by
antibodies raised against anti-p55 virus-like particles, suggesting a different antigenic properties for p24CA and p17MA antibodies depending on whether
they are produced against the mature soluble protein or the immature assembled form of the gag proteins [Truong1997]
80 38:9.6K
(38:96K)
p24 (121–130) p24 (253–262 HXB2) NPPIPVGEIY no Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein HIV component: p24-p15
References Hinkula1990
• 38:9.6K: Called 38:96K – epitope defined by peptide blocking of binding to native protein – WB reactive with p53 and p24 [Hinkula1990]
• 38:9.6K: UK Medical Research Council AIDS reagent: ARP365
81 EB1A9 p24 (121–135) p24 (253–267 LAI) NPPIPVGEIYKRWII Vaccine murine (IgG1)
Vaccine Vector/Type: inactivated virus Strain: CBL-1 HIV component: virus
Donor R. B. Ferns and R. S. Tedder
References Ferns1987, Ferns1989
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• EB1A9: Reacted with both p55 and p24 – showed less than 75% homologous inhibition [Ferns1987]
• EB1A9: UK Medical Research Council AIDS reagent: ARP345
82 polyclonal p24 (121–152) Gag (253–284 LAI) NPPIPVGEIYKRWIILGLNKIVRMY-
SPTSILD
no Vaccine human (IgG)
Vaccine Vector/Type: lipopeptide Strain: LAI HIV component: p24 Adjuvant: QS21
References Pialoux2001
• 28 subjects were vaccinated with six HIV-1 peptides that were selected to be particularly rich in CTL epitopes, presented in lipopeptides with or without
adjuvant QS21 – HIV-specific Ab responses were detected in 25/28 (89%), proliferative in 19/28 (79%), and CTL in 13/24 (54%) of testable volunteers –
25/28 had Ab responses to peptide G2, 14/28 had proliferative responses, and CTL responses were detected [Pialoux2001]
83 30:3E5 p24 (141–170) p24 (273–302 HXB2) IVRMYSPTSILDIRQGPKEPFRDYV-
DRFYK
Vaccine murine (IgG1λ )
Vaccine Vector/Type: recombinant protein HIV component: p24-p15
Donor B. Wahren
References Hinkula1990
• 30:3E5: Epitope defined by peptide blocking of binding to native protein – WB reactive with p53 and p24 [Hinkula1990]
• 30:3E5: UK Medical Research Council AIDS reagent: ARP367
84 EF7 p24 (141–170) p24 (273–302 HXB2) IVRMYSPTSILDIRQGPKEPFRDYV-
DRFYK
Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein HIV component: p24-p15
References Hinkula1990, Lundin1996
• EF7: Epitope defined by peptide blocking of binding to native protein – WB reactive with p53 [Hinkula1990]
• EF7: Included as a control [Lundin1996]
• EF7: UK Medical Research Council AIDS reagent: ARP366
85 LH-104-E p24 (143–148) p24 (275–280 BRU) RMYSPT no Vaccine murine (IgG1κ)
Vaccine Vector/Type: peptide Strain: BRU
References Haaheim1991
• LH-104-E: Reacts with both p24 and p55 [Haaheim1991]
• LH-104-E: UK Medical Research Council AIDS reagent: ARP319
86 1B2C12 p24 (149–154) p24 (273–292 IIIB) SILDIR no Vaccine murine (IgG1)
Vaccine Vector/Type: purified HIV-1
References Janvier1990
• 1B2C12: Reacts with HIV-1 and HIV-2 – mapped to aa281-286 through Pepscan method [Janvier1990], and to aa273-292 through EIA pentadecapeptide
method [Janvier1992]
87 LH-104-K p24 (149–154) p24 (281–286 BRU) SILDIR no Vaccine murine (IgG1κ)
Vaccine Vector/Type: peptide Strain: BRU
References Haaheim1991
• LH-104-K: Binds exclusively with p24 (not p55) [Haaheim1991]
• LH-104-K: UK Medical Research Council AIDS reagent: ARP322
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88 LH-104-A p24 (152–157 +
219–224)
p24 (BRU) DIRQGP+QGVGGP no Vaccine murine (IgG1κ)
Vaccine Vector/Type: peptide HIV component: p24
References Haaheim1991
• LF-104-A: A 104 amino acid peptide was used to immunize mice – hexapeptide scans revealed two reactive p24 peptides – cross-competition studies
indicated the region 270-286 [Haaheim1991]
• LH-104-A: UK Medical Research Council AIDS reagent: ARP307
89 1.17.3 p24 (152–172) p24 (152–172 SIVmac) CVKQGPKEPFQSYVDRFYKSL no Vaccine murine (IgG1)
Vaccine Vector/Type: inactivated virus Strain: AGM TYO-7 HIV component: virus
References Otteken1992
• 1.17.3: Recognized an epitope present on HIV-2/SIVmac (MAC251/32H) and HIV-2smmH4, but not SIVagmTYO-1, HIV-1 IIIB or SIVmnd [Otteken1992]
90 1A7 p24 (152–172) p24 (152–172 SIVmac) CVKQGPKEPFQSYVDRFYKSL no Vaccine murine (IgG1)
Vaccine Vector/Type: inactivated virus Strain: AGM TYO-7 HIV component: virus
References Otteken1992
• 1A7: Recognized an epitope present on HIV-2/SIVmac (MAC251/32H) and HIV-2smmH4, but not SIVagmTYO-1, HIV-1 IIIB or SIVmnd [Otteken1992]
91 1F6 p24 (152–172) p24 (152–172 SIVmac) CVKQGPKEPFQSYVDRFYKSL no Vaccine murine (IgG1)
Vaccine Vector/Type: inactivated virus Strain: AGM TYO-7 HIV component: virus
References Otteken1992
• 1F6: Recognized an epitope present on HIV-2/SIVmac (MAC251/32H) and HIV-2smmH4, but not SIVagmTYO-1, HIV-1 IIIB or SIVmnd [Otteken1992]
92 23A5G4 p24 (153–172) p24 (285–304 IIIB) IRQGPKEPFRDYVDRFYKTL no Vaccine murine (IgG1)
Vaccine Vector/Type: protein HIV component: p24
References Janvier1990, Janvier1996
• 23A5G4: Mapped to aa209-217 through Pepscan method [Janvier1990] and to aa285-304 through EIA pentadecapeptide method [Janvier1992]
• 23A5G4: A few sera which were able to bind the linear sequence 178-192, but not sequence 288-302 in an indirect peptide ELISA inhibited the binding of
23A5G4 to the native p24 [Janvier1996]
93 23A5G5 p24 (153–172) p24 (285–304 BRU) IRQGPKEPFRDYVDRFYKTL no Vaccine murine (IgG)
Vaccine Vector/Type: protein Strain: IIIB HIV component: p24
References Robert-Hebmann1992b, Robert-Hebmann1992a
94 3D10G6 p24 (153–172) p24 (285–304 IIIB) IRQGPKEPFRDYVDRFYKTL no Vaccine murine (IgG1)
Vaccine Vector/Type: purified HIV-1
References Janvier1990
• 3D10G6: Epitope cross-reacts with HIV-1 and HIV-2 – mapped to aa260-267 through Pepscan method [Janvier1990] and to aa285-304 through EIA
pentadecapeptide method [Janvier1992]
95 polyclonal p24 (153–172) p24 (285–304 LAI) IRQGPKEPFRDYVDRFYKTL no Vaccine murine
Vaccine Vector/Type: recombinant protein, virus-like particle Strain: LAI HIV component: p24, p17, p55 Adjuvant: Freund’s adjuvant
References Truong1997
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• An ELISA assay was used to study a panel of Gag peptides – mature p24 CA epitopes mapped to residues 176-192, 201-218, 233-253, 285-304, and were
recognized by antibodies elicited by rp24CA – one p17MA epitope, residues 11-25, and one p24CA epitope, residues 176-192, were recognized by
antibodies raised against anti-p55 virus-like particles, suggesting a different antigenic properties for p24CA and p17MA antibodies depending on whether
they are produced against the mature soluble protein or the immature assembled form of the gag proteins [Truong1997]
96 F5-4 p24 (153–175) p24 (153–174 HXB2) IRQGPKEPFRDYVDRFYKTLRAE no murine
References Kusk1988, Kusk1992
• F5-4: Binds to a location in the most hydrophilic region of p24 [Kusk1988, Kusk1992]
97 MO9.42.2 p24 (153–178) p24 (285–310 BRU) IRQGPKEPFRDYVDRFYKTLRAEQAS no Vaccine murine (IgG)
Vaccine Vector/Type: virus Strain: HIV2 ROD HIV component: virus
References Robert-Hebmann1992b, Robert-Hebmann1992a
• MO9.42.2: Reacts with HIV-1s, HIV-2s, and SIVs in rec protein ELISA [Robert-Hebmann1992b]
98 MO9.50.2 p24 (153–178) p24 (285–310 BRU) IRQGPKEPFRDYVDRFYKTLRAEQAS no Vaccine murine (IgG)
Vaccine Strain: HIV2 ROD
References Robert-Hebmann1992b, Robert-Hebmann1992a
• MO9.50.2: Reacts with HIV-1s, HIV-2s, and SIVs in rec protein ELISA [Robert-Hebmann1992b]
99 V10 p24 (155–169) p24 (289–303 IIIB) QGPKEPFRDYVDRFY no virus murine
ReferencesMatsuo1992
• V10: Reacts with HIV-1 and SIV AGM analogous peptides [Matsuo1992]
100 V107 p24 (155–177) p24 (289–311 IIIB) QGPKEPFRDYVDRFYKTLRAEQA no virus murine
ReferencesMatsuo1992
• V107: Reacts with FIV, HIV-1 and SIV AGM analogous peptides [Matsuo1992]
101 LH-104-C p24 (156–161 +
219–224)
p24 (BRU) GPKEPF+QGVGGP no Vaccine murine (IgG3κ)
Vaccine Vector/Type: peptide HIV component: p24
References Haaheim1991
• LF-104-C: A 104 amino acid peptide was used to immunize mice – hexapeptide scans revealed two reactive p24 peptides – cross-competition studies
indicated the region 351-373 [Haaheim1991]
• LH-104-C: UK Medical Research Council AIDS reagent: ARP309
102 12-B-4 p24 (161–170) p24 (293–302 IIIB) FRDYVDRFYK no Vaccine murine (IgG1)
Vaccine Strain: IIIB HIV component: virus
References Niedrig1988, Niedrig1989
• 12-B-4: Epitope is defined as the overlap between two HIV-1 reactive peptides – cross-reacts with HIV-2 ROD and SIV MAC [Niedrig1988, Niedrig1989]
103 C5122 p24 (161–170) p24 (293–302 HXB2) FRDYVDRFYK no Vaccine murine (IgG1κ)
Vaccine Vector/Type: viral lysate HIV component: virus
References Hinkula1990
• C5122: Defined by peptide blocking of binding to native protein – WB reactive with p53 and p24 [Hinkula1990]
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104 9A4C4 p24 (170–188) p24 (303–317 IIIB) KTLRAEQASQEVKNWMTET no Vaccine murine (IgG1)
Vaccine Vector/Type: protein Strain: IIIB HIV component: p24
References Janvier1990, Robert-Hebmann1992b, Robert-Hebmann1992a
• 9A4C4: Mapped to aa260-267 through Pepscan method [Janvier1990] – and to aa303-317 through EIA pentadecapeptide method [Janvier1992]
105 11C10B10 p24 (171–185) p24 (303–317 IIIB) TLRAEQASQEVKNWM no Vaccine murine (IgG1)
Vaccine Vector/Type: protein HIV component: p24
References Janvier1990
• 11C10B10: Mapped to aa260-267 through Pepscan method [Janvier1990] and to aa303-317 through EIA pentadecapeptide method [Janvier1992]
106 11D11F2 p24 (171–185) p24 (303–317 IIIB) TLRAEQASQEVKNWM no Vaccine murine (IgG1)
Vaccine Vector/Type: protein HIV component: p24
References Janvier1990
• 11D11F2: Mapped to aa260-267 through Pepscan method [Janvier1990] and to aa303-317 through EIA pentadecapeptide method [Janvier1992]
107 CD12B4 p24 (171–185) p24 (303–317 LAI) TLRAEQASQEVKNWM Vaccine murine (IgG1)
Vaccine Vector/Type: inactivated virus Strain: CBL-1 HIV component: virus
Donor R. B. Ferns and R. S. Tedder
References Ferns1987, Ferns1989
• CD12B4: Reacted with both p55 and p24 – strain-specific binding [Ferns1987]
• CD12B4: UK Medical Research Council AIDS reagent: ARP346
108 BE3 p24 (176–190) p24 (308–322 HXB2) QASQEVKNWMTETLL no Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein HIV component: p24-p15
Donor B. Wahren
References Hinkula1990
• BE3: Defined by peptide blocking of binding to native protein – WB reactive with p53 and p24 [Hinkula1990]
• BE3: UK Medical Research Council AIDS reagent: ARP368
109 L14 p24 (176–190) p24 (308–322 HXB2) QASQEVKNWMTETLL no Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein HIV component: p24-p15
Donor B. Wahren
References Hinkula1990
• L14: Defined by peptide blocking of binding to native protein – WB reactive with p53 and p24 [Hinkula1990]
• L14: UK Medical Research Council AIDS reagent: ARP369
110 108/03 p24 (181–190) p24 (313–322 IIIB) VKNWMTETLL no Vaccine murine (IgG1)
Vaccine Vector/Type: beta-galactosidase fusion protein Strain: IIIB HIV component: p24
References Niedrig1991
• 108/03: Cross-reactive between HIV-1, HIV-2 and SIV MAC by multiple tests [Niedrig1991]
111 110/015 p24 (181–190) p24 (313–322 IIIB) VKNWMTETLL no Vaccine murine (IgG1)
Vaccine Vector/Type: beta-galactosidase fusion protein Strain: IIIB HIV component: p24
References Niedrig1991
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• 110/015: Cross-reactive between HIV-1, HIV-2 and SIV MAC by multiple tests [Niedrig1991]
112 32:32K p24 (199–222) p24 (331–354 HXB2) KTILKALGPAATLEEMMTACQGVG Vaccine murine (IgG1λ )
Vaccine Vector/Type: recombinant protein HIV component: p24-p15
References Hinkula1990
• 32:32K: Epitope defined by peptide blocking of binding to native protein – WB reactive with p53 and p24 [Hinkula1990]
• 32:32K: UK Medical Research Council AIDS reagent: ARP368
113 C5200 p24 (199–222) p24 (331–354 HXB2) KTILKALGPAATLEEMMTACQGVG Vaccine murine (IgG1κ)
Vaccine Vector/Type: viral lysate
References Hinkula1990
• C5200: Epitope defined by peptide blocking of binding to native protein [Hinkula1990]
114 FH2 p24 (201–215) p24 (333–347 HXB2) ILKALGPAATLEEMM no Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein HIV component: p24-p15
References Hinkula1990
• FH2: Defined by peptide blocking of binding to native protein – WB reactive with p53 and p24 [Hinkula1990]
115 13B5 p24 (205–214) p24 (205–213) LGPAATLEEM Vaccine murine
Vaccine Vector/Type: recombinant protein HIV component: p24
Ab type C-term Donor bioMerieux
References Berthet-Colominas1999
• 13B5: Fab which was bound to p24 capsid for crystallization and study of p24’s structure [Berthet-Colominas1999]
116 106/01 p24 (211–230) p24 (343–362 IIIB) LEEMMTACQGVGGPGHKARV no Vaccine murine (IgG1)
Vaccine Vector/Type: beta-galactosidase fusion protein Strain: IIIB HIV component: p24
References Niedrig1991
• 106/01: Cross-reactive between HIV-1, HIV-2 and SIV MAC by multiple tests [Niedrig1991]
117 LH-104-B p24 (225–230) p24 (357–362 BRU) GHKARV no Vaccine murine (IgG1κ)
Vaccine Vector/Type: peptide Strain: BRU
References Haaheim1991
• LH-104-B: Binds exclusively with p55 (not p24), in contrast to LH-104-I [Haaheim1991]
• LH-104-B: UK Medical Research Council AIDS reagent: ARP308
118 LH-104-I p24 (226–231) p24 (358–363 BRU) HKARVL no Vaccine murine (IgG1κ)
Vaccine Vector/Type: peptide Strain: BRU
References Haaheim1991
• LH-104-I: Binds exclusively with p24 (not p55), in contrast to LH-104-B [Haaheim1991]
• LH-104-I: UK Medical Research Council AIDS reagent: ARP321
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119 LH-104-G p24-p2p7p1p6
(231–5)
p24 (363–368 BRU) LAEAMS no Vaccine murine (IgG1κ)
Vaccine Vector/Type: peptide Strain: BRU
References Haaheim1991
• LH-104-G: Reacts with both p24 and p55, in contrast to LH-104-I [Haaheim1991]
• LH-104-G: This epitope overlaps the p24-p2 cleavage site, database note
• LH-104-G: UK Medical Research Council AIDS reagent: ARP320
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120 i5B11 p2p7p1p6 (19–28) p7 (5–14) NFRNQRKIVK no Vaccine rat (IgG2a)
Vaccine Vector/Type: protein HIV component: NCp7
References Otake1994, Tanchou1994, Tanchou1995
• i5B11: i5B11 and 15B11 may be two names for the same MAb
• i5B11: Epitope mapped by ELISA and BIAcore – inhibits NCp7 primer tRNA binding [Tanchou1994]
• i5B11: MAb reacts with NCp7, NCp15, and partially inhibits NCp7-tRNA interaction [Tanchou1995]
121 EC6 p2p7p1p6 (45–54) p15 (408–417 HXB2) PRKKGCWKCG no Vaccine murine (IgG2aκ)
Vaccine Vector/Type: recombinant protein HIV component: p24-p15
References Hinkula1990
• EC6: Epitope defined by peptide blocking of binding to native protein – WB reactive with p53 [Hinkula1990]
122 M12 p2p7p1p6 (45–54) p15 (408–417 HXB2) PRKKGCWKCG no Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein HIV component: p24-p15
References Hinkula1990
• M12: There is a p15 and a gp120 MAb both called M12
• M12: Epitope defined by peptide blocking of binding to native protein – WB reactive with p53 [Hinkula1990]
123 DG8 p2p7p1p6 (66–81) p7 (52–67) RQANFLGKIWPSYKGR Vaccine murine
Vaccine Vector/Type: protein HIV component: NCp7
References Tanchou1995
• DG8: Binds proximal to the second zinc-finger, inhibits NCp7-tRNA interaction [Tanchou1995]
124 EB5 p2p7p1p6 (66–81) p7 (52–67) RQANFLGKIWPSYKGR Vaccine murine
Vaccine Vector/Type: protein HIV component: NCp7
References Tanchou1995
• EB5: Binds proximal to the second zinc-finger – mutation at position 59 (Lys to Ser) results in 10-fold reduction in reactivity [Tanchou1995]
125 HH3 p2p7p1p6 (66–81) p7 (52–67) RQANFLGKIWPSYKGR no Vaccine murine (IgG2b)
Vaccine Vector/Type: protein HIV component: NCp7
References Tanchou1994, Tanchou1995
• HH3: Epitopes mapped by ELISA and BIAcore – does not inhibit NCp7 primer tRNA binding [Tanchou1994]
• HH3: Binds proximal to the second zinc-finger [Tanchou1995]
126 AD2 p2p7p1p6 (78–86) p7 (64–72) YKGRPGNFL no Vaccine murine (IgG)
Vaccine Vector/Type: protein HIV component: NCp7
References Tanchou1995
• AD2: Binds at C term of NCp7 [Tanchou1995]
127 CA5 p2p7p1p6 (78–86) p7 (64–72) YKGRPGNFL no Vaccine murine (IgG)
Vaccine Vector/Type: protein HIV component: NCp7
References Tanchou1995
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• CA5: Binds at C term of NCp7 [Tanchou1995]
128 DF3 p2p7p1p6 (78–86) p7 (64–72) YKGRPGNFL no Vaccine murine (IgG)
Vaccine Vector/Type: protein HIV component: NCp7
References Tanchou1995
• DF3: Binds at C term of NCp7 [Tanchou1995]
129 EC3 p2p7p1p6 (78–86) p7 (64–72) YKGRPGNFL no Vaccine murine (IgG)
Vaccine Vector/Type: protein HIV component: NCp7
References Tanchou1995
• EC3: Binds at C term of NCp7 [Tanchou1995]
130 FC12 p2p7p1p6 (78–86) p7 (64–72) YKGRPGNFL no Vaccine murine (IgG)
Vaccine Vector/Type: protein HIV component: NCp7
References Tanchou1995
• FC12: Binds at C term of NCp7, reacts with NCp15, inhibits NCp7-tRNA interaction [Tanchou1995]
131 GE4 p2p7p1p6 (78–86) p7 (64–72) YKGRPGNFL no Vaccine murine (IgG)
Vaccine Vector/Type: protein HIV component: NCp7
References Tanchou1995
• GE4: Binds at C term of NCp7 [Tanchou1995]
132 JB7 p2p7p1p6 (78–86) p7 (64–72) YKGRPGNFL no Vaccine murine (IgG)
Vaccine Vector/Type: protein HIV component: NCp7
References Tanchou1995
• JB7: Binds at C term of NCp7 [Tanchou1995]
133 JF11 p2p7p1p6 (78–86) p7 (64–72) YKGRPGNFL no Vaccine murine (IgG1)
Vaccine Vector/Type: protein HIV component: NCp7
References Tanchou1994, Tanchou1995
• JF11: Epitopes mapped by ELISA and BIAcore – does not inhibit NCp7 primer tRNA binding [Tanchou1994]
• JF11: Binds at C term of NCp7 [Tanchou1995]
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134 16/4/2 Gag p24 no Vaccine
Vaccine Vector/Type: DNA with CMV, MCK, or CMV/MCK hybrid promotors
References Bojak2002
• 16/4/2: The ability of three different promoters to induce Gag specific immune responses was compared. The cytomegaliovirus (CMV) early gene promoter,
which allows constitutive expression in different cells of host tissue, the tissue specific muscle creatine kinase (MCK) promoter, which may be restricted to
differentiated, multinucleated myofibers and so safer, and a hybrid MCK/CMV promoter – intramuscular immunization of BALB/c mice utilizing the MCK
promoter in combination with a codon optimized gag gene generated humoral (IgG1 (Th1) and IgG2a (Th2)) and CTL immune responses against HIV-1
Gag, however, the quantified immune parameters were clearly reduced as compared to CMV promotor-driven Gag expression [Bojak2002]
135 183-H12-5C Gag p24 no murine (IgG1)
Donor Bruce Chesebro and Kathy Wehrly, Rocky Mountain Laboratories, Hamilton, Montana
References Chesebro1992, Toohey1995, Wehrly1997
• 183-H12-5C: Used as antigen capture reagent for p24 ELISA [Chesebro1992, Toohey1995]
• 183-H12-5C: Cross-reacts with HIV1 and HIV-2 p24, and SIV p27 [Wehrly1997]
• 183-H12-5C: NIH AIDS Research and Reference Reagent Program: 3537
136 241-D Gag p24 no human (IgG1λ )
Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Gorny1989, Tyler1990, Robinson1991
• 241-D: An antibody by this name is available in the NIH AIDS Research and Reference Reagent Program, and they refer to the papers
[Gorny1989, Tyler1990, Robinson1991], but no p24 MAb by this name is discussed in these papers
• 241-D: MH AIDS Research and Reference Reagent program: 1244
137 2A6 Gag p17
Donor A. O. Arthur, Frederick Cancer Research and Development Center, Frederick, MD
References Pincus1998
• 2A6: Part of a panel of 17 MAbs used as controls testing for the dual specificity of MAb G11H3 for both p17 and mycoplasma [Pincus1998]
138 5E2.A3k Gag p24 (1–158 SF2) no murine (IgG1)
Donor Biodesign International, Kennebunk, Maine, USA
References Hochleitner2000a
• 5E2.A3k: The Ab binding site was studied with epitope excision (protein is bound in native conformation to immobilized MAb, then digested with
proteolytic enzymes) and extraction (protein is digested then allowed to react with Ab), followed by mass spectroscopy, as well as lysine modification – the
epitope is discontinuous, but involves the highly conserved N-term proline, and the antibody recognizes SIVs and HIV-2 as well as HIV-1 p24
[Hochleitner2000a]
139 71-31 Gag p24 no human (IgG1λ )
References Gorny1989, Robinson1990b, Robinson1991, Spear1993, Gorny1997, Gorny1998, Bandres1998
• 71-31: Did not enhance HIV-1 IIIB infection [Robinson1990b]
• 71-31: No enhancing or neutralizing activity [Robinson1991]
• 71-31: Did not mediate deposition of complement component C3 on HIV infected cells [Spear1993]
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• 71-31: Included as a negative control in studies that demonstrate that CXCR4 can bind to gp120 in the absence of CD4-gp120 interactions, and that this
binding can be enhanced by Env deglycosylation [Bandres1998]
• 71-31: NIH AIDS Research and Reference Reagent Program: 530
140 91-6 Gag p24 (121–240 IIIB) no HIV-1 infection human (IgG1λ )
References Gorny1989, Robinson1990b
• 91-6: No enhancing activity for HIV-1 IIIB [Robinson1990b]
• 91-6: NIH AIDS Research and Reference Reagent Program: 1239
141 98-4.3 Gag p24 no HIV-1 infection human (IgG1λ )
References Robinson1991
• 98-4.3: No enhancing or neutralizing activity [Robinson1991]
142 98-4.9 Gag p24 no HIV-1 infection murine (IgG3λ )
References Gorny1989
143 AC2 Gag p7 no Vaccine murine (IgG)
Vaccine Vector/Type: protein HIV component: NCp7
References Tanchou1995
• AC2: Binds NCp7 independent of Zn fingers, does not react with NCp15 [Tanchou1995]
144 BC1071 Gag p24 no HIV-1 infection murine
Donor Aalto BioReagents
References Schonning1999
• BC1071: The stoichiometry of MAb neutralization was tested and MAb BC1071 was used in this study for virion quantification [Schonning1999]
145 BE10 Gag p7 no Vaccine murine (IgG)
Vaccine Vector/Type: protein HIV component: NCp7
References Tanchou1995
• BE10: Binding NCp7 requires Zn fingers, does not react with NCp15, inhibits NCp7-tRNA interaction [Tanchou1995]
146 CD9 Gag p7 no Vaccine murine (IgG)
Vaccine Vector/Type: protein HIV component: NCp7
References Tanchou1995
• CD9: Binds NCp7 independent of Zn fingers, does not react with NCp15 [Tanchou1995]
147 CH9B2 Gag p17 Vaccine murine (IgG1)
Vaccine Vector/Type: inactivated virus Strain: CBL-1 HIV component: virus
Donor R. B. Ferns and R. S. Tedder
References Ferns1987, Ferns1989
• CH9B2: Reactive against p18 and p55 [Ferns1987]
• CH9B2: UK Medical Research Council AIDS reagent: ARP349
148 ED8 Gag p7 no Vaccine murine (IgG)
Vaccine Vector/Type: protein HIV component: NCp7
References Tanchou1995
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• ED8: Binds NCp7 independent of Zn fingers, does not react with NCp15 [Tanchou1995]
149 EH12E1 Gag p24 Vaccine murine (IgG1)
Vaccine Vector/Type: inactivated virus Strain: CBL-1 HIV component: virus
Donor R. B. Ferns and R. S. Tedder
References Ferns1987, Ferns1989
• EH12E1: Reacted with p55 and p24 in WB [Ferns1987]
• EH12E1: UK Medical Research Council AIDS reagent: ARP313
150 G11G1 Gag p17 rat
References Shang1991, Pincus1996
• G11G1: Immunotoxins were generated by linking Env MAbs to ricin A – immunotoxins mediated cell killing, but only if the antigen was expressed at the
cell surface – ricin-G11G1 did not mediate cell killing [Pincus1996]
151 G11H3 Gag p17
References Shang1991, Pincus1998
• G11H3: This MAb is cross-reactive between p17 and mycoplasma – this antibody binds strain specifically to the variable lipoprotein (Vlp) F of M.
hyorhinis, in the region of the carboxy-terminal repeat CGGSTPTPEQGNNQGGSTPTPEQGNSQVSK – the p17 epitope is discontinuous, but p17 and Vlp
F share the tetrapeptide SQVS [Pincus1998]
152 HyHIV-19 Gag p17 (JMH1) no Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: p17
References Liu1995, Ota1998a
• HyHIV-19: Does not react with p17 peptides – Ka is 3.7 x 106 M-1 for rec p17 – inhibited growth of HIV-1 JMH1 in MT-4 cells when added 24 hours after
the initial culture [Ota1998a]
153 IE8G2 Gag p24 Vaccine murine (IgG1)
Vaccine Vector/Type: inactivated virus Strain: CBL-1 HIV component: virus
Donor R. B. Ferns and R. S. Tedder
References Ferns1987, Ferns1989
• IE8G2: Reacted with both p55 and p24 – broadly reactive – showed less than 75% homologous inhibition [Ferns1987]
• IE8G2: UK Medical Research Council AIDS reagent: ARP347
154 V7-8 Gag p24 no HIV-1 infection murine (IgG3κ)
References Robinson1990b, Montefiori1991
• V7-8: Did not enhance HIV-1 IIIB infection [Robinson1990b]
• V7-8: Reacted with HIV-1IIIB, RF, and MN [Montefiori1991]
• V7-8: NIH AIDS Research and Reference Reagent Program: 381
155 anti-p24 Gag p24 Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein, virus-like particle HIV component: Gag, Pol, Nef, gp120
Donor Intracel Co
References Buonaguro2001
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• anti-p24: HIV-1 pr55 gag-based virus-like particles (VLP) carrying Nef and Pol open reading frames, as well as gp120 of the clade A isolate 94UG018,
were created using a Baculovirus expression system to package additional ORFS into the VLP – anti-V3 and anti-p24 Abs were used to assess the
expression levels and Gag and gp120-TM were found to be expressed at comparable levels on the VLP [Buonaguro2001]
156 human sera Gag p24 HIV-1 infection human (IgG)
References Binley1997b
• Retention of anti-Env antibodies and loss of anti-Gag antibodies during progression was studied, and suggested to be the result of the loss of T-cell help and
the unique ability of Env to stimulate B cells even in a backdrop of declining CD4 cells, because of the ability of Env to bind to the CD4 molecule
[Binley1997b]
157 polyclonal Gag Gag (LAI) Vaccine murine
Vaccine Vector/Type: DNA prime with recombinant protein boost Strain: LAI HIV component: Gag, Tat, Nef Adjuvant: IL18
References Billaut-Mulot2001
• DNA vaccinated BALB/c mice primed and boosted with a multiepitopic vaccine with IL18 showed lymphoproliferative and CTL responses –
co-administration of IL18 increased T-cell responses but decreased anti-HIV Ab levels [Billaut-Mulot2001]
158 polyclonal Gag p24 no Vaccine rat
Vaccine Vector/Type: gp120 depleted whole killed virus Strain: HZ321 (subtype A env, subtype G gag) HIV component: whole virus Adjuvant: CpG,
Freund’s adjuvant
ReferencesMoss2000
• Lewis rats co-immunized with HIV-1 antigen in Freund’s and with immunostimulatory sequences CpG stimulated increased IFNγ expressing CD4+ and
CD8+ T cells and anti-p24 antibodies relative to antigen in Freund’s without CpG [Moss2000]
159 polyclonal Gag p24 (SF2) Vaccine murine
Vaccine Vector/Type: recombinant protein Strain: SF2 HIV component: gp120, p24 Adjuvant: PLG+MF-59 microparticles
References O’Hagan2000
• Microparticles were used as an adjuvant for entrapped HIV-1 gp120 and induced strong serum IgG responses in mice – polylactide co-glycolide polymer
(PLG) microparticles in combination with MF-59 had the highest Ab response and also induced p24 specific CTL [O’Hagan2000]
160 polyclonal Gag Gag (SF2) Vaccine murine, guinea pig,
macaque
Vaccine Vector/Type: DNA, recombinant protein Strain: SF2 HIV component: p55 Adjuvant: PLG microparticles, aluminum phosphate, MF-59
References O’Hagan2001
• DNA vaccines of codon-optimized Env and Gag genes driven by CMV promotors absorbed on to PLG microparticles were more effective than naked DNA
at eliciting strong Ab responses (more rapid, higher titer, more stable), comparable to gp120 in MF-59 [O’Hagan2001]
161 polyclonal Gag p24 no Vaccine rabbit (IgG)
Vaccine Vector/Type: recombinant protein Strain: B subtype HIV component: p24
References Gupta2001
• Gag p24 is the mostly widely used HIV protein for serological based diagnostic kits — phage display libraries of HIV-1 p24 identified 2 epitope-rich
regions: 70% of the clones that were identified using immunized rabbit sera had DNA fragments from the N-terminal region spanning 150–240 of Gag, and
30% from the carboxy-terminal region of p24 containing amino acids 310–360 — subtype B and C comparisons were made [Gupta2001]
162 polyclonal Gag p55 no Vaccine murine
Vaccine Vector/Type: recombinant protein, virus-like particle Strain: LAI HIV component: V3, CD4BS, p55
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References Truong1996
• Antibodies raised against recombinant anti-p55 virus-like particles with the p24 region 196-226 deleted, bearing inserts of either the V3 or the CD4BS
regions of gp120 were studied – no neutralizing responses, weak Env and strong Gag responses were elicited – the major homology region (MHR) and
proximal sequences was found to be required for capsid assembly [Truong1996]
163 polyclonal Gag p24 (LAI) Vaccine rabbit (IgG)
Vaccine Vector/Type: virion, baculovirus and E. coli recombinant protein, peptides Strain: LAI HIV component: p24 Adjuvant: Freund’s complete
and incomplete adjuvant,
References Devito2000c
• To compare vaccine strategies, rabbits were immunized with virion HIV-1/Lai, baculovirus recombinant p24, E. coli recombinant p24-15, and p24-derived
peptides – the rabbit immunized with peptides had the broadest linear epitope responses – the capture ELISA method using anti-p24 IgG preparations was
shown to capture isolates from HIV-1 subtypes or clades A to G – only immunization with virion HIV-1/Lai and baculovirus recombinant p24 developed
IgG that was capable of efficiently capturing HIV-1 p24 in ELISA producing Abs able to recognise native configurations [Devito2000c]
164 polyclonal Gag Vaccine murine
Vaccine Vector/Type: DNA Adjuvant: CpG, phosphorothioate oligodeoxynucleotides (ODNs)
References Deml2001
• Immunization mice with a codon-optimized Gag was compared with a non-optimized Rev dependent Gag expression vector – Gag expression was at higher
levels and Rev independent with the codon-optimized Gag, and i.m. immunization gave a stronger Th1-driven humoral and cellular immune response –
intradermal immunization with either Gag DNA induced a Th2 response and no CTL [Deml2001]
165 polyclonal Gag yes HIV-1 infection human
ReferencesMontefiori2001
• In 7/9 patients in whom HAART was initiated during early seroconversion, NAbs to autologous strains were not found immediately following treatment
interuption after 1-3 years, and Env and Gag Abs were low or undetected by ELISA indicating, that early HAART suppresses the normal antibody response
to HIV-1, presumably by limiting the concentration of viral antigens needed to drive B-cell maturation – in 3 patients with a viral rebound autologous NAbs
rapidly appeared and correlated with spontaneous down-regulation of viremia – prolonged control of viremia after stopping treatment persisted in the
absence of detectable NAbs, suggesting that cellular immune responses alone can control viremia under certain circumstances – these results support the
notion that virus-specific B-cell priming, combined with CD8+ CTL induction, may be beneficial for HIV-1 vaccines that aim to suppress viremia in the
absence of complete protection to prevent disease and reduce the rate of virus transmission [Montefiori2001]
166 polyclonal Gag Vaccine murine (IgG)
Vaccine Vector/Type: virus-like particle HIV component: Env, Gag Adjuvant: Freund’s adjuvant
References Lebedev2000
• Virus-like particles (VLPs) in the form of spherical particles with yeast dsRNA enveloped in a polysaccharide matrix carrying the protein TBI, that contains
fragments of HIV Env and Gag, were used to immunize BALB/c mice and induced specific Abs against HIV-1 as measured by ELISA with TBI
[Lebedev2000]
167 polyclonal Gag no Vaccine murine (IgG1,
IgG2a)
Vaccine Vector/Type: DNA with CMV, MCK, or CMV/MCK hybrid promotors
References Bojak2002
593
DEC 2002
B
C
el
l
HIV Antibodies Tables Gag Antibodies
No. MAb ID HXB2 Location Author’s Location Sequence Neutralizing Immunogen Species(Isotype)
• The ability of three different promoters to induce Gag specific immune responses was compared. The cytomegaliovirus (CMV) early gene promoter, which
allows constitutive expression in different cells of host tissue, the tissue specific muscle creatine kinase (MCK) promoter, which may be restricted to
differentiated, multinucleated myofibers and so safer, and a hybrid MCK/CMV promoter – intramuscular immunization of BALB/c mice utilizing the MCK
promoter in combination with a codon optimized gag gene generated humoral (IgG1 (Th1) and IgG2a (Th2)) and CTL immune responses against HIV-1
Gag, however, the quantified immune parameters were clearly reduced as compared to CMV promotor-driven Gag expression [Bojak2002]
168 polyclonal Gag p24 no HIV-1 infection human
ReferencesMeles2002
• Indeterminant WB in Ethiopians: of 12,124 specimens blood specimens from Ethiopia, 1,437 (11.9%) were HIV-1-positive for antibody, and 91 (0.8%)
gave equivocal results, most often due to p24 reactivity – subsequent testing confirmed many of the indeterminants were HIV-negative – the American Red
Cross diagnostic criteria was more accurate than CDC or WHO, which would have given some false positive results [Meles2002]
169 polyclonal
HIVIG
Gag p24 P HIV-1 infection human
References Nichols2002
• NYBC-HIVIG derived from patients with high NAb titers and NABI-HIVIG derived from patients with high anti-p24 Ab titers were compared in
neutralizing assay against a panel of six primary isolates—both could neutralize all isolates tested but the NYBC-HIVIG dose required for 50%
neutralization was of 3.2 fold lower, showing that the source plasmas influence the effective concentration of NAb present in HIVIG [Nichols2002].
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170 1696 Protease (1–7) Protease (1–7 BH10) PQIYLWQ Vaccine murine (IgG)
Vaccine Vector/Type: protein HIV component: Protease
Ab type N-term
References Lescar1999
• 1696: MAb binds to HIV-1 and HIV-2, putative epitopes are PQIYLWQ and PQFSLWK respectively – Pro1 is critical, QIYLWQR residues 2-8, does not
compete - MAb disrupts catalytic activity – crystal structure of Fab at 3 A resolution reveals a deep cavity lined by acidic and hydrophobic residues – the
binding region is located within the region required for dimerization and the Fab structure could serve as a basis for drug design targeting this region
[Lescar1999]
171 10E7 Protease (36–46) Protease (38–45 HXB2) MSLPGRWKPKM no Vaccine hamster (IgG)
Vaccine Vector/Type: recombinant protein HIV component: Protease
References Croix1993, Bjorling1992
• 10E7: Immunodominant region of protease in Armenian hamster (but only weakly reactive in people, see: [Bjorling1992]) – peptide MSLPGRWKP blocks
protease binding [Croix1993]
172 F11.2.32 Protease (36–46) Protease (36–46 BH10) MSLPGRWKPKM Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: Protease
Ab type flap region
References Lescar1996, Lescar1997, Lescar1999
• F11.2.32: Binding leads to significant inhibition in proteolytic activity – crystal structure of Fab-peptide was determined to 2.2 A resolution – bound peptide
shows no structural similarity to the corresponding segment in native protease suggesting binding may distort protein structure [Lescar1997]
• F11.2.32: Distortion may occur in the flap region of the protein, important for regulating access of substrate to the catalytic site [Lescar1999]
173 13E1 Protease (38–45) Protease (38–45 HXB2) LPGRWKPK no Vaccine hamster (IgG)
Vaccine Vector/Type: recombinant protein HIV component: Protease
References Croix1993
• 13E1: Binds to MSLPGRWKPKM with sightly higher affinity [Croix1993]
174 8B11 Protease (38–45) Protease (38–45 HXB2) LPGRWKPK no Vaccine hamster (IgG)
Vaccine Vector/Type: recombinant protein HIV component: Protease
References Croix1993
• 8B11: Binds to MSLPGRWKPKM with sightly higher affinity [Croix1993]
175 8C10 Protease (38–45) Protease (38–45 HXB2) LPGRWKPK no Vaccine hamster (IgG)
Vaccine Vector/Type: recombinant protein HIV component: Protease
References Croix1993
• 8C10: Binds to MSLPGRWKPKM with sightly higher affinity [Croix1993]
176 8G5 Protease (38–45) Protease (38–45 HXB2) LPGRWKPK no Vaccine hamster (IgG)
Vaccine Vector/Type: recombinant protein HIV component: Protease
References Croix1993
• 8G5: Binds to MSLPGRWKPKM with sightly higher affinity [Croix1993]
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177 1E8 RT (65–73) RT (65–73) KKDSTKWRK no Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: RT Adjuvant: nitrocellulose
ReferencesWu1993, Gu1996
• 1E8: Inhibits RT activity, binding site overlaps with two AZT resistance mutations [Wu1993]
• 1E8: Significantly inhibits DNA polymerase activity of RT by hindering binding of dNTPs – additive or synergistic RT inhibition with nevirapine and
delavirdine [Gu1996]
178 1.152 B3 RT (294–302) RT (294–302) PLTEEAELE no Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: RT
References Orvell1991
• 1.152 B3: Weakly positive by immunofluorescence – binding inhibits RT enzymatic activity [Orvell1991]
179 1.158 E2 RT (294–302) RT (294–302) PLTEEAELE no Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: RT
References Orvell1991
• 1.158 E2: Negative by immunofluorescence – binding inhibits RT enzymatic activity [Orvell1991]
180 31D6 RT (294–318) RT (294–319) PLTEEAELELAENREILKEPVHGVY no Vaccine murine (IgG1)
Vaccine Vector/Type: E. coli Trp fusion protein HIV component: RT
References Szilvay1992
• 31D6: Strong inhibitor of RT, > 50% inhibition [Szilvay1992]
181 31G8 RT (294–318) RT (294–319) PLTEEAELELAENREILKEPVHGVY no Vaccine murine (IgG1)
Vaccine Vector/Type: E. coli Trp fusion protein HIV component: RT
References Szilvay1992
• 31G8: Weak inhibitor of RT, reactive by immunofluorescence [Szilvay1992]
182 32E7 RT (294–318) RT (294–319) PLTEEAELELAENREILKEPVHGVY no Vaccine murine (IgG1)
Vaccine Vector/Type: E. coli Trp fusion protein HIV component: RT
References Szilvay1992
• 32E7: Weak inhibitor of RT, reactive by immunofluorescence [Szilvay1992]
183 33D5 RT (294–318) RT (294–319) PLTEEAELELAENREILKEPVHGVY no Vaccine murine (IgG1)
Vaccine Vector/Type: E. coli Trp fusion protein HIV component: RT
References Szilvay1992
• 33D5: Weak inhibitor of RT, reactive by immunofluorescence [Szilvay1992]
184 5B2 RT (294–318) RT (294–319) PLTEEAELELAENREILKEPVHGVY no Vaccine murine (IgG1)
Vaccine Vector/Type: E. coli Trp fusion protein HIV component: RT
References Szilvay1992
• 5B2: There is an RT specific Ab [Szilvay1992] and a gp41 specific Ab [Tian2001] both called 5B2
• 5B2: Weak inhibitor of RT, reactive by immunofluorescence [Szilvay1992]
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• 5B2: UK Medical Research Council AIDS reagent: ARP3018
185 polyclonal RT (295–304) RT (295–304 PV22) LTEEAELELA no HIV-1 infection human (IgG)
References Grimison1995
186 1.153 G10 RT (350–354) RT (350–354) KTGKY no Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: RT
References Orvell1991
187 RTMAb8 RT (376–383) RT (532–539) TTESIVIW no Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein HIV component: RT
References Tisdale1988, Ferns1991
188 1D4A3 RT (384–387) RT (540–543) GKIP no Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein HIV component: RT
References Ferns1991
189 RT6H RT (384–387) RT (540–543) GKIP no Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein HIV component: RT
References Ferns1991
190 1.160 B3 RT (442–450) RT (442–450) VDGAANRET no Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: RT
References Orvell1991
191 polyclonal RT (521–531) RT (521–531 PV22) IIEQLIKKEKV no HIV-1 infection human (IgG)
References Grimison1995
192 C2003 RT (536–549) RT (703–716 BH10) VPAHKGIGGNEQVD no Vaccine rabbit (IgG)
Vaccine Vector/Type: peptide Strain: BH10
References DeVico1991
• C2003: Inhibits polymerase activity from a variety of retroviruses – RT protected from inhibition by preincubation with template primer [DeVico1991]
193 6B9 RT RT (155–250) yes Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: HXB2 HIV component: RT
Ab type palm domain
References Chiba1996, Chiba1997, Ohba2001
• 6B9: In contrast to MAb 7C4, which binds to the thumb region of RT, 6B9 binds to the palm subdomain and does not inhibit RT activity [Chiba1996]
194 5F RT RT (252–335) yes Vaccine murine
Vaccine Vector/Type: vaccinia Strain: HXB2 HIV component: RT
Ab type thumb domain
References Ohba2001
• 5F: BALB/c mice were vaccinated with vaccinia carrying RT and a phage display library was produced and panned with RT – Fabs 5F and 5G were cloned,
both recognizing an immunodominant neutralizing RT epitope in the region of the template primer-binding site in the thumb domain also recognized by
MAb 7C4 – sequencing revealed the heavy chains and light chains of 7C4, 5G and 7C4 are related [Ohba2001]
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195 5G RT RT (252–335) yes Vaccine murine
Vaccine Vector/Type: vaccinia Strain: HXB2 HIV component: RT
Ab type thumb domain
References Ohba2001
• 5G: BALB/c mice were vaccinated with vaccinia carrying RT and a phage display library was produced and panned with RT – Fabs 5F and 5G were cloned,
both recognizing an immunodominant neutralizing RT epitope in the region of the template primer-binding site in the thumb domain also recognized by
MAb 7C4 – sequencing revealed the heavy chains and light chains of 7C4, 5G and 7C4 are related [Ohba2001]
196 7C4 RT RT (252–335) yes Vaccine murine (IgG2a)
Vaccine Vector/Type: vaccinia Strain: HXB2 HIV component: RT
Ab type thumb domain
References Chiba1996, Chiba1997, Ohba2001
• 7C4: 7C4 was produced from a hybridoma cell line derived from a BALB/c mouse repeatedly immunized with RT in a vaccinia construct, and was found to
inhibit RT through binding to the template primer-binding site, a possible target for RT inhibitors [Chiba1996]
• 7C4: 7C4 inhibits RT from HIV-1 strains IIIB, Bru, and IMS-1 but not HIV-2 strains GH-1 and LAV-2, SIV MAC, nor SIV MND [Chiba1997]
• 7C4: Fabs 5F and 5G both recognize the same immunodominant neutralizing RT epitope in the region of the template primer-binding site in the thumb
domain recognized by MAb 7C4 – sequencing revealed the heavy chains and light chains of 7C4, 5G and 7C4 are related [Ohba2001]
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197 1C4 Integrase (1–16) Integrase (1–16 HXB2) FLDGIDKAQDEHEKYH no Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein Strain: HXB2 HIV component: Integrase
Ab type N-term
References Haugan1995, Nilsen1996
• 1C4: MAb interferes with integrase binding to DNA [Haugan1995]
• 1C4: One of a large set of MAbs that interact with the N-terminal part of integrase: 1C4, 2C11, 2E3, 3E11, 3F9, 5F8, 6G5, 7B6, 7C6 – these MAbs inhibit
end processing and DNA joining, but had little effect on integration activities [Nilsen1996]
198 2C11 Integrase (1–16) Integrase (1–16 HXB2) FLDGIDKAQDEHEKYH no Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein Strain: HXB2 HIV component: Integrase
Ab type N-term
References Nilsen1996
• 2C11: One of a large set of MAbs that interact with the N-terminal part of integrase: 1C4, 2C11, 2E3, 3E11, 3F9, 5F8, 6G5, 7B6, 7C6 – these MAbs inhibit
end processing and DNA joining, but had little effect on integration activities [Nilsen1996]
199 2E3 Integrase (1–16) Integrase (1–16 HXB2) FLDGIDKAQDEHEKYH no Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein Strain: HXB2 HIV component: Integrase
Ab type N-term
References Nilsen1996, Ovod1992
• 2E3: There are two MAbs called 2E3 – the other one binds to Nef [Ovod1992]
• 2E3: One of a large set of MAbs that interact with the N-terminal part of integrase: 1C4, 2C11, 2E3, 3E11, 3F9, 5F8, 6G5, 7B6, 7C6 – these MAbs inhibit
end processing and DNA joining, but had little effect on integration activities [Nilsen1996]
200 3E11 Integrase (1–16) Integrase (1–16 HXB2) FLDGIDKAQDEHEKYH no Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein Strain: HXB2 HIV component: Integrase
Ab type N-term
References Otteken1992, Nilsen1996
• 3E11: There is another MAb with this ID that recognizes p17 [Otteken1992]
• 3E11: Recognized an epitope present on HIV-2/SIVmac, SIVagm, HIV-1, and SIVmnd [Otteken1992]
• 3E11: One of a large set of MAbs that interact with the N-terminal part of integrase: 1C4, 2C11, 2E3, 3E11, 3F9, 5F8, 6G5, 7B6, 7C6 – these MAbs inhibit
end processing and DNA joining, but had little effect on integration activities [Nilsen1996]
201 3F9 Integrase (1–16) Integrase (1–16 HXB2) FLDGIDKAQDEHEKYH no Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein Strain: HXB2 HIV component: Integrase
Ab type N-term
References Nilsen1996
• 3F9: One of a large set of MAbs that interact with the N-terminal part of integrase: 1C4, 2C11, 2E3, 3E11, 3F9, 5F8, 6G5, 7B6, 7C6 – these MAbs inhibit
end processing and DNA joining, but had little effect on integration activities [Nilsen1996]
202 5F8 Integrase (1–16) Integrase (1–16 HXB2) FLDGIDKAQDEHEKYH no Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein Strain: HXB2 HIV component: Integrase
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Ab type N-term
References Haugan1995, Nilsen1996
• 5F8: There is another MAb with this ID that recognizes and unknown protein in HIV [Pinter1995]
• 5F8: MAb interferes with integrase binding to DNA [Haugan1995]
• 5F8: One of a large set of MAbs that interact with the N-terminal part of integrase: 1C4, 2C11, 2E3, 3E11, 3F9, 5F8, 6G5, 7B6, 7C6 – these MAbs inhibit
end processing and DNA joining, but had little effect on integration activities [Nilsen1996]
203 6G5 Integrase (1–16) Integrase (1–16 HXB2) FLDGIDKAQDEHEKYH no Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein Strain: HXB2 HIV component: Integrase
Ab type N-term
References Nilsen1996
• 6G5: One of a large set of MAbs that interact with the N-terminal part of integrase: 1C4, 2C11, 2E3, 3E11, 3F9, 5F8, 6G5, 7B6, 7C6 – these MAbs inhibit
end processing and DNA joining, but had little effect on integration activities [Nilsen1996]
204 7B6 Integrase (1–16) Integrase (1–16 HXB2) FLDGIDKAQDEHEKYH no Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein Strain: HXB2 HIV component: Integrase
Ab type N-term
References Nilsen1996
• 7B6: One of a large set of MAbs that interact with the N-terminal part of integrase: 1C4, 2C11, 2E3, 3E11, 3F9, 5F8, 6G5, 7B6, 7C6 – these MAbs inhibit
end processing and DNA joining, but had little effect on integration activities [Nilsen1996]
205 7C6 Integrase (1–16) Integrase (1–16 HXB2) FLDGIDKAQDEHEKYH no Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein Strain: HXB2 HIV component: Integrase
Ab type N-term
References Nilsen1996
• 7C6: One of a large set of MAbs that interact with the N-terminal part of integrase: 1C4, 2C11, 2E3, 3E11, 3F9, 5F8, 6G5, 7B6, 7C6 – these MAbs inhibit
end processing and DNA joining, but had little effect on integration activities [Nilsen1996]
206 6C5 Integrase (17–38) Integrase (17–38 HXB2) SNWRAMASDFNLPPVVAKEIVA no Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein Strain: HXB2 HIV component: Integrase
Ab type N-term
References Haugan1995, Nilsen1996
• 6C5: MAb interferes with integrase binding to DNA [Haugan1995]
• 6C5: This MAb inhibits end processing and DNA joining, but had little effect on integration activities [Nilsen1996]
207 8G4 Integrase (22–31 +
82–101)
Integrase (12–42 HXB2) MASDFNLPPV+GYIEAEVIPAETGQ-
ETAYFI?
no Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein Strain: HXB2 HIV component: Integrase
References Haugan1995, Nilsen1996
• 8G4: This MAb reacted strongly with peptides IN(12-31) and IN(22-42), and less strongly with peptide IN(82-101) – it did not react with a deletion mutant
of positions 17-38 – this MAb inhibits end processing and DNA joining, but had little effect on integration activities [Nilsen1996]
• 8G4: MAb interferes with integrase binding to DNA [Haugan1995]
208 17 (mAb17) Integrase (25–35) Integrase (25–35) DFNLPPVVAKE no Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: Integrase
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References Bizub-Bender1994, Levy-Mintz1996, Yi2000b
• 17: BALBc mice were immunized with rec integrase, hybridomas expressing anti-integrase Abs were generated, and the antibodies characterized – the Zn
finger motif is in the binding region – MAbs 14 and 17 form a competition group [Bizub-Bender1994]
• 17: Used for the creation of single chain variable antibody fragments (SFvs) for internal cellular expression – neutralization of IN activity prior to
integration, whether the Ab is expressed in the nucleolus or the cytoplasm – relative binding affinity to IN: 12 > 17 = 33 > 21 > 4 [Levy-Mintz1996]
• 17: Epitope mapped to helix-turn-helix motif in the N-term domain of Integrase, positions 25-35 – Zn binding stabilizes the Integrase-mAb17complex –
both MAb and Fab form of mAb17 inhibit Integrase activity – epitope region likely to be involved in protein-protein interaction [Yi2000b]
209 4D6 Integrase (42–55) Integrase (42–55 HXB2) KCQLKGEAMHGQVD no Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein Strain: HXB2 HIV component: Integrase
Ab type N-term
References Haugan1995, Nilsen1996
• 4D6: MAb interferes with integrase binding to DNA [Haugan1995]
• 4D6: This MAb inhibits end processing and DNA joining, and reduces reintegration activity [Nilsen1996]
210 7-16 (7-19) Integrase (50–159) Integrase (50–159
HXB2)
no Vaccine murine (IgG2b)
Vaccine Vector/Type: chimeric maltose binding protein (MBP) Strain: IIIB HIV component: Integrase
Ab type Integrase catalytic core Donor Yoshihiro Kitamura, Div of Mol Genetics, Nat Inst of Infectious Diseases, Musashimurayama, Japan
References Ishikawa1999
• 7-16: Binds to the central catalytic domain – the paper seems to sometimes call this antibody 7-16, sometimes 7-19, a possible typo [Ishikawa1999]
211 4F6 Integrase (56–102) Integrase (56–102
HXB2)
CSPGIWQLDCTHLEGKVILVAVHVA-
SGYIEAEVIPAETGQETAYFLL
no Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein Strain: HXB2 HIV component: Integrase
Ab type Integrase catalytic core
References Haugan1995, Nilsen1996
• 4F6: MAb binding had minimal effects on IN in vitro activities [Nilsen1996]
• 4F6: MAb interferes with integrase binding to DNA [Haugan1995]
212 anti-K159 Integrase (151–163) Integrase (163–175) VESMNKELKKIIG Vaccine rabbit (IgG)
Vaccine Vector/Type: peptide HIV component: Integrase
ReferencesMaroun1999, Maksiutov2002
• anti-K159: Both the peptide K159, SQGVVESMNKELKKIIGQVRDQAEHLKTA, and the Abs raised against this peptide inhibit Integrase activity – K159
was found to fulfill condition of minimal number of helical heptads to achieve the formation of a stable coiled-coil structure – Integrase is proposed to
function as a dimer interacting in this region [Maroun1999]
• anti-K159: This epitope is similar to a fragment of the human protein Apoptosis regulator BCL-W (KIAA0271), ESVNKEMEPLVGQV [Maksiutov2002]
213 5D9 Integrase (186–250) Integrase (186–250
HXB2)
no Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein Strain: HXB2 HIV component: Integrase
Ab type Integrase DNA binding domain
References Nilsen1996
• 5D9: MAb binding had minimal effects on IN in vitro activities [Nilsen1996]
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• 5D9: While C-term and N-term anti-Integrase MAbs interfere with Integrase-DNA binding, 5D9 which binds more centrally, does not [Haugan1995]
214 8-6 Integrase (211–227) Integrase (211–227
HXB2)
KELQKQITKIQNFRVYY no Vaccine murine (IgG1)
Vaccine Vector/Type: chimeric maltose binding protein (MBP) Strain: IIIB HIV component: Integrase
Donor Yoshihiro Kitamura, Div of Mol Genetics, Nat Inst of Infectious Diseases, Musashimurayama, Japan
References Ishikawa1999
• 8-6: Antibody binds proximal to the DNA binding region [Ishikawa1999]
215 19 (2-19,
scAb2-19)
Integrase (228–236) Integrase (228–236 LAI) RDSRNPLWK no Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: Integrase
References Bizub-Bender1994, Levy-Mintz1996, Kitamura1999
• 19: BALBc mice were immunized with rec integrase, hybridomas expressing anti-integrase Abs were generated, and the antibodies characterized – 19 has a
low binding affinity [Bizub-Bender1994]
• 19: Called 2-19, scAb2-19 is a single-chain Ab made from MAb 2-19 –acts intra-cellularly to block infection at low MOI by binding to integrase – scAb
interfered with the folding of Gag-Pol polyprotein, the Ab did not affect viral production in LAI transfected cells, but the virus produced was less infectious
– authors suggest that the epitope may be conformational [Kitamura1999]
216 2-19 Integrase (228–236) Integrase (228–236
HXB2)
RDSRNPLWK no Vaccine murine (IgG2b)
Vaccine Vector/Type: chimeric maltose binding protein (MBP) Strain: IIIB HIV component: Integrase
Ab type Integrase DNA binding domain Donor Yoshihiro Kitamura, Div of Mol Genetics, Nat Inst of Infectious Diseases, Musashimurayama, Japan
References Ishikawa1999
• 2-19: MAb inhibits RT-Integrase interaction, and the terminal cleavage and strand transfer functions of Integrase, but not the disintegration activity
[Ishikawa1999]
217 8-22 Integrase (237–252) Integrase (237–252
HXB2)
GPAKLLWKGEGAVVIQ no Vaccine murine (IgG1)
Vaccine Vector/Type: chimeric maltose binding protein (MBP) Strain: IIIB HIV component: Integrase
Ab type Integrase DNA binding domain Donor Yoshihiro Kitamura, Div of Mol Genetics, Nat Inst of Infectious Diseases, Musashimurayama, Japan
References Ishikawa1999
• 8-22: MAb inhibits the terminal cleavage and strand transfer functions of Integrase, but not the disintegration activity [Ishikawa1999]
218 4-20 Integrase (253–261) Integrase (253–261
HXB2)
DNSDIKVVP no Vaccine murine (IgG1)
Vaccine Vector/Type: chimeric maltose binding protein (MBP) Strain: IIIB HIV component: Integrase
Ab type Integrase DNA binding domain Donor Yoshihiro Kitamura, Div of Mol Genetics, Nat Inst of Infectious Diseases, Musashimurayama, Japan
References Ishikawa1999
• 4-20: Inhibits the terminal cleavage and strand transfer functions of Integrase, but not the disintegration activity [Ishikawa1999]
219 6-19 Integrase (262–270) Integrase (261–270
HXB2)
RRKAKIIRD no Vaccine murine (IgG2b)
Vaccine Vector/Type: chimeric maltose binding protein (MBP) Strain: IIIB HIV component: Integrase
Ab type Integrase DNA binding domain Donor Yoshihiro Kitamura, Div of Mol Genetics, Nat Inst of Infectious Diseases, Musashimurayama, Japan
References Ishikawa1999
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• 6-19: Inhibits the terminal cleavage and strand transfer functions of Integrase, but not the disintegration activity [Ishikawa1999]
220 7C3 Integrase (262–271) Integrase (262–271
HXB2)
RRKAKIIRDY no Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein Strain: HXB2 HIV component: Integrase
References Haugan1995, Nilsen1996
• 7C3: MAb interferes with integrase binding to DNA [Haugan1995]
• 7C3: A set of three MAbs recognize an epitope in this region, 7C3, 7F11, and 8E5 – all three HIV-1 MAbs cross-react with HIV-2 IN – these MAbs inhibit
end-processing, DNA joining and reintegration, and had little effect on disintegration [Nilsen1996]
221 7F11 Integrase (262–271) Integrase (262–271
HXB2)
RRKAKIIRDY no Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein Strain: HXB2 HIV component: Integrase
References Nilsen1996, Lasky1987
• 7F11: A set of three MAbs recognize an epitope in this region, 7C3, 7F11, and 8E5 – all three HIV-1 MAbs cross-react with HIV-2 IN – these MAbs inhibit
end-processing, DNA joining and reintegration, and had little effect on disintegration [Nilsen1996]
• 7F11: There is another MAb with this name that binds to gp120 [Lasky1987]
222 8E5 Integrase (262–271) Integrase (262–271
HXB2)
RRKAKIIRDY no Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein Strain: HXB2 HIV component: Integrase
References Haugan1995, Nilsen1996
• 8E5: MAb interferes with integrase binding to DNA [Haugan1995]
• 8E5: A set of three MAbs recognize an epitope in this region, 7C3, 7F11, and 8E5 – all three HIV-1 MAbs cross-react with HIV-2 IN – these MAbs inhibit
end-processing, DNA joining and reintegration, and had little effect on disintegration [Nilsen1996]
223 MAb 35 Integrase (264–273) Integrase (264–273) KAKIIRDYGK no Vaccine murine (IgGκ)
Vaccine Vector/Type: recombinant protein HIV component: Integrase
References Barsov1996, Acel1998
• MAb 35: There appears to be two different IN Abs with similar names: MAb 35 and 35 [Barsov1996, Bizub-Bender1994]
• MAb 35: Although MAb 35 does not inhibit HIV-1 IN, Fab 35 inhibits 3’-end processing, strand transfer and disintegration [Barsov1996]
• MAb 35: Integrase was shown to have intrinsic DNA polymerase activity that can catalyze gap repair – MAb 35 inhibits this activity [Acel1998]
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224 12 Pol Integrase (1–58) no Vaccine murine (IgG2a)
Vaccine Vector/Type: recombinant protein HIV component: Integrase
References Bizub-Bender1994, Levy-Mintz1996
• 12: BALBc mice were immunized with rec integrase, hybridomas expressing anti-integrase Abs were generated, and the antibodies characterized – the Zn
finger motif is in the binding region – MAbs 12, 13 and 35 form a competition group [Bizub-Bender1994]
• 12: Used for the creation of single-chain variable antibody fragments (SFvs) for internal cellular expression – neutralization of IN activity prior to
integration, whether the Ab is expressed in the nucleolus or the cytoplasm – relative binding affinity to IN: 12 > 17 = 33 > 21 > 4 [Levy-Mintz1996]
225 13 Pol Integrase (1–58) no Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: Integrase
References Bizub-Bender1994
• 13: BALBc mice were immunized with rec integrase, hybridomas expressing anti-integrase Abs were generated, and the antibodies characterized – the Zn
finger motif is in the binding region – MAbs 12, 13 and 35 form a competition group [Bizub-Bender1994]
226 14 Pol Integrase (1–58) no Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: Integrase
References Bizub-Bender1994
• 14: BALBc mice were immunized with rec integrase, hybridomas expressing anti-integrase Abs were generated, and the antibodies characterized – the Zn
finger motif is in the binding region – MAbs 14 and 17 form a competition group [Bizub-Bender1994]
227 16 Pol Integrase no Vaccine murine (IgG2a)
Vaccine Vector/Type: recombinant protein HIV component: Integrase
References Bizub-Bender1994
• 16: BALBc mice were immunized with rec integrase, hybridomas expressing anti-integrase Abs were generated, and the antibodies characterized
[Bizub-Bender1994]
228 1C12B1 Pol RT (431–521) Vaccine murine
Vaccine Vector/Type: recombinant protein HIV component: RT
References Ferns1991
• 1C12B1: Recognized both p66 and p51 in Western blot, binds to C terminus [Ferns1991]
• 1C12B1: UK Medical Research Council AIDS reagent: ARP384
229 21 Pol Integrase (58–141) no Vaccine murine (IgG2b)
Vaccine Vector/Type: recombinant protein HIV component: Integrase
References Bizub-Bender1994, Levy-Mintz1996
• 21: BALBc mice were immunized with rec integrase, hybridomas expressing anti-integrase Abs were generated, and the antibodies characterized
[Bizub-Bender1994]
• 21: Used for the creation of single chain variable antibody fragments (SFvs) for internal cellular expression – neutralization of IN activity prior to
integration, whether the Ab is expressed in the nucleolus or the cytoplasm – relative binding affinity to IN: 12 > 17 = 33 > 21 > 4 [Levy-Mintz1996]
230 32 (mAb32,
Fab32)
Pol Integrase (223–266) no Vaccine murine (IgG2b)
Vaccine Vector/Type: recombinant protein HIV component: Integrase
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References Bizub-Bender1994, Yi2000a, Yi2002
• 32: BALBc mice were immunized with rec integrase, hybridomas expressing anti-integrase Abs were generated, and the antibodies characterized – MAbs
32 and 33 form a competition group [Bizub-Bender1994]
• 32: Limited proteolysis combined with mass spectrometric analysis indicates Fab32 binds to two strands of the beta sheet, beta1 223F, 224R, 226Y, and
228R and beta5 264K and 266K [Yi2000a]
• 32: Called mAb32 – mAb33 and mAb32 compete for binding to the C-term domain of Integrase – while mAb32 only weakly inhibits IN activity, mAb33
inhibits strongly, mAb32 has a lower affinity than mAb33, and Fab32 does not inhibit at all while Fab33 inhibits DNA binding a catalytic activity [Yi2002]
231 35 Pol Integrase (1–58) no Vaccine murine (IgG2b)
Vaccine Vector/Type: recombinant protein HIV component: Integrase
References Bizub-Bender1994
• 35: There appears to be two IN Abs with similar names: MAb 35 and 35 [Barsov1996, Bizub-Bender1994]
• 35: BALBc mice were immunized with rec integrase, hybridomas expressing anti-integrase Abs were generated, and the antibodies characterized – the Zn
finger motif is in the binding region – MAbs 12, 13 and 35 form a competition group [Bizub-Bender1994]
232 3D12 Pol RT Vaccine murine (IgG2a)
Vaccine Vector/Type: vaccinia HIV component: RT
References Chiba1997
• 3D12: There is an anti-Nef MAb that also has this name (see [Chiba1997])
233 3F10 Pol RT Vaccine murine (IgG2a)
Vaccine Vector/Type: vaccinia HIV component: RT
References Chiba1997
234 4 Pol Integrase (141–172) no Vaccine murine (IgG2b)
Vaccine Vector/Type: recombinant protein HIV component: Integrase
References Bizub-Bender1994, Levy-Mintz1996
• 4: There is another MAb with this ID that reacts with gp41 [Oldstone1991, Bizub-Bender1994]
• 4: BALBc mice were immunized with rec integrase, hybridomas expressing anti-integrase Abs were generated, and the antibodies characterized – 4 has a
low binding affinity [Bizub-Bender1994]
• 4: Used for the creation of single chain variable antibody fragments (SFvs) for internal cellular expression – neutralization of IN activity prior to
integration, whether the Ab is expressed in the nucleolus or the cytoplasm – relative binding affinity to IN: 12 > 17 = 33 > 21 > 4 [Levy-Mintz1996]
235 6B9 Pol RT Vaccine murine (IgG2a)
Vaccine Vector/Type: vaccinia HIV component: RT
References Chiba1997
236 7C4 Pol RT Vaccine murine (IgG1)
Vaccine Vector/Type: vaccinia HIV component: RT
References Chiba1997
• 7C4: Dose-dependent inhibition of polymerase activity of RT of strains IIIB, Bru and IMS-1, but not HIV-2 strains GH-1 or LAV-2 or SIV strains MAC or
MND [Chiba1997]
237 RT-4 Pol RT no murine (IgG2b)
References Li1993, Gu1996
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• RT-4: Increased nevirapine and delavirdine inhibition, no effect on AZT inhibition [Gu1996]
238 RT7O Pol RT (231–315) Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: RT
Donor B. Ferns and R. Tedder
References Ferns1991
• RT7O: Conformational epitope located centrally in the protein – inhibited RT enzyme activity and thus may bind close to the active site of the enzyme
[Ferns1991]
• RT7O: UK Medical Research Council AIDS reagent: ARP381
239 RT7U Pol RT (231–315) Vaccine murine
Vaccine Vector/Type: recombinant protein HIV component: RT
Donor B. Ferns and R. Tedder
References Ferns1991
• RT7U: Has a conformational epitope – reacts with p66 and p51 in WB [Ferns1991]
• RT7U: UK Medical Research Council AIDS reagent: ARP380
240 anti-HIV-1 RT Pol RT murine (IgG)
References diMarzo Veronese1986, Maciejewski1995, Wainberg1995
• anti-HIV-1 RT: Cloned heavy and light chains to express Fab intracellularly, preventing HIV infection in vitro – this MAb was broadly cross-reactive with
clinical strains and even HIV-2 [Maciejewski1995]
• Commentary on Maciejewski et al. [Wainberg1995]
241 polyclonal Pol p55 no Vaccine Rhesus macaque
Vaccine Vector/Type: virus-like particle HIV component: Pr55gag, anchored gp120, V3+CD4 linear domains
ReferencesWagner1998b
• A VLP is a non-infectious virus-like particle self-assembled from HIV Pr55 gag – macaques were immunized with VLPs bound to either gp120 or V3+CD4
linear domains – gag and env CTL specific CTL were stimulated in each case, and Ab response to gag and gp120 and was elicited, but the gp120
neutralizing response occurred only with whole gp120, not V3+CD4 – despite the CTL and Ab response, immunized macaques were infected by
intervenous challenge with SHIV chimeric challenge stock [Wagner1998b]
242 polyclonal Pol RT Vaccine murine
Vaccine Vector/Type: DNA HIV component: Gag, Pol, Vif, Env Adjuvant: B7, IL-12
References Kim1997b
• A gag/pol, vif or CMN160 DNA vaccine, when delivered in conjunction with the plasmid encoding the co-stimulatory molecules B7 and IL-12, gave a
dramatic increase in both the cytotoxic and proliferative responses in mice, as well as Ab response detected by ELISA [Kim1997b]
243 polyclonal Pol RT (203–219) Vaccine murine (IgA)
Vaccine Vector/Type: Salmonella HIV component: RT
References Burnett2000
• A live attenuated bacterial vaccine, Salmonella SL3261-pHART, with an inserted HIV RT gene fragment in the Lpp-OmpA-HIV fusion protein, induced a
lymphoproliferative Th response and fecal RT-specific IgA in BALB/c mice [Burnett2000]
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244 33 (mAb33,
Fab33, 33D5,
mab 33)
Pol Integrase (223–268
HXB2)
no Vaccine murine (IgG2b)
Vaccine Vector/Type: recombinant protein HIV component: Integrase
Ab type C-term
References Bizub-Bender1994, Levy-Mintz1996, Yi2000a, Yi2002
• 33: BALBc mice were immunized with rec integrase, hybridomas expressing anti-integrase Abs were generated, and the antibodies characterized – MAbs
32 and 33 form a competition group [Bizub-Bender1994]
• 33: Used for the creation of single chain variable antibody fragments (SFvs) for internal cellular expression – neutralization of IN activity prior to
integration, whether the Ab is expressed in the nucleolus or the cytoplasm – relative binding affinity to IN: 12 > 17 = 33 > 21 > 4 [Levy-Mintz1996]
• 33: Limited proteolysis combined with mass spectrometric analysis were used to define the binding site for Fab32, but Fab33 binding to the Intergrase
C-term domain left it resistant to proteolytic digestion [Yi2000a]
• 33: Called mAb33 – mAb33 and mAb32 compete for binding to the C-term domain of Integrase – while mAb32 only weakly inhibits IN activity, mAb33
inhibits strongly, mAb32 has a lower affinity than mAb33, and Fab32 does not inhibit at all while Fab33 inhibits catalytic activity and DNA binding –
heteronuclear NMR indicated eight residues of Integrase are immobilized upon Fab33 binding, two in the core of the protein, and 6 on the outer face that
form a contiguous patch likely to contain the epitope – 223F, 224R, 226Y, 244K, 267I, and 268I, which may be a useful target for drug design – the
Fab33-IN complex is far more soluble than IN alone and may be useful for crystallization [Yi2002]
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245 TG002 Vif (34–47) Vif (34–47) KARGWFYRHHYESP? no Vaccine murine
Vaccine Vector/Type: recombinant protein HIV component: Vif
Donor Transgene
• TG002: This MAb was raised in response to a rec Vif protein derived from E. coli
• TG002: NIH AIDS Research and Reference Reagent Program: 2746
246 TG001 Vif (176–192) Vif (176–192) KPQKTKGHRGSHTMNGH? no Vaccine murine
Vaccine Vector/Type: recombinant protein HIV component: Vif
Ab type C-term Donor Transgene
• TG001: This antibody was raised in response to a rec Vif protein derived from E. coli
• TG001: NIH AIDS Research and Reference Reagent Program: 2745
247 J4 Vif (HXB2) chimeric
rabbit/human FAb
References Goncalves2002
• J4: The authors developed a Vif-specific intrabody single-chain FAb fragment of J4 called 14BL – when expressed intracellularly in the cytoplasm this
intrabody efficiently bound Vif protein and neutralized its infectivity enhancing function – intrabody-expressing transduced cells were shown to be highly
refractory to challenge with the laboratory strain NL43 and with primary isolates strains of HIV-1 [Goncalves2002]
248 polyclonal Vif Vif Vaccine murine
Vaccine Vector/Type: DNA HIV component: Gag, Pol, Vif, Env Adjuvant: B7, IL-12
References Kim1997b
• A gag/pol, vif or CMN160 DNA vaccine, when delivered in conjunction with the plasmid encoding the co-stimulatory molecules B7 and IL-12, gave a
dramatic increase in both the cytotoxic and proliferative responses in mice, as well as an Ab response detected by ELISA [Kim1997b]
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249 NT3/2D1.1 Tat (2–15) Tat EPVDPNLEPWNHPS Vaccine murine (IgG1a)
Vaccine Vector/Type: peptide HIV component: Tat
Ab type N-term
References Dingwall1989
• NT3/2D1.1: Immunoprecipitates and immunoblots HIV-1 tat protein [Dingwall1989]
• NT3/2D1.1: UK Medical Research Council AIDS reagent: ARP352
250 1.2 Tat (2–17) Tat (1–16) EPVDPRLEWKHPGSQ
References Ovod1992, Ranki1995
• 1.2: Weak expression of Tat observed in HIV+ brain tissue sample, in contrast to Nef [Ranki1995]
251 1D9D5 Tat (2–21) Tat EPVDPRLEWKHPGSQPKTA Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: Tat
Ab type N-term
ReferencesMhashilkar1995, Valvatne1996
• 1D9D5: Single chain antibodies, intrabodies, were engineered that can be stably expressed in the cytoplasm of mammalian cells – co-expression of an
N-term intrabody can inhibit transactivation of an HIV LTR-CAT construct and block import into nucleus, but intrabody specific for exon 2 did not inhibit
activity [Mhashilkar1995]
• 1D9D5: Exogenously delivered Tat can efficiently transactivate an HIV-LTR-CAT construct in HeLa cells in the presence of 1D9D5, suggesting when
considered with the results of [Mhashilkar1995], that free Tat and not Ab bound is taken up by cells [Valvatne1996]
252 1D2F11 Tat (49–86) Tat RKKRRQRRRPPQGSQTHQVSLSKQP-
TSQSRGDPTGPKE
Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: Tat
Ab type C-term
References Valvatne1996
• 1D2F11: MAb did not bind shorter peptides – this MAb inhibited exogenously delivered Tat transactivation of an HIV-LTR-CAT construct in HeLa cells by
inhibition of cellular uptake of Tat [Valvatne1996]
253 2D9E7 Tat (49–86) Tat RKKRRQRRRPPQGSQTHQVSLSKQP-
TSQSRGDPTGPKE
Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: Tat
Ab type C-term
References Valvatne1996
• 2D9E7: MAb did not bind shorter peptides – this MAb inhibited exogenously delivered Tat transactivation of an HIV-LTR-CAT construct in HeLa cells by
inhibition of cellular uptake of Tat, but less efficiently than MAbs 1D2F11 or 4B4C4 [Valvatne1996]
254 4B4C4 (4B4) Tat (49–86) Tat RKKRRQRRRPPQGSQTHQVSLSKQP-
TSQSRGDPTGPKE
Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: Tat
Ab type C-term
References Valvatne1996, Jensen1997
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• 4B4C4: MAb did not bind shorter peptides – this MAb inhibited exogenously delivered Tat transactivation of an HIV-LTR-CAT construct in HeLa cells by
inhibition of cellular uptake of Tat [Valvatne1996]
255 5G7D8 Tat (49–86) Tat RKKRRQRRRPPQGSQTHQVSLSKQP-
TSQSRGDPTGPKE
Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: Tat
Ab type C-term
References Valvatne1996
• 5G7D8: MAb did not bind shorter peptides – this MAb inhibited exogenously delivered Tat transactivation of an HIV-LTR-CAT construct in HeLa cells by
inhibition of cellular uptake of Tat, but less efficiently than 1D2F11 or 4B4C4 [Valvatne1996]
256 NT2/4D5.24 Tat (73–86) Tat PTSQPRGDPTGPKE Vaccine murine
Vaccine Vector/Type: peptide HIV component: Tat
Ab type C-term
References Dingwall1989
• NT2/4D5.24: Immunoprecipitates and immunoblots HIV-1 tat protein [Dingwall1989]
257 L-anti-Tat Tat Tat L P (when
lipidated)
Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: Tat
Donor AGMED, Inc., Bedford, MA USA
References Cruikshank1997
• L-anti-Tat: Lipidated antibody can be taken up by cells and effectively block IIIB and primary virus HIV-1 replication in actively and latently infected cells
[Cruikshank1997]
258 2D9D5 Tat Tat Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein HIV component: Tat
Ab type C-term
ReferencesMhashilkar1995
• 2D9D5: Single chain antibodies, intrabodies, were engineered that can be stably expressed in the cytoplasm of mammalian cells – co-expression of C-term
intrabody did not inhibit transactivation of an HIV LTR-CAT construct, in contrast to MAb 1D9D5 [Mhashilkar1995]
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259 4G9 Rev (5–15) Rev (5–15) SGDSDEELIRT? Vaccine murine
Vaccine Vector/Type: recombinant protein HIV component: Rev
References Jensen1997
• 4G9: Mapped binding location by protein footprinting [Jensen1997]
260 Ab2 Rev (32–50) Rev (32–49 BRU) EGTRQARRNRRRWRERQR Vaccine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: Rev
Donor Tony Lowe and Jonathan Karn, MRC Center, Cambridge
References Henderson1997
• Ab2: The Ab2 binding site overlaps the nuclear localization signal – Ab2 binding to Rev was blocked by bound HIV RNA – the cellular protein
importin-beta can bind in this Arg rich region – atypically, the Rev binds specifically to importin-beta, but not to the importin-beta-importin-alpha dimer
[Henderson1997]
261 10.1 Rev (33–48) Rev (33–48) GTRQARRNRRRRWRER?
References Ovod1992, Ranki1994, Ranki1995, Maksiutov2002
• 10.1: Binds to the RRE binding site – polyclonal anti-Rev Ab detected Rev in astrocytes in 4/5 brain autopsy samples, but only one of these was positive
using 10.1, suggesting most Rev was bound to RRE [Ranki1995]
• 10.1: This epitope is similar to a fragment of the human protein Complement 4 (containing C4A anaphlylatoxin), GRRNRRRR [Maksiutov2002].
262 3H6 Rev (38–43) Rev (38–44) RRNRRR Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein HIV component: Rev
References Orsini1995, Maksiutov2002
• 3H6: There is another MAb with this ID that recognizes gp41 [Pinter1995]
• 3H6: Directed against nucleolar localization/RRE binding domain – antigenic domain tentative, MAb failed to bind a RRNRRR Rev deletion mutant
[Orsini1995]
• 3H6: This epitope is similar to a fragment of the human protein Complement 4 (containing C4A anaphlylatoxin), GRRNRRRR [Maksiutov2002].
263 8E7 Rev (70–84) Rev (70–84) PVPLQLPPLERLTLD Vaccine murine (IgG2aκ)
Vaccine Vector/Type: recombinant protein HIV component: Rev
References Kalland1994a, Kalland1994b, Szilvay1995, Jensen1997, Boe1998, Maksiutov2002
• 8E7: 8E7 worked in indirect immunofluorescence and also detected Rev in WB assays – used to detect localization of Rev in several compartments
including the nucleoli, nucleoplasm, perinuclear zone, and cytoplasm – Rev co-localized with host cell factors known to assemble on nascent transcripts –
Rev shuttles continuously between cytoplasmic and nucleoplasmic compartments [Kalland1994a, Kalland1994b, Szilvay1995]
• 8E7: Peptide interaction mapped to aa 70-84, 75-88 – protein footprint to 65-88 [Jensen1997]
• 8E7: HIV-1 RNA and Rev localize to the same region in the nucleoplasm, but the splicing factor SC-35 localizes in different speckles with the nucleoplasm
than Rev – intron containing beta-globin was distributed similarly to HIV-1, suggesting Rev and HIV-1 RNAs interact at putative sites of mRNA
transcriptions and splicing [Boe1998]
• 8E7: This epitope is similar fragments of the human protein Epidermal growth factor receptor substrate 15, EPVPMSLPPA, and Insulin-like growth factor
binding protein complex acid labile chain precursor, QPPGLERLWLEGNPWDCG [Maksiutov2002]
264 9G2
(9G2G4D6E8)
Rev (70–84) Rev (70–84) PVPLQLPPLERLTLD Vaccine murine (IgG2aκ)
Vaccine Vector/Type: recombinant protein HIV component: Rev
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Donor Anne Marie Szilvay
References Kalland1994a, Jensen1997, Maksiutov2002
• 9G2: Worked in indirect immunofluorescence and also detected Rev in WB assays – used to detect localization of Rev throughout the cell [Kalland1994a]
• 9G2: Peptide interaction mapped to aa 70-84, 75-88 – protein footprint to 65-88 [Jensen1997]
• 9G2: This epitope is similar fragments of the human protein Epidermal growth factor receptor substrate 15, EPVPMSLPPA, and Insulin-like growth factor
binding protein complex acid labile chain precursor, QPPGLERLWLEGNPWDCG [Maksiutov2002]
• 9G2: Called 9G2G4D6E8: UK Medical Research Council AIDS reagent: ARP3058
265 Ab4 Rev (72–91) Rev (72–91 BRU) PLQLPPLERLTLDCNEDCGT Vaccine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: Rev
Donor Tony Lowe and Jonathan Karn, MRC Center, Cambridge
References Henderson1997, Maksiutov2002
• Ab4: The binding site overlaps the nuclear export signal – binding was not blocked by bound HIV RNA and may be accessible for protein interaction
[Henderson1997]
• Ab4: This epitope is similar fragments of the human protein Epidermal growth factor receptor substrate 15, EPVPMSLPPA, and Insulin-like growth factor
binding protein complex acid labile chain precursor, QPPGLERLWLEGNPWDCG [Maksiutov2002]
266 3G4 Rev (90–116) Rev (90–116) GTSGTQGVGSPQILVESPTVLESGT-
KE?
Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein HIV component: Rev
References Orsini1995
• 3G4: Binds to a region that can be dispensed with and still retain Rev function [Orsini1995]
267 1G10
(IG10F4)
Rev (96–105) Rev (95–105) GVGSPQILVE Vaccine murine (IgG2bκ)
Vaccine Vector/Type: recombinant protein HIV component: Rev
Donor Anne Marie Szilvay
References Kalland1994a
• 1G10: Bound Rev in indirect immunofluorescence and also detected Rev in WB – used to detect localization of Rev throughout the cell [Kalland1994a]
• 1G10: Peptide interaction mapped to aa 91-105, 96-110 – protein footprint to aa 10-20, and 95-105 [Jensen1997]
• 1G10: Called IG10F4: UK Medical Research Council AIDS reagent: ARP3060
268 1G7 Rev (96–105) Rev (95–105) GVGSPQILVE Vaccine murine (IgG2bκ)
Vaccine Vector/Type: recombinant protein HIV component: Rev
References Kalland1994a, Jensen1997
• 1G7: Worked in indirect immunofluorescence and also detected Rev in WB – used to detect localization of Rev throughout the cell [Kalland1994a]
• 1G7: Peptide interaction mapped to aa 91-105, 96-110 – protein footprint to aa 95-105 [Jensen1997]
269 Ab3 Rev (102–116) Rev (102–116 BRU) ILVESPTVLESDKTE Vaccine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: Rev
Donor Tony Lowe and Jonathan Karn, MRC, Cambridge
References Henderson1997
• Ab3: This binding site is at the carboxy end of Rev – Ab3 binding was not blocked by bound HIV RNA [Henderson1997]
270 2G2 Rev Rev Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein HIV component: Rev
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References Orsini1995
• 2G2: Does not bind to any of a set of glutathione S-transferase (GST) Rev fusion proteins, or to Rev in a RIPA buffer, suggesting a conformational epitope
[Orsini1995]
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271 M85 gp160 (30–51) gp120 (30–51 LAI) ATEKLWVTVYYGVPVWKEATTT no Vaccine murine (IgG1)
Vaccine Vector/Type: protein HIV component: Env
Ab type C1 Donor Fulvia di Marzo Veronese
References diMarzo Veronese1992, Moore1994c, Moore1994d, Moore1996, Ditzel1997, Wyatt1997
• M85: Immunoblot and RIP reactive for strains IIIB, 451, MN, RF, and RUTZ – binds deglycosylated gp120 [diMarzo Veronese1992]
• M85: C1 domain – mutation 40 Y/D impairs binding – the relative affinity for denatured/native gp120 is < .01, suggesting conformational component
[Moore1994c]
• M85: Binding inhibited by MAb 4D4#85, enhanced by conformationally sensitive anti-V3 MAb 5G11, and some anti-18 MAbs [Moore1996]
• M85: Binds efficiently to sgp120 but not soluble gp120+gp41, suggesting its gp120 epitope is blocked by gp41 binding [Wyatt1997]
272 7E2/4 gp160 (31–50) gp120 (31–50 LAI) TEKLWVTVYYGVPVWKEATT Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein HIV component: Env
Ab type C1 Donor S. Ranjbar, NIBSC, UK
ReferencesMoore1994c, Maksiutov2002
• 7E2/4: C1 domain – the relative affinity for denatured/native gp120 is .07, suggesting conformational component [Moore1994c]
• 7E2/4: This epitope has a high degree of similarity with the platelet membrane glycoprotein IIIA precursor (GLIIIA) (integrin beta- 3) (CD61):
PLYKEATSTF [Maksiutov2002]
• 7E2/4: UK Medical Research Council AIDS reagent: ARP3050
273 4D4#85 gp160 (41–50) gp120 (LAI) GVPVWKEATT Vaccine murine (IgG)
Vaccine Strain: LAI HIV component: Env
Ab type C1 Donor S. Nigida and L. Arthur, NCI, Frederick, MD USA
ReferencesMoore1994c, Moore1994d, Moore1996, Wyatt1997, Binley1998, Maksiutov2002
• 4D4#85: C1 domain – the relative affinity, denatured/native gp120 is 0.1 – mutation 45 W/S impairs binding [Moore1994c]
• 4D4#85: Inhibits binding of C1 MAb M85, C1-C5 discontinuous epitope MAbs 181 and 212A, and CD4 binding induced MAbs 48d and 17b [Moore1996]
• 4D4#85: Binds efficiently to sgp120 but not soluble gp120+gp41, suggesting its gp120 epitope is blocked by gp41 binding – does not bind to HXBc2 gp120
if the 19 C-term amino acids, in conjunction with C1 positions 31-50, are deleted [Wyatt1997]
• 4D4#85: A panel of MAbs were shown to bind with similar or greater affinity and similar competition profiles to a deglycosylated or variable loop deleted
core gp120 protein ( Delta V1, V2, and V3), thus such a core protein produces a structure closely approximating full length folded monomer [Binley1998]
• 4D4#85: This epitope has a high degree of similarity with the platelet membrane glycoprotein IIIA precursor (GLIIIA) (integrin beta- 3) (CD61):
PLYKEATSTF [Maksiutov2002]
274 M92 gp160 (41–50) gp120 (31–50 LAI) GVPVWKEATT no Vaccine rat (IgG1)
Vaccine Vector/Type: protein HIV component: Env
Ab type C1 Donor Fulvia di Marzo Veronese
References diMarzo Veronese1992, Moore1994c, Moore1994d, Maksiutov2002
• M92: Immunoblot reactive, RIP negative, but precipitates deglycosylated gp120 – reacts with strains IIIB, 451, MN, RF, and RUTZ
[diMarzo Veronese1992]
• M92: The relative affinity for denatured/native gp120 is 1 [Moore1994c]
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• M92: This epitope has a high degree of similarity with the platelet membrane glycoprotein IIIA precursor (GLIIIA) (integrin beta- 3) (CD61):
PLYKEATSTF [Maksiutov2002]
275 M86 gp160 (42–61) gp120 (42–61 LAI) VPVWKEATTTLFCASDAKAY no Vaccine murine (IgG1)
Vaccine Vector/Type: protein HIV component: Env
Ab type C1 Donor Fulvia di Marzo Veronese
References diMarzo Veronese1992, Moore1994c, Maksiutov2002
• M86: Immunoblot and RIP reactive for strains IIIB, 451, MN, RF, and RUTZ – binds deglycosylated gp120 [diMarzo Veronese1992]
• M86: C1 domain – the relative affinity for denatured/native gp120 is 1 [Moore1994c]
• M86: This epitope has a high degree of similarity with the platelet membrane glycoprotein IIIA precursor (GLIIIA) (integrin beta- 3) (CD61):
PLYKEATSTF [Maksiutov2002]
276 polyclonal gp160 (52–71) Env (42–61 LAI) LFCASDAKAYDTEVHNVWAT no Vaccine murine
Vaccine Vector/Type: vaccinia HIV component: Env
Ab type C1
References Collado2000
• Vaccinia p14 can elicit NAbs and p39 tends to be immunodominant, so these two proteins were fused to regions of HIV-1 Env – reduced glycosylation was
noted when p14 or p39 was placed in the N-term region of the fusion protein – chimeric proteins shifted the Env Ab response from V3 to either a C1 or C4
domain, depending on the construct – all chimeric Env proteins: 14kEnv, 39kEnv, and Env39k elicited a strong Ab response to the C1 region of gp120
(LFCASDAKAYDTEVHNVWAT), and Env39k mounted a strong response to the C4 region (KAMYAPPISGQIRCSSNITG) [Collado2000]
277 133/237 gp160 (61–70) gp120 (51–70 LAI) YDTEVHNVWA L Vaccine murine (IgG1)
Vaccine Vector/Type: protein Strain: IIIB HIV component: gp120
Ab type C1
References Niedrig1992b, Moore1994c, Moore1994d
• 133/237: Region of overlap for reactive peptides is WATHA – weak neutralization of lab strains [Niedrig1992b]
• 133/237: The relative affinity, denatured/native gp120 is 1.4 – mutation of position 69 W/L impairs binding [Moore1994c]
278 133/290 gp160 (61–70) gp120 (61–70 LAI) YDTEVHNVWA L Vaccine murine (IgG1)
Vaccine Vector/Type: protein Strain: IIIB HIV component: gp120
Ab type C1
References Niedrig1992b, Thali1993, Moore1994c, Moore1994d, Wyatt1995, Binley1997a, Wyatt1997, Binley1998
• 133/290: Region of overlap for reactive peptides is WATHA – weak neutralization of lab strains [Niedrig1992b]
• 133/290: The relative affinity for denatured/native gp120 is 2.2 – mutation in position 69 W/L impairs binding [Moore1994c]
• 133/290: Used for antigen capture assay, either to bind gp120 to the ELISA plate, or to quantify bound gp120 [Wyatt1995]
• 133/290: Reciprocal binding inhibition with the antibody 522-149, that binds to a discontinuous epitope – binding is enhanced by some C5 and C1 binding
site antibodies [Moore1996]
• 133/290: Binds efficiently to sgp120 but not soluble gp120+gp41, suggesting its gp120 epitope is blocked by gp41 binding [Wyatt1997]
• 133/290: A panel of MAbs were shown to bind with similar or greater affinity and similar competition profiles to a deglycosylated or variable loop deleted
core gp120 protein ( Delta V1, V2, and V3), thus such a core protein produces a structure closely approximating full length folded monomer [Binley1998]
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• 133/290: A combination of gp41 fusion with the GNC4 trimeric sequences and disruption of the YU2 gp120-gp41 cleavage site resulted in stable gp140
trimers (gp140-GNC4) that preserve and expose some neutralizing epitopes while occluding some non-neutralizing epitopes – CD4BS MAbs (F105 and
F91) and CD4i (17b and 48d) recognized gp140-GNC4 as well as gp120 or gp140 – non-neutralizing MAbs C11, A32, 522-149, M90, and #45 bound to the
gp140-GNC4 glycoprotein at reduced levels compared to gp120 – MAbs directed at the extreme termini of gp120 C1 (135/9 and 133/290) and C5 (CRA-1
and M91) bound efficiently to gp140-GNC4 [Yang2000]
279 133/11 gp160 (64–78) gp120 (64–78) EVHNVWATHACVPTD L Vaccine murine (IgG1)
Vaccine Vector/Type: protein Strain: IIIB HIV component: gp120
Ab type C1
References Niedrig1992b
• 133/11: Region of overlap for reactive peptides is WATHA – weak neutralization of lab strains [Niedrig1992b]
280 D/3G5 gp160 (73–82) gp120 (73–82 LAI) ACVPTDPNPQ no Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp120
Ab type C1
References Bristow1994
• D/3G5: C1 MAb generated in a study of the humoral immune response to Baculovirus-expressed mis-folded rgp120 and rgp160 [Bristow1994]
281 D/6A11 gp160 (73–82) gp120 (73–82 LAI) ACVPTDPNPQ no Vaccine murine
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp120
Ab type C1
References Bristow1994
• D/6A11: C1 MAb generated in a study of the humoral immune response to Baculovirus-expressed mis-folded rgp120 and rgp160 [Bristow1994]
282 D/5E12 gp160 (73–92) gp120 (73–92 LAI) ACVPTDPNPQEVVLVNVTEN no Vaccine murine
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp120
Ab type C1
References Bristow1994
• D/5E12: C1 MAb generated in a study of the humoral immune response to Baculovirus-expressed mis-folded rgp120 and rgp160 [Bristow1994]
283 L5.1 gp160 (79–93) gp120 (89–103 IIIB) PNPQEVVLVNVTENF Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: gp160
Ab type C1
References Akerblom1990
284 4A7C6 gp160 (81–90) gp120 (81–90 LAI) PQEVVLVNVT Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein HIV component: Env
Ab type C1 Donor R. Tedder
References Thiriart1989, Thali1993, Moore1993a, Moore1994c, Moore1994d, Moore1996
• 4A7C6: Bound preferentially to denatured IIIB gp120 [Moore1993a]
• 4A7C6: The relative affinity for denatured/native gp120 is 7.9 – mutation 88 N/P impairs binding [Moore1994c]
• 4A7C6: C1 region epitope (88 N/P substitutions abrogates binding), but substitutions 380 G/F and 420 I/R also impaired binding [Moore1994d]
• 4A7C6: Reciprocal binding inhibition with the antibody 133/192 – enhanced by anti-C5 antibodies, and C1 antibody 135/9 [Moore1996]
• 4A7C6: UK Medical Research Council AIDS reagent: ARP 360
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285 1D10 gp160 (81–100) gp120 (81–100 LAI) PQEVVLVNVTENFDMWKNDM L Vaccine rat
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp120
Ab type C1
References Dowbenko1988, Berman1991, Nakamura1992, Moore1994c
• 1D10: Cross-blocks 5B3 in IIIB-rsgp160 ELISA – type specific in rgp120 ELISA binding [Nakamura1992]
• 1D10: The relative affinity for denatured/native gp120 is 13 – mutation 88 N/P impairs binding [Moore1994c]
286 B242 gp160 (83–92) gp120 (83–92 LAI) EVVLVNVTEN no Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: NL43 HIV component: gp160
Ab type C1
References Bristow1994
• B242: C1 MAb generated in a study of the humoral immune response to Baculovirus-expressed mis-folded rgp160 IIIB:NL43, MicroGenSys [Bristow1994]
287 133/192 gp160 (91–100) gp120 (91–100 LAI) ENFDMWKNDM L Vaccine murine (IgG1)
Vaccine Vector/Type: protein Strain: IIIB HIV component: gp120
Ab type C1 DonorMatthias Niedrig
References Niedrig1992b, Moore1993c, Moore1994c, Moore1996, Trkola1996a, Binley1997a, Binley1998
• 133/192: Epitope seems complex, binds multiple peptides – weak neutralization of lab strain [Niedrig1992b]
• 133/192: The relative affinity for denatured/native gp120 is 1.8 [Moore1994c]
• 133/192: C1 region – substitutions 76P/Y, 113 D/A or R, 117 K/W, 420 I/R, 427 W/S impair binding, other substitutions enhanced binding [Moore1994d]
• 133/192: Reciprocal binding inhibition with the antibody 4A7C6 – enhanced by some anti-C5 and-C1 antibodies [Moore1996]
• 133/192: Does not neutralize JR-FL nor block gp120 interaction with CCR-5 in a MIP-1beta-CCR-5 competition study [Trkola1996a]
• 133/192: A panel of MAbs were shown to bind with similar or greater affinity and similar competition profiles to a deglycosylated or variable loop deleted
core gp120 protein ( Delta V1, V2, and V3), thus such a core protein produces a structure closely approximating full length folded monomer [Binley1998]
288 489.1(961) gp160 (91–100) gp120 (91–100 LAI) ENFDMWKNDM Vaccine murine (IgG)
Vaccine Strain: LAI HIV component: Env
Ab type C1 Donor C. Bruck, SKB, Belgium
ReferencesMoore1994c
• 489.1(961): The relative affinity for denatured/native gp120 is 1 [Moore1994c]
• 489.1(961): NIH AIDS Research and Reference Reagent Program: 961
289 5B3 gp160 (91–100) gp120 (91–100 LAI) ENFDMWKNDM no Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp160
Ab type C1
References Berman1991, Nakamura1992, Beretta1994, Moore1994c
• 5B3: Blocks gp120 -CD4 binding [Berman1991]
• 5B3: Cross-blocks 1D10 in competitive IIIB-rsgp160 ELISA – no neutralization – blocks IIIB-gp120 sCD4 binding – localized binding to residues 72-106
[Nakamura1992]
• 5B3: The relative affinity of denatured/native gp120 is 8.3 [Moore1994c]
290 B10 gp160 (91–100) gp120 (91–100 LAI) ENFDMWKNDM Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
Ab type C1
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References Abacioglu1994, Moore1994c
• B10: C1 region – epitope boundaries mapped by peptide scanning, FNMW core [Abacioglu1994]
• B10: The relative affinity for denatured/native gp120 is 0.4 [Moore1994c]
• B10: There is FNM/FDM polymorphism in LAI-based peptides, and N is essential (J. P. Moore, per. comm.)
291 B2 gp160 (91–100) gp120 (91–100 LAI) ENFDMWKNDM Vaccine murine (IgG2b)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
Ab type C1
References Thali1993, Abacioglu1994, Moore1994c, Moore1994d, Binley1997a
• B2: C1 region – epitope boundaries mapped by peptide scanning, FNMW core [Abacioglu1994]
• B2: The relative affinity for denatured/native gp120 is 1.4 [Moore1994c]
• B2: There is FNM/FDM polymorphism in LAI-based peptides, and N is essential (J. P. Moore, per. comm.)
292 C6 (Ch6) gp160 (91–100) gp120 (91–100 LAI) ENFDMWKNDM Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
Ab type C1
References Pincus1993a, Abacioglu1994, Moore1994c, Pincus1996
• C6: C1 region – epitope boundaries mapped by peptide scanning, FNMW core [Abacioglu1994]
• C6: The relative affinity for denatured/native gp120 is 0.9 [Moore1994c]
• C6: There is FNM/FDM polymorphism in LAI-based peptides – N is essential (J. P. Moore, per. comm.)
• C6: Called Ch6 – binds to gp120 but not to infected cells – when linked to ricin A, the immunotoxin did not mediate cell killing – sCD4 has no effect
[Pincus1993a, Pincus1996]
• C6: NIH AIDS Research and Reference Reagent Program: 810
293 MF49.1 gp160 (91–100) gp120 (91–100 LAI) ENFDMWKNDM Vaccine murine (IgG)
Vaccine Strain: LAI HIV component: Env
Ab type C1
References Thiriart1989, Moore1994c
• MF49.1: The relative affinity of denatured/native gp120 is 3.8 [Moore1994c]
294 T1.1 gp160 (91–100) gp120 (91–100 LAI) ENFDMWKNDM Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia HIV component: gp160
Ab type C1
References Akerblom1990, Broliden1990, Moore1994c
• T1.1: Also reacted in solid phase with gp120(234-248) NGTGPCTNVSTQCT [Akerblom1990]
• T1.1: No ADCC activity – reactive peptide: NVTENFNMWKNDMVEQ, IIIB [Broliden1990]
• T1.1: C1 region – the relative affinity for denatured/native gp120 is 1 [Moore1994c]
295 T7.1 gp160 (91–100) gp120 (91–100 LAI) ENFDMWKNDM Vaccine murine (IgG)
Vaccine Strain: LAI HIV component: Env
Ab type C1
References Akerblom1990, Bolmstedt1990, Moore1994c, Moore1994d
• T7.1: The relative affinity of denatured/native gp120 is 4.0 [Moore1994c]
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296 T9 gp160 (91–100) gp120 (91–100 LAI) ENFDMWKNDM Vaccine murine (IgG)
Vaccine Strain: LAI HIV component: Env
Ab type C1 Donor Lennart Akerblom, Britta Wahren and Jorma Hinkula
References Akerblom1990, Bolmstedt1990, Moore1994c, Moore1994d, Binley1997a
• T9: There are two HIV-Abs with the name T9, one binds to gp41, one to gp120
• T9: The relative affinity of denatured/native gp120 is 7.9 [Moore1994c]
• T9: Binds to the C1 region – 45 W/S, 88 N/P, 256 S/Y, 262 N/T, 475 M/S, 485 1.83, and 491 I/F enhanced binding, no substitution tested significantly
inhibited [Moore1994d]
297 GV4D3 gp160 (92–100) gp120 (92–100 IIIB) NFNMWKNDM Vaccine murine
Vaccine Vector/Type: protein-Ab complex HIV component: gp120 complexed with MAb M77
Ab type C1 Donor Patricia Earl and Christopher Broder, NIH
References Denisova1996
• GV4D3: When anti-V3 MAb M77 was bound to gp120 and used as an immunogen, it stimulated many MAbs to linear epitopes – MAbs GV4H4 and
GV5F9 are homologous to GV4D3 and were generated in the same experiment [Denisova1996]
298 B27 gp160 (93–96) gp120 (94–97 BH10) FNMW no Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: NL43 HIV component: gp160
Ab type C1
References Abacioglu1994, Bristow1994
• B27: C1 region – epitope boundaries mapped by peptide scanning [Abacioglu1994]
• B27: C1 MAb generated in a study of the humoral immune response to Baculovirus-expressed mis-folded rgp160 IIIB:NL43, MicroGenSys [Bristow1994]
299 B9 gp160 (93–96) gp120 (93–96 LAI) FNMW Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
Ab type C1
References Abacioglu1994
• B9: Binds C1 region – epitope boundaries mapped by peptide scanning [Abacioglu1994]
300 B35 gp160 (93–98) gp120 (94–99 BH10) FNMWKN Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
Ab type C1
References Abacioglu1994
• B35: C1 region – epitope boundaries mapped by peptide scanning [Abacioglu1994]
301 D/4B5 gp160 (93–101) gp120 (93–101 LAI) FNMWKNDMV no Vaccine murine
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp120
Ab type C1
References Bristow1994
• D/4B5: C1 MAb generated in a study of the humoral immune response to Baculovirus-expressed mis-folded rgp120 and rgp160 [Bristow1994]
302 D/5A11 gp160 (93–101) gp120 (93–101 LAI) FNMWKNDMV no Vaccine murine
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp120
Ab type C1
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References Bristow1994
• D/5A11: C1 MAb generated in a study of the humoral immune response to Baculovirus-expressed mis-folded rgp120 and rgp160 [Bristow1994]
303 D/6B2 gp160 (93–101) gp120 (93–101 LAI) FNMWKNDMV no Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp120
Ab type C1
References Bristow1994
• D/6B2: C1 MAb generated in a study of the humoral immune response to Baculovirus-expressed mis-folded rgp120 and rgp160 [Bristow1994]
304 B18 gp160 (101–110) gp120 (101–110 LAI) VEQMHEDIIS Vaccine murine (IgG2a)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
Ab type C1
References Abacioglu1994, Moore1994c
• B18: C1 region – epitope boundaries mapped by peptide scanning, HEDII core [Abacioglu1994]
• B18: The relative affinity for denatured/native gp120 is 1 [Moore1994c]
305 B20 gp160 (101–110) gp120 (101–110 LAI) VEQMHEDIIS Vaccine murine (IgG2a)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
Ab type C1
References Abacioglu1994, Moore1994c
• B20: C1 region – epitope boundaries mapped by peptide scanning – HEDII core [Abacioglu1994]
• B20: The relative affinity for denatured/native gp120 is 1 [Moore1994c]
306 MF39.1 (39.1) gp160 (101–110) gp120 (101–110 LAI) VEQMHEDIIS Vaccine murine (IgG)
Vaccine Strain: LAI HIV component: Env
Ab type C1
References Thiriart1989, Cook1994, Moore1994c
• MF39.1: Called 39.1, and is probably the same as MF39.1 – MAbs against the glycosphingolipid GalCer block HIV infection of normally susceptible CD4
negative cells from the brain and colon – MAbs against the N-terminal half of gp120 do not inhibit gp120 binding to GalCer – binding of GalCer to gp120
does not inhibit MAb binding [Cook1994]
• MF39.1: The relative affinity of denatured/native gp120 is 30 [Moore1994c]
307 187.2.1
(187.1)
gp160 (101–120) gp120 (101–120 LAI) VEQMHEDIISLWDQSLKPCV Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein HIV component: Env
Ab type C1 Donor Claudine Bruck and Clothilde Thiriart
References Thiriart1989, Moore1993a, Cook1994, Moore1994c, Moore1994d
• 187.2.1: Called 187.1, and is probably the same as 187.2.1 – bound preferentially to denatured IIIB gp120 [Moore1993a]
• 187.2.1: Called 187.1, and is probably the same as 187.2.1 – MAbs against the glycosphingolipid GalCer block HIV infection of normally susceptible CD4
negative cells from the brain and colon – MAbs against the N-terminal half of gp120 do not inhibit gp120 binding to GalCer – binding of GalCer to gp120
does not inhibit MAb binding [Cook1994]
• 187.2.1: The relative affinity for denatured/native gp120 is 7 – mutations 113 D/A (not D/R) and 117 K/W impair binding [Moore1994c]
• 187.2.1: UK Medical Research Council AIDS reagent: ARP332
308 37.1.1(ARP
327) (37.1)
gp160 (101–120) gp120 (101–120 LAI) VEQMHEDIISLWDQSLKPCV Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein HIV component: Env
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Ab type C1 Donor Claudine Bruck
References Thiriart1989, Moore1993a, Moore1994c
• 37.1.1: Called 37.1 – bound preferentially to denatured IIIB gp120 [Moore1993a]
• 37.1.1: The relative affinity for denatured/native gp120 is 8.6 – mutations 113 D/R (not D/A) and 117 K/W impair binding [Moore1994c]
• 37.1.1: UK Medical Research Council AIDS reagent: ARP327
309 6D8 gp160 (101–120) gp120 (101–120 LAI) VEQMHEDIISLWDQSLKPCV Vaccine rat
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp120
Ab type C1
References Dowbenko1988, Nakamura1992, Moore1994c
• 6D8: Highly cross reactive with multiple stains by rgp120 ELISA [Nakamura1992]
• 6D8: The relative affinity for denatured/native gp120 is 15 – mutations 113 D/R and 113 D/A impair binding [Moore1994c]
310 M96 gp160 (101–120) gp120 (101–120 LAI) VEQMHEDIISLWDQSLKPCV no Vaccine rat (IgG2a)
Vaccine Vector/Type: protein HIV component: Env
Ab type C1 Donor Fulvia di Marzo Veronese
References diMarzo Veronese1992, Moore1994c, Moore1994d
• M96: Immunoblot reactive for strains IIIB, 451, MN, RF, and RUTZ [diMarzo Veronese1992]
• M96: C1 region – the relative affinity for denatured/native gp120 is 6 [Moore1994c]
311 MF119.1 gp160 (101–120) gp120 (101–120 LAI) VEQMHEDIISLWDQSLKPCV Vaccine murine (IgG)
Vaccine Strain: LAI HIV component: Env
Ab type C1
References Thiriart1989, Moore1994c
• MF119.1: The relative affinity for denatured/native gp120 is 30 – mutations 113 D/A, 113 D/R, and 117 K/W impair binding [Moore1994c]
312 MF4.1 gp160 (101–120) gp120 (101–120 LAI) VEQMHEDIISLWDQSLKPCV Vaccine murine (IgG)
Vaccine Strain: LAI HIV component: Env
Ab type C1
References Thiriart1989, Moore1994c
• MF4.1: The relative affinity for denatured/native gp120 is 8 [Moore1994c]
313 MF53.1 gp160 (101–120) gp120 (101–120 LAI) VEQMHEDIISLWDQSLKPCV Vaccine murine (IgG)
Vaccine Strain: LAI HIV component: Env
Ab type C1
References Thiriart1989, Moore1994c
• MF53.1: The relative affinity for denatured/native gp120 is 10 [Moore1994c]
314 MF58.1 gp160 (101–120) gp120 (101–120 LAI) VEQMHEDIISLWDQSLKPCV Vaccine murine (IgG)
Vaccine Strain: LAI HIV component: Env
Ab type C1
References Thiriart1989, Moore1994c
315 MF77.1 gp160 (101–120) gp120 (101–120 LAI) VEQMHEDIISLWDQSLKPCV Vaccine murine (IgG)
Vaccine Strain: LAI HIV component: Env
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Ab type C1
References Thiriart1989, Moore1994c
• MF77.1: The relative affinity for denatured/native gp120 is 11 [Moore1994c]
316 T2.1 gp160 (101–120) gp120 (101–120 LAI) VEQMHEDIISLWDQSLKPCV Vaccine murine (IgG)
Vaccine Strain: LAI HIV component: Env
Ab type C1 Donor Lennart Akerblom, Britta Wahren and Jorma Hinkula
References Akerblom1990, Bolmstedt1990, Moore1994c, Moore1994d
• T2.1: The relative affinity for denatured/native gp120 is .27 – mutations 113 D/R, 106 E/A, and 117 D/A impair binding [Moore1994c]
317 11/65
(11/65a/5h)
gp160 (102–121) gp120 (311–321
HXB10)
EQMHEDIISLWDQSLKPCVK Vaccine rat (IgG2b)
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: gp120
Ab type C1
ReferencesMcKeating1992a, McKeating1993b, Peet1998
• 11/65: Binds only soluble gp120, not virion bound – used to quantify gp120 shedding – (numbering is incorrect in original?) [McKeating1992a]
• 11/65: Called 11/65a/5h – The most variable amino acids in the V3 loop were replaced with serines to make the immunodominant V3 loop less
immunogenic – these changes did not affect the ability of sCD4 or MAbs to V1/V2, C1 and C4 to bind – 11/65 was not affected by V3 serine substitutions –
mice injected with serine substituted gp120 had a reduced response relative to wildtype, and no enhanced immunogenicity of conserved regions [Peet1998]
• 11/65: UK Medical Research Council AIDS reagent: ARP3076
318 W1 gp160 (102–121) gp120 (102–121 LAI) EQMHEDIISLWDQSLKPCVK Vaccine murine (IgG)
Vaccine Strain: LAI HIV component: Env
Ab type C1 Donor D. Weiner, U. Penn.
ReferencesMoore1994c
• W1: The relative affinity for denatured/native gp120 is 6 – mutations 113 D/A, 113 D/R, and 117 K/W impair binding [Moore1994c]
319 T11 gp160 (102–125) gp120 (102–125) EQMHEDIISLWDQSLKPCVKLTPL Vaccine murine
Vaccine Vector/Type: recombinant protein HIV component: oligomeric gp140
Ab type C1 Donor R. Doms, Univ. of Pennsylvania
References Earl1994, Jagodzinski1996
• T11: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• T11: The sulfated polysaccharide, curdlan sulfate (CRDS), binds to the Envelope of T-tropic viruses and neutralizes virus – deletion of the V3 loop from
gp120 results in more potent T11 inhibition by CRDS [Jagodzinski1996]
320 GV1A8 gp160 (105–113) gp120 (105–113 IIIB) HEDIISLWD Vaccine murine
Vaccine Vector/Type: protein-Ab complex HIV component: gp120 complexed with MAb M77
Ab type C1
References Denisova1996
• GV1A8: When anti-V3 MAb M77 was bound to gp120 and used as an immunogen, it stimulated many MAbs to linear epitopes – MAbs GV7A4 and
GV5H5 are homologous to GV1A8 and were generated in the same experiment [Denisova1996]
321 11 gp160 (111–120) gp120 (101–120 LAI) LWDQSLKPCV Vaccine murine (IgG)
Vaccine Strain: LAI HIV component: Env
Ab type C1
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References Thiriart1989, Moore1994c
• 11: The relative affinity for denatured/native gp120 is 7.8 – mutation 113 D/R impairs binding [Moore1994c]
322 12G10 gp160 (111–120) gp120 (101–120 LAI) LWDQSLKPCV Vaccine murine (IgG)
Vaccine Strain: LAI HIV component: Env
Ab type C1
References Thiriart1989, Moore1994c
• 12G10: The relative affinity for denatured/native gp120 is 17 – mutation 117 K/W impairs binding [Moore1994c]
323 135/9
(87-135/9)
gp160 (111–120) gp120 (111–120 LAI) LWDQSLKPCV L Vaccine murine (IgG1)
Vaccine Vector/Type: protein Strain: IIIB HIV component: gp120
Ab type C1 DonorMatthias Niedrig
References Niedrig1992b, Moore1994c, Moore1994d, Moore1996, Trkola1996a, Binley1997a, Kropelin1998, Yang2000
• 135/9: Defines the epitope as gp120(114-123) MHEDIISLWD (core LWD?) – weak neutralization of lab strain [Niedrig1992b]
• 135/9: The relative affinity for denatured/native gp120 is 15 – mutation 113 D/R impairs binding to native and denatured, 113 D/A only to denatured
[Moore1994c]
• 135/9: Substitutions 106 E/A, 113 D/A or R, and 117 K/W impair binding, some substitutions enhance binding [Moore1994d]
• 135/9: Binding is enhanced by some anti-C1 and anti-C5 antibodies – enhances binding of some anti-V3, anti-C4 and anti-V2 MAbs – 135/9 binds to
predicted alpha-helix in C1 [Moore1996]
• 135/9: Does not neutralize JR-FL nor block gp120 interaction with CCR-5 in a MIP-1beta-CCR-5 competition study [Trkola1996a]
• 135/9: A panel of MAbs were shown to bind with similar or greater affinity and similar competition profiles to a deglycosylated or variable loop deleted
core gp120 protein ( Delta V1, V2, and V3), thus such a core protein produces a structure closely approximating full length folded monomer [Binley1998]
• 135/9: Noted to bind to C1 peptide HEDIISLWDQSLK – blocks gp120 interaction with CD4+ cells – blocking activity is additive when combined with
antibodies which bind in the C4 region of gp120 (F105, 388/389, and b12) [Kropelin1998]
• 135/9: A combination of gp41 fusion with the GNC4 trimeric sequences and disruption of the YU2 gp120-gp41 cleavage site resulted in stable gp140
trimers (gp140-GNC4) that preserve and expose some neutralizing epitopes while occluding some non-neutralizing epitopes – CD4BS MAbs (F105 and
F91) and CD4i (17b and 48d) recognized gp140-GNC4 as well as gp120 or gp140 – non-neutralizing MAbs C11, A32, 522-149, M90, and #45 bound to the
gp140-GNC4 glycoprotein at reduced levels compared to gp120 – MAbs directed at the extreme termini of gp120 C1 (135/9 and 133/290) and C5 (CRA-1
and M91) bound efficiently to gp140-GNC4 [Yang2000]
324 7C10 gp160 (111–120) gp120 (101–120 LAI) LWDQSLKPCV Vaccine murine (IgG)
Vaccine Strain: LAI HIV component: Env
Ab type C1
References Thiriart1989, Moore1994c
• 7C10: The relative affinity for denatured/native gp120 is 5.8 – mutation 117 K/W impairs binding [Moore1994c]
325 C4 gp160 (111–120) gp120 (101–120 LAI) LWDQSLKPCV Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
Ab type C1 Donor George Lewis
References Abacioglu1994, Moore1993a, Moore1994c
• C4: Bound preferentially to denatured IIIB gp120 [Moore1993a]
• C4: C1 region – epitope boundaries mapped by peptide scanning, BH10 core IISLW [Abacioglu1994]
• C4: The relative affinity for denatured/native gp120 is 10 [Moore1994c]
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326 MF46.1 gp160 (111–120) gp120 (101–120 LAI) LWDQSLKPCV Vaccine murine (IgG)
Vaccine Strain: LAI HIV component: Env
Ab type C1
References Thiriart1989, Moore1994c
• MF46.1: The relative affinity for denatured/native gp120 is 8.5 [Moore1994c]
327 6D5 gp160 (122–141) gp120 (122–141 LAI) LTPLCVSLKCTDLKNDTNTN Vaccine murine (IgG)
Vaccine Strain: LAI HIV component: Env
Ab type V2 Donor S. Nigida and L. Arthur, NCI, Frederick, MD USA
ReferencesMoore1994c, Moore1994d
• 6D5: The relative affinity for denatured/native gp120 is 15 – mutations Delta119-205 and 125 L/G impair binding [Moore1994c]
328 B33 gp160 (123–142) gp120 (123–142 LAI) TPLCVSLKCTDLGNATNTNS no Vaccine murine (IgG2bκ)
Vaccine Vector/Type: recombinant protein Strain: NL43 HIV component: gp160
Ab type V2 Donor Daniels
References Abacioglu1994, Bristow1994
• B33: There are two MAbs in the literature named B33, see also gp160(727-734) [Abacioglu1994]
• B33: Epitope boundaries mapped by peptide scanning [Abacioglu1994]
• B27: C1 MAb generated in a study of the humoral immune response to Baculovirus-expressed mis-folded rgp160 IIIB:NL43, MicroGenSys [Bristow1994]
• B33: UK Medical Research Council AIDS reagent: ARP304, gp160/41 binding
329 polyclonal
(VEI1)
gp160 (131–151) Env (131–151) CTDLKNDTNTNSSSGRMMMEK HIV-1 infection human
References Carlos1999
• Antibody response to the epitopes in a vaccine construct (VEI) containing peptides from 5 hypervariable regions of gp120 was detected in the sera of HIV-1
positive subjects, including sera from 6 non-subtype B infections – serum samples from San Francisco, Canada and Puerto Rico cohort showed presence of
antibodies against all five VEI hypervariable regions, but most consistently against the V3 region peptide NNNTRKSIRIGPGRAFYTTGDIGNIRQ
[Carlos1999]
330 35D10/D2 gp160 (139–155) gp120 NTKSSNWKEMDGEIK L Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Ab type V1 Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 35D10/D2: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2kappa MAbs were used to rapidly
create a panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120 – several of the MAbs obtained were effective at
neutralizing the autologous strain – C-term-V1- region was immunodominant in these mice and the ten V1-specific MAbs could potently neutralize
autologous strain SF162 but were highly type specific [He2002]
331 40H2/C7 gp160 (139–155) gp120 NTKSSNWKEMDGEIK L Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Ab type V1 Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
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• 40H2/C7: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2kappa MAbs were used to rapidly
create a panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120 – several of the MAbs obtained were effective at
neutralizing the autologous strain – C-term-V1- region was immunodominant in these mice and the ten V1-specific MAbs could potently neutralize
autologous strain SF162 but were highly type specific [He2002]
332 43A3/E4 gp160 (139–155) gp120 NTKSSNWKEMDGEIK Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Ab type V1 Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 43A3/E4: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2kappa MAbs were used to rapidly create
a panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120 – several of the MAbs obtained were effective at
neutralizing the autologous strain – C-term-V1- region was immunodominant in these mice and the ten V1-specific MAbs could potently neutralize
autologous strain SF162 but were highly type specific [He2002]
333 43C7/B9 gp160 (139–155) gp120 NTKSSNWKEMDGEIK L Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Ab type V1 Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 43C7/B9: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2kappa MAbs were used to rapidly create
a panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120 – several of the MAbs obtained were effective at
neutralizing the autologous strain – C-term-V1- region was immunodominant in these mice and the ten V1-specific MAbs could potently neutralize
autologous strain SF162 but were highly type specific [He2002]
334 45D1/B7 gp160 (139–155) gp120 NTKSSNWKEMDGEIK L Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Ab type V1 Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 45D1/B7: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2kappa MAbs were used to rapidly
create a panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120 – several of the MAbs obtained were effective at
neutralizing the autologous strain – C-term-V1- region was immunodominant in these mice and the ten V1-specific MAbs could potently neutralize
autologous strain SF162 but were highly type specific [He2002]
335 46E3/E6 gp160 (139–155) gp120 NTKSSNWKEMDGEIK Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Ab type V1 Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
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• 46E3/E6: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2kappa MAbs were used to rapidly create
a panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120 – several of the MAbs obtained were effective at
neutralizing the autologous strain – C-term-V1- region was immunodominant in these mice and the ten V1-specific MAbs could potently neutralize
autologous strain SF162 but were highly type specific [He2002]
336 58E1/B3 gp160 (139–155) gp120 NTKSSNWKEMDGEIK L Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Ab type V1 Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 58E1/B3: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2kappa MAbs were used to rapidly create
a panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120 – several of the MAbs obtained were effective at
neutralizing the autologous strain – C-term-V1- region was immunodominant in these mice and the ten V1-specific MAbs could potently neutralize
autologous strain SF162 but were highly type specific [He2002]
337 64B9/A6 gp160 (139–155) gp120 NTKSSNWKEMDGEIK L Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Ab type V1 Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 64B9/A6: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2kappa MAbs were used to rapidly
create a panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120 – several of the MAbs obtained were effective at
neutralizing the autologous strain – C-term-V1- region was immunodominant in these mice and the ten V1-specific MAbs could potently neutralize
autologous strain SF162 but were highly type specific [He2002]
338 69D2/A1 gp160 (139–155) gp120 NTKSSNWKEMDGEIK L Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Ab type V1 Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 69D2/A1: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2kappa MAbs were used to rapidly
create a panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120 – several of the MAbs obtained were effective at
neutralizing the autologous strain – C-term-V1- region was immunodominant in these mice and the ten V1-specific MAbs could potently neutralize
autologous strain SF162 but were highly type specific [He2002]
339 82D3/C3 gp160 (139–155) gp120 NTKSSNWKEMDGEIK Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Ab type V1 Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
627
DEC 2002
B
C
el
l
HIV Antibodies Tables gp160 Antibodies
No. MAb ID HXB2 Location Author’s Location Sequence Neutralizing Immunogen Species(Isotype)
References He2002
• 82D3/C3: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2kappa MAbs were used to rapidly
create a panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120 – several of the MAbs obtained were effective at
neutralizing the autologous strain – C-term-V1- region was immunodominant in these mice and the ten V1-specific MAbs could potently neutralize
autologous strain SF162 but were highly type specific [He2002]
340 2H1B gp160 (155–161) gp120 (370–376
HIV2ROD)
RNISFKA no Vaccine murine
Vaccine Vector/Type: peptide Strain: HIV-2 ROD
Ab type C3
ReferencesMatsushita1995
• 2H1B: Binds in WB, but binds poorly to Env on the cell surface [Matsushita1995]
341 697-D (697D,
697-30D)
gp160 (161–180) gp120 (161–180 IIIB) ISTSIRGKVQKEYAFFYKLD P (weak) HIV-1 infection human (IgG1λ )
Ab type V2 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center) or Cellular Products Inc, Buffalo NY
References Gorny1994, Forthal1995, Moore1995b, Trkola1996a, Binley1997a, Fouts1997, Parren1997c, Nyambi1998, Stamatatos1998, Gorny2000a,
Hioe2000, Nyambi2000, Edwards2002, Maksiutov2002
• 697-D: Conformational with weak reactivity to V2 peptide ISTSIRGKVQKEYAFFYKLD – neutralized 3/4 primary isolates, but none of 4 lab strains – V2
substitutions 176/177 FY/AT, 179/180 LD/DL, 183/184 PI/SG, and 192-194 YSL/GSS abrogate binding – anti-C4 MAbs G3-536 and G45-60 enhance
binding – mild oxidation of carbohydrate moieties inhibits binding [Gorny1994]
• 697-D: Not neutralizing, no ADCC activity, and no viral enhancing activity [Forthal1995]
• 697-D: Review: called 697/30D – neutralizes some primary, but not lab adapted strains [Moore1995b]
• 697-D: Partial inhibition of gp120 interaction with CCR-5 in a MIP-1beta-CCR-5 competition study [Trkola1996a]
• 697-D: Study shows neutralization is not predicted by MAb binding to JRFL monomeric gp120, but is associated with oligomeric Env binding – 697-D
bound monomer, did not bind oligomer or neutralize JRFL [Fouts1997]
• 697-D: Does not neutralize TCLA strains but neutralizes some primary isolates weakly [Parren1997c]
• 697-D: Using a whole virion-ELISA method, 18 human MAbs were tested for their ability to bind to a panel of 9 viruses from clades A, B, D, F, G, and H –
V2 Abs 697-D, 1361, and 1357 tended to bind weakly with a similar pattern of specificity to virions, and bound well to soluble gp120: weak binding to 1/4
B clade viruses (CA5), and weak binding to viruses from subtype A and D [Nyambi1998]
• 697-D: Called 697-30D – deleting the V2 loop of neutralization-resistant HIV-1 isolate SF162 does not abrogate its replication in PBMC or macrophages,
but it enhances its neutralization sensitivity to sera from patients with B clade infection up to 170-fold, and also enhances sensitivity to sera from clades A
through F – deletion of V1 or V2 did not enable neutralization by V2 MAbs G3.4, G3.136, or 687-30D [Stamatatos1998]
• 697-D: Binding of panel of 21 MAbs to soluble oligomeric gp140 versus gp41 or gp120 monomers was compared – no MAb was oligomer specific, though
anti-V3 and CD4BS MAbs reacted better with the oligomer and V2 and C5 tended to favor the monomer – V2 MAbs 697-D, 1357 and 1361 favored the
monomer by approximately 2 fold[Gorny2000a]
• 697-D: Ab responses, because of their capacity to alter antigen uptake and processing, can influence helper T cell responses – CD4BS MAbs or serum Ig
from HIV+ individuals inhibited proliferative responses of gp120 specific T cells – V2 MAb 697-D did not effect proliferation [Hioe2000]
• 697-D: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including 5 anti-V2 MAbs, which showed weak and sporadic
binding, with the most frequent binding to C and D clades [Nyambi2000]
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• 697-D: Called 697D – Truncation of the gp41 cytoplasmic domain of X4, R5, and X4R5 viruses forces a conformation that more closely resembles the CD4
bound state of the external Envelope, enhancing binding of CD4i MAbs 17b and 48d and of CD4BS MAbs F105, b12, and in most cases of glycosylation
site dependent MAb 2G12 and the anti-gp41 MAb 246D – in contrast, binding of the anti-V2 MAb 697D and the anti-V3 MAb 694/98D were not affected –
viruses bearing the truncation were more sensitive to neutralization by MAbs 48d, b12, and 2G12 – the anti-C5 MAb 1331A was used to track levels of cell
surface expression of the mutated proteins [Edwards2002]
• 697-D: Called 697D – Transgenic mice carrying human genes allowing production of fully human MAbs were used to rapidly create a panel of anti-HIV
gp120 MAb producing hybridomas by immunization with HIV SF162 gp120 – the previously described human MAbs 5145A, 4117C and 697D were used
as controls [He2002]
• 697-D: This epitope is similar to a fragment of the human protein macrophage colony stimulating factor I receptor SISIRLKVQK [Maksiutov2002].
342 6C4/S gp160 (162–169) gp120 (BH10) STSIRGKV Vaccine
Vaccine Vector/Type: protein Strain: BH10 HIV component: gp120
Donor S. Ranjbar (NIBSC, UK)
ReferencesMoore1993b
• 6C4/S: UK Medical Research Council AIDS reagent: ARP3049
343 C108G gp160 (162–169) gp120 (162–169 HXB2) STSIRGKV L HIV-1 infection chimpanzee (IgG1κ)
Donor S. Tilley, Public Health Research Institute, NY, NY
ReferencesWarrier1994, Wu1995, Warrier1995, Warrier1996, Ugolini1997, Mondor1998, Alsmadi1998
• C108G: Chimps were infected with HIV-1 IIIB, and this high affinity MAb gave potent neutralization of HIV-1 IIIB – binding not affected by reduction of
disulfide bonds – binding disrupted by removal of N-linked glycans – peptide binding lower affinity than glycosylated Env [Warrier1994]
• C108G: Strain specificity: LAI, BaL, HXB2 – conformational character – glycosylation site at 160 critical – mutation of conserved glycosylation site at 156
increased epitope exposure [Wu1995]
• C108G: Characterization of MAb variable region [Warrier1995]
• C108G: Synergistic neutralization of HIV-1 when combined with anti-V3 MAbs 0.5beta and C311E, or anti-CD4BS MAbs, 1125H and 5145A –
neutralization further enhanced by presence of both 1125H and 0.5beta [Warrier1996]
• C108G: Viral binding inhibition by C108G was correlated with neutralization (all other neutralizing MAbs tested showed some correlation except 2F5)
[Ugolini1997]
• C108G: Inhibits HX10 binding to both CD4 positive and negative HeLa cells[Mondor1998]
• C108G: A study of 6 anti-Env MAbs and their ability to bind or direct ADCC against target cells infected with IIIB, MN, SF-2, and RF – bound and
directed lysis against only IIIB – this is first demonstration of ADCC directed by a V2 specific MAb [Alsmadi1998]
344 10/76b gp160 (162–170) gp120 (162–171 BH10) STSIRGKVQ L (HXB10) Vaccine rat (IgG2a)
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: gp120
ReferencesMcKeating1993b, McKeating1993a, Shotton1995, Wu1995, McKeating1996b
• 10/76b: R to L substitution abrogated binding – human sera recognize epitope [McKeating1993b]
• 10/76b: Cross-competes with MAbs 10/76b and 11/4b – HXB2 neutralization escape mutant has the substitution I/T at residue 165 [Shotton1995]
• 10/76b: Included in cross-competition and neutralization studies [Shotton1995]
• 10/76b: HX10 strain specificity – binds native, deglycosylated, or denatured gp120 [Wu1995]
• 10/76b: Neutralizes HXB2, but fails to neutralize chimeric virus with gp120 from primary isolates in an HXB2 background [McKeating1996b]
• 10/76b: UK Medical Research Council AIDS reagent: ARP3077
345 11/41e gp160 (162–170) gp120 (162–171) STSIRGKVQ L (HXB10) Vaccine rat (IgG1)
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: gp120
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ReferencesMcKeating1993b, Shotton1995, Wu1995
• 11/41e: R to L abrogated binding – human sera recognize the epitope [McKeating1993b]
• 11/41e: Included in cross-competition and neutralization studies [Shotton1995]
• 11/41e: HX10 strain specificity – binds native and deglycosylated gp120 [Wu1995]
346 11/4b gp160 (162–170) gp120 (162–171) STSIRGKVQ L (HXB10) Vaccine rat (IgG2a)
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: gp120
ReferencesMcKeating1993b, Shotton1995, Wu1995, Moore1996
• 11/4b: A change from R to L abrogated binding – human sera recognize epitope [McKeating1993b]
• 11/4b: Cross-competes with MAbs 10/76b and 11/4c – HXB2 neutralization escape mutant has the substitution I/T at residue 165 [Shotton1995]
• 11/4b: HXB10 strain specificity – binds native, deglycosylated, or denatured gp120 [Wu1995]
• 11/4b: Linear V2 epitope – reciprocal binding enhancement of anti-V2 discontinuous epitope antibodies (in contrast to BAT085) and CD4 inducible
antibody 48d. Reciprocal inhibits BAT085 binding – inhibits CRA-3 binding CRA-3 does not inhibit 11/4b [Moore1996]
347 RSD-33 gp160 (162–170) gp120 (162–171) STSIRGKVQ Vaccine
Vaccine Vector/Type: protein Strain: BH10 HIV component: gp120
Donor R. Daniels (NIMR, UK)
ReferencesMoore1993b
348 11/4c
(11/4c/1j/4j)
gp160 (162–170) gp120 (152–181) STSIRGKVQ L (HXB2) Vaccine rat (IgG2a)
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: gp120
Ab type V2
ReferencesMcKeating1993b, Wu1995, Shotton1995, Peet1998
• 11/4c: R to L substitution abrogated binding – human sera recognize epitope [McKeating1993b]
• 11/4c: HX10 strain specificity – binds native, deglycosylated, or denatured gp120 [Wu1995]
• 11/4c: Cross-competes with MAbs 10/76b and 11/4b – HXB2 neutralization escape mutant has the substitution I/T at residue 165 [Shotton1995]
• 11/4c: Called 11/4c/1j/4j – The most variable amino acids in the V3 loop were replaced with serines to make the immunodominant V3 loop less
immunogenic – these changes did not affect the ability of sCD4 or MAbs to V1/V2, C1 and C4 to bind – 11/4c was not affected by V3 serine substitutions –
mice injected with serine substituted gp120 had a reduced response relative to wildtype, and no enhanced immunogenicity of conserved regions [Peet1998]
• 11/4c: UK Medical Research Council AIDS reagent: ARP3035
349 8.22.2 gp160 (162–178) gp120 TTSIRDKVQKEYALFYK Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Ab type V2 Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002, Maksiutov2002
• 8.22.2 : Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2kappa MAbs were used to rapidly create a
panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120 – several of the MAbs obtained were effective at
neutralizing the autologous strain – 8.22.2 was the only V2-specific MAb created and it could cross-compete with MAb 697D – 8.22.2 could cross-react
with BaL and JR-FL, two B clade R5 strains, but not B clade X4 or E clade viruses, and it could weakly neutralize autologous strain SF162 [He2002]
• 8.22.2: This epitope is similar to a fragment of the human protein macrophage colony stimulating factor I receptor SISIRLKVQK [Maksiutov2002].
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350 12b gp160 (162–181) gp120 (162–181) STSIRGKVQKEYAFFYKLDI L (HXB10) Vaccine rat (IgG2a)
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: gp120
Ab type V2
References Shotton1995, McKeating1996b, Maksiutov2002
• 12b: V2 MAb neutralized HXB2 – position 179-180 LD to DL abrogates binding – competes with 60b, but not 74 [Shotton1995]
• 12b: Neutralizes HXB2, but fails to neutralize chimeric virus with gp120 from primary isolates in an HXB2 background [McKeating1996b]
• 12b: This epitope is similar to a fragment of the human protein macrophage colony stimulating factor I receptor SISIRLKVQK [Maksiutov2002].
351 G3-136
(G3.136)
gp160 (170–180) gp120 (170–180 IIIB) QKEYAFFYKLD L Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp120
Ab type V2 Donor Tanox Biosystems Inc and David Ho, ADARC, NY
References Fung1992, Pirofski1993, Thali1993, Moore1993a, Moore1993b, Yoshiyama1994, Sattentau1995b, Stamatatos1995, Moore1996,
Poignard1996a, Binley1997a, Stamatatos1997, Ditzel1997, Wyatt1997, Parren1998a, Stamatatos1998, Ly2000
• G3-136: V2 region – binds and neutralizes IIIB and RF in CEM-SS cells, but not MN – neutralization activity against a few primary isolates in PBMC –
sCD4 binding inhibits binding (contrast with BAT085) – deglycosylation or reduction of gp120 by DTT diminishes reactivity [Fung1992]
• G3-136: Conformational, does not bind well to denatured gp120 – not reactive with SF-2 gp120, and does not inhibit HIV-1 sera from binding to IIIB
gp120 [Moore1993a]
• G3-136: Marginal binding to peptide, binding inhibited by 183/184 PI/SG substitution [Moore1993b]
• G3-136: Binding enhanced by selected antibodies to C1, C4, C5, V3 and anti-CD4 binding site MAbs – enhances binding of selected V3, C4 and anti-CD4
binding site MAbs [Moore1993b]
• G3-136: HIV-1 RF V2 substitutions 177 Y/H and 179 L/P in the V2 loop of RF reduce affinity [Yoshiyama1994]
• G3-136: The binding of conformation-dependent anti-V2, anti-V3, and anti-CD4BS MAbs to monomeric and virion-associated gp120 from HIV-1 isolates
with differences in cell tropism was studied – V2 loop epitopes are somewhat occluded in the oligomeric gp120 epitopes on the virion surface relative to the
gp120 monomer as indicated by an increase in the half-maximal binding values to macrophage-tropic isolates SF162 and SF128a – anti-V2 MAbs G3-4 and
G3.136 don’t bind to T-cell tropic SF2 [Stamatatos1995]
• G3-136: Bound preferentially to the monomeric rather than oligomeric form of LAI gp120 – neutralizes cell free Hx10 [Sattentau1995b]
• G3-136: Described epitope as STSIRGKVKEYAFFYKLDI – binds oligomer – binding of V2 MAbs G3-136, G3-4 or BAT123 did not significantly alter
gp120 dissociation from virus or expose the gp41 epitope of MAb 50-69, in contrast to anti-V3 MAbs [Poignard1996a]
• G3-136: Called G3.136 – does not mediate gp120 virion dissociation in contrast to anti-V2 MAb G3-4 – not neutralizing for SF162 or SF128A in either
primary macrophages or PBMC [Stamatatos1997]
• G3-136: Binds both gp120 and soluble gp120+gp41 complex efficiently, suggesting its gp120 epitope is not blocked by gp41 binding [Wyatt1997]
• G3-136: The MAb and Fab binding to the oligomeric form of gp120 and neutralization were highly correlated – authors suggest that neutralization is
determined by the fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
• G3-136: Called G3.136 – deleting the V2 loop of neutralization-resistant HIV-1 isolate SF162 does not abrogate its replication in PBMC or macrophages,
but it enhances its neutralization sensitivity to sera from patients with B clade infection up to 170-fold, and also enhances sensitivity to sera from clades A
through F – deletion of V1 or V2 did not enable neutralization by V2 MAbs G3.4, G3.136, or 687-30D [Stamatatos1998]
• G3-136: Called G3.136 – SF162 is a neutralization-resistant HIV-1 isolate – N-linked glycosylation modifications in the V2 loop of the SF162 gp120
revealed that these sites prevent neutralization by CD4BS MAbs (IgG1b12 and IgGCD4), and protect against neutralization by V3 MAbs (447-D and
391-95D) – V2-region glycosylation site mutations did not alter neutralization resistance to V2 MAbs (G3.4 and G3.136) or CD4i MAbs (17b and 48d) –
V2 glycosylation site modification allows infection of macrophages, probably due to glycosylated forms requiring fewer CCR5 molecules for viral entry
[Ly2000]
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352 G3-4 (G3.4) gp160 (170–180) gp120 (170–180 BH10) QKEYAFFYKLD L Vaccine murine (IgG2bκ)
Vaccine Vector/Type: protein Strain: IIIB HIV component: gp120
Ab type V2 Donor Tanox Biosystems Inc and David Ho, ADARC, NY
References Ho1991a, Ho1992, Fung1992, McKeating1992a, Moore1993a, Sullivan1993, Sattentau1993, Thali1993, Moore1993b, Moore1994b,
Gorny1994, Thali1994, Yoshiyama1994, Stamatatos1995, Wu1995, Sattentau1995b, Jagodzinski1996, Moore1996, Poignard1996a, Binley1997a,
Stamatatos1997, Ditzel1997, Wyatt1997, Parren1998a, Stamatatos1998, Ly2000, Srivastava2002
• G3-4: Binding is sensitive to removal of glycans by endo H – 50% neutralization of 4/9 primary isolates – has conformational features [Ho1991a]
• G3-4: Neutralizes IIIB and RF, not MN – blocks sCD4-gp120, not as potent as MAb 15e – V2 binding MAbs BAT085 and G3-136 block G3-4 gp120
binding – sensitive to reduction of gp120 by DTT [Ho1992]
• G3-4: Substitutions in residues 176 to 184 affect MAb recognition – substitutions in V2 can result in gp120-gp41 dissociation [Sullivan1993]
• G3-4: Increased binding in the presence of sCD4 [Sattentau1993]
• G3-4: Conformational, does not bind well to denatured gp120 – not reactive with SF-2 gp120, and does not inhibit HIV-1 sera from binding to IIIB gp120
[Moore1993a]
• G3-4: V2 region, marginal binding to peptide, binding inhibited by 183/184 PI/SG substitution [Moore1993b]
• G3-4: Conformationally sensitive – sporadic cross-reactivity among, and outside, B clade gp120s [Moore1994b]
• G3-4: Weakly neutralizing, IC 50 = 53 mug/ml [Gorny1994]
• G3-4: gp41 mutation (582 A/T) that reduces neutralization of anti-CD4 binding site MAbs does not alter G3-4s ability to neutralize [Thali1994]
• G3-4: Neutralizes RF – substitutions 177 Y/H and 179 L/P in the V2 loop of RF reduce affinity and result in neutralization escape [Yoshiyama1994]
• G3-4: The binding of conformation-dependent anti-V2, anti-V3, and anti-CD4BS MAbs to monomeric and virion-associated gp120 from HIV-1 isolates
with differences in cell tropism was studied – V2 loop epitopes are somewhat occluded in the oligomeric gp120 epitopes on the virion surface relative to the
gp120 monomer as indicated by an increase in the half-maximal binding values to macrophage-tropic isolates SF162 and SF128a – anti-V2 MAbs G3-4 and
G3.136 don’t bind to T-cell tropic SF2 [Stamatatos1995]
• G3-4: Reactive with BH10, RF, and MN – binds native, but not denatured or deglycosylated gp120, binds to deglycosylated V1V2 fusion protein,
suggesting importance of glycans outside the V1V2 region [Wu1995]
• G3-4: Bound preferentially to the monomeric rather than oligomeric form of LAI gp120 – neutralizes Hx10 cell-free virus [Sattentau1995b]
• G3-4: The sulfated polysaccharide curdlan sulfate (CRDS) binds to the Envelope of T-tropic viruses and neutralizes virus – deletion of the V3 loop from
gp120 results in more potent G3-4 binding inhibition by CRDS – G3-4 epitope described as 176-184 FYKLDIIPI and 191-193 YSL [Jagodzinski1996]
• G3-4: Binding enhanced by selected antibodies to C1, C4, C5, V3 and anti-CD4 binding site MAbs – enhances binding of selected V3, C4 and anti-CD4
binding site MAbs [Moore1996]
• G3-4: Described epitope as STSIRGKVKEYAFFYKLDI – binds oligomer – binding of V2 MAbs G3-136, G3-4 or BAT085 did not significantly alter
gp120 dissociation from virus or expose the gp41 epitope of MAb 50-69, in contrast to anti-V3 MAbs [Poignard1996a]
• G3-4: Called G3.4 – mediates gp120 virion dissociation in contrast to anti-V2 MAb G3-136 – not neutralizing for SF162 or SF128A in either primary
macrophages or PBMC [Stamatatos1997]
• G3-4: Binds both gp120 and soluble gp120+gp41 complex efficiently, suggesting its gp120 epitope is not blocked by gp41 binding [Wyatt1997]
• G3-4: The MAb and Fab binding to the oligomeric form of gp120 and neutralization were highly correlated – authors suggest that neutralization is
determined by the fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
• G3-4: Called G3.4 – Deleting the V2 loop of neutralization-resistant HIV-1 isolate SF162 does not abrogate its replication in PBMC or macrophages, but it
enhances its neutralization sensitivity to sera from patients with B clade infection up to 170-fold, and also enhances sensitivity to sera from clades A
through F – deletion of V1 or V2 did not enable neutralization by V2 MAbs G3.4, G3.136, or 687-30D [Stamatatos1998]
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• G3-4: Called G3.4 – SF162 is a neutralization-resistant HIV-1 isolate – N-linked glycosylation modifications in the V2 loop of the SF162 gp120 revealed
that these sites prevent neutralization by CD4BS MAbs (IgG1b12 and IgGCD4), and protect against neutralization by V3 MAbs (447-D and 391-95D) –
V2-region glycosylation site mutations did not alter neutralization resistance to V2 MAbs (G3.4 and G3.136) or CD4i MAbs (17b and 48d) – V2
glycosylation site modification allows infection of macrophages, probably due to glycosylated forms requiring fewer CCR5 molecules for viral entry
[Ly2000]
• G3-4: Called G3.4 – Oligomeric gp140 (o-gp140) derived from R5 primary isolate US4 was characterized for use as a vaccine reagent – antigen capture
ELISA was used to compare the antigenicity of gp120 and o-gp140 using a panel of well characterized MAbs – G3.4 recognized o-gp140 [Srivastava2002]
353 BAT085
(BAT-085)
gp160 (171–180) gp120 (170–180 IIIB) KEYAFFYKLD L Vaccine murine (IgG1)
Vaccine Vector/Type: inactivated virus Strain: IIIB HIV component: virus
Donor Tanox Biosystems Inc and David Ho, ADARC, NY
References Fung1987, Fung1992, Moore1993a, Pirofski1993, Thali1993, Moore1993b, D’Souza1994, Moore1994d, Gorny1994, Yoshiyama1994,
Wu1995, Sattentau1995b, Moore1996, Poignard1996a, Binley1997a, Ditzel1997, Parren1998a
• BAT085: V2 region – sCD4 does not block – neutralizes IIIB and some primary isolates, but not MN or RF – binds MN – deglycosylation or DDT
reduction of gp120 does not diminish reactivity [Fung1992]
• BAT085: Called BAT-85 – conformational, does not bind well to denatured gp120 – not reactive with SF-2 gp120, and does not inhibit HIV-1 sera from
binding to IIIB gp120 [Moore1993a]
• BAT085: 7/8 V2 murine MAbs required gp120 native structure to bind, but BAT085 was the exception – type-specific [Moore1993b]
• BAT085: Peptide affinities of G3-136 and G3-4 are 100-fold less than BAT085, but BAT085 has lower affinity for BH10 gp120 and is weaker at
neutralization [Moore1993b]
• BAT085: Multi-lab study for antibody characterization and assay comparison – did not bind MN or SF2 [D’Souza1994]
• BAT085: Interacts with two overlapping peptides with region of overlap KEYAFFYKLD [Gorny1994]
• BAT085: Neutralizes RF – substitution 177 Y/H in the V2 loop of RF does not inhibit neutralization, in contrast to MAbs G3-4 and SC258
[Yoshiyama1994]
• BAT085: HXB10 strain specificity – binds native, deglycosylated, or denatured gp120 [Wu1995]
• BAT085: Bound preferentially to the monomeric rather than oligomeric form of LAI gp120 – neutralizes cell free Hx10 [Sattentau1995b]
• BAT085: Binding is blocked by other V2 region antibodies, enhanced by several anti-C1 MAbs, and anti-V3 MAb G511 – reciprocal enhancement of CD4i
MAb 48d binding [Moore1996]
• BAT085: Epitope suggested to be QKEYAFFYKLD – binds oligomer – binding of V2 MAbs G3-136, G3-4 or BAT123 did not significantly alter gp120
dissociation from virus or expose the gp41 epitope of MAb 50-69, in contrast to anti-V3 MAbs [Poignard1996a]
• BAT085: The MAb and Fab binding to the oligomeric form of gp120 and neutralization were highly correlated – authors suggest that neutralization is
determined by the fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
354 60b gp160 (172–181) gp120 (172–181 HXB2) EYAFFYKLDI no Vaccine rat (IgG2b)
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: gp120
References Shotton1995
• 60b: V2 MAb did not neutralize HXB2 – bound to rgp120 in ELISA – substitutions 179-180 LD/DL and 191-193 YSL/GSS abrogate binding, as do
changes outside the minimum epitope – competes with 12b, but not 74 [Shotton1995]
355 74 gp160 (172–181) gp120 (172–181) EYAFFYKLDI no Vaccine rat (IgG1)
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: gp120
References Shotton1995
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• 74: V2 MAb did not neutralize HXB2 – did not bind rgp120 ELISA – position 179-180 LD to DL abrogates binding, as do changes outside the minimum
epitope – does not compete with 60b or 12b, and is enhanced by two conformation dependent MAbs [Shotton1995]
356 38/12b gp160 (172–191) gp120 (172–191 HXB2) EYAFFYKLDIIPIDNDTTSY Vaccine rat
Vaccine Vector/Type: protein Strain: BH10 HIV component: gp120
ReferencesWu1995
• 38/12b: Broad specificity: HXB2, MN, SF162 – binds native and deglycosylated gp120 [Wu1995]
357 38/60b gp160 (172–191) gp120 (172–191 HXB2) EYAFFYKLDIIPIDNDTTSY Vaccine rat
Vaccine Vector/Type: protein Strain: BH10 HIV component: gp120
ReferencesWu1995
• 38/60b: Strain specificity: HXB2 – binds native and deglycosylated gp120 [Wu1995]
358 polyclonal
(VEI2)
gp160 (176–196) Env FYKLDIVPIDNTTTSYRLISC HIV-1 infection human
References Carlos1999
• Antibody response to the epitopes in a vaccine construct (VEI) containing peptides from 5 hypervariable regions of gp120 was detected in the sera of HIV-1
positive subjects, including sera from 6 non-subtype B infections – serum samples from San Francisco, Canada and Puerto Rico cohort showed presence of
antibodies against all five VEI hypervariable regions, but most consistently against the V3 region peptide NNNTRKSIRIGPGRAFYTTGDIGNIRQ
[Carlos1999]
359 322-151 gp160 (211–221) gp120 (201–220 LAI) EPIPIHYCAPA Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein HIV component: Env
Donor G. Robey, Abbot Labs
ReferencesMoore1994c, Moore1994d
• 322-151: The relative affinity denatured/native gp120 is 30 [Moore1994c]
360 3D3.B8 gp160 (211–221) gp120 (211–220 LAI) EPIPIHYCAPA Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein HIV component: Env
References Bolmstedt1990, Moore1994c
• 3D3.B8: The relative affinity denatured/native gp120 is greater than 10 [Moore1994c]
361 4C11.D8 gp160 (211–221) gp120 (211–220 LAI) EPIPIHYCAPA Vaccine murine (IgM)
Vaccine Vector/Type: recombinant protein HIV component: Env
References Bolmstedt1990, Moore1994c
• 4C11.D8: The relative affinity denatured/native gp120 is greater than 10 [Moore1994c]
362 493-156 gp160 (211–230) gp120 (211–230 LAI) EPIPIHYCAPAGFAILKCNN Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein HIV component: Env
Donor G. Robey, Abbot Labs
ReferencesMoore1994c
• 493-156: The relative affinity denatured/native gp120 is >10 [Moore1994c]
363 110.1 gp160 (212–221) gp120 (200–217) PIPIHYCAPA no Vaccine human
Vaccine Vector/Type: recombinant protein HIV component: Env
References Pincus1993a, Pincus1996, Valenzuela1998
• 110.1: There is another antibody with this ID that binds to Env at positions 491-500 in LAI, see [Gosting1987]
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• 110.1: A panel of immunotoxins were generated by linking Env MAbs to ricin A – immunotoxins mediated cell killing, but killing was not directly
proportional to binding – 110.1-RAC did not mediate cell killing, and sCD4 has no effect [Pincus1993a, Pincus1996]
364 GV4H3 gp160 (219–226) gp120 (219–226 IIIB) APAGFAIL Vaccine murine
Vaccine Vector/Type: protein-Ab complex HIV component: gp120 complexed with MAb M77
References Denisova1996
• GV4H3: When anti-V3 MAb M77 was bound to gp120 and used as an immunogen, it stimulated many MAbs to linear epitopes [Denisova1996]
365 J1 gp160 (222–231) gp120 (222–231 LAI) GFAILKCNNK Vaccine murine (IgG1)
Vaccine Vector/Type: peptide Strain: LAI
Donor J. Hoxie, U. Penn.
ReferencesMoore1994c, Moore1994d, Cook1994
• J1: The relative affinity denatured/native gp120 is 30 [Moore1994c]
• J1: MAbs against the glycosphingolipid GalCer block HIV infection of normally susceptible CD4 negative cells from the brain and colon – MAbs against
the N-terminal half of gp120 do not inhibit gp120 binding to GalCer – binding of GalCer to gp120 does not inhibit MAb binding [Cook1994]
366 J3 gp160 (222–231) gp120 (222–231 LAI) GFAILKCNNK Vaccine murine (IgG1)
Vaccine Vector/Type: peptide Strain: LAI
Donor J. Hoxie, U. Penn.
ReferencesMoore1994c, Cook1994
• J3: The relative affinity denatured/native gp120 is 30 [Moore1994c]
• J3: MAbs against the glycosphingolipid GalCer block HIV infection of normally susceptible CD4 negative cells from the brain and colon – MAbs against
the N-terminal half of gp120 do not inhibit gp120 binding to GalCer – binding of GalCer to gp120 does not inhibit MAb binding [Cook1994]
367 1006-30-D gp160 (236–245) gp120 (241–251) KGSCKNVSTV human (IgG1λ )
Ab type C2
References Hioe2000, Nyambi2000
• 1006-30-D: Ab responses, because of their capacity to alter antigen uptake and processing, can influence helper T cell responses – CD4BS MAbs or serum
Ig from HIV+ individuals inhibited proliferative responses of gp120 specific T cells – C2 MAbs 1006-30-D and 847-D did not effect proliferation
[Hioe2000]
• 847-D: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including two C2 MAbs – the binding of anti-C2 MAbs was weak
to isolates from clades B, C, D, E, F, G, and they did not not bind to isolates from subtypes A and H – epitope is suggested to be in a 20 amino acid peptide
KGSCKNVSTVQCTHGIRPVV [Nyambi2000]
368 847-D gp160 (236–245) gp120 (241–251) KGSCKNVSTV human (IgG1λ )
Ab type C2
References Hioe2000, Nyambi2000
• 847-D: Ab responses, because of their capacity to alter antigen uptake and processing, can influence helper T cell responses – CD4BS MAbs or serum Ig
from HIV+ individuals inhibited proliferative responses of gp120 specific T cells – C2 MAbs 1006-30-D and 847-D did not effect proliferation [Hioe2000]
• 847-D: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including two C2 MAbs – the binding of anti-C2 MAbs was weak
to isolates from clades B, C, D, E, F, G, and they did not not bind to isolates from subtypes A and H – epitope is suggested to be in a 20 amino acid peptide
KGSCKNVSTVQCTHGIRPVV [Nyambi2000]
369 MF169.1 gp160 (252–261) gp120 (242–261 LAI) RPVVSTQLLL Vaccine murine (IgG)
Vaccine Strain: LAI HIV component: Env
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References Thiriart1989, Moore1994c, Moore1994d
• MF169.1: The relative affinity denatured/native gp120 is 11 – mutations 252 R/W, 257 T/G, and 257 T/R impair binding [Moore1994c]
370 MF170.1 gp160 (252–261) gp120 (242–261 LAI) RPVVSTQLLL Vaccine murine (IgG)
Vaccine Strain: LAI HIV component: Env
References Thiriart1989, Moore1994c, Moore1994d
• MF170.1: The relative affinity denatured/native gp120 is 15 – mutations 252 R/W, 257 T/G, and 257 T/R impair binding to denatured and native gp120, and
262N/T, 269 E/L and 281 A/V to only native gp120 [Moore1994c]
371 MF87.1 gp160 (252–261) gp120 (242–261 LAI) RPVVSTQLLL Vaccine murine (IgG)
Vaccine Strain: LAI HIV component: Env
References Thiriart1989, Moore1994c
• MF87.1: The relative affinity denatured/native gp120 is 10 – mutations 252 R/W, 257 T/G, and 257 T/R impair binding [Moore1994c]
372 213.1 gp160 (252–261) gp120 (242–261 LAI) RPVVSTQLLL Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: Env
Ab type C2 Donor Claudine Bruck
References Thiriart1989, Moore1993a, Moore1994c
• 213.1: Bound preferentially to denatured IIIB and SF2 gp120 [Moore1993a]
• 213.1: The relative affinity denatured/native gp120 is 100 – mutations 252 R/W, 257 T/G or T/R impair binding [Moore1994c]
• 213.1: UK Medical Research Council AIDS reagent: ARP334
373 B12 gp160 (252–271) gp120 (252–271 LAI) RPVVSTQLLLNGSLAEEEVV Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
Ab type C2
ReferencesMoore1994c, Maksiutov2002
• B12: C2 region – the relative affinity for denatured/native gp120 is 27 – mutations 257 T/R and 262 N/T impair binding [Moore1994c]
• B12: This epitope is similar to a fragment of human protein lymphatic endothelium-specific hyaluronan receptor LYVE-1, TTRLLVQGSLRAEE
[Maksiutov2002].
374 B13 (Bh13,
Chessie B13)
gp160 (252–271) gp120 (252–271 LAI) RPVVSTQLLLNGSLAEEEVV Vaccine murine (IgG2a)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
Ab type C2 Donor George Lewis, Institute of Human Virology, Baltimore MD, USA
References Pincus1993a, Moore1993a, Moore1994c, Abacioglu1994, Moore1994d, Pincus1996, Connor1998, Wang2002b, Maksiutov2002
• B13: Bound preferentially to denatured IIIB gp120 [Moore1993a]
• B13: The relative affinity for denatured/native gp120 is 30 – mutations 257 T/R and 269 E/L impair binding [Moore1994c]
• B13: C2 region – epitope boundaries mapped by peptide scanning, core epitope: TQLLLN [Abacioglu1994]
• B13: Called Bh13 – binds to gp120 but not to infected cells – when linked to ricin A, the immunotoxin did not mediate cell killing – sCD4 has no effect
[Pincus1993a, Pincus1996]
• B13: This epitope is similar to a fragment of human protein lymphatic endothelium-specific hyaluronan receptor LYVE-1, TTRLLVQGSLRAEE
[Maksiutov2002].
375 C13 gp160 (252–271) gp120 (252–271 LAI) RPVVSTQLLLNGSLAEEEVV Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
Ab type C2 Donor George Lewis
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ReferencesMoore1993a, Moore1994c, Abacioglu1994, Maksiutov2002
• C13: Bound preferentially to denatured IIIB gp120 [Moore1993a]
• C13: The relative affinity for denatured/native gp120 is 36 – mutations 257 T/R, 267 E/L, and 269 E/L impair binding [Moore1994c]
• C13: Epitope boundary extended to RPVVSTQLLLNGSLAEEEVVIR, to take into account the effect of a point mutation [Abacioglu1994]
• C13: This epitope is similar to a fragment of human protein lymphatic endothelium-specific hyaluronan receptor LYVE-1, TTRLLVQGSLRAEE
[Maksiutov2002].
• C13: NIH AIDS Research and Reference Reagent Program: 1209
376 M89 gp160 (252–271) gp120 (252–271 LAI) RPVVSTQLLLNGSLAEEEVV no Vaccine murine (IgG1)
Vaccine Vector/Type: protein HIV component: Env
Ab type C2 Donor Fulvia di Marzo Veronese
References diMarzo Veronese1992, Moore1994c, Moore1994d, Maksiutov2002
• M89: Immunoblot reactive, RIP negative, for strains IIIB, 451, MN, RF, and RUTZ [diMarzo Veronese1992]
• M89: C2 region – the relative affinity for denatured/native gp120 is >30 – mutations 257 T/R and 269 E/L impair binding [Moore1994c]
• M89: This epitope is similar to a fragment of human protein lymphatic endothelium-specific hyaluronan receptor LYVE-1, TTRLLVQGSLRAEE
[Maksiutov2002].
377 B21 gp160 (257–262) gp120 (257–262 BH10) TQLLLN Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
Ab type C2
References Abacioglu1994
• B21: C2 region, epitope boundaries mapped by peptide scanning [Abacioglu1994]
378 B23 gp160 (257–262) gp120 (257–262 BH10) TQLLLN Vaccine murine (IgG2a)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
Ab type C2
References Abacioglu1994
• B23: C2 region, epitope boundaries mapped by peptide scanning [Abacioglu1994]
379 B24 gp160 (257–262) gp120 (257–262 BH10) TQLLLN Vaccine murine (IgG2a)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
Ab type C2
References Abacioglu1994
• B24: C2 region, epitope boundaries mapped by peptide scanning [Abacioglu1994]
380 B25 gp160 (257–262) gp120 (257–262 BH10) TQLLLN Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
Ab type C2
References Abacioglu1994
• B25: C2 region, epitope boundaries mapped by peptide scanning [Abacioglu1994]
381 B3 gp160 (257–262) gp120 (257–262 BH10) TQLLLN Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
Ab type C2
References Abacioglu1994
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• B3: C2 region, epitope boundaries mapped by peptide scanning [Abacioglu1994]
382 B26 gp160 (257–263) gp120 (257–263 BH10) TQLLLNG Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
Ab type C2
References Abacioglu1994
• B26: C2 region, epitope boundaries mapped by peptide scanning [Abacioglu1994]
383 B29 gp160 (257–263) gp120 (257–263 BH10) TQLLLNG Vaccine murine (IgG2a)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
Ab type C2
References Abacioglu1994
• B29: C2 region, epitope boundaries mapped by peptide scanning [Abacioglu1994]
384 B36 gp160 (257–263) gp120 (257–263 BH10) TQLLLNG Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
Ab type C2
References Abacioglu1994
• B36: C2 region, epitope boundaries mapped by peptide scanning [Abacioglu1994]
385 110.E gp160 (262–281) gp120 (262–281 LAI) NGSLAEEEVVIRSVNFTDNA Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: Env
Ab type C2 Donor F. Traincard
ReferencesMoore1994c, Moore1994d, Maksiutov2002
• 110.E: The relative affinity for denatured/native gp120 is 7.3 [Moore1994c]
• 110.E: This epitope is similar to a fragment of human protein lymphatic endothelium-specific hyaluronan receptor LYVE-1, TTRLLVQGSLRAEE
[Maksiutov2002].
386 110.C gp160 (271–280) gp120 (271–280 LAI) VIRSVNFTDN Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: Env
Ab type C2 Donor F. Traincard, Hybridolabs, Institut Pasteur
ReferencesMoore1994c, Moore1994d, Valenzuela1998
• 110.C: The relative affinity for denatured/native gp120 is 1 [Moore1994c]
• 110.C: Only slightly reduces LAI viral binding or entry into CEM cells [Valenzuela1998]
387 IIIB-V3-26 gp160 (291–307) gp120 (299–304 IIIB) SVEINCTRPNNNTRKSI no Vaccine murine (IgG1)
Vaccine Vector/Type: peptide Strain: IIIB
Ab type V3
References Laman1992, Maksiutov2002
• IIIB-V3-26: Binds to the base of the V3 loop on denatured gp120 [Laman1992]
• IIIB-V3-26: This epitope is similar to a fragment of the FasI receptor precursor (Apptosis-mediating surface antigen fas) (APO- 1 antigen) (CD95 antigen),
VEINCTRQN [Maksiutov2002]
388 IIIB-V3-21
(V3-21)
gp160 (294–299) gp120 (299–304 IIIB) INCTRP no Vaccine murine (IgG1)
Vaccine Vector/Type: peptide Strain: IIIB
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Ab type V3 Donor J. Laman
References Laman1992, Laman1993, Valenzuela1998, Zhang2002, Maksiutov2002
• IIIB-V3-21: Binds to the base of the V3 loop on denatured gp120 [Laman1992]
• IIIB-V3-21: Binds to NP40 treated gp120, and epitope is probably obscured by local glycosylation [Laman1993]
• IIIB-V3-21: Does not block HIV-1 LAI binding or entry into CEM cells [Valenzuela1998]
• IIIB-V3-21: A rare mutation in the neutralization sensitive R2-strain in the proximal limb of the V3 region caused Env to become sensitive to neutralization
by MAbs directed against the CD4 binding site (CD4BS), CD4-induced (CD4i) epitopes, soluble CD4 (sCD4), and HNS2, a broadly neutralizing sera –
2/12 anti-V3 MAbs tested (19b and 694/98-D) neutralized R2, as did 2/3 anti-CD4BS MAbs (15e and IgG1b12), 2/2 CD4i MAbs (17b and 4.8D), and 2G12
and 2F5 – thus multiple epitopes on R2 are functional targets for neutralization and the neutralization sensitivity profile of R2 is intermediate between the
highly sensitive MN-TCLA strain and the typically resistant MN-primary strain [Zhang2002]
• IIIB-V3-21: This epitope is similar to a fragment of the FasI receptor precursor (Apptosis-mediating surface antigen fas) (APO- 1 antigen) (CD95 antigen),
VEINCTRQN [Maksiutov2002]
• IIIB-V3-21: UK Medical Research Council AIDS reagent: ARP3048
• IIIB-V3-21: NIH AIDS Research and Reference Reagent Program: 1725
389 polyclonal gp160 (296–327) gp120 (MN) CNYNKRKRIHIGPGRAFYTTKNIIG-
TIC
L rabbit (IgA, IgG)
Ab type V3
References FitzGerald1998
• Polyclonal response to MN, or Thai E V3 loop inserted into Pseudomonas Exotoxin for vaccination – inserts of 14 or 26 amino acids were used from MN or
a Thai E strain, constrained by disulfide bond – sera from vaccinated rabbit were reactive with strain-specific gp120 – administration to mucosal surfaces
elicits IgA [FitzGerald1998]
390 polyclonal gp160 (297–330) Env (303–335 LAI) TRPNNNTRKSIHIGPGRAFYATGEI-
IGDIRQAH
no Vaccine human (IgG)
Vaccine Vector/Type: lipopeptide Strain: LAI HIV component: V3 Adjuvant: QS21
Ab type V3
References Pialoux2001
• 28 subjects were vaccinated with six HIV-1 peptides that were selected to be particularly rich in CTL epitopes, presented in lipopeptides with or without
adjuvant QS21 – HIV-specific Ab responses were detected in 25/28 (89%), proliferative in 19/28 (79%), and CTL in 13/24 (54%) of testable volunteers –
14/28 had non-neutralizing Ab responses to this peptide (E), 7/24 had proliferative responses, and multiple CTL responses were detected [Pialoux2001]
391 MO97/V3 gp160 (299–308) gp120 (299–308 IIIB) PNNNTRKSIR no in vitro stimulation human (IgM)
Ab type V3
References Ohlin1992
• MO97: Generated through in vitro stimulation of uninfected-donor lymphocytes with rpB1 (IIIB Env 286-467) [Ohlin1992]
392 polyclonal gp160 (299–331) gp120 (306–338 BH10) PNNNTRKSIRIQRGPGRAFVTIGKI-
GNMRQAHC
L Vaccine rabbit (IgG)
Vaccine Vector/Type: peptide Strain: BH10
Ab type V3
References Neurath1990
• 21 V3 loop variant peptides spanning this region were tested and serological cross-reactivity correlated with divergence [Neurath1990]
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393 55/1l gp160 (300–315) gp120 (300–315) NNNTRKRIRIQRGPGR?
Ab type V3
References Peet1998
• 55/1l: The most variable amino acids in the V3 loop were replaced with serines to make the immunodominant V3 loop less immunogenic – these changes
did not affect the ability of sCD4 or MAbs to V1/V2, C1 and C4 to bind, and anti-V3 MAb 55/1l binding was abrogated by V3 serine substitutions in the
V3 loop – mice injected with serine substituted gp120 had a reduced response relative to wildtype, and no enhanced immunogenicity of conserved regions
[Peet1998]
394 8/38c
(8/38/1c)
gp160 (300–315) gp120 (300–315
HXB10)
NNNTRKRIRIQRGPGR L Vaccine rat (IgG2a)
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: gp120
Ab type V3 Donor C. Dean and C. Shotton, Institute for Cancer Research, Surrey, UK
ReferencesMcKeating1992a, Sattentau1995b, Jeffs1996, Parren1998a, Peet1998
• 8/38c: Binds to virion gp120 and neutralizes only in the presence of sCD4 [McKeating1992a]
• 8/38c: Binds equally well to monomer and oligomer, less rapid association rate than other anti-V3 antibodies, and an associated less potent neutralization of
lab strains [Sattentau1995b]
• 8/38c: Deletion of the V1V2 regions did not affect anti-V3 Abs ability to bind when compared to intact rec gp120 [Jeffs1996]
• 8/38c: The MAb and Fab binding to the oligomeric form of gp120 and neutralization were highly correlated – authors suggest that neutralization is
determined by the fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
• 8/38c: Called 8/38/1c: The most variable amino acids in the V3 loop were replaced with serines to make the immunodominant V3 loop less immunogenic –
these changes did not affect the ability of sCD4 or MAbs to V1/V2, C1 and C4 to bind, and anti-V3 MAb 8/38c binding was only diminished by V3 serine
substitutions C-term to the tip of the loop – mice injected with serine substituted gp120 had a reduced response relative to wildtype, and no enhanced
immunogenicity of conserved regions [Peet1998]
• 8/38c: UK Medical Research Council AIDS reagent: ARP3039
395 8/64b gp160 (300–315) gp120 (300–315
HXB10)
NNNTRKRIRIQRGPGR L Vaccine rat (IgM)
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: gp120
Ab type V3
ReferencesMcKeating1992a, Peet1998
• 8/64b: Binds to virion gp120 and neutralizes only in the presence of sCD4 [McKeating1992a]
• 8/64b: The most variable amino acids in the V3 loop were replaced with serines to make the immunodominant V3 loop less immunogenic – these changes
did not affect the ability of sCD4 or MAbs to V1/V2, C1 and C4 to bind, and anti-V3 MAb 8/64b binding was abrogated by V3 serine substitutions C-term
to the tip of the loop – mice injected with serine substituted gp120 had a reduced response relative to wildtype, and no enhanced immunogenicity of
conserved regions [Peet1998]
• 8/64b: UK Medical Research Council AIDS reagent: ARP3036
396 polyclonal gp160 (300–321) gp120 NYNKRKRIHIGPGRAFYTTK L HIV-1 infection, Vaccine human
Vaccine Vector/Type: peptide Strain: cocktail HIV component: V3
Ab type V3
References Bartlett1998
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• V3 peptide vaccine (MN, RF, EV91, and Can0A) with a C4 helper T cell epitope were used to vaccinate HLA-B7 HIV-infected patients – V3 Ab levels and
the anti-HIV proliferative response, but no decrease in HIV-1 RNA levels or increase in CD4 levels was observed [Bartlett1998]
397 polyclonal gp160 (300–321) gp120 NYNKRKRIHIGPGRAFYTTK HIV-1 exposed
seronegative
human (IgA)
Ab type V3
References Kaul1999
• HIV-1 Env-specific mucosal IgA found in genital track of 16/21 HIV-1 resistant chronically exposed Kenyan sex workers – 11/21 had detectable Th
responses [Kaul1999]
398 polyclonal gp160 (300–322) gp120 (IIIB) CNNTRKSIRIQRGPGRAFVTIGK L guinea pig (IgG)
Ab type V3 Donor D. Bolognesi and T. Matthews, Duke University
References Allaway1993
• Synergy with combinations of CD4-based molecules in inhibition of HIV-1 Env mediated cell fusion [Allaway1993]
399 polyclonal
(VEI3)
gp160 (300–328) Env NNNTRKSIRIGPGRAFYTTGDIGNI-
RQ
HIV-1 infection human
Ab type V3
References Carlos1999
• Antibody response to the epitopes in a vaccine construct (VEI) containing peptides from 5 hypervariable regions of gp120 was detected in the sera of HIV-1
positive subjects, including sera from 6 non-subtype B infections – serum samples from San Francisco, Canada and Puerto Rico cohort showed presence of
antibodies against all five VEI hypervariable regions, but most consistently against the V3 region peptide NNNTRKSIRIGPGRAFYTTGDIGNIRQ
[Carlos1999]
400 9284 (NEA
9284)
gp160 (301–312) gp120 (307–318 IIIB) NNTRKSIRIQRG L Vaccine murine (IgG1)
Vaccine Vector/Type: inactivated virus Strain: IIIB HIV component: virus
Ab type V3 Donor Dupont de Nemours, Les Ulis, France or Wilmington, Delaware
References Skinner1988b, Skinner1988a, Sattentau1991, Wyatt1992, McKeating1992a, Sattentau1993, Moore1993c, Trujillo1993, Thali1993,
VanCott1994, Thali1994, Cook1994, Okada1994, Sorensen1994, Sattentau1995b, VanCott1995, Fontenot1995, Moore1996, Poignard1996a, Cao1997b,
Binley1997a, Parren1998a, Schonning1998
• 9284: IIIB type-specific binding and neutralization [Skinner1988b]
• 9284: Two fold increase in binding to gp120 in the presence of bound sCD4 [Sattentau1991]
• 9284: Single amino acid substitutions in the C4 region (427 W/V or W/S) or at the base of the V3 loop (298 R/G) can significantly increase binding and
neutralization– position 427 is also important for CD4 binding and anti-CD4 binding site MAbs [Wyatt1992]
• 9284: Increased binding in the presence of sCD4 [Sattentau1993]
• 9284: Inhibits C4 region antibodies (G3-299, G3-519) which have conformational requirements [Moore1993c]
• 9284: Peptide RIQRGPGRAFVTIGKIGNMRQA – Reacts with three human brain proteins of 35, 55, 110 kd – called NEA-9284 [Trujillo1993]
• 9284: Does not bind MN gp120, just IIIB [VanCott1994]
• 9284: gp41 mutation that confers resistance to neutralization by anti-CD4 binding site antibodies does not reduce neutralizing efficiency of this V3 region
MAb [Thali1994]
• 9284: MAbs against the glycosphingolipid GalCer block HIV infection of normally susceptible CD4 negative cells from the brain and colon – this MAb can
inhibit gp120 binding to GalCer in vitro [Cook1994]
• 9284: Binding domain aa 301-310: TRKSIRIQRG – mutations in the V3 loop from basic residues can destroy virus infectivity and syncytium formation:
R306T, R309T and R313G can also reduce binding of V3 MAbs with two different binding sites: 9284 and 0.5beta – called NEA9284 [Okada1994]
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• 9284: Did not neutralize infection of HIV/HTLV-I pseudotype [Sorensen1994]
• 9284: Binds equally well to monomer and oligomer, rapid association and potent neutralization of lab strains – neutralizes cell-free virus Hx10
[Sattentau1995b]
• 9284: Used to monitor HIV-1 Env expression in infected H9 cells, binds native and reduced gp120s similarly [VanCott1995]
• 9284: Binds V3 loop – anti-C1 MAbs 133/290 and 135/9 enhance binding – reciprocal binding inhibition of other anti-V3 MAbs [Moore1996]
• 9284: V3 MAbs 9284, BAT123, 110.5, and 110.I could each significantly increase gp120 dissociation from virus, mimicking sCD4, and expose the gp41
epitope for MAb 50-69, in contrast to anti-V2 MAbs [Poignard1996a]
• 9284: Virus with the V1-V2 loop deleted was viable and more susceptible to neutralization by CD4i MAb 17b, and anti-V3 MAbs 1121, 9284, and 110.4,
but not to and CD4BS MAb F105 or sCD4 [Cao1997b]
• 9284: The MAb and Fab binding to the oligomeric form of gp120 and neutralization were highly correlated – authors suggest that neutralization is
determined by the fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
• 9284: In a study of the influence of the glycan at position 306 of the V3 loop on MAb recognition, 9284 was found to have an inaccessible epitope on the
oligomeric form of Env and anti-V3 MAbs were found to neutralize an HIV-BRU mutant virus that lacks the V3 loop glycan more efficiently than
HIV-BRU [Schonning1998]
401 polyclonal gp160 (301–325) gp120 (IIIB) NNTRKSIRIQRGPGRAFVTIGKIGN L Vaccine murine (IgA)
Vaccine Vector/Type: peptide Strain: IIIB Adjuvant: cholera toxin adjuvant
Ab type V3
References Bukawa1995
• Polyclonal secretory IgA antibody raised by mucosal immunization is able to neutralize IIIB, SF2, and MN – HIV-1 neutralization may be due to V3, CD4
or HPG30 component of the multicomponent peptide immunogen [Bukawa1995]
402 polyclonal gp160 (301–325) gp120 (IIIB) NNTRKSIRIQRGPGRAFVTIGKIGN L Vaccine murine (IgA22a)
Vaccine Vector/Type: DNA Strain: IIIB HIV component: Env, Rev
Ab type V3
References Sasaki1998
• An anti-env response was sought, and co-expression of Rev was required – intramuscular versus nasal vaccination with DNA vaccine with a QS21 adjuvant
was studied – QS21 enhanced the IgG2a response mediated via Th1 cytokines IFNgamma and IL-2 [Sasaki1998]
403 polyclonal gp160 (302–317) Env (B consensus) NTRKSIHIGPGRAF HIV-1 infection human
Ab type V3
ReferencesMorris2001
• Ab responses before HAART therapy and after one year of therapy were measured in 8 individuals that were classified HAART successes, and 10 patients
who were classified as HAART failures – V3 peptide antibody binding titers to the B-consensus and MN and SF2 variants, and neutralization of HIV-1 MN
and four subtype B clinical isolates were tested – subjects with strong anti-V3 and NAb humoral immune responses before starting HAART were more
likely to achieve sustained viral suppression to <500 copies RNA/ml on HAART – HIV-specific Ab responses declined after 1 year of successful viral
suppression on HAART [Morris2001]
404 polyclonal gp160 (302–318) Env NTRKSIHIGPGRAFY L P HIV-1 infection human
Ab type V3
References Bongertz2001
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• Non-transmitting mothers had an increased frequency of high neutralizing plasma Ab titers against HIV-1 MN (1:50 dilution, >90% neutralization, 33/88
pregnant women), compared to plasma from transmitting mothers (0/8 pregnant women) – non-transmitting mothers also had more potent neutralization
against primary isolates from transmitting mothers, but neutralization of autologous virus was comparable for non-transmitting (7/13) and transmitting
mothers (2/4) [Bongertz2001]
405 MAG 109 gp160 (302–321) gp120 (302–321 BH10) NTRKSIRIQRGPGRAFVTIG L Vaccine murine
Vaccine Vector/Type: sCD4-gp120 complex Strain: HXB2 HIV component: gp120
Ab type V3
References Kang1994
• MAG 109: Binds a V3 loop peptide – sensitive to both V3 loop mutations and a mutation at the base of the V1/V2 loop structure (120/121 VK/LE)
[Kang1994]
406 MAG 49 (#49) gp160 (302–321) gp120 (302–321 BH10) NTRKSIRIQRGPGRAFVTIG L Vaccine murine
Vaccine Vector/Type: sCD4-gp120 complex Strain: HXB2 HIV component: gp120
Ab type V3
References Kang1994, Moore1996
• MAG 49: Binds a V3 loop peptide – sensitive to both V3 loop mutations and a mutation at the base of the V1/V2 loop structure (120/121 VK/LE)
[Kang1994]
• MAG 49: Called #49 in this text. Binding enhanced by anti-C1 MAbs 133/290, 135/9, and by many anti-CD4 binding site MAbs – reciprocal enhancement
of some anti-V2 MAbs – reciprocal binding inhibition of anti-V3 MAbs [Moore1996]
407 MAG 53 gp160 (302–321) gp120 (302–321 BH10) NTRKSIRIQRGPGRAFVTIG L Vaccine murine
Vaccine Vector/Type: sCD4-gp120 complex Strain: HXB2 HIV component: gp120
Ab type V3
References Kang1994
• MAG 53: Binds a V3 loop peptide – sensitive to both V3 loop mutations and a mutation at the base of the V1/V2 loop structure (120/121 VK/LE)
[Kang1994]
408 MAG 56 gp160 (302–321) gp120 (302–321) NTRKSIRIQRGPGRAFVTIG L Vaccine murine
Vaccine Vector/Type: sCD4-gp120 complex Strain: HXB2 HIV component: gp120
Ab type V3
References Kang1994
• MAG 56: Binds a V3 loop peptide – sensitive to both V3 loop mutations and a mutation at the base of the V1/V2 loop structure (120/121 VK/LE)
[Kang1994]
409 1324-E
(1324E)
gp160 (303–308) Env (subtype CRF01) TRTSVR L HIV-1 infection human (IgG1κ)
Ab type V3 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Gorny1998, Zolla-Pazner1999a, Zolla-Pazner1999b, Nyambi2000
• 1324-E: A human MAb was derived from an HIV-1 E clade infection from a US service man who had served in Thailand, selected with the consensus V3
peptide from clade E – cross-reactive with V3 peptides, and gp120 from E, C and A clades, as well as cells infected with a C-clade primary isolate, but not
with B and D clade V3 peptides or rgp120 – neutralizes E clade virus adapted for growth in H9 cells, but not 5 primary E clade isolates, including the
autologous isolate – kinetic parameters were measured, 1324E was comparable to 447-52D [Gorny1998]
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• 1324-E: E clade stimulated MAb did not cross-react with B clade peptides nor did B clade derived peptides with an E clade V3 loop, but both E and B clade
stimulated Abs can cross-react with some peptides from other clades – this Ab showed strong binding to several E, A and F peptides, one C peptide, and no
reactivity with B peptides and most D peptides [Zolla-Pazner1999a]
• 1324-E: MAb reacted with peptides from E clade, while B clade derived MAbs could not [Zolla-Pazner1999b]
• 1324-E: Called 1324E – A panel of 47 human MAbs was tested against 26 HIV-1 group M primary isolates from clades A through H – 19 V3 MAbs were
tested, and of 494 combinations, 44% displayed some viral binding – V3 MAbs tended to have the most cross-reactive binding to clade A, B, C, and D
isolates, less to E, F, G, and H – 1324E showed poor cross-reactivity, and was the only MAb tested that was derived from a non-B clade infected patient, an
E clade infection was the source of 1324E [Nyambi2000]
410 polyclonal gp160 (303–319) gp120 (subtype C) CKRKIHIGPGQAFYT Vaccine murine (IgG2a,
IgG2b)
Vaccine Vector/Type: peptide in ISCOM or liposome HIV component: V3 Adjuvant: ISCOM
Ab type V3
References Ahluwalia1997
• A V3 loop peptide modified to resemble an Indian form (GPGQ) was incorporated into ISCOMS (immune stimulating complexes) or liposomes, and used
to immunize mice – the IgG2a/IgG2b antibody response was enhanced by the presentation in the ISCOM suggestive of a Th1 response [Ahluwalia1997]
411 MO99/V3 gp160 (304–308) gp120 (304–308 IIIB) RKSIR no in vitro stimulation human (IgM)
Ab type V3
References Ohlin1992
• MO99: Generated through in vitro stimulation of uninfected-donor lymphocytes with rpB1 (IIIB Env 286-467) [Ohlin1992]
412 C311E gp160 (304–313) gp120 (309–316 MN) RKRIHIGP L HIV-1 infection chimpanzee (IgG1)
Ab type V3
ReferencesWarrier1996, Alsmadi1998
• C311E: Chimps were infected with HIV-1 IIIB, and this resulting MAb gave synergistic neutralization of HIV-1 when combined with anti-V2 MAb C108G
[Warrier1996]
• C311E: A study of 6 anti-Env MAbs and their ability to bind or direct ADCC against target cells infected with IIIB, MN, SF-2, and RF – C311E bound and
directed lysis against all four strains [Alsmadi1998]
413 907 gp160 (304–314) gp120 (309–318) RKSIRIQRGPG L Vaccine murine (IgG1κ)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: gp160
References Chesebro1988, Pincus1989, Pincus1991, Pincus1996
• 907: Strain specific binding, and neutralization of only the LAV strain [Chesebro1988]
• 907: Coupled to ricin A chain (RAC), MAb 907 inhibited protein synthesis and cell growth in HIV-infected cells [Pincus1989]
• 907: Epitope sequence is based on database count of a specified location – 924-RAC immunotoxin is IIIB strain-specific [Pincus1991]
• 907: A panel of immunotoxins were generated by linking Env MAbs to ricin A – immunotoxins mediated cell killing, but killing was not directly
proportional to binding [Pincus1996]
414 924 gp160 (304–314) gp120 (309–318 IIIB) RKSIRIQRGPG Vaccine murine (IgG1κ)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: gp160
Ab type V3
References Chesebro1988, Pincus1991, Pincus1993a, Pincus1993b, Cook1994, Pincus1996, Pincus1998
• 924: HIV IIIB strain specific [Chesebro1988]
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• 924: Epitope sequence is based on database count of a specified location – 924-RAC immunotoxin is IIIB strain-specific [Pincus1991]
• 924: MAb was coupled to ricin A chain (RAC) – immunotoxin efficacy was not significantly decreased by sCD4, although the efficacy of gp41 MAb
immunotoxins in vitro increased 30-fold by sCD4 [Pincus1993a]
• 924: Ab response in IIIB lab workers was compared to gp160 LAI vaccine recipients – MAb 924 was used as a control – infected lab workers and a
vaccinia gp160 vaccine had strong V3 MAb response, but alum absorbed rec gp160 did not generate anti-V3 response [Pincus1993b]
• 924: MAbs against the glycosphingolipid GalCer block HIV infection of normally susceptible CD4 negative cells from the brain and colon – this MAb can
inhibit gp120 binding to GalCer in vitro [Cook1994]
• 924: A panel of immunotoxins were generated by linking Env MAbs to ricin A – immunotoxins mediated cell killing, but killing was not directly
proportional to binding [Pincus1996]
415 polyclonal gp160 (304–318) gp120 (304–318 LAI) RKSIRIQRGPGRAFV in vitro stimulation human (IgG, IgM)
Ab type V3
References Chin1995
• Mimicking the humoral immune response in vitro supports isotype switching – human IgG MAbs were generated from naive donors [Chin1995]
416 polyclonal gp160 (304–318) gp120 (304–318 LAI) RKSIRIQRGPGRAFV Vaccine human (IgG, IgM)
Vaccine Vector/Type: peptide Strain: LAI
Ab type V3
References Zafiropoulos1997
• IgG to IgM isotype switching in response to primary and secondary peptide vaccinations was studied – the immunogen contained a V3 loop fragment and a
tetanus toxin helper epitope [Zafiropoulos1997]
417 10F10 gp160 (304–320) gp120 (MN) RKRIHIGPGRAFYTT L Vaccine murine (IgG1)
Vaccine Vector/Type: peptide Strain: MN HIV component: gp120
Ab type V3
References Duarte1994
• 2C4: Putative epitope lies within IHIGPGRAFYT – generated by multi-epitope polypeptide immunization – recognize MN and SC (TRSIHIGPGRAFYTT)
peptides, lower affinity for SF2 [Duarte1994]
418 2C4 gp160 (304–320) gp120 (MN) RKRIHIGPGRAFYTT L (MN) Vaccine murine (IgG2a)
Vaccine Vector/Type: peptide Strain: MN
Ab type V3
References Duarte1994
• 2C4: Putative epitope lies within IHIGPGRAFYT – neutralizes MN, not IIIB and SF2 – generated by multi-epitope polypeptide immunization – recognize
MN and SC (TRSIHIGPGRAFYTT) peptides, lower affinity for SF2 [Duarte1994]
419 412-D
(412-10D,
412, 412D)
gp160 (304–320) gp120 (MN) RKRIHIGPGRAFYTT L HIV-1 infection human (IgG1κ)
Ab type V3 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Gorny1993, Spear1993, VanCott1994, Fontenot1995, Gorny1998, Nyambi1998, Zolla-Pazner1999a, Zolla-Pazner1999b, Nyambi2000
• 412-D: Neutralizes MN, does not bind SF2 or HXB2 – not reactive with hexa or heptapeptides by Pepscan [Gorny1993]
• 412-D: Mediated deposition of complement component C3 on HIV infected cells, enhanced by second Ab binding, rabbit anti-human IgG [Spear1993]
• 412-D: Called 412-10D – relatively rapid dissociation and weak homologous neutralization [VanCott1994]
• 412-D: Called 412 – The tip of the V3 loop was presented in a mucin backbone – higher valency correlates with stronger affinity constant [Fontenot1995]
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• 412-D: Kinetic parameters were measured, and the association rates were similar, but dissociation rate constants were quite variable for V3 MAbs, 412-D
has a relatively fast dissociation, thus low affinity among V3 MAbs [Gorny1998]
• 412-D: Using a whole virion-ELISA method, 18 human MAbs were tested for their ability to bind to a panel of 9 viruses from clades A, B, D, F, G, and H –
412-D was bound only to B clade virions and to D clade MAL [Nyambi1998]
• 412-D: Review of clade specificity and anti-V3 HIV-1-Abs [Zolla-Pazner1999a]
• 412-D: MAb peptide-reactivity pattern clustered with immunological related MAbs: 391.5, 412 and 418, all selected with MN V3 peptide – the core amino
acids HIGPGR tended to be critical for reactivity in this group [Zolla-Pazner1999b]
• 412-D: A panel of 47 human MAbs was tested against 26 HIV-1 group M primary isolates from clades A through H – 19 V3 MAbs were tested, and of 494
combinations, 44% displayed some viral binding – V3 MAbs tended to have the most cross-reactive binding to clade A, B, C, and D isolates, less to E, F, G,
and H – 412-D showed limited reactivity [Nyambi2000]
420 polyclonal gp160 (304–320) gp120 (MN) RKRIHIGPGRAFYTT L (MN
ALA-1)
HIV-1 infection human
Ab type V3
References Spear1994
• 40% of antibody in serum that can bind to native viral proteins on MN-infected cells can be blocked by the peptide RKRIHIGPGRAFYTT, which can also
block 75-95% of the complement activation on HIV infected cells [Spear1994]
421 CGP 47 439 gp160 (304–322) gp120 RKRIRIQRGPGRAFVTIGK? L Vaccine human (Ig)
Vaccine Vector/Type: protein Strain: IIIB HIV component: gp120
Ab type V3
References Liou1989, Safrit1993, Gunthard1994, Gauduin1998, Jacobson1998
• CGP 47 439: passive transfer to Hu-PBS-SCID mice confers protection against challenge with homologous cell-free virus – CGP 47 439 is a
BAT123-human Ig chimera [Safrit1993]
• CGP 47 439: Phase I/IIA clinical trial studying multidose tolerability, immunogenicity and pharmacokinetic responses – GP 47 439 was well tolerated,
serum t_1/2 was 8-16 days, and a virus burden reduction was noted in some patients [Gunthard1994]
• CGP 47 439: Post-exposure passive transfer of murine BAT123 can confer protection to hu-PBL-SCID mice challenged with HIV-1 LAI – this protection is
not elicited by CGP 47 439, suggesting that the protection is mediated by complement – the protective ability of BAT123 is lost when mice were treated with
cobra venom factor, which inactivates serum complement – in this circumstance complement activation provided a protective advantage [Gauduin1998]
• CGP 47 439: Review of passive immunotherapy, summarizing [Gunthard1994] in relation to other studies [Jacobson1998]
422 polyclonal gp160 (304–322) (MN) RKRIHIGPGRAFYTTKN HIV-1 infection human
Ab type V3
References Cheingsong-Popov1992
• The Ab response of 829 HIV-1 infected subjects from eight geographic areas to a set of different V3 peptides was determined by ELISA and cross-inhibition
studies – the Ab binding pattern was highly variable, depended on the geographic origin of the sample – 297 sera were tested in a neutralization assay – there
was a correlation between Ab binding to the MN V3 loop and MN neutralizing titer, but with neutralization of IIIB or CBL-4 [Cheingsong-Popov1992]
423 178.1
(178.1.1)
gp160 (305–309) gp120 (305–309 BH10) KSiRI L Vaccine murine (IgG2a)
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: yeast derived gp160
Ab type V3 Donor C. Thiriart, Smith Kline and MRC AIDS reagent project
References Thiriart1989, Back1993, Moore1993a, Cook1994
• 178.1: Reacts to gp120 and gp160 in RIPA EIA and immunoblot [Thiriart1989]
• 178.1: Called 178.1.1 – conformational, does not bind well to denatured gp120 [Moore1993a]
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• 178.1: gp41 amino acid substitutions 668 (N/S) and 675 (I/M) in gp41 interfere with 5023s neutralization potency, region 662-675 is
ELDKWANLWNWFNI [Back1993]
• 178.1: MAbs against the glycosphingolipid GalCer block HIV infection of normally susceptible CD4 negative cells from the brain and colon – this MAb
can inhibit gp120 binding to GalCer in vitro – binding of GalCer to gp120 inhibited but did not completely block MAb binding[Cook1994]
• 178.1: UK Medical Research Council AIDS reagent: ARP331
424 257-D (257,
257-2-D-IV,
257-D-IV,
257, 257-2D,
257D,
ARP3023)
gp160 (305–309) gp120 (MN) KRIHI L HIV-1 infection human (IgG1λ )
Ab type V3 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Gorny1991, D’Souza1991, Karwowska1992b, Gorny1993, Cavacini1993a, Spear1993, D’Souza1994, VanCott1994, Stamatatos1995,
D’Souza1995, Zolla-Pazner1995a, Schutten1995a, Schutten1995b, Fontenot1995, Wisnewski1996, Schutten1996, Schutten1997, Stamatatos1997,
Hill1997, Hioe1997b, LaCasse1998, Yang1998, Gorny1998, Stamatatos1998, Zolla-Pazner1999a, Zolla-Pazner1999b, Beddows1999, Oggioni1999,
Nyambi2000, Park2000, York2001, Zhang2002
• 257-D: Called 257-2-D-IV – potent neutralizing MAb [D’Souza1991]
• 257-D: Reacts with MN, NY5, CDC4 and SF2, does not cross-react with RF, WM52, or HXB2 [Karwowska1992b]
• 257-D: Neutralizes MN – binds SF2: KSIYI – specificity: MN, SF2, NY5, RF. [Gorny1993]
• 257-D: Additive MN or SF2 neutralization when combined with CD4 binding site MAb F105 – does not neutralize RF [Cavacini1993a]
• 257-D: Mediated deposition of complement component C3 on HIV infected cells, enhanced by second Ab binding, rabbit anti-human IgG – complement
mediated virolysis of MN, but not in the presence of sCD4 [Spear1993]
• 257-D: Included a multi-lab study for antibody characterization and assay comparison – best NAb against MN, but not IIIB [D’Souza1994]
• 257-D: Potent MN neutralization, slow dissociation constant [VanCott1994]
• 257-D: The binding of conformation-dependent anti-V2, anti-V3, and anti-CD4BS MAbs to monomeric and virion-associated gp120 from HIV-1 isolates
with differences in cell tropism was studied – V3 loop epitopes were less accessible to Ab binding on the virion surface than in the gp120 monomer,
particularly for macrophage-tropic isolates SF162 and SF128a, relative to T-cell tropic SF2 – sCD4 association with gp120 better revealed this V3 epitope
on TCLA SF2 and dual tropic (MU3) viruses than on macrophage tropic isolates [Stamatatos1995]
• 257-D: Called 257-D-IV – could neutralize MN and closely related JRCSF, but not 2 B subtype and 1 D subtype primary isolates in a multi-laboratory study
involving 11 labs [D’Souza1995]
• 257-D: In serotyping study using flow-cytometry, bound only to virus with KRIHI [Zolla-Pazner1995a]
• 257-D: Only inhibition of SI phenotype virus, and strong enhancement of NSI phenotype chimeric viruses, that incorporated different envs from the same
donor [Schutten1995a]
• 257-D: Comparable affinity for SI and NSI viruses, in contrast to MAb MN215 [Schutten1995b]
• 257-D: 257-D is V H5 – V-region heavy chain usage was examined and a bias of enhanced V H1 and V H4, and reduced V H3, was noted among HIV
infected individuals [Wisnewski1996]
• 257-D: IIIB neutralizing MAbs in vitro fail to neutralize in a mouse model it in vivo [Schutten1996]
• 257-D: Neutralized (>90%) an SI-env chimeric virus and enhanced (>200%) an NSI-env chimeric virus [Schutten1997]
• 257-D: Binds less extensively than MAb 391-95D on the surface of HIV-1 isolates SF162 and SF128A – neutralizes less potently than 391-95D – stronger
neutralization of primary macrophage targets than PBMC [Stamatatos1997]
• 257-D: Called 257 – gp120 can inhibit MIP-1alpha from binding to CCR5, but this inhibitory effect is blocked by pre-incubation of gp120 with three
anti-V3 MAbs: 447, 257, 1027 – MAb 670 which binds in the C5 region had no effect [Hill1997]
• 257-D: A T-cell line-adapted (TCLA) derivative of SI primary isolate 168P acquired the ability to be neutralized by anti-V3 MAbs – the primary isolate
could use either CCR5 or CXCR4, and was not neutralized when infection was directed via either pathway, however the TCLA derivative uses CXCR4 only
and is neutralized [LaCasse1998]
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• 257-D: A neutralization assay was developed based on hemi-nested PCR amplification of the LTR (HNPCR) – LTR-HNPCR consistently revealed HIV
DNA and was shown to be a rapid, specific and reliable neutralization assay based on tests with 6 MAbs and 5 isolates [Yang1998]
• 257-D: Kinetic parameters were measured, and the association rates were similar, but dissociation rate constants were quite variable for V3 MAbs, 257-D
has a slow dissociation, thus the highest affinity among V3 MAbs [Gorny1998]
• 257-D: Called 257D – deleting the V2 loop of neutralization-resistant HIV-1 isolate SF162 does not abrogate its replication in PBMC or macrophages, but it
enhances its neutralization sensitivity to sera from patients with B clade infection up to 170-fold, and also enhances sensitivity to sera from clades A
through F – deletion of V1 or V2 did not enable neutralization by V3 MAbs 391-95D or 257D [Stamatatos1998]
• 257-D: Review of clade specificity and anti-V3 HIV-1-Abs [Zolla-Pazner1999a]
• 257-D: MAb peptide reactivity pattern clustered with immunological related MAbs: 1108, 386, 268, 311, 257, 694.8 – the amino acids HI tended to be
critical for reactivity in this group [Zolla-Pazner1999b]
• 257-D: rgp120 derived from a R5X4 subtype B virus, HIV-1 W61D, was used to vaccinate healthy volunteers and the resulting sera were compared with
sera from HIV-1 positive subjects and neutralizing MAbs – 257-D bound rgp120 W61D but could only neutralize the W61D isolate following T-cell line
adaptation [Beddows1999]
• 257-D: Study of a live-vector mucosal vaccine that expresses HIV-1 V3 domains using the bacterium Streptococcus gordonii which can express
heterologous Ag and can colonize the oral cavity and vagina of mice – 268-D and 257-D recognized S. gordonii expressing the V3 domain of MN – the
vaccine stimulated V3-specific IgG2a in mice [Oggioni1999]
• 257-D: A panel of 47 human MAbs was tested against 26 HIV-1 group M primary isolates from clades A through H – 19 V3 MAbs were tested, and of 494
combinations, 44% displayed some viral binding – V3 MAbs tended to have the most cross-reactive binding to clade A, B, C, and D isolates, less to E, F, G,
and H – 257-D showed intermediate reactivity [Nyambi2000]
• 257-D: Called 257D – six mutations in MN change the virus from a high-infectivity neutralization resistant phenotype to low-infectivity neutralization
sensitive – V3, CD4BS, and CD4i MAbs are 20-100 fold more efficient at neutralizing the sensitive form – the mutation L544P reduced binding of all
MAbs against gp120 by causing conformational changes [Park2000]
• 257-D: Abs against the V3 loop (50.1, 58.2, 59.1, 257-D, 268-D, 447-52D), CD4BS (IgG1b12, 559-64D, F105), CD4i (17b), and to gp41 (2F5, F240) each
showed similar binding efficiency to Env derived from related pairs of primary and TCLA lines (primary: 168P and 320SI, and TCLA: 168C and
320SI-C3.3), but the TCLA lines were much more susceptible to neutralization suggesting that the change in TCLA lines that make them more susceptible
to NAbs alters some step after binding [York2001]
• 257-D: Called ARP3023: Herpesvirus saimiri-immortalized CD4+ T lymphocytes (HVS T cells) were used to isolate virus and perform HIV-1
neutralization assays, and compared with a standard PBMC protocol – neutralization sensitivities to a panel of MAbs and to homologous or heterologous
plasma/sera were similar for HVS T cells (CN-2 cells) and PBMCs [Vella2002]
• 257-D: A rare mutation in the neutralization sensitive R2-strain in the proximal limb of the V3 region caused Env to become sensitive to neutralization by
MAbs directed against the CD4 binding site (CD4BS), CD4-induced (CD4i) epitopes, soluble CD4 (sCD4), and HNS2, a broadly neutralizing sera – 2/12
anti-V3 MAbs tested (19b and 694/98-D) neutralized R2, as did 2/3 anti-CD4BS MAbs (15e and IgG1b12), 2/2 CD4i MAbs (17b and 4.8D), and 2G12 and
2F5 – thus multiple epitopes on R2 are functional targets for neutralization and the neutralization sensitivity profile of R2 is intermediate between the highly
sensitive MN-TCLA strain and the typically resistant MN-primary strain [Zhang2002]
• 257-D: UK Medical Research Council AIDS reagent: ARP3023
• 257-D: NIH AIDS Research and Reference Reagent Program: 1510
425 311-11-D
(311-11D,
311, 311D,
311-D)
gp160 (305–313) gp120 KRIHIGP L HIV-1 infection human (IgG1λ )
Ab type V3 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Gorny1991, Gorny1993, Spear1993, Gorny1998, Zolla-Pazner1999a, Zolla-Pazner1999b, Nyambi2000
• 311-11-D: Neutralizes MN – binds SF2: KSIYIGP [Gorny1993]
• 311-11-D: Mediated deposition of complement component C3 on HIV infected cells, enhanced by second Ab binding, rabbit anti-human IgG [Spear1993]
648
DEC 2002
gp160 Antibodies HIV Antibodies Tables
B
C
ell
No. MAb ID HXB2 Location Author’s Location Sequence Neutralizing Immunogen Species(Isotype)
• 311-11-D: Review of clade specificity and anti-V3 HIV-1-Abs [Zolla-Pazner1999a]
• 311-11-D: MAb peptide reactivity pattern clustered with immunological related MAbs: 1108, 386, 268, 311, 257, 694.8 – the amino acids HI tended to be
critical for reactivity in this group [Zolla-Pazner1999b]
• 311-11-D: A panel of 47 human MAbs was tested against 26 HIV-1 group M primary isolates from clades A through H – 19 V3 MAbs were tested, and of
494 combinations, 44% displayed some viral binding – V3 MAbs tended to have the most cross-reactive binding to clade A, B, C, and D isolates, less to E,
F, G, and H – 311-11D showed weak reactivity [Nyambi2000]
426 41148D gp160 (305–313) gp120 (MN) KRIHIGP L HIV-1 infection human (IgG1)
Ab type V3
References Pinter1993b, Alsmadi1998
• 41148D: Neutralizes less potently than 4117C, reacts with MN, IIIB, SF2 [Pinter1993b]
• 41148D: A study of 6 anti-Env MAbs and their ability to bind or direct ADCC against target cells infected with IIIB, MN, SF-2, and RF – bound and
directed lysis against strains IIIB, MN, SF-2, comparable to 4117C, however 41148D is 10x less efficient at neutralization, showing ADCC and
neutralization don’t always correlate [Alsmadi1998]
427 391/95-D
(391-95D,
391.5,
391/95D)
gp160 (305–318) gp120 (MN) KRIHIGPGRAFY L HIV-1 infection human (IgG1κ)
Ab type V3 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Gorny1991, Gorny1993, Fontenot1995, Stamatatos1995, Seligman1996, Stamatatos1997, Stamatatos1998, Zolla-Pazner1999a,
Zolla-Pazner1999b, Ly2000, Park2000, Guillon2002, Lawson2002, Zhang2002
• 391/95-D: Neutralizes MN – binds to SF2, not IIIB [Gorny1993]
• 391/95-D: The binding of conformation-dependent anti-V2, anti-V3, and anti-CD4BS MAbs to monomeric and virion-associated gp120 from HIV-1
isolates with differences in cell tropism was studied – V3 loop epitopes were less accessible to Ab binding on the virion surface than in the gp120 monomer,
particularly for macrophage-tropic isolates SF162 and SF128a, relative to T-cell tropic SF2 – sCD4 association with gp120 better revealed this V3 epitope
on macrophage tropic and dual tropic (MU3) viruses, but not in TCLA SF2 [Stamatatos1995]
• 391/95-D: Competition ELISAs with serial deletions estimated the epitope to be KRIHIGPGRAFY – unconstrained peptide had higher affinity than cyclic
[Seligman1996]
• 391/95-D: Called 391-95D – binds more extensively than MAb 257-D on the surface of HIV-1 isolates SF162 and SF128A – neutralizes more potently than
257-D – stronger neutralization of primary macrophage targets than PBMC – binding post-gp120-sCD4 association related to anti-V3 Abs neutralizing
capacity [Stamatatos1997]
• 391/95-D: Called 391-95D – deleting the V2 loop of neutralization-resistant HIV-1 isolate SF162 does not abrogate its replication in PBMC or
macrophages, but it enhances its neutralization sensitivity to sera from patients with B clade infection up to 170-fold, and also enhances sensitivity to sera
from clades A through F – deletion of V1 or V2 did not enable neutralization by V3 MAbs 391-95D or 257D [Stamatatos1998]
• 391/95-D: Review of clade specificity and anti-V3 HIV-1-Abs [Zolla-Pazner1999a]
• 391/95-D: Called 391.5 – MAb peptide-reactivity pattern clustered with immunological related MAbs: 391.5, 412 and 418, all selected with MN V3
peptide – the core amino acids HIGPGR tended to be critical for reactivity in this group [Zolla-Pazner1999b]
• 391/95-D: Called 391-95D – SF162 is a neutralization-resistant HIV-1 isolate – N-linked glycosylation modifications in the V2 loop of the SF162 gp120
revealed that these sites prevent neutralization by CD4BS MAbs (IgG1b12 and IgGCD4), and protect against neutralization by V3 MAbs (447-D and
391-95D) – V2-region glycosylation site mutations did not alter neutralization resistance to V2 MAbs (G3.4 and G3.136) or CD4i MAbs (17b and 48d) –
V2 glycosylation site modification allows infection of macrophages, probably due to glycosylated forms requiring fewer CCR5 molecules for viral entry
[Ly2000]
• 391/95-D: Called 391/95D – six mutations in MN change the virus from a high-infectivity neutralization resistant phenotype to low-infectivity
neutralization sensitive – V3, CD4BS, and CD4i MAbs are 20-100 fold more efficient at neutralizing the sensitive form – the mutation L544P reduced
binding of all MAbs against gp120 by causing conformational changes [Park2000]
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• 391/95-D: The affect of Ab binding on infectivity was studied by pseudotyping three related envs with different phenotypes – R5 viruses were preferentially
enhanced, not X4 – the V3 region was the main determinant of Ab-mediated enhancement and modulation of the interaction between CCR5 and gp120 is
critical – tests with MAbs anti-V3 391/95-D and CD4BS-specific GP68 indicate that Ab specificity did not determine whether or not infectivity was
enhanced or neutralized, rather the phenotype was determined by Env conformation [Guillon2002]
• 391/95-D: The phenotype and genotype of viral env sequences were studied over a period of seroconversion in one individual – Env trans-complementation
demonstrated infectivity of clones derived pre-seroconversion were not influenced by MAb 391/95-D, but post-seroconversion clones were enhanced in the
presence of 391/95-D, although the V3 binding region was unchanged – a change in the CD4-binding site was observed (NL43 427 Glu–>Lys) to be present
in the post-seroconversion 391/95-D enhanced clone (see [Guillon2002]) [Lawson2002]
• 391/95-D: A rare mutation in the neutralization sensitive R2-strain in the proximal limb of the V3 region caused Env to become sensitive to neutralization
by MAbs directed against the CD4 binding site (CD4BS), CD4-induced (CD4i) epitopes, soluble CD4 (sCD4), and HNS2, a broadly neutralizing sera –
2/12 anti-V3 MAbs tested (19b and 694/98-D) neutralized R2, as did 2/3 anti-CD4BS MAbs (15e and IgG1b12), 2/2 CD4i MAbs (17b and 4.8D), and 2G12
and 2F5 – thus multiple epitopes on R2 are functional targets for neutralization and the neutralization sensitivity profile of R2 is intermediate between the
highly sensitive MN-TCLA strain and the typically resistant MN-primary strain [Zhang2002]
428 Aw gp160 (305–320) gp120 (Gun-1wt) KSITIGPGRAFHAI L Vaccine rat
Vaccine Vector/Type: peptide Strain: Gun-1 HIV component: V3
Ab type V3
ReferencesMcKnight1995
• Aw: Rat antibodies were raised against V3 peptides that represent either the wildtype (wt), or brain-cell tropic variant (v) of the isolate Gun-1 – Aw gives
weak neutralization of both wildtype and v strains [McKnight1995]
429 Bw gp160 (305–320) gp120 (Gun-1wt) KSITIGPGRAFHAI L Vaccine rat
Vaccine Vector/Type: peptide Strain: Gun-1 HIV component: V3
Ab type V3
ReferencesMcKnight1995
• Bw: Rat antibodies were raised against V3 peptides that represent either the wildtype (wt), or brain-cell tropic variant (v) of the isolate Gun-1 – Bw gives
weak neutralization of only the wildtype strain, does not bind to variant [McKnight1995]
430 DO142-10
(DO 142-10)
gp160 (305–320) gp120 (MN) KRIHIGPGRAFYTT L HIV-1 infection human Fab (IgG1)
Ab type V3
References Seligman1996, Ditzel1997, Parren1997c, Parren1997a, Parren1998a, Sullivan1998a
• DO142-10: Fab fragment – competition ELISAs with serial deletions defined the epitope KRIHIGPGRAFYTT [Seligman1996]
• DO142-10: Phage expression libraries panned against MN peptide were used to select Fab DO142-10 – Fab binds MN gp120, but not a primary isolate rec
gp120 [Ditzel1997]
• DO142-10: Neutralizes TCLA strains but not primary isolates [Parren1997c]
• DO142-10: Binds to gp120 MN and an MN V3 peptide with equal affinity, but binds a consensus B peptide and JRCSF less well, and to IIIB gp120 not at
all [Parren1997a]
• DO142-10: The rank order of Fab binding affinity to monomeric gp120 (Loop 2 > 3B3 > b12 = DO8i > b11 > b3 > b14 > b13 > DO142-10 > DA48 > L17)
was markedly different that Fab binding affinity to the mature oligomeric form (3B3 > b12 > DO142-10 > Loop 2 > b11 > L17 > b6 > DO8i > b14 > DA48
> b3 > b13) and binding to oligomeric form and neutralization were correlated for both Fabs and MAbs – authors suggest that neutralization is determined
by the fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
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• DO124-10: The HIV-1 virus YU2 entry can be enhanced by MAbs binding to the CD4BS, V3 loop, and CD4i epitopes – the activation for this enhanced
entry state could be conferred on HxB2 by introducing the YU2 V3 loop, or the YU2 V3 and V1/V2 loops – a similar effect is observed by sub-neutralizing
concentrations of sCD4 and the effect is dependent of CCR5 – Fab Ab fragment DO124-10 also enhances YU2 entry, ruling out Fc interactions or Env
cross-linking as a mechanism – while DO124-10 enhances YU2 entry 6-fold, it neutralizes HXBc2 under identical conditions [Sullivan1998a]
431 Dv gp160 (305–320) gp120 (Gun-1v) KSITIGSGRAFHAI L Vaccine rat
Vaccine Vector/Type: peptide Strain: Gun-1 HIV component: V3
Ab type V3
ReferencesMcKnight1995
• Dv: Rat antibodies were raised against V3 peptides that represent either the wildtype (wt), or brain-cell tropic variant (v) of the isolate Gun-1 –
neutralization of only the variant strain, does not bind to wildtype [McKnight1995]
432 Fv gp160 (305–320) gp120 (Gun-1v) KSITIGSGRAFHAI L Vaccine rat
Vaccine Vector/Type: peptide Strain: Gun-1 HIV component: V3
Ab type V3
ReferencesMcKnight1995
• Fv: Rat antibodies were raised against V3 peptides that represent either the wildtype (wt), or brain-cell tropic variant (v) of the isolate Gun-1 –
neutralization of only the variant strain, does not bind to wildtype [McKnight1995]
433 Gv gp160 (305–320) gp120 (Gun-1v) KSITIGSGRAFHAI L Vaccine rat
Vaccine Vector/Type: peptide Strain: Gun-1 HIV component: V3
Ab type V3
ReferencesMcKnight1995
• Gv: Rat antibodies were raised against V3 peptides that represent either the wildtype (wt), or brain-cell tropic variant (v) of the isolate Gun-1 –
neutralization of only the variant strain, does not bind to wildtype [McKnight1995]
434 Hv gp160 (305–320) gp120 (Gun-1v) KSITIGSGRAFHAI L Vaccine rat
Vaccine Vector/Type: peptide Strain: Gun-1 HIV component: V3
Ab type V3
ReferencesMcKnight1995
• Hv: Rat antibodies were raised against V3 peptides that represent either the wildtype (wt), or brain-cell tropic variant (v) of the isolate Gun-1 –
neutralization of only the variant strain, does not bind to wildtype [McKnight1995]
435 polyclonal gp160 (305–322) gp140 (SF162) KSITIGPGRAFYATGD yes Vaccine rabbit, Rhesus
macaque (IgG)
Vaccine Vector/Type: DNA with CMV promotor Strain: SF162, SF162DeltaV2 HIV component: gp140 Adjuvant: MF-59C
Ab type V3
References Barnett2001
• SF162DeltaV2 is a virus that has a 30 amino acids deletion in the V2 loop that does not abrogate its infectivity but renders it highly susceptible to
neutralization – when incorporated into a codon-optimized DNA vaccine with a CMV promoter, delivered by gene gun, SF162DeltaV2 gave higher
neutralizing Ab titers against SF162 than did SF162 itself, and Abs that cross-neutralized non-homologous primary isolates were obtained only when
SF162DeltaV2, but not intact SF162, was used as the immunogen – NAbs titers specific for SF162 increased with multiple immunizations, while titers for
non-homologous isolates decreased, but anti-V3 peptide binding Abs were not likely the source of this distinction because anti-V3 titers were much lower
than those against the entire envelope, and the second booster immunization did not increase the titer of anti-V3 loop Abs [Barnett2001]
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436 50.1
(R/V3-50.1,
Fab 50.1)
gp160 (306–310) gp120 (MN) RIHIG L Vaccine murine (IgG1κ)
Vaccine Vector/Type: peptide Strain: MN HIV component: V3
Ab type V3 DonorMary White-Scharf, Repligen Corporation, Cambridge, MA
References D’Souza1991, White-Scharf1993, Potts1993, Ghiara1993, Rini1993, Bou-Habib1994, VanCott1994, Robert-Guroff1994, Moore1994b,
VanCott1995, Fontenot1995, Seligman1996, Berman1997, LaCasse1998, Stanfield1999, Hoffman1999, Park2000, York2001, Zhang2002
• 50.1: Called R/V3-50.1 – potent neutralizing of lab strains[D’Souza1991]
• 50.1: Epitope defined by peptide reactivity and changes affinity with amino acid substitutions – epitope RIHIGP [White-Scharf1993]
• 50.1: No synergistic neutralization of MN when combined with CD4BS MAb F105 – isotype stated to be IgG2a [Potts1993]
• 50.1: Crystal structure of a 24 amino acid peptide from the V3 loop bound to 59.1 and 50.1 Fab fragments – epitope KRIHIGP [Ghiara1993]
• 50.1: Crystal structure of V3 loop bound to 50.1 – light chain binds just to the left of GPG, heavy chain binds further to the left [Rini1993]
• 50.1: No neutralization of primary isolate JR-CSF – greater affinity for and neutralization of T cell tropic strain T-CSF, derived from JR-CSF
[Bou-Habib1994]
• 50.1: Potent MN neutralization, slow dissociation rate [VanCott1994]
• 50.1: Chimeric MN V3 loop in an HXB2 background allows increased FACS signal, Ab affinity, and viral neutralization [Robert-Guroff1994]
• 50.1: Shows modest cross-reactivity among B clade gp120s, little outside B clade [Moore1994b]
• 50.1: Used to monitor HIV-1 Env expression in infected H9 cells [VanCott1995]
• 50.1: Competition ELISAs with serial deletions produced comparable estimate of epitope length to crystal structure and alanine substitution – KRIHIGP
[Seligman1996]
• 50.1: Binds to 6/7 isolates from breakthrough cases from a MN gp120 vaccine trial [Berman1997]
• 50.1: A T-cell line-adapted (TCLA) derivative of SI primary isolate 168P acquired the ability to be neutralized by anti-V3 MAbs – the primary isolate could
use either CCR5 or CXCR4, and was not neutralized when infection was directed via either pathway, however the TCLA derivative uses CXCR4 only and is
neutralized [LaCasse1998]
• 50.1: The crystal structure of V3 loop peptides bound to Fabs was obtained – conformational changes in the tip of the V3 loop (GPGR) were observed when
different Fabs were bound [Stanfield1999]
• 50.1: Called R/V3-50.1 – six mutations in MN change the virus from a high-infectivity neutralization resistant phenotype to low-infectivity neutralization
sensitive – V3, CD4BS, and CD4i MAbs are 20-100 fold more efficient at neutralizing the sensitive form – the mutation L544P reduced binding of all
MAbs against gp120 by causing conformational changes – 50.1 could only neutralize the sensitive form [Park2000]
• 50.1: Abs against the V3 loop (50.1, 58.2, 59.1, 257-D, 268-D, 447-52D), CD4BS (IgG1b12, 559-64D, F105), CD4i (17b), and to gp41 (2F5, F240) each
showed similar binding efficiency to Env derived from related pairs of primary and TCLA lines (primary: 168P and 320SI, and TCLA: 168C and
320SI-C3.3), but the TCLA lines were much more susceptible to neutralization suggesting that the change in TCLA lines that make them more susceptible
to NAbs alters some step after binding – the dissociation constant, Kd of 50.1 for the cell associated primary and TCLA Envs was equal, 7nM [York2001]
• 50.1: Called R/V3-50.1 – A rare mutation in the neutralization sensitive R2-strain in the proximal limb of the V3 region caused Env to become sensitive to
neutralization by MAbs directed against the CD4 binding site (CD4BS), CD4-induced (CD4i) epitopes, soluble CD4 (sCD4), and HNS2, a broadly
neutralizing sera – 2/12 anti-V3 MAbs tested (19b and 694/98-D) neutralized R2, as did 2/3 anti-CD4BS MAbs (15e and IgG1b12), 2/2 CD4i MAbs (17b
and 4.8D), and 2G12 and 2F5 – thus multiple epitopes on R2 are functional targets for neutralization and the neutralization sensitivity profile of R2 is
intermediate between the highly sensitive MN-TCLA strain and the typically resistant MN-primary strain [Zhang2002]
• 50.1: NIH AIDS Research and Reference Reagent Program: 1289
437 polyclonal gp160 (306–318) gp120 (NY5) KKGIAIGPGRTLY (IgM)
Ab type V3
ReferencesMetlas1999b, Metlas1999a
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• Auto-Abs that react with the V3 loop of NY5 are present in the sera of HIV- individuals, and are predominantly IgM [Metlas1999b]
438 BAT123
(BAT-123,
CGP 47 439)
gp160 (306–322) gp120 (308–322 HXB2) RIRIQRGPGRAFVTIGK L Vaccine murine (IgG1κ)
Vaccine Vector/Type: inactivated virus Strain: IIIB HIV component: virus
Ab type V3 Donor Tanox Biosystems Inc and David Ho, ADARC, NY
References Fung1987, Liou1989, Fung1990, Moore1993a, Safrit1993, Thali1993, Pirofski1993, Gauduin1995, Sattentau1995b, Poignard1996a,
Andrus1998, Parren1998a, Gauduin1998
• BAT123: CGP 47 439 is a BAT123 chimera that has a human IgG1 Fc domain
• BAT123: Anti-idiotypic MAb, AB19-4i, stimulates anti-anti-ID which neutralizes MN and IIIB [Fung1990]
• BAT123: Called BAT-123 – conformational, does not bind well to denatured gp120 – not reactive with SF-2 gp120 – does not inhibit HIV-1 sera from
binding to IIIB gp120 [Moore1993a]
• BAT123: Passive transfer to Hu-PBS-SCID mice confers protection against challenge with homologous cell-free virus [Safrit1993]
• BAT123: Variable region sequenced – heavy chain: V 3660-SB32, D unknown, J H3 – light chain: V kappa21, J kappa2 [Pirofski1993]
• BAT123: Passive transfer of BAT123 to hu-PBL-SCID mice 1 hour prior to inoculation with HIV-1 LAI, or up to four hours post-exposure, could protect
mice from infection – the protection, like the MAb, was specific for the viral strain LAI [Gauduin1995]
• BAT123: Binds with high affinity to monomer and oligomer, rapid association and potent neutralization of lab strain [Sattentau1995b]
• BAT123: Epitope described as RGPGRAFVTIGK – V3 MAbs 9284, BAT123, 110.5, and 110.I could each significantly increase gp120 dissociation from
virus (BAT123 less so than the others), mimicking sCD4, and expose the gp41 epitope for MAb 50-69, in contrast to anti-V2 MAbs [Poignard1996a]
• BAT123: Post-exposure prophylaxis was effective when MAb 694/98-D was delivered 15 min post-exposure to HIV-1 LAI in hu-PBL-SCID mice, but
declined to 50% if delivered 60 min post-exposure, and similar time constraints have been observed for HIVIG, 2F5 and 2G12, in contrast to MAb BAT123
that could protect delivered 4 hours post infection [Andrus1998]
• BAT123: The MAb and Fab binding to the oligomeric form of gp120 and neutralization were highly correlated – authors suggest that neutralization is
determined by the fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
• BAT123: Post-exposure passive transfer of murine BAT123 can confer protection to hu-PBL-SCID mice challenged with HIV-1 LAI – this protection is not
elicited by CGP 47 439, a BAT123 chimera that has a human IgG1 Fc domain, suggesting that the protection is mediated by complement – the protective
ability of BAT123 is lost when mice were treated with cobra venom factor, which inactivates serum complement – IgG1 does not fix complement efficiently
so an IgG2 MAb might perform better [Gauduin1998]
439 838-D (838) gp160 (307–311) Env (RF) KSITK L HIV-1 infection human (IgG1λ )
Ab type V3 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Gorny1997, Hioe1997b, Nyambi1998, Zolla-Pazner1999a, Zolla-Pazner1999b, Gorny2000a, Nyambi2000, He2002
• 838-D: Five human MAbs against were derived from HIV-infected North American subjects after selection by the V3 RF peptide – 838-D was
cross-reactive with V3 peptides from clade A and C, and could bind to 5/8 B clade V3 peptides – 50% neutralization of RF was obtained [Gorny1997]
• 838-D: Four primary isolates showed distinct patterns of sensitivity to neutralization by polyclonal sera or plasma and MAbs – BZ167 was the only isolate
inhibited by all polyclonal sera and plasma tested, and was also neutralized by 8/17 MAbs, in particular anti-V3 loop (419-D, 447-52D, 782-D, and 838-D),
anti-CD4bd (559/64-D, 654-D and 830-D and a cluster II of gp41 directed MAb (98-6) – isolates 92HT593 and 91US056 were neutralized by V3 loop
(419-D, and 447-52D)and cluster II gp41 (98-6) MAbs at higher concentrations – US4 was neutralized by some of the polyclonal sera/plasma tested and not
at all by MAbs individually or by a cocktail of ten MAbs consisting of 419-D, 447-52D, 782-D, 838-D, 559/64-D, 654-D, 450-D, 670-D, 1281-D and 98-6
[Hioe1997b]
• 838-D: Using a whole virion-ELISA method, 18 human MAbs were tested for their ability to bind to a panel of 9 viruses from clades A, B, D, F, G, and H –
838-D bound B clade virions but had limited cross-reactivity with other clades, with low levels of binding to A and D virions [Nyambi1998]
• 838-D: Review of clade specificity and anti-V3 HIV-1-Abs – this Ab showed strong binding to many A, B, C and F peptides, poor binding to D and E
[Zolla-Pazner1999a]
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• 838-D: MAb peptide-reactivity pattern clustered with immunological related MAbs: 838, 782, 1027, 908, and 1006, all selected with RF V3 peptide – the
core amino acids KSITK tended to be critical for reactivity in this group [Zolla-Pazner1999b]
• 838-D: Binding of panel of 21 MAbs to soluble oligomeric gp140 versus gp41 or gp120 monomers was compared – no MAb was oligomer specific, though
anti-V3 and CD4BS MAbs reacted better with the oligomer and V2 and C5 tended to favor the monomer – V3 MAbs 447-52D, 838-D, and 1334 bound
with a 7-10 fold preference for the oligomer [Gorny2000a]
• 838-D: A panel of 47 human MAbs was tested against 26 HIV-1 group M primary isolates from clades A through H – 19 V3 MAbs were tested, and of 494
combinations, 44% displayed some viral binding – V3 MAbs tended to have the most cross-reactive binding to clade A, B, C, and D isolates, less to E, F, G,
and H – 838-D showed intermediate reactivity [Nyambi2000]
• 838-D: Called 838 – Transgenic mice carrying human genes allowing production of fully human MAbs were used to rapidly create a panel of anti-HIV
gp120 MAb producing hybridomas by immunization with HIV SF162 gp120 – the previously described human MAbs 5145A(CD4BS) , 4117C (plus
others, V3) and 697D (and SC258, V2) were used as controls [He2002]
• 838-D: A rare mutation in the neutralization sensitive R2-strain in the proximal limb of the V3 region caused Env to become sensitive to neutralization by
MAbs directed against the CD4 binding site (CD4BS), CD4-induced (CD4i) epitopes, soluble CD4 (sCD4), and HNS2, a broadly neutralizing sera – 2/12
anti-V3 MAbs tested (19b and 694/98-D) neutralized R2, as did 2/3 anti-CD4BS MAbs (15e and IgG1b12), 2/2 CD4i MAbs (17b and 4.8D), and 2G12 and
2F5 – thus multiple epitopes on R2 are functional targets for neutralization and the neutralization sensitivity profile of R2 is intermediate between the highly
sensitive MN-TCLA strain and the typically resistant MN-primary strain [Zhang2002]
440 1006-15D
(1006)
gp160 (307–312) gp120 (RF) KSITKG no HIV-1 infection human (IgG1λ )
Ab type V3 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Gorny1997, Zolla-Pazner1999a, Zolla-Pazner1999b, Nyambi2000, He2002
• 1006-15D: Five human MAbs against were derived from HIV-infected North American subjects after selection by the V3 RF peptide – was somewhat
cross-reactive with V3 peptides from clade A, C and other B clade V3 peptides, but not E clade [Gorny1997]
• 1006-15D: Review of clade specificity and anti-V3 HIV-1-Abs – this Ab showed strong binding to several B and F peptides, one C peptide, and some
reactivity with A peptides – no binding was observed with D and E peptides [Zolla-Pazner1999a]
• 1006-15D: MAb peptide-reactivity pattern clustered with immunological related MAbs: 838, 782, 1027, 908, and 1006, all selected with RF V3 peptide –
the core amino acids KSITK tended to be critical for reactivity in this group [Zolla-Pazner1999b]
• 1006-15D: A panel of 47 human MAbs was tested against 26 HIV-1 group M primary isolates from clades A through H – 19 V3 MAbs were tested, and of
494 combinations, 44% displayed some viral binding – V3 MAbs tended to have the most cross-reactive binding to clade A, B, C, and D isolates, less to E,
F, G, and H – 1006-15D showed strong cross-reactivity [Nyambi2000]
• 1006-15D: Called 1006 – Transgenic mice carrying human genes allowing production of fully human MAbs were used to rapidly create a panel of anti-HIV
gp120 MAb producing hybridomas by immunization with HIV SF162 gp120 – the previously described human MAbs 5145A(CD4BS) , 4117C (plus
others, V3) and 697D (and SC258, V2) were used as controls [He2002]
441 782-D (782) gp160 (307–312) Env (RF) KSITKG L HIV-1 infection human (IgG1λ )
Ab type V3 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Gorny1997, Hioe1997b, Zolla-Pazner1999a, Zolla-Pazner1999b, Nyambi2000
• 782-D: Five human MAbs against were derived from HIV-infected North American subjects after selection by the V3 RF peptide – 782-D was not
cross-reactive with V3 peptides from clade A or E, but could bind to 3/8 B clade V3 peptides, and 1/2 C clade V3 peptides – 50% neutralization of RF was
obtained [Gorny1997]
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• 782-D: Four primary isolates showed distinct patterns of sensitivity to neutralization by polyclonal sera or plasma and MAbs – BZ167 was the only isolate
inhibited by all polyclonal sera and plasma tested, and was also neutralized by 8/17 MAbs, in particular anti-V3 loop (419-D, 447-52D, 782-D, and 838-D),
anti-CD4bd (559/64-D, 654-D and 830-D and a cluster II of gp41 directed MAb (98-6) – isolates 92HT593 and 91US056 were neutralized by V3 loop
(419-D, and 447-52D)and cluster II gp41 (98-6) MAbs at higher concentrations – US4 was neutralized by some of the polyclonal sera/plasma tested and not
at all by MAbs individually or by a cocktail of ten MAbs consisting of 419-D, 447-52D, 782-D, 838-D, 559/64-D, 654-D, 450-D, 670-D, 1281-D and 98-6
[Hioe1997b]
• 782-D: Review of clade specificity and anti-V3 HIV-1-Abs – this Ab showed strong binding to several B and F peptides, one C peptide, and some reactivity
with A and D peptides [Zolla-Pazner1999a]
• 782-D: MAb peptide-reactivity pattern clustered with immunological related MAbs: 838, 782, 1027, 908, and 1006, all selected with RF V3 peptide – the
core amino acids KSITK tended to be critical for reactivity in this group [Zolla-Pazner1999b]
• 782-D: A panel of 47 human MAbs was tested against 26 HIV-1 group M primary isolates from clades A through H – 19 V3 MAbs were tested, and of 494
combinations, 44% displayed some viral binding – V3 MAbs tended to have the most cross-reactive binding to clade A, B, C, and D isolates, less to E, F, G,
and H – 782-D showed intermediate reactivity [Nyambi2000]
442 908-D (908,
908-12D)
gp160 (307–312) gp120 (RF) KSITKG L HIV-1 infection human (IgG1λ )
Ab type V3 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Gorny1997, Zolla-Pazner1999a, Zolla-Pazner1999b, Nyambi2000
• 908-D: Five human MAbs against were derived from HIV-infected North American subjects after selection by the V3 RF peptide – 908-D was not
cross-reactive with V3 peptides from clade E, but could bind to 6/8 B clade V3 peptides, 2/4 A clade, and 1/2 C clade – 50% neutralization of RF was
obtained [Gorny1997]
• 908-D: Review of clade specificity and anti-V3 HIV-1-Abs – this Ab showed strong binding to several A, B, C and F peptides, and poor binding to E and D
peptides [Zolla-Pazner1999a]
• 908-D: MAb peptide-reactivity pattern clustered with immunological related MAbs: 838, 782, 1027, 908, and 1006, all selected with RF V3 peptide – the
core amino acids KSITK tended to be critical for reactivity in this group [Zolla-Pazner1999b]
• 908-D: A panel of 47 human MAbs was tested against 26 HIV-1 group M primary isolates from clades A through H – 19 V3 MAbs were tested, and of 494
combinations, 44% displayed some viral binding – V3 MAbs tended to have the most cross -reactive binding to clade A, B, C, and D isolates, less to E, F,
G, and H – 908-D showed strong cross-reactivity, but achieved only 50% neutralization on 2/5 isolates tested [Nyambi2000]
443 1027-15D
(1027,
1027-D,
1027D)
gp160 (307–313) Env (RF) KSITKGP no HIV-1 infection human (IgG1λ )
Ab type V3 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Gorny1997, Zolla-Pazner1999a, Zolla-Pazner1999b, Nyambi2000, Zhang2002
• 1027-15D: Five human MAbs against were derived from HIV-infected North American subjects after selection by the V3 RF peptide – 1027-15D was not
cross-reactive with V3 peptides from clade A or E, but could bind to 3/8 B clade V3 peptides, and 1/2 C clade V3 peptides [Gorny1997]
• 1027-15D: Review of clade specificity and anti-V3 HIV-1-Abs – this Ab showed moderate binding to several B and F peptides, one C peptide, and was not
reactivity with A, D and E peptides [Zolla-Pazner1999a]
• 1027-15D: MAb peptide-reactivity pattern clustered with immunological related MAbs: 838, 782, 1027, 908, and 1006, all selected with RF V3 peptide –
the core amino acids KSITK tended to be critical for reactivity in this group [Zolla-Pazner1999b]
• 1027-15D: A panel of 47 human MAbs was tested against 26 HIV-1 group M primary isolates from clades A through H – 19 V3 MAbs were tested, and of
494 combinations, 44% displayed some viral binding – V3 MAbs tended to have the most cross-reactive binding to clade A, B, C, and D isolates, less to E,
F, G, and H – 1027-15D showed strong cross-reactivity [Nyambi2000]
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• 1027-15D: Called 1027-D – A rare mutation in the neutralization sensitive R2-strain in the proximal limb of the V3 region caused Env to become sensitive
to neutralization by MAbs directed against the CD4 binding site (CD4BS), CD4-induced (CD4i) epitopes, soluble CD4 (sCD4), and HNS2, a broadly
neutralizing sera – 2/12 anti-V3 MAbs tested (19b and 694/98-D) neutralized R2, as did 2/3 anti-CD4BS MAbs (15e and IgG1b12), 2/2 CD4i MAbs (17b
and 4.8D), and 2G12 and 2F5 – thus multiple epitopes on R2 are functional targets for neutralization and the neutralization sensitivity profile of R2 is
intermediate between the highly sensitive MN-TCLA strain and the typically resistant MN-primary strain [Zhang2002]
444 F19.26-4 gp160 (307–319) gp120 (312–324 LAI) IRIQRGPGRAFVT L Vaccine murine (IgG2aκ)
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp120
Ab type V3
References Boudet1994
• F19.26-4: Strain specific – used to raise anti-idiotype antibodies [Boudet1994]
445 F19.48-3 gp160 (307–319) gp120 (312–324 LAI) IRIQRGPGRAFVT L Vaccine murine (IgG2aκ)
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp120
Ab type V3
References Boudet1994
• F19.48-3: Strain specific – used to raise anti-idiotype antibodies [Boudet1994]
446 F19.57-11 gp160 (307–319) gp120 (312–324 LAI) IRIQRGPGRAFVT L (LAI) Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp120
Ab type V3
References Boudet1991, Boudet1994, Boudet1995
• F19.57-11: MAb F19.57-11 is strain specific for LAI – used to raise anti-idiotype rabbit antibodies (called 57-B Ab2) [Boudet1994]
• F19.57-11: Anti-anti-idiotypic antibodies (Ab3) were raised in BALBc mice that had greater breadth of reactivity than the original F19.57-11 (Ab3 could
also recognize 1282 and SF2, with aa TRK(R or S)IYIGPGRA(WY or FH)T) [Boudet1995]
447 M77 gp160 (307–320) gp120 (IIIB) IRIQRGPGRAFVTI L HIV-1 infection human (IgG)
Ab type V3 Donor Advanced BioScience Laboratories, Rockville, MD, commercial
References Pal1992, diMarzo Veronese1992, diMarzo Veronese1993, Watkins1993, Cook1994, DeVico1995, Denisova1995, Watkins1996, Denisova2000
• M77: IIIB-specific MAb, immunoprecipitates deglycosylated form [diMarzo Veronese1992]
• M77: Antibody binding to viral isolates from IIIB infected lab worker followed through time – A to T substitution resulted in the loss of neutralization and
native gp120 binding, but not peptide binding [diMarzo Veronese1993]
• M77: MAbs against the glycosphingolipid GalCer block HIV infection of normally susceptible CD4 negative cells from the brain and colon – this MAb can
inhibit gp120 binding to GalCer in vitro [Cook1994]
• M77: Reacted with both reduced and non-reduced covalently cross-linked gp120-CD4 complex [DeVico1995]
• M77: Conformational rearrangements upon binding of M77 to gp120 generates novel epitopes called metatopes [Denisova1995]
• M77: Stated to be a murine MAb – a neutralization escape mutant (HXB2 A281V) was selected by growth of HXB2 in the presence of broadly neutralizing
sera – M77 neutralization was only slightly reduced by this mutation [Watkins1993]
• M77: Used M77 bound to gp120 as an immunogen – analysis of polyclonal and monoclonal (62 MAbs were generated) response suggests the M77-gp120
immunogen generated MAbs to more linear epitopes than gp120 alone or gp120 bound to CD4 [Denisova1996]
• M77: Native M77 is highly strain specific, and V3 binding is primarily dependent on its heavy chain – a light chain switched Fab version of M77 could
recognize HIV-1 strains that had substitutions on the left side of the V3 loop – R in GPGR is likely to be critical for binding [Watkins1996]
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• M77: M77 is highly strain specific for IIIB, but anti-idiotypic Abs directed against M77 can in turn elicit an Ab response with expanded HIV
cross-reactivity – this mechanism may serve to prolong the primary response and to counter-balance viral immune evasion by mutation [Denisova2000]
448 SP.BAL114 gp160 (308–317) gp120 (BAL) SIHIGPGRAF L murine? (IgG2aκ)
Ab type V3
References Arendrup1995
• Authors suggest that during in vivo immunoselection of escape virus, the V3 domain gains increasing resemblance to that of lab strains [Arendrup1995]
449 SP.SF2:104 gp160 (308–317) gp120 (SF2) SIYIGPGRAF L HIV-1 infection (IgG2aκ)
Ab type V3
References Arendrup1993, Arendrup1995
• SP.SF2:104: Anti-V3 antibody that could neutralize primary virus isolated from a time point of neutralization resistance of autologous virus [Arendrup1993]
• SP.SF2:104: Authors suggest that during in vivo immunoselection of escape virus, the V3 domain gains increasing resemblance to lab strains
[Arendrup1995]
450 polyclonal gp160 (308–319) gp120 (304–318 LAI) RIHIGPGRAFYT HIV-1 infection human (IgG, IgM)
Ab type V3
References Langedijk1995
• Polylconal sera from six individuals tested for reactivity against a panel of peptides based on autologous sequences provide evidence for immunological
escape mutations in the tip of the V3 loop [Langedijk1995]
451 19b gp160 (308–320) gp120 -I----G--FY-T L HIV-1 infection human (IgG1)
Ab type V3 Donor James Robinson, University of Connecticut, Storrs
References Scott1990, Moore1994b, Moore1994a, Sattentau1995a, Moore1995c, Moore1995a, Moore1995b, Gauduin1996, Wu1996, Trkola1996a,
D’Souza1997, Binley1997a, Fouts1997, Ugolini1997, Boots1997, Parren1997c, Mondor1998, Parren1998a, Trkola1998, Binley1999, Park2000,
Kolchinsky2001, Schulke2002, Zhang2002, Poignard2003
• 19b: V3 loop binding MAb that is more broadly clade cross-reactive than most (binds to 19/29 clade B and 10/12 clade E gp120s) [Moore1994b]
• 19b: Competition studies with human sera from seroconverting individuals showed that anti-CD4 BS antibodies can arise very early in infection,
comparable or prior to anti-V3 antibodies [Moore1994a]
• 19b: Formalin inactivation of virus at 0.1% formalin for 10 hours at 4 degrees was optimal for inactivation of virus while maintaining epitope integrity
[Sattentau1995c]
• 19b: Binds to some gp120s from clades A,B,C,E, and F – weakly neutralized some B and one C clade virus [Moore1995c]
• 19b: Despite broad gp120 binding reactivity, not broadly neutralizing [Moore1995a]
• 19b: Review: more broadly cross-reactive than anti-V3 tip MAb 447-D [Moore1995b]
• 19b: Not as effective as IgG1b12 at neutralization ex vivo of virus direct from plasma of HIV-1 infected individuals [Gauduin1996]
• 19b: MIP-1alpha binding to CCR-5 expressing cells can be inhibited by gp120-sCD4 – binding of 19b blocks this inhibition [Wu1996]
• 19b: Inhibits gp120 interaction with CCR-5 in a MIP-1beta-CCR-5 competition study [Trkola1996a]
• 19b: In a multilaboratory blinded study, failed to consistently neutralize any of nine B clade primary isolates – there were four sequences with variations in
the defined epitope among the 9 isolates tested [D’Souza1997]
• 19b: Study shows neutralization is not predicted by MAb binding to JRFL monomeric gp120, but is associated with oligomeric Env binding – 19b bound
monomer, did not bind oligomer or neutralize JRFL [Fouts1997]
• 19b: Viral binding inhibition by 19b was weakly correlated with neutralization (all other neutralizing MAbs tested showed some correlation except 2F5)
[Ugolini1997]
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• 19b: Abs that recognize discontinuous epitopes can identify mimotopes from a phage peptide display library – 19b has an epitope involving the tip of the
V3 loop, with 5 or 6 essential amino acids distributed within a 12 amino acid stretch – the previously determined binding site was confirmed -I—-G–FY-T
and some tolerated variants described, the I can be I, V, or L, the Y can be Y, F, or W – probably a beta-turn is required for FY or FF binding, but WY in can
bind with out the context of the turn [Boots1997]
• 19b: Neutralizes TCLA strains but not primary isolates [Parren1997c]
• 19b: Used as a control in this Hx10 binding and neutralizing MAb study because 19b does not bind to Hx10 [Mondor1998]
• 19b: The MAb and Fab binding to the oligomeric form of gp120 and neutralization were highly correlated – authors suggest that neutralization is
determined by the fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
• 19b: No detectable neutralizing activity among primary isolates with different co-receptor usage – some neutralization of TCLA strains [Trkola1998]
• 19b: The MAbs with the broadest neutralizing activity, IgG1b12, 2G12 and 2F5, all have high affinity for the native trimer, indicating that they were raised
in an immune response to the oligomer on the virion surface rather than dissociated subunits – a disulfide linked gp120-gp41 (SOS gp140) was created to
mimic the native conformation of Env and explore its potential as an immunogen – SOS gp140 is recognized by NAbs IgG1b12, 2G12, and CD4-IgG2, and
also by anti-V3 MAbs 19b and 83.1 – SOSgp140 is not recognized by C4 region MAbs that neutralize only TCLA strains, G3-42 and G3-519 – nor did it
bind C11, 23A, and M90, MAbs that bind to gp120 C1 and C5, where it interacts with gp41 – MAbs that bind CD4 inducible epitopes, 17b and A32 were
very strongly induced by CD4 in SOS gp140 – anti-gp41 MAbs that bind in the region that interacts with gp120, 7B2, 2.2B, T4, T15G1 and 4D4, did not
bind to SOSgp140, in contrast to 2F5, which binds to the only gp41 epitope that is well exposed in native gp120-gp41 complexes [Binley1999]
• 19b: Six mutations in MN change the virus from a high-infectivity neutralization resistant phenotype to low-infectivity neutralization sensitive – V3,
CD4BS, and CD4i MAbs are 20-100 fold more efficient at neutralizing the sensitive form but 19b was an exception and required around 950 ng/ml to
neutralize either form [Park2000]
• 19b: Mutations in two glycosylation sites in the V2 region of HIV-1 ADA at positions 190 and 197 (187 DNTSYRLINCNTS 199) cause the virus to
become CD4-independent and able to enter cells through CCR5 alone – these same mutations tended to increase the neutralization sensitivity of the virus,
including to 19b [Kolchinsky2001].
• 19b: Ab binding characteristics of SOS gp140 were tested using SPR and RIPA – SOS gp140 is gp120-gp41 bound by a disulfide bond – NAbs 2G12, 2F5,
IgG1b12, CD4 inducible 17b, and 19b bound to SOS gp140 better than uncleaved gp140 (gp140unc) and gp120 – non-neutralizing MAbs 2.2B (binds to
gp41 in gp140unc) and 23A (binds gp120) did not bind SOS gp140 [Schulke2002]
• 19b: A rare mutation in the neutralization sensitive R2-strain in the proximal limb of the V3 region caused Env to become sensitive to neutralization by
MAbs directed against the CD4 binding site (CD4BS), CD4-induced (CD4i) epitopes, soluble CD4 (sCD4), and HNS2, a broadly neutralizing sera – 2/12
anti-V3 MAbs tested (19b and 694/98-D) neutralized R2, as did 2/3 anti-CD4BS MAbs (15e and IgG1b12), 2/2 CD4i MAbs (17b and 4.8D), and 2G12 and
2F5 – thus multiple epitopes on R2 are functional targets for neutralization and the neutralization sensitivity profile of R2 is intermediate between the highly
sensitive MN-TCLA strain and the typically resistant MN-primary strain [Zhang2002]
• 19b: Virion capture assays are not a good preditor of neutralization, and the presentation of epitopes using this assay seems to be different from that of
functional Envelope spikes on primary isolates – F105 and b6 could efficiently block the b12-mediated capture of infectious virions in a virus capture, but
did not inhibit b12 neutralization – while b12 was potent at neutralizing the three primary virions JR-CSF, A DA, and 89.6, the Abs F105, 19b, and Fab b6
were overall very poor neutralizers [Poignard2003]
452 4G10 gp160 (308–322) gp120 (308–322 LAI) RIQRGPGRAFVTGK Vaccine murine
Vaccine Vector/Type: HBcAg fusion HIV component: V3
Ab type V3 Donor Dr. Albrecht von Brunn, Max-von-Pettenkofer-Institut, Ludwig-Maximilians-Universitat Munchen, Germany
References vonBrunn1993
• 4G10: A 25 amino acid V3-loop sequence fused to HBcAg enhanced V3 immunogenicity [vonBrunn1993]
• 4G10: NIH AIDS Research and Reference Reagent Program: 2534
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453 5F7 gp160 (308–322) gp120 (308–322 LAI) RIQRGPGRAFVTGK Vaccine murine
Vaccine Vector/Type: HBcAg fusion HIV component: V3
Ab type V3 Donor Dr. Albrecht von Brunn, Max-von-Pettenkofer-Institut, Ludwig-Maximilians-Universitat Munchen, Germany
References vonBrunn1993
• 5F7: A 25 amino acid V3-loop sequence fused to HBcAg enhanced V3 immunogenicity [vonBrunn1993]
• 5F7: NIH AIDS Research and Reference Reagent Program: 2533
454 G3-523 gp160 (308–322) gp120 (308–322) RIQRGPGRAFVTIGK murine
Ab type V3
ReferencesMatsushita1988, Jagodzinski1996
• G3-523: The sulfated polysaccharide curdlan sulfate (CRDS) binds to the Envelope of T-tropic viruses and neutralizes virus – CRDS inhibits G3-523
binding [Jagodzinski1996]
455 MN215 gp160 (308–322) gp120 (MN) RIHIGPGRAFYTTKN L HIV-1 infection human (IgG1)
Ab type V3
References Schutten1995b
• MN215: Minimum epitope for MAB using the Dutch consensus is AFYTTGE, different than defined for MN – generated by EBV transformation of PBMC
– displayed higher affinity for NSI than for SI glycoproteins – amino acids HIGP were essential for binding [Schutten1995b]
456 Nea 9301 gp160 (308–323) gp120 (IIIB) RIQRGPGRAFVTIGKI murine
Ab type V3 Donor Dupont, commercial
ReferencesWagner1996
457 4117C gp160 (309–315) gp120 IXIGPGR L HIV-1 infection human (IgG1λ )
Ab type V3
References Tilley1991b, Tilley1992, diMarzo Veronese1993, Pinter1993a, Pinter1993b, Alsmadi1998, He2002
• 4117C: Potent neutralizing activity against MN, SF-2, and NY-5 – synergy with CD4BS MAb 1125H [Tilley1991b]
• 4117C: Neutralizes SF2 and MN synergistically combined with anti-CD4 binding site discontinuous MAb [Pinter1993a, Tilley1992]
• 4117C: Binds V3 loop – does not immunoprecipitate soluble gp120, does react with gp120 on intact virions [Pinter1993b]
• 4117C: A study of 6 anti-Env MAbs and their ability to bind or direct ADCC against target cells infected with IIIB, MN, SF-2, and RF – bound and directed
lysis against MN and SF2, but not IIIB and RF [Alsmadi1998]
• 4117C: Transgenic mice carrying human genes allowing production of fully human MAbs were used to rapidly create a panel of anti-HIV gp120 MAb
producing hybridomas by immunization with HIV SF162 gp120 – the previously described human MAbs 5145A(CD4BS) , 4117C (plus others, V3) and
697D (and SC258, V2) were used as controls [He2002]
458 419-D (419,
419D)
gp160 (309–315) gp120 (MN) IHIGPGR L HIV-1 infection human (IgG1λ )
Ab type V3 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References
Karwowska1992b, Gorny1993, Spear1993, Fontenot1995, Hioe1997b, Nyambi1998, Zolla-Pazner1999a, Zolla-Pazner1999b, Nyambi2000, He2002
• 419-D: MN, NY5 and SF2 strain specific, does not cross-react with RF, CDC4, WM52 or HXB2 [Karwowska1992b]
• 419-D: Neutralizes MN – binds SF2: IYIGPGR [Gorny1993]
• 419-D: Mediated deposition of complement component C3 on HIV infected cells, enhanced by second Ab binding, rabbit anti-human IgG [Spear1993]
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• 419-D: Four primary isolates showed distinct patterns of sensitivity to neutralization by polyclonal sera or plasma and MAbs – BZ167 was the only isolate
inhibited by all polyclonal sera and plasma tested, and was also neutralized by 8/17 MAbs, in particular anti-V3 loop (419-D, 447-52D, 782-D, and 838-D),
anti-CD4bd (559/64-D, 654-D and 830-D and a cluster II of gp41 directed MAb (98-6) – isolates 92HT593 and 91US056 were neutralized by V3 loop
(419-D, and 447-52D)and cluster II gp41 (98-6) MAbs at higher concentrations – US4 was neutralized by some of the polyclonal sera/plasma tested and not
at all by MAbs individually or by a cocktail of ten MAbs consisting of 419-D, 447-52D, 782-D, 838-D, 559/64-D, 654-D, 450-D, 670-D, 1281-D and 98-6
[Hioe1997b]
• 419-D: Using a whole virion-ELISA method, 18 human MAbs were tested for their ability to bind to a panel of 9 viruses from clades A, B, D, F, G, and H –
419-D bound to 3/4 B clade virions, and to D clade MAL [Nyambi1998]
• 419-D: Review of clade specificity and anti-V3 HIV-1-Abs – epitope is described as KRIHIGP [Zolla-Pazner1999a]
• 419-D: MAb peptide-reactivity pattern clustered with immunological related MAbs: 1334, 419, 504, 447, 453 and 537 – the core amino acids GP tended to
be critical for reactivity in this group [Zolla-Pazner1999b]
• 419-D: A panel of 47 human MAbs was tested against 26 HIV-1 group M primary isolates from clades A through H – 19 V3 MAbs were tested, and of 494
combinations, 44% displayed some viral binding – V3 MAbs tended to have the most cross-reactive binding to clade A, B, C, and D isolates, less to E, F, G,
and H – 419-D showed intermediate reactivity, and no neutralization when tested against five strains – discrepancy between the epitope as described in
earlier papers and as described here, KRIHIGP [Nyambi2000]
• 419-D: Called 419 – Transgenic mice carrying human genes allowing production of fully human MAbs were used to rapidly create a panel of anti-HIV
gp120 MAb producing hybridomas by immunization with HIV SF162 gp120 – the previously described human MAbs 5145A(CD4BS) , 4117C (plus
others, V3) and 697D (and SC258, V2) were used as controls [He2002]
459 453-D (453) gp160 (309–315) gp120 (MN) IHIGPGR L HIV-1 infection human (IgG1λ )
Ab type V3 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Gorny1991, Gorny1993, VanCott1994, Fontenot1995, Zolla-Pazner1999a, Zolla-Pazner1999b, Nyambi2000
• 453-D: Neutralizes MN – binds SF2: IYIGPGR – specificity: MN, SF2, NY5, RF [Gorny1993]
• 453-D: Moderate homologous neutralization, moderately slow dissociation rate [VanCott1994]
• 453-D : Called 453, epitope described as KRIHIGPGR – the tip of the V3 loop was presented in a mucin backbone – higher valency correlates with stronger
affinity constant [Fontenot1995]
• 453-D: Review of clade specificity and anti-V3 HIV-1-Abs [Zolla-Pazner1999a]
• 453-D : MAb peptide-reactivity pattern clustered with immunological related MAbs: 1334, 419, 504, 447, 453 and 537 – the core amino acids GP tended to
be critical for reactivity in this group – MAb 268, with a previously defined core epitope identical to 453 (HIGPGR), was not part of this reactivity group,
illustrating that context can be critical [Zolla-Pazner1999b]
• 453-D: A panel of 47 human MAbs was tested against 26 HIV-1 group M primary isolates from clades A through H – 19 V3 MAbs were tested, and of 494
combinations, 44% displayed some viral binding – V3 MAbs tended to have the most cross-reactive binding to clade A, B, C, and D isolates, less to E, F, G,
and H – 453-D showed intermediate reactivity [Nyambi2000]
460 504-D (504,
504-10D)
gp160 (309–315) gp120 (MN) IHIGPGR L HIV-1 infection human (IgG1κ)
Ab type V3 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Gorny1993, Zolla-Pazner1999a, Zolla-Pazner1999b, Nyambi2000
• 504-D – Neutralizes MN – binds SF2: IYIGPGR [Gorny1993]
• 504-D: Review of clade specificity and anti-V3 HIV-1-Abs [Zolla-Pazner1999a]
• 504-D: MAb peptide-reactivity pattern clustered with immunological related MAbs: 1334, 419, 504, 447, 453 and 537 – the core amino acids GP tended to
be critical for reactivity in this group [Zolla-Pazner1999b]
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• 504-D: A panel of 47 human MAbs was tested against 26 HIV-1 group M primary isolates from clades A through H – 19 V3 MAbs were tested, and of 494
combinations, 44% displayed some viral binding – V3 MAbs tended to have the most cross-reactive binding to clade A, B, C, and D isolates, less to E, F, G,
and H – 504-D showed weak reactivity [Nyambi2000]
461 83.1 (MAb
83.1)
gp160 (309–315) gp120 (SF2) IYIGPGR L Vaccine murine (IgG1)
Vaccine Vector/Type: peptide Strain: MN HIV component: V3
Ab type V3 DonorMary White-Scharf, Repligen Corporation, Cambridge, MA
ReferencesWhite-Scharf1993, Potts1993, Jelonek1999, Keller1999, Binley1999
• 83.1: Neutralizes SF2 [White-Scharf1993]
• 83.1: Study of synergism of neutralization and binding comparing F105 and sCD4 with the V3 MAbs: 50.1, 59.1, 83.1, and 58.2 – synergy was observed,
and the data suggest that binding of one ligand (F105) can increase the binding of the second (e. g. V3 loop MAbs) due to conformational changes
[Potts1993]
• 83.1: Maternally transferred anti-V3 loop MAb selectively inhibits the anti-V3 loop Ab component of the IgG response to rgp120 SF2 in 21 day old BALBc
mice [Jelonek1999]
• 83.1: 19 day old mice injected with 83.1 have a shift in IgG1 response away from the V3 loop upon vaccination, without decreasing the total IgG anti-gp120
response, suggesting that prior treatment with a MAb can mask immunogenic sites and shift the immune response to vaccination [Keller1999]
• 83.1: The MAbs with the broadest neutralizing activity, IgG1b12, 2G12 and 2F5, all have high affinity for the native trimer, indicating that they were raised
in an immune response to the oligomer on the virion surface rather than dissociated subunits – a disulfide linked gp120-gp41 (SOS gp140) was created to
mimic the native conformation of Env and explore its potential as an immunogen – SOS gp140 is recognized by NAbs IgG1b12, 2G12, and CD4-IgG2, and
also by anti-V3 MAbs 19b and 83.1 – SOSgp140 is not recognized by C4 region MAbs that neutralize only TCLA strains, G3-42 and G3-519 – nor did it
bind C11, 23A, and M90, MAbs that bind to gp120 C1 and C5, where it interacts with gp41 – MAbs that bind CD4 inducible epitopes, 17b and A32 were
very strongly induced by CD4 in SOS gp140 – anti-gp41 MAbs that bind in the region that interacts with gp120, 7B2, 2.2B, T4, T15G1 and 4D4, did not
bind to SOSgp140, in contrast to 2F5, which binds to the only gp41 epitope that is well exposed in native gp120-gp41 complexes [Binley1999]
462 5023B gp160 (309–316) gp120 (309–316 BH10) IQRGPGra no Vaccine murine (IgG)
Vaccine Vector/Type: peptide Strain: BH10 HIV component: V3
Ab type V3
References Langedijk1991
• 5023B: Generation and fine mapping of murine MAbs [Langedijk1991]
463 F58/D1 (F58) gp160 (309–316) gp120 (IIIB) IxxGPGRA L Vaccine murine (IgG1)
Vaccine Vector/Type: virus derived protein HIV component: gp120
Ab type V3
References Akerblom1990, Broliden1991, Moore1993c, Millar1998, Jackson1999
• F58/D1: Binding to native gp120 1-3 fold greater than to denatured – 314G/W substitution abolishes binding, changes outside the loop have little effect
[Moore1993c]
• F58/D1: The interaction of a 17-amino-acid neutralizing microantibody (MicroAB) based on F58 and HIV-1 env was studied by electrospray ionization
mass spectrometry [Millar1998]
• F58/D1: A 17 amino acid MicroAB was made from the third complementarity-determining region of the heavy chain of MAb – F58 neutralized 5x’s more
efficiently in terms of mass than the original MAb, 32-fold less on a molar basis – neutralization does not involve initial attachment, but fusion and events in
early infection [Jackson1999]
464 P1/D12 gp160 (309–316) gp120 IxxGPGRA L Vaccine murine (IgG)
Vaccine Vector/Type: virus derived protein Strain: IIIB HIV component: gp120
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Ab type V3
References Akerblom1990, Moore1993c
• P1/D12: Binding to native gp120 1-3 fold greater than to denatured – 314G/W substitution abolishes binding, changes outside the loop have little effect
[Moore1993c]
465 P4/D10
(P4D10)
gp160 (309–316) gp120 IxxGPGRA L Vaccine murine (IgG1κ)
Vaccine Vector/Type: virus derived protein Strain: IIIB HIV component: gp120
Ab type V3
References
Akerblom1990, Broliden1990, Broliden1991, Marks1992, Moore1993c, Arendrup1993, Hinkula1994, Jacobson1998, Schonning1998, Schonning1999
• P4/D10: Neutralizing and ADCC activity [Broliden1990]
• P4/D10: Variable domain sequenced and is identical to F58/H3 [Marks1992]
• P4/D10: Binding to native gp120 3 fold greater than to denatured – 314G/W substitution abolishes binding, changes outside the loop have little effect
[Moore1993c]
• P4/D10: Primary isolates from different time points from one individual were not susceptible to neutralization by P4/D10 [Arendrup1993]
• P4/D10: Used for passive immunotherapy in four late-stage HIV-infected patients – the serum level of p24 did not decrease in any of these four – see also
MAb F58/H3 [Hinkula1994]
• P4/D10: Review of passive immunotherapy, summarizing [Hinkula1994] in relation to other studies [Jacobson1998]
• P4/D10: Called P4D10 – In a study of the influence of the glycan at position 306 of the V3 loop on MAb recognition, anti-V3 MAbs were found to
neutralize an HIV-BRU mutant virus that lacks the V3 loop glycan more efficiently than HIV-BRU – Ab binding site was suggested to be 314-323 of BRU
[Schonning1998]
• P4/D10: Called P4D10 – the stoichiometry of MAb neutralization was tested and the data indicated that binding for neutralization was was incremental not
all or none, i.e., each envelope oligomer binds a single MAb and each Env oligomer bound reduces the chances of infection – MAb BC1071 was used for
virion quantification – P4D10 binds only to Env with a glycosylation site mutation at the base of the V3 loop A308T [Schonning1999]
466 IIIB-13 V3
(1044-13
IIIB-V3-13
1727)
gp160 (309–317) gp120 (308–316 IIIB) IQRGPGRAF L Vaccine murine (IgG1)
Vaccine Vector/Type: peptide Strain: IIIB
Ab type V3
References Laman1992, Laman1993, D’Souza1994, Watkins1993, Chakrabarti2002, Zhang2002
• IIIB-13 V3: Also known as 1044-13 and as IIIB-V3-13 (J. P. Moore, per. comm.)
• IIIB-13 V3: Neutralizes IIIB but not MN [Laman1992]
• IIIB-13 V3: Included in a panel of antibodies used in a multi-lab study for antibody characterization and assay comparison, some neutralization of strains
other than IIIB [D’Souza1994]
• IIIB-13 V3: Called IIIB-V3-13 – a neutralization escape mutant (HXB2 A281V) was selected by growth of HXB2 in the presence of broadly neutralizing
sera – IIIB-V3-13 neutralization was only slightly reduced by this mutation [Watkins1993]
• IIIB-13 V3: Called 1727: Used as a standard for comparing immune responses to modified gp140 (gp140deltaCFI), with C-term mutations intended to
mimic a fusion intermediate and stabilize trimer formation – experiment showed enhanced humoral immunity without diminishing the CTL response in
mice injected with a DNA vaccine [Chakrabarti2002]
• IIIB-13 V3: A rare mutation in the neutralization sensitive R2-strain in the proximal limb of the V3 region caused Env to become sensitive to neutralization
by MAbs directed against the CD4 binding site (CD4BS), CD4-induced (CD4i) epitopes, soluble CD4 (sCD4), and HNS2, a broadly neutralizing sera –
2/12 anti-V3 MAbs tested (19b and 694/98-D) neutralized R2, as did 2/3 anti-CD4BS MAbs (15e and IgG1b12), 2/2 CD4i MAbs (17b and 4.8D), and 2G12
and 2F5 – thus multiple epitopes on R2 are functional targets for neutralization and the neutralization sensitivity profile of R2 is intermediate between the
highly sensitive MN-TCLA strain and the typically resistant MN-primary strain [Zhang2002]
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• IIIB-13 V3: UK Medical Research Council AIDS reagent: ARP3046
• IIIB-13 V3: NIH AIDS Research and Reference Reagent Program: 1727
467 IIIB-34 V3
(IIIB-V3-34)
gp160 (309–317) gp120 (308–316 IIIB) IQRGPGRAF L Vaccine murine (IgG1)
Vaccine Vector/Type: peptide Strain: IIIB
Ab type V3
References Laman1992, Laman1993
• IIIB-34 V3: Neutralizes IIIB but not MN – QXGPG are critical amino acids for binding by Pepscan analysis [Laman1992]
• IIIB-34 V3: Called IIIB-V3-34 – IIIB strain specific neutralization – binding is reduced somewhat by DTT or SDS-DTT, enhanced by NP40, but binds to
native and denatured gp120 [Laman1993]
• IIIB-34 V3: UK Medical Research Council AIDS reagent: ARP3047
468 A47/B1 gp160 (309–318) gp120 (307–316 IIIB) IQRGPGRAFV L Vaccine murine (IgG)
Vaccine Vector/Type: protein Strain: IIIB HIV component: gp120
Ab type V3
References Akerblom1990
469 D59/A2 gp160 (309–318) gp120 (307–316 IIIB) IQRGPGRAFV L Vaccine murine (IgG)
Vaccine Vector/Type: protein Strain: IIIB HIV component: gp120
Ab type V3
References Akerblom1990
470 G44/H7 gp160 (309–318) gp120 (307–316 IIIB) IQRGPGRAFV L Vaccine murine (IgG)
Vaccine Vector/Type: protein Strain: IIIB HIV component: gp120
Ab type V3
References Akerblom1990
471 M096/V3 gp160 (309–318 +
329–338)
gp120 (dis 309–318) IQRGPGRAFV+AHCNISRAKW in vitro stimulation human (IgM)
Ab type V3
References Ohlin1992
• M096: Generated in response to IIIB Env 286-467 upon in vitro stimulation of uninfected-donor lymphocytes, and binds to two peptides: 309-318 +
329-338 [Ohlin1992]
472 µ5.5 (5.5,
mu5.5,
Rmu5.5)
gp160 (309–319) gp120 (MN) IHIGPGRAFYT L P murine (IgG1κ)
Ab type V3
ReferencesMaeda1992, Okamoto1998
• mu5.5: sCD4 causes loss of IIIB type-specificity for MAb 0.5beta, allowing binding and neutralization of MN, in contrast to MAb mu5.5 [Maeda1992]
• mu5.5: Rmu5.5 is a humanized antibody of mouse MAb m5.5 – neutralized primary isolates with similar V3 loops – passive transfer of MAb to SCID-hu or
hu-PBL-SCID mice conferred protection [Okamoto1998]
473 loop 2 (Loop
2, IgG1 Loop
2)
gp160 (309–320) gp120 SISGPGRAFYTG L HIV-1 infection human Fab
Ab type V3 Donor D. Burton, Scripps Research Institute, La Jolla, CA
References Barbas III1993, Moore1994b, Wu1996, Ditzel1997, Ugolini1997, Parren1997c, Parren1997a, Mondor1998, Parren1998a, Sullivan1998a
• loop2: Also known as Loop 2, IgG1 Loop 2 was a obtained by engineering Fab loop2 into an IgG1 molecule
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• loop 2: Sequences of the heavy and light chain Fab variable regions were generated [Barbas III1993]
• loop 2: Called Loop 2 – shows modest cross-reactivity among B clade gp120s, little outside B clade [Moore1994b]
• loop 2: MIP-1alpha binding to CCR-5 expressing cells can be inhibited by gp120-sCD4 – binding of loop 2 blocks this inhibition [Wu1996]
• loop 2: Binds to gp120 from MN and SF2 but not LAI [Ditzel1997]
• loop 2: Viral binding inhibition by loop 2 MAb or Fab was correlated with neutralization (all other neutralizing MAbs tested showed some correlation
except 2F5) [Ugolini1997]
• loop 2: Epitope is suggested to be GPGRAF – binds to 10/17 US clade B monomeric gp120s – IgG1 form can neutralize MN and 2 primary isolates tested
[Parren1997a]
• loop 2: Neutralizes TCLA strains but not primary isolates [Parren1997c]
• loop 2: The rank order of Fab binding affinity to monomeric gp120 (Loop 2 > 3B3 > b12 = DO8i > b11 > b3 > b14 > b13 > DO142-10 > DA48 > L17) was
markedly different than Fab binding affinity to the mature oligomeric form (3B3 > b12 > DO142-10 > Loop 2 > b11 > L17 > b6 > DO8i > b14 > DA48 > b3
> b13) and binding to oligomeric form and neutralization were correlated for both Fabs and MAbs – authors suggest that neutralization is determined by the
fraction of Ab sites occupied on a virion irrespective of the epitope – binding affinity of divalent IgG1 loop 2 is only 2-fold greater than monovalent Fab
loop 2, suggesting the IgG1 form may bind with only one arm [Parren1998a]
• loop 2: The HIV-1 virus YU2 entry can be enhanced by MAbs binding to the CD4BS, V3 loop, and CD4i epitopes – the activation for this enhanced entry
state could be conferred on HxB2 by introducing the YU2 V3 loop, or the YU2 V3 and V1/V2 loops – a similar effect is observed by sub-neutralizing
concentrations of sCD4 and the effect is dependent of CCR5 – loop 2 enhances YU2 at concentrations up to 20 ug/ml [Sullivan1998a]
474 268-D
(268-11-D-IV,
268D, 268,
268-11D,
268-10D,
MAb 268,
268-10-D,
ARP3024)
gp160 (310–315) gp120 (MN) HIGPGR L HIV-1 infection human (IgG1λ )
Ab type V3 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Gorny1991, D’Souza1991, Karwowska1992b, Gorny1993, Spear1993, VanCott1994, Stamatatos1995, Zolla-Pazner1995a, Fontenot1995,
McKeating1996b, Wisnewski1996, Hioe1997b, Stamatatos1997, LaCasse1998, Zolla-Pazner1999a, Zolla-Pazner1999b, Beddows1999, Oggioni1999,
Laisney1999, Hioe2000, Nyambi2000, Park2000, York2001, Vella2002, Zhang2002
• 268-D: Called 268-11-D-IV – strain specific weakly neutralizing [D’Souza1991]
• 268-D: Reacts with MN, NY5, CDC4, RF and SF2, does not cross-react with WM52 or HXB2 [Karwowska1992b]
• 268-D: Neutralizes MN – binds SF2: YIGPGR – specificity: MN, SF2, NY5, RF, CDC4 [Gorny1993]
• 268-D: Mediated deposition of complement component C3 on HIV infected cells, but not in the presence of sCD4 [Spear1993]
• 268-D: Moderate dissociation rate and homologous neutralization titer [VanCott1994]
• 268-D: Serotyping study using flow-cytometry, if H of HIGPGR was substituted in virus, 268-D did not bind [Zolla-Pazner1995a]
• 268-D: The binding of conformation-dependent anti-V2, anti-V3, and anti-CD4BS MAbs to monomeric and virion-associated gp120 from HIV-1 isolates
with differences in cell tropism was studied – V3 loop epitopes were less accessible to Ab binding on the virion surface than in the gp120 monomer,
particularly for macrophage-tropic isolates SF162 and SF128a, relative to T-cell tropic SF2 – sCD4 association with gp120 did not influence the binding of
268-D to virion-associated gp120, although sCD4 binding did alter epitope exposure for other anti-V3 MAbs [Stamatatos1995]
• 268-D: Failed to neutralize HXB2 and chimeric virus with gp120 from primary isolates in an HXB2 background [McKeating1996b]
• 268-D: 268-D is V H4 – V-region heavy chain usage was examined and a bias of enhanced V H1 and V H4, and reduced V H3, was noted among HIV
infected individuals [Wisnewski1996]
• 268-D: Poor reactivity against HIV-1 isolates SF162 and SF128A and no neutralization, in contrast to MAbs 391/95-D and 257-D [Stamatatos1997]
• 268-D: A T-cell line-adapted (TCLA) derivative of SI primary isolate 168P acquired the ability to be neutralized by anti-V3 MAbs – the primary isolate
could use either CCR5 or CXCR4, and was not neutralized when infection was directed via either pathway, however the TCLA derivative uses CXCR4 only
and is neutralized [LaCasse1998]
• 268-D: Review of clade specificity and anti-V3 HIV-1-Abs [Zolla-Pazner1999a]
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• 268-D: Peptide reactivity pattern clustered with immunological related MAbs: 1108, 386, 268, 311, 257, 694.8 – the amino acids HI tended to be critical for
reactivity in this group – MAb 453, with an identical core epitope to 268 based on prior experiments (HIGPGR), was not part of this reactivity group,
illustrating that context can be critical [Zolla-Pazner1999b]
• 268-D: rgp120 derived from a R5X4 subtype B virus, HIV-1 W61D, was used to vaccinate healthy volunteers and the resulting sera were compared with
sera from HIV-1 positive subjects and neutralizing MAbs – 268-D bound rgp120 W61D but could only neutralize the W61D isolate following T-cell line
adaptation [Beddows1999]
• 268-D: Called 268-11D – Study of a live-vector mucosal vaccine that expresses HIV-1 V3 domains using the bacterium Streptococcus gordonii which can
express heterologous Ag and can colonize the oral cavity and vagina of mice – 268-D and 257-D recognized S. gordonii expressing the V3 domain of MN –
the vaccine stimulated V3-specific IgG2a in mice [Oggioni1999]
• 268-D: Called MAb 268 – To identify potential mimotopes of V3, a hexapeptide phage library was screened with MAb 268 – two hexamers were identified,
HLGPGR or KAIHRI that bind to 268 with the same binding site as the V3 loop and inhibit 268 MN gp120 – KLH conjugated hexamer KAIHRI stimulates
Abs in rabbits that cross-react with ML gp120 [Laisney1999]
• 268-D: Ab responses, because of their capacity to alter antigen uptake and processing, can influence helper T cell responses – CD4BS MAbs or serum Ig
from HIV+ individuals inhibited proliferative responses of gp120 specific T cells – V3 MAbs 447-52-D and 268-10-D did not effect proliferation
[Hioe2000]
• 268-D: A panel of 47 human MAbs was tested against 26 HIV-1 group M primary isolates from clades A through H – 19 V3 MAbs were tested, and of 494
combinations, 44% displayed some viral binding – V3 MAbs tended to have the most cross-reactive binding to clade A, B, C, and D isolates, less to E, F, G,
and H – 268-D showed weak reactivity [Nyambi2000]
• 268-D: Called 268D – six mutations in MN change the virus from a high-infectivity neutralization resistant phenotype to low-infectivity neutralization
sensitive – V3, CD4BS, and CD4i MAbs are 20-100 fold more efficient at neutralizing the sensitive form – the mutation L544P reduced binding of all
MAbs against gp120 by causing conformational changes [Park2000]
• 268-D: Abs against the V3 loop (50.1, 58.2, 59.1, 257-D, 268-D, 447-52D), CD4BS (IgG1b12, 559-64D, F105), CD4i (17b), and to gp41 (2F5, F240) each
showed similar binding efficiency to Env derived from related pairs of primary and TCLA lines (primary: 168P and 320SI, and TCLA: 168C and
320SI-C3.3), but the TCLA lines were much more susceptible to neutralization suggesting that the change in TCLA lines that make them more susceptible
to NAbs alters some step after binding – one of the TCLA V3 viruses 320SI-C3.3 shows reduced binding with this MAb, the sequence of the epitope in
320SI is HIGPGR and in 320SI-C3.3 is RIGPGR [York2001]
• 268-D: Called ARP3024: Herpesvirus saimiri-immortalized CD4+ T lymphocytes (HVS T cells) were used to isolate virus and perform HIV-1
neutralization assays, and compared with a standard PBMC protocol – neutralization sensitivities to a panel of MAbs and to homologous or heterologous
plasma/sera were similar for HVS T cells (CN-2 cells) and PBMCs [Vella2002].
• 268-D: A rare mutation in the neutralization sensitive R2-strain in the proximal limb of the V3 region caused Env to become sensitive to neutralization by
MAbs directed against the CD4 binding site (CD4BS), CD4-induced (CD4i) epitopes, soluble CD4 (sCD4), and HNS2, a broadly neutralizing sera—2/12
anti-V3 MAbs tested (19b and 694/98-D) neutralized R2, as did 2/3 anti-CD4BS MAbs (15e and IgG1b12), 2/2 CD4i MAbs (17b and 4.8D), and 2G12 and
2F5—thus multiple epitopes on R2 are functional targets for neutralization and the neutralization sensitivity profile of R2 is intermediate between the highly
sensitive MN-TCLA strain and the typically resistant MN-primary strain [Zhang2002].
• 268-D: UK Medical Research Council AIDS reagent: ARP3024
• 268-D: NIH AIDS Research and Reference Reagent Program: 1511
475 386-D (386,
386-10D,
386D)
gp160 (310–315) gp120 (MN) HIGPGR L HIV-1 infection human (IgG1λ )
Ab type V3 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Karwowska1992b, Gorny1993, VanCott1994, Fontenot1995, Zolla-Pazner1999a, Zolla-Pazner1999b, Nyambi2000
• 386-D: Neutralizes MN – binds SF2: YIGPGR – specificity: MN, SF2, NY5, RF, CDC4 [Gorny1993]
• 386-D: Slow dissociation rate, potent homologous neutralization [VanCott1994]
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• 386-D: Review of clade specificity and anti-V3 HIV-1-Abs [Zolla-Pazner1999a]
• 386-D: Peptide reactivity pattern clustered with immunological related MAbs: 1108, 386, 268, 311, 257, 694.8 – the amino acids HI tended to be critical for
reactivity in this group [Zolla-Pazner1999b]
• 386-D: A panel of 47 human MAbs was tested against 26 HIV-1 group M primary isolates from clades A through H – 19 V3 MAbs were tested, and of 494
combinations, 44% displayed some viral binding – V3 MAbs tended to have the most cross-reactive binding to clade A, B, C, and D isolates, less to E, F, G,
and H – 386-D showed intermediate reactivity [Nyambi2000]
476 5042A gp160 (310–315) gp120 (310–315 BH10) QrGPGR L Vaccine murine (IgG)
Vaccine Vector/Type: peptide Strain: BH10 HIV component: V3
Ab type V3
References Langedijk1991, Gorny1991
• 5042A: Generation and fine mapping of murine MAbs [Langedijk1991]
477 5042B gp160 (310–315) gp120 (310–315 BH10) QRGPGr no Vaccine murine (IgG)
Vaccine Vector/Type: peptide Strain: BH10 HIV component: V3
Ab type V3
References Langedijk1991
• 5042B: Generation and fine mapping of murine MAbs [Langedijk1991]
478 418-D (418,
418D)
gp160 (310–316) gp120 (MN) HIGPGRA L HIV-1 infection human (IgG1κ)
Ab type V3 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Karwowska1992b, Gorny1993, Zolla-Pazner1999a, Zolla-Pazner1999b, Nyambi2000, Zhang2002
• 418-D: MN strain specific, does not cross-react with SF2, NY5, RF, CDC4 WM52 or HXB2 [Karwowska1992b]
• 418-D: Neutralizes MN, does not bind to SF2 or HXB2 [Gorny1993]
• 418-D: Review of clade specificity and anti-V3 HIV-1-Abs [Zolla-Pazner1999a]
• 418-D: Called 418 – MAb peptide-reactivity pattern clustered with immunological related MAbs: 391.5, 412 and 418, all selected with MN V3 peptide –
the core amino acids HIGPGR tended to be critical for reactivity in this group [Zolla-Pazner1999b]
• 418-D: A panel of 47 human MAbs was tested against 26 HIV-1 group M primary isolates from clades A through H – 19 V3 MAbs were tested, and of 494
combinations, 44% displayed some viral binding – V3 MAbs tended to have the most cross-reactive binding to clade A, B, C, and D isolates, less to E, F, G,
and H – 418-D showed intermediate reactivity [Nyambi2000]
• 418-D: A rare mutation in the neutralization sensitive R2-strain in the proximal limb of the V3 region caused Env to become sensitive to neutralization by
MAbs directed against the CD4 binding site (CD4BS), CD4-induced (CD4i) epitopes, soluble CD4 (sCD4), and HNS2, a broadly neutralizing sera – 2/12
anti-V3 MAbs tested (19b and 694/98-D) neutralized R2, as did 2/3 anti-CD4BS MAbs (15e and IgG1b12), 2/2 CD4i MAbs (17b and 4.8D), and 2G12 and
2F5 – thus multiple epitopes on R2 are functional targets for neutralization and the neutralization sensitivity profile of R2 is intermediate between the highly
sensitive MN-TCLA strain and the typically resistant MN-primary strain [Zhang2002]
479 5021 gp160 (310–316) gp120 QrGPGRa L Vaccine murine (IgG)
Vaccine Vector/Type: peptide Strain: BH10 HIV component: V3
Ab type V3
References Durda1988, Durda1990, Langedijk1991, Moore1993c
• 5021: Generation and fine mapping of murine MAbs [Langedijk1991]
• 5021: Binding to native gp120 100-300 fold greater than to denatured – 314G/W substitution abolishes binding, changes outside the loop have little effect
[Moore1993c]
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480 5025B gp160 (310–316) gp120 (310–316 BH10) QRGPGra no Vaccine murine (IgG)
Vaccine Vector/Type: peptide Strain: BH10 HIV component: V3
Ab type V3
References Langedijk1991
• 5025B: Generation and fine mapping of murine MAbs [Langedijk1991]
481 5042 gp160 (310–316) gp120 QRGPGRA L Vaccine murine
Vaccine Vector/Type: peptide
Ab type V3
References Durda1988, Durda1990, Moore1993c
• 5042: Binding to native gp120 100-300 fold greater than to denatured – 314G/W substitution abolishes binding, changes outside the loop have little effect
[Moore1993c]
482 110.3 gp160 (310–317) gp120 (308–328 BRU) QRGPGRAF L Vaccine murine (IgG1κ)
Vaccine Vector/Type: infected-cell lysate Strain: BRU HIV component: virus
Ab type V3
References Thomas1988, Evans1989, Langedijk1992, Pirofski1993, Connelly1994
• 110.3: Included as a control [Evans1989]
• 110.3: MAb variable region sequenced – heavy chain: V 7138(40), D deletion, J H4 – light chain: V kappa21(47), J kappa2 [Pirofski1993]
• 110.3: An anti-idiotypic MAb generated against 110.3 both mimics and binds to V3, suggesting that the V3 loop may associated with itself [Connelly1994]
483 110.4 gp160 (310–317) gp120 (308–328 BRU) QRGPGRAF L Vaccine murine (IgG1κ)
Vaccine Vector/Type: infected-cell lysate Strain: BRU HIV component: virus
Ab type V3 Donor Genetic Systems Corp, Seattle WA, E. Kinney-Thomas
References Thomas1988, Thali1992b, Langedijk1992, Thali1993, Pirofski1993, Arendrup1993, Thali1994, Boudet1994, Connelly1994, McDougal1996,
Valenzuela1998, Cao1997b, Guillerm1998
• 110.4: 313 P/S substitution in the V3 region disrupts binding [Thali1992b]
• 110.4: MAb variable region sequenced – heavy chain: V 3660-SB32, D closest to DSP2.3, 2.4 and .6, J H2 – light chain: V kappa21, J kappa2
[Pirofski1993]
• 110.4: Primary isolates from different time points from one individual were not susceptible to neutralization by 110.4 [Arendrup1993]
• 110.4: gp41 mutation that confers resistance to neutralization by anti-CD4 binding site antibodies does not reduce neutralizing efficiency of this V3 region
MAb [Thali1994]
• 110.4: An anti-idiotypic MAb generated against 110.3 also blocks binding of 110.4 [Connelly1994]
• 110.4: Neutralizes HIV-1 LAI [McDougal1996]
• 110.4: Neutralization of LAI in CEM cells by anti-V3 MAbs 110.4 and N11-20 is through inhibition of viral binding to the cell [Valenzuela1998]
• 110.4: Virus with the V1-V2 loop deleted was viable and more susceptible to neutralization by CD4i MAb 17b, and anti-V3 MAbs 1121, 9284, and 110.4,
but not to and CD4BS MAb F105 or sCD4 [Cao1997b]
• 110.4: Used for flow cytometry in a study of the anti-CD4, CDR3 loop MAb called 13B8.2, in a study of HIV-1 induced programmed cell death
[Guillerm1998]
484 110.5 gp160 (310–317) gp120 (308–328 BRU) QRGPGRAF L Vaccine murine (IgG1κ)
Vaccine Vector/Type: infected-cell lysate Strain: BRU HIV component: virus
Ab type V3 Donor E. Kinney-Thomas or Genetic Systems, Seattle WA
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References Thomas1988, Moore1990b, Cordell1991, Sattentau1991, Langedijk1992, McKeating1992a, Pirofski1993, Moore1993c, Thali1993,
Klasse1993a, Sattentau1995c, Sattentau1995b, Moore1996, Poignard1996a, McDougal1996, Jeffs1996, Binley1997a, Ugolini1997, Parren1998a
• 110.5: Did not induce dissociation of gp120, as sCD4 did – discrepancy with [Poignard1996a], that was suggested to be due to MAb interference with
detection, as the gp120-MAb complex was denatured in the Poignard study [Moore1990b]
• 110.5: Binding insensitive to gp120 reduction [Cordell1991]
• 110.5: Two fold increase in binding to gp120 in the presence of bound sCD4 [Sattentau1991]
• 110.5: Variable region sequenced – heavy chain: V 3660-SB32, D closest to DSP2.3, 2.4 and .6, J H2 – light chain: V kappa21, J kappa2 [Pirofski1993]
• 110.5: Thrombin cleavage of V3 loop between R-315 and A-316 abrogates binding – can inhibit C4 region antibody which has conformational
requirements (G3-299) – binding to native gp120 100-300 fold greater than to denatured [Moore1993c]
• 110.5: The gp41 mutation 582(Ala to Thr) results in conformational changes in gp120 that confer neutralization resistance to conformationally sensitive
neutralizing MAbs – neutralization efficiency of 110.5 is not affected [Reitz1988, Klasse1993a]
• 110.5: Pretreatment of HX10-infected H9 cells with sCD4 decreases signal from 110.5 at 37 degrees due to dissociation of gp120-gp41 [Sattentau1995c]
• 110.5: Binds with high affinity to monomer and oligomer, rapid association and potent neutralization of lab strains – neutralizes cell-free Hx10
[Sattentau1995b]
• 110.5: Reciprocal binding inhibition with other anti-V3 MAbs – enhances binding of some anti-V2 MAbs – binding enhanced by some CD4 binding site
MAbs [Moore1996]
• 110.5: V3 MAbs 9284, BAT123, 110.5, and 110.I could each significantly increase gp120 dissociation from virus, mimicking sCD4, and expose the gp41
epitope for MAb 50-69, in contrast to anti-V2 MAbs [Poignard1996a]
• 110.5: Neutralizes HIV-1 LAI [McDougal1996]
• 110.5: Deletion of the V1V2 regions did not affect anti-V3 Abs ability to bind when compared to intact rec gp120 [Jeffs1996]
• 110.5: Viral binding inhibition by 110.5 was correlated with neutralization (all other neutralizing MAbs tested showed some correlation except 2F5)
[Ugolini1997]
• 110.5: The MAb and Fab binding to the oligomeric form of gp120 and neutralization were highly correlated – authors suggest that neutralization is
determined by the fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
485 58.2 gp160 (310–317) gp120 (MN) HIGPGRAF L Vaccine murine (IgG1κ)
Vaccine Vector/Type: peptide Strain: MN HIV component: V3
Ab type V3 Donor Repligen Corp.
ReferencesWhite-Scharf1993, Potts1993, Moore1994b, Seligman1996, Stanfield1999, York2001
• 58.2: Epitope defined by peptide reactivity and changes in affinity with amino acid substitutions – 4/7 primarily isolates were neutralized
[White-Scharf1993]
• 58.2: Did not synergistically neutralize MN in combination with MAb F105 – there was synergistic neutralization when combined with sCD4 [Potts1993]
• 58.2: Modest cross-reactivity among B clade gp120s, little outside B clade – core epitope as I-IHIG [Moore1994b]
• 58.2: Competition ELISAs with serial deletions produced longer estimates of epitope length, RIHIGPGRAFY, than Alanine substitution, suggesting
significance of non-contact residues [Seligman1996]
• 58.2: The crystal structure of Fab 58.2 bound to V3 loop peptides was obtained – conformational changes in the tip of the V3 loop (GPGR) were observed
when different MAbs were bound – 58.2’s epitope was defined as KRKRIHIGPGRAFY [Stanfield1999]
• 58.2: 58.2’s epitope was noted to be IGPGRAF – Abs against the V3 loop (50.1, 58.2, 59.1, 257-D, 268-D, 447-52D), CD4BS (IgG1b12, 559-64D, F105),
CD4i (17b), and to gp41 (2F5, F240) each showed similar binding efficiency to Env derived from related pairs of primary and TCLA lines (primary: 168P
and 320SI, and TCLA: 168C and 320SI-C3.3), but the TCLA lines were much more susceptible to neutralization suggesting that the change in TCLA lines
that make them more susceptible to NAbs alters some step after binding [York2001]
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486 polyclonal gp160 (310–318) gp120 QRGPGRAFV? L Vaccine murine (IgA, IgG1,
IgG2a)
Vaccine Vector/Type: peptide Brucella abortus (Ba) conjugate, peptide keyhole limpet hemocyanin (KLH) conjugate, peptide lipopolysaccharide (LPS)
conjugate Strain: MN HIV component: V3
References Golding2002a
• Internasal (i.n.) immunization with V3-Ba induced mucosal anti-V3 NAbs and IFN-gamma secreting T cells – V3-Ba, V3-KLH and V3-LPS could each
induce serum and mucosal IgA and IgG in BALB/c mice – i.n. plus i.p. immunizations gave higher titers than i.n. alone – the response to V3-KLH was
mainly restricted to IgG1, and to V3-Ba, IgG2a – class II KO mice (CD4+-deficient) did not respond to V3-KLH, but did respond to V3-Ba, suggesting that
V3-Ba may be effective in eliciting Ab responses in HIV-1 infected individuals that have impaired CD4+ T cell function [Golding2002a]
487 537-D (537) gp160 (311–315) gp120 (MN) IGPGR L HIV-1 infection human (IgG1λ )
Ab type V3 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Karwowska1992b, Gorny1992, Gorny1993, VanCott1994, Fontenot1995, Zolla-Pazner1999a, Zolla-Pazner1999b, Nyambi2000
• 537-D: Reacts with MN, NY5, CDC4, RF, WM52 and SF2, but does not cross-react with HXB2 [Karwowska1992b]
• 537-D: MN type specific neutralization observed – binds SF2, also IGPGR [Gorny1992, Gorny1993]
• 537-D: Moderate homologous neutralization, relatively rapid dissociation constant [VanCott1994]
• 537-D: Review of clade specificity and anti-V3 HIV-1-Abs [Zolla-Pazner1999a]
• 537-D: MAb peptide-reactivity pattern clustered with immunological related MAbs: 1334, 419, 504, 447, 453 and 537 – the core amino acids GP tended to
be critical for reactivity in this group [Zolla-Pazner1999b]
• 537-D: A panel of 47 human MAbs was tested against 26 HIV-1 group M primary isolates from clades A through H – 19 V3 MAbs were tested, and of 494
combinations, 44% displayed some viral binding – V3 MAbs tended to have the most cross-reactive binding to clade A, B, C, and D isolates, less to E, F, G,
and H – 537-D showed weak reactivity [Nyambi2000]
488 5020 gp160 (311–316) gp120 (311–316 BH10) RGPGRA no Vaccine murine (IgG)
Vaccine Vector/Type: peptide Strain: BH10 HIV component: V3
Ab type V3
References Langedijk1991
• 5020: Generation and fine mapping of murine MAbs [Langedijk1991]
489 RC25 gp160 (311–316) gp120 (JRFL) IGPGRA L humanized murine
Ab type V3
References Kimura2002
• RC25: RC25 is a humanized MAb that recognizes the epitope IGPGRA – it has strong neutralizing activity against JRFL (R5 virus) and weak against
NL4-3 (X4 virus) and is used as a control in a study of NAb activity in patients undergoing HAART [Kimura2002]
490 5023A (5023,
NEA-9205,
NEA 9205)
gp160 (311–317) gp120 (311–317 BH10) RgPGRAF L Vaccine murine (IgG)
Vaccine Vector/Type: peptide Strain: BH10 HIV component: V3
Ab type V3 Donor Paul Durda, Du Pont de Nemours and Co
References Langedijk1991, D’Souza1991, Back1993, Rovinski1995
• 5023A: Generation and Fine mapping of murine MAbs [Langedijk1991]
• 5023A: Called 5023 – Langedijk also has an MAb called 5023B – strong cross-reactive neutralizing MAb [D’Souza1991]
• 5023A: Called 5023 – Langedijk also has an MAb called 5023B – gp41 amino acid substitutions 668 (N/S) and 675 (I/M) in gp41 interfere with 5023s
neutralization potency, region 662-675 is ELDKWANLWNWFNI [Back1993]
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• 5023A: Called 5023 in this paper – Used to precipitate gp160 in immunoblots in a study examining the feasibility of using unprocessed gp160 glycoprotein
as an immunogen [Rovinski1995]
• 5023A: Called NEA-9205 – The N306 glycan of the V3 loop makes the tip of the V3 loop inaccessible to this MAb in oligomeric Env, loss of this glycan
enhances neutralization sensitivity [Schonning1998]
491 110.6 gp160 (311–318) gp120 (BRU) RGPGRAFV L (weak) Vaccine murine (IgG1λ )
Vaccine Vector/Type: infected-cell lysate Strain: BRU HIV component: virus
Ab type V3
References Thomas1988, Pirofski1993, Langedijk1992
• 110.6: Variable region sequenced – heavy chain: V J558-146b.1alpha, D closest to DSP16.2, J H3 – light chain: V lambda1, J lambda1 [Pirofski1993]
492 polyclonal gp160 (311–318) gp120 (MN) IGPGRAFY L Vaccine murine (IgG2a)
Vaccine Vector/Type: B. abortus complex Strain: SF2, MN HIV component: gp120
Ab type V3
References Golding1995
• Ab is evoked even in mice depleted of CD4+ cells
493 10/36e gp160 (311–321) gp120 (311–321
HXB10)
RGPGRAFVTIG L (HXB10) Vaccine rat (IgG2a)
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: gp120
Ab type V3
ReferencesMcKeating1992a, McKeating1993b, Peet1998
• 10/36e: Binding to virion gp120 enhanced by sCD4 [McKeating1992a]
• 10/36e: The most variable amino acids in the V3 loop were replaced with serines to make the immunodominant V3 loop less immunogenic – these changes
did not affect the ability of sCD4 or MAbs to V1/V2, C1 and C4 to bind, but anti-V3 MAb 10/36e binding was dramatically diminished by V3 serine
substitutions – mice injected with serine substituted gp120 had a reduced response relative to wildtype, and no enhanced immunogenicity of conserved
regions [Peet1998]
494 10/54
(10/54ow/6i/6i)
gp160 (311–321) gp120 (311–321
HXB10)
RGPGRAFVTIG L (HXB10) Vaccine rat (IgG1)
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: gp120
Ab type V3
ReferencesMcKeating1992a, McKeating1993a, McKeating1993b, Peet1998
• 10/54: Binding to virion gp120 enhanced by sCD4 [McKeating1992a]
• 10/54: Studied in the context of a neutralization escape mutant [McKeating1993a]
• 10/54: Called 10/54ow/6i/6i: The most variable amino acids in the V3 loop were replaced with serines to make the immunodominant V3 loop less
immunogenic – these changes did not affect the ability of sCD4 or MAbs to V1/V2, C1 and C4 to bind, but anti-V3 MAb 10/54 binding was dramatically
diminished by V3 serine substitutions – mice injected with serine substituted gp120 had a reduced response relative to wildtype, and no enhanced
immunogenicity of conserved regions [Peet1998]
495 11/85b
(11/85b/14I/14I)
gp160 (311–321) gp120 (311–321
HXB10)
RGPGRAFVTIG L (HXB2) Vaccine rat (IgG2b)
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: gp120
Ab type V3
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ReferencesMcKeating1992a, McKeating1993b
• 11/85b: Binding to virion gp120 enhanced by sCD4 [McKeating1992a]
496 polyclonal gp160 (311–322) gp120 (MN) IGPGRAFYTTKN L (MN
ALA-1)
Vaccine guinea pig
Vaccine Vector/Type: human rhinovirus 14 Strain: MN HIV component: V3
Ab type V3
References Smith1998
• The tip of the MN V3 loop (IGPGRAFYTTKN) was inserted into cold-causing human rhinovirus 14 (HRV14) – chimeras were immunoselected, and
chimeric viruses were neutralized by anti-V3 loop antibodies – chimeric viruses elicited potent NAbs against ALA-1 and MN [Smith1998]
497 0.5β (0.5 beta,
0.5beta)
gp160 (311–324) gp120 (316–330 HXB2) RGPGRAFVTIGKIG L (IIIB) Vaccine murine (IgG1κ)
Vaccine Vector/Type: protein Strain: IIIB HIV component: Env
Ab type V3 Donor Shuzo Matsushita or Toshio Hattori of Kumamoto University
ReferencesMatsushita1988, Skinner1988b, Skinner1988a, Reitz1988, Nara1990, D’Souza1991, Matsushita1992, Emini1992, Maeda1992,
McKeating1992a, Sperlagh1993, diMarzo Veronese1993, Moore1993c, Klasse1993a, Watkins1993, Cook1994, Thali1994, Okada1994, Boudet1994,
Broder1994, Zvi1995b, Zvi1995a, Jagodzinski1996, Warrier1996, McDougal1996, Jeffs1996, Huang1997, Zvi1997, Wyatt1997, Faiman1997,
Tugarinov1999, Fortin2000, Jagodzinski2000, Tugarinov2000, Zvi2000
• 0.5beta: Type-specific neutralization of IIIB – does not neutralize MN or RF [Matsushita1988, Skinner1988b]
• 0.5beta: Emergence of virus resistant to MAb 0.5beta and autologous sera neutralization in IIIB infected chimps [Nara1990]
• 0.5beta: Potent neutralizing activity [D’Souza1991]
• 0.5beta: Chimeric mouse-human MAb Cbeta1 was constructed by combining the human Cgamma1 and Ckappa constant regions with the 0.5beta murine
MAb – ADCC and neutralizing activity[Matsushita1992]
• 0.5beta: sCD4 causes loss of IIIB type-specificity, allowing binding and neutralization of MN, in contrast to MAb mu5.5 [Maeda1992]
• 0.5beta: Monoclonal anti-idiotype antibodies that mimic the 0.5beta epitope were generated [Sperlagh1993]
• 0.5beta: Neutralization of virus carrying an A to T substitution (contrast with MAb M77) [diMarzo Veronese1993]
• 0.5beta: Binding to native gp120 100-300 fold greater than to denatured [Moore1993c]
• 0.5beta: The gp41 mutation 582(Ala to Thr) results in conformational changes in gp120 that confer neutralization resistance to some antiserum and
conformationally sensitive neutralizing MAbs – neutralization efficiency of 0.5beta is not affected [Reitz1988, Klasse1993a]
• 0.5beta: A neutralization escape mutant (HXB2 A281V) was selected by growth of HXB2 in the presence of broadly neutralizing sera – of the MAbs tested
, 0.5beta neutralization was the most profoundly affected by this mutation [Watkins1993]
• 0.5beta: MAbs against the glycosphingolipid GalCer block HIV infection of normally susceptible CD4 negative cells from the brain and colon – this MAb
can inhibit gp120 binding to GalCer in vitro [Cook1994]
• 0.5beta: gp41 mutation that confers resistance to neutralization by anti-CD4 binding site antibodies does not reduce neutralizing efficiency of this V3 region
MAb [Thali1994]
• 0.5beta: Binding domain aa 310-319: RGPGRAFVTIGKIG – mutations in the V3 loop from basic residues can destroy virus infectivity and syncytium
formation: R306T, R309T and R313G can also reduce binding of V3 MAbs with two different binding sites: 9284 and 0.5beta [Okada1994]
• 0.5beta: Type-specific neutralization of IIIB – does not neutralize SF2 [Broder1994]
• 0.5beta: The interactions of the peptide RKSIRIQRGPGRAFVT 0.5beta were studied by NMR, and hydrophobic interactions between the two Is and the V
form the base of a 12 amino acid loop with GPGR at the apex[Zvi1995b]
• 0.5beta: NMR of 0.5beta bound NNTRKSIRIQRGPGRAFVTIGKIG suggests that the bound amino acids are in the region SIRIQRGPGRAFVT
[Zvi1995a]
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• 0.5beta: The sulfated polysaccharide curdlan sulfate (CRDS) binds to the Envelope of T-tropic viruses and neutralizes virus – CRDS inhibits 0.5beta
binding – 0.5beta epitope described as GPGRAFVTIG [Jagodzinski1996]
• 0.5beta: Synergistic neutralization of HIV-1 when combined with anti-V2 MAb C108G [Warrier1996]
• 0.5beta: Deletion of the V1V2 regions did not affect anti-V3 Abs ability to bind when compared to intact rec gp120 [Jeffs1996]
• 0.5beta: Relative to the native peptide, an O-linked alpha-galactosamine modified V3 peptide enhanced binding to 0.5 beta, while an N-linked
beta-glucosamine modified peptide showed reduced binding [Huang1997]
• 0.5beta: The structure of a 17 amino acid V3 peptide bound to the Fab was studied using NMR [Zvi1997]
• 0.5beta: Binds both gp120 and soluble gp120+gp41 complex efficiently, suggesting its gp120 epitope is not blocked by gp41 binding [Wyatt1997]
• 0.5beta: The Fv fragment was purified and the temperature dependence and effect of mutations was studied [Faiman1997]
• 0.5beta: NMR structure reveals that Ab bound IIIB-V3 peptide adopts an unexpected type VI cis proline beta-turn [Tugarinov1999]
• 0.5beta: Host encoded intercellular adhesion molecule (ICAM-1) is incorporated by the HIV-1 virion and enhances viral infectivity – ICAM-1 does not
modify virus sensitivity to antibodies 0.5beta or 4.8D or sCD4, but neutralizing ability of F105 was diminished in ICAM bearing virions in the presence of
lymphocyte function-association antigen-1 (LFA-1) Ab [Fortin2000]
• 0.5beta: MAbs 0.5beta and G3-42 were used to study synthesis of oligomeric and monomeric forms of Env – inhibition of glycosylation by tunicamycin
results in reduction of oligomeric gp120 at the cell surface and of monomer in the cytoplasm – neither MAb recognized non-glycosylated Env precursor
[Jagodzinski2000]
• 0.5beta: 14/18 residues of peptide P1053, RKSIRIQRGPGRAFVTIG, were shown to be involved in the Ab recognition site using NMR – QRGPGR forms
a beta-hairpin turn at the center of the binding pocket [Tugarinov2000]
• 0.5beta: NMR and mutation cycles were employed to generate a model of the peptide-antibody complex, showing aa residues that interact or do not
contribute to the binding of MAb 0.5beta Fv with the peptide – F96(L) of 0.5beta binds to Pro13, H52(H) interacts with Ile7, Ile9, Gln10, and D56(H)
interacts with Arg11 of the V3 loop peptide – RGPG retains hairpin conformation binds in the center of a groove [Zvi2000]
• 0.5beta: UK Medical Research Council AIDS reagent: ARP3025
• 0.5beta: NIH AIDS Research and Reference Reagent Program: 1591
498 Cβ1, 0.5β gp160 (311–324) gp120 (316–330 HXB2) RGPGRAFVTIGKIG L Vaccine humanized murine
(IgG1)
Vaccine Vector/Type: protein Strain: IIIB HIV component: Env
Ab type V3
References Emini1992, Matsushita1992, Kimura2002, Ferrantelli2002
• Cbeta1: passive transfer to chimpanzees confers protection against challenge with homologous cell-free virus – mouse 0.5beta human IgG1 chimera
[Emini1992]
• Cbeta1: Chimeric mouse-human MAb Cbeta1 was constructed by combining the human Cgamma1 and Ckappa constant regions with the 0.5beta murine
MAb – ADCC and neutralizing activity [Matsushita1992]
• Cbeta1: Defines epitope as IQRGPGRA – strong neutralizing activity against NL4-3 (X4 virus) and none against JRFL (R5 virus) – used as a control in a
study of NAb activity in patients undergoing HAART [Kimura2002]
• Cbeta1: Review of passive immunoprophylaxis with human NAbs that also includes this chimeric mouse-human MAb, noting it protected 2/2 Chimpanzees
from HIV-1 IIIB infection in the Emini et al study published in 1992 [Ferrantelli2002]
499 NM-01 gp160 (312–315) gp120 (MN) GPGR L Vaccine murine (IgG)
Vaccine Vector/Type: human rhinovirus 14 Strain: MN HIV component: V3
Ab type V3 DonorM. Terada
References Ohno1991, Yoshida1997, Smith1998
• NM-01: Resistance mutation selected by propagation of molecular cloned isolate in the presence of NM-01 [Yoshida1997]
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• NM-01: The tip of the MN V3 loop was inserted into cold-causing human rhinovirus 14 (HRV14) – chimeras were immunoselected, and chimeric viruses
were neutralized by anti-V3 loop antibodies, and NM-01 was among the Abs used – chimeric viruses elicited potent NAbs in guinea pigs against ALA-1
and MN [Smith1998]
500 1026 gp160 (312–317) gp120 (MN) GPGRAF L Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein Strain: MN HIV component: gp120
Ab type V3
References Nakamura1993, Bou-Habib1994
• 1026: Bound diverse strains, neutralizing activity against MN, close to GPGRAF [Nakamura1993]
• 1026: Greater affinity for T cell-tropic strain T-CSF, derived from JR-CSF, than to the primary isolate JR-CSF [Bou-Habib1994]
501 1034 gp160 (312–317) gp120 (MN) GPGRAF L Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein Strain: MN HIV component: gp120
Ab type V3
References Bou-Habib1994, Berman1997
• 1034: Greater affinity for T cell tropic T-CSF, derived from JR-CSF, than to the primary isolate JR-CSF, close to GPGRAF [Bou-Habib1994]
• 1034: Binds to 5/7 isolates from breakthrough cases from a MN gp120 vaccine trial [Berman1997]
502 59.1
(R/V3-59.1)
gp160 (312–317) gp120 (308–313 MN) GPGRAF L Vaccine murine (IgG1)
Vaccine Vector/Type: peptide Strain: MN HIV component: V3
Ab type V3 DonorMary White-Scharf and A. Profy, Repligen Corporation
References D’Souza1991, White-Scharf1993, Potts1993, Ghiara1993, Bou-Habib1994, D’Souza1994, Seligman1996, Ghiara1997, Smith1998,
Stanfield1999, York2001
• 59.1: Called R/V3-59.1 – potent neutralizing MAb [D’Souza1991]
• 59.1: Epitope defined by peptide reactivity and binding affinity with amino acid substitutions – GPGRAF [White-Scharf1993]
• 59.1: Synergistic neutralization of MN when combined with sCD4 or the CD4BS MAb F105 [Potts1993]
• 59.1: Crystal structure of a 24 amino acid peptide from the V3 loop bound to 59.1 Fab fragment – contact residues IGPGRAF [Ghiara1993]
• 59.1: Greater affinity for T-cell tropic strain T-CSF than the primary isolate JR-CSF, from which T-CSF was derived [Bou-Habib1994]
• 59.1: Multi-lab study for antibody characterization and assay comparison – neutralizes MN and IIIB [D’Souza1994]
• 59.1: Competition ELISAs with serial deletions produced longer estimate of epitope length than x-ray crystallography or Alanine substitution,
RIHIGPGRAFYTT, suggesting significance of non-contact residues [Seligman1996]
• 59.1: A conformationally restricted analog of the tip of the V3 loop was constructed and bound with Fab 59.1 – crystal structure shows interactions between
59.1 and an MN peptide and 59.1 and the modified peptide are similar, but NMR studies reveal that the modified peptide is more ordered in solution,
retaining the Fab bound form [Ghiara1997]
• 59.1: The tip of the MN V3 loop was inserted into cold causing human rhinovirus 14 (HRV14) – chimeras were immunoselected, and chimeric viruses were
neutralized by anti-V3 loop antibodies, and 59.1 was among the Abs used – chimeric viruses elicited potent NAbs in guinea pigs against ALA-1 and MN
[Smith1998]
• 59.1: The crystal structure of V3 loop peptides bound to Fabs was obtained – conformational changes in the tip of the V3 loop (GPGR) were observed when
different MAbs were bound [Stanfield1999]
• 59.1: Abs against the V3 loop (50.1, 58.2, 59.1, 257-D, 268-D, 447-52D), CD4BS (IgG1b12, 559-64D, F105), CD4i (17b), and to gp41 (2F5, F240) each
showed similar binding efficiency to Env derived from related pairs of primary and TCLA lines (primary: 168P and 320SI, and TCLA: 168C and
320SI-C3.3), but the TCLA lines were much more susceptible to neutralization suggesting that the change in TCLA lines that make them more susceptible
to NAbs alters some step after binding [York2001]
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503 polyclonal gp160 (312–317) gp120 (316–321) GPGRAF Vaccine rabbit (Ig)
Vaccine Vector/Type: polyepitope, protein HIV component: gp160 Adjuvant: BSA
Ab type V3
References Lu2000c, Lu2000b
• High titer response to ELDKWA and RILAVERYLKD was observed upon vaccination with multiple-epitope vaccine
CG-GPGRAFY-G-ELDKWA-G-RILAVERYLKD conjugated to BSA, a weak response to GPGRAFY – immunization with
CG-(ELDKWA-GPGRAFY)_2-K was also tried, yielding a strong Ab response to ELDKWA, weak to GPGRAF – gp160 vaccination yielded strong Ab
response but not to any of the peptides studied here [Lu2000c, Lu2000b]
504 10E3 gp160 (312–318) gp120 (317–323 IIIB) GPGRAFY Vaccine murine (IgG)
Vaccine Vector/Type: peptide keyhole limpet hemocyanin (KLH) conjugate Strain: IIIB HIV component: V3
Ab type V3
References Tian2001
• 10E3: Peptides GPGRAFY and ELDKWAG were conjugated to KLH and used to raise mouse monoclonal Ab – MAb hybridomas were generated with
defined specificity – 10E3 binds to the peptide GPGRAFY and to rgp160 [Tian2001]
505 polyclonal gp160 (312–318) gp120 (317–323) GPGRAFY Vaccine murine, rabbit
Vaccine Vector/Type: peptide HIV component: V3 Adjuvant: BSA
Ab type V3
References Yu2000
• High levels of epitope-specific Abs were induced by the peptide-BSA conjugates C-(GPGRAF)_4-BSA or C-(TRPNNNTRKSIRIQRGPGRAFYTIG
KI)-BSA but not by rgp160 vaccine [Yu2000]
506 N11-20
(110-H)
gp160 (312–320) gp120 (317–325) GPGRAFVTI L (LAI) murine (IgG1κ)
Ab type V3 Donor J. C. Mazie, Hybridolab, Institut Pasteur
References Valenzuela1998
• N11-20: Neutralization of LAI in CEM cells by anti-V3 MAbs 110.4 and N11-20 is through inhibition of virus binding to the cell [Valenzuela1998]
507 5025A (5025) gp160 (313–317) gp120 (313–317 BH10) pgRAF L Vaccine murine (IgG)
Vaccine Vector/Type: peptide Strain: BH10 HIV component: V3
Ab type V3 Donor Paul Durda, Du Pont de Nemours and Co
References Langedijk1991, D’Souza1991
• 5025A: Generation and fine mapping of murine MAbs [Langedijk1991]
• 5025: Called 5025 – strain specific weakly neutralizing [D’Souza1991]
508 N70-1.9b gp160 (313–318) gp120 (316–322) PGRAFY L HIV-1 infection human (IgG1)
Ab type V3
References Robinson1990a, Scott1990
• N70-1.9b: Type specificity [Robinson1990a]
• N70-1.9b: Type specific neutralization, ADCC directed against MN infected cells [Scott1990]
509 902 gp160 (313–324) gp120 (IIIB) PGRAFVTIGKIG L Vaccine murine (IgG1κ)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: gp160
Ab type V3 Donor Bruce Chesebro, Rocky Mountain National Laboratory, Montana
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References Chesebro1988, Laman1993, Broder1994, Earl1994, Sakaida1997
• 902: Strain specific neutralization of HIV [Chesebro1988]
• 902: Epitope may be partially masked or altered in the oligomeric molecule [Broder1994]
• 902: Used as a control in a study of the influence of oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• 902: V3-BH10 peptide with loop-structure inhibits IL-2 induced T-cell proliferation, thought to be due to altering intracellular signaling, and MAb 908 can
block the peptide inhibition [Sakaida1997]
• 902: NIH AIDS Research and Reference Reagent Program: 522
510 694/98-D
(694/98,
694.8,
694/98D)
gp160 (314–317) gp120 (IIIB) GRAF L HIV-1 infection human (IgG1λ )
Ab type V3 Donor Drs. S. Zolla-Pazner and M. Gorny, NYU Med Center NY, NY
References Gorny1991, Gorny1992, Gorny1993, Cavacini1993a, Spear1993, Gorny1994, Laal1994, VanCott1994, Cook1994, VanCott1995,
Zolla-Pazner1995a, Forthal1995, Li1997, Zolla-Pazner1997, Smith1998, Li1998, Andrus1998, Nyambi1998, Schonning1998, Zolla-Pazner1999a,
Zolla-Pazner1999b, Altmeyer1999, Nyambi2000, Park2000, Edwards2002, He2002, Zhang2002
• 694/98-D: This MAb was first described here [Skinner1988b]
• 694/98-D: Type-specific lab isolate neutralization was observed – binds with 1-3 fold greater affinity to gp120 than to peptides [Gorny1992]
• 694/98-D: Neutralizes MN and IIIB (GRAF) – binds SF2 (GRAF) – binding reactivity: MN, IIIB, SF2, NY5, RF, CDC4, WM52 [Gorny1993]
• 694/98-D: Called 694-D – complement mediated virolysis of IIIB, but not in the presence of sCD4 [Spear1993]
• 694/98-D: 50% neutralization of HIV-IIIB at a concentration of 0.15mug/ml [Gorny1994]
• 694/98-D: Potent neutralization of IIIB – no neutralization synergy in combination with CD4 binding domain MAbs [Laal1994]
• 694/98-D: GRVY did not alter peptide binding – GRVI and GQAW enhanced dissociation – GQVF and GQAL did not bind [VanCott1994]
• 694/98-D: MAbs against the glycosphingolipid GalCer block HIV infection of normally susceptible CD4 negative cells from the brain and colon – V3
MAbs can inhibit gp120 binding to GalCer in vitro – binding of GalCer to gp120 inhibited but did not completely block MAb binding[Cook1994]
• 694/98-D: Human HIV-1 infected sera and MAb 694/98 have high reactivity to MN and RF infected H9 cells, but Genentech rec gp120 IIIB vaccine
recipients do not [VanCott1995]
• 694/98-D: Serotyping study using flow-cytometry – bound GRAX bearing virus in 10/11 cases – somewhat conformation dependent [Zolla-Pazner1995a]
• 694/98-D: ADCC activity, and no viral enhancing activity [Forthal1995]
• 694/98-D: One of 14 human MAbs tested for ability to neutralize a chimeric SHIV-vpu+, which expressed HIV-1 IIIB env – could only achieve 50%
neutralization alone – all Ab combinations tested showed synergistic neutralization – 694/98-D has synergistic response with MAbs F105, 15e, b12, 2F5,
17b, 2G12, and 48d, and with HIVIG [Li1997]
• 694/98-D: Used to study pre- and post-exposure prophylaxis Hu-PBL-SCID mice infected by an intraperitoneal injection of HIV-1 LAI – MAb half-life in
plasma in mice is 9 days – 2 hours post-694/98-D mice were challenged with LAI, and at an Ab concentration of 1.32 mg/Kg, 50% of the mice were
infected – one of the infected mice carried the resistant form GRTF rather than GRAF (critical amino acids for binding are GRA) – post-exposure
prophylaxis was effective if delivered 15 min post-exposure, but declined to 50% if delivered 60 min post-exposure, and similar time constraints have been
observed for HIVIG, 2F5 and 2G12, in contrast to MAb BAT123 that could protect delivered 4 hours post infection [Andrus1998]
• 694/98-D: The tip of the MN V3 loop was inserted into cold causing human rhinovirus 14 (HRV14) – chimeras were immunoselected, and chimeric viruses
were neutralized by anti-V3 loop antibodies, and 694/98-D was among the Abs used – chimeric viruses elicited potent NAbs in guinea pigs against ALA-1
and MN [Smith1998]
• 694/98-D: Neutralization synergy was observed when the MAbs 694/98-D (V3), 2F5 (gp41), and 2G12 (gp120 discontinuous) were used in combination,
and even greater neutralizing potential was seen with the addition of a fourth MAb, F105 (CD4 BS) [Li1998]
• 694/98-D: Using a whole virion-ELISA method, 18 human MAbs were tested for their ability to bind to a panel of 9 viruses from clades A, B, D, F, G, and
H – 694/98-D bound only to B and D clade virions and had limited cross reactivity [Nyambi1998]
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• 694/98-D: In a study of the influence of the glycan at position 306 of the V3 loop on MAb recognition, anti-V3 MAbs were found to neutralize an
HIV-BRU mutant virus that lacks the V3 loop glycan more efficiently than HIV-BRU [Schonning1998]
• 694/98-D: Review of clade specificity and anti-V3 HIV-1-Abs [Zolla-Pazner1999a]
• 694/98-D: MAb peptide reactivity pattern clustered with immunological related MAbs: 1108, 386, 268, 311, 257, 694.8 – the amino acids HI tended to be
critical for reactivity in this group [Zolla-Pazner1999b]
• 694/98-D: A Semliki Forest virus (SFV) expression system carrying BX08 env was used to study the conformation of gp120 – intracytoplasmic gp120 was
recognized by the anti-V3 MAbs K24 and F5.5, while gp120 at the plasma membrane was detected only by conformation dependent MAbs 2G12, 670-D
and 694/98D and not linear V3 MAbs – expression in rat brain also showed that surface-expressed Env was recognized only by the conformation-dependent
antibodies and not by anti-V3 antibodies [Altmeyer1999]
• 694/98-D: A panel of 47 human MAbs was tested against 26 HIV-1 group M primary isolates from clades A through H – 19 V3 MAbs were tested, and of
494 combinations, 44% displayed some viral binding – V3 MAbs tended to have the most cross-reactive binding to clade A, B, C, and D isolates, less to E,
F, G, and H – 694/98-D showed intermediate reactivity [Nyambi2000]
• 694/98-D: Called 694/98D – six mutations in MN change the virus from a high-infectivity neutralization resistant phenotype to low-infectivity
neutralization sensitive – V3, CD4BS, and CD4i MAbs are 20-100 fold more efficient at neutralizing the sensitive form – the mutation L544P reduced
binding of all MAbs against gp120 by causing conformational changes [Park2000]
• 694/98-D: Called 694/98D – Truncation of the gp41 cytoplasmic domain of X4, R5, and X4R5 viruses forces a conformation that more closely resembles
the CD4 bound state of the external Envelope, enhancing binding of CD4i MAbs 17b and 48d and of CD4BS MAbs F105, b12, and in most cases of
glycosylation site dependent MAb 2G12 and the anti-gp41 MAb 246D – in contrast, binding of the anti-V2 MAb 697D and the anti-V3 MAb 694/98D were
not affected – viruses bearing the truncation were more sensitive to neutralization by MAbs 48d, b12, and 2G12 – the anti-C5 MAb 1331A was used to
track levels of cell surface expression of the mutated proteins [Edwards2002]
• 694/98-D: Called 694 – Transgenic mice carrying human genes allowing production of fully human MAbs were used to rapidly create a panel of anti-HIV
gp120 MAb producing hybridomas by immunization with HIV SF162 gp120 – the previously described human MAbs 5145A(CD4BS) , 4117C (plus
others, V3) and 697D (and SC258, V2) were used as controls [He2002]
511 MO101/V3,C4 gp160 (314–323 +
494–503)
gp120 (dis 314–323) GRAFVTIGKI+LGVAPTKAKR in vitro stimulation human (IgM)
Ab type V3-C4
References Ohlin1992
• MO101: Generated in response to IIIB Env 286-467 upon in vitro stimulation of uninfected-donor lymphocytes – reacts with peptides 314-323 + 494-503
from the V3 and C4 regions [Ohlin1992]
512 MO101/V3,C4 gp160 (314–323 +
494–503)
gp120 (314–323) GRAFVTIGKI+LGVAPTKAKR in vitro stimulation human (IgM)
Ab type V3-C5
References Ohlin1992
• MO101: Generated through in vitro stimulation of uninfected-donor lymphocytes with pB1 containing IIIB Env 286-467 – reacts with peptides from the V3
and C4 regions, positions 314-323 + 494-503, peptides GRAFVTIGKI + LGVAPTKAKR [Ohlin1992]
513 MO101/V3,C4 gp160 (314–323 +
494–503)
gp120 (494–503) GRAFVTIGKI+LGVAPTKAKR in vitro stimulation human (IgM)
Ab type V3-C5
References Ohlin1992
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• MO101: Generated through in vitro stimulation of uninfected-donor lymphocytes with pB1 containing IIIB Env 286-467 – reacts with peptides from the V3
and C4 regions, positions 314-323 + 494-503, peptides GRAFVTIGKI + LGVAPTKAKR [Ohlin1992]
514 9205
(NEA-9205
NEA9205)
gp160 (315–317) gp120 (IIIB) RAF(corereactivity) L Vaccine murine (IgG1)
Vaccine Vector/Type: peptide Strain: IIIB HIV component: V3
Ab type V3 Donor NEN, Boston MA, commercial
References Durda1990, Trujillo1993, Allaway1993, VanCott1994, Fontenot1995, Schonning1998, Schonning1999, Gram2002
• 9205: Also see MAb called 5023A
• 9205: Called NEA-9205, epitope RIQRGPGRAFVTIGK – reacts with three human brain proteins of 35, 55, 110 kd molecular weight – similar to 9284 –
RAF is the core reactivity [Trujillo1993]
• 9205: Synergy with combinations of CD4-based molecules in inhibition of HIV-1 Env mediated cell fusion [Allaway1993]
• 9205: Neutralizes IIIB but not MN – significantly slower dissociation constant for IIIB than MN [VanCott1994]
• 9205: Called NEA-9205 – The N306 glycan of the V3 loop makes the tip of the V3 loop inaccessible to this MAb in oligomeric Env, loss of this glycan
enhances neutralization sensitivity [Schonning1998]
• 9205: Called NEA-9205 – the stoichiometry of MAb neutralization was tested and the data indicated that binding for neutralization was was incremental
not all or none, i.e., each envelope oligomer binds a single MAb and each Env oligomer bound reduces the chances of infection – 9205 binds only to Env
with a glycosylation site mutation in the V3 loop, A308T [Schonning1999]
• 9205: Called NEA9205 – gp120 capture ELISAs with MAbs D7324 (anti-C-term) or 9205 (anti-V3) were compared in a study of orientation of
glycosylation sites – CD4 binding could only inhibit deglycosylation when gp120 was bound to the plate by D7324, not by 9205, while Abs from HIV-1
infected people inhibited deglycosylation most effectively when gp120 was caught by 9205 [Gram2002]
515 110.I gp160 (316–322) gp120 (316–322) AFVTIGK L Vaccine murine
Vaccine Vector/Type: recombinant protein HIV component: gp120
Ab type V3 Donor F. Traincard, Pasteur Institute, France
ReferencesMoore1993c, Moore1994c, Sattentau1995b, Moore1996, Poignard1996a, Wyatt1997, Parren1998a
• 110.I: Binds to carboxy-terminal side of the V3 loop – inhibits binding of C4 region MAb G3-299 [Moore1993c]
• 110.I: Binds equally well to monomer and oligomer, rapid association and potent neutralization of lab strains [Sattentau1995b]
• 110.I: Reciprocal binding inhibition with other anti-V3 and anti-C4 MAbs – and enhances binding of some anti-V2 MAbs – binding enhanced by some
anti-CD4 binding site MAbs [Moore1996]
• 110.I: Epitope suggested to be RAFVTIGK – V3 MAbs 9284, BAT123, 110.5, and 110.I could each significantly increase gp120 dissociation from virus,
mimicking sCD4, and expose the gp41 epitope for MAb 50-69, in contrast to anti-V2 MAbs [Poignard1996a]
• 110.I: Binds both gp120 and soluble gp120+gp41 complex efficiently, suggesting its gp120 epitope is not blocked by gp41 binding [Wyatt1997]
• 110.I: The MAb and Fab binding to the oligomeric form of gp120 and neutralization were highly correlated – authors suggest that neutralization is
determined by the fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
516 anti-HIV-2
polyclonal
gp160 (317–320 +
333–225)
gp120 (dis 315–318
SBL6669 HIV-2)
FHSQ+WCR Vaccine guinea pig (IgG)
Vaccine Vector/Type: peptide Strain: HIV-2 SBL6669-ISY HIV component: V3
Ab type HIV-2 V3
ReferencesMorner1999
• Neutralizing Abs against HIV-2 V3 are produced when peptides spanning two non-contiguous parts of the V3 loop are used for vaccination including amino
acids 315-318 near the tip (FHSQ) and 329-331 (WCR) at the C-term Cys [Morner1999]
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517 IIIB-V3-01 gp160 (320–328) gp120 (IIIB) IGKIGNMRQ no Vaccine murine (IgG1)
Vaccine Vector/Type: peptide Strain: IIIB HIV component: V3
Ab type V3 Donor Jon Laman
References Laman1993
• IIIB-V3-01: Specific for carboxy-terminal flank of the IIIB V3 loop – epitope is hidden native gp120, exposed on denaturation [Laman1993]
• IIIB-V3-01: UK Medical Research Council AIDS reagent: ARP3046
• IIIB-V3-01: NIH AIDS Research and Reference Reagent Program: 1726
518 D/6D1 gp160 (346–377) gp120 (351–382 LAI) ASKLREQFGNNKTIIFKQSSGGDPE-
IVTHSFN
no Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp120
Ab type V4
References Bristow1994
• D/6D1: V4 MAb generated in a study of the humoral immune response to Baculovirus-expressed mis-folded rgp120 and rgp160 [Bristow1994]
519 4D7/4 gp160 (360–380) gp120 (361–380 LAI) IFKQSSGGDPEIVTHSFNCGG Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: Env
Ab type V4 Donor S. Ranjbar, NIBSC, UK
ReferencesMoore1994c
• 4D7/4: C3 region – the relative affinity for denatured/native gp120 is >10 [Moore1994c]
• 4D7/4: UK Medical Research Council AIDS reagent: ARP3051
520 36.1(ARP
329)
gp160 (361–381) gp120 (362–381 LAI) FKQSSGGDPEIVTHSFNCGGE Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: Env
Ab type V4
References Thiriart1989, Moore1994c
• 36.1: The relative affinity for denatured/native gp120 is >30 – mutations 380 G/F, 381 E/P impair binding [Moore1994c]
• 36.1: UK Medical Research Council AIDS reagent: ARP329
521 C12 gp160 (361–381) gp120 (362–381 LAI) FKQSSGGDPEIVTHSFNCGGE Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
Ab type V4 Donor George Lewis
ReferencesMoore1993a, Moore1994c, Abacioglu1994, Moore1994d
• C12: Bound preferentially to denatured IIIB gp120 [Moore1993a]
• C12: The relative affinity for denatured/native gp120 is >30 – mutations 380 G/F, 381 E/P, and 384 Y/E impair binding – also binds GEFFYCNSTQLFNS,
gp120(380-393 LAI) [Moore1994c]
• C12: C3 region – epitope boundaries mapped by peptide scanning, core FNCGG [Abacioglu1994]
522 110.D gp160 (380–393) gp120 (380–393 LAI) GEFFYCNSTQLFNS no Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: Env
Ab type C3 Donor F. Traincard, Pasteur Institute, France
ReferencesMoore1994c, Valenzuela1998
678
DEC 2002
gp160 Antibodies HIV Antibodies Tables
B
C
ell
No. MAb ID HXB2 Location Author’s Location Sequence Neutralizing Immunogen Species(Isotype)
• 110.D: The relative affinity for denatured/native gp120 is >50 [Moore1994c]
523 B32 gp160 (380–393) gp120 (380–393 LAI) GEFFYCNSTQLFNS Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
Ab type C3
ReferencesMoore1994c, Abacioglu1994
• B32: The relative affinity for denatured/native gp120 is >100 – mutations 380 G/F, 381 G/P, 382 F/L, 384 Y/E, and 386 N/R impair binding [Moore1994c]
• B32: C3 region – epitope boundaries mapped by peptide scanning – FFY(core) [Abacioglu1994]
524 polyclonal
(VEI4)
gp160 (391–413) Env FNSTWFNSTWSTEGSNNTEGSDT HIV-1 infection human
Ab type V4
References Carlos1999
• Antibody response to the epitopes in a vaccine construct (VEI) containing peptides from 5 hypervariable regions of gp120 was detected in the sera of HIV-1
positive subjects, including sera from 6 non-subtype B infections – serum samples from San Francisco, Canada and Puerto Rico cohort showed presence of
antibodies against all five VEI hypervariable regions, but most consistently against the V3 region peptide NNNTRKSIRIGPGRAFYTTGDIGNIRQ
[Carlos1999]
525 B15 gp160 (395–400) gp120 (395–400 BH10) WFNSTW Vaccine murine (IgG2b)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
Ab type V4 Donor George Lewis
ReferencesMoore1993a, Moore1993c, Abacioglu1994
• B15: Bound preferentially to denatured IIIB gp120 [Moore1993a]
• B15: Binds native BH10 gp120 with 5 fold less affinity than denatured – does not bind native or denatured MN gp120 [Moore1993c]
• B15: V4 region – epitope boundaries mapped by peptide scanning [Abacioglu1994]
526 B34 gp160 (395–400) gp120 (395–400 BH10) WFNSTW Vaccine murine (IgG2b)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
Ab type V4
References Abacioglu1994
• B34: V4 region – epitope boundaries mapped by peptide scanning [Abacioglu1994]
527 7F11 gp160 (397–439) gp120 (IIIB) Vaccine murine
Vaccine Vector/Type: protein HIV component: gp120
References Lasky1987, Nilsen1996
• 7F11: There is another MAb with this name that binds to integrase [Nilsen1996]
528 5C2E5 gp160 (422–431) gp120 (406–415 IIIB) QFINMWQEVK Vaccine murine
Vaccine Vector/Type: protein HIV component: gp120
Ab type C4 Donor T. Gregory and R. Ward, Genentech, San Francisco
References Lasky1987, Cordell1991
• 5C2E5: Blocks the gp120-CD4 interaction [Lasky1987]
• 5C2E5: Cross-competition with MAbs 5C2E5, ICR38.8f and ICR38.1a [Cordell1991]
529 G3-211 gp160 (423–437) gp120 (423–437 IIIB) IINMWQKVGKAMYAP L Vaccine murine (IgG1)
Vaccine Vector/Type: virus derived protein Strain: IIIB HIV component: gp120
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Ab type C4
References Sun1989
• G3-211, 42, 299, 508, 519, 536, 537: Cross-react with diverse strains by immunofluorescence – blocks HIV binding to CD4+ cells – different neutralization
efficiencies [Sun1989]
530 G3-537 gp160 (423–437) gp120 (423–437 IIIB) IINMWQKVGKAMYAP L Vaccine murine (IgG1)
Vaccine Vector/Type: virus derived protein Strain: IIIB HIV component: gp120
Ab type C4
References Sun1989, Ho1991b, McKeating1992b
• G3-537, 211, 299, 508, 519, 536, 42: Cross-react with diverse strains by immunofluorescence – blocks HIV binding to CD4+ cells – different neutralization
efficiencies [Sun1989]
• G3-537: Weakly neutralizing – binds to a linear binding domain of gp120, NMWQEVGKAMYAPPISG [McKeating1992b]
531 polyclonal gp160 (425–436) gp120 NMWQEVGKAMYA L Vaccine murine (IgA)
Vaccine Vector/Type: peptide Strain: IIIB Adjuvant: cholera toxin adjuvant
Ab type CD4BS
References Bukawa1995
• Polyclonal secretory IgA antibody raised by mucosal immunization is able to neutralize IIIB, SF2, and MN – HIV-1 neutralization may be due to the V3,
CD4 or HPG30 component of the multicomponent peptide immunogen [Bukawa1995]
532 1795 gp160 (425–441) gp120 (425–441 IIIB) NMWQEVGKAMYAPPISG L Vaccine
Vaccine Vector/Type: poliovirus HIV component: Env
Ab type CD4BS
ReferencesMcKeating1992b
• 1795: CD4 binding site – weakly neutralizing – binding inhibited by WQEVGKAMYA, GKAM may be involved [McKeating1992b]
533 ICR38.1a
(38.1a,
388/389,
ARP388/389)
gp160 (429–438) gp120 (dis 427–436
BRU)
EVGKAMYAPP L Vaccine rat (IgG2b)
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: gp120
Ab type C3, C4
References Cordell1991, McKeating1992b, McKeating1992a, McKeating1992c, McKeating1993b, McKeating1993a, Moore1993c, Jeffs1996, Peet1998,
Kropelin1998, Vella2002
• ICR38.1a: Weakly neutralizing – binds linear determinant in the CD4 binding domain – cross-competition with MAbs G3-536, 5C2E5, and ICR38.8f
[McKeating1992b, Cordell1991]
• ICR38.1a: Unable to exert a synergistic effect in combination with V3 directed MAbs, in contrast to MAb 39.13g, that binds to a conformational epitope
involved in CD4 binding [McKeating1992a]
• ICR38.1a: Studied in the context of a neutralization escape mutant [McKeating1993a]
• ICR38.1a: Unreactive with solid-phase decapeptide, competed in solution phase assay – ICR 38.1a and ICR 38.8f were initially reported to be independent
MAbs, but are actually subclones of the same MAb [Moore1993c]
• ICR38.1a: Called 38.1a – 10 to 20 fold increased binding when V1/V2 or V1/V2 and V3 were deleted from gp120 [Jeffs1996]
• ICR38.1a: The most variable amino acids in the V3 loop were replaced with serines to make the immunodominant V3 loop less immunogenic – these
changes did not affect the ability of sCD4 or MAbs to V1/V2, C1 and C4 to bind – ICR38.1a was not affected by V3 serine substitutions – mice injected
with serine substituted gp120 had a reduced response relative to wildtype, and no enhanced immunogenicity of conserved regions [Peet1998]
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• ICR38.1a: Called 388/389 – anti-C1 region MAb 87-135/9 blocks gp120 interaction with CD4+ cells – blocking activity is additive when combined with
antibodies which bind in the C4 region of gp120 (F105, 388/389, and b12) [Kropelin1998]
• ICR38.1a: Called ARP388/ARP389: Herpesvirus saimiri-immortalized CD4+ T lymphocytes (HVS T cells) were used to isolate virus and perform HIV-1
neutralization assays, and compared with a standard PBMC protocol – neutralization sensitivities to a panel of MAbs and to homologous or heterologous
plasma/sera were similar for HVS T cells (CN-2 cells) and PBMCs – lists epitope as WQEVGKAMYA [Vella2002]
• ICR38.1a: UK Medical Research Council AIDS reagent: ARP388/ARP389
534 G3-299 gp160 (429–438) gp120 (429–438 BRU) EVGKAMYAPP L Vaccine murine (IgG1)
Vaccine Vector/Type: virus derived protein HIV component: gp120
Ab type C4 DonorM. Fung and Tanox Biosystems Inc and David Ho, ADARC, NY
References Sun1989, Moore1993c, Sattentau1995b, Moore1996, Poignard1996a, Binley1997a, Ditzel1997, Wyatt1997, Parren1998a
• G3-299: Best neutralization of IIIB in panel of 7 MAbs that bind overlapping epitope [Sun1989]
• G3-299: C4 region – binds HXB2 20mer KQIINMWQKVGKAMYAPPIS, and SF-2 and MN gp120s – G3-42, G3-299 lower affinity than G3-508, G3-519,
and G3-536 – bound native gp120, not denatured – poor peptide binding, epitope spans V3-C4 regions – 433A/L, 435Y/H and 430V/S substitutions
impaired binding, V3 loop cleavage or insertion abolished binding [Moore1993c]
• G3-299: Binds with higher affinity to monomer than to oligomer, slow association rate, although faster than other C4 MAbs tested, with more potent
neutralization of lab strain [Sattentau1995b]
• G3-299: Discontinuous V3-C4 epitope, binding enhanced by a few anti-C1, anti-CD4 binding site, and V2 MAbs – binding reciprocally inhibited by
anti-V3 MAbs – G3-229 enhances the binding of some anti-V2 MAbs [Moore1996]
• G3-299: Epitope described as KQIINMWQKVGKAMYAPPIS – binding resulted in slight gp120 dissociation from virus and exposure of the gp41 epitope
for MAb 50-69 [Poignard1996a]
• G3-299: Binds both gp120 and soluble gp120+gp41 complex efficiently, suggesting its gp120 epitope is not blocked by gp41 binding [Wyatt1997]
• G3-299: The MAb and Fab binding to the oligomeric form of gp120 and neutralization were highly correlated – authors suggest that neutralization is
determined by the fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
535 G3-42 (G3 42) gp160 (429–438) gp120 (429–438 BRU) EVGKAMYAPP L Vaccine murine (IgG1)
Vaccine Vector/Type: virus derived protein Strain: IIIB HIV component: gp120
Ab type C4 Donor Tanox Biosystems Inc and David Ho, ADARC, NY
References Sun1989, Moore1993c, Thali1993, Sattentau1995b, Jagodzinski1996, Moore1996, Poignard1996a, Trkola1996a, Binley1997a, Binley1999,
Jagodzinski2000
• G3-42: Neutralization of IIIB but not RF [Sun1989]
• G3-42: C4 region – binds HXB2 20mer KQIINMWQKVGKAMYAPPIS, and SF-2 and MN gp120s – G3-42, G3-299 have lower affinity than G3-508,
G3-519, and G3-536 – bound native gp120, not denatured – poor peptide binding, epitope spans V3-C4 regions – 433A/L, 435Y/H and 430V/S
substitutions impaired binding, V3 loop insertion abolished binding [Moore1993c]
• G3-42: Inhibits binding of CD4 inducible MAb 48d [Thali1993]
• G3-42: Binds with higher affinity to monomer than to oligomer, slow association rate [Sattentau1995b]
• G3-42: The sulfated polysaccharide curdlan sulfate (CRDS) binds to the Envelope of T-tropic viruses and neutralizes virus – CRDS potently inhibits G3-42
binding – G3-42 epitope described as KVGKAMYAPP [Jagodzinski1996]
• G3-42: Inhibits binding of many anti-V3, -CD4 binding site, and -C4 region MAbs – enhances binding of some anti-V2 region MAbs [Moore1996]
• G3-42: Epitope described as KQIINMWQKVGKAMYAPPIS – binding resulted in slight gp120 dissociation from virus and exposure of the gp41 epitope
for MAb 50-69 [Poignard1996a]
• G3-42: Called G3 42 – Does not inhibit gp120 interaction with CCR-5 in a MIP-1beta-CCR-5 competition study – described as V3-C4 discontinuous
epitope [Trkola1996a]
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• G3-42: The MAbs with the broadest neutralizing activity, IgG1b12, 2G12 and 2F5, all have high affinity for the native trimer, indicating that they were
raised in an immune response to the oligomer on the virion surface rather than dissociated subunits – a disulfide linked gp120-gp41 (SOS gp140) was
created to mimic the native conformation of Env and explore its potential as an immunogen – SOS gp140 is recognized by NAbs IgG1b12, 2G12, and
CD4-IgG2, and also by anti-V3 MAbs 19b and 83.1 – SOSgp140 is not recognized by C4 region MAbs that neutralize only TCLA strains, G3-42 and
G3-519 – nor did it bind C11, 23A, and M90, MAbs that bind to gp120 C1 and C5, where it interacts with gp41 – MAbs that bind CD4 inducible epitopes,
17b and A32 were very strongly induced by CD4 in SOS gp140 – anti-gp41 MAbs that bind in the region that interacts with gp120, 7B2, 2.2B, T4, T15G1
and 4D4, did not bind to SOSgp140, in contrast to 2F5, which binds to the only gp41 epitope that is well exposed in native gp120-gp41 complexes
[Binley1999]
• 0.5beta: MAbs 0.5beta and G3-42 were used to study synthesis of oligomeric and monomeric forms of Env – inhibition of glycosylation by tunicamycin
results in reduction of oligomeric gp120 at the cell surface and of monomer in the cytoplasm – neither MAb recognized non-glycosylated Env precursor
[Jagodzinski2000]
536 G3-508 (G3
508)
gp160 (429–438) gp120 (429–438 BRU) EVGKAMYAPP L Vaccine murine (IgG1)
Vaccine Vector/Type: virus derived protein Strain: IIIB HIV component: gp120
Ab type C4 DonorM. Fung and Tanox Biosystems Inc and David Ho, ADARC, NY
References Sun1989, Thali1993, Moore1993c, Sattentau1995b, Moore1996, Poignard1996a, Trkola1996a, Binley1997a, Parren1998a, Binley1998
• G3-508: Neutralization of IIIB and RF [Sun1989]
• G3-508: Inhibits binding of CD4 inducible MAb 48d [Thali1993]
• G3-508: C4 region – binds HXB2 20mer KQIINMWQKVGKAMYAPPIS, and SF-2 and MN gp120s – bound denatured with 10 fold greater affinity than
native – 433A/L, 435Y/H and 430V/S substitutions impaired binding [Moore1993c]
• G3-508: Binds with higher affinity to monomer than to oligomer, slow association rate [Sattentau1995b]
• G3-508: Inhibits binding of some V3, C4 and CD4 binding site MAbs, enhances binding of V2 region MAbs [Moore1996]
• G3-508: Binding resulted in slight gp120 dissociation from virus and exposure of the gp41 epitope for MAb 50-69 [Poignard1996a]
• G3-508: Called G3 508 – inhibits gp120 interaction with CCR-5 in a MIP-1beta-CCR-5 competition study [Trkola1996a]
• G3-508: The MAb and Fab binding to the oligomeric form of gp120 and neutralization were highly correlated – authors suggest that neutralization is
determined by the fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
• G3-508: A panel of MAbs were shown to bind with similar or greater affinity and similar competition profiles to a deglycosylated or variable loop deleted
core gp120 protein ( Delta V1, V2, and V3), thus such a core protein produces a structure closely approximating full length folded monomer [Binley1998]
537 G3-519 gp160 (429–438) gp120 (429–438 BRU) EVGKAMYAPP L Vaccine murine (IgG1)
Vaccine Vector/Type: virus derived protein Strain: IIIB HIV component: gp120
Ab type C4 Donor Tanox Biosystems Inc and David Ho, ADARC, NY
References
Sun1989, Moore1993a, Moore1993c, D’Souza1994, Sattentau1995b, Moore1996, Poignard1996a, Binley1997a, Wyatt1997, Parren1998a, Binley1999
• G3-519: Best neutralization of RF in panel of 7 MAbs that bind overlapping epitope [Sun1989]
• G3-519: Neutralizes IIIB, is reactive with SF-2 gp120, mild inhibition of HIV-1+ sera binding to IIIB gp120 [Moore1993a]
• G3-519: C4 region – binds HXB2 20mer KQIINMWQKVGKAMYAPPIS, and SF-2 and MN gp120s – bound denatured with 5 fold greater affinity than
native – 433A/L, 435Y/H, 438P/R and 430V/S substitutions impaired binding [Moore1993c]
• G3-519: Included in a multi-lab study for antibody characterization, and binding and neutralization assay comparison, also binds IIIB:
IINMWQKVGKAMYAPP [D’Souza1994]
• G3-519: Binds with higher affinity to monomer than to oligomer, slow association rate [Sattentau1995b]
• G3-519: Non-reciprocal enhanced binding in the presence of the C5 MAb 1C1 and the C1 MAb 135/9 – reciprocal enhanced binding with some V2 MAbs.
Inhibited binding the presence of some C4, V3 and CD4 binding site MAbs [Moore1996]
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• G3-519: Epitope described as KVGKAMYAPP – binding resulted in slight gp120 dissociation from virus but no significant exposure of the gp41 epitope
for MAb 50-69 [Poignard1996a]
• G3-519: Binds both gp120 and soluble gp120+gp41 complex efficiently, suggesting its gp120 epitope is not blocked by gp41 binding [Wyatt1997]
• G3-519: The MAb and Fab binding to the oligomeric form of gp120 and neutralization were highly correlated – authors suggest that neutralization is
determined by the fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
• G3-519: The MAbs with the broadest neutralizing activity, IgG1b12, 2G12 and 2F5, all have high affinity for the native trimer, indicating that they were
raised in an immune response to the oligomer on the virion surface rather than dissociated subunits – a disulfide linked gp120-gp41 (SOS gp140) was
created to mimic the native conformation of Env and explore its potential as an immunogen – SOS gp140 is recognized by NAbs IgG1b12, 2G12, and
CD4-IgG2, and also by anti-V3 MAbs 19b and 83.1 – SOSgp140 is not recognized by C4 region MAbs that neutralize only TCLA strains, G3-42 and
G3-519 – nor did it bind C11, 23A, and M90, MAbs that bind to gp120 C1 and C5, where it interacts with gp41 – MAbs that bind CD4 inducible epitopes,
17b and A32 were very strongly induced by CD4 in SOS gp140 – anti-gp41 MAbs that bind in the region that interacts with gp120, 7B2, 2.2B, T4, T15G1
and 4D4, did not bind to SOSgp140, in contrast to 2F5, which binds to the only gp41 epitope that is well exposed in native gp120-gp41 complexes
[Binley1999]
538 G3-536 gp160 (429–438) gp120 (429–438 BRU) EVGKAMYAPP L Vaccine murine (IgG1)
Vaccine Vector/Type: virus derived protein Strain: IIIB HIV component: gp120
Ab type C4 Donor Tanox Biosystems Inc and David Ho, ADARC, NY
References
Sun1989, Ho1991b, Cordell1991, McKeating1992b, Moore1993a, Moore1993c, Gorny1994, Sattentau1995b, Moore1996, Poignard1996a, Parren1998a
• G3-536: Weak neutralization of IIIB and RF – cross-react with diverse strains by immunofluorescence – blocks HIV binding to CD4+ cells –
epitope:IINMWQKVGKAMYAP [Sun1989]
• G3-536: Cross-competition with MAbs 5C2E5, ICR38.8f and ICR38.1a [Cordell1991]
• G3-536: Weakly neutralizing – binds to a linear determinant in the CD4 binding domain of gp120 [McKeating1992b]
• G3-536: Neutralizes IIIB, is reactive with SF-2 gp120, mild inhibition of HIV-1+ sera binding to IIIB gp120 [Moore1993a]
• G3-536: C4 region – binds HXB2 20mer KQIINMWQKVGKAMYAPPIS, and SF-2 and MN gp120s – bound denatured with 15 fold greater affinity than
native – 433A/L, 435Y/H, 438P/R, and 430V/S substitutions impaired binding [Moore1993c]
• G3-536: Enhances binding of anti-V2 MAb 697-D [Gorny1994]
• G3-536: Binds with higher affinity to monomer than to oligomer, slow association rate [Sattentau1995b]
• G3-536: Inhibits binding of some V3, C4 and CD4 binding site MAbs, enhances binding of V2 region MAbs [Moore1996]
• G3-536: Epitope described as KVGKAMYAPP [Poignard1996a]
• G3-536: The MAb and Fab binding to the oligomeric form of gp120 and neutralization were highly correlated – authors suggest that neutralization is
determined by the fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
539 ICR38.8f gp160 (429–438) gp120 (429–438 BRU) EVGKAMYAPP L Vaccine rat (IgG2b)
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: gp120
Ab type C4
References Cordell1991
• ICR38.8f: Weakly neutralizing – binds linear determinant in the CD4 binding domain – cross-competition with ICR38.1a, 5C2E5, and G3-536
[Cordell1991]
• ICR38.8f:ICR 38.1a and ICR 38.8f were initially reported to be independent MAbs, but are actually subclones of the same MAb [Moore1993c]
540 MO86/C3 gp160 (429–443) gp120 (429–443) EVGKAMYAPPISGQI in vitro stimulation human (IgM)
Ab type C4
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References Ohlin1992
• MO86: Generated in response to IIIB Env 286-467 upon in vitro stimulation of uninfected-donor lymphocytes [Ohlin1992]
541 13H8 gp160 (431–440) gp120 (412–453) GKAMYAPPIS L Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein Strain: MN
Ab type C4
References Nakamura1992, Nakamura1993, Jeffs1996
• 13H8: Cross blocks 5C2 in IIIB-rsgp160 ELISA – reactive with diverse strains in rgp120 ELISA [Nakamura1992]
• 13H8: Bound diverse strains, neutralizing activity against MN [Nakamura1993]
• 13H8: Binds V3 and C4 peptides (J. P. Moore, per. comm.)
• 13H8: 3 and 4.5 fold increased binding when V1/V2 or V1/V2 and V3 were deleted from gp120, respectively [Jeffs1996]
542 G45-60 gp160 (431–440) gp120 (429–438 BRU) GKAMYAPPIS L Vaccine murine (IgG1)
Vaccine Vector/Type: virus derived protein Strain: IIIB HIV component: gp120
Ab type C4
References Sun1989, Moore1993c, Gorny1994, Moore1996, Jagodzinski1996
• G45-60: C4 region – binds HXB2 20mer KQIINMWQKVGKAMYAPPI, decapeptide flanking peptides also bound – bound equivalently to native and
denatured gp120 – 433A/L and 435Y/H (not 430V/S) substitutions impaired binding [Moore1993c]
• G45-60: Enhances binding of anti-V2 MAb 697-D [Gorny1994]
• G45-60: Non-reciprocal enhancement of G45-60 binding by some C1 and C5 antibodies – reciprocal enhancement of some V2 region MAbs – reciprocal
inhibition with many MAbs that bind to the V3, C4 and CD4 binding site regions [Moore1996]
• G45-60: The sulfated polysaccharide curdlan sulfate (CRDS) binds to the Envelope of T-tropic viruses and neutralizes virus CRDS inhibits G45-60 binding
[Jagodzinski1996]
543 polyclonal gp160 (432–451) gp120 (42–61 LAI) KAMYAPPISGQIRCSSNITG no Vaccine murine
Vaccine Vector/Type: vaccinia HIV component: Env
Ab type C4
References Collado2000
• Vaccinia p14 can elicit NAbs and p39 tends to be immunodominant, so these two proteins were fused to regions of HIV-1 Env – reduced glycosylation was
noted when p14 or p39 was placed in the N-term region of the fusion protein – chimeric proteins shifted the Env Ab response from V3 to either a C1 or C4
domain, depending on the construct – all chimeric Env proteins: 14kEnv, 39kEnv, and Env39k elicited a strong Ab response to the C1 region of gp120
(LFCASDAKAYDTEVHNVWAT), and Env39k mounted a strong response to the C4 region (KAMYAPPISGQIRCSSNITG) [Collado2000]
544 1662 gp160 (433–439) gp120 (IIIB) AMYAPPI no Vaccine
Vaccine Vector/Type: poliovirus HIV component: Env
Ab type C4
ReferencesMcKeating1992b
• 1662: Did not bind to native gp120, epitope not exposed [McKeating1992b]
545 1663 gp160 (433–439) gp120 (IIIB) AMYAPPI no Vaccine
Vaccine Vector/Type: poliovirus HIV component: Env
Ab type C4
ReferencesMcKeating1992b
• 1663: Did not bind to native gp120, epitope not exposed [McKeating1992b]
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546 1664 gp160 (433–439) gp120 (IIIB) AMYAPPI no Vaccine
Vaccine Vector/Type: poliovirus HIV component: Env
Ab type C4
ReferencesMcKeating1992b
• 1664: Did not bind to native gp120, epitope not exposed [McKeating1992b]
547 1697 gp160 (433–439) gp120 (IIIB) AMYAPPI no Vaccine
Vaccine Vector/Type: poliovirus HIV component: Env
Ab type C4
ReferencesMcKeating1992b
• 1697: Did not bind to native gp120, epitope not exposed [McKeating1992b]
548 1794 gp160 (433–442) gp120 (IIIB) AMYAPPISGQ no Vaccine
Vaccine Vector/Type: poliovirus HIV component: Env
Ab type C4
ReferencesMcKeating1992b
• 1794: Did not bind to native gp120, epitope not exposed [McKeating1992b]
549 1804 gp160 (433–442) gp120 (IIIB) AMYAPPISGQ no Vaccine
Vaccine Vector/Type: poliovirus HIV component: Env
Ab type C4
ReferencesMcKeating1992b
• 1804: Did not bind to native gp120, epitope not exposed [McKeating1992b]
550 1807 gp160 (433–442) gp120 (IIIB) AMYAPPISGQ no Vaccine
Vaccine Vector/Type: poliovirus HIV component: Env
Ab type C4
ReferencesMcKeating1992b
• 1807: Did not bind to native gp120, epitope not exposed [McKeating1992b]
551 1808 gp160 (433–442) gp120 (IIIB) AMYAPPISGQ no Vaccine
Vaccine Vector/Type: poliovirus HIV component: Env
Ab type C4
ReferencesMcKeating1992b
• 1808: Did not bind to native gp120, epitope not exposed [McKeating1992b]
552 polyclonal
(VEI5)
gp160 (454–474) Env LTRDGGNNNNESEIFRPGGGD HIV-1 infection human
Ab type V1, V2, V3, V4, V5
References Carlos1999
• Antibody response to the epitopes in a vaccine construct (VEI) containing peptides from 5 hypervariable regions of gp120 was detected in the sera of HIV-1
positive subjects, including sera from 6 non-subtype B infections – serum samples from San Francisco, Canada and Puerto Rico cohort showed presence of
antibodies against all five VEI hypervariable regions, but most consistently against the V3 region peptide NNNTRKSIRIGPGRAFYTTGDIGNIRQ
[Carlos1999]
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553 polyclonal gp160 (460–467) gp120 (LAI) NNNNGSEI HIV-1 infection, Vaccine human
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
Ab type V5
References Loomis-Price1997
• HIV-1+ positive individuals were given a gp160 vaccine as immunotherapy, and this region was the most reactive new epitope as measured by a modified
Pepscan technique which improved sensitivity – 4/14 showed vaccine-induced reactivity [Loomis-Price1997]
554 CRA1(ARP
323) (CRA-1)
gp160 (461–470) gp120 (451–470 LAI) SNNESEIFRL no Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: Env
Ab type V5-C5 DonorM. Page, NIBSC, UK
ReferencesMoore1993a, Moore1994d, Moore1994c, Moore1996, Trkola1996a, Yang2000
• CRA1: Bound preferentially to denatured IIIB and SF2 gp120 [Moore1993a]
• CRA1: Some C5 mutations abrogate binding 470 P/L or G, 475 M/S, some C2 mutations enhance binding [Moore1994d]
• CRA1: The relative affinity for denatured/native gp120 is 24 – C5 mutations 470 P/L or G, 475 M/S impairs binding to the native gp120 – only mutation
470 P/L impairs binding to denatured [Moore1994c]
• CRA1: C5 region linear epitope, binds weakly to nondenatured monomeric gp120 – reciprocal binding inhibition with anti-C5 antibodies 1C1 and M91 –
non-reciprocal binding enhancement some C1 and V2 antibodies – non-reciprocal binding inhibition of some CD4 binding site antibodies [Moore1996]
• CRA1: Does not neutralize JR-FL nor block gp120 interaction with CCR-5 in a MIP-1beta-CCR-5 competition study [Trkola1996a]
• CRA1: A combination of gp41 fusion with the GNC4 trimeric sequences and disruption of the YU2 gp120-gp41 cleavage site resulted in stable gp140
trimers (gp140-GNC4) that preserve and expose some neutralizing epitopes while occluding some non-neutralizing epitopes – CD4BS MAbs (F105 and
F91) and CD4i (17b and 48d) recognized gp140-GNC4 as well as gp120 or gp140 – non-neutralizing MAbs C11, A32, 522-149, M90, and #45 bound to the
gp140-GNC4 glycoprotein at reduced levels compared to gp120 – MAbs directed at the extreme termini of gp120 C1 (135/9 and 133/290) and C5 (CRA-1
and M91) bound efficiently to gp140-GNC4 [Yang2000]
• CRA1: UK Medical Research Council AIDS reagent: ARP323
555 M91 gp160 (461–470) gp120 (451–470 LAI) SNNESEIFRL no Vaccine rat (IgG2a)
Vaccine Vector/Type: protein HIV component: Env
Ab type V5-C5 Donor Fulvia di Marzo Veronese
References diMarzo Veronese1992, Moore1994c, Moore1994d, Moore1996, Ditzel1997, Binley1998, Yang2000
• M91: Immunoblot reactive, RIP negative, but precipitates deglycosylated gp120 – reacts with strains IIIB, 451, MN, RF, and RUTZ
[diMarzo Veronese1992]
• M91: The relative affinity for denatured/native gp120 is 24 – mutation in position 470 P/L impairs binding [Moore1994c]
• M91: 470 P/L impairs binding, but not 475 D/V, in contrast to CRA1 – some C2 mutations can enhance binding [Moore1994d]
• M91: C5 region linear epitope, binds weakly to nondenatured monomeric gp120 – M91 binding was enhanced by 1C1, but 1C1 binding was inhibited by
M91 – non-reciprocal binding enhancement of C1 and V2 antibodies – non-reciprocal binding inhibition of CD4 binding site antibodies [Moore1996]
• M91: A panel of MAbs were shown to bind with similar or greater affinity and similar competition profiles to a deglycosylated or variable loop deleted core
gp120 protein ( Delta V1, V2, and V3), thus such a core protein produces a structure closely approximating full length folded monomer [Binley1998]
• M91: A combination of gp41 fusion with the GNC4 trimeric sequences and disruption of the YU2 gp120-gp41 cleavage site resulted in stable gp140
trimers (gp140-GNC4) that preserve and expose some neutralizing epitopes while occluding some non-neutralizing epitopes – CD4BS MAbs (F105 and
F91) and CD4i (17b and 48d) recognized gp140-GNC4 as well as gp120 or gp140 – non-neutralizing MAbs C11, A32, 522-149, M90, and #45 bound to the
gp140-GNC4 glycoprotein at reduced levels compared to gp120 – MAbs directed at the extreme termini of gp120 C1 (135/9 and 133/290) and C5 (CRA-1
and M91) bound efficiently to gp140-GNC4 [Yang2000]
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556 9201 gp160 (471–482) gp120 (475–486 LAI) GGGDMRDNWRSE no murine
Ab type C5 Donor Du Pont
ReferencesMcDougal1996
• 9201: Does not neutralize LAI [McDougal1996]
557 1C1 gp160 (471–490) gp120 (471–490 LAI) GGGDMRDNWRSELYKYKVVK Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: Env
Ab type C5 Donor Repligen Inc, Cambridge, MA, commercial
ReferencesMoore1994c, Moore1994d, VanCott1995, Moore1996
• 1C1: The relative affinity for denatured/native gp120 is 15 [Moore1994c]
• 1C1: C2 and V3 regions substitutions can influence binding [Moore1994d]
• 1C1: Linear epitope not exposed on conformationally intact gp120 [VanCott1995]
• 1C1: C5 region linear epitope, binds weakly to nondenatured monomeric gp120 – M91 binding was enhanced by 1C1, but 1C1 binding was inhibited by
M91 – non-reciprocal binding enhancement of some C1 and V2 antibodies – non-reciprocal binding inhibition of some CD4 binding site antibodies
[Moore1996]
558 3F5 gp160 (471–490) gp120 (471–490 LAI) GGGDMRDNWRSELYKYKVVK Vaccine murine (IgG)
Vaccine Strain: LAI HIV component: Env
Ab type C5 Donor S. Nigida, NCI, USA
ReferencesMoore1994c
• 3F5: The relative affinity for denatured/native gp120 is 100 [Moore1994c]
559 5F4/1 gp160 (471–490) gp120 (471–490 LAI) GGGDMRDNWRSELYKYKVVK Vaccine murine
Vaccine Vector/Type: peptide Strain: HIV-2 ROD
Ab type C5 Donor S. Ranjbar, NIBSC, UK
ReferencesMoore1994c
• 5F4/1: V5-C5 region – preferentially binds SDS-DTT denatured gp120 (>10 fold) – mutation 485 K/V impairs binding [Moore1994c]
560 660-178 gp160 (471–490) gp120 (471–490 LAI) GGGDMRDNWRSELYKYKVVK Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: Env
Ab type C5 Donor G. Robey, Abbott Labs
ReferencesMoore1994c, Moore1994d
• 660-178: The relative affinity for denatured/native gp120 is >100 [Moore1994c]
• 660-178: DeltaV1/V2 and DeltaV1/V2/V3 reduce binding – C2 and C5 mutations enhance binding [Moore1994d]
561 9301 gp160 (471–490) gp120 (471–490 LAI) GGGDMRDNWRSELYKYKVVK Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: Env
Ab type C5 Donor Dupont, commercial
References Skinner1988b, Moore1993a, Moore1994c, Moore1994d, Wagner1996
• 9301: Bound preferentially to denatured IIIB gp120 [Moore1993a]
• 9301: The relative affinity for denatured/native gp120 is 19 [Moore1994d]
• 9301: Wagner et al. claim that Nea 9301 is anti-V3 – might they have meant MAb 9305? [Wagner1996]
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562 B221 (221) gp160 (471–490) gp120 (471–490 LAI) GGGDMRDNWRSELYKYKVVK Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein Strain: NL43 HIV component: gp160
Ab type C5 Donor Rod Daniels
ReferencesMoore1993a, Bristow1994, Moore1994c
• B221: Called 221 – bound preferentially to denatured IIIB gp120 [Moore1993a]
• B221: MAb generated in a study of the humoral immune response to Baculovirus-expressed mis-folded rgp160 IIIB:NL43, MicroGenSys [Bristow1994]
• B221: The relative affinity for denatured/native gp120 is 12 – mutation 477 D/V impairs binding [Moore1994c]
• B221: Called 221 – C2 and V3 substitutions influence binding [Moore1994d]
• B221: UK Medical Research Council AIDS reagent: ARP301
563 8C6/1 gp160 (471–490) gp120 (471–490 LAI) GGGDMRDNWRSELYKYKVVK Vaccine murine (IgG)
Vaccine Strain: LAI
Ab type V5-C5 Donor S. Ranjbar, NIBSC, UK
ReferencesMoore1994c
• 8C6/1: V5-C5 region – preferentially binds SDS-DTT denatured gp120 (>30 fold) – mutation 485 K/V impairs binding [Moore1994c]
• 8C6/1: UK Medical Research Council AIDS reagent: ARP3052
564 H11 gp160 (472–477) gp120 (472–477 HXB2) GGDMRD murine
Ab type C5
References Pincus1993a, Pincus1996
• H11: Binds to gp120 but not to infected cells – when linked to ricin A, the immunotoxin did not mediate cell killing – sCD4 has no effect
[Pincus1993a, Pincus1996]
565 W2 gp160 (472–491) gp120 (472–491 LAI) GGDMRDNWRSELYKYKVVKI Vaccine murine (IgG)
Vaccine Strain: LAI HIV component: Env
Ab type C5 Donor D. Weiner, U. Penn., USA
ReferencesMoore1994c
• W2: The relative affinity for denatured/native gp120 is 30 – mutation 485 K/V impairs binding [Moore1994c]
566 M38 gp160 (485–504) gp120 (490–508) KYKVVKEIPLGVAPTKAKRR no Vaccine murine
Vaccine Vector/Type: virus Strain: IIIB HIV component: virus
Ab type C5
References Beretta1987, Grassi1991, Lopalco1993, DeSantis1994, Beretta1994, Maksiutov2002
• M38: Binds to gp120 and to a 80 kd human protein expressed on a small fraction of mononuclear cells in the lymph nodes [Beretta1987]
• M38: Binds to the carboxy terminus of gp120, in a gp41 binding region, and also to denatured human HLAs (antigenic homology) [Lopalco1993]
• M38: Infected individuals have HLA class I-gp120 cross-reactive antibodies [DeSantis1994]
• M38: This epitope is similar to a fragment of the human protein mast/stem cell growth factor receptor precursor, VVPTKADKRRSV, as well as to a
fragment of IFN-related IFRD2 (PC4-B) protein, ARTKARSRVRDKRA [Maksiutov2002].
567 Chim 1 (C-1) gp160 (487–493) gp120 (492–498 HXB2) KVVKEIP humanized
chimpanzee
References Pincus1993a, Pincus1996
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• Chim 1: Binds to gp120 but not to infected cells – when linked to ricin A, the immunotoxin did not mediate cell killing – sCD4 has no effect
[Pincus1993a, Pincus1996]
568 polyclonal gp160 (489–511) gp120 (495–516 BRU) KIEPLGVAPTKAKRRVVQREKR no HIV-1 infection human
References Hernandez2000, Maksiutov2002
• Chimeric peptide combining two peptides gp160(495-516 and 584-612) served as a specific and broadly reactive antigen for diagnostic detection of HIV-1
[Hernandez2000]
• This epitope is similar to a fragment of the human protein mast/stem cell growth factor receptor precursor, VVPTKADKRRSV, as well as to a fragment of
IFN-related IFRD2 (PC4-B) protein, ARTKARSRVRDKRA [Maksiutov2002].
569 1331A gp160 (490–511) gp120 (510–516) dwVVQREKR HIV-1 infection human (IgG3λ )
Ab type C5 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Nyambi1998, Gorny2000a, Hochleitner2000b, Nyambi2000, Gorny2002, Edwards2002
• 1331A: Using a whole virion-ELISA method, 18 human MAbs were tested for their ability to bind to a panel of 9 viruses from clades A, B, D, F, G, and H –
anti-C5 Abs 670-D and 1331A bound to 3/4 B clade viruses (they don’t bind to IIIB), and to subtype D MAL [Nyambi1998]
• 1331A: Core epitope dwVVQREKR maps to gp120(510-516) – binding of panel of 21 MAbs to soluble oligomeric gp140 versus gp41 or gp120 monomers
was compared – no MAb was oligomer specific, though anti-V3 and CD4BS MAbs reacted better with the oligomer and V2 and C5 tended to favor the
monomer – C5 MAbs 858-D, 989-D and 1331A bound with a 5-10 fold preference for the monomer[Gorny2000a]
• 1331A: The Ab binding site was studied with epitope excision (protein is bound in native conformation to immobilized MAb, then digested with proteolytic
enzymes) and extraction (protein is digested then allowed to react with Ab), followed by mass spectroscopy – two non-contiguous aa in C5 were protected,
E-507 and I-487, which are thought to be located on opposite sides of hydrophobic pocket involved in gp120/gp41 interaction [Hochleitner2000b]
• 1331A: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including 4 C5 MAbs, 2 bound well, 2 bound weakly – MAb 858-D
bound only 4/26, the worst of all anti-C5 MAbs tested, while MAb 1331A, which shares the same core epitope (positions 495-516), bound to 18/26
[Nyambi2000]
• 1331A: Conformation-dependent anti-V3 loop Abs may be more cross-reactive, so six new V3 MAbs were generated – the six new MAbs all bind to the tip
of the V3 loop and cross-compete with the MAb 447-52D and are conformationally sensitive – MAbs showed cross-clade binding to native, intact virions
and the strength binding was highly correlated with percent neutralization using the ghost cell or PHA blast assay – five well-characterized MAbs were used
as controls: anti-V3 447-52D (anti-V3 MAb for competition and neutralization studies), 654 (anti-CD4BS used as a conformation-sensitive MAb control),
1331A (anti-C5 used as a linear binding site MAb control as binding was not diminished by treating gp120 with DTT or sodium metaperiodate to reduce
disulfide bonds), and MAb 246 (anti-gp41 MAb that bound to primary isolates of all clades) [Gorny2002]
• 1331A: Truncation of the gp41 cytoplasmic domain of X4, R5, and X4R5 viruses forces a conformation that more closely resembles the CD4 bound state of
the external Envelope, enhancing binding of CD4i MAbs 17b and 48d and of CD4BS MAbs F105, b12, and in most cases of glycosylation site dependent
MAb 2G12 and the anti-gp41 MAb 246D – in contrast, binding of the anti-V2 MAb 697D and the anti-V3 MAb 694/98D were not affected – viruses
bearing the truncation were more sensitive to neutralization by MAbs 48d, b12, and 2G12 – the anti-C5 MAb 1331A was used to track levels of cell surface
expression of the mutated proteins [Edwards2002]
570 110.1 gp160 (491–500) gp120 (491–500 LAI) IEPLGVAPTK no Vaccine murine (IgG1κ)
Vaccine Vector/Type: infected-cell lysate Strain: BRU HIV component: virus
Ab type C5 Donor Genetic Systems Corp, Seattle WA, E. Kinney-Thomas
References
Gosting1987, Linsley1988, Thomas1988, Pincus1991, Moore1994c, Cook1994, McDougal1996, Binley1997a, Valenzuela1998, Maksiutov2002
• 110.1: There is another antibody with this ID that binds to gp120, but at aa 200-217 [Pincus1996]
• 110.1: Referred to as 110-1 – does not inhibit CD4-gp120 binding or neutralize HIV-1 strains [Linsley1988]
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• 110.1: Difference in the epitope: mapped to aa 421-429 (KQIINMWQE), the T1 sequence – poor efficacy as an immunotoxin when linked to RAC
[Pincus1991]
• 110.1: The relative affinity for denatured/native gp120 is 0.7 [Moore1994c]
• 110.1: MAbs against the glycosphingolipid GalCer block HIV infection of normally susceptible CD4 negative cells from the brain and colon – MAbs
against the carboxy-terminus of gp120 inhibit gp120 binding to GalCer but not as potently as anti-V3 MAbs – binding of GalCer to gp120 does not inhibit
MAb binding [Cook1994]
• 110.1: Does not neutralize HIV-1 LAI [McDougal1996]
• 110.1: Does effect LAI viral binding or entry into CEM cells [Valenzuela1998]
• 110.1: This epitope is similar to a fragment of the human protein mast/stem cell growth factor receptor precursor, VVPTKADKRRSV [Maksiutov2002]
571 42F gp160 (491–500) gp120 (491–500 HXB2) IEPLGVAPTK no HIV-1 infection human (IgG1λ )
Ab type C5
References Alsmadi1997, Alsmadi1998, Maksiutov2002
• 42F: 42F and 43F were isolated from a long term non-progressor by EBV transformation of PBMC – samples were taken 14 months apart – both MAbs
stained diverse strains of infected cells and directed ADCC – were more potent for ADCC if the cell was infected with HIV-1, rather than just presenting
absorbed gp120 [Alsmadi1997]
• 42F: A study of 6 anti-Env MAbs and their ability to bind or direct ADCC against target cells infected with IIIB, MN, SF-2, and RF – bound and directed
lysis against strains IIIB, MN, SF-2, and RF, but not a clone of MN [Alsmadi1998]
• 42F: This epitope is similar to a fragment of the human protein mast/stem cell growth factor receptor precursor, VVPTKADKRRSV [Maksiutov2002].
572 43F gp160 (491–500) gp120 (491–500 HXB2) IEPLGVAPTK no HIV-1 infection human (IgG1λ )
Ab type C5
References Alsmadi1997, Maksiutov2002
• 43F: 42F and 43F were isolated from a long term non-progressor by EBV transformation of PBMC – samples were taken 14 months apart – both MAbs
stained diverse strains of infected cells and directed ADCC – were more potent for ADCC if the cell was infected with HIV-1, rather than just presenting
absorbed gp120 [Alsmadi1997]
• 43F: This epitope is similar to a fragment of the human protein mast/stem cell growth factor receptor precursor, VVPTKADKRRSV [Maksiutov2002].
573 RV110026 gp160 (491–500) gp120 (491–500 LAI) IEPLGVAPTK Vaccine human
Vaccine Vector/Type: peptide Strain: LAI
Ab type C5 Donor Commercial, Olympus Inc
ReferencesMoore1994c, Moore1994d, Maksiutov2002
• RV110026: Preferentially binds SDS-DTT denatured gp120 (15 fold using R1/87 as capture reagent) [Moore1994c]
• RV110026: This epitope is similar to a fragment of the human protein mast/stem cell growth factor receptor precursor, VVPTKADKRRSV
[Maksiutov2002].
574 105-306 gp160 (492–500) gp120 (498–505
HAM112, O group)
KPFSVAPTP Vaccine murine (IgG1 κ)
Vaccine Vector/Type: recombinant protein Strain: HAM112 (group O) HIV component: gp160
Ab type C-term
References Scheffel1999
• 105-306: Overlapping peptides based on group O HAM112 Env were tested for MAb reactivity – 105-306 bound to two overlapping peptides
[Scheffel1999]
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575 GV1G2 gp160 (494–499) gp120 (494–499 IIIB) LGVAPT Vaccine murine
Vaccine Vector/Type: protein-Ab complex HIV component: gp120 complexed with MAb M77
Ab type C5
References Denisova1996
• GV1G2: When anti-V3 MAb M77 was bound to gp120 and used as an immunogen, it stimulated many MAbs to linear epitopes – MAbs GV12F6 and
GV3H1 are homologous to GV1G2 and were generated in the same experiment [Denisova1996]
576 750-D gp160 (498–504) gp120 (503–509) PTKAKRR no HIV-1 infection human (IgG3λ )
Ab type C-term
References Forthal1995, Hioe2000
• 750-D: Not neutralizing, positive ADCC activity, and no viral enhancing activity [Forthal1995]
• 750-D: Ab responses, because of their capacity to alter antigen uptake and processing, can influence helper T cell responses – CD4BS MAbs or serum Ig
from HIV+ individuals inhibited proliferative responses of gp120 specific T cells – C5 MAbs 450-D and 750-D did not effect proliferation [Hioe2000]
577 450-D
(450-D-3,
450D)
gp160 (498–504) gp120 (475–486 BH10) PTKAKRR(orRRVVQRE,orMRDNW-
RSELYKYdependingonreferen-
ce)
no HIV-1 infection human (IgG1λ )
Ab type C5 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu), NYU Med Center, NY, NY
References Durda1988, Karwowska1992a, Karwowska1992b, Spear1993, Laal1994, Gorny1994, Cook1994, Forthal1995, Manca1995a, Li1997,
Hioe1997b, Hioe2000, Hioe2001, Verrier2001
• 450-D: Bound to MN, SF-2 and IIIB, but was not neutralizing [Karwowska1992a]
• 450-D: Did not mediate deposition of complement component C3 on HIV infected cells [Spear1993]
• 450-D: Not neutralizing alone, could synergize anti-CD4 binding site antibody neutralization [Laal1994]
• 450-D: Epitope is defined as PTKAKRR [Gorny1994]
• 450-D: MAbs against the glycosphingolipid GalCer block HIV infection of normally susceptible CD4 negative cells from the brain and colon – MAbs
against the carboxy-terminus of gp120 do not inhibit gp120 binding to GalCer – binding of GalCer to gp120 does not inhibit MAb binding [Cook1994]
• 450-D: No neutralizing activity, no ADCC activity, and no viral enhancing activity [Forthal1995]
• 450-D: Virions complexed to gp120 Ab facilitate presentation of p66 RT epitopes to Th cells [Manca1995a]
• 450-D: One of 14 human MAbs tested for ability to neutralize a chimeric SHIV-vpu+, which expressed HIV-1 IIIB env – 50% neutralization could not be
achieved at a maximal concentration of 6 mug/ml [Li1997]
• 450-D: Four primary isolates showed distinct patterns of sensitivity to neutralization by polyclonal sera or plasma and MAbs – BZ167 was the only isolate
inhibited by all polyclonal sera and plasma tested, and was also neutralized by 8/17 MAbs, in particular anti-V3 loop (419-D, 447-52D, 782-D, and 838-D),
anti-CD4bd (559/64-D, 654-D and 830-D and a cluster II of gp41 directed MAb (98-6) – isolates 92HT593 and 91US056 were neutralized by V3 loop
(419-D, and 447-52D)and cluster II gp41 (98-6) MAbs at higher concentrations – US4 was neutralized by some of the polyclonal sera/plasma tested and not
at all by MAbs individually or by a cocktail of ten MAbs consisting of 419-D, 447-52D, 782-D, 838-D, 559/64-D, 654-D, 450-D, 670-D, 1281-D and 98-6
[Hioe1997b]
• 450-D: Ab responses, because of their capacity to alter antigen uptake and processing, can influence helper T cell responses – CD4BS MAbs or serum Ig
from HIV+ individuals inhibited proliferative responses of gp120 specific T cells – C5 MAbs 450-D and 750-D did not effect proliferation [Hioe2000]
• 450-D: CD4BS MAbs when complexed with gp120, inhibit proliferation of gp120-specific CD4 T-cells and IFN gamma production – 450-D does not have
this effect and was used as a control in this study [Hioe2001]
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• 450-D: A panel of 12 MAbs was used to identify those that could neutralize the dual-tropic primary isolate HIV-1 89.6 – six gave significant neutralization
at 2 to 10 ug/ml: 2F5, 50-69, IgG1b12, 447-52D, 2G12, and 670-D six did not have neutralizing activity: 654-D, 4.8D, 450-D, 246-D, 98-6, and 1281 – no
synergy, only additive effects were seen for pairwise combinations of MAbs, and antagonism was noted between gp41 MAbs 50-69 and 98-6, as well as
98-6 and 2F5 [Verrier2001]
578 670-D (670) gp160 (498–504) gp120 (503–509) PTKAKRR no HIV-1 infection human (IgG1λ )
Ab type C5 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu), NYU, NY
References
Zolla-Pazner1995a, Forthal1995, Hill1997, Gorny1997, Hioe1997b, Gorny1998, Nyambi1998, Altmeyer1999, Gorny2000b, Nyambi2000, Verrier2001
• 670-D: Group specific cross-clade binding in serotyping study using flow-cytometry [Zolla-Pazner1995a]
• 670-D: Not neutralizing, positive ADCC activity, and no viral enhancing activity, numbering provided suggests epitope is RRVVQRE [Forthal1995]
• 670-D: gp120 can inhibit MIP-1alpha from binding to CCR5, but this inhibitory effect is blocked by pre-incubation of gp120 with three anti-V3 MAbs:
447, 257, 1027 – MAb 670 which binds in the C5 region had no effect [Hill1997]
• 670-D: Four primary isolates showed distinct patterns of sensitivity to neutralization by polyclonal sera or plasma and MAbs – BZ167 was the only isolate
inhibited by all polyclonal sera and plasma tested, and was also neutralized by 8/17 MAbs, in particular anti-V3 loop (419-D, 447-52D, 782-D, and 838-D),
anti-CD4bd (559/64-D, 654-D and 830-D and a cluster II of gp41 directed MAb (98-6) – isolates 92HT593 and 91US056 were neutralized by V3 loop
(419-D, and 447-52D)and cluster II gp41 (98-6) MAbs at higher concentrations – US4 was neutralized by some of the polyclonal sera/plasma tested and not
at all by MAbs individually or by a cocktail of ten MAbs consisting of 419-D, 447-52D, 782-D, 838-D, 559/64-D, 654-D, 450-D, 670-D, 1281-D and 98-6
[Hioe1997b]
• 670-D: Using a whole virion-ELISA method, 18 human MAbs were tested for their ability to bind to a panel of 9 viruses from clades A, B, D, F, G, and H –
anti-C5 Abs 670-D and 1331A bound to 3/4 B clade viruses (they didn’t bind to IIIB), and to subtype D MAL – 670-D also reacted with subtype
A[Nyambi1998]
• 670-D: A Semliki Forest virus (SFV) expression system carrying BX08 env was used to study the conformation of gp120 – intracytoplasmic gp120 was
recognized by the anti-V3 MAbs K24 and F5.5, while gp120 at the plasma membrane was detected only by conformation dependent MAbs 2G12, 670-D
and 694/98D and not V3 MAbs – expression in rat brain also showed that surface-expressed Env was recognized only by the conformation-dependent
antibodies and not by anti-V3 antibodies [Altmeyer1999]
• 670-D: A gp120 C5 MAb used as a negative control in a study of anti-gp41 MAbs [Gorny2000b]
• 670-D: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including 4 C5 MAbs, 2 bound well, 2 bound weakly – MAb 670-D
bound 21/26, and was the most cross-reactive C5 MAb [Nyambi2000]
• 670-D: A panel of 12 MAbs was used to identify those that could neutralize the dual-tropic primary isolate HIV-1 89.6 – six gave significant neutralization
at 2 to 10 ug/ml: 2F5, 50-69, IgG1b12, 447-52D, 2G12, and 670-D six did not have neutralizing activity: 654-D, 4.8D, 450-D, 246-D, 98-6, and 1281 – no
synergy, only additive effects were seen for pairwise combinations of MAbs, and antagonism was noted between gp41 MAbs 50-69 and 98-6, as well as
98-6 and 2F5 [Verrier2001]
579 polyclonal gp160 (503–509) gp120 (471–477) RRVVQRE Vaccine murine (IgG)
Vaccine Vector/Type: peptide HIV component: gp120
References Jeyarajah1998
• Mice were immunized with peptide APTKAKRRVVQREKR – epitope excision and extraction combined with mass spectrometry was used to map the fine
structure of epitopes recognized by polyclonal Ab to HIV-1 Env – a major epitope was identified between positions 472 and 478 [Jeyarajah1998]
580 722-D gp160 (503–509) gp120 (503–509) RRVVQRE no HIV-1 infection human (IgG1κ)
Ab type C-term
References Laal1994, Forthal1995
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• 722-D: Not neutralizing alone, could synergize anti-CD4 binding site antibody neutralization [Laal1994]
• 722-D: No neutralizing activity, no ADCC activity, and no viral enhancing activity [Forthal1995]
581 polyclonal gp160 (503–511) gp120 (508–516) RRVVQREKR HIV-1 infection human
Ab type C-term
References Palker1987, Loomis-Price1997
• Most HIV-1+ individuals have an antibody response to this epitope – in this study, reactivity to RRVVQREKR was used as a positive control for HIV-1+
gp160 vaccine recipients [Loomis-Price1997]
582 1131-A gp160 (505–511) gp120 (510–516 LAI) VVQREKR no HIV-1 infection human (IgG3λ )
Ab type C-term
References Bandres1998
• 1131-A: A very high affinity antibody used in studies that demonstrate that CXCR4 can bind to gp120 in the absence of CD4-gp120 interactions, and that
this binding can be enhanced by Env deglycosylation [Bandres1998]
583 858-D gp160 (505–511) gp120 (510–516 LAI) VVQREKR no HIV-1 infection human (IgG)
Ab type C-term Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Zolla-Pazner1995a, Forthal1995, Gorny2000a, Nyambi2000
• 858-D: Group specific cross-clade binding in serotyping study using flow-cytometry [Zolla-Pazner1995a]
• 858-D: No neutralizing activity, no ADCC activity, and no viral enhancing activity [Forthal1995]
• 858-D: Binding of panel of 21 MAbs to soluble oligomeric gp140 versus gp41 or gp120 monomers was compared – no MAb was oligomer specific, though
anti-V3 and CD4BS MAbs reacted better with the oligomer and V2 and C5 tended to favor the monomer – C5 MAbs 858-D, 989-D and 1331A bound with
a 5-10 fold preference for the monomer[Gorny2000a]
• 858-D: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including 4 C5 MAbs, 2 bound well, 2 bound weakly – MAb 858-D
bound only 4/26, the worst of all anti-C5 MAbs tested, while MAb 1331A, which shares the same core epitope (positions 495-516), bound to 18/26 isolates
[Nyambi2000].
584 989-D gp160 (505–511) gp120 (LAI) VVQREKR HIV-1 infection human (IgG)
Ab type C-term Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Zolla-Pazner1995a, Gorny2000a, Nyambi2000
• 989-D: In serotyping study using flow-cytometry, showed B clade specificity, but only reacted with 7/11 B clade virus [Zolla-Pazner1995a]
• 989-D: Binding of panel of 21 MAbs to soluble oligomeric gp140 versus gp41 or gp120 monomers was compared – no MAb was oligomer specific, though
anti-V3 and CD4BS MAbs reacted better with the oligomer and V2 and C5 tended to favor the monomer – C5 MAbs 858-D, 989-D and 1331A bound with
a 5-10 fold preference for the monomer[Gorny2000a]
• 989-D: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including 4 C5 MAbs, 2 bound well, 2 bound weakly – MAb 989-D
bound to 6/26 isolates [Nyambi2000].
585 1A1 gp160 (525–543) gp41 (526–543 BH10) AAGSTMGAASMTLTVQARQ no HIV-1 infection human (IgG1κ)
Donor H. Katinger, Inst. Appl. Microbiol., Vienna, Austria
References Buchacher1994, Maksiutov2002
• 1A1: Human MAb generated using EBV transformation of PBL from HIV-1+ volunteers [Buchacher1994]
• 1A1: This epitope is similar to a fragment of the HLA class II histocompatibility antigen, GGSCMAALTVTLTV [Maksiutov2002]
586 24G3 gp160 (525–543) gp41 (526–543 BH10) AAGSTMGAASMTLTVQARQ no HIV-1 infection human (IgG1κ)
Donor H. Katinger, Inst. Appl. Microbiol., Vienna, Austria
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References Buchacher1992, Buchacher1994, Maksiutov2002
• 24G3: Human MAb generated by electrofusion of PBL from HIV-1+ volunteers with CB-F7 cells [Buchacher1994]
• 24G3: This epitope is similar to a fragment of the HLA class II histocompatibility antigen, GGSCMAALTVTLTV [Maksiutov2002]
587 25C2 (IAM
41-25C2)
gp160 (525–543) gp41 (526–543 BH10) AAGSTMGAASMTLTVQARQ no HIV-1 infection human (IgG1κ)
Donor H. Katinger, Inst. Appl. Microbiol., Vienna, Austria and Viral Testing Systems, Houston, TX
References Buchacher1992, Buchacher1994, Sattentau1995c, Maksiutov2002
• 25C2: Human MAb generated by electrofusion of PBL from HIV-1+ volunteers with CB-F7 cells – binds oligomeric and monomeric gp41, and gp160
[Buchacher1994]
• 25C2: Called IAM 41-25C2 – Binding domain overlaps sites that are critical for gp120-gp41 association – binding is enhanced by sCD4 – binding region
defined as: gp41(21-38 BH10) [Sattentau1995c]
• 25C2: This epitope is similar to a fragment of the HLA class II histocompatibility antigen, GGSCMAALTVTLTV [Maksiutov2002]
588 5F3 gp160 (525–543) gp41 (526–543 BH10) AAGSTMGAASMTLTVQARQ no HIV-1 infection human (IgG1κ)
Donor H. Katinger, Inst. Appl. Microbiol., Vienna, Austria
References Buchacher1994, Maksiutov2002
• 5F3: Human MAb generated by electrofusion of PBL from HIV-1+ volunteers with CB-F7 cells [Buchacher1994]
• 5F3: This epitope is similar to a fragment of the HLA class II histocompatibility antigen, GGSCMAALTVTLTV [Maksiutov2002]
589 α(566-586) gp160 (561–581) gp41 (566–586 BRU) AQQHLLQLTVWGIKQLQARIL HIV-1 infection human
References Poumbourios1992
590 PC5009 gp160 (572–591) gp41 (577–596 BRU) GIKQLQARILAVERYLKDQQ Vaccine murine
Vaccine Vector/Type: recombinant protein HIV component: gp160
References Poumbourios1992
• PC5009: Recognized only monomeric gp41 [Poumbourios1992]
591 polyclonal
α577-596
gp160 (572–591) gp41 (577–596 BRU) GIKQLQARILAVERYLKDQQ HIV-1 infection human
References Poumbourios1992
• alpha(577-596): Affinity purified from HIV-1+ plasma – preferentially bind oligomer [Poumbourios1992]
592 polyclonal gp160 (576–592) gp41 (583–599) LQARILAVERYLKDQQL HIV-1 infection human
References Klasse1993b
• 42 HIV-1 positive human sera were tested against wildtype peptide, and peptide with substitution 589 A to T: 11/42 reacted strongly with wildtype, weakly
with A589T – 31 reacted weakly with parental, even more weakly with substituted [Klasse1993b]
593 gp160 (577–583) gp41 (582–589) QARILAV yes HIV-1 exposed
seronegative
human (IgA)
Ab type Leucine zipper motif
References Clerici2002a
• Six sera from HIV-exposed uninfected individuals(EU), HIV-infected individuals and healthy controls were analyzed for IgA Abs – neutralizing activity
was observed with total IgA from both EU and HIV+ – the EU IgA exclusively bound to a distinctive epitope within gp41, QARILAV, in the coiled coil
pocket important for gp120-gp41 interactions – sera of QAFILAV-immunized BALB/c mice was neutralizing with the dose-dependent behavior similar to
2F5 [Clerici2002a]
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594 gp160 (577–583) gp41 (582–589) QARILAV yes Vaccine murine (IgA)
Vaccine Vector/Type: peptide HIV component: gp41 Adjuvant: keyhole limpit haemocyanin (KLH)
Ab type Leucine zipper motif
References Clerici2002a
• Six sera from HIV-exposed uninfected individuals(EU), HIV-infected individuals and healthy controls were analyzed for IgA Abs – neutralizing activity
was observed with total IgA from both EU and HIV+ – the EU IgA exclusively bound to a distinctive epitope within gp41, QARILAV – sera of
QAFILAV-immunized BALB/c mice was neutralizing with the dose-dependent behavior similar to 2F5 [Clerici2002a]
595 1F11 gp160 (578–612) gp41 (579–613 BH10) ARILAVERYLKDQQLLGIWGCSGKL-
ICTTAVPWNA
no HIV-1 infection human (IgG1κ)
Donor H. Katinger, Inst. Appl. Microbiol., Vienna, Austria
References Buchacher1992, Buchacher1994
• 1F11: Generated by electrofusion of PBL from HIV-1 positive volunteers with CB-F7 cells [Buchacher1994]
596 1H5 gp160 (578–612) gp41 (579–613 BH10) ARILAVERYLKDQQLLGIWGCSGKL-
ICTTAVPWNA
no HIV-1 infection human (IgG1κ)
References Buchacher1992, Buchacher1994
• 1H5: Generated by electrofusion of PBL from HIV-1 positive volunteers with CB-F7 cells [Buchacher1994]
597 3D9 gp160 (578–612) gp41 (579–613 BH10) ARILAVERYLKDQQLLGIWGCSGKL-
ICTTAVPWNA
no HIV-1 infection human (IgG1κ)
Donor H. Katinger, Inst. Appl. Microbiol., Vienna, Austria
References Buchacher1992, Buchacher1994
• 3D9: Generated by electrofusion of PBL from HIV-1 positive volunteers with CB-F7 cells [Buchacher1994]
598 4B3 gp160 (578–612) gp41 (579–613 BH10) ARILAVERYLKDQQLLGIWGCSGKL-
ICTTAVPWNA
no HIV-1 infection human (IgG1λ )
Donor H. Katinger, Inst. Appl. Microbiol., Vienna, Austria
References Buchacher1992, Buchacher1994, Chen1994b
• 4B3: Generated by electrofusion of PBL from HIV-1 positive volunteers with CB-F7 cells [Buchacher1994]
599 4D4 gp160 (578–612) gp41 (579–613 BH10) ARILAVERYLKDQQLLGIWGCSGKL-
ICTTAVPWNA
no HIV-1 infection human (IgG1λ )
Donor H. Katinger, Inst. Appl. Microbiol., Vienna, Austria and Viral Testing Systems, Houston, TX
References Buchacher1992, Buchacher1994, Chen1994b, Sattentau1995c, Binley1999
• 4D4: Generated by electrofusion of PBL from HIV-1 positive volunteers with CB-F7 cells [Buchacher1994]
• 4D4: The MAbs with the broadest neutralizing activity, IgG1b12, 2G12 and 2F5, all have high affinity for the native trimer, indicating that they were raised
in an immune response to the oligomer on the virion surface rather than dissociated subunits – a disulfide linked gp120-gp41 (SOS gp140) was created to
mimic the native conformation of Env and explore its potential as an immunogen – SOS gp140 is recognized by NAbs IgG1b12, 2G12, and CD4-IgG2, and
also by anti-V3 MAbs 19b and 83.1 – SOSgp140 is not recognized by C4 region MAbs that neutralize only TCLA strains, G3-42 and G3-519 – nor did it
bind C11, 23A, and M90, MAbs that bind to gp120 C1 and C5, where it interacts with gp41 – MAbs that bind CD4 inducible epitopes, 17b and A32 were
very strongly induced by CD4 in SOS gp140 – anti-gp41 MAbs that bind in the region that interacts with gp120, 7B2, 2.2B, T4, T15G1 and 4D4, did not
bind to SOSgp140, in contrast to 2F5, which binds to the only gp41 epitope that is well exposed in native gp120-gp41 complexes [Binley1999]
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600 4G2 gp160 (578–612) gp41 (579–613 BH10) ARILAVERYLKDQQLLGIWGCSGKL-
ICTTAVPWNA
no HIV-1 infection human (IgG1κ)
Donor H. Katinger, Inst. Appl. Microbiol., Vienna, Austria
References Buchacher1992, Buchacher1994
• 4G2: Generated by electrofusion of PBL from HIV-1 positive volunteers with CB-F7 cells [Buchacher1994]
601 polyclonal gp160 (579–589) gp41 (586–596 IIIB) RILAVERYLKD Vaccine murine, rabbit
Vaccine Vector/Type: peptide HIV component: gp41 Adjuvant: BSA
Ab type C-domain
References Xiao2000b
• Strong epitope-specific neutralizing antibody responses were induced using the peptide C(RILAVERYLKD)_2-BSA, but not full gp160 [Xiao2000b]
602 polyclonal gp160 (579–589) gp41 (586–596) RILAVERYLKD Vaccine rabbit (Ig)
Vaccine Vector/Type: polyepitope, protein HIV component: gp160 Adjuvant: BSA
Ab type N-term
References Lu2000c, Lu2000b
• High titer response to ELDKWA and RILAVERYLKD was observed upon vaccination with multiple-epitope vaccine
CG-GPGRAFY-G-ELDKWA-G-RILAVERYLKD conjugated to BSA, a weak response to GPGRAFY – immunization with
CG-(ELDKWA-GPGRAFY)_2-K was also tried, yielding a strong Ab response to both ELDKWA and GPGRAFY – gp160 vaccination yielded strong Ab
response but not to any of the peptides studied here [Lu2000c, Lu2000b]
603 polyclonal gp160 (579–599) gp41 (583–604) RILAVERYLKDQQLLGIWGCS no Vaccine rabbit
Vaccine Vector/Type: protein HIV component: desialylated gp160
References Benjouad1993
• MAbs raised against desialylated HIV-1 gp160 cross-react with HIV-2 gp140 due to immunodominant conserved epitope in gp41 [Benjouad1993]
604 2A2/26 gp160 (579–601) gp41 (584–606 BRU) RILAVERYLKDQQLLGIWGCSGK Vaccine murine (IgG)
Vaccine Vector/Type: protein HIV component: gp41
References Poumbourios1992, Poumbourios1995
• 2A2/26: Immunodominant region, binds both oligomer and monomer [Poumbourios1992]
• 2A2/26: Delta 550-561 (Delta LLRAIEAQQHLL), a region important for oligomer formation diminishes binding, Delta (550-561 +571-581) abrogates
binding [Poumbourios1995]
605 50-69
(SZ-50.69)
gp160 (579–603) gp41 (579–603 BH10) RILAVERYLKDQQLLGIWGCSGKLI no HIV-1 infection human (IgG2κ)
Ab type cluster I Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu), NYU, NY
References Till1989, Pinter1989, Gorny1989, Xu1991, Robinson1991, Sattentau1991, Eddleston1993, Spear1993, Laal1994, Chen1995, Sattentau1995c,
Manca1995a, McDougal1996, Poignard1996a, Binley1996, Klasse1996, Stamatatos1997, Boots1997, Hioe1997b, Mitchell1998, Gorny2000b,
Gorny2000a, Nyambi2000, Zwick2001b, Verrier2001
• 50-69: Combined with deglycosylated A chain of ricin is toxic to lines of HIV-infected T cells (H9) and monocytes (U937) [Till1989]
• 50-69: Reacts preferentially with gp160 oligomer, compared to gp41 monomer [Pinter1989]
• 50-69: Kills HIV-infected cells when coupled to deglycosylated ricin A chain [Gorny1989]
• 50-69: The epitope is affected by the conformation conferred by the two cysteines at amino acids 598 and 604 [Xu1991]
• 50-69: Enhances HIV-1 infection in vitro – synergizes with huMAb 120-16 in vitro to enhance HIV-1 infection to level approaching that found in
polyclonal anti-HIV serum [Robinson1991]
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• 50-69: Two fold increase in binding to gp120 in the presence of bound sCD4 [Sattentau1991]
• 50-69: Called SZ-50.69 – binds to an epitope within aa 579-613 [Eddleston1993]
• 50-69: Did not mediate deposition of complement component C3 on HIV infected cells unless cells were pre-incubated with sCD4 – complement mediated
virolysis of MN and IIIB in the presence of sCD4 [Spear1993]
• 50-69: Epitope described as cluster I, 601-604, conformational – does not neutralize IIIB or synergize neutralization by anti-V3 MAb 447-52D or by CD4
BS MAbs [Laal1994]
• 50-69: One of several anti-gp41 MAbs that bind to a gp41-maltose binding fusion protein designed to study the leucine zipper domain of gp41, showing
that the construct has retained aspects of normal gp41 conformation [Chen1995]
• 50-69: Preferentially binds oligomer – binding increased after pretreatment of infected cells with sCD4 – binding domain overlaps site that is critical for
gp120-gp41 association [Sattentau1995c]
• 50-69: Virions complexed to gp41 Ab facilitate presentation of p66 RT epitopes to Th cells [Manca1995a]
• 50-69: Does not neutralize HIV-1 LAI [McDougal1996]
• 50-69: Prebinding of anti-V3, and CD4i MAbs 48d and 17b, but not anti-V2 neutralizing MAbs, expose the 50-69 epitope [Poignard1996a]
• 50-69: Binds to a linear epitope located in the cluster I region – binding of 50-69 and 240-D inhibited by Fabs A1, A4, M8B, M26B, M12B and T2
[Binley1996]
• 50-69: Used to test exposure of gp41 upon sCD4 binding [Klasse1996]
• 50-69: Binding of anti-gp120 MAbs IgG1b12 or 654-30D does not mediate significant exposure of the gp41 epitopes for MAbs 2F5 and 50-69
[Stamatatos1997]
• 50-69: Abs that recognize discontinuous epitopes can identify mimotopes from a phage peptide display library – 50-69 maps to an immunodominant
domain in gp41 – three groups of peptides were selected, one which seems most closely related to gp41 sequence peptide consensus is WGCxx(RK)(x
n)LxC – the analogous gp41 sequence WGCSGKLIC is present in most M group clades, except D with a common L to H substitution [Boots1997]
• 50-69: Mutations in BH10 gp160, W596Y and T605A, as well as deletions of 605-609 (TTAVP) and 597-609 (GCSGKLICTTAVP), abrogate binding of
enhancing MAbs 86, 240D, 50-69, and 246-D – 5/6 enhancing MAbs identified to date bind to the immunodominant region 579-613 – identifies
non-contiguous W596-G597-C598 and C604-T605 as minimal epitope [Mitchell1998]
• 50-69: A cluster I epitope that binds to rgp41 567-647, recognizes a peptide N51-C43 complex trimer of heterodimers that approximates the core of the
fusogenic form of gp41 – this MAb doesn’t react with either of the peptides N51 or C43 individually – MAbs 50-69 and 1367 had similar properties – MAb
50-69 bound the fusogenic form of the protein in liquid phase [Gorny2000b]
• 50-69: Binding of panel of 21 MAbs to soluble oligomeric gp140 versus gp41 or gp120 monomers was compared – no MAb was oligomer specific, but
gp41 MAb 50-69 bound with a 5 fold preference for the oligomer, while other gp41 MAbs (1367, 98-6, 167-D, 1281, 1342, and 1379) did not show a
preference [Gorny2000a]
• 50-69: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including 5 cluster I anti-gp41 MAbs which showed good cross
clade reactivity – 50-69 bound the majority of isolates although binding was moderate to weak – specifies discontinuous binding site range as aa 579-613
[Nyambi2000]
• 50-69: This paper primarily concerns 4E10 and Z13, MAbs that both bind proximally to the 2F5 binding site to a conserved epitope, and that neutralize
some primary isolates from clades B, C, and E – MAb 50-69 binding to infected cells is enhanced by sCD4, while 4E10 and Z13 binding is essentially
unaltered [Zwick2001b]
• 50-69: A panel of 12 MAbs was used to identify those that could neutralize the dual-tropic primary isolate HIV-1 89.6 – six gave significant neutralization
at 2 to 10 ug/ml: 2F5, 50-69, IgG1b12, 447-52D, 2G12, and 670-D six did not have neutralizing activity: 654-D, 4.8D, 450-D, 246-D, 98-6, and 1281 – no
synergy, only additive effects were seen for pairwise combinations of MAbs, and antagonism was noted between gp41 MAbs 50-69 and 98-6, as well as
98-6 and 2F5 [Verrier2001]
• 50-69: NIH AIDS Research and Reference Reagent Program: 531
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606 9-11 gp160 (579–604) gp41 (584–609) RILAVERYLKDQQLLGIWGCSGKLIC Vaccine murine (IgG1)
Vaccine Vector/Type: protein HIV component: gp160
ReferencesMani1994
• 9-11: required the C-C disulfide bridge and loop formation, can bind simultaneously with 41-1 [Mani1994]
607 98-43 gp160 (579–604) gp41 (579–604 HXB2) RILAVERYLKDQQLLGIWGCSGKLIC no HIV-1 infection human (IgG2κ)
References Pinter1989, Gorny1989, Tyler1990, Xu1991
• 98-43: Reacts equally well with oligomer and monomer [Pinter1989]
• 98-43: Poor ADCC (in contrast to MAb 120-16, gp41(644-663)) [Tyler1990]
• 98-43: 579-604 binds in the immunodominant region [Xu1991]
• 98-43: NIH AIDS Research and Reference Reagent Program: 1241
608 41-1 (41.1) gp160 (579–608) gp41 (584–609) RILAVERYLKDQQLLGIWGCSGKLI-
CTTAV
Vaccine murine (IgG1κ)
Vaccine Vector/Type: protein HIV component: gp160
References Gosting1987, Dalgleish1988, Pincus1991, Pincus1993a, Mani1994, Pincus1996, Pincus1998
• 41-1: This antibody to gp41(584-609) [Mani1994] seems to have been named the same as a different MAb to gp41(735-752 IIIB) [Dalgleish1988]
• 41-1: Also called 41.1, although possibly not, the literature is confusing because two gp41 MAbs that bind to this region with similar names (dash versus
period) are listed as murine and human
• 41-1: Broadly reactive [Gosting1987]
• 41-1: This antibody seems to have been named the same as a different MAb to gp41(735-752) [Dalgleish1988]
• 41-1: Efficacious as an immunotoxin when coupled to RAC – gave linear epitope as gp160 579-603 [Pincus1991]
• 41-1: Called 41.1, and described as a human MAb – cross-competes with 41.4 – sCD4 enhances the efficacy of immunotoxins in vitro 30-fold – MAb was
coupled to ricin A chain (RAC) [Pincus1993a]
• 41-1: Did not require the C-C disulfide bridge and loop formation, can bind simultaneously with 9-11 [Mani1994]
• 41-1: Called 41.1, and described as a human MAb, binding 579-604 – a panel of immunotoxins was generated by linking Env MAbs to ricin A –
immunotoxins mediated cell killing, but killing was not directly proportional to binding [Pincus1996]
609 41.4 gp160 (579–608) gp41 (584–609) RILAVERYLKDQQLLGIWGCSGKLI-
CTTAV
Donor Jan McClure, Bristol-Myers Squibb Pharmaceutical Res Inst, Seattle, WA
References Pincus1993a
• 41.4: Binds to peptide weakly, but to gp160 with higher affinity than 41.1, and cross-competes with 41.1 – probably conformational – MAb was coupled to
ricin A chain (RAC) – sCD4 enhances the efficacy of immunotoxins in vitro 30-fold [Pincus1993a]
610 Fab A1 gp160 (579–608) gp41 (584–609 LAI) RILAVERYLKDQQLLGIWGCSGKLI-
CTTAV
no HIV-1 infection human (IgG1κ)
References Binley1996
• Fab A1: Binds to cluster I region – competes with MAbs 240-D and 50-69 – conformation sensitive – variable regions sequenced [Binley1996]
611 Fab A4 gp160 (579–608) gp41 (584–609 LAI) RILAVERYLKDQQLLGIWGCSGKLI-
CTTAV
no HIV-1 infection human (IgG1κ)
References Binley1996
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• Fab A4: Binds to cluster I region – competes with MAbs 240-D and 50-69 – conformation sensitive – variable regions sequenced [Binley1996]
612 Fab M12B gp160 (579–608) gp41 (584–609 LAI) RILAVERYLKDQQLLGIWGCSGKLI-
CTTAV
no HIV-1 infection human (IgG1κ)
References Binley1996
• Fab M12B: Binds to cluster I region – competes with MAbs 240-D and 50-69 – conformation sensitive – variable regions sequenced [Binley1996]
613 Fab M26B gp160 (579–608) gp41 (584–609 LAI) RILAVERYLKDQQLLGIWGCSGKLI-
CTTAV
no HIV-1 infection human (IgG1κ)
References Binley1996
• Fab M26B: Binds to cluster I region – competes with MAbs 240-D and 50-69 – conformation sensitive – variable regions sequenced [Binley1996]
614 Fab M8B gp160 (579–608) gp41 (584–609 LAI) RILAVERYLKDQQLLGIWGCSGKLI-
CTTAV
no HIV-1 infection human (IgG1κ)
References Binley1996
• Fab M8B: Binds to cluster I region – competes with MAbs 240-D and 50-69 – conformation sensitive – variable regions sequenced [Binley1996]
615 Fab T2 gp160 (579–608) gp41 (584–609 LAI) RILAVERYLKDQQLLGIWGCSGKLI-
CTTAV
no HIV-1 infection human (IgG1κ)
References Binley1996
• Fab T2: Binds to cluster I region – competes with MAbs 240-D and 50-69 – conformation sensitive – variable regions sequenced [Binley1996]
616 86 (No. 86) gp160 (579–613) gp41 (586–620 IIIB) RILAVERYLKDQQLLGIWGCSGKLI-
CTTAVPWNAS
no HIV-1 infection human (IgG1κ)
Donor Evan Hersh and Yoh-Ichi Matsumoto
References Sugano1988, Robinson1990b, Robinson1990c, Pincus1991, Moran1993, Wisnewski1996, Mitchell1998
• 86: Reacts with gp41 and also reacted weakly with gp120 [Sugano1988]
• 86: Antibody dependent enhancement (ADE) of HIV-1 IIIB infectivity in the presence of complement [Robinson1990b]
• 86: Peptide 586-620 blocks complement mediated ADE [Robinson1990c]
• 86: Poor immunotoxin activity when coupled to RAC – peptide binding stated to be aa 579-603 [Pincus1991]
• 86: Heavy (V HI) and light (V kappaI) chain sequenced – enhancing activity – similar germline sequence to MAb S1-1, but very different activity
[Moran1993]
• 86: 86 is V H1 – V-region heavy chain usage was examined and a bias of enhanced V H1 and V H4, and reduced V H3, was noted among HIV infected
individuals [Wisnewski1996]
• 86: Mutations in BH10 gp160, W596Y and T605A, as well as deletions of 605-609 (TTAVP) and 597-609 (GCSGKLICTTAVP), abrogate binding of
enhancing MAbs 86, 240D, 50-69, and 246-D – 5/6 enhancing MAbs identified to date bind to the immunodominant region 579-613 [Mitchell1998]
• 86: NIH AIDS Research and Reference Reagent Program: 380
617 polyclonal gp160 (580–597) gp41 (584–602) ILAVERYLKDQQLLGIWG no HIV-1 infection human
References Petrov1990
• Immunodominant and broadly reactive peptide [Petrov1990]
618 V10-9 gp160 (580–613) gp41 (586–620 IIIB) ILAVERYLKDQQLLGIWGCSGKLIC-
TTAVPWNAS
no HIV-1 infection human (IgG1κ)
References Robinson1990b, Robinson1990c
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• V10-9: Antibody dependent enhancement (ADE) of HIV-1 IIIB infectivity, synergistically enhanced by MAb 120-16 [Robinson1990b]
• V10-9: Peptide 586-620 blocks complement mediated ADE [Robinson1990c]
619 polyclonal gp160 (582–589) gp41 (589–596) AVERYLKD HIV-1 infection human
References Klasse1991
• Substitutions and deletions in peptide 583-599 were systematically studied – alterations in AVERYLKD abrogated the antigenicity of peptides with most of
14 human sera [Klasse1991]
620 polyclonal gp160 (584–604) gp41 (74–94) ERYLKDQLLGIWGCSGKLIC HIV-1 infection human
References Shafferman1989
• Immunogenic domain useful for diagnostics [Shafferman1989]
621 polyclonal gp160 (584–612) gp41 (587–617 BRU) ERYLKDQQLLGIWGCSGKLICTTAV-
PWNA
no HIV-1 infection human
References Hernandez2000
• Chimeric peptide combining two peptides gp160(495-516 and 584-612) served as a specific and broadly reactive antigen for diagnostic detection of HIV-1
[Hernandez2000]
622 2F11 gp160 (589–600) gp41 (589–600 HXB2) DQQLLGIWGCSG no HIV-1 infection human (IgG1)
References Eaton1994, Enshell-Seijffers2001
• 2F11: Enhances infectivity even in the absence of complement – does not mediate ADCC or neutralize virus [Eaton1994]
• 2F11: Monoclonal antibodies to this epitope have distinct phenotypes—41-7 and 1B8.env were found to be not neutralizing, 2F11 possibly enhancing, and
clone 3 beneficial [Enshell-Seijffers2001].
623 246-D
(SZ-246.D,
246, 246D)
gp160 (590–597) gp41 (579–604 HXB2) qqLLGIWg no HIV-1 infection human (IgG1κ)
Ab type cluster I Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu), NYU Med Center, NY, NY
References Xu1991, Robinson1991, Spear1993, Eddleston1993, Forthal1995, Manca1995a, Saarloos1995, Earl1997, Hioe1997b, Gorny2000b,
Nyambi2000, Verrier2001, Gorny2002, Edwards2002
• 246-D: Fine mapping indicates core is LLGI [Xu1991]
• 246-D: Did not mediate deposition of complement component C3 on HIV infected cells unless cells were pre-incubated with sCD4 [Spear1993]
• 246-D: No neutralizing activity, some enhancing activity [Robinson1991]
• 246-D: Called SZ-246.D [Eddleston1993]
• 246-D: No neutralizing activity, both ADCC and viral enhancing activity [Forthal1995]
• 246-D: Virions complexed to gp41 Ab facilitate presentation of p66 RT epitopes to Th cells [Manca1995a]
• 246-D: Ab-mediated activation of complement on HIV+ cells is higher than Ab independent activation—what has been termed “Ab independent” in fact
results in part from IgM in normal human serum that is HIV-cross-reactive [Saarloos1995]
• 246-D: Mutations in BH10 gp160, W596Y and T605A, as well as deletions of 605-609 (TTAVP) and 597-609 (GCSGKLICTTAVP), abrogate binding of
enhancing MAbs 86, 240D, 50-69, and 246-D – 5/6 enhancing MAbs identified to date bind to the immunodominant region 579-613 [Mitchell1998]
• 246-D: Four primary isolates showed distinct patterns of sensitivity to neutralization by polyclonal sera or plasma and MAbs – BZ167 was the only isolate
inhibited by all polyclonal sera and plasma tested, and was also neutralized by 8/17 MAbs, in particular anti-V3 loop (419-D, 447-52D, 782-D, and 838-D),
anti-CD4bd (559/64-D, 654-D and 830-D and a cluster II of gp41 directed MAb (98-6) – isolates 92HT593 and 91US056 were neutralized by V3 loop
(419-D, and 447-52D)and cluster II gp41 (98-6) MAbs at higher concentrations and 246-D neutralized 91US056 – US4 was neutralized by some of the
polyclonal sera/plasma tested and not at all by MAbs individually or by a cocktail of ten MAbs consisting of 419-D, 447-52D, 782-D, 838-D, 559/64-D,
654-D, 450-D, 670-D, 1281-D and 98-6 [Hioe1997b]
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• 246-D: This antibody, along with murine MAb D61, can be blocked by any of a group of 8 conformational MAbs (M10, D41, D54, T4, T6, T9, T10 and
T35) [Earl1997]
• 246-D: Core epitope aa 591 to 597, a cluster I epitope that does not bind to either a peptide complex that approximates the core of the fusogenic form of
gp41 or the individual peptides N51 and C43 that form this structure – MAbs 181-D and 246-D had similar properties [Gorny2000b]
• 246-D: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including 5 cluster I anti-gp41 MAbs which showed good cross
clade reactivity – 246-D bound strongly or moderately to all 26 HIV-1 group M clades viruses tested and showed the strongest binding of all anti-Env MAbs
tested, including the V3 and C5 region MAbs – notes core epitope as LLGI – no neutralizing activity was observed when 246-D was tested with five isolates
[Nyambi2000]
• 246-D: A panel of 12 MAbs was used to identify those that could neutralize the dual-tropic primary isolate HIV-1 89.6 – six gave significant neutralization
at 2 to 10 ug/ml: 2F5, 50-69, IgG1b12, 447-52D, 2G12, and 670-D six did not have neutralizing activity: 654-D, 4.8D, 450-D, 246-D, 98-6, and 1281 – no
synergy, only additive effects were seen for pairwise combinations of MAbs, and antagonism was noted between gp41 MAbs 50-69 and 98-6, as well as
98-6 and 2F5 [Verrier2001]
• 246-D: Called 246 – Conformation-dependent anti-V3 loop Abs may be more cross-reactive, so six new V3 MAbs were generated – the six new MAbs all
bind to the tip of the V3 loop and cross-compete with the MAb 447-52D and are conformationally sensitive – MAbs showed cross-clade binding to native,
intact virions and the strength binding was highly correlated with percent neutralization using the ghost cell or PHA blast assay – five well-characterized
MAbs were used as controls: anti-V3 447-52D (anti-V3 MAb for competition and neutralization studies), 654 (anti-CD4BS used as a
conformation-sensitive MAb control), 1331A (anti-C5 used as a linear binding site MAb control), and MAb 246 (anti-gp41 MAb that bound to primary
isolates of all clades tested, A, B, C, D, F and CRF01 (clade E) [Gorny2002]
• 246-D: Called 246D – Truncation of the gp41 cytoplasmic domain of X4, R5, and X4R5 viruses forces a conformation that more closely resembles the CD4
bound state of the external Envelope, enhancing binding of CD4i MAbs 17b and 48d and of CD4BS MAbs F105, b12, and in most cases of glycosylation
site dependent MAb 2G12 and the anti-gp41 MAb 246D – in contrast, binding of the anti-V2 MAb 697D and the anti-V3 MAb 694/98D were not affected –
viruses bearing the truncation were more sensitive to neutralization by MAbs 48d, b12, and 2G12 – the anti-C5 MAb 1331A was used to track levels of cell
surface expression of the mutated proteins [Edwards2002]
• 246-D: NIH AIDS Research and Reference Reagent Program: 1245
624 9G5A gp160 (591–594) gp41 (596–599 IIIB) QLLG anti-idiotype murine (IgM)
References Lopalco1993, Beretta1994
• 9G5A: Anti-idiotype to gp120 C terminus (C5 region) MAb M38 [Lopalco1993]
625 181-D
(SZ-181.D)
gp160 (591–597) gp41 (591–597 HXB2) qLLGIWg no HIV-1 infection human (IgG2κ)
Ab type cluster I Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu), NYU, NY
References Xu1991, Robinson1991, Eddleston1993, Forthal1995, Fontenot1995, Gorny2000b, Nyambi2000
• 181-D: Fine mapping indicates core is LLGIW [Xu1991]
• 181-D: No enhancing or neutralization activity [Robinson1991]
• 181-D: Called SZ-181.D [Eddleston1993]
• 181-D: No neutralizing, no ADCC, and no viral enhancing activity [Forthal1995]
• 181-D: Core epitope aa 591 to 597, a cluster I epitope that does not bind to either a peptide complex that approximates the core of the fusogenic form of
gp41 or the individual peptides N51 and C43 that form this structure – MAbs 181-D and 246-D had similar properties [Gorny2000b]
• 181-D: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including 5 cluster I anti-gp41 MAbs which showed good cross
clade reactivity – 181-D bound the majority of isolates although binding was moderate to weak [Nyambi2000]
626 polyclonal gp160 (591–608) gp41 QQLLGIWGCSGKLICTTA no HIV-1 infection human (IgG)
References Parekh2002
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• A simple enzyme immunoassay (EIA) that detects increasing levels of anti-HIV IgG after seroconversion can be used for detecting recent HIV-1 infection –
longitudinal specimens from 139 incident infections in the US and Thailand were used in the study – the method was generally applicable for HIV-1
subtypes A, B, C, D and E(CRF01) [Parekh2002]
627 240-D (F240) gp160 (592–600) gp41 (592–600 HXB2) LLGIWGCSG no HIV-1 infection human
Ab type cluster I Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu), NYU, NY
References Xu1991, Robinson1991, Spear1993, Binley1996, Wisnewski1995, Wisnewski1996, Mitchell1998, Nyambi2000
• 240-D: Fine mapping indicates core is IWG [Xu1991]
• 240-D: No neutralizing activity, some enhancing activity [Robinson1991]
• 240-D: Did not mediate deposition of complement component C3 on HIV infected cells [Spear1993]
• 240-D: Binds to a linear epitope located in the cluster I region – binding of 50-69 and 240-D inhibited by Fabs A1, A4, M8B, M26B, M12B and T2
[Binley1996]
• 240-D: Called F240 – F240 in V H3 – V-region heavy chain usage was examined and a bias of enhanced V H1 and V H4, and reduced V H3, was noted
among HIV infected individuals [Wisnewski1996]
• 240-D: Mutations in BH10 gp160, W596Y and T605A, as well as deletions of 605-609 (TTAVP) and 597-609 (GCSGKLICTTAVP), abrogate binding of
enhancing MAbs 86, 240D, 50-69, and 246-D – 5/6 enhancing MAbs identified to date bind to the immunodominant region 579-613 [Mitchell1998]
• 240-D: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including 5 cluster I anti-gp41 MAbs which showed good cross
clade reactivity – 246-D bound strongly or moderately to 24/26 HIV-1 group M clades viruses tested [Nyambi2000]
• 240-D: NIH AIDS Research and Reference Reagent Program: 1242
628 F240 gp160 (592–606) gp41 (592–606 BH10) LLGIWGCSGKLICTT no HIV-1 infection human (IgG1κ)
Ab type cluster I Donor L. Cavacina or M. Posner, Dept. of Med. Harvard Med. School, Boston MA, USA
References Cavacini1998a, York2001
• F240: Seems to be distinct from MAb 240-D, an antibody with a similar epitope in the immunodominant region of gp41 – dose-dependent reactivity with
HIV isolates RF, SF2, IIIB, and MN was observed – F240 had no neutralizing activity and enhances infection in the presence of complement – reactivity of
F240 is enhanced by preincubation of cells with sCD4 or anti-CD4BS MAb F105 – heavy and light chain variable domains were sequenced, and a strong
homology to hu MAb 3D6 was observed, as 3D6 binds to the same epitope, these MAbs may define a human Ab clonotype [Cavacini1998a]
• F240: Abs against the V3 loop (50.1, 58.2, 59.1, 257-D, 268-D, 447-52D), CD4BS (IgG1b12, 559-64D, F105), CD4i (17b), and to gp41 (2F5, F240) each
showed similar binding efficiency to Env derived from related pairs of primary and TCLA lines (primary: 168P and 320SI, and TCLA: 168C and
320SI-C3.3), but the TCLA lines were much more susceptible to neutralization suggesting that the change in TCLA lines that make them more susceptible
to NAbs alters some step after binding [York2001]
629 D49 gp160 (592–608) gp41 (597–613) LLGIWGCSGKLICTTAV Vaccine murine
Vaccine Vector/Type: protein HIV component: dimeric Env
Ab type cluster I
References Earl1994, Earl1997
• D49: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• D49: Binding maps to region 597-613: WGCSGKLICTTAVPWNA – immunodominant region containing two Cys residues [Earl1997]
630 D61 gp160 (592–608) gp41 (592–608 HXB2) LLGIWGCSGKLICTTAV Vaccine murine
Vaccine Vector/Type: protein HIV component: dimeric Env
Ab type cluster I Donor Patricia Earl and Christopher Broder, NIH
References Earl1994, Richardson1996, Weissenhorn1996, Earl1997, Golding2002b
• D61: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
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• D61: Linear gp41 epitope in the cluster I region – human sera blocked binding in oligomeric ELISA assay to a similar extent for gp41 MAbs D20, D43,
D61, and T4 [Richardson1996]
• D61: Does not precipitate gp41(21-166), but due to a structural difference in the disulfide bonding region near the two cysteines – the authors propose that
this region may change conformation during the activation of the membrane fusion state of the HIV-1 glycoprotein [Weissenhorn1996]
• D61: Binding maps to region 597-613: WGCSGKLICTTAVPWNA – immunodominant region containing two Cys residues – this antibody, along with
human MAb 246-D, can be blocked by any of a group of 8 conformational MAbs (M10, D41, D54, T4, T6, T9, T10 and T35) – members of this
competition group are blocked by sera from HIV-1+ individuals [Earl1997]
• D61: The fusion process was slowed by using a suboptimal temperature (31.5 C) to re-evaluate the potential of Abs targeting fusion intermediates to block
HIV entry – preincubation of E/T cells at 31.5 C enabled polyclonal anti-N-HR Ab and anti-six-helix bundle Abs to inhibit fusion, indicating six-helix
bundles form prior to fusion – the preincubation 31.5 C step did not alter the inhibitory activity of neutralizing Abs anti-gp41 2F5, or anti-gp120 2G12,
IG1b12, 48d, and 17b – nor did it alter two gp41 MAbs, T9 and D61, inability to inhibit fusion [Golding2002b]
631 T32 gp160 (592–608) gp41 (597–613) LLGIWGCSGKLICTTAV Vaccine murine
Vaccine Vector/Type: tetrameric Env HIV component: Env
Ab type cluster I Donor Patricia Earl and Christopher Broder, NIH
References Earl1994, Earl1997
• T32: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• T32: Binding maps to region 597-613: WGCSGKLICTTAVPWNA – immunodominant region containing two Cys residues [Earl1997]
632 T34 gp160 (592–608) gp41 (597–613) LLGIWGCSGKLICTTAV Vaccine murine
Vaccine Vector/Type: tetrameric Env HIV component: Env
Ab type cluster I Donor Patricia Earl and Christopher Broder, NIH
References Earl1994, Earl1997
• T34: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response – an oligomer with no
gp120/gp41 cleavage site was used as the immunogen [Earl1994]
• T34: Binding maps to region 597-613: WGCSGKLICTTAVPWNA – immunodominant region containing two Cys residues [Earl1997]
633 115.8 gp160 (593–604) gp41 (598–609) LGLIWGCSGKLIC Vaccine murine (IgM)
Vaccine Vector/Type: peptide HIV component: gp41
References Oldstone1991
• 115.8: Stimulated by immunization with the peptide: LGLIWGCSGKLIC (aa 598-609) – poor reactivity with CSGKLIC – reacts well with longer HIV-2
peptide NSWGCAFRQVC as well as CAFRQVC – disulfide bond between cysteines required [Oldstone1991]
634 M-1 gp160 (593–604) gp41 (598–609) LGIWGCSGKLIC Vaccine murine (IgG1,
IgG2b)
Vaccine Vector/Type: peptide HIV component: gp41
References Yamada1991
• M-1: Unlike M-22, did not react to 43-kd protein found in rat and human astrocytes [Yamada1991]
635 M-11 gp160 (593–604) gp41 (598–609) LGIWGCSGKLIC Vaccine murine (IgG1)
Vaccine Vector/Type: peptide HIV component: gp41
References Yamada1991
• M-11: Strongly reacted with a cellular 43-kd protein found in rat and human astrocytes as well as with gp41 [Yamada1991]
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636 M-13 gp160 (593–604) gp41 (598–609) LGIWGCSGKLIC Vaccine murine (IgG2b)
Vaccine Vector/Type: peptide HIV component: gp41
References Yamada1991
• M-13: Reacted with a cellular 43-kd protein found in rat and human astrocytes as well as with gp41 [Yamada1991]
637 M-2 gp160 (593–604) gp41 (598–609) LGIWGCSGKLIC Vaccine murine (IgG2b)
Vaccine Vector/Type: peptide HIV component: gp41
References Yamada1991
• M-2: Strongly reacted with a cellular 43-kd protein found in rat and human astrocytes as well as with gp41 [Yamada1991]
638 M-22 gp160 (593–604) gp41 (598–609) LGIWGCSGKLIC Vaccine murine (IgG2b)
Vaccine Vector/Type: peptide HIV component: gp41
References Yamada1991
• M-22: Strongest reaction of 12 anti-HIV-1 gp41 MAbs to a cellular 43-kd protein found in rat and human astrocytes [Yamada1991]
639 M-24 gp160 (593–604) gp41 (598–609) LGIWGCSGKLIC Vaccine murine (IgG1)
Vaccine Vector/Type: peptide HIV component: gp41
References Yamada1991
• M-24: Strongly reacted with a cellular 43-kd protein found in rat and human astrocytes as well as with gp41 [Yamada1991]
640 M-25 gp160 (593–604) gp41 (598–609) LGIWGCSGKLIC Vaccine murine (IgG1)
Vaccine Vector/Type: peptide HIV component: gp41
References Yamada1991
• M-25: Reacted with a cellular 43-kd protein found in rat and human astrocytes as well as with gp41 [Yamada1991]
641 M-28 gp160 (593–604) gp41 (598–609) LGIWGCSGKLIC Vaccine murine (IgG1)
Vaccine Vector/Type: peptide HIV component: gp41
References Yamada1991
• M-28: Strongly reacted with a cellular 43-kd protein found in rat and human astrocytes as well as with gp41 [Yamada1991]
642 M-29 gp160 (593–604) gp41 (598–609) LGIWGCSGKLIC Vaccine murine (IgG1)
Vaccine Vector/Type: peptide HIV component: gp41
References Yamada1991
• M-29: Unlike M-22, did not react to 43-kd protein found in rat and human astrocytes [Yamada1991]
643 M-36 gp160 (593–604) gp41 (598–609) LGIWGCSGKLIC Vaccine murine (IgG1)
Vaccine Vector/Type: peptide HIV component: gp41
References Yamada1991
• M-36: Unlike M-22, did not react to 43-kd protein found in rat and human astrocytes [Yamada1991]
644 M-4 gp160 (593–604) gp41 (598–609) LGIWGCSGKLIC Vaccine murine (IgG2b)
Vaccine Vector/Type: peptide HIV component: gp41
References Yamada1991
• M-4: Unlike M-22, did not react to 43-kd protein found in rat and human astrocytes [Yamada1991]
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645 M-6 gp160 (593–604) gp41 (598–609) LGIWGCSGKLIC Vaccine murine (IgG2b)
Vaccine Vector/Type: peptide HIV component: gp41
References Yamada1991
• M-6: Unlike M-22, did not react to 43-kd protein found in rat and human astrocytes [Yamada1991]
646 polyclonal
α598-609
gp160 (594–601) gp41 (598–609) GIWGCSGK HIV-1 infection human
References Poumbourios1992
• alpha(598-609): Affinity purified from HIV-1+ plasma – immunodominant region, binds oligomer and monomer [Poumbourios1992]
647 1B8.env gp160 (594–604) gp41 (594–605 HXB2) GIWGCSGKLIC no HIV-1 infection human (IgG2λ )
References Banapour1987, Enshell-Seijffers2001
• 1B8.env: Highly conserved epitope recognized by the majority of HIV-1 infected people – MAb does not neutralize [Banapour1987]
• 1B8.env: Monoclonal antibodies to this epitope have distinct phenotypes—41-7 and 1B8.env were found to be not neutralizing, 2F11 possibly enhancing,
and clone 3 beneficial [Enshell-Seijffers2001].
648 polyclonal gp160 (594–609) gp41 (601–616) GIWGCSGKLICTTAVP no HIV-1 infection human
References Petrov1990
• Immunodominant and broadly reactive peptide [Petrov1990]
649 clone 3 gp160 (597–606) gp41 (597–606) GCSGKLICTT L HIV-1 infection human (IgG1)
References Broliden1989, Cotropia1992, Cotropia1996, Enshell-Seijffers2001
• clone 3: Core binding domain gcsgkLIC – lack of serological activity to this region correlates with rapid progression in infants ([Broliden1989])
[Cotropia1992]
• clone 3: Inhibits replication of three diverse HIV-1 laboratory strains, as well as an AZT-resistant isolate [Cotropia1996]
• clone 3: Monoclonal antibodies to this epitope have distinct phenotypes—41-7 and 1B8.env were found to be not neutralizing, 2F11 possibly enhancing,
and clone 3 beneficial [Enshell-Seijffers2001].
650 4 gp160 (598–604) gp41 (598–609) CSGKLIC Vaccine murine (IgG2b)
Vaccine Vector/Type: peptide HIV component: gp41
References Oldstone1991, Bizub-Bender1994
• There is another MAb with this ID that reacts with integrase [Oldstone1991, Bizub-Bender1994]
• 4: Stimulated by immunization with the peptide: LGLIWGCSGKLIC (aa 598-609) – poor cross-reactivity with HIV-2 peptide CAFRQVC – slightly more
reactive with longer HIV-2 peptide NSWGCAFRQVC [Oldstone1991]
651 41-6 gp160 (598–604) gp41 (598–609) CSGKLIC Vaccine murine (IgG2b)
Vaccine Vector/Type: peptide HIV component: gp41
References Oldstone1991
• 41-6: Stimulated by immunization with the peptide: LGLIWGCSGKLIC (aa 598-609) – poor cross-reactivity with HIV-2 peptide CAFRQVC – slightly
more reactive with LGLIWGCSGKLIC and HIV-2 form NSWGCAFRQVC – disulfide bond between cysteines required [Oldstone1991]
652 41-7 gp160 (598–604) gp41 (605–611) CSGKLIC no HIV-1 infection human (IgG1κ)
References Bugge1990, Enshell-Seijffers2001
• 41-7: Sera from 6/6 HIV-1 positive, but no HIV-2 positive individuals, interfered with 41-7 binding – Ab does not neutralize [Bugge1990]
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• 41-7: Monoclonal antibodies to this epitope have distinct phenotypes—41-7 and 1B8.env were found to be not neutralizing, 2F11 possibly enhancing, and
clone 3 beneficial [Enshell-Seijffers2001].
653 68.1 gp160 (598–604) gp41 (598–609) CSGKLIC Vaccine murine (IgM)
Vaccine Vector/Type: peptide HIV component: gp41
References Oldstone1991
• 68.1: Stimulated by immunization with the peptide: LGLIWGCSGKLIC (aa 598-609) – cross-reactive with HIV-2 peptide CAFRQVC – more reactive with
longer HIV-1 peptide LGLIWGCSGKLIC and HIV-2 peptide NSWGCAFRQVC [Oldstone1991]
654 68.11 gp160 (598–604) gp41 (598–609) CSGKLIC Vaccine murine (IgM)
Vaccine Vector/Type: peptide HIV component: gp41
References Oldstone1991
• 68.11: Stimulated by immunization with the peptide: LGLIWGCSGKLIC (aa 598-609) – cross-reactive with HIV-2 peptide CAFRQVC – more reactive
with longer HIV-1 peptide LGLIWGCSGKLIC and HIV-2 peptide NSWGCAFRQVC [Oldstone1991]
655 75 gp160 (598–604) gp41 (598–609) CSGKLIC Vaccine rat (IgG)
Vaccine Vector/Type: peptide HIV component: gp41
References Oldstone1991
• 75: Stimulated by immunization with the peptide: LGLIWGCSGKLIC (aa 598-609) – poor cross-reactivity with HIV-2 peptide CAFRQVC – more reactive
with longer HIV-2 peptide NSWGCAFRQVC [Oldstone1991]
656 polyclonal gp160 (598–604) gp41 (603–609) CSGKLIC HIV-1 infection human
References Enshell-Seijffers2001
• Monoclonal antibodies to this epitope have distinct phenotypes – 41-7 and 1B8.env were found to be not neutralizing, 2F11 possibly enhancing, and clone 3
beneficial – isolated mimotope-presenting phages corresponding to the immunodominant gp41 epitope CSGKLIC were used to study the diversity of
polyclonal responses in 30 HIV+ sera, and all but one of the patients reacted showing distinctive variable polyclonal recognition patterns
[Enshell-Seijffers2001]
657 105-732 gp160 (599–606) gp41 (601–608
HAM112, O group)
KGRLICYT Vaccine murine (IgG2b κ)
Vaccine Vector/Type: recombinant protein Strain: HAM112 (group O) HIV component: gp160
References Scheffel1999
• 105-732: Overlapping peptides based on group O HAM112 Env were tested for MAb reactivity – MAb 105-732 bound to two overlapping peptides
[Scheffel1999]
658 3D6 (IAM
41-3D6)
gp160 (599–613) gp41 (604–617 BH10) SGKLICTTAVPWNAS no HIV-1 infection human (IgG1κ)
Ab type immunodominant region Donor H. Katinger, Inst. Appl. Microbiol., Vienna, Austria and Viral Testing Systems, Houston, TX
References
Felgenhauer1990, He1992, Chen1994b, Sattentau1995c, Stigler1995, Wisnewski1996, Kunert1998, Cavacini1998b, Cavacini1998a, Cavacini1999
• 3D6: Sequence of cDNA encoding V- regions [Felgenhauer1990]
• 3D6: Fab fragment crystal structure [He1992]
• 3D6: This MAb binds to HIV gp41, and to a 43 kd protein found in human T, B and monocyte cell lines, proposed molecular mimicry [Chen1994b]
• 3D6: Called IAM 41-3D6: binding increased after pretreatment of infected cells with sCD4 – binding domain overlaps site that is critical for gp120-gp41
association [Sattentau1995c]
• 3D6: Optimum peptide for binding 3D6 Fab was CSGKLICTTAVPW [Stigler1995]
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• 3D6: 3D6 is V H3 – V-region heavy chain usage was examined and a bias of enhanced V H1 and V H4, and reduced V H3, was noted among HIV infected
individuals [Wisnewski1996]
• 3D6: The complete V, J and D(H) domain was sequenced – in contrast the sequences of five neutralizing MAbs, 3D6 had very little somatic mutation, with
homologies of 97-98% relative to germline genes [Kunert1998]
• 3D6: Binds to the immunodominant region of gp41 – a strong homology between heavy variable domains of hu MAb 3D6 and MAb F20 was observed,
these MAbs may define a human Ab clonotype [Cavacini1998a]
• 3D6: Cavacini et al. note that both MAbs F223 and 3D6 are anti-HIV-1 Env MAbs that have an autoimmune response and that both use uses VH3 germline
genes [Cavacini1999]
659 F172-D8
(F172-D8,
scFvD8)
gp160 (604–615) gp41 (609–620) CTTAVPWNASWS? human
References Legastelois2000
• F172-D8: As an approach to intercellular immunization using a single-chain variable fragment, scFvD8 was constructed based on the MAb F172-D8,
directed at a loop in gp41 between the two heptad repeat regions – intracellular scFvD8 expression decreased gp160 expression and a scFvD8 transfected
cell line did not support infection by HIV-1 Ba-L or primary isolates [Legastelois2000]
660 D50 gp160 (632–655) gp41 (642–665) Vaccine murine
Vaccine Vector/Type: protein HIV component: dimeric Env
Ab type cluster II Donor Patricia Earl and Christopher Broder, NIH
References Earl1994, Binley1996, Richardson1996, Earl1997, Yang2000, Srivastava2002
• D50: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• D50: Thought to be a discontinuous epitope recognizing residues between 649-668 – designated cluster II – Fabs D5, D11, G1, T3, M12, M15, S6, S8, S9,
S10 block binding [Binley1996]
• D50: Richardson suggests this is a linear gp41 epitope [Richardson1996]
• D50: Found to bind to a linear peptide, between Env amino acids 642-655 – can be blocked by the conformation dependent MAbs D16, D17, D31, D36,
D37, D40, D44, D55, D59, T37, and T45 – the region is in the immunogenic cluster two region – reactive with 9/10 HIV-1 strains tested, all except HIV-1
ADA, in which the change E659D and E662A may result in the loss of binding (ELLE to DLLA) [Earl1997]
• D50: A combination of gp41 fusion with the GNC4 trimeric sequences and disruption of the YU2 gp120-gp41 cleavage site resulted in stable gp140 trimers
(gp140-GNC4) – gp41 MAbs T4, D12, T3, and D50 bound less efficiently to gp140-GNC4 than did pooled sera, but T4 and D12 recognized the
gp140-GNC4 timer equivalently to gp140(-), and T3 and D50 recognized the trimer at greater levels than gp140(-) [Yang2000]
• D50: Oligomeric gp140 (o-gp140) derived from R5 primary isolate US4 was characterized for use as a vaccine reagent – D50 was used to capture the
o-gp140 for ELISA to test the antigencity of o-gp140 using a panel of well characterized MAbs [Srivastava2002]
661 5-21-3 gp160 (642–665) gp41 (642–665 HXB2) IHSLIEESQNQQEKNEQELLELDK Vaccine murine
Vaccine Vector/Type: recombinant protein HIV component: gp41
References Hunt1990, Scheffel1999
• 5-21-3: Recognizes a contiguous, conformation-dependent epitope in a hydrophilic region [Hunt1990]
• 5-21-3: Binds group M gp41, used as a control in a study of group O MAbs [Scheffel1999]
662 120-16
(SZ-120.16)
gp160 (644–663) gp41 (644–663 HXB2) SLIEESQNQQEKNEQELLEL no HIV-1 infection human (IgG2κ)
References Andris1992, Robinson1990b, Tyler1990, Xu1991, Robinson1991, Eddleston1993, Forthal1995, Wisnewski1996
• 120-16: Antibody dependent enhancement (ADE) of HIV-1 IIIB infectivity, synergistically enhanced by MAb V10-9 [Robinson1990b]
• 120-16: Potent ADCC (in contrast to MAb 98-43, gp41(579-604)) [Tyler1990]
• 120-16: Less reactive region than AVERY region – most Abs involving this region bound conformational epitopes, this was the only linear one [Xu1991]
• 120-16: Synergizes with huMAb 50-69 in vitro to enhance HIV-1 infection [Robinson1991]
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• 120-16: Called SZ-120.16 [Eddleston1993]
• 120-16: No neutralizing activity, both ADCC and viral enhancing activity [Forthal1995]
• 120-16: 120-16 is V H4 – V-region heavy chain usage was examined and a bias of enhanced V H1 and V H4, and reduced V H3, was noted among HIV
infected individuals [Wisnewski1996]
663 98-6 (SZ-98.6,
98.6)
gp160 (644–663) gp41 (644–663 HXB2) SLIEESQNQQEKNEQELLEL no HIV-1 infection human (IgG2κ)
Ab type alpha-helical C-HR, hairpin intermediate Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu), NYU, NY
References Pinter1989, Gorny1989, Till1989, Robinson1990b, Tyler1990, Andris1992, Sattentau1991, Robinson1991, Xu1991, Eddleston1993,
Spear1993, Tani1994, Laal1994, Chen1995, Forthal1995, Manca1995a, Sattentau1995c, Wisnewski1996, Hioe1997b, Nyambi1998, Gorny2000b,
Gorny2000a, Nyambi2000, Taniguchi2000, Verrier2001, Golding2002b
• 98-6: Reacts preferentially with gp160 oligomer, compared to gp41 monomer [Pinter1989]
• 98-6: Kills HIV-infected cells when coupled to deglycosylated ricin A chain [Gorny1989]
• 98-6: Toxic to HIV-infected T cells (H9) and monocytes (U937) when coupled to deglycosylated A chain of ricin [Till1989]
• 98-6: No neutralizing or enhancing activity for HIV-1 IIIB [Robinson1990b]
• 98-6: Serves as target for antibody-dependent cellular cytotoxicity, ADCC [Tyler1990]
• 98-6: Two fold increase in binding to gp120 in the presence of bound sCD4 [Sattentau1991]
• 98-6: No neutralizing or enhancing activity [Robinson1991]
• 98-6: Appeared to be specific for a conformational or discontinuous epitope [Xu1991]
• 98-6: Called SZ-98.6 – binds to a conformational domain within aa 644-663 of gp41, and reacts with astrocytes, as do 167-7 and ND-15G1 [Eddleston1993]
• 98-6: Did not mediate deposition of complement component C3 on HIV infected cells, binding enhanced by sCD4 [Spear1993]
• 98-6: This MAb was expressed as a surface anti-gp41 monoclonal antibody receptor for gp41 on a CD4-negative B-cell line. Transfected cells could bind
HIV Envelope, but could not be infected by HIV-1. When CD4 delivered by retroviral constructs was expressed on these cells, they acquired the ability to
replicate HIV-1, and sIg/gp41 specifically enhanced viral replication [Tani1994]
• 98-6: Epitope described as cluster II, 644-663, conformational – does not neutralize IIIB or synergize neutralization by anti-V3 MAb 447-52D or by CD4
BS MAbs [Laal1994]
• 98-6: One of several anti-gp41 MAbs that bind to a gp41-maltose binding fusion protein designed to study the leucine zipper domain of gp41, showing that
the construct has retained aspects of normal gp41 conformation [Chen1995]
• 98-6: No neutralizing activity, positive ADCC activity, and no viral enhancing activity [Forthal1995]
• 98-6: Virions complexed to gp41 Ab facilitate presentation of p66 RT epitopes to Th cells [Manca1995a]
• 98-6: Preferentially recognizes oligomeric form of gp41 – enhanced binding to HIV-1 infected cells at 37 degrees relative to 4 degrees – addition of sCD4
enhances binding [Sattentau1995c]
• 98-6: 98-6 is V H4 – V-region heavy chain usage was examined and a bias of enhanced V H1 and V H4, and reduced V H3, was noted among HIV infected
individuals [Wisnewski1996]
• 98-6: Four primary isolates showed distinct patterns of sensitivity to neutralization by polyclonal sera or plasma and MAbs – BZ167 was the only isolate
inhibited by all polyclonal sera and plasma tested, and was also neutralized by 8/17 MAbs, in particular anti-V3 loop (419-D, 447-52D, 782-D, and 838-D),
anti-CD4bd (559/64-D, 654-D and 830-D and a cluster II of gp41 directed MAb (98-6) – isolates 92HT593 and 91US056 were neutralized by V3 loop
(419-D, and 447-52D)and cluster II gp41 (98-6) MAbs at higher concentrations – US4 was neutralized by some of the polyclonal sera/plasma tested and not
at all by MAbs individually or by a cocktail of ten MAbs consisting of 419-D, 447-52D, 782-D, 838-D, 559/64-D, 654-D, 450-D, 670-D, 1281-D and 98-6
[Hioe1997b]
• 98-6: Using a whole virion-ELISA method, 18 human MAbs were tested for their ability to bind to a panel of 9 viruses from clades A, B, D, F, G, and H –
anti-gp41 Abs 98-6, 1367 and 1342 were not able to bind detectably with any of the viruses from any clade [Nyambi1998]
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• 98-6: 98-6 and 2F5 both bind to a peptide N51-C43 complex trimer of heterodimers that approximates the core of the fusogenic form of gp41, and to C43
alone but not to N51 alone – 98-6 and 2F5 have comparable affinities for C43, but 98-6 has a higher affinity for the complex and the binding of 98-6 is not
inhibited by N51 [Gorny2000b]
• 98-6: Binding of panel of 21 MAbs to soluble oligomeric gp140 versus gp41 or gp120 monomers was compared – no MAb was oligomer specific, but gp41
MAb 50-69 bound with a 5 fold preference for the oligomer, while other gp41 MAbs (1367, 98-6, 167-D, 1281, 1342, and 1379) did not show a preference
[Gorny2000a]
• 98-6: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including 6 cluster II anti-gp41 MAbs – of these 2F5, 167-D, 126-6,
and 1281 bound across clades, but usually weakly, while 98-6 and 1342 had poor cross reactivity – Clade D isolates bound most consistently to cluster II
MAbs – no neutralizing activity was observed when tested against 5 isolates, but 98-6 did not bind to these isolates [Nyambi2000]
• 98-6: The fusogenic form of gp41 is recognized by 98-6, and the epitope is a conformational epitope formed by the interaction of two regions of gp41
which form an alpha-helical bundle [Taniguchi2000]
• 98-6: A panel of 12 MAbs was used to identify those that could neutralize the dual-tropic primary isolate HIV-1 89.6—six gave significant neutralization at
2 to 10 ug/ml: 2F5, 50-69, IgG1b12, 447-52D, 2G12, and 670-D, while six did not have neutralizing activity: 654-D, 4.8D, 450-D, 246-D, 98-6, and 1281 –
no synergy, only additive effects were seen for pairwise combinations of MAbs, and antagonism was noted between gp41 MAbs 50-69 and 98-6, as well as
98-6 and 2F5 [Verrier2001].
• 98-6: The fusion process was slowed by using a suboptimal temperature (31.5 C) to re-evaluate the potential of Abs targeting fusion intermediates to block
HIV entry – preincubation of E/T cells at 31.5 C enabled polyclonal anti-N-HR Ab and anti-six-helix bundle Abs to inhibit fusion, indicating six-helix
bundles form prior to fusion – 98-6 binds to a C-HR hairpin epitope and blocks fusion when added to a 2 hour E/T preincubation at 31.5 C, but if added
after 1 hour, doesn’t inhibit – this is in contrast to six-helix bundle Abs 167-D and 1281 that inhibit more efficiently when added after one hour of
incubation [Golding2002b]
• 98-6: NIH AIDS Research and Reference Reagent Program: 1240
664 167-7
(SZ-167.7)
gp160 (644–663) gp41 (644–663) SLIEESQNQQEKNEQELLEL HIV-1 infection human (IgG2λ )
Ab type cluster II
References Xu1991, Eddleston1993
• 167-7: Specific for a conformational epitope [Xu1991]
• 167-7: Called SZ-167.7 – binds to a conformational domain within aa 644-663 of gp41, and reacts with astrocytes, as do 98-6 and ND-15G1
[Eddleston1993]
665 ND-15G1 gp160 (644–663) gp41 (644–663 HXB2) SLIEESQNQQEKNEQELLEL HIV-1 infection human (IgG1κ)
Ab type cluster II
References Eddleston1993
• ND-15G1: Mapped to the conformational epitope within aa 644-663, and reacts with astrocytes, as do 98-6 and 167-7 [Eddleston1993]
666 167-D gp160 (644–663) gp41 (644–663 HXB2) SLIEESQNQQEKNEQELLEL no HIV-1 infection human (IgG1λ )
Ab type cluster II, six-helix bundle Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu), NYU, NY
References Spear1993, Forthal1995, Gorny2000b, Gorny2000a, Nyambi2000, Golding2002b
• 167-D: Did not mediate deposition of complement component C3 on HIV infected cells – complement mediated virolysis of MN and IIIB in the presence of
sCD4 [Spear1993]
• 167-D: No neutralizing activity, no ADCC activity, and no viral enhancing activity [Forthal1995]
• 167-D: Virions complexed to gp41 Ab facilitate presentation of p66 RT epitopes to Th cells [Manca1995a]
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• 167-D: This cluster II MAb binds to a conformational epitope in the region 644-663 – like most cluster II MAbs (126-6, 167-D, 1281, 1342, and 1379 all
reacted similarly) it binds to a peptide N51-C43 complex trimer of heterodimers that approximates the core of the fusogenic form of gp41, but not to C43
nor to N51 alone [Gorny2000b]
• 167-D: Binding of panel of 21 MAbs to soluble oligomeric gp140 versus gp41 or gp120 monomers was compared – no MAb was oligomer specific, but
gp41 MAb 50-69 bound with a 5 fold preference for the oligomer, while other gp41 MAbs (1367, 98-6, 167-D, 1281, 1342, and 1379) did not show a
preference [Gorny2000a]
• 167-D: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including 6 cluster II anti-gp41 MAbs – of these 2F5, 167-D, 126-6,
and 1281 bound across clades, but usually weakly, while 98-6 and 1342 had poor cross reactivity – Clade D isolates bound most consistently to cluster II
MAbs [Nyambi2000]
• 167-D: The fusion process was slowed by using a suboptimal temperature (31.5 C) to re-evaluate the potential of Abs targeting fusion intermediates to
block HIV entry – preincubation of E/T cells at 31.5 C enabled polyclonal anti-N-HR Ab and anti-six-helix bundle Abs to inhibit fusion, indicating
six-helix bundles form prior to fusion – 98-6 binds to a C-HR hairpin epitope and blocks fusion when added to a 2 hour E/T preincubation at 31.5 C, but if
added after 1 hour, doesn’t inhibit – this is in contrast to six-helix bundle Abs 167-D and 1281 that inhibit more efficiently when added after one hour of
incubation [Golding2002b]
667 2F5 (IAM
2F5,
IAM-41-2F5,
IAM2F5,
c2F5)
gp160 (656–671) gp41 (662–667 BH10) NEQELLELDKWASLWN L P HIV-1 infection human (IgG3κ)
Ab type adjacent to cluster II Donor Hermann Katinger, Institute of Applied Microbiology, Vienna, or Polymun Scientific Inc., Vienna, Austria, or Viral
Testing Systems Corp., Houson TX
References Buchacher1992, Muster1993, Allaway1993, Klasse1993a, Purtscher1994, Laal1994, Buchacher1994, D’Souza1994, Conley1994b, Thali1994,
Chen1994b, Muster1994, Beretta1994, D’Souza1995, Trkola1995, Sattentau1995c, Moore1995b, Neurath1995, Kessler1995, Calarota1996,
McKeating1996a, Poignard1996b, Sattentau1996, Conley1996, Pincus1996, McKeating1996b, Stoiber1996, Purtscher1996, Schutten1997, D’Souza1997,
Mo1997, Li1997, Kessler II1997, Moore1997, Mascola1997, Stamatatos1997, Turbica1997, Ugolini1997, Burton1997, Earl1997, Gorny1997, Andrus1998,
Mondor1998, Connor1998, Parren1998a, Yang1998, Trkola1998, Fouts1998, Ernst1998, Takefman1998, Li1998, Jiang1998, Parren1998b, Geffin1998,
Kunert1998, Frankel1998, Montefiori1999, Poignard1999, Beddows1999, Muhlbacher1999, Parren1999, Mascola1999, Mascola2000, Baba2000,
Robert-Guroff2000, Gorny2000b, Kunert2000, Liao2000, Lu2000c, Lu2000b, Nyambi2000, Park2000, Pai2002, Sanhadji2000, Coeffier2000, Xiao2000c,
Yang2000, Si2001, Dong2001, Kolchinsky2001, Tumanova2001, York2001, Zwick2001b, Zwick2001c, Mascola2001, Barnett2001, Moore2001,
Zeder-Lutz2001, Parker2001, Spenlehauer2001, Verrier2001, Stiegler2001, Hofmann-Lehmann2001, Xu2001, Root2001, Armbruster2002, Srivastava2002,
Golding2002b, Schulke2002, Tian2002, Ho2002, Xu2002, Chakrabarti2002, Joyce2002, Clerici2002a, Xiang2002b, Grundner2002, Mascola2002,
Kunert2002, Zhang2002, Ferrantelli2002, Liu2002
• 2F5: DKWA defined as the core sequence – highly conserved epitope neutralizing MAb [Buchacher1992, Muster1993]
• 2F5: Synergy with combinations of CD4-based molecules in inhibition of HIV-1 Env mediated cell fusion [Allaway1993]
• 2F5: Called IAM-41-2F5 – reports MAb to be IgG1 – the gp41 mutation 582(Ala to Thr) results in conformational changes in gp120 that confer
neutralization resistance to conformationally sensitive neutralizing MAbs – neutralization efficiency of 2F5 is not affected [Klasse1993a]
• 2F5: Broadly reactive neutralizing activity, ELDKWA is relatively conserved – neutralized 2 primary isolates [Purtscher1994]
• 2F5: Failed to show synergy with anti-CD4 binding site IIIB neutralizing antibodies [Laal1994]
• 2F5: MAb generated by electrofusion of PBL from HIV-1 positive volunteers with CB-F7 cells [Buchacher1994]
• 2F5: Included in a multi-lab study for antibody characterization binding and neutralization assay comparison [D’Souza1994]
• 2F5: Called IAM-41-2F5 – neutralized lab and primary isolates – t 1/2 dissociation 122 min for the peptide, and 156 min for gp41 – core D(K/R)W – Ab
resistant isolate had the sequence KLDNWA [Conley1994b]
• 2F5: gp41 mutation (582 A/T) that reduces neutralization of anti-CD4 binding site MAbs does not alter 2F5’s ability to neutralize [Thali1994]
• 2F5: 2F5 epitope ELDKWA inserted into an immunogenic loop in influenza virus hemagglutinin can elicit IIIB, MN and RF neutralizing sera in immunized
mice [Muster1994]
710
DEC 2002
gp160 Antibodies HIV Antibodies Tables
B
C
ell
No. MAb ID HXB2 Location Author’s Location Sequence Neutralizing Immunogen Species(Isotype)
• 2F5: Found to neutralize MN, JRCSF, and two B subtype primary isolates, but not a D subtype primary isolate, by most labs in a multi-laboratory study
involving 11 labs [D’Souza1995]
• 2F5: Cross-clade primary virus neutralizing activity – LDKW defined as the core epitope [Trkola1995]
• 2F5: Called IAM 41-2F5 – exposed in the presence of gp120 on the cell surface, while most of gp41 is masked – binds proximal to transmembrane region
[Sattentau1995c]
• 2F5: Review: binds to the only generally accepted strong neutralizing epitope outside of gp120, one of only 3 MAbs with strong broad activity against
primary viruses, the others are 2G12 and IgG1b12 – unique member of epitope cluster [Moore1995b] and John Moore, per comm 1996
• 2F5: MAb binding decreases the accessibility or alters the conformation of the gp41 fusion domain and of gp120 domains, including the binding site for the
CD4 cell receptor [Neurath1995]
• 2F5: Broad cross-clade neutralization of primary isolates – additive neutralization in combination with anti-CD4BS MAb IgG1b12 (Called BM12)
[Kessler1995]
• 2F5: Only 4/20 Argentinian and 3/43 Swedish HIV+ sera reacted with LLELDKWASL – sera reacting with peptides that contained ELDKWA tended to
have high neutralization titers – the region carboxyl terminal to EDLKWA was found to be more important for polyclonal sera AB binding, 670-675
WNWFDI – 2F5 bound most strongly to the peptide QELLELDKWA [Calarota1996]
• 2F5: ELDKWAS is in a gp41 binding region for the negative regulator of complement factor H (CFH) – Abs to HIV generally do not cause efficient
complement-mediated lysis, but binding of 2F5 can interfere with CHF binding, facilitating HIV destruction by complement [Stoiber1996]
• 2F5: Primary isolates from clade A, B, and E are neutralized by 2F5 – neutralization requires the LDKW motif – neutralization resistant isolates or 2F5
selected variants all had substitutions in the D or K [Purtscher1996]
• 2F5: Neutralizes HXB2, primary isolates, and chimeric virus with gp120 from primary isolates in an HXB2 background [McKeating1996b]
• 2F5: Review: one of three MAbs (IgG1b12, 2G12, and 2F5) generally accepted as having significant potency against primary isolates [Poignard1996b]
• 2F5: Review: only four epitopes have been described which can stimulate a useful neutralizing response to a broad spectrum of primary isolates,
represented by the binding sites of MAbs: 447-52-D, 2G12, Fab b12, and 2F5 [Sattentau1996]
• 2F5: 2F5 was infused into two chimpanzees which were then given an intravenous challenge with a primary HIV-1 isolate – both became infected, but with
delayed detection and prolonged decrease in viral load relative to controls, indicating that preexisting, neutralizing antibodies (passively administered or
actively elicited) affect the course of acute-phase virus replication and can be influential after the Ab can no longer be detected in the peripheral circulation
[Conley1996]
• 2F5: A panel of immunotoxins were generated by linking Env MAbs to ricin A – immunotoxins mediated cell killing, but killing was not directly
proportional to binding [Pincus1996]
• 2F5: Called IAM 2F5 – antibody mediated enhancement or inhibition seemed to be determined by isolate rather than antibody specificity – in this study,
only 2F5 inhibited the entry of all the viruses studied, irrespective of their phenotype, and directly proportional to its affinity to monomeric HIV-1 gp160
[Schutten1997]
• 2F5: Of three neutralizing MAbs (257-D, IgG1b12, and 2F5), 2F5 was the only one to inhibit the entry of all viruses studied, both SI and NSI, with a
potency proportional to its affinity for monomeric gp126 [Schutten1997]
• 2F5: In a multilab evaluation of monoclonal antibodies, only IgG1b12, 2G12, and 2F5 could neutralize at least half of the 9 primary test isolates at a
concentration of < 25 mug per ml for 90% viral inhibition – the isolates with no 2F5 neutralizing susceptibility had the sequences ALGQWA or ELDTWA
instead of EDLKWA – 7/9 primary isolates were neutralized, and ALDKWQ and ALDKWA were susceptible to neutralization [D’Souza1997]
• 2F5: A JRCSF variant that was selected for IgG1b12 resistance remained sensitive to MAbs 2G12 and 2F5, for combination therapy [Mo1997]
• 2F5: One of 14 human MAbs tested for ability to neutralize a chimeric SHIV-vpu+, which expressed HIV-1 IIIB Env – strong neutralizer of SHIV-vpu+ –
all Ab combinations tested showed synergistic neutralization – 2F5 has synergistic response with MAbs 694/98-D (anti-V3), 2G12, b12, and F105 [Li1997]
• 2F5: IgG1b12 was more potent with greater breadth than MAb 2F5 in an infection reduction assay including 35 primary isolates [Kessler II1997]
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• 2F5: Review: MAbs 2F5, 2G12 and IgG1b12 have potential for use in combination with CD4-IgG2 as an immunotherapeutic or immunoprophylactic –
homologous MAbs to these are rare in humans and vaccine strategies should consider including constructs that may enhance exposure of these MAbs’
epitopes [Moore1997]
• 2F5: Binding of anti-gp120 MAbs IgG1b12 or 654-30D does not mediate significant exposure of the gp41 epitopes for MAbs 2F5 and 50-69
[Stamatatos1997]
• 2F5: Using concentrations of Abs achievable in vivo, the triple combination of 2F5, 2G12 and HIVIG was found to be synergistic to have the greatest
breadth and magnitude of response against 15 clade B primary isolates [Mascola1997]
• 2F5: Used to standardize polyclonal response to CD4 BS [Turbica1997]
• 2F5: The only MAb out of a large panel to show no correlation between Viral binding inhibition and neutralization [Ugolini1997]
• 2F5: This review summarizes results about 2F5: it binds extracellularly, near the transmembrane domain, it is the only gp41 MAb that is neutralizing, it
reacts with many non-B clade viruses and has a paradoxically weak binding to virus, given the neutralizing titers [Burton1997]
• 2F5: Post-exposure prophylaxis was effective when MAb 694/98-D was delivered 15 min post-exposure to HIV-1 LAI in hu-PBL-SCID mice, but declined
to 50% if delivered 60 min post-exposure, and similar time constraints have been observed for HIVIG, 2F5 and 2G12, in contrast to MAb BAT123 that
could protect delivered 4 hours post infection [Andrus1998]
• 2F5: This MAb and the results of [Ugolini1997] are discussed – the authors propose that an Ab bound to gp41 would typically project less from the surface
of the virion and so be unable to interfere with attachment [Parren1998a]
• 2F5: Ab from gp120 vaccinated individuals prior to infection, who subsequently became HIV infected, could not achieve 90% neutralization of the primary
virus by which the individuals were ultimately infected – these viruses were not particularly refractive to neutralization, as determined by their susceptibility
to neutralization by MAbs 2G12, IgG1b12, 2F5 and 447-52D [Connor1998]
• 2F5: A neutralization assay was developed based on hemi-nested PCR amplification of the LTR (HNPCR) – LTR-HNPCR consistently revealed HIV DNA
and was shown to be a rapid, specific and reliable neutralization assay based on tests with 6 MAbs and 5 isolates [Yang1998]
• 2F5: A wide range of neutralizing titers was observed that was independent of co-receptor usage – 2F5 was the most potent of the MAbs tested [Trkola1998]
• 2F5: Points out that 2G12 and 2F5, potent neutralizing antibodies, were identified by screening for cell surface (oligomeric Envelope) reactivity [Fouts1998]
• 2F5: The ELDKWA epitope was inserted into the antigenic site B of influenza hemagglutinin and expressed on baculovirus infected insect cells, flanked by
3 additional random amino acids, xELDKWAxx – FACS was used to isolate the clone that displayed the epitope with the most markedly increased binding
capacity for 2F5, to identify particularly specific immunogenic constructs – PELDKWAPP was a high affinity form selected by FACS [Ernst1998]
• 2F5: Induces complement-mediated lysis in MN but not primary isolates – primary isolates are refractive to CML [Takefman1998]
• 2F5: Neutralization synergy was observed when the MAbs 694/98-D (V3), 2F5 (gp41), and 2G12 (gp120 discontinuous) were used in combination, and
even greater neutralizing potential was seen with the addition of a fourth MAb, F105 (CD4 BS) [Li1998]
• 2F5: Used as a control in the study of anti-gp41 MAb NC-1 – 2F5 does not react with HIV-2 gp41 or gp160 [Jiang1998]
• 2F5: MAbs 2G12, 2F5 and b12 are broadly neutralizing, as are some human polyconal sera, but this paper describes a set of primary isolates that are
resistant to all three MAbs and 2 broadly neutralizing sera – results indicate that resistance levels of pediatric isolates might be higher than adult isolates –
resistance in general did not seem to be conferred by a loss of binding affinity for gp120 or gp41, rather by a more global perturbation of oligomeric
Envelope [Parren1998b]
• 2F5: The natural immune response to the epitope of 2F5, ELDKWA, was studied in perinatally infected children and levels of reactivity to this epitope were
correlated with absolute CD4 numbers over time and health status – 3/10 children who had no antibody reactivity to ELDKWA had substitutions in the
epitope (ALDKWA, ELDQWA, and KLDKWA) – 2F5 competed with the ELDKWA-reactive sera depending on the serum titer [Geffin1998]
712
DEC 2002
gp160 Antibodies HIV Antibodies Tables
B
C
ell
No. MAb ID HXB2 Location Author’s Location Sequence Neutralizing Immunogen Species(Isotype)
• 2F5: The complete V, J and D(H) domain was sequenced – unlike non-neutralizing anti-gp41 MAb 3D6, five neutralizing MAbs (2F5, 2G12, 1B1, 1F7, and
3D5) showed extensive somatic mutations giving evidence of persistent antigenic pressure over long periods – in contrast to Geffin98, where multiple
pediatric sera were found to compete with 2F5, cross-competition was noted to be very rare in sera from HIV+ adults – Kunert et al. propose that because
there is a binding site of human complement factor H which overlaps the 2F5 binding site, it may generally be masked from the immune system – 2F5 also
has a remarkably long CDR3 loop of 22 amino acids, and this region could not be readily assigned to any described D(H) fragment, leading to the
suggestion of recombination of two fragments from novel regions [Kunert1998]
• 2F5: Infection of dendritic cells cultured from CD14+ blood cells or from cadaveric human skin was blocked by neutralizing MAbs IgG1b12, or 2F5 and
2G12 delivered together, but not by control non-neutralizing anti-gp120 MAb 4.8D, indicating that NAbs could interrupt early mucosal transmission events
[Frankel1998]
• 2F5: rgp120 derived from a R5X4 subtype B virus was used to vaccinate healthy volunteers and the resulting sera were compared with sera from HIV-1
positive subjects and neutralizing MAbs [Beddows1999]
• 2F5: A meeting summary presented results regarding neutralization –MAbs 2G12 and 2F5 tested for their ability to neutralize primary isolate infection of
genetically engineered cell lines (cMAGI and others, presented by T. Matthews, A. Trkola, J. Bradac) – an advantage of such cells lines over PBMCs is that
markers (X-Gal) can be added for staining to simplify the assay – the consensus of the meeting was that these engineered cell lines did not improve the
sensitivity of detection of primary isolate neutralization – D. Burton and J. Mascola presented results concerning passive immunization and protection of
hu-PBL-SCID mice and macaques, respectively, and both found combinations of MAbs that were able to achieve 99% neutralization in vitro corresponded
to efficacy in vivo [Montefiori1999]
• 2F5: Hu-PBL-SCID mice were infected with HIV-1s JRCSF and SF162 to study the effect of NAbs on an established infection – no significant differences
in the initial rate of decrease in viral load or the plateau levels of viral RNA between the b12 treated and control mice were seen – in most of the Ab treated
mice b12 escape mutants were observed with varying patterns of mutations – a combination of b12, 2G12 and 2F5 protected 1/3 mice, and an isolate from
one of the other two was resistant to neutralization by all three MAbs [Poignard1999]
• 2F5: In a study of 116 HIV-1+ individuals, Ab reactivity to a peptide encompassing the ELDKWA peptide decreased in CDC stage C patients compared
with stage A patients, and longitudinal studies showed a decline in 6/8 patients, while overall Ab reactivity to rec soluble gp160 stayed constant
[Muhlbacher1999]
• 2F5: Review of the neutralizing Ab response to HIV-1 [Parren1999]
• 2F5: Combinations of HIVIG, 2F5, 2G12 were administered in passive-transfer experiments 24 hours prior to challenge with pathogenic SHIV 89.6PD –
3/6 animals given HIVIG/2F5/2G12 were completely protected, the others had reduced viremia and normal CD4 counts – 1/3 monkeys given 2F5/2G12
showed transient infection, the other two had reduced viral load – all monkeys that received HIVIG, 2F5, or 2G12 alone became infected and developed
high-level plasma viremia, although animals that got HIVIG or 2G12 had a less profound CD4 T cell decline [Mascola1999]
• 2F5: Because HIV-1 is most often transmitted across mucosal surfaces, the ability of passive transfer of infused HIVIG/2F5/2G12 to protect against
mucosal exposure of macaques to pathogenic SHIV 89.6PD was studied – HIVIG/2F5/2G12 protected 4/5 animals against vaginal challenge, 2F5/2G12
combined protected 2/5 animals, and 2G12 alone protected 2/4 animals – in contrast, Mascola and co-workers had previously shown single MAbs could not
protect against intervenous challenge – Ab treated animals that got infected through vaginal innoculation had low viral loads and only modest declines in
CD4 counts – the infused Abs were detected in the nasal, vaginal, and oral mucosa [Mascola2000]
• 2F5: Paper uses IgG1 form of 2F5 – a triple combination of 2F5, F105 and 2G12 effectively neutralized perinatal infection of macaque infants when
challenged with SHIV-vpu+ – the plasma half-life was 4.2 +/- 0.8 days [Baba2000]
• 2F5: A mini-review of observations of passive administration of IgG NAbs conferring protection against intervenous or vaginal SHIV challenge, that
considers why IgG MAbs might protect against mucosal challenge [Robert-Guroff2000]
• 2F5: MAbs 98-6 and 2F5 both bind to a peptide N51-C43 complex trimer of heterodimers that approximates the core of the fusogenic form of gp41, and to
C43 alone but not to N51 alone – 98-6 and 2F5 have comparable affinities for C43, but 98-6 has a higher affinity for the complex and 2F5 may bind to an
epitope of C43 that is directly involved with complex formation –and IgG1 rec form of the Ab was used in this study [Gorny2000b]
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• 2F5: 2F5 is a candidate for immunotherapy, but generally IgG1 has a longer half life in humans than IgG3, so the isotype was switched – rec CHO-derived
MAb 2F5 IgG1kappa and hybridoma-derived MAb 2F5 IgG3kappa displayed identical specificity, in vitro function, and epitope (ELDKWA) – it remains to
be determined if isotype switching will prolongs beta-clearance [Kunert2000]
• 2F5: Low levels of anti-ELDKWA antibodies are observed in HIV-1+ individuals, so a C-domain P2 peptide linked to a carrier was used to immunize mice
and rabbits, and stimulated a high-level anti-ELDKWA response [Liao2000]
• 2F5: A rare mutation in the neutralization sensitive R2-strain in the proximal limb of the V3 region caused Env to become sensitive to neutralization by
MAbs directed against the CD4 binding site (CD4BS), CD4-induced (CD4i) epitopes, soluble CD4 (sCD4), and HNS2, a broadly neutralizing sera – 2/12
anti-V3 MAbs tested (19b and 694/98-D) neutralized R2, as did 2/3 anti-CD4BS MAbs (15e and IgG1b12), 2/2 CD4i MAbs (17b and 4.8D), and 2G12 and
2F5 – thus multiple epitopes on R2 are functional targets for neutralization and the neutralization sensitivity profile of R2 is intermediate between the highly
sensitive MN-TCLA strain and the typically resistant MN-primary strain [Zhang2002]
• 2F5: ELDKWA peptide vaccine study [Lu2000c]
• 2F5: ELDKWA peptide vaccine study [Lu2000b]
• 2F5: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including 6 cluster II anti-gp41 MAbs – of these 2F5, 167-D, 126-6,
and 1281 bound across clades, but usually weakly, while 98-6 and 1342 had poor cross reactivity – Clade D isolates bound most consistently to cluster II
MAbs [Nyambi2000]
• 2F5: Six mutations in MN change the virus from a high-infectivity neutralization resistant phenotype to low-infectivity neutralization sensitive – V3,
CD4BS, and CD4i gp120 specific MAbs are 20-100 fold more efficient at neutralizing the sensitive form – gp41 MAbs bind less, and 2F5 behaves the
opposite of gp120 MAbs in that it neutralizes the "sensitive" form less efficiently [Park2000]
• 2F5: ELDKWAS co-crystallized bound to the Fab’ 2F5 fragment showed the epitope peptide in a type I beta-turn conformation [Pai2002]
• 2F5: 2F5 or sCD4-IgG chimeric immunoadhesin were transferred into 3T3 cells, incorporated into a collagen structure called the neo-organ, and
transplanted into SCIDhu mice that were then challenged with MN or LAI – the continuous production of the therapeutic molecules in this context resulted
in dramatic reduction of viral load [Sanhadji2000]
• 2F5: A combination of gp41 fusion with the GNC4 trimeric sequences and disruption of the YU2 gp120-gp41 cleavage site resulted in stable gp140 trimers
(gp140-GNC4) – gp41 MAbs T4, D12, T3, and D50 bound less efficiently to gp140-GNC4 than did pooled sera, but T4 and D12 recognized the
gp140-GNC4 timer equivalently to gp140(-), and T3 and D50 recognized the trimer at greater levels than gp140(-) – 2F5 did not bind efficiently to these
constructs, presumably because of the YU2 strain has a substitution in the 2F5 epitope (ALDKWA instead of ELDKWA) [Yang2000]
• 2F5: SHIV-HXBc2 is a neutralization sensitive non-pathogenic virus, and several in vivo passages through monkey’s yielded highly pathogenic SHIV KU-1
– HXBc2 and the KU-1 clone HXBc2P3.2 differ in 12 amino acids in gp160 – substitutions in both gp120 and gp41 reduced the ability of sCD4, IgG1b12,
F105 and AG1121 to Env achieve saturation and full occupancy, and neutralize KU-1 – 17b and 2F5 also bound less efficiently to HXBc2P3.2, although
2G12 was able to bind both comparably [Si2001]
• 2F5: ELNKWA is an escape variant not recognized by the broadly neutralizing MAb 2F5, which recognizes the core epitope ELDKWA – Abs were raised
against the peptide escape variant CGELNKWAGELNKWA linked to KLH carrier – these polyclonal antibodies, like the monoclonal antibody TH-Ab1
also raised to ELNKWA, could recognize ELDKWA and escape mutant peptide epitopes ELEKWA and ELDEWA [Dong2001]
• 2F5: Mutations in two glcosylation sites in the V2 region of HIV-1 ADA at positions 190 and 197 (187 DNTSYRLINCNTS 199) cause the virus to become
CD4-independent and able to enter cells through CCR5 alone – these same mutations tended to increase the neutralization sensitivity of the virus, including
to antibody 2F5 [Kolchinsky2001]
• 2F5: A peptide called 5-Helix was designed that binds to the C-peptide region of gp41 – 5-Helix is a potent inhibitor of HIV-1 entry that binds immediately
COOH-terminal to the C-peptide region targeted by 5-Helix – the conformation of the bound 2F5 epitope is a hairpin turn [Root2001]
• 2F5: A phage peptide library was screened with MAb 2F5, and from the peptides that bound the amino acids DKW were found to be most critical for
binding – the mimetic peptide RDWSFDRWSLSEFWL elicited a cross-reactive Ab response to gp41 when used to immunize rabbits [Tumanova2001]
714
DEC 2002
gp160 Antibodies HIV Antibodies Tables
B
C
ell
No. MAb ID HXB2 Location Author’s Location Sequence Neutralizing Immunogen Species(Isotype)
• 2F5: Abs against the V3 loop (50.1, 58.2, 59.1, 257-D, 268-D, 447-52D), CD4BS (IgG1b12, 559-64D, F105), CD4i (17b), and to gp41 (2F5, F240) each
showed similar binding efficiency to Env derived from related pairs of primary and TCLA lines (primary: 168P and 320SI, and TCLA: 168C and
320SI-C3.3), but the TCLA lines were much more susceptible to neutralization suggesting that the change in TCLA lines that make them more susceptible
to NAbs alters some step after binding [York2001]
• 2F5: This paper primarily concerns 4E10 and Z13, MAbs that both bind proximally to the 2F5 binding site to a conserved epitope, and that neutralize some
primary isolates from clades B, C, and E – the minimal 2F5 epitope is determined to be EQELLELDKWASLW, based on screening a gp160 fragment
expression library, longer than previous studies – broadly neutralizing MAbs 2F5, IgG1b12, and 4E10 and Z13 fail to neutralize different subsets of viruses
[Zwick2001b]
• 2F5: Neutralization synergy between anti-HIV NAbs b12, 2G12, 2F5, and 4E10 was studied – a classic fixed-ratio method was used, as well as a method
where one Ab was fixed at a low neutralization titer and the other was varied – using primary isolates, a two-four fold enhancement of neutralization was
observed with MAb pairs, and a ten-fold enhancement with a quadruple Ab combination – no synergy was observed with any MAb pair in the neutralization
of TCLA strain HXB2 [Zwick2001c]
• 2F5: Review of studies in macaques that have shown immune control of pathogenic SHIV viremia, improved clinical outcome, and protection, and the
implications of the observations for HIV vaccines [Mascola2001]
• 2F5: SF162DeltaV2 is a virus that has a 30 amino acids deletion in the V2 loop that does not abrogate its infectivity but renders it highly susceptible to
neutralization – when incorporated into a codon-optimized DNA vaccine with a CMV promoter and delivered by gene gun, SF162DeltaV2 gave higher
neutralizing Ab titers against SF162 than did SF162 itself, and Abs that cross-neutralized non-homologous primary isolates were obtained only when
SF162DeltaV2, but not intact SF162, was used as the immunogen – Control MAbs 2F5 and 2G12 could neutralize all of the following primary isolates:
91US056(R5), 92US714(R5), 92US660(R5), 92HT593(R5X4), and BZ167(R5X4), while after the first protein boost, the sera from two SF162DeltaV2
immunized macaques could neutralize 91US056(R5), 92US714(R5), 92US660(R5) and ADA(R5), but not 92HT593(R5X4) or 92US657(R5) – the pattern
of cross-recognition shifted after the second boost [Barnett2001]
• 2F5: Moore and colleagues review the data concerning the lack of a clear relationship between genetic subtype and serotype – 2F5 is considered in some
detail, as it represents a rare vulnerability from the neutralizing antibody perspective, although while it is apparently linear, attempts to present the peptide
to the immune system have failed to elicit neutralizing Abs [Moore2001]
• 2F5: Neutralizing synergy between MAbs 1b12, 2G12 and 2F5 was studied using surface plasmon resonance to determine the binding kinetics for these
three mAbs with respect to monomeric and oligomeric env protein gp160 IIIB – the 2G12 epitope is highly accessible on both monomeric and oligomeric
Envs, 1b12 is highly accessible on monomers but not oligomers, and 2F5 on neither form – binding of 2G12 exposes the 2F5 epitope on gp160 oligomers
[Zeder-Lutz2001]
• 2F5: Matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) in combination with proteolytic protection was used to identify the
functional epitope for MAb 2F5, NEQELLELDKWASLWN, in the disulfide bond associated gp120/gp41 protein SOS-gp140 (JRFL) – this minimal
epitope is much larger than the ELDKWA core epitope previously defined by peptide ELISA, and this could help explain why ELDKWA-peptides are poor
immunogens in terms of eliciting a 2F5-like antibody response [Parker2001]
• 2F5: A luciferase-reporter gene-expressing T-cell line was developed to facilitate neutralization and drug-sensitivity assays – luciferase and p24 antigen
neutralization titer end points were found comparable using NAb from sera from HIV+ donors, and MAbs 2F5, 2G12 and IgG1b12 [Spenlehauer2001]
• 2F5: A panel of 12 MAbs was used to identify those that could neutralize the dual-tropic primary isolate HIV-1 89.6 – six gave significant neutralization at
2 to 10 ug/ml: 2F5, 50-69, IgG1b12, 447-52D, 2G12, and 670-D six did not have neutralizing activity: 654-D, 4.8D, 450-D, 246-D, 98-6, and 1281 – no
synergy, only additive effects were seen for pairwise combinations of MAbs, and antagonism was noted between gp41 MAbs 50-69 and 98-6, as well as
98-6 and 2F5 [Verrier2001]
• 2F5: 4E10 binds proximal to 2F5 and neutralizes primary isolates of clades A, B, C, D, and E – viruses that were resistant to 2F5 were neutralized by 4E10
and vice versa [Stiegler2001]
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• 2F5: A combination of MAbs IgG1b12, 2F5, and 2G12 was given postnatally to four neonates macaques that were then challenged with highly pathogenic
SHIV89.6P – one of the four infants remained uninfected after oral challenge, two infants had no or a delayed CD4(+) T-cell decline
[Hofmann-Lehmann2001]
• 2F5: Twenty HIV clade C isolates from five different countries were susceptible to neutralization by anti-clade B MAbs in a synergistic quadruple
combination of mAbs IgG1b12, 2G12, 2F5, and 4E10 [Xu2001]
• 2F5: Oligomeric gp140 (o-gp140) derived from R5 primary isolate US4 was characterized for use as a vaccine reagent – antigen capture ELISA was used to
compare the antigenicity of gp120 and o-gp140 using a panel of well characterized MAbs – 2F5 recognized o-gp140 [Srivastava2002]
• 2F5: The fusion process was slowed by using a suboptimal temperature (31.5 C) to re-evaluate the potential of Abs targeting fusion intermediates to block
HIV entry – preincubation of E/T cells at 31.5 C enabled polyclonal anti-N-HR Ab and anti-six-helix bundle Abs to inhibit fusion, indicating six-helix
bundles form prior to fusion – the preincubation 31.5 C step did not alter the inhibitory activity of neutralizing Abs anti-gp41 2F5, or anti-gp120 2G12,
IG1b12, 48d, and 17b [Golding2002b]
• 2F5: Ab binding characteristics of SOS gp140 were tested using SPR and RIPA – SOS gp140 is gp120-gp41 bound by a disulfide bond – NAbs 2G12, 2F5,
IgG1b12, CD4 inducible 17b, and 19b bound to SOS gp140 better than uncleaved gp140 (gp140unc) and gp120 – non-neutralizing MAbs 2.2B (binds to
gp41 in gp140unc) and 23A (binds gp120) did not bind SOS gp140 – SOS gp140-2F5-IgG1b12 formed multiple ring structures composed of two SOS
gp140 proteins bridged by two Ab molecules, while 2F5 and 2G12 formed extended chains rather than closed rings [Schulke2002]
• 2F5: Expanding the minimal epitope ELDKWA to an end-capped, linear nonapeptide, Ac-LELDKWASL-amide attained maximal affinity within a set of
native gp41-sequence peptides – scanning single residue substitutions confirmed that essential recognition requirements were the central DKW core
sequence and the importance of the terminal Leu residues for high-affinity binding – high specificity binding pockets at central Lys and Trp side-chains and
an absolute requirement for the carboxylate group of the Asp side chain were found – the nine residue fragment flanked by pairs of Ser and constrained by a
disulfide bridge had high affinity for 2F5 [Tian2002]
• 2F5: ELDKWAS was embedded into a beta-turn-like conformational site on a framework of an antibody specific for human leukocyte antigen HLA-DR –
this construct was recognized by 2F5, and is suggested as an adjuvant-independent vaccine candidate [Ho2002]
• 2F5: Passive immunization of neonate macaques with a combination of F105+2G12+2F5 conferred complete protection against oral challenge with
SHIV-vpu+ or – the combination b12+2G12+2F5 conferred partial protection against SHIV89.6 – such combinations may be useful for prophylaxis at birth
and against milk born transmission – the synergistic combination of IgG1b12, 2G12, 2F5, and 4E10 neutralized a collection of HIV clade C primary
isolates [Xu2002]
• 2F5: A modified gp140 (gp140deltaCFI), with C-term mutations intended to mimic a fusion intermediate and stabilize trimer formation, retained antigenic
conformational determinants as defined by binding to CD4 and to MAbs 2F5, 2G12, F105, and b12, and enhanced humoral immunity without diminishing
the CTL response in mice injected with a DNA vaccine [Chakrabarti2002]
• 2F5: DP178 is a peptide derived from the C-term heptad repeat of gp41 that is a potent inhibitor of viral-mediated fusion—it contains the 2F5 epitope but
fails to stimulate 2F5-like NAbs upon immunization—the peptide was extended to force an increase in helicity, and the modified peptide had a increase in
affinity for 2F5, but upon guinea pig immunization although high peptide-specific Ab titers were achieved the sera were incapable of viral
neutralization—the authors propose that 2F5 may bind with low affinity to a maturation intermediate, which may account for its breadth and why it is hard
to recreate the epitope, but also suggests that the high concentrations required for neutralization are not relevant in vivo [Joyce2002].
• 2F5: Six sera from HIV-exposed uninfected individuals(EU) had IgA neutralizing activity dominated by recognition of a distinctive epitope within gp41,
QARILAV – sera of QAFILAV-immunized BALB/c mice was neutralizing with the dose-dependent behavior similar to 2F5 [Clerici2002a]
• 2F5: A combination of MAbs 2F5 and 2G12 given in multiple infusions was found to be safe and well tolerated even in high doses in a phase I study of
seven HIV-1 infected healthy volunteers—the median elimination half-life was 7.94 days for 2F5, and 16.48 for 2G12—no anti-2F5 or anti-2G12 IgM or
IgG responses were detected—although there was some transient increases, overall plasma viral RNA levels decreased in 6/7 volunteers, by a median of
0.62 log_10 [Armbruster2002].
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• 2F5: A series of mutational changes were introduced into the YU2 gp120 that favored different conformations – 375 S/W seems to favor a conformation of
gp120 closer to the CD4-bound state, and is readily bound by sCD4 and CD4i MAbs (17b, 48d, 49e, 21c and 23e) but binding of anti-CD4BS MAbs (F105,
15e, IgG1b12, 21h and F91 was markedly reduced – IgG1b12 failed to neutralize this mutant, while neutralization by 2G12 was enhanced – 2F5 did not
neutralize either WT or mutant, probably due to polymorphism in the YU2 epitope – another mutant, 423 I/P, disrupted the gp120 bridging sheet, favored a
different conformation and did not bind CD4, CCR5, or CD4i antibodies, but did bind to CD4BS MAbs [Xiang2002b]
• 2F5: HIV-1 gp160∆CT (cytoplasmic tail-deleted) proteoliposomes (PLs) containing native, trimeric envelope glycoproteins from R5 strains YU2 and JRFL,
and X4 strain HXBc2, were made in a physiologic membrane setting as candidate immunogens for HIV vaccines—2F5 bound to gp160∆CT with a
reconstituted membrane ten-fold better than the same protein on beads (except for the YU2 form that doesn’t bind 2F5)—anti-CD4BS MAbs IgG1b12 and
F105, A32 (C1-C4), C11 (C1-C5), and 39F (V3) MAbs bound gp160∆CT PLs indistinguishably from gp160∆CT expressed on the cell surface
[Grundner2002].
• 2F5: Rhesus macaques were better protected from vaginal challenge with SHIV89.6D (MAb 2G12, 2/4; MAbs 2F5/2G12, 2/5; and HIVIG/2F5/2G12, 4/5
infected) than from intravenous challenge (MAb 2G12, 0/3; MAbs 2F5/2G12, 1/3; and HIVIG/2F5/2G12, 3/6 infected)– the animals that were infected by
vaginal challenge after Ab infusion had low or undetectable viral RNA levels and modest CD4 T-cell decline [Mascola2002]
• 2F5: A 2F5 anti-idiotype murine MAb Ab2/3H6 was developed that blocks 2F5 binding to a synthetic epitope peptide and to gp160 in an ELISA
competition assay – Ab2/3H6 diminished the neutralizing potency of 2F5 – Ab2/3H6 Fab fragments were capable of inducing neutralizing Abs and
2F5-epitope specific responses in immunized B6D2F1 mice [Kunert2002]
• 2F5: Review of NAbs that notes that 2F5 alone or in combination with other MAbs can protect some macaques against SHIV infection, that it is safe and
well tolerated in humans, and that illustrates gp41’s conformational change and exposure of the 2F5 epitope in the transient pre-hairpin form
[Ferrantelli2002]
• 2F5: Review of NAbs that discusses mechanisms of neutralization, passive transfer of NAbs and protection in animal studies, and vaccine strategies
[Liu2002]
• 2F5: UK Medical Research Council AIDS reagent: ARP3063
• 2F5: NIH AIDS Research and Reference Reagent Program: 1475
668 polyclonal gp160 (662–667) gp41 (662–667) ELDKWA no Vaccine guinea pig
Vaccine HIV component: gp41 peptide
References Joyce2002
• 2F5: DP178 is a peptide derived from the C-term heptad repeat of gp41 that is a potent inhibitor of viral-mediated fusion – it contains ELDKWA but fails to
stimulate 2F5-like NAbs upon immunization – the peptide was extended to force an increase in helicity, and the modified peptide had a increase in affinity
for 2F5, but upon guinea pig immunization although high peptide-specific Ab titers were achieved the sera were incapable of viral neutralization – the
authors propose that 2F5 may be a low affinity maturation intermediate, which may account for its breadth and why it is hard to recreate the NAb response,
but also suggests that the high concentrations required for neutralization are not relevant in vivo [Joyce2002]
669 5B2 gp160 (662–667) Env (669–674 IIIB) ELDKWA Vaccine murine (IgG)
Vaccine Vector/Type: peptide keyhole limpet hemocyanin (KLH) conjugate Strain: IIIB HIV component: gp41
Ab type C-domain
References Tian2001
• 5B2: There is an RT specific Ab [Szilvay1992] and a gp41 specific Ab [Tian2001] both called 5B2
• 5B2: Peptides GPGRAFY and ELDKWA were conjugated to keyhole limpet hemocyanin and used to raise mouse MAbs – MAb hybridomas were
generated with defined specificity – 5B2 and 9G11 bind to the peptide and to rgp41 [Tian2001]
670 9G11 gp160 (662–667) Env (669–674 IIIB) ELDKWA Vaccine murine (IgG)
Vaccine Vector/Type: peptide keyhole limpet hemocyanin (KLH) conjugate Strain: IIIB HIV component: gp41
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Ab type C-domain
References Tian2001
• 9G11: Peptides GPGRAFY and ELDKWA were conjugated to KLH and used to raise mouse monoclonal Ab—MAb hybridomas were generated with
defined specificity—5B2 and 9G11 bind to the peptide and to rgp41 [Tian2001].
671 TH-Ab1 gp160 (662–667) gp41 (669–674) ELNKWA L P Vaccine rabbit (IgG1)
Vaccine Vector/Type: peptide keyhole limpet hemocyanin (KLH) conjugate Strain: B clade TH936705 HIV component: gp41 Adjuvant: Freund’s
adjuvant
Ab type C-domain
References Xiao2000a, Dong2001
• TH-Ab1: ELNKWA is an escape variant not recognized by the broadly neutralizing MAb 2F5, which recognizes the core epitope ELDKWA—Abs were
raised against the peptide escape variant CGELNKWAGELNKWA linked to KLH carrier—these polyclonal antibodies, like the MAb TH-Ab1 also raised to
ELNKWA, could recognize ELDKWA and escape mutant peptide epitopes ELEKWA and ELDEWA [Dong2001].
672 polyclonal gp160 (662–667) gp41 ELDKWA L P Vaccine rabbit
Vaccine Vector/Type: peptide HIV component: gp41
Ab type C-domain
References Liao2000
• Low levels of anti-ELDKWA antibodies are observed in HIV-1+ individuals, so a C-domain P2 peptide linked to a carrier was used to immunize mice and
rabbits, and stimulated a high-level anti-ELDKWA response in mice and rabbits – vaccine was C-TSLIHSLIEESQNQQEKNEQELLELDKWA linked to
carrier peptide K/G [(KGGG)_7-K] [Liao2000]
673 polyclonal gp160 (662–667) gp41 (669–674) ELDKWA Vaccine murine, rabbit
Vaccine Vector/Type: peptide HIV component: Env Adjuvant: BSA
Ab type C-domain
References Xiao2000b
• Strong epitope-specific neutralizing antibody responses were induced using a Env peptide bound to BSA, C(ELDKWAG)_4-BSA, but not full gp160
[Xiao2000b]
674 polyclonal gp160 (662–667) gp41 (662–667 BH10) ELDKWA L Vaccine murine (IgG, IgA)
Vaccine Vector/Type: influenza Strain: BH10 HIV component: gp41 peptide
Ab type C-domain
ReferencesMuster1994, Muster1995
• Sustained ELDKWA specific IgA response in mucosa of immunized mice [Muster1995]
675 polyclonal gp160 (662–667) gp120 (669–674) ELDKWA Vaccine rabbit (Ig)
Vaccine Vector/Type: polyepitope, protein HIV component: gp160 Adjuvant: BSA
Ab type C-domain
References Lu2000c, Lu2000b
• High titer response to ELDKWA and RILAVERYLKD was observed upon vaccination with multiple-epitope vaccine
CG-GPGRAFY-G-ELDKWA-G-RILAVERYLKD conjugated to BSA, with a weak response to GPGRAFY – immunization with
CG-(ELDKWA-GPGRAFY)_2-K was also tried, yielding a strong Ab response to both ELDKWA and GPGRAFY – gp160 vaccination yielded strong Ab
response but not to any of the peptides studied here [Lu2000c, Lu2000b]
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676 4E10 gp160 (671–676) gp160 (671–676 MN) NWFDIT P HIV-1 infection human (IgG3κ)
Donor Herman Katinger, Inst. Appl. Microbiol. University of Agricultural Science, Vienna, Austria
References Buchacher1992, Buchacher1994, D’Souza1994, Stiegler2001, Zwick2001b, Zwick2001c, Xu2001, Xu2002, Ferrantelli2002
• 4E10: MAbs generated by hybridoma, electrofusion of PBL from HIV-1+ volunteers with CB-F7 heteromyeloma cells – also binds to MHC class II
proteins – anti-class II Abs are only found in HIV-1 positive people – this paper maps 4E10’s binding site to AEGTDRV, gp160(823-829), but the later
Zwick et al. study in 2001 revised the epitope location [Buchacher1994]
• 4E10: Included in a multi-lab study for antibody characterization, binding and neutralization assay comparison [D’Souza1994]
• 4E10: 4E10 binds proximal to 2F5 and neutralizes primary isolates of clades A, B, C, D, and E – viruses that were resistant to 2F5 were neutralized by
4E10 and vice versa [Stiegler2001]
• 4E10: MAbs 4E10 and Z13 both bind proximally to 2F5 to a conserved linear epitope that has some conformational aspects – both bind to MN virions, bind
weakly to infected cells in a manner that is not disrupted by sCD4 and neutralize some primary isolates from clades B, C, and E – maps minimal 4E10
epitope to NWFDIT, contrary to an earlier report – different strains were refractive to neutralization by broadly neutralizing Abs IgG1b12, 2F5, Z13 and
4E10 [Zwick2001b]
• 4E10: Neutralization synergy between anti-HIV NAbs b12, 2G12, 2F5, and 4E10 was studied – a classic fixed-ratio method was used, as well as a method
where one Ab was fixed at a low neutralization titer and the other was varied – using primary isolates, a two-four fold enhancement of neutralization was
observed with MAb pairs, and a ten-fold enhancement with a quadruple Ab combination – no synergy was observed with any MAb pair in the neutralization
of TCLA strain HXB2 [Zwick2001c]
• 4E10: Twenty HIV clade C isolates from five different countries were susceptible to neutralization by anti-clade B MAbs in a synergistic quadruple
combination of mAbs IgG1b12, 2G12, 2F5, and 4E10 [Xu2001]
• 4E10: Passive immunization of neonate macaques with a combination of F105+2G12+2F5 conferred complete protection against oral challenge with
SHIV-vpu+ —the combination b12+2G12+2F5 conferred partial protection against SHIV89.6—such combinations may be useful for prophylaxis at birth
and against milk born transmission—the synergistic combination of IgG1b12, 2G12, 2F5, and 4E10 neutralized a collection of HIV clade C primary
isolates [Xu2002].
• 4E10: Review of NAbs illustrating gp41’s conformational change and exposure of the 4E10/Z13 epitope in the transient pre-hairpin form [Ferrantelli2002]
677 Z13 gp160 (671–676) gp41 (671–676 MN) NWFDIT P HIV-1 infection human (IgG1κ)
Ab type C-term
References Zwick2001b, Ferrantelli2002
• Z13: MAb 4E10 and FAb Z13 both bind proximally to 2F5 to a relatively conserved linear epitope that has some conformational aspects – both bind to MN
virions, bind weakly to infected cells in a manner that is not disrupted by sCD4 and can neutralize some primary isolates from clades B, C, and E – Z13 was
selected using a phage display library with the MN gp41 peptide LLELDKWASLWNWFDITNWSW from an HIV infected donor who had an exceptionally
broad NAb response – different strains were refractive to neutralization by broadly neutralizing Abs IgG1b12, 2F5, Z13 and 4E10 – epitope location noted
here is by analogy to MAb 4E10 [Zwick2001b]
• Z13: Review of NAbs that notes Z13 is a phage display generated FAb fragment from a B clade infected individual and that illustrates gp41’s
conformational change and exposure of the 4E10/Z13 epitope in the transient pre-hairpin form [Ferrantelli2002]
678 B30 gp160 (720–734) gp41 (720–734 BH10) HLPIPRGPDRPEGIE Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
Donor George Lewis
References Abacioglu1994
• B30: Epitope boundaries mapped by peptide scanning [Abacioglu1994]
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679 polyclonal gp160 (724–745) gp41 (731–752) PRGPDRPEGIEEEGGERDRDRS Vaccine murine (IgA, IgG2a)
Vaccine Vector/Type: Cowpea mosaic virus Strain: IIIB HIV component: gp41 peptide
References Durrani1998
• Comparison of intranasal and oral immunization of HIV-1 peptide expressed in a plant viral vector – intranasal gave the better response [Durrani1998]
680 41S-2 gp160 (725–745) gp160 (732–750) RGPDRPEGIEEEGGERDRDRS yes Vaccine murine (IgG2bκ)
Vaccine Vector/Type: peptide keyhole limpet hemocyanin (KLH) conjugate HIV component: gp41
References Hifumi2000
• 41S-2: BALBc mice were immunized with gp41 peptide and a MAb specific for the peptide was generated – isolated MAb light chains displayed
proteolytic activity toward the peptide epitope which may be due to a catalytic triad on light chain (Asp73, Ser76, and His79) – no catalytic activity was
observed for the whole antibody [Hifumi2000]
681 447-52D
(447/52-DII,
447-52-D,
447d,
447-52-D,
447-D, 447,
447D)
gp160 (726–729) gp120 (MN) GPXR L HIV-1 infection human (IgG3λ )
Ab type V3 Donor Dr. Susan Zolla-Pazner, NYU Med Center NY, NY, or Cellular Products Inc, Buffalo, NY, USA
References Gorny1992, Buchbinder1992, Karwowska1992b, Gorny1993, Keller1993, Cavacini1993a, Spear1993, Conley1994a, Laal1994, VanCott1994,
Gorny1994, Moore1994a, Sattentau1995a, Fontenot1995, Saarloos1995, Zolla-Pazner1995a, Zolla-Pazner1995b, Moore1995a, Moore1995b, Forthal1995,
Jagodzinski1996, Trkola1996a, Sattentau1996, D’Souza1997, Binley1997a, Fouts1997, Hioe1997a, Hioe1997b, Boots1997, Parren1997c, Hill1997,
Gorny1997, Inouye1998, Mondor1998, Smith1998, Parren1998a, Zolla-Pazner1999a, Zolla-Pazner1999b, Connor1998, Gorny1998, Nyambi1998,
Hioe1999, Beddows1999, Gorny2000a, Grovit-Ferbas2000, Hioe2000, Ly2000, Nyambi2000, Park2000, York2001, Verrier2001, Srivastava2002,
Sharon2002, Gorny2002, He2002, Ferrantelli2002, Poignard2003
• 447-52D: Requires GPXR at the tip of the V3 loop – neutralizes a broad array of B clade lab isolates [Gorny1992]
• 447-52D: 60-fold increase in neutralization potency when combined 1:1 with human MAb 588-D [Buchbinder1992]
• 447-52D: Reacts with MN, NY5, CDC4, SF2, RF, WM52, and HXB2 [Karwowska1992b]
• 447-52D: Neutralizes MN and IIIB: GPGR, and binds SF2: GPGR [Gorny1993]
• 447-52D: Peptide phage library showed that any of the residues ADGLMNQRS in the X position tolerated in peptides that react well with the antibody
[Keller1993]
• 447-52D: Additive neutralization of MN and SF2 when combined with CD4 binding site MAb F105 – supra-additive neutralization of RF [Cavacini1993a]
• 447-52D: Complement mediated virolysis of IIIB, but not in the presence of sCD4 [Spear1993]
• 447-52D: Requires GPxR at the tip of the V3 loop, common in B clade – neutralized primary isolates [Conley1994a]
• 447-52D: Neutralization synergy in combination with CD4 binding domain MAbs [Laal1994]
• 447-52D: GPGQ in MAL resulted in enhanced dissociation – GPGQ in CM234 or K14T did not bind – binding affected by identity of amino acids flanking
GPGR core [VanCott1994]
• 447-52D: Mild oxidation of carbohydrate moieties does not alter binding [Gorny1994]
• 447-52D: Competition studies with human sera from seroconverting individuals showed that anti-CD4 BS antibodies can arise very early in infection,
comparable or prior to anti-V3 antibodies [Moore1994a]
• 447-52D: Called 447d – Formalin inactivation of virus at 0.1% formalin for 10 hours at 4 degrees was optimal for inactivation of virus while maintaining
epitope integrity [Sattentau1995c]
• 447-52D: Called 447 – The tip of the V3 loop was presented in a mucin backbone – higher valency correlates with stronger affinity constant [Fontenot1995]
• 447-52D: Ab-mediated activation of complement on HIV+ cells is higher than Ab independent activation—what has been termed “Ab independent” in fact
results in part from IgM in normal human serum that is HIV-cross-reactive [Saarloos1995]
• 447-52D: Serotyping study using flow-cytometry – bound only to GPGR V3 loop tips [Zolla-Pazner1995a]
• 447-52D: Neutralization of primary and prototype laboratory HIV-1 isolates using a resting cell assay enhances sensitivity [Zolla-Pazner1995b]
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• 447-52D: Binding affected by identity of amino acids flanking GPGR core – poor breadth of primary virus neutralization [Moore1995a]
• 447-52D: Review: the V3 loop motif GPGR is not common outside subtype B isolates, MAb 19b is more cross-reactive [Moore1995b]
• 447-52D: Neutralizing (- complement), no ADCC activity, and no viral enhancing activity [Forthal1995]
• 447-52D: Called 447-52-D – The sulfated polysaccharide curdlan sulfate (CRDS) binds to the Envelope of T-tropic viruses and neutralizes virus – CRDS
inhibits binding [Jagodzinski1996]
• 447-52D: Neutralizes JR-FL – strongly inhibits gp120 interaction with CCR-5 in a MIP-1beta-CCR-5 competition study [Trkola1996a]
• 447-52D: Review: called 447-52-D – only four epitopes have been described which can stimulate a useful neutralizing response to a broad spectrum of
primary isolates, represented by the binding sites of MAbs: 447-52-D, 2G12, Fab b12, and 2F5 [Sattentau1996]
• 447-52D: In a multilaboratory blinded study, failed to consistently neutralize any of nine B clade primary isolates – many of these isolates had the GPGR
motif at the apex of the V3 loop [D’Souza1997]
• 447-52D: Study shows neutralization is not predicted by MAb binding to JRFL monomeric gp120, but is associated with oligomeric Env binding – 447-52D
bound monomer, oligomer, and neutralized JRFL [Fouts1997]
• 447-52D: Tested using a resting cell neutralization assay [Hioe1997a]
• 447-52D: Four primary isolates showed distinct patterns of sensitivity to neutralization by polyclonal sera or plasma and MAbs – BZ167 was the only
isolate inhibited by all polyclonal sera and plasma tested, and was also neutralized by 8/17 MAbs, in particular anti-V3 loop (419-D, 447-52D, 782-D, and
838-D), anti-CD4bd (559/64-D, 654-D and 830-D and a cluster II of gp41 directed MAb (98-6) – isolates 92HT593 and 91US056 were neutralized by V3
loop (419-D, and 447-52D)and cluster II gp41 (98-6) MAbs at higher concentrations – US4 was neutralized by some of the polyclonal sera/plasma tested
and not at all by MAbs individually or by a cocktail of ten MAbs consisting of 419-D, 447-52D, 782-D, 838-D, 559/64-D, 654-D, 450-D, 670-D, 1281-D
and 98-6 [Hioe1997b]
• 447-52D: Viral binding inhibition by 447-D was correlated with neutralization (all other neutralizing MAbs tested showed some correlation except 2F5)
[Ugolini1997]
• 447-52D: Neutralizes TCLA strains but not primary isolates [Parren1997c]
• 447-52D: Called 447 – gp120 can inhibit MIP-1alpha from binding to CCR5, but this inhibitory effect is blocked by pre-incubation of gp120 with three
anti-V3 MAbs: 447, 257, 1027 – MAb 670 which binds in the C5 region had no effect [Hill1997]
• 447-52D: Abs that recognize discontinuous epitopes can identify mimotopes from a phage peptide display library – 447-52D has an epitope involving the
tip of the V3 loop, that was previously studied with this method [Keller1993] – in Keller et al., with no competition, LxGPxR was the most common
six-mer, 38% of the peptides – after competition with a gp120 IIIB ligand (QRGPGR)i, RGPxR was the most common and one peptide had the sequence
QRGPGR, showing type specific mimotopes can be enriched by strain specific ligand competition protocols [Boots1997]
• 447-52D: Used as a control for comparison to five V3 RF selected antibodies – 447-52D was reactive with A, B, and C clade peptides, but not E
[Gorny1997]
• 447-52D: Called 447-D – 447-D resistance took longer to acquire in virus with the M184V substituted RT, and had the form (AAC N to TAC Y) at position
5 of the V3 loop, rather than the GPGR to GPGR resistance found with wildtype RT [Inouye1998]
• 447-52D: Inhibits binding of Hx10 to both CD4 positive and negative HeLa cells [Mondor1998]
• 447-52D: Called 447-52-D – The tip of the MN V3 loop was inserted into cold causing human rhinovirus 14 (HRV14) – chimeras were immunoselected,
and chimeric viruses were neutralized by anti-V3 loop antibodies, and 447-52D was among the Abs used – chimeric viruses elicited potent NAbs in guinea
pigs against ALA-1 and MN [Smith1998]
• 447-52D: The MAb and Fab binding to the oligomeric form of gp120 and neutralization were highly correlated – authors suggest that neutralization is
determined by the fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
• 447-52D: Ab from gp120 vaccinated individuals prior to infection, who subsequently became HIV infected, could not achieve 90% neutralization of the
primary virus by which the individuals were ultimately infected – these viruses were not particularly refractive to neutralization, as determined by their
susceptibility to neutralization by MAbs 2G12, IgG1b12, 2F5 and 447-52D [Connor1998]
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• 447-52D: Kinetic parameters were measured, and the association rates were similar, but dissociation rate constants were quite variable for V3 MAbs, 1324E
was comparable to 447-52D [Gorny1998]
• 447-52D: Using a whole virion-ELISA method, 18 human MAbs were tested for their ability to bind to a panel of 9 viruses from clades A, B, D, F, G, and
H – 447-52D was the most potent and cross-reactive of 18 human MAbs tested and was the only MAb which bound to virions from isolates CA20 (subtype
F), CA13 (subtype H), and VI526 (subtype G) [Nyambi1998]
• 447-52D: Review of clade specificity and anti-V3 HIV-1-Abs [Zolla-Pazner1999a]
• 447-52D: MAb peptide-reactivity pattern clustered with the immunological related MAbs: 1334, 419, 504, 447, 453 and 537 – the core amino acids GP
tended to be critical for reactivity in this group – 447 reacted with peptides containing GPGR, but also with many lacking this sequence (GPGQ, for
example), and it failed to react with 2/14 peptides containing GPGR, illustrating the importance of context [Zolla-Pazner1999b]
• 447-52D: The presence of leukocyte function-associated molecule 1 (LFA-1) promotes virus infectivity and hinders neutralization, and anti-LFA-1 MAbs
can enhance the neutralizing effect of anti-HIV V3 MAb 447-52D and anti-HIV CD4BS MAb IgG1b12 – non-neutralizing anti-HIV CD4BS MAb 654-D
did not become neutralizing in the presence of anti-LFA-1 MAbs [Hioe1999]
• 447-52D: rgp120 derived from a R5X4 subtype B virus, HIV-1 W61D, was used to vaccinate healthy volunteers and the resulting sera were compared with
sera from HIV-1 positive subjects and neutralizing MAbs – TCLA strains showed enhanced 447-52D neutralization sensitivity relative to PBMC-adapted
lines (32X increase between HIV-1(M2424/PBMC(p0)) and HIV-1(M2424/H9(p9)) and a >128X increase between HIV-1(W61D/PBMC) and
HIV-1(W61D/SupT1) isolates) [Beddows1999]
• 447-52D: Binding of panel of 21 MAbs to soluble oligomeric gp140 versus gp41 or gp120 monomers was compared – no MAb was oligomer specific,
though anti-V3 and CD4BS MAbs reacted better with the oligomer and V2 and C5 tended to favor the monomer – V3 MAbs 447-52D, 838-D, and 1334
bound with a 7-10 fold preference for the oligomer [Gorny2000a]
• 447-52D: To determine the antigenicity of virus killed by thermal and chemical inactivation, retention of conformation-dependent neutralization epitopes
was examined, and exposure of CD4BS epitopes was found to be enhanced (MAbs IgG1b12, 205-46-9, and 205-43-1) – binding to 2G12 and 447-52D
epitopes was essentially unaltered – the 17b CD4i epitope was also exposed [Grovit-Ferbas2000]
• 447-52D: Ab responses, because of their capacity to alter antigen uptake and processing, can influence helper T cell responses – CD4BS MAbs or serum Ig
from HIV+ individuals inhibited proliferative responses of gp120 specific T cells – V3 MAbs 447-52-D and 268-10-D did not effect proliferation
[Hioe2000]
• 447-52D: Called 447D – SF162 is a neutralization-resistant HIV-1 isolate – N-linked glycosylation modifications in the V2 loop of the SF162 gp120
revealed that these sites prevent neutralization by CD4BS MAbs (IgG1b12 and IgGCD4), and protect against neutralization by V3 MAbs (447D and
391-95D) – V2-region glycosylation site mutations did not alter neutralization resistance to V2 MAbs (G3.4 and G3.136) or CD4i MAbs (17b and 48d) –
V2 glycosylation site modification allows infection of macrophages, probably due to glycosylated forms requiring fewer CCR5 molecules for viral entry
[Ly2000]
• 447-52D: A panel of 47 human MAbs was tested against 26 HIV-1 group M primary isolates from clades A through H – 19 V3 MAbs were tested, and of
494 combinations, 44% displayed some viral binding – V3 MAbs tended to have the most cross-reactive binding to clade A, B, C, and D isolates, less to E,
F, G, and H – 447-52D showed the highest cross-reactivity, bound to 24/26 viruses tested, but achieved 90% neutralization only against MN, 50% against
CA5, and no neutralization was observed for 3 other isolates tested [Nyambi2000]
• 447-52D: Six mutations in MN change the virus from a high-infectivity neutralization resistant phenotype to low-infectivity neutralization sensitive – V3,
CD4BS, and CD4i MAbs are 20-100 fold more efficient at neutralizing the sensitive form – the mutation L544P reduced binding of all MAbs against gp120
by causing conformational changes [Park2000]
• 447-52D: Abs against the V3 loop (50.1, 58.2, 59.1, 257-D, 268-D, 447-52D), CD4BS (IgG1b12, 559-64D, F105), CD4i (17b), and to gp41 (2F5, F240)
each showed similar binding efficiency to Env derived from related pairs of primary and TCLA lines (primary: 168P and 320SI, and TCLA: 168C and
320SI-C3.3), but the TCLA lines were much more susceptible to neutralization suggesting that the change in TCLA lines that make them more susceptible
to NAbs alters some step after binding – the dissociation constant, Kd of 447-52D for the cell associated primary and TCLA Envs was equal, 3nM
[York2001]
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• 447-52D: A panel of 12 MAbs was used to identify those that could neutralize the dual-tropic primary isolate HIV-1 89.6 – six gave significant
neutralization at 2 to 10 ug/ml: 2F5, 50-69, IgG1b12, 447-52D, 2G12, and 670-D six did not have neutralizing activity: 654-D, 4.8D, 450-D, 246-D, 98-6,
and 1281 – no synergy, only additive effects were seen for pairwise combinations of MAbs, and antagonism was noted between gp41 MAbs 50-69 and 98-6,
as well as 98-6 and 2F5 [Verrier2001]
• 447-52D: Oligomeric gp140 (o-gp140) derived from R5 primary isolate US4 was characterized for use as a vaccine reagent—antigen capture ELISA was
used to compare the antigenicity of gp120 and o-gp140 using a panel of well characterized MAbs—447-D recognized the gp120 monomer much more
readily than o-gp140, suggesting the V3 loop is less exposed on o-gp140 than it is on the intact virions [Srivastava2002].
• 447-52D: The feasibility of determining the NMR structure of the V3(MN) peptide bound to the 447-52D Fab fragment was tested and a general strategy
for obtaining NMR structures of V3 peptide-Fab fragments developed – preliminary NMR spectra for 447-52D complexed to a 23 amino acid V3 peptide
was obtained [Sharon2002]
• 447-52D: Conformation-dependent anti-V3 loop Abs may be more cross-reactive, so six new V3 MAbs were generated – the six new MAbs all bind to the
tip of the V3 loop and cross-compete with the MAb 447-52D and are conformationally sensitive – MAbs showed cross-clade binding to native, intact
virions of clades A(N=2), B(N=4), and F(N=2), limited binding to C(N=3) and D(N=3), and did not bind to CRF01(subtype E, N=2) – the strength binding
was highly correlated with percent neutralization using the ghost cell or PHA blast assay – five well-characterized MAbs were used as controls: anti-V3
447-52D (anti-V3 MAb for competition and neutralization studies), 654 (anti-CD4BS used as a conformation-sensitive MAb control), 1331A (anti-C5 used
as a linear binding site MAb control), MAb 246 (anti-gp41 MAb that bound to primary isolates of all clades) – 447-52D bound to primary isolates from all
clades except CRF01 (E), was conformationally sensitive and showed the some of the most potent neutralizing activity [Gorny2002]
• 447-52D: Transgenic mice carrying human genes allowing production of fully human MAbs were used to rapidly create a panel of anti-HIV gp120 MAb
producing hybridomas by immunization with HIV SF162 gp120 – the previously described human MAbs 5145A(CD4BS) , 4117C (plus others, V3) and
697D (and SC258, V2) were used as controls [He2002]
• 447-52D: Review of NAbs [Ferrantelli2002]
• 447-52D: Virion capture assays are not a good preditor of neutralization, and the presentation of epitopes using this assay seems to be different from that of
functional Envelope spikes on primary isolates – F105 and b6 could efficiently block the b12-mediated capture of infectious virions in a virus capture, but
did not inhibit b12 neutralization – Ab 447-52D was able to potently neutralize 89.6 and to neutralize JR-CSF at a high concentration but poorly neutralized
ADA – b12 was potent at neutralizing the three primary virions JR-CSF, ADA, and 89.6, but anti-V3 Abs 447-52D and 19b, which did not neutralize
JR-CSF and ADA, captured amounts of p24 equal to or higher than the amounts captured by the neutralizing Ab b12 [Poignard2003]
682 C8 gp160 (727–732) gp41 (727–732 BH10) PDRPEG no Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
References Pincus1993a, Pincus1993b, Abacioglu1994, McLain2001
• C8: Immunotoxin of C8 coupled to ricin-A does not mediate cells killing, and is not affected by sCD4 [Pincus1993a]
• C8: Ab response in IIIB lab workers was compared to gp160 LAI vaccine recipients – C8 was used as a control – the dominant response among vaccinees
was to this mid-gp41 region, but not among the infected lab workers – Abs binding this region do not neutralize, bind to infected cells, nor serve as
immunotoxins [Pincus1993b]
• C8: Epitope boundaries mapped by peptide scanning [Abacioglu1994]
• C8: The substitution 725 RG (P[R–>G]GPDRPEGIEEEGGERDRDRS) alters the antigenic exposure of this region on the virion resulting in the loss of the
downstream neutralizing epitope ERDRD, increased exposure of the epitope GPDRPEG in the virion, while the epitope IEEE remains unchanged
[McLain2001]
683 B31 gp160 (727–734) gp41 (727–734 BH10) PDRPEGIE Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
References Abacioglu1994
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• B31: Epitope boundaries mapped by peptide scanning [Abacioglu1994]
684 B33 gp160 (727–734) gp41 (727–734 BH10) PDRPEGIE no Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: NL43 HIV component: gp160
References Abacioglu1994, Bristow1994
• B33: There are two MAbs in the literature named B33, see also gp120, positions 123-142 – MAb generated in a study of the humoral immune response to
Baculovirus-expressed mis-folded rgp160 IIIB:NL43, MicroGenSys [Bristow1994]
• B33: Epitope boundaries mapped by peptide scanning IgG1 [Abacioglu1994]
685 1576 gp160 (728–745) gp41 (735–752 IIIB) DRPEGIEEEGGERDRDRS no Vaccine murine
Vaccine Vector/Type: poliovirus Strain: IIIB HIV component: gp41 peptide
References Vella1993
• 1576: Not neutralizing [Vella1993]
686 1578 gp160 (728–745) gp41 (735–752 IIIB) DRPEGIEEEGGERDRDRS no Vaccine murine
Vaccine Vector/Type: poliovirus Strain: IIIB HIV component: gp41 peptide
References Evans1989, Vella1993
• 1578: No neutralizing activity – epitope may be formed by regions from both poliovirus and HIV [Evans1989]
• 1578: Core epitope: IEEE – in this study, neutralized IIIB, but not RF or MN [Vella1993]
687 1579 gp160 (728–745) gp41 (735–752 IIIB) DRPEGIEEEGGERDRDRS no Vaccine murine
Vaccine Vector/Type: poliovirus Strain: IIIB HIV component: gp41 peptide
References Vella1993
• 1579: Core epitope: IEEE – neutralized IIIB, but not RF or MN [Vella1993]
688 1583 gp160 (728–745) gp41 (735–752 IIIB) DRPEGIEEEGGERDRDRS no Vaccine murine
Vaccine Vector/Type: poliovirus Strain: IIIB HIV component: gp41 peptide
References Evans1989, Vella1993, Sattentau1995c
• 1583: Neutralizing activity, less broad than 1577 [Evans1989]
• 1583: Core epitope: ERDRD – Could neutralize HIV IIIB but not HIV RF [Vella1993]
• 1583: Cytoplasmic domain, epitope not exposed at the surface of HIV-1 infected cells [Sattentau1995c]
689 1899 gp160 (728–745) gp41 (735–752 IIIB) DRPEGIEEEGGERDRDRS no Vaccine murine
Vaccine Vector/Type: poliovirus Strain: IIIB HIV component: gp41 peptide
References Vella1993
• 1899: Could neutralize HIV IIIB and HIV RF [Vella1993]
690 1907 gp160 (728–745) gp41 (735–752 IIIB) DRPEGIEEEGGERDRDRS no Vaccine murine
Vaccine Vector/Type: poliovirus Strain: IIIB HIV component: gp41 peptide
References Vella1993
• 1907: Could not neutralize HIV IIIB, RF or MN [Vella1993]
691 1908 gp160 (728–745) gp41 (735–752 IIIB) DRPEGIEEEGGERDRDRS no Vaccine murine
Vaccine Vector/Type: poliovirus Strain: IIIB HIV component: gp41 peptide
References Evans1989, Vella1993, Sattentau1995c
• 1908: Neutralized IIIB, but not RF or MN [Vella1993]
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• 1908: Cytoplasmic domain, epitope not exposed at the surface of HIV-1 infected cells [Sattentau1995c]
692 1909 gp160 (728–745) gp41 (735–752 IIIB) DRPEGIEEEGGERDRDRS no Vaccine murine
Vaccine Vector/Type: poliovirus Strain: IIIB HIV component: gp41 peptide
References Vella1993
• 1909: Neutralized HIV IIIB but not HIV RF [Vella1993]
693 41-1 gp160 (728–745) gp41 (735–752 IIIB) DRPEGIEEEGGERDRDRS no Vaccine murine (IgMκ)
Vaccine Vector/Type: peptide Strain: IIIB HIV component: gp41 peptide
ReferencesMani1994, Dalgleish1988
• 41-1: This antibody gp41(735-752 IIIB) [Dalgleish1988] seems to have been named the same as a different MAb to gp41(584-609) [Mani1994]
• 41-1: Neutralizes HIV-1 but not HIV-2 strains [Dalgleish1988]
694 41-2 gp160 (728–745) gp41 (735–752 IIIB) DRPEGIEEEGGERDRDRS no Vaccine murine (IgMκ)
Vaccine Vector/Type: peptide Strain: IIIB HIV component: gp41 peptide
References Dalgleish1988
• 41-2: Neutralizes HIV-1 but not HIV-2 strains [Dalgleish1988]
695 41-3 gp160 (728–745) gp41 (735–752 IIIB) DRPEGIEEEGGERDRDRS no Vaccine murine (IgMκ)
Vaccine Vector/Type: peptide Strain: IIIB HIV component: gp41 peptide
References Dalgleish1988
• 41-3: Neutralizes HIV-1 but not HIV-2 strains [Dalgleish1988]
696 ED6 gp160 (728–745) gp41 (735–752 IIIB) DRPEGIEEEGGERDRDRS no murine (IgM)
References Evans1989
697 LA9
(121-134)
gp160 (728–745) gp41 (735–752 IIIB) DRPEGIEEEGGERDRDRS no murine (IgM)
References Evans1989
698 1575 gp160 (728–745) gp41 (735–752 IIIB) DRPEGIEEEGGERDRDRS no Vaccine murine
Vaccine Vector/Type: poliovirus Strain: IIIB HIV component: gp41 peptide
Ab type C-term Donor C. Vella, NIBSC, Potters Bar UK
References Evans1989, Vella1993, Buratti1997, Cleveland2000a
• 1575: Neutralizing activity, less broad than 1577 [Evans1989]
• 1575: Core epitope: IEEE – neutralized IIIB, but not RF or MN [Vella1993]
• 1575: Study shows that MAb 1575 can recognize the IEEE sequence in both gp41, and in the HPG30 region of the p17 protein – motif is conserved in both
regions in different HIV-1 clades [Buratti1997]
• 1575: Ab binding to IEEE suppresses neutralizing Ab binding to adjacent epitope ERDRD [Cleveland2000a]
699 88-158/02 gp160 (732–747) gp41 (732–752 IIIB) GIEEEGGERDRDRSIR Vaccine murine (IgG2b)
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp41
References Niedrig1992a
• 88-158/02: Mild inhibition of in vitro activity at high MAb concentrations – profound enhancing activity at low concentrations – significant reactivity to
virion – domain non-immunogenic in humans [Niedrig1992a]
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700 88-158/022 gp160 (732–747) gp41 (732–752 IIIB) GIEEEGGERDRDRSIR Vaccine murine (IgG2b)
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp41
References Niedrig1992a
• 88-158/022: Mild inhibition of in vitro activity at high MAb concentrations – profound enhancing activity at low concentrations – significant reactivity to
virion – domain non-immunogenic in humans [Niedrig1992a]
701 88-158/079 gp160 (732–747) gp41 (732–752 IIIB) GIEEEGGERDRDRSIR Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp41
References Niedrig1992a
• 88-158/079: Mild inhibition of HIV in vitro at high MAb concentrations – profound enhancing activity at low concentrations – weak binding to virion –
domain non-immunogenic in humans [Niedrig1992a]
702 polyclonal gp160 (733–736) gp41 (735–752 IIIB) IEEE L Vaccine murine (IgG)
Vaccine Vector/Type: Cowpea mosaic virus HIV component: gp41 peptide
Ab type C-term
References Cleveland2000b, McLain2001
• When PRGPDRPEGIEEEGGERDRDRS was used as antigen an immunodominant, non-neutralizing response to IEEE was observed, but immunization
GERDRDR shifts the response to ERDRD [Cleveland2000b]
• The substitution 725 RG (P[R–>G]GPDRPEGIEEEGGERDRDRS) alters the antigenic exposure of this region on the virion resulting in the loss of the
downstream neutralizing epitope ERDRD, increased exposure of the epitope GPDRPEG in the virion, while the epitope IEEE remains unchanged
[McLain2001]
703 polyclonal gp160 (733–736) gp41 (735–752 NL43) IEEE L Vaccine murine (IgG)
Vaccine Vector/Type: Cowpea mosaic virus HIV component: gp41 peptide
Ab type C-term
ReferencesMcLain2001
• The substitution 725 RG (P[R–>G]GPDRPEGIEEEGGERDRDRS) alters the antigenic exposure of this region on the virion resulting in the loss of the
downstream neutralizing epitope ERDRD, increased exposure of the epitope GPDRPEG in the virion, while the epitope IEEE remains unchanged
[McLain2001]
704 B8 gp160 (733–741) gp41 (733–741 BH10) IEEEGGERD no Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: LAI HIV component: gp160
References Pincus1993b, Abacioglu1994
• B8: Ab response in IIIB lab workers was compared to gp160 LAI vaccine recipients – B8 was used as a control – the dominant response among vaccinees
was to this mid-gp41 region, but not among the infected lab workers – Abs binding this region do not neutralize, bind to infected cells, nor serve as
immunotoxins [Pincus1993b]
• B8: Epitope boundaries mapped by peptide scanning [Abacioglu1994]
705 1577 gp160 (739–743) gp41 (735–752 IIIB) ERDRD no Vaccine murine
Vaccine Vector/Type: poliovirus Strain: IIIB HIV component: gp41 peptide
Ab type C-term Donor C. Vella or Morag Ferguson (NIBSC, Potters Bar UK)
References Evans1989, D’Souza1991, Vella1993, Cleveland2000a
• 1577: Raised against IIIB peptide chimera – neutralized African and American HIV-1 lab strains [Evans1989]
• 1577: Non-neutralizing in this multi-lab study [D’Souza1991]
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• 1577: Core epitope: ERDRD – could neutralize HIV IIIB and HIV RF [Vella1993]
• 1577: Ab binding to IEEE suppresses neutralizing Ab binding to adjacent epitope ERDRD [Cleveland2000a]
• 1577: UK Medical Research Council AIDS reagent: ARP317
• 1577: NIH AIDS Research and Reference Reagent Program: 1172
706 polyclonal gp160 (739–743) gp41 (735–752 IIIB) ERDRD L Vaccine murine (IgG)
Vaccine Vector/Type: Cowpea mosaic virus HIV component: gp41 peptide
Ab type C-term
References Cleveland2000b, McLain2001
• ERDRD-specific IgG recognizes an externalized loop of the gp41 C-terminal tail with high affinity – neutralized HIV-1 B clade strains IIIB, NL-4.3, RF,
MN and D clade virus CBL-4, but HXB-2D (clade B) was not recognized – when PRGPDRPEGIEEEGGERDRDRS was used as antigen an
immunodominant, non-neutralizing response to IEEE was observed, but immunization GERDRDR shifts the response to ERDRD – NAb does not inhibit
attachment of free virus, but does inhibit by an event that precedes fusion-entry [Cleveland2000b]
• The substitution 725 RG (P[R–>G]GPDRPEGIEEEGGERDRDRS) alters the antigenic exposure of this region on the virion resulting in the loss of the
downstream neutralizing epitope ERDRD, increased exposure of the epitope GPDRPEG in the virion, while the epitope IEEE remains unchanged
[McLain2001]
707 DZ gp160 (822–855) gp41 (827–860 BRU) VAEGTDRVIEVVQGACRAIRHIPRR-
IRQGLERIL
L Vaccine human (IgG1λ )
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: gp60
References Boyer1991
• DZ: Weakly neutralizing IIIB – binds to peptides 827-843 and 846-860 of BRU – reacted specifically with IIIB and RF [Boyer1991]
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708 Env gp120 (IIIB) Vaccine murine (IgG1)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: gp120 Adjuvant: GM-CSF
References Rodríguez1999
• The murine Ab response to a chimeric of granulocyte-macrophage colony stimulating factor GM-CSF/gp120 in vaccinia was not higher titer that the
response to a gp120-vaccinia construct, but the breadth of the Ab response was greater, in particular to the C-term region of gp120 – a cellular response of
greater intensity was trigged to the GM-CSF/gp120 vaccinia construct, as measured by Elispot assay [Rodríguez1999]
709 Env Env (384–467) Vaccine rabbit, Rhesus
macaque
Vaccine Vector/Type: hepatitis B surface antigen lipoprotein particles HsBAg HIV component: V3 Adjuvant: LAI
ReferencesMichel1993
• Immunization with recombinant HIV1 V3/HBsAg hybrid particles into rabbits or macaques elicited and maintained for several months anti-V3 or HIV-1
Env proliferative, CTL and Ab responses [Michel1993]
710 Env gp120 and p55 Vaccine murine (IgG1)
Vaccine Vector/Type: virus-like particle Strain: gp120 A clade UG5.94UG018, HIV-1 IIIB HIV component: gp120 and Pr55gag
References Buonaguro2002
• BALB/c mice were given intraperitoneal immunization with virus-like particlea (VLPs) expressing recombinant subtype A gp120 and Pr55gag in the
absence of adjuvants. High dose-independent humoral responses against both gp120 and p24 peptides were detected. Antibodies able to elicit 50%
neutralization against IIIB and the autologous clade A virus were obtained [Buonaguro2002]
711 Env Y HIV-1 infection, Vaccine human
References Burton2000
• This review article touches on why natural immune responses do not tend to favor potent neutralizing Ab production, and discusses possible vaccine
strategies to counter this problem [Burton2000]
712 Env P HIV-1 infection human
References Pellegrin1996
• Detection of an autologous NAb response in 12 patients with primary infections was delayed – for patients with a viral isolate obtained at month 1,
autologous NAbs to viral isolates were generally not observed before month 6, and there was no apparent relationship between the emergence of
neutralizing activity and the decrease of plasma viral load [Pellegrin1996]
713 102-135 Env gp41 (HAM112, O
group)
Vaccine murine (IgG1 κ)
Vaccine Vector/Type: recombinant protein Strain: HAM112 (group O) HIV component: gp160
References Scheffel1999
• 102-135: Overlapping peptides based on group O HAM112 Env were tested for MAb reactivity – 102-135 bound to two non-contiguous peptides in
combination, assumed to form some type of helical structure, and not to either individually [Scheffel1999]
714 1025 Env gp120
References Berman1997
• 1025: Binds to 1/7 isolates from breakthrough cases from a MN gp120 vaccine trial [Berman1997]
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715 105-134 Env gp41 (652–681
HAM112, O group)
Vaccine murine (IgG1 κ)
Vaccine Vector/Type: recombinant protein Strain: HAM112 (group O) HIV component: gp160
References Scheffel1999
• 105-134: Overlapping peptides based on group O HAM112 Env were tested for MAb reactivity [Scheffel1999]
716 10E9 Env gp41 HIV-1 infection murine (IgG1)
References Papsidero1988
• 10E9: 100/100 HIV+ human sera could inhibit 10E9 binding [Papsidero1988]
717 126-50 Env gp41 (HXB2) no HIV-1 infection human (IgG2κ)
References Robinson1990b, Tyler1990, Robinson1991, Xu1991
• 126-50: No enhancing activity for HIV-1 IIIB [Robinson1990b]
• 126-50: Serves as target for antibody-dependent cellular cytotoxicity ADCC [Tyler1990]
• 126-50: No enhancing or neutralizing activity [Robinson1991]
• 126-50: Specific for a conformational epitope [Xu1991]
718 12H2 Env gp41 (530–677 HXB2) no Vaccine murine (IgMκ)
Vaccine Vector/Type: Semliki-Forest Virus HIV component: Env
References Giraud1999
• 12H2: Env in a Semliki-Forest Virus (SFV) vector was used to vaccinate mice intramuscularly as naked RNA, and an Ab response was induced to Env from
which 12H2 was derived – and advantage of this method is that the protein is properly expressed [Giraud1999]
719 13.10 (No. 13) Env gp120 no HIV-1 infection human (IgG1λ )
Donor Evan Hersh and Yoh-Ichi Matsumoto
References Lake1989, Moran1993, Wisnewski1996
• 13.10: First HIV-1 specific human-mouse hybridoma that produces a MAb that binds to gp120 and gp160 [Lake1989]
• 13.10: Heavy (V HI) and light (V lambdaII) chain sequenced – no enhancing or neutralizing activity – called No. 13 [Moran1993]
• 13.10: 13.10 is V H1 – V-region heavy chain usage was examined and a bias of enhanced V H1 and V H4, and reduced V H3, was noted among HIV
infected individuals [Wisnewski1996]
• 13.10: NIH AIDS Research and Reference Reagent Program: 377
720 1B1 Env Env L HIV-1 infection human
Donor Herman Katinger, Inst. Appl. Microbiol. University of Agricultural Science, Vienna, Austria
References Buchacher1994, Purtscher1994, Kunert1998
• 1B1: Generated by electrofusion of PBL from HIV-1 positive volunteers with CB-F7 cells [Buchacher1994]
• 1B1: The complete V, J and D(H) domain was sequenced – unlike non-neutralizing anti-gp41 MAb 3D6, five neutralizing MAbs (2F5, 2G12, 1B1, 1F7, and
3D5) showed extensive somatic mutations giving evidence of persistent antigenic pressure over long periods [Kunert1998]
721 1F7 Env Env L HIV-1 infection human
Donor Herman Katinger, Inst. Appl. Microbiol. University of Agricultural Science, Vienna, Austria
References Buchacher1994, Purtscher1994, Kunert1998, Grant2000
• 1F7: Generated by electrofusion of PBL from HIV-1 positive volunteers with CB-F7 cells [Buchacher1994]
• 1F7: The complete V, J and D(H) domain was sequenced – unlike non-neutralizing anti-gp41 MAb 3D6, five neutralizing MAbs (2F5, 2G12, 1B1, 1F7, and
3D5) showed extensive somatic mutations giving evidence of persistent antigenic pressure over long periods [Kunert1998]
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• 1F7: There is an anti-idiotype MAb named 1F7 that was raised against pooled IgG from HIV-1+ subjects that recognizes a set of antibodies against HIV
Gag, Pol, and Env, and this MAb is reported to inhibit anti-HIV CTL activity—this is not the same as the 1F7 described by Buchacher et al. [Grant2000].
722 2.2B Env gp41 no
References Binley1999, Schulke2002
• 2.2B: The MAbs with the broadest neutralizing activity, IgG1b12, 2G12 and 2F5, all have high affinity for the native trimer, indicating that they were raised
in an immune response to the oligomer on the virion surface rather than dissociated subunits – a disulfide linked gp120-gp41 (SOS gp140) was created to
mimic the native conformation of Env and explore its potential as an immunogen – SOS gp140 is recognized by NAbs IgG1b12, 2G12, and CD4-IgG2, and
also by anti-V3 MAbs 19b and 83.1 – SOSgp140 is not recognized by C4 region MAbs that neutralize only TCLA strains, G3-42 and G3-519 – nor did it
bind C11, 23A, and M90, MAbs that bind to gp120 C1 and C5, where it interacts with gp41 – MAbs that bind CD4 inducible epitopes, 17b and A32 were
very strongly induced by CD4 in SOS gp140 – anti-gp41 MAbs that bind in the region that interacts with gp120, 7B2, 2.2B, T4, T15G1 and 4D4, did not
bind to SOSgp140, in contrast to 2F5, which binds to the only gp41 epitope that is well exposed in native gp120-gp41 complexes [Binley1999]
• 2.2B: Ab binding characteristics of SOS gp140 were tested using SPR and RIPA – SOS gp140 is gp120-gp41 bound by a disulfide bond – NAbs 2G12, 2F5,
IgG1b12, CD4 inducible 17b, and 19b bound to SOS gp140 better than uncleaved gp140 (gp140unc) and gp120 – non-neutralizing MAbs 2.2B (binds to
gp41 in gp140unc) and 23A (binds gp120) did not bind SOS gp140 [Schulke2002]
723 30D Env gp120 no
References Yang2002
• 30D: Uncleaved soluble gp140 (YU2 strain, R5 primary isolate) can be stabilized in an oligomer by fusion with a C-term trimeric GCN4 motif or using a
T4 trimeric motif derived from T4 bacteriophage fibritin—stabilized oligomer gp140∆683(-FT) showed strong preferential recognition by NAbs IgG1b12
and 2G12 relative to the gp120 monomer, in contrast to poorly neutralizing MAbs F105, F91, 17b, 48d, and 39F which showed reduced levels of binding,
and C11, A32, and 30D which did not bind the stabilized oligomer [Yang2002].
724 31710B Env gp41 human (IgG1)
References Alsmadi1998
• 31710B: A study of 6 anti-Env MAbs and their ability to bind or direct ADCC against target cells infected with IIIB, MN, SF-2, and RF – bound and
directed lysis against all four strains [Alsmadi1998]
725 38B5/C9 Env gp120 (SF162) no Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 38B5/C9: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2κ MAbs were used to rapidly create a
panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120—11 of the MAbs were conformation dependent, but did
not block sCD4 binding—these MAbs were part of the same competition group, and enhanced binding of the CD4BS MAb 38G3/A9 and anti-CD4BS
MAbs also enhanced their binding—these MAbs tended to be very cross-reactive but could not neutralize autologous SF162—38B5/C9 bound to most R5
and X4 B clade viruses, as well as one of two E clade viruses [He2002].
726 39H10/A11 Env gp120 (SF162) no Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
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Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 39H10/A11: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2κ MAbs were used to rapidly create
a panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120—11 of the MAbs were conformation dependent, but did
not block sCD4 binding—these MAbs were part of the same competition group, and enhanced binding of the CD4BS MAb 38G3/A9 and anti-CD4BS
MAbs also enhanced their binding—these MAbs tended to be very cross-reactive but could not neutralize autologous SF162—39H10/A11 bound to three
R5 and three X4 B clade viruses, as well as two E clade viruses [He2002].
727 3D5 Env Env L HIV-1 infection human
Donor Herman Katinger, Inst. Appl. Microbiol. University of Agricultural Science, Vienna, Austria
References Buchacher1994, Purtscher1994, Kunert1998
• 3D5: Generated by electrofusion of PBL from HIV-1 positive volunteers with CB-F7 cells [Buchacher1994]
• 3D5: The complete V, J and D(H) domain was sequenced – unlike non-neutralizing anti-gp41 MAb 3D6, five neutralizing MAbs (2F5, 2G12, 1B1, 1F7, and
3D5) showed extensive somatic mutations giving evidence of persistent antigenic pressure over long periods [Kunert1998]
728 3H6 Env gp41 murine
References Pinter1995
• 3H6: There is another MAb with this ID that recognizes Rev [Orsini1995]
• 3H6: Generated in response to virus grown in protein-free medium [Pinter1995]
729 40D3/C11 Env gp120 (SF162) no Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 40D3/C11: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2κ MAbs were used to rapidly create a
panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120—11 of the MAbs were conformation dependent, but did
not block sCD4 binding—these MAbs were part of the same competition group, and enhanced binding of the CD4BS MAb 38G3/A9 and anti-CD4BS
MAbs also enhanced their binding—these MAbs tended to be very cross-reactive but could not neutralize autologous SF162—40D3/C11 bound to most R5
and X4 B clade viruses, as well as one of two E clade viruses [He2002].
730 49B11/A1 Env gp120 (SF162) no Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 49B11/A1: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2κ MAbs were used to rapidly create a
panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120—11 of the MAbs were conformation dependent, but did
not block sCD4 binding—these MAbs were part of the same competition group, and enhanced binding of the CD4BS MAb 38G3/A9 and anti-CD4BS
MAbs also enhanced their binding—these MAbs tended to be very cross-reactive but could not neutralize autologous SF162—49B11/A1 bound to most R5
and X4 B clade viruses, as well as one of two E clade viruses [He2002].
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731 52G5/B9 Env gp120 (SF162) no Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 52G5/B9: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2κ MAbs were used to rapidly create a
panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120—11 of the MAbs were conformation dependent, but did
not block sCD4 binding—these MAbs were part of the same competition group, and enhanced binding of the CD4BS MAb 38G3/A9 and anti-CD4BS
MAbs also enhanced their binding—these MAbs tended to be very cross-reactive but could not neutralize autologous SF162—52G5/B9 bound to most R5
and X4 B clade viruses, as well as one of two E clade viruses [He2002].
732 55E4/H1 Env gp120 (SF162) no Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 55E4/H1: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2κ MAbs were used to rapidly create a
panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120—11 of the MAbs were conformation dependent, but did
not block sCD4 binding—these MAbs were part of the same competition group, and enhanced binding of the CD4BS MAb 38G3/A9 and anti-CD4BS
MAbs also enhanced their binding—these MAbs tended to be very cross-reactive but could not neutralize autologous SF162—55E4/H1 bound to most R5
and X4 B clade viruses, as well as one of two E clade viruses [He2002].
733 56C4/C8 Env gp120 (SF162) no Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 56C4/C8: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2κ MAbs were used to rapidly create a
panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120—11 of the MAbs were conformation dependent, but did
not block sCD4 binding—these MAbs were part of the same competition group, and enhanced binding of the CD4BS MAb 38G3/A9 and anti-CD4BS
MAbs also enhanced their binding—these MAbs tended to be very cross-reactive but could not neutralize autologous SF162—56C4/C8 bound to some R5
and X4 B clade viruses, as well as one of two E clade viruses [He2002].
734 57B6/F1 Env gp120 (SF162) no Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
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• 57B6/F1: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2κ MAbs were used to rapidly create a
panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120—11 of the MAbs were conformation dependent, but did
not block sCD4 binding—these MAbs were part of the same competition group, and enhanced binding of the CD4BS MAb 38G3/A9 and anti-CD4BS
MAbs also enhanced their binding—these MAbs tended to be very cross-reactive but could not neutralize autologous SF162—57B6/F1 bound some R5 and
X4 B clade viruses, and no E clade viruses [He2002].
735 57H5/D7 Env gp120 (SF162) no Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 57H5/D7: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2κ MAbs were used to rapidly create a
panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120—11 of the MAbs were conformation dependent, but did
not block sCD4 binding—these MAbs were part of the same competition group, and enhanced binding of the CD4BS MAb 38G3/A9 and anti-CD4BS
MAbs also enhanced their binding—these MAbs tended to be very cross-reactive but could not neutralize autologous SF162—57H5/D7 bound to most R5
and X4 B clade viruses, as well as one of two E clade viruses [He2002].
736 63G4/E2 Env gp120 (SF162) no Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 63G4/E2: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2κ MAbs were used to rapidly create a
panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120—11 of the MAbs were conformation dependent, but did
not block sCD4 binding—these MAbs were part of the same competition group, and enhanced binding of the CD4BS MAb 38G3/A9 and anti-CD4BS
MAbs also enhanced their binding—these MAbs tended to be very cross-reactive but could not neutralize autologous SF162—63G4/E2 bound to three R5
and three X4 B clade viruses, as well as two E clade viruses [He2002].
737 65B12/C5 Env gp120 (SF162) no Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 65B12/C5: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2κ MAbs were used to rapidly create a
panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120—11 of the MAbs were conformation dependent, but did
not block sCD4 binding—these MAbs were part of the same competition group, and enhanced binding of the CD4BS MAb 38G3/A9 and anti-CD4BS
MAbs also enhanced their binding—these MAbs tended to be very cross-reactive but could not neutralize autologous SF162—65B12/C5 bound some R5
and X4 B clade viruses, and no E clade viruses [He2002].
738 6E10 Env gp120 L Vaccine
Vaccine Vector/Type: recombinant protein HIV component: gp160
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Donor Phil Berman
References Berman1991
739 7-1054 Env gp36 (HIV-2) no murine
References Scheffel1999
• Binds HIV-2 gp36, used as a control in a study of group O MAbs [Scheffel1999]
740 7B2 Env gp41 no
References Binley1999
• 7B2: The MAbs with the broadest neutralizing activity, IgG1b12, 2G12 and 2F5, all have high affinity for the native trimer, indicating that they were raised
in an immune response to the oligomer on the virion surface rather than dissociated subunits – a disulfide linked gp120-gp41 (SOS gp140) was created to
mimic the native conformation of Env and explore its potential as an immunogen – SOS gp140 is recognized by NAbs IgG1b12, 2G12, and CD4-IgG2, and
also by anti-V3 MAbs 19b and 83.1 – SOSgp140 is not recognized by C4 region MAbs that neutralize only TCLA strains, G3-42 and G3-519 – nor did it
bind C11, 23A, and M90, MAbs that bind to gp120 C1 and C5, where it interacts with gp41 – MAbs that bind CD4 inducible epitopes, 17b and A32 were
very strongly induced by CD4 in SOS gp140 – anti-gp41 MAbs that bind in the region that interacts with gp120, 7B2, 2.2B, T4, T15G1 and 4D4, did not
bind to SOSgp140, in contrast to 2F5, which binds to the only gp41 epitope that is well exposed in native gp120-gp41 complexes [Binley1999]
741 85G11/D8 Env gp120 (SF162) no Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: deglycosylated gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 85G11/D8: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2κ MAbs were used to rapidly create a
panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120—three of the MAbs were conformation dependent, but did
not block sCD4 binding and were part of the same competition group—these MAbs were all raised against a deglycosylated form of gp120—they could not
neutralize autologous SF162 and bound some R5 and X4 B clade viruses, and no E clade viruses [He2002].
742 87E4/A8 Env gp120 (SF162) no Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: deglycosylated gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 87E4/A8: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2κ MAbs were used to rapidly create a
panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120—three of the MAbs were conformation dependent, but did
not block sCD4 binding and were part of the same competition group—these MAbs were all raised against a deglycosylated form of gp120—they could not
neutralize autologous SF162 and bound some R5 and X4 B clade viruses, and no E clade viruses [He2002].
743 97B1/E8 Env gp120 (SF162) no Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: deglycosylated gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
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References He2002
• 97B1/E8: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2κ MAbs were used to rapidly create a
panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120—three of the MAbs were conformation dependent, but did
not block sCD4 binding and were part of the same competition group—these MAbs were all raised against a deglycosylated form of gp120—they could not
neutralize autologous SF162 and bound some R5 and X4 B clade viruses, and no E clade viruses [He2002].
744 A9 Env gp120 (IIIB) Vaccine murine (IgG1)
Vaccine Vector/Type: chimeric GM-CSF Strain: IIIB HIV component: gp120 Adjuvant: GM-CSF
References delReal1999
• A9: Murine antibody response to the chimeric construction granulocyte-macrophage colony stimulating factor GM-CSF/gp120 was tested, MAbs from
normal mice were gp120 specific, MAbs from nude mice bound gp120 but were polyreactive, and from reconstituted mice were half way between – the
anti-gp120 response used a high frequency of VH81X, VHQ52, and VH7183 genes, a family used during fetal life and associated with autoimmunity – A9
was a gp120 from a BALBc reconstructed nude mouse and had VH gene 7183-2 [delReal1999]
745 B4 Env gp120 (IIIB) Vaccine murine (IgM)
Vaccine Vector/Type: chimeric GM-CSF Strain: IIIB HIV component: gp120
References delReal1999
• B4: Murine antibody response to the chimeric construction granulocyte-macrophage colony stimulating factor GM-CSF/gp120 was tested, MAbs from
normal mice were gp120 specific, MAbs from nude mice bound gp120 but were polyreactive, and from reconstituted mice were half way between – the
anti-gp120 response used a high frequency of VH81X, VHQ52, and VH7183 genes, a family used during fetal life and associated with autoimmunity – B4
was an anti-gp120 from a BALBc reconstructed nude mouse and had VH gene J606 [delReal1999]
746 B5 Env gp120 (IIIB) Vaccine murine (IgG1)
Vaccine Vector/Type: chimeric GM-CSF Strain: IIIB HIV component: gp120 Adjuvant: GM-CSF
References delReal1999
• B5: Murine antibody response to the chimeric construction granulocyte-macrophage colony stimulating factor GM-CSF/gp120 was tested, MAbs from
normal mice were gp120 specific, MAbs from nude mice bound gp120 but were polyreactive, and from reconstituted mice were half way between – the
anti-gp120 response used a high frequency of VH81X, VHQ52, and VH7183 genes, a family used during fetal life and associated with autoimmunity – B5
was a gp120 specific MAb from a BALBc mouse and had VH gene J558 [delReal1999]
747 B6 Env gp120 (IIIB) Vaccine murine (IgM)
Vaccine Vector/Type: chimeric GM-CSF Strain: IIIB HIV component: gp120
References delReal1999
• B6: Murine antibody response to the chimeric construction granulocyte-macrophage colony stimulating factor GM-CSF/gp120 was tested, MAbs from
normal mice were gp120 specific, MAbs from nude mice bound gp120 but were polyreactive, and from reconstituted mice were half way between – the
anti-gp120 response used a high frequency of VH81X, VHQ52, and VH7183 genes, a family used during fetal life and associated with autoimmunity – B6
was a gp120 from a BALBc reconstructed nude mouse and had VH gene J558 [delReal1999]
748 BAT267 Env gp120 L Vaccine murine (IgG1)
Vaccine Vector/Type: inactivated virus Strain: IIIB HIV component: virus
References Fung1987
749 BAT401 Env gp120 L Vaccine murine (IgG1)
Vaccine Vector/Type: inactivated virus Strain: IIIB HIV component: virus
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References Fung1987
750 BAT509 Env gp120 L Vaccine murine (IgG1)
Vaccine Vector/Type: inactivated virus Strain: IIIB HIV component: virus
References Fung1987
751 C31 Env gp120 no HIV-1 infection human (IgG1κ)
References Boyer1991
• C31: Broadly-reactive group specific MAb – high yield cultivation of human MAb [Boyer1991]
752 D1 Env gp41 (IIIB) Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
References Otteken1996
• D1: MAbs D1, D16, had T37 bind to oligomeric gp160 equally well – pulse label experiments of MAb binding to noncleavable gp160 revealed that these
MAbs bound with a delay, epitopes forming with a half life of 30 min [Otteken1996]
753 D12 Env gp41 (IIIB) L Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
Donor Patricia Earl and Christopher Broder, NIH
References Earl1994, Broder1994, Richardson1996, Earl1997, Otteken1996, LaBranche1999
• D12: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• D12: One of 18 MAbs (e. g. D4 and D40) that bind to a conformation-dependent epitope in gp41 that bind preferentially, but not exclusively, to oligomers –
neutralizes IIIB and SF2 [Broder1994]
• D12: This antibody was blocked more strongly by human sera than other anti-gp41 MAbs (D20, D43, D61, and T4) in a oligomeric ELISA assay
[Richardson1996]
• D12: MAbs D10 and D12 are very easily blocked by human sera from HIV+ individuals [Earl1997]
• D12: MAbs D4, D10, D11, D12, and D41 all bind only to complete oligomer – pulse label experiments of MAb binding to noncleavable gp160 revealed
that these MAbs bound with a delay, epitopes forming with a half life of 30 min [Otteken1996]
• D12: D12 was used in WB of HIV-1 transmembrane proteins in a study which showed that determinants of HIV-1 CD4 independence map outside regions
required for coreceptor specificity – IIIBx, a CD4-independent variant of IIIB, has a truncated gp41 [LaBranche1999]
• D12: A combination of gp41 fusion with the GNC4 trimeric sequences and disruption of the YU2 gp120-gp41 cleavage site resulted in stable gp140 trimers
(gp140-GNC4) – gp41 MAbs T4, D12, T3, and D50 bound less efficiently to gp140-GNC4 than did pooled sera, but T4 and D12 recognized the
gp140-GNC4 timer equivalently to gp140(-), and T3 and D50 recognized the trimer at greater levels than gp140(-) [Yang2000]
754 D16 Env gp41 (IIIB) L Vaccine murine (IgG)
Vaccine Vector/Type: protein HIV component: dimeric Env
Donor Patricia Earl and Christopher Broder, NIH
References Earl1994, Weissenhorn1996, Earl1997
• D16: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• D16: Precipitates both oligomeric gp140 and soluble monomeric gp41(21-166)that lacks the fusion peptide and membrane anchor, along with MAbs D16,
D38, D40, D41, and D54 [Weissenhorn1996]
• D16: One of eleven MAbs (D16, D17, D31, D36, D37, D40, D44, D55, D59, T37, and T45) that are conformation dependent and that can block the binding
of the MAb D50 that binds to the linear peptide gp41(642-665) – reactive with 9/10 HIV-1 strains all except HIV-1 ADA, which has the change E659D and
E662A that may result in the loss of binding (ELLE to DLLA) [Earl1997]
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755 D4 Env gp120 (IIIB) Vaccine murine (IgG1)
Vaccine Vector/Type: chimeric GM-CSF Strain: IIIB HIV component: gp120
References delReal1999
• D4: Murine antibody response to the chimeric construction granulocyte-macrophage colony stimulating factor GM-CSF/gp120 was tested, MAbs from
normal mice were gp120 specific, MAbs from nude mice bound gp120 but were polyreactive, and from reconstituted mice were half way between – the
anti-gp120 response used a high frequency of VH81X, VHQ52, and VH7183 genes, a family used during fetal life and associated with autoimmunity – D4
was a gp120 from a BALBc reconstructed nude mouse and had VH gene J558 [delReal1999]
756 D43 Env gp41 (HXB2) Vaccine murine (IgG)
Vaccine Vector/Type: protein HIV component: dimeric Env
Donor Patricia Earl and Christopher Broder, NIH
References Earl1994, Richardson1996, Earl1997
• D43: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• D43: This is a linear gp41 epitope, mapping in the region 635-678 – human sera blocked binding in oligomeric ELISA assay to a similar extent for gp41
MAbs D20, D43, D61, and T4 [Richardson1996]
• D43: Partially conformation dependent – doesn’t bind to short peptides, but does bind to the region spanning 641-683 – binding can be blocked by MAbs
T3, D38 and D45 – MAbs in this competition group reacted with 9/10 HIV-1 strains, not binding to JRFL [Earl1997]
757 F223 Env gp120 no HIV-1 infection human (IgG3λ )
References Cavacini1999
• F223: binds to HIV-1 gp120 and to uninfected lymphocytes binding to a 159-kd auto-antigen expressed on most B cells and a small fraction of T and NK
cells – the antibody enhances HIV-1 infection in a complement-dependent manner – F223 light chains have a strong homology with VLgamma2, the heavy
chain to the germline gene VH3-H.11 – N-linked carbohydrates are key for recognition of both gp120 and the autoantigen – MAb 3D6 also uses VH3 and
has autoreactivity [Cavacini1999]
758 F285 Env Env HIV-1 infection human (IgG1)
ReferencesWisnewski1995, Wisnewski1996
• F285: F285 is V H1 – V-region heavy chain usage was examined and a bias of enhanced V H1 and V H4, and reduced V H3, was noted among HIV
infected individuals [Wisnewski1996]
759 F7 Env gp120 (IIIB) Vaccine murine (IgG1)
Vaccine Vector/Type: chimeric GM-CSF Strain: IIIB HIV component: gp120 Adjuvant: GM-CSF
References delReal1999
• F7: Murine antibody response to the chimeric construction granulocyte-macrophage colony stimulating factor GM-CSF/gp120 was tested, MAbs from
normal mice were gp120 specific, MAbs from nude mice bound gp120 but were polyreactive, and from reconstituted mice were half way between – the
anti-gp120 response used a high frequency of VH81X, VHQ52, and VH7183 genes, a family used during fetal life and associated with autoimmunity – F7
was a gp120 specific MAb from a BALBc mouse and had VH gene 7183(81X), previously found expressed only in fetal liver [delReal1999]
760 Fab A12 Env gp41 (LAI) no HIV-1 infection human (IgG1κ)
References Binley1996
• Fab A12: Uncharacterized epitope – variable regions sequenced [Binley1996]
761 Fab A2 Env gp41 (LAI) no HIV-1 infection human (IgG1λ )
References Binley1996
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• Fab A2: Uncharacterized epitope – variable regions sequenced [Binley1996]
762 Fab L9 Env gp41 (LAI) no HIV-1 infection human (IgG1κ)
References Binley1996
• Fab L9: Uncharacterized epitope – variable regions sequenced [Binley1996]
763 G12 Env gp120 (IIIB) Vaccine murine (IgM)
Vaccine Vector/Type: chimeric GM-CSF Strain: IIIB HIV component: gp120
References delReal1999
• G12: Murine antibody response to the chimeric construction granulocyte-macrophage colony stimulating factor GM-CSF/gp120 was tested, MAbs from
normal mice were gp120 specific, MAbs from nude mice bound gp120 but were polyreactive, and from reconstituted mice were half way between – the
anti-gp120 response used a high frequency of VH81X, VHQ52, and VH7183 genes, a family used during fetal life and associated with autoimmunity – G12
was a gp120 from a BALBc reconstructed nude mouse and had VH gene 7183-6 [delReal1999]
764 G2 Env gp120 (IIIB) Vaccine murine (IgM)
Vaccine Vector/Type: chimeric GM-CSF Strain: IIIB HIV component: gp120
References delReal1999
• G2: Murine antibody response to the chimeric construction granulocyte-macrophage colony stimulating factor GM-CSF/gp120 was tested, MAbs from
normal mice were gp120 specific, MAbs from nude mice bound gp120 but were polyreactive, and from reconstituted mice were half way between – the
anti-gp120 response used a high frequency of VH81X, VHQ52, and VH7183 genes, a family used during fetal life and associated with autoimmunity – G2
was a gp120 from a BALBc reconstructed nude mouse and had VH gene Q52 [delReal1999]
765 H2 Env gp41 human (IgMκ)
Donor BioInvent, Lund, Sweden, commercial
ReferencesMuller1991
• H2: Anti-idiotypic MAbs (10B3 and 2All) against MAb H2 were generated by immunization of BALBc mice with H2 – they also react with seropositive
sera [Muller1991]
766 H8 Env gp120 (IIIB) Vaccine murine (IgM)
Vaccine Vector/Type: chimeric GM-CSF Strain: IIIB HIV component: gp120
References delReal1999
• H8: Murine antibody response to the chimeric construction granulocyte-macrophage colony stimulating factor GM-CSF/gp120 was tested, MAbs from
normal mice were gp120 specific, MAbs from nude mice bound gp120 but were polyreactive, and from reconstituted mice were half way between – the
anti-gp120 response used a high frequency of VH81X, VHQ52, and VH7183 genes, a family used during fetal life and associated with autoimmunity – H8
was a gp120 from a BALBc reconstructed nude mouse and had VH gene Q52 [delReal1999]
767 HBW4 Env gp120 (IIIB) HIV-1 infection human (IgG1λ )
ReferencesMoran1993, Wisnewski1995, Wisnewski1996
• HBW4: Heavy (V HII) and light (V lambdaII) chain sequenced [Moran1993]
• HBW4: HBW4 is V H2 – V-region heavy chain usage was examined and a bias of enhanced V H1 and V H4, and reduced V H3, was noted among HIV
infected individuals [Wisnewski1996]
768 HIVIG Env gp120 P HIV-1 infection human
References Nichols2002
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• NYBC-HIVIG derived from patients with high NAb titers and NABI-HIVIG derived from patients with high anti-p24 Ab titers were compared in
neutralizing assay against a panel of six primary isolates – both could neutralize all isolates tested but the NYBC-HIVIG dose required for 50%
neutralization was of 3.2 fold lower, showing source plasmas influence the effective concentration of NAb present in HIVIG [Nichols2002]
769 IVI-4G6 Env gp41 Vaccine murine (IgG2b)
Donor K. Miyakoshi (Feji-Rebio Co, Tokyo, Japan)
References Yin2001
• IVI-4G6: A bi-specific Ab (BFA) was made by combining Fab fragments of gp41-specific MAb IVI-4G6 and CD3-specific Mab UCHT1 – the BFA
suppressed HIV-1 propagation culture and eliminated latently infected cells [Yin2001]
770 K14 Env gp41 no human (IgG1)
References Teeuwsen1990, Schutten1995a, Schutten1995b, Schutten1996, Schutten1997
• K14: Did not bind to peptides spanning gp41, but it does not react with Env deletion mutant 643-692 – does not react with HIV-2 – competition experiments
showed this was an immunodominant conserved epitope in HIV-1 positive sera from Europe and Africa [Teeuwsen1990]
• K14: Reduced affinity for both SI and NSI viruses relative to MAb MN215, failed to neutralize SI strain [Schutten1995b]
• K14: In a study of NSI and SI virus neutralization, K14 did not influence viral entry [Schutten1997]
771 M25 Env gp41 Vaccine murine (IgGκ)
Vaccine Vector/Type: purified HIV-1
References diMarzo Veronese1985, Watkins1996
• M25: heavy and light chains cloned and sequenced – binding requires heavy and light chain in combination, in contrast to M77 [Watkins1996]
772 MAG 6B Env gp120 no Vaccine murine
Vaccine Vector/Type: sCD4-gp120 complex Strain: HXB2 HIV component: gp120
Donor C. Y. Kang, IDEC Inc
References Kang1994
• MAG 6B: Amino acid substitutions that reduce binding 10 fold: 256 S/Y, 257 T/R or G or A, 262 N/T, 368 D/R or T, 370 E/R or Q, 381 E/P, 384 Y/E, 421
K/L, 475 M/S, 477 D/V [Kang1994]
773 MO28 Env gp41 no in vitro stimulation human (IgM)
References Ohlin1989
• MO28: This antibody was raised by in vitro stimulation with a recombinant Env penv9 – the discontinuous epitope involves hydrophobic regions 632-646,
677-681 and 687-691, proximal to and spanning the transmembrane region – this specificity is unusual in HIV-1 positive sera [Ohlin1989]
774 MO30 Env gp41 no in vitro stimulation human (IgM)
References Ohlin1989
• MO30: This antibody was raised by in vitro stimulation with a recombinant Env penv9 – the discontinuous epitope involves hydrophobic regions 632-646,
677-681 and 687-691, proximal to and spanning the transmembrane region – this specificity is unusual in HIV-1 positive sera [Ohlin1989]
775 MO43 Env gp41 no in vitro stimulation human (IgM)
References Ohlin1989
• MO43: This antibody was raised by in vitro stimulation with a recombinant Env penv9 – the discontinuous epitope of MO43 involves hydrophobic regions
632-646, 677-681 and 687-691, proximal to and spanning the transmembrane region – this specificity is unusual in HIV-1 positive sera [Ohlin1989]
776 N2-4 Env gp41 no HIV-1 infection human (IgG1κ)
Donor Evan Hersh and Yoh-Ichi Matsumoto
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References Robinson1990b
• N2-4: No enhancing activity for HIV-1 IIIB [Robinson1990b]
• N2-4: NIH AIDS Research and Reference Reagent Program: 528
777 N70-2.3a Env gp120 (dis) no HIV-1 infection human (IgG1)
Donor James Robinson, Tulane University, LA
References Robinson1990a, Takeda1992
• N70-2.3a: Broad reactivity [Robinson1990a]
• N70-2.3a: Fc receptor mediated enhancement of HIV-1 infection – binds a conformational site in the carboxyl half of gp120, distinct from 1.5e
[Takeda1992]
778 P43110 Env gp120
Donor Advanced Biosciences (Kensington, MD)
References diMarzo Veronese1992, VanCott1995
• P43110: Does not recognized denatured form of the gp120 protein [VanCott1995]
779 P5-3 Env gp120 HIV-1 infection human (IgG1λ )
Donor Evan Hersh and Yoh-Ichi Matsumoto
References Robinson1990b, Pincus1991
• P5-3: No enhancing activity for HIV-1 IIIB [Robinson1990b]
• P5-3: Poor immunotoxin activity when coupled to RAC – isotype specified as: IgG3lambda [Pincus1991]
• P5-3: NIH AIDS Research and Reference Reagent Program: 378
780 T15G1 Env gp41 no
References Binley1999
• T15G1: The MAbs with the broadest neutralizing activity, IgG1b12, 2G12 and 2F5, all have high affinity for the native trimer, indicating that they were
raised in an immune response to the oligomer on the virion surface rather than dissociated subunits – a disulfide linked gp120-gp41 (SOS gp140) was
created to mimic the native conformation of Env and explore its potential as an immunogen – SOS gp140 is recognized by NAbs IgG1b12, 2G12, and
CD4-IgG2, and also by anti-V3 MAbs 19b and 83.1 – SOSgp140 is not recognized by C4 region MAbs that neutralize only TCLA strains, G3-42 and
G3-519 – nor did it bind C11, 23A, and M90, MAbs that bind to gp120 C1 and C5, where it interacts with gp41 – MAbs that bind CD4 inducible epitopes,
17b and A32 were very strongly induced by CD4 in SOS gp140 – anti-gp41 MAbs that bind in the region that interacts with gp120, 7B2, 2.2B, T4, T15G1
and 4D4, did not bind to SOSgp140, in contrast to 2F5, which binds to the only gp41 epitope that is well exposed in native gp120-gp41 complexes
[Binley1999]
781 T20 Env gp120 (IIIB) no Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
Donor P. Earl, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
References Earl1994, Otteken1996, Sugiura1999
• T20: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• T20: Pulse label experiments of 4 MAbs (D20, D27, T20, and T22) binding to noncleavable gp140 revealed that these anti-CD4BS MAbs bound with a
delay, and that the epitope formed with a t 1/2 of about 10 minutes [Otteken1996]
• T20: A comparison of 25 gp120 specific, conformation dependent MAbs was done – T20 is part of a group of MAbs labeled AII – all AII MAbs were
broadly cross-reactive with gp160 from B-clade R5, X4, and R5X4 viruses, and could only partially blocked CD4 binding [Sugiura1999]
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782 T27 Env gp120 (IIIB) no Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
Donor P. Earl, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
References Earl1994, Sugiura1999
• T27: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• T27: A comparison of 25 gp120 specific, conformation dependent MAbs was done – T27 is part of a group of MAbs labeled AII – all AII MAbs were
broadly cross-reactive with gp160 from B-clade R5, X4, and R5X4 viruses, and could only partially blocked CD4 binding [Sugiura1999]
783 T3 Env gp41 (HXB2) Vaccine murine (IgG)
Vaccine Vector/Type: tetrameric Env HIV component: Env
References Earl1994, Earl1997, Zwick2001b, Yang2000
• T3: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• T3: Partially conformation dependent – doesn’t bind to short peptides, but does bind to the region spanning 641-683 – binding can be blocked by MAbs
D43, D38 and D45 – MAbs in this competition group reacted with 9/10 HIV-1 strains, not binding to JRFL [Earl1997]
• T3: T3 partially competes with MAb Z13, but not MAb 4E10, both of which bind to gp41 proximally to the 2F5 epitope and have a broad neutralizing
potential [Zwick2001b]
• T3: A combination of gp41 fusion with the GNC4 trimeric sequences and disruption of the YU2 gp120-gp41 cleavage site resulted in stable gp140 trimers
(gp140-GNC4) – gp41 MAbs T4, D12, T3, and D50 bound less efficiently to gp140-GNC4 than did pooled sera, but T4 and D12 recognized the
gp140-GNC4 timer equivalently to gp140(-), and T3 and D50 recognized the trimer at greater levels than gp140(-) [Yang2000]
784 T30 Env gp41 no Vaccine murine
Vaccine Vector/Type: tetrameric Env HIV component: Env
References Earl1994, Earl1997
• T30: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• T30: Binds in the region 580 to 640, but does not bind to peptides spanning this region – binding depends on N-linked glycosylation of Asn 616 – no other
antibody tested inhibited binding, but binding could be inhibited by sera from HIV+ individuals [Earl1997]
785 T4 Env gp41 (IIIB) L Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
References Earl1994, Broder1994, Richardson1996, Weissenhorn1996, Otteken1996, Earl1997, Binley1999, Stamatatos2000, Yang2000, Srivastava2002
• T4: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• T4: one of five MAbs (T4, T6, T9, T10 and T35) in a competition group that bind to a conformation-dependent epitope in gp41 and is oligomer specific –
neutralizes IIIB and SF2 [Broder1994]
• T4: Does not bind to soluble monomeric gp41(21-166) that lacks the fusion peptide and membrane anchor, only to the oligomer gp140, as does T6
[Weissenhorn1996]
• T4: MAbs T4 and T6 bind only to oligomer, and pulse chase experiments indicate that the epitope is very slow to form, requiring one to two hours
[Otteken1996]
• T4: This antibody, along with 7 others (M10, D41, D54, T6, T9, T10 and T35), can block the linear murine MAb D61, and the human MAb 246-D, which
both bind to the immunodominant region near the two Cys in gp41 – most of these antibodies are oligomer dependent – all of the MAbs are reactive with
ten different HIV-1 strains – members of this competition group are blocked by sera from HIV-1+ individuals [Earl1997]
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• T4: The MAbs with the broadest neutralizing activity, IgG1b12, 2G12 and 2F5, all have high affinity for the native trimer, indicating that they were raised in
an immune response to the oligomer on the virion surface rather than dissociated subunits – a disulfide linked gp120-gp41 (SOS gp140) was created to
mimic the native conformation of Env and explore its potential as an immunogen – SOS gp140 is recognized by NAbs IgG1b12, 2G12, and CD4-IgG2, and
also by anti-V3 MAbs 19b and 83.1 – SOSgp140 is not recognized by C4 region MAbs that neutralize only TCLA strains, G3-42 and G3-519 – nor did it
bind C11, 23A, and M90, MAbs that bind to gp120 C1 and C5, where it interacts with gp41 – MAbs that bind CD4 inducible epitopes, 17b and A32 were
very strongly induced by CD4 in SOS gp140 – anti-gp41 MAbs that bind in the region that interacts with gp120, 7B2, 2.2B, T4, T15G1 and 4D4, did not
bind to SOSgp140, in contrast to 2F5, which binds to the only gp41 epitope that is well exposed in native gp120-gp41 complexes [Binley1999]
• T4: Soluble gp140 derived from SF162, a neutralization-resistant primary isolate, and SF162AV2 a neutralization-susceptible isolate with 30 amino acids
deleted from the V2 loop, were generated with or without the gp120-gp41 cleavage site intact – all forms are recognized by oligomer-specific MAb T4 and
show enhanced binding of CD4i MAb 17b when sCD4 is bound – the fused forms are less efficiently recognized than the cleaved forms by polyclonal
neutralizing sera from HIV-infected patients – the V3 loop is more exposed on the fused form [Stamatatos2000]
• T4: A combination of gp41 fusion with the GNC4 trimeric sequences and disruption of the YU2 gp120-gp41 cleavage site resulted in stable gp140 trimers
(gp140-GNC4) – gp41 MAbs T4, D12, T3, and D50 bound less efficiently to gp140-GNC4 than did pooled sera, but T4 and D12 recognized the
gp140-GNC4 timer equivalently to gp140(-), and T3 and D50 recognized the trimer at greater levels than gp140(-) [Yang2000]
• T4: Oligomeric gp140 (o-gp140) derived from R5 primary isolate US4 was characterized for use as a vaccine reagent – antigen capture ELISA was used to
compare the antigenicity of gp120 and o-gp140 using a panel of well characterized MAbs – T4 recognized o-gp140 [Srivastava2002]
786 multiple Fabs Env gp120 HIV-1 infection human
References Burton1991
• A panel of anti-gp120 Fabs was generated by antigen selection from a random combinatorial library prepared from bone marrow from an asymptomatic
individual [Burton1991]
787 multiple
MAbs
Env gp120 Vaccine murine
Vaccine Vector/Type: protein HIV component: gp120
References Denisova1996
• When gp120 was used as an immunogen, in contrast to gp120 bound to an anti-V3 MAb, few MAbs were generated and all bound better to the native than
to the denatured protein – MAbs generated were: G1B12, G2F7, G9G8, G12F12, G1B8, G11F11, G9E8, G1B11, G1B6, G6F2, G2E7 [Denisova1996]
788 multiple
MAbs
Env gp120 Vaccine murine
Vaccine Vector/Type: gp120-CD4 complex HIV component: gp120
References Denisova1996
• When gp120-CD4 was used as an immunogen, in contrast to gp120 bound to an anti-V3 MAb, few MAbs were generated and all bound better to the native
than to the denatured protein – MAbs generated were: CG43, CG41, CG49, CG53, CG42, CG4, CG46, CG40, CG52, CG51, CG48, CG50, CG125,
CG124, CG121 [Denisova1996]
789 multiple
MAbs
Env gp120 Vaccine murine
Vaccine Vector/Type: protein-Ab complex HIV component: gp120 complexed with MAb M77
References Denisova1996
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• When anti-V3 MAb M77 was bound to gp120 and used as an immunogen, it stimulated many MAbs to linear epitopes, as well as an array of MAbs to
discontinuous epitope – 10 of 36 MAbs were mapped to linear epitopes and are mentioned elsewhere in this database, the others are: GV5H1, GV4D5,
GV4G10, GV1A8, GV10H5, GV8E11, GV2H4, GV6E6, GV1F7, GV1G9, GV4G5, GV6B12, GV1E8, GV2B7, GV1B11, GV6H5, GV6G2, GV6B5,
GV1E10, GV5E3, GV5B9, GV5F4, GV6G4, GV1A12, GV5C11, GV6B6, GV3C10 [Denisova1996]
790 polyclonal Env Env L P HIV-1 infection human (IgG3)
References Scharf2001
• IgG3: HIVIG was separated into immunoglobulin classes and IgG3 neutralization of HIV strains X4, R5 and X4R5 strains was superior to IgG1 and IgG2,
and IgG3 was also a more potent inhibitor of viral fusion – the IgG3 advantage was lost when only Fabs were considered, indicating the IgG3 neutralization
efficacy is enhanced due to a longer hinge region of the heavy chain in comparison to IgG1 and IgG2 [Scharf2001]
791 polyclonal Env gp140 (IIIB) L Vaccine rabbit (IgG)
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: gp140, gp120 Adjuvant: MPL-SE adjuvant, QS21 adjuvant
References Earl2001
• Immunization of rabbits with oligomeric gp140 induced production of higher levels of cross-reactive neutralizing Abs than immunization with gp120 –
immunization of Rhesus macaques with gp140 yielded strong NAb against IIIB, modest against other lab-adapted strains, and no NAb activity against
primary isolates – most neutralizing activity could not be blocked by a V3 peptide – 3/4 vaccinated macaques showed no viral replication upon intravenous
challenge with SHIV-HXB2 [Earl2001]
792 polyclonal Env gp160 (IIIB) HIV-1 infection, Vaccine human
Vaccine Vector/Type: recombinant protein Strain: NL43 HIV component: gp160 Adjuvant: alum
References Cox1999
• 60 asymptomatic HIV-1 infected patients were vaccinated with rec gp160 in alum, produced in a baculovirus expression vector in insect cells (VaxSyn), 64
received placebo, and all were followed in a 5 year longitudinal study – a mean of 78% of vaccinated and 82% of those receiving placebo had demonstrable
ADCC at the different time intervals in the study, and the vaccine did not enhance ADCC production – patients with rapid and slow disease progression
showed similar ADCC levels [Cox1999]
793 polyclonal Env gp160 (89.6) yes Vaccine Rhesus macaque
Vaccine Vector/Type: modified vaccinia Ankara Strain: 89.6 HIV component: SIVmac239 Gag/Pol and HIV-1 89.6P Env Adjuvant: IL2/Ig
References Barouch2001b
• Four rhesus macaques were vaccinated with a modified vaccinia Ankara (MVA) vaccine that elicited strong CTL responses as well as antibody responses.
The animals were infected when challenged with pathogenic SHIV-89.6P, but had potent CTL responses, secondary NAb responses upon challenge, partial
preservation of CD4+ T-cell counts, lower viral loads, and no evidence of disease or mortality by day 168 after challenge—monkeys that got a sham vaccine
had high viral load, progressed to disease, and 2/4 were dead by day 168 [Barouch2001b].
794 polyclonal Env gp160 no HIV-1 infection human
References Ahmad2001
• High CD4+ T-cell count and low viral load was correlated with high ADCC anti-HIV-1 Env Ab titers in a study of 46 HIV-1 infected individuals from all
disease stages [Ahmad2001]
795 polyclonal Env gp160 P HIV-1 infection human (IgG)
References Beirnaert2001
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• Neutralizing antibodies are thought to inhibit HIV entry by blocking either binding or fusion – six broadly cross-neutralizing sera that can neutralize group
M and O viruses inhibit the binding to PBMCs – the nine primary isolates tested in this study represented very diverse subtypes and recombinant forms, and
different co-receptor usage [Beirnaert2001]
796 polyclonal Env gp160 P HIV-1 infection human (IgG)
References Beirnaert2000
• Sera from 66 HIV individuals from diverse geographic locations could neutralize primary isolates to different extents: broad cross-neutralizing isolates
could neutralize 14 primary isolates from HIV-1 group M clades A-H and three O isolates, limited cross-neutralizing sera neutralized some isolates, and
non-neutralizing sera—6/7 broadly neutralizing sera were from African women, despite only 14/66 study subjects being women—ability to neutralize three
key isolates, MN lab (envB/gagB, X4 coreceptor), VI525 (envG/gagH, envA/gagA, R5X4) and CA9 (Group O, R5) was predictive of being able to
neutralize an additional set of 14 primary isolates [Beirnaert2000].
797 polyclonal Env gp120 (SF2) L Vaccine murine, baboon
Vaccine Vector/Type: recombinant protein Strain: SF2 HIV component: gp120 Adjuvant: PLG+MF-59 microparticles
References O’Hagan2000
• Microparticles were used as an adjuvant for entrapped HIV-1 gp120 and induced strong serum IgG responses in mice – polylactide co-glycolide polymer
(PLG) microparticles in combination with MF-59 had the highest response [O’Hagan2000]
798 polyclonal Env gp120 (SF2, US4) Vaccine murine, guinea pig,
macaque
Vaccine Vector/Type: DNA, recombinant protein Strain: SF2, US4 HIV component: gp120 Adjuvant: PLG microparticles, aluminum phosphate,
MF-59
References O’Hagan2001
• DNA vaccines of codon-optimized Env and Gag genes driven by CMV promotors and absorbed on to PLG microparticles were more effective than naked
DNA at eliciting strong Ab responses (more rapid, higher titer, more stable), comparable to gp120 in MF-59 [O’Hagan2001]
799 polyclonal Env gp120 L HIV-1 infection chimpanzee (IgG)
References Shibata1999, Moore1999
• polyclonal: Purified IgG from chimpanzee sera infected with several HIV-1 strains was used for passive administration to macaques which were
subsequently challenged with the virulent SHIV bearing the HIV-1 env DH12 – in vitro neutralization correlated with protection in vivo [Shibata1999]
• polyclonal: Commentary discussing this finding noting the particularly high neutralization titer and limited breadth of the chimpanzee sera used in this
study [Moore1999]
800 polyclonal Env gp160 (MN) L P HIV-1 infection human (IgA)
ReferencesMoja2000
• 15 samples isolated from parotid saliva were selected for study as they had anti-Env IgA – IgA neutralizing activity was detected that was not directed at
either EDELKWA or the V3 loop [Moja2000]
801 polyclonal Env gp120 L Vaccine
Vaccine Vector/Type: recombinant protein Strain: SF2, MN HIV component: gp120
ReferencesMcElrath2000
• After 3 immunizations, 210/241 (87%) HIV-1 uninfected vaccinees in a phase II trial developed NAbs – of 140 patients receiving 4 vaccinations, 53% had
persistent neutralizing antibodies to homologous virus, and 34% to heterologous virus, measured at day 728 after initial immunization – immunogens were
well tolerated– but IVDUs had a decreased Ab response relative to lower risk groups [McElrath2000]
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802 polyclonal Env gp120 Vaccine murine
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: gp120 Adjuvant: GM-CSF/gp120 chimera
References Rodríguez1999
• The murine Ab response to a chimeric of granulocyte-macrophage colony stimulating factor GM-CSF/gp120 in vaccinia was not higher titer that the
response to a gp120-vaccinia construct, but the breadth of the Ab response was greater – a cellular response of greater intensity was trigged to the
GM-CSF/gp120 vaccinia construct, as measured by proliferation and Elispot [Rodríguez1999]
803 polyclonal Env gp120 (YU2) Vaccine murine (IgG)
Vaccine Vector/Type: stabilized Env trimer Strain: YU2, HXBc2 HIV component: Env
Donor Joseph Sodroski, Harvard Medical School
References Yang2001
• Soluble Env trimers were created that were designed to mimic functional Env oligomers – stabilized timers could induce neutralizing antibodies more
effectively than gp120, and Abs to the YU2 trimer were cross-reactive within clade B and could neutralize several primary and TCLA reactive strains – the
stabilized primers did not neutralize primary isolates outside the B clade, from clades C, D, and E – HXBc2 stabilized trimer antigen elicited strong
neutralizing Abs against the homologous isolate HXBc2 TCLA strain, but not against primary isolates [Yang2001]
804 polyclonal Env gp120 (MN) Vaccine human
Vaccine Vector/Type: recombinant protein Strain: MN HIV component: gp120 Adjuvant: QS21, alum
References Evans2001
• Vaccination with QS21 adjuvant and rsgp120 elicited stronger and more sustained neutralizing antibody responses and lymphocyte proliferation with lower
doses of rsgp120 than alum formulations, suggesting QS21 may be a means to reduce the does of soluble protein [Evans2001]
805 polyclonal Env gp120 yes HIV-1 infection human
References Binley2000
• HAART inhibited the development of anti-gp120 Ab when initiated during primary infection and sometimes in patients treated within 2 years of HIV-1
infection – HAART during primary infection usually did not inhibit the development of weak NAb responses against autologous virus – 3/4 patients
intermittently adherent developed high titers of autologous NAbs, largely coincident with brief viremic periods [Binley2000]
806 polyclonal Env gp120 (SIV) yes HIV-1 infection macaque
References Reitter1998
• This study concerned an SIV mutated strain that lacked 4th, 5th and 6th sites for N-linked glycosylation – monkeys infected with the mutant viruses had
increased neutralizing activity in their sera relative to monkeys infected with the parental strain [Reitter1998]
807 polyclonal Env Env yes HIV-1 infection human
References Kim2001
• After HAART reduction of viral load to <400 for three visits over a 12 month interval, 2/11 patients were found to have increased anti-Env Ab binding
titers, and neutralizing Abs titers increased against primary isolates US1, and CM237 – no NAB titer increase was seen to more readily neutralized isolate
BZ167 – this suggests that in certain individuals the control of HIV-1 by HAART may augment immune control of HIV [Kim2001]
808 polyclonal Env Env yes HIV-1 exposed
seronegative
human (IgA)
References Kaul2001b
• Kaul et al. provide a concise summary of the findings concerning the presence of Mucosal IgA in highly exposed, uninfected subjects, arguing for a role in
protection [Kaul2001b]
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809 polyclonal Env gp120 yes Vaccine human
Vaccine Vector/Type: recombinant protein Strain: SF2 HIV component: gp120 Adjuvant: MF-59
References Nitayaphan2000
• A phase I/II trial was conducted in 52 seronegative Thais immunizing with rgp120 SF2 – the vaccine was safe and 39/40 developed NAb responses to the
autologous SF2, while 22/40 were able to cross-neutralize the heterologous strain MN [Nitayaphan2000]
810 polyclonal Env gp120 (SF2) yes Vaccine macaque
Vaccine Vector/Type: recombinant protein Strain: SF2 HIV component: gp120, p24 Adjuvant: ISCOM
References Heeney1998a
• The immune responses induced in Rhesus monkeys using two different immunization strategies was studied – one vaccine group was completely protected
from challenge infection, the other vaccinees and controls became infected – protected animals had high titers of heterologous NAbs, and HIV-1-specific T
helper responses – increases in RANTES, MIP 1 alpha and MIP 1 beta produced by circulating CD8+ T cells were also associated with protection
[Heeney1998a]
811 polyclonal Env gp120 Vaccine macaque
Vaccine Vector/Type: peptide, recombinant protein Strain: SF2, SF33 HIV component: gp120 Adjuvant: ISCOM, MF-59
References Verschoor1999
• Attempts were made to broaden immune responses induced in Rhesus monkeys by immunization of animals previously immunized that had resisted
homologous challenge, with a second immunization with ISCOM-peptides or a boost with gp120 from SF33 – animals didn’t survive a second challenge
heterologous challenge virus SHIV(SF33) raising concerns about early antigenic sin [Verschoor1999]
812 polyclonal Env gp120 yes Vaccine baboon
Vaccine Vector/Type: recombinant protein Strain: SF2 (subtype B), CM235 (CRF01) HIV component: gp120 Adjuvant: MF-59
References VanCott1999
• Immunization with rgp120 CM235 (CRF01) induced Abs capable of neutralizing TCLA subtype E (CRF01) and subtype B isolates, while rgp120SF2
induced Abs could only neutralize subtype B TCLA isolates – neither immunogen induced Abs capable of neutralizing primary HIV-1 isolates – both
rgp120CM235 and rgp120SF2 induced Abs to regions within C1, V1/V2, V3, and C5, but unique responses were induced by rgp120CM235 to epitopes
within C2, and by rgp120SF2 to multiple epitopes within C3, V4, and C4 – CM235 baboon sera bound 3- to 12-fold more strongly than the SF2 baboon sera
to all subtype E gp120s while binding to subtype B gp120s (except SF2) were within two to threefold for the SF2 and CM235 baboon sera [VanCott1999]
813 polyclonal Env gp140 (SF162DeltaV2) yes Vaccine rabbit, Rhesus
macaque (IgG)
Vaccine Vector/Type: DNA with CMV promotor Strain: SF162, SF162∆V2 HIV component: gp140 Adjuvant: MF-59C
References Barnett2001
• SF162∆V2 is a virus that has a 30 amino acids deletion in the V2 loop that does not abrogate its infectivity but renders it highly susceptible to
neutralization—when incorporated into a codon-optimized DNA vaccine with a CMV promoter and delivered by gene gun, SF162∆V2 gave higher
neutralizing Ab titers against SF162 than did SF162 itself, and Abs that cross-neutralized non-homologous primary isolates were obtained only when
SF162∆V2, but not intact SF162, was used as the immunogen—Control MAbs 2F5 and 2G12 could neutralize all of the following primary isolates:
91US056(R5), 92US714(R5), 92US660(R5), 92HT593(R5X4), and BZ167(R5X4), while after the first protein boost, the sera from two SF162∆V2
immunized macaques could neutralize 91US056(R5), 92US714(R5), 92US660(R5) and ADA(R5), but not 92HT593(R5X4) or 92US657(R5)—the pattern
of cross-recognition shifted after the second boost [Barnett2001].
814 polyclonal Env gp120 HIV-1 infection human (IgG)
References Binley1997b
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• Retention of anti-Env antibodies and loss of anti-Gag antibodies during progression was studied, and suggested to be the result of the loss of T-cell help and
the unique ability of Env to stimulate B cells even in a backdrop of declining CD4 cells, because of the ability of Env to bind to the CD4 molecule
[Binley1997b]
815 polyclonal Env gp120 (W61D) L Vaccine human
Vaccine Vector/Type: recombinant protein Strain: W61D HIV component: gp120
References Beddows1999
• rgp120 derived from a R5X4 subtype B virus, HIV-1 W61D, was used to vaccinate healthy volunteers and the resulting sera were compared with HIV-1
positive subjects – vaccinee sera had more potent responses to linear V1/V2 and V3 epitopes than did the sera from HIV-1+ individuals, but could only
neutralize homologous or heterologous virus only after adaptation to T-cell lines – neutralization activity was lost after re-adaptation to growth in PBMCs –
in contrast, sera from infected individuals could neutralize both PBMC and T-cell line adapted viruses [Beddows1999]
816 polyclonal Env gp120 L Vaccine Rhesus macaque
Vaccine Vector/Type: virus-like particle HIV component: Pr55gag, anchored gp120, V3+CD4 linear domains
ReferencesWagner1998b
• A VLP is a non-infectious virus-like particle self-assembled from HIV Pr55 gag – macaques were immunized with VLPs bound to either gp120 or V3+CD4
linear domains – Gag and Env specific CTL were stimulated in each case, and Ab response to gag and gp120 and was elicited, but the gp120 neutralizing
response occurred only with whole gp120, not V3+CD4 – despite the CTL and Ab response, immunized macaques were infected by intervenous challenge
with SHIV chimeric challenge stock [Wagner1998b]
817 polyclonal Env gp120 (IIIB) Vaccine murine
Vaccine Vector/Type: DNA HIV component: gp120, gp160
References Shiver1997
• DNA vaccinations of BALBc mice with a gp120 or gp160 DNA vaccine elicited a strong T cell proliferative response with Th1-like secretion of gamma
interferon and IL-2, with little or no IL-4, as well as antigen specific gp120 Abs [Shiver1997]
818 polyclonal Env gp120 L Vaccine murine
Vaccine Vector/Type: DNA HIV component: Gag, Pol, Vif, Env Adjuvant: B7, IL-12
References Kim1997b
• A gag/pol, vif or CMN160 DNA vaccine, when delivered in conjunction with the plasmid encoding the co-stimulatory molecules B7 and IL-12, gave a
dramatic increase in both the cytotoxic and proliferative responses in mice – the Ab response was detected by ELISA, but the CMN160 DNA vaccinated
mice showed a neutralizing Ab response [Kim1997b]
819 polyclonal Env gp120 P HIV-1 infection human
References Bradney1999
• Sera were taken from long term non-progressors and evidence for viral escape was noted – serum could neutralize earlier autologous isolates, but not
contemporary isolates [Bradney1999]
820 polyclonal Env gp120 L P Vaccine human
Vaccine Vector/Type: canarypox prime with rgp120 boost Strain: SF2 HIV component: Gag and Env
References Belshe1998
• NAbs were obtained by a HIV-1 gag/env in canary pox vaccination of eight volunteers after boosting with rgp120 against lab strains – 1/8 primary isolates
was neutralized, BZ167[Belshe1998]
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821 polyclonal Env gp120 L Vaccine human
Vaccine Vector/Type: canarypox prime with rgp120 boost Strain: LAI, MN, SF2 HIV component: Gag, Protease, and gp120 Adjuvant: MF-59
References Belshe2001
• A phase 2 trial was conducted in 435 volunteers with vCP201, a canary pox vector carrying gp120 (MN in vCP201, and SF2 in the boost), p55 (LAI) and
protease (LAI), either alone or with a gp120 boost – NAbs against MN were obtained in 56% of those who received vCP201 alone, and in 94% of those
who got the prime with the gp120 boost [Belshe1998]
822 polyclonal Env gp120 human (Ig V_H3)
References Neshat2000
• HIV-1 gp120 appears to be a B cell superantigen that binds to members of the V_H3 Ig gene family—the gp120 binding site was localized to the Fab
portion of the Ab, and discontinuous residues in the V_H region were critical [Neshat2000].
823 polyclonal Env gp41 (539–684 BH10) Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein HIV component: gp41
References Bai2000
• Murine rsgp41 antisera recognized a common epitope on human IFNα (aa 29-35 and aa 123-140) and on human IFNβ (aa 31-37 and aa 125-142),
suggesting that elevated levels of Ab to IFNs found in HIV+ individuals may be due to a cross-reactive gp41 response [Bai2000].
824 polyclonal Env gp120 (BH10) Vaccine murine (IgG)
Vaccine Vector/Type: DNA Strain: ADA, IIIB, 89.6 HIV component: gp120 Adjuvant: C3d fusion
References Ross2001
• gp120 was fused with murine complement protein C3d in a DNA vaccine to enhance the titers of Ab to Env – fusion to C3d resulted in a more rapid onset
of Ab response and avidity maturation, after three immunizations in BALB/c mice with DNA on a gold bead delivered with a gene gun, but not in strong
neutralizing Ab response [Ross2001]
825 polyclonal Env gp120 (SF162DeltaV2) Vaccine Rhesus macaque
Vaccine Vector/Type: DNA prime with recombinant protein boost Strain: SF162∆V2 HIV component: gp140 Adjuvant: MF-59C
References Cherpelis2001b, Cherpelis2001a
• Two animals were immunized both intradermally and intramuscularly at weeks 0, 4, and 8 with a codon optimized DNA vector expressing the SF162V2
gp140 envelope with an intact gp120-gp41 cleavage site, and both developed lymphoproliferative responses and potent neutralizing Abs – CD8+ T
lymphocytes were depleted in the animals and they were challenged with SHIV162P4 – at peak viremia, plasma viral levels in the vaccinated animals were
1 to 4 logs lower than those in the unvaccinated animals [Cherpelis2001b]
• HIV-1 SF162∆V2 gp140 envelope was used in a DNA-prime plus protein-boost vaccination methodology in Rhesus macaques, the animals were depleted
of their CD8+ T lymphocytes, and challenged with pathogenic SHIV(SF162P4)—the vaccinated macaques had lower peak viremia, rapidly cleared virus
from the periphery, and developed delayed seroconversion to SIV core antigens relative to non-vaccinated controls [Cherpelis2001a].
826 polyclonal Env gp120 P HIV-1 infection human
References Sarmati2001
• Some HIV-1 infected patients have increasing CD4 counts despite failing ARV, and CD4 levels are correlated with HIV-1 specific NAbs – no correlation
was found between NAbs and viral load in this patients [Sarmati2001]
827 polyclonal Env gp41 (539–684 BH10) Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein HIV component: gp41
References Bai2000
748
DEC 2002
Env Antibodies HIV Antibodies Tables
B
C
ell
No. MAb ID HXB2 Location Author’s Location Sequence Neutralizing Immunogen Species(Isotype)
• There is a common epitope in HIV-1 gp41, and IFNalpha and IFNbeta [Bai2000]
828 polyclonal Env gp120 (IIIB) no human (IgM)
References Llorente1999
• Combinatorial antibody analysis by phage display and flow cytometry demonstrated that gp120 in HIV-1 negative people is recognized by IgM, but not IgG
Abs – IgM Fab reactivity is observed throughout the entire sequence of HIV-1 IIIB gp120 and is characterized by low affinity binding and near germline
configuration reflecting a lack of maturation of the IgM repertoire – no neutralizing activity was observed in a non-infected individual before isotope
switching [Llorente1999]
829 polyclonal Env gp120 (SF2) L Vaccine human (IgM)
Vaccine Vector/Type: recombinant protein Strain: SF2 HIV component: gp120
References Locher1999
• High risk volunteers were vaccinated with SF2 gp120 – 3 breakthrough cases were studied – SF2 neutralizing Abs were observed, but Ab titers to
autologous virus were never high and took 6 months after HIV-1 infection to develop – viral loads were similar to HIV-1 infected individuals who had not
been vaccinated [Locher1999]
830 polyclonal Env gp120 (subtype A, B, C,
D, CRF01)
yes Vaccine murine (IgG)
Vaccine Vector/Type: formaldehyde-fixed whole-cell HIV component: gp120
References LaCasse1999, Nunberg2002
• In this study, immunogens were generated that were thought to capture transient envelope-CD4-coreceptor structures that arise during HIV binding and
fusion by formaldehyde-fixation of co-cultures of cells expressing HIV-1 Env and those expressing CD4 and CCR5 receptors – these cells elicited NAbs in
CD4- and CCR5-transgenic mice that neutralized 23/24 primary isolates from clades A-E [LaCasse1999]
• A retraction was printed (Science 296:1025, 2002) noting that an unknown cytotoxic effect of these complex sera accounted for a major fraction of the
neutralization reported in [LaCasse1999] [Nunberg2002]
831 polyclonal Env (B consensus) P HIV-1 infection human
ReferencesMorris2001
• Ab responses before HAART therapy and after one year of therapy were measured in 8 individuals that were classified HAART successes, and 10 patients
who were classified as HAART failures – V3 peptide antibody binding titers to the B-consensus and MN and SF2 variants, and neutralization of HIV-1 MN
and four subtype B clinical isolates were tested – subjects with strong anti-V3 and NAb humoral immune responses before starting HAART were more
likely to achieve sustained viral suppression to <500 copies RNA/ml on HAART – HIV-specific Ab responses declined after 1 year of successful viral
suppression on HAART [Morris2001]
832 polyclonal Env P HIV-1 infection human (IgG)
References Pilgrim1997
• Sera from long-term nonprogressors(LTNP) had broader NAbs against heterologous primary isolates and were more likely to neutralize the
contemporaneous autologous isolate than were sera from short-term nonprogressors and normal progressors – in 4 individuals followed from acute
infection, NAbs were detected against the early autologous isolate by 5-40 weeks, and not detected in an additional 2 cases after 27-45 weeks [Pilgrim1997]
833 polyclonal Env P HIV-1 infection human
ReferencesMoog1997
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• Autologous and heterologous NAbs were studied in 18 individuals who were sampled early after sero-conversion and followed longitudinally – autologous
NAbs were not detected in sera collected at the same time as the viruses were isolated – NAbs detected against the seroconversion autologous strains were
not detected one year after seroconversion, and were highly specific to the virus present at the early phase of HIV infection – heterologous neutralization of
primary isolates were not detected until after 2 years [Moog1997]
834 polyclonal Env yes HIV-1 infection human
ReferencesMontefiori2001
• In 7/9 patients in whom HAART was initiated during early seroconversion, NAbs to autologous strains were not found immediately following treatment
interuption after 1-3 years, and Env and Gag Abs were low or undetected by ELISA indicating, that early HAART suppresses the normal antibody response
to HIV-1, presumably by limiting the concentration of viral antigens needed to drive B-cell maturation – in 3 patients with a viral rebound autologous NAbs
rapidly appeared and correlated with spontaneous down-regulation of viremia – prolonged control of viremia after stopping treatment persisted in the
absence of detectable NAbs, suggesting that cellular immune responses alone can control viremia under certain circumstances – these results support the
notion that virus-specific B-cell priming, combined with CD8+ CTL induction, may be beneficial for HIV-1 vaccines that aim to suppress viremia in the
absence of complete protection to prevent disease and reduce the rate of virus transmission [Montefiori2001]
835 polyclonal Env HIV-1 infection human (IgG)
References Scala1999
• Random peptide libraries were screened using sera from HIV-infected subjects to identify mimotopes, peptides that mimic conformational or linear epitopes
specifically recognized by Abs from HIV-1 infected individuals – the sera of simian SHIV-infected monkeys also recognized the specific peptides, and mice
immunized with the selected peptides elicited HIV-specific Abs that neutralized HIV-1 isolates IIIB and NL4-3 [Scala1999]
836 polyclonal Env L Vaccine murine (IgG)
Vaccine Vector/Type: peptide HIV component: mimotopes
References Scala1999
• Random peptide libraries were screened using sera from HIV-infected subjects to identify mimotopes, peptides that mimic conformational or linear epitopes
specifically recognized by Abs from HIV-1 infected individuals – the sera of simian SHIV-infected monkeys also recognized the specific peptides, and mice
immunized with the selected peptides elicited HIV-specific Abs that neutralized HIV-1 isolates IIIB and NL4-3 [Scala1999]
837 polyclonal Env Vaccine murine (IgG)
Vaccine Vector/Type: virus-like particle HIV component: Env, Gag Adjuvant: Freund’s adjuvant
References Lebedev2000
• Virus-like particles (VLPs) in the form of spherical particles with yeast dsRNA enveloped in a polysaccharide matrix carrying the protein TBI, that contains
fragments of HIV Env and Gag, were used to immunize BALB/c mice and induced specific Abs against HIV-1 as measured by ELISA with TBI
[Lebedev2000]
838 polyclonal Env P HIV-1 infection human
References Donners2002
• A difference in neutralization patterns between African and European plasma is observed, especially in African women, who tended to have
cross-neutralizing Abs against primary isolates [Donners2002].
839 polyclonal Env L HIV-1 infection human (IgG)
References Dianzani2002
• Immune complexes(ICs) in the plasma contained HIV RNA (80%-100%) in association with HIV-specific IgG NAbs indicating that the HIV in the plasma
of carriers is frequently composed of antibody-neutralized HIV as ICs [Dianzani2002]
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840 polyclonal Env Env P HIV-1 infection human (IgG)
References Kimura2002
• Significant neutralization activity against autologous isolates was observed in 13/19 HIV+ patients at initiation of HAART therapy which persisted during
therapy, increasing in one patient, and declining in one patient – 3/6 patients with no detectable NAb at the start of therapy developed NAb responses – of
the four patients with increased NAb responses, three had low level viral rebounds (blips) [Kimura2002]
841 polyclonal Env P HIV-1 exposed
seronegative
human (IgA)
References Devito2000b
• Mucosal and plasma HIV-specific IgA that can neutralize primary isolates is present saliva (11/15 tested) and plasma (11/15) and cervicovaginal fluid
(11/14) from highly exposed persistently seronegative (HEPS) individuals [Devito2000b]
842 polyclonal Env P HIV-1 exposed
seronegative
human (IgA)
References Devito2000a
• IgA from the genital tract, saliva and plasma from highly exposed persistently seronegative (HEPS) individuals can inhibit transcytosis of HIV-1 across a
transwall system that provides a tight epithelial cell layer—50% of the IgA samples studied were able to inhibit transcytosis of at least one of two primary
isolates tested, indicating this may be an important mechanism against sexual acquisition of HIV-1 [Devito2000a].
843 polyclonal Env P HIV-1 exposed
seronegative
human (IgA)
References Broliden2001
• IgA isolated from the saliva, genital tract, and plasma of most highly exposed persistently seronegative (HEPS) sex workers in a Kenyan cohort could
neutralize a B, A and D clade primary isolates and could inhibit transcytosis of HIV across a transwall model of the human mucosal epithelium
[Broliden2001]
844 polyclonal Env P HIV-1 exposed
seronegative
human (IgA)
References Devito2002
• IgA isolated from the saliva, genital tract, and plasma of most highly exposed persistently seronegative (HEPS) Kenyan sex workers mediated broad
cross-clade neutralization of primary isolates (A, B, C, D, and CRF01) – 6/10 HEPS individuals that were persistently exposed to a stable HIV+ B clade
infected partner showed less breadth of neutralization, and were able to neutralize clade A and B primary isolates, but not clades C, D, or CRF01
[Devito2002]
845 polyclonal Env P HIV-1 exposed
seronegative
human (IgA)
ReferencesMazzoli1999
• Serum HIV-specific IgA is present in highly exposed persistently seronegative individuals (HEPS) in the absence of serum IgG – serum IgA can be found in
productively infected individuals and exposed seronegatives at similar titers – 5/15 sera from HEPS had neutralizing activity, 2 of these in purified IgA –
HIV-1 specific serum IgA concentrations declined after one year of interruption of at-risk sex [Mazzoli1999]
846 polyclonal Env P HIV-1 exposed
seronegative
human (IgA)
References Beyrer1999
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• HIV-specific anti-gp160 IgA is present in cervical lavage from 6/13 HIV-exposed seronegative Thai female sex workers [Beyrer1999]
847 polyclonal Env Vaccine murine
Vaccine Vector/Type: DNA Strain: modified HXB2/BaL recombinant
References Chakrabarti2002
• A modified gp140 (gp140∆CFI), with C-term mutations intended to mimic a fusion intermediate and stabilize trimer formation, retained antigenic
conformational determinants as defined by binding to CD4 and to MAbs 2F5, 2G12, F105, and b12, and enhanced humoral immunity without diminishing
the CTL response in mice injected with a DNA vaccine [Chakrabarti2002].
848 polyclonal Env Vaccine murine
Vaccine Vector/Type: protein Strain: IIIB, 89.6 HIV component: C4-V3 Adjuvant: Freund’s adjuvant, alpha2-macroglobin, monophosphoryl lipid A
with GMCSF
References Liao2002
• HIV-envelope peptides coupled to α2-macroglobin were much more immunogenic when formulated in monophosphoryl lipid A with GM-CSF than in
complete or incomplete Freund’s adjuvant or in monophosphoryl lipid A with GM-CSF alone [Liao2002].
849 polyclonal Env gp120 P Vaccine Rhesus macaque
Vaccine Vector/Type: gp120-CD4 complex, gp140-CD4 complex Strain: IIIB HIV component: gp120, gp140 Adjuvant: QS21
References Fouts2002
• gp120-CD4 and gp140-CD4 complexes were used for i.m. vaccination of rhesus macaques and neutralizing Ig was recovered using affinity chromatography
using a chimeric HIV-BAL gp120 with a mimetic peptide that induces a CD4-triggered mimetic structure – the sera and affinity purified Ab were broadly
neutralizing against primary X4, R5, and R5X4 isolates from multiple subtypes but did not react as well against lab-adapted isolates [Fouts2002]
850 polyclonal Env P HIV-1 infection human
References Pastori2002
• HAART initiated during primary infection was studied in seven patients and had different effects on NAb production—in some cases, α-Env Abs were
inhibited during primary infection, and in some cases strong NAbs against autologous virus were induced [Pastori2002].
851 polyclonal Env gp120 L HIV-1 infection chimpanzee (IgG)
References Igarashi1999, Moore1999
• The rate of virus clearance in the circulation in rhesus macaques receiving a continuous infusion of cell-free viral dual-tropic virus isolate HIV-1DH12
particles in the presence and absence of virus-specific antibodies was measured – the clearance of physical and infectious viral particles is very rapid in
naive animals, with half-lives ranging from 13 to 26 minutes, but clearance cold be acheived with a half life of 3.9-7.2 minutes when chimpanzee
neutralizing Abs were present to help to remove virions from the blood [Igarashi1999]
• polyclonal: Commentary discussing this finding noting the particularly high neutralization titer and limited breadth of the chimpanzee sera used in this
study [Moore1999]
852 polyclonal Env gp120 L Vaccine human
Vaccine Vector/Type: canarypox prime with rgp120 boost Strain: gp120 MN and gp41 LAI, rgp120 SF2 Adjuvant: MF-59
References Gupta2002
• Vaccine trial protocol 022A in 150 HIV-1 uninfected adults (130 completed the study) showed high titer ALVAC vaccine in combination with gp120 was
safe and immunogenic in HIV-1 negative volunteers – NAb responses were detected in 95% of vaccinees, with higher titers in recipients of sequential versus
simultaneous dosing of the two vaccines and in vaccinia naive volunteers [Gupta2002]
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853 101-342 Env gp120 (476–505
HAM112, O group)
Vaccine murine (IgG2a κ)
Vaccine Vector/Type: recombinant protein Strain: HAM112 (group O) HIV component: gp160
Ab type C-term
References Scheffel1999
• 101-342: Overlapping peptides based on group O HAM112 Env were tested for MAb reactivity [Scheffel1999]
854 101-451 Env gp120 (498–527
HAM112, O group)
Vaccine murine (IgG2b κ)
Vaccine Vector/Type: recombinant protein Strain: HAM112 (group O) HIV component: gp160
Ab type C-term
References Scheffel1999
• 101-451: Overlapping peptides based on group O HAM112 Env were tested for MAb reactivity [Scheffel1999]
855 120-1 Env gp120 (503–532) no Vaccine murine (IgMκ)
Vaccine Vector/Type: peptide
Ab type C-term
References Chanh1986, Dalgleish1988
856 212A Env gp120 no HIV-1 infection human
Ab type C1 Donor James Robinson, Tulane University, LA
References Robinson1992, Moore1994d, Moore1996, Binley1997a, Fouts1997, Ditzel1997, Wyatt1997, Parren1997c, Sullivan1998b, Binley1998
• 212A: Mutations that inhibit binding: C1 (45 W/S) and V5 (463 N/D) – and enhance binding: V2 (179/180 LD/DL) and C5 (495 G/K) [Moore1994d]
• 212A: Binding enhanced by anti-V3 MAb 5G11 – reciprocal inhibition with anti-C1 MAbs [Moore1996]
• 212A: Study shows neutralization is not predicted by MAb binding to JRFL monomeric gp120, but is associated with oligomeric Env binding – 212A
bound monomer, did not bind oligomer or neutralize JRFL [Fouts1997]
• 212A: Binds efficiently to sgp120 but not soluble gp120+gp41, suggesting its gp120 epitope is blocked by gp41 binding – does not bind to HXBc2 gp120 if
the 19 C-term amino acids are deleted [Wyatt1997]
• 212A: Does not neutralize TCLA strains or primary isolates [Parren1997c]
• 212A: Does not compete with binding of MAb generated in response to gp120-CD4 complex, CG10 [Sullivan1998b]
• 212A: A panel of MAbs were shown to bind with similar or greater affinity and similar competition profiles to a deglycosylated or variable loop deleted
core gp120 protein ( Delta V1, V2, and V3), thus such a core protein produces a structure closely approximating full length folded monomer [Binley1998]
857 522-149 Env gp120 no Vaccine
Vaccine Vector/Type: recombinant protein HIV component: Env
Ab type C1 Donor G. Robey, Abbott Inc.
ReferencesMoore1996, Trkola1996a, Binley1998, Yang2000
• 522-149: Binding is enhanced by C5 antibodies M91 and 1C1 – mutual binding-inhibition with anti-C1 antibody 133/290 – binding is destroyed by a W/L
(position 61, LAI) gp120 amino acid substitution – other C1 antibodies enhance binding to gp120 [Moore1996]
• 522-149: Does not neutralize JR-FL nor block gp120 interaction with CCR-5 in a MIP-1beta-CCR-5 competition study [Trkola1996a]
• 522-149: A panel of MAbs were shown to bind with similar or greater affinity and similar competition profiles to a deglycosylated or variable loop deleted
core gp120 protein ( Delta V1, V2, and V3), thus such a core protein produces a structure closely approximating full length folded monomer [Binley1998]
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• 522-149: A combination of gp41 fusion with the GNC4 trimeric sequences and disruption of the YU2 gp120-gp41 cleavage site resulted in stable gp140
trimers (gp140-GNC4) that preserve and expose some neutralizing epitopes while occluding some non-neutralizing epitopes – CD4BS MAbs (F105 and
F91) and CD4i (17b and 48d) recognized gp140-GNC4 as well as gp120 or gp140 – non-neutralizing MAbs C11, A32, 522-149, M90, and #45 bound to the
gp140-GNC4 glycoprotein at reduced levels compared to gp120 – MAbs directed at the extreme termini of gp120 C1 (135/9 and 133/290) and C5 (CRA-1
and M91) bound efficiently to gp140-GNC4 [Yang2000]
858 L19 Env gp120 (HXBc2) HIV-1 infection human Fab (IgG1)
Ab type C1
References Ditzel1997
• L19: gp120 immobilized on solid phase by capture with anti-CD4 BS MAb L72 was used for the selection of Fabs – six N-term Fabs, L19 L34, L35, L52,
L59, and L69, were obtained that have a similar epitope to Fab p7 [Ditzel1997]
859 M90 Env gp120 no Vaccine (IgG1)
Vaccine Vector/Type: protein HIV component: Env
Ab type C1 Donor Fulvia di Marzo Veronese
References diMarzo Veronese1992, DeVico1995, Moore1996, Ditzel1997, Wyatt1997, Binley1998, Binley1999
• M90: Reactive only with native gp120, so binds to a discontinuous epitope – reacts with multiple strains [diMarzo Veronese1992]
• M90: Reacted with both non-reduced (but not denatured) covalently cross-linked gp120-CD4 complex [DeVico1995]
• M90: Reciprocal inhibition of binding of other anti-C1 MAbs – inhibits CD4 binding site MAbs – enhances binding of V2 MAbs G3-4 and SC258
[Moore1996]
• M90: Binds efficiently to sgp120 but not soluble gp120+gp41, suggesting its gp120 epitope is blocked by gp41 binding – does not bind to HXBc2 gp120 if
the 19 C-term amino acids, in conjunction with C1 positions 31-82, are deleted [Wyatt1997]
• M90: A panel of MAbs were shown to bind with similar or greater affinity and similar competition profiles to a deglycosylated or variable loop deleted core
gp120 protein ( Delta V1, V2, and V3), thus such a core protein produces a structure closely approximating full length folded monomer [Binley1998]
• M90: The MAbs with the broadest neutralizing activity, IgG1b12, 2G12 and 2F5, all have high affinity for the native trimer, indicating that they were raised
in an immune response to the oligomer on the virion surface rather than dissociated subunits – a disulfide linked gp120-gp41 (SOS gp140) was created to
mimic the native conformation of Env and explore its potential as an immunogen – SOS gp140 is recognized by NAbs IgG1b12, 2G12, and CD4-IgG2, and
also by anti-V3 MAbs 19b and 83.1 – SOSgp140 is not recognized by C4 region MAbs that neutralize only TCLA strains, G3-42 and G3-519 – nor did it
bind C11, 23A, and M90, MAbs that bind to gp120 C1 and C5, where it interacts with gp41 – MAbs that bind CD4 inducible epitopes, 17b and A32 were
very strongly induced by CD4 in SOS gp140 – anti-gp41 MAbs that bind in the region that interacts with gp120, 7B2, 2.2B, T4, T15G1 and 4D4, did not
bind to SOSgp140, in contrast to 2F5, which binds to the only gp41 epitope that is well exposed in native gp120-gp41 complexes [Binley1999]
• M90: A combination of gp41 fusion with the GNC4 trimeric sequences and disruption of the YU2 gp120-gp41 cleavage site resulted in stable gp140
trimers (gp140-GNC4) that preserve and expose some neutralizing epitopes while occluding some non-neutralizing epitopes – CD4BS MAbs (F105 and
F91) and CD4i (17b and 48d) recognized gp140-GNC4 as well as gp120 or gp140 – non-neutralizing MAbs C11, A32, 522-149, M90, and #45 bound to the
gp140-GNC4 glycoprotein at reduced levels compared to gp120 – MAbs directed at the extreme termini of gp120 C1 (135/9 and 133/290) and C5 (CRA-1
and M91) bound efficiently to gp140-GNC4 [Yang2000]
860 MAG 104 Env gp120 no Vaccine murine
Vaccine Vector/Type: sCD4-gp120 complex Strain: HXB2 HIV component: gp120
Ab type C1 Donor C. Y. Kang, IDEC Inc
References Kang1994
• MAG 104: Only observed amino acid substitution that reduces binding: 88 N/P and 106 E/A – does not bind to C1 region 20 mer peptides, tentative
classification conformationally sensitive anti-C1 MAb [Kang1994]
754
DEC 2002
Env Antibodies HIV Antibodies Tables
B
C
ell
No. MAb ID HXB2 Location Author’s Location Sequence Neutralizing Immunogen Species(Isotype)
861 MAG 45 (#45) Env gp120 no Vaccine murine
Vaccine Vector/Type: sCD4-gp120 complex Strain: HXB2 HIV component: gp120
Ab type C1 Donor C. Y. Kang, IDEC Inc
References Kang1994, Moore1996, Wyatt1997, Yang2000
• MAG 45: Only observed amino acid substitution that reduces binding: 88 N/P – does not bind to C1 region 20 mer peptides, tentative classification
conformationally sensitive anti-C1 MAb [Kang1994]
• MAG 45: Reciprocal binding inhibition with anti-C1-C5 and anti-C1-C4 discontinuous MAbs – binding enhanced by anti-V3 5G11 – inhibits binding of
anti-CD4 binding site MAbs [Moore1996]
• MAG 45: Called #45 – binds to efficiently sgp120 but not soluble gp120+gp41, suggesting its gp120 epitope is blocked by gp41 binding – does not bind to
HXBc2 gp120 if the 19 C-term amino acids, in conjunction with C1 positions 31-50, are deleted [Wyatt1997]
• MAG 45: Called #45 – a combination of gp41 fusion with the GNC4 trimeric sequences and disruption of the YU2 gp120-gp41 cleavage site resulted in
stable gp140 trimers (gp140-GNC4) that preserve and expose some neutralizing epitopes while occluding some non-neutralizing epitopes – CD4BS MAbs
(F105 and F91) and CD4i (17b and 48d) recognized gp140-GNC4 as well as gp120 or gp140 – non-neutralizing MAbs C11, A32, 522-149, M90, and #45
bound to the gp140-GNC4 glycoprotein at reduced levels compared to gp120 – MAbs directed at the extreme termini of gp120 C1 (135/9 and 133/290) and
C5 (CRA-1 and M91) bound efficiently to gp140-GNC4 [Yang2000]
862 MAG 95 Env gp120 no Vaccine murine
Vaccine Vector/Type: sCD4-gp120 complex Strain: HXB2 HIV component: gp120
Ab type C1 Donor C. Y. Kang, IDEC Inc
References Kang1994
• MAG 95: Only observed amino acid substitution that reduces binding: 88 N/P – does not bind to C1 region 20 mer peptides, tentative classification
conformationally sensitive anti-C1 MAb [Kang1994]
863 MAG 97 Env gp120 no Vaccine murine
Vaccine Vector/Type: sCD4-gp120 complex Strain: HXB2 HIV component: gp120
Ab type C1 Donor C. Y. Kang, IDEC Inc
References Kang1994
• MAG 97: Only observed amino acid substitution that reduces binding: 88 N/P – does not bind to C1 region 20 mer peptides, tentative classification
conformationally sensitive anti-C1 MAb [Kang1994]
864 T9 Env gp41 Vaccine murine (IgG)
Ab type C1 Donor Patricia Earl and Christopher Broder, NIH
References Broder1994, Earl1997, Golding2002b
• There are two HIV-Abs with the name T9, one binds to gp41, one to gp120
• T9: One of five MAbs (T4, T6, T9, T10 and T35) in a competition group that bind to a conformation-dependent epitope in gp41 and is oligomer specific –
neutralizes IIIB and SF2 [Broder1994]
• T9: This antibody, along with 7 others (M10, D41, D54, T6, T4, T10 and T35), can block the linear murine MAb D61, and the human MAb 246-D, which
both bind to the immunodominant region near the two Cys in gp41 – most of these antibodies are oligomer dependent – all of the MAbs are reactive with
ten different HIV-1 strains – members of this competition group are blocked by sera from HIV-1+ individuals [Earl1997]
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• T9: The fusion process was slowed by using a suboptimal temperature (31.5 C) to re-evaluate the potential of Abs targeting fusion intermediates to block
HIV entry – preincubation of E/T cells at 31.5 C enabled polyclonal anti-N-HR Ab and anti-six-helix bundle Abs to inhibit fusion, indicating six-helix
bundles form prior to fusion – the preincubation 31.5 C step did not alter the inhibitory activity of neutralizing Abs anti-gp41 2F5, or anti-gp120 2G12,
IG1b12, 48d, and 17b – nor did it alter two gp41 MAbs, T9 and D61, inability to inhibit fusion [Golding2002b]
865 p7 Env gp120 (HXBc2) HIV-1 infection human Fab (IgG1)
Ab type C1
References Ditzel1997, Parren1997c
• p7: gp120 immobilized on solid phase by capture with sCD4 was used for selection of Fabs – three novel N-term Fabs were obtained that bind to similar
epitopes, p7, p20, and p35 – a C1 W/S substitution at position 45 abolished binding, a Y/D at position 45 reduced binding, and C5 region substitutions 475
M/S and 493 P/K enhanced binding – compete with MAbs M85, M90 and 212A, but not M91 and G3-299 [Ditzel1997]
• p7: Does not neutralize TCLA strains or primary isolates [Parren1997c]
866 L100 Env gp120 (HXBc2) HIV-1 infection human Fab (IgG1)
Ab type C1-C2
References Ditzel1997, Parren1997c, Parren1997a
• L100: Does not neutralize TCLA strains or primary isolates [Parren1997c]
• L100: gp120 immobilized on solid phase by capture with sCD4 and then masked with Fab p7 allowed selection of a new Fab, L100, with a novel specificity
for C1 and C2 – gp120 C1 substitutions 69 W/L and 76 P/Y abolish L100 binding, and C2 substitutions 252 R/W, 256 S/Y, 262 N/T and 267 E/L abolish or
strongly inhibit L100 binding – inhibits binding of MAbs M90 and G3-299, but not M85, 212A, and M91 [Ditzel1997, Parren1997a]
867 2/11c (211c,
2.11c, 211/c,
2-11c)
Env gp120 L (weak) HIV-1 infection human
Ab type C1-C4 Donor James Robinson, Tulane University, LA
ReferencesMoore1996, Trkola1996a, Binley1997a, Fouts1997, Li1997, Wyatt1997, Binley1998, Xiang2002a
• 2/11c: Inhibits binding of anti-C1, -C5, -C4, -V3 and anti-CD4 binding site MAbs – induces binding of some anti-V2 and CD4i MAbs (48d and 17b) –
similar reactivity pattern to A32, but less cross-reactive and lower affinity – A32 and 211/c are unique among known human and rodent MAbs [Moore1996]
• 2/11c: Called 211c – does not neutralize JR-FL nor block gp120 interaction with CCR-5 in a MIP-1beta-CCR-5 competition study [Trkola1996a]
• 2/11c: Study shows neutralization is not predicted by MAb binding to JRFL monomeric gp120, but is associated with oligomeric env binding – 2/11c bound
monomer, did not bind oligomer or neutralize JRFL [Fouts1997]
• 2/11c: Called 2.11c – One of 14 human MAbs tested for ability to neutralize a chimeric SHIV-vpu+, which expressed HIV-1 IIIB env – 50% neutralization
could not be achieved at a maximal concentration of 67 mug/ml [Li1997]
• 2/11c: Binds efficiently to sgp120 but not soluble gp120+gp41, suggesting its gp120 epitope is blocked by gp41 binding – does not bind to HXBc2 gp120 if
the 19 C-term amino acids, in conjunction with C1 positions 31-74, are deleted [Wyatt1997]
• 2/11c: Called 211/c – a panel of MAbs were shown to bind with similar or greater affinity and similar competition profiles to a deglycosylated or variable
loop deleted core gp120 protein ( Delta V1, V2, and V3), thus such a core protein produces a structure closely approximating full length folded monomer
[Binley1998]
• 2/11c: Used as a negative control in a study of CD4i MAbs [Xiang2002a]
868 A32 Env gp120 no HIV-1 infection human (IgG1)
Ab type C1-C4 Donor James Robinson, Tulane University, New Orleans, LA, USA
ReferencesMoore1994b, Wyatt1995, Moore1995b, Moore1996, Wu1996, Trkola1996a, Binley1997a, Fouts1997, Burton1997, Wyatt1997, Boots1997,
Parren1997c, Sullivan1998b, Binley1998, Binley1999, Yang2000, Yang2002, Grundner2002
• A32: Reacted with virtually every gp120 monomer of every clade tested, most conserved gp120 monomer epitope known [Moore1994b]
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• A32: Epitope is better exposed upon CD4 binding to gp120 – binding of A32 enhances binding of 48d and 17b – studies using a V1/V2 deletion mutant
demonstrated that enhanced binding of 48d in the presence sCD4 involves the V1/V2 loops, with more significant involvement of V2 [Wyatt1995]
• A32: Review: epitope is distinct from CD4BS MAbs, 48d and 17b, and 2G12 [Moore1995b]
• A32: Reciprocal inhibition of binding of anti-C1, -C5, -C4, -V3 and anti-CD4 binding site MAbs – induces binding of some anti-V2 and sCD4 inducible
MAbs (48d and 17b) – very similar competition pattern to 2/11c, A32 and 211/c are unique among known human and rodent MAbs [Moore1996]
• A32: Not neutralizing – binds domains that interact with gp41 – MIP-1alpha binding to CCR-5 expressing cells can be inhibited by gp120-sCD4 and
binding of A32 does not block this inhibition [Wu1996]
• A32: Does not neutralize JR-FL, or any strain strongly – partial inhibition of gp120 interaction with CCR-5 in a MIP-1beta-CCR-5 competition study
[Trkola1996a]
• A32: Study shows neutralization is not predicted by MAb binding to JRFL monomeric gp120, but is associated with oligomeric env binding – A32 bound
monomer, did not bind oligomer or neutralize JRFL [Fouts1997]
• A32: Review [Burton1997]
• A32: Binds efficiently to sgp120 but not soluble gp120+gp41, suggesting its gp120 epitope is blocked by gp41 binding [Wyatt1997]
• A32: Does not neutralize TCLA strains or primary isolates [Parren1997c]
• A32: Abs that recognize discontinuous epitopes can identify mimotopes from a phage peptide display library – A32 has a unique epitope involving mostly
C2 but C1 and C4 contribute – six quite variable phage inserts were recognized, with a consensus of LPWYN – a central Trp was the most conserved
element, consistent with W427 being an important residue for binding gp120 [Boots1997]
• A32: Enhances binding of CD4i MAbs 17b and 48d, and a MAb generated in response to gp120-CD4 complex, CG10 [Sullivan1998b]
• A32: A panel of MAbs were shown to bind with similar or greater affinity and similar competition profiles to a deglycosylated or variable loop deleted core
gp120 protein ( Delta V1, V2, and V3), thus such a core protein produces a structure closely approximating full length folded monomer [Binley1998]
• A32: The MAbs with the broadest neutralizing activity, IgG1b12, 2G12 and 2F5, all have high affinity for the native trimer, indicating that they were raised
in an immune response to the oligomer on the virion surface rather than dissociated subunits – a disulfide linked gp120-gp41 (SOS gp140) was created to
mimic the native conformation of Env and explore its potential as an immunogen – SOS gp140 is recognized by NAbs IgG1b12, 2G12, and CD4-IgG2, and
also by anti-V3 MAbs 19b and 83.1 – SOSgp140 is not recognized by C4 region MAbs that neutralize only TCLA strains, G3-42 and G3-519 – nor did it
bind C11, 23A, and M90, MAbs that bind to gp120 C1 and C5, where it interacts with gp41 – MAbs that bind CD4 inducible epitopes, 17b and A32 were
very strongly induced by CD4 in SOS gp140 – anti-gp41 MAbs that bind in the region that interacts with gp120, 7B2, 2.2B, T4, T15G1 and 4D4, did not
bind to SOSgp140, in contrast to 2F5, which binds to the only gp41 epitope that is well exposed in native gp120-gp41 complexes [Binley1999]
• A32: A combination of gp41 fusion with the GNC4 trimeric sequences and disruption of the YU2 gp120-gp41 cleavage site resulted in stable gp140 trimers
(gp140-GNC4) that preserve and expose some neutralizing epitopes while occluding some non-neutralizing epitopes – CD4BS MAbs (F105 and F91) and
CD4i (17b and 48d) recognized gp140-GNC4 as well as gp120 or gp140 – non-neutralizing MAbs C11, A32, 522-149, M90, and #45 bound to the
gp140-GNC4 glycoprotein at reduced levels compared to gp120 – MAbs directed at the extreme termini of gp120 C1 (135/9 and 133/290) and C5 (CRA-1
and M91) bound efficiently to gp140-GNC4 [Yang2000]
• A32: Uncleaved soluble gp140 (YU2 strain, R5 primary isolate) can be stabilized in an oligomer by fusion with a C-term trimeric GCN4 motif or using a
T4 trimeric motif derived from T4 bacteriophage fibritin – stabilized oligomer gp140 delta683(-FT) showed strong preferential recognition by NAbs
IgG1b12 and 2G12 relative to the gp120 monomer, in contrast to poorly neutralizing MAbs F105, F91, 17b, 48d, and 39F which showed reduced levels of
binding, and C11, A32, and 30D which did not bind the stabilized oligomer [Yang2002]
• A32: HIV-1 gp160deltaCT (cytoplasmic tail-deleted) proteoliposomes (PLs) containing native, trimeric envelope glycoproteins from R5 strains YU2 and
JRFL, and X4 strain HXBc2, were made in a physiologic membrane setting as candidate immunogens for HIV vaccines – 2F5 bound to gp160deltaCT with
a reconstituted membrane ten-fold better than the same protein on beads – anti-CD4BS MAbs IgG1b12 and F105, A32 (C1-C4), C11 (C1-C5), and 39F
(V3) MAbs bound gp160deltaCT PLs indistinguishably from gp160deltaCT expressed on the cell surface – non-neutralizing MAbs C11 and A32 bound
with lower affinity than NAb IgG1b12 – the MAb 17b was sCD4 inducible on gp160deltaCT PL [Grundner2002]
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869 C11 (c11) Env gp120 no HIV-1 infection human
Ab type C1-C5 Donor James Robinson, Tulane University, LA
References Robinson1992, Moore1994d, Moore1996, Trkola1996a, Wu1996, Binley1997a, Fouts1997, Wyatt1997, Parren1997c, Sullivan1998b,
Binley1999, Yang2002, Grundner2002, Basmaciogullari2002
• C11: Mutations that inhibit binding: C1 (45 W/S, 88 N/P) – V5 (463 N/D) – and C5 (491 I/F, 493 P/K and 495 G/K) and enhance binding: C1 (36 V/L) –
V1-V2 (152/153 GE/SM) – and DeltaV1/V2/V3 [Moore1994d]
• C11: Binding enhanced by anti-V3 MAb 5G11 – reciprocal inhibition with anti-C1 MAbs [Moore1996]
• C11: Did not block ability of gp120-sCD4 complexes to inhibit MIP-1alpha binding – binds to gp41-binding domain [Wu1996]
• C11: Does not neutralize JR-FL nor block gp120 interaction with CCR-5 in a MIP-1beta-CCR-5 competition study [Trkola1996a]
• C11: Study shows neutralization is not predicted by MAb binding to JRFL monomeric gp120, but is associated with oligomeric Env binding – C11 bound
monomer, did not bind oligomer or neutralize JRFL [Fouts1997]
• C11: Binds efficiently to sgp120 but not soluble gp120+gp41, suggesting its gp120 epitope is blocked by gp41 binding – partial re-exposure if sCD4 was
bound – does not bind to HXBc2 gp120 if the 19 C-term amino acids are deleted [Wyatt1997]
• C11: Does not neutralize TCLA strains or primary isolates [Parren1997c]
• C11: Does not compete with binding of MAb generated in response to gp120-CD4 complex, CG10 [Sullivan1998b]
• C11: The MAbs with the broadest neutralizing activity, IgG1b12, 2G12 and 2F5, all have high affinity for the native trimer, indicating that they were raised
in an immune response to the oligomer on the virion surface rather than dissociated subunits – a disulfide linked gp120-gp41 (SOS gp140) was created to
mimic the native conformation of Env and explore its potential as an immunogen – SOS gp140 is recognized by NAbs IgG1b12, 2G12, and CD4-IgG2, and
also by anti-V3 MAbs 19b and 83.1 – SOSgp140 is not recognized by C4 region MAbs that neutralize only TCLA strains, G3-42 and G3-519 – nor did it
bind C11, 23A, and M90, MAbs that bind to gp120 C1 and C5, where it interacts with gp41 – MAbs that bind CD4 inducible epitopes, 17b and A32 were
very strongly induced by CD4 in SOS gp140 – anti-gp41 MAbs that bind in the region that interacts with gp120, 7B2, 2.2B, T4, T15G1 and 4D4, did not
bind to SOSgp140, in contrast to 2F5, which binds to the only gp41 epitope that is well exposed in native gp120-gp41 complexes [Binley1999]
• C11: Uncleaved soluble gp140 (YU2 strain, R5 primary isolate) can be stabilized in an oligomer by fusion with a C-term trimeric GCN4 motif or using a
T4 trimeric motif derived from T4 bacteriophage fibritin – stabilized oligomer gp140 delta683(-FT) showed strong preferential recognition by NAbs
IgG1b12 and 2G12 relative to the gp120 monomer, in contrast to poorly neutralizing MAbs F105, F91, 17b, 48d, and 39F which showed reduced levels of
binding, and C11, A32, and 30D which did not bind the stabilized oligomer [Yang2002]
• C11: HIV-1 gp160deltaCT (cytoplasmic tail-deleted) proteoliposomes (PLs) containing native, trimeric envelope glycoproteins from R5 strains YU2 and
JRFL, and X4 strain HXBc2, were made in a physiologic membrane setting as candidate immunogens for HIV vaccines – 2F5 bound to gp160deltaCT with
a reconstituted membrane ten-fold better than the same protein on beads – anti-CD4BS MAbs IgG1b12 and F105, A32 (C1-C4), C11 (C1-C5), and 39F
(V3) MAbs bound gp160deltaCT PLs indistinguishably from gp160deltaCT expressed on the cell surface – non-neutralizing MAbs C11 and A32 bound
with lower affinity than NAb IgG1b12 – the MAb 17b was sCD4 inducible on gp160deltaCT PL [Grundner2002]
• C11: gp120 mutants were used to define the CXCR4 binding site using CXCR4 displayed on paramagnetic proteoliposomes (PMPLs) to reduce
non-specific gp120 binding – basic residues in the V3 loop and the beta19 strand (RIKQ, positions 419-422) were involved, and deletion of the V1-V2 loops
allowed CD4-independent CXCR4 binding – MAbs 17b (CD4i) and F105 (CD4BS) were used to study conformational changes in the mutants – C11 was
used to detect gp120 binding to CXCR4 or CCR5 on PMPLs [Basmaciogullari2002]
870 L81 Env gp120 no HIV-1 infection human (IgG1)
Ab type C1-C5
References Ditzel1997, Parren1997c
• L81: gp120 immobilized on solid phase by capture with anti-CD4 BS MAb L72 was used for selection of Fabs – L81 binding is abolished by C1
substitution 45 W/S, C5 substitution 491 I/F, and C3 substitution L/A [Ditzel1997]
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• L81: Does not neutralize TCLA strains or primary isolates [Parren1997c]
871 2F19C Env gp120 (HIV2ROD) APGK no Vaccine murine
Vaccine Vector/Type: peptide Strain: HIV-2 ROD
Ab type C3
ReferencesMatsushita1995
• 2F19C: Binds in WB, but binds poorly to Env on the cell surface, APGK is the core binding region [Matsushita1995]
872 B2C Env gp120 (HIV2ROD) HYQ(core) L Vaccine murine
Vaccine Vector/Type: peptide Strain: HIV-2 ROD
Ab type C3
ReferencesMatsushita1995
• B2C: Viral neutralization was type-specific for HIV-2 ROD [Matsushita1995]
873 polyclonal Env P HIV-1 infection human (IgG)
Ab type C3
ReferencesWang2002a
• Autologous NAbs were studied in 3 patients on HAART that rebounded – phylogenetic analysis of env (V1-V5) sequences indicated that rebound viruses
had evolved from or preexisted in baseline populations – HIV-1 rebound viruses from all 3 patients were resistant to neutralization by autologous IgG,
unlike the baseline viruses – mutations in the C3 region was responsible for conferring neutralization resistance against autologous antibody in 2 of 3
patients [Wang2002a]
874 1024 Env gp120
Ab type C4
References Berman1997
• 1024: Binds to 1/7 isolates from breakthrough cases from a MN gp120 vaccine trial [Berman1997]
875 23A (2.3A) Env gp120 no
Ab type C5 Donor James Robinson, Tulane University, LA
References Thali1992a, Thali1993, Wu1996, Trkola1996a, Fouts1997, Binley1999, Schulke2002
• 23A: Called 2.3A – Did not block ability of gp120-sCD4 complexes to inhibit MIP-1alpha binding – binds to gp41-binding domain of gp120 [Wu1996]
• 23A: C5 binding MAb – does not inhibit gp120 interaction with CCR-5 in a MIP-1beta-CCR-5 competition study [Trkola1996a]
• 23A: Study shows neutralization is not predicted by MAb binding to JRFL monomeric gp120, but is associated with oligomeric env binding – 23A bound
monomer, did not bind oligomer or neutralize JRFL [Fouts1997]
• 23A: The MAbs with the broadest neutralizing activity, IgG1b12, 2G12 and 2F5, all have high affinity for the native trimer, indicating that they were raised
in an immune response to the oligomer on the virion surface rather than dissociated subunits – a disulfide linked gp120-gp41 (SOS gp140) was created to
mimic the native conformation of Env and explore its potential as an immunogen – SOS gp140 is recognized by NAbs IgG1b12, 2G12, and CD4-IgG2, and
also by anti-V3 MAbs 19b and 83.1 – SOSgp140 is not recognized by C4 region MAbs that neutralize only TCLA strains, G3-42 and G3-519 – nor did it
bind C11, 23A, and M90, MAbs that bind to gp120 C1 and C5, where it interacts with gp41 – MAbs that bind CD4 inducible epitopes, 17b and A32 were
very strongly induced by CD4 in SOS gp140 – anti-gp41 MAbs that bind in the region that interacts with gp120, 7B2, 2.2B, T4, T15G1 and 4D4, did not
bind to SOSgp140, in contrast to 2F5, which binds to the only gp41 epitope that is well exposed in native gp120-gp41 complexes [Binley1999]
• 23A: Ab binding characteristics of SOS gp140 were tested using SPR and RIPA – SOS gp140 is gp120-gp41 bound by a disulfide bond – NAbs 2G12, 2F5,
IgG1b12, CD4 inducible 17b, and 19b bound to SOS gp140 better than uncleaved gp140 (gp140unc) and gp120 – non-neutralizing MAbs 2.2B (binds to
gp41 in gp140unc) and 23A (binds gp120) did not bind SOS gp140 [Schulke2002]
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876 D7324 Env gp120 Vaccine sheep
Vaccine HIV component: gp120
Ab type C5 Donor Aalto BioReagents Ltd, Dublin, Ireland or Cliniqa Inc., Fallbrook, CA, USA
ReferencesMoore1990a, Sattentau1991, Moore1993b, Moore1993c, Wyatt1995, Trkola1996a, Ditzel1997, Ugolini1997, Mondor1998, Binley1998,
Sanders2002, Gram2002, Xiang2002a, Basmaciogullari2002, Poignard2003, Herrera2003
• D7324: Binding unaltered by gp120 binding to sCD4, in contrast to 110.5, 9284, 50-69 and 98-6 [Sattentau1991]
• D7324: Binds to the last 15 amino acids in gp120 – used for antigen capture ELISA [Wyatt1995]
• D7324: Epitope in C5 – Does not neutralize JR-FL nor block gp120 interaction with CCR-5 in a MIP-1beta-CCR-5 competition study [Trkola1996a]
• D7324: Called NEA9205 – gp120 capture ELISAs with MAbs D7324 (anti-C-term) or 9205 (anti-V3) were compared in a study of orientation of
glycosylation sites – CD4 binding could only inhibit deglycosylation when gp120 was bound to the plate by D7324, not by 9205, while Abs from HIV-1
infected people inhibited deglycosylation most effectively when gp120 was caught by 9205 [Gram2002]
• D7324: Used to capture gp120 onto solid phase for epitope mapping [Moore1993b], [Moore1993c], [Ditzel1997], [Binley1998], [Sanders2002],
[Xiang2002a], [Basmaciogullari2002], [Poignard2003], [Herrera2003]
877 10/46c Env gp120 Vaccine rat
Vaccine Vector/Type: recombinant protein HIV component: gp120
Ab type CD4BS
References Cordell1991, Jeffs1996, Peet1998
• 10/46c: Increased binding when V1/V2 or V1/V2 and V3 were deleted from gp120 [Jeffs1996]
• 10/46c: The most variable amino acids in the V3 loop were replaced with serines to make the immunodominant V3 loop less immunogenic – these changes
did not affect the ability of sCD4 or MAbs to V1/V2, C1 and C4 to bind – 10/46c was not affected by V3 serine substitutions – mice injected with serine
substituted gp120 had a reduced response relative to wildtype, and no enhanced immunogenicity of conserved regions [Peet1998]
878 1027-30-D Env Env human (IgG1κ)
Ab type CD4BS Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Hioe2000
• 1027-30-D: Ab responses, because of their capacity to alter antigen uptake and processing, can influence helper T cell responses – anti-CD4 binding site
MAbs or serum Ig from HIV+ individuals inhibited proliferative responses of gp120 specific T cells – CD4BS MAbs 654-D, 559/64-D, 588-D, 830-D,
1027-30-D, and 1202-30D strongly diminished proliferation [Hioe2000]
879 1125H
(1125h)
Env gp120 L (MN) HIV-1 infection human (IgG1κ)
Ab type CD4BS Donor Shermaine Tilley, Public Health Research Institute, USA
References
Tilley1991a, Tilley1991b, Thali1992a, Wyatt1992, Pinter1993b, D’Souza1995, Warrier1996, Pincus1996, Wyatt1998a, Alsmadi1998, Yang1998
• 1125H: Binding to gp120 inhibited by CD4 – epitope is destroyed by reduction, but not by removal of N-linked sugars – potent neutralization of MN, RF,
SF-2 and IIIB – neutralization synergy with anti-V3 MAb 4117C [Tilley1991b]
• 1125H: Amino acid substitutions in HXB2 that strongly inhibit binding: 88, 102, 117, 113, 257, 368, 370, 421, 427, 457, 470, 480 [Thali1992a]
• 1125H: Binding to soluble gp120 enhanced by the presence of an anti-V3 HuMAb, 41148D [Pinter1993b]
• 1125H: Precipitation of Delta 297-329 env glycoprotein, with has a deleted V3 loop, is much more efficient that precipitation of wild type [Wyatt1992]
• 1125H: Neutralization was MN specific – failed to neutralize JRCSF, and 2 B subtype and 1 D subtype primary isolates in a multi-laboratory study
involving 11 labs [D’Souza1995]
• 1125H: Synergistic neutralization of HIV-1 when combined with anti-V2 MAb C108G [Warrier1996]
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• 1125H: A panel of immunotoxins were generated by linking Env MAbs to ricin A – immunotoxins mediated cell killing, but killing was not directly
proportional to binding [Pincus1996]
• 1125H: Called 1125h – summary of the implications of the crystal structure of the core of gp120 bound to CD4 and 17b with what is known about
mutations that reduce NAb binding – probable mechanism of neutralization by CD4BS Ab is direct interference with CD4 binding [Wyatt1998a]
• 1125H: A study of 6 anti-Env MAbs and their ability to bind or direct ADCC against target cells infected with IIIB, MN, SF-2, and RF – bound and directed
lysis against all four strains [Alsmadi1998]
• 1125H: A neutralization assay was developed based on hemi-nested PCR amplification of the LTR (HNPCR) – LTR-HNPCR consistently revealed HIV
DNA and was shown to be a rapid, specific and reliable neutralization assay based on tests with 6 MAbs and 5 isolates [Yang1998]
880 120-1B1 Env gp120 L human
Ab type CD4BS Donor Virus Testing Systems Corp., Houston, TX
ReferencesWatkins1993
• 120-1B1: A neutralization escape mutant (HXB2 A281V) was selected by growth of HXB2 in the presence of broadly neutralizing sera – 120-1B1 was not
affected by this mutation [Watkins1993]
881 1202-D
(1202-30-D)
Env Env human (IgG1κ)
Ab type CD4BS Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Nyambi1998, Hioe2000, Nyambi2000
• 1202-D: Using a whole virion-ELISA method, 18 human MAbs were tested for their ability to bind to a panel of 9 viruses from clades A, B, D, F, G, and H
– CD4-BS Abs tended to bind weakly without clade specificity to virions, but bound well to soluble gp120 – 1202-D did not bind to any B clade viruses,
and weakly bound A, C, and G clade isolates – 559/64-D, 558-D and 1202-D had similar reactivities [Nyambi1998]
• 1202-D: Called 1202-30D – Ab responses, because of their capacity to alter antigen uptake and processing, can influence helper T cell responses – anti-CD4
binding site MAbs or serum Ig from HIV+ individuals inhibited proliferative responses of gp120 specific T cells – CD4BS MAbs 654-D, 559/64-D, 588-D,
830-D, 1027-30-D, and 1202-30D strongly diminished proliferation [Hioe2000]
• 1202-D: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including 6 CD4BS MAbs – CD4BS MAbs bound consistently to
most isolates of clade D, but poorly to isolates of other clades with the exception of broadly reactive MAb IgG1b12[Nyambi2000]
882 1331E Env gp120 (IIIB) HIV-1 infection human (IgG1κ)
Ab type CD4BS Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Gorny2000a
• 1331E: Inhibits sCD4 binding to rec gp120 LAI – binding of panel of 21 MAbs to soluble oligomeric gp140 versus gp41 or gp120 monomers was
compared – no MAb was oligomer specific, though anti-V3 and CD4BS MAbs reacted better with the oligomer and V2 and C5 tended to favor the
monomer – CD4BS MAbs 559/64-D, 654-D, 729-D, 9CL and 1331E bound with a 5-13 fold preference for the oligomer [Gorny2000a]
883 1570 (1570A,
1570C,
1570D)
Env Env (PR12, BH10) HIV-1 infection human
Ab type CD4BS
References Jeffs2001
• 1570: BH10 was mutated to form the PR12 protein with the first 74 C-terminal amino acids and the V1, V2 and V3 hypervariable loops deleted and a very
well exposed CD4 binding domain (CD4bd) – this proteins was used to select three new human CD4BS MAbs 1570, 1595 and 1599 – three MAbs were
isolated from one individual, 1570A, C and D but all were determined to have the same V(H)3 region – 1570 was able to bind to a panel of recombinant
proteins from the A, B, C, D, and E subtypes [Jeffs2001]
884 1595 Env Env (PR12, BH10) HIV-1 infection human
Ab type CD4BS
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References Jeffs2001
• 1595: BH10 was mutated to form the PR12 protein with the first 74 C-terminal amino acids and the V1, V2 and V3 hypervariable loops deleted and a very
well exposed CD4 binding domain (CD4bd) – this proteins was used to select three new human CD4BS MAbs 1570, 1595 and 1599 – 1595 was able to
bind gp120 from the A, B, and D clades from a panel of recombinant proteins from the A, B, C, D, and E subtypes [Jeffs2001]
885 1599 Env Env (PR12, BH10) HIV-1 infection human
Ab type CD4BS
References Jeffs2001
• 1599: BH10 was mutated to form the PR12 protein with the first 74 C-terminal amino acids and the V1, V2 and V3 hypervariable loops deleted and a very
well exposed CD4 binding domain (CD4bd) – this proteins was used to select three new human CD4BS MAbs 1570, 1595 and 1599 – 1599 was able to
bind gp120 only from the B clade from a panel of recombinant proteins from the A, B, C, D, and E subtypes [Jeffs2001]
886 15e (1.5e,
1.5E, 15E)
Env gp120 L HIV-1 infection human (IgG1κ)
Ab type CD4BS Donor James Robinson, Tulane University, LA, and David Ho, ADARC, NY, NY
References Robinson1990a, Thali1991, Cordell1991, Ho1991b, Koup1991, Ho1992, Wyatt1992, Thali1992a, Takeda1992, Moore1993a, Thali1993,
Wyatt1993, Bagley1994, Thali1994, Cook1994, Moore1994b, Moore1994a, Sattentau1995b, Lee1995, McKeating1996b, Moore1996, Poignard1996a,
Trkola1996a, McDougal1996, Wisnewski1996, Binley1997a, Fouts1997, Li1997, Wyatt1997, Berman1997, Parren1997c, Wyatt1998a, Parren1998a,
Sullivan1998b, Binley1998, Trkola1998, Fouts1998, Sullivan1998a, Park2000, Kolchinsky2001, Xiang2002b, Zhang2002, Pantophlet2003
• 15e: Broadly neutralizing, binds multiple strains, competes with CD4 for gp120 binding, DTT reduction of env abrogates binding – more potent blocking of
gp120-sCD4 binding than MAbs G3-536 and G3-537 [Ho1991b]
• 15e: Cross-competes with MAbs ICR 39.13g and ICR 39.3b [Cordell1991]
• 15e: Binds to gp120 of HIV-1 IIIB, but not RF – mediates ADCC – deletion of the V3 loop from gp120 does not alter ADCC activity [Koup1991]
• 15e: gp120 mutants that affect 15e epitope binding: 113, 257, 368, 370, 421, 427, 475 – four of these coincide with amino acids important for the CD4
binding domain [Ho1992]
• 15e: Precipitation of Delta 297-329 env glycoprotein, with a deleted V3 loop, is much more efficient that precipitation of wild type [Wyatt1992]
• 15e: Amino acid substitutions in HXB2 that strongly inhibit binding, similar to [Ho1992], some additional, 88, 102, 117, 113, 257, 368, 370, 421, 427, 457,
470, 480 [Thali1992a]
• 15e: Called N70-1.5e – does not enhance infection of HIV-1 IIIB and MN [Thali1992a]
• 15e: Conformational, does not bind denatured gp120 – neutralizes IIIB – reactive with SF-2 gp120 – strong inhibition of HIV+ human sera binding to IIIB
gp120 [Moore1993a]
• 15e: Binding to Delta V1/2 and Delta V1/2/3 mutant glycoproteins is greater than binding to wildtype gp120 [Wyatt1993]
• 15e: Called 15E – a neutralization escape mutant (HXB2 A281V) was selected by growth of HXB2 in the presence of broadly neutralizing sera – 15E
neutralization was not affected by this mutation [Watkins1993]
• 15e: Heavy chain is V HIV, V2-1 – light chain is V_kappaI, Hum01/012. Compared to 21h and F105 [Bagley1994]
• 15e: A mutation in gp41, 582 A/T, confers resistance to neutralization (also confers resistance to MAbs F105, 48d, 21h and 17b) [Thali1994]
• 15e: MAbs against the glycosphingolipid GalCer block HIV infection of normally susceptible CD4 negative cells from the brain and colon – anti-CD4
MAbs moderately inhibit gp120 binding to GalCer, possibly through steric hindrance – binding of GalCer to gp120 inhibited but did not completely block
15e binding [Cook1994]
• 15e: Cross-reactive with gp120 proteins from clades B and D, less so with A and C, and not reactive with clade E and F [Moore1994b]
• 15e: Binds with higher affinity to monomer than to oligomer, moderate association rate [Sattentau1995b]
• 15e: The V4 and V5 domains are essential for 1.5e binding, in contrast to the V1, V2, and V3 loops [Lee1995]
• 15e: Called 1.5e – Neutralizes HXB2, but fails to neutralize chimeric virus with gp120 from primary isolates in an HXB2 background [McKeating1996b]
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• 15e: gp120 binding enhanced by anti-V3 MAb 5G11 and anti-V2 MAb G3-136 – binding inhibited by other CD4 binding site MAbs, antibodies that bind to
gp120 only when CD4 is bound, and CD4-IgG [Moore1996]
• 15e: Anti-CD4BS MAbs 15e, 21h, and IgG1b12 did not cause gp120 dissociation from virus, or exposure of the gp41 epitope of MAb 50-69, in contrast to
CD4i MAb 48d and anti-V3 neutralizing MAbs [Poignard1996a]
• 15e: Inhibits gp120 interaction with CCR-5 in a MIP-1beta-CCR-5 competition study [Trkola1996a]
• 15e: Neutralizes HIV-1 LAI less potently than V3 specific MAbs [McDougal1996]
• 15e: 15e is V H4 – V-region heavy chain usage was examined and a bias of enhanced V H1 and V H4, and reduced V H3, was noted among HIV infected
individuals [Wisnewski1996]
• 15e: Study shows neutralization is not predicted by MAb binding to JRFL monomeric gp120, but is associated with oligomeric Env binding – 15e bound
monomer, did not bind oligomer or neutralize JRFL [Fouts1997]
• 15e: One of 14 human MAbs tested for ability to neutralize a chimeric SHIV-vpu+, which expressed HIV-1 IIIB env – 15e could only achieve 50%
neutralization, but could act synergistically with anti-V3 MAb 694/98-D to achieve 90% [Li1997]
• 15e: Does not bind to HXBc2 gp120 if the 19 C-term amino acids, in conjunction with C1 positions 31-93, are deleted [Wyatt1997]
• 15e: Called 1.5E – Binds to 7/7 isolates from breakthrough cases from a MN gp120 vaccine trial [Berman1997]
• 15e: Neutralizes TCLA strains, but not primary isolates [Parren1997c]
• 15e: Summary of the implications of the crystal structure of the core of gp120 bound to CD4 and 17b with what is known about mutations that reduce NAb
binding – probable mechanism of neutralization by CD4BS Ab is direct interference with CD4 binding [Wyatt1998a]
• 15e: The MAb and Fab binding to the oligomeric form of gp120 and neutralization were highly correlated – authors suggest that neutralization is
determined by the fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
• 15e: A panel of MAbs were shown to bind with similar or greater affinity and similar competition profiles to a deglycosylated or variable loop deleted core
gp120 protein ( Delta V1, V2, and V3), thus such a core protein produces a structure closely approximating full length folded monomer – CD4BS MAbs
15e, F91 and IgG1b12 bound better to the deleted protein than to wild type [Binley1998]
• 15e: Competes with CG-10 binding, a MAb raised against a gp120 CD4 complex, this was probably due to the disruption of CD4-gp120 by 15e
[Sullivan1998b]
• 15e: No detectable neutralizing activity among primary isolates with different co-receptor usage – some neutralization of TCLA strains [Trkola1998]
• 15e: CD4BS MAbs 15e, 21h, and F91 bind with even lower affinity than 205-43-1 and 205-42-15 to JRFL oligomer [Fouts1998]
• 15e: Called 1.5e – the HIV-1 virus YU2 entry can be enhanced by MAbs binding to the CD4BS, V3 loop, and CD4i epitopes – the activation for this
enhanced entry state could be conferred on HxB2 by introducing the YU2 V3 loop, or the YU2 V3 and V1/V2 loops – a similar effect is observed by
sub-neutralizing concentrations of sCD4 and the effect is dependent of CCR5 – 1.5e enhances and does not neutralize YU2 env even at 50 ug/ml
[Sullivan1998a]
• 15e: Six mutations in MN change the virus from a high-infectivity neutralization resistant phenotype to low-infectivity neutralization sensitive – V3,
CD4BS, and CD4i MAbs are 20-100 fold more efficient at neutralizing the sensitive form – the mutation L544P reduced binding of all MAbs against gp120
by causing conformational changes [Park2000]
• 15e: Mutations in two glcosylation sites in the V2 region of HIV-1 ADA at positions 190 and 197 (187 DNTSYRLINCNTS 199) cause the virus to become
CD4-independent and able to enter cells through CCR5 alone – these same mutations tended to increase the neutralization sensitivity of the virus, including
to 15e [Kolchinsky2001]
• 15e: A series of mutational changes were introduced into the YU2 gp120 that favored different conformations – 375 S/W seems to favor a conformation of
gp120 closer to the CD4-bound state, and is readily bound by sCD4 and CD4i MAbs (17b, 48d, 49e, 21c and 23e) but binding of anti-CD4BS MAbs (F105,
15e, IgG1b12, 21h and F91 was markedly reduced – IgG1b12 failed to neutralize this mutant, while neutralization by 2G12 was enhanced – 2F5 did not
neutralize either WT or mutant, probably due to polymorphism in the YU2 epitope – another mutant, 423 I/P, disrupted the gp120 bridging sheet, favored a
different conformation and did not bind CD4, CCR5, or CD4i antibodies, but did bind to CD4BS MAbs [Xiang2002b]
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• 15e: A rare mutation in the neutralization sensitive R2-strain in the proximal limb of the V3 region caused Env to become sensitive to neutralization by
MAbs directed against the CD4 binding site (CD4BS), CD4-induced (CD4i) epitopes, soluble CD4 (sCD4), and HNS2, a broadly neutralizing sera – 2/12
anti-V3 MAbs tested (19b and 694/98-D) neutralized R2, as did 2/3 anti-CD4BS MAbs (15e and IgG1b12), 2/2 CD4i MAbs (17b and 4.8D), and 2G12 and
2F5 – thus multiple epitopes on R2 are functional targets for neutralization and the neutralization sensitivity profile of R2 is intermediate between the highly
sensitive MN-TCLA strain and the typically resistant MN-primary strain [Zhang2002]
• 15e: Alanine scanning mutagenesis was used to compare substitutions that affected anti-CD4BS NAb b12 – rec gp120s were engineered to contain
combinations of Alanine substitutions that enhanced b12 binding, and while binding of b12 to these gp120 monomers was generally maintained or
increased, binding by five non-neutralizing anti-CD4bs MAbs (b3, b6, F105, 15e, and F91) was reduced or completely abolished [Pantophlet2003]
• 15e: UK Medical Research Council AIDS reagent: ARP3016
887 205-43-1 Env gp120 no HIV-1 infection human
Ab type CD4BS
References Fouts1998, Grovit-Ferbas2000
• 205-43-1: Rank order of CD4BS antibodies oligomer binding is IgG1b12 = 2G6 = 205-46-9 > 205-43-1 = 205-42-15 > 15e = 21h = F91, and the only thing
notably distinguishing about neutralizing IgG1b12 is that it depends on residues in V2 [Fouts1998]
• 205-43-1: To determine the antigenicity of virus killed by thermal and chemical inactivation, retention of conformation-dependent neutralization epitopes
was examined, and exposure of CD4BS epitopes was found to be enhanced (MAbs IgG1b12, 205-46-9, and 205-43-1) – binding to 2G12 and 447-52D
epitopes was essentially unaltered – the 17b CD4i epitope was also exposed [Grovit-Ferbas2000]
888 205-46-9 Env gp120 no HIV-1 infection human
Ab type CD4BS
References Fouts1998, Grovit-Ferbas2000
• 205-46-9: Binds JRSF oligomer with high affinity as does IgG1b12, but IgG1b12 is neutralizing, 205-46-9 is not – conclusions of this paper contrast with
Parren98 – authors propose a model where 205-46-9 and 2G6 may inhibit CD4 binding, but cause a conformational shift which enhances CCR5 binding and
thus counteracts the neutralizing effect – rank order of CD4BS antibodies oligomer binding is IgG1b12 = 2G6 = 205-46-9 > 205-43-1 = 205-42-15 > 15e =
21h = F91, and the only thing notably distinguishing about neutralizing IgG1b12 is that it depends on residues in V2 [Fouts1998]
• 205-46-9: To determine the antigenicity of virus killed by thermal and chemical inactivation, retention of conformation-dependent neutralization epitopes
was examined, and exposure of CD4BS epitopes was found to be enhanced (MAbs IgG1b12, 205-46-9, and 205-43-1) – binding to 2G12 and 447-52D
epitopes was essentially unaltered – the 17b CD4i epitope was also exposed [Grovit-Ferbas2000]
889 21h (2.1H) Env gp120 L HIV-1 infection human (IgG1)
Ab type CD4BS Donor James Robinson, Tulane University, LA
References Ho1991b, Thali1992a, Ho1992, Wyatt1993, Moore1993a, Moore1994b, Moore1994a, Bagley1994, Thali1994, Sattentau1995b, Moore1996,
Poignard1996a, Wisnewski1996, McKeating1996b, Binley1997a, Fouts1997, Li1997, Ugolini1997, Wyatt1997, Parren1997c, Wyatt1998a, Parren1998a,
Fouts1998, Xiang2002b
• 21h: Amino acid substitutions in HXB2 that inhibit binding, some shared with CD4 binding inhibition, 88, 113, 257, 368, 370, 421, 470, 480 [Thali1992a]
• 21h: Binding to Delta V1/2 and Delta V1/2/3 mutant glycoproteins is greater than binding to wildtype gp120 [Wyatt1993]
• 21h: Conformational, does not bind denatured gp120 – neutralizes IIIB – reactive with SF-2 gp120 – strong inhibition of HIV+ human sera binding to IIIB
gp120 [Moore1993a]
• 21h: Has strong cross-reactivity with gp120 monomers from most subtypes, A-F, with the least reactivity to clade E [Moore1994b]
• 21h: Competition studies with human sera from seroconverting individuals showed that anti-CD4 BS antibodies can arise very early in infection,
comparable or prior to anti-V3 antibodies [Moore1994a]
• 21h: Heavy chain is V HIII, VDP-35 – light chain is V_lambdaIIIa, Hum318. Compared to 15e and F105 [Bagley1994]
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• 21h: A mutation in gp41, 582 A/T, confers resistance to neutralization (also confers resistance to MAbs F105, 48d, 15e and 17b) [Thali1994]
• 21h: Binds with higher affinity to monomer than to oligomer, moderate association rate [Sattentau1995b]
• 21h: Anti-CD4 binding site MAb – reciprocal inhibition by anti-C1, -C4 and other anti-CD4 binding site antibodies – enhanced by some anti-V2 MAbs and
anti-V3 MAb 5G11 – enhances binding of some anti-V3 and -V2 MAbs [Moore1996]
• 21h: Anti-CD4BS MAbs 15e, 21h, and IgG1b12 did not cause gp120 dissociation from virus, or exposure of the gp41 epitope of MAb 50-69, in contrast to
CD4i MAb 48d and anti-V3 neutralizing MAbs [Poignard1996a]
• 21h: 21h is V H3 – V-region heavy chain usage was examined and a bias of enhanced V H1 and V H4, and reduced V H3, was noted among HIV infected
individuals [Wisnewski1996]
• 21h: Called 2.1H – Neutralizes HXB2, but fails to neutralize chimeric virus with gp120 from primary isolates in an HXB2 background [McKeating1996b]
• 21h: Study shows neutralization is not predicted by MAb binding to JRFL monomeric gp120, but is associated with oligomeric Env binding – 21h bound
monomer, did not bind oligomer or neutralize JRFL [Fouts1997]
• 21h: One of 14 human MAbs tested for ability to neutralize a chimeric SHIV-vpu+, which expressed HIV-1 IIIB env – 50% neutralization could not be
achieved at a maximal concentration of 67 mug/ml [Li1997]
• 21h: Viral binding inhibition by 21h strongly correlated with neutralization (all other neutralizing MAbs tested showed some correlation except 2F5)
[Ugolini1997]
• 21h: Binds both gp120 and soluble gp120+gp41 complex efficiently, suggesting its gp120 epitope is not blocked by gp41 binding – major deletions in C1
and C5 and deletions of the V1V2 and V3 loops do not diminish binding [Wyatt1997]
• 21h: Neutralizes TCLA strains, but not primary isolates [Parren1997c]
• 21h: Summary of the implications of the crystal structure of the core of gp120 bound to CD4 and 17b with what is known about mutations that reduce NAb
binding – probable mechanism of neutralization by CD4BS Ab is direct interference with CD4 binding [Wyatt1998a]
• 21h: The MAb and Fab binding to the oligomeric form of gp120 and neutralization were highly correlated – authors suggest that neutralization is
determined by the fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
• 21h: CD4BS MAbs 15e, 21h, and F91 bind with even lower affinity than 205-43-1 and 205-42-15 to JRFL oligomer – conclusions of this paper contrast
with [Parren1998a] [Fouts1998]
• 21h: A series of mutational changes were introduced into the YU2 gp120 that favored different conformations—375 S/W seems to favor a conformation of
gp120 closer to the CD4-bound state, and is readily bound by sCD4 and CD4i MAbs (17b, 48d, 49e, 21c and 23e) but binding of anti-CD4BS MAbs (F105,
15e, IgG1b12, 21h and F91) was markedly reduced—IgG1b12 failed to neutralize this mutant, while neutralization by 2G12 was enhanced—2F5 did not
neutralize either WT or mutant, probably due to polymorphism in the YU2 epitope—another mutant, 423 I/P, disrupted the gp120 bridging sheet, favored a
different conformation and did not bind CD4, CCR5, or CD4i antibodies, but did bind to CD4BS MAbs [Xiang2002b].
• 21h: UK Medical Research Council AIDS reagent: ARP3017
890 28A11/B1 Env gp120 (SF162) L Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Ab type CD4BS Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 28A11/B1: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2κ MAbs were used to rapidly create a
panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120—6 anti-CD4BS MAbs competed with anti-CD4BS MAb
5145A, blocked sCD4 binding and were conformationally sensitive—4/6 could neutralize the autologous strain SF162, and were broadly cross-reactive with
B clade R5 and X4 strains (not E clade)—28A11/B1 was one of these four MAbs [He2002].
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891 2G6 Env gp120
Ab type CD4BS Donor Herman Katinger, Inst. Appl. Microbiol. University of Agricultural Science, or Polymun Scientific Inc., Vienna, Austria
References Fouts1998
• 2G6: Binds to JRFL oligomer with an affinity comparable to IgG1b12, but does not neutralize the virus, so binding of oligomer is not always predictive of
neutralization – conclusions of this paper contrast with [Parren1998a] – authors propose a model where 205-46-9 and 2G6 may inhibit CD4 binding, but
cause a conformational shift which enhances CCR5 binding and thus counteracts the neutralizing effect [Fouts1998]
892 35F3/E2 Env gp120 (SF162) L Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Ab type CD4BS Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 35F3/E2: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2κ MAbs were used to rapidly create a
panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120—6 anti-CD4BS MAbs competed with anti-CD4BS MAb
5145A, blocked sCD4 binding and were conformationally sensitive—4/6 could neutralize the autologous strain SF162, and were broadly cross-reactive with
B clade R5 and X4 strains (not E clade)—35F3/E2 was one of these four MAbs [He2002].
893 38G3/A9 Env gp120 (SF162) L Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Ab type CD4BS Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 38G3/A9: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2κ MAbs were used to rapidly create a
panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120—6 anti-CD4BS MAbs competed with anti-CD4BS MAb
5145A, blocked sCD4 binding and were conformationally sensitive—4/6 could neutralize the autologous strain SF162, and were broadly cross-reactive with
B clade R5 and X4 strains (not E clade)—38G3/A9 was one of these four MAbs [He2002].
894 428 Env gp120 HIV-1 infection human
Ab type CD4BS
References Karwowska1992a, Jeffs1996
• 428: Slight, not significant increased binding when V1/V2 or V1/V2 and V3 were deleted from gp120 [Jeffs1996]
895 448-D (448D) Env gp120 L HIV-1 infection human (IgG1λ )
Ab type CD4BS Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu), NYU Med Center, NY, NY
References Karwowska1992a, McKeating1992c, Spear1993, Laal1994, Forthal1995, Manca1995a, Li1997, Wyatt1998a, Nyambi2000
• 448-D: Conformational – reactive with IIIB gp120 in RIP, but not WB assay [Karwowska1992a]
• 448-D: Called 448D – blocks gp120-CD4 binding – substitutions at gp120 residues 88, 113, 117, 257, 368 and 370 reduce binding – epitope similar to rat
MAbs 39.13g and 39.3b [McKeating1992c]
• 448-D: Did not mediate deposition of complement component C3 on HIV infected cells [Spear1993]
• 448-D: Dissociation constant gp120 IIIB 0.029 – neutralizes IIIB, acts synergistically with anti-V3 MAb 447-52D [Laal1994]
• 448-D: Neutralizing activity, positive ADCC activity, and no viral enhancing activity [Forthal1995]
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• 448-D: Virions complexed to gp120 Ab facilitate presentation of p66 RT epitopes to Th cells [Manca1995a]
• 448-D: One of 14 human MAbs tested for ability to neutralize a chimeric SHIV-vpu+, which expressed HIV-1 IIIB env [Li1997]
• 448-D: Summary of the implications of the crystal structure of the core of gp120 bound to CD4 and 17b with what is known about mutations that reduce
NAb binding – probable mechanism of neutralization by CD4BS Ab is direct interference with CD4 binding [Wyatt1998a]
• 448-D: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including 6 CD4BS MAbs – CD4BS MAbs bound consistently to
most isolates of clade D, but poorly to isolates of other clades with the exception of broadly reactive MAb IgG1b12[Nyambi2000]
896 44D2/D5 Env gp120 (SF162) no Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Ab type CD4BS Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 44D2/D5: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2κ MAbs were used to rapidly create a
panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120—6 anti-CD4BS MAbs competed with anti-CD4BS MAb
5145A, blocked sCD4 binding and were conformationally sensitive—4/6 could neutralize the autologous strain SF162, and were broadly cross-reactive with
B clade R5 and X4 strains (not E clade)—44D2/D5 could not neutralize autologous SF162, and while it was cross-reactive, it was at lower affinity [He2002].
897 48-16 Env gp120 no HIV-1 infection human (IgGκ)
Ab type CD4BS
References Fevrier1995
• 48-16: Broadly cross-reactive, reacts outside the CD4 binding site and V3 region—competes with sera from 45 seropositive subjects—binding affinity 2–5
×10−9 M [Fevrier1995].
898 50-61A Env gp120 L HIV-1 infection human (IgGκ)
Ab type CD4BS
References Fevrier1995
• 50-61A: Neutralizes lab strains LAI and SF2 – competes with sera from 45 seropositive subjects – binding affinity 2.4 x 10-10 M [Fevrier1995]
899 5145A Env gp120 L HIV-1 infection human (IgG1)
Ab type CD4BS
References Pinter1993a, Warrier1996, Pincus1996, Alsmadi1998, He2002
• 5145A: Potent and broadly cross-reactive neutralization of lab strains [Pinter1993a]
• 5145A: Synergistic neutralization of HIV-1 when combined with anti-V2 MAb C108G [Warrier1996]
• 5145A: A panel of immunotoxins were generated by linking Env MAbs to ricin A – immunotoxins mediated cell killing, but killing was not directly
proportional to binding [Pincus1996]
• 5145A: A study of 6 anti-Env MAbs and their ability to bind or direct ADCC against target cells infected with IIIB, MN, SF-2, and RF – bound and directed
lysis against all four strains [Alsmadi1998]
• 5145A: Transgenic mice carrying human genes allowing production of fully human MAbs were used to rapidly create a panel of anti-HIV gp120 MAb
producing hybridomas by immunization with HIV SF162 gp120 – the previously described human MAbs 5145A, 4117C and 697D were used as controls
[He2002]
900 558-D Env gp120 L HIV-1 infection human
Ab type CD4BS Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu), NYU Med Center, NY, NY
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ReferencesMcKeating1992c, Nyambi1998
• 558-D: Blocks gp120-CD4 binding – binds a panel of mutants all except for 256 S/Y and 262 N/T, which are probably conformationally disruptive
[McKeating1992c]
• 558-D: Using a whole virion-ELISA method, 18 human MAbs were tested for their ability to bind to a panel of 9 viruses from clades A, B, D, F, G, and H –
CD4BS Abs tended to bind weakly without clade specificity to virions, but bound well to soluble gp120 – 558-D did not bind to any B clade viruses, and
weakly bound to clade A, C, and G isolates – 559/64-D, 558-D and 1202-D had similar reactivities [Nyambi1998]
901 559/64-D
(559,
559-64D)
Env gp120 (LAI) L HIV-1 infection human (IgG1κ)
Ab type CD4BS Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu), NYU Med Center, NY, NY
References Karwowska1992a, McKeating1992c, Spear1993, Stamatatos1995, Forthal1995, Jeffs1996, Hioe1997a, Hioe1997b, Nyambi1998, Gorny2000a,
Hioe2000, Nyambi2000, Hioe2001, York2001
• 559/64-D: Conformational – reactive with IIIB gp120 in RIP, but not WB assay [Karwowska1992a]
• 559/64-D: Did not mediate deposition of complement component C3 on HIV infected cells [Spear1993]
• 559/64-D: Called 559-64D – The binding of conformation-dependent anti-V2, anti-V3, and anti-CD4BS MAbs to monomeric and virion-associated gp120
from HIV-1 isolates with differences in cell tropism was studied – CD4BS loop epitopes are somewhat occluded in the oligomeric gp120 epitopes on the
virion surface relative to the gp120 monomer as indicated by an increase in the half-maximal binding values to macrophage-tropic isolates SF162 and
SF128a and to T-cell tropic SF2 – binding of anti-CD4BS MAbs to SF2 resulted in a significant amount of dissociation of gp120 from virion surface
[Stamatatos1995]
• 559/64-D: Neutralizing activity, no ADCC activity, and no viral enhancing activity [Forthal1995]
• 559/64-D: Called 559 – slight, not significant increased binding when V1/V2 or V1/V2 and V3 were deleted from gp120 [Jeffs1996]
• 559/64-D: Used in the development of resting cell neutralization assay [Hioe1997a]
• 559/64-D: Four primary isolates showed distinct patterns of sensitivity to neutralization by polyclonal sera or plasma and MAbs – BZ167 was the only
isolate inhibited by all polyclonal sera and plasma tested, and was also neutralized by 8/17 MAbs, in particular anti-V3 loop (419-D, 447-52D, 782-D, and
838-D), anti-CD4bd (559/64-D, 654-D and 830-D and a cluster II of gp41 directed MAb (98-6) – isolates 92HT593 and 91US056 were neutralized by V3
loop (419-D, and 447-52D)and cluster II gp41 (98-6) MAbs at higher concentrations – US4 was neutralized by some of the polyclonal sera/plasma tested
and not at all by MAbs individually or by a cocktail of ten MAbs consisting of 419-D, 447-52D, 782-D, 838-D, 559/64-D, 654-D, 450-D, 670-D, 1281-D
and 98-6 [Hioe1997b]
• 559/64-D: Using a whole virion-ELISA method, 18 human MAbs were tested for their ability to bind to a panel of 9 viruses from clades A, B, D, F, G, and
H – CD4BS Abs tended to bind weakly without clade specificity to virions, but bound well to soluble gp120 – 559/64-D did not bind to any B clade viruses,
and weakly bound clade A, C, and G isolates – 559/64-D, 558-D and 1202-D had similar reactivities [Nyambi1998]
• 559/64-D: Binding of panel of 21 MAbs to soluble oligomeric gp140 versus gp41 or gp120 monomers was compared – no MAb was oligomer specific,
though anti-V3 and CD4BS MAbs reacted better with the oligomer and V2 and C5 tended to favor the monomer – CD4BS MAbs 559/64-D, 654-D, 729-D,
9CL and 1331E bound with a 5-13 fold preference for the oligomer [Gorny2000a]
• 559/64-D: Ab responses, because of their capacity to alter antigen uptake and processing, can influence helper T cell responses – anti-CD4 binding site
MAbs or serum Ig from HIV+ individuals inhibited proliferative responses of gp120 specific T cells – CD4BS MAbs 654-D, 559/64-D, 588-D, 830-D,
1027-30-D, and 1202-30D strongly diminished proliferation [Hioe2000]
• 559/64-D: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including 6 CD4BS MAbs – CD4BS MAbs bound consistently
to most isolates of clade D, but poorly to isolates of other clades with the exception of broadly reactive MAb IgG1b12[Nyambi2000]
• 559/64-D: CD4BS MAbs when complexed with gp120, inhibit proliferation of gp120-specific CD4 T-cells and IFNγ production—anti-CD4BS MAbs
inhibit gp120 presentation by altering the uptake and/or processing of gp120 by the APCs, not by blocking of gp120 attachment to CD4 on the surface of
APCs [Hioe2001].
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• 559/64-D: Abs against the V3 loop (50.1, 58.2, 59.1, 257-D, 268-D, 447-52D), CD4BS (IgG1b12, 559-64D, F105), CD4 induced or CD4i (17b), and to
gp41 (2F5, F240) each showed similar binding efficiency to Env derived from related pairs of primary and TCLA lines (primary: 168P and 320SI, and
TCLA: 168C and 320SI-C3.3), but the TCLA lines were much more susceptible to neutralization suggesting that the change in TCLA lines that make them
more susceptible to NAbs alters some step after binding [York2001]
902 55D5/F9 Env gp120 (SF162) L Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Ab type CD4BS Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 55D5/F9: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2κ MAbs were used to rapidly create a
panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120—6 anti-CD4BS MAbs competed with anti-CD4BS MAb
5145A, blocked sCD4 binding and were conformationally sensitive—4/6 could neutralize the autologous strain SF162, and were broadly cross-reactive with
B clade R5 and X4 strains (not E clade)—55D5/F9 was one of these four MAbs [He2002].
903 588-D (588) Env gp120 L HIV-1 infection human (IgG1κ)
Ab type CD4BS Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu), NYU Med Center, NY, NY
References Karwowska1992a, Buchbinder1992, Moore1993a, Jeffs1996, Nyambi1998, Hioe2000, Nyambi2000
• 588-D: Conformational – reactive with IIIB gp120 in RIP, but not WB assay [Karwowska1992a]
• 588-D: 4-fold increase in neutralization potency for 588-D when combined 1:1 with human MAb 447-D [Buchbinder1992]
• 588-D: Weak neutralization of IIIB – strong inhibition of HIV+ human sera binding to IIIB gp120 [Moore1993a]
• 588-D: Called 588 – slight, not significant increased binding when V1/V2 or V1/V2 and V3 were deleted from gp120 [Jeffs1996]
• 588-D: Using a whole virion-ELISA method, 18 human MAbs were tested for their ability to bind to a panel of 9 viruses from clades A, B, D, F, G, and H –
CD4-BS Abs tended to bind weakly without clade specificity to virions, but bound well to soluble gp120 – 588-D did not bind to any B clade viruses, and
weakly bound a clade A, C, and G clade isolate – 559/64-D, 558-D and 1202-D reacted had similar reactivities [Nyambi1998]
• 588-D: Ab responses, because of their capacity to alter antigen uptake and processing, can influence helper T cell responses – anti-CD4 binding site MAbs
or serum Ig from HIV+ individuals inhibited proliferative responses of gp120 specific T cells – CD4BS MAbs 654-D, 559/64-D, 588-D, 830-D, 1027-30-D,
and 1202-30D strongly diminished proliferation [Hioe2000]
• 588-D: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including 6 CD4BS MAbs – CD4BS MAbs bound consistently to
most isolates of clade D, but poorly to isolates of other clades with the exception of broadly reactive MAb IgG1b12[Nyambi2000]
904 654-D
(654-30D,
654/30D,
654-D100,
654.30D, 654)
Env gp120 (LAI) L HIV-1 infection human (IgGκ)
Ab type CD4BS Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu), NYU Med Center, NY, NY
References Karwowska1993, Laal1994, Gorny1994, Stamatatos1995, Li1997, Stamatatos1997, Gorny1997, Hioe1997b, Gorny1998, Schonning1998,
Nyambi1998, Stamatatos1998, Hioe1999, Gorny2000a, Hioe2000, Hioe2001, Nyambi2000, Verrier2001, Gorny2002
• 654-D: Dissociation constant gp120 IIIB 0.008 – neutralizes IIIB, acts synergistically with anti-V3 MAb 447-52D – reported to be human(IgG1lambda)
[Laal1994]
• 654-D: Mild oxidation of carbohydrate moieties inhibits binding [Gorny1994]
769
DEC 2002
B
C
el
l
HIV Antibodies Tables Env Antibodies
No. MAb ID HXB2 Location Author’s Location Sequence Neutralizing Immunogen Species(Isotype)
• 654-D: Called 654-30D – The binding of conformation-dependent anti-V2, anti-V3, and anti-CD4BS MAbs to monomeric and virion-associated gp120
from HIV-1 isolates with differences in cell tropism was studied – CD4BS loop epitopes are somewhat occluded in the oligomeric gp120 epitopes on the
virion surface relative to the gp120 monomer as indicated by an increase in the half-maximal binding values to macrophage-tropic isolates SF162 and
SF128a and to T-cell tropic SF2 – binding of anti-CD4BS MAbs to SF2 resulted in a significant amount of dissociation of gp120 from virion surface
[Stamatatos1995]
• 654-D: Called 654-30D – One of 14 human MAbs tested for ability to neutralize a chimeric SHIV-vpu+, which expressed HIV-1 IIIB env [Li1997]
• 654-D: Anti-CD4 BS MAb 654-30D and IgG1b12 have comparable binding affinities, neither mediates gp120-virion dissociation, but IgG1b12 can
neutralize SF128A and SF162 and 654-D cannot – 654-D actually enhances infection by both viruses in primary macrophages [Stamatatos1997]
• 654-D: Four primary isolates showed distinct patterns of sensitivity to neutralization by polyclonal sera or plasma and MAbs – BZ167 was the only isolate
inhibited by all polyclonal sera and plasma tested, and was also neutralized by 8/17 MAbs, in particular anti-V3 loop (419-D, 447-52D, 782-D, and 838-D),
anti-CD4bd (559/64-D, 654-D and 830-D and a cluster II of gp41 directed MAb (98-6) – isolates 92HT593 and 91US056 were neutralized by V3 loop
(419-D, and 447-52D)and cluster II gp41 (98-6) MAbs at higher concentrations – US4 was neutralized by some of the polyclonal sera/plasma tested and not
at all by MAbs individually or by a cocktail of ten MAbs consisting of 419-D, 447-52D, 782-D, 838-D, 559/64-D, 654-D, 450-D, 670-D, 1281-D and 98-6
[Hioe1997b]
• 654-D: Called 654-D100 – 654-D100 and IgG1b12 neutralized viruses HIV-BRU and a mutated virus that lacks the V3 loop glycan equally effectively – in
contrast, sera from guinea pigs immunized with BRU gp120 neutralize viruses more effectively that lack the V3 glycan[Schonning1998]
• 654-D: Using a whole virion-ELISA method, 18 human MAbs were tested for their ability to bind to a panel of 9 viruses from clades A, B, D, F, G, and H –
CD4-BS Abs tended to bind very weakly without clade specificity to virions, but bound well to soluble gp120 – 654-D bound only to JRFL [Nyambi1998]
• 654-D: Called 654.30D – deleting the V2 loop of neutralization-resistant HIV-1 isolate SF162 does not abrogate its replication in PBMC or macrophages,
but it enhances its neutralization sensitivity to sera from patients with B clade infection up to 170-fold, and also enhances sensitivity to sera from clades A
through F – deletion of V2 but not V1 slightly allowed neutralization by CD4BS MAb 654.30D [Stamatatos1998]
• 654-D: The presence of leukocyte function-associated molecule 1 (LFA-1) promotes virus infectivity and hinders neutralization, and anti-LFA-1 MAbs can
enhance the neutralizing effect of anti-HIV V3 MAb 447-52D and anti-HIV CD4BS MAb IgG1b12 – non-neutralizing anti-HIV CD4BS MAb 654-D did
not become neutralizing in the presence of anti-LFA-1 MAbs [Hioe1999]
• 654-D: Binding of panel of 21 MAbs to soluble oligomeric gp140 versus gp41 or gp120 monomers was compared – no MAb was oligomer specific, though
anti-V3 and CD4BS MAbs reacted better with the oligomer and V2 and C5 tended to favor the monomer – CD4BS MAbs 559/64-D, 654-D, 729-D, 9CL
and 1331E bound with a 5-13 fold preference for the oligomer [Gorny2000a]
• 654-D: Ab responses, because of their capacity to alter antigen uptake and processing, can influence helper T cell responses – CD4BS MAbs or serum Ig
from HIV+ individuals inhibited proliferative responses of gp120 specific T cells – MAb 654-D strongly diminished proliferation – there is a discrepancy in
isotyping this antibody, previous reports indicated IgG1kappa, while Hioe suggests it is IgG1lambda [Hioe2000]
• 654-D: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including 6 CD4BS MAbs – CD4BS MAbs bound consistently to
most isolates of clade D, but poorly to isolates of other clades with the exception of broadly reactive MAb IgG1b12 – 654-D had the weakest binding among
CD4BS MAbs, binding to only 4/26 isolates [Nyambi2000]
• 654-D: CD4BS MAbs when complexed with gp120, inhibit proliferation of gp120-specific CD4 T-cells and IFN gamma production – anti-CD4BS MAbs
inhibit gp120 presentation by altering the uptake and/or processing of gp120 by the APCs, not by blocking of gp120 attachment to CD4 on the surface of
APCs [Hioe2001]
• 654-D: A panel of 12 MAbs was used to identify those that could neutralize the dual-tropic primary isolate HIV-1 89.6—six gave significant neutralization
at 2 to 10 ug/ml: 2F5, 50-69, IgG1b12, 447-52D, 2G12, and 670-D, while six did not have neutralizing activity: 654-D, 4.8D, 450-D, 246-D, 98-6, and
1281—no synergy, only additive effects were seen for pairwise combinations of MAbs, and antagonism was noted between gp41 MAbs 50-69 and 98-6, as
well as 98-6 and 2F5 [Verrier2001].
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• 654-D: Called 654: Conformation-dependent anti-V3 loop Abs may be more cross-reactive, so six new V3 MAbs were generated – the six new MAbs all
bind to the tip of the V3 loop and cross-compete with the MAb 447-52D and are conformationally sensitive – MAbs showed cross-clade binding to native,
intact virions and the strength binding was highly correlated with percent neutralization using the ghost cell or PHA blast assay – five well-characterized
MAbs were used as controls: anti-V3 447-52D (anti-V3 MAb for competition and neutralization studies), 654 (anti-CD4BS used as a
conformation-sensitive MAb control), 1331A (anti-C5 used as a linear binding site MAb control), and MAb 246 (anti-gp41 MAb that bound to primary
isolates of all clades) [Gorny2002]
905 67G6/C4 Env gp120 (SF162) no Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Ab type CD4BS Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 67G6/C4: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2κ MAbs were used to rapidly create a
panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120—6 anti-CD4BS MAbs competed with anti-CD4BS MAb
5145A, blocked sCD4 binding and were conformationally sensitive—4/6 could neutralize the autologous strain SF162, and were broadly cross-reactive with
B clade R5 and X4 strains (not E clade)—67G6/C4 could not neutralize autologous SF162, and its binding was strain-specific [He2002].
906 729-D
(729-30D)
Env gp120 (LAI) L HIV-1 infection human (IgG1κ)
Ab type CD4BS Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu), NYU Med Center, NY, NY
References Laal1994, D’Souza1997, Li1997, Parren1997c, Gorny2000a
• 729-D: Dissociation constant gp120 IIIB 0.025 – neutralizes IIIB, acts synergistically with anti-V3 MAb 447-52D [Laal1994]
• 729-D: In a multilaboratory blinded study, failed to consistently neutralize any of nine B clade primary isolates – reported here to have a lambda light chain,
but originally reported in [Laal1994] to be IgG1kappa [D’Souza1997]
• 729-D: Called 720-30D – one of 14 human MAbs tested for ability to neutralize chimeric SHIV-vpu+, which expressed HIV-1 IIIB env [Li1997]
• 729-D: Neutralizes TCLA strains, but not primary isolates [Parren1997c]
• 729-D: Binding of panel of 21 MAbs to soluble oligomeric gp140 versus gp41 or gp120 monomers was compared – no MAb was oligomer specific, though
anti-V3 and CD4BS MAbs reacted better with the oligomer and V2 and C5 tended to favor the monomer – CD4BS MAbs 559/64-D, 654-D, 729-D, 9CL
and 1331E bound with a 5-13 fold preference for the oligomer [Gorny2000a]
907 830D (830-D) Env gp120 L human (IgG1κ)
Ab type CD4BS
References Hioe1997b, Wyatt1998a, Hioe2000
• 830D: Called 830-D: Four primary isolates showed distinct patterns of sensitivity to neutralization by polyclonal sera or plasma and MAbs – BZ167 was the
only isolate inhibited by all polyclonal sera and plasma tested, and was also neutralized by 8/17 MAbs, in particular anti-V3 loop (419-D, 447-52D, 782-D,
and 838-D), anti-CD4bd (559/64-D, 654-D and 830-D and a cluster II of gp41 directed MAb (98-6) – isolates 92HT593 and 91US056 were neutralized by
V3 loop (419-D, and 447-52D)and cluster II gp41 (98-6) MAbs at higher concentrations – US4 was neutralized by some of the polyclonal sera/plasma
tested and not at all by MAbs individually or by a cocktail of ten MAbs consisting of 419-D, 447-52D, 782-D, 838-D, 559/64-D, 654-D, 450-D, 670-D,
1281-D and 98-6 [Hioe1997b]
• 830D: Summary of the implications of the crystal structure of the core of gp120 bound to CD4 and 17b with what is known about mutations that reduce
NAb binding – probable mechanism of neutralization by CD4BS Ab is direct interference with CD4 binding [Wyatt1998a]
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• 830D: Ab responses, because of their capacity to alter antigen uptake and processing, can influence helper T cell responses – anti-CD4 binding site MAbs
or serum Ig from HIV+ individuals inhibited proliferative responses of gp120 specific T cells – CD4BS MAbs 654-D, 559/64-D, 588-D, 830-D, 1027-30-D,
and 1202-30D strongly diminished proliferation [Hioe2000]
908 9CL Env gp120 (LAI) HIV-1 infection human
Ab type CD4BS Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu), NYU Med Center, NY, NY
References Gorny2000a
• 9CL: Binding of panel of 21 MAbs to soluble oligomeric gp140 versus gp41 or gp120 monomers was compared – no MAb was oligomer specific, though
anti-V3 and CD4BS MAbs reacted better with the oligomer and V2 and C5 tended to favor the monomer – CD4BS MAbs 559/64-D, 654-D, 729-D, 9CL
and 1331E bound with a 5-13 fold preference for the oligomer [Gorny2000a]
909 BM12 Env gp120 L HIV-1 infection human
Ab type CD4BS
References Kessler1995
• BM12: Broad cross-clade neutralization of primary isolates – additive effect in combination with MAb 2F5 [Kessler1995]
910 D20 Env gp120 (IIIB) no Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
Ab type CD4BS Donor P. Earl, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
References Earl1994, Broder1994, Richardson1996, Otteken1996, Earl1997, Sugiura1999
• D20: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• D20: Binding completely blocked by pooled human sera [Broder1994]
• D20: Human sera blocked binding in oligomeric ELISA assay to a similar extent for gp41 MAbs D20, D43, D61, and T4 [Richardson1996]
• D20: Pulse label experiments of 4 MAbs (D20, D27, T20, and T22) binding to noncleavable gp160 revealed that these anti-CD4 MAbs bound with a delay,
and that the epitope formed with a t 1/2 of about 10 minutes [Otteken1996]
• D20: Used for comparison in a study of gp41 antibodies – D20 binds to a greater extent to cell surface expressed Env than any of 38 conformation
dependent anti-gp41 MAbs [Earl1997]
• D20: A comparison of 25 gp120 specific, conformation dependent MAbs was done – D20 is part of a group of MAbs labeled A1 – all A1 MAbs were
broadly cross-reactive with gp160 from B-clade R5, X4, and R5X4 viruses, blocked CD4 binding, were sensitive to mutations in gp120 positions 368 and
370 that directly contact CD4 [Sugiura1999]
911 D21 Env gp120 (IIIB) Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
Ab type CD4BS Donor P. Earl, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
References Earl1994, Sugiura1999
• D21: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• D21: A comparison of 25 gp120 specific, conformation dependent MAbs was done – D21 is part of a group of MAbs labeled A1 – all A1 MAbs were
broadly cross-reactive with gp160 from B-clade R5, X4, and R5X4 viruses, blocked CD4 binding, were sensitive to mutations in gp120 positions 368 and
370 that directly contact CD4 [Sugiura1999]
912 D24 Env gp120 (IIIB) no Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
Ab type CD4BS Donor P. Earl, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
References Earl1994, Sugiura1999
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• D24: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• D24: A comparison of 25 gp120 specific, conformation dependent MAbs was done – D24 is part of a group of MAbs labeled B-I, that had limited
cross-reactivity – of seven clade B isolates BH8 and B-al were they only two that consistently reacted with B-I MAbs – B-I MAbs fully blocked CD4
binding [Sugiura1999]
913 D25 Env gp120 (IIIB) Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
Ab type CD4BS Donor P. Earl, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
References Earl1994, Sugiura1999
• D25: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• D25: A comparison of 25 gp120 specific, conformation dependent MAbs was done – D25 is part of a group of MAbs labeled A1 – all A1 MAbs were
broadly cross-reactive with gp160 from B-clade R5, X4, and R5X4 viruses, blocked CD4 binding, were sensitive to mutations in gp120 positions 368 and
370 that directly contact CD4 [Sugiura1999]
914 D28 Env gp120 (IIIB) no Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
Ab type CD4BS Donor P. Earl, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
References Earl1994, Sugiura1999
• D28: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• D28: A comparison of 25 gp120 specific, conformation dependent MAbs was done – D28 is part of a group of MAbs labeled B-I, that had limited
cross-reactivity – of seven clade B isolates BH8 and B-al were they only two that consistently reacted with B-I MAbs – B-I MAbs fully blocked CD4
binding [Sugiura1999]
915 D35 Env gp120 (IIIB) Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
Ab type CD4BS Donor P. Earl, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
References Earl1994, Sugiura1999
• D35: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• D35: A comparison of 25 gp120 specific, conformation dependent MAbs was done – D35 is part of a group of MAbs labeled B-I, that had limited
cross-reactivity – of seven clade B isolates BH8 and B-al were they only two that consistently reacted with B-I MAbs – B-I MAbs fully blocked CD4
binding [Sugiura1999]
916 D39 Env gp120 (IIIB) Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
Ab type CD4BS Donor P. Earl, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
References Earl1994, Sugiura1999
• D39: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• D39: A comparison of 25 gp120 specific, conformation dependent MAbs was done – D39 is part of a group of MAbs labeled A1 – all A1 MAbs were
broadly cross-reactive with gp160 from B-clade R5, X4, and R5X4 viruses, blocked CD4 binding, were sensitive to mutations in gp120 positions 368 and
370 that directly contact CD4 [Sugiura1999]
917 D42 Env gp120 (IIIB) Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
Ab type CD4BS Donor P. Earl, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
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References Earl1994, Sugiura1999
• D42: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• D42: A comparison of 25 gp120 specific, conformation dependent MAbs was done – D42 is part of a group of MAbs labeled B-I, that had limited
cross-reactivity – of seven clade B isolates BH8 and B-al were they only two that consistently reacted with B-I MAbs – B-I MAbs fully blocked CD4
binding [Sugiura1999]
918 D52 Env gp120 (IIIB) Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
Ab type CD4BS Donor P. Earl, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
References Earl1994, Sugiura1999
• D52: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• D52: A comparison of 25 gp120 specific, conformation dependent MAbs was done – D52 is part of a group of MAbs labeled B-I, that had limited
cross-reactivity – of seven clade B isolates BH8 and B-al were they only two that consistently reacted with B-I MAbs – B-I MAbs fully blocked CD4
binding [Sugiura1999]
919 D53 Env gp120 (IIIB) Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
Ab type CD4BS Donor P. Earl, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
References Earl1994, Sugiura1999
• D53: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• D53: A comparison of 25 gp120 specific, conformation dependent MAbs was done – D53 is part of a group of MAbs labeled B-I, that had limited
cross-reactivity – of seven clade B isolates BH8 and B-al were they only two that consistently reacted with B-I MAbs – B-I MAbs fully blocked CD4
binding [Sugiura1999]
920 D60 Env gp120 (IIIB) no Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
Ab type CD4BS Donor P. Earl, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
References Earl1994, Richardson1996, Sugiura1999
• D60: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• D60: A comparison of 25 gp120 specific, conformation dependent MAbs was done – D60 is part of a group of MAbs labeled B-I, that had limited
cross-reactivity – of seven clade B isolates BH8 and B-al were they only two that consistently reacted with B-I MAbs – B-I MAbs fully blocked CD4
binding [Sugiura1999]
921 DA48 Env gp120 (BRU) HIV-1 infection human
Ab type CD4BS
References Parren1998a, Sullivan1998a
• DA48: The rank order of Fab binding affinity to monomeric gp120 (Loop 2 > 3B3 > b12 = DO8i > b11 > b3 > b14 > b13 > DO142-10 > DA48 > L17) was
markedly different than Fab binding affinity to the mature oligomeric form (3B3 > b12 > DO142-10 > Loop 2 > b11 > L17 > b6 > DO8i > b14 > DA48 > b3
> b13) and binding to oligomeric form and neutralization were correlated for both Fabs and MAbs – authors suggest that neutralization is determined by the
fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
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• DA48: The HIV-1 virus YU2 entry can be enhanced by MAbs binding to the CD4BS, V3 loop, and CD4i epitopes – the activation for this enhanced entry
state could be conferred on HxB2 by introducing the YU2 V3 loop, or the YU2 V3 and V1/V2 loops – a similar effect is observed by sub-neutralizing
concentrations of sCD4 and the effect is dependent of CCR5 – Fab Ab fragment DA48 also enhances YU2 entry, ruling out Fc interactions or Env
cross-linking as a mechanism – while DA48 enhances YU2, it neutralizes HXBc2 – DA48 was obtained by panning libraries derived from bone marrow
from a >15 year long term non-progressor against BRU gp120 [Sullivan1998a]
922 DO8i Env gp120 (BRU) HIV-1 infection human Fab
Ab type CD4BS
References Parren1998a
• DO8i: The rank order of Fab binding affinity to monomeric gp120 (Loop 2 > 3B3 > b12 = DO8i > b11 > b3 > b14 > b13 > DO142-10 > DA48 > L17) was
markedly different than Fab binding affinity to the mature oligomeric form (3B3 > b12 > DO142-10 > Loop 2 > b11 > L17 > b6 > DO8i > b14 > DA48 > b3
> b13) and binding to oligomeric form and neutralization were correlated for both Fabs and MAbs – authors suggest that neutralization is determined by the
fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
• DO8i – the HIV-1 virus YU2 entry can be enhanced by MAbs binding to the CD4BS, V3 loop, and CD4i epitopes – the activation for this enhanced entry
state could be conferred on HxB2 by introducing the YU2 V3 loop, or the YU2 V3 and V1/V2 loops – a similar effect is observed by sub-neutralizing
concentrations of sCD4 and the effect is dependent of CCR5 – Fab fragment DO8i also enhances YU2 entry, ruling out Fc interactions or Env cross-linking
as a mechanism, while neutralizing HXBc2 – DO8i was obtained by panning libraries derived from bone marrow from a long term asymptomatic donor
against BRU gp120 [Sullivan1998a]
923 F105 (F-105) Env gp120 L HIV-1 infection human (IgG1κ)
Ab type CD4BS DonorMarshall Posner, Boston MA
References Posner1991, Thali1991, Thali1992a, Marasco1992, Wyatt1992, Posner1992b, Posner1992a, Moore1993a, Posner1993, Cavacini1993a,
Cavacini1993b, Wyatt1993, Montefiori1993, Potts1993, Klasse1993a, Pincus1993b, Watkins1993, Marasco1993, Bagley1994, Thali1994, Cook1994,
Cavacini1994b, Cavacini1994a, Earl1994, Chen1994a, Turbica1995, Posner1995, Cavacini1995, Sullivan1995, Khouri1995, Jagodzinski1996, Wolfe1996,
McDougal1996, Wisnewski1996, Pincus1996, Litwin1996, Chen1996, Parren1997c, D’Souza1997, Li1997, Cao1997b, Wyatt1997, Wyatt1998a,
Cavacini1998b, Li1998, Cavacini1998a, Brand1998, Sullivan1998a, Kropelin1998, Sugiura1999, Giraud1999, Cavacini1999, Oscherwitz1999a,
Robert-Guroff2000, Baba2000, Park2000, Yang2000, Si2001, Kolchinsky2001, York2001, Yang2002, Xu2002, Chakrabarti2002, Xiang2002b,
Edwards2002, Grundner2002, Basmaciogullari2002, Zhang2002, Ferrantelli2002, Liu2002, Pantophlet2003
• F105: First description of F105, binds topographically near the CD4-binding site – inhibits binding of free, infectious virions to uninfected HT-H9 cells, but
does not react with virus adsorbed to uninfected HT-H9 cells – soluble rCD4 pre-bound to infected cells inhibits F105 binding – F105 inhibits infection of
HT-H9 cells in standard neutralization assays with HIV-1 and MN strains [Posner1991]
• F105: F105 neutralization escape mutants result from changes in amino acids in discontinuous regions: C2, 256-262 and C3, 386-370 [Thali1991]
• F105: Amino acid substitutions that impair F105 neutralization inhibit gp120-CD4 interaction [Thali1992a]
• F105: MAb cDNA sequence – V H4 V71-4 rearranged with a D H D-D fusion product of dlr4 and da4, and with J H5 – V kappa is from the Humvk325
germline gene joined with Jkappa 2 [Marasco1992]
• F105: Precipitation of Delta 297-329 env glycoprotein, which has a deleted V3 loop, is much more efficient than precipitation of wild type [Wyatt1992]
• F105: F105 mediates ADCC against SF2 through the CD16+ population of PBMC – does not mediate complement-dependent cytotoxicity [Posner1992b]
• F105: Significant enhancement of F105 binding to RF infected cells preincubated with V3-specific MAbs V3-2 and V3-1 [Posner1992a]
• F105: Called F-105 – neutralizes IIIB – strong inhibition of HIV+ human sera binding to IIIB gp120 [Moore1993a]
• F105: F105 binds to and neutralizes selected lab strains and 3/9 HIV-1 primary isolates – synergistic enhancement of neutralization by seropositive sera
[Posner1993]
• F105: No neutralization of primary isolates observed (John Moore, pers comm)
• F105: Additive MN or SF2 neutralization when combined with anti-V3 MAbs 447-52D and 257-D [Cavacini1993a]
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• F105: Serum from all asymptomatic HIV-1 positive people tested block F105 binding, but only from 27% of symptomatic individuals [Cavacini1993b]
• F105: Binding to Delta V1/2 and Delta V1/2/3 mutant glycoproteins is 2.4- and 13-fold greater, respectively, than binding to wildtype gp120 [Wyatt1993]
• F105: Study of synergism between F105 and sera from vaccinated volunteers with V3-loop specific neutralization activity – 2/3 sera demonstrated
neutralization synergy, and 3/3 binding/fusion-inhibition synergy [Montefiori1993]
• F105: Study of synergism of neutralization and binding comparing F105 and sCD4 with the V3 MAbs: 50.1, 59.1, 83.1, and 58.2 – synergy was observed,
and the data suggest that binding of one ligand (F105) can increase the binding of the second (e. g. V3 loop MAbs) due to conformational changes
[Potts1993]
• F105: The gp41 mutation 582(Ala to Thr) results in conformational changes in gp120 that confer neutralization resistance to a class of conformation
sensitive neutralizing MAbs – required >81 fold higher concentrations to neutralize the mutant than wild type [Klasse1993a]
• F105: Ab response in IIIB lab workers was compared to gp160 LAI vaccine recipients – F105 was used as a control – infected lab workers and some of the
gp160 vaccinees had a MAb response that could inhibit gp120-CD4 binding, at lower titers than the infected lab workers [Pincus1993b]
• F105: A neutralization escape mutant (HXB2 A281V) was selected by growth of HXB2 in the presence of broadly neutralizing sera – F105 neutralization
was not affected by this mutation [Watkins1993]
• F105: Comparison of MAb F105 sequences with those of MAbs 21h and 15e [Bagley1994]
• F105: A mutation in gp41, 582 A/T, confers resistance to neutralization (also confers resistance to MAbs 48d, 21h, 15e and 17b) [Thali1994]
• F105: MAbs against the glycosphingolipid GalCer block HIV infection of normally susceptible CD4 negative cells from the brain and colon – anti-CD4
MAbs moderately inhibit gp120 binding to GalCer, possibly through steric hindrance – binding of GalCer to gp120 inhibited but did not completely block
F105 binding[Cook1994]
• F105: Administered intravenously to four cynomologus monkeys, plasma pharmacokinetics and biological activity tested [Cavacini1994b]
• F105: Fab fragments show reduced capacity to neutralize IIIB, MN, and RF compared to intact IgG1, suggesting bivalent interaction may be important in
binding and neutralization [Cavacini1994a]
• F105: Used as a positive control for CD4 BS antibodies in a study of the influence of oligomeric structure of Env in determining the repertoire of the Ab
response [Earl1994]
• F105: A human CD4+ T lymphocyte line was transduced to express Fab fragments of F105 – heavy and light chains are joined by an inter-chain linker – in
the transduced cells infected with HIV-1, the Fab binds intracellularly to the envelope protein and inhibits HIV-1 production – secreted Fab fragments
neutralize cell-free HIV-1 – combined intra- and extracellular binding activities of the expressed Fab make transduced cells resistant to HIV-1 infection and
also can protect surrounding lymphocytes by secreting neutralizing antibodies [Marasco1993, Chen1994a]
• F105: An immunoassay for titrating CD4BS serum antibody was developed using a gp120-coated solid phase and competition with MAb F105 – 109/110
French HIV-1+ sera and 51/56 HIV-1+ African sera had detectable CD4BS Abs using this assay, demonstrating CD4 binding site conservation among
diverse subtypes – CD4BS Abs were detected soon after seroconversion and persisted – 0/21 HIV-2+ sera reacted, indicating that the HIV-1 and HIV-2
CD4BS Abs are not cross-reactive [Turbica1995]
• F105: Eight patient phase Ia trial for use as an immunotherapeutic – no clinical or biochemical side effects observed, plasma levels of 10 ug/ml maintained
for 21 days [Posner1995]
• F105: Efficient neutralization of T-cell adapted lines HXBc2 and MN, no neutralization of primary isolates 89.6, ADA and YU2 – even some enhancement
of infection of ADA and YU2 was observed [Sullivan1995]
• F105: Biotinylated F105 was used for competition studies with Ab derived from pregnant HIV-1+ women – a correlation between maternal anti-CD4 BS
Abs overlapping the F105 binding site and lack of HIV-1 transmission to infants was noted [Khouri1995]
• F105: Changing heavy chain from IgG1 to IgG3 increased neutralization efficiency [Cavacini1995]
• F105: The sulfated polysaccharide curdlan sulfate (CRDS) binds to the Envelope of T-tropic viruses and neutralizes virus – deletion of the V3 loop results
in less potent inhibition of F105 binding by CRDS – binding site of F105 described as 256-257 ST, 368-370 DPE, 421 K, and 470-484
PGGGDMRDNWRSELY [Jagodzinski1996]
• F105: Phase I study – MAb clearance in plasma has a 13 day half-life [Wolfe1996]
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• F105: Neutralizes HIV-1 LAI less potently than V3 specific MAbs [McDougal1996]
• F105: F105 is V H4 – V-region heavy chain usage was examined and a bias of enhanced V H1 and V H4, and reduced V H3, was noted among HIV
infected individuals [Wisnewski1996]
• F105: A panel of immunotoxins were generated by linking Env MAbs to ricin A – immunotoxins mediated cell killing, but killing was not directly
proportional to binding [Pincus1996]
• F105: Binding of F105 to oligomeric gp120 occurs despite the fact it cannot neutralize primary isolates [Litwin1996]
• F105: Intracellular co-expression of heavy and light chains of the Fab105 fragment MAb F105 was enhanced by inclusion of an internal ribosome entry site
(IRES) sequence – the Fab105 IRES expression cassette was cloned into an adeno-associated virus (AAV) shuttle vector, and transduced into human
lymphocytes which were able to produce and secrete the Fab105 fragments while maintaining normal growth – several primary HIV-1 patient isolates were
effectively blocked [Chen1996]
• F105: Neutralizes TCLA strains, but not primary isolates [Parren1997c]
• F105: In a multilaboratory blinded study, failed to neutralize any of nine B clade primary isolates [D’Souza1997]
• F105: One of 14 human MAbs tested for ability to neutralize a chimeric SHIV-vpu+, which expressed HIV-1 IIIB env – F105 could only achieve 50%
neutralization alone – all Ab combinations tested showed synergistic neutralization – F105 has synergistic response with MAbs 694/98-D (anti-V3), 48d,
2F5, and 2G12, and also with HIVIG [Li1997]
• F105: Virus with the V1-V2 loop deleted was viable and more susceptible to neutralization by CD4i MAb 17b, and anti-V3 MAbs 1121, 9284, and 110.4,
but not to a CD4BS MAb, F105 or sCD4 [Cao1997b]
• F105: Binds both gp120 and soluble gp120+gp41 complex efficiently, suggesting its gp120 epitope is not blocked by gp41 binding – does not bind to
HXBc2 gp120 if the 19 C-term amino acids, in conjunction with C1 positions 31-93, are deleted [Wyatt1997]
• F105: Summary of the implications of the crystal structure of the core of gp120 bound to CD4 and 17b with what is known about mutations that reduce
NAb binding – probable mechanism of neutralization by CD4BS Ab is direct interference with CD4 binding [Wyatt1998a]
• F105: Phase I dose escalation study, single dose of 100 or 500 mg/m2 was given to 4 HIV+ patients – sustained levels, no immune response against F105,
no toxicity, infused Ab retained function – there was no evidence of anti-HIV-1 activity and virus was not diminished at day 1 or 7, by culture or plasma
RNA [Cavacini1998b]
• F105: Neutralization synergy was observed when the MAbs 694/98-D (V3), 2F5 (gp41), and 2G12 (gp120 discontinuous) were used in combination, and
even greater neutralizing potential was seen with the addition of a fourth MAb, F105 (CD4 BS) [Li1998]
• F105: The MAb F240 binds to the immunodominant region of gp41 and enhances infection in the presence of complement – reactivity of F240 is enhanced
by preincubation of cells with sCD4 or anti-CD4BS MAb F105 [Cavacini1998a]
• F105: Immunoprecipitation of gp120 and gp160 expressed from a rec Semliki Forest virus by F105 and IgG1b12 indicated that the SFV expressed HIV-1
Env was folded appropriately – and SVF-HIV-1 Env vaccine gave the strongest anti-HIV-1 Env response in mice, when compared to an HIV-1 Env DNA
vaccine and a rgp160 protein [Brand1998]
• F105: A comparison of 25 gp120 specific, conformation dependent MAbs was done and F105 was used for competition studies – F105 did cross-compete
with multiple CD4BS specific MAbs, however most could not neutralize even the autologous NL4-3 strains [Sugiura1999]
• F105: F105 enhances viral entry of viruses carrying the YU2 envelope glycoproteins, but neutralizes HXBc2 [Sullivan1998a]
• F105: Anti-C1 region MAb 87-135/9 blocks gp120 interaction with CD4+ cells – blocking activity is additive when combined with antibodies which bind
in the C4 region of gp120 (F105, 388/389, and b12) [Kropelin1998]
• F105: A mini-review of observations of passive administration of IgG NAbs conferring protection against intervenous or vaginal SHIV challenge, that
considers why IgG MAbs might protect against mucosal challenge [Robert-Guroff2000]
• F105: A triple combination of 2F5, F105 and 2G12 effectively neutralized perinatal infection of macaque infants when challenged with SHIV-vpu+ – the
plasma half-life was 7.2 +/- 2.2 days [Baba2000]
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• F105: Host encoded intercellular adhesion molecule (ICAM-1) is incorporated by the HIV-1 virion and enhances viral infectivity – ICAM-1 does not
modify virus sensitivity to antibodies 0.5beta or 4.8D or sCD4, but neutralizing ability of F105 was diminished in ICAM bearing virions in the presence of
lymphocyte function-association antigen-1 (LFA-1) Ab [Fortin2000]
• F105: Six mutations in MN change the virus from a high-infectivity neutralization resistant phenotype to low-infectivity neutralization sensitive – V3,
CD4BS, and CD4i MAbs are 20-100 fold more efficient at neutralizing the sensitive form, although F105 was an exception and cannot neutralize either
form of MN – the mutation L544P reduced binding of all MAbs against gp120 by causing conformational changes [Park2000]
• F105: A combination of gp41 fusion with the GNC4 trimeric sequences and disruption of the YU2 gp120-gp41 cleavage site resulted in stable gp140
trimers (gp140-GNC4) that preserve and expose some neutralizing epitopes while occluding some non-neutralizing epitopes – CD4BS MAbs (F105 and
F91) and CD4i (17b and 48d) recognized gp140-GNC4 as well as gp120 or gp140 – non-neutralizing MAbs C11, A32, 522-149, M90, and #45 bound to the
gp140-GNC4 glycoprotein at reduced levels compared to gp120 – MAbs directed at the extreme termini of gp120 C1 (135/9 and 133/290) and C5 (CRA-1
and M91) bound efficiently to gp140-GNC4 [Yang2000]
• F105: SHIV-HXBc2 is a neutralization sensitive non-pathogenic virus, and several in vivo passages through monkies yielded highly pathogenic SHIV
KU-1—HXBc2 and the KU-1 clone HXBc2P3.2 differ in 12 amino acids in gp160—substitutions in both gp120 and gp41 reduced the ability of sCD4,
IgG1b12, F105 and AG1121 to Env achieve saturation and full occupancy, and neutralize KU-1—17b and 2F5 also bound less efficiently to HXBc2P3.2,
although 2G12 was able to bind both comparably [Si2001].
• F105: Mutations in two glcosylation sites in the V2 region of HIV-1 ADA at positions 190 and 197 (187 DNTSYRLINCNTS 199) cause the virus to
become CD4-independent and able to enter cells through CCR5 alone – these same mutations tended to increase the neutralization sensitivity of the virus,
including to F105 [Kolchinsky2001]
• F105: Abs against the V3 loop (50.1, 58.2, 59.1, 257-D, 268-D, 447-52D), CD4BS (IgG1b12, 559-64D, F105), CD4i (17b), and to gp41 (2F5, F240) each
showed similar binding efficiency to Env derived from related pairs of primary and TCLA lines (primary: 168P and 320SI, and TCLA: 168C and
320SI-C3.3), but the TCLA lines were much more susceptible to neutralization suggesting that the change in TCLA lines that make them more susceptible
to NAbs alters some step after binding [York2001]
• F105: Uncleaved soluble gp140 (YU2 strain, R5 primary isolate) can be stabilized in an oligomer by fusion with a C-term trimeric GCN4 motif or using a
T4 trimeric motif derived from T4 bacteriophage fibritin—stabilized oligomer gp140δ683(-FT) showed strong preferential recognition by NAbs IgG1b12
and 2G12 relative to the gp120 monomer, in contrast to poorly neutralizing MAbs F105, F91, 17b, 48d, and 39F which showed reduced levels of binding,
and C11, A32, and 30D which did not bind the stabilized oligomer [Yang2002].
• F105: Passive immunization of neonate macaques with a combination of F105+2G12+2F5 conferred complete protection against oral challenge with
SHIV-vpu+ or – the combination b12+2G12+2F5 conferred partial protection against SHIV89.6 – such combinations may be useful for prophylaxis at birth
and against milk born transmission – the synergistic combination of IgG1b12, 2G12, 2F5, and 4E10 neutralized a collection of HIV clade C primary
isolates [Xu2002]
• F105: A modified gp140 (gp140deltaCFI), with C-term mutations intended to mimic a fusion intermediate and stabilize trimer formation, retained antigenic
conformational determinants as defined by binding to CD4 and to MAbs 2F5, 2G12, F105, and b12, and enhanced humoral immunity without diminishing
the CTL response in mice injected with a DNA vaccine [Chakrabarti2002]
• F105: A series of mutational changes were introduced into the YU2 gp120 that favored different conformations – 375 S/W seems to favor a conformation of
gp120 closer to the CD4-bound state, and is readily bound by sCD4 and CD4i MAbs (17b, 48d, 49e, 21c and 23e) but binding of anti-CD4BS MAbs (F105,
15e, IgG1b12, 21h and F91 was markedly reduced – IgG1b12 failed to neutralize this mutant, while neutralization by 2G12 was enhanced – 2F5 did not
neutralize either WT or mutant, probably due to polymorphism in the YU2 epitope – another mutant, 423 I/P, disrupted the gp120 bridging sheet, favored a
different conformation and did not bind CD4, CCR5, or CD4i antibodies, but did bind to CD4BS MAbs [Xiang2002b]
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• F105: Truncation of the gp41 cytoplasmic domain of X4, R5, and X4R5 viruses forces a conformation that more closely resembles the CD4 bound state of
the external Envelope, enhancing binding of CD4i MAbs 17b and 48d and of CD4BS MAbs F105, b12, and in most cases of glycosylation site dependent
MAb 2G12 and the anti-gp41 MAb 246D – in contrast, binding of the anti-V2 MAb 697D and the anti-V3 MAb 694/98D were not affected – viruses
bearing the truncation were more sensitive to neutralization by MAbs 48d, b12, and 2G12 – the anti-C5 MAb 1331A was used to track levels of cell surface
expression of the mutated proteins [Edwards2002]
• F105: HIV-1 gp160δCT (cytoplasmic tail-deleted) proteoliposomes (PLs) containing native, trimeric envelope glycoproteins from R5 strains YU2 and
JRFL, and X4 strain HXBc2, were made in a physiologic membrane setting as candidate immunogens for HIV vaccines—2F5 bound to gp160δCT with a
reconstituted membrane ten-fold better than the same protein on beads, while such an affinity difference was not seen with F105 and 2G12—anti-CD4BS
MAbs IgG1b12 and F105, A32 (C1-C4), C11 (C1-C5), and 39F (V3) MAbs bound gp160δCT PLs indistinguishably from gp160δCT expressed on the cell
surface [Grundner2002].
• F105: gp120 mutants were used to define the CXCR4 binding site using CXCR4 displayed on paramagnetic proteoliposomes (PMPLs) to reduce
non-specific gp120 binding—basic residues in the V3 loop and the β19 strand (RIKQ, positions 419-422) were involved, and deletion of the V1-V2 loops
allowed CD4-independent CXCR4 binding—MAbs 17b (CD4i) and F105 (CD4BS) were used to study conformational changes in the mutants—the affinity
of ∆V1 and ∆V1-V2 mutants for F105 was comparable to the wildtype—V3 mutants did not affect F105 binding—the K421A mutation in the β19 strand
dramatically reduced F105 affinity, consistent with what is known about the F105 epitope [Basmaciogullari2002].
• F105: A rare mutation in the neutralization sensitive R2-strain in the proximal limb of the V3 region caused Env to become sensitive to neutralization by
MAbs directed against the CD4 binding site (CD4BS), CD4-induced (CD4i) epitopes, soluble CD4 (sCD4), and HNS2, a broadly neutralizing sera – 2/12
anti-V3 MAbs tested (19b and 694/98-D) neutralized R2, as did 2/3 anti-CD4BS MAbs (15e and IgG1b12), 2/2 CD4i MAbs (17b and 4.8D), and 2G12 and
2F5 – thus multiple epitopes on R2 are functional targets for neutralization and the neutralization sensitivity profile of R2 is intermediate between the highly
sensitive MN-TCLA strain and the typically resistant MN-primary strain [Zhang2002]
• F105: Review of NAbs that notes that F105 binds the CD4BS, in combination with other MAbs it can protect some macaques against SHIV infection, and
that it has strong ADCC activity [Ferrantelli2002]
• F105: Review of NAbs that discusses mechanisms of neutralization, passive transfer of NAbs and protection in animal studies, and vaccine strategies
[Liu2002]
• F105: Virion capture assays are not a good preditor of neutralization, and the presentation of epitopes using this assay seems to be different from that of
functional Envelope spikes on primary isolates – F105 and b6 could efficiently block the b12-mediated capture of infectious virions in a virus capture, but
did not inhibit b12 neutralization – while b12 was potent at neutralizing the three primary virions JR-CSF, ADA, and 89.6, the Abs F105, 19b, and Fab b6
were overall very poor neutralizers [Poignard2003]
• F105: Alanine scanning mutagenesis was used to compare substitutions that affected anti-CD4BS NAb b12 – rec gp120s were engineered to contain
combinations of Alanine substitutions that enhanced b12 binding, and while binding of b12 to these gp120 monomers was generally maintained or
increased, binding by five non-neutralizing anti-CD4bs MAbs (b3, b6, F105, 15e, and F91) was reduced or completely abolished [Pantophlet2003]
• F105: NIH AIDS Research and Reference Reagent Program: 857
924 F91 (F-91) Env gp120 No
Ab type CD4BS Donor James Robinson, University of Connecticut, Storrs
ReferencesMoore1993a, Moore1994b, Moore1996, Fouts1997, Mondor1998, Parren1998a, Binley1998, Fouts1998, Yang2000, Yang2002, Xiang2002b,
Pantophlet2003
• F91: Called F-91 – neutralizes IIIB – reactive with SF-2 gp120 – strong inhibition of HIV+ human sera binding to IIIB gp120 [Moore1993a]
• F91: Has strong cross-reactivity with gp120 monomers from most subtypes, A-F [Moore1994b]
• F91: Unusual pattern of reciprocal enhancement with several anti-V2 and V3 directed MAbs – reciprocal inhibition of other CD4BS MAbs [Moore1996]
• F91: Study shows neutralization is not predicted by MAb binding to JRFL monomeric gp120, but is associated with oligomeric Env binding – F91 bound
monomer, did not bind oligomer or neutralize JRFL [Fouts1997]
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• F91: Weak inhibition of binding of Hx10 to CD4 positive or negative cells, weakly neutralizing [Mondor1998]
• F91: The MAb and Fab binding to the oligomeric form of gp120 and neutralization were highly correlated – authors suggest that neutralization is
determined by the fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
• F91: A panel of MAbs were shown to bind with similar or greater affinity and similar competition profiles to a deglycosylated or variable loop deleted core
gp120 protein ( Delta V1, V2, and V3), thus such a core protein produces a structure closely approximating full length folded monomer – CD4BS MAbs
15e, F91 and IgG1b12 bound better to the deleted protein than to wild type [Binley1998]
• F91: CD4BS MAbs 15e, 21h, and F91 bind with even lower affinity than 205-43-1 and 205-42-15 to JRFL oligomer – conclusions of this paper contrast
with [Parren1998a] [Fouts1998]
• F91: A combination of gp41 fusion with the GNC4 trimeric sequences and disruption of the YU2 gp120-gp41 cleavage site resulted in stable gp140 trimers
(gp140-GNC4) that preserve and expose some neutralizing epitopes while occluding some non-neutralizing epitopes – CD4BS MAbs (F105 and F91) and
CD4i (17b and 48d) recognized gp140-GNC4 as well as gp120 or gp140 – non-neutralizing MAbs C11, A32, 522-149, M90, and #45 bound to the
gp140-GNC4 glycoprotein at reduced levels compared to gp120 – MAbs directed at the extreme termini of gp120 C1 (135/9 and 133/290) and C5 (CRA-1
and M91) bound efficiently to gp140-GNC4 [Yang2000]
• F91: Uncleaved soluble gp140 (YU2 strain, R5 primary isolate) can be stabilized in an oligomer by fusion with a C-term trimeric GCN4 motif or using a T4
trimeric motif derived from T4 bacteriophage fibritin – stabilized oligomer gp140 delta683(-FT) showed strong preferential recognition by NAbs IgG1b12
and 2G12 relative to the gp120 monomer, in contrast to poorly neutralizing MAbs F105, F91, 17b, 48d, and 39F which showed reduced levels of binding,
and C11, A32, and 30D which did not bind the stabilized oligomer [Yang2002]
• F91: A series of mutational changes were introduced into the YU2 gp120 that favored different conformations – 375 S/W seems to favor a conformation of
gp120 closer to the CD4-bound state, and is readily bound by sCD4 and CD4i MAbs (17b, 48d, 49e, 21c and 23e) but binding of anti-CD4BS MAbs (F105,
15e, IgG1b12, 21h and F91 was markedly reduced – IgG1b12 failed to neutralize this mutant, while neutralization by 2G12 was enhanced – 2F5 did not
neutralize either WT or mutant, probably due to polymorphism in the YU2 epitope – another mutant, 423 I/P, disrupted the gp120 bridging sheet, favored a
different conformation and did not bind CD4, CCR5, or CD4i antibodies, but did bind to CD4BS MAbs [Xiang2002b]
• F91: Alanine scanning mutagenesis was used to compare substitutions that affected anti-CD4BS NAb b12 – rec gp120s were engineered to contain
combinations of Alanine substitutions that enhanced b12 binding, and while binding of b12 to these gp120 monomers was generally maintained or
increased, binding by five non-neutralizing anti-CD4bs MAbs (b3, b6, F105, 15e, and F91) was reduced or completely abolished [Pantophlet2003]
925 GP13
(ARP3054)
Env gp120 L HIV-1 infection human (IgG1)
Ab type CD4BS
References
Schutten1993, Back1993, Bagley1994, Schutten1995a, Schutten1995b, Bolmstedt1996, Wisnewski1996, Schutten1996, Schutten1997, Vella2002
• GP13: Neutralized a broad range of HIV-1 strains from phylogenetically different subfamilies – the following gp120 amino acid substitutions strongly
inhibit binding: 256(S/Y), 257(T/G), 262(N/T), 368(D/R or K), 370(E/R or Q or D), 384(Y/E) [Schutten1993]
• GP13: Mutations in a neutralization resistant isolate obtained by passage of the IIIB isolate in chimpanzees reduced neutralization, but the escape was not
as clear as seen with anti-V3 MAbs [Back1993]
• GP13: Neutralizes IIIB – only slight inhibition of SI phenotype, and strong enhancement of NSI phenotype chimeric viruses, that incorporated different
envs from the same donor [Schutten1995a]
• GP13: Neutralizes T-cell adapted viruses but not the SI strain 16.2, despite high binding affinity [Schutten1995b]
• GP13: Sera were obtained from guinea pigs vaccinated either with gp160, or with gp160 lacking N-linked glycans at N406, N448, and N463 – these sera
could block equally well both the CD4 BS MAb GP13 and the V3 MAb F58/H3 [Bolmstedt1996]
• GP13: GP13 is V H5 – V-region heavy chain usage was examined and a bias of enhanced V H1 and V H4, and reduced V H3, was noted among HIV
infected individuals [Wisnewski1996]
• GP13: IIIB neutralizing MAbs in vitro fail to neutralize in a mouse model it in vivo [Schutten1996]
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• GP13: Neutralized (50%) an SI-env chimeric virus and enhanced (>5 fold) an NSI-env chimeric virus [Schutten1997]
• GP13: Called ARP3054: Herpesvirus saimiri-immortalized CD4+ T lymphocytes (HVS T cells) were used to isolate virus and perform HIV-1
neutralization assays, and compared with a standard PBMC protocol – neutralization sensitivities to a panel of MAbs and to homologous or heterologous
plasma/sera were similar for HVS T cells (CN-2 cells) and PBMCs [Vella2002]
• GP13: UK Medical Research council AIDS reagent: ARP3054
926 GP44 Env gp120 L HIV-1 infection human (IgG1)
Ab type CD4BS
References Schutten1993, Bagley1994, Wisnewski1996
• GP44: Exhibited a more restricted pattern of neutralizing activity than GP13 and GP68 – the following gp120 amino acid substitutions strongly inhibit
binding: 256(S/Y), 257(T/G), 262(N/T), 368(D/R or K), 370(E/R or Q or D) [Schutten1993]
• GP44: GP44 is V H1 – V-region heavy chain usage was examined and a bias of enhanced V H1 and V H4, and reduced V H3, was noted among HIV
infected individuals [Wisnewski1996]
927 GP68 Env gp120 L HIV-1 infection human (IgG1)
Ab type CD4BS
References Schutten1993, Klasse1993a, Bagley1994, Schutten1995a, Guillon2002
• GP68: Neutralized a broad range of HIV-1 lab strains from phylogenetically different subfamilies – the following gp120 amino acid substitutions strongly
inhibit binding: 117(K/W), 256(S/Y), 257(T/G), 262(N/T), 368(D/R or K), 370(E/R or Q), 384(Y/E), 435(Y/H) [Schutten1993]
• GP68: The gp41 mutation 582(Ala to Thr) results in conformational changes in gp120 that confer neutralization resistance to a class of conformation
sensitive neutralizing MAbs – GP68 required markedly higher concentrations to neutralize the mutant than wild type [Klasse1993a]
• GP68: Neutralizes IIIB – only slight inhibition of SI phenotype, and strong enhancement of NSI phenotype chimeric viruses, that incorporated different
envs from the same donor [Schutten1995a]
• GP68: GP68 is V H1 – V-region heavy chain usage was examined and a bias of enhanced V H1 and V H4, and reduced V H3, was noted among HIV
infected individuals [Wisnewski1996]
• GP68: The affect of Ab binding on infectivity was studied by pseudotyping three related envs with different phenotypes – R5 viruses were preferentially
enhanced, not X4 – the V3 region was the main determinant of Ab-mediated enhancement and modulation of the interaction between CCR5 and gp120 is
critical – tests with MAbs anti-V3 391/95-D and CD4BS-specific GP68 indicate that Ab specificity did not determine whether or not infectivity was
enhanced or neutralized, rather the phenotype was determined by Envelope conformation [Guillon2002]
• GP68: UK Medical Research Council AIDS reagent: ARP3055
928 HF1.7 Env gp120 L anti-idiotype murine (IgM)
Ab type CD4BS
References Chanh1987
• HF1.7: An anti-Id antibody stimulated by anti-CD4 MAb Leu-3a binds to recombinant gp160, suggesting HF1.7 mimics CD4 [Chanh1987]
929 HT5 Env gp120 L (weak) HIV-1 infection human
Ab type CD4BS Donor Ciba-Geigy AG (Basel, Switzerland), and Tanox Biosystems, Houston, Texas
ReferencesMoore1994b, Moore1995a, Fouts1997, Fouts1998, Herrera2003
• HT5: HT5, HT6, and HT7 are also known as 205-43-1, 205-42-15, and 205-46-9, respectively [Fouts1998]
• HT5: Despite highly cross-reactive binding to many primary and T-cell adapted viral strains, only weakly neutralizes IIIB and MN [Moore1995a]
• HT5: 205-46-9 was cross-reactive across clades A-F, 205-43-1 very cross-reactive but not quite as extensive 205-46-9 [Moore1994b]
• HT5: MAbs IgG1b12, HT5, HT6, and HT7 cross-compete for binding to monomeric gp120, bind equally well, inhibit gp120-sCD4 interactions, but only
IgG1b12 neutralizes JRFL [Fouts1997]
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• HT5: HT5 and HT6 bind JRSF oligomer but with low affinity, and are not neutralizing – conclusions of this paper contrast with [Parren1998a] [Fouts1998]
• HT5: Called 205-43-1 – CD4BS MAbs b12 (neutralizing) and 205-42-15, 204-43-1, 205-46-9 (nonneutralizing) all cross-competed for binding to
monomeric gp120, indicating the topological proximity of their epitopes, however, the nonneutralizing CD4BS MAbs did not interfere with the
neutralization activity of MAb b12 – the nonneutralizing MAbs partially competed with b12 for Env binding of the surface of Env-transfected cells – this
suggests Env has two categories of binding site for CD4BS MAbs, one recognized by both b12 and nonneutralizing CD4BS MAbs, the other is recognized
by only b12 – Ab-gp120 interactions based on the use of monomeric gp120 or Env-transfected cells do not predict the outcome of HIV-1 neutralization
assays, and they should be interpreted with caution [Herrera2003]
930 HT6 Env gp120 L (weak) HIV-1 infection human
Ab type CD4BS Donor Ciba-Geigy AG Basel, Switzerland, and Tanox Biosystems, Houston, Texas
ReferencesMoore1994b, Moore1995a, Fouts1997, Fouts1998, Herrera2003
• HT6: HT5, HT6, and HT7 are also known as 205-43-1 , 205-42-15, and 205-46-9, respectively [Fouts1998]
• HT6: Despite highly cross-reactive binding to many primary and T-cell adapted viral strains, only weakly neutralizes IIIB and MN [Moore1995a]
• HT6: 205-46-9 was cross-reactive across clades A-F, 205-43-1 was not quite as extensively cross-reactive [Moore1994b]
• HT6: MAbs IgG1b12, HT5, HT6, and HT7 cross-compete for binding to monomeric gp120, bind equally well, inhibit gp120-sCD4 interactions, but only
IgG1b12 neutralizes JRFL [Fouts1997]
• HT6: HT5 and HT6 bind JRSF oligomer but with low affinity, and are not neutralizing – conclusions of this paper contrast with [Parren1998a] [Fouts1998]
• HT6: Called 205-42-15 – CD4BS MAbs b12 (neutralizing) and 205-42-15, 204-43-1, 205-46-9 (nonneutralizing) all cross-competed for binding to
monomeric gp120, indicating the topological proximity of their epitopes, however, the nonneutralizing CD4BS MAbs did not interfere with the
neutralization activity of MAb b12 – the nonneutralizing MAbs partially competed with b12 for Env binding of the surface of Env-transfected cells – this
suggests Env has two categories of binding site for CD4BS MAbs, one recognized by both b12 and nonneutralizing CD4BS MAbs, the other is recognized
by only b12 – Ab-gp120 interactions based on the use of monomeric gp120 or Env-transfected cells do not predict the outcome of HIV-1 neutralization
assays, and they should be interpreted with caution [Herrera2003]
931 HT7 Env gp120 L (IIIB) HIV-1 infection human
Ab type CD4BS Donor Ciba-Geigy AG (Basel, Switzerland), and Tanox Biosystems, Houston, Texas
ReferencesMoore1994b, Moore1995a, Fouts1997, Fouts1998, Herrera2003
• HT7: HT5, HT6, and HT7 are also known as 205-43-1 , 205-42-15, and 205-46-9, respectively [Fouts1998]
• HT7: Despite highly cross-reactive binding to many primary and T-cell adapted viral strains, only neutralizes IIIB well, with sporadic weak neutralization
of other isolates [Moore1995a]
• HT7: 205-46-9 was cross-reactive across clades A-F, 205-43-1 was cross-reactive, but not quite as extensive [Moore1994b]
• HT7: MAbs IgG1b12, HT5, HT6, and HT7 cross-compete for binding to monomeric gp120, bind equally well, inhibit gp120-sCD4 interactions, but only
IgG1b12 neutralizes JRFL [Fouts1997]
• HT7: Binds JRSF oligomer with high affinity, at least as high as IgG1b12, but IgG1b12 is neutralizing, H7 is not – conclusions of this paper contrast with
[Parren1998a] – authors propose a model where H7 may inhibit CD4 binding, but cause a conformational shift which enhances CCR5 binding and thus
counteracts the neutralizing effect [Fouts1998]
• HT7: Called 205-46-9 – CD4BS MAbs b12 (neutralizing) and 205-42-15, 204-43-1, 205-46-9 (nonneutralizing) all cross-competed for binding to
monomeric gp120, indicating the topological proximity of their epitopes, however, the nonneutralizing CD4BS MAbs did not interfere with the
neutralization activity of MAb b12 – the nonneutralizing MAbs partially competed with b12 for Env binding of the surface of Env-transfected cells – this
suggests Env has two categories of binding site for CD4BS MAbs, one recognized by both b12 and nonneutralizing CD4BS MAbs, the other is recognized
by only b12 – Ab-gp120 interactions based on the use of monomeric gp120 or Env-transfected cells do not predict the outcome of HIV-1 neutralization
assays, and they should be interpreted with caution [Herrera2003]
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932 ICR 39.13g
(ICR39.13g,
39.13g)
Env gp120 L Vaccine rat (IgG2b)
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: gp120
Ab type CD4BS Donor Jackie Cordell and C. Dean
References Cordell1991, McKeating1992a, McKeating1992c, McKeating1993b, Moore1993a, Thali1993, Klasse1993a, McLain1994, Beretta1994,
McKeating1996b, Armstrong1996a, Klasse1996, Peet1998, Vella2002
• ICR 39.13g: Cross-competes with MAbs ICR 39.3b and 15e [Cordell1991]
• ICR 39.13g: Binds to a conformational epitope involved in CD4 binding – exerts a synergistic effect in combination with V3 directed MAbs
[McKeating1992a]
• ICR 39.13g: Neutralization activity against HXB10, RF, SF-2 and MN strains of HIV-1 [McKeating1993b]
• ICR 39.13g: Conformational, does not bind denatured gp120 – weak neutralization of IIIB – strong inhibition of HIV+ human sera binding to IIIB gp120
[Moore1993a]
• ICR 39.13g: Strongly inhibits CD4 inducible MAb 48d [Thali1993]
• ICR 39.13g: Kinetics of neutralization studied – no lag for 39.3b, while ICR 39.13g and ICR 41.1i have lags of 5 and 15 min respectively – mediates
neutralization with 2.3 molecules of IgG [McLain1994]
• ICR 39.13g: The gp41 mutation 582(Ala to Thr) results in conformational changes in gp120 that confer neutralization resistance to a class of conformation
sensitive neutralizing MAbs – ICR 39.13g required moderately higher concentrations to neutralize the mutant than wild type [Klasse1993a]
• ICR 39.13g: Called 39.13g Neutralizes HXB2, but fails to neutralize chimeric virus with gp120 from primary isolates in an HXB2 background
[McKeating1996b]
• ICR 39.13g: Post-attachment neutralization mechanism, in contrast to MAb 39.3b [Armstrong1996a]
• ICR 39.13g: Variants of LAI have differing neutralization susceptibility to 39.13g [Klasse1996]
• ICR 39.13g: The most variable amino acids in the V3 loop were replaced with serines to make the immunodominant V3 loop less immunogenic – these
changes did not affect the ability of sCD4 or MAbs to V1/V2, C1 and C4 to bind – ICR 39.13g was not affected by V3 serine substitutions – mice injected
with serine substituted gp120 had a reduced response relative to wildtype, and no enhanced immunogenicity of conserved regions [Peet1998]
• ICR 39.13g: Called ARP390/391, but no such entry was found at the UK Medical Research Council AIDS reagent web site: Herpesvirus
saimiri-immortalized CD4+ T lymphocytes (HVS T cells) were used to isolate virus and perform HIV-1 neutralization assays, and compared with a standard
PBMC protocol – neutralization sensitivities to a panel of MAbs and to homologous or heterologous plasma/sera were similar for HVS T cells (CN-2 cells)
and PBMCs [Vella2002]
• ICR 39.13g: UK Medical Research Council AIDS reagent: ARP390
933 ICR 39.3b
(39.3, 39.3b,
ICR39.3b)
Env gp120 L Vaccine rat (IgG2b)
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: gp120
Ab type CD4BS Donor J. Cordell and C. Dean
References Cordell1991, McKeating1992c, Moore1993c, McLain1994, Armstrong1996a, Jeffs1996, Wyatt1998a
• ICR 39.3b: also known as 39.3, 39.3b and ICR39.3b
• ICR 39.3b: Cross-competes with MAbs ICR 39.13g and 15e [Cordell1991]
• ICR 39.3b: Conformational, does not bind to denatured IIIB [Moore1993a]
• ICR 39.3b: Kinetics of neutralization studied – no lag for 39.3b, while ICR 39.13g and ICR 41.1i have lags of 5 and 15 min respectively [McLain1994]
• ICR 39.3b: Neutralizes only if the antibody is added prior to the attachment of the virus to the cell, in contrast to 39.13g [Armstrong1996a]
• ICR 39.3b: Called 39.3b – increased binding when V1/V2 or V1/V2 and V3 were deleted from gp120 [Jeffs1996]
• ICR 39.3b: Called 39.3 – summary of the implications of the crystal structure of the core of gp120 bound to CD4 and 17b with what is known about
mutations that reduce NAb binding – probable mechanism of neutralization by CD4BS Ab is direct interference with CD4 binding [Wyatt1998a]
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• ICR 39.3b: UK Medical Research Council AIDS reagent: ARP391
934 IgG1b12 (Fab
b12, Fab 3B3,
MAb
IgG1b12,
IgG1-b12,
IgG1 b12,
IgGB12,
b4/12, b12,
1b12, im-
munoglobulin
G1b12,
ARP3065,
IgG1 b12)
Env gp120 L P HIV-1 infection human (IgG1κ)
Ab type CD4BS Donor D. Burton, Scripps Research Institute, La Jolla, CA, also J. Geltowsky and J. Pyati, R. W. Johnson Pharmaceutical Research Inst.
La Jolla, CA
References Burton1991, Barbas III1992, Roben1994, Burton1994, Moore1994b, Sattentau1995a, Moore1995a, Moore1995b, Parren1995, Trkola1995,
Ditzel1995, Sullivan1995, Yang1997c, Moore1996, Gauduin1996, Poignard1996b, Poignard1996a, Trkola1996a, Sattentau1996, McKeating1996a,
D’Souza1997, Schutten1997, Mo1997, Fouts1997, Li1997, Kessler II1997, Moore1997, Stamatatos1997, Ditzel1997, Ugolini1997, Wyatt1997,
Burton1997, Boots1997, Parren1997c, Parren1997b, Parren1997a, Valenzuela1998, Wyatt1998a, Mondor1998, Parren1998a, Connor1998, Binley1998,
Fouts1998, Takefman1998, Parren1998b, Brand1998, Schonning1998, Sullivan1998a, Frankel1998, Kropelin1998, Stamatatos1998, Poignard1999,
Jackson1999, Hioe1999, Montefiori1999, Giraud1999, Beddows1999, Binley1999, Grovit-Ferbas2000, Ly2000, Nyambi2000, Park2000, Si2001,
Kolchinsky2001, Saphire2001a, Saphire2001b, Yang2001, York2001, Zwick2001a, Zwick2001b, Zwick2001c, Parren2001, Poignard2001,
Zeder-Lutz2001, Spenlehauer2001, Verrier2001, Hofmann-Lehmann2001, Xu2001, Srivastava2002, Golding2002b, Sanders2002, Schulke2002, Yang2002,
Saphire2002, Scanlan2002, Xu2002, Chakrabarti2002, Vella2002, Xiang2002b, Edwards2002, Grundner2002, Zhang2002, Klasse2002, Ferrantelli2002,
Liu2002, Poignard2003, Pantophlet2003, Herrera2003
• IgG1b12: Fab b12 was derived from IgG1b12, Fab 3B3 was derived from Fab b12 by random mutagenesis and selected for increased affinity to sgp120 –
database note
• IgG1b12: The original Fab fragment was derived from a combinatorial phage library from bone marrow of an HIV-1 positive individual who had been
asymptomatic for six years [Burton1991]
• IgG1b12: Anti-CD4 binding site Fab, potent neutralizing activity, greater affinity for a subpopulation of gp120 molecules suggested to be in a mature
confirmation – mutations in gp120 that abrogate binding: 368 D/R or D/T, 370 E/R, and 477 D/V, of clone HXBc2 of LAI – sensitive to V1 and V2
substitutions [Roben1994]
• IgG1b12: Very potent neutralization, of primary and lab strains, at concentrations that could be achieved by passive immunization – reduced binding with
A,C, and D clade viruses relative to B clade, poor reactivity with E clade – isolates that were refractive to neutralization by sera from HIV-1+ donors could
be neutralized by IgG1 b12 [Burton1994]
• IgG1b12: Cross-reactive with some gp120s, (but not all), from clades A-D – not reactive with gp120 from clades E or F [Moore1994b]
• IgG1b12: Formalin inactivation of virus at 0.1% formalin for 10 hours at 4 degrees was optimal for inactivation of virus while maintaining epitope integrity
[Sattentau1995c]
• IgG1b12: Anti-CD4 binding site MAb – very potent neutralization of a number of primary isolates [Moore1995a]
• IgG1b12: Complete protection against HIV-1 infection was achieved in hu-PBL-SCID mice by passive immunization with physiologically relevant doses –
pharmacokinetics showed serum half-life of 30.2 +/- 1.3 hours for Fab b12 and 7.4 +/- 0.7 days for IgG1 b12 in mice, but IgG1 half-lives in human are
generally between 21-23 days [Parren1995, Parren1997a]
• IgG1b12: Called BM12 – broad cross-clade neutralization of primary isolates – additive neutralization in combination with MAb 2F5 [Kessler1995]
• IgG1b12: Review: unusual properties for anti-CD4 BS MAb: sensitive to V2 substitutions, preferential recognition of the oligomer on the cell surface
[Moore1995b]
• IgG1b12: Could potently neutralize primary isolates from within clade B, but showed a slight reduction in efficacy outside of clade B [Trkola1995]
• IgG1b12: Because Fab b12 shows reduction in binding when the V2 loop is deleted and when aa 183/184 PI/SG substitutions are made competition studies
were done with Fab L78 and anti-V2 MAbs SC258 and 684-238 and they do not compete with IgG1b12 [Ditzel1995]
• IgG1b12: Fab b12 showed potent neutralization of T-cell-line-adapted strains, but much reduced neutralization of 3 primary isolates – 2 of the 3 primary
isolates also had reduced binding affinity, but the third was as efficiently immunoprecipitated as HXBc2 [Sullivan1995]
• IgG1b12: Saturation mutagenesis of the complementarity-determining region and optimization strategies were used to create very high affinity versions of
this Fab – increased affinity was dominated by a slowing of the off rate [Yang1997c]
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• IgG1b12: Potent neutralizing ex vivo of virus taken directly from plasma of HIV-1 infected individuals – little correlation between neutralization sensitivity
of passaged virus and plasma derived virus – more effective than MAb 19b [Gauduin1996]
• IgG1b12: Review: Unique among anti-CD4BS MAbs in terms of being potent against both lab adapted virus and primary isolates – one of three MAbs
(IgG1b12, 2G12, and 2F5) generally accepted as having significant potency against primary isolates [Poignard1996b]
• IgG1b12: Anti-CD4BS MAbs 15e, 21h, and IgG1b12 did not cause gp120 dissociation from virus, or exposure of the gp41 epitope of MAb 50-69, in
contrast to CD4i MAb 48d and anti-V3 neutralizing MAbs [Poignard1996a]
• IgG1b12: Neutralizes JR-FL – inhibits gp120 interaction with CCR-5 in a MIP-1beta-CCR-5 competition study [Trkola1996a]
• IgG1b12: Review: Only four epitopes have been described which can stimulate a useful neutralizing response to a broad spectrum of primary isolates,
represented by the binding sites of MAbs: 447-52-D, 2G12, Fab b12, and 2F5 [Sattentau1996]
• IgG1b12: In a multilab evaluation of monoclonal antibodies, only IgG1b12, 2G12, and 2F5 could neutralize at least half of the 9 primary test isolates at a
concentration of < 25 mug per ml for 90% viral inhibition – IgG1b12 failed to neutralize only 1/9 primary isolates, although there was some variation
between test sites [D’Souza1997]
• IgG1b12: Inhibited some SI- and NSI-env chimeric viruses but enhanced one NSI-env chimeric virus 3 fold [Schutten1997]
• IgG1b12: JRCSF was cultured in the presence of IgG1b12 until a 100-fold resistance to neutralization was selected – resistance was due to three changes:
V2 substitution D182N and C3 substitution P365L conferred resistance, and V2 D164N was also required for a viable virus – IgG1b12 resistant virus
remained sensitive to MAbs 2G12 and 2F5 [Mo1997]
• IgG1b12: Study shows neutralization is not predicted by MAb binding to JRFL monomeric gp120, but is associated with oligomeric Env binding –
IgG1b12 bound monomer, oligomer, and neutralized JRFL [Fouts1997]
• IgG1b12: b12 was used in its IgG1 form – of 14 human MAbs, the most potent neutralizer of SHIV-vpu+, which expressed HIV-1 IIIB env – all Ab
combinations tested showed synergistic neutralization – b12 has a synergistic response with MAbs 694/98-D (anti-V3), 2F5, and 2G12 [Li1997]
• IgG1b12: 35 primary isolates were tested and all were neutralized by IgG1b12 (including 4, UG270, RW92/026, ZB20, and 301727 which been had
reported as not neutralized by IgG1b12 [Trkola1995]) – IgG1b12 could neutralize even when added after the virus to the culture – selection for 400-fold
increased affinity did not enhance neutralization by antibody – IgG1b12 was more potent with greater breadth than MAb 2F5 [Kessler II1997]
• IgG1b12: Review: MAbs 2F5, 2G12 and IgG1b12 have potential for use in combination with CD4-IgG2 as an immunotherapeutic or immunoprophylactic
– homologous MAbs to these are rare in humans and vaccine strategies should consider including constructs that may enhance exposure of these MAbs’
epitopes [Moore1997]
• IgG1b12: Viral binding inhibition by IgG1b12 strongly correlated with neutralization (all other neutralizing MAbs tested showed some correlation except
2F5) [Ugolini1997]
• IgG1b12: Major deletions in C1 and C5 and deletions of the V1V2 and V3 loops do not diminish binding [Wyatt1997]
• IgG1b12: This is a review that includes a description of IgG1b12, noting approximately equivalent affinities for sgp120 and unprocessed gp160, and
somewhat enhanced affinity for the native oligomer on TCLA viruses – primary viruses have reduced affinity, but still in the useful range for neutralization
– there can be complete protection in hu-PBL-SCID mice with Ab even when administered several hours after viral challenge – competes with sCD4, but
unlike other CD4BS antibodies, it is sensitive to mutations in V2 [Burton1997]
• IgG1b12: In this review, the technique and potential application of Fab expression and selection in phage display libraries, and subsequent production of
IgG molecules is discussed – b12 is exceptionally potent at neutralization and can successfully neutralize most B clade primary isolates, and many isolates
from other subtypes as well – 3B3 was derived from b12 by selection for higher affinity using the CDR walking strategy – 3B3 has 8-fold enhancement of
binding, a linear correlation was found between neutralization and affinity, and 3B3 can neutralize strains b12 cannot [Parren1997a]
• IgG1b12: Abs that recognize discontinuous epitopes can identify mimotopes from a phage peptide display library – IgG1b12 blocks CD4 binding and is the
most potent neutralizing Ab – many 15 and 21-mer phage inserts were recognized, but it was not possible to derive a consensus – common features were a
W and at least one acidic residue, and one sequence was found multiple times: NWPRWWEEFVDKHSS, and this peptide could compete with gp120 – two
short stretches found in the phage peptides might mimic gp120 components of the epitope: positions 382-384, FFY(I), and 423-426 I(FV)I(V)NM
[Boots1997]
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• IgG1b12: Fab b12 is unusual in that it binds to gp140 and monomeric gp120 with similar affinities, and with a higher affinity to the native
oligomer—authors propose this antibody may be exceptional because it binds the virus rather than viral debris—IgG1b12 can protect against infection prior
to or shortly after challenge of hu-PBL-SCID mice with TCLA strains and primary strains, but the serum concentrations required in vivo were higher than
for in vitro neutralization [Parren1997c, Parren1997b].
• IgG1b12: MAb was slightly more efficient at neutralization than Fab – inhibits viral binding to cells and viral entry – doesn’t affect CD4-independent
binding to T-cells [Valenzuela1998]
• IgG1b12: Summary of the implications of the crystal structure of the core of gp120 bound to CD4 and 17b with what is known about mutations that reduce
NAb binding – probable mechanism of neutralization by CD4BS Ab is direct interference with CD4 binding – IgG1b12 is an unusual CD4BS antibody
because it is particularly potent as a neutralizing antibody and it is susceptible to changes in the V1-V2 stem loop structure, and so it may disrupt an
interaction between CD4 and conserved amino acids on the V1-V2 stem [Wyatt1998a]
• IgG1b12: Enhances binding of Hx10 to CD4 positive or negative HeLa cells, inhibits binding to CD4+ T-cell line A3.01 – neutralizes HeLa and A3.01 cell
Hx10 infection [Mondor1998]
• IgG1b12: IgG1b12, Fab b12 and 3B3 derived from b12 were all included in this study – the rank order of Fab binding affinity to monomeric gp120 (Loop 2
> 3B3 > b12 = DO8i > b11 > b3 > b14 > b13 > DO142-10 > DA48 > L17) was markedly different than Fab binding affinity to the mature oligomeric form
(3B3 > b12 > DO142-10 > Loop 2 > b11 > L17 > b6 > DO8i > b14 > DA48 > b3 > b13) and binding to oligomeric form and neutralization were correlated
for both Fabs and MAbs – authors suggest that neutralization is determined by the fraction of Ab sites occupied on a virion irrespective of the epitope –
binding affinity of divalent IgG1b12 is 17-fold greater than monovalent Fab b12 [Parren1998a]
• IgG1b12: Ab from gp120 vaccinated individuals prior to infection, who subsequently became HIV infected, could not achieve 90% neutralization of the
primary virus by which the individuals were ultimately infected – these viruses were not particularly refractive to neutralization, as determined by their
susceptibility to neutralization by MAbs 2G12, IgG1b12, 2F5 and 447-52D [Connor1998]
• IgG1b12: A panel of MAbs were shown to bind with similar or greater affinity and similar competition profiles to a deglycosylated or variable loop deleted
core gp120 protein ( Delta V1, V2, and V3), thus such a core protein produces a structure closely approximating full length folded monomer – CD4BS
MAbs 15e, F91 and IgG1b12 bound better to the deleted protein than to wild type [Binley1998]
• IgG1b12: Binds JRSF oligomer with high affinity, as do 205-46-9 and 2G6, but IgG1b12 is neutralizing, the other two are not – conclusions of this paper
contrast with Parren98 – authors propose a model where 205-46-9 and 2G6 may inhibit CD4 binding, but cause a conformational shift which enhances
CCR5 binding and thus counteracts the neutralizing effect – rank order of CD4BS antibodies oligomer binding is IgG1b12 = 2G6 = 205-46-9 > 205-43-1 =
205-42-15 > 15e = 21h = F91, and the only thing notably distinguishing about neutralizing IgG1b12 is that it depends on residues in V2 [Fouts1998]
• IgG1b12: Induces Complement-mediated lysis in MN but not primary isolates – primary isolates are refractive to CML [Takefman1998]
• IgG1b12: MAbs 2G12, 2F5 and b12 are broadly neutralizing, as are some human polyconal sera, but this paper describes a set of primary isolates that are
resistant to all three MAbs and 2 broadly neutralizing sera – results indicate that resistance levels of pediatric isolates might be higher than adult isolates –
resistance in general did not seem to be conferred by a loss of binding affinity for gp120 or gp41, rather by a more global perturbation of oligomeric
Envelope [Parren1998b]
• IgG1b12: Immunoprecipitation of gp120 and gp160 expressed from a rec Semliki Forest virus by F105 and IgG1b12 indicated that the SFV expressed
HIV-1 Env was folded appropriately – and SVF-HIV-1 Env vaccine gave the strongest anti-HIV-1 Env response in mice, when compared to an HIV-1 Env
DNA vaccine and a rgp160 protein [Brand1998]
• IgG1b12: MAbs 654-D100 and IgG1b12 neutralized viruses HIV-BRU and a mutated virus that lacks the V3 loop glycan equally effectively – in contrast,
sera from guinea pigs immunized with BRU gp120 neutralize viruses more effectively that lack the V3 glycan[Schonning1998]
• IgG1b12: Fab b12 – the HIV-1 virus YU2 entry can be enhanced by MAbs binding to the CD4BS, V3 loop, and CD4i epitopes – the activation for this
enhanced entry state could be conferred on HxB2 by introducing the YU2 V3 loop, or the YU2 V3 and V1/V2 loops – a similar effect is observed by
sub-neutralizing concentrations of sCD4 and the effect is dependent of CCR5 – Fab fragment b12 also enhances YU2 entry, ruling out Fc interactions or
Env cross-linking as a mechanism, while neutralizing HXBc2 [Sullivan1998a]
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• IgG1b12: anti-C1 region MAb 87-135/9 blocks gp120 interaction with CD4+ cells – blocking activity is additive when combined with antibodies which
bind in the C4 region of gp120 (F105, 388/389, and b12) [Kropelin1998]
• IgG1b12: Deleting the V2 loop of neutralization-resistant HIV-1 isolate SF162 does not abrogate its replication in PBMC or macrophages, but it enhances
its neutralization sensitivity to sera from patients with B clade infection up to 170-fold, and also enhances sensitivity to sera from clades A through F –
deletion of V2, but not V1, diminished neutralization by CD4BS MAb IgG1b12, in contrast to 654.30D and IgGCD4 [Stamatatos1998]
• IgG1b12: Infection of dendritic cells cultured from CD14+ blood cells or from cadaveric human skin was blocked by neutralizing MAbs IgG1b12, or 2F5
and 2G12 delivered together, but not by control non-neutralizing anti-gp120 MAb 4.8D, indicating that NAbs could interrupt early mucosal transmission
events [Frankel1998]
• IgG1b12: The presence of leukocyte function-associated molecule 1 (LFA-1) promotes virus infectivity and hinders neutralization, and anti-LFA-1 MAbs
can enhance the neutralizing effect of anti-HIV V3 MAb 447-52D and anti-HIV CD4BS MAb IgG1b12 – non-neutralizing anti-HIV CD4BS MAb 654-D
did not become neutralizing in the presence of anti-LFA-1 MAbs [Hioe1999]
• IgG1b12: rgp120 derived from a R5X4 subtype B virus was used to vaccinate healthy volunteers and the resulting sera were compared with sera from
HIV-1 positive subjects and neutralizing MAbs – TCLA strains showed enhanced IgG1b12 neutralization sensitivity relative to PBMC-adapted lines –
IgG1b12 was able to bind, with low affinity, to the rgp120 monomer HIV-1 W61D [Beddows1999]
• IgG1b12: A meeting summary presented results regarding neutralization – D. Burton and J. Mascola presented results concerning passive immunization and
protection of hu-PBL-SCID mice and macaques, respectively, and both found combinations of MAbs that were able to achieve 99% neutralization in vitro
corresponded to efficacy in vivo [Montefiori1999]
• IgG1b12: does not inhibit attachment of virus to cells and was used as a control of a study of neutralization by a MAb F58 based micro antibody
[Jackson1999]
• IgG1b12: Hu-PBL-SCID mice were infected with HIV-1s JRCSF and SF162 to study the effect of NAbs on an established infection – at day 6 post
infection, mice were given 50 mg/kg of b12, an amount that would have been protective if given up to 8 hours post-infection, and 100-fold higher than the
amount required for 90% neutralization in vitro – no significant differences in the initial rate of decrease in viral load or the plateau levels of viral RNA
between the b12 treated and control mice were seen – in most of the Ab treated mice escape mutants were observed with varying patterns of mutations – a
combination of b12, 2G12 and 2F5 protected 1/3 mice, and an isolate from one of the other two was resistant to neutralization by all three MAbs
[Poignard1999]
• IgG1b12: The MAbs with the broadest neutralizing activity, IgG1b12, 2G12 and 2F5, all have high affinity for the native trimer, indicating that they were
raised in an immune response to the oligomer on the virion surface rather than dissociated subunits – a disulfide linked gp120-gp41 (SOS gp140) was
created to mimic the native conformation of Env and explore its potential as an immunogen – SOS gp140 is recognized by NAbs IgG1b12, 2G12, and
CD4-IgG2, and also by anti-V3 MAbs 19b and 83.1 – SOSgp140 is not recognized by C4 region MAbs that neutralize only TCLA strains, G3-42 and
G3-519 – nor did it bind C11, 23A, and M90, MAbs that bind to gp120 C1 and C5, where it interacts with gp41 – MAbs that bind CD4 inducible epitopes,
17b and A32 were very strongly induced by CD4 in SOS gp140 – anti-gp41 MAbs that bind in the region that interacts with gp120, 7B2, 2.2B, T4, T15G1
and 4D4, did not bind to SOSgp140, in contrast to 2F5, which binds to the only gp41 epitope that is well exposed in native gp120-gp41 complexes
[Binley1999]
• IgG1b12: To determine the antigenicity of virus killed by thermal and chemical inactivation, retention of conformation-dependent neutralization epitopes
was examined, and exposure of CD4BS epitopes was found to be enhanced (MAbs IgG1b12, 205-46-9, and 205-43-1) – binding to 2G12 and 447-52D
epitopes was essentially unaltered – the 17b CD4i epitope was also exposed [Grovit-Ferbas2000]
• IgG1b12: SF162 is a neutralization-resistant HIV-1 isolate – N-linked glycosylation modifications in the V2 loop of the SF162 gp120 revealed that these
sites prevent neutralization by CD4BS MAbs (IgG1b12 and IgGCD4), and protect against neutralization by V3 MAbs (447-D and 391-95D) – V2-region
glycosylation site mutations did not enhance neutralization resistance to V2 MAbs (G3.4 and G3.136) or CD4i MAbs (17b and 48d) – V2 glycosylation site
modification allows increased infection of macrophages, probably due to glycosylated forms requiring fewer CCR5 molecules for viral entry [Ly2000]
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• IgG1b12: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including 6 CD4BS MAbs – CD4BS MAbs bound consistently to
most isolates of clade D, but poorly to isolates of other clades with the exception of broadly reactive MAb IgG1b12, binding to 22 of 26 isolates tested – 8
MAbs were tested for neutralization and MAb IgG1b12 was most potent, with 90% neutralization of 3/5 isolates tested [Nyambi2000]
• IgG1b12: Fab b12 was used – six mutations in MN change the virus from a high-infectivity neutralization resistant phenotype to low-infectivity
neutralization sensitive – V3, CD4BS, and CD4i MAbs are 20-100 fold more efficient at neutralizing the sensitive form – the mutation L544P reduced
binding of all MAbs against gp120 by causing conformational changes [Park2000]
• IgG1b12: SHIV-HXBc2 is a neutralization sensitive non-pathogenic virus, and several in vivo passages through monkey’s yielded highly pathogenic SHIV
KU-1 – HXBc2 and the KU-1 clone HXBc2P3.2 differ in 12 amino acids in gp160 – substitutions in both gp120 and gp41 reduced the ability of sCD4,
IgG1b12, F105 and AG1121 to Env achieve saturation and full occupancy, and neutralize KU-1 – 17b and 2F5 also bound less efficiently to HXBc2P3.2,
although 2G12 was able to bind both comparably [Si2001]
• IgG1b12: Mutations in two glcosylation sites in the V2 region of HIV-1 ADA at positions 190 and 197 (187 DNTSYRLINCNTS) cause the virus to become
CD4-independent and able to enter cells through CCR5 alone – these same mutations tended to increase the neutralization sensitivity of the virus, except the
mutation 197 S/R which resulted in a carbohydrate addition to 195 N that disrupts the IgG1b12 binding site [Kolchinsky2001]
• IgG1b12: This paper describes the technical aspects of the crystallization of b12 at a resolution of 2.7 angstroms with all 12 Ig domains resolved
[Saphire2001a]
• IgG1b12: This paper describes the biological implications of the crystal structure of b12 – a remarkable feature of this antibody is a long protruding
finger-like CDR H3 that can dock in the recessed CD4-binding site – a contact residues in gp120 are modeled, with numbering based on the variable
loop-deleted crystal structure of gp120 [Saphire2001b]
• IgG1b12: Primary isolates YU2 and ADA are more resistant to IgG1b12 neutralization than HXBc2: 90% Neutralization of HXBc2 is observed with 1.25
ug of IgG1b12, while ADA and YU2 require 2.5 and 5 ug respectively to achieve 50% neutralization, and 90% neutralization could not be achieved with 10
or 20 ug of IgG1b12, respectively [Yang2001]
• IgG1b12: Abs against the V3 loop (50.1, 58.2, 59.1, 257-D, 268-D, 447-52D), CD4BS (IgG1b12, 559-64D, F105), CD4i (17b), and to gp41 (2F5, F240)
each showed similar binding efficiency to Env derived from related pairs of primary and TCLA lines (primary: 168P and 320SI, and TCLA: 168C and
320SI-C3.3), but the TCLA lines were much more susceptible to neutralization suggesting that the change in TCLA lines that make them more susceptible
to NAbs alters some step after binding [York2001]
• IgG1b12: b12 recognizes a conformational epitope that overlaps with the CD4 binding site – a phage displayed peptide library was used to identify a
peptide which bound b12, called B2.1, which competes with b12 in competition assays – B2.1 has significant homology to the D loop of gp120: upper case
letters indicate residues B2.1 shares with gp120, heRsymFSDlenrcI – one of the goals of defining peptide mimics to the b12 epitope is to develop an
immunogen that can stimulate b12-like antibodies, but B2.1 cross-linked to phage and ovalbumin bound IgG1b12 did not elicit cross-reactive gp120 Abs in
mice or rabbits [Zwick2001a]
• IgG1b12: This paper primarily concerns 4E10 and Z13, MAbs that both bind proximally to the 2F5 binding site to a conserved epitope, and that neutralize
some primary isolates from clades B, C, and E – broadly neutralizing MAbs 2F5, IgG1b12, and 4E10 and Z13 fail to neutralize different subsets of viruses
[Zwick2001b]
• IgG1b12: Neutralization synergy between anti-HIV NAbs b12, 2G12, 2F5, and 4E10 was studied – a classic fixed-ratio method was used, as well as a
method where one Ab was fixed at a low neutralization titer and the other was varied – using primary isolates, a two-four fold enhancement of neutralization
was observed with MAb pairs, and a ten-fold enhancement with a quadruple Ab combination – no synergy was observed with any MAb pair in the
neutralization of TCLA strain HXB2 – whole IgG1b12 and b12 Fab fragments behaved similarly in the neutralization assays – there was no evidence for
cooperativity of binding between b12 and 2G12 to envelope spikes expressed on the cell surface of TCLA or primary isolates [Zwick2001c]
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• IgG1b12: Intravenous passive transfer of MAb b12 provides dose-dependent protection from infection to macaques vaginally challenged with the R5 virus
SHIV(162P4) – the primary isolate HIV-1SF162 is neutralized 90% (IC90) by b12 at 2 µg/ml, and SHIV162P4, derived from HIV-1SF162, was neutralized
by 90% at 2 µg/ml in PHA-activated PBMC from rhesus macaques – the 90% neutralization titers achieved in three groups of animals that were given 25-,
5-, and 1-mg/kg doses were approximately 1:400, 1:80, and 1:16, respectively – the half-life of IgG1 b12 in plasma was about 1 week, but while the peak
b12 plasma concentration was immediately after the infusion, the peak vaginal fluid concentration was 7-14 days later [Parren2001]
• IgG1b12: Structural aspects of the interaction of neutralizing Abs with HIV-1 Env are reviewed – Env essentially has three faces, one is largely inaccessible
on the native trimer, and two that exposed but have low immunogenicity on primary viruses – neutralization is suggested to occur by inhibition of the
interaction between gp120 and the target cell membrane receptors as a result of steric hindrance and it is noted that the attachment of approximately 70 IgG
molecules per virion is required for neutralization, which is equivalent to about one IgG molecule per spike – the 2G12, 17b and b12 epitopes are discussed
in detail – the structure of CD4-bound gp120 reveals features that HIV has evolved to escape anti-CD4BS Abs like IgG1b12 despite profound functional
constraints – CD4BS Abs must first access the CD4 binding site, deeply recessed within the gp120 core, and the Fab of an Ab molecule is "wider" than
CD4, and in addition the binding site is flanked by variable and glycosylated regions [Poignard2001]
• IgG1b12: Neutralizing synergy between MAbs 1b12, 2G12 and 2F5 was studied using surface plasmon resonance to determine the binding kinetics for
these three MAbs with respect to monomeric and oligomeric env protein gp160 IIIB – the 2G12 epitope is highly accessible on both monomeric and
oligomeric Envs, 1b12 is highly accessible on monomers but not oligomers, and 2F5 on neither form – binding of 2G12 exposes the 2F5 epitope on gp160
oligomers [Zeder-Lutz2001]
• IgG1b12: A luciferase-reporter gene-expressing T-cell line was developed to facilitate neutralization and drug-sensitivity assays – luciferase and p24 antigen
neutralization titer end points were found comparable using NAb from sera from HIV+ donors, and MAbs 2F5, 2G12 and IgG1b12 [Spenlehauer2001]
• IgG1b12: A panel of 12 MAbs was used to identify those that could neutralize the dual-tropic primary isolate HIV-1 89.6 – six gave significant
neutralization at 2 to 10 ug/ml: 2F5, 50-69, IgG1b12, 447-52D, 2G12, and 670-D six did not have neutralizing activity: 654-D, 4.8D, 450-D, 246-D, 98-6,
and 1281 – no synergy, only additive effects were seen for pairwise combinations of MAbs, and antagonism was noted between gp41 M Abs 50-69 and
98-6, as well as 98-6 and 2F5 [Verrier2001]
• IgG1b12: A combination of MAbs IgG1b12, 2F5, and 2G12 was given postnatally to four neonates macaques that were then challenged with highly
pathogenic SHIV89.6P – one of the four infants remained uninfected after oral challenge, two infants had no or a delayed CD4(+) T-cell decline – the most
potent combination included IgG1b12, which alone does not alone neutralize SHIV89.6P [Hofmann-Lehmann2001]
• IgG1b12: Twenty HIV clade C isolates from five different countries were susceptible to neutralization by anti-clade B MAbs in a synergistic quadruple
combination of mAbs IgG1b12, 2G12, 2F5, and 4E10 [Xu2001]
• IgG1b12: Oligomeric gp140 (o-gp140) derived from R5 primary isolate US4 was characterized for use as a vaccine reagent – antigen capture ELISA was
used to compare the antigenicity of gp120 and o-gp140 using a panel of well characterized MAbs – Abs directed against the CD4 binding site (IgGCD4 and
IgG1b12) reacted slightly more strongly with the gp120 monomer than with the oligomer, as did sCD4 [Srivastava2002]
• IgG1b12: The fusion process was slowed by using a suboptimal temperature (31.5 C) to re-evaluate the potential of Abs targeting fusion intermediates to
block HIV entry – preincubation of E/T cells at 31.5 C enabled polyclonal anti-N-HR Ab and anti-six-helix bundle Abs to inhibit fusion, indicating
six-helix bundles form prior to fusion – the preincubation 31.5 C step did not alter the inhibitory activity of neutralizing Abs anti-gp41 2F5, or anti-gp120
2G12, IG1b12, 48d, and 17b [Golding2002b]
• IgG1b12: Deglycosylation of gp120 does not significantly affect IG1b12 binding, in contrast to MAB 2G12 [Sanders2002]
• IgG1b12: Ab binding characteristics of SOS gp140 were tested using SPR and RIPA – SOS gp140 is gp120-gp41 bound by a disulfide bond – NAbs 2G12,
2F5, IgG1b12, CD4 inducible 17b, and 19b bound to SOS gp140 better than uncleaved gp140 (gp140unc) and gp120 – non-neutralizing MAbs 2.2B (binds
to gp41 in gp140unc) and 23A (binds gp120) did not bind SOS gp140 – SOS gp140-2F5-IgG1b12 formed multiple ring structures composed of two SOS
gp140 proteins bridged by two Ab molecules, while 2F5 and 2G12 formed extended chains rather than closed rings [Schulke2002]
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• IgG1b12: Uncleaved soluble gp140 (YU2 strain, R5 primary isolate) can be stabilized in an oligomer by fusion with a C-term trimeric GCN4 motif or using
a T4 trimeric motif derived from T4 bacteriophage fibritin—stabilized oligomer gp140∆683(-FT) showed strong preferential recognition by NAbs IgG1b12
and 2G12 relative to the gp120 monomer, in contrast to poorly neutralizing MAbs F105, F91, 17b, 48d, and 39F which showed reduced levels of binding,
and C11, A32, and 30D which did not bind the stabilized oligomer [Yang2002].
• IgG1b12: The crystal structure of IgG1b12 is resolved and is the first structure of an intact human Ab with an ordered, full length hinge – the structure is
extremely asymmetric and flexible with an antigen-binding site that has an unusually long CDR H3 region with a ten residue insertion that projects above
the rest of the antigen-binding site – this loop may be required for recognition of the recessed CD4 binding site of gp120 [Saphire2002]‘
• IgG1b12: Alanine scanning mutagenesis used in conjunction with competition and replacement studies of N-linked carbohydrates and sugars suggest that
the 2G12 epitope is formed from mannose residues contributed by the glycans attached to N295 and N332, with the other N-linked carbohydrates in
positions N339, N386, and N392 playing a role in maintaining conformation relevant to 2G12 binding – N295A and N332A mutants showed essentially
unchanged anti-CD4BS NAb b12 binding affinities, while N339A, N386A and N392A mutants displayed significantly lowered b12 affinity, presumably due
to conformational changes [Scanlan2002]
• IgG1b12: Passive immunization of neonate macaques with a combination of F105+2G12+2F5 conferred complete protection against oral challenge with
SHIV-vpu+ or – the combination b12+2G12+2F5 conferred partial protection against SHIV89.6 – such combinations may be useful for prophylaxis at birth
and against milk born transmission – the synergistic combination of IgG1b12, 2G12, 2F5, and 4E10 neutralized a collection of HIV clade C primary
isolates [Xu2002]
• IgG1b12: A modified gp140 (gp140∆CFI), with C-term mutations intended to mimic a fusion intermediate and stabilize trimer formation, retained antigenic
conformational determinants as defined by binding to CD4 and to MAbs 2F5, 2G12, F105, and b12, and enhanced humoral immunity without diminishing
the CTL response in mice injected with a DNA vaccine [Chakrabarti2002].
• IgG1b12: Called ARP3065: Herpesvirus saimiri-immortalized CD4+ T lymphocytes (HVS T cells) were used to isolate virus and perform HIV-1
neutralization assays, and compared with a standard PBMC protocol – neutralization sensitivities to a panel of MAbs and to homologous or heterologous
plasma/sera were similar for HVS T cells (CN-2 cells) and PBMCs [Vella2002]
• IgG1b12: A series of mutational changes were introduced into the YU2 gp120 that favored different conformations – 375 S/W seems to favor a
conformation of gp120 closer to the CD4-bound state, and is readily bound by sCD4 and CD4i MAbs (17b, 48d, 49e, 21c and 23e) but binding of
anti-CD4BS MAbs (F105, 15e, IgG1b12, 21h and F91 was markedly reduced – IgG1b12 failed to neutralize this mutant, while neutralization by 2G12 was
enhanced – 2F5 did not neutralize either WT or mutant, probably due to polymorphism in the YU2 epitope – another mutant, 423 I/P, disrupted the gp120
bridging sheet, favored a different conformation and did not bind CD4, CCR5, or CD4i antibodies, but did bind to CD4BS MAbs [Xiang2002b]
• IgG1b12: Truncation of the gp41 cytoplasmic domain of X4, R5, and X4R5 viruses forces a conformation that more closely resembles the CD4 bound state
of the external Envelope, enhancing binding of CD4i MAbs 17b and 48d and of CD4BS MAbs F105, b12, and in most cases of glycosylation site dependent
MAb 2G12 and the anti-gp41 MAb 246D – in contrast, binding of the anti-V2 MAb 697D and the anti-V3 MAb 694/98D were not affected – viruses
bearing the truncation were more sensitive to neutralization by MAbs 48d, b12, and 2G12 – the anti-C5 MAb 1331A was used to track levels of cell surface
expression of the mutated proteins [Edwards2002]
• IgG1b12: Truncation of the gp41 cytoplasmic domain of X4, R5, and X4R5 viruses forces a conformation that more closely resembles the CD4 bound state
of the external Envelope, enhancing binding of CD4i MAbs 17b and 48d and of CD4BS MAbs F105, b12, and in most cases of glycosylation site dependent
MAb 2G12 and the anti-gp41 MAb 246D – in contrast, binding of the anti-V2 MAb 697D and the anti-V3 MAb 694/98D were not affected – viruses
bearing the truncation were more sensitive to neutralization by MAbs 48d, b12, and 2G12 – the anti-C5 MAb 1331A was used to track levels of cell surface
expression of the mutated proteins [Edwards2002]
• IgG1b12: HIV-1 gp160∆CT (cytoplasmic tail-deleted) proteoliposomes (PLs) containing native, trimeric envelope glycoproteins from R5 strains YU2 and
JRFL, and X4 strain HXBc2, were made in a physiologic membrane setting as candidate immunogens for HIV vaccines—2F5 bound to gp160∆CT with a
reconstituted membrane ten-fold better than the same protein on beads—anti-CD4BS MAbs IgG1b12 and F105, A32 (C1-C4), C11 (C1-C5), and 39F (V3)
MAbs bound gp160∆CT PLs indistinguishably from gp160∆CT expressed on the cell surface—non-neutralizing MAbs C11 and A32 bound with lower
affinity than NAb IgG1b12—the MAb 17b was sCD4 inducible on gp160∆CT PL [Grundner2002].
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• IgG1b12: A rare mutation in the neutralization sensitive R2-strain in the proximal limb of the V3 region caused Env to become sensitive to neutralization by
MAbs directed against the CD4 binding site (CD4BS), CD4-induced (CD4i) epitopes, soluble CD4 (sCD4), and HNS2, a broadly neutralizing sera – 2/12
anti-V3 MAbs tested (19b and 694/98-D) neutralized R2, as did 2/3 anti-CD4BS MAbs (15e and IgG1b12), 2/2 CD4i MAbs (17b and 4.8D), and 2G12 and
2F5 – thus multiple epitopes on R2 are functional targets for neutralization and the neutralization sensitivity profile of R2 is intermediate between the highly
sensitive MN-TCLA strain and the typically resistant MN-primary strain [Zhang2002]
• IgG1b12: A broad review of NAbs that mentions IgG1b12 as an example of a NAb that does not alter the conformation of gp120, but interferes with CD4
binding [Klasse2002]
• IgG1b12: Review of NAbs that notes IgG1b12 is a recombinant IgG1 from a phage displayed Fab generated against gp120 from a B clade infected
individual, that it binds the CD4BS, that alone or in combination with other MAbs it can protect some macaques against SHIV infection, and that it has
strong ADCC activity [Ferrantelli2002]‘
• IgG1b12: Review of NAbs that discusses mechanisms of neutralization, passive transfer of NAbs and protection in animal studies, and vaccine strategies
[Liu2002]
• IgG1b12: Virion capture assays are not a good preditor of neutralization, and the presentation of epitopes using this assay seems to be different from that of
functional Envelope spikes on primary isolates – F105 and b6 could efficiently block the b12-mediated capture of infectious virions in a virus capture, but
did not inhibit b12 neutralization – b12 was potent at neutralizing the three primary virions JR-CSF, ADA, and 89.6, but anti-V3 Abs 447-52D and 19b,
which did not neutralize JR-CSF and ADA captured amounts of p24 equal to or higher than the amounts captured by the neutralizing Ab b12
[Poignard2003]
• IgG1b12: Called b12 – Alanine scanning mutagenesis was used to compare substitutions that affected anti-CD4BS NAb b12 binding to those that affect
binding of sCD4 and two non-neutralizing anti-CD4BS Abs b3 and b6 – while the epitope maps overlapped, there were some differences observed –
binding of CD4 was never in enhanced, indicating it had evolved to be optimal – rec gp120s were engineered to contain combinations of Alanine
substitutions that enhanced b12 binding, and while binding of b12 to these gp120 monomers was generally maintained or increased, binding by five
non-neutralizing anti-CD4bs MAbs (b3, b6, F105, 15e, and F91) was reduced or completely abolished – 2G12 binding was largely unperturbed, indicating
these proteins were not grossly misfolded – for twelve mutants, b12 neutralization sensitivity and affinity correlated, but for five mutants neutralization
efficiency was maintained or increased despite a decrease in affinity [Pantophlet2003]
• IgG1b12: Called b12 – CD4BS MAbs b12 (neutralizing) and 205-42-15, 204-43-1, 205-46-9 (nonneutralizing) all cross-competed for binding to
monomeric gp120, indicating the topological proximity of their epitopes, however, the nonneutralizing CD4BS MAbs did not interfere with the
neutralization activity of MAb b12 – the nonneutralizing MAbs partially competed with b12 for Env binding of the surface of Env-transfected cells – this
suggests Env has two categories of binding site for CD4BS MAbs, one recognized by both b12 and nonneutralizing CD4BS MAbs, the other is recognized
by only b12 – Ab-gp120 interactions based on the use of monomeric gp120 or Env-transfected cells do not predict the outcome of HIV-1 neutralization
assays, and they should be interpreted with caution [Herrera2003]
• IgG1b12: UK Medical Research Council AIDS reagent: ARP3065
• IgG1b12: NIH AIDS Research and Reference Reagent Program: 2640
935 IgGCD4
(IgG-CD4)
Env gp120 human (IgG)
Ab type CD4BS
References Capon1989, Stamatatos1998, Ly2000, Srivastava2002
• IgGCD4: An antibody-like immunoadhesins molecule was constructed incorporating the gp120-binding domain of CD4 [Capon1989]
• IgGCD4: Deleting the V2 loop of neutralization-resistant HIV-1 isolate SF162 does not abrogate its replication in PBMC or macrophages, but it enhances
its neutralization sensitivity to sera from patients with B clade infection up to 170-fold, and also enhances sensitivity to sera from clades A through F –
deletion of V2 but not V1 slightly enhanced neutralization by CD4BS MAb IgGCD4 [Stamatatos1998]
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• IgGCD4: SF162 is a neutralization-resistant HIV-1 isolate – N-linked glycosylation modifications in the V2 loop of the SF162 gp120 revealed that these
sites prevent neutralization by CD4BS MAbs (IgG1b12 and IgGCD4), and protect against neutralization by V3 MAbs (447-D and 391-95D) – V2-region
glycosylation site mutations did not alter neutralization resistance to V2 MAbs (G3.4 and G3.136) or CD4i MAbs (17b and 48d) – V2 glycosylation site
modification allows infection of macrophages, probably due to glycosylated forms requiring fewer CCR5 molecules for viral entry [Ly2000]
• IgGCD4: Oligomeric gp140 (o-gp140) derived from R5 primary isolate US4 was characterized for use as a vaccine reagent – antigen capture ELISA was
used to compare the antigenicity of gp120 and o-gp140 using a panel of well characterized MAbs – Abs directed against the CD4 binding site (IgGCD4 and
IgG1b12) reacted slightly more strongly with the gp120 monomer than with the oligomer, as did sCD4 [Srivastava2002]
936 L28 Env gp120 L HIV-1 infection human (IgG1κ)
Ab type CD4BS
References Ditzel1995
• L28: Substitutions at 257 T/R, 368 D/R, 370 E/R and 370 E/Q, 475 M/S 102 E/L and 463 N/D reduce binding – binding was enhanced by removal of the
V3 loop and by substitutions 45 W/S, 298 R/G, 381 E/P, 382 F/L, 420 I/R, 435 Y/H or Y/R – binding is sensitive to deglycosylation – heavy and light chain
variable region sequence is available [Ditzel1995]
937 L33 Env gp120 L HIV-1 infection human (IgG1κ)
Ab type CD4BS
References Ditzel1995
• L33: binding is sensitive to deglycosylation – heavy and light chain variable region sequence is available [Ditzel1995]
938 L41 Env gp120 L HIV-1 infection human (IgG1κ)
Ab type CD4BS
References Ditzel1995
• L41: Substitutions at 133 D/R, 256 S/Y, 257 T/R, 368 D/R or D/T, 370 E/Q or E/R, 384 Y/E, and 421 K/L reduce binding – paradoxically, this Fab was
retrieved from the library after masking with known anti-CD4BS MAbs – binding is sensitive to deglycosylation – heavy and light chain variable region
sequence is available [Ditzel1995]
939 L42 Env gp120 L HIV-1 infection human (IgG1κ)
Ab type CD4BS
References Ditzel1995
• L42: Substitutions at 257 T/R, 368 D/R, 370 E/R, 266 A/E and 477 D/V reduce binding – binding was significantly enhanced by 381 E/P and 382 F/L –
binding is sensitive to deglycosylation – heavy and light chain variable region sequence is available [Ditzel1995]
940 L52 Env gp120 L HIV-1 infection human (IgG1κ)
Ab type CD4BS
References Ditzel1995
• L52: Binding is sensitive to deglycosylation – heavy and light chain variable region sequence is available [Ditzel1995]
941 L72 Env gp120 murine
Ab type CD4BS Donor Dr. Hariharam, IDEC Pharmaceuticals Corp La Jolla, CA
References Ditzel1997
• L72: Used to bind gp120 to solid phase to select MAbs from a phage selection library [Ditzel1997]
942 M12 Env gp120 (IIIB) L Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
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Ab type CD4BS Donor P. Earl, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
References Earl1994, Sugiura1999
• M12: There is a p15 gag specific MAb also named M12
• M12: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• M12: A comparison of 25 gp120 specific, conformation dependent MAbs was done – M12 is part of a group of MAbs labeled A1 – all A1 MAbs were
broadly cross-reactive with gp160 from B-clade R5, X4, and R5X4 viruses, blocked CD4 binding, were sensitive to mutations in gp120 positions 368 and
370 that directly contact CD4 – 50% neutralization of NL4-3 was achieved with 21 ug/ml of M12 [Sugiura1999]
943 M13 Env gp120 (IIIB) L Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
Ab type CD4BS Donor P. Earl, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
References Earl1994, Sugiura1999
• M13: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• M13: A comparison of 25 gp120 specific, conformation dependent MAbs was done – M13 is part of a group of MAbs labeled A1 – all A1 MAbs were
broadly cross-reactive with gp160 from B-clade R5, X4, and R5X4 viruses, blocked CD4 binding, were sensitive to mutations in gp120 positions 368 and
370 that directly contact CD4 – 50% neutralization of NL4-3 was achieved with 35 ug/ml of M13 [Sugiura1999]
944 M6 Env gp120 (IIIB) no Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
Ab type CD4BS Donor P. Earl, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
References Earl1994, Sugiura1999
• M6: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• M6: A comparison of 25 gp120 specific, conformation dependent MAbs was done – M6 is part of a group of MAbs labeled A1 – all A1 MAbs were broadly
cross-reactive with gp160 from B-clade R5, X4, and R5X4 viruses, blocked CD4 binding, were sensitive to mutations in gp120 positions 368 and 370 that
directly contact CD4 [Sugiura1999]
945 MAG 116 Env gp120 L Vaccine murine
Vaccine Vector/Type: sCD4-gp120 complex Strain: HXB2 HIV component: gp120
Ab type CD4BS Donor C. Y. Kang, IDEC Inc
References Kang1994
• MAG 116: Amino acid substitutions that reduce binding 10 fold: 256 S/Y, 257 T/R, 368 D/R or T, 370 E/R or Q, 384 Y/E, 421 K/L – neutralizes MN, IIIB
and RF [Kang1994]
946 MAG 12B Env gp120 L Vaccine murine
Vaccine Vector/Type: sCD4-gp120 complex Strain: HXB2 HIV component: gp120
Ab type CD4BS Donor C. Y. Kang, IDEC Inc
References Kang1994
• MAG 12B: Amino acid substitutions that reduce binding 10 fold: 257 T/R, 368 D/R or T, 370 E/R or Q, 384 Y/E, 477 D/V – weak neutralization of IIIB
[Kang1994]
947 MAG 29B Env gp120 L Vaccine murine
Vaccine Vector/Type: sCD4-gp120 complex Strain: HXB2 HIV component: gp120
Ab type CD4BS Donor C. Y. Kang, IDEC Inc
References Kang1994
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• MAG 29B: Amino acid substitutions that reduce binding 10 fold: 257 T/R, 368 D/R or T, 370 E/R or Q, 384 Y/E, 386 N/Q, 421 K/L – weak neutralization
of IIIB [Kang1994]
948 MAG 3B Env gp120 no Vaccine murine
Vaccine Vector/Type: sCD4-gp120 complex Strain: HXB2 HIV component: gp120
Ab type CD4BS Donor C. Y. Kang, IDEC Inc
References Kang1994
• MAG 3B: Amino acid substitutions that reduce binding 10 fold: 256 S/Y, 257 T/R or A or G, 262 N/T, 368 D/R or T, 370 E/R or Q, 381 E/P, 384 Y/E, 421
K/L, 475 M/S, 477 D/V [Kang1994]
949 MAG 55 (#55) Env gp120 L Vaccine murine
Vaccine Vector/Type: sCD4-gp120 complex Strain: HXB2 HIV component: gp120
Ab type CD4BS Donor C. Y. Kang, IDEC Inc
References Kang1994, Moore1996
• MAG 55: Amino acid substitutions that reduce binding 10 fold: 256 S/Y, 257 T/R, 368 D/R or T, 370 E/R or Q, 384 Y/E, 421 K/L, 470 P/L, 475 M/S, 477
D/V – neutralizes MN, IIIB and RF [Kang1994]
• MAG 55: Called #55 – binding reciprocally inhibited by other anti-CD4 binding site MAbs, and by some C1-C5 MAbs – binding enhanced by anti-V3
MAb 110.5 and anti-V2 MAbs G3-136 and G3-4 – enhances binding of many anti-V3 and -V2 MAbs. [Moore1996]
950 MAG 72
(L72)
Env gp120 L Vaccine murine
Vaccine Vector/Type: sCD4-gp120 complex Strain: HXB2 HIV component: gp120
Ab type CD4BS Donor C. Y. Kang or Dr. Hariharam, IDEC Pharmaceuticals Corp, La Jolla, CA
References Kang1994, Ditzel1997
• MAG 72: Amino acid substitutions that reduce binding 10 fold: 257 T/R or A or G, 262 N/T, 368 D/R or T, 370 E/R or Q, 384 Y/E, 421 K/L, 477 D/V –
neutralizes MN, IIIB and RF [Kang1994]
• MAG 72: Called L72 – used to bind gp120 to solid phase to select MAbs from a phage selection library [Ditzel1997]
951 MAG 86 Env gp120 L Vaccine murine
Vaccine Vector/Type: sCD4-gp120 complex Strain: HXB2 HIV component: gp120
Ab type CD4BS Donor C. Y. Kang, IDEC Inc
References Kang1994
• MAG 86: Amino acid substitutions that reduce binding 10 fold: 256 S/Y, 257 T/R, 368 D/R or T, 370 E/R or Q, 384 Y/E, 421 K/L, 470 P/L, 477 D/V –
neutralizes MN, IIIB and RF [Kang1994]
952 MAG 96 Env gp120 L Vaccine murine
Vaccine Vector/Type: sCD4-gp120 complex Strain: HXB2 HIV component: gp120
Ab type CD4BS Donor C. Y. Kang, IDEC Inc
References Kang1994
• MAG 96: Amino acid substitutions that reduce binding 10 fold: 256 S/Y, 257 T/R, 368 D/R or T, 370 E/R – weak neutralization of IIIB [Kang1994]
953 MTW61D Env gp120 (W61D) L HIV-1 infection human
Ab type CD4BS
References Sullivan1998a
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• MTW61D – the HIV-1 virus YU2 entry can be enhanced by MAbs binding to the CD4BS, V3 loop, and CD4i epitopes – the activation for this enhanced
entry state could be conferred on HxB2 by introducing the YU2 V3 loop, or the YU2 V3 and V1/V2 loops – a similar effect is observed by sub-neutralizing
concentrations of sCD4 and the effect is dependent of CCR5 – Fab fragment MTW61D also enhances YU2 entry, ruling out Fc interactions or Env
cross-linking as a mechanism, while neutralizing HXBc2 – MTW61D was obtained by panning libraries derived from bone marrow from a long term
asymptomatic donor against gp120 from primary isolate W61D [Sullivan1998a]
954 S1-1 Env gp120 L HIV-1 infection human (IgG1λ )
Ab type CD4BS
References Lake1992, Moran1993, Wisnewski1996
• S1-1: Neutralizes IIIB and MN without complement, and neutralizes RF and a clinical isolate with complement – binds to native but not denatured gp120 –
inhibits sCD4-gp120 binding [Lake1992]
• S1-1: Heavy (V HI) and light (V lambdaIII) chain sequenced – no enhancing activity – similar germline sequence to MAb 86, but very different activity
[Moran1993]
• S1-1: S1-1 is V H1 – V-region heavy chain usage was examined and a bias of enhanced V H1 and V H4, and reduced V H3, was noted among HIV infected
individuals [Wisnewski1996]
955 T13 Env gp120 (IIIB) no Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
Ab type CD4BS Donor P. Earl, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
References Earl1994, Sugiura1999
• T13: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• T13: A comparison of 25 gp120 specific, conformation dependent MAbs was done – T13 is one of three MAbs labeled group Cb, that was type-specific for
BH8 – T13 fully blocked CD4 binding, and the deletion of the V3 loop enhanced binding 10-fold [Sugiura1999]
956 T49 Env gp120 (IIIB) no Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
Ab type CD4BS Donor P. Earl, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
References Earl1994, Sugiura1999
• T49: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• T49: A comparison of 25 gp120 specific, conformation dependent MAbs was done – T49 is one of three MAbs labeled group Cb, that was type-specific for
BH8 – T49 fully blocked CD4 binding, and the deletion of the V3 loop enhanced binding 10-fold [Sugiura1999]
957 T56 Env gp120 (IIIB) no Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
Ab type CD4BS Donor P. Earl, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
References Earl1994, Sugiura1999
• T56: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• T56: A comparison of 25 gp120 specific, conformation dependent MAbs was done – T56 is one of three MAbs labeled group Cb, that was type-specific for
BH8 – T56 fully blocked CD4 binding, and the deletion of the V3 loop enhanced binding 10-fold [Sugiura1999]
958 TH9 Env gp120 L human (IgG1κ)
Ab type CD4BS DonorMichael Fung, Tanox Biosystem, USA
References D’Souza1995, Yang1998
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• TH9: Found to neutralize MN, but not JRCSF, two B subtype primary isolates, or a D subtype primary isolate, by most labs in a multi-laboratory study
involving 11 labs[D’Souza1995]
• TH9: A neutralization assay was developed based on hemi-nested PCR amplification of the LTR (HNPCR) – LTR-HNPCR consistently revealed HIV DNA
and was shown to be a rapid, specific and reliable neutralization assay based on tests with 6 MAbs and 5 isolates [Yang1998]
959 anti-CD4BS
summary
Env gp120
Ab type CD4BS
References Thali1993, Moore1996
• Shared components of MAb epitopes and the discontinuous CD4 binding regions included Thr 257, Asp 368, Glu 370, Lys 421 through Trp 427 and Asp
457 [Thali1993]
• Anti-CD4 binding site antibodies (CD4BS) competitively inhibit CD4 binding to monomeric gp120, and they differ in precise dependence on gp120
residues, but generally require Asp-368 and Glu-370 [Moore1996]
960 b11 Env gp120 human
Ab type CD4BS
References Parren1998a
• b11: The rank order of Fab binding affinity to monomeric gp120 (Loop 2 > 3B3 > b12 = DO8i > b11 > b3 > b14 > b13 > DO142-10 > DA48 > L17) was
markedly different than Fab binding affinity to the mature oligomeric form (3B3 > b12 > DO142-10 > Loop 2 > b11 > L17 > b6 > DO8i > b14 > DA48 > b3
> b13) and binding to oligomeric form and neutralization were correlated for both Fabs and MAbs – authors suggest that neutralization is determined by the
fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
961 b13 Env gp120 human
Ab type CD4BS
References Parren1995, Parren1998a, Parren1997a
• b13: Fab b13 was used as a control in a hu-PBL SCID mouse study – animals were protected from HIV-1 SF2 infection by IgG1b12, somewhat by Fab b12,
but not by b13 [Parren1995, Parren1997a]
• b13: The rank order of Fab binding affinity to monomeric gp120 (Loop 2 > 3B3 > b12 = DO8i > b11 > b3 > b14 > b13 > DO142-10 > DA48 > L17) was
markedly different than Fab binding affinity to the mature oligomeric form (3B3 > b12 > DO142-10 > Loop 2 > b11 > L17 > b6 > DO8i > b14 > DA48 > b3
> b13) and binding to oligomeric form and neutralization were correlated for both Fabs and MAbs – authors suggest that neutralization is determined by the
fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
962 b14 Env gp120 human
Ab type CD4BS
References Parren1998a
• b14: The rank order of Fab binding affinity to monomeric gp120 (Loop 2 > 3B3 > b12 = DO8i > b11 > b3 > b14 > b13 > DO142-10 > DA48 > L17) was
markedly different than Fab binding affinity to the mature oligomeric form (3B3 > b12 > DO142-10 > Loop 2 > b11 > L17 > b6 > DO8i > b14 > DA48 > b3
> b13) and binding to oligomeric form and neutralization were correlated for both Fabs and MAbs – authors suggest that neutralization is determined by the
fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
963 b3 Env gp120 human
Ab type CD4BS
References Parren1997c, Parren1998a, Pantophlet2003
• b3: Neutralizes TCLA strains, but not primary isolates [Parren1997c]
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• b3: The rank order of Fab binding affinity to monomeric gp120 (Loop 2 > 3B3 > b12 = DO8i > b11 > b3 > b14 > b13 > DO142-10 > DA48 > L17) was
markedly different than Fab binding affinity to the mature oligomeric form (3B3 > b12 > DO142-10 > Loop 2 > b11 > L17 > b6 > DO8i > b14 > DA48 > b3
> b13) and binding to oligomeric form and neutralization were correlated for both Fabs and MAbs – authors suggest that neutralization is determined by the
fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
• b3: Alanine scanning mutagenesis was used to compare substitutions that affected anti-CD4BS NAb b12 binding to those that affect binding of sCD4 and
two non-neutralizing anti-CD4BS Abs b3 and b6 – while the epitope maps overlapped, there were some differences observed – binding of CD4 was never in
enhanced, indicating it had evolved to be optimal – rec gp120s were engineered to contain combinations of Alanine substitutions that enhanced b12 binding,
and while binding of b12 to these gp120 monomers was generally maintained or increased, binding by five non-neutralizing anti-CD4bs MAbs (b3, b6,
F105, 15e, and F91) was reduced or completely abolished – 2G12 binding was largely unperturbed, indicating these proteins were not grossly misfolded
[Pantophlet2003]
964 b6 Env gp120 L human
Ab type CD4BS Donor Dennis Burton, Scripps, San Diego, CA, USA
References Parren1997c, Parren1998a, Poignard2003, Pantophlet2003
• b6: Neutralizes TCLA strains, but not primary isolates [Parren1997c]
• b6: The rank order of Fab binding affinity to monomeric gp120 (Loop 2 > 3B3 > b12 = DO8i > b11 > b3 > b14 > b13 > DO142-10 > DA48 > L17) was
markedly different than Fab binding affinity to the mature oligomeric form (3B3 > b12 > DO142-10 > Loop 2 > b11 > L17 > b6 > DO8i > b14 > DA48 > b3
> b13) and binding to oligomeric form and neutralization were correlated for both Fabs and MAbs – authors suggest that neutralization is determined by the
fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
• b6: Virion capture assays are not a good preditor of neutralization, and the presentation of epitopes using this assay seems to be different from that of
functional Envelope spikes on primary isolates – F105 and b6 could efficiently block the b12-mediated capture of infectious virions in a virus capture, but
did not inhibit b12 neutralization – while b12 was potent at neutralizing the three primary virions JR-CSF, ADA, and 89.6, the Abs F105, 19b, and Fab b6
were overall very poor neutralizers [Poignard2003]
• b6: Alanine scanning mutagenesis was used to compare substitutions that affected anti-CD4BS NAb b12 binding to those that affect binding of sCD4 and
two non-neutralizing anti-CD4BS Abs b3 and b6 – while the epitope maps overlapped, there were some differences observed – binding of CD4 was never in
enhanced, indicating it had evolved to be optimal – rec gp120s were engineered to contain combinations of Alanine substitutions that enhanced b12 binding,
and while binding of b12 to these gp120 monomers was generally maintained or increased, binding by five non-neutralizing anti-CD4bs MAbs (b3, b6,
F105, 15e, and F91) was reduced or completely abolished – 2G12 binding was largely unperturbed, indicating these proteins were not grossly misfolded
[Pantophlet2003]
965 polyclonal Env gp120 no Vaccine murine
Vaccine Vector/Type: recombinant protein, virus-like particle Strain: LAI HIV component: V3, CD4BS, p55
Ab type CD4BS
References Truong1996
• Antibodies raised against recombinant anti-p55 virus-like particles with the p24 region 196-226 deleted, bearing inserts of either the V3 or the CD4BS
regions of gp120 were studied – no neutralizing responses, weak Env and strong Gag responses were elicited – the major homology region (MHR) and
proximal sequences was found to be required for capsid assembly [Truong1996]
966 D33 Env gp120 (IIIB) Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
Ab type CD4BS, C-term, N-term Donor P. Earl, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
References Earl1994, Sugiura1999
• D33: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
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• D33: A comparison of 25 gp120 specific, conformation dependent MAbs was done – D33 is part of a group of MAbs labeled A1 – all A1 MAbs were
broadly cross-reactive with gp160 from B-clade R5, X4, and R5X4 viruses, blocked CD4 binding, were sensitive to mutations in gp120 positions 368 and
370 that directly contact CD4 – D33 was unusual for the group of A1 MAbs, because while it blocked CD4 binding completely, but competed with MAbs
that did not in a BIAcore assay – both the N- and C-terminal ends of gp120 are involved in D33 binding [Sugiura1999]
967 Env gp120 yes human
Ab type CD4BS, CD4i, V3, V2
ReferencesMoore2001
• Moore and colleagues review structural aspects of gp120 and how they relate to antigenic domains, and review the data concerning the lack of a clear
relationship between genetic subtype and serotype – they suggest the primary goal in vaccine efforts should be to design an immunogen that can be shown
to elicit neutralizing antibodies against a significant proportion of primary isolates – assay artifacts that can result in confused interpretations are also
discussed, such as Ab binding to defective spikes, which does not affect HIV-1 infectivity, but can dominant an assay signal [Moore2001]
968 17b Env gp120 L P (weak) HIV-1 infection human
Ab type CD4i Donor James Robinson, Tulane University, New Orleans, LA, USA
References
Thali1993, Moore1993d, Thali1994, Beretta1994, Wyatt1995, Sattentau1995b, Moore1996, Poignard1996a, Wu1996, Trkola1996a, Binley1997a,
Fouts1997, Li1997, Weinberg1997, Ditzel1997, Cao1997b, Wyatt1997, Parren1997c, Kwong1998, Wyatt1998a, Moore1998, Rizzuto1998, Sullivan1998b,
Sullivan1998a, Binley1998, Stamatatos1998, Oscherwitz1999a, Hoffman1999, Binley1999, Grovit-Ferbas2000, Ly2000, Park2000, Salzwedel2000,
Stamatatos2000, Yang2000, Rizzuto2000, Si2001, Kolchinsky2001, York2001, Zhang2001a, Poignard2001, Srivastava2002, Golding2002b, Schulke2002,
Yang2002, Dowd2002, Xiang2002b, Xiang2002a, Edwards2002, Grundner2002, Basmaciogullari2002, Zhang2002, Arthos2002
• 17b: 48d and 17b have similar epitopes, and the pair are unique among human and rodent MAbs
• 17b: Epitope is better exposed upon CD4 binding to gp120 – competes with 15e and 21h, anti-CD4 binding site MAbs – 113 D/R, 252 R/W, 257 T/A or G,
370 E/D, 382 F/L, 420 I/R, 433A/L, 438 P/R and 475 M/S confer decreased sensitivity to neutralization [Thali1993]
• 17b: Binding of 48d is much more influenced by sequence variation among molecular clones of LAI than is binding of 17b [Moore1993d]
• 17b: A mutation in gp41, 582 A/T, confers resistance to neutralization (also confers resistance to MAbs F105, 48d, 21h and 15e) [Thali1994]
• 17b: Studies using a V1/V2 deletion mutant demonstrated that enhanced binding of 17b in the presence sCD4 involves the V1/V2 loops, with more
significant involvement of V2 – similar effect observed for 48d and A32 [Wyatt1995]
• 17b: Binds with higher affinity to monomer and oligomer, slow association rate, poor neutralization of lab strain – this is in contrast to 48d, which has very
different kinetics [Sattentau1995b]
• 17b: Many MAbs inhibit binding (anti-C1, -C5, -C4, -CD4BS) – anti-V3 MAb 5G11 enhances binding, as do C1-C4 discontinuous epitopes A32 and 2/11c
– enhances binding of some anti-V2 MAbs [Moore1996]
• 17b: Binding did not result in significant gp120 dissociation from virion, in contrast to 48d, although the gp41 epitope of MAb 50-69 was exposed
[Poignard1996a]
• 17b: MIP-1α binding to CCR-5 expressing cells can be inhibited by gp120-sCD4 — binding of 17b blocks this inhibition [Wu1996].
• 17b: Neutralizes JR-FL – inhibits gp120 interaction with CCR-5 in a MIP-1beta-CCR-5 competition study [Trkola1996a]
• 17b: Study shows neutralization is not predicted by MAb binding to JRFL monomeric gp120, but is associated with oligomeric Env binding – 17b bound
monomer, oligomer, and neutralized JRFL in the presence of sCD4, but if sCD4 was not present, 17b only bound monomer [Fouts1997]
• 17b: One of 14 human MAbs tested for ability to neutralize a chimeric SHIV-vpu+, which expressed HIV-1 IIIB env – 17b has synergistic response in
combination with anti-V3 MAb 694/98-D [Li1997]
• 17b: 48d binds to the IIIB protein and not IIIB V3 peptide, while binding to the Can0A V3 peptide, suggesting Can0A V3 is a conformer that mimics the
48d – it does not bind to 17b, distinguishing the epitopes [Weinberg1997]
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• 17b: Virus with the V1-V2 loop deleted was viable and more susceptible to neutralization by CD4i MAb 17b, and anti-V3 MAbs 1121, 9284, and 110.4, but
not to a CD4BS MAb, F105, or sCD4 [Cao1997b]
• 17b: Binds to sgp120 efficiently, but not soluble gp120+gp41, suggesting its gp120 epitope is blocked by gp41 binding – partial re-exposure if sCD4 was
bound – could not bind to HXBc2 gp120 if the 19 C-term amino acids were deleted in conjunction with amino acids 31-93 in C1, but binding was restored
in the presence of sCD4 [Wyatt1997]
• 17b: Neutralizes TCLA strains, but not primary isolates [Parren1997c]
• 17b: 17b Fab was co-crystallized with a gp120 core and CD4, and it’s binding site can be directly visualized—17b binds to the “bridging sheet” of gp120,
an antiparallel beta sheet region, contacting residues from the C4 region and the V1/V2 stem—the contact area is small for an Ab-antigen interactive
surface, and dominated in the Ab by the heavy chain—the center of the binding region has hydrophobic interactions, and the periphery charge interactions,
acidic on 17b and basic on gp120 [Kwong1998]
• 17b: Summary of the implications of the crystal structure of a gp120 core bound to CD4 and 17b, combined with what is known about mutations that
reduce NAb binding to gp120 – probable mechanism of neutralization is interference with chemokine receptor binding – mutations in 88N, 117K, 121K,
256S, 257T, N262, Delta V3, E370, E381, F 382, R 419, I 420, K 421, Q 422, I 423, W 427, Y 435, P 438, M 475 of HXBc2 (IIIB) reduce binding – the
only variable residues in gp120 that contact 17b are 202T and 434M – the contact points for 17b with the crystallized incomplete gp120 are mostly in the
heavy chain of the Ab, and there is a gap between 17b’s light chain and the partial gp120 which may be occupied by the V3 loop in a complete gp120
molecule – the authors propose that the V2 and V3 loops may mask the CD4i Ab binding site, and that the V2 loop may be repositioned upon CD4 binding
[Wyatt1998a]
• 17b: Moore and Binley provide a commentary on the papers by [Rizzuto1998], [Wyatt1998a] and [Kwong1998] – they point out 17b shares binding
elements in gp120 with chemokine receptor molecules, and that CD4 needs to bind to gp120 first to make the 17b epitope accessible and it may be sterically
blocked in the CD4 bound virus, thus making it a poor NAb for primary isolates [Moore1998]
• 17b: Site directed mutagenesis of a WU2 protein with the V1-V2 loops deleted revealed key residues for 17b-gp120 interaction and interaction of gp120
and CCR5 – mutations in residues that reduced 17b by 70% were R/D 419, I/R 420, Q/L 422, Y/S 435, I/S 423, K/D 121 and K/D 421– 17b can neutralize
HIV-1 strains that use different chemokine receptors, supporting a common region in gp120 in chemokine-receptor interaction [Rizzuto1998]
• 17b: sCD4 induces 17b binding in primary isolates and TCLA strains – amino acids that reduce the efficiency of binding were determined and found also to
compromise syncytia formation and viral entry – V1V2 deletion or sCD4 binding can expose the 17b epitope for both HXBc2 and macrophage tropic YU2
– neutralizing potency of 17b is probably weak due to poor exposure of the epitope – 17b epitope exposure upon sCD4 binding can occur over a wide range
of temperatures, consistent with the energy of CD4 binding being sufficient to drive the V1/V2 loop into a new conformation [Sullivan1998b]
• 17b: The HIV-1 virus YU2 entry can be enhanced by MAbs binding to the CD4BS, V3 loop, and CD4i epitopes – the activation for this enhanced entry
state could be conferred on HxB2 by introducing the YU2 V3 loop, or the YU2 V3 and V1/V2 loops, and the presence of V1/V2 increased the enhancement
– a similar effect is observed by sub-neutralizing concentrations of sCD4 and the effect is dependent of CCR5 – 17b enhances YU2 enhanced viral entry
10-fold, whereas HXBc2 was neutralized [Sullivan1998a]
• 17b: A panel of MAbs was shown to bind with similar or greater affinity and similar competition profiles to a deglycosylated or variable loop deleted core
gp120 protein ( Delta V1, V2, and V3), thus such a core protein produces a structure closely approximating full length folded monomer – CD4i MAbs 17b
and 48d bound better to the deleted protein than to wild type [Binley1998]
• 17b: Deleting the V2 loop of neutralization-resistant HIV-1 isolate SF162 does not abrogate its replication in PBMC or macrophages, but it enhances its
neutralization sensitivity to sera from patients with B clade infection up to 170-fold, and also enhances sensitivity to sera from clades A through F – deletion
of V2 but not V1 enabled neutralization by CD4i MAbs 17b and 48d [Stamatatos1998]
• 17b: A CD4-independent viral variant of IIIB, IIIBx, was generated on CXCR4-expressing cells – IIIBx exhibited greater exposure of the 17b and 48d
epitopes and enhanced neutralization by CD4i MAbs and by polyclonal human sera – the 17b epitope has significant overlap with the CCR5 coreceptor
binding site [Hoffman1999]
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• 17b: The MAbs with the broadest neutralizing activity, IgG1b12, 2G12 and 2F5, all have high affinity for the native trimer, indicating that they were raised
in an immune response to the oligomer on the virion surface rather than dissociated subunits – a disulfide linked gp120-gp41 (SOS gp140) was created to
mimic the native conformation of Env and explore its potential as an immunogen – SOS gp140 is recognized by NAbs IgG1b12, 2G12, and CD4-IgG2, and
also by anti-V3 MAbs 19b and 83.1 – SOSgp140 is not recognized by C4 region MAbs that neutralize only TCLA strains, G3-42 and G3-519 – nor did it
bind C11, 23A, and M90, MAbs that bind to gp120 C1 and C5, where it interacts with gp41 – MAbs that bind CD4 inducible epitopes, 17b and A32 were
very strongly induced by CD4 in SOS gp140 – anti-gp41 MAbs that bind in the region that interacts with gp120, 7B2, 2.2B, T4, T15G1 and 4D4, did not
bind to SOSgp140, in contrast to 2F5, which binds to the only gp41 epitope that is well exposed in native gp120-gp41 complexes [Binley1999]
• 17b: To determine the antigenicity of virus killed by thermal and chemical inactivation, retention of conformation-dependent neutralization epitopes was
examined, and exposure of CD4BS epitopes was found to be enhanced (MAbs IgG1b12, 205-46-9, and 205-43-1) – binding to 2G12 and 447-52D epitopes
was essentially unaltered – the 17b CD4i epitope was also exposed [Grovit-Ferbas2000]
• 17b: SF162 is a neutralization-resistant HIV-1 isolate – N-linked glycosylation modifications in the V2 loop of the SF162 gp120 revealed that these sites
prevent neutralization by CD4BS MAbs (IgG1b12 and IgGCD4), and protect against neutralization by V3 MAbs (447-D and 391-95D) – V2-region
glycosylation site mutations did not alter neutralization resistance to V2 MAbs (G3.4 and G3.136) or CD4i MAbs (17b and 48d) – V2 glycosylation site
modification allows infection of macrophages, probably due to glycosylated forms requiring fewer CCR5 molecules for viral entry [Ly2000]
• 17b: Six mutations in MN change the virus from a high-infectivity neutralization resistant phenotype to low-infectivity neutralization sensitive – V3,
CD4BS, and CD4i MAbs are 20-100 fold more efficient at neutralizing the sensitive form – the mutation L544P reduced binding of all MAbs against gp120
by causing conformational changes [Park2000]
• 17b: sCD4 can activate fusion between effector cells expressing Env and target cells expressing coreceptor (CCR5 or CXCR4) alone without CD4 – CD4i
MAbs 17b and 48d have little effect on a standard cell fusion assay but potently block sCD4 activated fusion – 17b was broadly cross-reactive inhibiting
sCD4 activated fusion with Env from clades A, B, C, D, E, F, and F/B [Salzwedel2000]
• 17b: Soluble gp140 derived from SF162, a neutralization-resistant primary isolate, and SF162AV2 a neutralization-susceptible isolate with 30 amino acids
deleted from the V2 loop, were generated with or without the gp120-gp41 cleavage site intact – all forms are recognized by oligomer-specific MAb T4 and
show enhanced binding of CD4i MAb 17b when sCD4 is bound – the fused forms are less efficiently recognized than the cleaved forms by polyclonal
neutralizing sera from HIV-infected patients – the V3 loop is more exposed on the fused form [Stamatatos2000]
• 17b: A combination of gp41 fusion with the GNC4 trimeric sequences and disruption of the YU2 gp120-gp41 cleavage site resulted in stable gp140 trimers
(gp140-GNC4) that preserve and expose some neutralizing epitopes while occluding some non-neutralizing epitopes – CD4BS MAbs (F105 and F91) and
CD4i (17b and 48d) recognized gp140-GNC4 as well as gp120 or gp140 – non-neutralizing MAbs C11, A32, 522-149, M90, and #45 bound to the
gp140-GNC4 glycoprotein at reduced levels compared to gp120 – MAbs directed at the extreme termini of gp120 C1 (135/9 and 133/290) and C5 (CRA-1
and M91) bound efficiently to gp140-GNC4 [Yang2000]
• 17b: Mutagenesis defines Ile-420, Lys-421, Gln-422, Pro-438, and Gly-441 to be important residues for CCR5 binding – these positions are located on two
strands that connect the gp120 bridging sheet and outer domain, suggesting a mechanism for conformational shifts induced by CD4 binding to facilitate
CCR5 binding [Rizzuto2000]
• SHIV-HXBc2 is a neutralization sensitive non-pathogenic virus, and several in vivo passages through monkey’s yielded highly pathogenic SHIV KU-1 –
HXBc2 and the KU-1 clone HXBc2P3.2 differ in 12 amino acids in gp160 – substitutions in both gp120 and gp41 reduced the ability of sCD4, IgG1b12,
F105 and AG1121 to Env achieve saturation and full occupancy, and neutralize KU-1 – 17b and 2F5 also bound less efficiently to HXBc2P3.2, although
2G12 was able to bind both comparably [Si2001]
• 17b: Mutations in two glycosylation sites in the V2 region of HIV-1 ADA at positions 190 and 197 (187 DNTSYRLINCNTS 199) cause the virus to become
CD4-independent and able to enter cells through CCR5 alone—these same mutations tended to increase the neutralization sensitivity of the virus, including
to 17b—only the CD4i antibodies 17b and 48d showed an increased affinity of the CD4 independent viruses relative to wild-type [Kolchinsky2001].
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• 17b: Abs against the V3 loop (50.1, 58.2, 59.1, 257-D, 268-D, 447-52D), CD4BS (IgG1b12, 559-64D, F105), CD4i (17b), and to gp41 (2F5, F240) each
showed similar binding efficiency to Env derived from related pairs of primary and TCLA lines (primary: 168P and 320SI, and TCLA: 168C and
320SI-C3.3), but the TCLA lines were much more susceptible to neutralization suggesting that the change in TCLA lines that make them more susceptible
to NAbs alters some step after binding – 17b bound at somewhat greater levels to 168C than to 168P, but this is not a general feature of 17b binding to
primary versus TCLA strains [York2001]
• 17b: 17b binds to a CD4 inducible epitope which partially overlaps the CCR5 binding site – JRFL, YU2, 89.6, and HXB2 and their C1-, V1/V2-, C5
-deletion mutants were used to study how 17b binding affects gp120-CD4 interactions – 17b reduced CD4-gp120 interactions by decreasing the on-rate and
increasing the off-rate of sCD4, while enhanced binding of sCD4 binding was observed for the 17b-bound, V1/V2 deleted gp120s – 17b was considered to
be a surrogate for CCR5, and the authors suggest that 17b binding may shift V1/V2 into a position that interferes with CD4 binding, forcing a release
[Zhang2001a]
• 17b: Structural aspects of the interaction of neutralizing Abs with HIV-1 Env are reviewed – Env essentially has three faces, one is largely inaccessible on
the native trimer, and two that exposed but have low immunogenicity on primary viruses – neutralization is suggested to occur by inhibition of the
interaction between gp120 and the target cell membrane receptors as a result of steric hindrance and it is noted that the attachment of approximately 70 IgG
molecules per virion is required for neutralization, which is equivalent to about one IgG molecule per spike – the 2G12, 17b and b12 epitopes are discussed
in detail – the 17b epitope is masked prior to CD4 binding by the V1-V2 loop and in contrast to sCD4, the binding of cell surface CD4 to virus does not
appear to make the epitope accessible to binding by 17b to allow neutralization [Poignard2001]
• 17b: Oligomeric gp140 (o-gp140) derived from R5 primary isolate US4 was characterized for use as a vaccine reagent – antigen capture ELISA was used to
compare the antigenicity of gp120 and o-gp140 using a panel of well characterized MAbs – 17b recognized both gp120 monomer and o-gp140
[Srivastava2002]
• 17b: The fusion process was slowed by using a suboptimal temperature (31.5 C) to re-evaluate the potential of Abs targeting fusion intermediates to block
HIV entry – preincubation of E/T cells at 31.5 C enabled polyclonal anti-N-HR Ab and anti-six-helix bundle Abs to inhibit fusion, indicating six-helix
bundles form prior to fusion – the preincubation 31.5 C step did not alter the inhibitory activity of neutralizing Abs anti-gp41 2F5, or anti-gp120 2G12,
IG1b12, 48d, and 17b [Golding2002b]
• 17b: Ab binding characteristics of SOS gp140 were tested using SPR and RIPA – SOS gp140 is gp120-gp41 bound by a disulfide bond – NAbs 2G12, 2F5,
IgG1b12, CD4 inducible 17b, and 19b bound to SOS gp140 better than uncleaved gp140 (gp140unc) and gp120 – non-neutralizing MAbs 2.2B (binds to
gp41 in gp140unc) and 23A (binds gp120) did not bind SOS gp140 [Schulke2002]
• 17b: Uncleaved soluble gp140 (YU2 strain, R5 primary isolate) can be stabilized in an oligomer by fusion with a C-term trimeric GCN4 motif or using a T4
trimeric motif derived from T4 bacteriophage fibritin—stabilized oligomer gp140∆683(-FT) showed strong preferential recognition by NAbs IgG1b12 and
2G12 relative to the gp120 monomer, in contrast to poorly neutralizing MAbs F105, F91, 17b, 48d, and 39F which showed reduced levels of binding, and
C11, A32, and 30D which did not bind the stabilized oligomer [Yang2002].
• 17b: CD4 residue Phe43 significantly contributes to the affinity of CD4-gp120 interactions – despite decreased affinities for gp120, CD4 proteins and
CD4-mimetic peptides lacking a Phe side-chain enhance binding of gp120 to 17b in a manner similar to Phe-bearing ligands indicating the Phe42
interaction is not critical for CD4-induced conformational changes in gp120 [Dowd2002]
• 17b: A series of mutational changes were introduced into the YU2 gp120 that favored different conformations – 375 S/W seems to favor a conformation of
gp120 closer to the CD4-bound state, and is readily bound by sCD4 and CD4i MAbs (17b, 48d, 49e, 21c and 23e) but binding of anti-CD4BS MAbs (F105,
15e, IgG1b12, 21h and F91 was markedly reduced – IgG1b12 failed to neutralize this mutant, while neutralization by 2G12 was enhanced – 2F5 did not
neutralize either WT or mutant, probably due to polymorphism in the YU2 epitope – another mutant, 423 I/P, disrupted the gp120 bridging sheet, favored a
different conformation and did not bind CD4, CCR5, or CD4i antibodies, but did bind to CD4BS MAbs [Xiang2002b]
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• 17b: Five CD4i MAbs were studied, 17b, 48d and three new MAbs derived by Epstein-Barr virus transformation of PBMC from an HIV+ long term
non-progressor – 23e and 21c were converted to hybridomas to increase Ab production – all compete with the well-characterized 17b CD4i MAb in an
ELISA antigen capture assay – critical binding residues are mapped and the CD4i MAb epitopes were distinct but share a common element near isoleucine
420, also important for CCR5 binding, and all five can block CCR5 binding to a sCD4-gp120 complex – the MAb 48d has the epitope most similar to the
CCR5 binding site [Xiang2002a]
• 17b: Truncation of the gp41 cytoplasmic domain of X4, R5, and X4R5 viruses forces a conformation that more closely resembles the CD4 bound state of
the external Envelope, enhancing binding of CD4i MAbs 17b and 48d and of CD4BS MAbs F105, b12, and in most cases of glycosylation site dependent
MAb 2G12 and the anti-gp41 MAb 246D – in contrast, binding of the anti-V2 MAb 697D and the anti-V3 MAb 694/98D were not affected – viruses
bearing the truncation were more sensitive to neutralization by MAbs 48d, b12, and 2G12 – the anti-C5 MAb 1331A was used to track levels of cell surface
expression of the mutated proteins [Edwards2002]
• 17b: HIV-1 gp160∆CT (cytoplasmic tail-deleted) proteoliposomes (PLs) containing native, trimeric envelope glycoproteins from R5 strains YU2 and JRFL,
and X4 strain HXBc2, were made in a physiologic membrane setting as candidate immunogens for HIV vaccines—2F5 bound to gp160∆CT with a
reconstituted membrane ten-fold better than the same protein on beads—anti-CD4BS MAbs IgG1b12 and F105, A32 (C1-C4), C11 (C1-C5), and 39F (V3)
MAbs bound gp160∆CT PLs indistinguishably from gp160∆CT expressed on the cell surface—non-neutralizing MAbs C11 and A32 bound with lower
affinity than NAb IgG1b12—the MAb 17b was sCD4 inducible on gp160∆CT PL [Grundner2002].
• 17b: gp120 mutants were used to define the CXCR4 binding site using CXCR4 displayed on paramagnetic proteoliposomes (PMPLs) to reduce
non-specific gp120 binding—basic residues in the V3 loop and the β19 strand (RIKQ, positions 419-422) were involved, and deletion of the V1-V2 loops
allowed CD4-independent CXCR4 binding—MAbs 17b (CD4i) and F105 (CD4BS) were used to study conformational changes in the mutants—the affinity
of ∆V1 and ∆V1-V2 for 17b was dramatically increased and no longer inducible in the presence of sCD4—V3 mutants R298A and R327A were not
recognized by 17b except in the presence of sCD4—mutations in the β19 strand dramatically reduced 17b affinity in the presence or absence of sCD4,
consistent with known 17b contact residues in this region [Basmaciogullari2002].
• 17b: A rare mutation in the neutralization sensitive R2-strain in the proximal limb of the V3 region caused Env to become sensitive to neutralization by
MAbs directed against the CD4 binding site (CD4BS), CD4-induced (CD4i) epitopes, soluble CD4 (sCD4), and HNS2, a broadly neutralizing sera – 2/12
anti-V3 MAbs tested (19b and 694/98-D) neutralized R2, as did 2/3 anti-CD4BS MAbs (15e and IgG1b12), 2/2 CD4i MAbs (17b and 4.8D), and 2G12 and
2F5 – thus multiple epitopes on R2 are functional targets for neutralization and the neutralization sensitivity profile of R2 is intermediate between the highly
sensitive MN-TCLA strain and the typically resistant MN-primary strain [Zhang2002]
• 17b: The two N-terminal domains of CD4, termed D1 and D2, when expressed in the absence of the remaining domains of CD4 retain the capacity to bind
to gp120—coding sequences of D1D2 and Igαtp were fused to create a large, multivalent rec protein D1D2Igαtp, which, unlike CD4, does not enhance
infection at sub-optimal concentrations—the MAb 17b can also enhance viral replication at sub-optimal concentrations, but D1D2-Igα inhibited the 17b
enhancement of two primary isolates [Arthos2002].
• 17b: NIH AIDS Research and Reference Reagent Program: 4091
969 21c Env gp120 (IIIB, J62) L HIV-1 infection human (IgG)
Ab type CD4i Donor James Robinson, Tulane University, New Orleans, LA, USA
References Xiang2002a, Xiang2002b
• 21c: Five CD4i MAbs were studied, 17b, 48d and three new MAbs derived by Epstein-Barr virus transformation of PBMC from an HIV+ long term
non-progressor – 23e and 21c were converted to hybridomas to increase Ab production – all compete with the well-characterized 17b CD4i MAb in an
ELISA antigen capture assay – critical binding residues are mapped and the CD4i MAb epitopes were distinct but share a common element near isoleucine
420, also important for CCR5 binding, and all five can block CCR5 binding to a sCD4-gp120 complex – the MAb 48d has the epitope most similar to the
CCR5 binding site [Xiang2002a]
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• 21c: A series of mutational changes were introduced into the YU2 gp120 that favored different conformations – 375 S/W seems to favor a conformation of
gp120 closer to the CD4-bound state, and is readily bound by sCD4 and CD4i MAbs (17b, 48d, 49e, 21c and 23e) but binding of anti-CD4BS MAbs (F105,
15e, IgG1b12, 21h and F91 was markedly reduced – IgG1b12 failed to neutralize this mutant, while neutralization by 2G12 was enhanced – 2F5 did not
neutralize either WT or mutant, probably due to polymorphism in the YU2 epitope – another mutant, 423 I/P, disrupted the gp120 bridging sheet, favored a
different conformation and did not bind CD4, CCR5, or CD4i antibodies, but did bind to CD4BS MAbs [Xiang2002b]
970 23e Env gp120 (IIIB, J62) L HIV-1 infection human (IgG)
Ab type CD4i Donor James Robinson, Tulane University, New Orleans, LA, USA
References Xiang2002a, Xiang2002b
• 23e: Five CD4i MAbs were studied, 17b, 48d and three new MAbs derived by Epstein-Barr virus transformation of PBMC from an HIV+ long term
non-progressor – 23e and 21c were converted to hybridomas to increase Ab production – all compete with the well-characterized 17b CD4i MAb in an
ELISA antigen capture assay – critical binding residues are mapped and the CD4i MAb epitopes were distinct but share a common element near isoleucine
420, also important for CCR5 binding, and all five can block CCR5 binding to a sCD4-gp120 complex – the MAb 48d has the epitope most similar to the
CCR5 binding site [Xiang2002a]
• 23e: A series of mutational changes were introduced into the YU2 gp120 that favored different conformations – 375 S/W seems to favor a conformation of
gp120 closer to the CD4-bound state, and is readily bound by sCD4 and CD4i MAbs (17b, 48d, 49e, 21c and 23e) but binding of anti-CD4BS MAbs (F105,
15e, IgG1b12, 21h and F91 was markedly reduced – IgG1b12 failed to neutralize this mutant, while neutralization by 2G12 was enhanced – 2F5 did not
neutralize either WT or mutant, probably due to polymorphism in the YU2 epitope – another mutant, 423 I/P, disrupted the gp120 bridging sheet, favored a
different conformation and did not bind CD4, CCR5, or CD4i antibodies, but did bind to CD4BS MAbs [Xiang2002b]
971 48d (4.8d,
4.8D)
Env gp120 L P (weak) HIV-1 infection human (IgG1κ)
Ab type CD4i Donor James Robinson, Tulane University, New Orleans, LA, USA
References Thali1993, Moore1993a, Moore1993d, Thali1994, Moore1994b, D’Souza1995, Sattentau1995a, Wyatt1995, Sattentau1995b, Moore1996,
Poignard1996a, Trkola1996a, Binley1997a, Li1997, Weinberg1997, Lee1997, Ugolini1997, Wyatt1997, Parren1997c, Frankel1998, Wyatt1998a,
Mondor1998, Parren1998a, Sullivan1998b, Yang1998, Binley1998, Stamatatos1998, Oscherwitz1999a, Hoffman1999, Fortin2000, Ly2000, Park2000,
Yang2000, Salzwedel2000, Kolchinsky2001, Verrier2001, Golding2002b, Yang2002, Xiang2002b, Xiang2002a, Edwards2002, Zhang2002
• 48d: 48d and 17b have similar epitopes, and the pair are unique among human and rodent MAbs
• 48d: Epitope is better exposed upon CD4 binding to gp120 – competes with ICR 39.13, 15e and 21h, anti-CD4 binding site MAbs – inhibited by
anti-CD4BS MAb ICR 39.13g and linear anti-C4 MAbs G3-42 and G3-508 – 113 D/R, 252 R/W, 257 T/A or G, 370 E/D, 382 F/L, 420 I/R, 421 K/L,
433A/L, 438 P/R and 475 M/S confer decreased sensitivity to neutralization [Thali1993]
• 48d: Called 4.8d – Neutralizes IIIB – reactive with SF-2 gp120 – does not inhibit HIV-1 sera from binding to IIIB gp120 [Moore1993a]
• 48d: Binding of 48d is much more influenced by sequence variation among molecular clones of LAI than is binding of 17b [Moore1993d]
• 48d: A mutation in gp41, 582 A/T, confers resistance to neutralization (also confers resistance to MAbs F105, 21h, 15e and 17b) [Thali1994]
• 48d: Poor cross-reactivity with gp120 from most clades [Moore1994b]
• 48d: Called 4.8D – Found to neutralize MN, but not JRCSF, two B subtype primary isolates, or a D subtype primary isolate, by most labs in a
multi-laboratory study involving 11 labs[D’Souza1995]
• 48d: Studies using a V1/V2 deletion mutant demonstrated that enhanced binding of 48d in the presence of sCD4 involves the V1/V2 loops, with more
significant involvement of V2 – similar effect observed for 17b and A32 [Wyatt1995]
• 48d: Formalin inactivation of virus at 0.1% formalin for 10 hours at 4 degrees was optimal for inactivation of virus while maintaining epitope integrity
[Sattentau1995c]
• 48d: Binds with similar affinity to monomer and oligomer, moderate association rate, potent neutralization – this is in contrast to 17b, which has very
different kinetics [Sattentau1995b]
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• 48d: Many MAbs inhibit binding (anti-C1, -C5, -C4, -CD4BS) – anti-C1-C4 discontinuous epitope MAbs A32 and 2/11c enhance binding – reciprocal
enhanced binding with some anti-V2 MAbs [Moore1996]
• 48d: Binding resulted in gp120 dissociation from virion, mimicking sCD4, and exposure of the gp41 epitope of MAb 50-69, in contrast to CD4BS MAbs
[Poignard1996a]
• 48d: Neutralizes JR-FL – slightly inhibits gp120 interaction with CCR-5 in a MIP-1beta-CCR-5 competition study [Trkola1996a]
• 48d: One of 14 human MAbs tested for ability to neutralize a chimeric SHIV-vpu+, which expressed HIV-1 IIIB env – all Ab combinations tested showed
synergistic neutralization – 48d has synergistic response with MAbs 694/98-D (anti-V3) and F105 [Li1997]
• 48d: 48d binds to the IIIB protein and not IIIB V3 peptide, while binding to the Can0A V3 peptide, suggesting Can0A V3 is a conformer that mimics the
48d, (but not 17b), epitope [Weinberg1997]
• 48d: Prefers CD4-gp120 complex to gp120 alone, but does not enhance fusion, in contrast to MAb CG10, in fact it inhibits syncytium formation [Lee1997]
• 48d: Viral binding inhibition by 48d was strongly correlated with neutralization (all other neutralizing MAbs tested showed some correlation except 2F5)
[Ugolini1997]
• 48d: Binds efficiently to sgp120 but not soluble gp120+gp41, suggesting its gp120 epitope is blocked by gp41 binding [Wyatt1997]
• 48d: Neutralizes TCLA strains, but not primary isolates [Parren1997c]
• 48d: Summary of the implications of the crystal structure of the core of gp120 bound to CD4 and 17b with what is known about mutations that reduce NAb
binding – probable mechanism of neutralization of 48d is interference with chemokine receptor binding – CD4 binding increases exposure of epitope due to
V2 loop movement – 88N, 117K, 121K, 256S, 257T, N262, delta V3, E370, E381, F 382, R 419, I 420, K 421, Q 422, I 423, W 427, Y 435, P 438, M 475
mutations in HXBc2 (IIIB) decrease binding [Wyatt1998a]
• 48d: Inhibits binding of Hx10 to both CD4 positive and CD4 negative HeLa cells [Mondor1998]
• 48d: The MAb and Fab binding to the oligomeric form of gp120 and neutralization were highly correlated – authors suggest that neutralization is
determined by the fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
• 48d: CD4i MAbs 17b and 48d compete with MAb CG10, and the binding sites may overlap – MAb A32 enhances binding of 17b, 48d and CG10
[Sullivan1998b]
• 48d: A neutralization assay was developed based on hemi-nested PCR amplification of the LTR (HNPCR) – LTR-HNPCR consistently revealed HIV DNA
and was shown to be a rapid, specific and reliable neutralization assay based on tests with 6 MAbs and 5 isolates [Yang1998]
• 48d: A panel of MAbs were shown to bind with similar or greater affinity and similar competition profiles to a deglycosylated or variable loop deleted core
gp120 protein ( Delta V1, V2, and V3), thus such a core protein produces a structure closely approximating full length folded monomer – CD4i MAbs 17b
and 48d bound better to the deleted protein than to wild type [Binley1998]
• 48d: Deleting the V2 loop of neutralization-resistant HIV-1 isolate SF162 does not abrogate its replication in PBMC or macrophages, but it enhances its
neutralization sensitivity to sera from patients with B clade infection up to 170-fold, and also enhances sensitivity to sera from clades A through F – deletion
of V2 but not V1 enabled neutralization by CD4i MAbs 17b and 48d [Stamatatos1998]
• 48d: Infection of dendritic cells cultured from CD14+ blood cells or from cadaveric human skin was blocked by neutralizing MAbs IgG1b12, or 2F5 and
2G12 delivered together, but not by control non-neutralizing anti-gp120 MAb 4.8D, indicating that NAbs could interrupt early mucosal transmission events
[Frankel1998]
• 48d: A CD4-independent viral variant of IIIB, IIIBx, was generated on CXCR4-expressing cells – IIIBx exhibited greater exposure of the 17b and 48d
epitopes and enhanced neutralization by CD4i MAbs and by polyclonal human sera [Hoffman1999]
• 48d: Called 4.8D – host encoded intercellular adhesion molecule (ICAM-1) is incorporated by the HIV-1 virion and enhances viral infectivity – ICAM-1
does not modify virus sensitivity to antibodies 0.5beta or 4.8D or sCD4, but neutralizing ability of F105 was diminished in ICAM bearing virions in the
presence of lymphocyte function-association antigen-1 (LFA-1) Ab [Fortin2000]
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• 48d: SF162 is a neutralization-resistant HIV-1 isolate – N-linked glycosylation modifications in the V2 loop of the SF162 gp120 revealed that these sites
prevent neutralization by CD4BS MAbs (IgG1b12 and IgGCD4), and protect against neutralization by V3 MAbs (447-D and 391-95D) – V2-region
glycosylation site mutations did not alter neutralization resistance to V2 MAbs (G3.4 and G3.136) or CD4i MAbs (17b and 48d) – V2 glycosylation site
modification allows infection of macrophages, probably due to glycosylated forms requiring fewer CCR5 molecules for viral entry [Ly2000]
• 48d: Six mutations in MN change the virus from a high-infectivity neutralization resistant phenotype to low-infectivity neutralization sensitive – V3,
CD4BS, and CD4i MAbs are 20-100 fold more efficient at neutralizing the sensitive form – the mutation L544P reduced binding of all MAbs against gp120
by causing conformational changes [Park2000]
• 48d: sCD4 can activate fusion between effector cells expressing Env and target cells expressing coreceptor (CCR5 or CXCR4) alone without CD4 – CD4i
MAbs 17b and 48d have little effect on a standard cell fusion assay but potently block sCD4 activated fusion [Salzwedel2000]
• 48d: A combination of gp41 fusion with the GNC4 trimeric sequences and disruption of the YU2 gp120-gp41 cleavage site resulted in stable gp140 trimers
(gp140-GNC4) that preserve and expose some neutralizing epitopes while occluding some non-neutralizing epitopes – CD4BS MAbs (F105 and F91) and
CD4i (17b and 48d) recognized gp140-GNC4 as well as gp120 or gp140 – non-neutralizing MAbs C11, A32, 522-149, M90, and #45 bound to the
gp140-GNC4 glycoprotein at reduced levels compared to gp120 – MAbs directed at the extreme termini of gp120 C1 (135/9 and 133/290) and C5 (CRA-1
and M91) bound efficiently to gp140-GNC4 [Yang2000]
• 48d: Mutations in two glcosylation sites in the V2 region of HIV-1 ADA at positions 190 and 197 (187 DNTSYRLINCNTS 199) cause the virus to become
CD4-independent and able to enter cells through CCR5 alone – these same mutations tended to increase the neutralization sensitivity of the virus, including
to 48d – only the CD4i antibodies 17b and 48d showed an increased affinity of the CD4 independent viruses relative to wild-type [Kolchinsky2001]
• 48d: Called 4.8d – A panel of 12 MAbs was used to identify those that could neutralize the dual-tropic primary isolate HIV-1 89.6 – six gave significant
neutralization at 2 to 10 ug/ml: 2F5, 50-69, IgG1b12, 447-52D, 2G12, and 670-D six did not have neutralizing activity: 654-D, 4.8D, 450-D, 246-D, 98-6,
and 1281 – no synergy, only additive effects were seen for pairwise combinations of MAbs, and antagonism was noted between gp41 MAbs 50-69 and 98-6,
as well as 98-6 and 2F5 [Verrier2001]
• 48d: The fusion process was slowed by using a suboptimal temperature (31.5 C) to re-evaluate the potential of Abs targeting fusion intermediates to block
HIV entry – preincubation of E/T cells at 31.5 C enabled polyclonal anti-N-HR Ab and anti-six-helix bundle Abs to inhibit fusion, indicating six-helix
bundles form prior to fusion – the preincubation 31.5 C step did not alter the inhibitory activity of neutralizing Abs anti-gp41 2F5, or anti-gp120 2G12,
IG1b12, 48d, and 17b [Golding2002b]
• 48d: Uncleaved soluble gp140 (YU2 strain, R5 primary isolate) can be stabilized in an oligomer by fusion with a C-term trimeric GCN4 motif or using a T4
trimeric motif derived from T4 bacteriophage fibritin – stabilized oligomer gp140 delta683(-FT) showed strong preferential recognition by NAbs IgG1b12
and 2G12 relative to the gp120 monomer, in contrast to poorly neutralizing MAbs F105, F91, 17b, 48d, and 39F which showed reduced levels of binding,
and C11, A32, and 30D which did not bind the stabilized oligomer [Yang2002]
• 48d: A series of mutational changes were introduced into the YU2 gp120 that favored different conformations – 375 S/W seems to favor a conformation of
gp120 closer to the CD4-bound state, and is readily bound by sCD4 and CD4i MAbs (17b, 48d, 49e, 21c and 23e) but binding of anti-CD4BS MAbs (F105,
15e, IgG1b12, 21h and F91 was markedly reduced – IgG1b12 failed to neutralize this mutant, while neutralization by 2G12 was enhanced – 2F5 did not
neutralize either WT or mutant, probably due to polymorphism in the YU2 epitope – another mutant, 423 I/P, disrupted the gp120 bridging sheet, favored a
different conformation and did not bind CD4, CCR5, or CD4i antibodies, but did bind to CD4BS MAbs [Xiang2002b]
• 48d: Five CD4i MAbs were studied, 17b, 48d and three new MAbs derived by Epstein-Barr virus transformation of PBMC from an HIV+ long term
non-progressor – 23e and 21c were converted to hybridomas to increase Ab production – all compete with the well-characterized 17b CD4i MAb in an
ELISA antigen capture assay – critical binding residues are mapped and the CD4i MAb epitopes were distinct but share a common element near isoleucine
420, also important for CCR5 binding, and all five can block CCR5 binding to a sCD4-gp120 complex – the MAb 48d has the epitope most similar to the
CCR5 binding site [Xiang2002a]
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• 48d: Truncation of the gp41 cytoplasmic domain of X4, R5, and X4R5 viruses forces a conformation that more closely resembles the CD4 bound state of
the external Envelope, enhancing binding of CD4i MAbs 17b and 48d and of CD4BS MAbs F105, b12, and in most cases of glycosylation site dependent
MAb 2G12 and the anti-gp41 MAb 246D – in contrast, binding of the anti-V2 MAb 697D and the anti-V3 MAb 694/98D were not affected – viruses
bearing the truncation were more sensitive to neutralization by MAbs 48d, b12, and 2G12 – the anti-C5 MAb 1331A was used to track levels of cell surface
expression of the mutated proteins [Edwards2002]
• 48d: Called 4.8D – A rare mutation in the neutralization sensitive R2-strain in the proximal limb of the V3 region caused Env to become sensitive to
neutralization by MAbs directed against the CD4 binding site (CD4BS), CD4-induced (CD4i) epitopes, soluble CD4 (sCD4), and HNS2, a broadly
neutralizing sera – 2/12 anti-V3 MAbs tested (19b and 694/98-D) neutralized R2, as did 2/3 anti-CD4BS MAbs (15e and IgG1b12), 2/2 CD4i MAbs (17b
and 4.8D), and 2G12 and 2F5 – thus multiple epitopes on R2 are functional targets for neutralization and the neutralization sensitivity profile of R2 is
intermediate between the highly sensitive MN-TCLA strain and the typically resistant MN-primary strain [Zhang2002]
• 48d: NIH AIDS Research and Reference Reagent Program: 1756
972 49e Env gp120 (IIIB, J62) L HIV-1 infection human (IgG)
Ab type CD4i Donor James Robinson, Tulane University, New Orleans, LA, USA
References Xiang2002a, Xiang2002b
• 49e: Five CD4i MAbs were studied, 17b, 48d and three new MAbs derived by Epstein-Barr virus transformation of PBMC from an HIV+ long term
non-progressor – 23e and 21c were converted to hybridomas to increase Ab production – all compete with the well-characterized 17b CD4i MAb in an
ELISA antigen capture assay – critical binding residues are mapped and the CD4i MAb epitopes were distinct but share a common element near isoleucine
420, also important for CCR5 binding, and all five can block CCR5 binding to a sCD4-gp120 complex – the MAb 48d has the epitope most similar to the
CCR5 binding site [Xiang2002a]
• 49e: A series of mutational changes were introduced into the YU2 gp120 that favored different conformations – 375 S/W seems to favor a conformation of
gp120 closer to the CD4-bound state, and is readily bound by sCD4 and CD4i MAbs (17b, 48d, 49e, 21c and 23e) but binding of anti-CD4BS MAbs (F105,
15e, IgG1b12, 21h and F91 was markedly reduced – IgG1b12 failed to neutralize this mutant, while neutralization by 2G12 was enhanced – 2F5 did not
neutralize either WT or mutant, probably due to polymorphism in the YU2 epitope – another mutant, 423 I/P, disrupted the gp120 bridging sheet, favored a
different conformation and did not bind CD4, CCR5, or CD4i antibodies, but did bind to CD4BS MAbs [Xiang2002b]
973 X5 Env (JRFL) P HIV-1 infection human
Ab type CD4i
ReferencesMoulard2002
• X5: The human Fab X5 was selected from a phage display library derived from an HIV-1 positive donor with a highly neutralizing serum – it was selected
for binding to purified gp120-CD4-coreceptor complexes – the Fab neutralizes PBMC infection by a selection of HIV-1 primary isolates from clades A, B,
C, D, E, F, and G, and neutralizes R5, X4, and R5X4 isolates – it binds to a conserved epitope on gp120 induced by CD4 binding, its binding is slightly
enhanced by CCR5 binding – while CD4i MAb 17b binds the CCR5 binding site, X5 also competes with Fab b12 which overlaps with the CD4 binding
site, suggesting the epitope for is near both the CD4 and CCR5 binding sites [Moulard2002]
974 T22 Env gp120 (IIIB) Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
Ab type Env oligomer Donor P. Earl, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
References Earl1994, Otteken1996, Sugiura1999
• T22: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• T22: Pulse label experiments of 4 MAbs (D20, D27, T20, and T22) binding to noncleavable gp140 revealed that these anti-CD4BS MAbs bound with a
delay, and that the epitope formed with a t 1/2 of about 10 minutes [Otteken1996]
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• T22: A comparison of 25 gp120 specific, conformation dependent MAbs was done – T22 is part of a group of MAbs labeled AII – all AII MAbs were
broadly cross-reactive with gp160 from B-clade R5, X4, and R5X4 viruses, and could only partially blocked CD4 binding [Sugiura1999]
975 polyclonal Env gp41 Vaccine rabbit (IgG)
Vaccine Vector/Type: peptide Adjuvant: gp41 N-HR and C-HR helical peptides
Ab type N-HR, C-HR, and six-helix bundle
References deRosny2001, Golding2002b
• A panel of Abs against gp41 heptad repeats N-HR, C-HR, and self-assembled stable N-HR and C-HR six helix bundles were generated [deRosny2001]
• The fusion process was slowed by using a suboptimal temperature (31.5 C) to re-evaluate the potential of Abs targeting fusion intermediates to block HIV
entry – preincubation of E/T cells at 31.5 C enabled polyclonal anti-N-HR Ab and anti-six-helix bundle Abs to inhibit fusion, indicating six-helix bundles
form prior to fusion – the preincubation 31.5 C step did not alter anti-C-HR Abs inability to inhibit fusion [Golding2002b]
976 2A2 Env gp41 no HIV-1 infection human (IgG1κ)
Ab type N-term
ReferencesWeissenhorn1996
• Soluble gp41(21-166) forms a rod like structure that can be visualized with electron microscopy, and 2A2 binds to one end of the rod [Weissenhorn1996]
977 AC4 Env gp120 (IIIB) yes Vaccine murine
Vaccine Vector/Type: recombinant protein HIV component: gp160
Ab type N-term
References Dickey2000
• AC4: Three MABs, ID6, AC4, and AD3 that bind to a discontinuous N-term first 204 aa of gp120 and generate ADCC were elicited through vaccination of
BALBc mice with rec gp160 – these MAbs do not depend on glycosylation and are cross-reactive with viruses from clades B and CRF01(AE) [Dickey2000]
978 AD3 Env gp120 (IIIB) yes Vaccine murine
Vaccine Vector/Type: recombinant protein HIV component: gp160
Ab type N-term
References Dickey2000, Cook1994
• AD3: There may be two Abs with this name that bind to the N-term region of gp120 [Cook1994, Dickey2000]
• AD3: Three MABs, ID6, AC4, and AD3 that bind to a discontinuous N-term first 204 aa of gp120 and generate ADCC were elicited through vaccination of
BALBc mice with rec gp160 – these MAbs do not depend on glycosylation and are cross-reactive with viruses from clades B and CRF01(AE) [Dickey2000]
979 AD3 Env gp120 (BH10) murine (IgG1)
Ab type N-term
References Ugen1993, Cook1994, Dickey2000
• AD3: There may be two Abs with this name that bind to the N-term region of gp120 [Cook1994, Dickey2000]
• AD3: MAbs against the glycosphingolipid GalCer block HIV infection of normally susceptible CD4 negative cells from the brain and colon – MAbs
against the N-terminal half of gp120 do not inhibit gp120 binding to GalCer – binding of GalCer to gp120 does not inhibit MAb binding [Cook1994]
• AD3: NIH AIDS Research and Reference Reagent Program: 2342
980 ID6 Env gp120 (1–193 BH10) murine (IgG1)
Ab type N-term
References Ugen1993, Cook1994, Dickey2000
• ID6: There may be two Abs with this name that bind to the N-term region of gp120 [Cook1994, Dickey2000]
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• ID6: MAbs against the glycosphingolipid GalCer block HIV infection of normally susceptible CD4 negative cells from the brain and colon – MAbs against
the N-terminal half of gp120 do not inhibit gp120 binding to GalCer – binding of GalCer to gp120 does not inhibit MAb binding [Cook1994]
• ID6: NIH AIDS Research and Reference Reagent Program: 2343
981 ID6 Env gp120 (IIIB) yes Vaccine murine (IgG2a)
Vaccine Vector/Type: recombinant protein HIV component: gp160
Ab type N-term
References Dickey2000, Cook1994
• ID6: There may be two Abs with this name that bind to the N-term region of gp120 [Cook1994, Dickey2000]
• ID6: Three MABs, ID6, AC4, and AD3 that bind to a discontinuous N-term first 204 aa of gp120 and generate ADCC were elicited through vaccination of
BALBc mice with rec gp160 – these MAbs do not depend on glycosylation and are cross-reactive with viruses from clades B and CRF01(AE) [Dickey2000]
982 11/68b Env gp120 L (HXB2) Vaccine rat (IgG1)
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: gp120
Ab type V1-V2 Donor Shotton and Dean
ReferencesMcKeating1993b, Shotton1995, Peet1998
• 11/68b: Changes at residues 183/184 (PI/SG) within V2, 435 (Y/H) in C4, abrogate binding [McKeating1993b]
• 11/68b: 435 (Y/H) in C4 does not abrogate binding (John Moore, per comm, 1996)
• 11/68b: Cross-competes with MAbs 62c, 66c, 66a, and CRA-4 – similar to MAb 62c – HXB2 neutralization escape mutant had a D/N substitution at
residue 185 – non-reciprocal inhibition of binding of CRA-3 and CRA-6 [Shotton1995]
• 11/68b: The most variable amino acids in the V3 loop were replaced with serines to make the immunodominant V3 loop less immunogenic – these changes
did not affect the ability of sCD4 or MAbs to V1/V2, C1 and C4 to bind – 11/68b was not affected by V3 serine substitutions – mice injected with serine
substituted gp120 had a reduced response relative to wildtype, and no enhanced immunogenicity of conserved regions [Peet1998]
• 11/68b: UK Medical Research Council AIDS reagent: ARP3041
983 62c Env gp120 no Vaccine rat (IgG1)
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: gp120
Ab type V1-V2
References Shotton1995
• 62c: Cross-competes with MAbs 11/68b, 66c, 66a, and CRA-4 – same cross-competition group as MAb 11/68b – non-reciprocal inhibition of binding of
CRA-3 and CRA-6 – substitutions 176-177 FY/AT, 179-180 LD/DL, 183-184 PI/SG, and 191-193 YSL/GSS abrogate binding – binds but does not
neutralize Hx10 [Shotton1995]
• 62c: UK Medical Research Council AIDS reagent: ARP3075
984 CRA-6
(CRA6)
Env gp120 no murine
Ab type V1-V2
References Shotton1995
• CRA-6: Called CRA6 – same competition group as CRA-3 [Shotton1995]
985 L15 Env gp120 P (weak) HIV-1 infection human (IgG1)
Ab type V1-V2
References Ditzel1997, Parren1997c
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• L15: gp120 immobilized on solid phase by capture with anti-CD4 BS MAb L72 was used for selection of Fabs – 2 anti-V2 Fabs were obtained with very
similar epitopes, L15 and L17 – deletions in V1 and V2 abolished binding, and rodent anti-V2 MAbs SC258, CRA3, G3-G4,G3-136, BAT-085, and 52-684
all compete with L15 [Ditzel1997]
• L15: Does not neutralize TCLA strains but neutralizes some primary isolates weakly [Parren1997c]
986 T52 Env gp120 (IIIB) Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
Ab type V1-V2 Donor P. Earl, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
References Earl1994, Sugiura1999
• T52: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• T52: A comparison of 25 gp120 specific, conformation dependent MAbs was done – T52 is one of two MAbs labeled B-II, that had limited cross-reactivity
with seven clade B isolates and did not fully blocked CD4 binding – deletion of V1/V2 loops abrogated binding [Sugiura1999]
987 T54 Env gp120 (IIIB) no Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
Ab type V1-V2 Donor P. Earl, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
References Earl1994, Sugiura1999
• T54: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• T54: A comparison of 25 gp120 specific, conformation dependent MAbs was done – T54 is one of two MAbs labeled B-II, that had limited cross-reactivity
with seven clade B isolates and did not fully blocked CD4 binding – deletion of V1/V2 loops abrogated binding [Sugiura1999]
988 polyclonal Env Env yes HIV-1 infection human
Ab type V1-V2 and V3-V5
References Gordon2000
• Primary isolates have great differences in susceptibility to neutralization – the variation in V1V2 and V3-V5 was measured by HTA in a set of viruses with a
range of neutralization susceptibilities, and greater variability was uncorrelated with resistance to neutralization [Gordon2000]
989 1088 Env gp120
Ab type V2
References Berman1997
• 1088: Binds weakly to 2/7 isolates from breakthrough cases from a MN gp120 vaccine trial [Berman1997]
990 110-B Env gp120 no Vaccine murine
Vaccine Vector/Type: infected-cell lysate Strain: BRU HIV component: virus
Ab type V2 Donor Hybridolabs, Institute Pasteur, Paris, France
ReferencesMoore1993b
• 110-B: specific for BH10, does not bind to MN, RF, or SF-2 gp120 – binding inhibited by deletion of the V2 loop, and the following amino acid
substitutions: 168 K/L, 176/177 FY/AT, 179/180 LD/DL, 183/184 PI/SG, and 192-194 YSL/GSS [Moore1993b]
991 1357 Env gp120 human (IgG1κ)
Ab type V2 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Nyambi1998, Gorny2000a, Nyambi2000
• 1357: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including 5 anti-V2 MAbs, which showed weak and sporadic
binding, with the most frequent binding to C and D clades [Nyambi2000]
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• 1357: Using a whole virion-ELISA method, 18 human MAbs were tested for their ability to bind to a panel of 9 viruses from clades A, B, D, F, G, and H –
V2 Abs 697-D, 1361, and 1357 tended to bind very weakly with a similar pattern of specificity to virions, but bound well to soluble gp120: weak binding
only to subtype D MAL [Nyambi1998]
• 1357: Blocks binding of MAb 697-D to rgp120, and doesn’t react with a protein from which V1V2 has been deleted – binding of panel of 21 MAbs to
soluble oligomeric gp140 versus gp41 or gp120 monomers was compared – no MAb was oligomer specific, though anti-V3 and CD4BS MAbs reacted
better with the oligomer and V2 and C5 tended to favor the monomer – V2 MAbs 697-D, 1357 and 1361 favored the monomer by approximately 2 fold
[Gorny2000a]
• 1357: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including 5 anti-V2 MAbs, which showed weak and sporadic
binding, with the most frequent binding to C and D clades [Nyambi2000]
992 1361 Env gp120 Vaccine human (IgG1κ)
Vaccine Vector/Type: protein HIV component: gp120
Ab type V2 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Nyambi1998, Gorny2000a, Nyambi2000
• 1361: Using a whole virion-ELISA method, 18 human MAbs were tested for their ability to bind to a panel of 9 viruses from clades A, B, D, F, G, and H –
V2 Abs 697-D, 1361, and 1357 tended to bind weakly with a similar pattern of specificity to virions, but bound well to soluble gp120: weak binding to 1/4
B clade viruses (CA5), and also weak binding to a subtype D virus, MAL [Nyambi1998]
• 1361: Blocks binding of MAb 697-D to rgp120, and doesn’t react with a protein from which V1V2 has been deleted – binding of panel of 21 MAbs to
soluble oligomeric gp140 versus gp41 or gp120 monomers was compared – no MAb was oligomer specific, though anti-V3 and CD4BS MAbs reacted
better with the oligomer and V2 and C5 tended to favor the monomer – V2 MAbs 697-D, 1357 and 1361 favored the monomer by approximately 2 fold
[Gorny2000a]
• 1361: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including 5 anti-V2 MAbs, which showed weak and sporadic
binding, with the most frequent binding to C and D clades [Nyambi2000]
993 1393A Env gp120 HIV-1 infection
Ab type V2
References Nyambi2000
• 1393A: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including 5 anti-V2 MAbs, which showed weak and sporadic
binding, with the most frequent binding to C and D clades [Nyambi2000]
994 66a Env gp120 L (HXB2) Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: gp120
Ab type V2
References Shotton1995
• 66a: Substitutions 176-177 FY/AT, 179-180 LD/DL, 183-184 PI/SG, and 191-193 YSL/GSS abrogate binding – same competition group as CRA4
[Shotton1995]
• 66a: UK Medical Research Council AIDS reagent: ARP3074
995 66c Env gp120 L (HXB2) Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: gp120
Ab type V2
References Shotton1995
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• 66c: Substitutions 176-177 FY/AT, 179-180 LD/DL, 183-184 PI/SG, and 191-193 YSL/GSS abrogate binding – same competition group as CRA4
[Shotton1995]
996 684-238
(52-684-238,
52-684)
Env gp120 L Vaccine murine
Vaccine Vector/Type: purified protein Strain: IIIB HIV component: gp120
Ab type V2 Donor Gerry Robey, Abbott Laboratories
ReferencesMoore1993b, Thali1993, Gorny1994, Ditzel1995, Moore1996, Ditzel1997
• 684-238: Specific for BH10 or HXB2, does not bind to MN, RF, or SF-2 gp120 – neutralizes BH10 – binding inhibited by deletion of the V2 loop, and the
following amino acid substitutions: 176/177FY/AT, 179/180LD/DL, 183/184PI/SG, and 192-194YSL/GSS [Moore1993b]
• 684-238: Weakly neutralizing, IC 50 = 84 mug/ml [Gorny1994]
• 684-238: Does not compete with IgG1b12, reciprocal inhibition with MAbs L39, L40, and L78 [Ditzel1995]
• 684-238: Limited reciprocal enhancement of binding with anti-V3 and C4 region antibodies – reciprocal inhibition with V2 region antibodies [Moore1996]
997 830A Env gp120 HIV-1 infection
Ab type V2
References Nyambi2000
• 830A: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including 5 anti-V2 MAbs, which showed weak and sporadic
binding, with the most frequent binding to C and D clades [Nyambi2000]
998 CRA-3
(CRA3)
Env gp120 no Vaccine murine (IgG2a)
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: gp120
Ab type V2 DonorMark Page, NIBSC AIDS reagent project, Potters Bar, Herts, UK
ReferencesMoore1993a, Moore1993b, Thali1993, Shotton1995, Moore1996, Ditzel1997
• CRA-3: Conformational, does not bind well to denatured gp120 [Moore1993a]
• CRA-3: specific for BH10 or HXB2, does not bind to MN, RF, or SF-2 gp120 – binding inhibited by deletion of the V2 loop, and the following amino acid
substitutions: 176/177 FY/AT, 179/180 LD/DL, 183/184 PI/SG, and 192-194 YSL/GSS – epitope probably involves stem of V1/V2 loop structure
[Moore1993b]
• CRA-3: Many MAbs enhance binding, including some anti-C5, C1, V4, and C4 MAbs – enhances binding of only a small number of anti-V3 loop MAbs
[Moore1996]
• CRA-3: Called CRA3 – Same competition group as CRA6 [Shotton1995]
• CRA-3: UK Medical Research Council AIDS reagent: ARP324
999 CRA-4
(CRA4)
Env gp120 L (HXB2) Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: gp120
Ab type V2 DonorMark Page, NIBS, MRC AIDS reagent repository, ARP 325
ReferencesMcKeating1993b, Moore1993a, Moore1993b, Thali1993, Shotton1995, Moore1996
• CRA-4: Changes at residues 191/192/193 (YSL/GSS) within V2, 435 (Y/H) in C4, abrogate binding – type-specific neutralization [McKeating1993b]
• CRA-4: Conformational, does not bind well to denatured gp120 [Moore1993a]
• CRA-4: Specific for BH10 and HXB2, does not bind to MN, RF, or SF-2 gp120 – binding inhibited by deletion of the V2 loop, and the following amino
acid substitutions: 176/177 FY/AT, 179/180 LD/DL, 183/184 PI/SG, and 192-194 YSL/GSS [Moore1993b]
• CRA-4: Cross-competes with MAbs 11/68b, 62c, 66c, 66a – similar to 66c and 66a – non-reciprocal inhibition by MAbs 12b, 60b and CRA-6
[Shotton1995]
• CRA-4: The only MAbs that enhanced binding were anti-V3 MAb 5G11 and anti-C1 MAb 135/9 binding – reciprocal inhibition of anti-V2 MAbs
[Moore1996]
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• CRA-4: UK Medical Research Council AIDS reagent: ARP325
1000 L17 Env gp120 human Fab
Ab type V2
References Ditzel1997, Parren1998a
• L17: The rank order of Fab binding affinity to monomeric gp120 (Loop 2 > 3B3 > b12 = DO8i > b11 > b3 > b14 > b13 > DO142-10 > DA48 > L17) was
markedly different than Fab binding affinity to the mature oligomeric form (3B3 > b12 > DO142-10 > Loop 2 > b11 > L17 > b6 > DO8i > b14 > DA48 > b3
> b13) and binding to oligomeric form and neutralization were correlated for both Fabs and MAbs – authors suggest that neutralization is determined by the
fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
1001 SC258 (52-
581-SC258)
Env gp120 L Vaccine murine
Vaccine Vector/Type: purified protein Strain: IIIB HIV component: gp120
Ab type V2 Donor Gerry Robey, Abbott Laboratories
ReferencesMoore1993b, Thali1993, Gorny1994, Yoshiyama1994, Moore1994b, Ditzel1995, Moore1996, Trkola1996a, Ditzel1997, He2002
• SC258: Called 52-581-SC258 – binds to BH10, MN, and RF gp120 – neutralizes BH10 – binding inhibited by deletion of the V2 loop, and the following
amino acid substitutions: 176/177 FY/AT, 179/180 LD/DL, 183/184 PI/SG, and 192-194 YSL/GSS [Moore1993b]
• SC258: HIV-1 RF V2 substitutions 177 Y/H and 179 L/P in the V2 loop of RF reduce affinity – 177 Y/H inhibits SC258 neutralization [Yoshiyama1994]
• SC258: Very poor reactivity with gp120 molecules outside of clade B [Moore1994b]
• SC258: Does not compete with IgG1b12 – reciprocal inhibition with MAbs L39, L40, and L78 [Ditzel1995]
• SC258: Several MAbs binding to various gp120 epitopes enhance binding, but the only MAb that SC258 enhanced binding of was anti-CD4 binding site
MAb F91 – reciprocal inhibition with V2 region antibodies [Moore1996]
• SC258: Does not inhibit gp120 interaction with CCR-5 in a MIP-1beta-CCR-5 competition study – listed as not neutralizing [Trkola1996a]
• SC258: Transgenic mice carrying human genes allowing production of fully human MAbs were used to rapidly create a panel of anti-HIV gp120 MAb
producing hybridomas by immunization with HIV SF162 gp120 – the previously described human MAbs 5145A(CD4BS) , 4117C (plus others, V3) and
697D (and SC258, V2) were used as controls [He2002]
1002 L25 Env gp120 L (weak) HIV-1 infection human (IgG1)
Ab type V2-CD4BS
References Ditzel1995, Ditzel1997, Parren1997c
• L25: gp120 immobilized on solid phase by capture with anti-CD4 BS MAb L72 was used for selection of Fabs – a single anti-V2-CD4 BS Fab was
obtained with with sensitivity to substitutions in the V2 and CD4 BS regions – rodent anti-V2 MAb SC258 competes with L25 [Ditzel1997]
• L25: Neutralizes TCLA strains weakly, but not primary isolates [Parren1997c]
1003 L39 Env gp120 no HIV-1 infection human (IgG1κ)
Ab type V2-CD4BS
References Ditzel1995
• L39: This Fab does not inhibit sCD4 binding, but is inhibited by sCD4, probably due to conformational changes – it is competed by anti-V2 MAbs, and
sensitive to amino acid substitutions in the V3 loop (similar patterns were observed for L39 and L78 gp120 amino acid substitutions enhancing or reducing
binding) – does not compete with CD4BS MAbs, but is sensitive to amino acid changes at positions 368 and 370 – binding unaffected by deglycosylation –
reciprocal inhibition with V2 MAbs SC258 and 684-238 – heavy and light chain variable region sequence is available [Ditzel1995]
1004 L40 Env gp120 no HIV-1 infection human (IgG1κ)
Ab type V2-CD4BS
References Ditzel1995
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• L40: This Fab does not inhibit sCD4 binding, but is inhibited by sCD4, probably due to conformational changes – it is competed by anti-V2 MAbs, and
sensitive to amino acid substitutions in the V3 loop (similar patterns were observed for L40 and L78 gp120 amino acid substitutions enhancing or reducing
binding) – does not compete with CD4BS MAbs, but is sensitive to amino acid changes at positions 368 and 370 – binding only partially affected by
deglycosylation – reciprocal inhibition with V2 MAbs SC258 and 684-238 – heavy and light chain variable region sequence is available [Ditzel1995]
1005 L78 Env gp120 L HIV-1 infection human (IgG1κ)
Ab type V2-CD4BS
References Ditzel1995
• L78: Substitutions at V2: (152/153 GE/SM, 183/184 PI/SG, 191/193 YL/GS), 262 N/T, V3 (314 G/W), CD4BS (257 T/R, 368 D/R, 370 E/R) inhibit
binding, and some C4 and C5 substitutions enhance binding – this Fab does not inhibit sCD4 binding, but is inhibited by sCD4, probably due to
conformational changes – it is competed by anti-V2 MAbs, and sensitive to amino acid substitutions in the V3 loop – does not compete with CD4BS MAbs,
but is sensitive to amino acid changes at positions 368 and 370 – Fab neutralizes MN and LAI – binding unaffected by deglycosylation – reciprocal
inhibition with V2 MAbs SC258 and 684-238 – heavy and light chain variable region sequence is available [Ditzel1995]
1006 Env gp120 HIV-1 infection human
Ab type V3
References Gilljam1999
• Sera from individuals with infections of HIV-1 subtype A-E were tested against purifed proteins from primary PBMC cultures. Sera reactivity tended not to
be strongly related to subtype, rather probably reflected the sum of reactivities to conserved and variable regions in the proteins. V3 peptide comparisons
showed some preference for within subtype binding [Gilljam1999].
1007 110.J Env gp120
Ab type V3 Donor F. Traincard, Pasteur Institute, France
References Thali1993, Moore1996
• 110.J: Inhibits sCD4-inducible anti-CD4 binding site MAb 48d [Thali1993]
• 110.J: Binds to carboxy-terminal side of the V3 loop – reciprocal binding inhibition with other anti-V3 and anti-C4 MAbs – and reciprocal enhanced
binding of some anti-V2 MAbs and anti-CD4 binding site MAbs [Moore1996]
1008 1334-D (1334,
1334D)
Env gp120 (HIV451) TRTSV HIV-1 infection human (IgG1κ)
Ab type V3 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Zolla-Pazner1999a, Zolla-Pazner1999b, Gorny2000a, Nyambi2000
• 1334-D: This MAb was selected on oligomeric gp160 from HIV451 [Zolla-Pazner1999a]
• 1334-D: MAb peptide-reactivity pattern clustered with immunological related MAbs: 1334, 419, 504, 447, 453 and 537 – the core amino acids GP tended
to be critical for reactivity in this group [Zolla-Pazner1999b]
• 1334-D: Called 1334 – binds to V3 peptides from MN, SF2, NY5, RF, and CDC4 strains as well as x-reactivity with peptides from A, C, D, F, G, and H
subtypes – was suggested to be IgG1lambda here – binding of panel of 21 MAbs to soluble oligomeric gp140 versus gp41 or gp120 monomers was
compared – no MAb was oligomer specific, though anti-V3 and CD4BS MAbs reacted better with the oligomer and V2 and C5 tended to favor the
monomer – V3 MAbs 447-52D, 838-D, and 1334 bound with a 7-10 fold preference for the oligomer [Gorny2000a]
• 1334-D: Called 1334D – A panel of 47 human MAbs was tested against 26 HIV-1 group M primary isolates from clades A through H – 19 V3 MAbs were
tested, and of 494 combinations, 44% displayed some viral binding – V3 MAbs tended to have the most cross-reactive binding to clade A, B, C, and D
isolates, less to E, F, G, and H – 1334D showed intermediate cross-reactivity [Nyambi2000]
1009 2182 Env (JRCSF) P HIV-1 infection human (IgG1λ )
Ab type V3 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
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References Gorny2002
• 2182: Conformation-dependent anti-V3 loop Abs may be more cross-reactive, so six new V3 MAbs were generated from cells of asymptomatic
HIV-1-infected individuals by selection of heterhybridomas using a V3-fusion protein (V3-fp), the HIV-1 JRCSF V3 loop inserted into a truncated murine
leukemia virus gp70 – the six new MAbs all bind to the tip of the V3 loop and cross-compete with the MAb 447-52D and are conformationally sensitive –
MAbs showed cross-clade binding to native, intact virions of clades A(N=2), B(N=4), and F(N=2), limited binding to C(N=3) and D(N=3), and did not bind
to CRF01(subtype E, N=2) – the strength binding was highly correlated with percent neutralization using the ghost cell or PHA blast assay – five
well-characterized MAbs were used as controls: anti-V3 447-52D (anti-V3 MAb for competition and neutralization studies), 654 (anti-CD4BS used as a
conformation-sensitive MAb control), 1331A (anti-C5 used as a linear binding site MAb control), MAb 246 (anti-gp41 MAb that bound to primary isolates
of all clades) – 5/6 MAbs were derived from individuals infected in the US, presumably with clade B, and one, 2182, was derived from an individual who
was infected abroad with clade A who is presently living in New York city – 2412 and 2456 were produced from cells obtained from the same individual,
while the other MAbs were each generated from different subjects – 2182 bound to 8/16 of the diverse isolates, not to any clade C or CRF01 [Gorny2002]
1010 2191 Env (JRCSF) P HIV-1 infection human (IgG1λ )
Ab type V3 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Gorny2002
• 2191: Conformation-dependent anti-V3 loop Abs may be more cross-reactive, so six new V3 MAbs were generated from cells of asymptomatic
HIV-1-infected individuals by selection of heterhybridomas using a V3-fusion protein (V3-fp), the HIV-1 JRCSF V3 loop inserted into a truncated murine
leukemia virus gp70 – the six new MAbs all bind to the tip of the V3 loop and cross-compete with the MAb 447-52D and are conformationally sensitive –
MAbs showed cross-clade binding to native, intact virions of clades A(N=2), B(N=4), and F(N=2), limited binding to C(N=3) and D(N=3), and did not bind
to CRF01(subtype E, N=2) – the strength binding was highly correlated with percent neutralization using the ghost cell or PHA blast assay – five
well-characterized MAbs were used as controls: anti-V3 447-52D (anti-V3 MAb for competition and neutralization studies), 654 (anti-CD4BS used as a
conformation-sensitive MAb control), 1331A (anti-C5 used as a linear binding site MAb control), MAb 246 (anti-gp41 MAb that bound to primary isolates
of all clades) – 5/6 MAbs were derived from individuals infected in the US, presumably with clade B, and one, 2182, was derived from an individual who
was infected abroad with clade A who is presently living in New York city – 2412 and 2456 were produced from cells obtained from the same individual,
while the other MAbs were each generated from different subjects – 2191 bound to 10/16 of the diverse isolates, not to any clade D or CRF01 [Gorny2002]
1011 2219 Env (JRCSF) P HIV-1 infection human (IgG1λ )
Ab type V3 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Gorny2002
• 2219: Conformation-dependent anti-V3 loop Abs may be more cross-reactive, so six new V3 MAbs were generated from cells of asymptomatic
HIV-1-infected individuals by selection of heterhybridomas using a V3-fusion protein (V3-fp), the HIV-1 JRCSF V3 loop inserted into a truncated murine
leukemia virus gp70 – the six new MAbs all bind to the tip of the V3 loop and cross-compete with the MAb 447-52D and are conformationally sensitive –
MAbs showed cross-clade binding to native, intact virions of clades A(N=2), B(N=4), and F(N=2), limited binding to C(N=3) and D(N=3), and did not bind
to CRF01(subtype E, N=2) – the strength binding was highly correlated with percent neutralization using the ghost cell or PHA blast assay – five
well-characterized MAbs were used as controls: anti-V3 447-52D (anti-V3 MAb for competition and neutralization studies), 654 (anti-CD4BS used as a
conformation-sensitive MAb control), 1331A (anti-C5 used as a linear binding site MAb control), MAb 246 (anti-gp41 MAb that bound to primary isolates
of all clades) – 5/6 MAbs were derived from individuals infected in the US, presumably with clade B, and one, 2182, was derived from an individual who
was infected abroad with clade A who is presently living in New York city – 2412 and 2456 were produced from cells obtained from the same individual,
while the other MAbs were each generated from different subjects – 2219 bound to 13/16 of the diverse isolates [Gorny2002]
1012 2412 Env (JRCSF) P HIV-1 infection human (IgG1λ )
Ab type V3 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Gorny2002
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• 2412: Conformation-dependent anti-V3 loop Abs may be more cross-reactive, so six new V3 MAbs were generated from cells of asymptomatic
HIV-1-infected individuals by selection of heterhybridomas using a V3-fusion protein (V3-fp), the HIV-1 JRCSF V3 loop inserted into a truncated murine
leukemia virus gp70 – the six new MAbs all bind to the tip of the V3 loop and cross-compete with the MAb 447-52D and are conformationally sensitive –
MAbs showed cross-clade binding to native, intact virions of clades A(N=2), B(N=4), and F(N=2), limited binding to C(N=3) and D(N=3), and did not bind
to CRF01(subtype E, N=2) – the strength binding was highly correlated with percent neutralization using the ghost cell or PHA blast assay – five
well-characterized MAbs were used as controls: anti-V3 447-52D (anti-V3 MAb for competition and neutralization studies), 654 (anti-CD4BS used as a
conformation-sensitive MAb control), 1331A (anti-C5 used as a linear binding site MAb control), MAb 246 (anti-gp41 MAb that bound to primary isolates
of all clades) – 5/6 MAbs were derived from individuals infected in the US, presumably with clade B, and one, 2182, was derived from an individual who
was infected abroad with clade A who is presently living in New York city – 2412 and 2456 were produced from cells obtained from the same individual,
while the other MAbs were each generated from different subjects – 2412 bound to 7/16 of the diverse isolates, and did not bind to any of the clade C, D or
CRF01 viruses [Gorny2002]
1013 2442 Env (JRCSF) P HIV-1 infection human (IgG1λ )
Ab type V3 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Gorny2002
• 2442: Conformation-dependent anti-V3 loop Abs may be more cross-reactive, so six new V3 MAbs were generated from cells of asymptomatic
HIV-1-infected individuals by selection of heterhybridomas using a V3-fusion protein (V3-fp), the HIV-1 JRCSF V3 loop inserted into a truncated murine
leukemia virus gp70 – the six new MAbs all bind to the tip of the V3 loop and cross-compete with the MAb 447-52D and are conformationally sensitive –
MAbs showed cross-clade binding to native, intact virions of clades A(N=2), B(N=4), and F(N=2), limited binding to C(N=3) and D(N=3), and did not bind
to CRF01(subtype E, N=2) – the strength binding was highly correlated with percent neutralization using the ghost cell or PHA blast assay – five
well-characterized MAbs were used as controls: anti-V3 447-52D (anti-V3 MAb for competition and neutralization studies), 654 (anti-CD4BS used as a
conformation-sensitive MAb control), 1331A (anti-C5 used as a linear binding site MAb control), MAb 246 (anti-gp41 MAb that bound to primary isolates
of all clades) – 5/6 MAbs were derived from individuals infected in the US, presumably with clade B, and one, 2182, was derived from an individual who
was infected abroad with clade A who is presently living in New York city – 2412 and 2456 were produced from cells obtained from the same individual,
while the other MAbs were each generated from different subjects – 2442 bound to 13/16 of the diverse isolates [Gorny2002]
1014 2456 Env (JRCSF) P HIV-1 infection human (IgG1λ )
Ab type V3 Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Gorny2002
• 2456: Conformation-dependent anti-V3 loop Abs may be more cross-reactive, so six new V3 MAbs were generated from cells of asymptomatic
HIV-1-infected individuals by selection of heterhybridomas using a V3-fusion protein (V3-fp), the HIV-1 JRCSF V3 loop inserted into a truncated murine
leukemia virus gp70 – the six new MAbs all bind to the tip of the V3 loop and cross-compete with the MAb 447-52D and are conformationally sensitive –
MAbs showed cross-clade binding to native, intact virions of clades A(N=2), B(N=4), and F(N=2), limited binding to C(N=3) and D(N=3), and did not bind
to CRF01(subtype E, N=2) – the strength binding was highly correlated with percent neutralization using the ghost cell or PHA blast assay – five
well-characterized MAbs were used as controls: anti-V3 447-52D (anti-V3 MAb for competition and neutralization studies), 654 (anti-CD4BS used as a
conformation-sensitive MAb control), 1331A (anti-C5 used as a linear binding site MAb control), MAb 246 (anti-gp41 MAb that bound to primary isolates
of all clades) – 5/6 MAbs were derived from individuals infected in the US, presumably with clade B, and one, 2182, was derived from an individual who
was infected abroad with clade A who is presently living in New York city – 2412 and 2456 were produced from cells obtained from the same individual,
while the other MAbs were each generated from different subjects – 2456 bound to 12/16 of the diverse isolates [Gorny2002]
1015 39F Env gp120 no
Ab type V3 Donor James Robinson, Tulane University, New Orleans, LA, USA
References Yang2002, Grundner2002
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• 39F: Uncleaved soluble gp140 (YU2 strain, R5 primary isolate) can be stabilized in an oligomer by fusion with a C-term trimeric GCN4 motif or using a T4
trimeric motif derived from T4 bacteriophage fibritin – stabilized oligomer gp140 delta683(-FT) showed strong preferential recognition by NAbs IgG1b12
and 2G12 relative to the gp120 monomer, in contrast to poorly neutralizing MAbs F105, F91, 17b, 48d, and 39F which showed reduced levels of binding,
and C11, A32, and 30D which did not bind the stabilized oligomer [Yang2002]
• 39F: HIV-1 gp160deltaCT (cytoplasmic tail-deleted) proteoliposomes (PLs) containing native, trimeric envelope glycoproteins from R5 strains YU2 and
JRFL, and X4 strain HXBc2, were made in a physiologic membrane setting as candidate immunogens for HIV vaccines – 2F5 bound to gp160deltaCT with
a reconstituted membrane ten-fold better than the same protein on beads – anti-CD4BS MAbs IgG1b12 and F105, A32 (C1-C4), C11 (C1-C5), and 39F
(V3) MAbs bound gp160deltaCT PLs indistinguishably from gp160deltaCT expressed on the cell surface [Grundner2002]
1016 55/68b Env gp120 (300–315)
Ab type V3
References Peet1998
• 55/68b: The most variable amino acids in the V3 loop were replaced with serines to make the immunodominant V3 loop less immunogenic – these changes
did not affect the ability of sCD4 or MAbs to V1/V2, C1 and C4 to bind, and anti-V3 MAb 55/68b binding was abrogated by V3 serine substitutions in the
V3 loop – mice injected with serine substituted gp120 had a reduced response relative to wildtype, and no enhanced immunogenicity of conserved regions
[Peet1998]
1017 5G11 Env gp120
Ab type V3 Donor S. Nigida and L. Arthur, NCI, Frederick, MD USA
ReferencesMoore1996
• 5G11: Binds to conformation sensitive epitope in the V3 loop – reciprocal inhibition of other V3 loop MAbs – reciprocal enhancement of some C1-C5
MAbs (unusual for an anti-V3 MAb) and CD4 binding site MAbs – and enhances binding of V2 MAbs [Moore1996]
1018 6.1 Env gp120 (SF162) no Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Ab type V3 Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 6.1: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2kappa MAbs were used to rapidly create a
panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120 – 3/4 V3 MAbs bound a similar linear epitope between
positions 11-30 of the MN V3 loop (8E11/A8, 6.1, and 6.7), but only 8E11/A8 could weakly neutralize autologous strain SF162 [He2002]
1019 6.7 Env gp120 (SF162) no Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Ab type V3 Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 6.7: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2kappa MAbs were used to rapidly create a
panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120 – 3/4 V3 MAbs bound a similar linear epitope between
positions 11-30 of the MN V3 loop (8E11/A8, 6.1, and 6.7), but only 8E11/A8 could weakly neutralize autologous strain SF162 [He2002]
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1020 8.27.3 Env gp120 (SF162) L Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Ab type V3 Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 8.27.3: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2kappa MAbs were used to rapidly create a
panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120 – 1/4 V3 MAbs, 8.27.3, bound a discontinuous epitope that
was broadly cross-reactive with B clade R5 and X4 strains (not E clade) and could neutralize autologous strain SF162 [He2002]
1021 8E11/A8 Env gp120 (SF162) L Vaccine human from
transgenic mice
(IgG2κ)
Vaccine Vector/Type: recombinant protein Strain: SF162 HIV component: gp120 Adjuvant: Ribi adjuvant (MPL+TDM)
Ab type V3 Donor Dr. Abraham Pinter, Public Health Research Institute, Newark, NJ, pinter@phri.org
References He2002
• 8E11/A8: Transgenic mice (strain XenoMouse G2) carrying human genes allowing production of fully human IgG2kappa MAbs were used to rapidly create
a panel of anti-HIV gp120 MAb-producing hybridomas by immunization with HIV SF162 gp120 – 3/4 V3 MAbs bound a similar linear epitope between
positions 11-30 of the MN V3 loop (8E11/A8, 6.1, and 6.7), but only 8E11/A8 could weakly neutralize autologous strain SF162 [He2002]
1022 9305 Env gp120 L murine
Ab type V3 Donor Du Pont, Wilmington DE
ReferencesMcDougal1996
1023 AG1121
(1121)
Env gp120 L
Ab type V3 Donor AGMED, Inc, Bedford, MA, USA or ImmunoDiagnostics, Inc, Woburn, MA, USA
References Sullivan1995, Cao1997b, Si2001
• AG1121: Recognizes monomeric gp120 from T-cell adapted line HXBc2 and primary isolate 89.6 equally well, but 89.6 was three-fold less sensitive to
neutralization by AG1121 than HXBc2 [Sullivan1995]
• AG1121: Called 1121 – Virus with the V1-V2 loop deleted was viable and more susceptible to neutralization by CD4i MAb 17b, and anti-V3 MAbs 1121,
9284, and 110.4, but not to and CD4BS MAb F105 or sCD4 [Cao1997b]
• AG1121: SHIV-HXBc2 is a neutralization sensitive non-pathogenic virus, and several in vivo passages through monkey’s yielded highly pathogenic SHIV
KU-1 – HXBc2 and the KU-1 clone HXBc2P3.2 differ in 12 amino acids in gp160 – substitutions in both gp120 and gp41 reduced the ability of sCD4,
IgG1b12, F105 and AG1121 to Env achieve saturation and full occupancy, and neutralize KU-1 – 17b and 2F5 also bound less efficiently to HXBc2P3.2,
although 2G12 was able to bind both comparably [Si2001]
1024 D47 Env gp120 (IIIB) Vaccine murine
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: Env
Ab type V3 Donor Patricia Earl, NIAID, NIH
References Earl1994, Richardson1996, Otteken1996, Wyatt1997, Earl1997, Salzwedel2000
• D47: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• D47: Used for capture of oligomeric Env for antigen capture ELISA – binding of this antibody to oligomeric Env IIIB was not blocked by human sera from
the US, consistent with a low prevalence of IIIB-like V3 strains [Richardson1996]
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• D47: Pulse label experiments of MAb binding to noncleavable gp160 revealed that this anti-V3 MAb bound immediately and binding stayed constant
through chase period [Otteken1996]
• D47: Binds both gp120 and soluble gp120+gp41 complex efficiently, suggesting its gp120 epitope is not blocked by gp41 binding [Wyatt1997]
• D47: Used for comparison in a study of gp41 antibodies – D47 binds to a greater extent to cell surface expressed Env than any of 38 conformation
dependent anti-gp41 MAbs [Earl1997]
• D47: sCD4 can activate fusion between effector cells expressing Env and target cells expressing coreceptor (CCR5 or CXCR4) alone without CD4 – V3
MAb D47 is strain specific and can inhibit sCD4 mediated infection, but only of the closely related LAV Env, while anti-CD4i MAbs were broadly
cross-neutralizing [Salzwedel2000]
1025 F5.5 Env gp120 (IIIB) murine
Ab type V3 Donor Hybridolabs, Institute Pasteur
References Altmeyer1999
• F5.5: A Semliki Forest virus (SFV) expression system carrying BX08 env was used to study the conformation of gp120 Env – intracytoplasmic gp120 was
recognized by the anti-V3 MAbs K24 and F5.5, while gp120 at the plasma membrane was detected only by conformation dependent MAbs 2G12, 670-D
and 694/98D and not V3 MAbs – expression in rat brain also showed that surface-expressed Env was recognized only by the conformation-dependent
antibodies and not by anti-V3 antibodies [Altmeyer1999]
1026 G3-1472 Env gp120
Ab type V3 DonorM. Fung
ReferencesMoore1996
• G3-1472: Binds to carboxy-terminal side of the V3 loop – reciprocal binding inhibition with other anti-V3 and anti-C4 MAbs – reciprocal enhanced
binding of some anti-V2 MAbs and anti-CD4 binding site MAbs – binding inhibited by anti-C4 MAbs [Moore1996]
1027 K24 Env gp120 (IIIB) murine
Ab type V3 Donor Hybridolabs, Institute Pasteur
References Altmeyer1999
• K24: A Semliki Forest virus (SFV) expression system carrying BX08 env was used to study the conformation of gp120 env – intracytoplasmic gp120 was
recognized by the anti-V3 MAbs K24 and F5.5, while gp120 at the plasma membrane was detected only by conformation dependent MAbs 2G12, 670-D
and 694/98D and not V3 MAbs – expression in rat brain also showed that surface-expressed Env was recognized only by the conformation-dependent
antibodies and not by anti-V3 antibodies [Altmeyer1999]
1028 TH1 Env gp120 L (MN,
JRCSF)
human (IgG1λ )
Ab type V3 DonorMichael Fung, Tanox Biosystem, USA
References D’Souza1995, Yang1998
• TH1: Found to neutralize MN and JRCSF, but not two B subtype primary isolates, nor a D subtype primary isolate, by most labs in a multi-laboratory study
involving 11 labs [D’Souza1995]
• TH1: A neutralization assay was developed based on hemi-nested PCR amplification of the LTR (HNPCR) – LTR-HNPCR consistently revealed HIV DNA
and was shown to be a rapid, specific and reliable neutralization assay based on tests with 6 MAbs and 5 isolates [Yang1998]
1029 anti-gp120/V3 Env gp120 Vaccine murine (IgG)
Vaccine Vector/Type: recombinant protein, virus-like particle Strain: A clade 94UG018 HIV component: Gag, Pol, Nef, gp120
Ab type V3 Donor Intracel Co
References Buonaguro2001
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• Anti-V3: HIV-1 pr55 gag-based virus-like particles (VLP) carrying Nef and Pol open reading frames as well as gp120 of the clade A isolate 94UG018 were
created using a Baculovirus expression system to package additional ORFS into the VLP – anti-V3 and anti-p24 antibodies were used to assess the
expression levels and Gag and gp120-TM were found to be expressed at comparable levels on the VLP [Buonaguro2001]
1030 polyclonal Env gp120 no Vaccine murine
Vaccine Vector/Type: recombinant protein, virus-like particle Strain: LAI HIV component: V3, CD4BS, p55
Ab type V3
References Truong1996
• Antibodies raised against recombinant anti-p55 virus-like particles with the p24 region 196-226 deleted, bearing inserts of either the V3 or the CD4BS
regions of gp120 were studied – no neutralizing responses, weak Env, and strong Gag responses were elicited – the major homology region (MHR) and
proximal sequences was found to be required for capsid assembly [Truong1996]
1031 polyclonal Env gp120 yes Vaccine human
Vaccine Vector/Type: canarypox prime with recombinant protein boost Strain: MN, SF2, LAI HIV component: gp120 MN, gp41 LAI, Gag LAI, partial
Pol LAI, rgp120 SF2 Adjuvant: MF-59
Ab type V3
References Verrier2000
• Serum Abs elicited by this vaccine reacted with V3 peptides from clades B, C, and F, reacted weakly with V3 peptides from clades A, D, G, and H, and did
not react with V3 peptides from clades E and O – neutralizing activity against 5 of 14 primary isolates tested was observed, including one B clade X4 virus,
two dualtropic B clade viruses (from clade B) and one clade B and one clade C R5 virus [Verrier2000]
1032 polyclonal Env gp120 (303–325) no in vitro stimulation human (IgM)
Ab type V3
References Sidorova1999
• Polyspecific anti-MN-24 antibodies were raised through V3 peptide, MN-24 stimulation of human cells, followed by EBV transformation: they react with
homologous and heterologous peptides and may be autoantibodies [Sidorova1999]
1033 polyclonal Env human
Ab type V3
References Guevara2002
• Viral RNA in serum and high titers of subtype C consensus V3 peptide binding Abs were the best independent predictors of mother to infant transmission of
HIV-1 subtype C – NAb to subtype B HIV-1(MN) was also correlated [Guevara2002]
1034 polyclonal Env L Vaccine murine (IgA)
Vaccine Vector/Type: HIV-1 captured on concavalin A-immobilized polystyrene nanospheres, Con A-NS Strain: IIIB HIV component: heat-inactivated
virus, gp120 Adjuvant: concavalin A-immobilized polystyrene nanospheres
Ab type V3
References Kawamura2002
• Vaginal fluids were collected after intravaginal immunization of BALB/c mice and analyzed for their anti-HIV-1 antibody levels using a IIIB-V3 ELISA and
IIIB neutralization assay – HIV-1 specific IgG was undetectable but anti-HIV IgA antibody response was identified in the vaginal fluids of immunized mice
with HIV concavalin A-immobilized polystyrene nanosheres [Kawamura2002]
1035 polyclonal Env L Vaccine human (IgG1,
IgG2a, IgA)
Vaccine Vector/Type: peptide Strain: MN, 89.6P HIV component: C4-V3 Adjuvant: IL-1alpha, IL-12, and IL-18 or GM-CSF, or cholera toxin, alum
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Ab type V3
References Bradney2002
• The cytokine-adjuvant combination IL-1alpha, IL-12 and IL-18 were found to stimulate potent mucosal antibody responses upon intranasal immunization
of mice – cholera toxin is the most widely used adjuvant, but is not safe for use in humans [Bradney2002]
1036 polyclonal Env Vaccine murine
Vaccine Vector/Type: peptide Strain: multiple epitope immunogen HIV component: V3 Adjuvant: Freund’s adjuvant
Ab type V3
References Hewer2002
• A synthetic peptide immunogen designated a multiple epitope immmunogen (MEI) was generated by synthesizing peptides with mixtures of frequently
found amino acids (>10%) from the C subtypes allowed in the synthetic peptide – when injected into mice, the C subtype MEI induced antibodies that
recognized the immunogen and whole virus as an antigen in ELIZAs – sera from eight HIV positive South Africans recognized the MEI peptide in ELISA
tests [Hewer2002]
1037 11/75a/21/41 Env gp120
Ab type V3 discontinuous
ReferencesMcKeating1992a, Peet1998
• 11/75a/21/41: The most variable amino acids in the V3 loop were replaced with serines to make the immunodominant V3 loop less immunogenic – these
changes did not affect the ability of sCD4 or MAbs to V1/V2, C1 and C4 to bind, but anti-V3 MAb 11/75a/21/41 binding was dramatically diminished by
V3 serine substitutions – mice injected with serine substituted gp120 had a reduced response relative to wildtype, and no enhanced immunogenicity of
conserved regions [Peet1998]
1038 41.1
(ICR41.1i,
ICR41)
Env gp120 (HXB10) L (HXB2) Vaccine rat (IgG2a)
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: gp120
Ab type V3 discontinuous Donor J. Cordell, Institute for Cancer Research, Sutton, Surrey, UK
ReferencesMcKeating1992a, McKeating1993b, Klasse1993a, McLain1994, Armstrong1996a, Armstrong1996b, Jeffs1996, Ugolini1997
• 41.1: The gp41 mutation 582(Ala to Thr) results in conformational changes in gp120 that confer neutralization resistance to conformationally sensitive
neutralizing MAbs – neutralization efficiency of 41.1 is not affected [Reitz1988, Klasse1993a]
• 41.1: Called ICR41.1i – Kinetics of neutralization studied – no lag for 39.3b, while ICR 39.13g and ICR 41.1i have lags of 5 and 15 min respectively –
neutralization mediated by 3 molecules of IgG per virion – most efficient at neutralization of the three MAbs studied – acts with multi-hit kinetics
[McLain1994]
• 41.1: Called ICR41.1i – IgG2c? – Neutralization was affected if the Ab was added after the virus bound to the host cells at 24 degrees C or below
[Armstrong1996a]
• 41.1: Called ICR41.1i – Neutralization occurs by blocking a post-fusion internalization event, in contrast to MAb F58 [Armstrong1996b]
• 41.1: Deletion of the V1V2 regions did not affect anti-V3 Abs ability to bind when compared to intact rec gp120 [Jeffs1996]
• 41.1: Viral binding inhibition by 41.1 was weakly correlated with neutralization (all other neutralizing MAbs tested showed some correlation except 2F5)
[Ugolini1997]
1039 55/45a/1l Env gp120
Ab type V3 discontinuous
References Peet1998
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• 55/45a/11: The most variable amino acids in the V3 loop were replaced with serines to make the immunodominant V3 loop less immunogenic – these
changes did not affect the ability of sCD4 or MAbs to V1/V2, C1 and C4 to bind, and anti-V3 MAb 55/45a/11 binding was only marginally diminished by
V3 serine substitutions – mice injected with serine substituted gp120 had a reduced response relative to wildtype, and no enhanced immunogenicity of
conserved regions [Peet1998]
1040 1108 Env Env HIV-1 infection human (IgG1λ )
Ab type V3 mimotope
References Zolla-Pazner1999a, Zolla-Pazner1999b
• 1108: Selected with peptide 987, a mimotope of anti-V3 MAb 447-D – MAb peptide reactivity pattern clustered with immunological related MAbs: 1108,
386, 268, 311, 257, 694.8 – the amino acids HI tended to be critical for reactivity in this group [Zolla-Pazner1999b]
• 1108: The sequence of peptide 987, used to select MAb 1108, is ADGAWRSVHLGPGRGSGSGMGK [Zolla-Pazner1999a]
1041 polyclonal Env HIV-1 infection human (IgA, IgG)
Ab type V3, V4
References Skott1999
• IgA and IgG from 45 HIV+ individuals was studied – people with low CD4+ cell counts had decreased levels IgA in saliva – sera and saliva IgA was
primarily directed toward Env – peptide ELISA studies indicated that teh dominant IgA eptiopes were the V4 region (aa 385-409) and the C-term part of the
V3 loop (aa 325-344), while the IgG response was directed towards the tip of the loop (aa 308-325) [Skott1999]
1042 polyclonal Env gp120 (IIIB) Vaccine rabbit
Vaccine Vector/Type: peptide Strain: MN HIV component: gp120 V3/C4 Adjuvant: mucosal adjuvant CT
Ab type V3-C4
References Zinckgraf1999
• Nasal mucosal immunization and boosting of HIV peptide and was superior for inducing serum IgG and vaginal secretory IgA compared to nasal
immunization and vaginal boosting – vaginal immunization and boosting resulted low serum IgG and vaginal IgA and a high vaginal IgG response
[Zinckgraf1999]
1043 D27 Env gp120 (IIIB) Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
Ab type V3-CD4BS Donor P. Earl, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
References Earl1994, Otteken1996, Sugiura1999
• D27: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
• D27: Pulse label experiments of 4 MAbs (D20, D27, T20, and T22) binding to noncleavable gp160 revealed that these anti-CD4 MAbs bound with a delay,
and that the epitope formed with a t 1/2 of about 10 minutes [Otteken1996]
• D27: A comparison of 25 gp120 specific, conformation dependent MAbs was done – D27 is one of two MAbs labeled group Ca, that was type-specific for
BH8 – D27 fully blocked CD4 binding, and the deletion of the V3 loop abrogated binding [Sugiura1999]
1044 D56 Env gp120 (IIIB) L Vaccine murine (IgG)
Vaccine Vector/Type: vaccinia Strain: IIIB HIV component: oligomeric gp140
Ab type V3-CD4BS Donor P. Earl, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
References Earl1994, Sugiura1999
• D56: Generated during a study of the influence of the oligomeric structure of Env in determining the repertoire of the Ab response [Earl1994]
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• D56: A comparison of 25 gp120 specific, conformation dependent MAbs was done – D56 is one of two MAbs labeled group Ca, that was type-specific for
BH8 – D56 fully blocked CD4 binding, and the deletion of the V3 loop abrogated binding – 12.5 ug/ml of D56 was required to achieve 50% neutralization
of HIV-1 NL4-3 [Sugiura1999]
1045 2G12 (c2G12) Env gp120 L P HIV-1 infection human (IgG1κ)
Ab type carbohydrates at glycosylation residues in C2, C3, C4, and V4 Donor Herman Katinger, Inst. Appl. Microbiol. or Polymun Scientific Inc.,
Vienna, Austria, MRC AIDS reagent project
References Buchacher1994, Trkola1995, Moore1995b, McKeating1996b, McKeating1996a, Trkola1996b, Moore1996, Poignard1996b, Trkola1996a,
Sattentau1996, D’Souza1997, Mo1997, Binley1997a, Fouts1997, Li1997, Moore1997, Mascola1997, Ugolini1997, Burton1997, Parren1997c, Andrus1998,
Wyatt1998a, Mondor1998, Parren1998a, Sullivan1998b, Connor1998, Binley1998, Trkola1998, Fouts1998, Takefman1998, Parren1998b, Li1998,
Wyatt1998b, Frankel1998, Kunert1998, Schonning1998, Montefiori1999, Beddows1999, Altmeyer1999, Poignard1999, Parren1999, Mascola1999,
Mascola2000, Binley1999, Robert-Guroff2000, Baba2000, Grovit-Ferbas2000, Park2000, Si2001, Mascola2001, Zwick2001c, Barnett2001, Moore2001,
Poignard2001, Zeder-Lutz2001, Verrier2001, Stiegler2001, Spenlehauer2001, Hofmann-Lehmann2001, Xu2001, Savarino2001, Golding2002b,
Sanders2002, Scanlan2002, Schulke2002, Yang2002, Xu2002, Chakrabarti2002, Armbruster2002, Edwards2002, Grundner2002, Mascola2002,
Zhang2002, Ferrantelli2002, Liu2002, Pantophlet2003, Herrera2003
• 2G12: Human MAb generated by electrofusion of PBL from HIV-1+ volunteers with CB-F7 cells [Buchacher1994]
• 2G12: Highly potent Cross-clade neutralizing activity [Trkola1995]
• 2G12: Conformationally sensitive epitope destroyed by mutations altering the N-linked glycosylation sites near the base of the V3 loop and the
amino-terminal flank of the V4 loop [Trkola1996b]
• 2G12: Binding weakly enhanced by some anti-C1, -C4, -V3, and CD4 binding site MAbs – unusual in that 2G12 binding neither enhanced or inhibited the
binding of other MAbs included in the study [Moore1996]
• 2G12: Review: binding site is distinct from CD4BS MAbs epitope and is unique among known gp120 MAbs, human or rodent [Moore1995b]
• 2G12: Review: exceptional capacity to neutralize primary isolates in terms of both breadth and potency – one of three MAbs (IgG1b12, 2G12, and 2F5)
generally accepted as having significant potency against primary isolates [Poignard1996b]
• 2G12: Neutralizes JR-FL – inhibits gp120 interaction with CCR-5 in a MIP-1beta-CCR-5 competition study [Trkola1996a]
• 2G12: Neutralizes primary isolates, HXB2, and chimeric virus with gp120 from primary isolates in an HXB2 background [McKeating1996b]
• 2G12: Review: Only four epitopes have been described which can stimulate a useful neutralizing response to a broad spectrum of primary isolates,
represented by the binding sites of MAbs: 447-52-D, 2G12, Fab b12, and 2F5 [Sattentau1996]
• 2G12: In a multilab evaluation of monoclonal antibodies, only IgG1b12, 2G12, and 2F5 could neutralize at least half of the 9 primary test isolates at a
concentration of < 25 mug per ml for 90% viral inhibition – neutralized 6 of 9 primary isolates [D’Souza1997]
• 2G12: A JRCSF variant that was selected for IgG1b12 resistance remained sensitive to MAbs 2G12 and 2F5, for combination therapy [Mo1997]
• 2G12: Study shows neutralization is not predicted by MAb binding to JRFL monomeric gp120, but is associated with oligomeric Env binding – 2G12
bound monomer, and weakly bound oligomer and neutralized JRFL [Fouts1997]
• 2G12: One of 14 human MAbs tested for ability to neutralize a chimeric SHIV-vpu+, which expressed HIV-1 IIIB Env – 2G12 was a strong neutralizer of
SHIV-vpu+ – all Ab combinations tested showed synergistic neutralization – 2G12 has synergistic response with MAbs 694/98-D (anti-V3), 2F5, F105, and
b12 [Li1997]
• 2G12: Review: MAbs 2F5, 2G12 and IgG1b12 have potential for use in combination with CD4-IgG2 as an immunotherapeutic or immunoprophylactic –
homologous MAbs to these are rare in humans and vaccine strategies should consider including constructs that may enhance exposure of these MAbs’
epitopes [Moore1997]
• 2G12: Using concentrations of Abs achievable in vivo, the triple combination of 2F5, 2G12 and HIVIG was found to be synergistic to have the greatest
breadth and magnitude of response against 15 clade B primary isolates [Mascola1997]
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• 2G12: Viral binding inhibition by 2G12 was strongly correlated with neutralization (all other neutralizing MAbs tested showed some correlation except
2F5) [Ugolini1997]
• 2G12: Review that discusses this MAb – reacts with residues at the base of the V3 loop and V4, and most of the changes that reduce binding are
glycosylation sites – it is not clear whether the binding site is peptidic or direct carbohydrate [Burton1997]
• 2G12: Neutralizes TCLA strains and primary isolates [Parren1997c]
• 2G12: Post-exposure prophylaxis was effective when MAb 694/98-D was delivered 15 min post-exposure to HIV-1 LAI in hu-PBL-SCID mice, but
declined to 50% if delivered 60 min post-exposure, and similar time constraints have been observed for HIVIG, 2F5 and 2G12, in contrast to MAb BAT123
that could protect delivered 4 hours post infection [Andrus1998]
• 2G12: The MAb and Fab binding to the oligomeric form of gp120 and neutralization were highly correlated – authors suggest that neutralization is
determined by the fraction of Ab sites occupied on a virion irrespective of the epitope [Parren1998a]
• 2G12: Summary of the implications of the crystal structure of gp120 combined with what is known about mutations that reduce NAb binding – probable
mechanism of neutralization by 2G12 is unknown, but dependent on proper glycosylation and 2G12 is predicted to be oriented toward the target cell when
bound, so neutralization may be due to steric hindrance – mutations in positions N 295, T 297, S 334, N 386, N 392 and N 397 HXBc2 (IIIB) decrease
2G12 binding, and the binding region is 25 angstroms from the CD4 binding site – probably the Ab binds in part to carbohydrates, which may account for
both its broad reactivity and the scarcity of Abs in the same competition group [Wyatt1998a]
• 2G12: Enhances Hx10 binding to CD4 positive or negative HeLa cells, but inhibited binding to CD4+ T-cell line A3.01 – neutralizes Hx10 infection of the
HeLa cells [Mondor1998]
• 2G12: Ab from gp120 vaccinated individuals prior to infection, who subsequently became HIV infected, could not achieve 90% neutralization of the
primary virus by which the individuals were ultimately infected – these viruses were not particularly refractive to neutralization, as determined by their
susceptibility to neutralization by MAbs 2G12, IgG1b12, 2F5 and 447-52D [Connor1998]
• 2G12: Does not compete with binding of MAb generated in response to gp120-CD4 complex, CG10 [Sullivan1998b]
• 2G12: A panel of MAbs were shown to bind with similar or greater affinity and similar competition profiles to a deglycosylated or variable loop deleted
core gp120 protein ( Delta V1, V2, and V3), thus such a core protein produces a structure closely approximating full length folded monomer – MAb 2G12
was the only exception to this, showing reduced binding efficiency [Binley1998]
• 2G12: A wide range of neutralizing titers was observed that was independent of co-receptor usage [Trkola1998]
• 2G12: Notes that 2G12 and 2F5, potent neutralizing antibodies, were identified by screening for cell surface (oligomeric Envelope) reactivity [Fouts1998]
• 2G12: Induces Complement-mediated lysis in MN but not primary isolates – primary isolates are refractive to CML [Takefman1998]
• 2G12: MAbs 2G12, 2F5 and b12 are broadly neutralizing, as are some human polyconal sera, but this paper describes a set of primary isolates that are
resistant to all three MAbs and 2 broadly neutralizing sera – results indicate that resistance levels of pediatric isolates might be higher than adult isolates –
resistance in general did not seem to be conferred by a loss of binding affinity for gp120 or gp41, rather by a more global perturbation of oligomeric
Envelope [Parren1998b]
• 2G12: Neutralization synergy was observed when the MAbs 694/98-D (V3), 2F5 (gp41), and 2G12 (gp120 discontinuous) were used in combination, and
even greater neutralizing potential was seen with the addition of a fourth MAb, F105 (CD4 BS) [Li1998]
• 2G12: Discussed in a review of the antigenic and receptor binding-domains of gp120 in relation to the structure of the molecule – antibodies are discussed
by category (anti-V2, anti-V3, CD4i, CD4BS...), however as 2G12 binds to a rarely immunogenic region, and it is dependent on glycosylation, it was
discussed individually [Wyatt1998b]
• 2G12: The complete V, J and D(H) domain was sequenced – unlike non-neutralizing anti-gp41 MAb 3D6, five neutralizing MAbs (2F5, 2G12, 1B1, 1F7,
and 3D5) showed extensive somatic mutations giving evidence of persistent antigenic pressure over long periods – 2G12 D(H) has the best homology to a
D(H) segment between D3-22 and D4-23, a region not usually considered for heavy-chain rearrangement because it lacks associated recombination signals
in the flanking regions, Kunert et al. suggest this may be why Abs that compete with 2G12 are rare [Kunert1998]
• 2G12: In a study of the influence of the glycan at position 306 of the V3 loop on MAb recognition, 2G12 was found to neutralize an HIV-BRU mutant virus
that lacks the V3 loop glycan and has a mutation at the tip of the loop more efficiently than it neutralizes HIV-BRU [Schonning1998]
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• 2G12: Infection of dendritic cells cultured from CD14+ blood cells or from cadaveric human skin was blocked by neutralizing MAbs IgG1b12, or 2F5 and
2G12 delivered together, but not by control non-neutralizing anti-gp120 MAb 4.8D, indicating that NAbs could interrupt early mucosal transmission events
[Frankel1998]
• 2G12: A meeting summary presented results regarding neutralization –MAbs 2G12 and 2F5 tested for their ability to neutralize primary isolate infection of
genetically engineered cell lines (cMAGI and others, presented by T. Matthews, A. Trkola, J. Bradac) – an advantage of such cells lines over PBMCs is that
markers (X-Gal) can be added for staining to simplify the assay – the consensus of the meeting was that these engineered cell lines did not improve the
sensitivity of detection of primary isolate neutralization – D. Burton and J. Mascola presented results concerning passive immunization and protection of
hu-PBL-SCID mice and macaques, respectively, and both found combinations of MAbs that were able to achieve 99% neutralization in vitro corresponded
to efficacy in vivo [Montefiori1999]
• 2G12: rgp120 derived from a R5X4 subtype B virus was used to vaccinate healthy volunteers and the resulting sera were compared with sera from HIV-1
positive subjects and neutralizing MAbs – 2G12 was able to bind with low affinity to the rgp120 monomer HIV-1 W61D [Beddows1999]
• 2G12: A Semliki Forest virus (SFV) expression system carrying BX08 Env was used to study the conformation of gp120 Env – intracytoplasmic gp120 was
recognized by the anti-V3 MAbs K24 and F5.5, while gp120 at the plasma membrane was detected only by conformation dependent MAbs 2G12, 670-D
and 694/98D and not V3 MAbs – expression in rat brain also showed that surface expressed Env was recognized only by the conformation-dependent
antibodies and not by anti-V3 antibodies [Altmeyer1999]
• 2G12: Hu-PBL-SCID mice were infected with HIV-1s JRCSF and SF162 to study the effect of NAbs on an established infection – no significant differences
in the initial rate of decrease in viral load or the plateau levels of viral RNA between the b12 treated and control mice were seen – in most of the Ab treated
mice b12 escape mutants were observed with varying patterns of mutations – a combination of b12, 2G12 and 2F5 protected 1/3 mice, and an isolate from
one of the other two was resistant to neutralization by all three MAbs [Poignard1999]
• 2G12: Review of the neutralizing Ab response to HIV-1 [Parren1999]
• 2G12: Combinations of HIVIG, 2F5, 2G12 were administered in passive-transfer experiments 24 hours prior to challenge with pathogenic SHIV 89.6PD –
3/6 animals given HIVIG/2F5/2G12 were completely protected, the others had reduced viremia and normal CD4 counts – 1/3 monkeys given 2F5/2G12
showed transient infection, the other two had reduced viral load – all monkeys that received HIVIG, 2F5, or 2G12 alone became infected and developed
high-level plasma viremia, although animals that got HIVIG or 2G12 had a less profound CD4 T cell decline [Mascola1999]
• 2G12: Because HIV-1 is most often transmitted across mucosal surfaces, the ability of passive transfer of infused HIVIG/2F5/2G12 to protect against
mucosal exposure of macaques to pathogenic SHIV 89.6PD was studied – HIVIG/2F5/2G12 protected 4/5 animals against vaginal challenge, 2F5/2G12
combined protected 2/5 animals, and 2G12 alone protected 2/4 animals – in contrast, Mascola and co-workers had previously shown single MAbs could not
protect against intervenous challenge – Ab treated animals that got infected through vaginal innoculation had low viral loads and only modest declines in
CD4 counts – the infused Abs were detected in the nasal, vaginal, and oral mucosa [Mascola2000]
• 2G12: Combinations of HIVIG, 2F5, 2G12 were administered in passive-transfer experiments 24 hours prior to challenge with pathogenic SHIV 89.6PD –
3/6 animals given HIVIG/2F5/2G12 were completely protected, the others had reduced viremia and normal CD4 counts – 1/3 monkeys given 2F5/2G12
showed transient infection, the other two had reduced viral load – all monkeys that received HIVIG, 2F5, or 2G12 alone became infected and developed
high-level plasma viremia, although animals that got HIVIG or 2G12 had a less profound CD4 T cell decline [Mascola1999]
• 2G12: The MAbs with the broadest neutralizing activity, IgG1b12, 2G12 and 2F5, all have high affinity for the native trimer, indicating that they were raised
in an immune response to the oligomer on the virion surface rather than dissociated subunits – a disulfide linked gp120-gp41 (SOS gp140) was created to
mimic the native conformation of Env and explore its potential as an immunogen – SOS gp140 is recognized by NAbs IgG1b12, 2G12, and CD4-IgG2, and
also by anti-V3 MAbs 19b and 83.1 – SOSgp140 is not recognized by C4 region MAbs that neutralize only TCLA strains, G3-42 and G3-519 – nor did it
bind C11, 23A, and M90, MAbs that bind to gp120 C1 and C5, where it interacts with gp41 – MAbs that bind CD4 inducible epitopes, 17b and A32 were
very strongly induced by CD4 in SOS gp140 – anti-gp41 MAbs that bind in the region that interacts with gp120, 7B2, 2.2B, T4, T15G1 and 4D4, did not
bind to SOSgp140, in contrast to 2F5, which binds to the only gp41 epitope that is well exposed in native gp120-gp41 complexes [Binley1999]
• 2G12: A mini-review of observations of passive administration of IgG NAbs conferring protection against intervenous or vaginal SHIV challenge, that
considers why IgG MAbs might protect against mucosal challenge [Robert-Guroff2000]
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• 2G12: A triple combination of 2F5, F105 and 2G12 effectively neutralized perinatal infection of macaque infants when challenged with SHIV-vpu+ – the
mean plasma half-life was 14.0 +/- 7.9 days, the longest of the three Abs [Baba2000]
• 2G12: To determine the antigenicity of virus killed by thermal and chemical inactivation, retention of conformation-dependent neutralization epitopes was
examined, and exposure of CD4BS epitopes was found to be enhanced (MAbs IgG1b12, 205-46-9, and 205-43-1) – binding to 2G12 and 447-52D epitopes
was essentially unaltered – the 17b CD4i epitope was also exposed [Grovit-Ferbas2000]
• 2G12: Six mutations in MN change the virus from a high-infectivity neutralization resistant phenotype to low-infectivity neutralization sensitive – V3,
CD4BS, and CD4i MAbs are 20-100 fold more efficient at neutralizing the sensitive form – 2G12 was an exception and could not neutralize MN in either
form [Park2000]
• 2G12: SHIV-HXBc2 is a neutralization sensitive non-pathogenic virus, and several in vivo passages through monkey’s yielded highly pathogenic SHIV
KU-1 – HXBc2 and the KU-1 clone HXBc2P3.2 differ in 12 amino acids in gp160 – substitutions in both gp120 and gp41 reduced the ability of sCD4,
IgG1b12, F105 and AG1121 to Env achieve saturation and full occupancy, and neutralize KU-1 – 17b and 2F5 also bound less efficiently to HXBc2P3.2,
although 2G12 was able to bind both comparably [Si2001]
• 2G12: Neutralization synergy between anti-HIV NAbs b12, 2G12, 2F5, and 4E10 was studied – a classic fixed-ratio method was used, as well as a method
where one Ab was fixed at a low neutralization titer and the other was varied – using primary isolates, a two-four fold enhancement of neutralization was
observed with MAb pairs, and a ten-fold enhancement with a quadruple Ab combination – no synergy was observed with any MAb pair in the neutralization
of TCLA strain HXB2 – there was no evidence for cooperativity of binding between b12 and 2G12 to envelope spikes expressed on the cell surface of
TCLA or primary isolates [Zwick2001c]
• 2G12: Review of studies in macaques that have shown immune control of pathogenic SHIV viremia, improved clinical outcome, and protection, and the
implications of the observations for HIV vaccines [Mascola2001]
• 2G12: SF162DeltaV2 is a virus that has a 30 amino acids deletion in the V2 loop that does not abrogate its infectivity but renders it highly susceptible to
neutralization – when incorporated into a codon-optimized DNA vaccine with a CMV promoter and delivered by gene gun, SF162DeltaV2 gave higher
neutralizing Ab titers against SF162 than did SF162 itself, and Abs that cross-neutralized non-homologous primary isolates were obtained only when
SF162DeltaV2, but not intact SF162, was used as the immunogen – Control MAbs 2F5 and 2G12 could neutralize all of the following primary isolates:
91US056(R5), 92US714(R5), 92US660(R5), 92HT593(R5X4), and BZ167(R5X4), while after the first protein boost, the sera from two SF162DeltaV2
immunized macaques could neutralize 91US056(R5), 92US714(R5), 92US660(R5) and ADA(R5), but not 92HT593(R5X4) or 92US657(R5) – the pattern
of cross-recognition shifted after the second boost [Barnett2001]
• 2G12: Moore and colleagues review structural aspects of gp120 and how they relate to antigenic domains, and review the data concerning the lack of a clear
relationship between genetic subtype and serotype – an exception exists for human MAb 2G12, which does not recognize CRF01 envelopes because of an
unusual additional disulfide bond in the V4 loop region that appears to be unique to the subtype E, CRF01 gp120 protein [Moore2001]
• 2G12: Structural aspects of the interaction of neutralizing Abs with HIV-1 Env are reviewed – Env essentially has three faces, one is largely inaccessible on
the native trimer, and two that exposed but have low immunogenicity on primary viruses – neutralization is suggested to occur by inhibition of the
interaction between gp120 and the target cell membrane receptors as a result of steric hindrance and it is noted that the attachment of approximately 70 IgG
molecules per virion is required for neutralization, which is equivalent to about one IgG molecule per spike – the 2G12, 17b and b12 epitopes are discussed
in detail – although it is potently neutralizing, 2G12 does not interfere with CD4 and coreceptor binding, and this Ab specificity is uncommon in sera from
HIV-1-infected individuals [Poignard2001]
• 2G12: Neutralizing synergy between MAbs 1b12, 2G12 and 2F5 was studied using surface plasmon resonance to determine the binding kinetics for these
three MAbs with respect to monomeric and oligomeric Env protein gp160 IIIB – the 2G12 epitope is highly accessible on both monomeric and oligomeric
Envs, 1b12 is highly accessible on monomers but not oligomers, and 2F5 on neither form – binding of 2G12 exposes the 2F5 epitope on gp160 oligomers –
2G12-gp160 oligomer interactions were best fitted to a two state model, with the first complex having a high association constant and fast dissociation, that
is stabilized by conformational changes induced by the binding of a second MAb [Zeder-Lutz2001]
• 2G12: A luciferase-reporter gene-expressing T-cell line was developed to facilitate neutralization and drug-sensitivity assays – luciferase and p24 antigen
neutralization titer end points were found comparable using NAb from sera from HIV+ donors, and MAbs 2F5, 2G12 and IgG1b12 [Spenlehauer2001]
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• 2G12: A panel of 12 MAbs was used to identify those that could neutralize the dual-tropic primary isolate HIV-1 89.6 – six gave significant neutralization at
2 to 10 ug/ml: 2F5, 50-69, IgG1b12, 447-52D, 2G12, and 670-D six did not have neutralizing activity: 654-D, 4.8D, 450-D, 246-D, 98-6, and 1281 – no
synergy, only additive effects were seen for pairwise combinations of MAbs, and antagonism was noted between gp41 MAbs 50-69 and 98-6, as well as
98-6 and 2F5 [Verrier2001]
• 2G12: A combination of MAbs IgG1b12, 2F5, and 2G12 was given postnatally to four neonates macaques that were then challenged with highly pathogenic
SHIV89.6P – one of the four infants remained uninfected after oral challenge, two infants had no or a delayed CD4(+) T-cell decline
[Hofmann-Lehmann2001]
• 2G12: Twenty HIV clade C isolates from five different countries were susceptible to neutralization by anti-clade B MAbs in a synergistic quadruple
combination of mAbs IgG1b12, 2G12, 2F5, and 4E10 [Xu2001]
• 2G12: Chloroquine reduces the HIV-1-infectivity of H9 IIIB cells, apparently through altering the conformation of envelope – there is a reduction of
reactivity of 2G12 to its epitope in chloroquine treated cultures [Savarino2001]
• 2G12: A phase I trial in seven HIV+ individuals was conducted with MAbs 2F5 and 2G12—no clinical or laboratory abnormalities were observed
throughout the study—eight infusions were administered over a 4-week period (total dose 14 g)—the elimination half-life (t_1/2) was calculated to be 7.94
(range, 3.46–8.31) days for 2F5 and 16.48 (range, 12.84–24.85) days for 2G12 [Armbruster2002].
• 2G12: The fusion process was slowed by using a suboptimal temperature (31.5 C) to re-evaluate the potential of Abs targeting fusion intermediates to block
HIV entry – preincubation of E/T cells at 31.5 C enabled polyclonal anti-N-HR Ab and anti-six-helix bundle Abs to inhibit fusion, indicating six-helix
bundles form prior to fusion – the preincubation 31.5 C step did not alter the inhibitory activity of neutralizing Abs anti-gp41 2F5, or anti-gp120 2G12,
IG1b12, 48d, and 17b [Golding2002b]
• 2G12: The 2G12 epitope is composed of carbohydrates involving high-mannose and hybrid glycans of residues 295, 332, and 392, with peripheral glycans
from 386 and 448 contributing on either flank, and with little direct gp120 protein surface involvement – these mannose residues are proximal to each other
near the chemokine receptor binding surface [Sanders2002]
• 2G12: Alanine scanning mutagenesis used in conjunction with competition and replacement studies of N-linked carbohydrates and sugars suggest that the
2G12 epitope is formed from mannose residues contributed by the glycans attached to N295 and N332, with the other N-linked carbohydrates in positions
N339, N386, and N392 playing a role in maintaining conformation relevant to 2G12 binding – N295A and N332A mutants showed essentially unchanged
anti-CD4BS NAb b12 binding affinities, while N339A, N386A and N392A mutants displayed significantly lowered b12 affinity, presumably due to
conformational changes [Scanlan2002]
• 2G12: Ab binding characteristics of SOS gp140 were tested using SPR and RIPA – SOS gp140 is gp120-gp41 bound by a disulfide bond – NAbs 2G12,
2F5, IgG1b12, CD4 inducible 17b, and 19b bound to SOS gp140 better than uncleaved gp140 (gp140unc) and gp120 – non-neutralizing MAbs 2.2B (binds
to gp41 in gp140unc) and 23A (binds gp120) did not bind SOS gp140 – 2G12 complexes with SOS gp140 or with gp120 had a very unusual linear structure
[Schulke2002]
• 2G12: Uncleaved soluble gp140 (YU2 strain, R5 primary isolate) can be stabilized in an oligomer by fusion with a C-term trimeric GCN4 motif or using a
T4 trimeric motif derived from T4 bacteriophage fibritin – stabilized oligomer gp140 delta683(-FT) showed strong preferential recognition by NAbs
IgG1b12 and 2G12 relative to the gp120 monomer, in contrast to poorly neutralizing MAbs F105, F91, 17b, 48d, and 39F which showed reduced levels of
binding, and MAbs C11, A32, and 30D which did not bind the stabilized oligomer [Yang2002]
• 2G12: Passive immunization of neonate macaques with a combination of F105+2G12+2F5 conferred complete protection against oral challenge with
SHIV-vpu+ or – the combination b12+2G12+2F5 conferred partial protection against SHIV89.6 – such combinations may be useful for prophylaxis at birth
and against milk born transmission – the synergistic combination of IgG1b12, 2G12, 2F5, and 4E10 neutralized a collection of HIV clade C primary
isolates [Xu2002]
• 2G12: A modified gp140 (gp140deltaCFI), with C-term mutations intended to mimic a fusion intermediate and stabilize trimer formation, retained antigenic
conformational determinants as defined by binding to CD4 and to MAbs 2F5, 2G12, F105, and b12, and enhanced humoral immunity without diminishing
the CTL response in mice injected with a DNA vaccine [Chakrabarti2002]
826
DEC 2002
Env Antibodies HIV Antibodies Tables
B
C
ell
No. MAb ID HXB2 Location Author’s Location Sequence Neutralizing Immunogen Species(Isotype)
• 2G12: A combination of MAbs 2F5 and 2G12 given in multiple infusions was found to be safe and well tolerated even in high doses in a phase I study of
seven HIV-1 infected healthy volunteers – the median elimination half-life was 7.94 days for 2F5, and 16.48 for 2G12 – no anti-2F5 or anti-2G12 IgM or
IgG responses were detected – although there was some transient increases, overall plasma viral RNA levels decreased in 6/7 volunteers, by a median of
0.62 log_10 [Armbruster2002]
• 2G12: Truncation of the gp41 cytoplasmic domain of X4, R5, and X4R5 viruses forces a conformation that more closely resembles the CD4 bound state of
the external Envelope, enhancing binding of CD4i MAbs 17b and 48d and of CD4BS MAbs F105, b12, and in most cases of glycosylation site dependent
MAb 2G12 and the anti-gp41 MAb 246D – in contrast, binding of the anti-V2 MAb 697D and the anti-V3 MAb 694/98D were not affected – viruses
bearing the truncation were more sensitive to neutralization by MAbs 48d, b12, and 2G12 – the anti-C5 MAb 1331A was used to track levels of cell surface
expression of the mutated proteins [Edwards2002]
• 2G12: HIV-1 gp160deltaCT (cytoplasmic tail-deleted) proteoliposomes (PLs) containing native, trimeric envelope glycoproteins from R5 strains YU2 and
JRFL, and X4 strain HXBc2, were made in a physiologic membrane setting as candidate immunogens for HIV vaccines – 2F5 bound to gp160deltaCT with
a reconstituted membrane ten-fold better than the same protein on beads, while such an affinity difference was not seen with F105 and 2G12 – anti-CD4BS
MAbs IgG1b12 and F105, A32 (C1-C4), C11 (C1-C5), and 39F (V3) MAbs bound gp160deltaCT PLs indistinguishably from gp160deltaCT expressed on
the cell surface [Grundner2002]
• 2G12: Rhesus macaques were better protected from vaginal challenge with SHIV89.6D (MAb 2G12, 2/4; MAbs 2F5/2G12, 2/5; and HIVIG/2F5/2G12, 4/5
infected) than from intravenous challenge (MAb 2G12, 0/3; MAbs 2F5/2G12, 1/3; and HIVIG/2F5/2G12, 3/6 infected)– the animals that were infected by
vaginal challenge after Ab infusion had low or undetectable viral RNA levels and modest CD4 T-cell decline [Mascola2002]
• 2G12: A rare mutation in the neutralization sensitive R2-strain in the proximal limb of the V3 region caused Env to become sensitive to neutralization by
MAbs directed against the CD4 binding site (CD4BS), CD4-induced (CD4i) epitopes, soluble CD4 (sCD4), and HNS2, a broadly neutralizing sera – 2/12
anti-V3 MAbs tested (19b and 694/98-D) neutralized R2, as did 2/3 anti-CD4BS MAbs (15e and IgG1b12), 2/2 CD4i MAbs (17b and 4.8D), and 2G12 and
2F5 – thus multiple epitopes on R2 are functional targets for neutralization and the neutralization sensitivity profile of R2 is intermediate between the highly
sensitive MN-TCLA strain and the typically resistant MN-primary strain [Zhang2002]
• 2G12: Review of NAbs that notes 2G12 alone or in combination with other MAbs can protect some macaques against SHIV infection, that it has strong
ADCC activity, and that it is safe and well tolerated in humans [Ferrantelli2002]
• 2G12: Review of NAbs that discusses mechanisms of neutralization, passive transfer of NAbs and protection in animal studies, and vaccine strategies
[Liu2002]
• 2G12: Alanine scanning mutagenesis was used to compare substitutions that affected anti-CD4BS NAb b12 – rec gp120s were engineered to contain
combinations of Alanine substitutions that enhanced b12 binding, and while binding of b12 to these gp120 monomers was generally maintained or
increased, binding by five non-neutralizing anti-CD4bs MAbs (b3, b6, F105, 15e, and F91) was reduced or completely abolished – 2G12 binding was
largely unperturbed, indicating these proteins were not grossly misfolded [Pantophlet2003]
• 2G12: CD4BS MAbs b12 (neutralizing) and 205-42-15, 204-43-1, 205-46-9 (nonneutralizing) all cross-competed for binding to monomeric gp120,
indicating the topological proximity of their epitopes, however, the nonneutralizing CD4BS MAbs did not interfere with the neutralization activity of MAb
b12 – 2G12 was used to normalize and as a control in these experiments [Herrera2003]
• 2G12: UK Medical Research council AIDS reagent: ARP3030
• 2G12: NIH AIDS Research and Reference Reagent Program: 1476
1046 1367 Env gp41 HIV-1 infection human (IgG1λ )
Ab type cluster I Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Nyambi1998, Gorny2000b, Gorny2000a, Nyambi2000
• 1367: Using a whole virion-ELISA method, 18 human MAbs were tested for their ability to bind to a panel of 9 viruses from clades A, B, D, F, G, and H –
anti-gp41 Abs 98-6, 1367 and 1342 were not able to bind detectably with any of the viruses from any clade [Nyambi1998]
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• 1367: A cluster I epitope that binds to rgp41 567-647, recognizes a peptide N51-C43 complex trimer of heterodimers that approximates the core of the
fusogenic form of gp41 – this MAb doesn’t react with either of the peptides N51 or C43 individually – MAbs 50-69 and 1367 had similar properties
[Gorny2000b]
• 1367: Binding of panel of 21 MAbs to soluble oligomeric gp140 versus gp41 or gp120 monomers was compared – no MAb was oligomer specific, but gp41
MAb 50-69 bound with a 5 fold preference for the oligomer, while other gp41 MAbs (1367, 98-6, 167-D, 1281, 1342, and 1379) did not show a preference
[Gorny2000a]
• 1367: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including 5 cluster I anti-gp41 MAbs which showed good cross clade
reactivity – 1367 weakly bound to the majority of isolates – no neutralizing activity was observed when tested with 5 isolates, but 1367 did not bind well to
these isolates [Nyambi2000]
1047 126-6
(SZ-126.6)
Env gp41 (HXB2) no HIV-1 infection human (IgG2κ)
Ab type cluster II Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu), NYU Med Center, NY, NY
References Robinson1990b, Robinson1991, Xu1991, Eddleston1993, Chen1995, Binley1996, Earl1997, Hioe1997b, Gorny2000b, Nyambi2000
• 126-6: No enhancing activity for HIV-1 IIIB [Robinson1990b]
• 126-6: No enhancing or neutralizing activity [Robinson1991]
• 126-6: Specific for a conformational epitope [Xu1991]
• 126-6: Called SZ-126.6 [Eddleston1993]
• 126-6: One of several anti-gp41 MAbs that bind to a gp41-maltose binding fusion protein designed to study the leucine zipper domain of gp41, showing
that the construct has retained aspects of normal gp41 conformation [Chen1995]
• 126-6: Discontinuous epitope recognizing residues between 649-668 – designated cluster II – Fabs D5, D11, G1, T3, M12, M15, S6, S8, S9, S10 block
binding [Binley1996]
• 126-6: This cluster II MAb binds to a conformational epitope in the region 644-663 – like most cluster II MAbs (126-6, 167-D, 1281, 1342, and 1379 all
reacted similarly) it binds to a peptide N51-C43 complex trimer of heterodimers that approximates the core of the fusogenic form of gp41, but not to C43
nor to N51 alone – MAb 126-6 was biotinylated and used as a probe to determine that anti-gp41 MAb 50-69 bound the fusogenic form of the protein in
liquid phase [Gorny2000b]
• 126-6: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including 6 cluster II anti-gp41 MAbs – of these 2F5, 167-D, 126-6,
and 1281 bound across clades, but usually weakly, while 98-6 and 1342 had poor cross reactivity – Clade D isolates bound most consistently to cluster II
MAbs [Nyambi2000]
• 126-6: NIH AIDS Research and Reference Reagent Program: 1243
1048 1342 Env gp41 no HIV-1 infection human (IgG1λ )
Ab type cluster II Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Nyambi1998, Gorny2000b, Gorny2000a, Nyambi2000
• 1342: Using a whole virion-ELISA method, 18 human MAbs were tested for their ability to bind to a panel of 9 viruses from clades A, B, D, F, G, and H –
anti-gp41 Abs 98-6, 1367 and 1342 were not able to bind detectably with any of the viruses from any clade [Nyambi1998]
• 1342: This cluster II MAb is a conformational epitope that binds in the region 644-663 – like most cluster II MAbs (126-6, 167-D, 1281, 1342, and 1379 all
reacted similarly) it binds to a peptide N51-C43 complex trimer of heterodimers that approximates the core of the fusogenic form of gp41, but not to C43
nor to N51 alone [Gorny2000b]
• 1342: Binds within the region gp41 647-682 – binding of panel of 21 MAbs to soluble oligomeric gp140 versus gp41 or gp120 monomers was compared –
no MAb was oligomer specific, but gp41 MAb 50-69 bound with a 5 fold preference for the oligomer, while other gp41 MAbs (1367, 98-6, 167-D, 1281,
1342, and 1379) did not show a preference [Gorny2000a]
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• 1342: 26 HIV-1 group M isolates (clades A to H) were tested for binding to 47 MAbs, including 6 cluster II anti-gp41 MAbs – of these 2F5, 167-D, 126-6,
and 1281 bound across clades, but usually weakly, while 98-6 and 1342 had poor cross reactivity – Clade D isolates bound most consistently to cluster II
MAbs – no neutralizing activity was observed when tested with 5 isolates, but 1342 did not bind to these isolates [Nyambi2000]
1049 1379 Env gp41 HIV-1 infection human (IgG1λ )
Ab type cluster II Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Gorny2000b, Gorny2000a
• 1379: This cluster II MAb binds to a conformational epitope in the region 644-663 – like most cluster II MAbs (126-6, 167-D, 1281, 1342, and 1379 all
reacted similarly) it binds to a peptide N51-C43 complex trimer of heterodimers that approximates the core of the fusogenic form of gp41, but not to C43
nor to N51 alone [Gorny2000b]
• 1379: Binds within the region gp41 647-682 – binding of panel of 21 MAbs to soluble oligomeric gp140 versus gp41 or gp120 monomers was compared –
no MAb was oligomer specific, but gp41 MAb 50-69 bound with a 5 fold preference for the oligomer, while other gp41 MAbs (1367, 98-6, 167-D, 1281,
1342, and 1379) did not show a preference [Gorny2000a]
1050 Fab D11 Env gp41 (LAI) no HIV-1 infection human (IgG1κ)
Ab type cluster II
References Binley1996
• Fab D11: Binds to cluster II region – competes with MAbs 126-6, Md-1 and D50 – conformation sensitive – variable regions sequenced [Binley1996]
1051 Fab D5 Env gp41 (LAI) no HIV-1 infection human (IgG1κ)
Ab type cluster II
References Binley1996
• Fab D5: Binds to cluster II region – competes with MAbs 126-6, Md-1 and D50 – conformation sensitive – variable regions sequenced [Binley1996]
1052 Fab G1 Env gp41 (LAI) no HIV-1 infection human (IgG1κ)
Ab type cluster II
References Binley1996
• Fab G1: Binds to cluster II region – competes with MAbs 126-6, Md-1 and D50 – conformation sensitive – variable regions sequenced [Binley1996]
1053 Fab M10 Env gp41 (LAI) no HIV-1 infection human (IgG1κ)
Ab type cluster II
References Binley1996, Parren1997c
• Fab M10: Binds to cluster II region – competes with MAbs 126-6, Md-1 and D50 – conformation sensitive – variable regions sequenced [Binley1996]
• Fab M10: Does not bind to MN native oligomer, but does bind to both LAI and MN rgp120 and rgp140 [Parren1997c]
1054 Fab M12 Env gp41 (LAI) no HIV-1 infection human (IgG1κ)
Ab type cluster II
References Binley1996
• Fab M12: Binds to cluster II region – competes with MAbs 126-6, Md-1 and D50 – conformation sensitive – variable regions sequenced [Binley1996]
1055 Fab M15 Env gp41 (LAI) no HIV-1 infection human (IgG1κ)
Ab type cluster II
References Binley1996
• Fab M15: Binds to cluster II region – competes with MAbs 126-6, Md-1 and D50 – conformation sensitive – variable regions sequenced [Binley1996]
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1056 Fab S10 Env gp41 (LAI) no HIV-1 infection human (IgG1κ)
Ab type cluster II
References Binley1996
• Fab S10: Binds to cluster II region – competes with MAbs 126-6, Md-1 and D50 – conformation sensitive – variable regions sequenced [Binley1996]
1057 Fab S6 Env gp41 (LAI) no HIV-1 infection human (IgG1κ)
Ab type cluster II
References Binley1996
• Fab S6: Binds to cluster II region – competes with MAbs 126-6, Md-1 and D50 – conformation sensitive – variable regions sequenced [Binley1996]
1058 Fab S8 Env gp41 (LAI) no HIV-1 infection human (IgG1κ)
Ab type cluster II
References Binley1996
• Fab S8: Binds to cluster II region – competes with MAbs 126-6, Md-1 and D50 – conformation sensitive – variable regions sequenced [Binley1996]
1059 Fab S9 Env gp41 (LAI) no HIV-1 infection human (IgG1κ)
Ab type cluster II
References Binley1996
• Fab S9: Binds to cluster II region – competes with MAbs 126-6, Md-1 and D50 – conformation sensitive – variable regions sequenced [Binley1996]
1060 Fab T3 Env gp41 (LAI) no HIV-1 infection human (IgG1κ)
Ab type cluster II
References Binley1996
• Fab T3: Binds to cluster II region – competes with MAbs 126-6, Md-1 and D50 – conformation sensitive – variable regions sequenced [Binley1996]
1061 Md-1 (MD-1) Env gp41 no human (IgG1λ )
Ab type cluster II Donor R. A. Myers State of Maryland Dept. of Health
ReferencesMyers1993, Chen1995, Binley1996
• Md-1: Called MD-1 – discontinuous epitope that binds in the N-terminal region – reacts exclusively with oligomer [Myers1993]
• Md-1: Called MD-1 – one of several anti-gp41 MAbs that bind to a gp41-maltose binding fusion protein designed to study the leucine zipper domain of
gp41, showing that the construct has retained aspects of normal gp41 conformation [Chen1995]
• Md-1: Discontinuous epitope recognizing residues between 563-672, does not recognize cluster I disulfide bridge region – reacts almost exclusively with
trimers and tetramers on WB – designated cluster II – Fabs D5, D11, G1, T3, M12, M15, S6, S8, S9, S10 block binding [Binley1996]
• Md-1: NIH AIDS Research and Reference Reagent Program: 1223
1062 1281 (1281-D) Env gp41 HIV-1 infection human (IgG1λ )
Ab type cluster II, six-helix bundle Donor Susan Zolla-Pazner (Zollas01@mcrcr6.med.nyu) (NYU Med. Center)
References Hioe1997b, Gorny2000b, Gorny2000a, Verrier2001, Golding2002b
• 1281: Called 1281-D: Four primary isolates showed distinct patterns of sensitivity to neutralization by polyclonal sera or plasma and MAbs – BZ167 was
the only isolate inhibited by all polyclonal sera and plasma tested, and was also neutralized by 8/17 MAbs, in particular anti-V3 loop (419-D, 447-52D,
782-D, and 838-D), anti-CD4bd (559/64-D, 654-D and 830-D and a cluster II of gp41 directed MAb (98-6) – isolates 92HT593 and 91US056 were
neutralized by V3 loop (419-D, and 447-52D)and cluster II gp41 (98-6) MAbs at higher concentrations – US4 was neutralized by some of the polyclonal
sera/plasma tested and not at all by MAbs individually or by a cocktail of ten MAbs consisting of 419-D, 447-52D, 782-D, 838-D, 559/64-D, 654-D, 450-D,
670-D, 1281-D and 98-6 [Hioe1997b]
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• 1281: This cluster II MAb binds to a conformational epitope in the region 644-663 – like most cluster II MAbs (126-6, 167-D, 1281, 1342, and 1379 all
reacted similarly) it binds to a peptide N51-C43 complex trimer of heterodimers that approximates the core of the fusogenic form of gp41, but not to C43
nor to N51 alone [Gorny2000b]
• 1281: Binds within the region gp41 647-682 – binding of panel of 21 MAbs to soluble oligomeric gp140 versus gp41 or gp120 monomers was compared –
no MAb was oligomer specific, but gp41 MAb 50-69 bound with a 5 fold preference for the oligomer, while other gp41 MAbs (1367, 98-6, 167-D, 1281,
1342, and 1379) did not show a preference [Gorny2000a]
• 1281: A panel of 12 MAbs was used to identify those that could neutralize the dual-tropic primary isolate HIV-1 89.6 – six gave significant neutralization at
2 to 10 ug/ml: 2F5, 50-69, IgG1b12, 447-52D, 2G12, and 670-D six did not have neutralizing activity: 654-D, 4.8D, 450-D, 246-D, 98-6, and 1281 – no
synergy, only additive effects were seen for pairwise combinations of MAbs, and antagonism was noted between gp41 MAbs 50-69 and 98-6, as well as
98-6 and 2F5 [Verrier2001]
• 1281: The fusion process was slowed by using a suboptimal temperature (31.5 C) to re-evaluate the potential of Abs targeting fusion intermediates to block
HIV entry – preincubation of E/T cells at 31.5 C enabled polyclonal anti-N-HR Ab and anti-six-helix bundle Abs to inhibit fusion, indicating six-helix
bundles form prior to fusion – 98-6 binds to a C-HR hairpin epitope and blocks fusion when added to a 2 hour E/T preincubation at 31.5 C, but if added
after 1 hour, doesn’t inhibit – this is in contrast to six-helix bundle Abs 167-D and 1281 that inhibit more efficiently when added after one hour of
incubation [Golding2002b]
1063 Fab A9 Env gp41 (LAI) no HIV-1 infection human (IgG1κ)
Ab type cluster III
References Binley1996
• Fab A9: Binds to cluster III region – competes with MAb Md-1, but not MAbs 126-6 and D50 – conformation sensitive – variable regions sequenced
[Binley1996]
1064 Fab G15 Env gp41 (LAI) no HIV-1 infection human (IgG1κ)
Ab type cluster III
References Binley1996
• Fab G15: Binds to cluster III region – competes with MAb Md-1, but not MAbs 126-6 and D50 – conformation sensitive – variable regions sequenced
[Binley1996]
1065 Fab G5 Env gp41 (LAI) no HIV-1 infection human (IgG1κ)
Ab type cluster III
References Binley1996
• Fab G5: Binds to cluster III region – competes with MAb Md-1, but not MAbs 126-6 and D50 – conformation sensitive – variable regions sequenced
[Binley1996]
1066 Fab L1 Env gp41 (LAI) no HIV-1 infection human (IgG1κ)
Ab type cluster III
References Binley1996
• Fab L1: Binds to cluster III region – competes with MAb Md-1, but not MAbs 126-6 and D50 – conformation sensitive – variable regions sequenced
[Binley1996]
1067 Fab L11 Env gp41 (LAI) no HIV-1 infection human (IgG1κ)
Ab type cluster III
References Binley1996
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• Fab L11: Binds to cluster III region – competes with MAb Md-1, but not MAbs 126-6 and D50 – conformation sensitive – variable regions sequenced
[Binley1996]
1068 Fab L2 Env gp41 (LAI) no HIV-1 infection human (IgG1κ)
Ab type cluster III Donor P. Perrin and D. Burton (Scripps Research Institute, La Jolla, California
References Binley1996, Earl1997
• Fab L2: Binds to cluster III region – competes with MAb Md-1, but not MAbs 126-6 and D50 – conformation sensitive – variable regions sequenced
[Binley1996]
1069 Chessie 8 Env gp41 murine (IgG)
Ab type cytoplasmic domain Donor G. Lewis
References Lewis1991, Poumbourios1995, Rovinski1995, Smith-Franklin2002
• Chessie 8: Used to precipitate gp160 in immunoblots in a study examining the feasibility of using unprocessed gp160 glycoprotein as an immunogen
[Rovinski1995]
• Chessie 8: This Ab was used in an in vitro study demonstrating that HIV-1 antibody and Fcgamma receptors can trap virus on the surface of follicular
dendritic cells (FDC)’s and extend the period of infectivity – blocking the FDC-Fcgamma receptor killing the FDC cell reduced their ability to maintain
infectivity, and FDC cells seemed to stabilize viral particles and decrease gp120 shedding [Smith-Franklin2002]
1070 8F101 Env gp120 Vaccine murine (IgG)
Vaccine Vector/Type: sCD4-gp120 complex Strain: HXB2 HIV component: gp120
Ab type gp120-CD4 complex
References DeVico1995
• 8F101: MAbs specifically reactive to crosslinked gp120 and CD4 were derived (8F101, 8F102) – conformation dependent – competition studies indicate
the epitope is immunogenic in infected humans [DeVico1995]
1071 8F102 Env gp120 Vaccine murine (IgG)
Vaccine Vector/Type: sCD4-gp120 complex Strain: HXB2 HIV component: gp120
Ab type gp120-CD4 complex
References DeVico1995
• 8F102: MAbs specifically reactive to crosslinked gp120 and CD4 were derived (8F101, 8F102) – conformation dependent – competition studies indicate
the epitope is immunogenic in infected humans [DeVico1995]
1072 CG-10
(CG10)
Env gp120 (IIIB) L Vaccine murine (IgG1)
Vaccine Vector/Type: sCD4-gp120 complex Strain: IIIB HIV component: gp120
Ab type gp120-CD4 complex Donor Jonathan Gershoni, Tel Aviv University, Isreal
References Gershoni1993, Wu1996, Lee1997, Rizzuto1998, Sullivan1998b, Oscherwitz1999a
• CG-10: Reacts exclusively with sCD4-gp120 complex, not with sCD4 or gp120 alone [Gershoni1993]
• CG-10: Called CG10 – MIP-1alpha binding to CCR-5 expressing cells can be inhibited by gp120-sCD4, and MAb CG10 does not block this inhibition
[Wu1996]
• CG-10: Called CG10 – Promotes envelope mediated cell fusion between CD4+ cells and cells infected with either T-cell and macrophage tropic viruses –
infection of HeLa CD4+ (MAGI) cells by HIV-1 LAI, ELI1, and ELI2 strains was increased two-to four-fold in the presence of CG10 [Lee1997]
• CG-10: Called CG10 – disrupts gp120-CCR5 interaction and competes with MAb 17b –binds near the conserved bridging sheet of gp120 – mutations in
positions K/D 121, T/D 123, K/D 207, K/D 421, Q/L 422, Y/S 435, M/A 434, K/A 432 and I/S 423 result in a 70% reduction in CG10 binding
[Rizzuto1998]
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• CG-10: Called CG10 – CD4BS MAb 15e competes with CG-10 binding, probably due to the disruption of CD4-gp120 by 15e – CD4i MAbs 17b and 48d
compete and the binding sites may overlap – MAb A32 enhances binding of 17b, 48d and CG10 – MAbs C11, 2G12 and 212A do not affect CG10 binding
– CG-10 can bind gp120 with V1/V2 and V3 deleted – HXBc2 mutations Delta 119-205, 314 G/W, 432 K/A, 183,184 PI/SG decrease CG-10 recognition,
HXBc2 mutations Delta 298-327 (V3), 384 Y/E, 298 R/G, 435 Y/S enhance recognition – the CD4 contribution to the CG10 epitope maps to the CD4
CDR2-like loop – CG10 can neutralize HIV-1 in the presence of sCD4 even though it does not do so in the context of cell surface CD4 binding to gp120
[Sullivan1998b]
1073 CG-25 Env gp120 L Vaccine murine (IgG1)
Vaccine Vector/Type: sCD4-gp120 complex HIV component: gp120
Ab type gp120-CD4 complex
References Gershoni1993
• CG-25: Reacts preferentially with sCD4-gp120, also with sCD4, not with gp120 [Gershoni1993]
1074 CG-4 (CG4) Env gp120 no Vaccine murine (IgG1)
Vaccine Vector/Type: sCD4-gp120 complex HIV component: gp120
Ab type gp120-CD4 complex Donor Jonathan Gershoni, Tel Aviv University, Isreal
References Gershoni1993
• CG-4: Reacts with gp120 and sCD4-gp120 complex, not with sCD4 [Gershoni1993]
1075 CG-76 Env gp120 L Vaccine murine (IgG1)
Vaccine Vector/Type: sCD4-gp120 complex HIV component: gp120
Ab type gp120-CD4 complex
References Gershoni1993
• CG-76: Reacts equally well with sCD4-gp120 and sCD4, but not with purified gp120 [Gershoni1993]
1076 CG-9 Env gp120 L Vaccine murine (IgG1)
Vaccine Vector/Type: sCD4-gp120 complex HIV component: gp120
Ab type gp120-CD4 complex
References Gershoni1993
• CG-9: Reacts preferentially with sCD4-gp120, also with sCD4, not with gp120 [Gershoni1993]
1077 105-518 Env gp41 (608–637
HAM112, O group)
Vaccine murine (IgG1 κ)
Vaccine Vector/Type: recombinant protein Strain: HAM112 (group O) HIV component: gp160
Ab type immunodominant region
References Scheffel1999
• 101-518: Overlapping peptides based on group O HAM112 Env were tested for MAb reactivity [Scheffel1999]
1078 31A1 Env gp41 no in vitro stimulation human (IgMκ/λ )
Ab type p24+gp41
References Pollock1989
• 31A1: Denatured virus was used for in vitro stimulation to generate Abs – Reacts with both p24 and gp41 [Pollock1989]
1079 39A64 Env gp41 no in vitro stimulation human (IgMκ/λ )
Ab type p24+gp41
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References Pollock1989
• 39A64: Denatured virus was used for in vitro stimulation to generate Abs – Reacts with both p24 and gp41 [Pollock1989]
1080 39B86 Env gp41 no in vitro stimulation human (IgMκ/λ )
Ab type p24+gp41
References Pollock1989
• 39B86: Denatured virus was used for in vitro stimulation to generate Abs – Reacts with both p24 and gp41 [Pollock1989]
1081 9303 Env gp41 no murine
Ab type p24+gp41 Donor Du Pont
ReferencesMcDougal1996
1082 NC-1 Env gp41 (IIIB) Vaccine murine (IgG2a)
Vaccine Vector/Type: peptide Strain: IIIB HIV component: a peptide that folds into a six helix bundle like gp41
Ab type six helix bundle Donor S. Jiang, New York Blood Center, NY, NY
References Jiang1998, Yang2000, Yang2002
• NC-1: Ab elicited in response to immunization with N36(L6)C34, a peptide that folds into a six helix bundle like gp41 – NC-1 binds to the surface of HIV-1
infected cells only in the presence of sCD4, recognizing the fusogenic core structure – binding affinity was decreased by point mutations that disrupt core
formation and abolish membrane fusion activity, (I573P and I573A) – NC-1 can recognize discontinuous epitopes from B clade isolate SC, but not E clade
strain N243, O group strain GAB, or HIV-2 ROD [Jiang1998]
• NC-1: A combination of gp41 fusion with the GNC4 trimeric sequences and disruption of the YU2 gp120-gp41 cleavage site resulted in stable gp140
trimers (gp140-GNC4) – approximately 16% of the gp140(-GNC4) stabilized trimer recognized by pooled sera was precipitated by NC-1, indicating that at
a fraction assumes a fusogenic gp41 six-helix bundle conformation – gp140(-) monomers were not able to bind to the NC-1, nor was gp130(-/GCN4)
glycoprotein, consistent with the expectation that the absence of C34 helices would preclude formation of the six-helix bundle [Yang2000]
• NC-1: Uncleaved soluble gp140 can be stabilized in an oligomer by fusion with a C-term trimeric GCN4 motif (gp140delta683(-/GCN4)) or using a T4
trimeric motif derived from T4 bacteriophage fibritin (gp140delta683(-/FT)) – NC-1 binds to 15% of the GCN4 motif trimers, but this was significantly
reduced for the T4 fibritin stabilized structures, indicating little is in the six-helix bundle, fusogenic conformation [Yang2002]
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1083 4H4 Nef (1–33) Nef (1–33 IIIB) MGGKWSKSSVVGWPTVRERMRRAPT-
VRERMRRAEPAADGVGAA
Vaccine human (IgG1)
Vaccine Vector/Type: recombinant protein Strain: IIIB HIV component: Nef
References Otake1994
• 4H4: This MAb, elicited by vaccination with a Nef fusion protein, could not detect Nef protein on the cell surface – C-term anti-Nef Abs could [Otake1994]
1084 polyclonal Nef (9–24) Nef (9–24) SVIGWLTVRERMRRAE no Vaccine murine (IgG)
Vaccine Vector/Type: DNA Strain: BRU HIV component: Nef
References Tahtinen2001
• BALB/c mice were immunized with a pBN-vector expressing HIV-1 nef, rev, or tat genes – DNA loaded onto gold microparticles was delivered using a
gene gun, and DNA dissolved in saline was given intradermally or intramuscularly – Nef gene gun immunized mice showed the strongest and most
long-lasting (6 months) Ab, CTL and proliferative responses – the highest IgG1/IgG2a ratio was observed in the gene gun immunized mice – three Ab
binding sites were found in Nef using peptide mapping, although some sera reacted only to complete Nef – Rev- or-Tat immunized mice did not generate an
Ab response [Tahtinen2001]
1085 13/042 Nef (11–20) Nef (11–24 BH10) VGWPTVRERM Vaccine murine
Vaccine Vector/Type: recombinant protein HIV component: Nef
References Schneider1991
• 13/042: Epitope mapped by overlapping decapeptides – core: TVRERM [Schneider1991]
1086 13/035 Nef (15–24) Nef (11–24 BH10) TVRERMRRAE Vaccine murine
Vaccine Vector/Type: recombinant protein HIV component: Nef
References Schneider1991
• 13/035: Epitope mapped by overlapping decapeptides – core: TVRERM [Schneider1991]
1087 AM5C6 Nef (28–43 + 78–92) Nef (28–43 BH10) DGVGAASRDLEKHGAI+KAAVDLSH-
FLK
Vaccine murine
Vaccine Vector/Type: recombinant protein HIV component: Nef
References Schneider1991, Maksiutov2002
• AM5C6: Epitope mapped by overlapping decapeptides – core: SRDL – also reacts with Nef(78-92) [Schneider1991]
• AM5C6: This epitope is similar to a fragment of the human protein vascular endothelial growth factor C, AEPDAGEATAYASKDLE [Maksiutov2002]
1088 AM5C6 Nef (28–43 + 78–92) Nef (28–43 BH10) DGVGAASRDLEKHGAI+KAAVDLSH-
FLK
Vaccine murine
Vaccine Vector/Type: recombinant protein HIV component: Nef
References Schneider1991, Maksiutov2002
• AM5C6: Epitope mapped by overlapping decapeptides – core: KAAVDL – also reacts with Nef(28-43) [Schneider1991]
• AM5C6: This epitope is similar to a fragment of the human protein vascular endothelial growth factor C, AEPDAGEATAYASKDLE [Maksiutov2002]
1089 25/03 Nef (30–43) Nef (30–43 BH10) VGAASRDLEKHGAI Vaccine murine
Vaccine Vector/Type: recombinant protein HIV component: Nef
References Schneider1991, Maksiutov2002
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• 25/03: Epitope mapped by overlapping decapeptides – core: ASRDLEK [Schneider1991]
• 25/03: This epitope is similar to a fragment of the human protein vascular endothelial growth factor C, AEPDAGEATAYASKDLE [Maksiutov2002]
1090 26/76 Nef (30–43) Nef (30–43 BH10) VGAASRDLEKHGAI Vaccine murine
Vaccine Vector/Type: recombinant protein HIV component: Nef
References Schneider1991, Maksiutov2002
• 26/76: Epitope mapped by overlapping decapeptides – core: SRDLEK [Schneider1991]
• 26/76: This epitope is similar to a fragment of the human protein vascular endothelial growth factor C, AEPDAGEATAYASKDLE [Maksiutov2002]
1091 3F2 Nef (31–40) Nef (31–40 BRU) GAASRDLEKH Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: BRU HIV component: Nef
References Ovod1992, Saito1994, Ranki1995, Maksiutov2002
• 3F2: Reacted with Nef from different HIV-1 strains (BRU, IIIB, RF, MN) [Ovod1992]
• 3F2: Faintly cross-reactive with astrocytes of uninfected control samples [Ranki1995]
• 3F2: This epitope is similar to a fragment of the human protein vascular endothelial growth factor C, AEPDAGEATAYASKDLE [Maksiutov2002]
• 3F2: UK Medical Research Council AIDS reagent: EVA3067.1
1092 3D12 Nef (31–50) Nef (31–50 BRU) GAASRDLEKHGAITSSNTAA Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: BRU HIV component: Nef
References Ovod1992, Saito1994, Ranki1995, Maksiutov2002
• 3D12: There is an anti-RT MAb that also has this name (see [Chiba1997]
• 3D12: Reacted with Nef from different HIV-1 strains (BRU, IIIB, RF, MN) [Ovod1992]
• 3D12: Over-expression of Nef in astrocytes from postmortem pediatric CNS tissues [Saito1994]
• 3D12: One of four antibodies used in combination to show HIV Nef protein expressed in astrocytes from 7/14 brain samples from HIV+ individuals – Nef
expression associated with dementia [Ranki1995]
• 3D12: This epitope is similar to a fragment of the human protein vascular endothelial growth factor C, AEPDAGEATAYASKDLE [Maksiutov2002]
• 3D12: UK Medical Research Council AIDS reagent: EVA3067.2
1093 polyclonal Nef (33–65) Nef (32–64 LAI, BRU) ASRDLEKHGAITSSNTAATNAACAW-
LEAQEEEE
HIV-1 infection, Vaccine murine (IgG1)
Vaccine Vector/Type: PLG, recombinant protein Strain: LAI, BRU HIV component: Nef Adjuvant: PLG, complete Freund’s adjuvant (CFA)
ReferencesMoureau2002, Maksiutov2002
• Nef encapsulated in poly(DL-lactide-co-glycolide) (PLG) had a more prolonged Ab response than Nef in PBS or in Freund’s adjuvant (CFA), still strong
after 7 months – the response was predominantly IgG1, a Th2 immune response – three linear epitopes, Nef 32-64, 118-167, and 185-205, were frequently
recognized by the sera of mice immunized with NefPLG or Nef-CFA, but not after immunization with Nef in PBS, which seemed to preferentially stimulate
an Ab response to conformational epitopes [Moureau2002]
• This epitope is similar to a fragment of the human protein vascular endothelial growth factor C, AEPDAGEATAYASKDLE [Maksiutov2002]
1094 polyclonal Nef (49–64) Nef (49–64) AATNAACAWLEAQEEE no Vaccine murine (IgG)
Vaccine Vector/Type: DNA Strain: BRU HIV component: Nef
References Tahtinen2001
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• BALB/c mice were immunized with a pBN-vector expressing HIV-1 nef, rev, or tat genes – DNA loaded onto gold microparticles was delivered using a
gene gun, and DNA dissolved in saline was given intradermally or intramuscularly – Nef gene gun immunized mice showed the strongest and most
long-lasting (6 months) Ab, CTL and proliferative responses – the highest IgG1/IgG2a ratio was observed in the gene gun immunized mice – three Ab
binding sites were found in Nef using peptide mapping, although some sera reacted only to complete Nef – Rev- or-Tat immunized mice did not generate an
Ab response [Tahtinen2001]
1095 3G12 Nef (51–71) Nef (51–71 BRU) TNAACAWLEAQEEEEVGFPVT Vaccine murine (IgG2a)
Vaccine Vector/Type: recombinant protein Strain: BRU HIV component: Nef
References Ovod1992
• 3G12: Reacted with Nef from different HIV-1 strains (BRU, IIIB, RF, MN) [Ovod1992]
1096 13/058 Nef (60–73) Nef (60–73 BH10) AQEEEEVGFPVTPQ Vaccine murine
Vaccine Vector/Type: recombinant protein HIV component: Nef
References Schneider1991
• 13/058: Epitope mapped by overlapping decapeptides – core: EEVGFP [Schneider1991]
1097 26/028 Nef (60–73) Nef (60–73 BH10) AQEEEEVGFPVTPQ Vaccine murine
Vaccine Vector/Type: recombinant protein HIV component: Nef
References Schneider1991
• 26/028: Epitope mapped by overlapping decapeptides – core: EEVGFPV [Schneider1991]
1098 2E3 Nef (61–80) Nef (61–80 BRU) QEEEEVGFPVTPQVPLRPMT Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: BRU HIV component: Nef
References Ovod1992, Nilsen1996
• 2E3: There are two MAbs with the name 2E3 – the other one binds to integrase [Nilsen1996]
• 2E3: Two isomorphic forms of Nef were identified, 2E3 reacted with the p24 but not p27 form, and was strain specific (MN and BRU reactive, not IIIB or
RF) [Ovod1992]
1099 polyclonal Nef (66–97) Nef (66–97 LAI) VGFPVTPQVPLRPMTYKAAVDLSHF-
LKEKGGL
no Vaccine human (IgG)
Vaccine Vector/Type: lipopeptide Strain: LAI HIV component: Nef Adjuvant: QS21
References Pialoux2001
• 28 subjects were vaccinated with six HIV-1 peptides that were selected to be particularly rich in CTL epitopes, presented in lipopeptides with or without
adjuvant QS21 – HIV-specific Ab responses were detected in 10/28, proliferative in 11/14, and CTL in 13/24 (54%) of testable volunteers – 10/28 had Ab
responses to this peptide (N1), 11/24 had proliferative responses, and CTL responses were detected [Pialoux2001]
1100 F14.11 Nef (83–88) Nef (83–88) AAVDLS Vaccine murine (IgG2aκ)
Vaccine Vector/Type: peptide HIV component: Nef
References De Santis1991, Chang1998
• F14.11: The MAb was made to a six aa region of Nef that is similar to a region found in thymosin alpha 1 protein – the MAb binds to the natural Nef
protein [De Santis1991]
• F14.11: Used as a control in a study of Nef-specific single chain Abs constructed from AG11 and EH1 [Chang1998]
1101 31/03 Nef (83–103) Nef (82–103 BH10) AAVDLSHFLKEKGGLEGLIHS Vaccine murine
Vaccine Vector/Type: recombinant protein HIV component: Nef
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References Schneider1991
• 31/03: Epitope mapped by overlapping decapeptides – mapping suggests complex epitope in this region [Schneider1991]
1102 polyclonal Nef (117–147) Nef (117–147 LAI) TQGYFPDWQNYTPGPGVRYPLTFGW-
CYKLVP
no Vaccine human (IgG)
Vaccine Vector/Type: lipopeptide Strain: LAI HIV component: Nef Adjuvant: QS21
References Pialoux2001
• 28 subjects were vaccinated with six HIV-1 peptides that were selected to be particularly rich in CTL epitopes, presented in lipopeptides with or without
adjuvant QS21 – HIV-specific Ab responses were detected in 25/28, proliferative in 3/24, and CTL in 13/24 (54%) of testable volunteers – 20/28 had
antibody responses to this particular peptide (N2), 3/24 had proliferative responses, and CTL responses were detected [Pialoux2001]
1103 polyclonal Nef (118–133) Nef (118–133) QGYFPDWQNYTPGPGV no Vaccine murine (IgG)
Vaccine Vector/Type: DNA Strain: BRU HIV component: Nef
References Tahtinen2001
• BALB/c mice were immunized with a pBN-vector expressing HIV-1 nef, rev, or tat genes—DNA loaded onto gold microparticles was delivered using a
gene gun, and DNA dissolved in saline was given intradermally or intramuscularly—Nef gene gun immunized mice showed the strongest and most
long-lasting (6 months) Ab, CTL and proliferative responses—the highest IgG1/IgG2a ratio was observed in the gene gun immunized mice—three Ab
binding sites were found in Nef using peptide mapping, although some sera reacted only to complete Nef—Rev- or Tat-immunized mice did not generate an
Ab response [Tahtinen2001].
1104 polyclonal Nef (119–168) Nef (118–167 LAI,
BRU)
GYFPDWQNYTPGPGVRYPLTFGWCY-
KLVPVEPDKVEEANKGENTSLLHPV
HIV-1 infection, Vaccine murine (IgG1)
Vaccine Vector/Type: PLG, recombinant protein Strain: LAI, BRU HIV component: Nef Adjuvant: PLG, complete Freund’s adjuvant (CFA)
ReferencesMoureau2002, Maksiutov2002
• Nef encapsulated in poly(DL-lactide-co-glycolide) (PLG) had a more prolonged Ab response than Nef in PBS or in Freund’s adjuvant (CFA), still strong
after 7 months – the response was predominantly IgG1, a Th2 immune response – three linear epitopes, Nef 32-64, 118-167, and 185-205, were frequently
recognized by the sera of mice immunized with NefPLG or Nef-CFA, but not after immunization with Nef in PBS, which seemed to preferentially stimulate
an Ab response to conformational epitopes [Moureau2002]
• This epitope is similar to a fragment of the human protein Bone-derived growth factor, PLEPAKLEE, and to Hematopoietic progenitor cell antigen CD34,
TSLHPVSQHG [Maksiutov2002]
1105 F1 Nef (148–157) Nef (148–157 IIIB) VEPDKVEEAN murine (IgM)
References Fujii1993, Otake1994, Fujii1996c, Fujii1996b
• F1: The C-term end of Nef is accessible to Abs at the cell surface – stained IIIB/M10, but not MN/M10, cells [Otake1994, Fujii1993]
• F1: Insect cells expressing myristylated Nef proteins on their cell surface can induce cytolysis of unstimulated CD4+ cells – this response is not due to
MHC restricted CTL activity – the cell surface of Nef expressing insect cells carry Nef that can be recognized by MAbs E7 and E9 but not F1 [Fujii1996c]
• F1: A carboxy-terminal domain of Nef on the cell surface induces cytolysis of CD4+ T cells [Fujii1996b]
1106 2F2 Nef (151–170) Nef (151–170 BRU) DKVEEANKGENTSLLHPVSL Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein HIV component: Nef
References Ovod1992, Saito1994, Ranki1995, Maksiutov2002
• 2F2: Strain specific (MN and BRU reactive, not IIIB or RF) [Ovod1992]
• 2F2: Over-expression of Nef in astrocytes from postmortem pediatric CNS tissue [Saito1994]
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• 2F2: One of four antibodies used in combination to show HIV Nef protein expressed in astrocytes from 7/14 brain samples from HIV+ individuals – Nef
expression associated with dementia [Ranki1995]
• 2F2: This epitope is similar to a fragment of the human protein Hematopoietic progenitor cell antigen CD34, TSLHPVSQHG[Maksiutov2002]
• 2F2: UK Medical Research Council AIDS reagent: EVA3067.3
1107 E9 Nef (158–181) Nef (158–206 IIIB) KGENTSLLHPVSLHGMDDPEREVL murine (IgM)
References Fujii1993, Otake1994, Fujii1996c, Fujii1996b, Maksiutov2002
• E9: The C-term end of Nef is accessible to Abs at the cell surface – stained IIIB/M10, but not MN/M10, cells [Otake1994, Fujii1993]
• E9: A carboxy-terminal domain of Nef on the cell surface induces cytolysis of CD4+ T cells [Fujii1996b]
• E9: Insect cells expressing myristylated Nef proteins on their cell surface can induce cytolysis of unstimulated CD4+ cells – this response is not due to
MHC restricted CTL activity – the cell surface of Nef expressing insect cells carry Nef that can be recognized by MAbs E7 and E9 but not F1 [Fujii1996c]
• E9: This epitope is similar to a fragment of the human protein Hematopoietic progenitor cell antigen CD34, TSLHPVSQHG[Maksiutov2002]
1108 3E6 Nef (161–180) Nef (161–180 BRU) NTSLLHPVSLHGMDDPEREV Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: BRU HIV component: Nef
References Ovod1992, Saito1994, Ranki1995, Maksiutov2002
• 3E6: Reacted with Nef from different HIV-1 strains (BRU, IIIB, RF, MN) [Ovod1992]
• 3E6: Faintly cross-reactive with astrocytes of uninfected control samples [Ranki1995]
• 3E6: This epitope is similar to a fragment of the human protein Hematopoietic progenitor cell antigen CD34, TSLHPVSQHG[Maksiutov2002]
• 3E6: UK Medical Research Council AIDS reagent: EVA3067.4
1109 2A3 Nef (171–190) Nef (171–190 BRU) HGMDDPEREVLEWRFDSRLA Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: BRU HIV component: Nef
References Ovod1992
• 2A3: Reacted with Nef from different HIV-1 strains (BRU, IIIB, MN, but not RF) [Ovod1992]
1110 2E4 Nef (171–190) Nef (171–190 BRU) HGMDDPEREVLEWRFDSRLA Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: BRU HIV component: Nef
References Ovod1992
• 2EA: Reacted with Nef from different HIV-1 strains (BRU, IIIB, MN but not RF) [Ovod1992]
1111 2H12 Nef (171–190) Nef (171–190 BRU) HGMDDPEREVLEWRFDSRLA Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: BRU HIV component: Nef
References Ovod1992, Saito1994, Ranki1995
• 2H12: Reacted with Nef from different HIV-1 strains (BRU, IIIB, RF, MN) [Ovod1992]
• 2H12: Over-expression of Nef in astrocytes from postmortem pediatric CNS tissue [Saito1994]
• 2H12: One of four antibodies used in combination to show HIV Nef protein expressed in astrocytes from 7/14 brain samples from HIV+ individuals – Nef
expression associated with dementia [Ranki1995]
1112 3A2 Nef (171–190) Nef (171–190 BRU) HGMDDPEREVLEWRFDSRLA Vaccine murine (IgG1)
Vaccine Vector/Type: recombinant protein Strain: BRU HIV component: Nef
References Ovod1992, Saito1994, Ranki1995
• 3A2: Reacted with Nef from different HIV-1 strains (BRU, IIIB, RF, MN) [Ovod1992]
• 3A2: Over-expression of Nef in astrocytes from postmortem pediatric CNS tissue [Saito1994]
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• 3A2: One of four antibodies used in combination to show HIV Nef protein expressed in astrocytes from 7/14 brain samples from HIV+ individuals – Nef
expression associated with dementia [Ranki1995]
• 3A2: UK Medical Research Council AIDS reagent: EVA3067.5
1113 NF1A1 Nef (173–206) Nef (173–206) MDDPEREVLEWRFDSRLAFHHVARE-
LHPEYFKNC
murine
References Kaminchik1990
• NF1A1: Recognizes the Nef protein of the two isolates BH10 and LAV1 – low affinity [Kaminchik1990]
1114 polyclonal Nef (186–206) Nef (185–205 LAI,
BRU)
DSRLAFHHVARELHPEYFKNC HIV-1 infection, Vaccine murine (IgG1)
Vaccine Vector/Type: PLG, recombinant protein Strain: LAI, BRU HIV component: Nef Adjuvant: PLG, complete Freund’s adjuvant (CFA)
ReferencesMoureau2002
• Nef encapsulated in poly(DL-lactide-co-glycolide) (PLG) had a more prolonged Ab response than Nef in PBS or in Freund’s adjuvant (CFA), still strong
after 7 months – the response was predominantly IgG1, a Th2 immune response – three linear epitopes, Nef 32-64, 118-167, and 185-205, were frequently
recognized by the sera of mice immunized with NefPLG or Nef-CFA, but not after immunization with Nef in PBS, which seemed to preferentially stimulate
an Ab response to conformational epitopes [Moureau2002]
1115 E7 Nef (192–206) Nef (192–206 IIIB) HHVARELHPEYFKNC murine (IgM)
References Fujii1993, Otake1994, Fujii1996c, Fujii1996a, Fujii1996b, Fujii1996d
• E7: The C-term end of Nef is accessible to Abs at the cell surface – stained IIIB/M10, but not MN/M10, cells [Otake1994, Fujii1993]
• E7: Insect cells expressing myristylated Nef proteins on their cell surface can induce cytolysis of unstimulated CD4+ cells – this response is not due to
MHC restricted CTL activity – the cell surface of Nef expressing insect cells carry Nef that can be recognized by MAbs E7 and E9 but not F1 [Fujii1996c]
• E7: Nef forms a homomeric oligomerizing structure, and using E7 and membrane immunofluorescence or immunoelectron microscopy, was shown to
clusters on the surface of HIV-1 infected CD4+ cells [Fujii1996a]
• E7: A carboxy-terminal domain of Nef on the cell surface induces cytolysis of CD4+ T cells [Fujii1996b]
• E7: Soluble Nef inhibits proliferation of CD4+ cells, and Nef cross-linking by MAbs may induce anti-CD4 cytocidal activity – sera from HIV+ individuals
contain soluble Nef, thus this may be important for immune dysfunction and disease progression [Fujii1996d]
1116 AE6 Nef (194–206) Nef (LAI) VARELHPEYFKNC Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein HIV component: Nef
Ab type C-term Donor Frank Jirik, Centre for Molecular Med and Therapeutics, U. B. C., Vancouver, B. C. Canada
References Chang1998
• AE6: The light and heavy chains of three MAbs (AG11, AE6, EH1) specific to C-terminus of NEF were cloned and variable regions sequenced – the
complementarity determining regions (CDR) of AG11 and AE6 were highly related (95.1% at the DNA level) and bound LAI Nef, but not SF2 Nef – EH1
bound to SF2 and LAI and cross-competed AG11 and AE6 but had a distinctive CDR (57.9% similar to AG11) – single chain Abs were constructed from
AG11 and EH1 [Chang1998]
1117 AG11 Nef (194–206) Nef (LAI) VARELHPEYFKNC Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein HIV component: Nef
Ab type C-term Donor Frank Jirik, Centre for Molecular Med and Therapeutics, U. B. C., Vancouver, B. C. Canada
References Chang1998
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• AG11: The light and heavy chains of three MAbs (AG11, AE6, EH1) specific to C-terminus of NEF were cloned and variable regions sequenced – the
complementarity determining regions (CDR) of AG11 and AE6 were highly related (95.1% at the DNA level) and bound LAI Nef, but not SF2 Nef – EH1
bound to SF2 and LAI and cross-competed AG11 and AE6 but had a distinctive CDR (57.9% similar to AG11) – single chain Abs were constructed from
AG11 and EH1 and subcloned into a eukaryotic expression vector with a green fluorescent protein marker to allow intracellular expression – the single
chain Abs bind Nef intracellularly and may be useful to better understand the role of Nef and as a gene therapy model [Chang1998]
1118 EH1 Nef (194–206) Nef (SF2) MARELHPEYYKDC Vaccine murine (IgG1κ)
Vaccine Vector/Type: recombinant protein HIV component: Nef
Ab type C-term Donor Frank Jirik, Centre for Molecular Med and Therapeutics, U. B. C., Vancouver, B. C. Canada
References Chang1998
• EH1: The light and heavy chains of three MAbs (AG11, AE6, EH1) specific to C-terminus of NEF were cloned and variable regions sequenced – the
complementarity determining regions (CDR) of AG11 and AE6 were highly related (95.1% at the DNA level) and bound LAI Nef, but not SF2 Nef – EH1
bound to SF2 and LAI and cross-competed AG11 and AE6 but had a distinctive CDR (57.9% similar to AG11) – single chain Abs were constructed from
AG11 and EH1 and subcloned into a eukaryotic expression vector with a green fluorescent protein marker to allow intracellular expression – the single
chain Abs bind Nef intracellularly and may be useful to better understand the role of Nef and as a gene therapy model [Chang1998]
1119 6.1 Nef Nef (dis JRCSF) murine
References Ranki1995
• 6.1: Raised against CNS primary isolates, stains astrocytes more densely than other Nef MAbs – Nef expression associated with dementia [Ranki1995]
• 6.1: NIAID Repository number 1123 [Ranki1995]
1120 NF2B2 Nef Nef (20–78 BH10) Vaccine murine
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: Nef
References Kaminchik1990
• NF2B2: Recognizes the Nef protein of the two isolates BH10 and LAV1 [Kaminchik1990]
• NF2B2: NIH AIDS Research and Reference Reagent Program: 456
1121 NF3A3 Nef Nef (20–78 BH10) Vaccine murine
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: Nef
References Kaminchik1990
• NF3A3: Recognizes the Nef protein of the two isolates BH10 and LAV1 – low affinity [Kaminchik1990]
1122 NF8B4 Nef Nef (BH10) Vaccine murine
Vaccine Vector/Type: recombinant protein Strain: BH10 HIV component: Nef
References Kaminchik1990
• NF8B4: Does not recognize Nef CNBr cleavage products – recognizes intact BH10 Nef but not LAV1 Nef [Kaminchik1990]
1123 AE6 Nef Nef murine
Ab type C-term Donor James Hoxie, Div of AIDS, NIAID, NIH
References Greenway1994, Tornatore1994
• AE6: NIH AIDS Research and Reference Reagent Program: 709
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1124 polyclonal HIV-1 HIV-1 infection human
References Fournier2002b
• Purified B lymphocytes secret only a fraction of Ig and anti-HIV-1 Ab compared with unfractionated cells because monocytes and natural killer cells
enhance both secretions by cell-to-cell contacts, involving adhesion and CD27, CD80 costimulatory molecules and IL-6 – cell-to-cell contacts and soluble
factors induce maturation of activated B cells in vitro to allow prolonged survival and terminal differentiation [Fournier2002b]
1125 polyclonal HIV-1 HIV-1 infection human
References Fournier2002a
• An early and sustained fall in plasma viral load to below detection was observed in 17 HAART responders while HIV-1 RNA remained detectable in 13
incomplete responders – HIV-1 specific Ab secretion decreased in parallel with plasma viral load – HIV-1 specific Abs became negative in only six
responders, and was correlated with greater increases of CD4 T-cell counts and higher levels of HIV-specific IgA secretion at baseline – persistent immune
activation may be due to residual HIV antigen [Fournier2002a]
1126 polyclonal HIV-1 HIV-1 infection human
References Subbramanian2002
• Sera from 39 patients were used to study the relative prevalence of neutralizing Abs (NAbs), ADCC-Abs and enhancing Abs – 69% of the sera were positive
for NAbs but only 39% could neutralize in the presence of complement – 60% had ADCC Abs – 72% mediated the enhancement of infection in the
presence of complement [Subbramanian2002]
1127 polyclonal HIV-1 HIV-1 infection human (IgA, IgG1)
References Battle-Miller2002
• In a study of HIV-1 infected women, ADCC Abs were detected in 16% (12/51) of cervicovaginal fluids, and 56% (25/45) of serum samples – 3 women had
ADCC in cervical lavage fluids, but not sera, suggesting local production [Battle-Miller2002]
1128 polyclonal HIV-1 HIV-1 infection human (IgA2, IgA1,
IgM)
ReferencesWu2002
• IgA1 accounted for the majority of anti-HIV-1 IgA in the saliva in HIV-1 infected individuals – there was no anti-gp41 IgA in saliva, in contrast to plasma –
lower levels of IgA and IgM were found in saliva than in plasma [Wu2002]
1129 polyclonal HIV-1 P HIV-1 infection human
References Hioe1997a
• Four primary isolates showed distinct patterns of sensitivity to neutralization by polyclonal sera or plasma and MAbs – BZ167 was the only isolate inhibited
by all polyclonal sera and plasma tested, and was also neutralized by 8/17 MAbs, in particular anti-V3 loop (419-D, 447-52D, 782-D, and 838-D),
anti-CD4bd (559/64-D, 654-D and 830-D and a cluster II of gp41 directed MAb (98-6) – isolates 92HT593 and 91US056 were neutralized by V3 loop
(419-D, and 447-52D)and cluster II gp41 (98-6) MAbs at higher concentrations – US4 was neutralized by some of the polyclonal sera/plasma tested and not
at all by MAbs individually or by a cocktail of ten MAbs consisting of 419-D, 447-52D, 782-D, 838-D, 559/64-D, 654-D, 450-D, 670-D, 1281-D and 98-6
[Hioe1997a]
1130 polyclonal HIV-1 no HIV-1 infection human (IgA, IgG)
References Oelemann2002
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• A urine based commercial EIA kit from Calypte Biomedical Corporation, Berkeley, CA was found to work well as a primary screening for HIV in Brazilian
samples – 76 HIV+ samples were correctly identified (100% sensitivity), and 278/284 negative samples 97.9% specificity [Oelemann2002]
1131 polyclonal HIV-1 HIV-1 no HIV-1 infection human (IgE)
References Secord1996, Pellegrino2002
• HIV-specific IgE found in clinically healthy HIV-1 infected children [Secord1996]
• Pediatric long term survivors (LTS) have been found to carry HIV-1 specific IgE – serum from these children inhibit HIV-1 production in culture, but this
inhibition did not seem to be due to neutralization, rather due to a cytoxic event – serum lost the HIV-1 inhibitory effect when depleted of IgE
[Pellegrino2002]
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Linear epitopes less than twenty-two amino acids long are shown with their
antibody ID and the experimental species.
Key Species
h human
p non-human primate
m murine
o other
Table IV-D.1: The species for which the epitopes react
IV-D-1 p17 Ab Epitope Map
MGARASVLSGGELDRWEKIRLRPGGKKKYKLKHIVWASRELERFAVNPGL
10 20 30 40 50
L14.17 (m)
polyclonal (m)
32/5.8.42 (m)
HyHIV-1 (m)
HyHIV-2 (m)
HyHIV-3 (m)
HyHIV-4 (m)
HyHIV-5 (m)
HyHIV-6 (m)
32/1.24.89 (m)
3B10 (m)
3E11 (m)
LETSEGCRQILGQLQPSLQTGSEELRSLYNTVATLYCVHQRIEIKDTKEA
60 70 80 90 100
B4f8 (o)
12H-D3b3 (o)
LDKIEEEQNKSKKKAQQAAADTGHSNQVSQNY
110 120 130
11H9 (m)
3-H-7 (m)
C5126 (m)
1D9 (m)
4C9 (m)
4H2B1 (m)
9G5 (m)
15-21 (m)
31-11 (m)
sc-FV p17 (m)
HyHIV-15 (m)
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IV-D-2 p24 Ab Epitope Map
PIVQNIQGQMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQ
10 20 30 40 50
3A6 (h) polyclonal (m)
111/182 (m) 3D3 (m)
112/021 (m) CD-4/1 (m)
112/047 (m) 15F8C7 (m)
ID8F6 (m)
F5-2 (m)
CB-13/5 (m)
DLNTMLNTVGGHQAAMQMLKETINEEAAEWDRVHPVHAGPIAPGQMREPR
60 70 80 90 100
polyclonal (m) 1109/01 (m)
CD-4/1 (m) 14D4E11 (m)
15F8C7 (m) 1G5C8 (m)
111/052 (m) 47-2 (m)
91-5 (h) 13-102-100 (m)
714/01 (m)
polyclonal (m)
111/073 (m)
113/038 (m)
1-E-4 (m)
1-E-9 (m)
10-E-7 (m)
10-G-9 (m)
11-C-5 (m)
2-E-4 (m)
2-H-4 (m)
8-D-2 (m)
8-G-9 (m)
8-H-7 (m)
C5123 (m)
1-B-7 (m)
3-B-7 (m)
6-D-12 (m)
6-E-7 (m)
8-D-5 (m)
FF1 (m)
113/072 (m)
25.3 (m)
RL4.72.1 (m)
GSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSI
110 120 130 140 150
25.3 (m) 38:9.6K (m) LH-104-E (m)
RL4.72.1 (m) EB1A9 (m) 1B2C12 (m)
406/01 (m) LH-104-K (m)
polyclonal (m)
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LDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKT
160 170 180 190 200
1B2C12 (m) 9A4C4 (m)
LH-104-K (m) 11C10B10 (m)
LH-104-A (m) 11D11F2 (m)
1.17.3 (m) 108/03 (m)
1A7 (m) 110/015 (m)
1F6 (m)
23A5G4 (m)
23A5G5 (m)
3D10G6 (m)
polyclonal (m)
V10 (m)
LH-104-C (m) CD12B4 (m)
12-B-4 (m)
C5122 (m)
BE3 (m)
L14 (m)
ILKALGPAATLEEMMTACQGVGGPGHKARVL
210 220 230
FH2 (m) LH-104-B (m)
13B5 (m) LH-104-I (m)
106/01 (m)
IV-D-3 p2p7p1p6 Ab Epitope Map
AEAMSQVTNSATIMMQRGNFRNQRKIVKCFNCGKEGHTARNCRAPRKKGC
10 20 30 40 50
i5B11 (o) EC6 (m)
M12 (m)
WKCGKEGHQMKDCTERQANFLGKIWPSYKGRPGNFLQSRPEPTAPPEESF
60 70 80 90 100
EC6 (m) DG8 (m)
M12 (m) EB5 (m)
HH3 (m)
AD2 (m)
CA5 (m)
DF3 (m)
EC3 (m)
FC12 (m)
GE4 (m)
JB7 (m)
JF11 (m)
RSGVETTTPPQKQEPIDKELYPLTSLRSLFGNDPSSQ
110 120 130
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IV-D-4 Protease Ab Epitope Map
PQVTLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMSLPGRWKPKMIGGI
10 20 30 40 50
1696 (m) 10E7 (o)
F11.2.32 (m)
13E1 (o)
8B11 (o)
8C10 (o)
8G5 (o)
GGFIKVRQYDQILIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF
60 70 80 90
IV-D-5 RT Ab Epitope Map
PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKI
10 20 30 40 50
GPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGL
60 70 80 90 100
1E8 (m)
KKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLP
110 120 130 140 150
QGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRT
160 170 180 190 200
KIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKD
210 220 230 240 250
SWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTEEAE
260 270 280 290 300
1.152 B3 (m)
1.158 E2 (m)
polyclonal (h)
LELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLK
310 320 330 340 350
1.152 B3 (m) 1.153 G10 (m)
1.158 E2 (m)
polyclonal (h)
TGKYARMRGAHTNDVKQLTEAVQKITTESIVIWGKTPKFKLPIQKETWET
360 370 380 390 400
1.153 G10 (m) RTMAb8 (m)
1D4A3 (m)
RT6H (m)
WWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRET
410 420 430 440 450
1.160 B3 (m)
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KLGKAGYVTNRGRQKVVTLTDTTNQKTELQAIYLALQDSGLEVNIVTDSQ
460 470 480 490 500
YALGIIQAQPDQSESELVNQIIEQLIKKEKVYLAWVPAHKGIGGNEQVDK
510 520 530 540 550
polyclonal (h)
C2003 (o)
LVSAGIRKVL
560
IV-D-6 Integrase Ab Epitope Map
FLDGIDKAQDEHEKYHSNWRAMASDFNLPPVVAKEIVASCDKCQLKGEAM
10 20 30 40 50
1C4 (m) 17 (m)
2C11 (m) 4D6 (m)
2E3 (m)
3E11 (m)
3F9 (m)
5F8 (m)
6G5 (m)
7B6 (m)
7C6 (m)
8G4 (m)
HGQVDCSPGIWQLDCTHLEGKVILVAVHVASGYIEAEVIPAETGQETAYF
60 70 80 90 100
4D6 (m)
LLKLAGRWPVKTIHTDNGSNFTGATVRAACWWAGIKQEFGIPYNPQSQGV
110 120 130 140 150
VESMNKELKKIIGQVRDQAEHLKTAVQMAVFIHNFKRKGGIGGYSAGERI
160 170 180 190 200
anti-K159 (o)
VDIIATDIQTKELQKQITKIQNFRVYYRDSRNPLWKGPAKLLWKGEGAVV
210 220 230 240 250
8-6 (m) 8-22 (m)
19 (m)
2-19 (m)
IQDNSDIKVVPRRKAKIIRDYGKQMAGDDCVASRQDED
260 270 280
8-22 (m) 6-19 (m)
4-20 (m)
7C3 (m)
7F11 (m)
8E5 (m)
MAb 35 (m)
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IV-D-7 Rev Ab Epitope Map
MAGRSGDSDEELIRTVRLIKLLYQSNPPPNPEGTRQARRNRRRRWRERQR
10 20 30 40 50
4G9 (m) Ab2
10.1
3H6 (m)
QIHSISERILGTYLGRSAEPVPLQLPPLERLTLDCNEDCGTSGTQGVGSP
60 70 80 90 100
8E7 (m) 1G10 (m)
9G2 (m) 1G7 (m)
Ab4
QILVESPTVLESGTKE
110
1G10 (m)
1G7 (m)
Ab3
IV-D-8 Tat Ab Epitope Map
MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKALGISYGRK
10 20 30 40 50
NT3/2D1.1 (m)
1.2
1D9D5 (m)
KRRQRRRAHQNSQTHQASLSKQPTSQPRGDPTGPKEXKKKVERETETDPF
60 70 80 90 100
NT2/4D5.24 (m)
D
101
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IV-D-9 Vif Ab Epitope Map
MENRWQVMIVWQVDRMRIRTWKSLVKHHMYVSGKARGWFYRHHYESPHPR
10 20 30 40 50
TG002 (m)
ISSEVHIPLGDARLVITTYWGLHTGERDWHLGQGVSIEWRKKRYSTQVDP
60 70 80 90 100
ELADQLIHLYYFDCFSDSAIRKALLGHIVSPRCEYQAGHNKVGSLQYLAL
110 120 130 140 150
AALITPKKIKPPLPSVTKLTEDRWNKPQKTKGHRGSHTMNGH
160 170 180 190
TG001 (m)
IV-D-10 Vpr Ab Epitope Map
MEQAPEDQGPQREPHNEWTLELLEELKNEAVRHFPRIWLHGLGQHIYETY
10 20 30 40 50
GDTWAGVEAIIRILQQLLFIHFRIGCRHSRIGVTRQRRARNGASRS
60 70 80 90
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IV-D-11 Vpu Ab Epitope Map
TQPIPIVAIVALVVAIIIAIVVWSIVIIEYRKILRQRKIDRLIDRLIERA
10 20 30 40 50
EDSGNESEGEISALVEMGVEMGHHAPWDVDDL
60 70 80
IV-D-12 gp160 Ab Epitope Map
MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWKEATT
10 20 30 40 50
7E2/4 (m)
4D4#85 (m)
M92 (o)
M86 (m)
TLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVVLVNVTENFNMWKNDM
60 70 80 90 100
M86 (m) D/3G5 (m) 133/192 (m)
polyclonal (m) 4A7C6 (m)
133/237 (m) L5.1 (m)
133/290 (m) 1D10 (o)
133/11 (m) 489.1(961) (m)
D/6A11 (m) 5B3 (m)
D/5E12 (m)
B242 (m)
B10 (m)
B2 (m)
C6 (m)
MF49.1 (m)
T1.1 (m)
T7.1 (m)
T9 (m)
GV4D3 (m)
B27 (m)
B9 (m)
B35 (m)
D/4B5 (m)
D/5A11 (m)
D/6B2 (m)
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VEQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTNTNSSSGRMIME
110 120 130 140 150
D/4B5 (m) 11 (m) polyclonal (h)
D/5A11 (m) 12G10 (m) 35D10/D2 (h)
D/6B2 (m) 135/9 (m) 40H2/C7 (h)
B18 (m) 6D5 (m)
B20 (m) B33 (m)
MF39.1 (m) 43A3/E4 (h)
187.2.1 (m) 43C7/B9 (h)
37.1.1(ARP 327) (m) 45D1/B7 (h)
6D8 (o) 46E3/E6 (h)
M96 (o) 58E1/B3 (h)
MF119.1 (m) 64B9/A6 (h)
MF4.1 (m) 69D2/A1 (h)
MF53.1 (m) 82D3/C3 (h)
MF58.1 (m)
MF77.1 (m)
T2.1 (m)
11/65 (o)
W1 (m)
GV1A8 (m)
7C10 (m)
C4 (m)
MF46.1 (m)
KGEIKNCSFNISTSIRGKVQKEYAFFYKLDIIPIDNDTTSYKLTSCNTSV
160 170 180 190 200
polyclonal (h) 697-D (h)
35D10/D2 (h) G3-136 (m)
40H2/C7 (h) G3-4 (m)
43A3/E4 (h) BAT085 (m)
43C7/B9 (h) 60b (o)
45D1/B7 (h) 74 (o)
46E3/E6 (h) 38/12b (o)
58E1/B3 (h) 38/60b (o)
64B9/A6 (h) polyclonal (h)
69D2/A1 (h)
82D3/C3 (h)
2H1B (m)
6C4/S
C108G (p)
10/76b (o)
11/41e (o)
11/4b (o)
11/4c (o)
RSD-33
8.22.2 (h)
12b (o)
ITQACPKVSFEPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHG
210 220 230 240 250
322-151 (m) 1006-30-D (h)
3D3.B8 (m) 847-D (h)
4C11.D8 (m)
493-156 (m)
110.1 (h)
GV4H3 (m)
J1 (m)
J3 (m)
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IRPVVSTQLLLNGSLAEEEVVIRSVNFTDNAKTIIVQLNTSVEINCTRPN
260 270 280 290 300
213.1 (m) 110.C (m) IIIB-V3-26 (m)
MF169.1 (m) IIIB-V3-21 (m)
MF170.1 (m) MO97/V3 (h)
MF87.1 (m) 55/1l
B12 (m) 8/38c (o)
B13 (m) 8/64b (o)
C13 (m)
M89 (m)
B21 (m)
B23 (m)
B24 (m)
B25 (m)
B3 (m)
B26 (m)
B29 (m)
B36 (m)
110.E (m)
NNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKLR
310 320 330 340 350
IIIB-V3-26 (m) 110.I (m)
MO97/V3 (h) anti-HIV-2 polyclonal (o)
55/1l
8/38c (o)
8/64b (o)
9284 (m)
polyclonal (h)
polyclonal (h)
MAG 109 (m)
MAG 49 (m)
MAG 53 (m)
MAG 56 (m)
1324-E (h) IIIB-V3-01 (m)
polyclonal (m)
MO99/V3 (h)
C311E (p)
907 (m)
924 (m)
polyclonal (h)
10F10 (m)
2C4 (m)
412-D (h)
polyclonal (h)
CGP 47 439 (h)
polyclonal (h)
178.1 (m)
257-D (h)
311-11-D (h)
41148D (h)
391/95-D (h)
Aw (o)
Bw (o)
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NNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKLR
310 320 330 340 350
DO142-10 (h)
Dv (o)
Fv (o)
Gv (o)
Hv (o)
polyclonal (po)
50.1 (m)
polyclonal
BAT123 (m)
838-D (h)
1006-15D (h)
782-D (h)
908-D (h)
1027-15D (h)
F19.26-4 (m)
F19.48-3 (m)
F19.57-11 (m)
M77 (h)
SP.BAL114 (m)
SP.SF2:104
polyclonal (h)
19b (h)
4G10 (m)
5F7 (m)
G3-523 (m)
MN215 (h)
Nea 9301 (m)
4117C (h)
419-D (h)
453-D (h)
504-D (h)
83.1 (m)
NNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKLR
310 320 330 340 350
5023B (m)
F58/D1 (m)
P1/D12 (m)
P4/D10 (m)
IIIB-13 V3 (m)
IIIB-34 V3 (m)
A47/B1 (m)
D59/A2 (m)
G44/H7 (m)
M096/V3 (h)
mu5.5 (m)
loop 2 (h)
268-D (h)
386-D (h)
5042A (m)
5042B (m)
418-D (h)
5021 (m)
5025B (m)
5042 (m)
110.3 (m)
110.4 (m)
110.5 (m)
58.2 (m)
polyclonal (m)
537-D (h)
5020 (m)
RC25 (hm)
5023A (m)
110.6 (m)
polyclonal (m)
10/36e (o)
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NNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKLR
310 320 330 340 350
10/54 (o)
11/85b (o)
polyclonal (o)
0.5beta (m)
Cbeta1, 0.5beta (hm)
NM-01 (m)
1026 (m)
1034 (m)
59.1 (m)
polyclonal (o)
10E3 (m)
polyclonal (mo)
N11-20 (m)
5025A (m)
N70-1.9b (h)
902 (m)
694/98-D (h)
MO101/V3,C4 (h)
9205 (m)
EQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNSTW
360 370 380 390 400
4D7/4 (m) B15 (m)
36.1(ARP 329) (m) B34 (m)
C12 (m)
110.D (m)
B32 (m)
STEGSNNTEGSDTITLPCRIKQIINMWQKVGKAMYAPPISGQIRCSSNIT
410 420 430 440 450
5C2E5 (m)
G3-211 (m)
G3-537 (m)
polyclonal (m)
1795
G3-299 (m)
G3-42 (m)
G3-508 (m)
G3-519 (m)
G3-536 (m)
ICR38.1a (o)
ICR38.8f (o)
MO86/C3 (h)
13H8 (m)
G45-60 (m)
polyclonal (m)
1662
1663
1664
1697
1794
1804
1807
1808
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GLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTK
460 470 480 490 500
polyclonal (m) polyclonal (h) M38 (m)
polyclonal (h) Chim 1 (hp)
CRA1(ARP 323) (m) 110.1 (m)
M91 (o) 42F (h)
9201 (m) 43F (h)
1C1 (m)
3F5 (m)
5F4/1 (m)
660-178 (m)
8C6/1 (m)
9301 (m)
B221 (m)
H11 (m) RV110026 (h)
W2 (m)
105-306 (m)
GV1G2 (m)
450-D (h)
670-D (h)
750-D (h)
AKRRVVQREKRAVGIGALFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQ
510 520 530 540 550
M38 (m) 1A1 (h)
450-D (h) 24G3 (h)
670-D (h) 25C2 (h)
750-D (h) 5F3 (h)
722-D (h)
polyclonal (m)
polyclonal (h)
1131-A (h)
858-D (h)
989-D (h)
QQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSG
560 570 580 590 600
alpha(566-586) (h) 246-D (h)
PC5009 (m)
polyclonal alpha577-596 (h)
polyclonal (h)
 (h) 240-D (h)
 (m) F240 (h)
polyclonal (o) 4 (m)
polyclonal (mo) 41-6 (m)
polyclonal (o)
polyclonal (h)
polyclonal (h) 41-7 (h)
polyclonal (h)
2F11 (h)
9G5A (m)
181-D (h)
polyclonal (h)
D49 (m)
D61 (m)
T32 (m)
T34 (m)
115.8 (m)
M-1 (m)
M-11 (m)
M-13 (m)
M-2 (m)
M-22 (m)
M-24 (m)
M-25 (m)
M-28 (m)
M-29 (m)
M-36 (m)
M-4 (m)
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QQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSG
560 570 580 590 600
M-6 (m)
polyclonal alpha598-609 (h)
1B8.env (h)
polyclonal (h)
clone 3 (h)
68.1 (m)
68.11 (m)
75 (o)
polyclonal (h)
105-732 (m)
3D6 (h)
KLICTTAVPWNASWSNKSLEQIWNHTTWMEWDREINNYTSLIHSLIEESQ
610 620 630 640 650
polyclonal (h) 120-16 (h)
polyclonal (h) 167-7 (h)
F240 (h) 167-D (h)
D49 (m) 98-6 (h)
D61 (m) ND-15G1 (h)
T32 (m)
T34 (m)
115.8 (m)
M-1 (m)
M-11 (m)
M-13 (m)
M-2 (m)
M-22 (m)
M-24 (m)
M-25 (m)
M-28 (m)
M-29 (m)
M-36 (m)
M-4 (m)
M-6 (m)
polyclonal alpha598-609 (h)
1B8.env (h)
polyclonal (h)
clone 3 (h)
4 (m)
41-6 (m)
41-7 (h)
68.1 (m)
68.11 (m)
75 (o)
polyclonal (h)
105-732 (m)
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KLICTTAVPWNASWSNKSLEQIWNHTTWMEWDREINNYTSLIHSLIEESQ
610 620 630 640 650
3D6 (h)
F172-D8 (h)
NQQEKNEQELLELDKWASLWNWFNITNWLWYIKLFIMIVGGLVGLRIVFA
660 670 680 690 700
120-16 (h)
167-7 (h)
167-D (h)
98-6 (h)
ND-15G1 (h)
2F5 (h)
5B2 (m)
9G11 (m)
TH-Ab1 (o)
polyclonal (m)
polyclonal (o)
polyclonal (o)
polyclonal (mo)
4E10 (h)
Z13 (h)
VLSIVNRVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDRDRSIRLVN
710 720 730 740 750
B30 (m)
41S-2 (m)
447-52D (h) 1577 (m)
C8 (m)
B31 (m)
B33 (m)
1575 (m)
1576 (m)
1578 (m)
1579 (m)
1583 (m)
1899 (m)
1907 (m)
1908 (m)
1909 (m)
41-1 (m)
41-2 (m)
41-3 (m)
ED6 (m)
LA9 (121-134) (m)
88-158/02 (m)
88-158/022 (m)
88-158/079 (m)
polyclonal (m)
B8 (m)
polyclonal (m)
GSLALIWDDLRSLCLFSYHRLRDLLLIVTRIVELLGRRGWEALKYWWNLL
760 770 780 790 800
QYWSQELKNSAVSLLNATAIAVAEGTDRVIEVVQGACRAIRHIPRRIRQG
810 820 830 840 850
LERILL
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IV-D-13 Nef Ab Epitope Map
MGGKWSKSSVIGWPTVRERMRRAEPAADRVGAASRDLEKHGAITSSNTAA
10 20 30 40 50
polyclonal (m) polyclonal (m)
13/042 (m) 25/03 (m)
13/035 (m)
AM5C6 (m)
26/76 (m)
3F2 (m)
3D12 (m)
TNAACAWLEAQEEEEVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLEGL
60 70 80 90 100
polyclonal (m) F14.11 (m)
3G12 (m) 31/03 (m)
13/058 (m)
26/028 (m)
2E3 (m)
IHSQRRQDILDLWIYHTQGYFPDXQNYTPGPGVRYPLTFGWCYKLVPVEP
110 120 130 140 150
31/03 (m) polyclonal (m) F1 (m)
DKIEEANKGENTSLLHPVSLHGMDDPEREVLEWRFDSRLAFHHVARELHP
160 170 180 190 200
F1 (m) 2A3 (m)
2F2 (m) polyclonal (m)
3E6 (m) E7 (m)
2E4 (m)
2H12 (m)
3A2 (m)
AE6 (m)
AG11 (m)
EH1 (m)
EYFKNC
206
polyclonal (m)
E7 (m)
AE6 (m)
AG11 (m)
EH1 (m)
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